STUDYID|DOMAIN|USUBJID|RSSEQ|RSGRPID|RSREFID|RSSPID|RSLNKID|RSLNKGRP|RSTESTCD|RSTEST|RSCAT|RSSCAT|RSORRES|RSORRESU|RSSTRESC|RSSTRESN|RSSTRESU|RSSTAT|RSREASND|RSNAM|RSMETHOD|RSLOBXFL|RSBLFL|RSDRVFL|RSEVAL|RSEVALID|RSACPTFL|VISITNUM|VISIT|VISITDY|TAETORD|EPOCH|RSDTC|RSDY|RSTPT|RSTPTNUM|RSELTM|RSTPTREF|RSRFTDTC|RSEVLINT|RSEVINTX|RSSTRTPT|RSSTTPT|RSENRTPT|RSENTPT
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||LOG10 IU/ML|PR WITH LYMPHOCYTOSIS||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|VENDOR|PATHOLOGIST|N|1||38||BASELINE|1962-10-09||||1967-12-01||1965-12-08|1972-02-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||SCOOPFUL|CYTOGENETIC PR||10^8 PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|1||38||SCREENING|1967-05-28||||1965-06-04||1960-10-20|1961-08-25||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||BONERESP|BONE RESPONSE||||COPIES/UG|IPR||/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|2||58||BLINDED TREATMENT|1963-03-02||||1964-06-12||1963-03-06|1961-09-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/KG/WEEK|PD/RELAPSE AFTER HI||RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|2||58||SCREENING|1968-10-27||||1971-06-19||1962-09-04|1967-08-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||STRUSTAT|STEROID USE STATUS||||CMOL|PD/RELAPSE AFTER HI||UM2|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||OBSERVATION|1960-07-18||||1964-03-20||1973-07-04|1960-11-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||TMRESP|TUMOR MARKER RESPONSE||||G/CAGE/DAY|RELAPSED DISEASE FROM CR||M/SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|3||39||LONG-TERM FOLLOW-UP|1965-08-09||||1960-03-31||1966-05-08|1967-09-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||LOG10 CFU/G|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UMOL/H/MMOL|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||OPEN LABEL TREATMENT|1971-07-30||||1970-10-22||1968-10-18|1967-06-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/MIN|PCR||EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|INTERVIEWER|READER|Y|4||88||BLINDED TREATMENT|1973-05-01||||1973-06-20||1962-10-27|1971-09-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||STRUSTAT|STEROID USE STATUS||||MG/G/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||COPIES/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|ADJUDICATOR|RADIOLOGIST 2|U|5||7||FOLLOW-UP|1963-06-16||||1970-01-07||1970-04-10|1965-11-11||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DIP|NPR||M3|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|DOMESTIC PARTNER|CARDIOLOGIST|N|5||7||BASELINE|1965-11-17||||1966-08-18||1964-05-05|1963-08-14||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||TRGRESP|TARGET RESPONSE||||NMOL/L|RELAPSED DISEASE FROM CR||UKAT/10^12 RBC|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|1||38||BASELINE|1971-12-03||||1962-03-02||1970-08-03|1960-02-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||CLINRESP|CLINICAL RESPONSE||||PMOL|CA125 50% RESPONSE||KG/CM2|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|INVESTIGATOR|ADJUDICATOR 1|Y|1||38||OPEN LABEL TREATMENT|1968-07-07||||1960-02-06||1961-08-09|1965-11-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||LIVRRESP|LIVER RESPONSE||||CM|SD-CT||KBQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|SPOUSE|FORENSIC PATHOLOGIST|NA|2||58||FOLLOW-UP|1968-06-15||||1964-08-29||1965-06-30|1960-05-28||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||NEWLPROG|NEW LESION PROGRESSION||||MET*H|CYTOGENETIC NO RESPONSE||MM/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|GUARDIAN|OPTOMETRIST|Y|2||58||OPEN LABEL TREATMENT|1962-03-17||||1963-06-22||1963-02-12|1969-09-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MS/MMHG|QUANTIFIABLE MRD POSITIVITY||TUBERCULIN UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|Y|3||39||OBSERVATION|1965-04-30||||1960-11-14||1971-04-30|1969-09-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KN/CM2|SCR||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|FRIEND|RATER 1|NA|3||39||TREATMENT|1961-01-28||||1964-11-30||1962-11-04|1961-08-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^9 ORGANISMS/G|CR-CT||10^6/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|ADJUDICATOR|ONCOLOGIST|NA|4||88||BASELINE|1962-09-22||||1968-10-08||1971-08-31|1967-09-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||TMRESP|TUMOR MARKER RESPONSE||||RAD|UNEQUIVOCAL||GBQ/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|GUARDIAN|READER 2|N|4||88||CONTINUATION TREATMENT|1966-01-24||||1964-09-30||1972-06-12|1968-02-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||TRGRESP|TARGET RESPONSE||||MESF|CPR||TITER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|FAMILY MEMBER|OPHTHALMOLOGIST|Y|5||7||WASHOUT|1970-06-22||||1960-03-23||1966-02-02|1964-10-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||VOXEL|DECREASED||CAN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|GUARDIAN|RATER 1|N|5||7||CONTINUATION TREATMENT|1963-02-03||||1962-02-16||1972-10-30|1962-06-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||METSIND|METASTATIC INDICATOR||||BLOCKS|NR||ABSORBANCE U/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|PROXY|DERMATOLOGIST|N|1||38||INDUCTION TREATMENT|1965-01-28||||1968-08-21||1970-03-26|1968-02-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||LIVRRESP|LIVER RESPONSE||||MG/KG/DAY|PCR||WEBER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SPOUSE|RATER|Y|1||38||CONTINUATION TREATMENT|1970-10-15||||1965-05-30||1964-07-22|1973-03-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PT_BR|PDU||MG/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|PROXY|ENDOCRINOLOGIST|U|2||58||OPEN LABEL TREATMENT|1963-02-13||||1973-08-13||1967-11-13|1960-05-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MM2|RELAPSED DISEASE||10^6/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||BASELINE|1965-07-28||||1963-10-13||1972-05-12|1972-07-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||LIVRRESP|LIVER RESPONSE||||FMOL|OPTIMAL MORPHOLOGIC RESPONSE||UIU/DL|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|SPOUSE|CLINICAL PATHOLOGIST|U|3||39||SCREENING|1964-02-23||||1967-06-16||1968-11-11|1971-09-25||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CY/CM|CRI||L/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|3||39||OBSERVATION|1971-04-20||||1966-10-23||1966-04-06|1960-02-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^4 CFU|CMR||MS2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|CAREGIVER|DERMATOLOGIST|N|4||88||BASELINE|1961-12-29||||1968-10-19||1971-07-12|1972-02-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||METBRESP|METABOLIC RESPONSE||||S*KPA|MR||UMOL/L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|INTERVIEWER|ONCOLOGIST|N|4||88||TREATMENT|1968-02-08||||1970-07-14||1965-02-05|1969-05-31||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||TRGRESP|TARGET RESPONSE||||CPM|ISD||DPM/0.5 ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||BLINDED TREATMENT|1971-04-19||||1964-10-31||1969-02-11|1968-07-15||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||OVRLRESP|OVERALL RESPONSE||||KA_U/DL|SD||UEQ|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|5||7||OPEN LABEL TREATMENT|1968-01-26||||1968-12-27||1967-02-06|1968-11-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||BONERESP|BONE RESPONSE||||ML/MIN/1.73M2|NPR||GTT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|1||38||CONTINUATION TREATMENT|1961-06-15||||1971-01-26||1972-11-28|1960-03-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 COPIES/ML|UNFAVORABLE RESPONSE||MG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|PARENT|DERMATOLOGIST|Y|1||38||FOLLOW-UP|1964-07-14||||1971-08-21||1963-02-19|1964-04-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||AMOL|CR-CT||K|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CHILD|RATER 1|NA|2||58||SCREENING|1969-12-21||||1962-10-29||1972-08-19|1965-10-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||TMRESP|TUMOR MARKER RESPONSE||||KA_U/DL|EQUIVOCAL||GENEQ/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|FRIEND|FORENSIC PATHOLOGIST|U|2||58||RUN-IN|1961-01-01||||1973-07-24||1968-08-06|1961-05-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DPM/ML|MORPHOLOGIC CR||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|3||39||TREATMENT|1967-01-29||||1968-11-03||1961-07-31|1965-02-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KIT|RELAPSED DISEASE FROM CR OR PR||CI/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|INTERVIEWER|RATER 1|NA|3||39||CONTINUATION TREATMENT|1967-02-22||||1968-11-24||1973-07-22|1965-12-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ENZYME U/G HB|CR||/10^5|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||OBSERVATION|1965-12-22||||1968-08-07||1960-04-08|1963-02-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TSP EQ|WORSENED||EID 50/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||TREATMENT|1973-02-14||||1962-03-08||1972-01-31|1962-08-10||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^7 PFU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^6 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|PARENT|HEMATOLOGIST|N|5||7||CONTINUATION TREATMENT|1966-01-02||||1968-07-02||1968-09-13|1970-03-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MSEC|RELAPSED DISEASE FROM CR||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|INTERVIEWER|NEUROLOGIST 1|NA|5||7||FOLLOW-UP|1964-12-10||||1961-01-29||1970-04-05|1969-10-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||BESTRESP|BEST OVERALL RESPONSE||||DB|CR||MMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|STUDY SUBJECT|OPTOMETRIST|U|1||38||OBSERVATION|1961-04-12||||1967-12-28||1966-03-12|1960-05-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MM3/MM2/YEAR|NOT ALL EVALUATED||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|SIBLING|PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1962-10-06||||1971-07-03||1970-11-03|1971-10-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UL/ML|PR-CT||UEQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|INVESTIGATOR|ADJUDICATOR 3|Y|2||58||SCREENING|1973-04-06||||1969-10-14||1963-05-21|1970-05-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||LIVRRESP|LIVER RESPONSE||||KG/MOL|PSA PROGRESSION||ABSORBANCE U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|SPOUSE|ADJUDICATOR|U|2||58||LONG-TERM FOLLOW-UP|1960-05-19||||1970-12-15||1969-08-24|1971-01-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TUBE|MAJOR PATHOLOGIC RESPONSE||G/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||BLINDED TREATMENT|1965-08-17||||1966-09-10||1972-09-21|1960-06-09||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MPH|COMPLETE MRD RESPONSE||VG/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|PROXY|RATER|NA|3||39||BASELINE|1965-10-02||||1972-07-06||1960-02-04|1966-06-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||SPLNRESP|SPLEEN RESPONSE||||10^7 TCID 50/DOSE|COMPLETE MRD RESPONSE||DB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|4||88||CONTINUATION TREATMENT|1962-10-10||||1964-10-09||1972-09-11|1961-03-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EJACULATE U|CYTOGENETIC PR||VOXEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|4||88||LONG-TERM FOLLOW-UP|1962-12-17||||1967-08-22||1965-05-29|1968-04-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MPL U|NON-PD||10^6 CFU|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|5||7||WASHOUT|1962-10-15||||1968-06-25||1967-10-24|1962-07-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||TRGRESP|TARGET RESPONSE||||CI/UL|CA125 75% RESPONSE||10^9 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|5||7||OBSERVATION|1969-05-03||||1963-12-20||1971-03-07|1966-09-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/CAGE/DAY|PARTIAL MORPHOLOGIC RESPONSE||DB|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST|N|1||38||BASELINE|1962-08-08||||1961-02-10||1962-03-21|1965-04-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||MOLRESP|MOLECULAR RESPONSE||||CPM|NPR||MSEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|1||38||BLINDED TREATMENT|1966-02-15||||1970-03-15||1970-04-07|1960-02-15||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||BONERESP|BONE RESPONSE||||BP|MAJOR PATHOLOGIC RESPONSE||PMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|2||58||RUN-IN|1960-07-10||||1971-04-24||1960-06-04|1966-06-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KIT|PR-CT||FT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|INVESTIGATOR|READER|N|2||58||BLINDED TREATMENT|1964-06-04||||1964-10-20||1965-06-18|1971-11-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||STEPS|PSEUDOPROGRESSION||TAMPON|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|INVESTIGATOR|RADIOLOGIST 1|Y|3||39||FOLLOW-UP|1966-10-13||||1969-07-21||1965-08-22|1962-05-16||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^4/HPF|PDU||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|CAREGIVER|RATER 1|NA|3||39||WASHOUT|1961-10-03||||1972-07-17||1966-01-10|1971-02-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||RDIORESP|RADIOLOGIC RESPONSE||||BOTTLE|CYTOGENETIC CR||UGEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|4||88||OBSERVATION|1965-03-26||||1963-07-03||1962-09-18|1972-08-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^7 CFU|CYTOGENETIC NO RESPONSE||MG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|INTERVIEWER|PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1969-08-15||||1964-01-22||1964-05-16|1967-02-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||STEPS|NON-PD||BQ/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|INTERVIEWER|FORENSIC PATHOLOGIST|N|5||7||BASELINE|1972-01-23||||1961-12-25||1969-09-20|1969-07-08||DURING||DURING|
TRIAL STUDY 134XCP|RS|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||L/DAY|WORSENED||MHZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|ADJUDICATOR|ONCOLOGIST 2|Y|5||7||FOLLOW-UP|1963-12-22||||1965-05-04||1960-07-27|1972-12-14||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^7 PFU|MR||DIOPTER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|GUARDIAN|NEUROLOGIST|Y|1||38||INDUCTION TREATMENT|1968-05-19||||1961-08-05||1961-07-21|1969-04-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL/S|INDETERMINATE RESPONSE||EQ|NOT DONE|||LIKERT SCALE 5-POINT|N|N|U|DOMESTIC PARTNER|READER 1|NA|1||38||RUN-IN|1971-04-03||||1961-03-07||1971-04-18|1964-09-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/MS|HI-P||DAGU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|2||58||TREATMENT|1964-07-10||||1971-07-24||1961-02-15|1969-11-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%/MIN|CHR||MEQ/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|GUARDIAN|MICROSCOPIST 2|N|2||58||LONG-TERM FOLLOW-UP|1966-01-03||||1971-04-24||1969-11-20|1972-01-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||TMRESP|TUMOR MARKER RESPONSE||||BREATHS/MIN|CHR||%(W/W)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|3||39||RUN-IN|1971-03-04||||1970-05-08||1963-05-04|1969-03-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||ANATRESP|ANATOMIC RESPONSE||||MG/DAY|RELAPSED DISEASE FROM CR||MG2/DL2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|ADJUDICATOR|MICROSCOPIST|U|3||39||LONG-TERM FOLLOW-UP|1964-02-01||||1969-07-31||1970-06-05|1969-08-27||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||SPLNRESP|SPLEEN RESPONSE||||M3|HI-P||M/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|4||88||TREATMENT|1961-10-07||||1971-07-27||1961-03-27|1971-03-04||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||CLINRESP|CLINICAL RESPONSE||||10^9 ORGANISMS/MG|PR||AMFI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|VENDOR|NEUROLOGIST|Y|4||88||OBSERVATION|1960-02-02||||1965-11-13||1966-06-05|1970-10-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PFU|UNEQUIVOCAL||PG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|GUARDIAN|CLINICAL PATHOLOGIST|NA|5||7||WASHOUT|1970-10-21||||1962-09-16||1972-01-18|1963-06-08||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||STRUSTAT|STEROID USE STATUS||||FMOL/L|UNEQUIVOCAL||DIOPTER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|CLINICAL STUDY SPONSOR|READER 2|NA|5||7||RUN-IN|1964-06-13||||1960-03-13||1966-07-01|1972-01-30||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||LIVRRESP|LIVER RESPONSE||||MJOULE/CM2|COMPLETE MRD RESPONSE||MBQ|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|SIBLING|PATHOLOGIST 2|U|1||38||SCREENING|1970-02-19||||1963-06-05||1966-12-26|1962-04-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/SEC|MRD NEGATIVITY||DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|FAMILY MEMBER|HEMATOLOGIST|U|1||38||OBSERVATION|1970-01-06||||1965-06-30||1961-04-02|1965-06-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||STRUSTAT|STEROID USE STATUS||||IMPLANT|SD-CT||AMU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|U|2||58||OBSERVATION|1965-06-23||||1962-04-02||1968-01-14|1967-11-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||TRGRESP|TARGET RESPONSE||||/2000 RBC|NE||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|INDEPENDENT ASSESSOR|RADIOLOGIST 2|N|2||58||INDUCTION TREATMENT|1964-08-14||||1968-01-26||1968-02-04|1964-10-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CD*S/M2|PD||10^7 PFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||BLINDED TREATMENT|1964-02-08||||1973-08-20||1972-11-11|1973-07-05||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG/DAY|IPR||VIAL|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|FRIEND|MICROSCOPIST 2|N|3||39||SCREENING|1961-12-19||||1961-12-01||1965-03-26|1963-09-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||NTRGRESP|NON-TARGET RESPONSE||||WATT|PARTIAL MORPHOLOGIC RESPONSE||UL|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|INTERVIEWER|ADJUDICATOR 2|NA|4||88||BLINDED TREATMENT|1967-05-31||||1965-02-26||1967-05-14|1971-10-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||BESTRESP|BEST OVERALL RESPONSE||||RNA COPIES/ML|UNEQUIVOCAL||M3|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|FRIEND|INTERNIST|N|4||88||TREATMENT|1970-10-14||||1967-01-27||1968-10-05|1961-01-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||STRUSTAT|STEROID USE STATUS||||10^9/DOSE|HI-P||L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|5||7||BASELINE|1963-12-09||||1961-08-29||1964-04-13|1971-03-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||OVRLRESP|OVERALL RESPONSE||||MMU/ML|CYTOGENETIC MINIMAL RESPONSE||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|DOMESTIC PARTNER|READER 1|Y|5||7||OPEN LABEL TREATMENT|1973-04-29||||1960-10-24||1970-02-09|1970-08-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||TRGRESP|TARGET RESPONSE||||UM/DAY|PR-CT||/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|SPOUSE|MICROSCOPIST 1|NA|1||38||FOLLOW-UP|1961-03-09||||1964-05-05||1964-12-21|1970-12-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/ML/MIN|STABLE||PIPE|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|CHILD|MICROSCOPIST 3|U|1||38||OPEN LABEL TREATMENT|1963-04-15||||1966-01-04||1968-09-03|1973-08-02||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 CFU/G|OPTIMAL MORPHOLOGIC RESPONSE||MG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|INVESTIGATOR|ADJUDICATOR|U|2||58||BLINDED TREATMENT|1962-04-08||||1962-11-19||1962-06-23|1969-10-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMOL/KG|NED||CI/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1972-03-09||||1963-10-16||1972-07-18|1972-07-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||LIVRRESP|LIVER RESPONSE||||NMOL/L/H|PCR||MG/ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|STUDY SUBJECT|ADJUDICATOR|NA|3||39||TREATMENT|1971-08-24||||1970-12-31||1962-06-27|1969-09-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||NEWLPROG|NEW LESION PROGRESSION||||100 IU/ML|MRD RELAPSE||PIXEL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|GUARDIAN|READER 3|N|3||39||SCREENING|1963-05-04||||1967-04-25||1967-02-19|1969-09-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PHERESIS UNIT|NON-CR/NON-PD||G/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|SIGNIFICANT OTHER|ENDOCRINOLOGIST|N|4||88||OBSERVATION|1966-07-16||||1973-07-31||1965-09-15|1963-12-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CMH2O/ML|MCR||CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|CHILD|ENDOCRINOLOGIST|U|4||88||CONTINUATION TREATMENT|1971-03-01||||1968-01-21||1960-01-05|1960-10-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL|SD-CT||CPM|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1968-12-14||||1967-09-12||1963-03-15|1961-12-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||TRGRESP|TARGET RESPONSE||||KBQ|PSA PROGRESSION||WAFER|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|5||7||OBSERVATION|1966-05-16||||1972-12-04||1973-01-07|1970-09-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BQ/KG|UNFAVORABLE RESPONSE||HR/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||SCREENING|1965-07-08||||1970-01-30||1968-09-03|1971-10-18||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE/DAY|IUPD||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|FRIEND|ENDOCRINOLOGIST|U|1||38||TREATMENT|1970-04-13||||1960-09-22||1968-11-27|1970-01-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||FFU|MRD NEGATIVITY||CUP|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2||58||BASELINE|1965-11-11||||1972-04-27||1970-03-06|1973-08-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||PATHRESP|PATHOLOGIC RESPONSE||||U/KG|DECREASED||MPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|FRIEND|OTOLARYNGOLOGIST|Y|2||58||WASHOUT|1970-02-12||||1971-06-22||1960-02-18|1961-05-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||ANATRESP|ANATOMIC RESPONSE||||10^8 PFU|DECREASED||RNA COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|DOMESTIC PARTNER|READER 3|NA|3||39||CONTINUATION TREATMENT|1969-07-23||||1970-11-24||1973-06-22|1964-08-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||CLINRESP|CLINICAL RESPONSE||||MMU/ML|PD FROM PR||MMU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|ADJUDICATOR|READER 1|N|3||39||CONTINUATION TREATMENT|1969-08-08||||1966-07-09||1971-01-10|1965-06-08||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||OVRLRESP|OVERALL RESPONSE||||SIEMENS|OPTIMAL MORPHOLOGIC RESPONSE||MS/MMHG|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|FAMILY MEMBER|CARDIOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1968-09-21||||1971-02-16||1967-02-19|1964-10-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UEQ|MOLECULAR MAJOR RESPONSE||NM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|4||88||BASELINE|1960-08-26||||1962-10-17||1972-02-24|1960-03-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||NTRGRESP|NON-TARGET RESPONSE||||/40 HPFS|NOT ALL EVALUATED||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|5||7||SCREENING|1973-02-23||||1960-01-02||1963-04-14|1965-06-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DIOPTER|FAVORABLE RESPONSE||10^6 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|PROXY|ADJUDICATOR 3|Y|5||7||TREATMENT|1963-05-16||||1965-04-21||1967-09-30|1970-08-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/CAGE/DAY|MRD RELAPSE||U/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|1||38||TREATMENT|1962-07-13||||1967-07-19||1973-01-29|1960-10-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||V/V|CR-CT||ML/100G/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|CHILD|MICROSCOPIST 3|U|1||38||RUN-IN|1971-02-05||||1965-11-23||1967-06-10|1968-06-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||CLINRESP|CLINICAL RESPONSE||||AGU/ML|QUANTIFIABLE MRD POSITIVITY||CYCLE/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|SIBLING|NEUROLOGIST 1|NA|2||58||FOLLOW-UP|1968-10-12||||1967-03-03||1973-09-05|1970-05-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MAMP|CYTOGENETIC MINOR RESPONSE||PG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|SPOUSE|DERMATOLOGIST|NA|2||58||TREATMENT|1962-06-28||||1967-11-22||1961-05-11|1967-04-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||OVRLRESP|OVERALL RESPONSE||||ML/M2/DAY|CYTOGENETIC PR||/MM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|FRIEND|RATER|NA|3||39||INDUCTION TREATMENT|1963-01-11||||1966-09-11||1969-10-14|1970-06-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/M2/MIN|MR||LOG10 ELISA UNIT/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|3||39||SCREENING|1962-03-11||||1970-06-02||1965-02-13|1961-11-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||NEWLPROG|NEW LESION PROGRESSION||||CAPFUL|SCR||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|4||88||TREATMENT|1967-09-27||||1964-05-09||1960-11-13|1963-07-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||FFU|MORPHOLOGIC LEUKEMIA-FREE STATE||/2500 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|N|SPOUSE|CLINICAL PATHOLOGIST|Y|4||88||BASELINE|1968-10-26||||1965-11-01||1963-05-17|1964-10-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||G/L|QUANTIFIABLE MRD POSITIVITY||G/CAGE/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|PROXY|INTERNIST|N|5||7||TREATMENT|1964-09-19||||1966-10-12||1965-06-12|1962-11-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||METBRESP|METABOLIC RESPONSE||||DPM/0.5 ML|CYTOGENETIC PR||10^6 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CAREGIVER|RATER 2|NA|5||7||OBSERVATION|1960-08-31||||1964-06-13||1969-08-08|1973-08-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CGY|NON-QUANTIFIABLE MRD POSITIVITY||ML/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|1||38||SCREENING|1971-11-21||||1967-05-27||1973-08-20|1971-08-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||NTRGRESP|NON-TARGET RESPONSE||||COPIES/UG|CCR||/VF|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|SPOUSE|PHYSIOTHERAPIST|N|1||38||WASHOUT|1972-05-16||||1964-06-03||1966-09-26|1965-10-26||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/M2|CPR||BLOCKS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|2||58||RUN-IN|1969-11-30||||1963-05-18||1973-07-26|1970-02-24||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||MOLRESP|MOLECULAR RESPONSE||||BQ/G|UNEQUIVOCAL||10^6 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|2||58||RUN-IN|1969-08-15||||1960-04-02||1965-09-25|1972-08-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||ANATRESP|ANATOMIC RESPONSE||||MGEQ|PDU||FEU|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|CLINICAL RESEARCH ASSOCIATE|RATER|U|3||39||FOLLOW-UP|1969-09-28||||1967-01-18||1963-05-08|1970-04-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||MOLRESP|MOLECULAR RESPONSE||||DYN|WORSENED||UG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|RATER|Y|3||39||TREATMENT|1960-07-25||||1967-08-27||1963-03-14|1965-05-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||NEWLPROG|NEW LESION PROGRESSION||||TRANSDUCING UNIT/ML|PD/RELAPSE AFTER HI||POINT|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|SPOUSE|NEUROLOGIST|U|4||88||RUN-IN|1972-06-25||||1963-11-28||1961-04-15|1966-11-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||TMRESP|TUMOR MARKER RESPONSE||||L/H/M2|SD||CAPSULE|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|SPOUSE|MICROSCOPIST 3|U|4||88||RUN-IN|1971-06-21||||1965-06-01||1972-12-22|1970-09-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IU/MMOL|MR||/VF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|PARENT|RADIOLOGIST 1|NA|5||7||OBSERVATION|1964-04-13||||1972-11-15||1972-11-24|1961-07-04||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GBQ/MG|PD-CT||C|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|5||7||OPEN LABEL TREATMENT|1961-06-14||||1972-12-27||1964-11-09|1968-08-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||ANATRESP|ANATOMIC RESPONSE||||PKAT/L|SCR||NG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|GUARDIAN|PATHOLOGIST 1|NA|1||38||CONTINUATION TREATMENT|1962-09-16||||1968-10-16||1965-11-10|1966-10-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||TMRESP|TUMOR MARKER RESPONSE||||PG/DL|UNFAVORABLE RESPONSE||G/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|1||38||OBSERVATION|1966-08-30||||1961-09-07||1961-04-01|1964-02-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||CLINRESP|CLINICAL RESPONSE||||UMOL/DL|PCR||CFU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|ADJUDICATOR|RADIOLOGIST 2|Y|2||58||SCREENING|1971-10-30||||1969-10-17||1966-12-18|1965-11-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/M2|SCR||CIGAR|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|INTERVIEWER|NEUROLOGIST 1|N|2||58||FOLLOW-UP|1973-06-21||||1970-09-01||1972-09-07|1963-11-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||METSIND|METASTATIC INDICATOR||||/LPF|MRD RELAPSE||BQ/UG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CHILD|MICROSCOPIST 1|NA|3||39||BASELINE|1964-05-29||||1960-05-28||1960-07-03|1960-07-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PPTH|PSEUDOPROGRESSION||/10^3|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|INTERVIEWER|OPTOMETRIST|NA|3||39||LONG-TERM FOLLOW-UP|1964-05-06||||1970-11-08||1967-01-12|1964-03-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMOL/MOL|CMR||UMOL/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|PROXY|MICROSCOPIST 3|U|4||88||SCREENING|1971-12-31||||1972-05-02||1960-05-26|1973-07-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DAY|MR||STEPS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||FOLLOW-UP|1972-08-20||||1969-10-06||1964-05-24|1961-05-19||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||OVRLRESP|OVERALL RESPONSE||||MILE|QUANTIFIABLE MRD POSITIVITY||G/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|5||7||BASELINE|1965-08-10||||1964-02-01||1969-01-13|1972-05-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||TRGRESP|TARGET RESPONSE||||G/CAGE/DAY|ISD||CMHG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|STUDY SUBJECT|ONCOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1968-11-08||||1970-12-02||1963-01-10|1971-09-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||ANATRESP|ANATOMIC RESPONSE||||SIEMENS|SMD||YD|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|1||38||SCREENING|1972-09-22||||1972-07-15||1964-11-03|1970-01-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||NTRGRESP|NON-TARGET RESPONSE||||ENZYME U/L|MR||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|DOMESTIC PARTNER|READER 3|Y|1||38||OBSERVATION|1962-05-09||||1961-10-13||1970-03-20|1971-10-12||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||METBRESP|METABOLIC RESPONSE||||/4.0 ML|PARTIAL MORPHOLOGIC RESPONSE||MG/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CHILD|ONCOLOGIST 1|U|2||58||WASHOUT|1968-06-12||||1965-04-10||1965-04-24|1960-12-17||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/U|MINOR PATHOLOGIC RESPONSE||CI/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|GUARDIAN|NEUROLOGIST|U|2||58||CONTINUATION TREATMENT|1968-12-30||||1964-12-30||1963-01-08|1963-08-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/DAY|IPR||UMOL/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|VENDOR|INTERNIST|U|3||39||OPEN LABEL TREATMENT|1969-06-18||||1967-03-09||1971-04-09|1966-03-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||ANATRESP|ANATOMIC RESPONSE||||CI|PDU||DB|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|INTERVIEWER|MICROSCOPIST 3|NA|3||39||INDUCTION TREATMENT|1968-10-18||||1963-06-02||1968-07-22|1972-05-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||AMU|MRD PERSISTENCE||CI/UG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|4||88||BASELINE|1971-01-11||||1964-11-30||1961-10-18|1973-05-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||MOLRESP|MOLECULAR RESPONSE||||CAPFUL|PARTIAL MORPHOLOGIC RESPONSE||10^6 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|INTERNIST|U|4||88||CONTINUATION TREATMENT|1961-08-20||||1970-02-13||1971-10-17|1968-03-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||OVRLRESP|OVERALL RESPONSE||||AGU/ML|ICPD||DAMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||RUN-IN|1965-01-28||||1961-01-04||1970-11-30|1961-12-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GY/H|NPR||10^6 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|INVESTIGATOR|READER|N|5||7||BLINDED TREATMENT|1971-03-01||||1964-07-11||1961-06-13|1961-08-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MNFI|PR-CT||MMOL2/L2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|ADJUDICATOR|OPHTHALMOLOGIST|NA|1||38||SCREENING|1962-12-16||||1965-11-03||1964-12-26|1969-11-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EU|PMD||10^6/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|PROXY|ONCOLOGIST 1|NA|1||38||BASELINE|1966-07-31||||1965-05-02||1969-04-23|1972-12-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||SPLNRESP|SPLEEN RESPONSE||||/VF|MR||CI/MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|FRIEND|ADJUDICATOR|N|2||58||FOLLOW-UP|1967-06-04||||1965-04-23||1972-02-29|1965-08-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||STRUSTAT|STEROID USE STATUS||||MPH|IPR||BAR|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|INTERVIEWER|READER 1|Y|2||58||OBSERVATION|1960-08-25||||1968-05-21||1964-08-15|1966-04-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||STRUSTAT|STEROID USE STATUS||||ML/M2/H|PSEUDOPROGRESSION||GBQ/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|SIGNIFICANT OTHER|NEUROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1962-03-09||||1970-08-11||1964-03-02|1971-04-19||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KG/CM2|DECREASED||BQ/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|FAMILY MEMBER|PHYSIOTHERAPIST|N|3||39||LONG-TERM FOLLOW-UP|1961-10-04||||1962-01-16||1967-05-28|1964-06-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DPM/0.5 ML|SMD||COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|SIBLING|RATER 1|U|4||88||OBSERVATION|1973-06-26||||1964-07-16||1967-09-14|1964-07-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||CYTORESP|CYTOGENETIC RESPONSE||||DMOL|RELAPSED DISEASE FROM CR OR PR||RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|DOMESTIC PARTNER|PATHOLOGIST 1|Y|4||88||TREATMENT|1968-06-10||||1966-09-16||1965-12-13|1968-04-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^9 ORGANISMS/ML|ICPD||MG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|CHILD|PATHOLOGIST 2|NA|5||7||FOLLOW-UP|1960-12-10||||1973-02-09||1969-09-07|1965-07-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MIN/DAY|COMPLETE MRD RESPONSE||L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|CAREGIVER|CLINICAL PATHOLOGIST|N|5||7||BASELINE|1968-08-29||||1965-03-01||1970-04-13|1969-05-26||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||TSP EQ|RELAPSED DISEASE FROM CR||UMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|FAMILY MEMBER|ADJUDICATOR 1|Y|1||38||BASELINE|1965-03-01||||1963-08-01||1972-03-08|1966-08-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PA|CCR||M|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|ADJUDICATOR|MICROSCOPIST|Y|1||38||TREATMENT|1961-01-28||||1960-11-25||1962-07-07|1968-03-02||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DRUM|MRD NEGATIVITY||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|PROXY|ONCOLOGIST|U|2||58||CONTINUATION TREATMENT|1966-10-04||||1966-09-29||1970-08-23|1964-08-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||LIVRRESP|LIVER RESPONSE||||MMHG/SEC|IPR||MV/SEC|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|SPOUSE|READER 1|U|2||58||BASELINE|1963-12-28||||1971-11-21||1961-07-13|1971-02-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||CLINRESP|CLINICAL RESPONSE||||APS U|SD||CYLINDER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3||39||FOLLOW-UP|1969-05-08||||1971-08-24||1962-07-12|1964-09-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MM3/MM2/YEAR|CYTOGENETIC NO RESPONSE||DISK|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|VENDOR|MICROSCOPIST 2|NA|3||39||WASHOUT|1969-05-30||||1972-01-14||1961-05-17|1963-09-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CAPSULE|HI-E||CL|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|U|4||88||OBSERVATION|1965-10-28||||1961-02-17||1968-07-03|1966-05-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UCI|MORPHOLOGIC CRI||100 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|ADJUDICATOR|RATER|N|4||88||TREATMENT|1969-07-03||||1968-10-19||1965-03-01|1961-05-31||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||TRGRESP|TARGET RESPONSE||||DPM/100MG|SD-CT||VG/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|CHILD|CLINICAL PATHOLOGIST|N|5||7||FOLLOW-UP|1968-11-11||||1971-08-17||1961-10-29|1969-10-22||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||OVRLRESP|OVERALL RESPONSE||||DIP|MAJOR PATHOLOGIC RESPONSE||KBQ/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|PARENT|OPHTHALMOLOGIST|U|5||7||BASELINE|1967-03-16||||1972-10-02||1972-11-18|1964-06-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PKAT|MRD NEGATIVITY||STRIP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|SPOUSE|INTERNIST|N|1||38||LONG-TERM FOLLOW-UP|1966-11-08||||1973-06-05||1970-04-11|1963-01-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||CYTORESP|CYTOGENETIC RESPONSE||||WAFER|IPR||BLOCKS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|CLINICAL STUDY SPONSOR|READER 1|Y|1||38||LONG-TERM FOLLOW-UP|1960-10-24||||1963-07-27||1962-04-09|1965-08-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CAL|ICR||10^3 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|INDEPENDENT ASSESSOR|READER 1|Y|2||58||TREATMENT|1966-05-27||||1973-05-18||1970-09-19|1965-08-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||LIVRRESP|LIVER RESPONSE||||SEC|PSEUDORESPONSE||PIPE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|GUARDIAN|READER|NA|2||58||WASHOUT|1972-04-23||||1961-09-25||1966-01-27|1967-10-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||MOLRESP|MOLECULAR RESPONSE||||NM|CYTOGENETIC CR||CM H2O|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|FAMILY MEMBER|OPHTHALMOLOGIST|NA|3||39||INDUCTION TREATMENT|1969-04-08||||1970-02-06||1966-05-09|1965-08-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||PATHRESP|PATHOLOGIC RESPONSE||||JOULE|PDU||KPA|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||WASHOUT|1972-11-07||||1971-10-14||1963-03-24|1962-11-07||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BAU|IMPROVED||LOG10 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|CHILD|PEDIATRIC NEUROLOGIST|NA|4||88||WASHOUT|1961-07-28||||1968-06-06||1972-11-24|1966-01-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||OVRLRESP|OVERALL RESPONSE||||IU/L|NPR||10^6/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|INTERVIEWER|READER|N|4||88||TREATMENT|1973-07-10||||1967-01-19||1973-06-29|1969-08-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||METBRESP|METABOLIC RESPONSE||||MG/ANIMAL|MR||UKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|CAREGIVER|OTOLARYNGOLOGIST|NA|5||7||BLINDED TREATMENT|1968-10-23||||1963-10-25||1968-12-28|1967-05-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MEQ/G|MAJOR PATHOLOGIC RESPONSE||10^6/G|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1963-08-05||||1971-06-30||1963-01-01|1963-11-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KG/L|CYTOGENETIC MINIMAL RESPONSE||ML/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|PARENT|READER 2|N|1||38||RUN-IN|1970-04-04||||1972-09-05||1966-02-06|1964-02-23||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOSM|RELAPSED DISEASE FROM CR OR PR||U/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|1||38||CONTINUATION TREATMENT|1970-08-31||||1968-04-30||1965-09-10|1966-09-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||STRUSTAT|STEROID USE STATUS||||FMOL/L/SEC|HI-N||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|2||58||TREATMENT|1960-02-02||||1969-06-20||1962-09-24|1966-03-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FFU|NE||BE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|CAREGIVER|RADIOLOGIST 1|N|2||58||BLINDED TREATMENT|1967-08-17||||1962-05-26||1961-07-18|1962-01-07||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||NEWLPROG|NEW LESION PROGRESSION||||MCI/L|IPR||KG/CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|SIGNIFICANT OTHER|RATER 1|U|3||39||TREATMENT|1968-05-20||||1968-11-23||1964-05-04|1972-05-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG2/DL2|PCR||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|DOMESTIC PARTNER|RATER|U|3||39||WASHOUT|1963-07-24||||1964-12-19||1967-07-28|1969-01-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/CL|NOT ALL EVALUATED||TUBERCULIN UNIT/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|GUARDIAN|PATHOLOGIST|NA|4||88||INDUCTION TREATMENT|1964-03-13||||1960-06-14||1962-10-29|1960-03-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||NEWLPROG|NEW LESION PROGRESSION||||CARTRIDGE|PR WITH LYMPHOCYTOSIS||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|INTERVIEWER|MICROSCOPIST 3|U|4||88||TREATMENT|1973-01-24||||1968-05-18||1972-05-27|1973-02-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||%|CMR||KHZ|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|INVESTIGATOR|PATHOLOGIST 1|NA|5||7||FOLLOW-UP|1960-06-07||||1966-10-15||1971-06-25|1969-10-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||BONERESP|BONE RESPONSE||||MG/ANIMAL|NED||MG/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|5||7||TREATMENT|1969-05-02||||1971-08-16||1960-08-05|1971-01-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CMH2O*S2/ML|PARTIAL MORPHOLOGIC RESPONSE||PT_BR|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|SPOUSE|CARDIOLOGIST|N|1||38||OPEN LABEL TREATMENT|1963-07-01||||1963-08-24||1973-08-10|1965-11-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||M/SEC2|MORPHOLOGIC CRI||CIGAR|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|1||38||FOLLOW-UP|1972-10-24||||1970-11-30||1967-07-06|1966-07-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||STRUSTAT|STEROID USE STATUS||||MM3/MM2/YEAR|CA125 50% RESPONSE||MS/MMHG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|2||58||OBSERVATION|1966-12-23||||1968-06-29||1966-09-02|1960-06-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DAGU/ML|NON-QUANTIFIABLE MRD POSITIVITY||HZ/S|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2||58||CONTINUATION TREATMENT|1971-12-22||||1965-06-18||1961-01-22|1965-04-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UKAT|CRI||DEG2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|FRIEND|RATER 1|U|3||39||BASELINE|1967-03-10||||1964-08-26||1962-07-28|1965-10-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/KG/MIN|UNFAVORABLE RESPONSE||UKAT/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|VENDOR|CARDIOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1967-08-19||||1961-01-29||1963-04-05|1970-09-26||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HPA|NPR||UG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1971-03-05||||1969-08-23||1967-08-08|1972-12-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||SPLNRESP|SPLEEN RESPONSE||||EID 50/ML|PSEUDORESPONSE||VG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|4||88||OPEN LABEL TREATMENT|1972-01-22||||1966-05-24||1970-01-27|1964-08-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PPM|INDETERMINATE RESPONSE||TROCHE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|5||7||WASHOUT|1964-04-11||||1961-01-06||1968-08-21|1969-06-08||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||PATHRESP|PATHOLOGIC RESPONSE||||L/S|MR||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|CHILD|HEMATOLOGIST|NA|5||7||WASHOUT|1970-07-25||||1965-01-07||1968-03-15|1961-06-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DPM/0.5 ML|ABSENT MORPHOLOGIC RESPONSE||SIEMENS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|VENDOR|FORENSIC PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1971-08-01||||1964-07-12||1968-11-24|1964-02-01||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FIU|NON-QUANTIFIABLE MRD POSITIVITY||MAC50|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|FRIEND|PHYSIOTHERAPIST|U|1||38||BLINDED TREATMENT|1964-04-09||||1967-10-31||1967-08-12|1970-03-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/BEAT|DECREASED||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|FRIEND|RATER 1|N|2||58||SCREENING|1960-09-30||||1968-01-14||1963-09-02|1964-12-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||BONERESP|BONE RESPONSE||||DPM/0.5 ML|FAVORABLE RESPONSE||LOG10 CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|PARENT|CLINICAL PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1971-09-02||||1963-12-10||1963-04-09|1965-12-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||DEG|HI-P||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|3||39||LONG-TERM FOLLOW-UP|1969-03-27||||1972-09-23||1971-06-15|1970-08-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||TMRESP|TUMOR MARKER RESPONSE||||ABSORBANCE U|HI-P||MPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|INTERVIEWER|NEUROLOGIST 2|Y|3||39||WASHOUT|1960-03-10||||1964-09-06||1973-08-20|1966-10-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||TRGRESP|TARGET RESPONSE||||EU|NED||PATCH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|CHILD|HEMATOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1969-07-07||||1963-04-01||1965-12-03|1960-01-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||SPLNRESP|SPLEEN RESPONSE||||G/CM2|CYTOGENETIC NO RESPONSE||ML/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|INTERVIEWER|PATHOLOGIST 1|NA|4||88||OBSERVATION|1966-08-14||||1964-01-17||1966-01-24|1964-08-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MEQ/DAY|ISD||NKAT/G HB|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|FRIEND|UROLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1970-02-15||||1961-05-08||1971-09-21|1967-10-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||MOLRESP|MOLECULAR RESPONSE||||MMHG|MORPHOLOGIC CR||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|DOMESTIC PARTNER|MICROSCOPIST 1|Y|5||7||BASELINE|1967-01-21||||1969-08-24||1970-11-01|1973-09-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NMOL/KG/DAY|NON-PD||AMPULE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|INDEPENDENT ASSESSOR|OPTOMETRIST|U|1||38||RUN-IN|1965-02-12||||1970-03-06||1971-08-19|1970-09-15||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UMOL/DAY|CA125 75% RESPONSE||FFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|CHILD|PHYSIOTHERAPIST|NA|1||38||SCREENING|1971-10-22||||1968-05-20||1972-09-06|1966-05-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UM/S|CYTOGENETIC NO RESPONSE||10^12/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2||58||SCREENING|1966-08-06||||1970-02-12||1962-05-30|1964-12-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/G/MIN|CR-CT||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|SPOUSE|ENDOCRINOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1969-02-21||||1973-02-23||1971-07-04|1966-05-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/M2|CYTOGENETIC CR||COPIES/UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|3||39||OPEN LABEL TREATMENT|1963-01-31||||1962-02-13||1961-10-29|1972-06-08||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/G|QUANTIFIABLE MRD POSITIVITY||/MONTH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|CAREGIVER|OPHTHALMOLOGIST|Y|3||39||SCREENING|1966-03-12||||1964-07-26||1964-11-01|1970-05-31||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/CAGE/WK|NED||V/SEC|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|GUARDIAN|RATER 2|NA|4||88||OPEN LABEL TREATMENT|1964-01-17||||1963-04-21||1966-01-29|1960-11-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/VF|PARTIAL MORPHOLOGIC RESPONSE||UMOL/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|ADJUDICATOR|MICROSCOPIST|U|4||88||OBSERVATION|1963-05-06||||1966-12-01||1972-05-21|1973-08-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||STRUSTAT|STEROID USE STATUS||||10^7 TCID 50/DOSE|STABLE||NMOL/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|GUARDIAN|MICROSCOPIST 1|NA|5||7||OPEN LABEL TREATMENT|1961-10-01||||1968-06-23||1973-08-03|1966-01-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ENZYME U/M2|CRI||VG/KG|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|ADJUDICATOR|MICROSCOPIST 3|Y|5||7||OPEN LABEL TREATMENT|1968-07-12||||1973-02-14||1965-03-23|1963-01-01||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/ANIMAL|IMPROVED||UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1971-04-04||||1969-06-12||1971-08-03|1967-11-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||BESTRESP|BEST OVERALL RESPONSE||||PG|PR WITH LYMPHOCYTOSIS||UMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|CHILD|PEDIATRIC NEUROLOGIST|NA|1||38||OPEN LABEL TREATMENT|1964-06-08||||1966-12-12||1969-11-17|1965-11-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||CLINRESP|CLINICAL RESPONSE||||UMOL/KG/MIN|PMD||EIA UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|VENDOR|PATHOLOGIST 1|U|2||58||SCREENING|1973-04-28||||1972-07-17||1968-09-06|1962-05-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^3 RNA COPIES/ML|CMR||NCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|PROXY|ONCOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1972-03-03||||1970-02-09||1960-02-27|1967-09-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||METSIND|METASTATIC INDICATOR||||10^9/DOSE|ABSENT MORPHOLOGIC RESPONSE||IN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|VENDOR|DERMATOLOGIST|Y|3||39||OBSERVATION|1963-10-14||||1965-07-17||1963-05-03|1961-05-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/H|PD||ANTIBODY UNIT|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|FRIEND|READER 2|NA|3||39||SCREENING|1969-05-27||||1972-11-21||1966-08-18|1971-06-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||CYTORESP|CYTOGENETIC RESPONSE||||EID 50/DOSE|STABLE||UMOL/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|CAREGIVER|ONCOLOGIST|U|4||88||SCREENING|1971-08-27||||1968-12-02||1968-06-02|1965-01-06||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DRAM|MORPHOLOGIC CR||M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|4||88||OPEN LABEL TREATMENT|1971-07-24||||1965-07-24||1960-01-12|1966-11-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||MOLRESP|MOLECULAR RESPONSE||||MOL/ML|CR-CT||G/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|GUARDIAN|RADIOLOGIST 1|NA|5||7||FOLLOW-UP|1970-09-08||||1973-03-22||1968-01-01|1970-05-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||HEP|PMD||VG/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|5||7||BLINDED TREATMENT|1969-08-10||||1970-12-25||1962-10-28|1971-03-31||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||NEWLIND|NEW LESION INDICATOR||||CI|MRD RELAPSE||BAR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|DOMESTIC PARTNER|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1961-09-27||||1971-06-20||1966-04-03|1969-09-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||BONERESP|BONE RESPONSE||||STEPS/MIN|RELAPSED DISEASE FROM CR||ABSORBANCE U/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|DOMESTIC PARTNER|ADJUDICATOR 2|NA|1||38||RUN-IN|1960-04-14||||1967-08-25||1960-01-16|1966-07-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^4/L|MRD NEGATIVITY||10^9 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|ADJUDICATOR|NEUROLOGIST 1|U|2||58||WASHOUT|1969-06-19||||1972-09-30||1966-11-09|1972-08-29||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KG/M2|STABLE||TUBE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|INVESTIGATOR|PATHOLOGIST 2|N|2||58||OPEN LABEL TREATMENT|1966-04-11||||1968-09-01||1973-02-09|1972-03-31||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/M2/MIN|STABLE||NU/CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|INTERVIEWER|NEUROLOGIST 1|N|3||39||TREATMENT|1971-11-27||||1966-02-17||1965-07-21|1968-11-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/DAY|HI-N||U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|PARENT|ENDOCRINOLOGIST|NA|3||39||BLINDED TREATMENT|1973-03-28||||1960-09-05||1965-09-05|1965-06-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||ANATRESP|ANATOMIC RESPONSE||||MG/KG/MIN|PSEUDORESPONSE||MMAL|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|RATER|NA|4||88||LONG-TERM FOLLOW-UP|1963-07-30||||1967-08-02||1973-08-08|1962-08-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||NEWLIND|NEW LESION INDICATOR||||10^3 COPIES/ML|CYTOGENETIC NO RESPONSE||WAFER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|INTERVIEWER|READER 1|U|4||88||SCREENING|1966-02-27||||1961-04-10||1971-10-23|1970-07-24||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/KG/H|CCR||ML/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|NA|5||7||RUN-IN|1971-06-08||||1964-02-02||1966-11-14|1968-04-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||BONERESP|BONE RESPONSE||||GRAVITATIONAL UNIT|PD||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|PROXY|NEUROLOGIST 2|N|5||7||BASELINE|1962-07-31||||1960-04-13||1967-01-14|1960-03-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KBQ|NOT ALL EVALUATED||ATM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|1||38||TREATMENT|1967-04-13||||1968-10-17||1968-01-02|1960-09-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MET*H|EQUIVOCAL||L/S/KPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|N|1||38||BASELINE|1969-01-09||||1962-06-05||1963-03-10|1972-02-25||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||METBRESP|METABOLIC RESPONSE||||L/H/M2|CR||BP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|DOMESTIC PARTNER|CARDIOLOGIST|Y|2||58||WASHOUT|1970-10-07||||1967-03-06||1967-07-25|1971-04-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SACHET|IMMUNOPHENOTYPIC CR||/100 HPFS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|FAMILY MEMBER|INTERNIST|U|2||58||RUN-IN|1966-05-14||||1970-03-04||1967-04-21|1967-03-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BISCUIT|PCR||CPM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|SIGNIFICANT OTHER|READER 2|N|3||39||BASELINE|1965-08-05||||1968-02-13||1961-08-12|1969-08-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||TMRESP|TUMOR MARKER RESPONSE||||TBSP|OPTIMAL MORPHOLOGIC RESPONSE||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|3||39||WASHOUT|1963-02-09||||1968-01-22||1969-12-14|1967-02-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||NEWLIND|NEW LESION INDICATOR||||UCI/KG|NON-QUANTIFIABLE MRD POSITIVITY||MM/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|SIBLING|MICROSCOPIST 2|NA|4||88||RUN-IN|1963-04-01||||1968-08-02||1971-04-05|1962-03-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||TMRESP|TUMOR MARKER RESPONSE||||CPM|CYTOGENETIC CR||MG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|INTERVIEWER|READER 3|U|4||88||BLINDED TREATMENT|1973-08-22||||1960-06-27||1963-08-18|1960-07-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||BONERESP|BONE RESPONSE||||% INHIBITION|DECREASED||U/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|PROXY|RADIOLOGIST 2|N|5||7||SCREENING|1967-04-29||||1963-07-18||1973-02-15|1962-10-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||SQU/ML|IPR||L/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|5||7||BLINDED TREATMENT|1969-01-31||||1968-04-10||1962-04-01|1971-08-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||EU|CR||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|PARENT|DERMATOLOGIST|U|1||38||TREATMENT|1965-12-06||||1966-11-12||1971-01-27|1962-05-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||NEWLPROG|NEW LESION PROGRESSION||||VIRTUAL PIXEL|MRD PERSISTENCE||UG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|INVESTIGATOR|FORENSIC PATHOLOGIST|N|1||38||OPEN LABEL TREATMENT|1968-03-04||||1967-12-13||1965-09-05|1963-07-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GTT|IUPD||LENS|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|SIBLING|ONCOLOGIST|N|2||58||OPEN LABEL TREATMENT|1963-07-25||||1966-12-13||1961-12-31|1965-04-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MM/MIN|INCREASED||CS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|DOMESTIC PARTNER|DERMATOLOGIST|Y|2||58||OBSERVATION|1967-04-14||||1972-12-14||1971-05-02|1960-05-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||CLINRESP|CLINICAL RESPONSE||||MG/MIN|WORSENED||C|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|FAMILY MEMBER|READER 1|NA|3||39||INDUCTION TREATMENT|1968-02-19||||1967-06-24||1962-04-22|1960-04-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DNA COPIES/ML|NR||ENZYME U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||RUN-IN|1972-04-13||||1970-08-16||1965-09-03|1960-06-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||ANATRESP|ANATOMIC RESPONSE||||U/CL|STABLE||UGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|PROXY|CLINICAL PATHOLOGIST|NA|4||88||BASELINE|1964-01-30||||1964-10-24||1965-02-26|1965-10-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||LIVRRESP|LIVER RESPONSE||||MPL U/ML|CPR||10^6 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|FRIEND|ONCOLOGIST|NA|4||88||OBSERVATION|1962-05-24||||1966-02-27||1962-10-31|1964-07-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/10^3|NOT ALL EVALUATED||UM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|PARENT|OPTOMETRIST|Y|5||7||WASHOUT|1965-11-21||||1966-07-30||1967-07-30|1969-02-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||SPLNRESP|SPLEEN RESPONSE||||PFU|MOLECULAR CR||/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 2|N|5||7||OPEN LABEL TREATMENT|1966-04-16||||1970-11-28||1971-10-16|1973-03-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MNFI|HI-E||TROCHE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|STUDY SUBJECT|READER|U|1||38||WASHOUT|1968-02-07||||1965-04-26||1969-06-17|1970-08-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||DROP|SMD||DEG/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|ADJUDICATION COMMITTEE|RATER 1|N|1||38||SCREENING|1961-03-06||||1968-10-04||1971-02-18|1964-11-16||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||NEWLPROG|NEW LESION PROGRESSION||||IU/G|PR WITH LYMPHOCYTOSIS||MV|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|2||58||FOLLOW-UP|1963-05-20||||1972-12-25||1967-06-04|1960-12-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||FMOL/G|PD||CCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|FRIEND|ADJUDICATOR 3|Y|2||58||LONG-TERM FOLLOW-UP|1972-08-02||||1960-09-12||1964-10-03|1971-12-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/ANIMAL/WK|MOLECULAR MAJOR RESPONSE||10^7/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|FAMILY MEMBER|DERMATOLOGIST|Y|3||39||TREATMENT|1972-11-23||||1971-04-16||1968-08-19|1966-04-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||CLINRESP|CLINICAL RESPONSE||||KA_U/DL|COMPLETE MRD RESPONSE||UKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|N|3||39||INDUCTION TREATMENT|1967-08-20||||1966-12-05||1969-08-28|1970-06-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||ANATRESP|ANATOMIC RESPONSE||||CM|PSEUDOPROGRESSION||M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|SIBLING|RADIOLOGIST 1|N|4||88||BASELINE|1962-12-06||||1965-11-09||1972-10-04|1969-12-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||MOLRESP|MOLECULAR RESPONSE||||M3|MRD RELAPSE||WEEKS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|CAREGIVER|ONCOLOGIST 2|N|4||88||INDUCTION TREATMENT|1964-03-01||||1973-07-19||1973-02-08|1962-03-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FARAD|MAJOR PATHOLOGIC RESPONSE||BU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|ADJUDICATOR|RATER 2|Y|5||7||TREATMENT|1962-06-26||||1965-12-08||1966-11-16|1962-03-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||ANATRESP|ANATOMIC RESPONSE||||CIGAR|CA125 50% RESPONSE||MG/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|GUARDIAN|ENDOCRINOLOGIST|NA|5||7||BLINDED TREATMENT|1963-07-14||||1965-01-18||1963-12-26|1966-05-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||TMRESP|TUMOR MARKER RESPONSE||||AMFI|CPR||KPA/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|FAMILY MEMBER|MICROSCOPIST 3|NA|1||38||WASHOUT|1972-04-23||||1969-08-25||1965-07-16|1966-07-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%(W/V)|HI-P||L/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|PROXY|MICROSCOPIST 3|N|1||38||WASHOUT|1970-01-03||||1969-01-11||1967-10-04|1973-05-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3 DNA COPIES/ML|MRD RELAPSE||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|STUDY SUBJECT|PATHOLOGIST 2|N|2||58||OPEN LABEL TREATMENT|1963-07-13||||1966-06-13||1967-05-17|1962-04-24||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^3 RNA COPIES/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|2||58||CONTINUATION TREATMENT|1966-10-08||||1964-08-29||1967-07-30|1972-09-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||NEWLIND|NEW LESION INDICATOR||||10^6 CFU/ML|UNFAVORABLE RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|N|3||39||INDUCTION TREATMENT|1971-03-22||||1971-11-26||1969-04-06|1966-10-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/M2/DAY|TREATMENT FAILURE||MMU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|ADJUDICATOR|INTERNIST|Y|3||39||WASHOUT|1969-11-30||||1967-11-21||1972-11-08|1965-12-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NMOL|ISD||UG/L/H|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|SIBLING|INTERNIST|Y|4||88||BASELINE|1970-01-12||||1969-04-09||1970-07-08|1971-11-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||NEWLIND|NEW LESION INDICATOR||||KA_U/DL|INDETERMINATE RESPONSE||UV|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|SIBLING|NEUROLOGIST 1|U|4||88||INDUCTION TREATMENT|1961-06-21||||1966-08-09||1972-12-22|1967-11-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||NEWLPROG|NEW LESION PROGRESSION||||CAPFUL|PR-CT||MG/M2/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|SIBLING|PHYSIOTHERAPIST|NA|5||7||OPEN LABEL TREATMENT|1971-05-28||||1970-11-17||1961-12-07|1968-07-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BOX|PSEUDOPROGRESSION||PACKAGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||WASHOUT|1964-12-11||||1971-07-01||1960-04-08|1963-03-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||SPLNRESP|SPLEEN RESPONSE||||G/ANIMAL/DAY|RELAPSED DISEASE FROM CR||PM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|CLINICAL STUDY SPONSOR|READER|NA|1||38||LONG-TERM FOLLOW-UP|1963-09-05||||1966-05-31||1961-03-28|1970-01-20||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||M3|NPR||G/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CAREGIVER|NEUROLOGIST|U|1||38||CONTINUATION TREATMENT|1961-11-03||||1973-01-20||1971-05-03|1962-10-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/H|PARTIAL MORPHOLOGIC RESPONSE||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SPOUSE|OPTOMETRIST|Y|2||58||LONG-TERM FOLLOW-UP|1969-07-04||||1969-08-14||1960-03-30|1961-10-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||LIVRRESP|LIVER RESPONSE||||L/H/M2|DISEASE TRANSFORMATION||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||BLINDED TREATMENT|1963-03-20||||1963-03-11||1963-07-24|1963-01-10||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||RAD|PARTIAL MORPHOLOGIC RESPONSE||NMOL/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|ADJUDICATION COMMITTEE|READER 1|N|3||39||BLINDED TREATMENT|1960-05-05||||1970-11-30||1968-09-25|1962-02-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/DAY|PSA PROGRESSION||U/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INVESTIGATOR|RATER 1|U|3||39||CONTINUATION TREATMENT|1969-03-23||||1961-07-18||1970-09-11|1962-09-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/G|IMPROVED||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1964-11-09||||1966-12-23||1964-09-17|1962-10-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PG|DECREASED||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|VENDOR|RATER 2|N|4||88||BLINDED TREATMENT|1967-03-16||||1966-10-14||1970-11-07|1962-04-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||TRGRESP|TARGET RESPONSE||||UMOL/L/MIN|PR||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|STUDY SUBJECT|PATHOLOGIST|U|5||7||FOLLOW-UP|1967-01-17||||1961-09-22||1965-10-20|1961-10-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||RDIORESP|RADIOLOGIC RESPONSE||||USP U|CPR||IU/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|CHILD|OTOLARYNGOLOGIST|U|5||7||WASHOUT|1969-03-19||||1963-11-30||1969-01-11|1963-03-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||SPLNRESP|SPLEEN RESPONSE||||CP|HI-E||G/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|SPOUSE|RADIOLOGIST|Y|1||38||FOLLOW-UP|1969-10-09||||1963-10-25||1961-09-05|1972-02-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||L/S|CA125 75% RESPONSE||NMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|PROXY|OPHTHALMOLOGIST|U|1||38||BASELINE|1969-06-01||||1967-01-21||1960-10-29|1965-06-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||MOLRESP|MOLECULAR RESPONSE||||NG/MOL|NON-ICR/NON-IUPD||MOSM/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|2||58||WASHOUT|1961-10-12||||1967-09-03||1967-04-11|1966-02-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||RING|HI-P||UG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|VENDOR|RATER 2|U|2||58||SCREENING|1966-12-14||||1971-11-09||1971-07-28|1973-07-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||ANATRESP|ANATOMIC RESPONSE||||UL|QUANTIFIABLE MRD POSITIVITY||UMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|FAMILY MEMBER|ONCOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1960-07-06||||1969-08-14||1961-10-19|1962-06-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||STRUSTAT|STEROID USE STATUS||||10^4/HPF|QUANTIFIABLE MRD POSITIVITY||%/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|PARENT|UROLOGIST|U|3||39||RUN-IN|1961-08-25||||1970-05-03||1972-10-10|1973-07-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^9 ORGANISMS/G|HI-P||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INVESTIGATOR|OPTOMETRIST|Y|4||88||BLINDED TREATMENT|1970-09-20||||1969-03-15||1970-02-22|1968-01-16||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||S^-1(%O2)^-1|HI-N||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|CHILD|MICROSCOPIST|U|4||88||FOLLOW-UP|1970-05-08||||1962-01-09||1969-11-19|1968-11-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||CLINRESP|CLINICAL RESPONSE||||VP/ML|PR WITH LYMPHOCYTOSIS||TITER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|5||7||OBSERVATION|1973-09-03||||1967-04-15||1963-07-02|1963-03-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||ANATRESP|ANATOMIC RESPONSE||||10^6 ORGANISMS|MOLECULAR CR||ABSORBANCE U|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||BLINDED TREATMENT|1963-11-29||||1966-09-15||1971-01-07|1966-08-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PMOL/10^10 CELLS|CA125 50% RESPONSE||GRAVITATIONAL UNIT|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||LONG-TERM FOLLOW-UP|1970-03-05||||1962-12-27||1964-03-14|1965-11-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||TMRESP|TUMOR MARKER RESPONSE||||NCI|TREATMENT FAILURE||10^6 CFU|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|INTERVIEWER|READER 2|NA|1||38||INDUCTION TREATMENT|1968-04-28||||1963-02-06||1966-12-11|1968-10-31||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CAPSULE|INDETERMINATE RESPONSE||CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|INTERVIEWER|OPTOMETRIST|U|2||58||WASHOUT|1961-12-19||||1970-07-28||1965-01-04|1961-09-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||G|NED||ML/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|SPOUSE|PATHOLOGIST|Y|2||58||WASHOUT|1972-10-12||||1973-08-21||1967-08-14|1967-10-04||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MM3/MM2/YEAR|CR-CT||CYLINDER|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|PARENT|ONCOLOGIST|N|3||39||INDUCTION TREATMENT|1969-08-08||||1970-05-24||1960-08-16|1963-10-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||LIVRRESP|LIVER RESPONSE||||MMHG/L/MIN|CA125 50% RESPONSE||PFU/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|3||39||INDUCTION TREATMENT|1967-07-17||||1961-01-03||1963-03-31|1966-03-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||NEWLIND|NEW LESION INDICATOR||||FRAMES/S|CR||G/DL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CHILD|ADJUDICATOR 2|U|4||88||RUN-IN|1969-11-09||||1964-02-04||1963-11-21|1969-05-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||OVRLRESP|OVERALL RESPONSE||||SCOOPFUL|CRI||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|4||88||LONG-TERM FOLLOW-UP|1965-11-28||||1961-09-24||1962-09-30|1961-02-06||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||100 IU/ML|UNEQUIVOCAL||10^3 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|SIGNIFICANT OTHER|PATHOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1968-07-20||||1964-12-31||1969-03-19|1961-08-22||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||FOZ_BR|NON-QUANTIFIABLE MRD POSITIVITY||KV|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1960-09-05||||1970-03-26||1971-09-27|1967-08-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||MOLRESP|MOLECULAR RESPONSE||||GPS U|CYTOGENETIC MINIMAL RESPONSE||MKAT|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|FAMILY MEMBER|RADIOLOGIST 2|Y|1||38||RUN-IN|1972-10-31||||1967-02-05||1967-12-25|1973-04-24||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BU|NON-PD||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|1||38||CONTINUATION TREATMENT|1968-02-23||||1961-11-06||1966-03-05|1967-04-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TRANSDUCING UNIT/ML|PMD||GBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|2||58||BLINDED TREATMENT|1968-12-29||||1971-12-16||1961-07-22|1965-03-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||SEC|PR||CI/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|ADJUDICATOR|ADJUDICATOR 3|U|2||58||TREATMENT|1960-05-23||||1971-11-14||1970-07-16|1962-05-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||NTRGRESP|NON-TARGET RESPONSE||||DDU|MOLECULAR CR||USIEMENS|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|CAREGIVER|MICROSCOPIST 1|N|3||39||INDUCTION TREATMENT|1962-10-15||||1965-01-25||1973-01-19|1960-08-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||LIVRRESP|LIVER RESPONSE||||UMOL/MG/MIN|MRD NEGATIVITY||GBQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|FAMILY MEMBER|RATER 1|U|3||39||SCREENING|1964-12-28||||1961-01-24||1967-05-02|1967-04-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DNA COPIES/ML|UNFAVORABLE RESPONSE||MEQ/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|INDEPENDENT ASSESSOR|UROLOGIST|U|4||88||CONTINUATION TREATMENT|1964-05-10||||1965-01-30||1961-03-31|1960-05-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MS2|FAVORABLE RESPONSE||MMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|U|4||88||CONTINUATION TREATMENT|1966-07-09||||1972-07-04||1960-01-14|1970-02-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||STRUSTAT|STEROID USE STATUS||||PFU/ML|CA125 50% RESPONSE||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|FRIEND|READER 3|U|5||7||OPEN LABEL TREATMENT|1960-02-17||||1968-03-26||1962-11-16|1965-10-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||OVRLRESP|OVERALL RESPONSE||||/7.5 ML|CMR||CAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1968-09-24||||1972-12-02||1972-04-01|1961-02-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||METBRESP|METABOLIC RESPONSE||||MG/ANIMAL|MINOR PATHOLOGIC RESPONSE||UG/L|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|ADJUDICATION COMMITTEE|UROLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1965-05-26||||1960-02-29||1966-07-13|1964-04-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||METSIND|METASTATIC INDICATOR||||PPB|CYTOGENETIC NO RESPONSE||UOSM|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|1||38||RUN-IN|1965-01-27||||1967-02-27||1969-07-08|1961-05-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MIU/L|PCR||G/U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|2||58||INDUCTION TREATMENT|1967-10-28||||1971-01-27||1960-06-10|1966-01-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||STRUSTAT|STEROID USE STATUS||||U/G/H|NON-PD||NMOL BCE/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|FRIEND|UROLOGIST|Y|2||58||TREATMENT|1963-11-09||||1965-06-03||1971-11-06|1964-07-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PFU/ANIMAL|OPTIMAL MORPHOLOGIC RESPONSE||TSP EQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1973-04-04||||1965-09-19||1963-12-22|1965-07-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/M2|CPR||CCID 50/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|3||39||OPEN LABEL TREATMENT|1968-08-24||||1968-02-23||1963-06-27|1971-03-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||RNA COPIES/ML|PD FROM PR||BREATHS/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|4||88||TREATMENT|1967-03-01||||1966-03-14||1969-04-24|1972-06-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NMOL/KG/DAY|NON-CR/NON-PD||10^3/L|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|STUDY SUBJECT|RADIOLOGIST 2|N|4||88||BLINDED TREATMENT|1960-10-11||||1970-11-12||1968-12-01|1966-04-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||NTRGRESP|NON-TARGET RESPONSE||||U/MG|PD FROM PR||DPM/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|FAMILY MEMBER|MICROSCOPIST 3|NA|5||7||CONTINUATION TREATMENT|1968-05-12||||1973-01-31||1966-02-15|1963-03-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||MOLRESP|MOLECULAR RESPONSE||||IN2|MCR||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|SIGNIFICANT OTHER|RADIOLOGIST|Y|5||7||BLINDED TREATMENT|1964-04-14||||1967-05-04||1970-08-09|1969-10-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/4.0 ML|NON-QUANTIFIABLE MRD POSITIVITY||LOG10 PFU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|DOMESTIC PARTNER|READER 3|Y|1||38||SCREENING|1965-09-09||||1970-06-05||1972-12-07|1965-11-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MU/L|ICR||APPLICATION|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|1||38||INDUCTION TREATMENT|1967-11-26||||1962-02-08||1962-07-29|1963-09-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||METBRESP|METABOLIC RESPONSE||||KA_U/DL|MCR||10^6 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|CAREGIVER|INTERNIST|U|2||58||OPEN LABEL TREATMENT|1961-08-25||||1968-03-14||1966-04-13|1960-04-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||OVRLRESP|OVERALL RESPONSE||||CI/KG|DISEASE TRANSFORMATION||MM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|2||58||FOLLOW-UP|1970-01-26||||1968-04-26||1966-08-13|1968-12-02||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/M2/DAY|RELAPSED DISEASE||MEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|STUDY SUBJECT|MICROSCOPIST 2|Y|3||39||INDUCTION TREATMENT|1962-03-10||||1963-09-28||1972-04-09|1971-08-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||BONERESP|BONE RESPONSE||||LOZENGE|CHR||/100 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|SIBLING|DERMATOLOGIST|NA|3||39||FOLLOW-UP|1965-02-05||||1970-05-27||1968-05-15|1961-12-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||1/(S*KPA)|CYTOGENETIC MINOR RESPONSE||GBQ/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CAREGIVER|ADJUDICATOR 2|U|4||88||INDUCTION TREATMENT|1961-10-06||||1969-06-10||1970-04-13|1966-01-13||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^9/G|SD||MOL/G|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|FRIEND|RADIOLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1964-07-19||||1966-04-29||1971-01-17|1967-06-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/KG/DAY|FAVORABLE RESPONSE||KV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|5||7||BASELINE|1968-04-16||||1967-04-22||1972-01-20|1969-07-07||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PPB|MOLECULAR CR||L/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|5||7||BASELINE|1970-07-29||||1966-08-09||1968-09-04|1962-07-03||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||NEWLIND|NEW LESION INDICATOR||||BEAM BREAKS|HI-P||BEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|STUDY SUBJECT|NEUROLOGIST|NA|1||38||OBSERVATION|1964-10-10||||1968-10-04||1967-06-13|1967-05-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GPS U|MOLECULAR CR||ML/BEAT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|U|1||38||BLINDED TREATMENT|1963-08-14||||1962-07-07||1964-10-25|1961-03-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MOL/DAY|COMPLETE MRD RESPONSE||PIPE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|2||58||TREATMENT|1966-01-12||||1967-10-25||1969-12-19|1965-04-01||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CPM|PR WITH LYMPHOCYTOSIS||MMOL/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|CAREGIVER|RATER|N|2||58||INDUCTION TREATMENT|1962-04-30||||1972-08-06||1960-03-17|1966-12-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||TMRESP|TUMOR MARKER RESPONSE||||PA|NON-PD||LX|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|NA|3||39||CONTINUATION TREATMENT|1960-06-25||||1965-04-24||1970-06-19|1966-11-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||STRUSTAT|STEROID USE STATUS||||PPTH|MRD RELAPSE||MG/KG/WEEK|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|INTERVIEWER|UROLOGIST|Y|3||39||INDUCTION TREATMENT|1973-05-07||||1962-10-18||1961-11-19|1969-07-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||C|MRD RELAPSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|SIBLING|ENDOCRINOLOGIST|Y|4||88||RUN-IN|1967-09-10||||1973-06-17||1963-12-19|1968-10-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DYN|WORSENED||NCI|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|4||88||OBSERVATION|1972-02-12||||1961-08-24||1967-12-04|1969-03-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||TRGRESP|TARGET RESPONSE||||MEQ/KG|PR-CT||MANSON U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||RUN-IN|1962-01-20||||1966-08-20||1968-12-16|1962-06-04||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||METSIND|METASTATIC INDICATOR||||NEBULE|MORPHOLOGIC CR||FT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|DOMESTIC PARTNER|OPHTHALMOLOGIST|U|5||7||BLINDED TREATMENT|1961-01-26||||1971-07-16||1961-09-03|1960-09-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/100G/MIN|CRI||/MBP|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|FRIEND|ONCOLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1960-07-09||||1968-09-20||1965-02-14|1973-01-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||RDIORESP|RADIOLOGIC RESPONSE||||FT3|CPR||RFU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CAREGIVER|RADIOLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1965-09-10||||1962-04-03||1966-11-05|1973-01-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TORR|HI-N||MCI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|VENDOR|CLINICAL PATHOLOGIST|NA|2||58||BASELINE|1967-07-20||||1969-01-29||1966-01-30|1969-11-25||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||METSIND|METASTATIC INDICATOR||||MM/H|PSA PROGRESSION||ENZYME U/M2|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|PARENT|ENDOCRINOLOGIST|N|2||58||INDUCTION TREATMENT|1970-02-15||||1973-08-17||1970-01-06|1966-10-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||LIVRRESP|LIVER RESPONSE||||GPL U|IPR||LM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|3||39||TREATMENT|1969-02-06||||1971-08-20||1971-10-17|1967-06-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||TMRESP|TUMOR MARKER RESPONSE||||INHALATION|HI-N||V/V|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|RATER 1|N|3||39||WASHOUT|1968-07-20||||1966-02-06||1968-09-16|1969-08-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HZ/S|UNEQUIVOCAL||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|INVESTIGATOR|ONCOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1960-12-17||||1973-08-04||1967-05-04|1962-10-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||RDIORESP|RADIOLOGIC RESPONSE||||FG|HI-N||PATCH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|DOMESTIC PARTNER|DERMATOLOGIST|U|4||88||BASELINE|1971-10-04||||1972-10-10||1968-12-24|1966-01-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 COPIES/ML|SD||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CAREGIVER|DERMATOLOGIST|N|5||7||OBSERVATION|1969-12-15||||1969-01-10||1969-08-26|1970-07-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UEQ/L|FAVORABLE RESPONSE||UV*SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|SIBLING|NEUROLOGIST 2|NA|5||7||FOLLOW-UP|1966-10-27||||1972-11-18||1972-08-22|1961-07-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/M2|PR-CT||GPS U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|STUDY SUBJECT|READER 1|N|1||38||TREATMENT|1964-07-19||||1966-09-28||1965-05-08|1970-07-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||TRGRESP|TARGET RESPONSE||||MJOULE/CM2|PD FROM PR||MOL/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1||38||SCREENING|1966-01-11||||1972-10-02||1971-06-06|1960-11-23||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||BESTRESP|BEST OVERALL RESPONSE||||MU/G|PSEUDORESPONSE||/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|GUARDIAN|ADJUDICATOR 3|U|2||58||LONG-TERM FOLLOW-UP|1971-04-29||||1966-07-05||1967-09-22|1969-02-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/L|OPTIMAL MORPHOLOGIC RESPONSE||L/S/KPA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|2||58||BLINDED TREATMENT|1970-05-29||||1960-01-03||1971-03-04|1968-08-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||BONERESP|BONE RESPONSE||||10^12/L|CMR||BQ/UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|VENDOR|OPTOMETRIST|N|3||39||BASELINE|1968-07-02||||1970-08-22||1971-03-20|1964-05-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/KG/MIN|RELAPSED DISEASE||MS2|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|GUARDIAN|RADIOLOGIST 2|U|3||39||RUN-IN|1961-12-23||||1966-08-05||1968-03-28|1969-03-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/KG/H|WORSENED||/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|FAMILY MEMBER|INTERNIST|U|4||88||BLINDED TREATMENT|1969-05-27||||1970-04-26||1964-03-12|1961-05-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||STRUSTAT|STEROID USE STATUS||||IMPLANT|ICPD||OSM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|INTERVIEWER|ENDOCRINOLOGIST|U|4||88||OPEN LABEL TREATMENT|1963-12-26||||1970-04-16||1960-04-19|1967-01-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CARTRIDGE|PD FROM PR||NKAT/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|SIBLING|ADJUDICATOR 1|NA|5||7||BLINDED TREATMENT|1963-02-09||||1973-03-01||1973-02-20|1961-07-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MJOULE/CM2|MRD RELAPSE||MG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|PARENT|MICROSCOPIST 1|Y|5||7||INDUCTION TREATMENT|1965-11-12||||1962-09-16||1965-07-12|1967-09-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||CLINRESP|CLINICAL RESPONSE||||KG/M2|PD-CT||NMOL BCE/NMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|INTERVIEWER|OTOLARYNGOLOGIST|NA|1||38||FOLLOW-UP|1960-10-31||||1966-05-15||1973-08-27|1967-10-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TABLET|CA125 75% RESPONSE||10^7 CFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|READER|N|1||38||INDUCTION TREATMENT|1966-04-06||||1971-08-15||1962-09-27|1967-01-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UMOL/MG/MIN|CYTOGENETIC MINOR RESPONSE||CG|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|ADJUDICATION COMMITTEE|READER 3|N|2||58||SCREENING|1970-08-07||||1970-06-20||1972-07-28|1968-03-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||TRGRESP|TARGET RESPONSE||||MG/ANIMAL|CYTOGENETIC MINIMAL RESPONSE||DPM|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|FRIEND|ADJUDICATOR 3|N|2||58||CONTINUATION TREATMENT|1969-06-15||||1963-12-24||1961-09-07|1970-12-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||ANATRESP|ANATOMIC RESPONSE||||NKAT/L|VGPR||ML/BREATH|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|STUDY SUBJECT|ADJUDICATOR 2|U|3||39||OPEN LABEL TREATMENT|1961-09-07||||1964-03-09||1961-05-06|1966-03-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||CLINRESP|CLINICAL RESPONSE||||POINT|CHR||MV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|READER 3|U|3||39||BASELINE|1969-12-13||||1964-07-01||1963-12-04|1972-10-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ATM|QUANTIFIABLE MRD POSITIVITY||M/SEC2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|HEALTH CARE PROFESSIONAL|READER 1|U|4||88||INDUCTION TREATMENT|1965-11-20||||1962-10-17||1968-12-16|1961-08-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NMOL/KG/DAY|HI-P||G/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CHILD|PATHOLOGIST|NA|4||88||INDUCTION TREATMENT|1961-10-10||||1964-05-12||1966-07-16|1964-05-04||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||METBRESP|METABOLIC RESPONSE||||ML/MIN/MMHG|CHR||ROENTGEN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|5||7||SCREENING|1962-06-28||||1971-06-23||1965-01-04|1972-12-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SCOOPFUL|SCR||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|5||7||SCREENING|1971-03-08||||1973-05-12||1972-02-15|1965-12-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||OVRLRESP|OVERALL RESPONSE||||OSM|RELAPSED DISEASE||DEG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|CHILD|READER|U|1||38||CONTINUATION TREATMENT|1968-07-10||||1961-09-27||1969-04-11|1964-06-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||METBRESP|METABOLIC RESPONSE||||APPLICATION|NED||APPLICATION|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|1||38||SCREENING|1961-06-13||||1968-07-02||1961-05-19|1966-06-25||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||CLINRESP|CLINICAL RESPONSE||||IU/ML|COMPLETE MRD RESPONSE||10^6 DNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||RUN-IN|1968-11-28||||1960-11-11||1971-02-28|1964-04-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UL/ML|CYTOGENETIC NO RESPONSE||MJOULE/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|U|2||58||LONG-TERM FOLLOW-UP|1964-01-05||||1960-05-08||1961-08-09|1967-04-11||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||NTRGRESP|NON-TARGET RESPONSE||||EP U|MAJOR PATHOLOGIC RESPONSE||MOL/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|3||39||FOLLOW-UP|1967-05-30||||1969-06-06||1963-08-18|1963-09-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/KG/DAY|CPR||LOG10 PFU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|ADJUDICATOR|ENDOCRINOLOGIST|Y|3||39||FOLLOW-UP|1967-12-13||||1973-01-24||1960-09-10|1968-08-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||NEWLIND|NEW LESION INDICATOR||||U|NED||NFIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|ADJUDICATOR|READER|Y|4||88||OPEN LABEL TREATMENT|1963-12-25||||1970-04-15||1968-09-29|1967-07-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||NEWLPROG|NEW LESION PROGRESSION||||VG/DOSE|MRD RELAPSE||CI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|4||88||CONTINUATION TREATMENT|1966-07-11||||1966-04-20||1967-04-24|1972-01-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||BONERESP|BONE RESPONSE||||10^9 ORGANISMS/MG|CR||10^4 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|PARENT|ONCOLOGIST 1|NA|5||7||SCREENING|1961-12-13||||1972-04-10||1964-07-12|1973-06-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||NEWLIND|NEW LESION INDICATOR||||MU/G|CR-CT||G/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-10-01||||1973-03-13||1965-02-16|1967-07-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||SCOOPFUL|PD/RELAPSE AFTER HI||BQ/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1||38||RUN-IN|1966-10-14||||1961-12-07||1972-01-21|1973-08-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PG|SD-CT||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|1||38||INDUCTION TREATMENT|1963-06-20||||1969-04-04||1966-09-13|1962-10-22||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||NTRGRESP|NON-TARGET RESPONSE||||%(W/W)|HI-N||/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|FAMILY MEMBER|ADJUDICATOR 1|N|2||58||BASELINE|1970-08-09||||1972-04-16||1961-12-21|1966-08-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||METSIND|METASTATIC INDICATOR||||10^4/L|INCREASED||KG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||FOLLOW-UP|1968-02-02||||1967-07-26||1971-12-04|1962-10-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MSEC|CPR||10^9 CFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|DOMESTIC PARTNER|READER 3|Y|3||39||TREATMENT|1967-11-28||||1960-08-21||1972-07-28|1972-12-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CS|SD||MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|3||39||BLINDED TREATMENT|1964-05-22||||1969-11-14||1962-06-17|1972-07-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU/G HB|NE||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|FRIEND|FORENSIC PATHOLOGIST|N|4||88||WASHOUT|1966-05-10||||1971-10-10||1962-08-29|1966-09-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MIU/L|IMPROVED||U|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|4||88||BASELINE|1966-04-04||||1967-06-22||1965-11-19|1973-06-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/5X10^4 WBC|NE||MBP|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|5||7||OBSERVATION|1969-05-03||||1964-11-05||1965-08-31|1964-08-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||JOULE|CPR||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|SIBLING|ONCOLOGIST|NA|5||7||OBSERVATION|1960-06-09||||1960-12-22||1966-10-31|1969-09-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||SPLNRESP|SPLEEN RESPONSE||||CI/ML|CA125 50% RESPONSE||U/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|INTERVIEWER|RADIOLOGIST|N|1||38||TREATMENT|1965-06-26||||1965-08-29||1971-04-11|1965-11-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||ANATRESP|ANATOMIC RESPONSE||||HOURS|CYTOGENETIC CR||OZ EQ|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||OBSERVATION|1972-01-07||||1963-12-09||1969-03-23|1973-04-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||OI50|COMPLETE MRD RESPONSE||MBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|2||58||CONTINUATION TREATMENT|1967-07-18||||1966-02-08||1963-09-08|1969-09-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CG|PD FROM PR||OI50|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|FAMILY MEMBER|ADJUDICATOR 1|N|2||58||CONTINUATION TREATMENT|1962-09-13||||1962-12-10||1969-12-02|1972-11-04||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||OVRLRESP|OVERALL RESPONSE||||HR/DAY|CRI||MDFI|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1969-02-13||||1972-10-03||1963-04-19|1965-02-12||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||TESLA|NON-CR/NON-PD||10^6 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|FAMILY MEMBER|PATHOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1972-06-01||||1963-01-22||1962-01-25|1968-09-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||OVRLRESP|OVERALL RESPONSE||||G/M2/DAY|HI-E||UM/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|SIBLING|NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1965-05-14||||1965-04-12||1971-02-25|1971-08-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BEATS/MIN|IMPROVED||H/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|PARENT|PATHOLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1966-11-25||||1961-11-08||1973-07-25|1960-07-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||TRGRESP|TARGET RESPONSE||||/200 HPFS|CRI||10^12/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|CHILD|RATER 2|NA|5||7||FOLLOW-UP|1964-11-29||||1964-04-05||1971-11-29|1966-08-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML*CMH2O|CYTOGENETIC MINIMAL RESPONSE||10^7 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|SPOUSE|READER 1|Y|5||7||BASELINE|1966-11-21||||1970-12-04||1962-04-03|1966-01-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||H/WK|NE||/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||INDUCTION TREATMENT|1964-12-11||||1964-12-05||1972-05-27|1971-01-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||METSIND|METASTATIC INDICATOR||||S/H|VGPR||UG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|INVESTIGATOR|RADIOLOGIST 2|U|1||38||SCREENING|1968-09-25||||1967-03-31||1963-01-30|1962-06-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||HZ|EQUIVOCAL||HZ|NOT DONE|||LIKERT SCALE 5-POINT|N|N|U|INTERVIEWER|PATHOLOGIST 1|U|2||58||INDUCTION TREATMENT|1963-03-10||||1970-03-12||1965-09-05|1968-09-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||LIVRRESP|LIVER RESPONSE||||DPM/ML|STABLE||GBQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INVESTIGATOR|INTERNIST|N|2||58||WASHOUT|1963-01-25||||1963-07-25||1965-09-12|1969-12-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RAD|CYTOGENETIC CR||YEARS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|VENDOR|OPTOMETRIST|Y|3||39||CONTINUATION TREATMENT|1961-04-11||||1973-04-07||1966-10-21|1967-07-19||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMHG*MIN/L|FAVORABLE RESPONSE||KS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||SCREENING|1971-01-03||||1970-04-12||1971-02-18|1967-12-03||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GRAIN|CYTOGENETIC MINIMAL RESPONSE||MOL/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|CAREGIVER|OPHTHALMOLOGIST|Y|4||88||RUN-IN|1963-03-02||||1972-04-18||1965-07-31|1965-04-08||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MOL|PR||MG/M2/H|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|VENDOR|RADIOLOGIST 2|N|4||88||BLINDED TREATMENT|1965-11-05||||1971-10-30||1973-06-02|1960-05-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/L|SMD||CI/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|CHILD|PATHOLOGIST|NA|5||7||FOLLOW-UP|1961-07-09||||1964-10-01||1967-10-08|1968-12-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GENEQ|PD-CT||KA_U/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|GUARDIAN|RATER|U|5||7||BASELINE|1971-04-06||||1967-02-16||1971-07-04|1970-09-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||AG|NPR||LINEAR FT*LB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|ADJUDICATOR|ONCOLOGIST 2|NA|1||38||BASELINE|1963-03-07||||1972-07-22||1973-07-28|1964-02-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||OVRLRESP|OVERALL RESPONSE||||OZ EQ|EQUIVOCAL||MG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|FAMILY MEMBER|NEUROLOGIST 1|Y|1||38||OBSERVATION|1965-10-31||||1972-03-14||1972-08-08|1961-04-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||OVRLRESP|OVERALL RESPONSE||||MCI|PDU||NMOL/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|2||58||FOLLOW-UP|1967-02-27||||1972-03-20||1964-01-18|1971-01-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PM|NON-QUANTIFIABLE MRD POSITIVITY||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|DOMESTIC PARTNER|ADJUDICATOR|Y|2||58||BASELINE|1964-09-21||||1960-09-08||1961-07-21|1965-01-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||V|PD/RELAPSE AFTER HI||VIRTUAL PIXEL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|CAREGIVER|READER 3|Y|3||39||OBSERVATION|1973-08-20||||1965-09-07||1969-03-13|1973-01-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI/KG|CYTOGENETIC PR||ML/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|3||39||BLINDED TREATMENT|1969-07-10||||1962-01-02||1967-05-16|1966-05-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||NTRGRESP|NON-TARGET RESPONSE||||/MM|RELAPSED DISEASE FROM CR OR PR||G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|VENDOR|UROLOGIST|N|4||88||WASHOUT|1960-11-10||||1967-05-24||1968-10-03|1960-01-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||TMRESP|TUMOR MARKER RESPONSE||||MN|INCREASED||ML/CAGE|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|4||88||BASELINE|1965-06-20||||1962-08-28||1962-10-19|1965-11-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CL|NON-ICR/NON-IUPD||JOULE|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|5||7||CONTINUATION TREATMENT|1961-04-17||||1964-04-17||1965-08-20|1966-12-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/BREATH|CR-CT||MS/MMHG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|ADJUDICATOR|FORENSIC PATHOLOGIST|Y|5||7||WASHOUT|1962-11-17||||1966-01-13||1963-04-30|1961-03-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^7/L|PMR||PIXELS/IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|INVESTIGATOR|RATER|U|1||38||OPEN LABEL TREATMENT|1968-06-21||||1971-08-04||1972-04-10|1960-04-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 TCID 50/UL|PR WITH LYMPHOCYTOSIS||PUFF|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|ADJUDICATION COMMITTEE|RATER 2|U|1||38||OBSERVATION|1965-05-13||||1962-11-12||1962-11-25|1973-02-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||TMRESP|TUMOR MARKER RESPONSE||||TCID 50/DOSE|NE||MMOL/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|DOMESTIC PARTNER|RATER 1|Y|2||58||INDUCTION TREATMENT|1968-05-01||||1965-11-06||1972-07-08|1962-09-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NG|QUANTIFIABLE MRD POSITIVITY||CI/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|INTERVIEWER|NEUROLOGIST 1|Y|2||58||WASHOUT|1960-11-17||||1963-06-26||1966-09-06|1960-10-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||STRUSTAT|STEROID USE STATUS||||UL|CHR||BAG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|3||39||TREATMENT|1972-08-31||||1960-12-05||1962-11-02|1971-12-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||PATHRESP|PATHOLOGIC RESPONSE||||NCI|SMD||LOG10 PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|DOMESTIC PARTNER|ADJUDICATOR|U|3||39||INDUCTION TREATMENT|1967-11-19||||1967-10-13||1965-07-31|1969-10-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||ANATRESP|ANATOMIC RESPONSE||||DNA COPIES/UG|SD||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1965-05-13||||1969-07-23||1973-01-07|1964-11-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||LIVRRESP|LIVER RESPONSE||||ML/M2|PD FROM PR||ML/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|SIGNIFICANT OTHER|UROLOGIST|N|4||88||RUN-IN|1967-03-29||||1961-04-28||1964-04-09|1961-01-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/7.5 ML|SCR||NGEQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|CHILD|FORENSIC PATHOLOGIST|NA|5||7||OBSERVATION|1973-03-29||||1961-03-22||1966-10-16|1960-08-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||CLINRESP|CLINICAL RESPONSE||||10^6 CFU/G|CYTOGENETIC MINOR RESPONSE||CFU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|SPOUSE|INTERNIST|Y|5||7||FOLLOW-UP|1972-11-10||||1960-11-04||1964-06-02|1969-03-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||METSIND|METASTATIC INDICATOR||||IU/DL|PSEUDORESPONSE||VIAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1||38||BLINDED TREATMENT|1970-02-09||||1968-09-08||1968-09-30|1968-11-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||BESTRESP|BEST OVERALL RESPONSE||||BOX|PSEUDORESPONSE||SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|1||38||WASHOUT|1970-04-22||||1966-12-15||1961-11-26|1966-02-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||SPLNRESP|SPLEEN RESPONSE||||ABSORBANCE U/ML|PD/RELAPSE AFTER HI||IU/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2||58||TREATMENT|1964-05-01||||1963-04-30||1964-08-25|1963-12-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UM|RELAPSED DISEASE||UOSM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|GUARDIAN|PATHOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1965-04-28||||1970-12-05||1971-08-04|1961-08-16||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/MIN/MMHG|DECREASED||10^6 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|INVESTIGATOR|MICROSCOPIST 1|Y|3||39||OBSERVATION|1966-07-16||||1961-06-03||1971-09-25|1971-07-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/40 HPFS|IMMUNOPHENOTYPIC CR||UMOL/MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|FRIEND|OPHTHALMOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1960-09-19||||1971-07-29||1964-09-06|1966-02-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MIN|NR||BISCUIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|CHILD|ONCOLOGIST|U|4||88||RUN-IN|1961-10-29||||1960-01-23||1963-11-13|1971-11-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MSEC|PR||MDFI|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|U|4||88||OBSERVATION|1973-01-07||||1969-05-05||1971-06-06|1967-08-11||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||NEWLPROG|NEW LESION PROGRESSION||||GAUSS|DISEASE TRANSFORMATION||ATM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|5||7||BASELINE|1960-08-20||||1964-09-26||1961-09-01|1963-05-30||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||SPLNRESP|SPLEEN RESPONSE||||NMOL BCE/NMOL|MR||LOG10 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|SPOUSE|READER|N|5||7||CONTINUATION TREATMENT|1960-07-04||||1964-01-27||1965-08-07|1961-11-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||BONERESP|BONE RESPONSE||||FMOL/G|PD/RELAPSE AFTER HI||AMU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|VENDOR|MICROSCOPIST|Y|1||38||WASHOUT|1972-02-10||||1968-08-14||1965-01-09|1973-02-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||ANATRESP|ANATOMIC RESPONSE||||IU|PD-CT||HEP|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|1||38||FOLLOW-UP|1967-07-02||||1969-01-25||1970-12-05|1964-08-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 ORGANISMS/ML|NON-CR/NON-PD||%/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|CAREGIVER|RATER|N|2||58||OBSERVATION|1973-08-02||||1965-06-17||1973-07-27|1968-08-30||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UOSM|PR||PG/DL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|SPOUSE|RATER 2|U|2||58||BLINDED TREATMENT|1969-02-11||||1964-05-12||1972-06-04|1961-04-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UOSM|UNEQUIVOCAL||FMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|N|3||39||OBSERVATION|1963-08-30||||1962-01-14||1960-11-04|1961-08-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||CYTORESP|CYTOGENETIC RESPONSE||||U/KG/MIN|MR||ENZYME U/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|CLINICAL STUDY SPONSOR|READER 1|N|3||39||OBSERVATION|1963-06-20||||1962-07-12||1965-10-05|1968-05-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||SCOOPFUL|COMPLETE MRD RESPONSE||APL U|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|4||88||CONTINUATION TREATMENT|1964-11-19||||1966-11-19||1963-03-13|1967-03-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PMOL/DL|NON-CR/NON-PD||UG/ML/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|CHILD|ADJUDICATOR 1|Y|4||88||INDUCTION TREATMENT|1970-07-27||||1972-06-22||1964-12-08|1972-10-12||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UV|CR-CT||WAFER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1968-01-08||||1967-12-13||1962-01-26|1971-01-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UMOL/MIN|PSEUDORESPONSE||U/CL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|DOMESTIC PARTNER|ONCOLOGIST|U|5||7||RUN-IN|1962-09-07||||1971-02-27||1969-03-24|1967-06-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||TMRESP|TUMOR MARKER RESPONSE||||BEAM BREAKS|SMD||KBQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|1||38||OPEN LABEL TREATMENT|1960-07-11||||1973-08-20||1969-01-12|1960-10-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/CAGE/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MEQ/UG|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|PARENT|MICROSCOPIST 2|N|1||38||WASHOUT|1960-02-04||||1961-01-05||1962-10-04|1965-04-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/200 HPFS|PSEUDORESPONSE||M|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|INDEPENDENT ASSESSOR|OPTOMETRIST|U|2||58||BLINDED TREATMENT|1962-02-28||||1963-11-14||1969-04-16|1968-05-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||STRUSTAT|STEROID USE STATUS||||NL|MOLECULAR MAJOR RESPONSE||FARAD|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|PROXY|ADJUDICATOR|NA|2||58||SCREENING|1973-03-21||||1964-03-19||1968-11-25|1970-05-12||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||NEWLPROG|NEW LESION PROGRESSION||||MM/2H|CCR||UG/L DDU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|3||39||OBSERVATION|1962-10-06||||1963-08-06||1971-03-27|1967-01-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||GENEQ|MOLECULAR MAJOR RESPONSE||M|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1973-03-23||||1973-08-25||1973-03-13|1972-11-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||BESTRESP|BEST OVERALL RESPONSE||||MM3/MM2/YEAR|PR-CT||MBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|ADJUDICATOR|PHYSIOTHERAPIST|NA|4||88||WASHOUT|1965-04-27||||1970-04-30||1966-03-08|1960-02-24||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/MOL|PD-CT||GTT|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|FAMILY MEMBER|ADJUDICATOR 2|N|4||88||RUN-IN|1961-04-11||||1964-12-27||1966-03-14|1964-08-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/DL|INDETERMINATE RESPONSE||DMOL|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|STUDY SUBJECT|NEUROLOGIST 2|N|5||7||OPEN LABEL TREATMENT|1970-02-10||||1971-11-03||1972-07-27|1966-01-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||NTRGRESP|NON-TARGET RESPONSE||||MJOULE/CM2|CA125 75% RESPONSE||/LPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|GUARDIAN|READER|N|5||7||LONG-TERM FOLLOW-UP|1973-07-27||||1963-09-11||1963-01-17|1966-10-14||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KHZ|MCR||MONTHS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|ADJUDICATOR|MICROSCOPIST 1|N|1||38||WASHOUT|1965-11-07||||1968-08-21||1962-09-09|1968-03-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/MG/MIN|CRI||PATCH|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|STUDY SUBJECT|PATHOLOGIST 1|U|1||38||RUN-IN|1966-03-14||||1960-12-11||1963-05-26|1962-04-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||STRUSTAT|STEROID USE STATUS||||HOUNSFIELD UNIT|NE||MM/SEC|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|FRIEND|CARDIOLOGIST|Y|2||58||WASHOUT|1963-04-24||||1962-09-16||1966-02-09|1970-01-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PT_BR|MR||PLUG|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|SIGNIFICANT OTHER|DERMATOLOGIST|U|2||58||INDUCTION TREATMENT|1963-04-13||||1969-08-03||1969-05-16|1966-08-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/DAY|ABSENT MORPHOLOGIC RESPONSE||L/MIN/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1960-02-04||||1966-01-08||1968-10-20|1962-07-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||METSIND|METASTATIC INDICATOR||||GPL U|IMMUNOPHENOTYPIC CR||RNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|GUARDIAN|CARDIOLOGIST|NA|3||39||OBSERVATION|1967-03-12||||1968-01-19||1961-06-30|1972-12-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^9/G|SMD||MILE|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|STUDY SUBJECT|PATHOLOGIST|N|4||88||FOLLOW-UP|1967-10-07||||1965-12-29||1972-02-20|1968-12-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DEG2|PD-CT||ML/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|4||88||INDUCTION TREATMENT|1973-03-24||||1964-11-23||1965-09-30|1972-09-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||CLINRESP|CLINICAL RESPONSE||||NKAT/G HB|CMR||UCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||SCREENING|1961-10-29||||1971-06-10||1972-07-21|1969-01-25||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||NEWLIND|NEW LESION INDICATOR||||GPL U|PR-CT||U/M2|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|5||7||SCREENING|1966-05-13||||1971-01-05||1965-10-08|1965-11-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||METBRESP|METABOLIC RESPONSE||||UMOL/DAY|IMMUNOPHENOTYPIC CR||MOSM/L|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|1||38||BLINDED TREATMENT|1969-11-29||||1968-11-11||1961-08-22|1966-03-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/LPF|CRI||NMOL BCE/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|INTERVIEWER|READER|NA|1||38||WASHOUT|1961-10-30||||1965-03-27||1964-04-18|1962-11-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML*CMH2O|IPR||MOSM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|FAMILY MEMBER|ADJUDICATOR 1|N|2||58||FOLLOW-UP|1968-08-10||||1970-06-25||1961-05-20|1973-05-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||LIVRRESP|LIVER RESPONSE||||G/G|CA125 75% RESPONSE||U/CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|VENDOR|RATER 1|Y|2||58||RUN-IN|1968-03-25||||1966-05-02||1967-12-02|1971-11-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||CYTORESP|CYTOGENETIC RESPONSE||||S/H|PR-CT||GPL U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|PARENT|RADIOLOGIST 2|Y|3||39||INDUCTION TREATMENT|1960-08-14||||1972-08-29||1968-05-12|1973-05-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||METSIND|METASTATIC INDICATOR||||UG/KG/MIN|PMR||EP U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|NA|3||39||SCREENING|1964-01-15||||1965-06-18||1961-06-25|1964-08-31||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/MG|PDU||10^9 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|STUDY SUBJECT|READER 3|Y|4||88||OPEN LABEL TREATMENT|1960-10-14||||1970-07-31||1970-12-15|1965-10-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||METSIND|METASTATIC INDICATOR||||MBP|CYTOGENETIC MINOR RESPONSE||UU/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|VENDOR|READER 3|U|4||88||OBSERVATION|1969-07-20||||1963-09-17||1972-10-10|1970-07-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||TMRESP|TUMOR MARKER RESPONSE||||TABLET|ABSENT MORPHOLOGIC RESPONSE||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|U|5||7||INDUCTION TREATMENT|1968-04-20||||1967-12-04||1966-08-05|1968-11-09||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||BESTRESP|BEST OVERALL RESPONSE||||PG|ICR||%(V/V)|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|SIBLING|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1966-11-11||||1960-03-25||1966-07-10|1963-10-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||LIVRRESP|LIVER RESPONSE||||UV2|ICR||CAN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|NON-HEALTH CARE PROFESSIONAL|READER 3|N|1||38||BLINDED TREATMENT|1965-03-24||||1962-03-08||1963-08-19|1960-01-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/7.5 ML|CR-CT||MEQ/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|STUDY SUBJECT|OTOLARYNGOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1963-10-08||||1960-04-07||1964-02-14|1971-04-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/ANIMAL/DAY|SCR||GBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|DOMESTIC PARTNER|ADJUDICATOR 3|Y|2||58||BASELINE|1971-11-26||||1965-05-19||1970-10-13|1973-05-25||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||METSIND|METASTATIC INDICATOR||||FRAMES/S|CRI||COPIES/UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|2||58||CONTINUATION TREATMENT|1960-02-29||||1967-09-21||1973-07-16|1965-02-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FEU|NR||MCI/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|SPOUSE|MICROSCOPIST 3|NA|3||39||RUN-IN|1973-01-15||||1960-07-16||1968-08-01|1966-03-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MM/2H|CRI||CI/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|INVESTIGATOR|CARDIOLOGIST|NA|3||39||FOLLOW-UP|1961-03-28||||1960-06-29||1960-09-26|1960-09-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||SPLNRESP|SPLEEN RESPONSE||||L/L|MOLECULAR CR||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|GUARDIAN|DERMATOLOGIST|Y|4||88||BASELINE|1972-02-12||||1966-08-26||1972-03-01|1969-09-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||TMRESP|TUMOR MARKER RESPONSE||||BAU/ML|PSEUDOPROGRESSION||VG/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|N|4||88||RUN-IN|1965-09-29||||1968-02-04||1965-10-17|1968-03-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||NEWLIND|NEW LESION INDICATOR||||SFC/10^6 PBMC|CYTOGENETIC NO RESPONSE||G/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|SPOUSE|RATER 1|U|5||7||OPEN LABEL TREATMENT|1971-02-23||||1965-02-17||1970-07-15|1960-04-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BLOCKS|MCR||U/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|DOMESTIC PARTNER|NEUROLOGIST 2|NA|5||7||BASELINE|1965-01-21||||1963-11-15||1971-01-24|1963-05-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^3 ORGANISMS/G|IMPROVED||/HPF|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||RUN-IN|1969-05-04||||1960-12-14||1962-05-01|1973-06-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/7.5 ML|NE||KEV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|PROXY|ADJUDICATOR 2|NA|1||38||OPEN LABEL TREATMENT|1962-05-06||||1960-05-21||1964-06-16|1963-05-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||NEWLIND|NEW LESION INDICATOR||||KG/L|CYTOGENETIC PR||MILE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|2||58||SCREENING|1962-09-03||||1969-06-16||1963-10-01|1966-09-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||SPLNRESP|SPLEEN RESPONSE||||AMPULE|MORPHOLOGIC CRI||UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|STUDY SUBJECT|MICROSCOPIST|U|2||58||OBSERVATION|1963-03-06||||1963-11-04||1960-04-01|1964-11-20||AFTER||DURING|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^3 ORGANISMS/ML|NON-PD||10^6 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|PARENT|READER 3|U|3||39||RUN-IN|1962-08-13||||1963-02-06||1971-12-25|1970-07-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/KG/MIN|CHR||10^9/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1970-08-12||||1966-02-09||1969-08-13|1969-11-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CMH2O*S2/ML|MRD RELAPSE||UG/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|PROXY|ONCOLOGIST 1|Y|4||88||TREATMENT|1969-05-30||||1971-05-01||1972-06-04|1973-07-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/200 HPFS|NON-ICR/NON-IUPD||MMHG/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|CHILD|PEDIATRIC NEUROLOGIST|N|4||88||RUN-IN|1967-03-14||||1972-11-05||1969-08-05|1967-01-31||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BAR|PR WITH LYMPHOCYTOSIS||UMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|SIBLING|RATER|NA|5||7||RUN-IN|1969-09-07||||1971-01-31||1960-01-10|1968-01-31||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MIN|NON-CR/NON-PD||U/MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|INTERVIEWER|MICROSCOPIST 2|N|5||7||OPEN LABEL TREATMENT|1972-12-03||||1965-10-09||1968-05-09|1971-04-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^4 CFU|CPR||ML/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|FRIEND|READER 1|U|1||38||BLINDED TREATMENT|1960-02-10||||1963-05-19||1965-11-17|1968-07-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||MOLRESP|MOLECULAR RESPONSE||||STEPS|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CI/MG|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|PROXY|OPTOMETRIST|N|1||38||WASHOUT|1970-07-28||||1961-12-23||1962-04-10|1965-04-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||SPLNRESP|SPLEEN RESPONSE||||HOMEOPATHIC DILUTION|NED||10^9 CFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|GUARDIAN|CLINICAL PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1960-06-17||||1962-06-15||1971-11-13|1965-07-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||CLINRESP|CLINICAL RESPONSE||||LOG10 TCID 50/UL|NON-PD||PKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|2||58||SCREENING|1972-03-16||||1969-01-13||1969-10-26|1967-12-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||STRUSTAT|STEROID USE STATUS||||NG|IMMUNOPHENOTYPIC CR||ARBITRARY U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|FRIEND|UROLOGIST|NA|3||39||CONTINUATION TREATMENT|1971-02-25||||1963-08-07||1970-10-11|1970-10-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||BESTRESP|BEST OVERALL RESPONSE||||PKAT|PD/RELAPSE AFTER HI||10^7 PFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|VENDOR|RADIOLOGIST 1|Y|3||39||INDUCTION TREATMENT|1966-07-12||||1969-01-05||1963-02-05|1961-06-15||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||MOLRESP|MOLECULAR RESPONSE||||IN|COMPLETE MRD RESPONSE||BAR|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|INTERVIEWER|FORENSIC PATHOLOGIST|U|4||88||OBSERVATION|1966-10-21||||1964-11-27||1970-09-14|1968-08-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||BONERESP|BONE RESPONSE||||MOL/G|INCREASED||G/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|SIBLING|ONCOLOGIST 2|NA|4||88||BLINDED TREATMENT|1962-01-26||||1968-10-11||1971-01-05|1962-11-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DPM/MG|ABSENT MORPHOLOGIC RESPONSE||BU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|FRIEND|READER|Y|5||7||OPEN LABEL TREATMENT|1967-09-22||||1960-05-25||1973-08-19|1967-09-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/DL|PARTIAL MORPHOLOGIC RESPONSE||U/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|PARENT|MICROSCOPIST 1|N|5||7||RUN-IN|1970-07-27||||1973-07-07||1970-09-29|1971-07-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^3 ORGANISMS/G|HI-P||CMH2O/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|CAREGIVER|RATER 1|N|1||38||TREATMENT|1963-07-23||||1961-05-17||1962-08-12|1965-08-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||%(V/V)|CR||UG/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1||38||OBSERVATION|1961-11-19||||1960-07-10||1961-11-09|1968-09-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UCI/KG|PDU||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|GUARDIAN|MICROSCOPIST 1|U|2||58||SCREENING|1969-11-17||||1961-08-24||1961-11-26|1970-01-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MGEQ|SD-CT||TABLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|FRIEND|READER|U|2||58||CONTINUATION TREATMENT|1972-05-26||||1962-07-27||1970-06-22|1971-07-13||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||NEWLPROG|NEW LESION PROGRESSION||||GMFI|MOLECULAR CR||MMOL/MOL|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|READER|U|3||39||SCREENING|1967-10-15||||1960-06-21||1962-07-27|1961-09-20||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||ANATRESP|ANATOMIC RESPONSE||||MM2|MOLECULAR MAJOR RESPONSE||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|PROXY|MICROSCOPIST 3|NA|3||39||OPEN LABEL TREATMENT|1966-11-01||||1963-06-07||1964-02-11|1967-04-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||ANATRESP|ANATOMIC RESPONSE||||SV|NOT ALL EVALUATED||S^-1(%O2)^-1|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|4||88||SCREENING|1965-10-14||||1963-11-16||1965-01-07|1964-06-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||ANATRESP|ANATOMIC RESPONSE||||PMOL/DL|SCR||UL/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|GUARDIAN|MICROSCOPIST|Y|4||88||OBSERVATION|1964-12-13||||1964-10-29||1968-03-22|1967-05-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||CLINRESP|CLINICAL RESPONSE||||GPELISA UNIT/ML|STABLE||DPM/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1965-11-28||||1966-05-21||1967-05-10|1969-03-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||TRGRESP|TARGET RESPONSE||||OZ|SD||10^3 CFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|VENDOR|CARDIOLOGIST|N|5||7||SCREENING|1960-04-25||||1969-02-18||1970-04-08|1967-08-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^4/L|SD||G/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|1||38||FOLLOW-UP|1970-01-14||||1965-09-03||1963-01-30|1969-03-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||NEWLPROG|NEW LESION PROGRESSION||||LOZENGE|NON-CR/NON-PD||OZ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|CAREGIVER|MICROSCOPIST 3|N|1||38||SCREENING|1960-08-17||||1961-10-26||1964-09-25|1967-06-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DNA COPIES/UG|FAVORABLE RESPONSE||PIXELS/CM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|GUARDIAN|RADIOLOGIST|U|2||58||INDUCTION TREATMENT|1964-10-31||||1960-08-03||1967-08-30|1963-04-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||BONERESP|BONE RESPONSE||||UCI|PDU||MOL/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|2||58||FOLLOW-UP|1971-05-10||||1972-12-08||1968-08-03|1962-05-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/G/MIN|HI-P||MMHG/L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|CAREGIVER|ONCOLOGIST 2|Y|3||39||BLINDED TREATMENT|1973-01-06||||1960-03-17||1962-04-08|1969-10-02||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||%|IPR||UG/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|PARENT|ADJUDICATOR 3|U|3||39||BASELINE|1965-04-01||||1970-12-23||1971-01-03|1962-12-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CAN|ISD||COPIES/UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|FRIEND|OPTOMETRIST|N|4||88||FOLLOW-UP|1962-06-24||||1961-06-11||1971-08-15|1963-01-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/M2/H|CA125 75% RESPONSE||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|ADJUDICATION COMMITTEE|RATER|NA|4||88||TREATMENT|1962-01-11||||1960-10-08||1972-04-22|1961-02-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/MBP|INDETERMINATE RESPONSE||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1966-07-02||||1964-10-05||1965-05-19|1965-12-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||BESTRESP|BEST OVERALL RESPONSE||||MCI/KG|PSEUDOPROGRESSION||ENZYME U/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|CAREGIVER|OTOLARYNGOLOGIST|U|5||7||BLINDED TREATMENT|1968-11-07||||1968-09-28||1970-05-28|1963-07-09||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||NEWLIND|NEW LESION INDICATOR||||10^7/L|CYTOGENETIC PR||10^9 CFU/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|PROXY|ONCOLOGIST|N|1||38||RUN-IN|1963-06-01||||1963-10-29||1968-01-13|1963-11-07||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||TRGRESP|TARGET RESPONSE||||PT_BR|NPR||MMOL/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|SPOUSE|RADIOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1972-07-14||||1970-01-17||1964-12-09|1972-07-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/KG/WEEK|CR||GPL U|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|2||58||FOLLOW-UP|1970-05-07||||1971-08-11||1966-08-20|1966-09-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||SPLNRESP|SPLEEN RESPONSE||||DMOL|PDU||ARBITRARY U|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|INDEPENDENT ASSESSOR|MICROSCOPIST|N|2||58||BASELINE|1964-05-05||||1967-12-18||1968-08-15|1968-05-16||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||NEWLPROG|NEW LESION PROGRESSION||||/VF|PSEUDORESPONSE||ML/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|VENDOR|HEMATOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1961-01-07||||1963-01-21||1964-02-16|1971-08-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DISK|SD-CT||UG/ML/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|SIGNIFICANT OTHER|ONCOLOGIST|NA|3||39||FOLLOW-UP|1965-01-26||||1962-07-04||1966-09-23|1967-08-16||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||S^-1(%O2)^-1|UNEQUIVOCAL||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|SIBLING|ONCOLOGIST 1|U|4||88||TREATMENT|1965-02-16||||1963-03-19||1961-09-03|1972-07-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/KG/MIN|PR-CT||DRINK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|INVESTIGATOR|CARDIOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1973-07-27||||1967-05-03||1969-05-10|1961-04-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||METBRESP|METABOLIC RESPONSE||||CAN|MAJOR PATHOLOGIC RESPONSE||CP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|CAREGIVER|CARDIOLOGIST|NA|5||7||BASELINE|1968-10-21||||1971-06-05||1963-04-01|1966-06-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/DL|CR||MV/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|ADJUDICATION COMMITTEE|RATER 2|U|5||7||OPEN LABEL TREATMENT|1972-03-18||||1960-09-03||1963-04-10|1968-11-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^9/L|INDETERMINATE RESPONSE||FT2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|INVESTIGATOR|HEMATOLOGIST|NA|1||38||FOLLOW-UP|1972-03-28||||1966-09-20||1969-01-15|1973-01-10||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||TMRESP|TUMOR MARKER RESPONSE||||DRUM|RELAPSED DISEASE FROM CR OR PR||10^7 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|FAMILY MEMBER|NEUROLOGIST 2|NA|1||38||BLINDED TREATMENT|1972-05-13||||1969-04-28||1967-10-10|1967-09-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||P|RELAPSED DISEASE FROM CR OR PR||MMOL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|2||58||CONTINUATION TREATMENT|1967-05-20||||1962-08-23||1963-12-26|1968-06-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||CLINRESP|CLINICAL RESPONSE||||KUSP|NON-PD||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|STUDY SUBJECT|READER|NA|2||58||RUN-IN|1969-10-03||||1960-11-10||1960-10-19|1970-02-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||VG/KG|NE||/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|PARENT|ONCOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1964-02-16||||1972-09-12||1972-01-25|1971-03-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||NEWLPROG|NEW LESION PROGRESSION||||PSEC|RELAPSED DISEASE FROM CR||CAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|ADJUDICATION COMMITTEE|READER|N|3||39||SCREENING|1966-06-05||||1962-07-24||1960-12-16|1965-07-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||TUBERCULIN UNIT/ML|MRD RELAPSE||CM/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|ADJUDICATOR|DERMATOLOGIST|NA|4||88||FOLLOW-UP|1961-02-02||||1970-06-25||1963-06-23|1962-06-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PATCH|MOLECULAR CR||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|VENDOR|READER 3|NA|4||88||LONG-TERM FOLLOW-UP|1971-06-07||||1963-05-15||1969-11-12|1969-10-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||OVRLRESP|OVERALL RESPONSE||||10^3 COPIES/ML|MRD NEGATIVITY||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|SPOUSE|RATER 1|N|5||7||SCREENING|1961-05-25||||1962-06-26||1973-05-20|1960-06-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PMOL/DAY|TREATMENT FAILURE||/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|PARENT|READER 2|U|5||7||BASELINE|1964-07-26||||1964-03-01||1968-10-15|1967-05-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TRANSDUCING UNIT/ML|IUPD||CYLINDER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|PARENT|READER 2|N|1||38||BLINDED TREATMENT|1965-07-21||||1961-10-30||1966-04-27|1967-06-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||L/DAY|CR||HZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||RUN-IN|1962-10-18||||1966-10-31||1966-06-21|1967-12-13||DURING||DURING|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||TMRESP|TUMOR MARKER RESPONSE||||MPA|PDU||ML/100G/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|ADJUDICATION COMMITTEE|READER 3|U|2||58||BASELINE|1965-04-06||||1969-09-27||1961-04-07|1970-08-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EIA UNIT|EQUIVOCAL||NSEC|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|RATER|Y|2||58||OPEN LABEL TREATMENT|1963-04-19||||1960-11-23||1961-01-14|1972-04-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||SPLNRESP|SPLEEN RESPONSE||||%|CR||UL/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|PARENT|HEMATOLOGIST|NA|3||39||BASELINE|1972-08-28||||1961-12-02||1967-06-12|1967-10-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||MOLRESP|MOLECULAR RESPONSE||||MMOL/G|SD-CT||U/G HB|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|INTERVIEWER|READER 3|NA|3||39||CONTINUATION TREATMENT|1963-11-25||||1961-02-24||1963-06-22|1962-05-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||USEC|CR-CT||MM/2H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|SPOUSE|RATER 1|N|4||88||TREATMENT|1966-03-22||||1961-01-31||1960-10-13|1966-04-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||ANATRESP|ANATOMIC RESPONSE||||MG/KG/MIN|CCR||CPM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|4||88||BLINDED TREATMENT|1960-02-29||||1970-02-21||1965-02-21|1971-07-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPFUL|NON-ICR/NON-IUPD||CFU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|FRIEND|RATER|Y|5||7||TREATMENT|1967-10-19||||1961-02-24||1965-02-18|1967-12-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||CLINRESP|CLINICAL RESPONSE||||ML/DL|PR||BOTTLE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|INVESTIGATOR|PATHOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1967-04-08||||1966-09-03||1964-03-08|1966-05-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||EU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UU/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|U|1||38||TREATMENT|1963-06-16||||1963-10-04||1969-09-30|1961-12-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMOL/MIN/KPA/L|PD FROM PR||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|SPOUSE|CLINICAL PATHOLOGIST|U|1||38||TREATMENT|1961-05-16||||1963-07-14||1965-12-16|1960-01-14||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UGEQ/L|INCREASED||BAG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|VENDOR|READER 3|NA|2||58||BASELINE|1960-02-05||||1972-11-30||1970-07-21|1969-08-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/BREATH|CR||OI50|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|SPOUSE|PATHOLOGIST|NA|2||58||WASHOUT|1962-07-23||||1963-05-14||1964-12-27|1962-02-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||VIAL|SD-CT||MET*MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|CHILD|ADJUDICATOR|Y|3||39||WASHOUT|1964-01-05||||1960-05-11||1965-03-20|1966-04-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||CYTORESP|CYTOGENETIC RESPONSE||||AMOL|MORPHOLOGIC CRI||LM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|INVESTIGATOR|OTOLARYNGOLOGIST|N|3||39||BASELINE|1966-09-28||||1962-01-30||1964-12-24|1965-11-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MDFI|CRI||U/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|FAMILY MEMBER|INTERNIST|NA|4||88||SCREENING|1961-10-27||||1973-08-09||1961-02-28|1961-06-30||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^4/L|HI-N||IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|4||88||WASHOUT|1967-04-11||||1968-03-21||1967-12-24|1970-06-23||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^4/HPF|MR||CARTRIDGE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|SIGNIFICANT OTHER|CARDIOLOGIST|Y|5||7||TREATMENT|1961-01-18||||1967-02-25||1963-06-18|1962-02-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/H|MORPHOLOGIC LEUKEMIA-FREE STATE||MMHG*MIN/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|SPOUSE|RADIOLOGIST 1|U|5||7||CONTINUATION TREATMENT|1966-12-02||||1961-06-08||1966-05-17|1961-05-28||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||OVRLRESP|OVERALL RESPONSE||||PPB|NON-QUANTIFIABLE MRD POSITIVITY||/200 HPFS|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|FRIEND|FORENSIC PATHOLOGIST|N|1||38||BLINDED TREATMENT|1965-07-22||||1965-11-12||1965-10-26|1967-04-21||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||NEWLIND|NEW LESION INDICATOR||||MPL U/ML|CPR||POUCH|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|PARENT|CARDIOLOGIST|N|1||38||TREATMENT|1966-05-17||||1972-12-27||1968-08-14|1961-01-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/L/H|PARTIAL MORPHOLOGIC RESPONSE||PG/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||SCREENING|1960-12-21||||1962-05-28||1968-04-03|1965-11-13||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/ANIMAL|MCR||/MONTH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1971-05-09||||1969-07-19||1961-01-06|1961-08-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||METBRESP|METABOLIC RESPONSE||||AFU|PSEUDORESPONSE||10^12/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||TREATMENT|1967-01-03||||1960-06-30||1969-11-09|1965-10-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GY/H|CA125 50% RESPONSE||G/G/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|ADJUDICATOR|DERMATOLOGIST|NA|3||39||WASHOUT|1971-07-05||||1973-08-21||1960-01-21|1971-04-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||NEWLIND|NEW LESION INDICATOR||||UV|HI-P||LOG10 TCID 50/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1969-08-07||||1969-12-09||1966-06-19|1968-09-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^4/HPF|PMD||M/SEC2|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|SIBLING|ONCOLOGIST 1|Y|4||88||INDUCTION TREATMENT|1963-02-27||||1965-11-06||1970-10-05|1965-09-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||TMRESP|TUMOR MARKER RESPONSE||||CFU/G|NED||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|CHILD|CLINICAL PATHOLOGIST|NA|5||7||OBSERVATION|1969-11-26||||1960-11-11||1963-03-22|1960-10-29||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||CYTORESP|CYTOGENETIC RESPONSE||||VG/KG|NR||CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|5||7||RUN-IN|1969-05-06||||1970-07-01||1964-07-20|1963-02-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||ANATRESP|ANATOMIC RESPONSE||||CMOL|QUANTIFIABLE MRD POSITIVITY||LOG10 TCID 50/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|VENDOR|FORENSIC PATHOLOGIST|N|1||38||RUN-IN|1972-09-11||||1972-05-02||1964-11-20|1962-05-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/CAGE/WK|MOLECULAR MAJOR RESPONSE||/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|READER 2|NA|1||38||SCREENING|1970-11-19||||1968-04-28||1964-01-20|1970-03-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||NTRGRESP|NON-TARGET RESPONSE||||GPELISA UNIT/ML|SD-CT||CD|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|2||58||WASHOUT|1965-03-26||||1962-05-21||1961-08-17|1972-12-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||MOLRESP|MOLECULAR RESPONSE||||DPM/0.5 ML|MRD RELAPSE||CCID 50/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|2||58||CONTINUATION TREATMENT|1962-05-07||||1962-12-07||1960-04-14|1971-07-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||OVRLRESP|OVERALL RESPONSE||||FRACTION OF 1|ABSENT MORPHOLOGIC RESPONSE||DEG/S|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|3||39||CONTINUATION TREATMENT|1964-11-02||||1960-11-07||1969-06-01|1970-06-20||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^11/L|NR||PATCH|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1970-06-23||||1971-12-20||1961-04-30|1970-12-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||KPA|NR||ML/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|INTERVIEWER|RATER|U|4||88||BLINDED TREATMENT|1967-03-15||||1962-06-12||1960-10-16|1969-06-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^7 CFU|DECREASED||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|INTERVIEWER|PATHOLOGIST|U|4||88||OBSERVATION|1967-08-18||||1972-06-17||1960-11-04|1969-06-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||1/(S*KPA)|DISEASE TRANSFORMATION||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|SIBLING|CARDIOLOGIST|N|5||7||RUN-IN|1968-09-09||||1960-11-04||1971-07-20|1969-08-23||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||LIVRRESP|LIVER RESPONSE||||VOXEL|NON-ICR/NON-IUPD||EU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|STUDY SUBJECT|NEUROLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1965-09-03||||1966-10-02||1968-02-17|1963-02-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||STRUSTAT|STEROID USE STATUS||||10^10/L|NOT ALL EVALUATED||MMAL|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|1||38||OBSERVATION|1962-03-17||||1971-06-22||1960-04-27|1969-01-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NMOL BCE/MMOL|SD-CT||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|SPOUSE|PATHOLOGIST 1|NA|1||38||RUN-IN|1966-11-01||||1962-03-29||1962-10-22|1961-04-21||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||ANATRESP|ANATOMIC RESPONSE||||TAMPON|HI-P||UMOL/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|2||58||RUN-IN|1968-09-20||||1961-04-22||1970-11-04|1963-01-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/L|COMPLETE MRD RESPONSE||UV|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|SIBLING|ONCOLOGIST 1|NA|2||58||FOLLOW-UP|1972-02-21||||1973-02-03||1960-06-12|1964-03-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||ANATRESP|ANATOMIC RESPONSE||||IU/KG/H|NON-PD||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|PARENT|OTOLARYNGOLOGIST|N|3||39||CONTINUATION TREATMENT|1973-06-05||||1960-08-06||1964-05-28|1961-10-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/MOL|CCR||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|PARENT|READER 3|U|3||39||TREATMENT|1967-04-04||||1964-07-15||1967-05-22|1966-02-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/10^5|PR||KG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|CAREGIVER|NEUROLOGIST 1|NA|4||88||CONTINUATION TREATMENT|1970-10-31||||1969-08-07||1966-11-14|1970-02-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||TRGRESP|TARGET RESPONSE||||PPB|EQUIVOCAL||10^9/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|ADJUDICATOR|OPTOMETRIST|U|4||88||TREATMENT|1965-01-25||||1966-12-02||1961-08-26|1962-05-09||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||PATHRESP|PATHOLOGIC RESPONSE||||FT|DECREASED||ANSON U|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|INVESTIGATOR|UROLOGIST|Y|5||7||CONTINUATION TREATMENT|1967-11-22||||1962-11-24||1969-07-22|1963-10-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL|NPR||GPELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|VENDOR|NEUROLOGIST 1|NA|5||7||OPEN LABEL TREATMENT|1960-01-21||||1972-03-17||1964-09-22|1971-08-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^8/L|PDU||NMOL/L/H|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|FAMILY MEMBER|DERMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1964-04-20||||1972-11-24||1964-03-18|1962-07-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ENZYME U|COMPLETE MRD RESPONSE||BU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|ADJUDICATOR|ONCOLOGIST 1|NA|1||38||CONTINUATION TREATMENT|1963-10-18||||1968-02-18||1972-06-28|1968-12-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||AMP|CMR||CG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|FRIEND|ADJUDICATOR|N|2||58||FOLLOW-UP|1970-04-19||||1972-12-05||1963-12-13|1971-03-25||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 PFU/ML|ABSENT MORPHOLOGIC RESPONSE||CM/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|ADJUDICATION COMMITTEE|HEMATOLOGIST|U|2||58||WASHOUT|1964-06-09||||1968-10-06||1960-08-11|1972-09-19||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||NEWLPROG|NEW LESION PROGRESSION||||BAR|CR||F|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|CAREGIVER|READER 1|NA|3||39||CONTINUATION TREATMENT|1973-04-08||||1971-11-16||1969-02-21|1968-04-15||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||METSIND|METASTATIC INDICATOR||||U/CL|CYTOGENETIC CR||10^12/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|STUDY SUBJECT|ADJUDICATOR 3|N|3||39||BASELINE|1964-10-29||||1960-01-03||1969-11-08|1966-05-06||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CL|IMMUNOPHENOTYPIC CR||TSP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|4||88||OPEN LABEL TREATMENT|1968-10-02||||1960-11-04||1968-06-18|1963-08-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||MOLRESP|MOLECULAR RESPONSE||||MMOL/DAY|PR||UG/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|READER|U|4||88||OPEN LABEL TREATMENT|1964-09-09||||1968-09-19||1970-11-09|1965-04-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||LIVRRESP|LIVER RESPONSE||||ML/H|CYTOGENETIC MINOR RESPONSE||/2500 WBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|5||7||RUN-IN|1961-03-01||||1962-02-01||1962-03-29|1965-01-07||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^12 IU/L|CRI||ML/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|FRIEND|OTOLARYNGOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1973-05-13||||1968-07-21||1961-06-26|1968-01-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOL/G|MORPHOLOGIC CRI||TUBERCULIN UNIT/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|ADJUDICATION COMMITTEE|READER 3|NA|1||38||SCREENING|1962-10-26||||1973-03-16||1960-04-15|1973-04-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SBE/ML|QUANTIFIABLE MRD POSITIVITY||DIP|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|ADJUDICATOR|NEUROLOGIST 1|Y|1||38||OBSERVATION|1970-04-27||||1966-08-31||1965-06-04|1963-05-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||BONERESP|BONE RESPONSE||||NMOL/MOL|MORPHOLOGIC LEUKEMIA-FREE STATE||IU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|STUDY SUBJECT|UROLOGIST|NA|2||58||CONTINUATION TREATMENT|1972-06-25||||1961-12-09||1964-02-25|1964-11-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||MOLRESP|MOLECULAR RESPONSE||||AU/ML|ISD||LOG10 TCID 50/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|CLINICAL RESEARCH ASSOCIATE|READER|Y|2||58||TREATMENT|1970-09-27||||1966-03-19||1970-08-11|1969-07-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CCID 50/ML|TREATMENT FAILURE||TRANSDUCING UNIT|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|U|3||39||SCREENING|1964-10-03||||1963-04-03||1968-03-11|1968-07-29||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||GPL U/ML|SMD||CI/MG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3||39||CONTINUATION TREATMENT|1962-02-18||||1965-08-24||1964-02-19|1960-12-12||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||CLINRESP|CLINICAL RESPONSE||||K|NED||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|PARENT|OTOLARYNGOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1960-06-24||||1963-06-01||1967-12-06|1964-06-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DRAM|PDU||CMH2O/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1971-03-18||||1967-08-04||1966-01-30|1963-12-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||BESTRESP|BEST OVERALL RESPONSE||||ENZYME U|PMD||/4.0 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|INVESTIGATOR|PATHOLOGIST 2|N|5||7||BLINDED TREATMENT|1971-02-09||||1962-06-20||1963-11-09|1970-11-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^8/L|CHR||P|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|INDEPENDENT ASSESSOR|INTERNIST|NA|5||7||SCREENING|1972-03-09||||1969-09-25||1968-04-13|1969-05-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||PATHRESP|PATHOLOGIC RESPONSE||||HOMEOPATHIC DILUTION|NON-PD||KS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|FAMILY MEMBER|RADIOLOGIST 2|N|1||38||BASELINE|1967-04-05||||1969-01-17||1962-03-29|1966-04-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL BCE/NMOL|INDETERMINATE RESPONSE||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|VENDOR|READER|Y|1||38||RUN-IN|1963-12-31||||1967-07-30||1970-05-05|1969-12-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BQ|HI-P||RING|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|INVESTIGATOR|NEUROLOGIST|U|2||58||FOLLOW-UP|1965-05-24||||1972-11-11||1964-04-29|1971-02-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CAPSULE|MINOR PATHOLOGIC RESPONSE||ENZYME U/G HB|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|CHILD|OPTOMETRIST|N|2||58||BASELINE|1961-05-29||||1962-12-28||1960-06-21|1965-09-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/MIN/1.73M2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||NFIU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|ADJUDICATOR|ADJUDICATOR 3|NA|3||39||TREATMENT|1973-02-19||||1970-09-21||1969-02-09|1966-11-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/S|INDETERMINATE RESPONSE||ML/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||CONTINUATION TREATMENT|1960-05-15||||1973-08-05||1961-03-09|1971-01-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/G/MIN|MRD RELAPSE||UMOL/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|FAMILY MEMBER|NEUROLOGIST 1|U|4||88||BLINDED TREATMENT|1968-05-19||||1963-08-22||1962-06-21|1965-02-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||BONERESP|BONE RESPONSE||||KHZ|HI-N||ENZYME U/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|4||88||WASHOUT|1965-11-18||||1960-03-14||1967-11-21|1965-07-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||BESTRESP|BEST OVERALL RESPONSE||||SACHET|CYTOGENETIC MINOR RESPONSE||MPL U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|INVESTIGATOR|NEUROLOGIST 2|Y|5||7||WASHOUT|1963-05-05||||1969-07-25||1963-03-15|1967-12-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/HPF|MCR||NMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|INVESTIGATOR|NEUROLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1970-01-12||||1965-12-21||1961-06-07|1966-07-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/MIN|UNFAVORABLE RESPONSE||G/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1963-05-15||||1963-01-27||1972-10-06|1964-11-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||METSIND|METASTATIC INDICATOR||||PMOL/10^9 CELLS|HI-N||ML/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|1||38||INDUCTION TREATMENT|1962-11-14||||1966-02-12||1964-02-12|1968-08-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UKAT/10^12 RBC|MAJOR PATHOLOGIC RESPONSE||UG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|PROXY|READER 3|N|2||58||RUN-IN|1970-07-20||||1962-04-15||1967-02-07|1961-10-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||NEWLIND|NEW LESION INDICATOR||||TUBERCULIN UNIT|NPR||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|GUARDIAN|CARDIOLOGIST|N|2||58||OPEN LABEL TREATMENT|1973-05-11||||1969-10-14||1961-12-03|1963-01-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/KG/MIN|MRD RELAPSE||CI/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|CHILD|RADIOLOGIST 1|Y|3||39||OPEN LABEL TREATMENT|1968-01-06||||1966-10-03||1969-11-06|1972-05-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O/ML|PR WITH LYMPHOCYTOSIS||U/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|ADJUDICATION COMMITTEE|RATER|Y|3||39||LONG-TERM FOLLOW-UP|1966-01-23||||1964-05-28||1964-07-14|1965-02-20||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KM|ICR||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1967-10-29||||1962-11-12||1960-03-02|1961-10-23||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||NEWLIND|NEW LESION INDICATOR||||MG/CM2|ISD||YD|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|PROXY|INTERNIST|NA|4||88||BLINDED TREATMENT|1962-12-03||||1969-05-19||1965-09-22|1966-11-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BE/ML|OPTIMAL MORPHOLOGIC RESPONSE||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|5||7||RUN-IN|1967-05-05||||1973-02-05||1962-04-11|1969-09-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL/DAY|HI-P||UKAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|5||7||BLINDED TREATMENT|1971-09-20||||1964-07-25||1972-11-13|1961-09-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/M2/H|UNFAVORABLE RESPONSE||ANTIBODY UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|1||38||WASHOUT|1972-08-09||||1970-11-23||1965-11-24|1968-06-26||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/10^12 RBC|CR-CT||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|GUARDIAN|ONCOLOGIST 2|NA|1||38||OBSERVATION|1964-09-17||||1972-02-20||1968-08-12|1964-07-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||BQ/KG|PD-CT||MMHG/L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|2||58||OPEN LABEL TREATMENT|1971-12-17||||1962-03-30||1965-10-11|1968-02-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|NE||MBQ/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|FAMILY MEMBER|ADJUDICATOR 2|Y|2||58||TREATMENT|1961-05-17||||1962-07-02||1965-01-29|1965-04-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||SPLNRESP|SPLEEN RESPONSE||||MG/KG/MIN|MAJOR PATHOLOGIC RESPONSE||U/MG|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|Y|PARENT|DERMATOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1962-01-26||||1970-04-24||1966-05-31|1960-10-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/MMHG/MIN/L|SD-CT||UL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|FAMILY MEMBER|READER|Y|3||39||BLINDED TREATMENT|1968-02-11||||1966-05-25||1970-07-16|1961-04-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||STRUSTAT|STEROID USE STATUS||||MMHG/L/MIN|INDETERMINATE RESPONSE||UMOL/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|PROXY|PHYSIOTHERAPIST|NA|4||88||OBSERVATION|1963-04-27||||1964-02-10||1968-05-23|1966-11-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||TMRESP|TUMOR MARKER RESPONSE||||DRAM|CCR||MS2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|4||88||FOLLOW-UP|1965-01-18||||1969-07-10||1970-12-04|1971-05-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^12/L|MRD RELAPSE||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|ADJUDICATOR|RADIOLOGIST 1|Y|5||7||TREATMENT|1962-05-19||||1968-12-02||1961-11-12|1963-05-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||METSIND|METASTATIC INDICATOR||||SHOCK WAVE|MRD PERSISTENCE||AMFI|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|GUARDIAN|CLINICAL PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1970-02-21||||1972-10-19||1967-02-04|1963-02-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/MIN|INCREASED||U/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|CAREGIVER|HEMATOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1960-09-29||||1963-07-01||1972-09-25|1967-02-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMU/ML|CR||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|CAREGIVER|DERMATOLOGIST|U|1||38||CONTINUATION TREATMENT|1972-03-28||||1961-04-02||1963-05-09|1961-06-01||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI/MG|EQUIVOCAL||RFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|FAMILY MEMBER|READER 3|N|2||58||WASHOUT|1963-08-21||||1964-06-28||1961-03-28|1960-05-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|2||||||BONERESP|BONE RESPONSE||||MV/SEC|PSEUDOPROGRESSION||LB|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|PARENT|RADIOLOGIST 2|N|2||58||CONTINUATION TREATMENT|1963-08-06||||1964-01-23||1960-07-24|1964-01-02||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI/UL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||WEEKS|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|3||39||RUN-IN|1972-02-19||||1969-03-30||1966-10-03|1971-10-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PATCH|PD/RELAPSE AFTER HI||CI/UL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|GUARDIAN|READER 2|Y|3||39||OPEN LABEL TREATMENT|1967-11-20||||1972-01-30||1964-11-01|1962-04-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UU/L|SD||KM/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|Y|4||88||FOLLOW-UP|1967-11-28||||1970-01-28||1968-06-10|1971-01-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|2||||||LIVRRESP|LIVER RESPONSE||||CM/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UEQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|4||88||SCREENING|1971-11-08||||1965-09-26||1962-11-22|1961-10-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DPM/MG|ICPD||UKAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|5||7||BASELINE|1966-09-06||||1962-02-25||1972-11-07|1964-02-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|A108F408-906C-4320-965A-D5D295BC5C31|2||||||BONERESP|BONE RESPONSE||||CYCLE/MIN|MAJOR PATHOLOGIC RESPONSE||MIN*MG/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|FAMILY MEMBER|READER|NA|5||7||OBSERVATION|1966-02-03||||1967-01-09||1966-12-23|1969-11-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||BONERESP|BONE RESPONSE||||MM/SEC|CRI||LM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|INTERVIEWER|ADJUDICATOR|N|1||38||RUN-IN|1961-12-26||||1964-07-08||1971-05-24|1964-12-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UEQ|QUANTIFIABLE MRD POSITIVITY||UMOL/L/SEC|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|SIGNIFICANT OTHER|PATHOLOGIST 2|U|1||38||FOLLOW-UP|1964-11-25||||1963-04-26||1965-04-28|1970-06-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FMOL/L/SEC|NPR||NM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|PROXY|NEUROLOGIST 1|U|2||58||TREATMENT|1971-06-21||||1971-12-17||1965-06-11|1961-09-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/H|CPR||VP/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|DOMESTIC PARTNER|READER|U|2||58||CONTINUATION TREATMENT|1961-05-01||||1972-12-30||1966-12-03|1963-03-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/M2/DAY|CR||PT_BR|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1971-09-28||||1960-02-18||1964-05-11|1969-04-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 CFU/G|NON-QUANTIFIABLE MRD POSITIVITY||MBP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|PROXY|CLINICAL PATHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1969-01-08||||1962-07-27||1960-07-14|1966-08-03||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MCI/KG|MRD PERSISTENCE||APPLICATION|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|VENDOR|READER|U|4||88||WASHOUT|1968-10-15||||1960-02-09||1971-11-24|1962-08-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||LIVRRESP|LIVER RESPONSE||||BP|SMD||V/V|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1965-04-22||||1966-06-01||1968-08-29|1964-11-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||BESTRESP|BEST OVERALL RESPONSE||||TROCHE|PARTIAL MORPHOLOGIC RESPONSE||MEQ/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|PROXY|OTOLARYNGOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1966-08-03||||1969-03-02||1960-07-22|1966-12-31||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||MOLRESP|MOLECULAR RESPONSE||||10^9 CFU|IPR||CCID 50/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|5||7||TREATMENT|1967-09-03||||1960-01-22||1968-10-15|1973-05-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MPS U|MORPHOLOGIC CR||APPLICATION|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INTERVIEWER|MICROSCOPIST 3|NA|1||38||INDUCTION TREATMENT|1964-02-20||||1960-11-12||1961-03-23|1963-02-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||NEWLPROG|NEW LESION PROGRESSION||||UG/KG|IMMUNOPHENOTYPIC CR||CI/UG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|1||38||WASHOUT|1966-10-16||||1968-03-14||1972-02-28|1973-04-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MEQ/KG|PD-CT||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|CAREGIVER|RADIOLOGIST 1|Y|2||58||WASHOUT|1960-06-01||||1968-02-22||1966-06-13|1964-10-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||BONERESP|BONE RESPONSE||||NMOL|IMMUNOPHENOTYPIC CR||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|SIBLING|OPHTHALMOLOGIST|Y|2||58||INDUCTION TREATMENT|1967-10-22||||1968-01-18||1964-01-16|1973-05-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CMHG|NR||/LPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1961-07-10||||1963-10-03||1968-01-25|1970-10-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||BONERESP|BONE RESPONSE||||10^6 ORGANISMS/MG|PSA PROGRESSION||MBQ/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CHILD|ONCOLOGIST 1|N|3||39||BASELINE|1968-10-11||||1960-06-09||1969-01-12|1965-06-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 DNA COPIES/ML|NON-CR/NON-PD||/MM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|INVESTIGATOR|PATHOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1970-04-18||||1967-04-26||1970-04-30|1965-08-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||MOLRESP|MOLECULAR RESPONSE||||/MBP|NON-ICR/NON-IUPD||FMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|4||88||BASELINE|1964-01-11||||1962-03-10||1970-05-12|1967-09-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||MOLRESP|MOLECULAR RESPONSE||||SIEMENS|MRD NEGATIVITY||PRESSOR UNITS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|CAREGIVER|MICROSCOPIST 1|NA|5||7||OPEN LABEL TREATMENT|1967-07-06||||1965-03-29||1966-06-26|1970-10-08||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MS/MMHG|DISEASE TRANSFORMATION||HEP|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|STUDY SUBJECT|READER 2|N|5||7||TREATMENT|1967-11-21||||1968-07-25||1973-09-07|1967-03-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||METBRESP|METABOLIC RESPONSE||||MMHG|IMPROVED||ML/BREATH|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|INDEPENDENT ASSESSOR|RADIOLOGIST 2|Y|1||38||BLINDED TREATMENT|1971-10-27||||1972-05-16||1963-03-17|1966-10-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3/L|PARTIAL MORPHOLOGIC RESPONSE||BOTTLE|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|PARENT|READER 3|U|1||38||RUN-IN|1962-05-19||||1965-12-11||1965-04-06|1968-06-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||TMRESP|TUMOR MARKER RESPONSE||||MBQ/UL|PR-CT||UMOL/H/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||TREATMENT|1972-12-19||||1973-06-16||1968-08-21|1969-04-05||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PPTH|CCR||UG/ML/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|FRIEND|ADJUDICATOR|NA|2||58||RUN-IN|1970-01-16||||1973-06-15||1972-02-25|1965-05-02||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||METBRESP|METABOLIC RESPONSE||||DAGU|FAVORABLE RESPONSE||CAPLET|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|STUDY SUBJECT|OTOLARYNGOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1967-02-14||||1961-08-09||1966-03-18|1963-12-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ARBITRARY U|SCR||UM/S|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|ADJUDICATOR|INTERNIST|NA|3||39||OPEN LABEL TREATMENT|1970-08-24||||1970-02-14||1964-10-18|1973-02-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MMOL/L|NON-PD||STEPS/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|4||88||TREATMENT|1965-07-11||||1970-05-11||1965-07-24|1966-10-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DPM/100MG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||VP/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1973-05-08||||1966-09-24||1968-04-03|1969-04-08||DURING||DURING|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MS/MMHG|SMD||STRIP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|HEALTH CARE PROFESSIONAL|READER 3|U|5||7||WASHOUT|1965-02-20||||1970-08-02||1965-02-09|1960-01-11||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MMOL/MIN/KPA/L|PD FROM PR||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|5||7||RUN-IN|1971-02-13||||1962-08-02||1972-12-03|1965-12-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||MOLRESP|MOLECULAR RESPONSE||||DEG|CRI||LM|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|1||38||OPEN LABEL TREATMENT|1973-03-20||||1962-12-09||1964-09-26|1964-07-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||OSM|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|1||38||INDUCTION TREATMENT|1968-01-24||||1969-02-12||1960-04-18|1964-05-12||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||EIA UNIT|PD-CT||CUP EQ|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|VENDOR|OPHTHALMOLOGIST|U|2||58||CONTINUATION TREATMENT|1961-12-09||||1968-04-23||1964-09-17|1966-02-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||METBRESP|METABOLIC RESPONSE||||ML/100G/MIN|NON-QUANTIFIABLE MRD POSITIVITY||UKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|VENDOR|READER|Y|2||58||RUN-IN|1965-05-12||||1969-07-04||1972-07-30|1965-02-12||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||SPLNRESP|SPLEEN RESPONSE||||TAMPON|PD/RELAPSE AFTER HI||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|3||39||SCREENING|1960-04-08||||1972-03-05||1963-09-12|1968-04-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||METSIND|METASTATIC INDICATOR||||NU/CL|MORPHOLOGIC CRI||L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|GUARDIAN|MICROSCOPIST 2|Y|3||39||INDUCTION TREATMENT|1972-05-23||||1967-07-14||1973-01-25|1962-09-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/UG|CR||M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|4||88||LONG-TERM FOLLOW-UP|1971-08-15||||1960-02-13||1964-02-12|1960-01-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/DOSE|ISD||BQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|4||88||WASHOUT|1968-08-28||||1965-05-09||1968-07-11|1965-10-25||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MM2|MOLECULAR CR||PACK YEAR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|SIBLING|CARDIOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1967-06-13||||1963-04-24||1964-05-29|1971-01-31||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/MOL|NON-ICR/NON-IUPD||NCI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|VENDOR|MICROSCOPIST 2|U|5||7||WASHOUT|1971-02-19||||1961-09-23||1971-02-21|1971-07-03||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^9/DOSE|STABLE||MG/L FEU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|1||38||WASHOUT|1961-10-08||||1970-10-01||1960-12-28|1963-11-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||MOLRESP|MOLECULAR RESPONSE||||MBQ|NON-QUANTIFIABLE MRD POSITIVITY||H*%|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|FRIEND|READER 2|U|1||38||OBSERVATION|1962-11-06||||1962-04-30||1971-09-15|1973-02-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||TRGRESP|TARGET RESPONSE||||KV|TREATMENT FAILURE||LOG10 TCID 50/UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|FAMILY MEMBER|OPTOMETRIST|Y|2||58||TREATMENT|1964-02-11||||1968-05-17||1964-12-02|1972-06-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 IU/ML|HI-E||L/H/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|2||58||WASHOUT|1967-07-02||||1963-02-09||1962-01-01|1968-08-07||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AMOL|CR||LOG10 TCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|INVESTIGATOR|MICROSCOPIST|Y|3||39||INDUCTION TREATMENT|1966-11-23||||1970-03-19||1970-01-23|1971-12-27||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UKAT/L|MOLECULAR MAJOR RESPONSE||CUP|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||OPEN LABEL TREATMENT|1966-03-21||||1973-07-27||1971-03-29|1972-03-17||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||MOLRESP|MOLECULAR RESPONSE||||UMOL|ABSENT MORPHOLOGIC RESPONSE||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|ADJUDICATOR|ADJUDICATOR 1|N|4||88||OPEN LABEL TREATMENT|1972-02-25||||1964-10-27||1973-08-26|1973-08-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||LENS|PR||KG/CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|N|4||88||FOLLOW-UP|1969-01-04||||1965-06-22||1967-07-01|1962-07-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/M2|IUPD||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|CAREGIVER|ADJUDICATOR 3|N|5||7||INDUCTION TREATMENT|1964-05-06||||1967-06-24||1964-06-01|1971-01-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/MIN|ICPD||STEPS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|5||7||RUN-IN|1965-10-02||||1966-01-23||1966-02-15|1969-03-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/M2/H|PDU||ML/MIN/MMHG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|GUARDIAN|ONCOLOGIST 2|NA|1||38||OPEN LABEL TREATMENT|1971-12-01||||1961-04-17||1973-08-17|1965-12-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||CLINRESP|CLINICAL RESPONSE||||IU/G HB|IPR||MU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|ADJUDICATION COMMITTEE|READER|U|1||38||OPEN LABEL TREATMENT|1960-04-11||||1962-12-04||1965-10-05|1965-08-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||MOLRESP|MOLECULAR RESPONSE||||S*KPA|PD||EU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|VENDOR|INTERNIST|NA|2||58||FOLLOW-UP|1964-02-28||||1962-06-09||1966-01-10|1972-07-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PMOL/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^7 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|DOMESTIC PARTNER|PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1967-04-07||||1962-03-18||1966-02-04|1971-05-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/ANIMAL|MRD RELAPSE||UG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|U|3||39||TREATMENT|1972-10-29||||1967-07-11||1973-01-07|1967-10-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/KG/MIN|IUPD||TUBERCULIN UNIT/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|SPOUSE|READER|Y|3||39||OPEN LABEL TREATMENT|1965-03-04||||1964-07-19||1968-12-07|1966-07-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3/L|CYTOGENETIC MINIMAL RESPONSE||MU|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|CHILD|PATHOLOGIST 1|U|4||88||BASELINE|1961-06-05||||1960-04-20||1965-07-14|1965-01-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UU/L|PSEUDOPROGRESSION||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|INTERVIEWER|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1964-07-14||||1973-05-22||1966-11-10|1963-03-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TITER|MRD RELAPSE||UMOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|5||7||BASELINE|1962-10-02||||1970-11-02||1972-05-26|1960-03-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||MOLRESP|MOLECULAR RESPONSE||||BAU/ML|MRD NEGATIVITY||CI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|GUARDIAN|MICROSCOPIST 3|Y|5||7||WASHOUT|1963-05-22||||1968-06-06||1972-02-17|1971-12-22||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||BESTRESP|BEST OVERALL RESPONSE||||CIGAR|CA125 75% RESPONSE||UG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|SPOUSE|HEMATOLOGIST|U|1||38||SCREENING|1968-04-23||||1971-12-09||1973-06-06|1966-12-22||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FRAMES/S|CYTOGENETIC MINIMAL RESPONSE||KN/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|STUDY SUBJECT|OTOLARYNGOLOGIST|N|1||38||BLINDED TREATMENT|1962-12-12||||1969-07-13||1964-03-26|1968-07-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KIT|PR||TAMPON|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|DOMESTIC PARTNER|READER|NA|2||58||INDUCTION TREATMENT|1961-12-09||||1972-09-01||1973-03-09|1973-01-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||BONERESP|BONE RESPONSE||||UMOL/L/SEC|MOLECULAR CR||TORR|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|SIBLING|READER 3|N|2||58||CONTINUATION TREATMENT|1970-09-03||||1971-06-29||1966-06-05|1963-08-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL BCE/MMOL|MCR||NEBULE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|CAREGIVER|ONCOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1973-07-14||||1962-06-26||1961-10-06|1970-02-23||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CYCLE/MIN|PR||PMOL/10^9 CELLS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|DOMESTIC PARTNER|RADIOLOGIST 1|N|3||39||INDUCTION TREATMENT|1966-10-09||||1968-03-21||1971-04-29|1968-03-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||NEWLPROG|NEW LESION PROGRESSION||||MEQ/L|MORPHOLOGIC CR||MMHG*MIN/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|FRIEND|ENDOCRINOLOGIST|NA|4||88||BLINDED TREATMENT|1960-04-17||||1971-09-27||1964-01-15|1962-12-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MMAL|MINOR PATHOLOGIC RESPONSE||WAFER|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|DOMESTIC PARTNER|RADIOLOGIST 1|Y|4||88||SCREENING|1960-10-14||||1960-02-18||1963-06-29|1970-04-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||V|PMR||CM/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|ADJUDICATOR|ENDOCRINOLOGIST|NA|5||7||BASELINE|1960-04-14||||1965-10-31||1962-08-20|1965-06-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||NTRGRESP|NON-TARGET RESPONSE||||PFU/DOSE|NOT ALL EVALUATED||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|SIBLING|READER 1|Y|5||7||FOLLOW-UP|1963-07-21||||1967-11-21||1961-02-09|1968-01-20||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/KG|PSA PROGRESSION||AGU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|PARENT|RATER|N|1||38||INDUCTION TREATMENT|1970-11-30||||1960-02-02||1966-11-07|1967-10-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PIXEL|ISD||BOX|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|1||38||INDUCTION TREATMENT|1961-03-03||||1962-03-29||1962-11-28|1971-11-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||MOLRESP|MOLECULAR RESPONSE||||10^6 ORGANISMS/G|NON-QUANTIFIABLE MRD POSITIVITY||ML/G/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|ADJUDICATION COMMITTEE|UROLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1962-01-22||||1970-01-09||1964-10-27|1973-07-29||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||STRUSTAT|STEROID USE STATUS||||LINEAR FT*LB|PD/RELAPSE AFTER HI||MCI|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|2||58||CONTINUATION TREATMENT|1971-09-05||||1972-12-05||1970-05-07|1965-02-11||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MG/MOL|INDETERMINATE RESPONSE||P|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|INTERVIEWER|PATHOLOGIST|Y|3||39||INDUCTION TREATMENT|1969-07-15||||1963-02-20||1964-03-11|1965-02-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG|RELAPSED DISEASE FROM CR||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|INVESTIGATOR|PATHOLOGIST 1|NA|3||39||OBSERVATION|1963-07-03||||1961-04-20||1965-09-23|1972-05-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/DL|INDETERMINATE RESPONSE||ML/CAGE/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|SIBLING|RADIOLOGIST 1|Y|4||88||SCREENING|1963-06-24||||1964-09-09||1970-04-22|1963-08-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/MIN|SCR||ML/CAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|4||88||TREATMENT|1960-08-05||||1972-05-18||1960-09-06|1970-08-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||NEWLIND|NEW LESION INDICATOR||||UL/ML|CYTOGENETIC MINOR RESPONSE||RNA COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|N|5||7||BLINDED TREATMENT|1965-07-09||||1963-10-02||1970-08-29|1961-01-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/L|MR||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|CLINICAL RESEARCH COORDINATOR|READER 3|NA|5||7||WASHOUT|1971-09-29||||1961-01-17||1966-07-23|1962-02-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||CLINRESP|CLINICAL RESPONSE||||ML/BEAT|PDU||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|VENDOR|RADIOLOGIST|U|1||38||BASELINE|1961-07-27||||1968-05-29||1966-12-08|1969-10-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 IU/ML|PMD||MET|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||TREATMENT|1964-02-27||||1972-05-20||1961-12-11|1967-07-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||METBRESP|METABOLIC RESPONSE||||DAYS|PD-CT||G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|STUDY SUBJECT|RATER|Y|2||58||INDUCTION TREATMENT|1963-05-04||||1968-02-07||1971-10-15|1968-06-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML|FAVORABLE RESPONSE||KA_U/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|DOMESTIC PARTNER|READER|U|2||58||OPEN LABEL TREATMENT|1968-02-11||||1972-02-10||1965-10-23|1966-02-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UU/L|SCR||UL/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|SIBLING|MICROSCOPIST 2|NA|3||39||INDUCTION TREATMENT|1972-11-24||||1969-07-27||1971-08-28|1967-06-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CM|HI-E||MMOL/MIN/KPA|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1970-05-11||||1967-04-24||1962-04-29|1966-08-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NG|CYTOGENETIC NO RESPONSE||NMOL/MOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|FRIEND|ENDOCRINOLOGIST|Y|4||88||OBSERVATION|1971-11-27||||1960-05-02||1962-11-23|1963-08-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||METSIND|METASTATIC INDICATOR||||MEQ/KG|NED||DEG/MM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 1|U|4||88||TREATMENT|1972-04-21||||1964-09-14||1965-04-01|1964-01-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CIGARETTE|MORPHOLOGIC CR||ENZYME U/M2|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|GUARDIAN|MICROSCOPIST 3|Y|5||7||BLINDED TREATMENT|1972-04-29||||1960-11-09||1968-12-19|1973-02-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^3 CFU|PD-CT||10^6 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|SIBLING|PHYSIOTHERAPIST|Y|5||7||WASHOUT|1964-02-06||||1972-01-12||1967-10-05|1973-06-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||APL U/ML|NPR||NMOL BCE/NMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|INVESTIGATOR|UROLOGIST|N|1||38||OBSERVATION|1967-04-13||||1961-02-18||1960-10-14|1961-07-03||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||APL U|PR-CT||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|1||38||SCREENING|1972-06-15||||1965-04-24||1964-06-14|1969-02-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SCOOPFUL|PR||PIXELS/IN|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|PROXY|OPHTHALMOLOGIST|N|2||58||SCREENING|1964-11-13||||1968-06-02||1969-02-10|1960-01-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/M2|OPTIMAL MORPHOLOGIC RESPONSE||GPS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|CAREGIVER|READER 3|Y|2||58||BLINDED TREATMENT|1969-06-09||||1972-04-18||1969-04-11|1973-06-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||ANATRESP|ANATOMIC RESPONSE||||BREATHS/MIN|MOLECULAR CR||CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|CHILD|ONCOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1962-04-20||||1962-04-15||1966-06-19|1967-08-14||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||NFIU|NON-CR/NON-PD||MCI/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|ADJUDICATION COMMITTEE|READER 2|N|3||39||SCREENING|1960-12-18||||1971-04-06||1967-05-23|1961-01-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||LIVRRESP|LIVER RESPONSE||||DPM/100MG|VGPR||MMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|VENDOR|RADIOLOGIST|Y|4||88||TREATMENT|1962-05-20||||1962-04-16||1965-03-09|1966-12-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||NEWLIND|NEW LESION INDICATOR||||KG/L|MORPHOLOGIC CR||ENZYME U/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|STUDY SUBJECT|OPTOMETRIST|NA|4||88||TREATMENT|1971-05-28||||1968-07-06||1967-03-19|1966-05-21||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||MOLRESP|MOLECULAR RESPONSE||||NMOL/G|MORPHOLOGIC CRI||PPM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|DOMESTIC PARTNER|RADIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1966-04-07||||1969-05-14||1960-10-16|1963-05-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MESF|PSEUDOPROGRESSION||MPS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5||7||INDUCTION TREATMENT|1973-01-29||||1970-05-10||1961-12-22|1967-03-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BREATHS/MIN|MORPHOLOGIC CR||KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|SIBLING|PATHOLOGIST 2|NA|1||38||OBSERVATION|1963-07-23||||1972-11-14||1964-05-18|1966-11-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/CM H2O|PMR||ANTIBODY UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|VENDOR|ENDOCRINOLOGIST|N|1||38||BASELINE|1961-03-08||||1969-06-22||1965-12-02|1970-08-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^5/L|MOLECULAR MAJOR RESPONSE||MS2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|STUDY SUBJECT|RATER 2|Y|2||58||INDUCTION TREATMENT|1973-07-08||||1966-07-06||1970-10-15|1964-04-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||CLINRESP|CLINICAL RESPONSE||||EJACULATE U|ICR||LOG10 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|PARENT|OTOLARYNGOLOGIST|U|2||58||BASELINE|1964-01-27||||1964-05-09||1962-09-11|1966-11-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/DOSE|UNEQUIVOCAL||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|3||39||FOLLOW-UP|1961-09-15||||1964-03-26||1961-10-08|1961-02-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MANSON U/ML|PDU||10^3 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|N|3||39||BASELINE|1963-02-28||||1961-12-27||1966-01-23|1967-10-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||OVRLRESP|OVERALL RESPONSE||||NMOL/DAY|PSEUDOPROGRESSION||MILE|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|STUDY SUBJECT|ONCOLOGIST|NA|4||88||INDUCTION TREATMENT|1965-09-25||||1970-04-09||1970-10-09|1962-12-06||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UCI/KG|QUANTIFIABLE MRD POSITIVITY||L/H/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|STUDY SUBJECT|RATER 2|N|4||88||BASELINE|1961-11-05||||1968-10-25||1966-02-28|1969-06-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||LIVRRESP|LIVER RESPONSE||||PIXELS/CM|PSA PROGRESSION||CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|5||7||LONG-TERM FOLLOW-UP|1960-08-22||||1969-07-14||1963-02-05|1969-02-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MKAT|MRD NEGATIVITY||DEG2|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|FRIEND|RADIOLOGIST 1|N|5||7||RUN-IN|1962-11-06||||1967-03-27||1970-05-01|1969-10-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MIN/DAY|CYTOGENETIC CR||INHALATION|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|PARENT|RATER|N|1||38||LONG-TERM FOLLOW-UP|1963-08-05||||1962-07-28||1960-01-04|1968-12-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MM/SEC|RELAPSED DISEASE FROM CR OR PR||CAPSULE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CAREGIVER|RATER|NA|1||38||RUN-IN|1960-12-12||||1965-12-10||1960-03-31|1970-01-30||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FT|CR||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|DOMESTIC PARTNER|READER 2|N|2||58||FOLLOW-UP|1970-12-25||||1973-07-29||1966-07-13|1969-04-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||BONERESP|BONE RESPONSE||||BQ/ML|PSEUDOPROGRESSION||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|INVESTIGATOR|PATHOLOGIST 2|N|2||58||WASHOUT|1970-11-08||||1965-01-31||1968-02-22|1965-04-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||K|NON-ICR/NON-IUPD||ML/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|FAMILY MEMBER|RADIOLOGIST|NA|3||39||SCREENING|1966-07-24||||1970-06-14||1960-11-25|1968-10-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/ML|IMMUNOPHENOTYPIC CR||G/DL|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|3||39||TREATMENT|1970-05-29||||1966-05-15||1962-07-10|1961-08-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MEQ/MMOL|NE||TRANSDUCING UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|PARENT|PATHOLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1962-06-25||||1960-06-17||1960-03-17|1972-05-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||OVRLRESP|OVERALL RESPONSE||||BQ/UG|OPTIMAL MORPHOLOGIC RESPONSE||ML/G/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|4||88||WASHOUT|1971-03-21||||1962-07-04||1965-08-20|1970-02-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||SPLNRESP|SPLEEN RESPONSE||||TAMPON|SD-CT||UG/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|PROXY|OPHTHALMOLOGIST|N|5||7||BLINDED TREATMENT|1972-05-26||||1973-02-25||1962-02-03|1962-03-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||TRGRESP|TARGET RESPONSE||||TUBERCULIN UNIT/ML|UNFAVORABLE RESPONSE||MV2/HZ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|5||7||BLINDED TREATMENT|1961-03-08||||1969-12-17||1971-10-17|1970-10-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CAPSULE|PSEUDORESPONSE||PACKET|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|ADJUDICATOR|RATER 1|Y|1||38||CONTINUATION TREATMENT|1970-03-25||||1970-11-02||1962-02-09|1972-05-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||ANATRESP|ANATOMIC RESPONSE||||MMHG/SEC|IPR||U/M2/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|FRIEND|PHYSIOTHERAPIST|N|1||38||BASELINE|1972-02-04||||1962-06-26||1961-07-29|1970-11-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/MMHG/MIN/L|PSEUDORESPONSE||BOX|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|SIBLING|HEMATOLOGIST|U|2||58||OBSERVATION|1970-04-11||||1967-05-18||1963-07-13|1973-01-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||L/DAY|PD-CT||LOG10 PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|CLINICAL STUDY SPONSOR|READER 3|Y|2||58||INDUCTION TREATMENT|1967-05-16||||1962-11-08||1971-04-27|1968-08-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MM3/MM2/YEAR|MR||ANSON U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|DOMESTIC PARTNER|OPTOMETRIST|Y|3||39||FOLLOW-UP|1962-02-27||||1965-08-07||1970-08-28|1966-06-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||SPLNRESP|SPLEEN RESPONSE||||10^3 ORGANISMS/G|CA125 75% RESPONSE||GTT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|SPOUSE|RADIOLOGIST 2|Y|3||39||BLINDED TREATMENT|1961-12-28||||1967-05-14||1973-03-10|1966-04-28||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||NTRGRESP|NON-TARGET RESPONSE||||PT_BR|INDETERMINATE RESPONSE||G/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|4||88||CONTINUATION TREATMENT|1967-07-16||||1960-10-09||1968-04-18|1960-04-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMHG/SEC|NOT ALL EVALUATED||IU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|4||88||BASELINE|1961-11-28||||1965-03-01||1972-02-08|1968-06-16||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^9 ORGANISMS|CYTOGENETIC PR||/100 WBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CHILD|OTOLARYNGOLOGIST|N|5||7||TREATMENT|1963-11-23||||1960-03-13||1970-07-27|1971-09-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/L|ICR||MOL/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|READER 1|U|5||7||RUN-IN|1963-02-16||||1964-03-24||1963-11-10|1965-12-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DAGU|CRI||KN/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|1||38||OPEN LABEL TREATMENT|1970-10-20||||1964-01-14||1971-04-16|1968-12-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^3 ORGANISMS/G|PMD||MEQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|CHILD|ADJUDICATOR|N|1||38||WASHOUT|1968-04-01||||1969-12-09||1968-06-22|1968-01-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/M2|EQUIVOCAL||ML/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|SPOUSE|PATHOLOGIST 2|U|2||58||OBSERVATION|1963-11-15||||1960-01-09||1960-07-30|1968-02-23||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MANSON U/ML|COMPLETE MRD RESPONSE||CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|SIBLING|PATHOLOGIST|N|2||58||OBSERVATION|1961-10-12||||1962-08-07||1971-01-18|1970-01-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||BONERESP|BONE RESPONSE||||PG|CYTOGENETIC PR||GPELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|SPOUSE|CARDIOLOGIST|NA|3||39||BASELINE|1964-11-20||||1967-04-05||1972-05-18|1969-11-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||CYTORESP|CYTOGENETIC RESPONSE||||LB|NON-PD||G/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|SIGNIFICANT OTHER|MICROSCOPIST|NA|3||39||BLINDED TREATMENT|1960-03-08||||1969-07-29||1971-09-22|1972-09-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MMHG*MIN/L|PD||%/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|STUDY SUBJECT|INTERNIST|Y|4||88||BLINDED TREATMENT|1962-08-29||||1968-09-11||1963-08-19|1960-11-05||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/S|NON-QUANTIFIABLE MRD POSITIVITY||10^3 COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|ADJUDICATOR|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1964-10-27||||1969-08-19||1966-05-31|1969-06-22||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||ANATRESP|ANATOMIC RESPONSE||||10^6/L|COMPLETE MRD RESPONSE||CY/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|CAREGIVER|ADJUDICATOR|Y|5||7||OBSERVATION|1961-06-26||||1963-07-06||1970-01-26|1960-01-05||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/G/DAY|MOLECULAR MAJOR RESPONSE||FEU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|GUARDIAN|NEUROLOGIST 1|Y|5||7||BLINDED TREATMENT|1969-03-20||||1968-10-02||1969-08-03|1966-03-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/M2/MIN|IMPROVED||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|PARENT|CLINICAL PATHOLOGIST|U|1||38||RUN-IN|1969-11-27||||1960-12-01||1963-06-12|1973-04-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||CLINRESP|CLINICAL RESPONSE||||GPL U/ML|ABSENT MORPHOLOGIC RESPONSE||PMOL/10^10 CELLS|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|SIBLING|NEUROLOGIST 1|Y|1||38||WASHOUT|1960-10-16||||1963-06-23||1961-07-24|1971-08-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||M|TREATMENT FAILURE||10^5/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|PARENT|PEDIATRIC NEUROLOGIST|U|2||58||SCREENING|1973-03-08||||1971-01-22||1973-04-30|1973-03-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ELISA UNIT|PDU||10^6 DNA COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|PROXY|NEUROLOGIST 1|NA|2||58||WASHOUT|1969-03-12||||1967-02-27||1967-06-15|1969-03-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UMOL/L/SEC|MRD RELAPSE||10^6/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CAREGIVER|DERMATOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1973-07-03||||1972-02-20||1962-05-21|1961-01-25||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MOL/DAY|PARTIAL MORPHOLOGIC RESPONSE||ENZYME U|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|FRIEND|OTOLARYNGOLOGIST|NA|3||39||CONTINUATION TREATMENT|1970-02-10||||1968-05-19||1967-02-18|1966-02-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||ANATRESP|ANATOMIC RESPONSE||||HR/DAY|IUPD||10^11/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|CLINICAL STUDY SPONSOR|UROLOGIST|U|4||88||BLINDED TREATMENT|1965-06-17||||1970-03-13||1961-06-04|1966-04-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||K|PMR||/10^5|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|CHILD|ADJUDICATOR 1|N|4||88||TREATMENT|1968-03-14||||1973-08-09||1969-04-18|1965-03-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/M2/H|CPR||PA|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|DOMESTIC PARTNER|RADIOLOGIST 2|Y|5||7||TREATMENT|1965-07-04||||1963-09-20||1962-04-22|1973-09-07||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||GBQ/MG|SD-CT||FT3|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|INTERVIEWER|PATHOLOGIST 2|N|5||7||WASHOUT|1964-02-13||||1970-07-10||1963-08-02|1970-09-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||TMRESP|TUMOR MARKER RESPONSE||||PFU/ML|PCR||PPB|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|PROXY|MICROSCOPIST|Y|1||38||BLINDED TREATMENT|1960-05-28||||1964-04-18||1972-09-13|1969-05-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||STEPS|MOLECULAR CR||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|CHILD|ADJUDICATOR 2|NA|1||38||SCREENING|1972-12-21||||1973-01-29||1968-08-15|1972-04-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/M2/MIN|IPR||%/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|PARENT|PATHOLOGIST|N|2||58||WASHOUT|1966-02-21||||1967-09-23||1966-04-29|1960-12-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/M2/H|PMR||ELISA UNIT/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|INTERNIST|Y|2||58||INDUCTION TREATMENT|1971-12-31||||1967-01-18||1970-04-29|1965-10-31||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CI/MG|PD/RELAPSE AFTER HI||10^6 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|PROXY|RATER|U|3||39||BLINDED TREATMENT|1967-12-09||||1965-01-23||1968-02-02|1964-02-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||TRGRESP|TARGET RESPONSE||||DYN|PR-CT||KDA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|INVESTIGATOR|NEUROLOGIST 1|Y|3||39||TREATMENT|1966-01-23||||1967-02-07||1970-12-30|1972-09-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||OVRLRESP|OVERALL RESPONSE||||MET*H|COMPLETE MRD RESPONSE||PELLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|4||88||TREATMENT|1964-06-18||||1966-09-29||1960-12-29|1960-02-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||NTRGRESP|NON-TARGET RESPONSE||||UV2|HI-N||CS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|SIBLING|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1971-10-07||||1972-07-12||1961-01-11|1966-02-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||OVRLRESP|OVERALL RESPONSE||||V|PSA PROGRESSION||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|CAREGIVER|READER|NA|5||7||BASELINE|1966-01-29||||1971-06-15||1965-12-15|1966-09-12||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||FMOL|CRI||/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|SPOUSE|RATER 1|Y|5||7||LONG-TERM FOLLOW-UP|1964-05-16||||1973-08-16||1971-11-18|1961-10-26||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CI/L|PD FROM PR||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|1||38||TREATMENT|1960-02-14||||1969-04-15||1966-03-28|1967-11-28||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||METSIND|METASTATIC INDICATOR||||SHOCK WAVE|CYTOGENETIC CR||V/V|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|GUARDIAN|ONCOLOGIST 2|U|1||38||BASELINE|1969-12-17||||1969-10-24||1963-04-04|1965-01-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||NTRGRESP|NON-TARGET RESPONSE||||PATCH|VGPR||ML/CM H2O|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|VENDOR|PHYSIOTHERAPIST|Y|2||58||TREATMENT|1966-10-23||||1962-12-23||1967-07-07|1970-08-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/G/H|STABLE||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||WASHOUT|1964-01-01||||1973-08-09||1964-11-16|1970-05-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||BONERESP|BONE RESPONSE||||FT|MRD PERSISTENCE||FINGERTIP UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|INTERVIEWER|ENDOCRINOLOGIST|U|3||39||FOLLOW-UP|1966-02-26||||1967-07-01||1965-05-21|1971-06-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||JOULE|CR-CT||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|3||39||CONTINUATION TREATMENT|1969-08-27||||1965-01-26||1963-09-11|1968-04-03||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^3 RNA COPIES/ML|MRD NEGATIVITY||DIOPTER|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BLINDED TREATMENT|1962-05-27||||1969-01-10||1967-12-15|1968-04-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||COULOMB|ICR||/CMH2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|4||88||OPEN LABEL TREATMENT|1973-06-06||||1969-05-15||1972-07-22|1965-04-03||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/G|MCR||DPM/100MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5||7||INDUCTION TREATMENT|1969-07-14||||1960-09-12||1960-02-22|1966-07-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||NEWLIND|NEW LESION INDICATOR||||CMH2O*S/ML|PR-CT||OZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|INTERVIEWER|FORENSIC PATHOLOGIST|Y|5||7||TREATMENT|1964-01-07||||1962-04-11||1960-08-03|1961-12-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI|INDETERMINATE RESPONSE||DYN|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1964-11-18||||1960-02-04||1968-08-03|1967-11-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||METBRESP|METABOLIC RESPONSE||||TORR|NED||NG/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|SIGNIFICANT OTHER|RADIOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1969-02-25||||1966-09-23||1969-01-05|1970-01-30||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/M2/H|CYTOGENETIC MINIMAL RESPONSE||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|PROXY|OPTOMETRIST|U|2||58||FOLLOW-UP|1970-10-27||||1960-01-29||1962-11-03|1960-04-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/DL|SCR||G/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|ADJUDICATOR|RADIOLOGIST 2|U|2||58||RUN-IN|1973-05-21||||1968-06-20||1962-05-21|1966-08-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9 CFU/G|QUANTIFIABLE MRD POSITIVITY||L/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|3||39||WASHOUT|1963-10-14||||1971-12-26||1966-07-19|1966-02-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||MOLRESP|MOLECULAR RESPONSE||||AMU|HI-E||LB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|STUDY SUBJECT|ADJUDICATOR|N|3||39||OPEN LABEL TREATMENT|1972-04-21||||1966-05-01||1967-11-01|1964-10-06||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EIA UNIT|PD FROM PR||U/KG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|FRIEND|RADIOLOGIST 2|U|4||88||INDUCTION TREATMENT|1969-03-23||||1973-05-21||1967-10-12|1973-03-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 ORGANISMS|PD||DDU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|VENDOR|PHYSIOTHERAPIST|U|4||88||BASELINE|1969-09-23||||1964-12-04||1964-02-28|1970-01-27||DURING||AFTER|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DISK|MOLECULAR CR||M/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|INVESTIGATOR|DERMATOLOGIST|NA|5||7||WASHOUT|1963-04-20||||1964-12-02||1962-10-10|1969-08-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||METSIND|METASTATIC INDICATOR||||V|RELAPSED DISEASE||IU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|PARENT|NEUROLOGIST 1|Y|5||7||INDUCTION TREATMENT|1964-12-09||||1963-12-28||1960-04-08|1967-02-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||OVRLRESP|OVERALL RESPONSE||||/2500 WBC|RELAPSED DISEASE FROM CR||V|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|1||38||OPEN LABEL TREATMENT|1967-08-12||||1968-08-10||1966-09-06|1968-01-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||APPLICATION|UNFAVORABLE RESPONSE||KCAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|RATER|N|1||38||WASHOUT|1972-10-31||||1971-01-13||1964-03-17|1972-06-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||OVRLRESP|OVERALL RESPONSE||||CM H2O|WORSENED||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|INTERVIEWER|INTERNIST|U|2||58||TREATMENT|1967-11-07||||1962-12-25||1972-04-26|1967-01-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/G/DAY|ICPD||UMOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|2||58||BASELINE|1961-09-11||||1960-12-24||1963-12-22|1970-04-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ELISA UNIT/ML|OPTIMAL MORPHOLOGIC RESPONSE||UKAT/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|CHILD|PATHOLOGIST 1|N|3||39||OBSERVATION|1966-03-30||||1962-07-28||1964-09-01|1960-01-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||METSIND|METASTATIC INDICATOR||||CMH2O*S2/ML|ICR||NMOL BCE/MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|STUDY SUBJECT|NEUROLOGIST 1|NA|3||39||INDUCTION TREATMENT|1965-05-22||||1962-03-28||1966-04-27|1960-11-09||DURING||DURING|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||CLINRESP|CLINICAL RESPONSE||||UKAT/L|PD-CT||U/G/H|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|SIBLING|PATHOLOGIST|U|4||88||FOLLOW-UP|1960-04-12||||1970-12-31||1960-02-11|1973-03-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/M2/DAY|WORSENED||TSP EQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|4||88||BLINDED TREATMENT|1970-08-28||||1960-08-13||1967-12-12|1965-06-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||MOLRESP|MOLECULAR RESPONSE||||IMPLANT|MORPHOLOGIC CRI||UG/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|GUARDIAN|READER 1|U|5||7||SCREENING|1965-12-23||||1973-08-15||1973-01-27|1967-08-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||SPLNRESP|SPLEEN RESPONSE||||UG/KG/MIN|DISEASE TRANSFORMATION||/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SIGNIFICANT OTHER|READER 3|NA|5||7||INDUCTION TREATMENT|1968-01-24||||1963-07-29||1968-08-25|1960-10-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|1||||||TRGRESP|TARGET RESPONSE||||ML|DECREASED||ML/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CAREGIVER|INTERNIST|NA|1||38||LONG-TERM FOLLOW-UP|1969-01-14||||1960-02-19||1967-10-02|1968-08-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|2||||||NEWLPROG|NEW LESION PROGRESSION||||NCI|FAVORABLE RESPONSE||UOSM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|VENDOR|OTOLARYNGOLOGIST|N|1||38||FOLLOW-UP|1964-05-28||||1962-02-01||1969-10-30|1960-05-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BEL|SD||MMHG*MIN/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|2||58||WASHOUT|1964-04-03||||1960-05-23||1972-11-23|1965-12-31||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||AU/ML|VGPR||UV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|PROXY|INTERNIST|Y|2||58||RUN-IN|1965-09-29||||1968-08-04||1972-01-14|1965-06-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FG|CYTOGENETIC CR||JAR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|INTERNIST|Y|3||39||LONG-TERM FOLLOW-UP|1961-11-16||||1970-07-31||1962-11-30|1969-09-12||DURING||AFTER|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|2||||||ANATRESP|ANATOMIC RESPONSE||||LOG10 PFU|MRD PERSISTENCE||PSEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|CAREGIVER|PHYSIOTHERAPIST|NA|3||39||RUN-IN|1964-05-28||||1972-09-06||1962-12-20|1960-01-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|1||||||BONERESP|BONE RESPONSE||||UG/KG/MIN|PR WITH LYMPHOCYTOSIS||ML/G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|GUARDIAN|DERMATOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1971-09-12||||1967-04-12||1967-10-23|1972-09-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|2||||||TRGRESP|TARGET RESPONSE||||10^9 CFU/G|WORSENED||NMOL BCE/MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|INTERVIEWER|NEUROLOGIST 2|Y|4||88||OBSERVATION|1970-12-14||||1961-02-18||1961-10-22|1966-01-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|1||||||BONERESP|BONE RESPONSE||||DAGU|COMPLETE MRD RESPONSE||TBSP|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|FRIEND|MICROSCOPIST 3|Y|5||7||OBSERVATION|1966-03-23||||1968-09-29||1968-03-11|1965-03-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|49017491-2C28-4F86-BF72-CF83651052F6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/S/M2|ISD||BLOCKS|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|INTERVIEWER|RADIOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1967-05-24||||1966-08-27||1971-11-24|1967-04-12||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||V|FAVORABLE RESPONSE||DB|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|PROXY|PATHOLOGIST 1|U|1||38||INDUCTION TREATMENT|1963-08-20||||1970-02-24||1962-04-19|1970-08-06||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||SFC/10^6 PBMC|INDETERMINATE RESPONSE||VG/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|1||38||BLINDED TREATMENT|1960-04-06||||1973-07-06||1973-03-14|1970-02-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/M2|SMD||MG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|GUARDIAN|RADIOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1970-12-25||||1967-07-22||1963-05-22|1961-08-30||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||TMRESP|TUMOR MARKER RESPONSE||||MPS U|HI-N||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|FAMILY MEMBER|RATER|N|2||58||SCREENING|1967-12-27||||1968-06-17||1960-06-05|1968-02-17||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||METBRESP|METABOLIC RESPONSE||||UG/M2|MOLECULAR MAJOR RESPONSE||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|FRIEND|MICROSCOPIST 3|N|3||39||WASHOUT|1964-10-26||||1968-12-27||1961-10-18|1963-12-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^4 CFU|SD-CT||IU/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|CAREGIVER|MICROSCOPIST 1|U|3||39||SCREENING|1967-11-10||||1963-11-26||1970-05-13|1961-12-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||M3|CA125 75% RESPONSE||MG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|U|4||88||LONG-TERM FOLLOW-UP|1968-01-26||||1965-11-25||1972-03-16|1964-08-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||STRUSTAT|STEROID USE STATUS||||MG/G/MIN|NE||U/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BASELINE|1962-03-28||||1969-09-24||1968-02-01|1967-06-28||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TUBERCULIN UNIT|MRD RELAPSE||/MS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|5||7||LONG-TERM FOLLOW-UP|1960-09-30||||1961-09-25||1968-12-22|1965-08-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/MOL|DISEASE TRANSFORMATION||LOG10 ELISA UNIT/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|SPOUSE|RATER 1|N|5||7||INDUCTION TREATMENT|1960-07-06||||1965-06-24||1964-02-22|1965-11-13||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||CYTORESP|CYTOGENETIC RESPONSE||||SACHET|MRD RELAPSE||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|1||38||TREATMENT|1964-11-05||||1965-04-17||1971-06-04|1962-08-30||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||APPLICATION|UNEQUIVOCAL||ML|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|STUDY SUBJECT|INTERNIST|NA|1||38||TREATMENT|1972-07-31||||1969-06-09||1966-09-15|1961-10-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||METBRESP|METABOLIC RESPONSE||||CAPLET|MORPHOLOGIC CR||C|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|FRIEND|OPTOMETRIST|NA|2||58||INDUCTION TREATMENT|1966-11-21||||1971-12-19||1963-09-24|1963-01-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||STRUSTAT|STEROID USE STATUS||||STEPS|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|FAMILY MEMBER|PHYSIOTHERAPIST|NA|2||58||OPEN LABEL TREATMENT|1962-09-11||||1963-03-14||1971-10-15|1962-02-18||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/KG/MIN|MOLECULAR CR||UG/L FEU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|3||39||FOLLOW-UP|1972-11-25||||1973-05-21||1965-05-06|1967-01-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/G/MIN|ISD||EP U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|DOMESTIC PARTNER|PATHOLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1971-07-31||||1966-07-19||1961-01-24|1963-08-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CAL|MAJOR PATHOLOGIC RESPONSE||CIGARETTE|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|STUDY SUBJECT|UROLOGIST|NA|4||88||BLINDED TREATMENT|1965-10-08||||1965-09-10||1968-01-01|1972-09-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%(W/W)|RELAPSED DISEASE FROM CR OR PR||LOG EID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|4||88||LONG-TERM FOLLOW-UP|1963-03-21||||1970-07-06||1960-12-12|1961-07-10||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||METSIND|METASTATIC INDICATOR||||ML/ANIMAL/DAY|NPR||TRACE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|CHILD|ADJUDICATOR|NA|5||7||BASELINE|1961-03-23||||1967-12-03||1962-07-14|1972-08-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||EU|CYTOGENETIC CR||CY/CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|SIGNIFICANT OTHER|ONCOLOGIST|N|5||7||RUN-IN|1965-09-05||||1973-03-07||1971-01-17|1969-05-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HEP|MRD PERSISTENCE||ML/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|INDEPENDENT ASSESSOR|UROLOGIST|N|1||38||BLINDED TREATMENT|1960-02-10||||1963-09-18||1964-01-15|1968-06-16||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TCID 50/DOSE|TREATMENT FAILURE||LOG10 ELISA UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|STUDY SUBJECT|ADJUDICATOR 2|Y|1||38||OBSERVATION|1970-01-14||||1964-12-19||1973-04-19|1973-06-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||SPLNRESP|SPLEEN RESPONSE||||/40 HPFS|TREATMENT FAILURE||UMOL/H/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|INVESTIGATOR|RADIOLOGIST|U|2||58||CONTINUATION TREATMENT|1968-04-02||||1965-05-20||1961-01-18|1969-03-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TABLET|CRI||BQ/UG|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|PARENT|ONCOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1962-02-04||||1969-06-15||1964-12-09|1960-12-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||%|UNFAVORABLE RESPONSE||BAR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|CAREGIVER|MICROSCOPIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1972-06-21||||1961-03-22||1966-10-30|1963-06-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||ANATRESP|ANATOMIC RESPONSE||||L/H/M2|MRD PERSISTENCE||TORR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|DOMESTIC PARTNER|HEMATOLOGIST|NA|3||39||OBSERVATION|1962-07-20||||1973-02-17||1970-12-08|1967-12-22||AFTER||DURING|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UMOL/MG/MIN|MR||BQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4||88||SCREENING|1963-01-08||||1971-06-11||1971-06-17|1962-07-07||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 TCID 50/UL|CHR||GMFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CAREGIVER|PATHOLOGIST 2|NA|4||88||SCREENING|1969-08-27||||1968-10-09||1971-02-04|1965-10-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||OVRLRESP|OVERALL RESPONSE||||ANTIBODY UNIT|IUPD||10^8/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|STUDY SUBJECT|ONCOLOGIST|NA|5||7||OBSERVATION|1964-03-23||||1965-06-10||1962-08-17|1961-12-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MDFI|CRI||UG/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|5||7||BASELINE|1965-01-09||||1965-06-06||1972-08-19|1964-10-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||METSIND|METASTATIC INDICATOR||||NL|MRD NEGATIVITY||%/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|1||38||CONTINUATION TREATMENT|1966-08-24||||1961-03-14||1964-01-22|1966-09-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^3 ORGANISMS|MINOR PATHOLOGIC RESPONSE||AGU/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|PARENT|ENDOCRINOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1964-10-28||||1960-01-12||1969-06-17|1965-05-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||CLINRESP|CLINICAL RESPONSE||||PA|MRD NEGATIVITY||10^6/EJACULATE U|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|INVESTIGATOR|MICROSCOPIST 2|U|2||58||BLINDED TREATMENT|1966-01-17||||1970-08-27||1962-07-09|1972-04-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||SPLNRESP|SPLEEN RESPONSE||||V/V|CYTOGENETIC MINIMAL RESPONSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|2||58||RUN-IN|1962-01-27||||1962-10-11||1968-12-24|1962-10-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||ANATRESP|ANATOMIC RESPONSE||||PPTH|MR||EVENTS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3||39||CONTINUATION TREATMENT|1962-12-17||||1972-11-21||1962-09-06|1962-02-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||USIEMENS|CYTOGENETIC NO RESPONSE||MV|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1965-02-16||||1967-06-10||1964-06-24|1967-05-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||CLINRESP|CLINICAL RESPONSE||||%(W/W)|PSEUDORESPONSE||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|4||88||CONTINUATION TREATMENT|1972-05-23||||1972-09-01||1968-03-18|1963-10-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||MOLRESP|MOLECULAR RESPONSE||||/KG|CA125 50% RESPONSE||MV2/HZ|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|4||88||SCREENING|1967-12-11||||1972-05-29||1973-09-02|1968-10-23||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||ANATRESP|ANATOMIC RESPONSE||||IU/KG|MORPHOLOGIC CR||H*%|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|5||7||RUN-IN|1967-01-08||||1967-12-05||1969-08-12|1968-05-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CAL|NON-CR/NON-PD||L/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||OBSERVATION|1965-09-22||||1973-02-11||1969-02-22|1963-06-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||NKAT|PD||DRAM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|INTERVIEWER|READER 3|N|1||38||OBSERVATION|1973-01-13||||1970-04-19||1966-03-02|1973-08-25||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||STRUSTAT|STEROID USE STATUS||||NMOL/L/H|PMR||UCI/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|DOMESTIC PARTNER|ADJUDICATOR 2|N|1||38||OPEN LABEL TREATMENT|1961-02-13||||1960-03-24||1971-03-14|1972-07-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||BONERESP|BONE RESPONSE||||IU/DAY|SCR||ML/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|VENDOR|ONCOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1971-12-09||||1961-07-19||1969-12-10|1966-07-22||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||TRGRESP|TARGET RESPONSE||||ML/MIN/1.73M2|HI-P||MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|FAMILY MEMBER|HEMATOLOGIST|N|2||58||WASHOUT|1964-10-11||||1971-11-13||1972-09-11|1971-01-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/2000 RBC|PSEUDORESPONSE||/MBP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|PARENT|FORENSIC PATHOLOGIST|N|3||39||WASHOUT|1970-03-06||||1971-05-29||1972-06-08|1961-09-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||AFU|PMR||ML/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|3||39||BLINDED TREATMENT|1972-05-14||||1973-05-02||1962-09-17|1968-12-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DNA COPIES/ML|STABLE||/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||OBSERVATION|1968-03-20||||1970-03-07||1967-03-10|1967-01-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||RDIORESP|RADIOLOGIC RESPONSE||||WEEKS|SCR||10^6 IU|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|ADJUDICATOR|MICROSCOPIST|N|4||88||INDUCTION TREATMENT|1963-10-09||||1967-05-22||1972-11-11|1963-01-05||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L FEU|IPR||U/M2|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|ADJUDICATOR|RADIOLOGIST 1|N|5||7||BASELINE|1972-10-09||||1962-05-01||1962-03-11|1967-09-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||LIVRRESP|LIVER RESPONSE||||G|NOT ALL EVALUATED||ECL UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|SPOUSE|RATER|N|5||7||OPEN LABEL TREATMENT|1967-10-19||||1969-03-11||1972-12-09|1965-08-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||CLINRESP|CLINICAL RESPONSE||||G/G|CHR||MCI|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|GUARDIAN|OTOLARYNGOLOGIST|NA|1||38||SCREENING|1964-09-03||||1973-01-25||1972-06-27|1969-08-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||CLINRESP|CLINICAL RESPONSE||||BQ|CYTOGENETIC MINOR RESPONSE||TITER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|STUDY SUBJECT|ONCOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1970-10-11||||1968-10-19||1972-04-24|1971-03-04||AFTER||DURING|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||OVRLRESP|OVERALL RESPONSE||||MU|CA125 50% RESPONSE||PG/L|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|SPOUSE|OPHTHALMOLOGIST|NA|2||58||SCREENING|1962-12-26||||1971-11-16||1965-03-22|1968-05-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^5/L|PDU||KEV|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|CAREGIVER|NEUROLOGIST 1|N|2||58||SCREENING|1963-02-12||||1965-02-13||1969-12-26|1967-10-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PACK YEAR|PR-CT||BOTTLE|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|U|3||39||RUN-IN|1963-03-02||||1968-08-27||1960-05-04|1966-09-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||NEWLPROG|NEW LESION PROGRESSION||||KG/CM|DISEASE TRANSFORMATION||SPRAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|INVESTIGATOR|HEMATOLOGIST|N|3||39||BLINDED TREATMENT|1964-10-18||||1961-02-28||1970-01-22|1971-05-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DL|CYTOGENETIC CR||U/DL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|Y|4||88||BASELINE|1967-09-19||||1968-12-02||1968-11-20|1962-03-15||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/KG/WEEK|PD-CT||UMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|PARENT|READER 2|U|4||88||TREATMENT|1962-03-23||||1970-02-21||1971-06-16|1973-09-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||METSIND|METASTATIC INDICATOR||||IU/G|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CAPLET|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|PROXY|CARDIOLOGIST|U|5||7||CONTINUATION TREATMENT|1972-04-11||||1968-12-26||1965-09-03|1966-11-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||OVRLRESP|OVERALL RESPONSE||||UGEQ|CHR||10^11/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|STUDY SUBJECT|DERMATOLOGIST|N|5||7||FOLLOW-UP|1960-06-09||||1961-08-29||1965-01-28|1973-02-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||BESTRESP|BEST OVERALL RESPONSE||||KG|IPR||MG/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|CAREGIVER|PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1967-09-18||||1961-01-09||1965-02-10|1971-09-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UKAT/L|CHR||KDA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|STUDY SUBJECT|NEUROLOGIST 1|NA|1||38||SCREENING|1973-01-06||||1964-01-18||1967-01-16|1968-02-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/MIN/1.73M2|PD||PG/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|SPOUSE|PATHOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1968-12-11||||1967-06-16||1972-07-26|1971-09-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||AMU|CYTOGENETIC NO RESPONSE||/100 HPFS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||CONTINUATION TREATMENT|1966-05-09||||1965-05-03||1969-05-25|1966-04-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||OVRLRESP|OVERALL RESPONSE||||RFU|STABLE||10^7 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|SIBLING|MICROSCOPIST 3|U|3||39||WASHOUT|1968-09-10||||1972-01-30||1968-12-31|1967-01-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||NEWLIND|NEW LESION INDICATOR||||UM/DAY|SMD||U/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|GUARDIAN|RADIOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1965-03-26||||1970-06-09||1962-02-28|1970-03-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KIT|PD FROM PR||UU/L|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|4||88||SCREENING|1967-11-08||||1966-07-23||1964-02-02|1968-08-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||METBRESP|METABOLIC RESPONSE||||LOG10 TCID 50/UL|CYTOGENETIC NO RESPONSE||CAPLET|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|NA|4||88||BLINDED TREATMENT|1967-04-24||||1968-07-07||1960-05-07|1972-06-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||NEWLPROG|NEW LESION PROGRESSION||||UG/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||MIU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|5||7||OPEN LABEL TREATMENT|1961-10-03||||1972-07-22||1972-01-19|1970-08-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/KG/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||G/ANIMAL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1966-09-26||||1972-06-08||1968-11-30|1966-07-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||INHALATION|NPR||MSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1968-10-09||||1962-01-05||1968-05-10|1972-12-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||NEWLPROG|NEW LESION PROGRESSION||||MOSM|NE||G/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|INTERVIEWER|READER 2|NA|1||38||INDUCTION TREATMENT|1960-11-20||||1966-10-06||1971-12-12|1960-08-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NMOL/L/MIN|PCR||UG/M2/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|CAREGIVER|NEUROLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1972-11-13||||1965-12-16||1966-10-03|1970-06-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/M2/DAY|HI-E||DPM/100MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|PROXY|INTERNIST|NA|2||58||INDUCTION TREATMENT|1962-02-25||||1960-01-26||1973-05-13|1961-08-31||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||TMRESP|TUMOR MARKER RESPONSE||||/10^3|CYTOGENETIC MINOR RESPONSE||IN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|SIBLING|OPTOMETRIST|NA|3||39||BASELINE|1970-04-24||||1965-07-27||1968-04-02|1966-07-06||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MBQ/UL|HI-E||ML/M2/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|FRIEND|MICROSCOPIST 3|N|3||39||SCREENING|1967-05-17||||1973-07-21||1968-01-29|1969-03-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||TITER|CYTOGENETIC MINOR RESPONSE||NMOL BCE/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|CAREGIVER|MICROSCOPIST|NA|4||88||INDUCTION TREATMENT|1961-08-22||||1969-04-01||1970-01-29|1972-08-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||TRGRESP|TARGET RESPONSE||||10^3 ORGANISMS|FAVORABLE RESPONSE||BLOCKS|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|FRIEND|READER 1|U|4||88||FOLLOW-UP|1968-02-25||||1960-06-21||1971-10-06|1964-10-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GRAIN|PMR||KHZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|INTERVIEWER|RATER 2|U|5||7||CONTINUATION TREATMENT|1964-09-09||||1963-10-08||1962-02-19|1966-08-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||MOLRESP|MOLECULAR RESPONSE||||GTT|MOLECULAR MAJOR RESPONSE||G/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|SIBLING|READER 2|NA|5||7||BLINDED TREATMENT|1960-07-05||||1968-11-29||1970-03-13|1972-08-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||RNA COPIES/ML|IMMUNOPHENOTYPIC CR||PIPE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|1||38||OBSERVATION|1964-11-06||||1973-05-08||1969-05-05|1969-11-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/ANIMAL|NON-CR/NON-PD||AFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|INVESTIGATOR|RATER|Y|1||38||CONTINUATION TREATMENT|1969-09-09||||1964-09-26||1963-01-29|1962-09-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||CLINRESP|CLINICAL RESPONSE||||ML/MIN|PR||LINEAR FT*LB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|INTERVIEWER|ONCOLOGIST 1|U|2||58||RUN-IN|1965-02-14||||1972-06-17||1960-02-05|1963-10-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DPM/100MG|OPTIMAL MORPHOLOGIC RESPONSE||%(W/V)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|2||58||OBSERVATION|1963-01-03||||1960-01-05||1971-06-02|1971-12-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||TMRESP|TUMOR MARKER RESPONSE||||MEQ/UL|IMPROVED||MMOL/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|ADJUDICATOR|DERMATOLOGIST|U|3||39||TREATMENT|1966-03-22||||1961-05-29||1964-09-13|1971-06-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||SPLNRESP|SPLEEN RESPONSE||||/MS|CA125 50% RESPONSE||10^9/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|INVESTIGATOR|INTERNIST|NA|3||39||SCREENING|1964-06-20||||1972-10-27||1964-12-09|1969-12-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/M2|MR||PUFF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BASELINE|1968-03-14||||1966-02-04||1965-09-01|1962-10-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||TMRESP|TUMOR MARKER RESPONSE||||POINT|NED||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|PROXY|MICROSCOPIST 1|N|4||88||FOLLOW-UP|1971-04-27||||1970-06-27||1972-08-25|1967-10-29||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||L/S|PD FROM PR||NL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|ADJUDICATOR|READER 1|Y|5||7||BLINDED TREATMENT|1969-10-11||||1966-07-01||1961-03-10|1962-03-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||COPIES/UL|DECREASED||UU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|5||7||SCREENING|1964-09-10||||1973-08-24||1962-07-09|1964-07-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||CLINRESP|CLINICAL RESPONSE||||U/KG|HI-E||MEQ/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|GUARDIAN|ONCOLOGIST|Y|1||38||INDUCTION TREATMENT|1967-11-13||||1962-07-20||1960-05-19|1966-03-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||OVRLRESP|OVERALL RESPONSE||||CMH2O*S/ML|HI-N||PIPE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|1||38||OBSERVATION|1964-06-19||||1972-04-27||1960-05-27|1960-03-16||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L/H|CR||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|ADJUDICATOR|RATER 1|NA|2||58||RUN-IN|1970-04-04||||1971-02-03||1963-08-19|1965-06-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||NEWLPROG|NEW LESION PROGRESSION||||MCI/L|IMPROVED||10^6 IU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|READER 3|N|2||58||OPEN LABEL TREATMENT|1973-05-09||||1971-06-21||1962-04-18|1963-04-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/G/MIN|WORSENED||NU/CL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|PROXY|RADIOLOGIST|U|3||39||OBSERVATION|1968-05-25||||1969-12-26||1972-01-06|1966-07-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||BESTRESP|BEST OVERALL RESPONSE||||100 IU/ML|RELAPSED DISEASE||MEQ/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|3||39||FOLLOW-UP|1965-03-01||||1967-04-10||1971-05-28|1962-07-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||TMRESP|TUMOR MARKER RESPONSE||||BAU/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||DPM/0.5 ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|PARENT|ENDOCRINOLOGIST|Y|4||88||OBSERVATION|1964-06-27||||1970-02-21||1962-08-03|1969-08-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^7/L|VGPR||G/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|4||88||CONTINUATION TREATMENT|1964-07-07||||1972-01-25||1969-09-03|1972-12-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||MOLRESP|MOLECULAR RESPONSE||||ANTI-XA IU|CA125 50% RESPONSE||HOURS|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|5||7||INDUCTION TREATMENT|1972-11-14||||1971-07-07||1967-08-30|1965-03-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||NEWLIND|NEW LESION INDICATOR||||BQ/MG|RELAPSED DISEASE FROM CR OR PR||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|VENDOR|OPHTHALMOLOGIST|U|5||7||RUN-IN|1971-07-26||||1965-06-16||1966-05-20|1968-03-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||L/S|CMR||MM/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|1||38||RUN-IN|1968-12-30||||1970-09-28||1969-05-28|1968-03-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/ML/DAY|NON-CR/NON-PD||NEEDLE GAUGE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|1||38||BLINDED TREATMENT|1968-02-06||||1968-03-25||1962-12-13|1968-12-30||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||OD UNIT|WORSENED||PMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|2||58||OBSERVATION|1966-06-14||||1970-10-20||1962-08-13|1970-04-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||TMRESP|TUMOR MARKER RESPONSE||||PIPE|IUPD||10^9 CFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|VENDOR|ONCOLOGIST 2|U|2||58||TREATMENT|1969-11-20||||1967-01-06||1968-08-22|1968-03-02||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||LIVRRESP|LIVER RESPONSE||||TCID 50/DOSE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||PA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1968-03-13||||1966-10-23||1967-06-26|1962-09-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DIOPTER|CR||NKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|3||39||TREATMENT|1961-03-20||||1965-01-03||1961-05-20|1966-12-14||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||H/WK|RELAPSED DISEASE FROM CR OR PR||G/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|FRIEND|HEMATOLOGIST|Y|4||88||BLINDED TREATMENT|1966-01-29||||1970-10-27||1961-06-26|1972-03-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||ANATRESP|ANATOMIC RESPONSE||||VG/DOSE|NE||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|PROXY|CLINICAL PATHOLOGIST|U|4||88||SCREENING|1965-04-29||||1971-02-15||1963-01-14|1962-07-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||SBE/ML|MRD PERSISTENCE||PPM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|SPOUSE|CLINICAL PATHOLOGIST|U|5||7||BLINDED TREATMENT|1973-04-10||||1970-06-25||1962-04-03|1968-01-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||NEWLPROG|NEW LESION PROGRESSION||||PMOL/L/H|EQUIVOCAL||G/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5||7||FOLLOW-UP|1970-06-10||||1969-08-02||1960-03-15|1972-06-15||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||LIVRRESP|LIVER RESPONSE||||BQ/KG|MAJOR PATHOLOGIC RESPONSE||EU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|1||38||WASHOUT|1971-03-17||||1967-01-11||1963-07-12|1960-07-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/BEAT|NON-PD||ML/M2|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|CAREGIVER|PHYSIOTHERAPIST|Y|1||38||CONTINUATION TREATMENT|1967-01-20||||1965-05-06||1972-09-20|1966-04-06||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||CLINRESP|CLINICAL RESPONSE||||UG/L/H|PR WITH LYMPHOCYTOSIS||VG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|CLINICAL STUDY SPONSOR|READER|NA|2||58||CONTINUATION TREATMENT|1964-12-13||||1971-07-24||1966-01-21|1963-07-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||MOLRESP|MOLECULAR RESPONSE||||IU/G|CHR||IU/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|SIGNIFICANT OTHER|RATER 1|NA|2||58||SCREENING|1960-01-30||||1964-08-19||1969-01-19|1964-02-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||RDIORESP|RADIOLOGIC RESPONSE||||NG|NE||MBQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|3||39||TREATMENT|1960-12-11||||1964-05-29||1967-08-03|1964-06-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||ANATRESP|ANATOMIC RESPONSE||||MS2|ISD||UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|DOMESTIC PARTNER|ONCOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1961-05-10||||1963-02-26||1965-08-18|1969-10-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||STRUSTAT|STEROID USE STATUS||||STEPS/MIN|HI-N||EIA UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|PROXY|READER 1|Y|4||88||BASELINE|1970-06-06||||1969-01-07||1967-02-17|1968-04-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||METBRESP|METABOLIC RESPONSE||||%/MIN|ICPD||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-05-22||||1961-05-20||1969-04-22|1971-01-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||STRUSTAT|STEROID USE STATUS||||VG/DOSE|PD FROM PR||MNFI|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|CAREGIVER|UROLOGIST|Y|5||7||INDUCTION TREATMENT|1970-06-22||||1971-05-12||1971-12-17|1968-07-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||NEWLPROG|NEW LESION PROGRESSION||||UG/ANIMAL|PSEUDOPROGRESSION||M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|PROXY|MICROSCOPIST 3|Y|5||7||OBSERVATION|1965-08-16||||1961-12-08||1970-09-15|1972-10-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||TRGRESP|TARGET RESPONSE||||MOL|CYTOGENETIC MINOR RESPONSE||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||BASELINE|1960-01-25||||1970-07-21||1962-03-31|1962-05-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CGY|PSEUDORESPONSE||10^5/HPF|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|PARENT|RADIOLOGIST 1|U|1||38||BLINDED TREATMENT|1970-11-30||||1964-07-21||1963-04-19|1968-08-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||MOLRESP|MOLECULAR RESPONSE||||L/MIN|WORSENED||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1969-08-13||||1965-08-07||1962-10-01|1972-05-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||TRGRESP|TARGET RESPONSE||||RAD|CR-CT||NG/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|GUARDIAN|NEUROLOGIST 2|Y|2||58||TREATMENT|1961-06-10||||1960-08-16||1962-12-08|1967-04-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||OVRLRESP|OVERALL RESPONSE||||NMOL/L/H|UNFAVORABLE RESPONSE||G/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||OPEN LABEL TREATMENT|1966-08-26||||1960-08-06||1973-04-27|1970-07-27||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/M2/MIN|CYTOGENETIC NO RESPONSE||MG/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|RATER|U|3||39||WASHOUT|1967-08-23||||1965-03-06||1963-02-01|1969-07-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||METBRESP|METABOLIC RESPONSE||||DRUM|SD||EQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|FRIEND|PATHOLOGIST|NA|4||88||FOLLOW-UP|1960-07-13||||1968-02-10||1963-02-19|1965-05-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NKAT/G HB|SD-CT||UG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|FRIEND|RADIOLOGIST|N|4||88||WASHOUT|1961-06-20||||1973-06-09||1969-04-01|1970-05-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/M2/H|SD-CT||KAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|DOMESTIC PARTNER|PATHOLOGIST|NA|5||7||SCREENING|1960-02-29||||1964-08-28||1969-03-18|1972-09-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||STRUSTAT|STEROID USE STATUS||||APS U|CYTOGENETIC MINIMAL RESPONSE||SCM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CHILD|OPTOMETRIST|Y|5||7||LONG-TERM FOLLOW-UP|1970-10-22||||1965-10-28||1965-03-01|1972-07-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||TRGRESP|TARGET RESPONSE||||EID 50/DOSE|ISD||ML/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|FAMILY MEMBER|ONCOLOGIST|NA|1||38||SCREENING|1972-04-05||||1964-11-15||1968-11-08|1965-10-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/MG/MIN|NE||FINGERTIP UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||RUN-IN|1967-09-14||||1968-04-18||1972-01-17|1973-08-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PSEC|INDETERMINATE RESPONSE||BQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|INTERVIEWER|FORENSIC PATHOLOGIST|Y|2||58||OBSERVATION|1963-07-17||||1960-03-11||1971-03-28|1969-12-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||BONERESP|BONE RESPONSE||||KALLIKREIN INHIBITOR UNIT|HI-P||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|PARENT|ENDOCRINOLOGIST|Y|2||58||FOLLOW-UP|1964-06-21||||1972-01-04||1972-05-10|1965-06-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||METBRESP|METABOLIC RESPONSE||||100 IU/ML|MRD NEGATIVITY||PMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|SIBLING|READER 2|N|3||39||FOLLOW-UP|1960-08-25||||1968-10-11||1965-02-19|1963-05-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ENZYME U/L|CYTOGENETIC PR||GRAIN|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|INTERVIEWER|DERMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1960-08-09||||1970-10-03||1969-09-11|1969-03-07||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UU/DL|IPR||MHZ|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|GUARDIAN|READER 3|N|4||88||SCREENING|1971-06-06||||1971-10-05||1967-08-30|1972-09-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O*S2/ML|CYTOGENETIC MINOR RESPONSE||MET*H|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1968-06-20||||1973-02-13||1969-08-29|1963-08-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||TRGRESP|TARGET RESPONSE||||10^6 CFU/ML|FAVORABLE RESPONSE||KHZ|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|5||7||TREATMENT|1961-05-28||||1960-01-01||1963-11-05|1968-09-11||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||TMRESP|TUMOR MARKER RESPONSE||||%/MIN|CHR||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OBSERVATION|1964-01-24||||1969-12-16||1968-07-23|1971-12-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/S|PD/RELAPSE AFTER HI||NL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|DOMESTIC PARTNER|INTERNIST|U|1||38||BASELINE|1960-06-18||||1961-01-22||1971-12-02|1966-01-11||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/(MIN*100ML)|MOLECULAR MAJOR RESPONSE||10^6/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|FAMILY MEMBER|INTERNIST|NA|1||38||SCREENING|1966-06-17||||1969-10-15||1965-09-28|1971-07-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||METSIND|METASTATIC INDICATOR||||IMPLANT|CHR||TBSP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|FAMILY MEMBER|ADJUDICATOR 1|U|2||58||OBSERVATION|1972-05-07||||1967-03-06||1967-06-07|1969-05-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UMOL/L/MIN|TREATMENT FAILURE||U/KG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|ADJUDICATOR|OPTOMETRIST|NA|2||58||WASHOUT|1969-03-11||||1962-10-31||1970-06-19|1973-01-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||OVRLRESP|OVERALL RESPONSE||||10^6 ORGANISMS/ML|STABLE||PMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3||39||FOLLOW-UP|1963-01-20||||1970-03-24||1968-01-26|1970-11-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||MOLRESP|MOLECULAR RESPONSE||||/10^5|PR WITH LYMPHOCYTOSIS||FT2|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|3||39||RUN-IN|1969-11-25||||1970-03-05||1969-10-20|1963-02-21||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PIPE|CYTOGENETIC PR||COPIES/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|4||88||BASELINE|1961-06-10||||1965-10-16||1964-11-26|1971-12-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NMOL BCE/MMOL|CRI||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|PROXY|RATER 2|N|4||88||TREATMENT|1967-02-08||||1969-11-23||1970-08-24|1965-09-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||LIVRRESP|LIVER RESPONSE||||10^9/G|VGPR||MOL/MG|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|INTERNIST|Y|5||7||TREATMENT|1960-12-26||||1972-06-06||1962-11-01|1961-11-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||METBRESP|METABOLIC RESPONSE||||SIEMENS|MORPHOLOGIC LEUKEMIA-FREE STATE||KG/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|GUARDIAN|CLINICAL PATHOLOGIST|U|5||7||SCREENING|1964-04-03||||1963-01-17||1961-02-28|1966-12-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||CLINRESP|CLINICAL RESPONSE||||MG/G/MIN|NE||MMOL/S|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|GUARDIAN|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1961-11-02||||1964-01-19||1964-01-18|1973-04-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MAC50|MINOR PATHOLOGIC RESPONSE||U/G|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|ADJUDICATOR|NEUROLOGIST 1|Y|1||38||INDUCTION TREATMENT|1969-03-31||||1963-07-10||1970-03-15|1970-08-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CMHG|PR WITH LYMPHOCYTOSIS||TESLA|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|STUDY SUBJECT|UROLOGIST|NA|2||58||INDUCTION TREATMENT|1970-03-27||||1968-01-11||1962-05-19|1972-06-25||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/ML/H|ICPD||MPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|VENDOR|RADIOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1960-09-17||||1962-11-18||1964-06-30|1971-09-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||STEPS/MIN|TREATMENT FAILURE||PSI|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|FRIEND|HEMATOLOGIST|Y|3||39||BLINDED TREATMENT|1962-12-14||||1973-08-30||1962-09-24|1966-01-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/H/MMOL|MINOR PATHOLOGIC RESPONSE||WEBER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|SIBLING|NEUROLOGIST 1|Y|3||39||SCREENING|1966-02-18||||1967-09-24||1973-05-22|1962-04-17||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/KG/DAY|ISD||RPM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|PARENT|ADJUDICATOR 3|U|4||88||WASHOUT|1965-08-11||||1968-06-17||1960-04-01|1970-06-11||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL BCE/L|PR WITH LYMPHOCYTOSIS||ML/CM H2O|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||TREATMENT|1960-02-15||||1966-09-27||1962-02-13|1963-01-31||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/M2/MIN|RELAPSED DISEASE FROM CR||ML/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|INVESTIGATOR|MICROSCOPIST 1|Y|5||7||RUN-IN|1973-07-06||||1968-05-16||1965-10-05|1973-01-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||TMRESP|TUMOR MARKER RESPONSE||||TUBERCULIN UNIT|PMR||GBQ/UG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|FRIEND|READER|NA|5||7||CONTINUATION TREATMENT|1970-11-12||||1970-01-24||1965-02-17|1968-11-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||OHM|NON-CR/NON-PD||STRIP|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|SIBLING|OPHTHALMOLOGIST|U|1||38||OPEN LABEL TREATMENT|1967-10-22||||1969-06-13||1969-08-03|1962-10-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BOLUS|PR-CT||PIXELS/IN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|GUARDIAN|NEUROLOGIST|Y|1||38||OBSERVATION|1962-12-28||||1972-10-08||1961-10-03|1966-07-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||CLINRESP|CLINICAL RESPONSE||||V|NED||BAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|GUARDIAN|RADIOLOGIST 2|Y|2||58||BLINDED TREATMENT|1968-06-07||||1966-10-25||1963-12-23|1960-10-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||NEWLIND|NEW LESION INDICATOR||||100 IU/ML|SMD||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|SIGNIFICANT OTHER|ADJUDICATOR|N|2||58||OPEN LABEL TREATMENT|1964-08-04||||1961-06-03||1972-01-29|1969-03-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KS|MOLECULAR CR||ML/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|GUARDIAN|OTOLARYNGOLOGIST|Y|3||39||TREATMENT|1963-01-22||||1962-02-12||1968-10-16|1972-06-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/VF|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|GUARDIAN|READER 3|Y|3||39||FOLLOW-UP|1970-06-01||||1972-04-29||1973-07-13|1968-03-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TESLA|ICR||CAPSULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|SIBLING|RADIOLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1967-08-01||||1973-06-23||1970-02-03|1964-01-10||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MONTHS|NE||LOG10 IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|ADJUDICATOR|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1966-01-07||||1964-03-23||1965-09-30|1961-01-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||BONERESP|BONE RESPONSE||||G/ANIMAL/WK|CYTOGENETIC CR||NMOL/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|CHILD|RATER 1|Y|5||7||WASHOUT|1961-10-14||||1966-02-17||1973-02-16|1972-07-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/KG/H|MORPHOLOGIC LEUKEMIA-FREE STATE||CD/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|PROXY|READER 2|NA|5||7||SCREENING|1966-01-02||||1964-06-04||1961-08-30|1968-06-15||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||M/SEC2|NON-ICR/NON-IUPD||KG/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|INTERVIEWER|MICROSCOPIST 1|NA|1||38||SCREENING|1970-09-08||||1966-05-24||1969-08-16|1972-01-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^3/L|IPR||G/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|STUDY SUBJECT|PHYSIOTHERAPIST|N|1||38||OPEN LABEL TREATMENT|1966-06-14||||1960-04-26||1962-08-28|1962-05-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||CLINRESP|CLINICAL RESPONSE||||SIEMENS|WORSENED||DPM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1965-03-05||||1961-12-28||1973-01-09|1963-04-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||S/H|MOLECULAR MAJOR RESPONSE||UMOL/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|CHILD|PEDIATRIC NEUROLOGIST|NA|2||58||BASELINE|1965-01-10||||1963-12-09||1971-02-25|1966-09-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/KG/DAY|CPR||G/M2/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1963-02-11||||1960-07-13||1963-06-05|1968-09-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/L|NPR||DPM/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|SPOUSE|RADIOLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1970-06-09||||1973-04-24||1960-05-10|1966-12-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^4 CFU|INCREASED||MAC50|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|4||88||LONG-TERM FOLLOW-UP|1968-11-22||||1972-09-11||1962-08-19|1960-02-05||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ANTI-XA IU/ML|CYTOGENETIC NO RESPONSE||SUPPOSITORY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|PARENT|RATER 1|NA|4||88||SCREENING|1963-04-03||||1961-11-18||1966-06-08|1962-02-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||ANATRESP|ANATOMIC RESPONSE||||BU|CCR||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|5||7||SCREENING|1970-07-26||||1960-12-06||1972-03-27|1969-12-21||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||METBRESP|METABOLIC RESPONSE||||ELISA UNIT/DOSE|NED||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|5||7||BASELINE|1960-09-15||||1970-02-21||1972-07-08|1962-10-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||OVRLRESP|OVERALL RESPONSE||||U/G/H|WORSENED||AMFI|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|STUDY SUBJECT|ADJUDICATOR 3|U|1||38||BASELINE|1963-03-03||||1966-11-23||1963-07-16|1965-07-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||LIVRRESP|LIVER RESPONSE||||DEG|PR||DISK|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|ADJUDICATOR|MICROSCOPIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1962-04-29||||1964-07-18||1961-01-10|1968-10-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ABSORBANCE U|IUPD||10^6/EJACULATE U|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|PARENT|READER|NA|2||58||INDUCTION TREATMENT|1962-06-06||||1962-08-13||1961-12-11|1970-08-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||VP/DOSE|NON-QUANTIFIABLE MRD POSITIVITY||U/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|PARENT|ADJUDICATOR|N|2||58||INDUCTION TREATMENT|1970-11-20||||1961-05-13||1960-12-17|1961-10-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ABSORBANCE U/ML|MRD NEGATIVITY||CMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|CHILD|ADJUDICATOR 2|Y|3||39||INDUCTION TREATMENT|1967-07-04||||1961-07-01||1964-04-29|1960-12-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DAYS/WK|SMD||FMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|SIGNIFICANT OTHER|ONCOLOGIST|Y|3||39||RUN-IN|1961-12-23||||1962-02-23||1971-01-23|1968-11-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/MMHG|PSA PROGRESSION||NMOL BCE/NMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|PROXY|PHYSIOTHERAPIST|NA|4||88||INDUCTION TREATMENT|1963-03-17||||1970-05-06||1962-05-27|1963-08-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||NEWLIND|NEW LESION INDICATOR||||10^9/DOSE|PR||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|PROXY|RATER|Y|4||88||OBSERVATION|1967-01-01||||1973-01-01||1967-06-23|1968-03-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/DAY|QUANTIFIABLE MRD POSITIVITY||ELISA UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|5||7||RUN-IN|1973-02-12||||1967-03-20||1965-11-22|1967-08-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9 ORGANISMS|MORPHOLOGIC LEUKEMIA-FREE STATE||UM/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|FRIEND|INTERNIST|U|5||7||WASHOUT|1971-03-15||||1961-06-14||1970-11-15|1966-07-28||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DIP|MORPHOLOGIC LEUKEMIA-FREE STATE||/5X10^4 WBC|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|ADJUDICATION COMMITTEE|RADIOLOGIST 1|NA|1||38||OPEN LABEL TREATMENT|1962-08-25||||1972-01-16||1967-09-08|1965-01-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||METBRESP|METABOLIC RESPONSE||||CD|NOT ALL EVALUATED||/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||WASHOUT|1960-05-08||||1966-04-04||1971-07-07|1963-01-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||METSIND|METASTATIC INDICATOR||||CIGAR|MRD NEGATIVITY||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|PROXY|RATER|N|2||58||OBSERVATION|1965-05-23||||1966-03-30||1964-05-29|1966-08-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/M2/H|PMD||CI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|2||58||OPEN LABEL TREATMENT|1968-09-20||||1960-10-23||1968-07-23|1960-10-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/G HB|CYTOGENETIC NO RESPONSE||MHZ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|PROXY|ONCOLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1963-02-08||||1961-08-18||1967-12-03|1964-03-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||STRUSTAT|STEROID USE STATUS||||PA|NED||VIAL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|3||39||LONG-TERM FOLLOW-UP|1962-03-06||||1966-08-03||1969-09-15|1962-08-26||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||STRUSTAT|STEROID USE STATUS||||NG/DL|MRD NEGATIVITY||CMH2O*S2/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|4||88||OBSERVATION|1964-07-09||||1971-07-11||1968-05-30|1973-07-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||METBRESP|METABOLIC RESPONSE||||KCAL|MOLECULAR CR||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BASELINE|1969-03-10||||1960-07-12||1968-04-13|1965-04-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMHG*MIN/L|IPR||DRUM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|5||7||CONTINUATION TREATMENT|1960-06-25||||1971-02-06||1966-12-18|1961-06-30||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||METSIND|METASTATIC INDICATOR||||%/S|PSA PROGRESSION||U/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|SIBLING|READER 1|NA|5||7||CONTINUATION TREATMENT|1972-07-07||||1963-01-10||1970-05-09|1968-08-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||TRGRESP|TARGET RESPONSE||||MGEQ|MOLECULAR CR||MG/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|ADJUDICATOR|RATER|N|1||38||CONTINUATION TREATMENT|1967-03-26||||1961-10-14||1969-07-10|1964-07-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||% INHIBITION|CYTOGENETIC PR||MMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|U|1||38||FOLLOW-UP|1963-06-21||||1963-09-25||1971-01-08|1967-07-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||TMRESP|TUMOR MARKER RESPONSE||||MOL/G|NON-ICR/NON-IUPD||MSEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|INVESTIGATOR|ADJUDICATOR 1|U|2||58||LONG-TERM FOLLOW-UP|1964-12-18||||1966-12-06||1963-08-19|1970-09-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||C|NED||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|FAMILY MEMBER|READER 3|NA|2||58||BASELINE|1960-06-11||||1963-05-22||1967-09-28|1970-02-06||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/MM|NPR||MET*H|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|3||39||FOLLOW-UP|1967-05-14||||1960-05-07||1963-05-11|1967-07-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/MOL|TREATMENT FAILURE||BQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|PROXY|READER|NA|3||39||BLINDED TREATMENT|1971-01-29||||1972-09-23||1966-08-17|1964-10-16||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||CLINRESP|CLINICAL RESPONSE||||ML|ICPD||PIXELS/CM|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|SPOUSE|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1973-01-26||||1962-09-20||1960-07-27|1971-09-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||BONERESP|BONE RESPONSE||||GENEQ|PD/RELAPSE AFTER HI||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1961-04-14||||1973-06-02||1971-05-26|1966-10-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/ML/DAY|MORPHOLOGIC CRI||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|U|5||7||RUN-IN|1971-08-01||||1963-10-25||1970-12-29|1961-07-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||LIVRRESP|LIVER RESPONSE||||NFIU|INCREASED||LINEAR FT*LB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|U|ADJUDICATOR|OPHTHALMOLOGIST|N|5||7||FOLLOW-UP|1968-06-11||||1961-09-07||1971-11-02|1973-04-09||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SACHET|PMD||PFU/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|FRIEND|NEUROLOGIST 1|NA|1||38||OBSERVATION|1960-02-13||||1970-02-24||1970-02-13|1970-11-27||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CM|PARTIAL MORPHOLOGIC RESPONSE||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|1||38||BASELINE|1971-07-16||||1969-03-07||1971-09-07|1970-02-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ELISA UNIT/DOSE|MRD PERSISTENCE||LOG10 PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|INVESTIGATOR|RATER 2|NA|2||58||RUN-IN|1972-03-21||||1962-04-20||1967-02-01|1963-06-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||STRUSTAT|STEROID USE STATUS||||MANSON U/ML|HI-P||NMOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|2||58||OPEN LABEL TREATMENT|1968-05-07||||1972-01-10||1969-04-09|1964-02-19||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PIXEL|NOT ALL EVALUATED||TESLA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|CHILD|MICROSCOPIST|N|3||39||CONTINUATION TREATMENT|1963-07-13||||1966-12-27||1970-08-11|1965-03-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||OVRLRESP|OVERALL RESPONSE||||MM3/MM2/YEAR|MRD PERSISTENCE||PFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|DOMESTIC PARTNER|DERMATOLOGIST|N|3||39||BASELINE|1961-11-20||||1965-01-20||1963-08-09|1972-02-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/ANIMAL/WK|CA125 50% RESPONSE||IU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|SIBLING|MICROSCOPIST 1|N|4||88||LONG-TERM FOLLOW-UP|1968-05-21||||1961-01-26||1966-10-30|1968-04-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ARBITRARY U|NR||G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|CHILD|PATHOLOGIST 1|U|4||88||BLINDED TREATMENT|1967-12-28||||1964-06-02||1962-05-26|1963-11-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/MIN|CR-CT||/5X10^4 WBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|5||7||INDUCTION TREATMENT|1970-05-11||||1962-04-29||1962-11-10|1966-06-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||CLINRESP|CLINICAL RESPONSE||||UMOL|MORPHOLOGIC CR||ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|5||7||OBSERVATION|1961-03-04||||1961-06-26||1960-08-23|1963-12-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/G|MRD PERSISTENCE||TRACE|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|PROXY|PATHOLOGIST 2|N|1||38||RUN-IN|1962-11-03||||1962-04-26||1960-11-11|1961-03-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||TMRESP|TUMOR MARKER RESPONSE||||COPIES/ML|MRD NEGATIVITY||BEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|STUDY SUBJECT|OPHTHALMOLOGIST|U|1||38||RUN-IN|1964-04-25||||1960-03-22||1973-06-12|1963-05-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||SPLNRESP|SPLEEN RESPONSE||||PA|IMMUNOPHENOTYPIC CR||ML/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|ADJUDICATOR|READER|Y|2||58||OBSERVATION|1968-10-05||||1966-09-03||1967-06-25|1968-04-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||ANATRESP|ANATOMIC RESPONSE||||COPIES/UG|PD-CT||OSM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|DOMESTIC PARTNER|MICROSCOPIST 1|U|2||58||LONG-TERM FOLLOW-UP|1966-05-08||||1969-09-21||1967-12-15|1969-09-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||LIVRRESP|LIVER RESPONSE||||ML/M2|HI-N||TABLET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|SPOUSE|ONCOLOGIST 1|NA|3||39||FOLLOW-UP|1963-02-10||||1966-07-28||1971-03-26|1962-11-15||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UOSM|NPR||KAT|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|3||39||OPEN LABEL TREATMENT|1960-11-24||||1960-11-21||1971-09-09|1961-10-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MMHG/SEC|CR||MMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|4||88||OBSERVATION|1971-05-29||||1960-02-17||1961-12-16|1963-02-07||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||LIVRRESP|LIVER RESPONSE||||IU/MMOL|STABLE||G/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|VENDOR|CLINICAL PATHOLOGIST|U|4||88||RUN-IN|1969-08-14||||1972-10-19||1965-07-14|1962-04-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MMOL/KG|PR||KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|5||7||TREATMENT|1963-08-07||||1962-10-13||1965-08-04|1964-12-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||LIVRRESP|LIVER RESPONSE||||L/MIN|PSEUDOPROGRESSION||U.CARR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|PROXY|FORENSIC PATHOLOGIST|U|5||7||INDUCTION TREATMENT|1968-06-01||||1968-04-04||1960-04-15|1965-10-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CAL|NON-QUANTIFIABLE MRD POSITIVITY||10^8/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1||38||INDUCTION TREATMENT|1972-11-17||||1972-11-12||1973-07-03|1973-02-09||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||METBRESP|METABOLIC RESPONSE||||ANTIBODY UNIT|CYTOGENETIC CR||FMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|1||38||FOLLOW-UP|1962-02-19||||1961-05-14||1972-05-13|1964-07-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||METBRESP|METABOLIC RESPONSE||||BQ/L|SD-CT||TSP|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|SIBLING|ADJUDICATOR 3|NA|2||58||FOLLOW-UP|1966-04-29||||1972-09-20||1968-04-02|1963-03-28||DURING||DURING|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||LENS|CYTOGENETIC MINOR RESPONSE||FL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|CAREGIVER|DERMATOLOGIST|NA|2||58||INDUCTION TREATMENT|1961-08-08||||1962-05-06||1965-08-19|1965-04-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||CLINRESP|CLINICAL RESPONSE||||FT3|HI-E||MAMP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|STUDY SUBJECT|CARDIOLOGIST|U|3||39||OBSERVATION|1965-06-25||||1970-07-20||1973-05-11|1961-07-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||PATHRESP|PATHOLOGIC RESPONSE||||HZ|NON-CR/NON-PD||M3|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|3||39||OBSERVATION|1969-08-13||||1962-02-18||1962-02-25|1971-12-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||METSIND|METASTATIC INDICATOR||||NG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||10^3 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|INTERVIEWER|PHYSIOTHERAPIST|U|4||88||SCREENING|1965-04-07||||1970-11-01||1970-11-04|1970-11-16||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||MOLRESP|MOLECULAR RESPONSE||||MV*MIN|SCR||LOG10 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|INDEPENDENT ASSESSOR|HEMATOLOGIST|U|4||88||OBSERVATION|1968-12-31||||1963-05-01||1965-07-13|1972-05-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NEWTON|PMD||/10^5|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|ADJUDICATOR|RATER 2|U|5||7||INDUCTION TREATMENT|1967-02-08||||1960-07-05||1969-10-08|1966-11-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/KG/WEEK|IPR||BEATS/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1965-05-14||||1968-11-12||1971-12-19|1962-02-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||CLINRESP|CLINICAL RESPONSE||||MPS U|CYTOGENETIC CR||KV|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|1||38||INDUCTION TREATMENT|1965-02-15||||1966-03-09||1963-05-22|1962-10-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TUBE|NON-ICR/NON-IUPD||LM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|1||38||SCREENING|1960-04-23||||1973-01-26||1960-09-05|1972-02-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UMOL/H/MMOL|MINOR PATHOLOGIC RESPONSE||BU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|ADJUDICATION COMMITTEE|UROLOGIST|Y|2||58||CONTINUATION TREATMENT|1966-09-10||||1964-12-14||1969-11-27|1972-04-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||VP/DOSE|ISD||10^6 IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|CAREGIVER|ONCOLOGIST 1|Y|2||58||BLINDED TREATMENT|1964-09-30||||1963-09-10||1965-06-24|1966-09-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UM|PDU||10^6 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|FAMILY MEMBER|READER 2|N|3||39||FOLLOW-UP|1961-07-19||||1964-02-26||1969-11-06|1963-04-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NMOL/KG/DAY|MRD NEGATIVITY||BISCUIT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|3||39||OPEN LABEL TREATMENT|1967-02-23||||1969-08-06||1973-05-22|1961-05-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||STRUSTAT|STEROID USE STATUS||||PACKET|PARTIAL MORPHOLOGIC RESPONSE||MPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|SPOUSE|ADJUDICATOR 3|Y|4||88||OBSERVATION|1962-10-05||||1969-11-09||1966-07-29|1964-07-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/M2/DAY|PD FROM PR||CMH2O/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|FAMILY MEMBER|OPHTHALMOLOGIST|NA|4||88||TREATMENT|1968-07-04||||1960-02-16||1966-03-02|1962-09-22||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/KG|VGPR||G/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|CHILD|ONCOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1971-11-11||||1965-09-25||1973-03-31|1972-08-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||BESTRESP|BEST OVERALL RESPONSE||||MILE|CR||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||RUN-IN|1971-01-16||||1966-06-24||1971-09-16|1970-10-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UL/ML|INDETERMINATE RESPONSE||L/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|SPOUSE|HEMATOLOGIST|NA|1||38||BLINDED TREATMENT|1966-08-10||||1961-05-22||1965-09-30|1968-04-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IU/KG|PD-CT||BQ/MG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|1||38||WASHOUT|1961-01-23||||1963-05-21||1968-04-10|1962-03-31||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/MM|MORPHOLOGIC LEUKEMIA-FREE STATE||MCI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|PARENT|ADJUDICATOR 3|Y|2||58||FOLLOW-UP|1961-01-14||||1966-05-15||1966-01-21|1969-11-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/L|CMR||PSEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|CHILD|OPHTHALMOLOGIST|NA|2||58||RUN-IN|1960-08-30||||1972-02-17||1973-08-30|1968-12-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL|COMPLETE MRD RESPONSE||MAMP|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INDEPENDENT ASSESSOR|INTERNIST|U|3||39||BASELINE|1972-04-04||||1972-11-04||1966-08-15|1970-04-13||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/2000 RBC|PR||DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|INVESTIGATOR|OTOLARYNGOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1972-11-27||||1962-04-09||1969-01-08|1969-11-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MV2/HZ|PD-CT||ML/M2/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|SIBLING|READER 2|U|4||88||LONG-TERM FOLLOW-UP|1961-09-12||||1971-04-11||1965-09-06|1972-04-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||TROCHE|INDETERMINATE RESPONSE||NCI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|DOMESTIC PARTNER|RADIOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1965-02-09||||1968-02-22||1967-05-09|1962-11-10||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||NEWLPROG|NEW LESION PROGRESSION||||TITER|FAVORABLE RESPONSE||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|VENDOR|PHYSIOTHERAPIST|NA|5||7||TREATMENT|1968-07-24||||1962-11-03||1966-12-20|1970-06-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MET*H|CPR||IU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|STUDY SUBJECT|ONCOLOGIST 2|Y|5||7||BASELINE|1969-04-10||||1966-02-05||1967-07-25|1960-09-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MEQ/UL|DECREASED||GY|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|INVESTIGATOR|ONCOLOGIST|NA|1||38||OBSERVATION|1966-07-01||||1969-01-06||1960-07-10|1962-12-28||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||METSIND|METASTATIC INDICATOR||||SPRAY|MORPHOLOGIC CR||IN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|1||38||OPEN LABEL TREATMENT|1964-10-17||||1963-01-10||1961-06-04|1962-07-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^7 CFU|RELAPSED DISEASE FROM CR OR PR||STRIP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIBLING|ADJUDICATOR 3|U|2||58||FOLLOW-UP|1963-02-16||||1961-08-28||1969-02-13|1972-09-13||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NEBULE|SCR||MCI|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|N|2||58||INDUCTION TREATMENT|1962-10-19||||1967-09-13||1972-05-20|1962-11-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||G/M2|DECREASED||UG/L/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|FRIEND|OPHTHALMOLOGIST|NA|3||39||SCREENING|1961-10-10||||1970-06-06||1971-03-20|1962-05-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||ANATRESP|ANATOMIC RESPONSE||||OD UNIT|HI-P||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|INVESTIGATOR|ONCOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1965-07-01||||1968-12-11||1972-10-27|1966-09-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||V/V|PD FROM PR||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|4||88||BLINDED TREATMENT|1969-06-20||||1968-01-26||1967-11-29|1961-12-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MCI/KG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|READER 3|N|4||88||RUN-IN|1967-07-30||||1971-09-09||1960-05-23|1969-05-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ELISA UNIT|HI-P||UMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|5||7||WASHOUT|1971-08-02||||1965-03-02||1962-05-04|1966-04-30||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MMHG*MIN/L|MRD PERSISTENCE||M/SEC2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CHILD|MICROSCOPIST 2|U|5||7||BASELINE|1972-08-25||||1961-12-17||1967-11-18|1963-07-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MBQ|PD/RELAPSE AFTER HI||PELLET|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|1||38||LONG-TERM FOLLOW-UP|1968-04-16||||1962-03-29||1961-10-24|1969-07-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UIU/DL|PD FROM PR||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|SIGNIFICANT OTHER|OPTOMETRIST|Y|1||38||WASHOUT|1963-07-02||||1969-02-04||1963-03-26|1970-04-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||BESTRESP|BEST OVERALL RESPONSE||||KUSP|NOT ALL EVALUATED||NMOL/L/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|PROXY|RATER 2|Y|2||58||OBSERVATION|1962-06-12||||1960-05-28||1973-07-17|1961-05-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||BESTRESP|BEST OVERALL RESPONSE||||PPTH|PSEUDOPROGRESSION||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|VENDOR|OPTOMETRIST|Y|2||58||BASELINE|1966-02-04||||1968-12-10||1967-11-12|1960-07-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NL|CYTOGENETIC MINIMAL RESPONSE||MG/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||FOLLOW-UP|1964-12-11||||1964-08-23||1960-12-11|1963-02-07||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||OVRLRESP|OVERALL RESPONSE||||G/CM2|UNFAVORABLE RESPONSE||MG/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|INVESTIGATOR|MICROSCOPIST|Y|3||39||SCREENING|1972-04-03||||1972-11-20||1969-01-26|1964-01-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MOL/G|WORSENED||CCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|PARENT|PATHOLOGIST 1|U|4||88||RUN-IN|1961-03-03||||1964-11-19||1965-11-08|1964-08-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/CM H2O|CA125 50% RESPONSE||FT|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|4||88||OBSERVATION|1965-12-22||||1966-05-15||1971-06-19|1966-07-25||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^4/L|PMD||IU/MG|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|UROLOGIST|Y|5||7||BASELINE|1960-01-08||||1968-11-30||1961-03-31|1970-06-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||STRUSTAT|STEROID USE STATUS||||ML/MMHG|PR WITH LYMPHOCYTOSIS||UG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||OBSERVATION|1970-03-15||||1972-03-13||1969-01-22|1972-04-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||SPLNRESP|SPLEEN RESPONSE||||M3|MRD RELAPSE||UMOL/MG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|CHILD|ONCOLOGIST|N|1||38||INDUCTION TREATMENT|1970-08-13||||1965-03-09||1963-08-08|1964-08-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||WEBER|DISEASE TRANSFORMATION||GPL U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|INTERVIEWER|ONCOLOGIST 1|Y|1||38||RUN-IN|1963-07-29||||1964-04-23||1970-11-07|1960-08-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CD*S/M2|CCR||U/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|SIBLING|RADIOLOGIST 1|U|2||58||INDUCTION TREATMENT|1961-04-22||||1962-04-26||1967-01-25|1960-01-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||MOLRESP|MOLECULAR RESPONSE||||MMOL/MIN/KPA/L|PSA PROGRESSION||PMOL/10^9 CELLS|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|U|2||58||OBSERVATION|1967-05-17||||1962-09-22||1973-03-26|1973-02-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PACKAGE|MORPHOLOGIC CRI||UOSM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|INTERVIEWER|RATER|N|3||39||RUN-IN|1972-02-20||||1968-12-27||1968-05-16|1960-12-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||SPLNRESP|SPLEEN RESPONSE||||/10^4|ICPD||NSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|PROXY|PATHOLOGIST|U|3||39||CONTINUATION TREATMENT|1967-01-24||||1966-12-14||1965-08-21|1968-10-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KDA|NR||MIN*MG/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1973-05-11||||1972-01-13||1967-11-11|1968-12-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AMPULE|PR||BQ/MG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|GUARDIAN|RATER|U|4||88||OBSERVATION|1970-06-30||||1970-11-25||1970-07-06|1966-03-01||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||NMOL/MOL|IPR||BU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|5||7||OBSERVATION|1970-11-16||||1965-08-04||1961-01-05|1964-12-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/KG/DAY|ICPD||/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|VENDOR|NEUROLOGIST 2|NA|5||7||TREATMENT|1961-12-05||||1970-01-20||1966-01-11|1969-10-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU|NR||10^11/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|ADJUDICATION COMMITTEE|NEUROLOGIST|U|1||38||TREATMENT|1965-12-20||||1963-08-04||1969-04-30|1973-04-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^6 DNA COPIES/ML|PR||KN/CM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1||38||BASELINE|1970-05-06||||1969-05-29||1972-12-18|1967-09-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^5/HPF|OPTIMAL MORPHOLOGIC RESPONSE||CCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|2||58||INDUCTION TREATMENT|1971-02-27||||1972-12-31||1966-04-02|1960-12-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||METSIND|METASTATIC INDICATOR||||RFU|MR||MMU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|GUARDIAN|PHYSIOTHERAPIST|NA|2||58||RUN-IN|1961-05-28||||1972-04-10||1964-10-13|1962-07-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||METBRESP|METABOLIC RESPONSE||||PMOL/DAY|PARTIAL MORPHOLOGIC RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|DOMESTIC PARTNER|PATHOLOGIST 1|U|3||39||TREATMENT|1962-08-07||||1971-10-28||1970-06-17|1965-10-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KG/L|IMPROVED||NG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CAREGIVER|ADJUDICATOR 3|NA|3||39||RUN-IN|1967-04-14||||1961-07-12||1962-06-21|1970-08-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||LIVRRESP|LIVER RESPONSE||||PPTH|PDU||IU/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|VENDOR|PATHOLOGIST|N|4||88||CONTINUATION TREATMENT|1964-02-22||||1969-03-08||1961-06-09|1971-01-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PL|PR WITH LYMPHOCYTOSIS||MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|4||88||FOLLOW-UP|1967-09-12||||1972-04-22||1962-08-12|1971-12-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||STRUSTAT|STEROID USE STATUS||||UG/ANIMAL|PSEUDOPROGRESSION||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|PARENT|ADJUDICATOR 2|N|5||7||TREATMENT|1965-09-06||||1964-02-04||1971-09-16|1965-04-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/VF|CMR||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|INVESTIGATOR|RADIOLOGIST|U|5||7||RUN-IN|1965-12-09||||1970-11-30||1964-04-13|1972-08-25||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BAU/ML|DECREASED||DB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|VENDOR|READER 1|NA|1||38||INDUCTION TREATMENT|1964-03-13||||1964-05-04||1962-11-13|1961-06-18||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||SPLNRESP|SPLEEN RESPONSE||||VOXEL|PD FROM PR||ML/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|FAMILY MEMBER|READER 2|NA|1||38||BASELINE|1966-01-06||||1962-10-14||1965-03-30|1960-08-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/M2/MIN|PR-CT||KIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|FRIEND|RATER|U|2||58||OPEN LABEL TREATMENT|1961-03-15||||1967-09-07||1968-05-09|1966-08-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||STRUSTAT|STEROID USE STATUS||||MSEC|NON-CR/NON-PD||PSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|FRIEND|MICROSCOPIST 2|Y|2||58||FOLLOW-UP|1971-06-05||||1973-02-27||1967-03-14|1969-03-07||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||STRUSTAT|STEROID USE STATUS||||DDU|RELAPSED DISEASE FROM CR||KG/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||BLINDED TREATMENT|1970-12-03||||1964-03-19||1968-05-13|1971-05-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IU/G HB|PMR||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|VENDOR|NEUROLOGIST 2|NA|3||39||OBSERVATION|1964-11-05||||1972-07-17||1971-11-15|1963-12-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OI50|ICPD||UG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1961-07-27||||1963-03-12||1966-07-29|1967-11-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/UL|RELAPSED DISEASE||10^6 RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|ADJUDICATOR|RATER|NA|4||88||FOLLOW-UP|1967-05-05||||1962-01-22||1961-10-23|1968-08-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||METBRESP|METABOLIC RESPONSE||||ML/M2|IPR||FEU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|Y|5||7||BLINDED TREATMENT|1964-12-25||||1972-12-20||1960-10-18|1963-05-17||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||NTRGRESP|NON-TARGET RESPONSE||||/5X10^4 WBC|ICR||KG/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CAREGIVER|RADIOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1960-10-30||||1965-10-22||1969-06-27|1963-03-14||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PNU/ML|PARTIAL MORPHOLOGIC RESPONSE||SBE/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|STUDY SUBJECT|READER|NA|1||38||INDUCTION TREATMENT|1965-10-08||||1964-03-07||1966-04-21|1961-06-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||SPLNRESP|SPLEEN RESPONSE||||ML/ANIMAL/DAY|IUPD||MMHG/L/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|INTERVIEWER|MICROSCOPIST 2|N|1||38||CONTINUATION TREATMENT|1964-05-04||||1963-01-15||1966-09-08|1967-03-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DROP|COMPLETE MRD RESPONSE||UL/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|ADJUDICATOR|UROLOGIST|Y|2||58||BLINDED TREATMENT|1967-03-10||||1966-06-28||1960-12-10|1964-01-09||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||LIVRRESP|LIVER RESPONSE||||U/G HB|SMD||MBQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CHILD|PEDIATRIC NEUROLOGIST|U|2||58||TREATMENT|1960-07-01||||1963-12-19||1966-06-06|1960-01-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||NTRGRESP|NON-TARGET RESPONSE||||/MONTH|NR||CMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|SPOUSE|ADJUDICATOR 1|U|3||39||FOLLOW-UP|1968-12-07||||1963-08-22||1963-10-22|1970-04-12||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/KG|CCR||NKAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|3||39||OBSERVATION|1967-12-01||||1972-08-29||1962-08-03|1973-07-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/MMOL|NON-CR/NON-PD||ML/MMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CAREGIVER|OPTOMETRIST|Y|4||88||SCREENING|1968-08-02||||1963-01-10||1964-06-13|1971-05-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||TMRESP|TUMOR MARKER RESPONSE||||K|MRD NEGATIVITY||MG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|SIBLING|READER|N|4||88||OPEN LABEL TREATMENT|1972-04-01||||1962-01-29||1967-11-29|1963-07-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||METBRESP|METABOLIC RESPONSE||||U/G/DAY|CA125 50% RESPONSE||RING|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|ADJUDICATOR|ONCOLOGIST 2|N|5||7||CONTINUATION TREATMENT|1968-08-13||||1967-02-19||1962-06-27|1971-09-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||ANATRESP|ANATOMIC RESPONSE||||CI/L|SCR||YD|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|SIGNIFICANT OTHER|MICROSCOPIST 3|N|5||7||SCREENING|1971-10-17||||1961-02-16||1963-05-01|1966-06-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||BONERESP|BONE RESPONSE||||PUFF|DISEASE TRANSFORMATION||U/CL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|STUDY SUBJECT|ADJUDICATOR 1|U|1||38||FOLLOW-UP|1969-05-07||||1964-07-06||1969-09-09|1971-07-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^5/L|PCR||UCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|1||38||SCREENING|1966-08-16||||1963-10-30||1964-11-01|1971-03-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/G|WORSENED||BQ/UG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|SIGNIFICANT OTHER|PATHOLOGIST 1|N|2||58||BASELINE|1968-08-07||||1962-12-23||1960-06-01|1972-03-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||L/DAY|HI-P||GY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||BASELINE|1970-04-16||||1965-03-26||1961-07-28|1966-09-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||ANATRESP|ANATOMIC RESPONSE||||HOMEOPATHIC DILUTION|RELAPSED DISEASE FROM CR||10^3 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|STUDY SUBJECT|HEMATOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1960-09-17||||1961-08-30||1964-02-04|1969-10-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NM|COMPLETE MRD RESPONSE||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|VENDOR|OPHTHALMOLOGIST|U|3||39||WASHOUT|1970-02-03||||1969-04-11||1966-04-20|1966-05-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KDA|DECREASED||BAG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|PROXY|NEUROLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1972-03-15||||1972-03-27||1965-01-28|1968-05-18||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||BESTRESP|BEST OVERALL RESPONSE||||DMOL|CYTOGENETIC NO RESPONSE||CYLINDER|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|ADJUDICATOR|FORENSIC PATHOLOGIST|Y|4||88||TREATMENT|1972-12-03||||1964-07-15||1971-03-08|1963-07-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||LIVRRESP|LIVER RESPONSE||||L/DAY|PCR||MOSM/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|PARENT|NEUROLOGIST|U|5||7||TREATMENT|1961-10-18||||1971-12-06||1971-10-20|1961-01-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||TRGRESP|TARGET RESPONSE||||U/G/H|PSA PROGRESSION||ML/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|INTERVIEWER|NEUROLOGIST|N|5||7||OBSERVATION|1962-09-21||||1965-02-25||1962-03-08|1969-10-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||NEWLPROG|NEW LESION PROGRESSION||||KG/CM|NON-QUANTIFIABLE MRD POSITIVITY||MPH|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|1||38||WASHOUT|1973-03-11||||1966-03-03||1961-01-22|1969-04-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||SPLNRESP|SPLEEN RESPONSE||||MEQ/KG|MCR||SFC/10^6 PBMC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|PARENT|ADJUDICATOR|U|1||38||OBSERVATION|1965-11-17||||1970-07-16||1972-12-06|1970-05-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/DL|IPR||VIAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|CHILD|HEMATOLOGIST|N|2||58||BASELINE|1965-12-16||||1968-07-14||1970-10-06|1968-07-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BOWL|UNFAVORABLE RESPONSE||YD|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|SPOUSE|CLINICAL PATHOLOGIST|N|2||58||TREATMENT|1966-08-28||||1967-05-08||1969-03-17|1964-01-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PKAT|MINOR PATHOLOGIC RESPONSE||/CMH2O|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|GUARDIAN|NEUROLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1966-08-10||||1965-02-07||1968-10-01|1972-09-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||STRUSTAT|STEROID USE STATUS||||GPELISA UNIT/ML|RELAPSED DISEASE FROM CR OR PR||CCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|INTERVIEWER|INTERNIST|U|3||39||BASELINE|1964-12-27||||1961-02-01||1966-08-20|1963-08-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||METBRESP|METABOLIC RESPONSE||||IN|PSEUDOPROGRESSION||ENZYME U/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|INVESTIGATOR|UROLOGIST|NA|4||88||CONTINUATION TREATMENT|1970-06-12||||1969-10-17||1963-06-27|1964-07-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||NEWLIND|NEW LESION INDICATOR||||PLUG|CYTOGENETIC PR||PACKAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|FRIEND|NEUROLOGIST|NA|4||88||FOLLOW-UP|1966-09-12||||1970-03-19||1965-10-06|1967-02-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||NEWLIND|NEW LESION INDICATOR||||PMOL/L|INDETERMINATE RESPONSE||ML/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1964-09-14||||1964-08-09||1961-08-27|1972-02-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||BONERESP|BONE RESPONSE||||OHM|SCR||CM H2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|5||7||BLINDED TREATMENT|1961-10-12||||1965-09-13||1962-02-06|1966-01-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||CLINRESP|CLINICAL RESPONSE||||CS|MORPHOLOGIC CR||MU/G|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|CLINICAL STUDY SPONSOR|RATER 1|NA|1||38||RUN-IN|1960-08-11||||1964-05-26||1970-06-01|1966-11-04||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DRUM|NON-CR/NON-PD||TROCHE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|CHILD|CARDIOLOGIST|N|1||38||CONTINUATION TREATMENT|1962-11-02||||1967-03-19||1968-04-25|1969-05-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||ANATRESP|ANATOMIC RESPONSE||||10^4/L|CYTOGENETIC NO RESPONSE||MG/M2/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|PARENT|READER 3|N|2||58||BASELINE|1967-05-28||||1966-03-15||1967-08-19|1968-07-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/KG/MIN|CA125 75% RESPONSE||/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|CAREGIVER|MICROSCOPIST 2|U|2||58||FOLLOW-UP|1967-04-27||||1972-05-06||1967-02-05|1970-06-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/KG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||DRAM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|SIGNIFICANT OTHER|READER 1|Y|3||39||LONG-TERM FOLLOW-UP|1965-04-13||||1965-06-14||1963-10-03|1972-01-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||NEWLIND|NEW LESION INDICATOR||||MOL/L|RELAPSED DISEASE||USP U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|STUDY SUBJECT|MICROSCOPIST 1|U|3||39||SCREENING|1960-07-22||||1967-02-19||1966-10-30|1960-11-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||MOLRESP|MOLECULAR RESPONSE||||KM|SD-CT||YD|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|ADJUDICATOR|ONCOLOGIST|Y|4||88||RUN-IN|1970-06-05||||1969-12-29||1969-02-01|1961-05-30||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||STEPS/MIN|QUANTIFIABLE MRD POSITIVITY||TUBE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|SPOUSE|READER|N|4||88||INDUCTION TREATMENT|1972-07-28||||1973-02-20||1967-05-21|1967-10-22||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||BESTRESP|BEST OVERALL RESPONSE||||SV|SD-CT||10^6 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|5||7||TREATMENT|1962-02-20||||1972-12-23||1960-03-28|1968-07-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/L|PARTIAL MORPHOLOGIC RESPONSE||IU/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|SIGNIFICANT OTHER|READER 2|U|5||7||WASHOUT|1961-10-14||||1963-10-06||1971-03-21|1961-06-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||NEWLIND|NEW LESION INDICATOR||||P|MOLECULAR MAJOR RESPONSE||COAT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|SPOUSE|CARDIOLOGIST|NA|1||38||WASHOUT|1973-02-13||||1967-02-21||1961-05-19|1964-05-14||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FMOL/G|PR WITH LYMPHOCYTOSIS||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|PROXY|RADIOLOGIST 1|N|1||38||CONTINUATION TREATMENT|1966-04-10||||1973-07-07||1961-09-28|1969-01-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||BESTRESP|BEST OVERALL RESPONSE||||PPTR|MRD NEGATIVITY||IU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2||58||FOLLOW-UP|1963-08-13||||1968-04-22||1967-11-01|1966-07-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/G/MIN|ICR||POINT|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|STUDY SUBJECT|OPHTHALMOLOGIST|Y|2||58||SCREENING|1967-08-24||||1964-01-29||1966-08-19|1967-10-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||STRUSTAT|STEROID USE STATUS||||RATIO|INCREASED||RATIO|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OBSERVATION|1969-08-11||||1970-03-01||1965-11-16|1964-01-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DPM/MG|IPR||PPB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|CAREGIVER|ONCOLOGIST 2|N|3||39||RUN-IN|1965-08-18||||1961-02-18||1964-07-19|1965-10-05||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MNFI|CYTOGENETIC MINIMAL RESPONSE||NEWTON|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|SIBLING|ADJUDICATOR 3|U|4||88||INDUCTION TREATMENT|1962-08-26||||1960-09-09||1971-05-08|1973-04-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/BREATH|NON-ICR/NON-IUPD||CPM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|VENDOR|READER 1|NA|4||88||FOLLOW-UP|1971-05-12||||1968-07-22||1973-01-18|1963-12-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||METBRESP|METABOLIC RESPONSE||||UG|PMR||DEG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|ADJUDICATOR|RADIOLOGIST 2|U|5||7||SCREENING|1969-03-29||||1971-07-19||1961-12-01|1967-09-20||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7 CFU/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ANTIBODY UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|DOMESTIC PARTNER|DERMATOLOGIST|N|5||7||BASELINE|1971-08-30||||1968-07-24||1967-06-20|1961-04-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EVENTS|HI-E||GBQ|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|ADJUDICATOR|RATER 2|U|1||38||LONG-TERM FOLLOW-UP|1967-06-23||||1965-10-13||1966-08-20|1962-04-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||STRUSTAT|STEROID USE STATUS||||ML/M2|ABSENT MORPHOLOGIC RESPONSE||PACKAGE|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|CLINICAL STUDY SPONSOR|RATER|N|1||38||WASHOUT|1972-08-22||||1966-02-17||1964-05-22|1961-12-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||NEWLPROG|NEW LESION PROGRESSION||||PFU/ANIMAL|PSA PROGRESSION||POUCH|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|U|2||58||BLINDED TREATMENT|1972-08-24||||1963-01-22||1962-09-20|1973-06-20||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MM|PCR||IU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|FAMILY MEMBER|NEUROLOGIST 2|Y|2||58||WASHOUT|1960-05-19||||1971-06-26||1973-06-25|1962-02-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MPH|PDU||UG/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|3||39||BLINDED TREATMENT|1964-08-10||||1964-08-28||1971-03-14|1964-10-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/CM3/MIN|HI-E||ML/CM3/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|PROXY|PHYSIOTHERAPIST|U|3||39||FOLLOW-UP|1968-11-06||||1969-03-22||1968-12-11|1970-05-23||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 ELISA UNIT|WORSENED||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|PARENT|ONCOLOGIST|NA|4||88||RUN-IN|1960-11-03||||1967-11-06||1968-10-05|1964-05-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG EID 50/DOSE|CYTOGENETIC NO RESPONSE||KCAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|CHILD|FORENSIC PATHOLOGIST|NA|4||88||TREATMENT|1962-07-14||||1962-11-16||1964-07-12|1970-11-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/M2/DAY|STABLE||MIN*MG/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|5||7||FOLLOW-UP|1962-07-30||||1965-07-08||1960-12-12|1965-07-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||AG|RELAPSED DISEASE||IU/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|SIBLING|ONCOLOGIST 2|N|5||7||BLINDED TREATMENT|1962-06-10||||1968-08-02||1972-05-13|1965-09-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/MONTH|SD-CT||ML/100G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|1||38||WASHOUT|1965-05-17||||1971-10-14||1968-04-10|1973-02-16||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||SPLNRESP|SPLEEN RESPONSE||||HOUNSFIELD UNIT|STABLE||VG/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|1||38||INDUCTION TREATMENT|1972-02-07||||1963-06-11||1967-05-18|1968-08-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KG/L|PSEUDOPROGRESSION||ML/KG|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1973-09-03||||1963-08-20||1969-10-04|1966-04-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/KG/MIN|CYTOGENETIC NO RESPONSE||MOL/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||WASHOUT|1965-01-15||||1968-03-09||1969-10-03|1964-03-27||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6 ORGANISMS|SD-CT||UU/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|ADJUDICATOR|RATER|NA|3||39||BASELINE|1961-06-15||||1963-12-31||1960-11-17|1964-08-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DAMOL/L|SMD||KA_U/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|STUDY SUBJECT|MICROSCOPIST 2|U|3||39||BLINDED TREATMENT|1967-12-03||||1968-06-15||1965-02-05|1968-06-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||TRGRESP|TARGET RESPONSE||||ML/H|VGPR||ML/MIN/MMHG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|DOMESTIC PARTNER|RADIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1963-10-09||||1967-05-01||1971-05-15|1966-04-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||BESTRESP|BEST OVERALL RESPONSE||||POUCH|CYTOGENETIC MINIMAL RESPONSE||PATCH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|PARENT|OPHTHALMOLOGIST|NA|4||88||OBSERVATION|1968-10-29||||1961-02-22||1973-03-17|1972-02-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/M2/MIN|CYTOGENETIC MINIMAL RESPONSE||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|Y|FRIEND|READER|NA|5||7||RUN-IN|1970-03-05||||1970-10-16||1966-05-07|1970-02-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||STRUSTAT|STEROID USE STATUS||||10^7 CFU/ML|PD-CT||YD|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|FRIEND|PATHOLOGIST 1|Y|5||7||WASHOUT|1961-10-30||||1963-05-30||1962-03-17|1961-12-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||MOLRESP|MOLECULAR RESPONSE||||RFU|TREATMENT FAILURE||LOG10 CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|VENDOR|READER|N|1||38||WASHOUT|1973-08-08||||1965-01-03||1963-02-10|1965-01-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||TRGRESP|TARGET RESPONSE||||S/H|PARTIAL MORPHOLOGIC RESPONSE||HZ/S|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|FRIEND|MICROSCOPIST 3|NA|1||38||BASELINE|1972-07-13||||1971-08-31||1967-05-07|1967-06-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KV|EQUIVOCAL||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|2||58||WASHOUT|1967-11-20||||1966-08-20||1971-04-13|1966-12-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/KG|MORPHOLOGIC CRI||RING|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|CAREGIVER|CARDIOLOGIST|NA|2||58||SCREENING|1972-08-03||||1969-11-24||1968-07-14|1969-03-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||METSIND|METASTATIC INDICATOR||||DISK|MOLECULAR MAJOR RESPONSE||DPM/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|3||39||WASHOUT|1962-02-07||||1972-01-26||1964-09-09|1967-11-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||NEWLIND|NEW LESION INDICATOR||||MCI|RELAPSED DISEASE FROM CR OR PR||U/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|PROXY|READER 3|N|3||39||TREATMENT|1966-08-20||||1966-05-24||1970-12-30|1960-05-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DRINK|NOT ALL EVALUATED||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|READER 3|NA|4||88||FOLLOW-UP|1970-06-25||||1964-10-30||1972-05-27|1969-10-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||TRGRESP|TARGET RESPONSE||||ML*CMH2O|SCR||UEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|DOMESTIC PARTNER|DERMATOLOGIST|N|4||88||OPEN LABEL TREATMENT|1960-01-04||||1960-07-13||1965-03-10|1960-07-02||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^3/HPF|CCR||MILE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||LONG-TERM FOLLOW-UP|1971-06-24||||1967-10-19||1972-06-11|1969-08-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||COPIES/UG|PD||GBQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|INTERVIEWER|MICROSCOPIST 1|U|5||7||LONG-TERM FOLLOW-UP|1972-02-16||||1964-12-22||1971-03-18|1968-07-02||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DYN|CA125 75% RESPONSE||MG/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|CAREGIVER|RATER|NA|1||38||OBSERVATION|1960-03-11||||1969-11-01||1970-03-06|1969-04-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BQ/ML|IMPROVED||PMOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|1||38||INDUCTION TREATMENT|1972-02-01||||1972-03-24||1968-01-24|1971-11-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||METSIND|METASTATIC INDICATOR||||TRANSDUCING UNIT/ML|NON-QUANTIFIABLE MRD POSITIVITY||LOG10 PFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|FRIEND|CLINICAL PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1967-11-21||||1966-06-02||1962-06-29|1972-03-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||NTRGRESP|NON-TARGET RESPONSE||||MG/DL|RELAPSED DISEASE FROM CR||MJOULE/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|SIBLING|UROLOGIST|U|2||58||BLINDED TREATMENT|1965-01-28||||1971-01-08||1971-07-05|1966-10-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||NEWLIND|NEW LESION INDICATOR||||MOSM/L|CYTOGENETIC MINOR RESPONSE||UG/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|3||39||FOLLOW-UP|1960-03-22||||1968-09-29||1962-05-24|1966-08-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ENZYME U/M2|COMPLETE MRD RESPONSE||L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|N|3||39||BLINDED TREATMENT|1972-08-10||||1970-07-06||1963-01-02|1972-03-31||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 ELISA UNIT/DOSE|PMD||CI/MG|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|STUDY SUBJECT|ADJUDICATOR 3|N|4||88||WASHOUT|1970-06-03||||1969-09-25||1967-02-25|1967-07-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||BONERESP|BONE RESPONSE||||MEQ/UL|ABSENT MORPHOLOGIC RESPONSE||FMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|RATER 1|Y|4||88||BASELINE|1962-10-03||||1963-01-23||1961-04-09|1960-01-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||RDIORESP|RADIOLOGIC RESPONSE||||FINGERTIP UNIT|MR||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|CLINICAL STUDY SPONSOR|RATER|Y|5||7||WASHOUT|1972-04-14||||1966-07-10||1969-11-11|1967-03-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||BONERESP|BONE RESPONSE||||%|MRD RELAPSE||ML/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|DOMESTIC PARTNER|ADJUDICATOR 2|Y|5||7||SCREENING|1966-05-19||||1970-11-29||1970-11-13|1967-07-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||S^-1(%O2)^-1|CYTOGENETIC MINIMAL RESPONSE||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|VENDOR|ADJUDICATOR 3|N|1||38||RUN-IN|1970-11-30||||1961-07-17||1969-01-14|1970-10-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||M2|INDETERMINATE RESPONSE||ECL UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|DOMESTIC PARTNER|PATHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1972-12-27||||1967-07-20||1966-05-14|1972-01-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||EID 50/ML|CMR||10^6 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|PARENT|ADJUDICATOR|N|2||58||BASELINE|1965-12-09||||1973-06-13||1970-01-31|1961-04-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||TRGRESP|TARGET RESPONSE||||G/L|ISD||KN/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|PROXY|RADIOLOGIST|NA|2||58||BLINDED TREATMENT|1960-06-07||||1971-02-05||1960-08-01|1965-11-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||VG/ML|NED||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||FOLLOW-UP|1970-07-12||||1960-11-19||1960-06-23|1962-08-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^3/L|CYTOGENETIC CR||UMOL/MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|3||39||FOLLOW-UP|1964-04-13||||1970-05-15||1970-02-08|1966-01-27||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||OVRLRESP|OVERALL RESPONSE||||MPA|HI-E||MASK|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|STUDY SUBJECT|MICROSCOPIST 1|U|4||88||OPEN LABEL TREATMENT|1967-04-02||||1961-06-20||1971-09-03|1961-07-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||MOLRESP|MOLECULAR RESPONSE||||MG/CM2|MRD PERSISTENCE||10^6 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|ADJUDICATION COMMITTEE|RATER|Y|4||88||OPEN LABEL TREATMENT|1968-06-07||||1968-02-10||1967-10-28|1960-04-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SFC/10^6 PBMC|MR||SBE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|5||7||WASHOUT|1967-03-07||||1970-01-19||1970-09-07|1968-11-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||TBSP|NON-QUANTIFIABLE MRD POSITIVITY||CONTAINER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|5||7||TREATMENT|1972-11-12||||1966-09-25||1971-09-02|1963-05-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||METSIND|METASTATIC INDICATOR||||UMOL/MIN|IPR||RING|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|PARENT|READER 1|U|1||38||BASELINE|1969-04-22||||1971-01-05||1972-11-14|1971-03-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||TRGRESP|TARGET RESPONSE||||VG/ML|RELAPSED DISEASE FROM CR OR PR||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|SIBLING|NEUROLOGIST|NA|1||38||RUN-IN|1969-03-13||||1971-07-22||1970-11-01|1968-12-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G/MOL|DECREASED||/10^4|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|INVESTIGATOR|READER 1|U|2||58||INDUCTION TREATMENT|1960-04-23||||1970-05-12||1967-08-16|1968-02-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||METBRESP|METABOLIC RESPONSE||||MG/DL|CHR||ML/S/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|INVESTIGATOR|PATHOLOGIST 2|Y|2||58||BASELINE|1962-08-23||||1970-07-10||1965-04-08|1966-08-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 CCID 50/DOSE|HI-N||FMOL/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|PARENT|MICROSCOPIST 3|Y|3||39||OBSERVATION|1967-08-19||||1972-12-05||1960-10-02|1972-07-04||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3 CFU/ML|SMD||GAUSS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|INTERVIEWER|MICROSCOPIST|Y|3||39||SCREENING|1970-02-13||||1973-08-17||1962-10-26|1965-06-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||L/H/M2|MRD PERSISTENCE||MG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|4||88||BASELINE|1962-01-29||||1969-06-29||1961-09-11|1971-10-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||LB|PR||SBE/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|CAREGIVER|ONCOLOGIST 2|N|4||88||RUN-IN|1970-05-18||||1972-09-25||1965-06-27|1972-05-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||CLINRESP|CLINICAL RESPONSE||||BU/ML|PSEUDORESPONSE||DYN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|INTERVIEWER|RATER|NA|5||7||INDUCTION TREATMENT|1966-09-28||||1970-11-10||1960-06-24|1964-05-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||NEWLIND|NEW LESION INDICATOR||||10^5/HPF|NOT ALL EVALUATED||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|5||7||WASHOUT|1961-06-13||||1965-07-12||1973-06-10|1965-01-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^6/EJACULATE U|HI-N||PATCH|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|PARENT|ENDOCRINOLOGIST|NA|1||38||RUN-IN|1971-02-09||||1966-10-02||1972-02-01|1971-06-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MET*MIN|RELAPSED DISEASE||MG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|CHILD|PHYSIOTHERAPIST|NA|1||38||FOLLOW-UP|1966-01-02||||1970-12-30||1966-04-19|1964-08-06||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||TRGRESP|TARGET RESPONSE||||G/CAGE|PR-CT||UG/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|FAMILY MEMBER|RADIOLOGIST|U|2||58||OPEN LABEL TREATMENT|1970-03-29||||1973-07-02||1963-09-17|1963-12-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||STRUSTAT|STEROID USE STATUS||||U/G|DECREASED||CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|INVESTIGATOR|DERMATOLOGIST|Y|2||58||SCREENING|1968-04-02||||1968-08-28||1962-11-28|1965-08-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/2000 RBC|OPTIMAL MORPHOLOGIC RESPONSE||TSP EQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|STUDY SUBJECT|MICROSCOPIST|Y|3||39||SCREENING|1965-06-09||||1968-04-15||1965-05-21|1969-01-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MIN/DAY|ISD||S/H|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|FRIEND|NEUROLOGIST 2|Y|3||39||BLINDED TREATMENT|1962-07-23||||1964-01-09||1970-08-26|1965-05-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||METSIND|METASTATIC INDICATOR||||USEC|PSEUDORESPONSE||VIRTUAL PIXEL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|4||88||RUN-IN|1962-09-10||||1967-07-15||1973-01-30|1966-02-21||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/G|WORSENED||G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|SIGNIFICANT OTHER|RADIOLOGIST|Y|4||88||SCREENING|1969-07-25||||1967-12-27||1969-08-29|1964-01-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||%|CMR||ML/MMHG|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|SIGNIFICANT OTHER|HEMATOLOGIST|U|5||7||OBSERVATION|1965-09-25||||1967-01-21||1971-11-20|1973-01-19||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/G|NPR||MCI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|5||7||FOLLOW-UP|1972-08-26||||1971-11-08||1968-04-20|1969-06-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||%|INDETERMINATE RESPONSE||MV2/HZ|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|RATER|NA|1||38||FOLLOW-UP|1972-12-30||||1960-04-10||1966-05-07|1968-10-30||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PG/CELL|DECREASED||ML/S/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|PARENT|PEDIATRIC NEUROLOGIST|N|1||38||CONTINUATION TREATMENT|1960-05-28||||1966-12-06||1960-02-07|1968-12-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MS/MMHG|MRD NEGATIVITY||STRIP|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1963-05-15||||1972-04-08||1968-02-18|1960-01-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^6 IU/ML|PCR||PA|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|ADJUDICATION COMMITTEE|UROLOGIST|NA|2||58||TREATMENT|1963-04-26||||1973-03-19||1965-07-16|1968-04-04||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 TCID 50/DOSE|CR||UMOL/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL STUDY SPONSOR|RATER 2|Y|3||39||FOLLOW-UP|1963-09-15||||1973-04-17||1970-02-18|1965-10-23||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/DAY|NOT ALL EVALUATED||GRAVITATIONAL UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|PARENT|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||FOLLOW-UP|1972-06-02||||1964-09-06||1971-07-09|1961-06-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/ANIMAL|NED||MOL/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|4||88||FOLLOW-UP|1971-08-19||||1967-07-02||1962-06-16|1968-06-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||GRAVITATIONAL UNIT|MORPHOLOGIC CR||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|FRIEND|ENDOCRINOLOGIST|N|4||88||OBSERVATION|1971-03-12||||1965-06-13||1970-10-09|1971-08-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TRANSDUCING UNIT/ML|FAVORABLE RESPONSE||/100 WBC|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|DOMESTIC PARTNER|ADJUDICATOR 3|U|5||7||BLINDED TREATMENT|1960-07-27||||1971-08-19||1970-04-01|1964-01-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||ANATRESP|ANATOMIC RESPONSE||||LOG10 CFU/G|NPR||CD*S/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|FRIEND|NEUROLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1965-04-18||||1968-04-11||1961-11-26|1964-04-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||GLOBULE|RELAPSED DISEASE||U/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|FAMILY MEMBER|READER 2|N|1||38||LONG-TERM FOLLOW-UP|1963-11-08||||1971-02-22||1966-04-10|1963-02-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/G/DAY|PR WITH LYMPHOCYTOSIS||MEQ/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|VENDOR|READER|N|1||38||OPEN LABEL TREATMENT|1963-10-05||||1971-07-15||1972-12-02|1972-10-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||BONERESP|BONE RESPONSE||||10^9 ORGANISMS/ML|NOT ALL EVALUATED||MU/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|2||58||BLINDED TREATMENT|1973-07-31||||1966-08-03||1971-11-17|1964-12-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||%(V/V)|SMD||TUBE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||SCREENING|1967-09-21||||1970-01-02||1973-06-25|1970-10-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/KG|NR||MCI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|STUDY SUBJECT|ADJUDICATOR 3|U|3||39||FOLLOW-UP|1961-02-11||||1967-09-29||1970-01-19|1964-02-16||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CM H2O|IUPD||PMOL/10^9 CELLS|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||FOLLOW-UP|1970-07-02||||1972-07-17||1972-01-31|1970-01-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CIGAR|CRI||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|STUDY SUBJECT|ADJUDICATOR|Y|4||88||FOLLOW-UP|1966-09-29||||1960-04-30||1967-04-26|1969-08-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PA|NON-ICR/NON-IUPD||L/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|SPOUSE|ADJUDICATOR 2|NA|4||88||OPEN LABEL TREATMENT|1967-01-30||||1966-03-06||1963-02-17|1972-06-08||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KBQ/UL|PSEUDOPROGRESSION||LM|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|N|5||7||LONG-TERM FOLLOW-UP|1962-11-01||||1967-02-05||1964-03-27|1965-11-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UV*SEC|PD||UG/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|5||7||OBSERVATION|1970-09-16||||1964-11-05||1967-03-08|1972-06-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L/MIN|MOLECULAR MAJOR RESPONSE||MKAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|U|1||38||OBSERVATION|1970-02-15||||1973-05-11||1968-07-05|1967-08-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||METBRESP|METABOLIC RESPONSE||||MM/H|MR||MMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|FAMILY MEMBER|OPTOMETRIST|U|1||38||WASHOUT|1966-06-16||||1972-09-15||1963-05-30|1967-04-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/MBP|PCR||PACK|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|GUARDIAN|OTOLARYNGOLOGIST|NA|2||58||BLINDED TREATMENT|1966-04-27||||1966-03-22||1964-08-29|1966-01-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||NEWLIND|NEW LESION INDICATOR||||ML|NON-CR/NON-PD||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|SPOUSE|DERMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1967-10-20||||1963-08-21||1960-08-19|1962-07-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||BESTRESP|BEST OVERALL RESPONSE||||MBP|STABLE||APL U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|SPOUSE|OPTOMETRIST|Y|3||39||BLINDED TREATMENT|1966-12-29||||1962-12-22||1973-07-27|1962-03-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||RFU|MRD PERSISTENCE||/VF|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|ADJUDICATOR|RADIOLOGIST|N|3||39||CONTINUATION TREATMENT|1965-03-01||||1963-03-28||1969-12-16|1972-12-29||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ENZYME U/L|INDETERMINATE RESPONSE||MPL U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|4||88||WASHOUT|1966-12-23||||1960-03-08||1967-05-22|1970-03-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||ANATRESP|ANATOMIC RESPONSE||||ML/G/DAY|PD-CT||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|CHILD|RATER 1|U|4||88||CONTINUATION TREATMENT|1971-04-13||||1969-01-12||1962-02-12|1966-09-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||NEWLPROG|NEW LESION PROGRESSION||||BAU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|FRIEND|NEUROLOGIST 1|U|5||7||OBSERVATION|1967-10-23||||1965-08-24||1971-06-25|1968-08-31||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||EQ|INCREASED||UMOL/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|SPOUSE|INTERNIST|U|5||7||CONTINUATION TREATMENT|1967-10-06||||1967-08-19||1967-03-16|1969-07-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^3 ORGANISMS/ML|MORPHOLOGIC CR||CI/UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|FRIEND|ENDOCRINOLOGIST|N|1||38||BLINDED TREATMENT|1971-12-09||||1960-06-11||1971-01-05|1972-05-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 CFU/G|SCR||CY/CM|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|1||38||BASELINE|1970-05-14||||1967-11-04||1967-09-27|1962-09-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/H/MMOL|RELAPSED DISEASE FROM CR||UG/DL|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|2||58||WASHOUT|1965-01-15||||1960-06-29||1963-04-19|1960-08-04||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^7 CFU/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||PG/CELL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|2||58||TREATMENT|1964-11-22||||1970-03-18||1965-02-19|1963-07-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||TRGRESP|TARGET RESPONSE||||MJOULE/CM2|MORPHOLOGIC CRI||ML/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|STUDY SUBJECT|ADJUDICATOR 3|U|3||39||WASHOUT|1964-05-29||||1960-03-23||1970-03-15|1962-06-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CM H2O|SCR||MKAT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|DOMESTIC PARTNER|OTOLARYNGOLOGIST|N|3||39||SCREENING|1962-09-11||||1966-05-09||1963-12-15|1970-02-24||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||STRUSTAT|STEROID USE STATUS||||EJACULATE U|INDETERMINATE RESPONSE||STEPS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|VENDOR|RADIOLOGIST 1|U|4||88||INDUCTION TREATMENT|1961-02-17||||1961-03-01||1962-08-10|1964-06-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SIEMENS|UNFAVORABLE RESPONSE||UGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||OBSERVATION|1972-04-14||||1961-12-16||1972-06-05|1971-12-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||STRIP|MOLECULAR MAJOR RESPONSE||UG/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||OBSERVATION|1972-11-06||||1962-07-03||1963-04-25|1966-10-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KM|HI-P||G/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CHILD|RATER 2|Y|5||7||WASHOUT|1968-01-11||||1962-04-07||1973-02-22|1968-03-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6 COPIES/ML|MAJOR PATHOLOGIC RESPONSE||UU/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|ADJUDICATOR|READER 2|NA|1||38||RUN-IN|1966-07-14||||1972-03-11||1964-03-11|1971-07-25||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||METSIND|METASTATIC INDICATOR||||CAPLET|MAJOR PATHOLOGIC RESPONSE||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|FAMILY MEMBER|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1960-08-20||||1964-08-29||1962-06-12|1961-09-13||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||CLINRESP|CLINICAL RESPONSE||||DEG/S|FAVORABLE RESPONSE||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|2||58||BASELINE|1964-09-09||||1963-06-30||1965-02-02|1970-03-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||AMP|MORPHOLOGIC CRI||FINGERTIP UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1962-03-06||||1973-01-06||1964-02-03|1971-10-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MIN|PDU||DAGU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|CHILD|MICROSCOPIST|Y|3||39||OPEN LABEL TREATMENT|1963-05-06||||1960-12-28||1968-09-18|1972-05-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||METSIND|METASTATIC INDICATOR||||KV|NPR||NKAT/G HB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|VENDOR|READER|NA|3||39||INDUCTION TREATMENT|1969-08-25||||1973-04-19||1970-03-31|1962-09-17||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||NEWLIND|NEW LESION INDICATOR||||U/M2/H|MRD RELAPSE||KM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||CONTINUATION TREATMENT|1971-01-15||||1970-11-10||1971-06-07|1968-04-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ANSON U|CPR||/500 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|CAREGIVER|MICROSCOPIST 1|NA|4||88||OBSERVATION|1966-06-20||||1962-01-05||1968-09-19|1969-01-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EJACULATE U|PD||YD|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|INDEPENDENT ASSESSOR|NEUROLOGIST|Y|5||7||TREATMENT|1960-10-05||||1963-10-05||1964-11-24|1973-02-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||SPLNRESP|SPLEEN RESPONSE||||ML/BREATH|CA125 50% RESPONSE||UEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|FRIEND|NEUROLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1969-04-18||||1967-08-16||1972-03-23|1973-07-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||TMRESP|TUMOR MARKER RESPONSE||||AG|SCR||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST|U|1||38||INDUCTION TREATMENT|1970-03-09||||1972-08-22||1962-03-10|1967-06-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/ML|CYTOGENETIC CR||GENEQ/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|VENDOR|MICROSCOPIST 1|NA|1||38||SCREENING|1965-04-20||||1967-06-09||1963-02-27|1970-03-26||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||FMOL/G|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/KG/WEEK|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|SPOUSE|PATHOLOGIST 1|U|2||58||TREATMENT|1965-05-15||||1971-12-02||1971-07-13|1971-09-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MIN/DAY|PR WITH LYMPHOCYTOSIS||MPL U|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|SIGNIFICANT OTHER|ADJUDICATOR 3|NA|2||58||CONTINUATION TREATMENT|1962-07-09||||1968-02-17||1970-08-25|1970-04-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||METSIND|METASTATIC INDICATOR||||10^6/HPF|CCR||ROENTGEN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||SCREENING|1967-07-09||||1967-07-03||1966-05-30|1971-02-03||DURING||DURING|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||IU/DL|PCR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|3||39||FOLLOW-UP|1966-07-06||||1968-08-27||1971-12-18|1965-07-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOL/L|SD-CT||CMHG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|DOMESTIC PARTNER|UROLOGIST|NA|4||88||BLINDED TREATMENT|1971-03-01||||1973-03-17||1963-03-25|1962-05-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^6 RNA COPIES/ML|CYTOGENETIC MINOR RESPONSE||ML/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|4||88||INDUCTION TREATMENT|1970-02-09||||1968-02-26||1973-05-13|1964-07-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KIU|QUANTIFIABLE MRD POSITIVITY||ML/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|ADJUDICATOR|OPHTHALMOLOGIST|NA|5||7||OBSERVATION|1970-05-31||||1967-05-18||1967-01-22|1969-10-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||GTT|PD/RELAPSE AFTER HI||MEQ/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|INTERVIEWER|READER 3|U|5||7||WASHOUT|1968-09-22||||1960-08-13||1972-06-14|1960-04-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||STRUSTAT|STEROID USE STATUS||||DEG|MRD PERSISTENCE||LOG10 TCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|1||38||BLINDED TREATMENT|1968-07-18||||1962-10-18||1966-02-01|1960-10-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UMOL/MIN|IMPROVED||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|PARENT|CLINICAL PATHOLOGIST|U|1||38||BLINDED TREATMENT|1963-10-08||||1963-06-06||1962-03-06|1964-11-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||NEWLPROG|NEW LESION PROGRESSION||||CI/UL|CR||SCOOPFUL|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|PROXY|INTERNIST|Y|2||58||WASHOUT|1969-06-30||||1967-04-25||1973-06-16|1973-08-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||BONERESP|BONE RESPONSE||||KIT|CYTOGENETIC NO RESPONSE||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|FAMILY MEMBER|NEUROLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1973-03-15||||1969-11-08||1961-09-13|1973-08-07||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/WEEK|NOT ALL EVALUATED||ML/CAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|CAREGIVER|MICROSCOPIST 2|Y|3||39||RUN-IN|1969-10-13||||1965-12-14||1963-02-11|1968-09-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||MOLRESP|MOLECULAR RESPONSE||||POUCH|DECREASED||CI/G|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|PROXY|MICROSCOPIST 3|U|3||39||RUN-IN|1971-10-24||||1962-05-15||1972-07-08|1966-10-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7 PFU|PR-CT||AMPULE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|ADJUDICATOR|MICROSCOPIST 2|Y|4||88||TREATMENT|1966-12-17||||1962-07-17||1964-09-09|1966-02-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||BONERESP|BONE RESPONSE||||EQ|HI-E||SFC/10^6 PBMC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|RATER 2|U|4||88||BASELINE|1962-08-17||||1961-09-13||1970-05-13|1965-03-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||METSIND|METASTATIC INDICATOR||||UGEQ/L|ABSENT MORPHOLOGIC RESPONSE||APPLICATION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|CHILD|PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1970-01-24||||1967-12-12||1970-10-13|1968-07-11||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||BONERESP|BONE RESPONSE||||CAL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UKAT/10^12 RBC|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|NA|CAREGIVER|PATHOLOGIST 1|NA|5||7||BASELINE|1963-11-19||||1962-03-14||1967-08-19|1970-06-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UEQ|CYTOGENETIC MINOR RESPONSE||10^3 CFU/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|1||38||WASHOUT|1963-02-23||||1969-08-12||1961-09-19|1960-05-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||CLINRESP|CLINICAL RESPONSE||||APL U|CYTOGENETIC MINOR RESPONSE||BE/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|FAMILY MEMBER|PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1969-10-16||||1965-06-09||1961-06-07|1966-07-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^3 ORGANISMS/G|NR||DIOPTER|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|INTERVIEWER|CLINICAL PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1966-06-09||||1967-02-20||1968-11-22|1965-03-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||TRGRESP|TARGET RESPONSE||||10^3 COPIES/ML|CR-CT||MV*MIN|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1968-07-30||||1960-04-24||1961-03-22|1960-12-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||NTRGRESP|NON-TARGET RESPONSE||||L/S|CYTOGENETIC CR||10^6 CFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|3||39||RUN-IN|1967-11-19||||1963-08-21||1965-05-23|1967-11-15||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UMOL/L|VGPR||V|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|SIBLING|READER 1|U|3||39||OBSERVATION|1967-10-16||||1962-10-29||1970-11-23|1961-05-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||BONERESP|BONE RESPONSE||||MONTHS|UNFAVORABLE RESPONSE||EP U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|SPOUSE|MICROSCOPIST 3|U|4||88||INDUCTION TREATMENT|1967-10-16||||1966-04-17||1960-11-12|1973-02-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||BONERESP|BONE RESPONSE||||/MS|MRD NEGATIVITY||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|DOMESTIC PARTNER|OTOLARYNGOLOGIST|N|4||88||INDUCTION TREATMENT|1972-08-16||||1964-07-15||1966-09-08|1962-12-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^5/L|CYTOGENETIC MINIMAL RESPONSE||UMOL/L/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|INVESTIGATOR|READER 1|N|5||7||OPEN LABEL TREATMENT|1961-11-23||||1962-05-01||1961-03-21|1965-09-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/100G/MIN|HI-P||MG/KG/WEEK|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|PROXY|CLINICAL PATHOLOGIST|Y|5||7||FOLLOW-UP|1962-08-23||||1973-01-18||1973-06-20|1963-06-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||TMRESP|TUMOR MARKER RESPONSE||||KDA|INDETERMINATE RESPONSE||BAG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|FRIEND|MICROSCOPIST 1|U|1||38||BLINDED TREATMENT|1967-11-27||||1973-05-07||1965-02-15|1969-08-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||ANATRESP|ANATOMIC RESPONSE||||MBQ|PMD||FMOL/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|INTERVIEWER|OPTOMETRIST|NA|1||38||OBSERVATION|1965-03-15||||1970-05-18||1970-11-09|1970-10-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||ANATRESP|ANATOMIC RESPONSE||||PPTH|PMD||SCM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|RATER|N|2||58||BASELINE|1968-05-09||||1969-10-14||1973-05-07|1960-03-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PT_US|HI-P||HENRY|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INTERVIEWER|RADIOLOGIST 1|U|2||58||INDUCTION TREATMENT|1970-04-09||||1964-10-09||1963-03-15|1964-10-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||STRUSTAT|STEROID USE STATUS||||ML/ANIMAL/WK|MRD RELAPSE||GBQ/MG|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|RATER 2|U|3||39||TREATMENT|1964-06-03||||1960-01-25||1972-01-24|1968-06-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MG|PCR||AG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INTERVIEWER|CLINICAL PATHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1962-08-27||||1962-09-15||1971-06-10|1966-08-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BEATS/MIN|PSEUDORESPONSE||MEQ/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|PROXY|RATER 1|Y|4||88||SCREENING|1967-08-05||||1972-02-24||1964-02-04|1965-10-04||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MS2|NOT ALL EVALUATED||DAYS/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|VENDOR|NEUROLOGIST 1|U|4||88||INDUCTION TREATMENT|1967-09-18||||1963-02-25||1966-12-11|1966-10-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||METBRESP|METABOLIC RESPONSE||||GENEQ|NE||VP/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|DOMESTIC PARTNER|READER|Y|5||7||TREATMENT|1960-04-09||||1968-01-25||1970-09-10|1967-08-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||TRGRESP|TARGET RESPONSE||||U/CL|NON-CR/NON-PD||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|SPOUSE|RADIOLOGIST|NA|5||7||BASELINE|1967-03-08||||1972-12-25||1968-06-25|1964-11-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||MOLRESP|MOLECULAR RESPONSE||||USP U|CYTOGENETIC PR||U/M2/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|1||38||RUN-IN|1970-10-21||||1962-11-27||1972-02-28|1969-09-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||BONERESP|BONE RESPONSE||||CFU/G|PR-CT||MEQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|CHILD|PEDIATRIC NEUROLOGIST|N|1||38||INDUCTION TREATMENT|1965-02-07||||1965-07-19||1972-05-01|1965-04-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||STRUSTAT|STEROID USE STATUS||||PFU/ML|COMPLETE MRD RESPONSE||UMOL/MOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|2||58||LONG-TERM FOLLOW-UP|1972-03-16||||1966-05-27||1967-01-14|1972-11-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||NEWLPROG|NEW LESION PROGRESSION||||VG/ML|UNFAVORABLE RESPONSE||WEBER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|CHILD|ONCOLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1972-09-23||||1965-08-15||1973-07-28|1964-02-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||L|NED||10^6 CFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|CHILD|MICROSCOPIST 1|U|3||39||LONG-TERM FOLLOW-UP|1971-12-15||||1960-04-08||1966-11-05|1969-06-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DIP|PCR||MEQ/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||FOLLOW-UP|1968-02-15||||1963-09-04||1971-08-08|1969-02-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/MIN|RELAPSED DISEASE||ENZYME U|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|STUDY SUBJECT|RATER 1|N|4||88||CONTINUATION TREATMENT|1972-01-29||||1962-04-13||1960-09-15|1966-04-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BE/ML|ABSENT MORPHOLOGIC RESPONSE||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1961-02-13||||1973-05-11||1972-01-29|1971-01-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||LIVRRESP|LIVER RESPONSE||||MEQ/G|SD-CT||MKAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|5||7||TREATMENT|1972-11-22||||1965-10-11||1961-02-05|1961-03-16||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||VG/KG|ABSENT MORPHOLOGIC RESPONSE||SCOOPFUL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|DOMESTIC PARTNER|ADJUDICATOR 1|Y|5||7||LONG-TERM FOLLOW-UP|1962-01-15||||1973-03-08||1966-04-13|1963-04-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|1||||||NEWLIND|NEW LESION INDICATOR||||ECL UNIT|TREATMENT FAILURE||DRINK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|FRIEND|UROLOGIST|NA|1||38||TREATMENT|1969-05-21||||1965-10-19||1966-03-10|1962-10-30||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MESF|CYTOGENETIC MINOR RESPONSE||UGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|PARENT|PATHOLOGIST 2|N|1||38||OPEN LABEL TREATMENT|1965-10-24||||1966-04-26||1968-10-11|1965-05-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|1||||||ANATRESP|ANATOMIC RESPONSE||||VOXEL|NED||MG/KG|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|SPOUSE|MICROSCOPIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-04-23||||1967-04-08||1964-10-07|1960-11-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^6 CFU/ML|MCR||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2||58||INDUCTION TREATMENT|1960-10-31||||1962-05-17||1973-01-27|1972-01-12||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MEQ|ICR||MG/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|3||39||OPEN LABEL TREATMENT|1968-06-14||||1972-12-30||1970-06-18|1967-06-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|2||||||NTRGRESP|NON-TARGET RESPONSE||||GY/MIN|RELAPSED DISEASE||S*KPA|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|ADJUDICATOR|FORENSIC PATHOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1965-12-14||||1964-01-01||1966-09-07|1969-03-07||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/5X10^4 WBC|CR-CT||V/V|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|STUDY SUBJECT|ADJUDICATOR|Y|4||88||FOLLOW-UP|1972-03-12||||1970-03-15||1972-11-19|1963-09-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|2||||||STRUSTAT|STEROID USE STATUS||||MCI|PD||GPL U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SPOUSE|NEUROLOGIST|NA|4||88||SCREENING|1962-06-16||||1965-04-12||1962-06-30|1961-12-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/G/H|UNFAVORABLE RESPONSE||/200 HPFS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|5||7||TREATMENT|1972-02-04||||1963-07-09||1971-01-16|1971-12-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|415D178A-275A-440C-8617-154441A48F8D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||V/V|TREATMENT FAILURE||F|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|FAMILY MEMBER|OPHTHALMOLOGIST|NA|5||7||INDUCTION TREATMENT|1962-04-30||||1966-07-06||1963-06-20|1970-03-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TSP|IPR||10^9/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|1||38||INDUCTION TREATMENT|1968-01-21||||1970-09-11||1968-06-26|1967-03-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||ANATRESP|ANATOMIC RESPONSE||||MGEQ|CCR||WEEKS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|1||38||BLINDED TREATMENT|1963-06-23||||1965-07-23||1960-08-09|1973-03-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||ANATRESP|ANATOMIC RESPONSE||||10^6 U|NON-CR/NON-PD||CD|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|SPOUSE|FORENSIC PATHOLOGIST|N|2||58||SCREENING|1967-07-25||||1962-05-21||1960-10-11|1971-04-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||POUCH|IMMUNOPHENOTYPIC CR||10^3 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|FAMILY MEMBER|ENDOCRINOLOGIST|N|2||58||WASHOUT|1968-11-02||||1960-07-26||1969-05-17|1968-11-05||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||STRUSTAT|STEROID USE STATUS||||L/H|CMR||VIAL|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|ADJUDICATOR|ENDOCRINOLOGIST|U|3||39||WASHOUT|1961-08-08||||1970-03-03||1965-04-07|1961-07-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||LIVRRESP|LIVER RESPONSE||||MPS U|MRD NEGATIVITY||DAGU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|INTERVIEWER|OTOLARYNGOLOGIST|U|3||39||INDUCTION TREATMENT|1970-01-11||||1962-12-05||1971-03-30|1963-03-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||KM|CR-CT||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|INTERVIEWER|ONCOLOGIST 2|N|4||88||FOLLOW-UP|1965-04-11||||1970-10-24||1961-05-09|1960-07-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/VF|HI-N||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|4||88||BASELINE|1966-12-18||||1970-05-28||1970-07-10|1969-10-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||LIVRRESP|LIVER RESPONSE||||DNA COPIES/UG|CA125 50% RESPONSE||CIGAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|5||7||WASHOUT|1972-09-03||||1960-07-25||1962-07-15|1971-10-11||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMAL|MRD RELAPSE||DAGU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|VENDOR|MICROSCOPIST 2|U|5||7||WASHOUT|1969-02-12||||1970-12-24||1972-08-31|1972-04-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML|CA125 50% RESPONSE||VG/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|VENDOR|FORENSIC PATHOLOGIST|N|1||38||TREATMENT|1967-12-06||||1961-11-03||1961-12-05|1969-01-17||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MEQ/G|PSA PROGRESSION||PSI|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|1||38||CONTINUATION TREATMENT|1965-04-26||||1961-09-11||1961-05-27|1965-03-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CCID 50/DOSE|ICPD||IN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|ADJUDICATOR|ADJUDICATOR 3|NA|2||58||WASHOUT|1972-03-03||||1965-03-29||1970-11-13|1972-02-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||METSIND|METASTATIC INDICATOR||||AMU|NPR||NMOL/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1960-01-17||||1970-08-04||1968-06-10|1965-05-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||OVRLRESP|OVERALL RESPONSE||||10^4 CFU/ML|NON-QUANTIFIABLE MRD POSITIVITY||UG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|VENDOR|NEUROLOGIST 2|NA|3||39||BLINDED TREATMENT|1960-07-02||||1969-07-18||1962-01-17|1967-05-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ELISA UNIT/ML|NED||STEPS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|SIBLING|OPTOMETRIST|N|3||39||INDUCTION TREATMENT|1969-07-28||||1963-02-06||1970-05-08|1971-03-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||TMRESP|TUMOR MARKER RESPONSE||||PG/DL|PMR||AMPULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|INTERVIEWER|RATER 2|U|4||88||FOLLOW-UP|1962-08-13||||1965-11-23||1963-01-05|1972-02-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||TRGRESP|TARGET RESPONSE||||PLUG|NON-CR/NON-PD||KAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|PARENT|READER 2|U|4||88||WASHOUT|1969-02-12||||1970-07-10||1961-05-19|1960-01-27||DURING||DURING|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^7 CFU/ML|STABLE||10^3 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|INVESTIGATOR|MICROSCOPIST 2|Y|5||7||TREATMENT|1969-09-23||||1966-09-09||1969-11-21|1965-04-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||VG/ML|MRD RELAPSE||MPL U/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|5||7||BLINDED TREATMENT|1962-03-14||||1971-08-17||1964-02-01|1960-05-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SPRAY|CHR||MOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|STUDY SUBJECT|READER 2|U|1||38||SCREENING|1964-06-28||||1966-12-02||1963-07-04|1973-07-16||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PT_US|TREATMENT FAILURE||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|INVESTIGATOR|READER 3|NA|1||38||OBSERVATION|1961-11-11||||1966-04-13||1961-11-16|1966-07-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||OSM|HI-E||10^6/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|ADJUDICATOR|READER 3|Y|2||58||WASHOUT|1971-01-31||||1967-04-05||1965-12-20|1968-11-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DIOPTER|UNFAVORABLE RESPONSE||KEV|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|GUARDIAN|CLINICAL PATHOLOGIST|U|2||58||WASHOUT|1969-08-26||||1961-09-22||1969-10-19|1963-05-10||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||MOLRESP|MOLECULAR RESPONSE||||10^3 CFU/G|PSA PROGRESSION||%(W/V)|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|DOMESTIC PARTNER|ONCOLOGIST 2|N|3||39||TREATMENT|1971-04-29||||1960-11-04||1961-07-04|1971-08-10||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PPTR|CYTOGENETIC NO RESPONSE||CD*S/M2|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|FRIEND|PATHOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1969-10-30||||1968-01-24||1967-11-12|1962-02-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||NEWLIND|NEW LESION INDICATOR||||FMOL/G|IMPROVED||UG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|INTERNIST|NA|4||88||BLINDED TREATMENT|1970-11-18||||1968-08-30||1970-01-18|1961-04-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MCI/L|SCR||UMOL/DL|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|CAREGIVER|ADJUDICATOR 1|U|4||88||FOLLOW-UP|1967-11-17||||1970-11-24||1968-02-26|1960-12-05||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||METBRESP|METABOLIC RESPONSE||||PNU/ML|MAJOR PATHOLOGIC RESPONSE||UGEQ/L|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|5||7||OBSERVATION|1961-01-24||||1961-11-28||1972-05-07|1961-01-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CM|MRD NEGATIVITY||10^6 IU/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|PROXY|RATER 1|U|5||7||BASELINE|1966-04-08||||1960-04-27||1966-02-08|1963-07-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||TRGRESP|TARGET RESPONSE||||MG/CM2|CHR||NL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|FRIEND|DERMATOLOGIST|Y|1||38||INDUCTION TREATMENT|1967-04-05||||1965-09-18||1971-05-06|1970-06-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||CYTORESP|CYTOGENETIC RESPONSE||||LOZENGE|ISD||WEEKS|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|ADJUDICATION COMMITTEE|OPTOMETRIST|U|1||38||OBSERVATION|1961-07-21||||1962-09-03||1970-01-05|1970-09-03||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||NTRGRESP|NON-TARGET RESPONSE||||HZ|PSEUDORESPONSE||BAG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1971-08-12||||1968-06-26||1968-09-22|1961-04-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ABSORBANCE U/ML|MINOR PATHOLOGIC RESPONSE||TUBERCULIN UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|SIGNIFICANT OTHER|UROLOGIST|N|2||58||BLINDED TREATMENT|1963-11-26||||1960-07-05||1962-12-01|1963-09-11||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||OVRLRESP|OVERALL RESPONSE||||MG/MIN|IPR||10^3/HPF|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|PROXY|RATER 2|U|3||39||SCREENING|1968-11-11||||1960-09-26||1960-09-07|1967-05-19||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||NTRGRESP|NON-TARGET RESPONSE||||CMOL/L|SD||UM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|SIGNIFICANT OTHER|RATER 1|U|3||39||CONTINUATION TREATMENT|1962-08-06||||1962-03-11||1964-04-27|1971-10-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG2/DL2|DISEASE TRANSFORMATION||HOMEOPATHIC DILUTION|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|INTERVIEWER|RADIOLOGIST|Y|4||88||RUN-IN|1972-06-25||||1964-06-21||1972-06-25|1966-03-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/CAGE/WK|MINOR PATHOLOGIC RESPONSE||KM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||SCREENING|1973-04-12||||1962-01-25||1969-06-14|1965-11-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MPH|MOLECULAR MAJOR RESPONSE||TRANSDUCING UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|PROXY|READER 1|U|5||7||BLINDED TREATMENT|1971-09-15||||1968-12-27||1960-10-25|1971-03-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||FARAD|CYTOGENETIC MINOR RESPONSE||MOSM/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|U|5||7||CONTINUATION TREATMENT|1967-10-04||||1964-01-09||1972-03-27|1966-10-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||LIVRRESP|LIVER RESPONSE||||UV2|INCREASED||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|FAMILY MEMBER|MICROSCOPIST|N|1||38||BLINDED TREATMENT|1963-12-20||||1970-01-09||1966-02-15|1967-02-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||METSIND|METASTATIC INDICATOR||||UG/ML/H|IPR||UMOL/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|SIGNIFICANT OTHER|PATHOLOGIST 2|N|1||38||CONTINUATION TREATMENT|1960-07-28||||1960-07-17||1970-09-09|1963-04-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||MOLRESP|MOLECULAR RESPONSE||||USP U|UNEQUIVOCAL||MIN/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|DOMESTIC PARTNER|OPTOMETRIST|N|2||58||BLINDED TREATMENT|1973-07-04||||1968-05-04||1971-07-07|1968-02-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||SPLNRESP|SPLEEN RESPONSE||||PACKET|MCR||CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|INTERVIEWER|ADJUDICATOR 3|U|2||58||OPEN LABEL TREATMENT|1964-01-10||||1966-09-21||1966-07-04|1964-07-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||NEWLIND|NEW LESION INDICATOR||||ML/MMHG/MIN/L|DECREASED||DIP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|SIGNIFICANT OTHER|MICROSCOPIST 2|U|3||39||TREATMENT|1965-09-26||||1970-03-27||1971-12-14|1964-08-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||MOLRESP|MOLECULAR RESPONSE||||PFU/ML|HI-P||NG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|CAREGIVER|MICROSCOPIST|U|3||39||TREATMENT|1967-03-19||||1972-01-09||1962-01-22|1970-12-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||LIVRRESP|LIVER RESPONSE||||OZ|PDU||SACHET|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|GUARDIAN|MICROSCOPIST|N|4||88||BASELINE|1962-09-08||||1961-04-18||1963-09-23|1967-11-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||OVRLRESP|OVERALL RESPONSE||||ML/MIN|COMPLETE MRD RESPONSE||MOSM/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|4||88||BASELINE|1971-06-04||||1960-04-15||1965-12-12|1965-09-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL BCE/L|PARTIAL MORPHOLOGIC RESPONSE||G/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|CHILD|READER 3|U|5||7||TREATMENT|1970-06-06||||1972-10-17||1961-08-23|1966-04-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||BONERESP|BONE RESPONSE||||NGEQ/L|NE||PMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|STUDY SUBJECT|ADJUDICATOR|NA|5||7||LONG-TERM FOLLOW-UP|1966-10-19||||1969-09-13||1968-04-28|1964-01-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||TRGRESP|TARGET RESPONSE||||ML|PSEUDORESPONSE||APL U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|INDEPENDENT ASSESSOR|MICROSCOPIST 2|U|1||38||OPEN LABEL TREATMENT|1961-03-03||||1973-01-31||1965-06-29|1962-10-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||BESTRESP|BEST OVERALL RESPONSE||||/VF|NR||CMHG|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|INVESTIGATOR|ADJUDICATOR|N|1||38||TREATMENT|1967-01-01||||1961-08-21||1973-02-16|1973-08-31||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/M2/H|IPR||S*KPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|2||58||INDUCTION TREATMENT|1966-04-06||||1970-05-15||1964-06-07|1963-10-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||ANATRESP|ANATOMIC RESPONSE||||PG/CELL|NON-ICR/NON-IUPD||NEBULE|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1961-02-12||||1973-06-25||1971-06-13|1972-10-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^3/HPF|PD-CT||BEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|STUDY SUBJECT|PATHOLOGIST 2|U|3||39||OBSERVATION|1969-08-06||||1965-08-25||1971-06-23|1972-08-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KEV|PARTIAL MORPHOLOGIC RESPONSE||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|READER 2|N|3||39||SCREENING|1962-04-20||||1971-10-19||1968-03-19|1967-11-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BAR|CPR||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|FAMILY MEMBER|NEUROLOGIST 1|U|4||88||SCREENING|1962-05-02||||1968-12-28||1971-11-25|1971-05-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SACHET|PDU||UCI/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||INDUCTION TREATMENT|1969-12-04||||1962-08-20||1968-03-14|1970-01-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||OVRLRESP|OVERALL RESPONSE||||10^9/L|NOT ALL EVALUATED||MS2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|FAMILY MEMBER|READER 2|Y|5||7||FOLLOW-UP|1966-08-18||||1971-10-05||1961-07-07|1972-05-25||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FT3|PMR||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|DOMESTIC PARTNER|RADIOLOGIST 1|N|5||7||SCREENING|1966-10-31||||1964-06-10||1962-02-21|1965-03-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ANTI-XA IU|PR WITH LYMPHOCYTOSIS||UG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|ADJUDICATOR|ADJUDICATOR|NA|1||38||SCREENING|1968-08-22||||1968-10-18||1969-11-28|1967-10-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/VF|CHR||TITER|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|INTERVIEWER|RATER 2|N|1||38||SCREENING|1971-05-26||||1970-12-15||1965-01-04|1964-12-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||BONERESP|BONE RESPONSE||||MBQ/UL|HI-E||/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|CHILD|NEUROLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1961-06-17||||1962-12-27||1967-05-16|1963-12-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||NEWLIND|NEW LESION INDICATOR||||MOL/L|NED||CI/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||TREATMENT|1972-06-17||||1962-09-03||1973-02-15|1961-11-27||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MET*H|PR||JDF UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|INVESTIGATOR|ONCOLOGIST|Y|3||39||FOLLOW-UP|1967-09-26||||1972-06-17||1966-01-15|1968-08-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DRAM|CYTOGENETIC PR||MM|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|SIBLING|RATER 2|Y|3||39||CONTINUATION TREATMENT|1965-09-24||||1960-06-29||1969-01-17|1965-01-10||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||SPLNRESP|SPLEEN RESPONSE||||C|ICR||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|4||88||CONTINUATION TREATMENT|1961-11-26||||1967-08-31||1966-03-08|1973-04-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/MG|PARTIAL MORPHOLOGIC RESPONSE||FL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|4||88||SCREENING|1973-01-10||||1966-09-20||1973-07-13|1973-09-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||STRUSTAT|STEROID USE STATUS||||UG/M2/H|OPTIMAL MORPHOLOGIC RESPONSE||UMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|INVESTIGATOR|MICROSCOPIST 2|U|5||7||BLINDED TREATMENT|1966-12-15||||1962-02-24||1969-11-18|1965-06-07||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL/KG/DAY|CYTOGENETIC NO RESPONSE||MV|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|PROXY|CARDIOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1972-10-30||||1965-12-23||1968-02-27|1966-01-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||MOLRESP|MOLECULAR RESPONSE||||MOL/L|IMPROVED||ML/S/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|1||38||SCREENING|1962-09-14||||1964-02-20||1972-02-24|1968-12-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||STRUSTAT|STEROID USE STATUS||||MIN|CYTOGENETIC PR||UEQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|INTERVIEWER|READER|NA|1||38||CONTINUATION TREATMENT|1965-11-04||||1972-01-28||1960-01-16|1967-03-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||TMRESP|TUMOR MARKER RESPONSE||||KM|DISEASE TRANSFORMATION||NU/CL|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|SIGNIFICANT OTHER|PATHOLOGIST 2|U|2||58||BLINDED TREATMENT|1963-11-06||||1967-07-20||1967-06-24|1960-03-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||SPLNRESP|SPLEEN RESPONSE||||ELISA UNIT/ML|QUANTIFIABLE MRD POSITIVITY||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|U|2||58||BLINDED TREATMENT|1968-09-26||||1965-07-12||1964-11-30|1973-02-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||BESTRESP|BEST OVERALL RESPONSE||||MOL/DAY|UNEQUIVOCAL||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|GUARDIAN|NEUROLOGIST 2|NA|3||39||INDUCTION TREATMENT|1971-05-20||||1961-12-27||1973-02-15|1967-08-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||GTT|IMPROVED||M|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|SIGNIFICANT OTHER|ENDOCRINOLOGIST|N|3||39||CONTINUATION TREATMENT|1962-04-18||||1963-10-06||1968-04-24|1969-09-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 ELISA UNIT|HI-P||GY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|SPOUSE|READER 3|U|4||88||INDUCTION TREATMENT|1967-09-13||||1970-06-08||1963-12-03|1963-12-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||OVRLRESP|OVERALL RESPONSE||||BQ/UL|PR WITH LYMPHOCYTOSIS||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|STUDY SUBJECT|RATER 1|U|4||88||WASHOUT|1961-11-06||||1964-08-11||1972-01-25|1960-12-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DEG/S|CR-CT||MILE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|FAMILY MEMBER|RADIOLOGIST 1|Y|5||7||SCREENING|1967-03-12||||1973-04-11||1971-04-18|1968-03-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||LIVRRESP|LIVER RESPONSE||||/5X10^4 WBC|MOLECULAR MAJOR RESPONSE||F|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||BASELINE|1967-07-18||||1964-09-12||1960-11-05|1961-10-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMHG/SEC|MINOR PATHOLOGIC RESPONSE||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|INTERVIEWER|OTOLARYNGOLOGIST|Y|1||38||BLINDED TREATMENT|1969-06-22||||1971-12-19||1962-12-24|1966-07-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||VIRTUAL PIXEL|CR-CT||100 IU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|CHILD|READER|N|1||38||LONG-TERM FOLLOW-UP|1968-10-25||||1963-03-10||1962-07-04|1967-09-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DNA COPIES/ML|NR||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|NA|2||58||BASELINE|1971-12-30||||1964-08-17||1969-06-06|1961-09-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||LIVRRESP|LIVER RESPONSE||||V/SEC|CYTOGENETIC CR||10^6 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|VENDOR|ONCOLOGIST 1|NA|2||58||SCREENING|1966-02-19||||1967-03-27||1965-03-25|1972-06-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CI|INDETERMINATE RESPONSE||MM/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|3||39||TREATMENT|1969-02-24||||1966-01-15||1971-02-03|1962-06-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/ANIMAL|ICR||NFIU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|N|3||39||CONTINUATION TREATMENT|1971-08-17||||1965-12-06||1970-03-15|1966-01-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||MOLRESP|MOLECULAR RESPONSE||||MG/M2/DAY|MINOR PATHOLOGIC RESPONSE||MG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|CAREGIVER|OTOLARYNGOLOGIST|U|4||88||OPEN LABEL TREATMENT|1965-01-01||||1968-04-02||1960-06-10|1965-07-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KG/MOL|SD||MPS U|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|VENDOR|PATHOLOGIST 2|N|4||88||RUN-IN|1961-10-08||||1968-05-12||1962-05-18|1963-06-28||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UOSM|MOLECULAR CR||ML/MMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|FRIEND|FORENSIC PATHOLOGIST|N|5||7||TREATMENT|1961-08-08||||1969-09-06||1961-03-20|1966-06-21||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CARTRIDGE|PD FROM PR||%(W/W)|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|VENDOR|READER 2|NA|5||7||FOLLOW-UP|1971-01-12||||1962-04-26||1965-04-29|1966-01-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||SEC|PR-CT||U/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|PROXY|PATHOLOGIST 2|N|1||38||BASELINE|1973-04-05||||1962-08-22||1962-02-09|1969-03-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CI/MG|CCR||MG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|FAMILY MEMBER|OPTOMETRIST|U|1||38||BASELINE|1967-09-11||||1965-12-07||1966-12-07|1969-04-26||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/G/H|NED||%(V/V)|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|GUARDIAN|NEUROLOGIST|N|2||58||INDUCTION TREATMENT|1964-08-26||||1967-04-03||1962-04-11|1970-12-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||NTRGRESP|NON-TARGET RESPONSE||||%/MIN|CA125 50% RESPONSE||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|2||58||OPEN LABEL TREATMENT|1970-12-09||||1965-07-11||1968-10-27|1973-07-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UMOL/MG/MIN|SD-CT||SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|U|3||39||OPEN LABEL TREATMENT|1968-10-26||||1968-01-14||1961-11-07|1962-04-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||RAD|MORPHOLOGIC LEUKEMIA-FREE STATE||ML/100G/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|GUARDIAN|OPTOMETRIST|U|3||39||TREATMENT|1969-12-22||||1968-01-17||1962-03-14|1972-03-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||HR/DAY|IMPROVED||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|SIBLING|UROLOGIST|NA|4||88||OBSERVATION|1963-08-31||||1963-04-25||1970-09-12|1963-09-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||METBRESP|METABOLIC RESPONSE||||AMU|CPR||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|STUDY SUBJECT|RATER|NA|4||88||CONTINUATION TREATMENT|1969-04-07||||1963-05-11||1963-03-20|1972-06-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||PATHRESP|PATHOLOGIC RESPONSE||||GMFI|HI-P||10^3/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|INVESTIGATOR|OTOLARYNGOLOGIST|U|5||7||WASHOUT|1963-12-08||||1971-05-18||1970-08-01|1966-12-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UM/S|CYTOGENETIC PR||/MM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|VENDOR|RATER 2|U|5||7||WASHOUT|1960-07-02||||1965-12-13||1969-10-27|1970-10-16||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/KG/H|SD-CT||MM/2H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|FRIEND|READER 2|N|1||38||LONG-TERM FOLLOW-UP|1964-08-16||||1963-03-26||1972-12-25|1967-05-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/G/MIN|RELAPSED DISEASE||ML/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1960-05-29||||1968-09-30||1961-06-26|1964-02-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MM/2H|CA125 75% RESPONSE||MG/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|2||58||RUN-IN|1966-05-05||||1967-11-03||1965-08-04|1964-09-27||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/G/H|ISD||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|2||58||SCREENING|1970-03-31||||1968-03-31||1972-01-18|1971-05-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||METBRESP|METABOLIC RESPONSE||||10^7 TCID 50/DOSE|IMPROVED||M|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|CHILD|UROLOGIST|NA|3||39||OPEN LABEL TREATMENT|1960-03-13||||1965-03-05||1970-11-05|1970-08-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||METBRESP|METABOLIC RESPONSE||||NEBULE|PDU||10^6 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|CHILD|READER 1|Y|3||39||INDUCTION TREATMENT|1961-01-07||||1965-01-28||1973-03-10|1962-11-03||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DAMOL/L|NR||MU|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|SPOUSE|CARDIOLOGIST|N|4||88||WASHOUT|1961-09-06||||1970-11-22||1966-07-25|1972-08-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||ANATRESP|ANATOMIC RESPONSE||||PA|PSEUDORESPONSE||MMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|4||88||FOLLOW-UP|1971-05-16||||1960-03-07||1971-07-26|1969-08-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||CLINRESP|CLINICAL RESPONSE||||FOZ_BR|PSEUDOPROGRESSION||UM/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|INVESTIGATOR|ENDOCRINOLOGIST|U|5||7||BLINDED TREATMENT|1960-01-14||||1960-05-04||1972-07-21|1967-03-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||ANATRESP|ANATOMIC RESPONSE||||KBQ|UNFAVORABLE RESPONSE||BP|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-06-26||||1964-12-09||1962-05-12|1973-04-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FMOL/L/SEC|CYTOGENETIC MINIMAL RESPONSE||HPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|PROXY|CARDIOLOGIST|Y|1||38||FOLLOW-UP|1968-04-20||||1963-03-08||1965-11-08|1972-02-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/10^4|HI-E||MG/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|PARENT|RATER 1|U|1||38||TREATMENT|1969-02-04||||1962-07-12||1964-10-01|1970-02-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DIP|IUPD||UCI/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|SIGNIFICANT OTHER|CARDIOLOGIST|N|2||58||FOLLOW-UP|1971-06-13||||1960-06-15||1960-09-03|1971-08-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||NEWLPROG|NEW LESION PROGRESSION||||CM|CR||MDFI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1965-02-09||||1969-10-21||1969-12-05|1965-12-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||METBRESP|METABOLIC RESPONSE||||U/DL|NOT ALL EVALUATED||FMOL/L/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|RATER|NA|3||39||OPEN LABEL TREATMENT|1967-05-12||||1962-11-09||1965-11-06|1968-12-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||OVRLRESP|OVERALL RESPONSE||||U/CL|STABLE||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|GUARDIAN|NEUROLOGIST 1|NA|3||39||INDUCTION TREATMENT|1969-04-11||||1965-04-12||1961-11-26|1960-10-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CCID 50/DOSE|STABLE||UCI/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|INDEPENDENT ASSESSOR|UROLOGIST|Y|4||88||OPEN LABEL TREATMENT|1971-06-26||||1970-02-10||1962-07-03|1973-05-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/G HB|OPTIMAL MORPHOLOGIC RESPONSE||UMOL/H/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|PROXY|ADJUDICATOR 2|U|4||88||SCREENING|1970-06-09||||1971-09-03||1973-08-31|1961-01-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||TRGRESP|TARGET RESPONSE||||MS/MMHG|TREATMENT FAILURE||GENEQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|5||7||RUN-IN|1970-02-19||||1964-12-02||1968-01-29|1965-08-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/MIN|NED||10^12/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|STUDY SUBJECT|UROLOGIST|Y|5||7||RUN-IN|1970-08-26||||1970-11-26||1970-04-08|1964-08-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||VG/KG|RELAPSED DISEASE||NMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|SIBLING|RADIOLOGIST 2|NA|1||38||BASELINE|1963-02-05||||1964-08-15||1973-06-29|1963-01-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MAC50|MOLECULAR CR||UG/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|1||38||OBSERVATION|1970-07-19||||1965-08-30||1962-06-20|1967-04-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/KG/DAY|PDU||LOG10 CCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||BASELINE|1971-08-18||||1967-10-30||1966-02-23|1962-05-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|2||||||NTRGRESP|NON-TARGET RESPONSE||||CMOL/L|FAVORABLE RESPONSE||TESLA|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|INTERVIEWER|PHYSIOTHERAPIST|U|2||58||TREATMENT|1962-05-28||||1966-10-05||1972-01-15|1968-06-30||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|1||||||BONERESP|BONE RESPONSE||||10^4 CFU|MINOR PATHOLOGIC RESPONSE||OZ EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|FAMILY MEMBER|PHYSIOTHERAPIST|NA|3||39||OBSERVATION|1968-09-26||||1972-02-26||1961-09-26|1971-01-31||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CM2|VGPR||10^9/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|VENDOR|RADIOLOGIST 2|Y|3||39||SCREENING|1960-06-27||||1966-11-28||1969-08-01|1967-08-14||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MV/SEC|PD/RELAPSE AFTER HI||STEPS/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|4||88||INDUCTION TREATMENT|1971-02-08||||1966-05-19||1969-01-22|1972-08-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|2||||||NTRGRESP|NON-TARGET RESPONSE||||MMHG*MIN/L|CA125 50% RESPONSE||OI50|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|4||88||LONG-TERM FOLLOW-UP|1961-12-11||||1961-11-23||1970-07-24|1968-01-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|1||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/L/MIN|IMPROVED||MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|FRIEND|CARDIOLOGIST|NA|5||7||CONTINUATION TREATMENT|1971-02-01||||1970-02-20||1960-09-17|1966-10-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|B3987A78-0D92-419D-A289-039C87C6C202|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KG/M2|HI-N||CMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|INTERVIEWER|ADJUDICATOR 2|NA|5||7||OPEN LABEL TREATMENT|1960-12-20||||1972-01-07||1970-01-01|1971-11-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||TRGRESP|TARGET RESPONSE||||WATT|FAVORABLE RESPONSE||KG/CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|STUDY SUBJECT|MICROSCOPIST 2|U|1||38||LONG-TERM FOLLOW-UP|1960-02-19||||1970-09-25||1971-01-10|1962-06-29||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3 CFU|SCR||MEQ/UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|1||38||TREATMENT|1968-11-12||||1964-12-08||1971-12-31|1971-08-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOSM|DECREASED||HOURS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|SIBLING|ADJUDICATOR 1|N|2||58||SCREENING|1966-08-02||||1962-08-06||1962-08-12|1969-05-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||SPLNRESP|SPLEEN RESPONSE||||%(W/V)|PMR||FEU|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|2||58||OPEN LABEL TREATMENT|1972-06-05||||1960-10-15||1965-04-23|1964-10-08||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||MOLRESP|MOLECULAR RESPONSE||||PRESSOR UNITS|PR-CT||WAFER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|GUARDIAN|HEMATOLOGIST|U|3||39||BASELINE|1965-10-11||||1966-10-13||1961-03-28|1971-07-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||ANATRESP|ANATOMIC RESPONSE||||UM|MORPHOLOGIC LEUKEMIA-FREE STATE||USEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|DOMESTIC PARTNER|READER|Y|3||39||LONG-TERM FOLLOW-UP|1971-02-26||||1969-09-04||1963-06-10|1960-11-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||NTRGRESP|NON-TARGET RESPONSE||||ELISA UNIT/DOSE|MAJOR PATHOLOGIC RESPONSE||PPTH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|ADJUDICATION COMMITTEE|RATER|Y|4||88||FOLLOW-UP|1972-03-09||||1967-08-27||1966-07-31|1966-04-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||S/H|NON-CR/NON-PD||NM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|SPOUSE|ENDOCRINOLOGIST|N|4||88||BLINDED TREATMENT|1965-03-24||||1967-08-08||1965-10-06|1962-03-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MOL/L|PR-CT||/MS|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|FRIEND|RADIOLOGIST|Y|5||7||INDUCTION TREATMENT|1969-08-13||||1960-08-26||1973-08-18|1966-05-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%(W/V)|CYTOGENETIC PR||MOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|SIBLING|RATER 2|Y|5||7||BASELINE|1971-02-10||||1963-01-10||1960-07-09|1961-12-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||ANATRESP|ANATOMIC RESPONSE||||KCAL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|CAREGIVER|OTOLARYNGOLOGIST|U|1||38||CONTINUATION TREATMENT|1968-07-06||||1960-02-18||1960-06-20|1960-05-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||METSIND|METASTATIC INDICATOR||||ML/CM H2O|CPR||UG/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|INDEPENDENT ASSESSOR|READER 2|NA|1||38||OBSERVATION|1962-05-21||||1960-11-29||1968-05-23|1969-09-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/DAY|RELAPSED DISEASE||G/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|HEALTH CARE PROFESSIONAL|RATER|U|2||58||CONTINUATION TREATMENT|1960-08-12||||1971-03-02||1966-11-30|1966-02-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||BONERESP|BONE RESPONSE||||10^4/L|DECREASED||UM/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|SIGNIFICANT OTHER|UROLOGIST|NA|2||58||CONTINUATION TREATMENT|1969-04-24||||1968-05-10||1971-09-20|1967-12-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KN/CM2|MCR||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|GUARDIAN|READER 1|N|3||39||INDUCTION TREATMENT|1961-09-10||||1962-11-21||1964-04-29|1960-12-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||BESTRESP|BEST OVERALL RESPONSE||||CY/CM|NON-CR/NON-PD||10^3 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|3||39||SCREENING|1962-04-01||||1970-01-08||1963-06-16|1969-06-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||GBQ/UG|CYTOGENETIC MINOR RESPONSE||MONTHS|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|PROXY|READER 2|Y|4||88||FOLLOW-UP|1971-11-18||||1960-09-23||1962-12-16|1971-04-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^5/L|NE||UCI/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|4||88||RUN-IN|1967-08-10||||1964-09-14||1969-01-03|1961-05-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||BESTRESP|BEST OVERALL RESPONSE||||MIN*MG/ML|MR||K|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|CAREGIVER|MICROSCOPIST|NA|5||7||LONG-TERM FOLLOW-UP|1967-06-10||||1969-07-24||1963-11-03|1960-12-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||STRUSTAT|STEROID USE STATUS||||HZ|ICR||ML/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|FAMILY MEMBER|READER 3|NA|5||7||CONTINUATION TREATMENT|1963-12-17||||1961-09-06||1961-07-07|1962-08-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/ML|NOT ALL EVALUATED||RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||LONG-TERM FOLLOW-UP|1961-05-07||||1970-09-16||1968-02-07|1960-04-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/CM|PR WITH LYMPHOCYTOSIS||CI/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|1||38||BASELINE|1963-07-08||||1960-12-03||1971-03-12|1963-03-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||RAD|NON-PD||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|VENDOR|MICROSCOPIST 3|N|2||58||RUN-IN|1960-09-27||||1968-04-09||1962-11-17|1969-05-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||BONERESP|BONE RESPONSE||||ML/ANIMAL/DAY|ABSENT MORPHOLOGIC RESPONSE||JOULE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|ADJUDICATOR|FORENSIC PATHOLOGIST|U|2||58||BLINDED TREATMENT|1967-09-20||||1961-05-12||1969-03-24|1966-08-31||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||NEWLPROG|NEW LESION PROGRESSION||||CPM|CYTOGENETIC NO RESPONSE||SFC/10^6 PBMC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|VENDOR|ONCOLOGIST 2|N|3||39||OBSERVATION|1967-10-02||||1964-10-20||1966-05-03|1965-12-11||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||METSIND|METASTATIC INDICATOR||||10^9/L|STABLE||RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|CAREGIVER|MICROSCOPIST 2|NA|3||39||CONTINUATION TREATMENT|1967-08-09||||1971-02-17||1972-04-05|1962-11-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||G|CA125 50% RESPONSE||UG/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|Y|4||88||CONTINUATION TREATMENT|1968-10-17||||1960-06-29||1969-07-06|1961-01-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||METSIND|METASTATIC INDICATOR||||/MBP|HI-N||DIP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|SPOUSE|OTOLARYNGOLOGIST|N|4||88||TREATMENT|1963-03-26||||1969-11-12||1970-06-07|1973-07-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||METBRESP|METABOLIC RESPONSE||||MMOL2/L2|FAVORABLE RESPONSE||EP U|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||OBSERVATION|1971-12-10||||1969-08-27||1972-12-15|1964-07-01||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||METSIND|METASTATIC INDICATOR||||UOSM|PR-CT||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|PARENT|ADJUDICATOR|N|5||7||SCREENING|1967-09-24||||1966-10-03||1968-01-27|1961-08-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||CLINRESP|CLINICAL RESPONSE||||10^6 COPIES/ML|EQUIVOCAL||U/MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|INTERVIEWER|ONCOLOGIST 1|N|1||38||WASHOUT|1967-05-28||||1970-12-14||1972-11-22|1971-07-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||BESTRESP|BEST OVERALL RESPONSE||||U/ML|UNEQUIVOCAL||VG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|1||38||OBSERVATION|1962-12-10||||1969-04-14||1968-12-04|1970-06-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RNA COPIES/ML|NON-PD||ML/MMHG|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|DOMESTIC PARTNER|RADIOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1969-07-22||||1962-03-09||1960-09-01|1971-02-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||SPLNRESP|SPLEEN RESPONSE||||KALLIKREIN INHIBITOR UNIT|INDETERMINATE RESPONSE||HEP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|CHILD|RATER 2|U|2||58||LONG-TERM FOLLOW-UP|1969-12-06||||1962-06-30||1973-07-13|1960-10-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UL/ML|ABSENT MORPHOLOGIC RESPONSE||LOG10 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|VENDOR|RADIOLOGIST 2|N|3||39||WASHOUT|1969-08-07||||1970-09-22||1963-01-13|1969-12-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||AU/ML|CR||NMOL BCE/MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|INVESTIGATOR|OTOLARYNGOLOGIST|Y|3||39||FOLLOW-UP|1961-07-07||||1968-08-13||1970-01-04|1972-01-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||NEWLPROG|NEW LESION PROGRESSION||||JOULE|CYTOGENETIC CR||UGEQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|4||88||BASELINE|1971-08-25||||1963-09-26||1970-10-28|1970-03-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||C|CYTOGENETIC CR||NMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|CHILD|PHYSIOTHERAPIST|N|4||88||LONG-TERM FOLLOW-UP|1963-02-19||||1971-10-15||1972-03-07|1967-12-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PIPE|STABLE||POUCH|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|FAMILY MEMBER|RATER 1|NA|5||7||SCREENING|1972-10-27||||1973-07-14||1967-11-25|1972-10-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UKAT/L|MCR||KM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|ADJUDICATOR|PATHOLOGIST|N|5||7||RUN-IN|1964-02-04||||1968-11-26||1972-10-06|1968-11-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||METBRESP|METABOLIC RESPONSE||||IU/MG|RELAPSED DISEASE||DRINK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||TREATMENT|1961-08-13||||1962-06-16||1973-03-29|1967-10-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||V/V|CYTOGENETIC MINIMAL RESPONSE||/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|1||38||BLINDED TREATMENT|1962-10-16||||1970-01-24||1963-01-31|1963-07-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MMOL/L|CRI||10^3 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||OBSERVATION|1967-01-27||||1962-04-22||1973-01-01|1962-04-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NMOL/L|UNEQUIVOCAL||/2500 WBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|ADJUDICATOR|MICROSCOPIST 1|NA|2||58||BASELINE|1966-12-06||||1964-12-14||1970-01-31|1969-11-02||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||SPLNRESP|SPLEEN RESPONSE||||MM/SEC|UNFAVORABLE RESPONSE||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|INDEPENDENT ASSESSOR|RADIOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1960-04-28||||1965-06-06||1972-06-10|1972-04-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MEQ|MAJOR PATHOLOGIC RESPONSE||10^3 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|FRIEND|PATHOLOGIST|N|3||39||RUN-IN|1969-06-21||||1967-03-12||1965-09-11|1961-06-23||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||BESTRESP|BEST OVERALL RESPONSE||||DNA COPIES/UG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CHILD|FORENSIC PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1970-04-24||||1970-10-24||1960-07-04|1962-06-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||OVRLRESP|OVERALL RESPONSE||||CUP EQ|CA125 50% RESPONSE||PG/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|GUARDIAN|ONCOLOGIST|U|4||88||SCREENING|1964-04-16||||1967-10-24||1969-08-04|1965-10-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||TRGRESP|TARGET RESPONSE||||FL|CHR||BLOCKS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|FAMILY MEMBER|MICROSCOPIST 2|Y|5||7||OBSERVATION|1967-08-03||||1960-05-15||1964-09-02|1962-06-11||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||TMRESP|TUMOR MARKER RESPONSE||||BREATHS/MIN|CYTOGENETIC PR||ML/KG/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CHILD|PEDIATRIC NEUROLOGIST|U|5||7||TREATMENT|1960-04-16||||1968-09-19||1961-09-03|1972-01-30||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||BESTRESP|BEST OVERALL RESPONSE||||BREATHS/MIN|MORPHOLOGIC CRI||GTT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|N|1||38||OPEN LABEL TREATMENT|1972-03-03||||1961-06-02||1963-09-29|1967-10-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||MOLRESP|MOLECULAR RESPONSE||||M2|RELAPSED DISEASE||MMHG/L/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|U|1||38||OBSERVATION|1964-06-27||||1969-04-24||1962-07-15|1963-02-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CM H2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|VENDOR|ADJUDICATOR 2|U|2||58||SCREENING|1963-09-06||||1972-02-28||1963-01-22|1970-02-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||NEWLIND|NEW LESION INDICATOR||||/MONTH|PSEUDORESPONSE||KAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|2||58||FOLLOW-UP|1960-10-21||||1965-05-24||1962-12-20|1963-03-09||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||BQ/ML|MRD NEGATIVITY||FARAD|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|CHILD|ADJUDICATOR 2|U|3||39||BLINDED TREATMENT|1964-06-28||||1972-01-12||1962-02-28|1963-12-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||SPLNRESP|SPLEEN RESPONSE||||LOG10 TCID 50/ML|OPTIMAL MORPHOLOGIC RESPONSE||PMOL/10^10 CELLS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|PROXY|ONCOLOGIST 1|U|3||39||BLINDED TREATMENT|1966-01-26||||1969-05-09||1973-05-15|1962-06-08||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||TRGRESP|TARGET RESPONSE||||UG/G/H|HI-E||ML/CAGE/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4||88||INDUCTION TREATMENT|1964-09-06||||1963-01-19||1963-10-31|1972-03-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/DL|HI-N||10^3 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|4||88||BLINDED TREATMENT|1964-11-30||||1971-07-13||1972-05-23|1965-01-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||MOLRESP|MOLECULAR RESPONSE||||10^9 CFU|TREATMENT FAILURE||U/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|GUARDIAN|CARDIOLOGIST|Y|5||7||TREATMENT|1968-01-31||||1973-04-01||1970-01-31|1967-03-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 U|PR-CT||MEQ/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|FRIEND|PHYSIOTHERAPIST|NA|5||7||OPEN LABEL TREATMENT|1964-07-15||||1967-02-21||1962-01-29|1963-03-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DEG2|NOT ALL EVALUATED||AMPULE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|FRIEND|UROLOGIST|NA|1||38||CONTINUATION TREATMENT|1967-01-09||||1965-09-17||1963-03-12|1970-06-07||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UIU/DL|NON-QUANTIFIABLE MRD POSITIVITY||UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|PARENT|RATER 2|NA|1||38||FOLLOW-UP|1960-09-06||||1973-05-29||1963-03-02|1969-05-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||METBRESP|METABOLIC RESPONSE||||BLOCKS|CCR||U/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|ADJUDICATOR|READER 1|NA|2||58||TREATMENT|1972-08-14||||1962-08-13||1961-08-12|1960-11-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UGEQ/L|CYTOGENETIC MINIMAL RESPONSE||KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|FRIEND|OPTOMETRIST|U|2||58||LONG-TERM FOLLOW-UP|1963-04-28||||1971-09-18||1960-01-28|1973-05-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BOTTLE|PARTIAL MORPHOLOGIC RESPONSE||ML/MMHG/MIN/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|3||39||SCREENING|1961-12-13||||1961-11-01||1968-12-10|1966-11-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||MOLRESP|MOLECULAR RESPONSE||||LOG EID 50/DOSE|PSEUDORESPONSE||KG|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|INVESTIGATOR|MICROSCOPIST 3|Y|3||39||FOLLOW-UP|1971-09-22||||1963-09-23||1973-03-10|1960-08-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||OVRLRESP|OVERALL RESPONSE||||USIEMENS|CYTOGENETIC CR||IU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|FRIEND|OTOLARYNGOLOGIST|Y|4||88||RUN-IN|1965-08-17||||1971-09-17||1967-04-02|1962-07-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||STRUSTAT|STEROID USE STATUS||||MG/M2/MIN|PD-CT||TCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|STUDY SUBJECT|OPTOMETRIST|NA|4||88||WASHOUT|1966-11-28||||1970-09-06||1961-10-01|1962-06-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||PATHRESP|PATHOLOGIC RESPONSE||||GRAIN|PSEUDORESPONSE||LOG10 PFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||TREATMENT|1972-12-12||||1960-03-29||1963-04-21|1969-02-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||MOLRESP|MOLECULAR RESPONSE||||MIN|HI-E||PIPE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|READER|N|5||7||BLINDED TREATMENT|1960-06-22||||1967-09-08||1973-06-11|1971-01-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||BQ/MG|SD-CT||CONTAINER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|INTERVIEWER|MICROSCOPIST 1|NA|1||38||CONTINUATION TREATMENT|1966-08-31||||1965-03-01||1962-02-27|1961-12-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KM/H|NR||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|FRIEND|RATER 1|U|1||38||CONTINUATION TREATMENT|1973-07-26||||1968-07-21||1968-10-25|1960-08-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||OVRLRESP|OVERALL RESPONSE||||MG/CM2|CYTOGENETIC NO RESPONSE||G/CAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|PARENT|ONCOLOGIST 2|Y|2||58||RUN-IN|1969-05-15||||1968-10-20||1971-10-14|1973-06-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PMOL|EQUIVOCAL||PMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|INVESTIGATOR|ONCOLOGIST 2|Y|2||58||RUN-IN|1966-09-24||||1973-03-17||1969-11-17|1960-07-11||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PACK|NPR||MIN/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|3||39||OBSERVATION|1971-02-06||||1961-11-05||1961-02-03|1963-12-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||OVRLRESP|OVERALL RESPONSE||||PKAT|ISD||CMHG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|GUARDIAN|INTERNIST|NA|3||39||BASELINE|1968-07-03||||1960-10-26||1969-03-26|1964-01-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PSEC|PSEUDORESPONSE||G/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|4||88||BASELINE|1964-05-25||||1964-12-31||1972-06-12|1970-06-14||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||CLINRESP|CLINICAL RESPONSE||||PKAT/L|NED||KBQ/UL|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|FAMILY MEMBER|PATHOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1967-01-21||||1960-06-14||1967-07-26|1966-03-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||TRGRESP|TARGET RESPONSE||||L|RELAPSED DISEASE||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|INTERVIEWER|DERMATOLOGIST|N|5||7||WASHOUT|1968-10-23||||1961-02-09||1963-07-24|1965-03-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||TMRESP|TUMOR MARKER RESPONSE||||MGEQ|NON-QUANTIFIABLE MRD POSITIVITY||MAC50|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|FRIEND|CLINICAL PATHOLOGIST|NA|5||7||BASELINE|1972-09-08||||1965-12-08||1968-07-08|1971-07-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|1||||||METBRESP|METABOLIC RESPONSE||||UM/S|NPR||LX|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|SIBLING|ADJUDICATOR|N|1||38||TREATMENT|1973-08-29||||1964-09-23||1961-07-21|1968-05-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|2||||||MOLRESP|MOLECULAR RESPONSE||||U/10^12 RBC|NON-ICR/NON-IUPD||NMOL BCE/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|1||38||RUN-IN|1964-04-06||||1973-02-25||1965-06-02|1973-03-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|1||||||ANATRESP|ANATOMIC RESPONSE||||CUP|RELAPSED DISEASE FROM CR OR PR||PIXEL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|2||58||SCREENING|1960-12-24||||1962-07-19||1972-07-20|1961-12-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/M2|NOT ALL EVALUATED||LINEAR FT*LB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|INVESTIGATOR|ONCOLOGIST 1|NA|2||58||WASHOUT|1962-05-26||||1966-09-05||1972-07-23|1963-02-03||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ABSORBANCE U/MIN|RELAPSED DISEASE||TSP EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|FAMILY MEMBER|PHYSIOTHERAPIST|NA|3||39||OBSERVATION|1968-11-09||||1962-03-04||1966-12-08|1965-07-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|2||||||METSIND|METASTATIC INDICATOR||||GRAIN|NON-PD||U/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|STUDY SUBJECT|RATER|U|3||39||BASELINE|1968-06-05||||1972-04-23||1966-10-31|1964-01-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|1||||||SPLNRESP|SPLEEN RESPONSE||||ML/S/M2|PR-CT||F|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|4||88||TREATMENT|1963-04-08||||1968-11-03||1966-05-26|1967-05-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|2||||||CYTORESP|CYTOGENETIC RESPONSE||||BAU/ML|HI-N||UG/L DDU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|VENDOR|UROLOGIST|U|4||88||BLINDED TREATMENT|1962-10-18||||1970-05-25||1972-06-16|1967-02-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|1||||||NTRGRESP|NON-TARGET RESPONSE||||L/H/M2|COMPLETE MRD RESPONSE||SYRINGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|FRIEND|MICROSCOPIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1969-06-15||||1971-03-14||1968-06-19|1969-07-11||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|499B5A47-893A-40DE-9B64-60967378C81A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/SEC/1.73M2|NON-QUANTIFIABLE MRD POSITIVITY||MMU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|SIBLING|MICROSCOPIST 1|U|5||7||SCREENING|1963-07-28||||1970-04-24||1972-09-27|1962-08-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||LIVRRESP|LIVER RESPONSE||||CAPFUL|ICR||PIXELS/IN|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|ADJUDICATION COMMITTEE|UROLOGIST|N|1||38||FOLLOW-UP|1966-06-10||||1970-01-29||1963-11-23|1962-09-05||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||ANATRESP|ANATOMIC RESPONSE||||/LSQN|CYTOGENETIC MINIMAL RESPONSE||LM|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1||38||TREATMENT|1964-04-28||||1963-07-26||1960-10-28|1962-05-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||SPLNRESP|SPLEEN RESPONSE||||/H|IPR||PL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|2||58||SCREENING|1963-06-12||||1971-03-18||1966-02-10|1962-01-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/DL|PSA PROGRESSION||DROP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|2||58||BLINDED TREATMENT|1960-10-09||||1966-11-13||1965-12-07|1960-10-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/S|NR||L/H/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|GUARDIAN|OPTOMETRIST|U|3||39||TREATMENT|1962-09-30||||1964-03-31||1971-11-04|1967-04-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/G HB|SCR||TROCHE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|INVESTIGATOR|CLINICAL PATHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1964-04-26||||1964-04-12||1970-03-12|1972-01-30||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/MOL|MRD PERSISTENCE||/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|4||88||OBSERVATION|1967-10-21||||1967-04-19||1963-09-02|1960-05-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TAMPON|IMPROVED||CM/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||TREATMENT|1971-02-15||||1972-01-21||1963-03-13|1964-10-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||V/V|ISD||ML/S/M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||BLINDED TREATMENT|1971-02-28||||1967-04-09||1966-09-01|1967-05-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||STRUSTAT|STEROID USE STATUS||||IU/ML|UNFAVORABLE RESPONSE||CM H2O|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|5||7||RUN-IN|1972-03-09||||1968-01-10||1960-10-10|1970-02-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||LIVRRESP|LIVER RESPONSE||||NMOL/G|PSA PROGRESSION||U/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|INTERVIEWER|ENDOCRINOLOGIST|U|1||38||FOLLOW-UP|1966-08-15||||1962-07-01||1971-11-05|1970-11-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FFU|PD||KV|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|PARENT|ADJUDICATOR 3|NA|1||38||BASELINE|1963-10-13||||1966-03-30||1962-04-06|1967-01-09||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||COPIES/ML|MAJOR PATHOLOGIC RESPONSE||VG/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|ADJUDICATION COMMITTEE|READER 3|NA|2||58||WASHOUT|1962-06-19||||1967-06-18||1969-01-17|1966-08-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||STRUSTAT|STEROID USE STATUS||||ML/DOSE|HI-E||CP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|2||58||WASHOUT|1964-10-12||||1960-10-24||1964-11-27|1973-02-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||SPLNRESP|SPLEEN RESPONSE||||C|MR||TITER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||RUN-IN|1964-04-04||||1964-10-09||1963-07-18|1972-11-12||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TCID 50/DOSE|VGPR||USP U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|INTERVIEWER|FORENSIC PATHOLOGIST|Y|3||39||SCREENING|1967-02-12||||1972-09-02||1963-07-24|1973-01-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||MOLRESP|MOLECULAR RESPONSE||||10^3/L|CMR||CGY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|PROXY|CLINICAL PATHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1962-02-09||||1962-05-28||1972-10-12|1967-06-15||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||AG|HI-P||/5X10^4 WBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|CAREGIVER|OPTOMETRIST|NA|4||88||BLINDED TREATMENT|1968-03-26||||1966-08-12||1968-02-29|1970-08-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||STRUSTAT|STEROID USE STATUS||||ML/KG|NON-ICR/NON-IUPD||MEQ/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|DOMESTIC PARTNER|MICROSCOPIST 3|U|5||7||TREATMENT|1967-05-15||||1968-11-27||1966-01-28|1973-02-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||BESTRESP|BEST OVERALL RESPONSE||||NSEC|IUPD||TITER|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|5||7||INDUCTION TREATMENT|1960-06-07||||1971-06-25||1964-08-11|1969-10-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||NEWLIND|NEW LESION INDICATOR||||FARAD|DISEASE TRANSFORMATION||NG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|DOMESTIC PARTNER|ONCOLOGIST|Y|1||38||RUN-IN|1969-09-18||||1961-02-05||1964-06-23|1971-09-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||LIVRRESP|LIVER RESPONSE||||H*%|NED||FT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|SIBLING|MICROSCOPIST 2|U|1||38||FOLLOW-UP|1968-05-10||||1965-09-01||1970-01-05|1970-09-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KM|CA125 50% RESPONSE||UCI/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|N|SIBLING|NEUROLOGIST|N|2||58||BLINDED TREATMENT|1963-05-23||||1964-12-24||1960-08-06|1966-06-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||TMRESP|TUMOR MARKER RESPONSE||||KCAL/DAY|PR||CMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|SPOUSE|ADJUDICATOR 3|NA|2||58||LONG-TERM FOLLOW-UP|1969-08-06||||1967-04-26||1967-07-14|1964-06-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^9 ORGANISMS/MG|DISEASE TRANSFORMATION||DROP|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|3||39||BASELINE|1973-07-30||||1969-09-21||1962-03-21|1964-10-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ANTIBODY UNIT|PARTIAL MORPHOLOGIC RESPONSE||MG/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1960-12-16||||1963-05-15||1962-02-04|1972-06-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||SPLNRESP|SPLEEN RESPONSE||||MIN/DAY|PR||CG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|CAREGIVER|UROLOGIST|Y|4||88||RUN-IN|1965-08-06||||1967-06-14||1961-11-02|1972-02-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ABSORBANCE U/MIN|SMD||POINT|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|U|4||88||INDUCTION TREATMENT|1961-07-20||||1969-08-24||1968-08-13|1961-08-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||LOG10 TCID 50/DOSE|PSEUDOPROGRESSION||FMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|5||7||SCREENING|1972-01-28||||1967-11-16||1961-07-11|1969-05-16||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||METSIND|METASTATIC INDICATOR||||PMOL/L|WORSENED||AMFI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|PARENT|OPTOMETRIST|NA|5||7||OPEN LABEL TREATMENT|1965-05-07||||1962-09-28||1964-12-13|1968-09-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NMOL/L|VGPR||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|ADJUDICATOR|ADJUDICATOR|N|1||38||TREATMENT|1972-06-10||||1964-05-24||1973-03-02|1960-02-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||SCM|PMR||%(W/V)|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|INTERVIEWER|PATHOLOGIST|N|1||38||TREATMENT|1961-04-02||||1970-10-09||1973-09-07|1967-12-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DEG/MM|MRD PERSISTENCE||MEQ/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|SPOUSE|ADJUDICATOR|Y|2||58||LONG-TERM FOLLOW-UP|1969-03-12||||1967-06-14||1966-03-03|1961-05-13||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||METBRESP|METABOLIC RESPONSE||||UMOL/MG/MIN|PARTIAL MORPHOLOGIC RESPONSE||G/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|CLINICAL RESEARCH ASSOCIATE|READER|N|2||58||TREATMENT|1966-02-12||||1961-04-23||1962-01-17|1971-02-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^9 ORGANISMS|CR||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|DOMESTIC PARTNER|MICROSCOPIST 2|U|3||39||OPEN LABEL TREATMENT|1971-01-21||||1963-12-10||1973-08-10|1973-05-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^4/HPF|PCR||USEC|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|DOMESTIC PARTNER|RADIOLOGIST|NA|3||39||INDUCTION TREATMENT|1960-06-29||||1967-11-16||1961-12-31|1967-06-14||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/KG|HI-N||NMOL BCE/NMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|INVESTIGATOR|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1970-08-30||||1963-10-05||1960-03-09|1971-02-10||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||SPLNRESP|SPLEEN RESPONSE||||%/S|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||IU/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CAREGIVER|ADJUDICATOR|N|4||88||INDUCTION TREATMENT|1963-03-25||||1961-07-24||1964-07-10|1968-08-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||STRUSTAT|STEROID USE STATUS||||KEV|CYTOGENETIC MINIMAL RESPONSE||MEQ/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|PROXY|ADJUDICATOR 2|U|5||7||BLINDED TREATMENT|1969-05-02||||1972-11-09||1961-04-28|1968-04-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/ANIMAL/DAY|MR||%(V/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|5||7||BASELINE|1972-12-05||||1969-12-31||1967-01-03|1967-11-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||KG/MOL|MAJOR PATHOLOGIC RESPONSE||MBQ/UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|1||38||BASELINE|1960-03-18||||1973-05-26||1973-04-19|1966-09-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||TUBE|PDU||MG/M2/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|FRIEND|PATHOLOGIST 1|N|1||38||WASHOUT|1972-05-31||||1967-06-20||1963-11-10|1971-11-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||LIVRRESP|LIVER RESPONSE||||MG/M2/DAY|CA125 75% RESPONSE||VIAL|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|INVESTIGATOR|ONCOLOGIST 2|Y|2||58||SCREENING|1961-02-19||||1972-08-15||1964-02-26|1962-04-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||METSIND|METASTATIC INDICATOR||||GMFI|MAJOR PATHOLOGIC RESPONSE||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||WASHOUT|1968-12-01||||1961-01-10||1971-01-05|1970-10-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||TRGRESP|TARGET RESPONSE||||U/10^12 RBC|IMPROVED||BAG|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|CHILD|READER 3|N|3||39||TREATMENT|1967-02-20||||1964-03-23||1964-02-28|1973-01-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||ANATRESP|ANATOMIC RESPONSE||||MEQ/UG|PD||MG/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|3||39||CONTINUATION TREATMENT|1965-09-19||||1962-01-01||1971-12-22|1963-01-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/L/H|IMPROVED||MBP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL STUDY SPONSOR|UROLOGIST|Y|4||88||OPEN LABEL TREATMENT|1972-05-28||||1966-06-21||1960-12-02|1972-06-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||M3|PD-CT||/MONTH|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|SIBLING|ADJUDICATOR|N|4||88||LONG-TERM FOLLOW-UP|1967-02-05||||1962-12-06||1967-03-31|1969-01-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||ANATRESP|ANATOMIC RESPONSE||||10^10/L|RELAPSED DISEASE||BOWL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|PROXY|DERMATOLOGIST|U|5||7||FOLLOW-UP|1968-05-24||||1973-05-07||1962-04-30|1967-04-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||METSIND|METASTATIC INDICATOR||||MHZ|INCREASED||10^6 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|VENDOR|OPHTHALMOLOGIST|N|5||7||TREATMENT|1960-06-22||||1969-01-29||1963-07-23|1960-05-31||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/SEC/1.73M2|PSEUDORESPONSE||FMOL/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|1||38||OPEN LABEL TREATMENT|1969-05-29||||1968-06-03||1967-08-29|1967-10-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||NEWLIND|NEW LESION INDICATOR||||10^11/L|RELAPSED DISEASE||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|1||38||OBSERVATION|1965-01-10||||1972-03-11||1971-02-24|1972-10-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IMPLANT|MOLECULAR CR||ENZYME U/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|2||58||FOLLOW-UP|1962-03-12||||1963-05-19||1969-01-11|1971-12-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BQ/UL|CYTOGENETIC MINIMAL RESPONSE||VP/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|CAREGIVER|MICROSCOPIST 2|U|2||58||BASELINE|1969-12-21||||1963-12-05||1968-06-27|1971-07-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FMOL|PR-CT||IU/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|CAREGIVER|HEMATOLOGIST|NA|3||39||SCREENING|1972-11-30||||1965-08-11||1963-04-16|1965-10-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DL|MORPHOLOGIC CRI||MG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|CAREGIVER|CLINICAL PATHOLOGIST|U|3||39||OBSERVATION|1963-06-19||||1972-11-22||1970-10-15|1972-02-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||METSIND|METASTATIC INDICATOR||||BOLUS|EQUIVOCAL||UEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|4||88||INDUCTION TREATMENT|1967-06-13||||1967-08-25||1962-05-12|1971-10-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UGEQ/L|CMR||MS2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|CHILD|ONCOLOGIST 2|N|4||88||BLINDED TREATMENT|1966-03-03||||1963-02-17||1971-04-03|1965-04-02||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||BONERESP|BONE RESPONSE||||UG/DAY|MRD RELAPSE||NG|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|ADJUDICATION COMMITTEE|OPTOMETRIST|NA|5||7||FOLLOW-UP|1962-06-22||||1968-05-29||1961-04-16|1969-07-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CL|RELAPSED DISEASE FROM CR||LENS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|ADJUDICATOR|READER 2|U|5||7||WASHOUT|1971-05-07||||1972-04-23||1968-02-15|1965-12-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||CYTORESP|CYTOGENETIC RESPONSE||||AMP|NE||VIAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|PARENT|INTERNIST|U|1||38||OPEN LABEL TREATMENT|1969-01-02||||1963-10-18||1973-05-27|1971-02-09||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/DL|PR||%/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|SIBLING|RATER 1|NA|1||38||LONG-TERM FOLLOW-UP|1964-12-04||||1966-02-06||1969-02-10|1966-01-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||LIVRRESP|LIVER RESPONSE||||BOTTLE|IMPROVED||10^6 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|2||58||WASHOUT|1971-08-02||||1972-08-31||1960-09-14|1964-11-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||JAR|NED||/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|SIBLING|UROLOGIST|Y|2||58||RUN-IN|1964-02-28||||1969-01-14||1964-05-10|1964-02-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/KG/H|MOLECULAR MAJOR RESPONSE||U/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|VENDOR|READER 1|N|3||39||BLINDED TREATMENT|1961-02-06||||1963-11-23||1965-05-27|1973-01-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/MG|VGPR||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1965-08-07||||1970-01-07||1969-11-17|1971-03-17||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||ANATRESP|ANATOMIC RESPONSE||||LOG10 TCID 50/DOSE|HI-P||10^12 IU/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|VENDOR|ADJUDICATOR|N|4||88||BLINDED TREATMENT|1973-06-05||||1962-08-25||1970-08-21|1960-06-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SQU/ML|PSA PROGRESSION||UMOL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|INTERVIEWER|ADJUDICATOR 2|NA|4||88||CONTINUATION TREATMENT|1973-06-11||||1962-09-26||1962-03-17|1961-04-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KG/CM2|MOLECULAR CR||BQ/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|FRIEND|UROLOGIST|U|5||7||BASELINE|1961-12-02||||1960-01-23||1968-03-08|1964-11-19||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||TRGRESP|TARGET RESPONSE||||AMOL|NON-CR/NON-PD||SQU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|FRIEND|HEMATOLOGIST|NA|5||7||BLINDED TREATMENT|1969-03-28||||1963-09-15||1960-02-06|1966-03-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||GMFI|TREATMENT FAILURE||CP|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|PARENT|RATER 1|U|1||38||RUN-IN|1961-09-03||||1961-04-07||1963-03-30|1966-10-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||NEWLPROG|NEW LESION PROGRESSION||||IN|NE||AMP|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|SIBLING|ADJUDICATOR 2|NA|1||38||BASELINE|1971-09-02||||1961-09-06||1969-06-10|1967-06-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||OVRLRESP|OVERALL RESPONSE||||P|HI-N||10^5/HPF|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|Y|2||58||FOLLOW-UP|1967-12-25||||1962-05-21||1960-09-12|1967-01-10||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/MS|PD/RELAPSE AFTER HI||UL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1966-03-14||||1965-09-19||1969-07-01|1972-12-31||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||BONERESP|BONE RESPONSE||||ML/ANIMAL/WK|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ENZYME U|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|SPOUSE|RATER|Y|3||39||SCREENING|1962-01-30||||1968-03-09||1969-07-04|1963-07-30||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||LOG10 TCID 50/DOSE|SCR||ENZYME U/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|CAREGIVER|READER 1|Y|3||39||FOLLOW-UP|1973-01-25||||1972-10-11||1972-06-18|1964-11-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||NEWLIND|NEW LESION INDICATOR||||SEC|CYTOGENETIC MINIMAL RESPONSE||UMOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|PARENT|PATHOLOGIST 2|N|4||88||SCREENING|1963-06-06||||1967-12-04||1963-10-08|1970-12-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||MOLRESP|MOLECULAR RESPONSE||||BU|MINOR PATHOLOGIC RESPONSE||G/M2/DAY|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|PROXY|PATHOLOGIST 1|Y|4||88||WASHOUT|1968-07-16||||1967-03-23||1963-01-09|1972-09-08||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MEQ/ML|MRD RELAPSE||UG/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|DOMESTIC PARTNER|PATHOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1969-08-08||||1971-02-17||1965-04-11|1965-03-20||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KG/CM|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||HOMEOPATHIC DILUTION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|CHILD|PATHOLOGIST|NA|5||7||SCREENING|1964-09-26||||1971-07-16||1965-12-15|1971-09-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||NEWLIND|NEW LESION INDICATOR||||IU/DAY|CYTOGENETIC CR||ML/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|DOMESTIC PARTNER|PHYSIOTHERAPIST|N|1||38||LONG-TERM FOLLOW-UP|1969-04-01||||1969-08-13||1960-03-21|1972-07-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||METSIND|METASTATIC INDICATOR||||MEQ/DL|CYTOGENETIC PR||MEQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|DOMESTIC PARTNER|ONCOLOGIST 1|Y|1||38||BLINDED TREATMENT|1968-07-14||||1973-01-25||1963-02-20|1970-06-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||L/DAY|MAJOR PATHOLOGIC RESPONSE||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||FOLLOW-UP|1964-10-19||||1966-06-07||1968-05-17|1970-10-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||STRUSTAT|STEROID USE STATUS||||ML/M2/MIN|CR||U/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|INVESTIGATOR|HEMATOLOGIST|N|2||58||RUN-IN|1973-07-17||||1960-12-15||1969-03-29|1967-03-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GBQ/MG|NON-ICR/NON-IUPD||GENEQ/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|PROXY|ADJUDICATOR 3|Y|3||39||FOLLOW-UP|1965-09-08||||1967-03-30||1962-07-05|1972-02-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||OVRLRESP|OVERALL RESPONSE||||CYCLE/MIN|ABSENT MORPHOLOGIC RESPONSE||ML/CM3/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|INVESTIGATOR|READER 1|Y|3||39||RUN-IN|1971-04-06||||1967-03-12||1968-10-23|1963-02-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TRANSDUCING UNIT/ML|PR-CT||10^3/HPF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|GUARDIAN|INTERNIST|NA|4||88||BASELINE|1965-10-19||||1972-08-18||1969-05-09|1969-04-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||LIVRRESP|LIVER RESPONSE||||UCI/L|UNFAVORABLE RESPONSE||G/U|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|4||88||WASHOUT|1969-01-27||||1970-03-08||1971-06-27|1969-01-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/G|CR||ENZYME U/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|SIBLING|OTOLARYNGOLOGIST|Y|5||7||WASHOUT|1970-01-25||||1972-01-06||1965-04-21|1963-11-25||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||OVRLRESP|OVERALL RESPONSE||||IU/ML|PMD||GTT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|SIBLING|MICROSCOPIST 3|NA|5||7||BASELINE|1964-08-03||||1972-03-08||1963-02-22|1967-03-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||APPLICATION|PD FROM PR||UV*SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|INTERVIEWER|ONCOLOGIST|U|1||38||BLINDED TREATMENT|1963-04-15||||1968-01-19||1962-06-23|1967-03-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||TMRESP|TUMOR MARKER RESPONSE||||MBQ|OPTIMAL MORPHOLOGIC RESPONSE||FT2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|PARENT|INTERNIST|Y|1||38||FOLLOW-UP|1963-09-24||||1968-11-04||1970-07-21|1966-06-14||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||TMRESP|TUMOR MARKER RESPONSE||||MASK|INCREASED||MOL/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|U|2||58||BLINDED TREATMENT|1972-09-22||||1964-06-09||1961-06-02|1973-08-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BOWL|HI-P||ML/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|SIBLING|PEDIATRIC NEUROLOGIST|U|2||58||FOLLOW-UP|1964-08-04||||1963-06-26||1960-12-20|1973-06-30||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FG|MINOR PATHOLOGIC RESPONSE||GY/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1972-03-15||||1966-03-31||1964-11-02|1962-06-25||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||TUBE|NED||MG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||FOLLOW-UP|1971-10-28||||1965-01-08||1965-07-02|1961-08-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||ANATRESP|ANATOMIC RESPONSE||||PMOL/DL|FAVORABLE RESPONSE||DMOL|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|CAREGIVER|PATHOLOGIST|NA|4||88||RUN-IN|1961-09-09||||1970-01-17||1965-08-23|1966-01-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||TMRESP|TUMOR MARKER RESPONSE||||WATT|MR||IU|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|INVESTIGATOR|ENDOCRINOLOGIST|Y|4||88||WASHOUT|1960-10-02||||1965-01-29||1966-10-04|1964-03-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||CLINRESP|CLINICAL RESPONSE||||BQ/MG|IUPD||KM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|STUDY SUBJECT|ADJUDICATOR 1|U|5||7||BASELINE|1963-07-08||||1970-04-27||1967-05-27|1960-03-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||NTRGRESP|NON-TARGET RESPONSE||||FMOL/L/SEC|NE||L/L|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|N|5||7||WASHOUT|1962-05-24||||1964-04-21||1968-01-03|1969-08-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/ML|MR||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|CAREGIVER|NEUROLOGIST 2|N|1||38||INDUCTION TREATMENT|1962-06-28||||1970-02-18||1967-04-14|1967-12-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||BONERESP|BONE RESPONSE||||ELISA UNIT/ML|NON-CR/NON-PD||MOL/MG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|PROXY|NEUROLOGIST|NA|1||38||TREATMENT|1963-06-07||||1964-05-25||1968-10-13|1960-10-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||STRUSTAT|STEROID USE STATUS||||MOSM|SD||NMOL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|FAMILY MEMBER|ADJUDICATOR|Y|2||58||CONTINUATION TREATMENT|1972-04-24||||1967-08-10||1968-05-05|1965-01-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||LIVRRESP|LIVER RESPONSE||||MPA|NE||UMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|PROXY|INTERNIST|N|2||58||WASHOUT|1966-04-20||||1964-04-30||1961-09-07|1969-12-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||APPLICATION|IMMUNOPHENOTYPIC CR||ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|3||39||BASELINE|1961-02-11||||1965-05-14||1965-09-05|1966-10-25||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MILE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||OHM|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||BLINDED TREATMENT|1962-09-08||||1962-07-03||1970-08-17|1966-04-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||COULOMB|PD/RELAPSE AFTER HI||BAU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|4||88||FOLLOW-UP|1971-03-02||||1965-01-28||1961-11-05|1960-12-25||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||OVRLRESP|OVERALL RESPONSE||||APS U|PD||PMOL/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|ADJUDICATOR|ONCOLOGIST 1|Y|4||88||TREATMENT|1964-09-18||||1965-01-07||1966-05-26|1963-07-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PKAT|CYTOGENETIC MINOR RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||FOLLOW-UP|1971-12-05||||1963-01-20||1965-12-10|1964-11-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||MOLRESP|MOLECULAR RESPONSE||||GPL U|MORPHOLOGIC LEUKEMIA-FREE STATE||L/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|VENDOR|ENDOCRINOLOGIST|Y|5||7||SCREENING|1965-06-01||||1965-11-23||1971-11-07|1962-04-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||NEWLIND|NEW LESION INDICATOR||||10^9 CFU/ML|ISD||MASK|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|FRIEND|PHYSIOTHERAPIST|NA|1||38||LONG-TERM FOLLOW-UP|1961-03-08||||1971-04-21||1963-04-29|1967-07-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DISK|CA125 75% RESPONSE||10^6 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|FAMILY MEMBER|RATER|U|1||38||OBSERVATION|1968-07-12||||1964-04-08||1968-06-08|1967-10-20||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||STRUSTAT|STEROID USE STATUS||||MG/M2|CR-CT||WEEKS|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|ADJUDICATOR|READER 1|U|2||58||WASHOUT|1968-08-25||||1966-04-18||1970-04-20|1965-12-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||ANATRESP|ANATOMIC RESPONSE||||CMOL|NON-QUANTIFIABLE MRD POSITIVITY||PPB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|INVESTIGATOR|OTOLARYNGOLOGIST|Y|2||58||FOLLOW-UP|1972-07-21||||1968-11-24||1970-09-27|1966-07-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||NEWLIND|NEW LESION INDICATOR||||ML/CAGE|INDETERMINATE RESPONSE||TUBE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|N|CAREGIVER|PATHOLOGIST 1|N|3||39||OBSERVATION|1970-01-11||||1969-09-08||1970-02-18|1962-10-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI/L|NON-QUANTIFIABLE MRD POSITIVITY||L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|GUARDIAN|RATER 1|N|3||39||BASELINE|1970-12-26||||1968-12-09||1970-05-05|1960-07-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||NEWLPROG|NEW LESION PROGRESSION||||GBQ/UG|CA125 50% RESPONSE||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||SCREENING|1971-01-27||||1966-02-12||1963-11-26|1973-01-19||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||OVRLRESP|OVERALL RESPONSE||||PACK|CRI||ENZYME U/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|DOMESTIC PARTNER|ADJUDICATOR|NA|4||88||OBSERVATION|1969-01-23||||1967-11-14||1963-01-30|1971-02-12||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||NEWLIND|NEW LESION INDICATOR||||TUBE|PD-CT||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|SPOUSE|MICROSCOPIST 1|NA|5||7||RUN-IN|1967-04-14||||1965-07-19||1971-07-01|1962-10-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||NEWLIND|NEW LESION INDICATOR||||GENEQ/ML|SCR||CL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|FRIEND|ADJUDICATOR|NA|5||7||OPEN LABEL TREATMENT|1960-10-17||||1970-11-04||1965-06-29|1971-12-30||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EU|RELAPSED DISEASE FROM CR||G/CAGE/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|FAMILY MEMBER|DERMATOLOGIST|Y|1||38||WASHOUT|1973-05-16||||1967-10-02||1967-11-30|1964-04-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||GENEQ|UNEQUIVOCAL||/MM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|CAREGIVER|NEUROLOGIST|Y|1||38||CONTINUATION TREATMENT|1966-03-25||||1964-04-25||1972-05-10|1963-06-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PG/L|SD||HOUNSFIELD UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|2||58||OPEN LABEL TREATMENT|1964-11-13||||1966-02-11||1970-05-03|1971-05-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TESLA|NON-CR/NON-PD||PA|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|2||58||SCREENING|1966-03-28||||1970-02-05||1964-07-09|1969-03-05||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KG/L|CYTOGENETIC MINOR RESPONSE||ML*CMH2O|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|PROXY|OPTOMETRIST|N|3||39||LONG-TERM FOLLOW-UP|1961-08-06||||1968-11-20||1961-01-12|1972-11-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||ANATRESP|ANATOMIC RESPONSE||||10^10/L|MRD NEGATIVITY||10^4 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 2|NA|3||39||CONTINUATION TREATMENT|1972-03-28||||1967-11-27||1966-12-12|1960-09-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMHG*MIN/L|HI-E||UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||INDUCTION TREATMENT|1968-11-19||||1970-10-29||1971-09-30|1970-11-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||BONERESP|BONE RESPONSE||||NG|CCR||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|PARENT|READER 2|Y|4||88||RUN-IN|1971-05-06||||1960-11-02||1964-08-30|1962-01-28||DURING||AFTER|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||% INHIBITION|MOLECULAR CR||U/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|INTERVIEWER|FORENSIC PATHOLOGIST|U|5||7||SCREENING|1970-02-26||||1965-07-06||1969-08-16|1971-01-21||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||FRACTION OF 1|RELAPSED DISEASE FROM CR||UG/M2/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|5||7||TREATMENT|1965-06-30||||1968-04-15||1965-04-10|1962-04-30||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||TRGRESP|TARGET RESPONSE||||PATCH|CR||PMOL/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|FRIEND|NEUROLOGIST 1|U|1||38||LONG-TERM FOLLOW-UP|1972-02-11||||1962-02-22||1970-03-26|1966-06-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||STRUSTAT|STEROID USE STATUS||||UCI/KG|UNEQUIVOCAL||KG/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|Y|1||38||WASHOUT|1973-01-18||||1967-06-18||1965-07-13|1969-10-02||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||ANATRESP|ANATOMIC RESPONSE||||M3|PMD||MM/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|INVESTIGATOR|PATHOLOGIST 2|Y|2||58||BLINDED TREATMENT|1965-09-11||||1966-08-28||1961-07-15|1963-01-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MIU/L|NPR||GAUSS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|2||58||BASELINE|1972-06-05||||1965-08-25||1963-06-29|1973-03-25||DURING||DURING|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/H|HI-P||PATCH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|READER 1|NA|3||39||LONG-TERM FOLLOW-UP|1960-05-23||||1961-02-03||1962-04-03|1960-06-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PIXELS/CM|VGPR||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|ADJUDICATOR|ADJUDICATOR 1|U|3||39||BASELINE|1971-05-02||||1966-09-02||1964-07-21|1970-01-30||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MS2|NED||PACKAGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|ADJUDICATION COMMITTEE|NEUROLOGIST|U|4||88||CONTINUATION TREATMENT|1964-01-03||||1970-04-11||1971-01-18|1969-12-31||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||STRUSTAT|STEROID USE STATUS||||MBQ|MOLECULAR CR||10^9 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|ADJUDICATOR|PHYSIOTHERAPIST|U|4||88||OPEN LABEL TREATMENT|1964-11-13||||1970-05-24||1970-09-19|1963-11-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/ML/H|INCREASED||ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|FRIEND|OPHTHALMOLOGIST|U|5||7||OPEN LABEL TREATMENT|1966-09-03||||1967-07-12||1973-07-06|1971-07-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/BEAT|NON-PD||K|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|FAMILY MEMBER|ADJUDICATOR 3|U|5||7||SCREENING|1960-07-26||||1964-09-24||1965-08-14|1966-07-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|1||||||STRUSTAT|STEROID USE STATUS||||U/ANIMAL|PSEUDOPROGRESSION||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||OPEN LABEL TREATMENT|1968-09-01||||1960-04-12||1966-10-26|1973-03-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|2||||||STRUSTAT|STEROID USE STATUS||||MEQ/DL|NR||G/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|1||38||FOLLOW-UP|1964-11-21||||1964-09-07||1962-05-03|1972-09-18||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|1||||||ANATRESP|ANATOMIC RESPONSE||||MOL/ML|SCR||KDA|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|SIBLING|PHYSIOTHERAPIST|N|2||58||BASELINE|1966-05-30||||1973-07-13||1967-04-11|1962-12-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PT_US|CA125 75% RESPONSE||RAD|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|DOMESTIC PARTNER|OPTOMETRIST|NA|2||58||INDUCTION TREATMENT|1960-04-02||||1967-01-16||1965-06-11|1960-02-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|1||||||SPLNRESP|SPLEEN RESPONSE||||CD*S/M2|MORPHOLOGIC CRI||MHZ|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|3||39||OPEN LABEL TREATMENT|1973-05-22||||1963-11-16||1964-04-10|1971-08-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|2||||||METSIND|METASTATIC INDICATOR||||10^3 CFU|CYTOGENETIC MINIMAL RESPONSE||OHM|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|PROXY|ADJUDICATOR|N|3||39||INDUCTION TREATMENT|1971-09-06||||1969-07-29||1968-12-10|1960-01-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|1||||||ANATRESP|ANATOMIC RESPONSE||||DROP|CYTOGENETIC NO RESPONSE||/5X10^4 WBC|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|FRIEND|OPHTHALMOLOGIST|U|4||88||OPEN LABEL TREATMENT|1970-06-12||||1971-06-26||1964-12-07|1967-03-04||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|2||||||METSIND|METASTATIC INDICATOR||||10^6 U|NON-CR/NON-PD||MMHG*MIN/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|4||88||BASELINE|1960-06-10||||1961-06-13||1968-03-17|1967-12-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|1||||||MOLRESP|MOLECULAR RESPONSE||||ML/(MIN*100ML)|UNFAVORABLE RESPONSE||10^8 PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BLINDED TREATMENT|1971-08-11||||1960-09-02||1962-01-03|1967-12-08||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|70196099-5D40-4048-AABF-EB40CE345328|2||||||LIVRRESP|LIVER RESPONSE||||UG/M2|PD FROM PR||DEG2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1965-01-25||||1960-01-13||1960-07-21|1972-05-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^4 CFU|PMD||WATT|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1961-05-15||||1967-02-16||1963-10-30|1960-08-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ENZYME U|CYTOGENETIC MINIMAL RESPONSE||TBSP|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|1||38||LONG-TERM FOLLOW-UP|1967-03-27||||1973-02-09||1964-12-16|1969-05-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||STRUSTAT|STEROID USE STATUS||||MMHG/SEC|NE||10^3 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1961-08-17||||1962-01-08||1961-07-13|1964-02-06||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CIGARETTE|MORPHOLOGIC CRI||GRAIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|CAREGIVER|PATHOLOGIST 1|NA|2||58||OBSERVATION|1973-04-01||||1970-09-30||1968-04-16|1971-11-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||METBRESP|METABOLIC RESPONSE||||MIN*MG/ML|PD-CT||L/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|INTERVIEWER|NEUROLOGIST 1|N|3||39||BLINDED TREATMENT|1962-06-03||||1969-02-01||1973-09-04|1968-01-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SYRINGE|PR-CT||ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|CHILD|PEDIATRIC NEUROLOGIST|NA|3||39||RUN-IN|1970-01-01||||1973-02-20||1969-01-16|1972-12-02||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||MOLRESP|MOLECULAR RESPONSE||||PFU/ML|HI-N||GMFI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|4||88||BLINDED TREATMENT|1960-04-29||||1973-02-20||1962-12-13|1962-03-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ANTIBODY UNIT|NOT ALL EVALUATED||PL|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|STUDY SUBJECT|INTERNIST|N|4||88||CONTINUATION TREATMENT|1969-09-02||||1965-12-01||1968-09-12|1968-03-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||OSM|ISD||UG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|FAMILY MEMBER|OPHTHALMOLOGIST|U|5||7||FOLLOW-UP|1970-03-05||||1969-10-16||1972-07-12|1972-03-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG10 PFU|QUANTIFIABLE MRD POSITIVITY||MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|FAMILY MEMBER|DERMATOLOGIST|U|5||7||FOLLOW-UP|1966-05-02||||1964-10-04||1970-11-15|1962-09-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^8 PFU|SMD||DROP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|1||38||RUN-IN|1970-02-15||||1971-11-16||1964-10-30|1968-09-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/MIN|PR-CT||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|1||38||WASHOUT|1967-06-04||||1960-02-27||1970-08-21|1962-04-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DIP|CYTOGENETIC NO RESPONSE||10^6 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|2||58||TREATMENT|1972-09-12||||1973-07-28||1962-03-14|1969-06-13||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NEEDLE GAUGE|RELAPSED DISEASE FROM CR||P|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|DOMESTIC PARTNER|MICROSCOPIST 2|NA|2||58||SCREENING|1968-02-16||||1969-02-07||1960-07-05|1963-07-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DEG2|MORPHOLOGIC CR||MEQ/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|FRIEND|PATHOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1972-09-24||||1964-07-14||1961-11-11|1966-07-30||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||G/KG/DAY|PDU||KA_U/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|3||39||CONTINUATION TREATMENT|1969-08-22||||1970-04-01||1960-01-23|1964-10-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/MG|IMMUNOPHENOTYPIC CR||/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|4||88||FOLLOW-UP|1971-10-04||||1960-01-28||1973-03-29|1970-08-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DEG/S|MAJOR PATHOLOGIC RESPONSE||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|UROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1965-01-09||||1967-07-08||1973-02-14|1964-05-10||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||METSIND|METASTATIC INDICATOR||||UG/L FEU|MRD RELAPSE||UIU/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|INTERVIEWER|PATHOLOGIST|NA|5||7||INDUCTION TREATMENT|1970-12-31||||1961-06-08||1961-11-15|1963-08-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KV|QUANTIFIABLE MRD POSITIVITY||U/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|5||7||OPEN LABEL TREATMENT|1966-10-09||||1965-03-22||1972-04-15|1970-06-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||% INHIBITION|ISD||MG/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||BASELINE|1970-08-12||||1960-05-11||1972-08-04|1964-08-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6/L|IPR||FINGERTIP UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|PROXY|CARDIOLOGIST|Y|1||38||RUN-IN|1971-04-23||||1972-09-01||1967-12-26|1968-08-18||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PIXELS/IN|PMR||/7.5 ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|SIBLING|UROLOGIST|U|2||58||OBSERVATION|1970-05-01||||1972-06-09||1969-10-06|1960-10-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||STRUSTAT|STEROID USE STATUS||||ML/DL|CA125 50% RESPONSE||ML/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||RUN-IN|1965-11-10||||1965-11-08||1962-11-30|1964-06-30||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CUP EQ|PDU||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|U|3||39||RUN-IN|1964-06-28||||1962-06-28||1962-08-30|1972-03-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MET*H|ISD||L/H/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|3||39||RUN-IN|1960-08-12||||1962-06-27||1967-09-19|1967-08-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/G|PARTIAL MORPHOLOGIC RESPONSE||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|VENDOR|DERMATOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1971-05-16||||1963-12-30||1967-06-15|1961-05-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||LIVRRESP|LIVER RESPONSE||||TRANSDUCING UNIT/ML|SMD||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|4||88||TREATMENT|1966-12-22||||1970-07-29||1965-05-29|1965-02-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||LIVRRESP|LIVER RESPONSE||||ML/DL|CYTOGENETIC PR||RFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|INDEPENDENT ASSESSOR|RATER 1|N|5||7||BLINDED TREATMENT|1969-02-23||||1960-10-16||1968-09-27|1972-10-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||USEC|DISEASE TRANSFORMATION||UMOL/MG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|INDEPENDENT ASSESSOR|MICROSCOPIST 3|U|5||7||OPEN LABEL TREATMENT|1964-12-26||||1966-05-21||1965-07-01|1964-07-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|1||||||METSIND|METASTATIC INDICATOR||||ABSORBANCE U/ML|ICR||MG/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|SIGNIFICANT OTHER|MICROSCOPIST 1|Y|1||38||BLINDED TREATMENT|1969-03-09||||1969-01-06||1960-09-03|1964-08-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|2||||||LIVRRESP|LIVER RESPONSE||||TORR|DECREASED||PG/CELL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|1||38||FOLLOW-UP|1972-12-02||||1965-01-16||1967-08-12|1972-06-14||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|1||||||LIVRRESP|LIVER RESPONSE||||STEPS/MIN|CA125 75% RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|ADJUDICATION COMMITTEE|READER 1|Y|2||58||BASELINE|1970-06-14||||1965-05-26||1968-04-22|1970-04-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|2||||||MOLRESP|MOLECULAR RESPONSE||||U/ANIMAL|PCR||CI/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|INTERVIEWER|ONCOLOGIST 2|N|2||58||SCREENING|1964-01-20||||1963-05-27||1971-04-29|1963-09-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|1||||||CLINRESP|CLINICAL RESPONSE||||CI/ML|PMR||NMOL/L/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|3||39||RUN-IN|1973-05-08||||1973-06-23||1971-03-06|1965-03-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UCI|PCR||KM/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|3||39||FOLLOW-UP|1970-03-09||||1961-09-10||1960-10-22|1966-06-30||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||OI50|MAJOR PATHOLOGIC RESPONSE||FL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|N|4||88||OPEN LABEL TREATMENT|1966-07-11||||1969-08-03||1961-06-15|1965-03-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|2||||||TMRESP|TUMOR MARKER RESPONSE||||UEQ|CMR||MEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|INTERVIEWER|UROLOGIST|U|4||88||OBSERVATION|1966-10-10||||1968-05-30||1973-06-08|1964-04-05||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|1||||||TRGRESP|TARGET RESPONSE||||KPA|NON-ICR/NON-IUPD||MV/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|SPOUSE|OTOLARYNGOLOGIST|U|5||7||FOLLOW-UP|1970-08-23||||1960-11-23||1971-10-12|1972-09-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|186520B9-8AAD-4063-B48F-16040EF49944|2||||||STRUSTAT|STEROID USE STATUS||||U/CL|CHR||KM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5||7||BASELINE|1966-08-29||||1970-10-22||1966-01-06|1961-07-12||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^4 CFU/ML|NOT ALL EVALUATED||NEEDLE GAUGE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|CLINICAL STUDY SPONSOR|READER 1|N|1||38||BLINDED TREATMENT|1967-11-03||||1968-12-27||1960-06-25|1969-10-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI/G|TREATMENT FAILURE||UU/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|INTERVIEWER|READER|U|1||38||BLINDED TREATMENT|1961-05-09||||1962-03-24||1970-05-02|1967-04-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||OVRLRESP|OVERALL RESPONSE||||NG/DL|MINOR PATHOLOGIC RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|PARENT|ONCOLOGIST|U|2||58||BASELINE|1971-09-24||||1965-06-29||1963-12-08|1960-09-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||METBRESP|METABOLIC RESPONSE||||PUFF|NR||U/L|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2||58||TREATMENT|1967-02-23||||1963-09-04||1969-06-05|1971-05-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MBP|VGPR||/VF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|PARENT|FORENSIC PATHOLOGIST|Y|3||39||SCREENING|1972-07-17||||1969-12-03||1965-07-18|1968-12-30||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||BESTRESP|BEST OVERALL RESPONSE||||WEBER|MORPHOLOGIC LEUKEMIA-FREE STATE||CI/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|INTERVIEWER|RATER 1|N|3||39||WASHOUT|1960-09-20||||1960-05-13||1972-03-04|1967-02-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||BESTRESP|BEST OVERALL RESPONSE||||CI/MG|MORPHOLOGIC CRI||MMHG/L/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|4||88||SCREENING|1960-10-28||||1965-03-07||1961-01-29|1964-03-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UCI/KG|NPR||PKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|DOMESTIC PARTNER|RATER 1|NA|4||88||BASELINE|1966-03-27||||1967-10-18||1960-01-24|1962-04-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||BESTRESP|BEST OVERALL RESPONSE||||APPLICATION|MR||10^10/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|ADJUDICATOR|OTOLARYNGOLOGIST|NA|5||7||BLINDED TREATMENT|1972-08-26||||1970-03-11||1967-08-01|1962-10-22||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||SPLNRESP|SPLEEN RESPONSE||||NMOL/DAY|UNEQUIVOCAL||BAU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|FAMILY MEMBER|ONCOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1963-07-14||||1968-10-06||1964-06-07|1971-09-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/G/H|TREATMENT FAILURE||PELLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|INTERVIEWER|INTERNIST|Y|1||38||LONG-TERM FOLLOW-UP|1969-08-31||||1962-08-06||1963-08-28|1968-04-21||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||SPLNRESP|SPLEEN RESPONSE||||%(W/V)|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||U/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|SIBLING|READER 2|Y|1||38||BLINDED TREATMENT|1965-08-25||||1964-01-17||1960-04-15|1960-09-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/MMHG|MINOR PATHOLOGIC RESPONSE||AMP|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|SIBLING|PATHOLOGIST 2|Y|2||58||WASHOUT|1963-09-24||||1966-04-04||1963-07-08|1964-05-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||MOLRESP|MOLECULAR RESPONSE||||FARAD|RELAPSED DISEASE FROM CR||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|2||58||LONG-TERM FOLLOW-UP|1966-09-26||||1969-03-18||1973-06-05|1963-01-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IMPLANT|CHR||G/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|SIGNIFICANT OTHER|HEMATOLOGIST|N|3||39||OBSERVATION|1966-08-26||||1971-09-13||1970-08-19|1963-06-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||MOLRESP|MOLECULAR RESPONSE||||10^6 U|PR-CT||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|FRIEND|RATER 2|N|3||39||FOLLOW-UP|1969-05-26||||1968-07-28||1961-04-28|1970-12-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||BU/ML|CR||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|ADJUDICATOR|UROLOGIST|NA|4||88||FOLLOW-UP|1964-07-10||||1965-12-05||1966-11-24|1966-10-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||JDF UNIT|CPR||OZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|4||88||FOLLOW-UP|1964-04-06||||1968-09-14||1969-02-04|1972-01-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||H*%|FAVORABLE RESPONSE||NG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||TREATMENT|1973-04-11||||1972-11-11||1962-11-25|1968-06-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ENZYME U/M2|CMR||DRAM|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||BLINDED TREATMENT|1960-08-24||||1973-01-16||1966-03-22|1970-07-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/DAY|FAVORABLE RESPONSE||MILE|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|PARENT|READER 2|NA|1||38||BLINDED TREATMENT|1961-10-19||||1970-07-31||1962-01-23|1970-10-16||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||MOLRESP|MOLECULAR RESPONSE||||ML/BEAT|UNEQUIVOCAL||PELLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|FRIEND|ADJUDICATOR 2|Y|1||38||SCREENING|1961-04-12||||1972-08-24||1973-06-26|1963-01-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||MOLRESP|MOLECULAR RESPONSE||||PACKAGE|HI-E||SYRINGE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|GUARDIAN|RADIOLOGIST 1|NA|2||58||BASELINE|1967-09-24||||1963-09-10||1973-02-10|1960-05-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||NEWLIND|NEW LESION INDICATOR||||JAR|MINOR PATHOLOGIC RESPONSE||MAC50|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|INVESTIGATOR|ADJUDICATOR 2|U|2||58||SCREENING|1960-04-10||||1963-06-21||1970-03-23|1962-03-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||L/MIN/M2|IMMUNOPHENOTYPIC CR||BAG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|CAREGIVER|OTOLARYNGOLOGIST|NA|3||39||RUN-IN|1962-11-12||||1968-09-01||1972-03-26|1965-08-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||NTRGRESP|NON-TARGET RESPONSE||||PPTR|CHR||VP/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|INDEPENDENT ASSESSOR|READER 3|Y|3||39||BLINDED TREATMENT|1966-02-15||||1970-11-20||1970-02-09|1960-09-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||GTT|NPR||PG/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|INTERVIEWER|ONCOLOGIST|U|4||88||FOLLOW-UP|1968-07-25||||1960-05-23||1960-10-10|1963-02-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 DNA COPIES/ML|EQUIVOCAL||%/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1961-05-31||||1961-03-13||1965-02-04|1973-05-03||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||FMOL|MOLECULAR CR||CUP|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|SIBLING|FORENSIC PATHOLOGIST|N|5||7||FOLLOW-UP|1965-09-25||||1972-07-16||1968-11-19|1963-09-23||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||NTRGRESP|NON-TARGET RESPONSE||||WATT|MORPHOLOGIC LEUKEMIA-FREE STATE||NEEDLE GAUGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1970-02-19||||1972-10-29||1962-02-08|1973-04-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||NTRGRESP|NON-TARGET RESPONSE||||SHOCK WAVE|STABLE||MSEC|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|SIBLING|HEMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1963-05-29||||1972-05-19||1964-06-24|1972-05-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MONTHS|PARTIAL MORPHOLOGIC RESPONSE||PA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|INVESTIGATOR|ADJUDICATOR 3|N|1||38||INDUCTION TREATMENT|1972-07-04||||1965-01-18||1966-05-28|1971-12-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PACK YEAR|SD||MJOULE/CM2|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|CHILD|MICROSCOPIST|Y|2||58||OBSERVATION|1964-08-07||||1971-01-15||1967-06-06|1970-07-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||BESTRESP|BEST OVERALL RESPONSE||||100 IU/ML|RELAPSED DISEASE FROM CR||CAN|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|GUARDIAN|ADJUDICATOR 1|U|2||58||FOLLOW-UP|1964-11-19||||1961-10-13||1961-12-02|1965-05-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PPM|NON-QUANTIFIABLE MRD POSITIVITY||DB|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|GUARDIAN|MICROSCOPIST 2|NA|3||39||BASELINE|1965-09-21||||1965-10-06||1968-12-27|1962-11-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/M2|PSEUDORESPONSE||MPL U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||OBSERVATION|1971-04-06||||1968-07-02||1967-05-16|1965-04-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^4/L|PR-CT||OSM|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|CAREGIVER|NEUROLOGIST|NA|4||88||WASHOUT|1960-05-19||||1971-05-17||1964-01-26|1966-03-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ/G|MRD PERSISTENCE||FMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|4||88||BLINDED TREATMENT|1968-09-23||||1966-09-07||1969-02-28|1962-09-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||NEWLIND|NEW LESION INDICATOR||||GPELISA UNIT/ML|OPTIMAL MORPHOLOGIC RESPONSE||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|5||7||SCREENING|1968-07-02||||1961-10-28||1968-11-19|1960-01-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MIN*MG/ML|HI-E||U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|CAREGIVER|ONCOLOGIST 2|N|5||7||CONTINUATION TREATMENT|1971-09-29||||1971-11-15||1968-02-03|1967-02-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GPS U|MORPHOLOGIC LEUKEMIA-FREE STATE||PFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|1||38||CONTINUATION TREATMENT|1973-02-14||||1969-03-25||1970-12-17|1963-03-04||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^7 CFU|CYTOGENETIC CR||U/MMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1970-06-20||||1965-03-04||1963-06-03|1973-01-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||CLINRESP|CLINICAL RESPONSE||||G/CAGE/WK|MORPHOLOGIC CR||M/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|FAMILY MEMBER|PATHOLOGIST 2|U|2||58||INDUCTION TREATMENT|1966-03-24||||1968-03-16||1971-04-10|1965-02-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PFU/DOSE|NOT ALL EVALUATED||UMOL/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INVESTIGATOR|OTOLARYNGOLOGIST|NA|2||58||WASHOUT|1960-01-13||||1973-07-31||1964-01-13|1972-06-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||TMRESP|TUMOR MARKER RESPONSE||||KBQ/UL|MR||10^3/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|FAMILY MEMBER|PATHOLOGIST 1|NA|3||39||BASELINE|1962-05-07||||1960-09-06||1961-11-08|1967-01-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^3 CFU/G|CCR||MG/ML/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|ADJUDICATOR|INTERNIST|Y|3||39||RUN-IN|1961-06-09||||1973-03-19||1962-01-12|1968-05-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MDFI|PMR||UMOL/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|CHILD|MICROSCOPIST|Y|4||88||OPEN LABEL TREATMENT|1960-07-07||||1960-05-02||1973-02-03|1962-02-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||SPLNRESP|SPLEEN RESPONSE||||FMOL/L/SEC|VGPR||MV*MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|4||88||RUN-IN|1961-09-03||||1960-08-13||1965-09-01|1971-04-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/G/DAY|MCR||PMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|5||7||OPEN LABEL TREATMENT|1968-05-08||||1969-09-24||1973-04-29|1968-01-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BE/ML|HI-E||/10^5|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|SIGNIFICANT OTHER|NEUROLOGIST 1|U|5||7||OBSERVATION|1962-05-01||||1970-12-24||1969-03-19|1967-12-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||TRGRESP|TARGET RESPONSE||||HOMEOPATHIC DILUTION|CA125 50% RESPONSE||MU/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|INVESTIGATOR|HEMATOLOGIST|Y|1||38||TREATMENT|1971-08-28||||1964-08-09||1967-06-06|1965-11-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DNA COPIES/UG|PDU||MEQ/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|1||38||LONG-TERM FOLLOW-UP|1964-07-04||||1971-01-02||1962-05-16|1964-01-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||FARAD|STABLE||GBQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|PARENT|RATER 1|U|2||58||BASELINE|1971-11-26||||1965-03-09||1965-12-26|1969-09-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 ELISA UNIT/DOSE|NOT ALL EVALUATED||TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|ADJUDICATOR|FORENSIC PATHOLOGIST|NA|2||58||OBSERVATION|1962-12-17||||1964-11-28||1962-01-31|1965-05-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||GBQ/MG|CYTOGENETIC MINOR RESPONSE||P|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|SIBLING|RATER 1|U|3||39||CONTINUATION TREATMENT|1968-10-07||||1962-04-21||1972-03-04|1971-01-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||BESTRESP|BEST OVERALL RESPONSE||||U|NPR||/2000 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|STUDY SUBJECT|READER|N|3||39||BASELINE|1972-10-27||||1961-10-20||1965-11-11|1967-09-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||SPLNRESP|SPLEEN RESPONSE||||MILE|PARTIAL MORPHOLOGIC RESPONSE||/CMH2O|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|U|4||88||OBSERVATION|1968-10-05||||1963-05-15||1962-11-26|1968-04-02||DURING||DURING|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||BONERESP|BONE RESPONSE||||PT_US|CYTOGENETIC PR||10^3/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|INVESTIGATOR|NEUROLOGIST 1|U|4||88||FOLLOW-UP|1967-08-30||||1968-01-18||1967-01-27|1965-06-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/DOSE|ABSENT MORPHOLOGIC RESPONSE||%(V/V)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|FRIEND|PATHOLOGIST 2|U|5||7||TREATMENT|1969-02-14||||1970-08-26||1969-02-15|1963-11-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||ANATRESP|ANATOMIC RESPONSE||||PPTH|PARTIAL MORPHOLOGIC RESPONSE||CMOL/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|INDEPENDENT ASSESSOR|UROLOGIST|Y|5||7||BLINDED TREATMENT|1964-12-12||||1968-04-17||1971-04-08|1971-12-02||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||METSIND|METASTATIC INDICATOR||||ML/CM3/MIN|SD-CT||DEG2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|ADJUDICATOR|ONCOLOGIST|U|1||38||SCREENING|1967-01-26||||1968-03-30||1965-07-11|1966-03-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||BONERESP|BONE RESPONSE||||UG/M2|INCREASED||OD UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|PARENT|PATHOLOGIST|U|1||38||FOLLOW-UP|1960-10-18||||1972-05-30||1966-06-12|1966-09-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MDFI|PD-CT||ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||INDUCTION TREATMENT|1966-08-05||||1972-03-17||1971-12-05|1971-12-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||NTRGRESP|NON-TARGET RESPONSE||||MMHG*MIN/L|NON-PD||PKAT/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|SIBLING|MICROSCOPIST 1|N|2||58||FOLLOW-UP|1961-10-02||||1967-12-08||1965-01-07|1961-01-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||LIVRRESP|LIVER RESPONSE||||MIU/L|ICR||DISK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|3||39||OPEN LABEL TREATMENT|1966-05-30||||1973-02-19||1961-08-05|1972-08-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BQ|NON-PD||DROP|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|3||39||RUN-IN|1972-11-15||||1964-04-30||1972-07-02|1967-12-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||TRGRESP|TARGET RESPONSE||||KDA|STABLE||CMH2O/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|ADJUDICATOR|INTERNIST|NA|4||88||LONG-TERM FOLLOW-UP|1961-03-17||||1964-05-19||1960-08-04|1962-09-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||NEWLIND|NEW LESION INDICATOR||||MPS U|CYTOGENETIC CR||KM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|4||88||INDUCTION TREATMENT|1970-05-23||||1971-11-19||1972-05-24|1963-04-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||BONERESP|BONE RESPONSE||||10^8 PFU|IUPD||LM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|DOMESTIC PARTNER|ONCOLOGIST|N|5||7||RUN-IN|1973-06-03||||1962-04-05||1968-12-17|1971-11-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^3 ORGANISMS|SD||EJACULATE U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|INDEPENDENT ASSESSOR|CARDIOLOGIST|N|5||7||CONTINUATION TREATMENT|1969-09-02||||1969-07-09||1972-01-15|1971-12-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/M2|TREATMENT FAILURE||V|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|INTERVIEWER|ADJUDICATOR 3|Y|1||38||OPEN LABEL TREATMENT|1963-06-05||||1964-08-29||1973-06-16|1969-06-22||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MSEC|IMMUNOPHENOTYPIC CR||KV|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|1||38||WASHOUT|1967-09-04||||1960-01-26||1968-11-03|1966-09-30||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||TRGRESP|TARGET RESPONSE||||/MM|INCREASED||KIU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|INTERVIEWER|PATHOLOGIST|NA|2||58||INDUCTION TREATMENT|1960-04-17||||1966-10-06||1972-08-10|1966-10-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UMOL/L/H|PSEUDORESPONSE||U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|FRIEND|PATHOLOGIST 1|Y|2||58||BLINDED TREATMENT|1971-09-27||||1969-12-06||1964-12-03|1972-03-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||MOLRESP|MOLECULAR RESPONSE||||/WK|NOT ALL EVALUATED||BOTTLE|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|N|ADJUDICATION COMMITTEE|RADIOLOGIST 2|U|3||39||FOLLOW-UP|1969-11-13||||1961-08-16||1969-04-07|1971-04-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/S/M2|CCR||SIEMENS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|DOMESTIC PARTNER|OPTOMETRIST|N|3||39||TREATMENT|1968-09-12||||1969-06-03||1968-02-03|1961-05-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/MS|PSEUDORESPONSE||CI/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|4||88||CONTINUATION TREATMENT|1967-02-15||||1960-01-15||1973-03-06|1971-03-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UMOL/DL|NON-PD||BQ/UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|4||88||INDUCTION TREATMENT|1966-05-24||||1967-01-09||1971-10-17|1965-08-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||USP U|CMR||10^3 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|INVESTIGATOR|MICROSCOPIST 2|Y|5||7||BLINDED TREATMENT|1963-02-03||||1961-05-07||1966-04-30|1967-06-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 ORGANISMS/G|PR WITH LYMPHOCYTOSIS||MJOULE/CM2|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|FRIEND|MICROSCOPIST|N|5||7||LONG-TERM FOLLOW-UP|1960-11-02||||1964-05-19||1962-09-20|1967-12-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6/HPF|INDETERMINATE RESPONSE||10^6 CFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|CHILD|RATER|U|1||38||OBSERVATION|1961-12-03||||1969-11-19||1966-02-27|1965-10-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ECL UNIT|CR||UMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|SIBLING|MICROSCOPIST|NA|1||38||TREATMENT|1961-01-17||||1967-12-25||1961-02-04|1960-05-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||OVRLRESP|OVERALL RESPONSE||||UG/M2/DAY|MOLECULAR CR||HOMEOPATHIC DILUTION|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|PARENT|HEMATOLOGIST|U|2||58||SCREENING|1967-07-19||||1971-11-10||1960-05-29|1968-06-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||TMRESP|TUMOR MARKER RESPONSE||||FL|UNEQUIVOCAL||MPL U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|CHILD|OTOLARYNGOLOGIST|Y|2||58||INDUCTION TREATMENT|1971-12-05||||1966-03-15||1964-12-12|1972-02-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|3||39||RUN-IN|1962-12-16||||1969-10-05||1964-09-06|1962-09-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%(W/V)|HI-E||FOZ_BR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|PARENT|INTERNIST|NA|3||39||BLINDED TREATMENT|1972-04-06||||1967-10-22||1973-04-29|1967-07-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACK YEAR|MORPHOLOGIC CR||MS/MMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|PROXY|MICROSCOPIST|Y|4||88||CONTINUATION TREATMENT|1960-10-14||||1962-09-16||1960-04-11|1961-01-11||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||BESTRESP|BEST OVERALL RESPONSE||||FMOL/G|MCR||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|CHILD|ONCOLOGIST 2|Y|4||88||INDUCTION TREATMENT|1961-01-27||||1972-03-17||1971-07-29|1965-03-15||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||RDIORESP|RADIOLOGIC RESPONSE||||COPIES/UG|MRD RELAPSE||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1970-05-23||||1960-03-24||1972-04-25|1972-06-16||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CI|NE||MAMP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|INTERVIEWER|MICROSCOPIST 2|NA|5||7||FOLLOW-UP|1973-05-04||||1971-06-03||1964-12-06|1965-06-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||NEWLPROG|NEW LESION PROGRESSION||||MAC50|IMPROVED||KAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|1||38||BASELINE|1964-03-16||||1963-08-16||1966-10-28|1972-09-14||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||HEP|STABLE||ENZYME U/L|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|CAREGIVER|CARDIOLOGIST|N|1||38||INDUCTION TREATMENT|1962-10-30||||1972-04-26||1964-10-25|1964-06-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||STRUSTAT|STEROID USE STATUS||||MG/L|CRI||L/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|2||58||OBSERVATION|1960-06-30||||1967-04-24||1965-10-10|1964-02-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/KG|MRD PERSISTENCE||MG/ML/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|VENDOR|PEDIATRIC NEUROLOGIST|NA|2||58||TREATMENT|1962-10-14||||1972-03-02||1965-05-05|1971-02-02||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||LIVRRESP|LIVER RESPONSE||||10^9 CFU/ML|UNFAVORABLE RESPONSE||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|3||39||INDUCTION TREATMENT|1969-01-14||||1967-10-17||1966-08-02|1968-09-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DL|PR WITH LYMPHOCYTOSIS||/10^4|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|CLINICAL STUDY SPONSOR|READER 1|Y|3||39||SCREENING|1968-06-13||||1973-07-19||1966-01-30|1962-11-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||FINGERTIP UNIT|QUANTIFIABLE MRD POSITIVITY||U/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|4||88||RUN-IN|1962-05-08||||1962-03-31||1967-01-08|1970-06-14||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OZ EQ|SCR||MV|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|SPOUSE|RATER 1|U|4||88||LONG-TERM FOLLOW-UP|1960-10-03||||1967-11-17||1964-04-25|1961-04-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UKAT|PR-CT||PG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|SIBLING|RATER 1|Y|5||7||CONTINUATION TREATMENT|1967-12-30||||1962-02-03||1962-01-10|1965-10-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||100 IU/ML|OPTIMAL MORPHOLOGIC RESPONSE||JDF UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|SIGNIFICANT OTHER|RATER|U|5||7||TREATMENT|1973-02-03||||1961-10-13||1973-08-19|1963-07-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TCID 50/DOSE|NED||KHZ|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|GUARDIAN|READER 3|Y|1||38||LONG-TERM FOLLOW-UP|1970-03-15||||1972-08-15||1968-02-20|1960-10-08||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||BONERESP|BONE RESPONSE||||KA_U/DL|PR||UG/ML/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CAREGIVER|RATER|N|1||38||CONTINUATION TREATMENT|1960-04-22||||1972-06-14||1963-02-09|1965-04-09||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BAU/ML|NR||MM/SEC|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FAMILY MEMBER|RATER|NA|2||58||FOLLOW-UP|1962-01-13||||1973-07-31||1969-02-14|1966-05-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||NEWLIND|NEW LESION INDICATOR||||POUCH|UNFAVORABLE RESPONSE||BEAM BREAKS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|STUDY SUBJECT|MICROSCOPIST|N|2||58||WASHOUT|1961-05-11||||1966-07-22||1969-05-11|1969-03-04||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KBQ|RELAPSED DISEASE||MMOL/L|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|GUARDIAN|PATHOLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1960-03-13||||1967-02-10||1965-05-01|1968-02-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||SPLNRESP|SPLEEN RESPONSE||||KM/H|EQUIVOCAL||/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 1|U|3||39||TREATMENT|1960-07-13||||1962-08-22||1965-10-31|1964-12-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LX|PD-CT||MESF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|INTERVIEWER|NEUROLOGIST 2|U|4||88||SCREENING|1963-05-09||||1968-06-12||1960-11-29|1960-05-28||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||BONERESP|BONE RESPONSE||||ELISA UNIT/ML|CYTOGENETIC MINIMAL RESPONSE||EID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|INVESTIGATOR|RADIOLOGIST|N|4||88||RUN-IN|1973-03-02||||1960-10-27||1960-04-22|1967-08-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/L|CYTOGENETIC PR||RING|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|DOMESTIC PARTNER|RATER|U|5||7||OBSERVATION|1962-05-24||||1964-02-20||1961-10-30|1970-04-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/5X10^4 WBC|PD/RELAPSE AFTER HI||10^7/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|DOMESTIC PARTNER|DERMATOLOGIST|NA|5||7||CONTINUATION TREATMENT|1968-08-01||||1967-06-12||1967-02-23|1968-06-15||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||BONERESP|BONE RESPONSE||||CMH2O*S2/ML|INDETERMINATE RESPONSE||UIU/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|1||38||OBSERVATION|1964-02-07||||1971-04-04||1967-08-23|1971-06-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^4 CFU/ML|RELAPSED DISEASE||UOSM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|CHILD|PATHOLOGIST|Y|1||38||SCREENING|1961-03-11||||1964-10-07||1969-01-01|1972-11-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/G/MIN|NON-QUANTIFIABLE MRD POSITIVITY||UV*SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|INDEPENDENT ASSESSOR|READER|Y|2||58||WASHOUT|1964-07-11||||1965-07-09||1962-02-05|1965-12-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||TRGRESP|TARGET RESPONSE||||/H|CYTOGENETIC MINOR RESPONSE||STEPS/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|GUARDIAN|OPTOMETRIST|U|2||58||INDUCTION TREATMENT|1965-12-11||||1960-12-30||1971-10-09|1972-05-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/KG/DOSE|PMD||UG/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|FAMILY MEMBER|PATHOLOGIST 2|N|3||39||INDUCTION TREATMENT|1970-11-02||||1963-11-08||1969-01-24|1973-03-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/MIN|PR WITH LYMPHOCYTOSIS||G/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|FRIEND|PEDIATRIC NEUROLOGIST|U|3||39||FOLLOW-UP|1965-11-10||||1969-08-27||1962-04-04|1969-04-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||TRGRESP|TARGET RESPONSE||||10^6/G|CYTOGENETIC MINIMAL RESPONSE||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|DOMESTIC PARTNER|READER 2|NA|4||88||CONTINUATION TREATMENT|1973-02-25||||1964-06-29||1973-04-16|1971-08-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GENEQ|CR-CT||10^9/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|VENDOR|PATHOLOGIST|NA|4||88||BASELINE|1964-11-22||||1967-11-28||1970-11-01|1966-12-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||AU/ML|SD-CT||CL|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|5||7||SCREENING|1962-02-11||||1963-02-17||1969-04-06|1968-09-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||SPLNRESP|SPLEEN RESPONSE||||MMOL/L|COMPLETE MRD RESPONSE||MMOL2/L2|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|ADJUDICATOR|READER 1|Y|5||7||OPEN LABEL TREATMENT|1960-08-23||||1966-07-09||1969-08-22|1971-12-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ATM|PSEUDORESPONSE||CD/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1961-12-07||||1968-08-17||1971-06-09|1969-08-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||TRGRESP|TARGET RESPONSE||||NG/DL|DISEASE TRANSFORMATION||TESLA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|STUDY SUBJECT|RATER 1|N|1||38||BLINDED TREATMENT|1964-05-17||||1972-10-19||1970-07-25|1964-08-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MET*H|ISD||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|DOMESTIC PARTNER|CARDIOLOGIST|N|2||58||FOLLOW-UP|1966-06-19||||1970-03-11||1964-03-20|1964-06-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||LIVRRESP|LIVER RESPONSE||||ML/M2/DAY|MINOR PATHOLOGIC RESPONSE||PMOL/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|2||58||INDUCTION TREATMENT|1960-01-04||||1965-07-10||1964-02-08|1967-06-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||STRUSTAT|STEROID USE STATUS||||MMU/ML|MOLECULAR MAJOR RESPONSE||V/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|3||39||INDUCTION TREATMENT|1964-08-06||||1960-03-01||1964-11-06|1972-08-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CD/M2|MRD RELAPSE||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|ADJUDICATOR|PHYSIOTHERAPIST|N|3||39||LONG-TERM FOLLOW-UP|1969-09-17||||1965-11-25||1969-01-09|1969-09-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MS2|CHR||NMOL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|STUDY SUBJECT|NEUROLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1971-07-24||||1968-11-17||1969-06-18|1968-03-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||SPLNRESP|SPLEEN RESPONSE||||BAG|FAVORABLE RESPONSE||NKAT/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|INTERVIEWER|OTOLARYNGOLOGIST|NA|4||88||TREATMENT|1961-09-05||||1972-09-26||1969-02-13|1965-12-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TRANSDUCING UNIT/ML|MOLECULAR CR||V|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|SIBLING|ONCOLOGIST 1|Y|5||7||OBSERVATION|1961-12-28||||1964-03-02||1970-02-10|1964-01-26||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/40 HPFS|MINOR PATHOLOGIC RESPONSE||MMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1962-02-02||||1971-12-13||1969-04-19|1961-08-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/S|COMPLETE MRD RESPONSE||DAYS/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|SIGNIFICANT OTHER|ADJUDICATOR|N|1||38||BLINDED TREATMENT|1969-08-13||||1964-04-25||1963-03-28|1970-10-14||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||NEWLPROG|NEW LESION PROGRESSION||||NMOL BCE/NMOL|MORPHOLOGIC CR||HOURS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|CAREGIVER|NEUROLOGIST 1|N|1||38||BASELINE|1969-10-14||||1972-09-26||1967-04-08|1963-10-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||LIVRRESP|LIVER RESPONSE||||G/G|HI-E||HZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|SIBLING|NEUROLOGIST 2|N|2||58||BLINDED TREATMENT|1970-06-08||||1964-05-04||1966-09-30|1961-01-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/KG/H|PARTIAL MORPHOLOGIC RESPONSE||PMOL/10^9 CELLS|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|2||58||BLINDED TREATMENT|1969-04-21||||1960-11-25||1966-08-29|1971-10-11||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PFU/DOSE|PDU||L/H/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|3||39||CONTINUATION TREATMENT|1961-05-04||||1972-03-16||1969-02-21|1963-08-03||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^9 ORGANISMS/G|MRD RELAPSE||DPM/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|INTERVIEWER|RATER|Y|3||39||TREATMENT|1968-07-09||||1961-04-02||1970-12-09|1970-12-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||NEWLIND|NEW LESION INDICATOR||||UMOL/MOL|OPTIMAL MORPHOLOGIC RESPONSE||DAYS/WK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|INVESTIGATOR|ONCOLOGIST 1|NA|4||88||WASHOUT|1968-01-25||||1961-11-24||1964-11-20|1962-02-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||OVRLRESP|OVERALL RESPONSE||||ANTI-XA IU|CMR||TSP|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|GUARDIAN|RADIOLOGIST 2|Y|4||88||BASELINE|1963-12-22||||1962-05-11||1962-08-06|1965-09-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||SPLNRESP|SPLEEN RESPONSE||||U/CL|IMPROVED||FT2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1969-11-11||||1971-03-27||1971-02-07|1961-11-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||VIAL|FAVORABLE RESPONSE||DAYS/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|PROXY|RADIOLOGIST 1|N|5||7||RUN-IN|1968-11-05||||1961-08-16||1962-01-18|1963-08-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/ANIMAL/WK|PSEUDOPROGRESSION||MEQ/KG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|FRIEND|OPTOMETRIST|NA|1||38||CONTINUATION TREATMENT|1971-01-01||||1968-11-16||1967-04-29|1973-01-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/ML/DAY|CPR||VP/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|SIGNIFICANT OTHER|RATER 2|NA|1||38||TREATMENT|1973-08-26||||1970-08-27||1962-06-24|1969-01-24||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||RDIORESP|RADIOLOGIC RESPONSE||||FG|INDETERMINATE RESPONSE||NMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|INTERVIEWER|READER 2|Y|2||58||RUN-IN|1967-12-01||||1967-04-13||1962-03-29|1973-01-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||BONERESP|BONE RESPONSE||||MPS U|MINOR PATHOLOGIC RESPONSE||MMHG*MIN/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|VENDOR|NEUROLOGIST 1|N|2||58||FOLLOW-UP|1963-03-16||||1973-05-22||1966-08-28|1963-01-15||DURING||AFTER|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^9/DOSE|MORPHOLOGIC CR||COAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|3||39||BASELINE|1969-05-19||||1962-01-04||1967-12-18|1964-05-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||APL U/ML|CHR||PMOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|SIBLING|READER 1|Y|3||39||BLINDED TREATMENT|1961-03-03||||1973-03-08||1965-09-18|1963-09-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||NTRGRESP|NON-TARGET RESPONSE||||HENRY|TREATMENT FAILURE||MIN/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|INVESTIGATOR|CARDIOLOGIST|NA|4||88||RUN-IN|1962-12-05||||1970-04-03||1962-11-02|1965-02-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||OVRLRESP|OVERALL RESPONSE||||MN|MRD RELAPSE||OZ EQ|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|4||88||INDUCTION TREATMENT|1961-01-24||||1960-09-23||1963-09-24|1962-09-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||TMRESP|TUMOR MARKER RESPONSE||||PMOL/L|RELAPSED DISEASE||GBQ|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|STUDY SUBJECT|OPHTHALMOLOGIST|U|5||7||CONTINUATION TREATMENT|1966-07-12||||1961-05-15||1970-08-08|1969-02-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||BONERESP|BONE RESPONSE||||UG/L DDU|PSA PROGRESSION||G/G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|FRIEND|PATHOLOGIST 1|NA|5||7||BASELINE|1964-12-12||||1971-05-09||1970-06-18|1960-07-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||STRUSTAT|STEROID USE STATUS||||F|HI-N||NEBULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|Y|1||38||FOLLOW-UP|1971-11-20||||1961-11-08||1964-06-17|1964-04-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||H*%|HI-N||MOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1962-01-03||||1967-04-15||1971-09-04|1971-09-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||ANATRESP|ANATOMIC RESPONSE||||G/CAGE/DAY|WORSENED||PELLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|2||58||CONTINUATION TREATMENT|1967-02-12||||1971-07-24||1969-02-18|1973-02-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KIU|CR-CT||F|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|STUDY SUBJECT|ADJUDICATOR 2|Y|2||58||LONG-TERM FOLLOW-UP|1960-02-01||||1966-02-12||1964-09-26|1971-09-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CAN|SD||DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|VENDOR|UROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1964-05-29||||1965-10-23||1964-09-06|1963-10-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||METSIND|METASTATIC INDICATOR||||GENEQ|PR-CT||10^3/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||LONG-TERM FOLLOW-UP|1965-09-11||||1963-11-29||1972-04-15|1965-05-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||BONERESP|BONE RESPONSE||||MU/G|PMD||G/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|4||88||INDUCTION TREATMENT|1969-03-04||||1964-08-14||1965-09-28|1970-02-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||TRGRESP|TARGET RESPONSE||||G/G/DAY|RELAPSED DISEASE FROM CR OR PR||ML/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|4||88||INDUCTION TREATMENT|1967-09-24||||1966-08-10||1973-04-18|1965-02-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NCI|PMR||MEQ/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|DOMESTIC PARTNER|MICROSCOPIST 1|Y|5||7||TREATMENT|1965-09-21||||1962-01-15||1962-04-13|1965-04-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||RNA COPIES/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|PATHOLOGIST 1|U|5||7||OPEN LABEL TREATMENT|1972-01-08||||1961-09-13||1968-08-06|1973-08-28||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||MOLRESP|MOLECULAR RESPONSE||||MMHG/L/MIN|NON-ICR/NON-IUPD||ML/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|INDEPENDENT ASSESSOR|INTERNIST|Y|1||38||INDUCTION TREATMENT|1969-06-17||||1970-05-10||1967-08-12|1966-08-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O*S/ML|MRD RELAPSE||VOXEL|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|CHILD|ONCOLOGIST 2|NA|1||38||OPEN LABEL TREATMENT|1965-07-11||||1971-11-08||1965-07-21|1973-02-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CMOL|CRI||UIU/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|INDEPENDENT ASSESSOR|READER 1|NA|2||58||RUN-IN|1971-11-28||||1964-02-23||1971-09-08|1967-08-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||SACHET|OPTIMAL MORPHOLOGIC RESPONSE||ML/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|PARENT|ONCOLOGIST 2|N|2||58||RUN-IN|1970-07-10||||1968-08-13||1960-06-15|1972-10-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||MOLRESP|MOLECULAR RESPONSE||||BLOCKS|UNFAVORABLE RESPONSE||HEP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|VENDOR|UROLOGIST|U|3||39||OBSERVATION|1969-10-05||||1965-07-11||1961-09-28|1972-09-16||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||RDIORESP|RADIOLOGIC RESPONSE||||TRANSDUCING UNIT/ML|SD-CT||LOZENGE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|CAREGIVER|ONCOLOGIST 2|U|3||39||WASHOUT|1964-08-30||||1960-03-01||1962-05-16|1966-12-21||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||GLOBULE|NPR||ENZYME U/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|VENDOR|PHYSIOTHERAPIST|N|4||88||RUN-IN|1963-01-04||||1968-06-03||1969-05-22|1971-12-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MOL/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||U/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|DOMESTIC PARTNER|READER 3|NA|4||88||WASHOUT|1969-10-13||||1960-12-06||1970-12-28|1973-04-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/KG|DECREASED||LOG10 ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|5||7||BASELINE|1964-11-16||||1970-07-04||1973-06-18|1960-06-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||SPRAY|UNEQUIVOCAL||PIPE|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|CHILD|PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1961-12-10||||1971-03-13||1963-10-03|1969-06-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PPM|PR-CT||DRUM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|GUARDIAN|ONCOLOGIST|N|1||38||BASELINE|1970-05-12||||1965-01-04||1963-05-09|1960-08-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/L/H|SD-CT||H*%|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|PROXY|RADIOLOGIST|NA|1||38||SCREENING|1968-12-29||||1963-04-22||1961-03-26|1967-01-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||SPLNRESP|SPLEEN RESPONSE||||S^-1(%O2)^-1|NON-CR/NON-PD||PRESSOR UNITS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|FAMILY MEMBER|MICROSCOPIST 2|Y|2||58||INDUCTION TREATMENT|1966-10-15||||1962-06-15||1972-08-29|1965-05-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||BESTRESP|BEST OVERALL RESPONSE||||NCI|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/4.0 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|READER|NA|2||58||SCREENING|1972-08-05||||1972-09-09||1963-04-19|1969-10-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||YEARS|PDU||/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|ADJUDICATOR|READER 2|Y|3||39||OBSERVATION|1967-08-04||||1964-07-05||1968-07-29|1969-06-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/VF|NR||KM/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|STUDY SUBJECT|NEUROLOGIST 1|U|3||39||INDUCTION TREATMENT|1966-01-21||||1965-04-06||1966-05-11|1962-12-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||TRGRESP|TARGET RESPONSE||||ML/CAGE|NPR||UGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|DOMESTIC PARTNER|READER 1|N|4||88||INDUCTION TREATMENT|1970-06-01||||1971-09-18||1969-01-27|1969-12-15||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/G/H|RELAPSED DISEASE||DEG/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|PROXY|READER 1|U|4||88||OPEN LABEL TREATMENT|1972-03-11||||1961-10-20||1968-09-01|1972-07-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||TMRESP|TUMOR MARKER RESPONSE||||APS U|PD FROM PR||NG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|PARENT|HEMATOLOGIST|Y|5||7||TREATMENT|1971-03-08||||1960-03-03||1962-05-22|1964-10-28||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GBQ/MG|VGPR||UG/G/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|VENDOR|INTERNIST|U|5||7||BASELINE|1972-12-09||||1970-05-22||1970-03-23|1973-06-14||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||OVRLRESP|OVERALL RESPONSE||||FRAMES/S|PSEUDORESPONSE||MJOULE/CM2|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|INTERVIEWER|MICROSCOPIST|NA|1||38||OPEN LABEL TREATMENT|1964-02-12||||1973-01-28||1960-07-11|1960-03-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||STRUSTAT|STEROID USE STATUS||||10^3 CFU|MAJOR PATHOLOGIC RESPONSE||ML/(MIN*100ML)|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|FAMILY MEMBER|MICROSCOPIST|Y|1||38||BASELINE|1961-12-26||||1964-04-15||1966-09-21|1971-11-16||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/G HB|MR||LENS|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-09-24||||1970-11-26||1972-03-19|1961-01-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/G/MIN|MAJOR PATHOLOGIC RESPONSE||CL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|INDEPENDENT ASSESSOR|READER 3|Y|2||58||TREATMENT|1962-10-17||||1971-02-06||1961-06-24|1960-06-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||METSIND|METASTATIC INDICATOR||||APPLICATION|WORSENED||AMP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|3||39||BLINDED TREATMENT|1961-01-05||||1968-04-12||1960-08-23|1963-09-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||CYTORESP|CYTOGENETIC RESPONSE||||H*%|PR-CT||BQ/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|3||39||SCREENING|1961-01-18||||1971-04-16||1964-11-01|1962-09-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||NEWLPROG|NEW LESION PROGRESSION||||STEPS/MIN|INCREASED||M/SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|PARENT|INTERNIST|NA|4||88||INDUCTION TREATMENT|1960-03-14||||1966-04-03||1970-03-09|1963-10-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KPA/L/SEC|SD||10^9 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|SPOUSE|PATHOLOGIST 1|NA|4||88||FOLLOW-UP|1961-05-22||||1972-05-22||1962-09-09|1969-01-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/BEAT|NON-PD||G/U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|SIBLING|RATER|NA|5||7||OPEN LABEL TREATMENT|1962-03-14||||1969-05-18||1964-03-15|1968-03-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SIEMENS|SD-CT||MAC50|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|N|5||7||CONTINUATION TREATMENT|1969-11-20||||1972-01-06||1962-08-24|1961-04-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||METBRESP|METABOLIC RESPONSE||||NFIU|SD-CT||TESLA|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|NON-HEALTH CARE PROFESSIONAL|RATER|NA|1||38||WASHOUT|1961-11-30||||1960-06-09||1962-02-13|1964-09-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||S*KPA|DISEASE TRANSFORMATION||MMHG/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|SPOUSE|DERMATOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1962-10-05||||1962-04-18||1973-08-28|1970-03-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||CYTORESP|CYTOGENETIC RESPONSE||||NMOL/MOL|PR||MG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|CHILD|READER 3|NA|2||58||FOLLOW-UP|1964-08-22||||1972-11-04||1960-08-06|1971-09-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||MOLRESP|MOLECULAR RESPONSE||||DEG2|PARTIAL MORPHOLOGIC RESPONSE||BAU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|PARENT|NEUROLOGIST 2|U|2||58||CONTINUATION TREATMENT|1961-05-04||||1971-08-15||1970-07-22|1965-11-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||NEWLPROG|NEW LESION PROGRESSION||||LENS|PD/RELAPSE AFTER HI||IU/KG|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|FRIEND|PEDIATRIC NEUROLOGIST|U|3||39||BLINDED TREATMENT|1968-08-02||||1972-04-14||1961-06-18|1972-07-05||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||NEWLIND|NEW LESION INDICATOR||||ML/(MIN*100ML)|OPTIMAL MORPHOLOGIC RESPONSE||10^3 CFU/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|INDEPENDENT ASSESSOR|PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1969-01-07||||1962-06-23||1962-04-08|1963-03-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||NEWLIND|NEW LESION INDICATOR||||CCID 50/DOSE|MRD NEGATIVITY||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|4||88||FOLLOW-UP|1960-11-27||||1963-12-15||1961-08-15|1964-04-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/L|PD FROM PR||UU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|4||88||INDUCTION TREATMENT|1965-06-09||||1971-06-10||1969-08-07|1965-05-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||TUBERCULIN UNIT|MORPHOLOGIC CR||TABLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|RATER 1|U|5||7||OBSERVATION|1970-05-08||||1968-05-27||1961-04-14|1966-10-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||METSIND|METASTATIC INDICATOR||||IU/KG|PR WITH LYMPHOCYTOSIS||CI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|SIBLING|ENDOCRINOLOGIST|NA|5||7||BASELINE|1961-12-08||||1960-11-05||1960-09-23|1972-04-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FG|PMR||OHM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CHILD|RADIOLOGIST 1|NA|1||38||RUN-IN|1966-01-04||||1968-04-16||1971-06-15|1972-06-18||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^9 ORGANISMS|PARTIAL MORPHOLOGIC RESPONSE||H*%|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|1||38||SCREENING|1965-05-08||||1968-08-09||1964-11-02|1970-12-25||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML*CMH2O|UNEQUIVOCAL||MBP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|2||58||LONG-TERM FOLLOW-UP|1964-09-19||||1970-12-14||1968-08-19|1968-02-25||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||MOLRESP|MOLECULAR RESPONSE||||HZ|EQUIVOCAL||KDA|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|2||58||BASELINE|1968-08-18||||1964-09-24||1968-06-09|1966-04-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/L|CRI||MJOULE/CM2|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|3||39||FOLLOW-UP|1961-12-10||||1965-04-02||1973-06-25|1962-02-19||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G|CHR||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|FAMILY MEMBER|MICROSCOPIST|N|3||39||LONG-TERM FOLLOW-UP|1969-04-27||||1972-06-28||1971-08-07|1964-11-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||NTRGRESP|NON-TARGET RESPONSE||||BQ/G|CHR||V|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||BASELINE|1966-04-21||||1972-07-04||1968-11-01|1960-02-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/S/KPA|CR||MOSM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|CAREGIVER|ADJUDICATOR 1|N|4||88||SCREENING|1960-04-01||||1961-03-28||1972-02-26|1963-02-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ENZYME U/G HB|SCR||MG/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|5||7||TREATMENT|1960-03-24||||1971-09-20||1963-10-14|1968-08-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FOZ_US|CMR||ML/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|SPOUSE|ADJUDICATOR 3|NA|5||7||OPEN LABEL TREATMENT|1966-06-14||||1970-09-18||1965-05-16|1972-05-03||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/H|PR-CT||/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|1||38||BASELINE|1962-12-22||||1970-03-28||1967-05-02|1970-07-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||METBRESP|METABOLIC RESPONSE||||/MM|PARTIAL MORPHOLOGIC RESPONSE||HZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|CAREGIVER|ADJUDICATOR|NA|1||38||INDUCTION TREATMENT|1969-05-21||||1966-08-31||1961-05-29|1965-05-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||HR/DAY|HI-E||FRACTION OF 1|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|GUARDIAN|CLINICAL PATHOLOGIST|N|2||58||CONTINUATION TREATMENT|1968-10-20||||1965-01-17||1962-12-13|1963-09-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/10^4|PR||RING|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|CAREGIVER|READER 1|Y|2||58||OPEN LABEL TREATMENT|1964-04-24||||1962-03-31||1973-03-27|1968-01-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||BONERESP|BONE RESPONSE||||ENZYME U|CR-CT||SYRINGE|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1965-06-20||||1961-04-04||1960-11-12|1967-02-03||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||STRUSTAT|STEROID USE STATUS||||UU/DL|HI-N||ML/(MIN*100ML)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|3||39||WASHOUT|1970-07-27||||1961-09-05||1971-03-23|1969-08-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||METSIND|METASTATIC INDICATOR||||FT2|MORPHOLOGIC LEUKEMIA-FREE STATE||ELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|N|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||INDUCTION TREATMENT|1963-08-27||||1969-10-18||1966-05-06|1964-10-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||STRUSTAT|STEROID USE STATUS||||U/L|SD-CT||U/MG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|PROXY|ONCOLOGIST 1|NA|4||88||OBSERVATION|1960-07-05||||1963-08-31||1969-06-05|1972-08-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||HZ|PD/RELAPSE AFTER HI||ML/BEAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|ADJUDICATION COMMITTEE|MICROSCOPIST|U|5||7||RUN-IN|1970-01-21||||1971-06-12||1961-06-10|1967-10-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||TMRESP|TUMOR MARKER RESPONSE||||MEQ/UL|ICR||DAYS/MONTH|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|PARENT|ONCOLOGIST|U|5||7||WASHOUT|1967-01-04||||1963-06-26||1966-06-05|1964-01-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CAPLET|MORPHOLOGIC LEUKEMIA-FREE STATE||CM|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1961-09-11||||1960-03-10||1968-01-07|1972-08-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IU/KG|EQUIVOCAL||10^9 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|SPOUSE|CARDIOLOGIST|Y|1||38||BASELINE|1966-04-17||||1971-10-26||1963-06-04|1969-07-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||TRGRESP|TARGET RESPONSE||||MV2/HZ|SMD||MPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|FAMILY MEMBER|ADJUDICATOR 2|NA|2||58||FOLLOW-UP|1962-09-21||||1961-06-18||1961-04-12|1969-10-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/L|QUANTIFIABLE MRD POSITIVITY||MNFI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|ADJUDICATOR|RATER 1|Y|2||58||BLINDED TREATMENT|1967-11-14||||1969-01-02||1964-10-28|1967-08-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||STEPS/MIN|STABLE||% INHIBITION|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|SIBLING|ONCOLOGIST|Y|3||39||INDUCTION TREATMENT|1964-06-12||||1965-10-07||1972-02-17|1961-11-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UM|CMR||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|SIBLING|NEUROLOGIST 1|U|3||39||INDUCTION TREATMENT|1962-11-02||||1970-11-19||1961-12-22|1971-04-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||MOLRESP|MOLECULAR RESPONSE||||NMOL/DAY|PDU||NEBULE|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|Y|4||88||OPEN LABEL TREATMENT|1961-08-04||||1964-03-31||1969-08-23|1968-01-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MEQ|SD-CT||MM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|CHILD|UROLOGIST|NA|4||88||WASHOUT|1961-03-20||||1965-05-07||1963-12-02|1973-03-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||WATT|STABLE||MSEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|FAMILY MEMBER|OTOLARYNGOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1966-02-02||||1973-03-18||1969-11-18|1960-09-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||MOLRESP|MOLECULAR RESPONSE||||KAT|NON-PD||BU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|INVESTIGATOR|PATHOLOGIST|U|5||7||BLINDED TREATMENT|1965-08-31||||1969-10-13||1962-04-18|1971-11-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PM|PR WITH LYMPHOCYTOSIS||/200 HPFS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||FOLLOW-UP|1967-05-13||||1970-08-05||1969-03-23|1960-03-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 PFU/ML|NON-QUANTIFIABLE MRD POSITIVITY||SIEMENS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|STUDY SUBJECT|HEMATOLOGIST|N|1||38||OBSERVATION|1963-03-20||||1973-06-09||1962-05-14|1971-04-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||NTRGRESP|NON-TARGET RESPONSE||||MHZ|CYTOGENETIC PR||KUSP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|STUDY SUBJECT|HEMATOLOGIST|U|2||58||SCREENING|1971-11-24||||1967-12-02||1969-01-30|1973-04-18||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||BESTRESP|BEST OVERALL RESPONSE||||ROENTGEN|SCR||10^12/L|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|FRIEND|ENDOCRINOLOGIST|NA|2||58||FOLLOW-UP|1960-08-17||||1968-09-22||1967-06-04|1971-06-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/CM|IUPD||SV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|STUDY SUBJECT|UROLOGIST|U|3||39||SCREENING|1960-01-22||||1971-05-10||1970-04-10|1971-09-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GY|CYTOGENETIC CR||U/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|SIGNIFICANT OTHER|RATER 2|N|3||39||TREATMENT|1960-01-29||||1971-06-03||1963-03-18|1962-12-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||BESTRESP|BEST OVERALL RESPONSE||||PG/CELL|NR||U/CL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||TREATMENT|1971-09-01||||1969-08-27||1970-03-08|1972-09-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||NTRGRESP|NON-TARGET RESPONSE||||G/M2/DAY|INDETERMINATE RESPONSE||G/CAGE|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|4||88||BASELINE|1963-03-01||||1964-03-12||1965-08-14|1960-11-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KG/MOL|HI-P||U|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|FAMILY MEMBER|MICROSCOPIST|Y|5||7||CONTINUATION TREATMENT|1965-08-08||||1972-04-01||1971-06-18|1973-06-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||G/G/DAY|HI-N||MANSON U/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|ADJUDICATOR|ENDOCRINOLOGIST|U|5||7||FOLLOW-UP|1970-07-29||||1973-04-16||1964-07-19|1966-06-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DNA COPIES/ML|IMPROVED||GY/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1968-05-24||||1973-05-02||1967-02-08|1962-10-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UU/DL|MINOR PATHOLOGIC RESPONSE||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|ADJUDICATOR|UROLOGIST|N|1||38||BASELINE|1969-05-30||||1961-01-06||1961-07-26|1963-02-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||ANATRESP|ANATOMIC RESPONSE||||PMOL/DL|CYTOGENETIC MINOR RESPONSE||TUBE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SIBLING|ENDOCRINOLOGIST|Y|2||58||OBSERVATION|1963-06-22||||1966-01-29||1972-02-16|1967-12-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CPM|INCREASED||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|CAREGIVER|MICROSCOPIST|Y|2||58||FOLLOW-UP|1965-03-21||||1965-10-13||1961-08-20|1965-06-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||CLINRESP|CLINICAL RESPONSE||||MM/2H|CCR||PSI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|3||39||RUN-IN|1960-06-25||||1963-11-30||1969-02-02|1969-01-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||NEWLPROG|NEW LESION PROGRESSION||||MCI/KG|TREATMENT FAILURE||UCI|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 2|Y|3||39||OBSERVATION|1971-10-09||||1966-09-19||1968-01-23|1966-08-10||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMOL/MOL|MORPHOLOGIC CR||MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|PROXY|ONCOLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1968-06-01||||1970-11-09||1961-08-28|1964-07-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MMOL/MOL|CR-CT||UIU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|STUDY SUBJECT|PHYSIOTHERAPIST|Y|4||88||BLINDED TREATMENT|1966-01-22||||1960-01-12||1966-09-12|1963-12-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||FRACTION OF 1|NOT ALL EVALUATED||MOSM/KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|5||7||CONTINUATION TREATMENT|1970-05-08||||1969-02-26||1962-11-24|1968-02-12||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/10^12 RBC|INDETERMINATE RESPONSE||ML/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|5||7||BLINDED TREATMENT|1966-05-07||||1967-09-01||1966-08-19|1968-03-19||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||TRGRESP|TARGET RESPONSE||||MM/MIN|STABLE||DISK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|U|1||38||OBSERVATION|1969-06-16||||1969-04-27||1960-10-13|1972-09-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||NEWLPROG|NEW LESION PROGRESSION||||PPM|ISD||MMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|INDEPENDENT ASSESSOR|RATER|NA|1||38||RUN-IN|1969-05-16||||1968-06-17||1965-03-04|1965-12-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||METSIND|METASTATIC INDICATOR||||U/G|INDETERMINATE RESPONSE||MPH|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|FRIEND|MICROSCOPIST|U|2||58||OBSERVATION|1963-01-19||||1960-12-12||1970-02-02|1962-08-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||BESTRESP|BEST OVERALL RESPONSE||||KBQ|DECREASED||BOLUS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|INTERVIEWER|ONCOLOGIST 2|N|2||58||TREATMENT|1971-03-16||||1960-06-07||1968-08-26|1966-10-13||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||DAMOL/L|RELAPSED DISEASE||10^7 PFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|3||39||BASELINE|1962-10-07||||1961-05-15||1967-11-07|1972-04-24||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/DAY|IPR||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|HEALTH CARE PROFESSIONAL|READER 3|NA|3||39||INDUCTION TREATMENT|1962-11-17||||1963-11-10||1963-12-21|1971-12-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O/ML|MCR||PIXELS/IN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|FAMILY MEMBER|INTERNIST|U|4||88||CONTINUATION TREATMENT|1960-04-20||||1965-01-24||1964-10-02|1972-10-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||SPRAY|CCR||NM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|GUARDIAN|RATER|N|4||88||WASHOUT|1970-06-10||||1960-02-22||1965-11-25|1973-03-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/LSQN|QUANTIFIABLE MRD POSITIVITY||KIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|5||7||INDUCTION TREATMENT|1964-01-24||||1964-09-12||1963-10-24|1963-05-08||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||BONERESP|BONE RESPONSE||||L/KG|COMPLETE MRD RESPONSE||FARAD|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|FRIEND|NEUROLOGIST|Y|5||7||WASHOUT|1970-01-06||||1968-09-02||1961-07-27|1973-05-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/LPF|PR-CT||BQ/G|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|STUDY SUBJECT|READER 1|Y|1||38||BASELINE|1968-10-01||||1963-05-25||1969-01-07|1971-02-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG|ICPD||/MBP|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|1||38||WASHOUT|1962-10-15||||1971-07-22||1972-01-06|1960-10-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||METSIND|METASTATIC INDICATOR||||DIP|CCR||UCI/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|2||58||OBSERVATION|1970-08-05||||1964-07-14||1965-01-19|1968-04-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||METBRESP|METABOLIC RESPONSE||||USEC|ICPD||MEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|PARENT|RADIOLOGIST 1|N|2||58||TREATMENT|1967-12-16||||1969-06-15||1970-11-22|1962-11-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/H|UNFAVORABLE RESPONSE||MPL U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|GUARDIAN|ADJUDICATOR 1|N|3||39||CONTINUATION TREATMENT|1963-11-25||||1962-07-28||1972-05-26|1962-03-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||STRUSTAT|STEROID USE STATUS||||UG/DAY|PR WITH LYMPHOCYTOSIS||NMOL BCE/NMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST|N|3||39||BASELINE|1960-01-12||||1969-07-03||1972-01-12|1969-08-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^11/L|ICPD||10^6 IU/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|FRIEND|RATER 2|NA|4||88||RUN-IN|1968-02-02||||1961-03-18||1971-12-29|1962-12-30||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||ANATRESP|ANATOMIC RESPONSE||||FRACTION OF 1|ISD||10^4 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|STUDY SUBJECT|MICROSCOPIST 1|U|4||88||OBSERVATION|1963-11-19||||1972-10-08||1970-01-05|1962-03-28||DURING||DURING|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^6 ORGANISMS/G|MOLECULAR MAJOR RESPONSE||WEBER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|FRIEND|OPTOMETRIST|U|5||7||INDUCTION TREATMENT|1973-04-11||||1968-07-11||1967-12-07|1973-02-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/4.0 ML|PR WITH LYMPHOCYTOSIS||PG/DL|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|READER 1|N|5||7||OBSERVATION|1961-12-09||||1960-03-21||1966-08-25|1964-09-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|1||||||STRUSTAT|STEROID USE STATUS||||CYCLE/MIN|CRI||MS2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|1||38||FOLLOW-UP|1960-02-05||||1969-03-24||1971-11-07|1962-01-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PPTH|SMD||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|CAREGIVER|UROLOGIST|Y|1||38||TREATMENT|1961-09-13||||1965-02-26||1972-02-15|1965-04-02||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|1||||||METSIND|METASTATIC INDICATOR||||MEQ|CCR||BAG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|SIGNIFICANT OTHER|DERMATOLOGIST|Y|2||58||FOLLOW-UP|1969-04-27||||1971-03-05||1965-11-27|1967-03-11||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|2||||||ANATRESP|ANATOMIC RESPONSE||||10^3 ORGANISMS/ML|INDETERMINATE RESPONSE||IU/G HB|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|FAMILY MEMBER|PATHOLOGIST|N|2||58||RUN-IN|1967-01-10||||1970-10-07||1964-01-16|1968-09-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|1||||||TRGRESP|TARGET RESPONSE||||MONTHS|UNEQUIVOCAL||QUANTITY SUFFICIENT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|3||39||RUN-IN|1965-03-08||||1966-05-15||1961-05-21|1963-05-09||DURING||DURING|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|2||||||METSIND|METASTATIC INDICATOR||||NCI|INDETERMINATE RESPONSE||10^6 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|FRIEND|NEUROLOGIST 1|U|3||39||WASHOUT|1972-05-01||||1964-08-12||1965-03-29|1967-05-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|1||||||NEWLIND|NEW LESION INDICATOR||||ABSORBANCE U|MR||MMHG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|PARENT|ONCOLOGIST|U|4||88||SCREENING|1969-04-26||||1964-06-27||1972-08-09|1964-11-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|2||||||TRGRESP|TARGET RESPONSE||||NMOL/L/MIN|INCREASED||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|GUARDIAN|ONCOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1971-06-14||||1973-04-12||1972-03-01|1966-09-11||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G/CAGE/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|FRIEND|NEUROLOGIST 2|Y|5||7||FOLLOW-UP|1968-10-15||||1962-01-14||1966-06-16|1967-07-30||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A1FAB383-1757-4832-B888-90C133842EF8|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^9 ORGANISMS/G|PD||POINT|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|5||7||INDUCTION TREATMENT|1971-08-09||||1963-02-09||1969-07-12|1968-06-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||FIU|CMR||G/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|CHILD|ADJUDICATOR 2|U|1||38||INDUCTION TREATMENT|1972-10-15||||1963-06-27||1964-01-22|1972-12-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FEU|INDETERMINATE RESPONSE||KG/M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|VENDOR|RADIOLOGIST 1|NA|1||38||CONTINUATION TREATMENT|1962-07-15||||1973-01-31||1965-07-24|1963-05-09||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NMOL/KG/DAY|CYTOGENETIC MINIMAL RESPONSE||NKAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|STUDY SUBJECT|RADIOLOGIST 1|Y|2||58||FOLLOW-UP|1967-12-01||||1970-12-11||1973-02-12|1971-04-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||ANATRESP|ANATOMIC RESPONSE||||HOURS|IMMUNOPHENOTYPIC CR||NEBULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|DOMESTIC PARTNER|ONCOLOGIST 1|N|2||58||SCREENING|1960-05-02||||1971-01-19||1969-06-06|1965-12-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DPM/0.5 ML|MRD NEGATIVITY||MG/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|CLINICAL STUDY SPONSOR|READER 1|Y|3||39||INDUCTION TREATMENT|1969-11-22||||1971-11-25||1966-07-03|1962-12-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||CYTORESP|CYTOGENETIC RESPONSE||||LOZENGE|PR-CT||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|SPOUSE|INTERNIST|N|3||39||WASHOUT|1963-03-11||||1960-02-21||1967-04-14|1967-04-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||NEWLIND|NEW LESION INDICATOR||||F|INCREASED||TRACE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|CHILD|NEUROLOGIST 2|NA|4||88||SCREENING|1962-06-27||||1965-04-08||1963-02-20|1963-09-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UM2|IMMUNOPHENOTYPIC CR||MM/2H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|4||88||SCREENING|1969-11-04||||1962-09-07||1962-08-09|1966-04-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MCI/KG|NR||CAN|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|CAREGIVER|ADJUDICATOR 1|NA|5||7||CONTINUATION TREATMENT|1973-03-03||||1961-01-14||1962-07-03|1964-12-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||METSIND|METASTATIC INDICATOR||||M2|MRD NEGATIVITY||/4.0 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|CHILD|RATER|NA|5||7||BASELINE|1960-01-11||||1968-10-21||1966-05-28|1966-12-25||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UG/L|WORSENED||ENZYME U|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||TREATMENT|1968-06-15||||1965-05-15||1973-06-25|1966-08-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KG/MOL|MOLECULAR MAJOR RESPONSE||PIXEL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INTERVIEWER|RADIOLOGIST|Y|1||38||FOLLOW-UP|1965-12-14||||1960-07-19||1972-06-05|1973-03-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DRUM|HI-N||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|CHILD|PHYSIOTHERAPIST|N|2||58||LONG-TERM FOLLOW-UP|1963-01-21||||1962-01-28||1960-07-10|1967-12-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^8 PFU|NON-ICR/NON-IUPD||ABSORBANCE U/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1967-10-01||||1965-04-16||1969-03-07|1972-09-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||SQU/ML|CA125 75% RESPONSE||ANTIBODY UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|PROXY|RATER 1|Y|3||39||OPEN LABEL TREATMENT|1968-03-26||||1971-03-07||1971-08-27|1962-05-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||ANATRESP|ANATOMIC RESPONSE||||MOSM/KG|SD||GY/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1962-02-21||||1960-07-21||1968-08-16|1973-05-17||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||NEWLPROG|NEW LESION PROGRESSION||||%(W/W)|CPR||PT_US|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|DOMESTIC PARTNER|ONCOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-05-29||||1962-11-05||1969-11-19|1967-09-15||DURING||AFTER|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||NEWLIND|NEW LESION INDICATOR||||KPA/L/SEC|PSEUDORESPONSE||DAGU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|PARENT|MICROSCOPIST 1|NA|4||88||OPEN LABEL TREATMENT|1972-04-30||||1973-04-25||1967-11-03|1972-10-13||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||RDIORESP|RADIOLOGIC RESPONSE||||GBQ/UG|HI-N||ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|INVESTIGATOR|ENDOCRINOLOGIST|N|5||7||OBSERVATION|1964-03-12||||1968-10-26||1968-07-14|1973-07-12||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL/KG|PSEUDOPROGRESSION||GLOBULE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|PARENT|ADJUDICATOR 2|Y|5||7||WASHOUT|1964-01-05||||1967-01-28||1968-12-26|1973-07-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||METSIND|METASTATIC INDICATOR||||BISCUIT|EQUIVOCAL||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|READER 1|NA|1||38||TREATMENT|1971-08-27||||1968-08-09||1968-01-23|1972-07-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||G/KG|NON-ICR/NON-IUPD||10^9 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|1||38||BASELINE|1970-09-04||||1964-09-13||1965-05-03|1962-09-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||KDA|SD||MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|2||58||INDUCTION TREATMENT|1969-06-21||||1970-07-07||1968-02-17|1962-03-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||NTRGRESP|NON-TARGET RESPONSE||||TORR|MORPHOLOGIC CRI||UG/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||TREATMENT|1960-09-03||||1973-05-01||1962-08-02|1970-07-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/CM H2O|VGPR||10^7 CFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|VENDOR|PATHOLOGIST 1|U|3||39||TREATMENT|1969-10-21||||1960-12-14||1969-07-30|1968-05-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CFU/G|CCR||MG/M2/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|3||39||FOLLOW-UP|1965-03-21||||1966-12-01||1970-11-01|1969-01-26||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||STRUSTAT|STEROID USE STATUS||||NL|MRD PERSISTENCE||CMHG|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|VENDOR|RATER|NA|4||88||LONG-TERM FOLLOW-UP|1972-08-13||||1964-02-14||1969-09-11|1969-10-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CGY|PARTIAL MORPHOLOGIC RESPONSE||CMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|DOMESTIC PARTNER|ONCOLOGIST 1|U|4||88||RUN-IN|1968-06-15||||1961-10-05||1973-08-07|1968-11-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UU/DL|CYTOGENETIC CR||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|SPOUSE|HEMATOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1971-09-09||||1968-11-14||1972-06-22|1968-07-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/DL|STABLE||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|5||7||TREATMENT|1964-05-19||||1966-10-28||1965-08-03|1968-08-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/SEC/1.73M2|CA125 50% RESPONSE||U/MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|1||38||OPEN LABEL TREATMENT|1971-06-28||||1964-07-11||1963-07-31|1963-05-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KPA/L/SEC|VGPR||PT_BR|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1964-10-24||||1971-03-24||1968-11-20|1961-05-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||NEWLPROG|NEW LESION PROGRESSION||||L/S/KPA|PCR||MIN*MG/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|ADJUDICATOR|ONCOLOGIST 1|Y|2||58||SCREENING|1970-01-01||||1969-01-24||1961-11-26|1968-12-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||STRUSTAT|STEROID USE STATUS||||BQ/UL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|ADJUDICATOR|CARDIOLOGIST|Y|2||58||OBSERVATION|1970-10-29||||1971-09-04||1965-06-21|1968-04-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||NTRGRESP|NON-TARGET RESPONSE||||FG|INDETERMINATE RESPONSE||LB|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|INTERVIEWER|PATHOLOGIST|N|3||39||TREATMENT|1964-02-19||||1970-07-18||1968-03-22|1972-02-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||L|HI-N||MKAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|INTERVIEWER|NEUROLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1960-09-21||||1961-04-29||1960-04-13|1964-05-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^10/L|PD FROM PR||/500 WBC|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|STUDY SUBJECT|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1960-10-08||||1966-08-26||1972-05-31|1971-09-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||NEWLIND|NEW LESION INDICATOR||||DEG/S|PD FROM PR||G/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|4||88||TREATMENT|1965-02-24||||1972-10-10||1961-10-02|1966-04-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^7/L|PCR||DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|VENDOR|MICROSCOPIST 2|Y|5||7||INDUCTION TREATMENT|1963-08-03||||1965-12-29||1964-10-15|1966-03-21||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||CYTORESP|CYTOGENETIC RESPONSE||||WATT|CCR||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|5||7||INDUCTION TREATMENT|1968-07-05||||1972-10-05||1964-07-31|1966-04-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^9/G|CR||/2500 WBC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|CLINICAL STUDY SPONSOR|INTERNIST|Y|1||38||INDUCTION TREATMENT|1965-12-30||||1965-08-30||1962-02-02|1961-06-21||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||BONERESP|BONE RESPONSE||||FMOL/G|IMPROVED||NFIU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|CHILD|READER 2|N|1||38||BLINDED TREATMENT|1962-02-09||||1968-06-22||1961-05-19|1966-10-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/CM2|PARTIAL MORPHOLOGIC RESPONSE||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|DOMESTIC PARTNER|MICROSCOPIST 2|Y|2||58||OPEN LABEL TREATMENT|1964-07-02||||1968-03-04||1965-07-25|1960-07-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/BREATH|CYTOGENETIC MINIMAL RESPONSE||MG/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|FRIEND|RADIOLOGIST 2|Y|2||58||FOLLOW-UP|1969-01-27||||1962-02-20||1963-04-30|1961-03-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||METBRESP|METABOLIC RESPONSE||||GY|CHR||M|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|CHILD|MICROSCOPIST 3|NA|3||39||OPEN LABEL TREATMENT|1960-07-30||||1960-08-07||1967-04-02|1963-10-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^3 ORGANISMS|SD||L/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|SIBLING|CARDIOLOGIST|N|3||39||SCREENING|1969-06-25||||1961-12-10||1961-11-28|1961-10-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||MOLRESP|MOLECULAR RESPONSE||||MG/M2|ABSENT MORPHOLOGIC RESPONSE||MMOL/MIN/KPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|ADJUDICATION COMMITTEE|READER 2|N|4||88||LONG-TERM FOLLOW-UP|1964-09-14||||1967-12-23||1960-10-03|1972-06-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MM2|CYTOGENETIC MINIMAL RESPONSE||KG/CM2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|FRIEND|UROLOGIST|U|4||88||BASELINE|1963-12-11||||1973-07-23||1970-09-02|1966-04-17||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/10^5|ICR||GRAVITATIONAL UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|FRIEND|CLINICAL PATHOLOGIST|Y|5||7||RUN-IN|1965-03-02||||1969-03-07||1967-02-06|1971-05-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||NEWLIND|NEW LESION INDICATOR||||CM/MIN|IPR||HZ/S|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|5||7||SCREENING|1961-02-24||||1972-08-02||1968-08-28|1961-11-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/KG|PCR||PPTH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|ADJUDICATOR|READER 1|U|1||38||BASELINE|1962-06-30||||1967-09-13||1961-11-20|1969-05-28||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||CLINRESP|CLINICAL RESPONSE||||PACK|MINOR PATHOLOGIC RESPONSE||ML/CAGE/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|INTERVIEWER|MICROSCOPIST 2|U|1||38||CONTINUATION TREATMENT|1964-04-12||||1971-10-17||1963-09-24|1961-06-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMHG/SEC|MRD NEGATIVITY||UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|U|2||58||OPEN LABEL TREATMENT|1964-08-26||||1963-07-11||1964-09-17|1962-12-24||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||OVRLRESP|OVERALL RESPONSE||||GPS U|MRD RELAPSE||NG/L|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|INTERVIEWER|NEUROLOGIST 2|N|2||58||RUN-IN|1961-04-19||||1970-01-07||1967-07-18|1960-11-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||ANATRESP|ANATOMIC RESPONSE||||MPA|IPR||U.CARR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|3||39||WASHOUT|1972-11-09||||1972-12-30||1967-05-12|1969-06-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||METBRESP|METABOLIC RESPONSE||||OI50|ICPD||MM/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1962-01-13||||1972-08-14||1973-08-04|1969-08-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||MOLRESP|MOLECULAR RESPONSE||||ML/CAGE/DAY|PARTIAL MORPHOLOGIC RESPONSE||CIGAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|CAREGIVER|RATER 2|U|4||88||LONG-TERM FOLLOW-UP|1970-08-25||||1964-08-28||1969-09-18|1962-01-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||MOLRESP|MOLECULAR RESPONSE||||NKAT|SCR||AMPULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|4||88||WASHOUT|1973-02-15||||1960-11-05||1968-09-24|1961-05-07||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||BESTRESP|BEST OVERALL RESPONSE||||KM|PD||% INHIBITION|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CHILD|READER 2|N|5||7||OPEN LABEL TREATMENT|1966-07-30||||1971-09-19||1960-01-24|1963-10-23||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||RDIORESP|RADIOLOGIC RESPONSE||||TUBE|MAJOR PATHOLOGIC RESPONSE||MU/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|CHILD|HEMATOLOGIST|U|5||7||WASHOUT|1963-01-20||||1967-08-01||1969-09-28|1964-03-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||LIVRRESP|LIVER RESPONSE||||BLOCKS|HI-E||FT3|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|SIBLING|ADJUDICATOR|NA|1||38||WASHOUT|1967-03-11||||1971-05-23||1972-10-26|1973-08-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NEEDLE GAUGE|PSA PROGRESSION||NMOL/ML/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|SIBLING|MICROSCOPIST 2|Y|1||38||RUN-IN|1962-07-09||||1965-11-25||1964-11-17|1961-06-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MEQ/UG|SCR||L/S/KPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|GUARDIAN|HEMATOLOGIST|NA|2||58||BLINDED TREATMENT|1962-02-12||||1966-05-03||1960-12-29|1963-03-04||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMOL/DAY|HI-E||COAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||SCREENING|1966-11-17||||1960-08-30||1965-02-16|1965-10-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||BONERESP|BONE RESPONSE||||10^9 ORGANISMS/MG|SCR||MG/G/H|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|PROXY|RADIOLOGIST 1|U|3||39||RUN-IN|1970-01-08||||1970-01-18||1962-04-09|1962-01-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||LIVRRESP|LIVER RESPONSE||||MOL/MG|PMR||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|CAREGIVER|READER 1|N|3||39||OBSERVATION|1960-09-19||||1967-08-25||1965-11-08|1971-07-12||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||YD|MORPHOLOGIC LEUKEMIA-FREE STATE||KIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|PARENT|RATER 1|NA|4||88||BLINDED TREATMENT|1969-09-27||||1964-07-31||1964-10-12|1961-11-30||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||NEWLPROG|NEW LESION PROGRESSION||||MMOL/G|CR||MV|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|VENDOR|RADIOLOGIST|N|4||88||BASELINE|1967-12-10||||1971-12-09||1971-08-02|1967-04-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||OVRLRESP|OVERALL RESPONSE||||UG/G/MIN|UNFAVORABLE RESPONSE||H/WK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|5||7||WASHOUT|1961-06-15||||1962-09-18||1968-11-01|1960-03-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||METSIND|METASTATIC INDICATOR||||10^3/L|PR||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|INTERVIEWER|PATHOLOGIST 1|Y|5||7||WASHOUT|1964-10-10||||1969-11-20||1962-07-22|1960-09-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MPL U/ML|UNEQUIVOCAL||/CMH2O|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|GUARDIAN|MICROSCOPIST|Y|1||38||LONG-TERM FOLLOW-UP|1966-08-11||||1966-03-28||1968-09-22|1963-08-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|2||||||BESTRESP|BEST OVERALL RESPONSE||||MM/MIN|DISEASE TRANSFORMATION||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|1||38||OBSERVATION|1970-10-01||||1965-06-20||1966-06-08|1972-08-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^9/L|RELAPSED DISEASE FROM CR OR PR||BEL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|2||58||TREATMENT|1969-03-04||||1965-07-21||1964-04-04|1960-03-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|2||||||NEWLPROG|NEW LESION PROGRESSION||||/2000 RBC|CYTOGENETIC MINOR RESPONSE||TABLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|2||58||SCREENING|1973-07-17||||1968-08-04||1966-11-21|1960-07-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3 ORGANISMS|MORPHOLOGIC CR||UMOL/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|CAREGIVER|MICROSCOPIST 1|NA|3||39||OBSERVATION|1973-05-24||||1965-12-16||1969-09-18|1967-11-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MV|INDETERMINATE RESPONSE||10^7 CFU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|3||39||BLINDED TREATMENT|1972-06-30||||1972-02-23||1963-05-17|1972-05-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|1||||||RDIORESP|RADIOLOGIC RESPONSE||||U/G/H|OPTIMAL MORPHOLOGIC RESPONSE||LOZENGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|Y|4||88||BLINDED TREATMENT|1962-03-18||||1963-07-24||1969-04-26|1971-11-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|2||||||SPLNRESP|SPLEEN RESPONSE||||NEBULE|HI-P||MV|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|GUARDIAN|RATER|NA|4||88||RUN-IN|1972-10-10||||1970-11-21||1963-12-30|1971-04-22||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CMH2O*S/ML|IMPROVED||PMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|5||7||BASELINE|1971-11-23||||1973-08-08||1969-04-02|1972-10-10||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|9F622B53-71F8-4362-99A5-251993E3A946|2||||||TMRESP|TUMOR MARKER RESPONSE||||BEAM BREAKS|NOT ALL EVALUATED||MAMP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|5||7||BASELINE|1962-01-11||||1961-09-19||1963-09-09|1966-05-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GPS U|FAVORABLE RESPONSE||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||WASHOUT|1970-03-24||||1969-11-10||1973-03-12|1971-06-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||TRGRESP|TARGET RESPONSE||||% INHIBITION|SMD||10^9 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|PROXY|OTOLARYNGOLOGIST|U|1||38||CONTINUATION TREATMENT|1960-03-03||||1973-05-29||1969-04-19|1962-07-31||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||OVRLRESP|OVERALL RESPONSE||||L/S/KPA|IUPD||P|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|2||58||CONTINUATION TREATMENT|1962-09-28||||1960-10-09||1971-12-27|1970-09-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||BONERESP|BONE RESPONSE||||LM|IUPD||G/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|2||58||WASHOUT|1967-07-07||||1963-08-30||1962-02-17|1960-10-16||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||BOX|NE||SFC/10^6 PBMC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER|U|3||39||WASHOUT|1970-12-08||||1964-08-30||1972-04-06|1962-01-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||METSIND|METASTATIC INDICATOR||||U/G|MOLECULAR MAJOR RESPONSE||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|INVESTIGATOR|PEDIATRIC NEUROLOGIST|U|3||39||INDUCTION TREATMENT|1962-02-22||||1970-04-03||1972-02-07|1972-09-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PACK YEAR|INCREASED||PG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|4||88||WASHOUT|1971-02-11||||1965-07-29||1970-12-06|1965-05-23||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||BONERESP|BONE RESPONSE||||GLOBULE|PSA PROGRESSION||ANSON U|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|INTERVIEWER|HEMATOLOGIST|U|4||88||INDUCTION TREATMENT|1968-09-30||||1962-06-18||1972-09-07|1965-12-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TSP|RELAPSED DISEASE||ML/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|INVESTIGATOR|ENDOCRINOLOGIST|N|5||7||TREATMENT|1962-12-22||||1968-10-24||1968-05-20|1965-04-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UV|CYTOGENETIC CR||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|CLINICAL STUDY SPONSOR|READER 2|Y|5||7||BLINDED TREATMENT|1966-09-05||||1964-01-27||1970-10-03|1961-02-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||L/S/KPA|ICR||UCI/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|VENDOR|ONCOLOGIST|Y|1||38||WASHOUT|1962-11-22||||1973-06-03||1964-01-24|1965-12-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|2||||||RDIORESP|RADIOLOGIC RESPONSE||||DAMOL/L|COMPLETE MRD RESPONSE||MBQ|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|CHILD|RATER|Y|1||38||OBSERVATION|1967-06-08||||1971-03-24||1967-03-03|1964-11-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|1||||||BONERESP|BONE RESPONSE||||ENZYME U/L|PD FROM PR||U/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1965-06-16||||1972-09-20||1972-05-03|1968-06-09||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CARTRIDGE|CYTOGENETIC MINOR RESPONSE||TBSP|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|PATHOLOGIST|NA|2||58||OBSERVATION|1965-09-07||||1964-03-18||1965-05-20|1966-11-08||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|1||||||ANATRESP|ANATOMIC RESPONSE||||10^3/L|MRD NEGATIVITY||PSI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|DOMESTIC PARTNER|MICROSCOPIST|NA|3||39||SCREENING|1968-10-09||||1961-02-08||1966-06-03|1963-02-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|2||||||ANATRESP|ANATOMIC RESPONSE||||BU/ML|PR WITH LYMPHOCYTOSIS||ML/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|INTERVIEWER|NEUROLOGIST 2|NA|3||39||TREATMENT|1971-04-24||||1961-04-06||1973-06-22|1972-05-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DDU|PR WITH LYMPHOCYTOSIS||PIXELS/CM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|VENDOR|ONCOLOGIST|N|4||88||BLINDED TREATMENT|1973-09-01||||1969-06-29||1966-06-06|1972-03-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|2||||||MOLRESP|MOLECULAR RESPONSE||||GRAVITATIONAL UNIT|ICR||1/(S*KPA)|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|PARENT|ENDOCRINOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1964-09-03||||1973-08-09||1969-08-17|1973-06-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^12 IU/L|MORPHOLOGIC CR||PMOL/10^10 CELLS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|PARENT|MICROSCOPIST|N|5||7||WASHOUT|1973-01-28||||1960-01-03||1969-06-17|1971-01-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|448246D1-5625-4F69-B214-3A8848E86C28|2||||||LIVRRESP|LIVER RESPONSE||||V/V|PR WITH LYMPHOCYTOSIS||FT2|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|PROXY|ONCOLOGIST 1|NA|5||7||OPEN LABEL TREATMENT|1964-02-09||||1960-07-28||1972-03-05|1965-03-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||NEWLPROG|NEW LESION PROGRESSION||||UG/L|STABLE||KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|1||38||RUN-IN|1969-06-28||||1960-06-28||1962-01-03|1962-12-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FT3|TREATMENT FAILURE||G/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|INTERNIST|NA|1||38||SCREENING|1961-09-08||||1970-07-18||1972-11-22|1960-08-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/S/M2|CA125 50% RESPONSE||COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||BLINDED TREATMENT|1960-08-12||||1970-01-14||1960-07-29|1964-11-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KIU|MINOR PATHOLOGIC RESPONSE||UG/L FEU|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|FAMILY MEMBER|READER 2|Y|2||58||RUN-IN|1973-03-10||||1960-03-29||1966-12-26|1970-07-08||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||SPLNRESP|SPLEEN RESPONSE||||L/MIN|NON-QUANTIFIABLE MRD POSITIVITY||IU/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|GUARDIAN|MICROSCOPIST 3|N|3||39||INDUCTION TREATMENT|1964-04-13||||1969-11-01||1961-09-20|1962-04-04||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||OVRLRESP|OVERALL RESPONSE||||CL|MR||LB|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|SPOUSE|MICROSCOPIST 3|NA|3||39||RUN-IN|1961-02-23||||1970-12-23||1961-05-05|1968-06-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||LIVRRESP|LIVER RESPONSE||||ML/CM3/MIN|PDU||STEPS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|SIBLING|OPTOMETRIST|Y|4||88||SCREENING|1965-04-22||||1967-08-28||1972-06-04|1971-07-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||TMRESP|TUMOR MARKER RESPONSE||||CM H2O|MCR||SHOCK WAVE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BLINDED TREATMENT|1961-06-15||||1969-02-20||1967-11-03|1964-07-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MILE|IMPROVED||MEQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|PROXY|ADJUDICATOR 2|U|5||7||OBSERVATION|1960-03-07||||1963-01-26||1963-07-20|1972-03-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NG/DL|CA125 50% RESPONSE||PMOL/10^10 CELLS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|CHILD|ENDOCRINOLOGIST|NA|5||7||WASHOUT|1969-12-07||||1961-09-27||1963-09-15|1967-03-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||CLINRESP|CLINICAL RESPONSE||||FMOL/L|IUPD||CMH2O/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|VENDOR|UROLOGIST|N|1||38||RUN-IN|1970-12-18||||1967-03-11||1967-09-23|1964-11-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GPL U/ML|PD||CM/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|ADJUDICATION COMMITTEE|READER 3|Y|1||38||WASHOUT|1969-11-01||||1965-03-15||1968-04-18|1968-09-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||TRGRESP|TARGET RESPONSE||||UM/S|NON-QUANTIFIABLE MRD POSITIVITY||ML/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|FAMILY MEMBER|OPTOMETRIST|NA|2||58||FOLLOW-UP|1973-08-13||||1966-06-26||1972-02-28|1962-08-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||NEWLIND|NEW LESION INDICATOR||||M/SEC2|PSEUDORESPONSE||NU/CL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|PROXY|NEUROLOGIST 1|U|2||58||BLINDED TREATMENT|1961-06-01||||1970-10-09||1964-12-02|1967-11-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PG|ICR||L/H/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|STUDY SUBJECT|PATHOLOGIST 1|N|3||39||WASHOUT|1967-02-25||||1970-04-17||1960-02-18|1971-05-06||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||NTRGRESP|NON-TARGET RESPONSE||||UOSM|PD-CT||BISCUIT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|FAMILY MEMBER|PATHOLOGIST|U|3||39||SCREENING|1968-01-19||||1969-03-26||1961-03-30|1967-05-07||AFTER||DURING|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/CMH2O|PCR||APS U|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|FRIEND|NEUROLOGIST 2|U|4||88||INDUCTION TREATMENT|1967-04-03||||1964-02-06||1966-09-13|1963-01-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||RDIORESP|RADIOLOGIC RESPONSE||||TRANSDUCING UNIT|UNEQUIVOCAL||MPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|PROXY|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1970-09-15||||1967-10-19||1960-01-09|1971-08-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MMHG/SEC|CA125 75% RESPONSE||10^9/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|5||7||OPEN LABEL TREATMENT|1966-07-11||||1961-01-21||1964-07-18|1966-07-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CI/UL|INCREASED||MIN/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|SIBLING|READER|Y|5||7||TREATMENT|1973-05-31||||1969-09-05||1968-11-17|1961-07-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOL/G|IUPD||OZ EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|STUDY SUBJECT|PATHOLOGIST 1|U|1||38||OBSERVATION|1964-05-17||||1962-11-17||1962-12-02|1962-12-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL BCE/MMOL|MOLECULAR CR||NMOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|SPOUSE|NEUROLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1970-04-28||||1971-08-12||1967-09-10|1965-03-02||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|1||||||METSIND|METASTATIC INDICATOR||||/500 WBC|CPR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|2||58||BASELINE|1961-12-07||||1963-09-21||1968-12-21|1965-08-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|2||||||TMRESP|TUMOR MARKER RESPONSE||||UOSM|OPTIMAL MORPHOLOGIC RESPONSE||PMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||BASELINE|1972-02-08||||1968-07-02||1964-10-24|1964-01-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SHOCK WAVE|PMR||CM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|INVESTIGATOR|RADIOLOGIST 1|N|3||39||SCREENING|1962-11-11||||1968-05-16||1964-12-22|1967-11-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TRACE|CYTOGENETIC NO RESPONSE||U/CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|FRIEND|MICROSCOPIST 1|U|3||39||OBSERVATION|1969-06-15||||1960-01-22||1965-11-03|1962-08-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI|CR-CT||U/G HB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|GUARDIAN|NEUROLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1972-08-07||||1963-06-11||1970-04-29|1961-01-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|2||||||NEWLPROG|NEW LESION PROGRESSION||||GTT|PSEUDORESPONSE||10^9 CFU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|DOMESTIC PARTNER|RATER 2|Y|4||88||SCREENING|1962-01-08||||1964-04-03||1967-06-24|1968-06-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PFU/DOSE|PD FROM PR||ENZYME U/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|PROXY|CLINICAL PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-11-01||||1971-01-05||1964-01-30|1966-06-11||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5545846C-F90F-4346-A075-05999641B872|2||||||CLINRESP|CLINICAL RESPONSE||||MV|MORPHOLOGIC LEUKEMIA-FREE STATE||CG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|SIGNIFICANT OTHER|READER 2|N|5||7||BASELINE|1964-12-06||||1971-07-11||1965-09-02|1968-01-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6 U|OPTIMAL MORPHOLOGIC RESPONSE||FMOL/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|ADJUDICATOR|RATER 1|U|1||38||TREATMENT|1960-02-25||||1964-12-01||1961-08-15|1972-06-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^3 DNA COPIES/ML|PR WITH LYMPHOCYTOSIS||NG/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|STUDY SUBJECT|PHYSIOTHERAPIST|NA|1||38||BASELINE|1964-03-10||||1973-08-12||1961-07-22|1969-09-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UM/S|PD/RELAPSE AFTER HI||MOL/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|PARENT|MICROSCOPIST 3|U|2||58||INDUCTION TREATMENT|1969-11-17||||1972-07-10||1963-08-03|1963-12-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||COPIES/UG|MOLECULAR CR||ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|FAMILY MEMBER|READER|Y|2||58||WASHOUT|1969-08-06||||1969-06-09||1968-09-16|1971-06-29||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||STRUSTAT|STEROID USE STATUS||||ML/CM H2O|SD-CT||% INHIBITION|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|PROXY|NEUROLOGIST 2|Y|3||39||INDUCTION TREATMENT|1967-10-07||||1961-02-20||1967-12-06|1969-02-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||G/DL|FAVORABLE RESPONSE||RFU|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|FAMILY MEMBER|ADJUDICATOR 2|Y|3||39||FOLLOW-UP|1961-10-31||||1964-05-11||1960-10-31|1971-04-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||METBRESP|METABOLIC RESPONSE||||DIP|IUPD||UG/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|VENDOR|ENDOCRINOLOGIST|NA|4||88||FOLLOW-UP|1973-04-05||||1965-02-04||1967-10-08|1961-10-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ARBITRARY U|ISD||IU/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|SIBLING|PATHOLOGIST 1|Y|4||88||SCREENING|1968-11-22||||1969-10-07||1968-05-06|1965-11-24||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||METBRESP|METABOLIC RESPONSE||||AMU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MG/M2/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|PROXY|NEUROLOGIST|N|5||7||BLINDED TREATMENT|1973-05-29||||1972-01-20||1969-08-25|1964-04-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CI/ML|PSEUDOPROGRESSION||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|PROXY|ONCOLOGIST 2|U|5||7||FOLLOW-UP|1966-06-04||||1966-03-10||1967-12-31|1971-01-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|1||||||METSIND|METASTATIC INDICATOR||||AMFI|NON-QUANTIFIABLE MRD POSITIVITY||ML/BEAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST|Y|1||38||FOLLOW-UP|1963-12-08||||1960-10-31||1961-04-14|1962-06-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/WK|NON-PD||/CMH2O|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1||38||BASELINE|1960-06-16||||1965-06-25||1971-06-27|1963-04-09||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|1||||||OVRLRESP|OVERALL RESPONSE||||ML/M2/MIN|COMPLETE MRD RESPONSE||USIEMENS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||INDUCTION TREATMENT|1965-11-06||||1969-02-26||1971-12-28|1973-05-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||RAD|IMMUNOPHENOTYPIC CR||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|STUDY SUBJECT|NEUROLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1963-01-29||||1964-12-07||1970-03-29|1972-08-07||AFTER||DURING|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KAT|COMPLETE MRD RESPONSE||VOXEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|FRIEND|PHYSIOTHERAPIST|NA|3||39||TREATMENT|1968-02-06||||1971-10-29||1964-06-02|1967-01-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|2||||||NEWLPROG|NEW LESION PROGRESSION||||LOG10 CFU/ML|ISD||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|SIBLING|NEUROLOGIST 2|Y|3||39||SCREENING|1973-01-16||||1972-06-01||1964-06-28|1973-04-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|1||||||OVRLRESP|OVERALL RESPONSE||||DPM/100MG|ABSENT MORPHOLOGIC RESPONSE||AMU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|4||88||INDUCTION TREATMENT|1967-11-03||||1962-10-09||1963-06-29|1960-12-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|2||||||STRUSTAT|STEROID USE STATUS||||LINEAR FT*LB|CCR||OZ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|PARENT|ONCOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1960-03-26||||1969-07-02||1965-04-18|1970-02-18||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MASK|SMD||KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|5||7||BLINDED TREATMENT|1961-03-11||||1960-02-07||1960-05-20|1961-11-25||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|111541DB-D863-4C68-9E62-B8741A62401C|2||||||ANATRESP|ANATOMIC RESPONSE||||DISK|MORPHOLOGIC CR||DPM/100MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|GUARDIAN|NEUROLOGIST|N|5||7||INDUCTION TREATMENT|1961-06-13||||1961-07-21||1972-10-15|1962-09-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||LIVRRESP|LIVER RESPONSE||||UMOL/MIN|NE||TAMPON|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|FAMILY MEMBER|PATHOLOGIST|NA|1||38||FOLLOW-UP|1971-04-27||||1971-06-14||1960-08-31|1962-07-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KPA|NON-CR/NON-PD||ML/CM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|CHILD|ONCOLOGIST 2|N|1||38||FOLLOW-UP|1961-05-13||||1969-07-07||1970-06-10|1967-08-10||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||METSIND|METASTATIC INDICATOR||||PMOL/DAY|VGPR||BREATHS/30S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|VENDOR|CLINICAL PATHOLOGIST|Y|2||58||OBSERVATION|1963-12-22||||1965-09-27||1964-07-08|1961-10-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||METBRESP|METABOLIC RESPONSE||||SPRAY|PD||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|2||58||RUN-IN|1966-10-10||||1963-08-15||1960-01-16|1966-02-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||NEWLPROG|NEW LESION PROGRESSION||||MM3/MM2/YEAR|UNEQUIVOCAL||U/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|CAREGIVER|MICROSCOPIST|N|3||39||INDUCTION TREATMENT|1960-12-20||||1968-01-06||1972-02-16|1963-04-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/DAY|PR-CT||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|3||39||FOLLOW-UP|1973-07-03||||1965-12-15||1972-05-17|1972-01-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ATM|NON-PD||NMOL BCE/L|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|SPOUSE|DERMATOLOGIST|U|4||88||FOLLOW-UP|1966-01-03||||1970-06-05||1970-11-13|1960-10-28||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KG/CM2|NED||MOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1966-03-26||||1972-09-10||1962-06-22|1972-03-12||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||ANATRESP|ANATOMIC RESPONSE||||WATT|PD FROM PR||L/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|5||7||WASHOUT|1965-10-13||||1964-01-30||1969-07-16|1973-03-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||CLINRESP|CLINICAL RESPONSE||||CY/CM|PDU||LENS|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|GUARDIAN|OTOLARYNGOLOGIST|U|5||7||SCREENING|1972-01-15||||1963-11-09||1966-11-16|1970-03-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||MOLRESP|MOLECULAR RESPONSE||||UMOL/DL|FAVORABLE RESPONSE||/7.5 ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|FAMILY MEMBER|READER 2|NA|1||38||INDUCTION TREATMENT|1962-05-31||||1960-03-01||1972-01-17|1966-10-30||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||BESTRESP|BEST OVERALL RESPONSE||||PPTH|CR||M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|U|1||38||SCREENING|1960-06-14||||1968-06-02||1973-07-25|1964-10-22||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/DL|INDETERMINATE RESPONSE||IU/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|FRIEND|PATHOLOGIST|Y|2||58||FOLLOW-UP|1971-01-25||||1973-01-07||1970-11-24|1965-06-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||NEWLPROG|NEW LESION PROGRESSION||||LOG10 CFU/G|PD FROM PR||NU/CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|CHILD|ADJUDICATOR 3|NA|2||58||BASELINE|1971-02-25||||1968-09-07||1962-07-03|1970-07-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||YD|MOLECULAR MAJOR RESPONSE||MG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|DOMESTIC PARTNER|ONCOLOGIST 1|NA|3||39||SCREENING|1965-12-31||||1971-11-07||1966-08-11|1968-04-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||STRUSTAT|STEROID USE STATUS||||IMPLANT|ABSENT MORPHOLOGIC RESPONSE||MASK|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|SPOUSE|ONCOLOGIST 2|NA|3||39||WASHOUT|1963-06-24||||1969-02-21||1973-08-16|1967-08-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||CYTORESP|CYTOGENETIC RESPONSE||||LINEAR FT*LB|NE||G/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|ADJUDICATOR|RATER|NA|4||88||SCREENING|1963-10-23||||1972-07-06||1967-11-09|1961-07-20||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/KG/DAY|HI-E||G/CAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|PARENT|UROLOGIST|N|4||88||TREATMENT|1964-07-11||||1968-01-31||1972-09-16|1970-11-04||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||SPLNRESP|SPLEEN RESPONSE||||U/M2|PD FROM PR||SV|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|INVESTIGATOR|RADIOLOGIST 1|U|5||7||OBSERVATION|1962-07-02||||1963-09-28||1968-07-02|1970-04-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/BEAT|PSEUDOPROGRESSION||10^7/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|5||7||SCREENING|1960-08-20||||1973-05-31||1969-10-27|1973-01-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||METSIND|METASTATIC INDICATOR||||KG|RELAPSED DISEASE FROM CR OR PR||IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|READER 2|U|1||38||BLINDED TREATMENT|1963-01-22||||1973-01-21||1964-08-24|1966-03-31||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||STRUSTAT|STEROID USE STATUS||||MONTHS|SD-CT||/MS|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|DOMESTIC PARTNER|ADJUDICATOR|NA|1||38||FOLLOW-UP|1965-02-17||||1961-04-18||1967-06-19|1969-05-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/MG|SD-CT||LOG10 TCID 50/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|2||58||FOLLOW-UP|1966-04-05||||1965-07-08||1971-07-13|1969-08-03||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/M2/DAY|MORPHOLOGIC CR||ML/100G/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|SIGNIFICANT OTHER|ADJUDICATOR|N|2||58||WASHOUT|1963-10-25||||1968-12-17||1969-03-16|1966-03-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||MOLRESP|MOLECULAR RESPONSE||||PL|HI-E||BOX|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|CAREGIVER|RATER|Y|3||39||BLINDED TREATMENT|1972-05-02||||1973-08-23||1971-01-15|1968-10-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||OVRLRESP|OVERALL RESPONSE||||ML/S|NON-QUANTIFIABLE MRD POSITIVITY||CMH2O*S/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|FAMILY MEMBER|RATER 1|N|3||39||OPEN LABEL TREATMENT|1963-01-29||||1972-01-25||1966-01-17|1972-07-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CAPFUL|PSEUDORESPONSE||ML/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|4||88||FOLLOW-UP|1961-04-04||||1964-01-10||1968-07-04|1971-06-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||TRGRESP|TARGET RESPONSE||||UG/M2/MIN|UNFAVORABLE RESPONSE||POINT|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|PARENT|READER 1|U|4||88||BLINDED TREATMENT|1972-07-14||||1971-02-12||1960-06-15|1970-07-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||METBRESP|METABOLIC RESPONSE||||UG/DOSE|NON-ICR/NON-IUPD||10^6 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|5||7||SCREENING|1964-03-12||||1964-07-10||1962-12-10|1970-08-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||TRGRESP|TARGET RESPONSE||||UG/MIN|SD-CT||ML/MIN/MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|PROXY|MICROSCOPIST 1|NA|5||7||BLINDED TREATMENT|1961-07-03||||1972-09-30||1964-02-05|1962-06-22||AFTER||DURING|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NMOL/KG/DAY|PR-CT||MG/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|GUARDIAN|MICROSCOPIST 1|NA|1||38||TREATMENT|1963-05-14||||1969-03-14||1969-06-16|1969-10-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||METBRESP|METABOLIC RESPONSE||||PIXELS/CM|PR-CT||MG/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|FRIEND|RATER 2|Y|1||38||LONG-TERM FOLLOW-UP|1962-09-03||||1969-10-23||1967-10-22|1965-09-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^6/L|PR WITH LYMPHOCYTOSIS||CMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|PROXY|MICROSCOPIST 2|NA|2||58||BLINDED TREATMENT|1972-09-10||||1972-02-22||1970-06-21|1965-01-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||SPLNRESP|SPLEEN RESPONSE||||MU|SD-CT||GRAIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|STUDY SUBJECT|RATER 1|Y|2||58||BASELINE|1968-01-30||||1964-06-07||1962-07-06|1964-05-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/MIN|CHR||CONTAINER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|3||39||OPEN LABEL TREATMENT|1969-03-12||||1961-08-01||1965-06-09|1969-01-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MEQ/DAY|CYTOGENETIC NO RESPONSE||WAFER|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|Y|3||39||RUN-IN|1964-03-21||||1963-02-23||1971-06-08|1966-01-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MV2/HZ|TREATMENT FAILURE||CI/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|PARENT|OPTOMETRIST|N|4||88||BLINDED TREATMENT|1964-10-15||||1964-04-27||1970-09-07|1971-02-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||NEWLIND|NEW LESION INDICATOR||||10^6 ORGANISMS|SD||USP U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|INVESTIGATOR|MICROSCOPIST 2|NA|4||88||OBSERVATION|1963-08-13||||1965-11-23||1967-02-02|1973-02-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CYLINDER|RELAPSED DISEASE FROM CR OR PR||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|5||7||INDUCTION TREATMENT|1967-02-22||||1962-12-13||1963-11-17|1961-01-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||BESTRESP|BEST OVERALL RESPONSE||||IU/KG|NE||UMOL/H/MMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|INVESTIGATOR|MICROSCOPIST 3|N|5||7||FOLLOW-UP|1963-09-20||||1966-03-06||1966-02-03|1965-02-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PL|CYTOGENETIC CR||CUP|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|1||38||LONG-TERM FOLLOW-UP|1967-11-19||||1960-09-30||1967-03-26|1970-05-11||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MM2|MRD NEGATIVITY||MILE|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|VENDOR|ONCOLOGIST 2|Y|1||38||WASHOUT|1971-01-24||||1971-07-05||1968-12-04|1967-01-31||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MIU/L|NED||MESF|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1968-06-23||||1965-07-31||1966-07-17|1961-08-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||ANATRESP|ANATOMIC RESPONSE||||MOL/MOL|SD||MMHG*MIN/L|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|SPOUSE|PHYSIOTHERAPIST|Y|2||58||BLINDED TREATMENT|1968-04-22||||1961-01-14||1962-09-06|1960-09-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||NEWLIND|NEW LESION INDICATOR||||MMOL/G|PD FROM PR||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|FRIEND|RADIOLOGIST|U|3||39||SCREENING|1973-09-08||||1968-11-01||1970-07-09|1972-05-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||SPLNRESP|SPLEEN RESPONSE||||MOSM/KG|MRD PERSISTENCE||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|3||39||WASHOUT|1972-03-26||||1968-04-12||1970-02-03|1961-01-02||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||LIVRRESP|LIVER RESPONSE||||FFU|PSEUDOPROGRESSION||/HPF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|4||88||CONTINUATION TREATMENT|1969-07-19||||1962-09-09||1961-12-23|1971-12-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||METBRESP|METABOLIC RESPONSE||||ML/KG|CR-CT||GTT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|4||88||WASHOUT|1968-07-09||||1963-03-25||1962-11-22|1960-08-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||BESTRESP|BEST OVERALL RESPONSE||||OZ|NON-QUANTIFIABLE MRD POSITIVITY||U/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|PARENT|FORENSIC PATHOLOGIST|NA|5||7||TREATMENT|1966-05-20||||1970-10-10||1966-03-14|1964-12-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PA|IMPROVED||LOG10 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1969-08-24||||1972-06-13||1968-12-10|1962-02-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/CM2|HI-N||CMH2O*S/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|1||38||RUN-IN|1971-09-09||||1968-03-03||1970-10-07|1973-02-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^11/L|HI-E||C|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|SIBLING|MICROSCOPIST 1|Y|1||38||BLINDED TREATMENT|1972-12-25||||1966-01-18||1967-12-11|1965-09-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||NTRGRESP|NON-TARGET RESPONSE||||MG/ANIMAL|PARTIAL MORPHOLOGIC RESPONSE||M3|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|PARENT|NEUROLOGIST 2|N|2||58||WASHOUT|1964-10-24||||1971-03-28||1964-12-18|1965-07-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BOTTLE|VGPR||NEBULE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|PARENT|ENDOCRINOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1962-03-05||||1967-04-24||1968-12-18|1970-09-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||LIVRRESP|LIVER RESPONSE||||COULOMB|MRD PERSISTENCE||10^7 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CLINICAL STUDY SPONSOR|UROLOGIST|U|3||39||CONTINUATION TREATMENT|1968-01-04||||1966-05-14||1960-05-23|1967-08-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||BONERESP|BONE RESPONSE||||G/ANIMAL/WK|INCREASED||DNA COPIES/UG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|CAREGIVER|READER 1|NA|3||39||CONTINUATION TREATMENT|1961-01-04||||1966-01-26||1972-12-14|1972-12-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LX|NON-CR/NON-PD||MN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|SIBLING|MICROSCOPIST 3|Y|4||88||TREATMENT|1972-12-04||||1969-04-25||1968-08-08|1966-10-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||MOLRESP|MOLECULAR RESPONSE||||MOSM/L|FAVORABLE RESPONSE||BQ/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1963-12-27||||1962-07-15||1969-11-22|1960-03-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DDU|RELAPSED DISEASE FROM CR OR PR||IN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|PARENT|PATHOLOGIST 2|NA|5||7||SCREENING|1960-03-27||||1961-10-13||1967-11-05|1968-11-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||CLINRESP|CLINICAL RESPONSE||||LINEAR FT*LB|NPR||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|5||7||WASHOUT|1964-11-09||||1962-12-28||1960-03-18|1971-11-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||BESTRESP|BEST OVERALL RESPONSE||||PELLET|CHR||10^10/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|INVESTIGATOR|UROLOGIST|N|1||38||OPEN LABEL TREATMENT|1970-05-06||||1973-04-17||1960-03-16|1965-09-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||METSIND|METASTATIC INDICATOR||||ML/ANIMAL|CR-CT||IU/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|1||38||TREATMENT|1971-12-10||||1962-11-20||1967-12-29|1972-09-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||CLINRESP|CLINICAL RESPONSE||||MG/M2|MAJOR PATHOLOGIC RESPONSE||NMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1962-08-05||||1969-09-07||1967-01-29|1963-10-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||METBRESP|METABOLIC RESPONSE||||UG/ANIMAL|CYTOGENETIC MINIMAL RESPONSE||USP U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST|U|2||58||OBSERVATION|1969-10-07||||1966-07-11||1968-08-31|1966-11-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||CLINRESP|CLINICAL RESPONSE||||10^6 ORGANISMS|PR||ML/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST|Y|3||39||BLINDED TREATMENT|1971-06-12||||1970-04-13||1961-05-29|1973-07-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CS|COMPLETE MRD RESPONSE||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||BASELINE|1960-07-25||||1963-08-10||1967-04-20|1963-11-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 IU|NON-PD||%|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|DOMESTIC PARTNER|ONCOLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1971-08-06||||1965-10-19||1967-12-29|1966-11-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||TRGRESP|TARGET RESPONSE||||ARBITRARY U|MOLECULAR MAJOR RESPONSE||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|4||88||TREATMENT|1969-05-07||||1963-12-04||1973-06-24|1967-08-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/MG|HI-P||ML/(MIN*100ML)|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|U|FAMILY MEMBER|RADIOLOGIST 1|N|5||7||OBSERVATION|1961-03-19||||1960-10-03||1966-04-22|1961-03-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FOZ_BR|QUANTIFIABLE MRD POSITIVITY||10^6 DNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|5||7||SCREENING|1971-05-04||||1967-01-15||1971-09-27|1972-06-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||NEWLIND|NEW LESION INDICATOR||||CD|SCR||VG/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|1||38||SCREENING|1973-08-01||||1964-01-02||1960-11-09|1972-02-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MPL U|CA125 50% RESPONSE||MG2/DL2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|STUDY SUBJECT|UROLOGIST|Y|1||38||BASELINE|1970-10-20||||1973-05-15||1968-01-07|1973-04-29||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||CLINRESP|CLINICAL RESPONSE||||PACK YEAR|NED||MMAL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-12-05||||1965-10-12||1962-04-28|1961-10-30||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CG|IUPD||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|FAMILY MEMBER|UROLOGIST|U|2||58||CONTINUATION TREATMENT|1961-05-11||||1961-02-21||1968-06-14|1963-12-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/S|PCR||KDA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|SPOUSE|RATER 2|U|3||39||WASHOUT|1961-09-08||||1966-11-09||1973-01-15|1963-03-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PELLET|STABLE||ML/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|CHILD|PEDIATRIC NEUROLOGIST|N|3||39||TREATMENT|1973-07-21||||1968-03-23||1970-07-17|1960-09-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ANTI-XA IU/ML|NED||ML/CM H2O|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|4||88||OBSERVATION|1962-02-26||||1969-03-27||1973-03-24|1969-02-24||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||METBRESP|METABOLIC RESPONSE||||PATCH|CYTOGENETIC PR||KEV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|FRIEND|ADJUDICATOR|Y|4||88||BASELINE|1968-02-15||||1967-11-24||1962-05-09|1968-01-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL/MIN/KPA/L|COMPLETE MRD RESPONSE||CAPLET|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|DOMESTIC PARTNER|ADJUDICATOR|Y|5||7||RUN-IN|1972-03-11||||1962-07-18||1967-08-24|1961-09-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/ANIMAL|CYTOGENETIC PR||FMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|DOMESTIC PARTNER|RADIOLOGIST 1|Y|5||7||BLINDED TREATMENT|1971-02-10||||1971-09-25||1969-10-31|1973-04-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/DAY|OPTIMAL MORPHOLOGIC RESPONSE||PSEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|FRIEND|OPHTHALMOLOGIST|NA|1||38||OBSERVATION|1965-03-06||||1960-02-17||1969-06-16|1968-09-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||MOLRESP|MOLECULAR RESPONSE||||BAG|MRD PERSISTENCE||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|SIBLING|MICROSCOPIST 3|N|1||38||FOLLOW-UP|1972-05-10||||1963-09-13||1972-06-18|1968-02-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/MIN|EQUIVOCAL||OSM|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|2||58||WASHOUT|1966-11-25||||1972-04-05||1962-07-27|1967-02-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||METSIND|METASTATIC INDICATOR||||VG/KG|CR-CT||10^6 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|2||58||TREATMENT|1971-07-13||||1969-11-26||1971-07-28|1963-07-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||AMPULE|INCREASED||KIU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|STUDY SUBJECT|NEUROLOGIST|N|3||39||OBSERVATION|1970-06-20||||1973-06-21||1969-11-10|1968-09-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NL|MINOR PATHOLOGIC RESPONSE||STEPS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|SIBLING|DERMATOLOGIST|N|3||39||BASELINE|1961-11-14||||1972-07-26||1962-02-11|1970-12-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||NEWLIND|NEW LESION INDICATOR||||MOL/DAY|PR||DB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|NA|4||88||INDUCTION TREATMENT|1967-06-07||||1968-07-05||1963-09-22|1963-02-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 CFU|MRD RELAPSE||BP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|FRIEND|RATER 1|NA|4||88||FOLLOW-UP|1967-01-04||||1967-10-27||1970-02-08|1968-07-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||BESTRESP|BEST OVERALL RESPONSE||||HZ|HI-P||DPM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|SIGNIFICANT OTHER|READER 2|N|5||7||TREATMENT|1968-11-21||||1960-04-09||1967-10-12|1964-12-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MIN*MG/ML|TREATMENT FAILURE||EJACULATE U|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|FRIEND|HEMATOLOGIST|NA|5||7||WASHOUT|1962-04-30||||1973-04-05||1966-06-22|1961-08-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KM|FAVORABLE RESPONSE||IU/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|1||38||BLINDED TREATMENT|1968-09-26||||1968-04-29||1966-03-21|1964-05-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KUSP|MRD NEGATIVITY||UMOL/KG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|RATER 2|N|1||38||BASELINE|1963-01-31||||1972-06-19||1961-10-17|1965-02-23||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/DAY|PD||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|2||58||BLINDED TREATMENT|1964-02-11||||1967-01-29||1972-10-04|1965-08-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||METBRESP|METABOLIC RESPONSE||||L|PARTIAL MORPHOLOGIC RESPONSE||EVENTS|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|VENDOR|ADJUDICATOR|Y|2||58||WASHOUT|1963-07-11||||1961-06-30||1960-08-20|1971-12-17||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PATCH|NR||UIU/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|3||39||TREATMENT|1969-01-18||||1969-10-22||1963-04-15|1964-11-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/M2/H|MAJOR PATHOLOGIC RESPONSE||PMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|3||39||BASELINE|1965-11-27||||1965-03-07||1968-01-07|1964-10-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/G/H|PCR||BQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|GUARDIAN|MICROSCOPIST|Y|4||88||RUN-IN|1965-10-17||||1967-06-07||1966-08-08|1969-10-03||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||CYTORESP|CYTOGENETIC RESPONSE||||APL U/ML|MORPHOLOGIC CR||MOL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|4||88||BLINDED TREATMENT|1973-03-21||||1970-11-08||1962-03-31|1973-08-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/ML|RELAPSED DISEASE||UMOL/L/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|DOMESTIC PARTNER|ONCOLOGIST 1|Y|5||7||WASHOUT|1968-11-24||||1967-04-01||1965-04-08|1964-09-28||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PFU/ML|MRD NEGATIVITY||BREATHS/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|FRIEND|NEUROLOGIST 1|U|5||7||RUN-IN|1962-01-15||||1961-12-10||1961-05-31|1964-04-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||STRUSTAT|STEROID USE STATUS||||ELISA UNIT|NOT ALL EVALUATED||MPS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|1||38||OPEN LABEL TREATMENT|1973-05-27||||1970-09-05||1967-08-03|1963-03-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/L FEU|MORPHOLOGIC CRI||APL U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|1||38||WASHOUT|1969-04-10||||1973-04-08||1969-06-16|1968-08-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||METBRESP|METABOLIC RESPONSE||||10^6/HPF|CHR||UG/KG/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|2||58||OBSERVATION|1973-07-22||||1972-03-26||1963-08-15|1970-12-10||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BEAM BREAKS|PD FROM PR||ML/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|ADJUDICATION COMMITTEE|RATER 2|N|2||58||LONG-TERM FOLLOW-UP|1968-05-14||||1960-07-24||1972-10-28|1971-11-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|MORPHOLOGIC CRI||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|INVESTIGATOR|ENDOCRINOLOGIST|Y|3||39||INDUCTION TREATMENT|1973-06-05||||1972-10-04||1968-04-19|1972-01-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PSEC|HI-P||MG/G/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||SCREENING|1968-10-13||||1970-10-04||1964-06-04|1973-07-11||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||LIVRRESP|LIVER RESPONSE||||NMOL|ABSENT MORPHOLOGIC RESPONSE||/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|SIGNIFICANT OTHER|ONCOLOGIST 2|Y|4||88||FOLLOW-UP|1960-09-19||||1966-05-24||1962-10-02|1966-06-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BQ/KG|DECREASED||EU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|ADJUDICATOR|RATER|Y|4||88||RUN-IN|1960-01-16||||1962-05-18||1963-02-06|1971-04-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 CFU|PDU||GBQ/UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|VENDOR|RADIOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1971-09-28||||1963-08-21||1969-01-11|1967-02-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/KG|VGPR||HZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|SIBLING|NEUROLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1960-02-10||||1973-05-17||1962-11-08|1969-02-11||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||POINT|PSA PROGRESSION||BQ/UL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|VENDOR|ONCOLOGIST 2|Y|1||38||SCREENING|1969-04-01||||1969-02-18||1960-10-08|1971-02-06||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BREATHS/MIN|RELAPSED DISEASE FROM CR||PIPE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|FAMILY MEMBER|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1963-03-22||||1969-03-23||1969-07-20|1973-03-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||WATT|ICPD||IU/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|2||58||OBSERVATION|1964-10-23||||1961-02-08||1960-07-15|1973-01-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||NEWLIND|NEW LESION INDICATOR||||NMOL/ML/MIN|CA125 75% RESPONSE||AMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|INTERVIEWER|RATER 2|N|2||58||BASELINE|1966-03-19||||1968-08-26||1966-11-29|1969-12-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U.CARR|MAJOR PATHOLOGIC RESPONSE||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1972-09-06||||1973-02-06||1961-05-10|1964-10-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||APL U/ML|MOLECULAR CR||ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|SIBLING|RADIOLOGIST 2|NA|3||39||RUN-IN|1969-04-29||||1962-10-28||1965-05-05|1965-07-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||STRUSTAT|STEROID USE STATUS||||VP/DOSE|PR WITH LYMPHOCYTOSIS||LOG10 ELISA UNIT/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|4||88||WASHOUT|1966-11-17||||1963-01-02||1969-10-08|1970-07-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CFU/G|SD||KA_U/DL|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|FRIEND|NEUROLOGIST 2|U|4||88||TREATMENT|1972-11-01||||1962-05-03||1971-06-03|1968-11-01||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^4/HPF|FAVORABLE RESPONSE||M/SEC2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|INVESTIGATOR|RATER 2|NA|5||7||BLINDED TREATMENT|1965-06-02||||1960-07-15||1971-11-27|1961-05-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||METSIND|METASTATIC INDICATOR||||MOL/DAY|NON-QUANTIFIABLE MRD POSITIVITY||NMOL/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|U|5||7||WASHOUT|1964-07-14||||1962-10-26||1961-04-15|1963-09-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/10^12 RBC|CR-CT||NMOL/L/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|SIGNIFICANT OTHER|HEMATOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1960-09-15||||1967-06-04||1966-09-12|1965-04-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/40 HPFS|CA125 50% RESPONSE||SIEMENS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|1||38||OBSERVATION|1972-11-29||||1972-05-31||1963-05-01|1968-10-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TRACE|RELAPSED DISEASE FROM CR||ML/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|FAMILY MEMBER|ENDOCRINOLOGIST|U|2||58||CONTINUATION TREATMENT|1969-08-28||||1961-03-25||1963-01-25|1964-07-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MV*MIN|MINOR PATHOLOGIC RESPONSE||DRAM|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|2||58||OBSERVATION|1967-11-21||||1965-02-27||1967-07-02|1965-08-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ROENTGEN|NON-PD||UM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||BLINDED TREATMENT|1967-09-06||||1970-06-19||1969-02-13|1970-06-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||ANATRESP|ANATOMIC RESPONSE||||UG/KG/H|PD-CT||L/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|FRIEND|NEUROLOGIST 1|U|3||39||INDUCTION TREATMENT|1972-06-16||||1970-10-28||1965-06-27|1972-07-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||POUCH|CYTOGENETIC NO RESPONSE||MM/SEC|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|4||88||SCREENING|1971-11-20||||1963-04-04||1962-12-30|1973-05-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||BESTRESP|BEST OVERALL RESPONSE||||MOL/ML|SD||10^3 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|4||88||FOLLOW-UP|1965-07-02||||1972-08-04||1972-11-20|1968-04-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PFU|ICPD||BQ|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|5||7||CONTINUATION TREATMENT|1969-09-16||||1963-08-04||1971-07-22|1973-01-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||METSIND|METASTATIC INDICATOR||||IU/KG|PD-CT||UEQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|5||7||BLINDED TREATMENT|1972-04-14||||1962-07-23||1960-12-23|1969-02-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MJOULE/CM2|CCR||SBE/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|GUARDIAN|ADJUDICATOR 1|NA|1||38||CONTINUATION TREATMENT|1961-09-10||||1965-06-22||1970-08-17|1970-05-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||TMRESP|TUMOR MARKER RESPONSE||||UL|PCR||L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|ADJUDICATOR|PHYSIOTHERAPIST|NA|1||38||FOLLOW-UP|1967-11-17||||1969-03-21||1972-10-12|1962-04-25||DURING||DURING|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TUBERCULIN UNIT|INCREASED||H/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|SIGNIFICANT OTHER|OPTOMETRIST|N|2||58||SCREENING|1970-09-03||||1967-04-03||1961-12-09|1973-03-05||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||BESTRESP|BEST OVERALL RESPONSE||||MOSM|CYTOGENETIC CR||PMOL/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|STUDY SUBJECT|PATHOLOGIST|N|2||58||RUN-IN|1969-11-15||||1963-04-03||1968-12-21|1966-01-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||OVRLRESP|OVERALL RESPONSE||||UG/L DDU|MR||UG/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|INTERVIEWER|PATHOLOGIST|NA|3||39||BLINDED TREATMENT|1966-05-24||||1973-01-05||1972-02-23|1971-01-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/M2/DAY|MOLECULAR CR||IU/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|STUDY SUBJECT|PHYSIOTHERAPIST|NA|3||39||RUN-IN|1969-07-10||||1968-03-12||1972-03-13|1970-04-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||MOLRESP|MOLECULAR RESPONSE||||/LPF|CR-CT||CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|INVESTIGATOR|RATER 1|N|4||88||FOLLOW-UP|1963-05-20||||1960-01-25||1961-12-10|1971-10-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||METSIND|METASTATIC INDICATOR||||10^5/L|MORPHOLOGIC LEUKEMIA-FREE STATE||NMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|CAREGIVER|PATHOLOGIST|N|4||88||OPEN LABEL TREATMENT|1970-04-18||||1963-09-13||1970-05-23|1963-08-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||MOLRESP|MOLECULAR RESPONSE||||MET|RELAPSED DISEASE FROM CR||VG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|5||7||RUN-IN|1968-03-21||||1969-06-15||1968-09-05|1971-07-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||FOZ_BR|IMMUNOPHENOTYPIC CR||ABSORBANCE U/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|GUARDIAN|PHYSIOTHERAPIST|Y|5||7||INDUCTION TREATMENT|1960-10-23||||1961-06-29||1960-02-26|1965-07-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ROENTGEN|ICPD||U/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||RUN-IN|1972-04-07||||1969-03-15||1964-01-12|1961-07-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PUFF|MRD NEGATIVITY||MOL/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||SCREENING|1963-08-17||||1971-02-15||1960-05-10|1962-04-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||LIVRRESP|LIVER RESPONSE||||SCM|PMD||CYCLE/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|PROXY|ADJUDICATOR 1|NA|2||58||LONG-TERM FOLLOW-UP|1972-05-13||||1963-11-01||1972-06-16|1966-09-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||NEWLIND|NEW LESION INDICATOR||||RING|MCR||/200 HPFS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|2||58||SCREENING|1967-02-21||||1966-11-11||1963-06-23|1964-02-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DYN|NE||KUSP|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|SIBLING|RADIOLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1968-01-18||||1969-11-02||1964-02-29|1972-12-03||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KBQ|STABLE||MG/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|3||39||BLINDED TREATMENT|1963-09-28||||1969-06-14||1965-06-18|1961-01-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||BONERESP|BONE RESPONSE||||EJACULATE U|NOT ALL EVALUATED||10^9/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|PROXY|CLINICAL PATHOLOGIST|U|4||88||OPEN LABEL TREATMENT|1965-02-14||||1971-02-05||1969-01-01|1961-06-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||TRGRESP|TARGET RESPONSE||||SCOOPFUL|PSEUDORESPONSE||FT3|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|READER|NA|4||88||TREATMENT|1961-05-15||||1961-09-09||1962-05-06|1964-04-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||LOG10 CFU/G|CA125 50% RESPONSE||PSEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|STUDY SUBJECT|INTERNIST|Y|5||7||BLINDED TREATMENT|1968-08-29||||1973-04-03||1966-04-14|1960-08-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DDU|PSEUDOPROGRESSION||KBQ/UL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|INTERVIEWER|ONCOLOGIST 1|Y|5||7||BLINDED TREATMENT|1961-11-07||||1972-01-16||1961-11-05|1970-09-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||ANATRESP|ANATOMIC RESPONSE||||MDFI|SD||PRESSOR UNITS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1962-06-17||||1966-09-18||1971-05-01|1964-04-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6 COPIES/ML|COMPLETE MRD RESPONSE||MG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|VENDOR|UROLOGIST|U|1||38||TREATMENT|1968-04-21||||1972-03-07||1965-05-07|1960-01-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||ANATRESP|ANATOMIC RESPONSE||||PIXELS/CM|DECREASED||/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|2||58||BLINDED TREATMENT|1965-05-20||||1970-04-28||1966-10-29|1964-01-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CM|VGPR||BQ/L|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|U|2||58||RUN-IN|1970-05-01||||1962-05-29||1961-11-19|1961-01-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||NEWLIND|NEW LESION INDICATOR||||10^4 CFU/ML|QUANTIFIABLE MRD POSITIVITY||MU/G|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|FAMILY MEMBER|OTOLARYNGOLOGIST|Y|3||39||OBSERVATION|1965-04-20||||1960-03-26||1971-02-27|1970-04-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PSEC|PD/RELAPSE AFTER HI||MEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|Y|3||39||OPEN LABEL TREATMENT|1969-05-01||||1965-04-25||1969-11-02|1973-03-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||TRGRESP|TARGET RESPONSE||||MIN*MG/ML|MRD PERSISTENCE||GBQ/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|STUDY SUBJECT|NEUROLOGIST|U|4||88||TREATMENT|1971-06-23||||1969-09-20||1962-01-26|1966-05-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||COULOMB|PR-CT||10^7/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|CLINICAL STUDY SPONSOR|READER 1|Y|4||88||CONTINUATION TREATMENT|1960-05-26||||1964-04-16||1968-12-24|1972-03-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||LIVRRESP|LIVER RESPONSE||||TORR|SD-CT||UCI/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|5||7||OBSERVATION|1961-05-26||||1967-12-04||1965-08-31|1965-12-23||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ATM|PARTIAL MORPHOLOGIC RESPONSE||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|5||7||OPEN LABEL TREATMENT|1966-02-26||||1966-01-22||1971-01-20|1968-11-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||BESTRESP|BEST OVERALL RESPONSE||||NKAT/G HB|MORPHOLOGIC CR||MOL/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|SPOUSE|HEMATOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1968-02-15||||1966-12-14||1968-01-18|1968-01-22||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KG/CM|ICPD||QUANTITY SUFFICIENT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|INVESTIGATOR|INTERNIST|NA|1||38||OBSERVATION|1967-01-30||||1969-10-20||1966-12-31|1960-03-23||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||BONERESP|BONE RESPONSE||||ENZYME U/G HB|PSEUDORESPONSE||CD*S/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|2||58||SCREENING|1962-09-13||||1964-01-02||1962-08-16|1964-03-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/DAY|CMR||KCAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|STUDY SUBJECT|RADIOLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1971-11-25||||1973-04-24||1960-02-11|1960-06-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ENZYME U/M2|MRD PERSISTENCE||PPTR|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|STUDY SUBJECT|NEUROLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1973-05-07||||1972-03-23||1973-02-24|1967-10-19||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CI|IUPD||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|SPOUSE|HEMATOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1961-12-17||||1968-08-03||1963-03-13|1966-01-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||LIVRRESP|LIVER RESPONSE||||SEC|PSEUDOPROGRESSION||STEPS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|4||88||LONG-TERM FOLLOW-UP|1963-03-04||||1965-08-24||1970-07-05|1970-04-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||TRGRESP|TARGET RESPONSE||||UMOL/L/SEC|MORPHOLOGIC LEUKEMIA-FREE STATE||/MBP|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|PARENT|PATHOLOGIST 1|NA|4||88||RUN-IN|1964-05-22||||1966-03-26||1963-10-18|1968-08-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||METBRESP|METABOLIC RESPONSE||||DPM/ML|CR-CT||MMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|CAREGIVER|MICROSCOPIST 1|N|5||7||LONG-TERM FOLLOW-UP|1960-07-01||||1968-10-27||1969-06-07|1962-02-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||TMRESP|TUMOR MARKER RESPONSE||||KBQ/UL|CYTOGENETIC CR||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|PROXY|RATER 1|NA|5||7||INDUCTION TREATMENT|1972-04-19||||1968-11-25||1962-06-07|1969-01-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||POINT|RELAPSED DISEASE||AMP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|ADJUDICATION COMMITTEE|ADJUDICATOR|Y|1||38||RUN-IN|1966-11-21||||1960-02-16||1972-04-14|1966-08-13||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||ANATRESP|ANATOMIC RESPONSE||||POUCH|PD FROM PR||KAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|N|1||38||SCREENING|1969-09-12||||1969-08-19||1966-08-08|1967-11-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^7/L|COMPLETE MRD RESPONSE||GY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|2||58||TREATMENT|1961-12-27||||1965-04-30||1966-06-21|1968-05-15||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||OVRLRESP|OVERALL RESPONSE||||ML/MMHG/MIN/L|PD||MOSM/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|SIBLING|PATHOLOGIST 1|U|2||58||BLINDED TREATMENT|1968-08-03||||1973-01-12||1970-09-16|1973-09-06||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||NTRGRESP|NON-TARGET RESPONSE||||IMPLANT|STABLE||/MONTH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|VENDOR|CLINICAL PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1970-06-01||||1970-11-18||1962-02-24|1972-07-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||STRUSTAT|STEROID USE STATUS||||IU/DAY|PDU||/10^3|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|CHILD|READER 2|Y|3||39||OBSERVATION|1965-09-06||||1967-05-20||1963-02-09|1963-06-01||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||RDIORESP|RADIOLOGIC RESPONSE||||GENEQ|MINOR PATHOLOGIC RESPONSE||SHOCK WAVE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|PARENT|PEDIATRIC NEUROLOGIST|Y|4||88||TREATMENT|1971-12-27||||1966-06-12||1967-09-11|1964-06-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SCOOPFUL|IPR||G/U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|SPOUSE|MICROSCOPIST 1|N|4||88||OBSERVATION|1970-03-31||||1966-07-22||1972-06-22|1963-11-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||STRUSTAT|STEROID USE STATUS||||ATM|ICR||MEQ/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|DOMESTIC PARTNER|ADJUDICATOR 3|N|5||7||FOLLOW-UP|1964-01-27||||1972-03-18||1965-06-23|1970-09-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/L|MAJOR PATHOLOGIC RESPONSE||NKAT/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|5||7||OBSERVATION|1962-08-08||||1969-07-13||1963-05-01|1960-06-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||G/G|RELAPSED DISEASE FROM CR OR PR||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||TREATMENT|1968-04-14||||1972-10-23||1967-12-08|1963-11-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||OVRLRESP|OVERALL RESPONSE||||BQ/UL|MOLECULAR CR||PG/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|SIBLING|ADJUDICATOR 1|N|1||38||OBSERVATION|1971-08-11||||1969-08-21||1968-09-09|1961-04-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||CLINRESP|CLINICAL RESPONSE||||CL|MRD PERSISTENCE||TRANSDUCING UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|2||58||CONTINUATION TREATMENT|1971-08-28||||1967-07-22||1968-05-07|1972-12-09||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KCAL|MRD RELAPSE||VP/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|VENDOR|READER 2|N|2||58||FOLLOW-UP|1963-09-19||||1961-11-11||1970-08-15|1962-01-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PPM|ISD||H*%|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|ADJUDICATOR|READER 1|Y|3||39||OBSERVATION|1972-05-08||||1966-07-18||1961-10-16|1970-10-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CMHG|NON-CR/NON-PD||YEARS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|STUDY SUBJECT|READER 1|N|3||39||RUN-IN|1966-09-01||||1962-11-12||1971-01-31|1960-04-03||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||NTRGRESP|NON-TARGET RESPONSE||||MG/KG/MIN|PR WITH LYMPHOCYTOSIS||UG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|PARENT|RATER|Y|4||88||INDUCTION TREATMENT|1969-07-05||||1971-06-18||1965-12-12|1960-04-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||NEWLIND|NEW LESION INDICATOR||||10^3 DNA COPIES/ML|PD||ML/MIN/MMHG|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|SPOUSE|DERMATOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1964-06-02||||1972-01-12||1965-03-10|1967-06-24||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/MS|MORPHOLOGIC LEUKEMIA-FREE STATE||CP|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|5||7||FOLLOW-UP|1969-06-27||||1962-10-18||1965-11-04|1964-08-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||H/WK|CMR||MG/L FEU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1960-03-08||||1960-03-28||1966-01-22|1970-09-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||BONERESP|BONE RESPONSE||||10^3 DNA COPIES/ML|MOLECULAR CR||ML/CM|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|PROXY|MICROSCOPIST|Y|1||38||OPEN LABEL TREATMENT|1963-07-27||||1970-06-04||1969-12-18|1962-05-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^7 PFU|CA125 75% RESPONSE||G/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CAREGIVER|PATHOLOGIST 1|U|1||38||INDUCTION TREATMENT|1971-12-26||||1967-11-28||1973-08-12|1963-08-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||METSIND|METASTATIC INDICATOR||||UMOL/DAY|MRD RELAPSE||APL U|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FRIEND|NEUROLOGIST 2|U|2||58||OPEN LABEL TREATMENT|1970-11-05||||1973-03-28||1973-01-25|1972-12-21||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||BESTRESP|BEST OVERALL RESPONSE||||TABLET|NPR||MAC50|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|DOMESTIC PARTNER|READER 1|N|2||58||FOLLOW-UP|1966-05-02||||1966-03-25||1961-12-03|1972-04-29||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BQ/L|CMR||CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|SPOUSE|NEUROLOGIST 2|NA|3||39||BASELINE|1961-02-13||||1960-08-18||1973-06-09|1962-03-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||MOLRESP|MOLECULAR RESPONSE||||G/L|PCR||APL U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|CLINICAL STUDY SPONSOR|READER 1|NA|3||39||FOLLOW-UP|1960-12-02||||1973-05-20||1965-08-08|1971-07-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FRAMES/S|NR||POINT|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|STUDY SUBJECT|RADIOLOGIST 1|Y|4||88||SCREENING|1973-09-04||||1970-08-31||1964-02-10|1970-11-03||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||CLINRESP|CLINICAL RESPONSE||||KBQ/UL|CR||FT3|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|4||88||OBSERVATION|1972-03-13||||1972-07-17||1962-08-17|1971-06-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DISK|NED||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|VENDOR|ADJUDICATOR 2|NA|5||7||WASHOUT|1962-03-27||||1967-11-17||1967-05-01|1961-05-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||SPLNRESP|SPLEEN RESPONSE||||U/CL|PD||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|INTERVIEWER|OPHTHALMOLOGIST|N|5||7||OBSERVATION|1962-01-08||||1965-07-19||1960-02-14|1963-04-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||MOLRESP|MOLECULAR RESPONSE||||PATCH|MINOR PATHOLOGIC RESPONSE||USP U|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|SIBLING|NEUROLOGIST 1|NA|1||38||TREATMENT|1969-08-15||||1964-04-29||1967-11-09|1969-11-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||OVRLRESP|OVERALL RESPONSE||||CM/S|MORPHOLOGIC LEUKEMIA-FREE STATE||UMOL|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|CAREGIVER|RATER|Y|1||38||BLINDED TREATMENT|1972-02-02||||1962-08-05||1966-06-07|1961-12-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/MMOL|EQUIVOCAL||LOG10 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|STUDY SUBJECT|CLINICAL PATHOLOGIST|Y|2||58||OBSERVATION|1970-07-16||||1961-05-23||1970-02-24|1966-11-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||TMRESP|TUMOR MARKER RESPONSE||||MG/L|SD-CT||10^3 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||SCREENING|1964-09-26||||1968-01-21||1965-06-09|1968-01-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||SPLNRESP|SPLEEN RESPONSE||||LOG10 COPIES/ML|PD/RELAPSE AFTER HI||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|SIBLING|PATHOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1963-02-15||||1969-12-24||1962-03-13|1967-06-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||NEWLIND|NEW LESION INDICATOR||||/MM|NON-CR/NON-PD||UG/G/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|3||39||OBSERVATION|1973-06-18||||1964-12-23||1962-05-22|1966-03-01||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||NTRGRESP|NON-TARGET RESPONSE||||DYN|DISEASE TRANSFORMATION||UMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|4||88||RUN-IN|1963-05-29||||1967-08-11||1968-01-20|1963-02-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DPM|SCR||FARAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|SPOUSE|ADJUDICATOR 2|Y|4||88||RUN-IN|1967-03-12||||1960-07-23||1968-06-09|1963-07-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TITER|IPR||TSP EQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|ADJUDICATOR|READER|NA|5||7||WASHOUT|1966-07-19||||1962-03-08||1970-04-15|1965-09-26||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||LIVRRESP|LIVER RESPONSE||||OD UNIT|PR-CT||DPM/0.5 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|ADJUDICATOR|ADJUDICATOR 2|U|5||7||CONTINUATION TREATMENT|1962-01-07||||1970-03-04||1963-09-02|1961-02-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MPS U|NE||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|VENDOR|MICROSCOPIST 3|U|1||38||WASHOUT|1966-02-20||||1970-04-09||1965-12-23|1961-12-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/40 HPFS|MORPHOLOGIC CRI||KAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1969-04-28||||1972-08-20||1972-04-26|1971-02-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UV2|CRI||MAC50|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|CHILD|UROLOGIST|N|2||58||RUN-IN|1963-07-18||||1966-10-25||1965-03-27|1969-02-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CMOL/L|IMPROVED||PG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|INVESTIGATOR|DERMATOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-09-09||||1966-01-09||1972-11-13|1964-05-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/10^3|STABLE||BREATHS/30S|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|PARENT|MICROSCOPIST 2|N|3||39||BLINDED TREATMENT|1966-05-01||||1967-02-22||1961-03-03|1962-04-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ANTIBODY UNIT|QUANTIFIABLE MRD POSITIVITY||IN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|SIGNIFICANT OTHER|DERMATOLOGIST|NA|3||39||RUN-IN|1972-01-04||||1971-06-26||1964-01-08|1973-06-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||OVRLRESP|OVERALL RESPONSE||||ECL UNIT|HI-E||PNU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|PROXY|CARDIOLOGIST|N|4||88||SCREENING|1972-03-31||||1971-05-04||1962-01-28|1969-01-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||EIA UNIT|SMD||OZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|FRIEND|ONCOLOGIST|Y|4||88||WASHOUT|1973-08-07||||1966-11-25||1965-09-28|1962-11-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PATCH|MRD NEGATIVITY||MG/KG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|GUARDIAN|MICROSCOPIST|NA|5||7||WASHOUT|1960-10-11||||1973-07-05||1963-11-09|1970-09-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KG/MOL|SD-CT||UG/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|DOMESTIC PARTNER|READER|NA|5||7||FOLLOW-UP|1962-01-28||||1971-12-06||1960-04-04|1960-07-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||NEWLIND|NEW LESION INDICATOR||||U/M2/DAY|UNEQUIVOCAL||MEQ/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|1||38||SCREENING|1965-01-24||||1961-03-31||1969-08-21|1966-07-31||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^3 CFU/ML|PSA PROGRESSION||EID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|1||38||BLINDED TREATMENT|1969-01-01||||1960-11-19||1968-05-04|1963-01-08||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KA_U/DL|STABLE||AMFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|FAMILY MEMBER|RADIOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1970-09-06||||1966-07-04||1967-04-13|1966-12-31||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/G/MIN|MRD RELAPSE||MM/2H|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|2||58||BLINDED TREATMENT|1966-08-04||||1970-08-10||1972-04-30|1966-08-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UCI|NON-QUANTIFIABLE MRD POSITIVITY||GBQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|INVESTIGATOR|PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1966-03-23||||1969-11-22||1962-05-28|1970-12-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||STRUSTAT|STEROID USE STATUS||||MEQ/UL|NON-QUANTIFIABLE MRD POSITIVITY||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|FAMILY MEMBER|ENDOCRINOLOGIST|N|3||39||BLINDED TREATMENT|1972-10-30||||1971-01-29||1973-07-06|1961-11-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||SPLNRESP|SPLEEN RESPONSE||||10^4/L|CYTOGENETIC MINOR RESPONSE||ML/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|U|4||88||BASELINE|1966-01-21||||1967-08-11||1967-10-12|1965-02-24||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CM|PD FROM PR||G/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|SIBLING|PATHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1968-05-03||||1966-02-08||1970-01-07|1961-09-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||BONERESP|BONE RESPONSE||||UKAT/L|OPTIMAL MORPHOLOGIC RESPONSE||VP/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|5||7||TREATMENT|1964-01-27||||1965-07-07||1970-05-13|1972-12-21||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||STRUSTAT|STEROID USE STATUS||||ML/M2/MIN|EQUIVOCAL||KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|CAREGIVER|ONCOLOGIST 2|N|5||7||RUN-IN|1971-05-05||||1969-04-05||1968-01-17|1960-06-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/S/M2|PD||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CHILD|ONCOLOGIST 2|Y|1||38||FOLLOW-UP|1973-06-08||||1969-07-25||1964-03-02|1961-06-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/ML/MIN|MINOR PATHOLOGIC RESPONSE||MET*MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|1||38||OPEN LABEL TREATMENT|1962-02-24||||1964-04-23||1964-08-23|1960-04-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/G/H|SD||S*KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|2||58||LONG-TERM FOLLOW-UP|1965-05-29||||1967-08-01||1972-03-06|1967-02-04||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UMOL/L/SEC|PDU||DB|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|2||58||RUN-IN|1960-11-16||||1963-06-22||1970-07-21|1967-08-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||METBRESP|METABOLIC RESPONSE||||%/MIN|UNEQUIVOCAL||PKAT/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|STUDY SUBJECT|DERMATOLOGIST|U|3||39||WASHOUT|1970-10-29||||1972-12-11||1965-09-26|1969-12-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||ANATRESP|ANATOMIC RESPONSE||||MAMP|PR WITH LYMPHOCYTOSIS||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|CHILD|OPTOMETRIST|NA|3||39||OPEN LABEL TREATMENT|1965-04-12||||1966-01-13||1964-10-07|1970-12-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MCI/KG|CPR||ML/G/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1964-12-25||||1967-07-27||1960-01-03|1968-08-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||NEWLPROG|NEW LESION PROGRESSION||||RNA COPIES/ML|IMPROVED||PACK YEAR|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|FRIEND|ONCOLOGIST 1|U|4||88||OBSERVATION|1969-05-31||||1972-07-22||1969-01-11|1962-08-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||MOLRESP|MOLECULAR RESPONSE||||10^6 IU|OPTIMAL MORPHOLOGIC RESPONSE||UV|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|PROXY|CLINICAL PATHOLOGIST|U|5||7||SCREENING|1964-08-21||||1972-02-21||1968-10-02|1969-07-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||JOULE|SD-CT||U/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|CAREGIVER|ONCOLOGIST 1|Y|5||7||BASELINE|1960-11-21||||1970-07-25||1967-03-22|1965-11-05||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||ANATRESP|ANATOMIC RESPONSE||||G/KG/DAY|CYTOGENETIC NO RESPONSE||DAYS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|INTERVIEWER|RATER|Y|1||38||RUN-IN|1965-12-01||||1966-12-29||1969-04-06|1962-06-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KUSP|SD-CT||/SEC|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|INVESTIGATOR|ADJUDICATOR 1|U|1||38||INDUCTION TREATMENT|1968-12-21||||1969-05-31||1966-10-29|1961-03-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||BONERESP|BONE RESPONSE||||GPL U/ML|PR||PMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|GUARDIAN|PATHOLOGIST|U|2||58||BLINDED TREATMENT|1972-05-31||||1960-10-21||1971-05-14|1966-03-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||BONERESP|BONE RESPONSE||||ML/M2|CPR||UEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1963-11-29||||1966-12-03||1965-08-23|1965-09-28||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/M2/MIN|PCR||MG/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|DOMESTIC PARTNER|ONCOLOGIST|U|3||39||BASELINE|1969-12-29||||1967-08-15||1973-01-21|1963-02-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||METBRESP|METABOLIC RESPONSE||||UGEQ|CA125 50% RESPONSE||/2000 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|3||39||SCREENING|1969-08-24||||1968-05-09||1969-06-24|1964-03-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||COPIES/ML|NON-QUANTIFIABLE MRD POSITIVITY||LOG10 TCID 50/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|INTERVIEWER|HEMATOLOGIST|Y|4||88||OBSERVATION|1965-11-12||||1968-04-13||1966-06-26|1962-09-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||NTRGRESP|NON-TARGET RESPONSE||||UU/L|IUPD||BP|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|4||88||FOLLOW-UP|1970-09-19||||1967-12-16||1971-07-14|1969-12-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NM|ICR||AMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|5||7||FOLLOW-UP|1964-07-12||||1961-07-12||1968-01-08|1964-03-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MILE|CR-CT||K|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|READER 3|U|5||7||OBSERVATION|1960-09-19||||1964-06-07||1962-08-24|1970-01-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||OVRLRESP|OVERALL RESPONSE||||10^6/G|UNEQUIVOCAL||G/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|PROXY|HEMATOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1961-12-09||||1966-08-29||1972-05-06|1973-09-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||CLINRESP|CLINICAL RESPONSE||||BQ/G|STABLE||10^3 DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|1||38||RUN-IN|1970-04-02||||1963-02-10||1968-11-12|1966-04-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||INHALATION|SMD||NG/DL|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|RATER|NA|2||58||INDUCTION TREATMENT|1971-12-23||||1967-07-11||1962-10-01|1965-08-20||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||BONERESP|BONE RESPONSE||||10^12 IU/L|PR-CT||10^9 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|GUARDIAN|READER 1|U|2||58||INDUCTION TREATMENT|1968-02-24||||1965-10-16||1962-07-04|1960-08-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MOSM/KG|ICR||MKAT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|FAMILY MEMBER|RATER 2|NA|3||39||OPEN LABEL TREATMENT|1968-01-25||||1965-04-16||1960-09-07|1971-01-01||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||METBRESP|METABOLIC RESPONSE||||MOSM/KG|NR||DAMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|DOMESTIC PARTNER|READER|Y|3||39||RUN-IN|1965-02-24||||1960-12-29||1967-11-05|1965-05-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||RDIORESP|RADIOLOGIC RESPONSE||||NKAT/L|CYTOGENETIC CR||MG/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|SPOUSE|OPHTHALMOLOGIST|Y|4||88||BLINDED TREATMENT|1970-09-01||||1969-08-01||1968-03-11|1971-03-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||TRGRESP|TARGET RESPONSE||||BOTTLE|MORPHOLOGIC CRI||LX|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||CONTINUATION TREATMENT|1971-07-23||||1971-08-20||1963-06-29|1966-09-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/DL|MRD PERSISTENCE||/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|PARENT|RATER|U|5||7||RUN-IN|1968-06-06||||1969-03-06||1969-08-15|1967-03-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PT_US|MRD PERSISTENCE||CD/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5||7||SCREENING|1966-03-08||||1961-08-26||1967-09-30|1961-04-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CYCLE/MIN|COMPLETE MRD RESPONSE||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|1||38||BASELINE|1961-12-19||||1964-08-20||1968-06-22|1961-09-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||FOZ_BR|INCREASED||G/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|1||38||INDUCTION TREATMENT|1972-10-18||||1969-12-18||1963-05-23|1968-04-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||METSIND|METASTATIC INDICATOR||||CI/ML|INCREASED||JOULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|CHILD|MICROSCOPIST 3|U|2||58||OPEN LABEL TREATMENT|1960-06-12||||1971-07-18||1965-05-26|1963-07-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CAPLET|CYTOGENETIC CR||MM|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|STUDY SUBJECT|NEUROLOGIST 2|Y|2||58||TREATMENT|1967-03-08||||1972-03-26||1963-11-08|1971-07-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/G/DAY|COMPLETE MRD RESPONSE||UCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|PARENT|READER 1|Y|3||39||BLINDED TREATMENT|1963-05-13||||1963-12-27||1966-01-20|1970-04-09||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||CYTORESP|CYTOGENETIC RESPONSE||||M|CRI||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|DOMESTIC PARTNER|PATHOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1970-05-20||||1972-10-21||1961-11-21|1960-10-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KHZ|UNEQUIVOCAL||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1965-09-19||||1963-04-19||1962-05-02|1967-06-19||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||CLINRESP|CLINICAL RESPONSE||||YD|ABSENT MORPHOLOGIC RESPONSE||10^6 ORGANISMS/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|RATER 2|NA|4||88||SCREENING|1965-01-01||||1968-03-11||1972-03-28|1963-08-09||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MEQ|ICR||UIU/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|5||7||FOLLOW-UP|1963-06-26||||1960-08-28||1970-02-24|1961-08-06||AFTER||DURING|
TRIAL STUDY 134XCP|RS|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||GLOBULE|CYTOGENETIC MINOR RESPONSE||OI50|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|FRIEND|ADJUDICATOR 3|U|5||7||BASELINE|1968-09-28||||1960-05-13||1961-08-27|1972-01-22||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UEQ/L|DECREASED||GENEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|1||38||BLINDED TREATMENT|1964-08-07||||1971-05-24||1967-06-24|1973-01-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||ANATRESP|ANATOMIC RESPONSE||||MM/H|CCR||MMOL/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|ADJUDICATOR|RADIOLOGIST|U|1||38||TREATMENT|1961-01-19||||1964-06-01||1973-08-18|1960-01-28||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/CAGE|UNEQUIVOCAL||/VF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|SIBLING|MICROSCOPIST 2|N|2||58||BASELINE|1964-04-29||||1961-05-31||1961-08-12|1973-06-24||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||TMRESP|TUMOR MARKER RESPONSE||||CMH2O/ML|MOLECULAR MAJOR RESPONSE||PIPE|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|FRIEND|ADJUDICATOR 3|N|2||58||BASELINE|1964-12-01||||1973-09-05||1963-01-15|1967-03-09||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GBQ/G|SD||DRINK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|CAREGIVER|NEUROLOGIST 1|Y|3||39||RUN-IN|1966-11-24||||1969-03-07||1964-08-24|1964-06-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/G/H|PSEUDORESPONSE||DPM/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|3||39||OPEN LABEL TREATMENT|1961-04-02||||1962-05-31||1967-04-28|1960-11-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CM H2O|MAJOR PATHOLOGIC RESPONSE||MAC50|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|4||88||SCREENING|1971-10-11||||1970-12-02||1967-06-17|1972-05-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||NEWLPROG|NEW LESION PROGRESSION||||SUPPOSITORY|HI-N||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|FRIEND|PHYSIOTHERAPIST|U|4||88||FOLLOW-UP|1961-05-19||||1970-06-15||1960-07-27|1968-01-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/G/DAY|PR WITH LYMPHOCYTOSIS||PA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|PROXY|ADJUDICATOR 1|Y|5||7||WASHOUT|1962-12-21||||1969-10-05||1972-02-28|1961-05-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||TMRESP|TUMOR MARKER RESPONSE||||DNA COPIES/UG|RELAPSED DISEASE||MNFI|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|INTERVIEWER|MICROSCOPIST 3|NA|5||7||LONG-TERM FOLLOW-UP|1966-08-02||||1962-12-23||1968-03-18|1970-10-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||CLINRESP|CLINICAL RESPONSE||||PFU/ANIMAL|CCR||DEG/MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|PARENT|READER 3|NA|1||38||BASELINE|1960-12-18||||1960-10-22||1973-01-19|1971-03-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG/KG/DOSE|CMR||MM/2H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1967-12-20||||1973-03-19||1962-04-15|1968-05-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||METBRESP|METABOLIC RESPONSE||||NKAT/G HB|CPR||VIAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|DOMESTIC PARTNER|NEUROLOGIST 2|U|2||58||BLINDED TREATMENT|1971-06-22||||1969-12-08||1970-08-18|1969-01-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/M2/MIN|IPR||MG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|INDEPENDENT ASSESSOR|READER|U|2||58||LONG-TERM FOLLOW-UP|1970-10-19||||1962-01-25||1960-10-20|1967-08-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/ML/DAY|SMD||V/V|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|SIGNIFICANT OTHER|NEUROLOGIST 2|U|3||39||FOLLOW-UP|1966-12-02||||1972-05-07||1960-07-07|1973-07-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DAMOL/L|PSA PROGRESSION||ML/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|CAREGIVER|PEDIATRIC NEUROLOGIST|N|3||39||OPEN LABEL TREATMENT|1973-03-03||||1962-09-22||1969-07-27|1963-07-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||RDIORESP|RADIOLOGIC RESPONSE||||USIEMENS|NON-CR/NON-PD||NG/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|VENDOR|PEDIATRIC NEUROLOGIST|NA|4||88||WASHOUT|1964-03-14||||1961-12-21||1963-09-08|1967-12-30||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||CYTORESP|CYTOGENETIC RESPONSE||||VP/DOSE|HI-P||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|INVESTIGATOR|OTOLARYNGOLOGIST|N|4||88||SCREENING|1968-04-10||||1962-05-03||1961-01-11|1969-10-07||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/L|CYTOGENETIC NO RESPONSE||MMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|5||7||BASELINE|1972-04-04||||1968-02-04||1964-08-06|1966-08-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MJOULE/CM2|MOLECULAR MAJOR RESPONSE||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|5||7||RUN-IN|1970-03-24||||1962-04-09||1966-09-09|1968-04-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||BONERESP|BONE RESPONSE||||ABSORBANCE U/MIN|CYTOGENETIC MINOR RESPONSE||U/M2/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|1||38||TREATMENT|1969-01-06||||1964-07-16||1967-01-25|1972-04-15||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/MIN/KPA|CYTOGENETIC MINOR RESPONSE||ML/MMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|1||38||OBSERVATION|1971-12-24||||1972-03-15||1960-03-01|1969-10-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GTT|PR||MM/2H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|ADJUDICATOR|ENDOCRINOLOGIST|U|2||58||OBSERVATION|1972-11-10||||1969-11-11||1960-09-05|1971-11-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||MOLRESP|MOLECULAR RESPONSE||||PHERESIS UNIT|IUPD||NCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|SIBLING|UROLOGIST|NA|2||58||RUN-IN|1967-07-24||||1972-11-15||1962-03-15|1970-04-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7 CFU/ML|PSEUDORESPONSE||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|3||39||BASELINE|1961-08-26||||1962-05-29||1970-12-08|1964-01-28||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/500 WBC|PMR||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|STUDY SUBJECT|ONCOLOGIST 2|Y|3||39||SCREENING|1967-10-30||||1973-06-20||1962-11-15|1964-11-28||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/DOSE|CYTOGENETIC CR||K|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|ADJUDICATOR|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1961-10-13||||1961-10-21||1969-06-07|1965-03-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||BESTRESP|BEST OVERALL RESPONSE||||MEQ/L|EQUIVOCAL||10^6 IU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|GUARDIAN|ADJUDICATOR 3|U|4||88||SCREENING|1960-12-26||||1964-11-21||1967-10-20|1967-06-25||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||METSIND|METASTATIC INDICATOR||||/MBP|CA125 50% RESPONSE||GBQ/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|5||7||OBSERVATION|1971-03-22||||1968-06-03||1965-02-21|1963-12-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KM/H|DECREASED||KG/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|FRIEND|PATHOLOGIST 2|N|5||7||SCREENING|1968-02-03||||1965-06-14||1971-09-08|1965-01-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||SPLNRESP|SPLEEN RESPONSE||||BOLUS|IPR||MEQ/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|1||38||RUN-IN|1970-06-28||||1973-02-19||1960-10-19|1973-08-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||CLINRESP|CLINICAL RESPONSE||||/5X10^4 WBC|IPR||TRACE|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|GUARDIAN|READER|U|1||38||FOLLOW-UP|1963-12-04||||1967-02-16||1965-09-05|1964-06-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ATM|MORPHOLOGIC CR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|SPOUSE|OTOLARYNGOLOGIST|N|2||58||FOLLOW-UP|1965-06-23||||1971-04-14||1972-10-30|1968-03-20||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CI/UL|CYTOGENETIC PR||UMOL/MOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|PROXY|MICROSCOPIST 1|Y|2||58||BLINDED TREATMENT|1973-07-21||||1968-04-29||1967-08-09|1971-06-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/DL|CCR||UG/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|PARENT|RATER|N|3||39||TREATMENT|1961-02-12||||1966-04-24||1965-10-17|1972-11-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MET|CMR||/LPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|3||39||FOLLOW-UP|1969-11-05||||1964-01-06||1971-02-25|1967-05-21||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||%/S|SCR||MMU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|PROXY|PATHOLOGIST 1|Y|4||88||WASHOUT|1961-03-21||||1967-09-03||1964-01-30|1962-05-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UMOL/DAY|PR-CT||LOG10 CCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|STUDY SUBJECT|ADJUDICATOR 1|NA|4||88||RUN-IN|1964-02-11||||1962-08-21||1964-02-09|1963-11-16||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PL|CYTOGENETIC PR||BAU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|ADJUDICATION COMMITTEE|INTERNIST|N|5||7||SCREENING|1971-04-10||||1967-07-09||1968-04-15|1973-03-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/MS|CCR||ENZYME U/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|PARENT|PATHOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1966-06-05||||1960-06-21||1961-10-03|1969-01-27||DURING||DURING|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%|IMMUNOPHENOTYPIC CR||CL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|CAREGIVER|RADIOLOGIST 1|NA|1||38||OPEN LABEL TREATMENT|1972-02-19||||1966-07-13||1972-09-02|1970-08-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LENS|IPR||DPM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|VENDOR|RADIOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1969-05-07||||1961-04-11||1968-11-01|1973-08-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||OVRLRESP|OVERALL RESPONSE||||MM2|CYTOGENETIC CR||%(W/V)|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|VENDOR|RATER 2|U|2||58||WASHOUT|1969-02-05||||1967-01-22||1963-10-25|1971-09-07||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||SPLNRESP|SPLEEN RESPONSE||||AMU|NON-CR/NON-PD||MOSM/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|CHILD|CLINICAL PATHOLOGIST|N|2||58||SCREENING|1960-02-11||||1973-01-29||1970-03-01|1970-02-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||NEWLPROG|NEW LESION PROGRESSION||||BAG|MRD PERSISTENCE||10^3 RNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|CAREGIVER|ONCOLOGIST|NA|3||39||OBSERVATION|1960-01-17||||1968-12-07||1967-06-16|1960-01-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||DPM/0.5 ML|MORPHOLOGIC CR||UM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|SIGNIFICANT OTHER|NEUROLOGIST|Y|3||39||OBSERVATION|1972-03-19||||1970-11-06||1965-04-20|1960-12-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||PATHRESP|PATHOLOGIC RESPONSE||||TESLA|CR||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|VENDOR|MICROSCOPIST 3|N|4||88||OBSERVATION|1960-02-20||||1962-11-15||1969-08-30|1966-07-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||NEWLPROG|NEW LESION PROGRESSION||||ML/MIN/1.73M2|CYTOGENETIC PR||NEEDLE GAUGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|READER 1|NA|4||88||BASELINE|1966-10-19||||1970-03-26||1972-10-12|1970-08-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||MOLRESP|MOLECULAR RESPONSE||||KPA/L/SEC|IMMUNOPHENOTYPIC CR||DPM/MG|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|ADJUDICATOR|MICROSCOPIST 1|U|5||7||BLINDED TREATMENT|1962-09-03||||1960-10-09||1961-02-10|1970-02-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||BESTRESP|BEST OVERALL RESPONSE||||MOL|MORPHOLOGIC LEUKEMIA-FREE STATE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|SIBLING|NEUROLOGIST 2|U|5||7||CONTINUATION TREATMENT|1972-10-19||||1963-02-13||1961-01-03|1967-10-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KUSP|PSA PROGRESSION||10^9/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|STUDY SUBJECT|ONCOLOGIST 1|Y|1||38||SCREENING|1973-08-07||||1967-01-25||1971-02-25|1964-09-23||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^4/L|CYTOGENETIC MINIMAL RESPONSE||KG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|1||38||BLINDED TREATMENT|1963-12-23||||1962-02-27||1968-10-24|1966-03-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PG/DL|STABLE||% INHIBITION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CHILD|READER 2|Y|2||58||OBSERVATION|1965-10-20||||1971-12-18||1969-10-21|1973-05-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||VP/DOSE|NE||CI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|PARENT|MICROSCOPIST|U|2||58||LONG-TERM FOLLOW-UP|1968-05-12||||1973-04-01||1966-03-29|1972-10-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/SEC/1.73M2|NON-ICR/NON-IUPD||MET*H|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|FRIEND|NEUROLOGIST 1|N|3||39||WASHOUT|1968-03-06||||1967-09-29||1963-09-01|1962-03-27||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ/KG|VGPR||UKAT/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|PARENT|ONCOLOGIST|N|3||39||TREATMENT|1966-12-21||||1971-01-03||1972-04-04|1969-05-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL2/L2|MRD RELAPSE||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|VENDOR|NEUROLOGIST|U|4||88||SCREENING|1969-10-15||||1965-12-20||1967-09-28|1972-08-31||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||NTRGRESP|NON-TARGET RESPONSE||||KS|HI-N||KM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|STUDY SUBJECT|READER 2|U|4||88||OBSERVATION|1966-12-03||||1968-04-22||1972-02-29|1961-02-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MESF|IUPD||MONTHS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|5||7||BASELINE|1970-06-25||||1961-11-13||1970-07-18|1964-01-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||MOLRESP|MOLECULAR RESPONSE||||GPL U|NR||F|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|SIBLING|PATHOLOGIST 2|N|5||7||RUN-IN|1967-03-11||||1967-04-06||1963-12-14|1969-03-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||BESTRESP|BEST OVERALL RESPONSE||||IU/KG/H|SD-CT||FOZ_BR|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|CAREGIVER|OPTOMETRIST|Y|1||38||TREATMENT|1969-08-01||||1972-02-29||1971-07-16|1973-08-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||NEWLPROG|NEW LESION PROGRESSION||||MNFI|MRD NEGATIVITY||MOL/MG|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|N|1||38||SCREENING|1967-11-16||||1962-01-21||1965-08-08|1960-10-14||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU/G|MRD PERSISTENCE||FMOL/L/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|ADJUDICATION COMMITTEE|READER|U|2||58||BLINDED TREATMENT|1968-01-17||||1967-03-22||1961-06-09|1970-04-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MEQ/MMOL|HI-N||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|CAREGIVER|PATHOLOGIST 1|N|2||58||RUN-IN|1962-09-08||||1971-08-29||1969-02-18|1965-05-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||MOLRESP|MOLECULAR RESPONSE||||GY/H|OPTIMAL MORPHOLOGIC RESPONSE||/MBP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|INTERVIEWER|CARDIOLOGIST|U|3||39||RUN-IN|1963-03-30||||1971-10-19||1972-01-04|1960-12-19||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PACK|RELAPSED DISEASE FROM CR||GPL U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|INVESTIGATOR|MICROSCOPIST|NA|3||39||OPEN LABEL TREATMENT|1969-04-11||||1960-08-15||1970-09-08|1970-04-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UMOL/DL|ABSENT MORPHOLOGIC RESPONSE||SV|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|4||88||FOLLOW-UP|1965-10-30||||1961-01-23||1961-03-08|1960-02-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MNFI|PD/RELAPSE AFTER HI||10^6 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|READER 2|Y|4||88||WASHOUT|1970-03-04||||1972-07-22||1964-12-13|1968-11-20||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GBQ|SCR||ML/BEAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|SIGNIFICANT OTHER|UROLOGIST|N|5||7||INDUCTION TREATMENT|1966-04-30||||1960-05-10||1963-04-18|1973-07-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL|MAJOR PATHOLOGIC RESPONSE||ENZYME U|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|CAREGIVER|ONCOLOGIST|Y|5||7||BASELINE|1969-10-23||||1970-07-04||1968-12-27|1962-10-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|1||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/DAY|INCREASED||MPL U|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||SCREENING|1961-11-14||||1971-12-15||1972-02-12|1973-07-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/BREATH|CYTOGENETIC MINOR RESPONSE||CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|1||38||FOLLOW-UP|1968-10-02||||1965-08-21||1963-08-28|1972-02-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|1||||||STRUSTAT|STEROID USE STATUS||||CAN|MORPHOLOGIC LEUKEMIA-FREE STATE||U/G HB|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|INVESTIGATOR|CARDIOLOGIST|NA|2||58||INDUCTION TREATMENT|1963-02-03||||1967-09-19||1966-09-09|1962-02-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|2||||||NEWLIND|NEW LESION INDICATOR||||UIU/DL|QUANTIFIABLE MRD POSITIVITY||NSEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|PARENT|PEDIATRIC NEUROLOGIST|U|2||58||RUN-IN|1965-08-26||||1971-11-30||1969-12-09|1960-02-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||AU/ML|ISD||CI/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|3||39||WASHOUT|1971-02-27||||1963-01-22||1963-10-08|1964-02-26||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|2||||||MOLRESP|MOLECULAR RESPONSE||||FOZ_US|PD||MOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1961-04-20||||1972-03-30||1964-10-01|1962-01-17||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|1||||||TMRESP|TUMOR MARKER RESPONSE||||BAU|CYTOGENETIC PR||10^6/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|4||88||WASHOUT|1961-02-14||||1965-10-09||1965-03-10|1969-09-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|2||||||CLINRESP|CLINICAL RESPONSE||||MEQ/KG|CYTOGENETIC PR||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|INDEPENDENT ASSESSOR|RATER 1|Y|4||88||BLINDED TREATMENT|1963-09-20||||1967-07-16||1969-07-04|1968-10-22||DURING||AFTER|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|1||||||CLINRESP|CLINICAL RESPONSE||||MMOL2/L2|RELAPSED DISEASE FROM CR||DAYS/MONTH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|ADJUDICATION COMMITTEE|READER 3|N|5||7||CONTINUATION TREATMENT|1960-04-09||||1971-06-08||1960-04-24|1962-01-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|6633CC54-D711-4780-A833-A71756D8B234|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/L DDU|RELAPSED DISEASE||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|5||7||BASELINE|1960-05-07||||1962-07-01||1961-01-12|1961-11-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||OVRLRESP|OVERALL RESPONSE||||FOZ_BR|RELAPSED DISEASE||DEG/S|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|1||38||BLINDED TREATMENT|1961-11-30||||1972-10-27||1965-12-22|1971-08-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||METSIND|METASTATIC INDICATOR||||PM|CR||WEEKS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|FRIEND|PEDIATRIC NEUROLOGIST|NA|1||38||WASHOUT|1971-08-02||||1972-06-04||1961-06-20|1960-03-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||TRGRESP|TARGET RESPONSE||||RNA COPIES/ML|HI-P||FG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|FRIEND|ADJUDICATOR 3|Y|2||58||BLINDED TREATMENT|1964-05-03||||1963-12-11||1965-09-05|1968-03-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AMFI|IPR||10^6/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|STUDY SUBJECT|READER 2|NA|2||58||OPEN LABEL TREATMENT|1966-08-02||||1960-06-10||1963-07-07|1963-03-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%|ICR||MOSM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|SPOUSE|CARDIOLOGIST|Y|3||39||BLINDED TREATMENT|1973-02-11||||1972-08-31||1971-03-12|1970-06-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||CLINRESP|CLINICAL RESPONSE||||DRINK|RELAPSED DISEASE||JOULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|ADJUDICATION COMMITTEE|READER 3|U|3||39||OPEN LABEL TREATMENT|1968-05-25||||1961-03-03||1969-03-21|1969-08-14||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||NEWLIND|NEW LESION INDICATOR||||PACKAGE|INCREASED||SFC/10^6 PBMC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|GUARDIAN|NEUROLOGIST 2|NA|4||88||FOLLOW-UP|1963-03-28||||1972-05-27||1973-01-02|1968-08-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MPA|HI-N||KG/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|INTERVIEWER|NEUROLOGIST 1|Y|4||88||WASHOUT|1969-01-12||||1971-06-04||1961-03-04|1965-06-09||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||SPLNRESP|SPLEEN RESPONSE||||CI/L|ICPD||KG/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|CAREGIVER|PHYSIOTHERAPIST|U|5||7||OPEN LABEL TREATMENT|1968-11-26||||1970-04-25||1964-02-28|1969-01-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CI/G|ISD||MEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|FAMILY MEMBER|MICROSCOPIST 2|N|5||7||BASELINE|1965-12-11||||1960-06-21||1969-11-08|1971-08-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^7 CFU/ML|HI-N||KPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|ADJUDICATION COMMITTEE|CARDIOLOGIST|U|1||38||BASELINE|1971-04-09||||1967-07-11||1972-03-20|1972-02-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||NTRGRESP|NON-TARGET RESPONSE||||NMOL/ML/MIN|CA125 75% RESPONSE||%(W/W)|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|ADJUDICATOR|ADJUDICATOR|U|1||38||RUN-IN|1961-06-23||||1966-12-09||1965-01-31|1965-02-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/H|MOLECULAR CR||NG/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|2||58||OBSERVATION|1969-02-23||||1967-08-04||1967-10-20|1971-08-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CYLINDER|QUANTIFIABLE MRD POSITIVITY||/WK|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|ADJUDICATOR|PATHOLOGIST 1|U|2||58||FOLLOW-UP|1969-03-30||||1962-12-16||1965-09-08|1967-11-28||DURING||DURING|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/M2/MIN|CR-CT||DEG/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|CHILD|RATER 1|NA|3||39||TREATMENT|1973-04-20||||1961-02-06||1971-04-24|1968-08-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PMOL/10^9 CELLS|MAJOR PATHOLOGIC RESPONSE||KG/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|VENDOR|ADJUDICATOR 2|N|3||39||WASHOUT|1972-12-06||||1965-10-07||1967-11-02|1970-10-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 COPIES/ML|OPTIMAL MORPHOLOGIC RESPONSE||10^9 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|4||88||LONG-TERM FOLLOW-UP|1963-02-24||||1965-02-17||1963-01-11|1961-11-22||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||METBRESP|METABOLIC RESPONSE||||10^3/L|MINOR PATHOLOGIC RESPONSE||/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|FAMILY MEMBER|RATER 2|Y|4||88||TREATMENT|1970-02-09||||1969-05-02||1967-03-14|1963-06-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^8/L|PCR||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|5||7||SCREENING|1961-01-18||||1970-01-27||1967-02-27|1963-11-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/MOL|CCR||UG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|SIBLING|MICROSCOPIST 1|U|5||7||OBSERVATION|1970-05-13||||1967-01-25||1962-08-02|1961-08-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||SPLNRESP|SPLEEN RESPONSE||||TRACE|OPTIMAL MORPHOLOGIC RESPONSE||CS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|1||38||BASELINE|1963-09-26||||1973-05-12||1962-04-10|1965-08-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||RDIORESP|RADIOLOGIC RESPONSE||||U/G/DAY|VGPR||UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|N|1||38||TREATMENT|1972-01-08||||1965-11-20||1968-12-18|1963-05-15||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/SEC|MRD NEGATIVITY||MCI/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|SPOUSE|INTERNIST|NA|2||58||SCREENING|1965-09-14||||1970-12-24||1966-04-10|1969-08-23||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||PATHRESP|PATHOLOGIC RESPONSE||||FMOL/G|MORPHOLOGIC CRI||P|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|SIBLING|NEUROLOGIST 1|U|2||58||INDUCTION TREATMENT|1963-08-31||||1964-11-04||1966-04-18|1972-04-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/UL|MCR||UG/L DDU|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|SPOUSE|RATER|NA|3||39||OPEN LABEL TREATMENT|1968-09-26||||1960-03-29||1971-10-09|1962-07-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||SPLNRESP|SPLEEN RESPONSE||||MV*MIN|ISD||/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||INDUCTION TREATMENT|1970-12-12||||1961-03-08||1968-08-28|1972-11-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||MOLRESP|MOLECULAR RESPONSE||||MPH|QUANTIFIABLE MRD POSITIVITY||GENEQ/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|NA|INDEPENDENT ASSESSOR|READER|N|4||88||BLINDED TREATMENT|1966-07-21||||1964-05-04||1966-01-12|1964-12-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML|CHR||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|4||88||INDUCTION TREATMENT|1970-07-11||||1968-12-14||1969-06-20|1961-11-17||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/ML|MINOR PATHOLOGIC RESPONSE||G/L|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|Y|5||7||LONG-TERM FOLLOW-UP|1965-10-11||||1962-05-01||1966-09-01|1967-04-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||STRUSTAT|STEROID USE STATUS||||FFU|ISD||OD UNIT|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1970-02-25||||1970-11-30||1967-03-23|1963-04-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||SPLNRESP|SPLEEN RESPONSE||||JOULE|VGPR||BQ|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|SIGNIFICANT OTHER|OPTOMETRIST|N|1||38||OBSERVATION|1971-01-25||||1963-12-03||1964-05-02|1965-03-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 CFU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||JDF UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|1||38||BLINDED TREATMENT|1962-10-17||||1967-09-08||1970-08-24|1969-08-11||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UM/S|IMPROVED||UM/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|INVESTIGATOR|ENDOCRINOLOGIST|U|2||58||CONTINUATION TREATMENT|1966-09-13||||1972-08-13||1969-10-29|1961-12-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||BONERESP|BONE RESPONSE||||BAU/ML|PSEUDOPROGRESSION||NCI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|VENDOR|NEUROLOGIST 2|Y|2||58||RUN-IN|1960-06-05||||1962-03-08||1960-11-30|1971-08-31||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MG|ABSENT MORPHOLOGIC RESPONSE||MMOL2/L2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CHILD|RADIOLOGIST 2|U|3||39||BLINDED TREATMENT|1973-06-24||||1969-05-29||1969-03-03|1965-05-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/MM|SCR||ML/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|INVESTIGATOR|DERMATOLOGIST|N|3||39||CONTINUATION TREATMENT|1960-08-16||||1969-09-17||1963-06-01|1966-02-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||TRGRESP|TARGET RESPONSE||||UU/DL|HI-P||MHZ|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|RATER|NA|4||88||OBSERVATION|1964-02-02||||1968-07-29||1971-03-13|1968-10-17||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/100G/MIN|NON-CR/NON-PD||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|4||88||TREATMENT|1972-08-28||||1963-03-31||1969-03-08|1963-03-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||NTRGRESP|NON-TARGET RESPONSE||||U/MG|PD-CT||H*%|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|CHILD|DERMATOLOGIST|Y|5||7||RUN-IN|1969-12-31||||1970-05-09||1963-08-18|1966-08-25||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/MS|FAVORABLE RESPONSE||OZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1966-03-20||||1961-02-21||1960-03-15|1960-01-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||JAR|NED||EU|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|NA|1||38||CONTINUATION TREATMENT|1968-06-07||||1963-08-03||1968-05-19|1964-11-12||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||L/S/KPA|PSEUDORESPONSE||MIN*MG/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|INVESTIGATOR|MICROSCOPIST 2|NA|1||38||BLINDED TREATMENT|1969-12-09||||1971-09-25||1964-03-15|1973-01-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||STRUSTAT|STEROID USE STATUS||||MIU/L|NON-QUANTIFIABLE MRD POSITIVITY||CAPFUL|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|INVESTIGATOR|RADIOLOGIST 2|NA|2||58||BASELINE|1972-08-27||||1964-10-12||1969-05-27|1966-09-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||M2|PMD||CMHG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|2||58||OPEN LABEL TREATMENT|1973-08-01||||1965-07-29||1967-03-11|1965-04-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||CLINRESP|CLINICAL RESPONSE||||G/CAGE/WK|NED||DAYS/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|FRIEND|READER 2|NA|3||39||BLINDED TREATMENT|1963-12-20||||1972-10-22||1968-08-30|1967-03-06||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MG/L FEU|CCR||CAPLET|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||INDUCTION TREATMENT|1973-03-06||||1970-11-29||1961-05-01|1972-05-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CYLINDER|PD/RELAPSE AFTER HI||DEG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|ADJUDICATOR|RATER 1|NA|4||88||BLINDED TREATMENT|1963-10-25||||1964-02-20||1969-04-12|1967-09-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||OVRLRESP|OVERALL RESPONSE||||CI/G|PSEUDOPROGRESSION||GBQ/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|SPOUSE|RADIOLOGIST|N|4||88||TREATMENT|1969-01-24||||1964-06-04||1968-04-11|1962-04-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||METSIND|METASTATIC INDICATOR||||ML/(MIN*100ML)|MRD NEGATIVITY||KAT|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|GUARDIAN|PATHOLOGIST|N|5||7||SCREENING|1965-12-14||||1968-07-21||1964-06-23|1967-02-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||TRGRESP|TARGET RESPONSE||||BAU|CYTOGENETIC NO RESPONSE||MEQ|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|STUDY SUBJECT|ADJUDICATOR 2|U|5||7||OPEN LABEL TREATMENT|1971-10-06||||1966-10-28||1960-11-28|1970-01-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||LIVRRESP|LIVER RESPONSE||||/2000 RBC|PSA PROGRESSION||BLOCKS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|INTERVIEWER|UROLOGIST|N|1||38||FOLLOW-UP|1967-01-08||||1965-02-06||1970-01-23|1972-06-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TUBERCULIN UNIT/ML|NE||M3|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|SIBLING|PATHOLOGIST 1|Y|1||38||RUN-IN|1964-10-22||||1969-10-13||1968-01-24|1962-06-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TBSP|DISEASE TRANSFORMATION||PA|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|INVESTIGATOR|ONCOLOGIST 1|N|2||58||SCREENING|1969-12-27||||1960-08-05||1968-03-07|1962-01-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/ML|RELAPSED DISEASE FROM CR||IU/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||FOLLOW-UP|1970-02-22||||1971-01-31||1973-08-22|1961-02-21||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||AMU|UNFAVORABLE RESPONSE||AGU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OBSERVATION|1967-11-05||||1970-07-26||1971-07-03|1970-04-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||LIVRRESP|LIVER RESPONSE||||PT_US|CYTOGENETIC PR||BAU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3||39||RUN-IN|1971-10-14||||1964-02-08||1964-10-01|1971-02-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||METSIND|METASTATIC INDICATOR||||UM/S|UNEQUIVOCAL||CAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|4||88||BLINDED TREATMENT|1968-06-10||||1963-05-18||1961-02-11|1963-06-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||LIVRRESP|LIVER RESPONSE||||BQ/ML|HI-P||VG/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|DOMESTIC PARTNER|READER 1|NA|4||88||OPEN LABEL TREATMENT|1965-01-04||||1970-06-08||1961-09-20|1968-12-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DPM/ML|NPR||G/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|5||7||RUN-IN|1962-09-15||||1960-02-06||1967-10-09|1969-07-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/M2/H|MORPHOLOGIC CR||MG/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|SIGNIFICANT OTHER|RATER 2|N|5||7||BLINDED TREATMENT|1969-01-26||||1968-01-21||1969-11-12|1962-07-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||NEWLIND|NEW LESION INDICATOR||||PG/L|SMD||MNFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|CLINICAL STUDY SPONSOR|READER 1|Y|1||38||SCREENING|1971-05-19||||1962-08-07||1971-12-30|1963-10-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||NEWLPROG|NEW LESION PROGRESSION||||HPA|CYTOGENETIC NO RESPONSE||S/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|PROXY|ONCOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1971-11-25||||1960-06-05||1961-05-20|1970-06-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/ML|INCREASED||LOG10 CFU/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1963-05-22||||1960-01-17||1968-04-30|1970-03-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/H|TREATMENT FAILURE||NMOL BCE/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|FRIEND|RATER|U|2||58||SCREENING|1967-02-16||||1963-11-08||1972-12-31|1962-11-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||BESTRESP|BEST OVERALL RESPONSE||||/SEC|RELAPSED DISEASE FROM CR OR PR||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|GUARDIAN|PEDIATRIC NEUROLOGIST|N|3||39||OBSERVATION|1967-07-16||||1971-01-11||1967-05-22|1969-04-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/KG/DOSE|ABSENT MORPHOLOGIC RESPONSE||U/MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|VENDOR|RATER 2|NA|3||39||CONTINUATION TREATMENT|1970-09-20||||1971-02-25||1964-02-14|1972-10-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||TRGRESP|TARGET RESPONSE||||PIXEL|MORPHOLOGIC LEUKEMIA-FREE STATE||HPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|GUARDIAN|OTOLARYNGOLOGIST|U|4||88||INDUCTION TREATMENT|1965-07-02||||1967-08-15||1969-01-01|1972-08-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||OVRLRESP|OVERALL RESPONSE||||S/H|IMPROVED||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|INDEPENDENT ASSESSOR|OPTOMETRIST|U|4||88||INDUCTION TREATMENT|1961-12-14||||1972-01-04||1963-07-28|1971-03-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||NTRGRESP|NON-TARGET RESPONSE||||RFU|SD||PPTR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|VENDOR|READER 3|U|5||7||OPEN LABEL TREATMENT|1968-12-21||||1966-11-17||1968-11-14|1966-10-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PPTH|CA125 50% RESPONSE||10^6 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|STUDY SUBJECT|ADJUDICATOR 3|N|5||7||TREATMENT|1965-05-22||||1965-09-30||1970-03-10|1969-09-21||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GENEQ/ML|IMMUNOPHENOTYPIC CR||CI/UG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||SCREENING|1967-10-30||||1973-05-24||1970-06-18|1961-09-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/DAY|PD FROM PR||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|INVESTIGATOR|RADIOLOGIST 1|U|1||38||INDUCTION TREATMENT|1962-04-24||||1963-08-09||1967-06-25|1970-06-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||ANATRESP|ANATOMIC RESPONSE||||PACKAGE|UNFAVORABLE RESPONSE||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|INVESTIGATOR|UROLOGIST|Y|2||58||FOLLOW-UP|1965-02-22||||1966-01-07||1963-10-20|1972-12-05||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MM3/MM2/YEAR|NON-PD||DEG/MM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||CONTINUATION TREATMENT|1965-02-17||||1972-06-02||1968-11-17|1960-11-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||METBRESP|METABOLIC RESPONSE||||MMOL/S|RELAPSED DISEASE FROM CR OR PR||UG/H|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|READER 2|U|3||39||TREATMENT|1961-11-09||||1968-09-12||1962-04-23|1964-11-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KEV|SD-CT||MMOL2/L2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|3||39||OBSERVATION|1973-06-01||||1970-12-11||1971-08-29|1968-01-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||ANATRESP|ANATOMIC RESPONSE||||MMHG/L/MIN|MAJOR PATHOLOGIC RESPONSE||UU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|4||88||SCREENING|1966-05-15||||1968-07-09||1960-07-31|1966-04-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PPM|IUPD||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|4||88||INDUCTION TREATMENT|1973-06-16||||1968-03-11||1969-10-25|1968-07-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||L/H/M2|MCR||CI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|5||7||WASHOUT|1973-08-04||||1963-12-01||1968-09-05|1969-11-09||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||TMRESP|TUMOR MARKER RESPONSE||||MV2/HZ|NR||CMHG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|SIBLING|HEMATOLOGIST|NA|5||7||SCREENING|1967-09-01||||1970-06-08||1964-06-12|1973-04-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||C|RELAPSED DISEASE||ML/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|INVESTIGATOR|UROLOGIST|Y|1||38||OPEN LABEL TREATMENT|1972-09-11||||1969-10-06||1961-07-08|1971-02-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/MONTH|CA125 50% RESPONSE||MG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|INVESTIGATOR|DERMATOLOGIST|U|1||38||BASELINE|1968-02-13||||1960-03-14||1972-12-03|1962-11-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG|IUPD||MU|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||FOLLOW-UP|1971-08-09||||1966-09-16||1960-09-30|1969-06-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^6 ORGANISMS/MG|EQUIVOCAL||MESF|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|2||58||RUN-IN|1969-09-02||||1965-05-08||1966-08-19|1961-11-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||BONERESP|BONE RESPONSE||||ABSORBANCE U/ML|IPR||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1969-10-15||||1962-12-23||1969-04-07|1965-11-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||TRGRESP|TARGET RESPONSE||||L/H/M2|EQUIVOCAL||UG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|FRIEND|PHYSIOTHERAPIST|N|3||39||LONG-TERM FOLLOW-UP|1965-09-22||||1973-01-29||1966-08-02|1967-01-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||RDIORESP|RADIOLOGIC RESPONSE||||OHM|CYTOGENETIC PR||MPL U/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|4||88||FOLLOW-UP|1960-09-04||||1962-04-15||1961-07-14|1962-07-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||LIVRRESP|LIVER RESPONSE||||CY/CM|QUANTIFIABLE MRD POSITIVITY||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|Y|FAMILY MEMBER|DERMATOLOGIST|U|4||88||INDUCTION TREATMENT|1966-12-17||||1972-09-19||1960-04-20|1961-02-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||LIVRRESP|LIVER RESPONSE||||V/SEC|MOLECULAR MAJOR RESPONSE||UG/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|INDEPENDENT ASSESSOR|READER 1|Y|5||7||SCREENING|1970-02-14||||1967-02-07||1967-11-25|1960-01-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DRUM|IUPD||G/CAGE/WK|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||LONG-TERM FOLLOW-UP|1967-06-10||||1962-09-11||1967-08-04|1971-11-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|1||||||SPLNRESP|SPLEEN RESPONSE||||PMOL/10^9 CELLS|CYTOGENETIC MINOR RESPONSE||/10^5|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|SIBLING|UROLOGIST|Y|1||38||OPEN LABEL TREATMENT|1965-07-26||||1972-10-26||1965-09-07|1972-06-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IN|CA125 50% RESPONSE||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|PARENT|PEDIATRIC NEUROLOGIST|N|1||38||RUN-IN|1966-05-14||||1973-05-17||1971-04-10|1964-07-03||DURING||DURING|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||OHM|SMD||SUPPOSITORY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|VENDOR|MICROSCOPIST 1|U|2||58||WASHOUT|1966-12-09||||1970-05-30||1961-01-20|1962-02-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||F|NON-PD||DROP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|FAMILY MEMBER|READER 2|Y|2||58||SCREENING|1969-05-22||||1969-12-05||1971-11-10|1967-05-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|1||||||TMRESP|TUMOR MARKER RESPONSE||||PSI|CPR||UMOL/L/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|STUDY SUBJECT|MICROSCOPIST 3|Y|3||39||TREATMENT|1960-01-22||||1971-11-05||1970-10-27|1969-01-13||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|2||||||ANATRESP|ANATOMIC RESPONSE||||UL|MOLECULAR MAJOR RESPONSE||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|3||39||TREATMENT|1961-01-20||||1965-09-18||1960-08-18|1967-05-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|1||||||MOLRESP|MOLECULAR RESPONSE||||10^3 DNA COPIES/ML|NON-CR/NON-PD||10^7/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||OBSERVATION|1960-12-26||||1967-01-27||1961-05-23|1970-03-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MM/2H|CHR||UKAT/10^12 RBC|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|INTERVIEWER|MICROSCOPIST 1|Y|4||88||CONTINUATION TREATMENT|1966-03-10||||1964-09-10||1969-08-26|1970-09-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|1||||||MOLRESP|MOLECULAR RESPONSE||||TUBERCULIN UNIT/ML|INDETERMINATE RESPONSE||BE/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|5||7||BASELINE|1963-10-19||||1966-11-11||1962-04-29|1971-03-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|054D4740-C675-4904-B912-B00A0B089F12|2||||||CYTORESP|CYTOGENETIC RESPONSE||||NFIU|HI-N||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|SPOUSE|RADIOLOGIST 1|N|5||7||WASHOUT|1967-12-06||||1964-06-09||1964-10-18|1972-03-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EJACULATE U|HI-E||MIN/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|PROXY|OPHTHALMOLOGIST|U|1||38||CONTINUATION TREATMENT|1973-06-21||||1962-09-02||1965-06-30|1968-09-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||BESTRESP|BEST OVERALL RESPONSE||||MMU/ML|PSEUDOPROGRESSION||BAR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|DOMESTIC PARTNER|PATHOLOGIST|Y|1||38||WASHOUT|1968-05-01||||1965-11-01||1961-04-06|1971-08-03||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||SPLNRESP|SPLEEN RESPONSE||||GENEQ/ML|CYTOGENETIC CR||%(W/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|ADJUDICATOR|READER|NA|2||58||WASHOUT|1960-07-07||||1967-08-07||1963-01-03|1963-01-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||TMRESP|TUMOR MARKER RESPONSE||||NKAT|QUANTIFIABLE MRD POSITIVITY||MMOL/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|STUDY SUBJECT|UROLOGIST|Y|2||58||WASHOUT|1963-08-05||||1969-06-20||1963-05-08|1968-11-05||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||MOLRESP|MOLECULAR RESPONSE||||U|SD||IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|ADJUDICATOR|MICROSCOPIST 2|Y|3||39||WASHOUT|1969-07-11||||1969-04-04||1968-10-30|1967-06-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FMOL/L|PMR||PSI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|3||39||FOLLOW-UP|1964-07-11||||1972-03-14||1964-06-02|1961-12-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||STRUSTAT|STEROID USE STATUS||||U/M2/DAY|COMPLETE MRD RESPONSE||10^8/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|4||88||SCREENING|1963-08-24||||1962-02-21||1972-12-07|1964-01-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MMOL/DAY|CYTOGENETIC PR||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|GUARDIAN|READER 3|NA|4||88||WASHOUT|1968-10-23||||1965-02-01||1971-10-16|1970-05-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||RDIORESP|RADIOLOGIC RESPONSE||||U/G/H|IUPD||OI50|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|GUARDIAN|OTOLARYNGOLOGIST|N|5||7||INDUCTION TREATMENT|1967-11-06||||1964-01-18||1967-09-07|1962-03-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||ANATRESP|ANATOMIC RESPONSE||||FOZ_BR|PSEUDOPROGRESSION||PELLET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|5||7||RUN-IN|1965-08-06||||1965-07-08||1961-01-02|1972-03-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SHOCK WAVE|MCR||/SEC|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|SIBLING|CARDIOLOGIST|NA|1||38||RUN-IN|1965-12-09||||1972-03-25||1962-02-14|1969-02-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||BONERESP|BONE RESPONSE||||% INHIBITION|RELAPSED DISEASE FROM CR||U/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|FAMILY MEMBER|ENDOCRINOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1965-02-21||||1972-12-24||1971-09-09|1965-05-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||NEWLPROG|NEW LESION PROGRESSION||||%(W/W)|MOLECULAR MAJOR RESPONSE||MM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||RUN-IN|1969-10-08||||1972-12-28||1969-03-17|1960-02-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MOL|ABSENT MORPHOLOGIC RESPONSE||RATIO|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|SIBLING|PATHOLOGIST|Y|2||58||RUN-IN|1970-03-05||||1973-02-14||1963-04-18|1970-09-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||MOLRESP|MOLECULAR RESPONSE||||MG/MOL|NON-CR/NON-PD||FOZ_BR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|Y|PROXY|PEDIATRIC NEUROLOGIST|NA|3||39||RUN-IN|1962-02-27||||1966-09-28||1965-02-24|1966-06-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||METSIND|METASTATIC INDICATOR||||U/G/MIN|PR||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|ADJUDICATOR|READER 2|U|3||39||LONG-TERM FOLLOW-UP|1973-03-30||||1970-09-15||1962-08-08|1967-04-28||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||NEWLIND|NEW LESION INDICATOR||||KG/CM2|INDETERMINATE RESPONSE||VG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|CHILD|ADJUDICATOR 3|NA|4||88||BLINDED TREATMENT|1967-01-10||||1966-06-09||1962-08-06|1962-08-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||METBRESP|METABOLIC RESPONSE||||SCOOPFUL|CYTOGENETIC CR||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BASELINE|1961-06-06||||1960-10-07||1960-04-16|1967-08-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||TRGRESP|TARGET RESPONSE||||MCI/KG|STABLE||MMOL2/L2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|STUDY SUBJECT|INTERNIST|Y|5||7||INDUCTION TREATMENT|1967-11-30||||1971-05-12||1961-11-18|1961-10-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||TRGRESP|TARGET RESPONSE||||CD|PSEUDORESPONSE||UL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|FRIEND|OPTOMETRIST|NA|5||7||FOLLOW-UP|1967-05-27||||1972-09-20||1965-01-05|1967-10-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||APL U|NON-QUANTIFIABLE MRD POSITIVITY||AG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1964-04-22||||1962-10-28||1969-05-20|1960-02-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PKAT|WORSENED||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|CAREGIVER|ADJUDICATOR|Y|1||38||SCREENING|1965-07-07||||1963-05-02||1967-07-28|1964-03-16||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||STRUSTAT|STEROID USE STATUS||||ML/BREATH|IMPROVED||10^6 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|SPOUSE|ADJUDICATOR 1|Y|2||58||BASELINE|1969-10-29||||1970-12-29||1960-12-28|1971-01-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KG/CM|NON-QUANTIFIABLE MRD POSITIVITY||UG/M2/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|FAMILY MEMBER|PHYSIOTHERAPIST|Y|2||58||WASHOUT|1966-04-15||||1968-11-16||1963-08-28|1960-02-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CD/M2|NON-QUANTIFIABLE MRD POSITIVITY||ML/(MIN*100ML)|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|SPOUSE|RADIOLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1970-08-11||||1962-10-30||1960-08-26|1966-01-03||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||MOLRESP|MOLECULAR RESPONSE||||BAR|PD||PT_BR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|GUARDIAN|ONCOLOGIST|N|3||39||SCREENING|1971-08-13||||1968-06-25||1963-08-05|1972-04-17||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/M2/DAY|CRI||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|DOMESTIC PARTNER|ONCOLOGIST 1|NA|4||88||TREATMENT|1966-09-28||||1973-04-09||1966-02-12|1961-08-07||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CFU/ML|IUPD||TESLA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|4||88||INDUCTION TREATMENT|1972-12-16||||1969-02-27||1965-10-05|1968-03-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||TRGRESP|TARGET RESPONSE||||10^3/HPF|TREATMENT FAILURE||PPB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||TREATMENT|1964-09-27||||1960-01-09||1973-06-12|1962-05-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/DL|MRD PERSISTENCE||KBQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|N|5||7||BASELINE|1972-08-05||||1964-06-22||1973-06-09|1972-02-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||TMRESP|TUMOR MARKER RESPONSE||||CGY|DISEASE TRANSFORMATION||FT2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|GUARDIAN|RATER 2|NA|1||38||INDUCTION TREATMENT|1962-11-06||||1960-08-12||1962-10-08|1965-02-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||L/DAY|CYTOGENETIC PR||GY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|U|1||38||RUN-IN|1973-04-02||||1965-08-09||1967-09-02|1971-09-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||STRUSTAT|STEROID USE STATUS||||MOL/L|UNEQUIVOCAL||/10^5|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1967-01-18||||1966-07-01||1969-01-09|1969-04-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||PATHRESP|PATHOLOGIC RESPONSE||||TRANSDUCING UNIT/ML|PD FROM PR||UCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|PROXY|ONCOLOGIST 2|N|2||58||BLINDED TREATMENT|1962-03-14||||1961-11-03||1971-09-23|1966-01-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||NTRGRESP|NON-TARGET RESPONSE||||UG/L|PMD||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|3||39||INDUCTION TREATMENT|1967-08-05||||1967-01-22||1961-05-10|1963-04-30||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^9 ORGANISMS/MG|PD||NMOL BCE/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|PROXY|ADJUDICATOR 2|N|3||39||RUN-IN|1969-01-01||||1965-12-12||1963-12-16|1966-09-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||BONERESP|BONE RESPONSE||||U/MG|MORPHOLOGIC CRI||KG/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1960-10-11||||1964-04-26||1961-01-08|1969-01-30||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UGEQ|PD-CT||ROENTGEN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|FAMILY MEMBER|RATER|N|4||88||INDUCTION TREATMENT|1967-01-30||||1971-08-13||1960-07-28|1966-04-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^7/L|CYTOGENETIC NO RESPONSE||IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|5||7||BASELINE|1965-03-09||||1963-07-04||1972-06-18|1968-09-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NMOL/G|PMD||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|SPOUSE|PATHOLOGIST|N|5||7||WASHOUT|1967-05-17||||1969-06-11||1967-08-11|1965-04-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TABLET|CR||MEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|PROXY|ADJUDICATOR|NA|1||38||OBSERVATION|1969-04-30||||1973-01-08||1967-01-20|1963-12-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||WATT|MAJOR PATHOLOGIC RESPONSE||APL U/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|INVESTIGATOR|CLINICAL PATHOLOGIST|U|1||38||INDUCTION TREATMENT|1969-07-08||||1972-02-03||1971-02-27|1970-05-19||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||YD|CHR||PNU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|GUARDIAN|ADJUDICATOR 1|U|2||58||WASHOUT|1970-12-18||||1962-11-04||1962-09-25|1972-12-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/L FEU|RELAPSED DISEASE FROM CR||ML/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|INTERVIEWER|PATHOLOGIST 2|NA|2||58||BASELINE|1966-11-08||||1962-04-09||1964-01-22|1972-11-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||BESTRESP|BEST OVERALL RESPONSE||||BEAM BREAKS|PSEUDOPROGRESSION||UMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|VENDOR|RADIOLOGIST 2|Y|3||39||OBSERVATION|1965-11-07||||1960-01-07||1966-02-08|1970-10-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BP|MORPHOLOGIC CR||SCM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|FAMILY MEMBER|MICROSCOPIST|NA|3||39||LONG-TERM FOLLOW-UP|1960-02-11||||1960-01-23||1973-08-10|1964-04-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||NEWLPROG|NEW LESION PROGRESSION||||MIN/DAY|COMPLETE MRD RESPONSE||TBSP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|ADJUDICATOR|PHYSIOTHERAPIST|U|4||88||BLINDED TREATMENT|1964-02-18||||1971-08-10||1969-08-24|1968-04-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||M|INDETERMINATE RESPONSE||EU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|SIBLING|MICROSCOPIST 3|Y|4||88||FOLLOW-UP|1960-05-15||||1967-02-14||1972-01-26|1960-04-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KUSP|COMPLETE MRD RESPONSE||CD|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|VENDOR|RADIOLOGIST|N|5||7||WASHOUT|1968-12-23||||1962-02-17||1963-03-11|1973-08-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||METBRESP|METABOLIC RESPONSE||||PRESSOR UNITS|MRD RELAPSE||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|PROXY|ONCOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1971-01-28||||1966-01-26||1971-08-18|1965-06-03||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||TRGRESP|TARGET RESPONSE||||WATT|CPR||S*KPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|SPOUSE|NEUROLOGIST 2|N|1||38||WASHOUT|1967-05-28||||1971-02-20||1962-01-06|1964-07-28||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CM/MIN|IMPROVED||MM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|1||38||TREATMENT|1960-11-27||||1970-03-25||1960-07-27|1965-01-10||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||METBRESP|METABOLIC RESPONSE||||BQ/UG|PCR||TORR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|CHILD|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1968-01-18||||1960-05-10||1961-03-11|1964-05-21||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||NEWLPROG|NEW LESION PROGRESSION||||CM/S|MINOR PATHOLOGIC RESPONSE||BQ/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|PROXY|PEDIATRIC NEUROLOGIST|N|2||58||BLINDED TREATMENT|1968-09-21||||1961-02-17||1963-05-08|1965-10-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||RAD|PD-CT||M|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|SPOUSE|PATHOLOGIST 2|Y|3||39||SCREENING|1967-10-28||||1960-11-16||1966-07-13|1969-12-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||ANATRESP|ANATOMIC RESPONSE||||MMHG|PSA PROGRESSION||NSEC|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|3||39||RUN-IN|1965-10-11||||1964-07-03||1964-10-01|1963-07-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||NTRGRESP|NON-TARGET RESPONSE||||HOMEOPATHIC DILUTION|MOLECULAR CR||MM/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||SCREENING|1963-06-20||||1973-06-24||1964-01-30|1964-08-03||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||L/MIN/M2|IPR||BOTTLE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|PARENT|OTOLARYNGOLOGIST|U|4||88||RUN-IN|1967-08-14||||1971-11-19||1970-10-09|1969-01-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||G/M2/DAY|NED||/10^4|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|N|5||7||SCREENING|1968-12-13||||1970-11-09||1967-11-26|1969-03-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/M2/H|HI-N||PNU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|PROXY|MICROSCOPIST|Y|5||7||RUN-IN|1968-09-02||||1967-01-26||1963-10-16|1965-11-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MV2/HZ|SCR||MEQ/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|SPOUSE|NEUROLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1966-09-26||||1972-05-01||1967-04-23|1967-05-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||SCM|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|DOMESTIC PARTNER|RATER 1|N|1||38||BLINDED TREATMENT|1967-01-13||||1960-10-30||1964-03-13|1965-06-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NM|MRD PERSISTENCE||LOG10 ELISA UNIT/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||BASELINE|1969-07-04||||1966-09-02||1968-06-08|1970-08-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9 CFU/ML|QUANTIFIABLE MRD POSITIVITY||LOG10 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|CAREGIVER|DERMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1970-08-11||||1970-10-25||1971-01-13|1965-03-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|1||||||METBRESP|METABOLIC RESPONSE||||ML/KG|STABLE||PATCH|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|FAMILY MEMBER|INTERNIST|U|3||39||CONTINUATION TREATMENT|1967-07-07||||1967-08-21||1972-03-12|1963-09-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U|PMD||NMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|PROXY|CLINICAL PATHOLOGIST|NA|3||39||INDUCTION TREATMENT|1961-06-27||||1961-04-17||1966-09-14|1961-02-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MEQ/MMOL|NE||CI/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|GUARDIAN|RATER 2|Y|4||88||LONG-TERM FOLLOW-UP|1972-05-13||||1969-08-14||1966-08-13|1964-03-23||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^3 ORGANISMS/ML|NON-QUANTIFIABLE MRD POSITIVITY||KG/M2|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|NA|SPOUSE|OTOLARYNGOLOGIST|N|4||88||BLINDED TREATMENT|1972-05-12||||1970-04-07||1960-05-07|1965-09-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DMOL|PD/RELAPSE AFTER HI||BEATS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|FRIEND|OTOLARYNGOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-08-10||||1962-11-18||1960-08-08|1965-04-01||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|729D254F-628C-4D35-8906-A1344833A610|2||||||METBRESP|METABOLIC RESPONSE||||LX|MOLECULAR CR||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|ADJUDICATOR|NEUROLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1960-12-17||||1970-02-24||1967-08-25|1970-06-23||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PELLET|STABLE||S^-1(%O2)^-1|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|PARENT|NEUROLOGIST 1|Y|1||38||BLINDED TREATMENT|1964-02-29||||1967-07-15||1964-06-10|1966-12-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DPM/MG|PD FROM PR||ENZYME U/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1965-11-18||||1961-12-27||1970-12-14|1971-01-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/L/H|IMMUNOPHENOTYPIC CR||MASK|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|STUDY SUBJECT|RADIOLOGIST 2|U|2||58||OBSERVATION|1972-07-05||||1968-07-02||1971-07-31|1970-10-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/MIN/MMHG|MRD NEGATIVITY||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CAREGIVER|READER 1|Y|2||58||INDUCTION TREATMENT|1966-08-23||||1970-04-05||1960-02-27|1971-06-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^7 CFU/ML|MR||MU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|FRIEND|NEUROLOGIST 1|Y|3||39||BASELINE|1966-09-21||||1962-12-04||1961-09-28|1973-06-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DRUM|CMR||GBQ/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|PARENT|DERMATOLOGIST|N|3||39||INDUCTION TREATMENT|1973-05-15||||1964-11-30||1970-10-03|1961-11-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 ORGANISMS|SD-CT||MOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|SIBLING|ADJUDICATOR 2|U|4||88||TREATMENT|1970-11-02||||1964-06-05||1967-11-13|1960-10-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||LIVRRESP|LIVER RESPONSE||||AGU/ML|NED||DEG2|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||TREATMENT|1970-10-07||||1971-10-21||1964-09-08|1970-08-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||LIVRRESP|LIVER RESPONSE||||ML|PR WITH LYMPHOCYTOSIS||U/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|GUARDIAN|OPHTHALMOLOGIST|N|5||7||WASHOUT|1968-04-01||||1968-06-03||1969-04-01|1965-08-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||BESTRESP|BEST OVERALL RESPONSE||||/LSQN|PMD||BAG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|ADJUDICATOR|DERMATOLOGIST|NA|5||7||SCREENING|1966-11-15||||1967-07-26||1966-08-26|1963-09-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||METBRESP|METABOLIC RESPONSE||||DEG2|PSEUDOPROGRESSION||UG/L FEU|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1||38||OBSERVATION|1972-10-06||||1962-02-07||1961-08-27|1967-11-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CIGARETTE|NON-ICR/NON-IUPD||UG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|FRIEND|PATHOLOGIST 1|NA|1||38||BLINDED TREATMENT|1967-12-31||||1969-12-14||1961-12-30|1969-08-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||LIVRRESP|LIVER RESPONSE||||G/MOL|PDU||PL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|ADJUDICATOR|PATHOLOGIST|Y|2||58||RUN-IN|1961-06-26||||1973-05-10||1970-11-17|1966-06-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||TRGRESP|TARGET RESPONSE||||FT2|HI-P||10^6 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|2||58||CONTINUATION TREATMENT|1960-02-25||||1960-01-16||1972-12-13|1971-01-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/L|DISEASE TRANSFORMATION||MU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|ADJUDICATOR|PATHOLOGIST 2|Y|3||39||RUN-IN|1963-10-12||||1972-05-20||1965-10-01|1965-06-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ANTI-XA IU/ML|PD FROM PR||PG/CELL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||BASELINE|1973-06-24||||1966-03-03||1973-04-14|1960-11-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||NTRGRESP|NON-TARGET RESPONSE||||OHM|MOLECULAR CR||KCAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|FRIEND|MICROSCOPIST|Y|4||88||SCREENING|1962-10-29||||1967-08-09||1971-04-09|1963-04-10||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PPTR|CYTOGENETIC CR||MEQ/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|PROXY|PATHOLOGIST 1|Y|4||88||BASELINE|1968-08-28||||1971-03-21||1960-11-08|1960-12-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/KG/MIN|MORPHOLOGIC CR||FRAMES/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|DOMESTIC PARTNER|READER|Y|5||7||LONG-TERM FOLLOW-UP|1973-05-31||||1961-06-18||1971-11-09|1967-09-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CYLINDER|PR WITH LYMPHOCYTOSIS||UG/L DDU|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|5||7||OBSERVATION|1960-05-01||||1968-01-20||1970-09-18|1972-03-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BREATHS/30S|CR||WEEKS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|FRIEND|ENDOCRINOLOGIST|NA|1||38||OBSERVATION|1961-04-11||||1961-02-13||1965-11-06|1963-05-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||BESTRESP|BEST OVERALL RESPONSE||||NKAT|SMD||DROP|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|VENDOR|ADJUDICATOR|U|1||38||RUN-IN|1971-01-03||||1968-09-30||1970-06-15|1968-03-13||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||NEWLPROG|NEW LESION PROGRESSION||||UL/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MEQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|CHILD|PATHOLOGIST 2|N|2||58||BASELINE|1970-07-31||||1971-03-11||1960-02-13|1962-05-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^6 COPIES/ML|MOLECULAR MAJOR RESPONSE||DAGU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|PARENT|OPHTHALMOLOGIST|NA|2||58||CONTINUATION TREATMENT|1963-01-18||||1962-01-16||1967-03-20|1967-03-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||TRGRESP|TARGET RESPONSE||||MET*MIN|MOLECULAR MAJOR RESPONSE||IU/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|3||39||BASELINE|1961-10-13||||1972-02-05||1967-03-30|1962-05-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||BONERESP|BONE RESPONSE||||OHM|CR||G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|3||39||OBSERVATION|1971-05-26||||1964-03-01||1964-02-19|1968-09-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^4 CFU|MORPHOLOGIC CRI||TRANSDUCING UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|INTERVIEWER|ONCOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1969-10-05||||1968-08-15||1963-03-27|1962-08-31||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^7 PFU|MRD PERSISTENCE||ROENTGEN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|PROXY|OPHTHALMOLOGIST|N|4||88||FOLLOW-UP|1964-02-06||||1971-02-10||1961-10-30|1964-09-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TSP EQ|ABSENT MORPHOLOGIC RESPONSE||MMOL2/L2|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1967-03-27||||1969-08-31||1971-02-28|1971-01-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CI/KG|SMD||UL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|SIGNIFICANT OTHER|READER 3|U|5||7||SCREENING|1970-09-13||||1960-04-08||1966-09-28|1968-06-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/DAY|NON-CR/NON-PD||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|INTERVIEWER|ONCOLOGIST|N|1||38||OPEN LABEL TREATMENT|1968-03-29||||1970-08-15||1960-10-27|1971-12-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KA_U/DL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||OHM|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|INDEPENDENT ASSESSOR|INTERNIST|U|1||38||INDUCTION TREATMENT|1968-08-04||||1967-06-15||1966-02-25|1967-09-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||RDIORESP|RADIOLOGIC RESPONSE||||KBQ/UL|NOT ALL EVALUATED||10^6 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|SPOUSE|OTOLARYNGOLOGIST|NA|2||58||RUN-IN|1970-04-14||||1961-07-08||1963-07-19|1972-06-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/H|ICR||UG/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|STUDY SUBJECT|RATER 1|Y|2||58||CONTINUATION TREATMENT|1960-04-07||||1963-07-10||1973-01-19|1964-01-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE|CPR||K|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|3||39||BASELINE|1966-03-20||||1962-07-01||1961-03-04|1962-02-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||NTRGRESP|NON-TARGET RESPONSE||||LOG10 CFU/ML|CCR||BAR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|GUARDIAN|DERMATOLOGIST|Y|3||39||INDUCTION TREATMENT|1967-07-20||||1971-02-25||1961-10-23|1971-07-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||OVRLRESP|OVERALL RESPONSE||||MEQ|FAVORABLE RESPONSE||PG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|STUDY SUBJECT|UROLOGIST|N|4||88||BASELINE|1960-10-23||||1972-01-05||1970-02-17|1969-08-15||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PLUG|RELAPSED DISEASE||/VF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1964-06-09||||1966-11-27||1960-01-16|1964-06-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/MIN|CYTOGENETIC CR||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|INTERVIEWER|MICROSCOPIST 1|U|5||7||INDUCTION TREATMENT|1967-01-20||||1960-09-26||1964-03-18|1962-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/M2|NED||KIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|SPOUSE|ENDOCRINOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1962-02-13||||1961-03-26||1960-04-23|1964-02-23||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EVENTS|MORPHOLOGIC CR||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1961-10-03||||1969-07-12||1968-09-30|1969-09-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UMOL/L/H|IMMUNOPHENOTYPIC CR||DPM/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|PARENT|FORENSIC PATHOLOGIST|Y|1||38||SCREENING|1966-05-27||||1964-01-06||1969-06-17|1966-04-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||TRGRESP|TARGET RESPONSE||||BEL|NON-PD||WEBER|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|U|2||58||SCREENING|1966-10-08||||1962-12-21||1967-05-30|1972-12-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||LIVRRESP|LIVER RESPONSE||||/2000 RBC|HI-N||10^4/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|PARENT|MICROSCOPIST 2|Y|2||58||OPEN LABEL TREATMENT|1969-08-01||||1963-06-13||1969-08-15|1966-06-24||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||CLINRESP|CLINICAL RESPONSE||||MDFI|CCR||BOX|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR|U|3||39||TREATMENT|1960-05-23||||1963-02-14||1964-09-30|1964-01-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TROCHE|HI-E||MG/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|SIGNIFICANT OTHER|READER 1|N|3||39||OPEN LABEL TREATMENT|1971-01-01||||1967-01-05||1969-08-15|1964-02-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/L|CRI||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|PARENT|READER 3|Y|4||88||OBSERVATION|1962-11-21||||1966-12-17||1966-01-11|1971-06-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PMOL/10^10 CELLS|MOLECULAR MAJOR RESPONSE||MOSM/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|STUDY SUBJECT|NEUROLOGIST 1|Y|4||88||SCREENING|1961-09-03||||1963-10-17||1960-02-05|1971-04-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/L/H|IPR||L/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|5||7||FOLLOW-UP|1960-07-27||||1960-03-26||1973-04-30|1960-02-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NGEQ/L|MORPHOLOGIC CRI||LOG10 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|FAMILY MEMBER|RADIOLOGIST 1|U|5||7||TREATMENT|1962-12-28||||1961-02-25||1960-11-10|1964-06-11||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9 ORGANISMS|IPR||10^6 DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|1||38||BASELINE|1964-04-23||||1970-05-09||1968-05-02|1965-12-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||METSIND|METASTATIC INDICATOR||||LOG10 ELISA UNIT|HI-P||MOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|1||38||RUN-IN|1966-07-20||||1971-08-25||1961-01-25|1964-01-04||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/KG/DAY|CYTOGENETIC CR||PPTR|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|GUARDIAN|NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1963-03-21||||1962-07-13||1961-01-04|1961-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACK YEAR|NED||POINT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|VENDOR|PATHOLOGIST 2|U|2||58||BLINDED TREATMENT|1965-07-11||||1967-11-28||1963-02-21|1962-12-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||NTRGRESP|NON-TARGET RESPONSE||||UL/KG/DAY|PR||JAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|ADJUDICATION COMMITTEE|READER 3|N|3||39||SCREENING|1962-10-18||||1973-08-21||1969-04-11|1964-08-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/CM2|IPR||/MS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|FRIEND|PHYSIOTHERAPIST|Y|3||39||FOLLOW-UP|1971-11-07||||1968-10-10||1971-01-14|1963-04-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/2500 WBC|MR||MSEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|GUARDIAN|READER 2|N|4||88||SCREENING|1968-03-01||||1969-12-11||1971-12-04|1969-06-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||OVRLRESP|OVERALL RESPONSE||||CYLINDER|RELAPSED DISEASE FROM CR OR PR||S^-1(%O2)^-1|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|FRIEND|READER 1|N|4||88||RUN-IN|1967-08-15||||1967-06-04||1961-12-11|1970-04-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||METBRESP|METABOLIC RESPONSE||||DEG/MM|CA125 50% RESPONSE||PFU/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|CHILD|ADJUDICATOR 3|NA|5||7||CONTINUATION TREATMENT|1969-09-16||||1968-12-01||1963-05-14|1961-11-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMAL|PR||C|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|SPOUSE|READER 3|U|5||7||BLINDED TREATMENT|1964-02-21||||1969-10-12||1964-04-14|1964-08-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||BONERESP|BONE RESPONSE||||UL/KG/DAY|PSA PROGRESSION||DAGU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|CHILD|MICROSCOPIST|NA|1||38||OBSERVATION|1965-04-02||||1961-10-02||1968-06-19|1972-05-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||CLINRESP|CLINICAL RESPONSE||||%(W/V)|MAJOR PATHOLOGIC RESPONSE||/MM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|1||38||SCREENING|1967-05-04||||1971-04-22||1963-12-27|1961-11-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SUPPOSITORY|SD-CT||/10^5|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|SIGNIFICANT OTHER|OPTOMETRIST|NA|2||58||INDUCTION TREATMENT|1968-04-14||||1973-09-04||1968-01-28|1973-07-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||BONERESP|BONE RESPONSE||||IU/KG|ISD||MBQ/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1961-12-09||||1966-06-23||1969-05-17|1972-07-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||SPLNRESP|SPLEEN RESPONSE||||CM|NR||DPM/0.5 ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|STUDY SUBJECT|NEUROLOGIST|Y|3||39||OBSERVATION|1965-09-21||||1968-01-05||1963-10-05|1964-02-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||LIVRRESP|LIVER RESPONSE||||MOSM|PD||LOG10 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|GUARDIAN|RADIOLOGIST|NA|3||39||BASELINE|1973-04-14||||1968-04-09||1960-08-08|1963-06-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DPM/ML|IPR||BAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||LONG-TERM FOLLOW-UP|1968-05-23||||1967-09-27||1964-03-22|1972-04-28||DURING||DURING|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TUBERCULIN UNIT/ML|NON-ICR/NON-IUPD||OSM|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||FOLLOW-UP|1964-01-24||||1971-11-30||1960-11-07|1968-03-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PA|FAVORABLE RESPONSE||ML/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|FRIEND|READER|U|5||7||TREATMENT|1961-09-03||||1967-02-08||1966-07-27|1969-11-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SEC|CYTOGENETIC PR||MET*H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|FRIEND|ONCOLOGIST 1|Y|5||7||BASELINE|1961-08-08||||1962-06-25||1969-06-07|1972-02-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CI/UL|HI-N||UCI|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|DOMESTIC PARTNER|ADJUDICATOR|Y|1||38||OBSERVATION|1961-03-29||||1969-08-26||1973-05-25|1970-03-04||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||TMRESP|TUMOR MARKER RESPONSE||||KM/H|MCR||KG/L|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|INVESTIGATOR|CARDIOLOGIST|NA|1||38||RUN-IN|1972-03-27||||1962-07-15||1960-05-30|1968-04-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EJACULATE U|CYTOGENETIC MINOR RESPONSE||MG/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|VENDOR|HEMATOLOGIST|U|2||58||BLINDED TREATMENT|1965-09-20||||1970-05-14||1971-10-30|1965-02-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||AGU/ML|CR-CT||MM/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|INTERVIEWER|DERMATOLOGIST|NA|2||58||BASELINE|1972-03-09||||1967-01-21||1971-03-26|1962-10-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/KG|NED||PMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|FAMILY MEMBER|RATER 1|Y|3||39||FOLLOW-UP|1965-11-03||||1968-01-25||1972-02-01|1962-07-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/M2|MAJOR PATHOLOGIC RESPONSE||CM2|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|ADJUDICATOR|RATER|N|3||39||SCREENING|1964-01-21||||1970-05-23||1962-04-15|1972-08-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/MM2|CR-CT||VG/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|ADJUDICATOR|PATHOLOGIST 1|NA|4||88||FOLLOW-UP|1973-04-02||||1966-12-12||1971-10-10|1967-08-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TSP EQ|ISD||10^9 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|SIBLING|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1973-06-24||||1965-12-15||1968-07-19|1965-03-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BEAM BREAKS|CRI||BEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|STUDY SUBJECT|ONCOLOGIST 1|N|5||7||RUN-IN|1972-09-24||||1972-02-06||1962-11-25|1971-09-21||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||BONERESP|BONE RESPONSE||||FFU|RELAPSED DISEASE||/MONTH|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INTERVIEWER|CARDIOLOGIST|NA|5||7||WASHOUT|1962-01-13||||1969-01-10||1971-10-14|1963-10-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UCI|MORPHOLOGIC CRI||PA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|SPOUSE|RATER|U|1||38||OBSERVATION|1969-03-19||||1969-10-03||1964-07-24|1962-09-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||NEWLIND|NEW LESION INDICATOR||||JOULE|RELAPSED DISEASE||10^6 ORGANISMS|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|CAREGIVER|HEMATOLOGIST|Y|1||38||WASHOUT|1960-01-31||||1971-07-01||1961-12-07|1969-09-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||TRGRESP|TARGET RESPONSE||||CUP|CA125 75% RESPONSE||NSEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|FRIEND|RADIOLOGIST 2|Y|2||58||RUN-IN|1962-01-30||||1962-03-29||1961-09-19|1960-04-29||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||TORR|PD||KIU|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|DOMESTIC PARTNER|PATHOLOGIST 2|N|2||58||FOLLOW-UP|1968-05-25||||1963-04-21||1968-01-12|1965-11-29||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BQ|ICR||U/G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|INTERVIEWER|OPTOMETRIST|Y|3||39||OBSERVATION|1971-11-01||||1966-04-10||1963-09-15|1965-02-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KEV|CYTOGENETIC CR||G/ANIMAL/WK|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|VENDOR|DERMATOLOGIST|N|3||39||WASHOUT|1973-01-11||||1961-11-05||1963-04-28|1961-02-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||S*KPA|HI-P||MPH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|4||88||TREATMENT|1962-12-30||||1969-04-25||1961-10-09|1963-04-21||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CARTRIDGE|CYTOGENETIC NO RESPONSE||RING|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|CLINICAL STUDY SPONSOR|RATER 2|N|4||88||INDUCTION TREATMENT|1960-11-20||||1966-12-15||1961-07-07|1973-05-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/ML|CPR||L/S|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|ADJUDICATOR|ONCOLOGIST 2|U|5||7||FOLLOW-UP|1960-09-02||||1965-06-30||1971-10-03|1961-07-15||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6/EJACULATE U|NOT ALL EVALUATED||10^6 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|STUDY SUBJECT|ONCOLOGIST|NA|5||7||INDUCTION TREATMENT|1969-03-09||||1968-10-02||1960-11-10|1970-12-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||NEWLPROG|NEW LESION PROGRESSION||||NKAT/G HB|MR||MG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|SPOUSE|ONCOLOGIST|N|1||38||WASHOUT|1965-07-22||||1972-02-14||1970-09-11|1972-09-12||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||BONERESP|BONE RESPONSE||||MOL/ML|OPTIMAL MORPHOLOGIC RESPONSE||PMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|GUARDIAN|NEUROLOGIST 1|N|1||38||RUN-IN|1962-08-03||||1973-03-10||1965-06-28|1961-07-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CM|CRI||IN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|SIBLING|RATER 1|U|2||58||SCREENING|1970-04-07||||1965-08-07||1973-03-12|1966-09-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||OVRLRESP|OVERALL RESPONSE||||MM|PMD||BQ/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|2||58||INDUCTION TREATMENT|1966-03-21||||1962-01-05||1961-12-28|1963-06-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MMOL|CYTOGENETIC CR||/40 HPFS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|PARENT|PATHOLOGIST 2|U|3||39||BASELINE|1969-07-19||||1972-08-14||1970-12-18|1965-09-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||MOLRESP|MOLECULAR RESPONSE||||JAR|NON-QUANTIFIABLE MRD POSITIVITY||COPIES/UG|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|3||39||BASELINE|1966-06-17||||1967-12-02||1960-12-02|1965-10-03||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||ANATRESP|ANATOMIC RESPONSE||||OZ|PCR||ML/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||WASHOUT|1968-02-01||||1970-07-18||1960-01-17|1961-08-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||APL U/ML|HI-N||PATCH|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|VENDOR|PATHOLOGIST 1|NA|4||88||WASHOUT|1963-07-01||||1966-02-15||1966-07-17|1971-06-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MOL/MOL|MAJOR PATHOLOGIC RESPONSE||10^5/HPF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|DOMESTIC PARTNER|ADJUDICATOR|Y|5||7||BASELINE|1967-06-10||||1969-08-05||1961-08-23|1967-01-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BOTTLE|NPR||APPLICATION|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|SIBLING|ONCOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1964-07-13||||1970-04-06||1960-06-17|1963-11-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/10^12 RBC|PD||MG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|INDEPENDENT ASSESSOR|RATER|NA|1||38||OBSERVATION|1965-05-26||||1969-03-19||1967-04-12|1970-07-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||CYTORESP|CYTOGENETIC RESPONSE||||M/SEC2|CMR||CM/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|PROXY|ONCOLOGIST 1|N|1||38||BASELINE|1960-08-05||||1973-04-18||1966-05-24|1960-01-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||BONERESP|BONE RESPONSE||||USP U|MORPHOLOGIC CR||U/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|FAMILY MEMBER|UROLOGIST|N|2||58||BLINDED TREATMENT|1972-07-22||||1970-03-07||1964-04-27|1963-10-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/SEC/1.73M2|MR||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|FRIEND|PATHOLOGIST 2|N|2||58||INDUCTION TREATMENT|1969-09-20||||1967-02-03||1967-05-23|1960-09-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||RDIORESP|RADIOLOGIC RESPONSE||||FINGERTIP UNIT|PSEUDOPROGRESSION||MNFI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|SIBLING|DERMATOLOGIST|N|3||39||WASHOUT|1965-04-22||||1967-05-10||1965-09-23|1963-07-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||CLINRESP|CLINICAL RESPONSE||||UG/G/MIN|MRD PERSISTENCE||CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|PARENT|RADIOLOGIST 2|N|3||39||BLINDED TREATMENT|1963-02-26||||1972-05-02||1972-05-22|1963-01-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||VG/KG|NOT ALL EVALUATED||GY/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|FAMILY MEMBER|NEUROLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1966-08-06||||1970-01-30||1973-06-20|1965-11-16||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||ANATRESP|ANATOMIC RESPONSE||||PPB|NE||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|VENDOR|MICROSCOPIST 2|NA|4||88||FOLLOW-UP|1962-11-12||||1969-03-12||1965-11-14|1973-04-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||OVRLRESP|OVERALL RESPONSE||||JDF UNIT|PARTIAL MORPHOLOGIC RESPONSE||IU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|5||7||BASELINE|1967-03-25||||1970-06-21||1962-04-13|1963-09-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||METSIND|METASTATIC INDICATOR||||G/ANIMAL/DAY|OPTIMAL MORPHOLOGIC RESPONSE||MMU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|5||7||TREATMENT|1962-02-18||||1964-11-22||1967-07-22|1960-06-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/L|PD FROM PR||10^3 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|INTERVIEWER|READER 2|NA|1||38||BASELINE|1969-08-19||||1962-10-02||1971-05-31|1971-06-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DEG|FAVORABLE RESPONSE||DAGU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|STUDY SUBJECT|READER 3|Y|1||38||WASHOUT|1971-02-23||||1966-06-26||1970-05-09|1964-10-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LINEAR FT*LB|NED||ENZYME U/G HB|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|SPOUSE|READER 1|U|2||58||RUN-IN|1960-03-06||||1962-09-18||1971-12-01|1960-08-13||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||%(W/W)|CPR||/200 HPFS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|FRIEND|FORENSIC PATHOLOGIST|NA|2||58||INDUCTION TREATMENT|1963-05-12||||1967-12-06||1971-12-09|1963-01-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||L/MIN|CYTOGENETIC CR||QUANTITY SUFFICIENT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|CHILD|ADJUDICATOR 3|N|3||39||BLINDED TREATMENT|1960-03-15||||1971-06-14||1968-04-23|1967-03-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||LIVRRESP|LIVER RESPONSE||||CM/MIN|OPTIMAL MORPHOLOGIC RESPONSE||UG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|FAMILY MEMBER|OTOLARYNGOLOGIST|Y|3||39||BASELINE|1960-09-30||||1960-07-27||1969-08-22|1973-01-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||CLINRESP|CLINICAL RESPONSE||||10^3 ORGANISMS/G|NON-PD||CMHG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|PARENT|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1963-05-06||||1961-07-04||1973-01-02|1969-03-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||NEWLPROG|NEW LESION PROGRESSION||||HOURS|EQUIVOCAL||BOTTLE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4||88||LONG-TERM FOLLOW-UP|1967-01-07||||1972-02-27||1971-12-14|1971-01-15||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||ANATRESP|ANATOMIC RESPONSE||||MMOL/DAY|PMD||L/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|SPOUSE|HEMATOLOGIST|Y|5||7||CONTINUATION TREATMENT|1961-11-19||||1963-09-07||1967-11-29|1968-09-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 DNA COPIES/ML|CA125 75% RESPONSE||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|5||7||CONTINUATION TREATMENT|1964-06-18||||1962-05-24||1963-05-20|1962-03-02||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HPA|HI-P||MEQ/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|CAREGIVER|READER 3|NA|1||38||OPEN LABEL TREATMENT|1968-12-16||||1971-06-17||1960-07-02|1963-11-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||NEWLPROG|NEW LESION PROGRESSION||||CONTAINER|HI-E||CI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||WASHOUT|1968-01-28||||1966-09-23||1960-03-11|1972-08-29||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||TMRESP|TUMOR MARKER RESPONSE||||YD|NON-CR/NON-PD||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|SIBLING|PATHOLOGIST|N|2||58||BLINDED TREATMENT|1964-01-05||||1962-02-24||1961-09-13|1968-07-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||VG/KG|NON-PD||MMHG/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||OPEN LABEL TREATMENT|1960-04-05||||1968-03-30||1972-10-24|1964-07-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||TRGRESP|TARGET RESPONSE||||M/SEC2|PCR||LM|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|RATER 2|NA|3||39||BLINDED TREATMENT|1960-10-18||||1972-07-08||1964-08-12|1967-01-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||TRGRESP|TARGET RESPONSE||||CCID 50/DOSE|PDU||PPB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|INTERVIEWER|PATHOLOGIST 1|NA|3||39||OBSERVATION|1960-12-11||||1970-12-18||1961-10-29|1967-07-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||BESTRESP|BEST OVERALL RESPONSE||||EVENTS|STABLE||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|4||88||OPEN LABEL TREATMENT|1960-07-16||||1969-01-26||1963-04-19|1965-03-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||NEWLPROG|NEW LESION PROGRESSION||||NMOL/L/H|IUPD||POUCH|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|GUARDIAN|RADIOLOGIST|N|4||88||CONTINUATION TREATMENT|1960-09-23||||1969-08-26||1965-04-17|1966-08-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TORR|CYTOGENETIC PR||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|SIBLING|FORENSIC PATHOLOGIST|Y|5||7||TREATMENT|1961-04-07||||1961-03-19||1966-04-25|1969-04-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL/S|IMMUNOPHENOTYPIC CR||UG/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|FAMILY MEMBER|MICROSCOPIST 2|Y|5||7||SCREENING|1972-09-02||||1962-05-15||1964-10-03|1964-11-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||KA_U/DL|NON-QUANTIFIABLE MRD POSITIVITY||MCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||OBSERVATION|1966-05-16||||1967-06-23||1965-02-21|1964-07-14||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||NEWLPROG|NEW LESION PROGRESSION||||MPS U|NE||KEV|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|CAREGIVER|RATER|U|1||38||WASHOUT|1961-01-31||||1972-08-04||1965-10-02|1964-05-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||BONERESP|BONE RESPONSE||||U/CL|RELAPSED DISEASE FROM CR||BOLUS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|PROXY|MICROSCOPIST 3|NA|2||58||WASHOUT|1968-03-12||||1972-06-09||1966-06-19|1962-11-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||SPLNRESP|SPLEEN RESPONSE||||CIGAR|NOT ALL EVALUATED||CM H2O|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|SIBLING|ENDOCRINOLOGIST|U|2||58||RUN-IN|1961-03-05||||1971-04-30||1969-11-22|1968-08-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CM/MIN|NPR||G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|GUARDIAN|FORENSIC PATHOLOGIST|Y|3||39||BASELINE|1973-03-24||||1967-08-18||1964-03-30|1969-03-06||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||TRGRESP|TARGET RESPONSE||||LX|PMD||UM/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|FAMILY MEMBER|RADIOLOGIST 1|Y|3||39||SCREENING|1968-09-11||||1971-01-09||1961-11-26|1964-01-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||SBE/ML|HI-N||P|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|INTERVIEWER|MICROSCOPIST|U|4||88||SCREENING|1972-06-29||||1962-02-23||1972-12-01|1963-06-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/UG|PR WITH LYMPHOCYTOSIS||ML/100G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|4||88||CONTINUATION TREATMENT|1972-10-21||||1965-09-11||1962-07-03|1967-04-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||STRUSTAT|STEROID USE STATUS||||CAN|PMR||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|INVESTIGATOR|READER 1|U|5||7||OPEN LABEL TREATMENT|1967-10-25||||1969-11-30||1971-11-03|1963-08-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EVENTS|HI-P||BE/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|INDEPENDENT ASSESSOR|PATHOLOGIST|Y|5||7||BASELINE|1972-06-09||||1961-03-29||1970-07-20|1962-04-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/KG|MINOR PATHOLOGIC RESPONSE||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|INTERVIEWER|PATHOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1966-06-16||||1968-01-05||1962-06-02|1973-08-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/MIN|NON-ICR/NON-IUPD||GY/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|STUDY SUBJECT|ADJUDICATOR|U|1||38||LONG-TERM FOLLOW-UP|1971-11-15||||1960-04-20||1966-05-04|1965-09-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3/HPF|NPR||GY/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|GUARDIAN|READER 1|U|2||58||LONG-TERM FOLLOW-UP|1962-02-17||||1973-01-11||1973-02-24|1973-07-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PG/CELL|IPR||10^6 IU|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|SIBLING|PATHOLOGIST 2|U|2||58||OBSERVATION|1970-06-15||||1960-04-15||1960-04-17|1968-05-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||NTRGRESP|NON-TARGET RESPONSE||||BQ/MG|DISEASE TRANSFORMATION||PT_US|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|DOMESTIC PARTNER|NEUROLOGIST 1|NA|3||39||SCREENING|1971-10-24||||1968-12-01||1960-10-31|1968-10-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KPA|IMMUNOPHENOTYPIC CR||KUSP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|GUARDIAN|PHYSIOTHERAPIST|N|3||39||INDUCTION TREATMENT|1963-11-24||||1968-03-09||1971-07-10|1964-01-22||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%(V/V)|CMR||HR/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|ADJUDICATOR|HEMATOLOGIST|N|4||88||TREATMENT|1961-09-11||||1966-07-15||1962-10-17|1966-12-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/M2/MIN|CA125 50% RESPONSE||UKAT/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|PARENT|ONCOLOGIST 2|U|4||88||OBSERVATION|1967-01-08||||1961-06-05||1960-08-03|1964-08-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ELISA UNIT/DOSE|INCREASED||IMPLANT|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|FAMILY MEMBER|ADJUDICATOR 2|U|5||7||WASHOUT|1972-05-08||||1966-08-15||1972-10-11|1971-06-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||TMRESP|TUMOR MARKER RESPONSE||||FMOL/L|PR||UCI|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|SPOUSE|INTERNIST|Y|5||7||WASHOUT|1963-01-06||||1964-10-17||1968-10-11|1963-08-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^6/L|MCR||WEBER|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|1||38||WASHOUT|1969-08-08||||1961-01-17||1967-02-17|1971-06-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||NTRGRESP|NON-TARGET RESPONSE||||MM/H|TREATMENT FAILURE||GY/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|1||38||BLINDED TREATMENT|1965-02-10||||1964-10-25||1963-11-25|1973-09-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/L/H|CYTOGENETIC NO RESPONSE||AMFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|CLINICAL RESEARCH ASSOCIATE|RATER|N|2||58||FOLLOW-UP|1963-06-06||||1960-02-19||1965-05-06|1965-01-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||OVRLRESP|OVERALL RESPONSE||||UV|CYTOGENETIC CR||10^9/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|SPOUSE|RADIOLOGIST 2|U|2||58||OBSERVATION|1970-09-02||||1969-09-10||1967-07-01|1967-07-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3 COPIES/ML|SMD||10^9/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|SIBLING|ONCOLOGIST 2|U|3||39||TREATMENT|1965-09-01||||1963-04-11||1970-09-30|1963-05-07||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||NTRGRESP|NON-TARGET RESPONSE||||CI/MG|MR||10^6 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|SIBLING|UROLOGIST|NA|3||39||RUN-IN|1963-10-29||||1961-05-07||1961-09-04|1970-04-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||METSIND|METASTATIC INDICATOR||||UCI|OPTIMAL MORPHOLOGIC RESPONSE||L/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|4||88||BLINDED TREATMENT|1966-11-26||||1963-01-04||1970-02-06|1964-04-15||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TITER|MR||MG/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||OBSERVATION|1971-05-17||||1970-04-21||1970-05-26|1964-05-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/2500 WBC|CHR||M3|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CAREGIVER|ADJUDICATOR|Y|5||7||RUN-IN|1968-05-05||||1967-04-27||1962-08-10|1972-09-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||LIVRRESP|LIVER RESPONSE||||UM2|UNEQUIVOCAL||UG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5||7||RUN-IN|1962-06-06||||1969-01-06||1967-03-15|1969-10-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||BONERESP|BONE RESPONSE||||MEQ/ML|HI-E||STRIP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|SPOUSE|RATER 1|N|1||38||OPEN LABEL TREATMENT|1966-02-18||||1968-06-27||1968-04-05|1961-08-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||STRUSTAT|STEROID USE STATUS||||UMOL/L/MIN|IMMUNOPHENOTYPIC CR||PIXELS/CM|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1966-02-05||||1971-05-07||1968-02-12|1964-07-31||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GAUSS|PDU||H*%|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|FAMILY MEMBER|READER 2|U|2||58||CONTINUATION TREATMENT|1972-10-21||||1965-02-01||1965-11-14|1968-03-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/MMOL|PR||PSEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|2||58||OBSERVATION|1960-12-20||||1964-04-02||1968-06-17|1961-07-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ENZYME U/L|MORPHOLOGIC CRI||ML*CMH2O|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1960-08-21||||1966-07-27||1961-01-04|1965-02-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||MOLRESP|MOLECULAR RESPONSE||||NG/DAY|CMR||IU/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|VENDOR|RATER 1|U|3||39||FOLLOW-UP|1973-01-25||||1970-10-29||1967-12-03|1969-04-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||BESTRESP|BEST OVERALL RESPONSE||||/LSQN|RELAPSED DISEASE FROM CR||%|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|PARENT|ADJUDICATOR 1|Y|4||88||OPEN LABEL TREATMENT|1964-03-05||||1964-12-07||1964-09-25|1969-06-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||NEWLIND|NEW LESION INDICATOR||||APPLICATION|CYTOGENETIC CR||PRESSOR UNITS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|DOMESTIC PARTNER|PATHOLOGIST|Y|4||88||RUN-IN|1966-11-03||||1970-05-20||1973-08-25|1969-11-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UV*SEC|CRI||MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|INVESTIGATOR|OPHTHALMOLOGIST|NA|5||7||INDUCTION TREATMENT|1970-09-27||||1963-11-01||1972-04-10|1964-11-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||OVRLRESP|OVERALL RESPONSE||||ANTIBODY UNIT|NPR||NKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|INTERVIEWER|ONCOLOGIST 1|NA|5||7||FOLLOW-UP|1968-05-05||||1970-08-04||1972-02-29|1971-11-19||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GPL U/ML|MAJOR PATHOLOGIC RESPONSE||MGEQ|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|1||38||TREATMENT|1972-08-24||||1960-06-26||1963-10-29|1960-06-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||L/S|IMPROVED||CUP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|INTERVIEWER|ONCOLOGIST 2|U|1||38||INDUCTION TREATMENT|1969-02-14||||1972-06-28||1971-03-12|1965-12-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KCAL|MORPHOLOGIC LEUKEMIA-FREE STATE||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|2||58||BASELINE|1961-11-15||||1970-02-18||1968-12-14|1970-05-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MAMP|NR||ML/MIN/MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|2||58||FOLLOW-UP|1965-05-06||||1969-03-03||1972-01-21|1971-09-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||BONERESP|BONE RESPONSE||||/MBP|CYTOGENETIC NO RESPONSE||L/S/KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|3||39||TREATMENT|1970-09-06||||1973-05-25||1970-09-22|1961-09-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||NEWLPROG|NEW LESION PROGRESSION||||S/H|MOLECULAR CR||/MONTH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|PROXY|INTERNIST|Y|3||39||FOLLOW-UP|1962-12-01||||1970-08-10||1965-12-27|1967-06-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||NTRGRESP|NON-TARGET RESPONSE||||KM|MRD NEGATIVITY||UGEQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|INTERVIEWER|CLINICAL PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1971-06-18||||1966-10-12||1969-05-22|1962-08-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||NTRGRESP|NON-TARGET RESPONSE||||PA|NON-QUANTIFIABLE MRD POSITIVITY||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||RUN-IN|1970-04-12||||1964-11-28||1971-03-23|1968-01-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MOL|NPR||TABLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|FAMILY MEMBER|ADJUDICATOR 2|NA|5||7||OBSERVATION|1965-06-06||||1971-03-04||1960-05-27|1966-10-31||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PMOL/DL|PR-CT||FMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|SIBLING|NEUROLOGIST|NA|5||7||BLINDED TREATMENT|1968-10-11||||1961-06-26||1968-08-02|1972-03-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9/DOSE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|ADJUDICATOR|READER 1|U|1||38||TREATMENT|1963-08-19||||1970-02-09||1970-08-07|1966-04-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG10 ELISA UNIT|PD/RELAPSE AFTER HI||MEQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|1||38||BLINDED TREATMENT|1970-03-08||||1965-07-31||1966-05-12|1960-02-16||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 CFU/G|INDETERMINATE RESPONSE||M/SEC2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|FAMILY MEMBER|PATHOLOGIST 2|Y|2||58||WASHOUT|1965-12-30||||1964-10-19||1961-01-19|1968-05-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||RING|HI-P||UL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|STUDY SUBJECT|RATER 2|N|2||58||INDUCTION TREATMENT|1973-05-04||||1964-06-03||1968-03-05|1962-12-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||NEWLPROG|NEW LESION PROGRESSION||||JDF UNIT|PD-CT||UMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|3||39||INDUCTION TREATMENT|1966-12-30||||1968-10-04||1971-12-03|1970-10-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||STRUSTAT|STEROID USE STATUS||||MOL/DAY|MCR||AFU|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|INTERVIEWER|MICROSCOPIST|U|3||39||TREATMENT|1962-04-04||||1966-07-30||1968-11-27|1973-07-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||OD UNIT|CYTOGENETIC MINIMAL RESPONSE||BREATHS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|CHILD|MICROSCOPIST|N|4||88||BASELINE|1973-04-20||||1973-02-17||1963-06-08|1968-01-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||OHM|PCR||GRAVITATIONAL UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|STUDY SUBJECT|MICROSCOPIST 2|U|4||88||RUN-IN|1969-09-25||||1966-02-28||1960-07-04|1968-02-01||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||SPLNRESP|SPLEEN RESPONSE||||DEG/MM|PMR||UKAT|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|STUDY SUBJECT|PATHOLOGIST|N|5||7||TREATMENT|1966-10-22||||1961-09-07||1963-05-21|1969-01-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||BESTRESP|BEST OVERALL RESPONSE||||PUFF|ICPD||DIP|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|5||7||BLINDED TREATMENT|1964-04-11||||1966-10-04||1968-03-28|1970-03-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||OVRLRESP|OVERALL RESPONSE||||KIU|CA125 50% RESPONSE||10^3 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|1||38||OBSERVATION|1960-10-20||||1960-08-30||1968-09-04|1964-04-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||BONERESP|BONE RESPONSE||||P|MAJOR PATHOLOGIC RESPONSE||/5X10^4 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|1||38||CONTINUATION TREATMENT|1967-01-27||||1961-02-07||1965-07-31|1967-06-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/M2/H|PMD||MBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2||58||CONTINUATION TREATMENT|1973-06-02||||1971-11-18||1966-08-28|1963-01-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/DL|PD/RELAPSE AFTER HI||FINGERTIP UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|SIBLING|READER 2|Y|2||58||SCREENING|1962-03-24||||1969-07-27||1963-08-23|1963-11-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||NEWLIND|NEW LESION INDICATOR||||COPIES/UL|PD-CT||ML/CAGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3||39||SCREENING|1966-08-09||||1968-05-12||1964-11-29|1964-05-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ROENTGEN|ICPD||MG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|PARENT|INTERNIST|NA|3||39||RUN-IN|1969-12-23||||1965-04-11||1973-01-19|1965-09-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ECL UNIT|NPR||ML/S|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|4||88||TREATMENT|1964-10-03||||1966-09-09||1960-02-22|1962-05-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||NEWLPROG|NEW LESION PROGRESSION||||IMPLANT|TREATMENT FAILURE||MEQ/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|SPOUSE|READER 1|NA|4||88||RUN-IN|1969-11-13||||1964-08-09||1973-03-21|1962-02-06||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PUFF|INCREASED||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|SIBLING|DERMATOLOGIST|U|5||7||OPEN LABEL TREATMENT|1960-11-02||||1972-12-04||1964-07-09|1966-09-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||SPLNRESP|SPLEEN RESPONSE||||DAGU/ML|NON-CR/NON-PD||IU/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|CHILD|MICROSCOPIST 1|NA|5||7||FOLLOW-UP|1960-11-04||||1967-07-07||1963-07-17|1963-10-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||CLINRESP|CLINICAL RESPONSE||||KG/L|PD FROM PR||GLOBULE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|INVESTIGATOR|READER|NA|1||38||OBSERVATION|1966-01-19||||1969-09-09||1963-12-23|1970-01-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||NTRGRESP|NON-TARGET RESPONSE||||PM|CHR||SCOOPFUL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1||38||BLINDED TREATMENT|1965-11-29||||1963-08-28||1972-10-16|1970-07-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||GTT|SMD||CAPSULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|U|2||58||OPEN LABEL TREATMENT|1965-04-27||||1960-11-01||1969-06-05|1968-06-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||OVRLRESP|OVERALL RESPONSE||||PFU/ANIMAL|MAJOR PATHOLOGIC RESPONSE||IU/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|PARENT|CARDIOLOGIST|Y|2||58||INDUCTION TREATMENT|1960-03-22||||1960-05-10||1968-06-08|1972-09-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU|WORSENED||10^3 DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|PARENT|ONCOLOGIST 1|NA|3||39||BLINDED TREATMENT|1971-01-15||||1973-01-06||1960-03-07|1965-10-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||LIVRRESP|LIVER RESPONSE||||MG/L|PD FROM PR||FEU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|FRIEND|ADJUDICATOR 2|NA|3||39||BASELINE|1973-03-08||||1966-03-24||1961-11-30|1960-12-20||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||TRGRESP|TARGET RESPONSE||||AU/ML|MAJOR PATHOLOGIC RESPONSE||KUSP|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|PARENT|ADJUDICATOR 2|U|4||88||WASHOUT|1960-10-27||||1964-05-01||1960-12-30|1965-08-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/MMOL|MCR||MEQ/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|CAREGIVER|MICROSCOPIST 1|Y|4||88||INDUCTION TREATMENT|1973-08-28||||1968-01-30||1969-12-10|1973-05-29||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/L|DECREASED||FT2|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|5||7||FOLLOW-UP|1964-03-11||||1962-12-04||1960-02-08|1966-12-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/G|RELAPSED DISEASE FROM CR OR PR||CUP EQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|5||7||FOLLOW-UP|1968-01-03||||1963-01-19||1970-11-06|1970-01-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||ANATRESP|ANATOMIC RESPONSE||||OZ EQ|SD||PACKAGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|VENDOR|PATHOLOGIST 1|N|1||38||BASELINE|1961-07-31||||1970-03-16||1962-07-09|1963-03-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MBQ/UL|NED||ECL UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|1||38||SCREENING|1967-12-13||||1962-05-06||1966-12-22|1973-08-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||SPLNRESP|SPLEEN RESPONSE||||MPS U|NON-ICR/NON-IUPD||L/S/KPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|FRIEND|NEUROLOGIST|U|2||58||INDUCTION TREATMENT|1972-05-03||||1971-03-28||1968-02-13|1963-08-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/KG|NON-ICR/NON-IUPD||HZ/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|INTERVIEWER|ADJUDICATOR 3|N|2||58||BASELINE|1965-01-09||||1965-04-22||1969-11-09|1970-10-10||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/L|EQUIVOCAL||PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|3||39||CONTINUATION TREATMENT|1972-02-26||||1966-06-11||1970-11-23|1963-04-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||USIEMENS|PR WITH LYMPHOCYTOSIS||GBQ/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|SIGNIFICANT OTHER|NEUROLOGIST 1|N|3||39||BLINDED TREATMENT|1970-09-09||||1972-06-01||1966-02-14|1961-06-16||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||OVRLRESP|OVERALL RESPONSE||||NMOL/KG/DAY|PR-CT||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|N|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||BLINDED TREATMENT|1965-04-10||||1963-11-14||1970-09-09|1968-07-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/L|CYTOGENETIC CR||VOXEL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|GUARDIAN|READER|NA|4||88||BLINDED TREATMENT|1963-10-06||||1968-01-22||1967-12-31|1962-04-10||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||WATT|CYTOGENETIC CR||KM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|CHILD|ENDOCRINOLOGIST|Y|5||7||INDUCTION TREATMENT|1960-05-03||||1962-12-13||1971-12-08|1965-03-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GBQ/UG|MOLECULAR CR||ML/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|GUARDIAN|NEUROLOGIST|U|5||7||OBSERVATION|1967-07-23||||1973-06-04||1960-11-22|1968-03-15||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||APPLICATION|PD||10^8/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|FAMILY MEMBER|MICROSCOPIST 3|NA|1||38||BASELINE|1965-11-22||||1969-11-07||1973-08-01|1968-09-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|2||||||OVRLRESP|OVERALL RESPONSE||||MOSM/KG|QUANTIFIABLE MRD POSITIVITY||NMOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|GUARDIAN|UROLOGIST|Y|1||38||TREATMENT|1968-04-04||||1964-04-27||1964-10-29|1968-02-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|1||||||CYTORESP|CYTOGENETIC RESPONSE||||LOG EID 50/DOSE|STABLE||U/CL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|VENDOR|ADJUDICATOR 3|NA|2||58||LONG-TERM FOLLOW-UP|1961-08-21||||1965-01-21||1962-01-26|1961-04-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|2||||||NEWLPROG|NEW LESION PROGRESSION||||VG/KG|MOLECULAR MAJOR RESPONSE||CI/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|SPOUSE|PATHOLOGIST 1|U|2||58||OPEN LABEL TREATMENT|1961-04-21||||1961-04-19||1965-07-14|1963-01-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|1||||||STRUSTAT|STEROID USE STATUS||||UL/KG/DAY|HI-N||VIRTUAL PIXEL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|INVESTIGATOR|ONCOLOGIST|N|3||39||BASELINE|1967-02-10||||1961-04-18||1972-03-06|1960-04-24||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DAYS/MONTH|WORSENED||NG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|SIBLING|CARDIOLOGIST|Y|3||39||BASELINE|1967-03-06||||1969-01-12||1963-02-02|1970-12-31||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CG|CYTOGENETIC MINOR RESPONSE||NG|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|CLINICAL RESEARCH COORDINATOR|READER 3|NA|4||88||OBSERVATION|1965-08-11||||1971-01-16||1971-06-28|1969-08-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|2||||||BONERESP|BONE RESPONSE||||DROP|RELAPSED DISEASE||PMOL/10^10 CELLS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|STUDY SUBJECT|NEUROLOGIST|Y|4||88||SCREENING|1973-05-25||||1967-05-02||1965-09-27|1966-07-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MKAT|INDETERMINATE RESPONSE||VP/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|PARENT|HEMATOLOGIST|N|5||7||OPEN LABEL TREATMENT|1969-04-02||||1961-04-30||1960-04-29|1970-10-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|54507F00-0C16-4F35-A762-104B47390283|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/KG|CRI||RFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|INDEPENDENT ASSESSOR|READER|N|5||7||FOLLOW-UP|1965-02-02||||1966-06-23||1966-09-21|1972-07-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KG/CM|PD-CT||VG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|1||38||RUN-IN|1970-03-31||||1968-12-11||1964-04-08|1964-03-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MEQ/DL|PDU||100 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|NA|1||38||FOLLOW-UP|1966-10-20||||1969-06-15||1968-12-22|1964-11-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMOL/MOL|CR||UM/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|PARENT|ADJUDICATOR|NA|2||58||LONG-TERM FOLLOW-UP|1966-04-07||||1970-05-22||1961-02-02|1973-02-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||TMRESP|TUMOR MARKER RESPONSE||||LB|OPTIMAL MORPHOLOGIC RESPONSE||MANSON U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||CONTINUATION TREATMENT|1968-04-22||||1960-04-16||1968-09-12|1960-10-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||TMRESP|TUMOR MARKER RESPONSE||||M/SEC2|MRD PERSISTENCE||/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|PARENT|ADJUDICATOR 1|Y|3||39||SCREENING|1960-04-07||||1972-07-16||1967-11-30|1960-04-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||METBRESP|METABOLIC RESPONSE||||PG/CELL|FAVORABLE RESPONSE||DYN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|SIBLING|RATER 2|Y|3||39||BASELINE|1960-08-10||||1973-05-01||1973-03-06|1969-10-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||BONERESP|BONE RESPONSE||||UMOL/MIN|HI-E||PMOL/L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|SIBLING|UROLOGIST|U|4||88||RUN-IN|1966-05-28||||1960-06-09||1964-07-11|1963-08-18||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/CAGE/WK|RELAPSED DISEASE FROM CR OR PR||HOMEOPATHIC DILUTION|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|INTERVIEWER|OPHTHALMOLOGIST|NA|4||88||CONTINUATION TREATMENT|1962-06-21||||1966-10-07||1965-03-08|1960-12-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||MOLRESP|MOLECULAR RESPONSE||||UMOL/KG/MIN|CR-CT||ML/CAGE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OPEN LABEL TREATMENT|1967-08-24||||1960-01-20||1968-04-15|1973-05-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MCI|RELAPSED DISEASE FROM CR OR PR||ML/CM3/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1969-04-26||||1962-05-04||1968-06-28|1964-10-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/H|PSEUDOPROGRESSION||CCID 50/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|CHILD|FORENSIC PATHOLOGIST|Y|1||38||OBSERVATION|1964-05-29||||1967-05-24||1963-04-30|1962-08-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||TMRESP|TUMOR MARKER RESPONSE||||U/DL|WORSENED||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|1||38||WASHOUT|1967-04-18||||1966-09-23||1970-09-30|1960-02-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/L DDU|DECREASED||VG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1970-07-28||||1966-01-10||1971-11-27|1966-02-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||EQ|MORPHOLOGIC LEUKEMIA-FREE STATE||L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|INTERVIEWER|PATHOLOGIST 2|NA|2||58||BLINDED TREATMENT|1964-11-27||||1966-02-13||1964-04-10|1963-10-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||YEARS|HI-N||UG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|STUDY SUBJECT|MICROSCOPIST 3|N|3||39||INDUCTION TREATMENT|1967-12-19||||1966-08-16||1972-08-26|1963-05-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UV2|RELAPSED DISEASE FROM CR||ANTI-XA IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|GUARDIAN|READER 2|Y|3||39||INDUCTION TREATMENT|1973-05-26||||1973-01-31||1962-03-02|1968-11-28||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||ANATRESP|ANATOMIC RESPONSE||||TITER|RELAPSED DISEASE FROM CR||CIGARETTE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|FRIEND|ADJUDICATOR 2|Y|4||88||CONTINUATION TREATMENT|1973-05-27||||1966-04-02||1971-03-06|1967-07-31||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UM|MRD NEGATIVITY||VG/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|UROLOGIST|Y|4||88||WASHOUT|1967-07-04||||1969-02-22||1966-06-04|1971-05-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MOL/MG|PMR||IU/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|PROXY|NEUROLOGIST 2|N|5||7||WASHOUT|1972-01-29||||1963-08-27||1969-02-22|1965-07-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CI/L|RELAPSED DISEASE FROM CR||HPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|U|5||7||WASHOUT|1961-05-17||||1969-08-21||1967-02-20|1965-07-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/10^5|UNFAVORABLE RESPONSE||CCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||FOLLOW-UP|1962-03-04||||1963-05-12||1972-07-24|1963-09-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KG/M2|CA125 50% RESPONSE||IU/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|ADJUDICATOR|RATER 2|Y|1||38||OBSERVATION|1972-10-01||||1969-05-08||1972-11-17|1970-11-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||OVRLRESP|OVERALL RESPONSE||||NKAT/L|CYTOGENETIC MINOR RESPONSE||NEBULE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|2||58||CONTINUATION TREATMENT|1973-03-23||||1969-09-08||1966-12-02|1960-08-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EVENTS|SCR||MILE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|2||58||OBSERVATION|1961-09-26||||1960-01-09||1962-04-19|1960-03-04||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||METSIND|METASTATIC INDICATOR||||UMOL/DAY|CYTOGENETIC CR||/VF|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|CAREGIVER|OTOLARYNGOLOGIST|U|3||39||OPEN LABEL TREATMENT|1966-02-22||||1963-01-02||1966-08-12|1963-10-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||HOMEOPATHIC DILUTION|ISD||10^6 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|INVESTIGATOR|OPHTHALMOLOGIST|U|3||39||SCREENING|1960-03-21||||1969-02-03||1971-11-12|1962-11-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/KG/DAY|HI-E||MG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||SCREENING|1971-12-19||||1961-06-22||1963-06-09|1963-05-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||OVRLRESP|OVERALL RESPONSE||||PT_US|IPR||MPL U|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|FAMILY MEMBER|NEUROLOGIST 2|NA|4||88||LONG-TERM FOLLOW-UP|1964-07-31||||1972-04-13||1973-05-28|1963-02-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||ANATRESP|ANATOMIC RESPONSE||||IU/L|EQUIVOCAL||10^12/L|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|GUARDIAN|ENDOCRINOLOGIST|N|5||7||BLINDED TREATMENT|1961-05-12||||1972-10-25||1962-09-09|1960-01-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UMOL/H/MMOL|MRD RELAPSE||CI/MG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|CHILD|CLINICAL PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1964-06-12||||1973-02-02||1966-03-28|1972-05-05||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||TRGRESP|TARGET RESPONSE||||G/KG/DAY|MRD PERSISTENCE||PACK|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|Y|1||38||CONTINUATION TREATMENT|1972-10-09||||1967-09-30||1969-09-07|1971-01-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||OVRLRESP|OVERALL RESPONSE||||KG/L|CRI||CS|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||CONTINUATION TREATMENT|1962-07-31||||1960-07-19||1972-12-26|1973-03-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||CLINRESP|CLINICAL RESPONSE||||CCID 50/DOSE|ICR||DAGU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|DOMESTIC PARTNER|NEUROLOGIST 1|U|2||58||BLINDED TREATMENT|1972-11-27||||1970-01-25||1969-07-23|1965-03-08||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||BONERESP|BONE RESPONSE||||10^4 CFU|NON-PD||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|PARENT|ADJUDICATOR 1|Y|2||58||OPEN LABEL TREATMENT|1963-03-14||||1966-04-09||1960-10-15|1963-08-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||TMRESP|TUMOR MARKER RESPONSE||||MKAT|UNFAVORABLE RESPONSE||10^11/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|PARENT|FORENSIC PATHOLOGIST|N|3||39||TREATMENT|1969-09-25||||1970-11-23||1965-01-18|1967-02-15||AFTER||DURING|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||STRUSTAT|STEROID USE STATUS||||BQ/ML|UNFAVORABLE RESPONSE||G/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|3||39||INDUCTION TREATMENT|1965-02-08||||1963-06-12||1969-11-22|1971-02-20||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PSEC|PD||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|4||88||WASHOUT|1972-06-01||||1969-07-20||1961-05-23|1968-12-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||QUANTITY SUFFICIENT|RELAPSED DISEASE||PMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|CAREGIVER|MICROSCOPIST|N|4||88||WASHOUT|1961-05-03||||1962-09-28||1963-01-29|1969-10-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/CAGE|INCREASED||MCI/L|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|ADJUDICATION COMMITTEE|READER 1|Y|5||7||TREATMENT|1969-07-24||||1971-05-23||1971-10-10|1966-06-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||BESTRESP|BEST OVERALL RESPONSE||||DAYS/WK|PD||PIXELS/IN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|RATER|N|5||7||SCREENING|1963-05-29||||1968-03-28||1964-10-10|1966-11-14||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||ANATRESP|ANATOMIC RESPONSE||||MDFI|PDU||PPB|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|INTERVIEWER|ENDOCRINOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1965-04-28||||1964-04-22||1970-03-11|1967-10-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^5/HPF|NR||BQ/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|STUDY SUBJECT|MICROSCOPIST|NA|1||38||TREATMENT|1965-07-07||||1970-01-21||1966-09-27|1963-02-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HOUNSFIELD UNIT|PR-CT||UMOL/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CAREGIVER|INTERNIST|U|2||58||CONTINUATION TREATMENT|1962-11-12||||1971-03-28||1963-12-14|1960-08-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/H|CYTOGENETIC MINIMAL RESPONSE||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|FRIEND|CLINICAL PATHOLOGIST|N|2||58||CONTINUATION TREATMENT|1961-07-23||||1961-11-09||1963-02-11|1960-12-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||CYTORESP|CYTOGENETIC RESPONSE||||NKAT|EQUIVOCAL||AFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|STUDY SUBJECT|MICROSCOPIST|N|3||39||SCREENING|1960-11-22||||1965-05-12||1966-06-13|1966-04-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/MMHG|SCR||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|SPOUSE|RADIOLOGIST 1|N|3||39||BASELINE|1967-01-25||||1969-08-28||1963-03-25|1966-11-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CMH2O*S2/ML|VGPR||G/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|4||88||FOLLOW-UP|1966-01-10||||1969-09-19||1967-12-04|1970-08-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL2/L2|NPR||CMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|READER|NA|4||88||BLINDED TREATMENT|1967-08-29||||1960-03-15||1970-11-05|1966-10-04||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||LIVRRESP|LIVER RESPONSE||||CD*S/M2|COMPLETE MRD RESPONSE||NEBULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|CAREGIVER|ONCOLOGIST 1|NA|5||7||BASELINE|1963-04-30||||1961-11-27||1968-04-25|1961-07-28||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^8 PFU|MORPHOLOGIC CR||BEL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1963-03-22||||1972-12-03||1963-07-29|1962-04-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||FOZ_BR|RELAPSED DISEASE FROM CR||GPELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|INVESTIGATOR|READER|NA|1||38||BLINDED TREATMENT|1970-06-07||||1972-02-17||1965-01-03|1969-03-28||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|2||||||SPLNRESP|SPLEEN RESPONSE||||ML/CAGE/WK|MR||BAU|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|INTERVIEWER|ONCOLOGIST 2|N|1||38||LONG-TERM FOLLOW-UP|1964-10-19||||1961-09-01||1970-06-15|1970-05-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|1||||||TRGRESP|TARGET RESPONSE||||UMOL/DL|CCR||AG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|SPOUSE|MICROSCOPIST 1|U|2||58||OBSERVATION|1962-12-31||||1963-10-29||1962-03-06|1968-07-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BOLUS|PCR||OD UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|ADJUDICATOR|MICROSCOPIST 2|N|2||58||OBSERVATION|1972-07-14||||1960-04-30||1971-02-22|1960-08-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||S/H|NPR||U/M2/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|FAMILY MEMBER|RATER 1|Y|3||39||RUN-IN|1967-04-02||||1967-08-10||1969-11-15|1973-01-31||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^9 CFU|PCR||USIEMENS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||SCREENING|1972-03-09||||1965-10-10||1970-12-04|1967-06-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|1||||||METSIND|METASTATIC INDICATOR||||/4.0 ML|EQUIVOCAL||ML/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|SPOUSE|PEDIATRIC NEUROLOGIST|NA|4||88||RUN-IN|1965-12-20||||1967-02-07||1971-11-17|1965-07-03||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/M2|CA125 50% RESPONSE||MMOL/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|VENDOR|MICROSCOPIST 3|N|4||88||LONG-TERM FOLLOW-UP|1969-11-02||||1961-04-04||1969-11-09|1967-09-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|1||||||NEWLIND|NEW LESION INDICATOR||||JOULE|NED||BOLUS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|ONCOLOGIST 1|NA|5||7||FOLLOW-UP|1968-05-11||||1963-06-13||1963-03-31|1969-03-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|61B02780-0C99-47F8-93B2-CA839876604E|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6 IU/ML|CR-CT||NCI|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|5||7||WASHOUT|1963-08-11||||1971-01-14||1967-07-22|1960-09-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||NEWLPROG|NEW LESION PROGRESSION||||SPRAY|PSEUDORESPONSE||KIU|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|STUDY SUBJECT|RATER|U|1||38||FOLLOW-UP|1972-10-15||||1967-05-15||1973-04-13|1960-04-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^3 ORGANISMS|MORPHOLOGIC CRI||BQ/UL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|SIBLING|DERMATOLOGIST|U|1||38||RUN-IN|1961-11-26||||1966-09-12||1970-05-16|1962-01-13||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||TMRESP|TUMOR MARKER RESPONSE||||%(V/V)|NON-QUANTIFIABLE MRD POSITIVITY||MV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|INVESTIGATOR|UROLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1966-12-15||||1963-04-11||1964-04-06|1973-02-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||BONERESP|BONE RESPONSE||||%(W/W)|PDU||KG/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|2||58||INDUCTION TREATMENT|1964-10-28||||1960-03-28||1968-02-02|1961-11-05||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||U|PARTIAL MORPHOLOGIC RESPONSE||DNA COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|READER 1|NA|3||39||SCREENING|1969-11-19||||1961-07-10||1969-06-18|1966-02-13||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||MOLRESP|MOLECULAR RESPONSE||||BEAM BREAKS|NED||TRACE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|SPOUSE|READER 2|Y|3||39||OPEN LABEL TREATMENT|1973-05-07||||1965-01-29||1967-05-14|1968-10-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^3 COPIES/ML|STABLE||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1969-12-01||||1966-04-16||1964-05-15|1968-08-20||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MMOL/MIN/KPA/L|SD||MM/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1961-09-06||||1971-01-19||1964-07-05|1960-11-04||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||LIVRRESP|LIVER RESPONSE||||10^11/L|CYTOGENETIC CR||MOL/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|FRIEND|PEDIATRIC NEUROLOGIST|Y|5||7||RUN-IN|1963-02-28||||1962-04-28||1960-08-22|1969-09-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||BONERESP|BONE RESPONSE||||FMOL/L|MORPHOLOGIC CRI||UV2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|CAREGIVER|RADIOLOGIST|U|5||7||RUN-IN|1969-09-22||||1963-02-05||1967-07-11|1963-04-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||METBRESP|METABOLIC RESPONSE||||MMOL/S|PMR||G/U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|STUDY SUBJECT|ADJUDICATOR 3|Y|1||38||WASHOUT|1970-03-14||||1960-03-10||1966-04-04|1964-05-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||CLINRESP|CLINICAL RESPONSE||||UMOL/MOL|NON-ICR/NON-IUPD||CAN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1||38||OPEN LABEL TREATMENT|1971-05-16||||1967-01-17||1962-05-04|1967-07-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||%(V/V)|CYTOGENETIC MINIMAL RESPONSE||G/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|DOMESTIC PARTNER|MICROSCOPIST 1|N|2||58||OPEN LABEL TREATMENT|1970-05-31||||1960-04-15||1969-03-06|1969-04-24||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/KG/H|RELAPSED DISEASE FROM CR||KDA|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|2||58||WASHOUT|1962-04-24||||1968-12-04||1964-10-20|1973-06-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MPL U/ML|VGPR||MET*H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|3||39||BASELINE|1962-08-29||||1968-12-30||1971-08-28|1962-02-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UM/DAY|UNEQUIVOCAL||DPM/0.5 ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|READER 3|N|3||39||RUN-IN|1960-10-20||||1961-11-20||1963-05-27|1969-02-03||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/100 HPFS|IUPD||MBQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|FAMILY MEMBER|READER 2|N|4||88||WASHOUT|1969-01-12||||1970-04-25||1960-08-09|1970-08-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||SACHET|SMD||UEQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|GUARDIAN|READER 3|N|4||88||SCREENING|1969-10-06||||1968-03-06||1970-04-09|1964-07-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||STRUSTAT|STEROID USE STATUS||||G/L|NE||V/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|5||7||OBSERVATION|1965-12-18||||1967-06-16||1962-12-09|1961-05-27||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MAMP|MINOR PATHOLOGIC RESPONSE||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|FRIEND|MICROSCOPIST|U|5||7||FOLLOW-UP|1973-03-07||||1964-07-21||1972-04-20|1965-08-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||CYTORESP|CYTOGENETIC RESPONSE||||G/G|PR WITH LYMPHOCYTOSIS||BU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|STUDY SUBJECT|RATER|U|1||38||TREATMENT|1971-03-11||||1971-10-24||1961-04-04|1972-01-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||STRUSTAT|STEROID USE STATUS||||PIXELS/IN|QUANTIFIABLE MRD POSITIVITY||LM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|CAREGIVER|PATHOLOGIST 2|U|1||38||INDUCTION TREATMENT|1970-09-03||||1973-06-25||1963-05-09|1966-10-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||LIVRRESP|LIVER RESPONSE||||10^6 CFU/G|HI-E||UG/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|2||58||RUN-IN|1971-02-07||||1966-11-27||1966-11-11|1967-03-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||ANATRESP|ANATOMIC RESPONSE||||10^3 COPIES/ML|MINOR PATHOLOGIC RESPONSE||PA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1972-03-04||||1971-10-27||1964-04-04|1968-05-30||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||LIVRRESP|LIVER RESPONSE||||DEG/MM|DECREASED||MG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|PARENT|OPHTHALMOLOGIST|U|3||39||CONTINUATION TREATMENT|1972-07-23||||1960-11-27||1962-04-28|1967-05-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||RDIORESP|RADIOLOGIC RESPONSE||||G/DL|PR||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|CLINICAL RESEARCH ASSOCIATE|READER|NA|3||39||SCREENING|1972-05-11||||1970-06-09||1970-03-07|1961-08-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||TRGRESP|TARGET RESPONSE||||NG/DAY|MR||PIXEL|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|FRIEND|NEUROLOGIST 1|N|4||88||TREATMENT|1965-07-15||||1964-04-14||1973-04-10|1968-07-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ANSON U|PSA PROGRESSION||PG/L|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|CHILD|ADJUDICATOR 3|NA|4||88||SCREENING|1967-03-16||||1960-03-26||1962-06-18|1971-08-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/HPF|RELAPSED DISEASE FROM CR||SFC/10^6 PBMC|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|SIBLING|RADIOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1968-01-14||||1962-06-18||1967-10-22|1966-03-31||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||OVRLRESP|OVERALL RESPONSE||||BQ/UL|ABSENT MORPHOLOGIC RESPONSE||MM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|5||7||BASELINE|1964-08-09||||1969-11-16||1961-10-13|1973-07-14||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FMOL|NED||LOG10 TCID 50/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|FRIEND|OTOLARYNGOLOGIST|NA|1||38||TREATMENT|1969-03-19||||1960-05-05||1967-07-16|1965-12-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 IU/ML|MOLECULAR MAJOR RESPONSE||U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|FAMILY MEMBER|DERMATOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1966-11-16||||1961-12-25||1964-10-25|1967-09-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/G HB|RELAPSED DISEASE FROM CR||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|FAMILY MEMBER|HEMATOLOGIST|NA|2||58||BASELINE|1967-03-16||||1971-08-16||1964-10-14|1969-02-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DRUM|RELAPSED DISEASE FROM CR OR PR||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|INTERVIEWER|ADJUDICATOR|U|2||58||CONTINUATION TREATMENT|1970-01-31||||1972-08-05||1962-04-15|1968-01-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 ORGANISMS/ML|WORSENED||KG/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|VENDOR|MICROSCOPIST 3|N|3||39||SCREENING|1967-05-21||||1962-05-22||1963-08-27|1967-08-30||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/WK|CA125 75% RESPONSE||MG/L FEU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|PROXY|MICROSCOPIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1966-12-21||||1967-07-03||1963-12-04|1961-03-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||METBRESP|METABOLIC RESPONSE||||ML/100G/MIN|NR||10^11/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|ADJUDICATOR|OPTOMETRIST|N|4||88||BASELINE|1973-04-02||||1961-07-04||1960-11-05|1967-12-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ENZYME U/L|SD-CT||KEV|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|CHILD|MICROSCOPIST 3|N|4||88||OPEN LABEL TREATMENT|1972-10-04||||1972-10-09||1966-08-18|1971-12-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||METSIND|METASTATIC INDICATOR||||EID 50/ML|IMPROVED||GPL U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|INTERVIEWER|PHYSIOTHERAPIST|U|5||7||RUN-IN|1964-05-05||||1971-12-15||1967-08-03|1967-07-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/MIN/MMHG|NPR||%|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|DOMESTIC PARTNER|PATHOLOGIST 2|Y|5||7||FOLLOW-UP|1960-12-05||||1970-08-21||1972-12-11|1963-03-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DPM/100MG|PCR||PT_US|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|ADJUDICATOR|RADIOLOGIST 2|NA|1||38||SCREENING|1970-07-05||||1960-11-16||1963-11-10|1967-05-11||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||BESTRESP|BEST OVERALL RESPONSE||||MCI/L|SD||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|STUDY SUBJECT|INTERNIST|N|1||38||INDUCTION TREATMENT|1971-04-25||||1967-08-30||1973-03-19|1968-10-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||BESTRESP|BEST OVERALL RESPONSE||||CAPSULE|OPTIMAL MORPHOLOGIC RESPONSE||L/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|2||58||TREATMENT|1965-06-06||||1968-07-25||1969-07-03|1971-12-22||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||VG/DOSE|EQUIVOCAL||10^4/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|N|2||58||OBSERVATION|1969-04-06||||1968-09-25||1973-05-16|1965-01-10||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||OVRLRESP|OVERALL RESPONSE||||PPB|SMD||MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|CHILD|RADIOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1968-05-31||||1961-12-25||1960-12-22|1964-11-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/H/MMOL|DECREASED||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1960-03-31||||1970-10-08||1972-09-06|1972-09-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||NEWLIND|NEW LESION INDICATOR||||SCOOPFUL|ICPD||MG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 1|NA|4||88||WASHOUT|1967-03-27||||1972-07-02||1965-11-07|1970-05-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DAYS/MONTH|COMPLETE MRD RESPONSE||IU/MG|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|INTERVIEWER|RADIOLOGIST 1|N|4||88||INDUCTION TREATMENT|1963-03-10||||1973-07-28||1962-03-13|1966-06-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||METBRESP|METABOLIC RESPONSE||||/LPF|NON-QUANTIFIABLE MRD POSITIVITY||ML/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|INVESTIGATOR|RADIOLOGIST 1|N|5||7||FOLLOW-UP|1966-09-08||||1966-01-10||1973-06-26|1964-08-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||CLINRESP|CLINICAL RESPONSE||||H*%|NR||COAT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|INVESTIGATOR|PATHOLOGIST 1|U|5||7||INDUCTION TREATMENT|1965-01-14||||1961-10-11||1961-05-24|1972-11-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|1||||||TMRESP|TUMOR MARKER RESPONSE||||MOSM/L|SD||10^6 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|SIGNIFICANT OTHER|ADJUDICATOR 3|U|1||38||LONG-TERM FOLLOW-UP|1970-02-13||||1966-07-21||1971-10-15|1963-08-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/KG/H|NE||MV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|PROXY|PHYSIOTHERAPIST|Y|1||38||WASHOUT|1968-09-03||||1966-01-02||1964-09-08|1960-08-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||RFU|ICPD||SPRAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|2||58||WASHOUT|1970-03-03||||1963-07-27||1972-12-21|1967-09-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/L|PCR||MGEQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|2||58||SCREENING|1967-07-03||||1968-08-23||1960-12-27|1962-06-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/DOSE|IPR||MMHG/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|3||39||WASHOUT|1960-02-10||||1968-01-07||1963-11-27|1960-11-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|2||||||STRUSTAT|STEROID USE STATUS||||JAR|NED||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|DOMESTIC PARTNER|ONCOLOGIST 2|N|3||39||OBSERVATION|1967-11-12||||1967-05-21||1964-03-03|1964-03-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|1||||||METSIND|METASTATIC INDICATOR||||UMOL/MOL|NED||KM/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|HEALTH CARE PROFESSIONAL|UROLOGIST|U|4||88||WASHOUT|1965-03-27||||1964-09-28||1971-11-06|1973-05-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CI|NR||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|INTERVIEWER|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1972-05-07||||1961-12-25||1969-02-10|1970-01-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/U|PSEUDOPROGRESSION||DROP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|5||7||CONTINUATION TREATMENT|1968-04-28||||1969-02-14||1964-02-10|1970-07-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|91282D87-4943-4527-8F33-27A5C153951C|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NGEQ/L|SCR||/500 WBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|PROXY|MICROSCOPIST 3|N|5||7||OBSERVATION|1968-03-21||||1972-09-28||1972-04-15|1968-04-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 CFU/G|CYTOGENETIC MINIMAL RESPONSE||NMOL BCE/NMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|PARENT|ENDOCRINOLOGIST|N|1||38||INDUCTION TREATMENT|1970-09-05||||1963-11-12||1969-09-09|1972-09-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||OVRLRESP|OVERALL RESPONSE||||TRANSDUCING UNIT|PSEUDORESPONSE||%|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|PROXY|OTOLARYNGOLOGIST|Y|1||38||WASHOUT|1967-04-17||||1961-06-25||1963-12-19|1960-10-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||L/MIN|NON-CR/NON-PD||KM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|INVESTIGATOR|OPHTHALMOLOGIST|U|2||58||OBSERVATION|1961-05-25||||1967-09-14||1970-06-06|1969-11-04||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MM/H|STABLE||FMOL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||WASHOUT|1965-02-14||||1965-02-04||1968-12-22|1964-07-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||CLINRESP|CLINICAL RESPONSE||||ML/M2/DAY|STABLE||MBP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|INVESTIGATOR|PATHOLOGIST 1|NA|3||39||FOLLOW-UP|1961-07-21||||1970-03-06||1967-05-12|1968-10-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||NEWLIND|NEW LESION INDICATOR||||UG/G/MIN|MRD RELAPSE||MMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|3||39||FOLLOW-UP|1963-10-09||||1969-04-18||1971-08-09|1968-10-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||STRUSTAT|STEROID USE STATUS||||CG|MINOR PATHOLOGIC RESPONSE||H*%|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|4||88||RUN-IN|1966-08-11||||1973-07-20||1961-08-24|1967-02-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/G/DAY|MRD RELAPSE||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|CHILD|PATHOLOGIST 2|NA|4||88||BASELINE|1966-03-11||||1962-09-07||1963-08-14|1971-06-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||RDIORESP|RADIOLOGIC RESPONSE||||LM|CYTOGENETIC CR||SBE/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|FAMILY MEMBER|OPHTHALMOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1964-01-05||||1962-07-22||1971-06-09|1967-12-05||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||OVRLRESP|OVERALL RESPONSE||||ML/M2/DAY|MAJOR PATHOLOGIC RESPONSE||UKAT/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|FAMILY MEMBER|MICROSCOPIST 1|U|5||7||FOLLOW-UP|1971-09-07||||1972-04-11||1972-12-22|1969-11-11||DURING||DURING|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^4 CFU/ML|CYTOGENETIC CR||L/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|1||38||WASHOUT|1966-01-30||||1971-12-30||1964-02-10|1971-01-28||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CS|MORPHOLOGIC CRI||PSEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|GUARDIAN|ADJUDICATOR|Y|1||38||WASHOUT|1966-04-09||||1966-08-24||1970-09-05|1966-08-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DPM/100MG|PSEUDORESPONSE||%(W/V)|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|INTERVIEWER|RATER 1|Y|2||58||BLINDED TREATMENT|1972-04-28||||1960-02-05||1962-06-03|1961-10-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PELLET|ISD||DIOPTER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|SPOUSE|RADIOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1971-04-27||||1963-02-15||1968-03-31|1960-10-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||METSIND|METASTATIC INDICATOR||||MV|RELAPSED DISEASE FROM CR||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|INTERVIEWER|READER 1|NA|3||39||FOLLOW-UP|1962-12-21||||1964-11-02||1965-04-11|1971-04-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||VOXEL|COMPLETE MRD RESPONSE||/40 HPFS|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|CAREGIVER|NEUROLOGIST 2|NA|3||39||INDUCTION TREATMENT|1965-12-25||||1964-02-08||1967-09-03|1972-02-21||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||TMRESP|TUMOR MARKER RESPONSE||||MG/CM2|MRD RELAPSE||VP/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|Y|4||88||TREATMENT|1967-09-01||||1960-10-20||1971-05-02|1964-11-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||VG/KG|MRD NEGATIVITY||NEEDLE GAUGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|INTERVIEWER|RADIOLOGIST|N|4||88||BASELINE|1968-04-03||||1969-04-16||1962-06-23|1973-07-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DPM/MG|CA125 75% RESPONSE||FOZ_US|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1962-05-30||||1965-05-01||1963-04-03|1972-05-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/KG|PSA PROGRESSION||MEQ|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|VENDOR|READER 1|Y|5||7||CONTINUATION TREATMENT|1960-07-06||||1964-06-03||1960-08-27|1965-06-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||L/L|MAJOR PATHOLOGIC RESPONSE||L/S/KPA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|FRIEND|INTERNIST|U|1||38||RUN-IN|1968-01-01||||1970-07-27||1969-05-17|1968-04-27||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||OZ|CYTOGENETIC NO RESPONSE||OHM|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|HEALTH CARE PROFESSIONAL|RATER|Y|1||38||CONTINUATION TREATMENT|1961-02-28||||1967-02-15||1967-11-15|1968-08-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||CLINRESP|CLINICAL RESPONSE||||PHERESIS UNIT|NON-QUANTIFIABLE MRD POSITIVITY||10^3/HPF|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|CAREGIVER|HEMATOLOGIST|NA|2||58||RUN-IN|1968-03-27||||1961-01-19||1967-12-16|1962-05-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||LIVRRESP|LIVER RESPONSE||||10^8/L|SD-CT||FOZ_BR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|SIBLING|READER 2|U|2||58||INDUCTION TREATMENT|1961-01-10||||1963-03-14||1968-11-01|1969-09-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TBSP|CCR||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1965-07-19||||1961-07-07||1965-02-01|1960-08-11||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||TMRESP|TUMOR MARKER RESPONSE||||TAMPON|NR||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|DOMESTIC PARTNER|RADIOLOGIST 2|Y|3||39||OBSERVATION|1967-09-09||||1967-03-21||1960-09-04|1961-03-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||TRGRESP|TARGET RESPONSE||||/MONTH|UNEQUIVOCAL||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|Y|4||88||BLINDED TREATMENT|1967-06-14||||1968-04-06||1970-02-20|1964-02-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||NEWLPROG|NEW LESION PROGRESSION||||CAL|UNFAVORABLE RESPONSE||MG/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|4||88||TREATMENT|1969-12-20||||1973-08-13||1973-04-07|1964-11-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KCAL|PMD||PSEC|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|VENDOR|INTERNIST|NA|5||7||INDUCTION TREATMENT|1969-11-11||||1962-07-05||1967-08-12|1969-12-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CPM|CRI||UG/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|ADJUDICATOR|ONCOLOGIST 2|NA|5||7||RUN-IN|1966-02-21||||1962-02-17||1973-01-03|1963-01-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||OVRLRESP|OVERALL RESPONSE||||MV2/HZ|NED||AFU|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|CHILD|READER|NA|1||38||OBSERVATION|1964-10-24||||1967-09-29||1962-03-27|1961-10-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||ANATRESP|ANATOMIC RESPONSE||||U/KG/H|MOLECULAR MAJOR RESPONSE||TBSP|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST|U|1||38||INDUCTION TREATMENT|1960-08-29||||1960-03-18||1960-01-16|1973-03-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MPL U/ML|FAVORABLE RESPONSE||NMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|DOMESTIC PARTNER|OPTOMETRIST|U|2||58||LONG-TERM FOLLOW-UP|1966-07-02||||1962-02-20||1964-11-09|1970-08-23||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PACKET|CA125 50% RESPONSE||AMP|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|2||58||SCREENING|1968-12-18||||1969-02-24||1966-02-03|1962-08-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||METSIND|METASTATIC INDICATOR||||HENRY|QUANTIFIABLE MRD POSITIVITY||G/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|SIBLING|UROLOGIST|Y|3||39||FOLLOW-UP|1961-10-06||||1963-08-02||1973-06-18|1969-08-31||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||SV|PR-CT||RATIO|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|3||39||TREATMENT|1966-07-26||||1967-07-02||1972-03-19|1968-06-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MKAT|TREATMENT FAILURE||ML/CM H2O|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|STUDY SUBJECT|NEUROLOGIST 2|Y|4||88||TREATMENT|1973-05-10||||1963-09-18||1962-03-25|1967-07-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||NTRGRESP|NON-TARGET RESPONSE||||/MS|INDETERMINATE RESPONSE||NEEDLE GAUGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|CHILD|NEUROLOGIST 1|Y|4||88||INDUCTION TREATMENT|1969-01-21||||1960-10-26||1963-05-23|1966-02-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||NEWLIND|NEW LESION INDICATOR||||PPTR|MR||KCAL|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|GUARDIAN|INTERNIST|U|5||7||WASHOUT|1967-11-20||||1960-06-08||1965-03-16|1968-10-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||TRGRESP|TARGET RESPONSE||||M|NPR||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|SIGNIFICANT OTHER|INTERNIST|N|5||7||SCREENING|1973-05-02||||1964-09-28||1966-05-02|1962-02-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DB|NON-PD||NFIU|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|DOMESTIC PARTNER|ONCOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1960-11-22||||1973-01-02||1960-11-13|1968-10-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||NEWLPROG|NEW LESION PROGRESSION||||G/KG|MRD PERSISTENCE||10^7 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|U|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|NA|1||38||BASELINE|1972-03-25||||1963-08-22||1962-05-27|1961-11-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MGEQ|PD/RELAPSE AFTER HI||GPS U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|N|2||58||BLINDED TREATMENT|1967-06-16||||1971-09-22||1961-07-16|1968-04-26||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL|CPR||YD|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|VENDOR|RATER 2|N|2||58||CONTINUATION TREATMENT|1962-02-21||||1972-07-10||1970-10-04|1967-09-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BAU|HI-P||PMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|PROXY|OTOLARYNGOLOGIST|NA|3||39||RUN-IN|1963-12-08||||1960-08-13||1970-09-16|1963-11-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MM/2H|IMMUNOPHENOTYPIC CR||FEU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|FRIEND|ADJUDICATOR 1|N|3||39||OPEN LABEL TREATMENT|1964-11-19||||1966-12-08||1960-07-27|1965-07-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||LIVRRESP|LIVER RESPONSE||||RFU|MRD NEGATIVITY||GENEQ/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||BASELINE|1962-02-04||||1965-05-19||1969-03-06|1967-08-01||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||MOLRESP|MOLECULAR RESPONSE||||EJACULATE U|FAVORABLE RESPONSE||MEQ/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|U|4||88||BLINDED TREATMENT|1963-12-03||||1967-12-11||1966-02-15|1970-04-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||NTRGRESP|NON-TARGET RESPONSE||||RATIO|CR-CT||DISK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|CAREGIVER|PATHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1963-02-03||||1963-05-24||1964-03-22|1970-01-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||ANATRESP|ANATOMIC RESPONSE||||ML/M2/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||CMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|SIGNIFICANT OTHER|INTERNIST|NA|5||7||WASHOUT|1969-12-27||||1964-03-03||1964-10-07|1961-07-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MEQ|CYTOGENETIC MINOR RESPONSE||PSI|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|1||38||FOLLOW-UP|1966-10-06||||1962-12-01||1969-10-13|1965-06-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|2||||||ANATRESP|ANATOMIC RESPONSE||||OD UNIT|RELAPSED DISEASE FROM CR||UG/L FEU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|1||38||CONTINUATION TREATMENT|1967-10-02||||1972-04-19||1969-12-21|1970-08-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|1||||||LIVRRESP|LIVER RESPONSE||||10^3/HPF|MAJOR PATHOLOGIC RESPONSE||BAU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|CHILD|PATHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1971-02-25||||1961-09-03||1965-03-09|1969-02-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|2||||||STRUSTAT|STEROID USE STATUS||||MMOL/S|PD FROM PR||%(V/V)|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|PARENT|OTOLARYNGOLOGIST|NA|2||58||INDUCTION TREATMENT|1969-09-01||||1967-04-24||1963-04-10|1967-07-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|1||||||METBRESP|METABOLIC RESPONSE||||PSI|MRD NEGATIVITY||PPTR|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|ADJUDICATOR|CARDIOLOGIST|U|3||39||SCREENING|1966-07-18||||1965-07-11||1966-12-18|1970-08-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|2||||||SPLNRESP|SPLEEN RESPONSE||||SCM|PDU||G/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|DOMESTIC PARTNER|MICROSCOPIST|NA|3||39||FOLLOW-UP|1966-10-27||||1966-12-08||1965-07-07|1961-09-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TRANSDUCING UNIT|CA125 50% RESPONSE||/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|INVESTIGATOR|ONCOLOGIST|N|4||88||CONTINUATION TREATMENT|1973-05-15||||1970-08-22||1969-07-18|1966-08-14||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|2||||||TRGRESP|TARGET RESPONSE||||MG/MIN|NON-CR/NON-PD||/MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|GUARDIAN|PEDIATRIC NEUROLOGIST|U|4||88||SCREENING|1962-12-09||||1973-03-04||1972-03-20|1960-12-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CD/M2|WORSENED||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|INDEPENDENT ASSESSOR|READER 3|Y|5||7||BLINDED TREATMENT|1960-11-20||||1973-04-11||1961-08-19|1972-03-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|810B0B08-9236-41EC-8879-924661FA224E|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TRACE|NON-CR/NON-PD||UL/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|5||7||INDUCTION TREATMENT|1967-09-24||||1964-03-10||1965-01-10|1972-05-31||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||/2000 RBC|MAJOR PATHOLOGIC RESPONSE||% INHIBITION|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|1||38||RUN-IN|1961-06-02||||1962-03-23||1968-12-18|1968-10-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CS|HI-E||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|FRIEND|ADJUDICATOR 3|NA|1||38||FOLLOW-UP|1968-12-01||||1971-04-30||1972-07-29|1964-12-10||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||LIVRRESP|LIVER RESPONSE||||/5X10^4 WBC|SCR||G/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|2||58||WASHOUT|1961-01-28||||1966-06-05||1971-11-27|1963-09-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 DNA COPIES/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UL/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|PARENT|OPTOMETRIST|Y|2||58||LONG-TERM FOLLOW-UP|1966-07-30||||1960-05-31||1971-12-07|1972-09-22||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CL|PSA PROGRESSION||CI/L|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|3||39||INDUCTION TREATMENT|1970-01-05||||1971-06-15||1964-10-06|1971-04-05||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||NEWLIND|NEW LESION INDICATOR||||ANTIBODY UNIT|RELAPSED DISEASE||MHZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|INVESTIGATOR|ONCOLOGIST 2|N|3||39||SCREENING|1964-10-01||||1963-10-03||1969-06-08|1966-12-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||ANATRESP|ANATOMIC RESPONSE||||KBQ|MOLECULAR MAJOR RESPONSE||UG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|DOMESTIC PARTNER|ENDOCRINOLOGIST|U|4||88||SCREENING|1972-10-01||||1966-12-18||1962-03-14|1967-08-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||NEWLIND|NEW LESION INDICATOR||||C|RELAPSED DISEASE FROM CR||PA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1960-01-11||||1971-12-01||1967-09-03|1970-08-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||STRUSTAT|STEROID USE STATUS||||/LSQN|CYTOGENETIC CR||BOTTLE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1967-02-21||||1967-09-04||1973-01-19|1962-12-11||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UL/DOSE|RELAPSED DISEASE FROM CR OR PR||NMOL BCE/NMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|PARENT|PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1970-04-14||||1971-08-15||1969-03-18|1969-11-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||KCAL|SCR||MEQ/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|FRIEND|PEDIATRIC NEUROLOGIST|N|1||38||BASELINE|1969-10-18||||1960-12-08||1962-04-24|1963-03-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TROCHE|DECREASED||UMOL/L/SEC|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|SIBLING|ADJUDICATOR|U|1||38||OPEN LABEL TREATMENT|1965-08-09||||1970-09-03||1972-03-09|1973-03-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||P|PSA PROGRESSION||ML/G/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|SIBLING|OPTOMETRIST|N|2||58||OBSERVATION|1973-03-11||||1971-10-21||1967-09-20|1961-12-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/L|ABSENT MORPHOLOGIC RESPONSE||MEQ/DL|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|CHILD|PHYSIOTHERAPIST|NA|2||58||SCREENING|1966-11-10||||1972-04-27||1971-12-13|1967-02-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOL/L|PSEUDORESPONSE||NKAT/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||OBSERVATION|1970-09-07||||1967-05-17||1961-11-02|1965-04-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/DL|SD-CT||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|PARENT|ADJUDICATOR|U|3||39||LONG-TERM FOLLOW-UP|1968-05-04||||1968-08-16||1967-12-06|1972-01-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||STRUSTAT|STEROID USE STATUS||||TESLA|HI-N||TSP|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|FAMILY MEMBER|RATER|Y|4||88||BASELINE|1969-07-09||||1967-03-25||1968-08-02|1965-10-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ABSORBANCE U/ML|HI-E||%(V/V)|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|CHILD|MICROSCOPIST 1|Y|4||88||TREATMENT|1969-06-21||||1970-05-26||1973-04-17|1962-10-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||TMRESP|TUMOR MARKER RESPONSE||||U.CARR|NED||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|FRIEND|NEUROLOGIST|Y|5||7||OBSERVATION|1972-05-27||||1960-09-30||1967-06-15|1961-02-27||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NG|DECREASED||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|FAMILY MEMBER|CARDIOLOGIST|U|5||7||BLINDED TREATMENT|1967-06-16||||1961-01-16||1961-12-12|1968-11-28||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||LIVRRESP|LIVER RESPONSE||||FOZ_US|RELAPSED DISEASE||LOG10 IU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|CHILD|PATHOLOGIST 2|NA|1||38||BASELINE|1969-10-20||||1961-12-05||1962-12-07|1962-11-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KPA|MORPHOLOGIC CR||UG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|CHILD|NEUROLOGIST 1|N|1||38||INDUCTION TREATMENT|1970-04-11||||1971-09-29||1964-09-05|1968-01-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||STRUSTAT|STEROID USE STATUS||||ML/ANIMAL/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|2||58||OBSERVATION|1971-01-05||||1969-02-24||1966-04-26|1967-01-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||NTRGRESP|NON-TARGET RESPONSE||||MMOL2/L2|NON-CR/NON-PD||MDFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|2||58||LONG-TERM FOLLOW-UP|1972-10-24||||1969-01-09||1973-01-31|1963-06-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CMHG|PR||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3||39||BASELINE|1970-05-03||||1970-03-26||1968-09-17|1972-10-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||%(W/V)|CYTOGENETIC NO RESPONSE||/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|3||39||RUN-IN|1968-05-14||||1969-10-21||1964-09-28|1966-03-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||STRUSTAT|STEROID USE STATUS||||/DAY|IMMUNOPHENOTYPIC CR||MG/ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|SIBLING|ADJUDICATOR 3|N|4||88||CONTINUATION TREATMENT|1969-11-12||||1972-10-14||1964-09-26|1962-02-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BEAM BREAKS|TREATMENT FAILURE||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|4||88||SCREENING|1972-06-24||||1969-05-12||1972-09-24|1966-08-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||STRUSTAT|STEROID USE STATUS||||SQU/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||G/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|FAMILY MEMBER|PATHOLOGIST|Y|5||7||TREATMENT|1961-03-26||||1972-08-22||1969-09-18|1967-04-13||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||LIVRRESP|LIVER RESPONSE||||MG2/DL2|DISEASE TRANSFORMATION||MBP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|PROXY|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1965-07-29||||1966-05-15||1965-03-14|1966-03-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||BESTRESP|BEST OVERALL RESPONSE||||UCI/L|PDU||SUPPOSITORY|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|SIBLING|PATHOLOGIST 2|N|1||38||RUN-IN|1971-04-27||||1972-05-27||1968-10-22|1973-05-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||TMRESP|TUMOR MARKER RESPONSE||||MPH|QUANTIFIABLE MRD POSITIVITY||ML/CM|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|PROXY|MICROSCOPIST|Y|1||38||INDUCTION TREATMENT|1963-06-02||||1970-05-15||1967-06-16|1967-11-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PIPE|ISD||10^7 PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||OPEN LABEL TREATMENT|1967-06-28||||1971-10-19||1972-10-22|1967-07-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||COULOMB|MORPHOLOGIC CRI||P|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|2||58||OPEN LABEL TREATMENT|1961-06-08||||1970-01-23||1968-04-25|1966-01-16||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NMOL BCE/MMOL|MOLECULAR MAJOR RESPONSE||UM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|FRIEND|MICROSCOPIST 2|NA|3||39||WASHOUT|1971-12-12||||1961-02-11||1970-11-16|1966-12-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||MOLRESP|MOLECULAR RESPONSE||||MG/ML/DAY|ICPD||UIU/L|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|3||39||SCREENING|1970-12-12||||1966-02-18||1968-04-06|1973-03-04||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SPRAY|MORPHOLOGIC CR||FOZ_US|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||SCREENING|1971-10-09||||1960-12-11||1968-12-21|1964-09-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||CLINRESP|CLINICAL RESPONSE||||DEG/S|MRD NEGATIVITY||ML/KG|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|4||88||BLINDED TREATMENT|1966-09-29||||1972-07-17||1964-04-24|1968-01-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL/L/MIN|TREATMENT FAILURE||10^4/HPF|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|STUDY SUBJECT|HEMATOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1965-05-30||||1961-04-22||1967-12-03|1972-01-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||METSIND|METASTATIC INDICATOR||||SPRAY|PR||U/CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|STUDY SUBJECT|CARDIOLOGIST|U|5||7||RUN-IN|1966-09-10||||1972-09-10||1962-08-25|1961-02-26||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||NEWLIND|NEW LESION INDICATOR||||/DAY|PD FROM PR||UM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|SIBLING|NEUROLOGIST 2|U|1||38||WASHOUT|1961-03-18||||1963-04-04||1970-11-13|1964-07-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||SPLNRESP|SPLEEN RESPONSE||||NL|PR WITH LYMPHOCYTOSIS||MMOL2/L2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|1||38||LONG-TERM FOLLOW-UP|1968-12-25||||1971-04-07||1966-04-09|1965-04-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||BESTRESP|BEST OVERALL RESPONSE||||/5X10^4 WBC|INDETERMINATE RESPONSE||TRANSDUCING UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|PROXY|PHYSIOTHERAPIST|NA|2||58||OPEN LABEL TREATMENT|1961-11-04||||1966-10-01||1964-01-17|1960-05-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KEV|MINOR PATHOLOGIC RESPONSE||/10^4|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|VENDOR|NEUROLOGIST|NA|2||58||CONTINUATION TREATMENT|1963-03-20||||1972-05-25||1973-03-01|1966-11-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/BREATH|HI-P||EU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|PARENT|PATHOLOGIST 1|U|3||39||RUN-IN|1968-01-09||||1973-03-12||1965-09-22|1972-03-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||BESTRESP|BEST OVERALL RESPONSE||||NEEDLE GAUGE|NED||U/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|INDEPENDENT ASSESSOR|OPTOMETRIST|U|3||39||CONTINUATION TREATMENT|1960-07-10||||1973-01-21||1968-07-29|1972-12-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||LIVRRESP|LIVER RESPONSE||||MG/G/H|CYTOGENETIC CR||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|GUARDIAN|PHYSIOTHERAPIST|N|4||88||CONTINUATION TREATMENT|1970-11-18||||1966-12-16||1962-07-25|1963-12-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BE/ML|MRD RELAPSE||HZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|4||88||WASHOUT|1965-05-31||||1961-06-11||1960-10-24|1966-06-18||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MOL/G|CYTOGENETIC CR||HZ/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|CHILD|DERMATOLOGIST|N|5||7||INDUCTION TREATMENT|1966-08-27||||1968-07-20||1970-06-01|1965-02-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^3 ORGANISMS/ML|CPR||DAYS/MONTH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|5||7||RUN-IN|1970-11-24||||1961-09-03||1966-08-03|1962-01-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|1||||||MOLRESP|MOLECULAR RESPONSE||||MILE|MORPHOLOGIC CRI||GBQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1||38||TREATMENT|1971-05-06||||1968-01-09||1962-09-05|1970-02-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TORR|MOLECULAR MAJOR RESPONSE||MAC50|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|FRIEND|RADIOLOGIST 2|NA|1||38||RUN-IN|1968-11-07||||1970-02-05||1970-09-27|1970-06-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FRAMES/S|NE||KUSP|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|SIBLING|OTOLARYNGOLOGIST|N|2||58||CONTINUATION TREATMENT|1967-08-05||||1964-07-11||1962-10-18|1967-06-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^9 ORGANISMS/ML|NPR||DNA COPIES/UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|FRIEND|MICROSCOPIST 2|Y|2||58||OPEN LABEL TREATMENT|1960-11-15||||1971-08-27||1963-03-04|1963-04-17||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||AMP|STABLE||KEV|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|PROXY|NEUROLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1973-03-04||||1965-04-06||1969-09-25|1971-03-31||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|2||||||BONERESP|BONE RESPONSE||||KA_U/DL|CA125 75% RESPONSE||G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|3||39||BASELINE|1967-09-18||||1962-03-04||1966-03-12|1969-01-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|1||||||NEWLIND|NEW LESION INDICATOR||||HEP|ISD||VG/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1969-03-14||||1960-12-13||1972-12-29|1964-10-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|2||||||PATHRESP|PATHOLOGIC RESPONSE||||G/U|MAJOR PATHOLOGIC RESPONSE||CM|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|GUARDIAN|OTOLARYNGOLOGIST|N|4||88||BLINDED TREATMENT|1965-11-14||||1968-01-01||1965-09-26|1965-06-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|1||||||TRGRESP|TARGET RESPONSE||||DIP|IPR||BOLUS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|5||7||CONTINUATION TREATMENT|1969-10-15||||1961-01-14||1963-12-26|1960-04-15||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|42DD827A-E788-4E61-8E9F-421136A16166|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/L/H|UNEQUIVOCAL||MOSM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|PROXY|MICROSCOPIST 3|N|5||7||BLINDED TREATMENT|1965-07-16||||1964-01-28||1966-10-13|1967-12-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UMOL/L/MIN|MRD NEGATIVITY||KIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|1||38||WASHOUT|1965-09-22||||1965-11-16||1968-07-18|1966-07-07||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||NTRGRESP|NON-TARGET RESPONSE||||UCI|COMPLETE MRD RESPONSE||UMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INTERVIEWER|MICROSCOPIST 1|N|1||38||FOLLOW-UP|1973-06-02||||1970-04-14||1971-01-05|1964-10-08||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UKAT/10^12 RBC|NON-CR/NON-PD||PIPE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|FRIEND|RADIOLOGIST|Y|2||58||WASHOUT|1964-04-18||||1967-11-27||1964-06-25|1966-12-09||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PG|PD-CT||MGEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|SIGNIFICANT OTHER|READER 3|N|2||58||RUN-IN|1961-04-12||||1970-06-01||1970-10-01|1963-02-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||V/SEC|CYTOGENETIC MINOR RESPONSE||ML/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|PROXY|MICROSCOPIST 2|Y|3||39||BASELINE|1970-05-07||||1963-04-07||1969-11-15|1964-06-27||DURING||DURING|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TESLA|NE||VG/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|FAMILY MEMBER|OPHTHALMOLOGIST|Y|3||39||TREATMENT|1970-07-06||||1966-12-17||1972-10-15|1963-06-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9/L|NON-CR/NON-PD||SEC|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|4||88||BLINDED TREATMENT|1969-07-26||||1965-05-03||1965-04-24|1966-03-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/M2|NON-ICR/NON-IUPD||UM/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|FRIEND|NEUROLOGIST 1|NA|4||88||CONTINUATION TREATMENT|1971-11-13||||1967-08-31||1971-04-24|1970-02-09||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||NTRGRESP|NON-TARGET RESPONSE||||PACK YEAR|ICPD||CUP EQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|5||7||TREATMENT|1965-01-10||||1961-04-27||1971-01-30|1964-01-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^11/L|PD||STRIP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|INTERVIEWER|ONCOLOGIST 1|Y|5||7||TREATMENT|1960-08-01||||1961-09-20||1963-08-09|1966-07-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RATIO|CR-CT||SACHET|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|STUDY SUBJECT|INTERNIST|Y|1||38||INDUCTION TREATMENT|1965-02-20||||1973-04-19||1961-03-25|1973-06-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||BONERESP|BONE RESPONSE||||EJACULATE U|MRD PERSISTENCE||U/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|ADJUDICATOR|MICROSCOPIST 2|N|1||38||RUN-IN|1969-05-11||||1968-10-30||1973-04-15|1973-05-22||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||MOLRESP|MOLECULAR RESPONSE||||CD/M2|INDETERMINATE RESPONSE||MEQ/KG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||LONG-TERM FOLLOW-UP|1962-06-06||||1972-12-15||1966-06-28|1973-08-11||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CM2|PSA PROGRESSION||AMU|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|ADJUDICATOR|PATHOLOGIST|U|2||58||FOLLOW-UP|1972-05-02||||1969-01-29||1964-10-27|1965-06-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||TMRESP|TUMOR MARKER RESPONSE||||BREATHS/30S|PR-CT||MG2/DL2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|INVESTIGATOR|PHYSIOTHERAPIST|Y|3||39||BASELINE|1966-03-05||||1965-06-25||1961-05-01|1962-04-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^10/L|EQUIVOCAL||UG/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|3||39||BLINDED TREATMENT|1968-08-11||||1960-01-16||1967-02-27|1960-01-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BQ/MG|NON-PD||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|INVESTIGATOR|PATHOLOGIST 2|Y|4||88||RUN-IN|1963-05-28||||1964-07-10||1966-01-12|1960-10-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||STRUSTAT|STEROID USE STATUS||||CI/UL|NED||ML/SEC/1.73M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|STUDY SUBJECT|READER 3|U|4||88||RUN-IN|1971-04-08||||1971-12-09||1970-11-21|1964-02-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UMOL/DAY|CYTOGENETIC MINIMAL RESPONSE||DMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||FOLLOW-UP|1964-01-26||||1967-03-20||1973-05-07|1970-02-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||MOLRESP|MOLECULAR RESPONSE||||ENZYME U/L|PMD||EJACULATE U|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|5||7||FOLLOW-UP|1962-10-01||||1972-03-22||1967-04-20|1968-05-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/G HB|CA125 50% RESPONSE||DAGU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1960-11-13||||1960-02-27||1965-12-20|1964-12-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||NEWLPROG|NEW LESION PROGRESSION||||V/SEC|NON-CR/NON-PD||10^4 CFU|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|GUARDIAN|CLINICAL PATHOLOGIST|U|1||38||BASELINE|1973-08-23||||1960-08-23||1965-08-31|1963-05-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CMOL/L|CPR||TAMPON|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|CLINICAL RESEARCH COORDINATOR|READER 3|U|2||58||BLINDED TREATMENT|1961-04-19||||1968-07-08||1971-07-01|1968-02-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||BONERESP|BONE RESPONSE||||ML/BEAT|UNFAVORABLE RESPONSE||CYLINDER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|CAREGIVER|ONCOLOGIST 1|NA|2||58||BASELINE|1965-03-01||||1963-01-19||1965-11-24|1973-03-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DMOL|RELAPSED DISEASE FROM CR OR PR||V/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|3||39||TREATMENT|1971-12-15||||1968-07-17||1961-08-12|1972-01-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||METBRESP|METABOLIC RESPONSE||||UEQ|CYTOGENETIC MINIMAL RESPONSE||10^3 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|GUARDIAN|UROLOGIST|NA|3||39||TREATMENT|1966-03-28||||1960-04-18||1969-04-11|1965-05-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NG/DAY|ICPD||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|ADJUDICATION COMMITTEE|UROLOGIST|NA|4||88||WASHOUT|1968-10-27||||1962-10-19||1963-04-06|1967-12-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/100 WBC|PSA PROGRESSION||BQ/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|PARENT|OPTOMETRIST|Y|4||88||BLINDED TREATMENT|1969-12-14||||1969-10-27||1965-12-17|1965-01-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||OVRLRESP|OVERALL RESPONSE||||KPA|MOLECULAR MAJOR RESPONSE||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|5||7||CONTINUATION TREATMENT|1962-09-23||||1964-12-09||1968-01-27|1970-05-11||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/ANIMAL|ICR||ML/CAGE|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|VENDOR|OPHTHALMOLOGIST|N|5||7||BASELINE|1965-02-03||||1960-05-20||1963-11-14|1970-03-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TRANSDUCING UNIT|NED||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|CAREGIVER|RADIOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1972-01-16||||1969-04-19||1967-08-10|1963-01-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||NEWLIND|NEW LESION INDICATOR||||BEATS/MIN|MRD NEGATIVITY||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|SPOUSE|MICROSCOPIST 2|N|1||38||WASHOUT|1970-08-27||||1961-02-22||1961-11-03|1968-09-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||BONERESP|BONE RESPONSE||||KG/CM|COMPLETE MRD RESPONSE||CGY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|U|2||58||BLINDED TREATMENT|1969-07-06||||1964-09-29||1970-05-03|1970-02-17||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CCID 50/ML|IPR||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||FOLLOW-UP|1973-07-06||||1962-06-26||1964-11-07|1970-01-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KV|MRD PERSISTENCE||CPM|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1969-11-03||||1970-07-03||1967-12-01|1967-02-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KG/MOL|OPTIMAL MORPHOLOGIC RESPONSE||CMHG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|ADJUDICATOR|PATHOLOGIST|Y|3||39||INDUCTION TREATMENT|1962-01-13||||1961-03-05||1960-11-27|1962-02-25||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||ANATRESP|ANATOMIC RESPONSE||||HOURS|SD-CT||MN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|CAREGIVER|MICROSCOPIST 1|Y|4||88||WASHOUT|1972-11-27||||1969-06-19||1964-11-24|1962-01-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||NEWLPROG|NEW LESION PROGRESSION||||MDFI|SMD||UM/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|N|4||88||FOLLOW-UP|1964-09-17||||1966-12-09||1962-11-12|1963-11-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||RDIORESP|RADIOLOGIC RESPONSE||||U/KG/DAY|CCR||MM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|PROXY|INTERNIST|NA|5||7||BLINDED TREATMENT|1963-01-07||||1964-09-12||1962-03-10|1971-04-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||ANATRESP|ANATOMIC RESPONSE||||DAMOL/L|ABSENT MORPHOLOGIC RESPONSE||MOL/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|5||7||BASELINE|1961-06-21||||1967-11-18||1964-07-11|1965-07-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GAUSS|NE||KEV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|CHILD|MICROSCOPIST|U|1||38||OBSERVATION|1962-03-22||||1963-05-20||1965-08-15|1969-06-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UEQ|NE||10^9 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||SCREENING|1971-12-25||||1960-05-12||1964-04-08|1960-01-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||NTRGRESP|NON-TARGET RESPONSE||||PACK YEAR|CYTOGENETIC MINOR RESPONSE||IMPLANT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|N|2||58||FOLLOW-UP|1967-09-13||||1961-06-19||1968-03-22|1960-12-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||NEWLPROG|NEW LESION PROGRESSION||||SACHET|HI-P||U/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|DOMESTIC PARTNER|HEMATOLOGIST|U|2||58||OPEN LABEL TREATMENT|1967-11-16||||1967-06-09||1969-07-03|1968-08-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||TRGRESP|TARGET RESPONSE||||FMOL/G|IMPROVED||AGU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|FRIEND|OPTOMETRIST|N|3||39||LONG-TERM FOLLOW-UP|1969-04-14||||1961-12-30||1966-08-01|1969-03-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||STRUSTAT|STEROID USE STATUS||||UV*SEC|CA125 50% RESPONSE||EU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|3||39||WASHOUT|1970-08-19||||1971-06-13||1963-09-16|1966-03-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/G|MRD NEGATIVITY||U/L|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|FRIEND|ADJUDICATOR 3|NA|4||88||CONTINUATION TREATMENT|1962-09-12||||1964-04-08||1967-01-30|1968-02-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||ANATRESP|ANATOMIC RESPONSE||||U/M2/H|HI-P||ML/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|STUDY SUBJECT|MICROSCOPIST 3|NA|4||88||INDUCTION TREATMENT|1968-11-08||||1969-01-23||1971-08-30|1968-08-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CYLINDER|PR||ML/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|CHILD|RATER|U|5||7||OPEN LABEL TREATMENT|1968-12-13||||1971-04-14||1962-12-22|1969-01-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||NEWLPROG|NEW LESION PROGRESSION||||JAR|VGPR||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|5||7||WASHOUT|1970-04-22||||1967-08-29||1973-06-21|1970-11-07||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EID 50/DOSE|ISD||PL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|1||38||CONTINUATION TREATMENT|1966-09-30||||1960-10-13||1961-07-13|1971-05-02||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE/DAY|MORPHOLOGIC CRI||OI50|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|1||38||BLINDED TREATMENT|1963-07-28||||1966-04-22||1963-08-24|1971-01-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PNU/ML|NON-ICR/NON-IUPD||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|STUDY SUBJECT|NEUROLOGIST|Y|2||58||WASHOUT|1966-03-07||||1963-04-18||1969-09-05|1971-12-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^6/L|OPTIMAL MORPHOLOGIC RESPONSE||PMOL/10^9 CELLS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|2||58||SCREENING|1972-11-19||||1964-12-30||1962-06-12|1960-12-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||BONERESP|BONE RESPONSE||||MSEC|PD/RELAPSE AFTER HI||MPH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|FAMILY MEMBER|MICROSCOPIST 2|Y|3||39||OPEN LABEL TREATMENT|1969-11-08||||1961-07-31||1972-12-08|1967-06-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CP|MOLECULAR MAJOR RESPONSE||1/(S*KPA)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|3||39||FOLLOW-UP|1961-04-26||||1968-12-27||1968-08-04|1963-02-17||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||BONERESP|BONE RESPONSE||||MDFI|SCR||CMH2O/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|GUARDIAN|READER 3|U|4||88||WASHOUT|1963-02-26||||1962-07-16||1972-08-05|1965-05-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NMOL/L/H|PSEUDOPROGRESSION||ABSORBANCE U/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|DOMESTIC PARTNER|PATHOLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1967-09-06||||1963-07-23||1971-05-06|1960-11-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/MMHG|RELAPSED DISEASE FROM CR OR PR||CD*S/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|PARENT|READER 2|U|5||7||LONG-TERM FOLLOW-UP|1963-02-20||||1967-09-08||1967-02-25|1961-08-30||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MOL/MOL|NON-PD||MMOL/MIN/KPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|U|5||7||BLINDED TREATMENT|1967-10-26||||1962-01-07||1973-02-16|1966-01-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KAT|INCREASED||L/H/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|STUDY SUBJECT|HEMATOLOGIST|U|1||38||SCREENING|1972-03-03||||1972-04-06||1969-08-30|1973-04-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||MOLRESP|MOLECULAR RESPONSE||||ML|SD||/5X10^4 WBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|SIBLING|PHYSIOTHERAPIST|N|1||38||BLINDED TREATMENT|1961-02-03||||1968-02-02||1960-03-02|1962-01-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HOUNSFIELD UNIT|DECREASED||TRANSDUCING UNIT/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|INDEPENDENT ASSESSOR|RATER|U|2||58||WASHOUT|1965-07-10||||1970-03-23||1970-12-04|1961-06-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||NEWLPROG|NEW LESION PROGRESSION||||VIRTUAL PIXEL|MORPHOLOGIC CRI||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|PARENT|READER|NA|2||58||CONTINUATION TREATMENT|1972-11-19||||1972-06-30||1960-11-02|1965-11-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/BREATH|MOLECULAR MAJOR RESPONSE||/MM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|CHILD|CLINICAL PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1968-07-24||||1971-10-31||1965-12-22|1968-08-26||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/ANIMAL|MRD PERSISTENCE||KM/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|RATER 2|NA|3||39||BASELINE|1970-06-13||||1973-05-03||1971-10-23|1971-12-28||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DRINK|RELAPSED DISEASE FROM CR||/HPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|CHILD|PATHOLOGIST 1|U|4||88||BASELINE|1969-04-19||||1962-01-17||1969-09-13|1966-02-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||BESTRESP|BEST OVERALL RESPONSE||||CMH2O*S/ML|MR||10^3 CFU/G|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|PARENT|NEUROLOGIST 1|NA|4||88||RUN-IN|1968-04-12||||1965-12-11||1965-03-06|1966-11-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||MOLRESP|MOLECULAR RESPONSE||||UMOL/L/MIN|IUPD||GENEQ/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|GUARDIAN|READER 3|NA|5||7||CONTINUATION TREATMENT|1963-06-14||||1962-05-18||1972-02-17|1964-08-31||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^6/HPF|CPR||MV|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|NA|STUDY SUBJECT|READER 2|U|5||7||CONTINUATION TREATMENT|1964-10-21||||1972-01-31||1973-04-07|1963-08-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||CYTORESP|CYTOGENETIC RESPONSE||||TAMPON|INCREASED||IU/KG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|SIBLING|READER|Y|1||38||SCREENING|1960-07-28||||1963-04-21||1963-08-19|1968-01-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||BONERESP|BONE RESPONSE||||PM|MORPHOLOGIC LEUKEMIA-FREE STATE||HEP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|CAREGIVER|ONCOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1967-09-05||||1960-02-06||1964-12-22|1960-06-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||OVRLRESP|OVERALL RESPONSE||||UV2|NR||GMFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|SPOUSE|UROLOGIST|U|2||58||INDUCTION TREATMENT|1965-10-26||||1972-10-24||1963-07-07|1961-10-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||IN2|MAJOR PATHOLOGIC RESPONSE||MIN/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|2||58||BASELINE|1962-05-22||||1962-06-18||1969-09-26|1972-11-15||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||METSIND|METASTATIC INDICATOR||||LOG10 ELISA UNIT/DOSE|MAJOR PATHOLOGIC RESPONSE||GBQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|INTERVIEWER|NEUROLOGIST 1|Y|3||39||OBSERVATION|1964-09-15||||1964-08-09||1961-05-19|1970-11-02||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||OVRLRESP|OVERALL RESPONSE||||G/KG|CR-CT||MPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|GUARDIAN|RATER 1|N|3||39||RUN-IN|1964-07-09||||1965-06-20||1973-03-06|1969-09-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||NEWLPROG|NEW LESION PROGRESSION||||NMOL/MOL|PR-CT||CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|INDEPENDENT ASSESSOR|READER|N|4||88||INDUCTION TREATMENT|1966-07-07||||1973-08-21||1967-02-14|1973-04-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||TRGRESP|TARGET RESPONSE||||CG|MR||VG/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|GUARDIAN|RATER 1|Y|4||88||OBSERVATION|1972-04-19||||1961-11-12||1967-09-14|1962-05-07||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||L/H|PD/RELAPSE AFTER HI||USP U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|SIBLING|NEUROLOGIST|U|5||7||FOLLOW-UP|1964-11-12||||1972-08-22||1969-12-21|1960-10-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/G/H|MINOR PATHOLOGIC RESPONSE||ROENTGEN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|FAMILY MEMBER|OPHTHALMOLOGIST|NA|5||7||BASELINE|1965-06-05||||1966-05-18||1967-06-28|1967-09-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||METBRESP|METABOLIC RESPONSE||||10^3 DNA COPIES/ML|TREATMENT FAILURE||CIGARETTE|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|1||38||FOLLOW-UP|1962-09-27||||1966-08-30||1963-02-05|1964-09-01||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||ANATRESP|ANATOMIC RESPONSE||||S*KPA|MRD NEGATIVITY||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|ADJUDICATOR|HEMATOLOGIST|NA|1||38||SCREENING|1963-06-03||||1967-11-28||1963-08-23|1963-12-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||LM|DECREASED||DRAM|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|SIGNIFICANT OTHER|RADIOLOGIST|NA|2||58||BLINDED TREATMENT|1969-05-18||||1963-02-11||1971-05-12|1961-09-06||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MMHG/L/MIN|MRD RELAPSE||ML/H|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|STUDY SUBJECT|MICROSCOPIST 3|U|2||58||WASHOUT|1963-07-30||||1969-03-31||1961-02-18|1968-01-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MMOL|EQUIVOCAL||VG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|DOMESTIC PARTNER|RATER|Y|3||39||WASHOUT|1968-03-11||||1973-05-13||1969-11-22|1966-04-05||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||LOG10 IU/ML|PSEUDORESPONSE||PIXEL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|CAREGIVER|PATHOLOGIST 1|N|3||39||OBSERVATION|1964-11-07||||1965-11-28||1969-05-19|1970-11-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||METSIND|METASTATIC INDICATOR||||CI/L|HI-E||CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|INVESTIGATOR|ADJUDICATOR 1|N|4||88||OBSERVATION|1969-09-19||||1960-09-22||1970-11-28|1960-12-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/L DDU|PCR||U/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|4||88||FOLLOW-UP|1969-01-04||||1962-05-26||1967-05-22|1961-08-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/KG/WEEK|IUPD||U/M2/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|CHILD|PATHOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1968-06-29||||1970-02-01||1961-01-23|1968-01-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||NEWLPROG|NEW LESION PROGRESSION||||U/KG|CR-CT||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|INTERVIEWER|RADIOLOGIST 2|Y|5||7||TREATMENT|1973-06-30||||1964-07-10||1972-01-16|1962-06-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/G/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|FAMILY MEMBER|MICROSCOPIST 3|Y|1||38||FOLLOW-UP|1971-08-09||||1971-10-19||1961-11-01|1963-09-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|2||||||OVRLRESP|OVERALL RESPONSE||||G/ANIMAL/WK|COMPLETE MRD RESPONSE||10^3/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|U|SIGNIFICANT OTHER|OPTOMETRIST|U|1||38||WASHOUT|1972-10-29||||1964-01-28||1972-02-11|1961-05-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|1||||||NEWLPROG|NEW LESION PROGRESSION||||NU/CL|IMMUNOPHENOTYPIC CR||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|SIBLING|PATHOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1972-10-12||||1968-07-08||1964-01-04|1971-06-22||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/MOL|MCR||TRACE|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|CHILD|NEUROLOGIST 1|U|2||58||OBSERVATION|1965-06-28||||1970-03-21||1971-01-07|1970-06-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/MOL|STABLE||U/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|3||39||INDUCTION TREATMENT|1968-06-13||||1961-11-28||1969-11-07|1969-10-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|2||||||RDIORESP|RADIOLOGIC RESPONSE||||BLOCKS|CHR||MG/KG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|SIBLING|RATER 1|Y|3||39||WASHOUT|1973-02-04||||1971-08-17||1971-09-23|1967-05-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|1||||||TRGRESP|TARGET RESPONSE||||PFU/ANIMAL|MINOR PATHOLOGIC RESPONSE||LOG10 PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|CHILD|RATER 2|NA|4||88||OPEN LABEL TREATMENT|1962-01-14||||1970-01-15||1970-03-06|1966-11-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|2||||||PATHRESP|PATHOLOGIC RESPONSE||||IU/DL|PR-CT||EJACULATE U|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|4||88||SCREENING|1966-10-16||||1961-08-17||1969-08-27|1961-05-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/SEC/1.73M2|UNEQUIVOCAL||COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|CHILD|READER 3|N|5||7||TREATMENT|1962-12-15||||1966-10-18||1962-08-27|1972-06-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|573C9228-D341-491C-9D66-0D0435E2C631|2||||||RDIORESP|RADIOLOGIC RESPONSE||||FMOL/L/SEC|PDU||UG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|5||7||LONG-TERM FOLLOW-UP|1961-05-27||||1966-05-30||1972-10-28|1962-08-11||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||NEWLIND|NEW LESION INDICATOR||||IU/G|MAJOR PATHOLOGIC RESPONSE||10^3 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|FAMILY MEMBER|RADIOLOGIST 1|N|1||38||INDUCTION TREATMENT|1963-05-20||||1966-05-19||1961-10-11|1961-01-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/DOSE|STABLE||UG/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|STUDY SUBJECT|MICROSCOPIST 1|Y|1||38||SCREENING|1964-12-09||||1968-09-16||1969-07-03|1972-06-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||METBRESP|METABOLIC RESPONSE||||MU/L|CRI||UM/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1962-01-22||||1971-05-04||1963-09-11|1964-01-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CIGARETTE|NED||CAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||OBSERVATION|1967-09-24||||1971-12-17||1969-06-15|1971-05-17||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/ANIMAL|CR-CT||CI/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|CLINICAL RESEARCH ASSOCIATE|READER 3|N|3||39||RUN-IN|1969-08-01||||1961-04-28||1963-09-20|1968-04-21||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||NTRGRESP|NON-TARGET RESPONSE||||CI/ML|EQUIVOCAL||LOG10 PFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|INTERVIEWER|MICROSCOPIST|U|3||39||BLINDED TREATMENT|1968-04-22||||1967-12-13||1970-05-12|1970-04-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CAGE/DAY|STABLE||TSP EQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|DOMESTIC PARTNER|RATER 2|Y|4||88||CONTINUATION TREATMENT|1967-10-27||||1967-03-20||1968-12-08|1962-08-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GBQ/UG|NED||L/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|4||88||SCREENING|1960-11-30||||1965-11-30||1964-11-13|1961-03-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/MBP|MORPHOLOGIC LEUKEMIA-FREE STATE||BAU|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|STUDY SUBJECT|READER 1|N|5||7||INDUCTION TREATMENT|1964-12-18||||1969-10-29||1963-04-07|1971-08-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||PATHRESP|PATHOLOGIC RESPONSE||||BQ/ML|ICPD||GENEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|GUARDIAN|READER 1|U|5||7||TREATMENT|1971-12-06||||1967-11-27||1972-06-23|1971-09-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DRAM|MRD PERSISTENCE||M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|CAREGIVER|RATER 2|N|1||38||SCREENING|1970-07-14||||1960-05-05||1968-06-18|1973-05-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/ML|SMD||DRAM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|FRIEND|ONCOLOGIST 2|Y|1||38||BASELINE|1961-09-03||||1967-04-25||1971-03-07|1973-02-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UU/DL|CYTOGENETIC PR||CI/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|STUDY SUBJECT|CARDIOLOGIST|Y|2||58||TREATMENT|1967-07-11||||1968-07-13||1960-04-26|1960-03-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CYLINDER|SMD||POINT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|CHILD|ADJUDICATOR 2|N|2||58||WASHOUT|1971-12-14||||1973-06-18||1963-02-22|1973-08-12||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||OVRLRESP|OVERALL RESPONSE||||10^3 RNA COPIES/ML|SD||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1972-06-15||||1965-10-26||1966-04-26|1966-06-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/KG/MIN|SCR||UM2|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||BASELINE|1967-05-02||||1973-03-07||1965-05-27|1962-12-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||CLINRESP|CLINICAL RESPONSE||||EVENTS|SCR||LOG EID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|GUARDIAN|RADIOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1966-04-04||||1967-09-05||1962-07-27|1963-04-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PKAT/L|PARTIAL MORPHOLOGIC RESPONSE||DIP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|4||88||BLINDED TREATMENT|1966-03-24||||1967-12-26||1962-12-11|1968-07-14||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||MOLRESP|MOLECULAR RESPONSE||||CMHG|NON-QUANTIFIABLE MRD POSITIVITY||MG/ML/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CAREGIVER|NEUROLOGIST|NA|5||7||INDUCTION TREATMENT|1961-07-01||||1970-07-26||1969-03-09|1964-11-18||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||METSIND|METASTATIC INDICATOR||||LOG10 ELISA UNIT/DOSE|ICR||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|5||7||BASELINE|1969-06-21||||1973-02-19||1966-06-12|1970-05-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||SPLNRESP|SPLEEN RESPONSE||||UCI/L|CPR||10^7/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|CHILD|HEMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1962-04-02||||1972-04-06||1961-08-17|1964-04-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||SPLNRESP|SPLEEN RESPONSE||||ELISA UNIT|CYTOGENETIC MINOR RESPONSE||PSI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|SIBLING|ADJUDICATOR 3|NA|1||38||SCREENING|1968-12-02||||1968-05-22||1964-12-13|1971-01-25||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||MOLRESP|MOLECULAR RESPONSE||||1/(S*KPA)|NON-QUANTIFIABLE MRD POSITIVITY||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|2||58||OBSERVATION|1973-08-02||||1967-05-24||1968-01-28|1968-04-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||BESTRESP|BEST OVERALL RESPONSE||||MMHG/L/MIN|SD-CT||ML/SEC/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|PARENT|PEDIATRIC NEUROLOGIST|Y|2||58||INDUCTION TREATMENT|1962-03-06||||1964-01-09||1967-02-01|1965-09-29||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||METSIND|METASTATIC INDICATOR||||CAL|RELAPSED DISEASE FROM CR OR PR||MM/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|GUARDIAN|RATER 1|N|3||39||BASELINE|1971-10-24||||1970-04-24||1970-11-30|1962-09-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||TMRESP|TUMOR MARKER RESPONSE||||UGEQ|MRD PERSISTENCE||UMOL/MG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|3||39||BASELINE|1961-06-09||||1964-09-03||1964-08-28|1965-09-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/DL|SD-CT||CG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|SIGNIFICANT OTHER|READER 3|Y|4||88||CONTINUATION TREATMENT|1972-09-20||||1971-04-26||1967-05-28|1968-05-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TAMPON|MOLECULAR CR||LM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|CHILD|RATER|NA|4||88||WASHOUT|1962-03-03||||1970-02-04||1967-08-31|1968-03-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||P|WORSENED||PUFF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|SIGNIFICANT OTHER|DERMATOLOGIST|Y|5||7||BASELINE|1960-04-21||||1972-03-28||1965-05-14|1963-02-03||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||BONERESP|BONE RESPONSE||||MET|MR||BEAM BREAKS|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|5||7||RUN-IN|1962-12-18||||1970-03-24||1973-03-08|1967-12-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CG|MCR||SBE/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|ADJUDICATOR|OPTOMETRIST|N|1||38||RUN-IN|1967-09-06||||1964-12-21||1966-03-04|1968-06-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^3/HPF|IPR||INHALATION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1963-08-10||||1969-07-14||1964-07-10|1962-06-07||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^7 CFU/ML|PMD||DIOPTER|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|CLINICAL RESEARCH ASSOCIATE|INTERNIST|N|2||58||OBSERVATION|1963-12-17||||1973-06-22||1971-11-13|1962-12-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KPA/L/SEC|EQUIVOCAL||PT_US|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|SPOUSE|MICROSCOPIST 2|N|2||58||INDUCTION TREATMENT|1973-06-15||||1967-06-10||1966-09-11|1965-06-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MMOL/MIN/KPA|CR||BISCUIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|FAMILY MEMBER|ADJUDICATOR 2|Y|3||39||CONTINUATION TREATMENT|1969-10-27||||1973-01-30||1971-11-13|1972-02-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||CLINRESP|CLINICAL RESPONSE||||CP|MRD RELAPSE||LOG10 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|SIBLING|FORENSIC PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-02-25||||1960-04-26||1966-01-27|1961-11-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/M2|COMPLETE MRD RESPONSE||UEQ/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|READER|N|4||88||SCREENING|1967-07-17||||1963-11-11||1967-12-05|1967-08-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||BONERESP|BONE RESPONSE||||MOL/DAY|PD FROM PR||MG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|4||88||SCREENING|1967-11-13||||1967-04-30||1964-01-29|1967-01-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||METBRESP|METABOLIC RESPONSE||||SYRINGE|PR WITH LYMPHOCYTOSIS||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|5||7||SCREENING|1973-04-14||||1967-06-06||1963-03-02|1962-06-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/CAGE|PMR||PMOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|INTERVIEWER|NEUROLOGIST 1|U|5||7||SCREENING|1965-11-17||||1962-05-01||1973-05-21|1966-11-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UMOL/L|MR||UKAT/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|CAREGIVER|ENDOCRINOLOGIST|Y|1||38||TREATMENT|1966-06-29||||1973-07-28||1967-05-03|1964-08-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||BESTRESP|BEST OVERALL RESPONSE||||U.CARR|NE||UG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|1||38||BASELINE|1971-10-26||||1965-10-01||1964-08-27|1968-09-10||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||NTRGRESP|NON-TARGET RESPONSE||||ELISA UNIT|VGPR||C|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|2||58||WASHOUT|1971-03-18||||1971-08-11||1971-01-31|1961-12-20||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||NEWLIND|NEW LESION INDICATOR||||/2000 RBC|IUPD||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|SPOUSE|OPHTHALMOLOGIST|NA|2||58||CONTINUATION TREATMENT|1971-12-02||||1960-07-17||1967-09-16|1968-05-07||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||METSIND|METASTATIC INDICATOR||||GPS U|MORPHOLOGIC CRI||MBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|SPOUSE|READER 2|N|3||39||LONG-TERM FOLLOW-UP|1963-12-23||||1966-06-12||1970-08-31|1965-12-09||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||OVRLRESP|OVERALL RESPONSE||||UL/DOSE|PMR||PKAT|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|INDEPENDENT ASSESSOR|UROLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-06-13||||1970-08-08||1972-12-15|1961-05-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||SPLNRESP|SPLEEN RESPONSE||||CD/M2|COMPLETE MRD RESPONSE||PPTR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|INVESTIGATOR|ADJUDICATOR 2|Y|4||88||CONTINUATION TREATMENT|1972-08-16||||1961-06-29||1967-01-28|1964-10-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/KG|OPTIMAL MORPHOLOGIC RESPONSE||UM/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|INTERVIEWER|RATER 1|NA|4||88||SCREENING|1969-06-26||||1964-07-22||1967-10-13|1973-01-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||OVRLRESP|OVERALL RESPONSE||||PIPE|MORPHOLOGIC CR||DRUM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|5||7||INDUCTION TREATMENT|1966-03-09||||1963-07-21||1960-01-10|1964-11-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CI/UL|PSEUDORESPONSE||V|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||INDUCTION TREATMENT|1967-02-13||||1970-08-22||1964-06-20|1961-03-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BEAM BREAKS|IMPROVED||GBQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|CLINICAL STUDY SPONSOR|UROLOGIST|NA|1||38||OPEN LABEL TREATMENT|1971-08-31||||1969-10-31||1963-07-11|1972-11-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||BQ|ABSENT MORPHOLOGIC RESPONSE||%(W/V)|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|INVESTIGATOR|ADJUDICATOR 3|N|1||38||OBSERVATION|1961-05-14||||1965-10-12||1962-04-03|1965-10-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||%(V/V)|IUPD||SBE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|CHILD|PEDIATRIC NEUROLOGIST|NA|2||58||INDUCTION TREATMENT|1965-09-01||||1970-04-09||1972-04-30|1962-06-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GMFI|PD||GBQ/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|INTERVIEWER|NEUROLOGIST 2|Y|2||58||OBSERVATION|1960-06-29||||1968-04-28||1960-09-07|1960-07-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||METSIND|METASTATIC INDICATOR||||MG/CM2|NE||L/S|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|N|3||39||FOLLOW-UP|1970-09-25||||1967-06-02||1960-03-09|1960-05-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||ANATRESP|ANATOMIC RESPONSE||||CAPLET|TREATMENT FAILURE||IU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CLINICAL RESEARCH COORDINATOR|READER 3|Y|3||39||RUN-IN|1970-07-19||||1968-05-13||1961-08-27|1971-10-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/DAY|CCR||UG/ML/H|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||INDUCTION TREATMENT|1960-09-06||||1973-02-27||1962-04-02|1966-08-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SACHET|CYTOGENETIC PR||PPB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|CHILD|DERMATOLOGIST|Y|4||88||SCREENING|1972-12-01||||1969-05-01||1963-09-09|1969-08-03||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DEG2|NOT ALL EVALUATED||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||BASELINE|1972-04-02||||1972-12-13||1972-08-27|1973-03-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%(W/V)|EQUIVOCAL||PPTR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|INDEPENDENT ASSESSOR|ADJUDICATOR 3|N|5||7||INDUCTION TREATMENT|1961-03-04||||1972-04-13||1961-03-30|1973-05-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||TMRESP|TUMOR MARKER RESPONSE||||/2000 RBC|IPR||MG/ML/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|CHILD|READER 2|NA|1||38||RUN-IN|1960-12-24||||1960-08-08||1962-09-03|1973-07-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DPM/100MG|MORPHOLOGIC CRI||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1970-02-06||||1967-07-22||1972-11-21|1961-11-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||METBRESP|METABOLIC RESPONSE||||ML/(MIN*100ML)|WORSENED||KHZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|2||58||TREATMENT|1961-05-19||||1964-03-21||1961-01-27|1967-01-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||%(W/V)|CYTOGENETIC PR||UG/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|FAMILY MEMBER|ONCOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1965-08-25||||1972-10-05||1970-07-09|1961-08-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^10/L|PR WITH LYMPHOCYTOSIS||/MS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|CLINICAL STUDY SPONSOR|RATER 1|NA|3||39||BLINDED TREATMENT|1968-08-07||||1961-06-13||1960-10-10|1963-04-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/ANIMAL/DAY|PD FROM PR||10^11/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|CHILD|UROLOGIST|Y|3||39||BLINDED TREATMENT|1962-03-17||||1966-09-22||1969-08-07|1962-02-12||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||NEWLIND|NEW LESION INDICATOR||||NEWTON|CPR||MMHG*MIN/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|FAMILY MEMBER|HEMATOLOGIST|N|4||88||TREATMENT|1960-01-26||||1971-01-01||1961-01-23|1963-04-10||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^9/G|HI-N||UG/G/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|STUDY SUBJECT|ENDOCRINOLOGIST|N|4||88||SCREENING|1963-11-18||||1963-04-06||1971-06-01|1966-12-19||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CMH2O*S/ML|MAJOR PATHOLOGIC RESPONSE||ML/CM|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|VENDOR|RADIOLOGIST 2|NA|5||7||TREATMENT|1961-02-14||||1960-10-27||1969-09-30|1970-10-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||NCI|CMR||/100 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|SIBLING|MICROSCOPIST 2|U|5||7||BASELINE|1969-12-12||||1973-01-28||1973-06-09|1972-09-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||METSIND|METASTATIC INDICATOR||||IU/L|IUPD||UG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CHILD|NEUROLOGIST 1|U|1||38||TREATMENT|1965-09-10||||1961-04-06||1973-05-23|1963-04-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U.CARR|CCR||L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|FRIEND|RATER 2|N|1||38||BLINDED TREATMENT|1967-07-12||||1962-12-27||1961-09-05|1969-11-12||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||METBRESP|METABOLIC RESPONSE||||CMHG|PD/RELAPSE AFTER HI||DEG/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|2||58||INDUCTION TREATMENT|1965-05-17||||1965-06-29||1960-01-26|1972-01-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||MOLRESP|MOLECULAR RESPONSE||||FRACTION OF 1|PR WITH LYMPHOCYTOSIS||BOWL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|DOMESTIC PARTNER|ONCOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1970-04-26||||1965-02-25||1963-08-17|1965-07-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MN|RELAPSED DISEASE||UG/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1969-03-15||||1967-10-07||1961-06-01|1964-07-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CD*S/M2|HI-E||G/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|PROXY|READER 2|Y|3||39||OPEN LABEL TREATMENT|1963-11-21||||1967-01-12||1963-08-20|1965-05-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||NEWLPROG|NEW LESION PROGRESSION||||MS2|CYTOGENETIC PR||10^8 PFU|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|GUARDIAN|ENDOCRINOLOGIST|NA|4||88||BASELINE|1972-05-12||||1971-02-19||1962-04-14|1966-06-30||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FT|MINOR PATHOLOGIC RESPONSE||KG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|PARENT|OPTOMETRIST|U|4||88||FOLLOW-UP|1962-01-19||||1961-03-13||1972-07-30|1968-04-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||STRUSTAT|STEROID USE STATUS||||IU/DAY|PD FROM PR||MET*MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||TREATMENT|1961-09-14||||1969-09-10||1965-02-22|1973-04-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||OVRLRESP|OVERALL RESPONSE||||ANTI-XA IU|IPR||SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|CHILD|INTERNIST|Y|5||7||RUN-IN|1968-07-07||||1970-01-07||1970-10-04|1960-01-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||LIVRRESP|LIVER RESPONSE||||UG/DAY|PR WITH LYMPHOCYTOSIS||PHERESIS UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|1||38||OBSERVATION|1962-03-17||||1968-08-05||1972-05-16|1965-08-11||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||CLINRESP|CLINICAL RESPONSE||||10^8/L|CR||/100 WBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|STUDY SUBJECT|RADIOLOGIST 1|Y|1||38||CONTINUATION TREATMENT|1970-12-17||||1968-04-29||1969-11-27|1970-06-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||STRUSTAT|STEROID USE STATUS||||DEG2|STABLE||PPM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|CHILD|RATER 2|Y|2||58||TREATMENT|1967-08-04||||1967-10-03||1972-11-19|1973-07-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||METBRESP|METABOLIC RESPONSE||||KDA|EQUIVOCAL||MV|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|STUDY SUBJECT|RATER 2|NA|2||58||OBSERVATION|1966-03-21||||1963-11-04||1964-11-21|1960-10-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/S|ICR||MMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|INVESTIGATOR|DERMATOLOGIST|NA|3||39||RUN-IN|1960-01-04||||1967-05-03||1967-02-10|1961-01-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GLOBULE|NED||BISCUIT|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|PROXY|INTERNIST|N|3||39||OPEN LABEL TREATMENT|1972-04-22||||1965-08-14||1960-11-08|1960-04-09||DURING||DURING|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FMOL/L/SEC|NR||MCI/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|INTERVIEWER|DERMATOLOGIST|NA|4||88||BASELINE|1971-10-07||||1972-10-08||1964-11-30|1970-07-30||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||BONERESP|BONE RESPONSE||||M/SEC2|INCREASED||NG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|INTERVIEWER|CLINICAL PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1960-09-19||||1971-01-12||1971-12-09|1970-07-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||STRUSTAT|STEROID USE STATUS||||UG/CM2|NON-CR/NON-PD||10^7/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1964-03-23||||1961-06-09||1963-07-08|1966-12-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||MOLRESP|MOLECULAR RESPONSE||||NKAT/G HB|CPR||OZ|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||OBSERVATION|1964-04-17||||1968-11-20||1964-05-06|1961-11-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/DL|SCR||CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|ADJUDICATOR|MICROSCOPIST|U|1||38||CONTINUATION TREATMENT|1964-01-10||||1960-05-26||1966-11-07|1966-08-26||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||BONERESP|BONE RESPONSE||||/MBP|MINOR PATHOLOGIC RESPONSE||G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|FAMILY MEMBER|PHYSIOTHERAPIST|N|1||38||WASHOUT|1967-11-12||||1968-07-06||1965-11-11|1968-05-14||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FT3|FAVORABLE RESPONSE||L/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|GUARDIAN|NEUROLOGIST 1|U|2||58||CONTINUATION TREATMENT|1968-10-12||||1961-11-12||1964-01-26|1971-12-26||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CM H2O|NE||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|2||58||WASHOUT|1967-10-03||||1961-09-10||1961-11-02|1962-03-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||STEPS|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|3||39||FOLLOW-UP|1967-11-08||||1967-11-08||1969-12-15|1961-01-31||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||LIVRRESP|LIVER RESPONSE||||/SEC|DISEASE TRANSFORMATION||LENS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|SIGNIFICANT OTHER|ADJUDICATOR|NA|3||39||SCREENING|1967-04-09||||1966-10-22||1972-02-13|1965-09-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||AFU|MRD RELAPSE||10^4 CFU|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|SPOUSE|ADJUDICATOR 1|NA|4||88||TREATMENT|1973-01-29||||1964-02-07||1970-02-25|1964-08-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||BONERESP|BONE RESPONSE||||10^6 ORGANISMS/MG|VGPR||MG/KG/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|VENDOR|CARDIOLOGIST|NA|4||88||INDUCTION TREATMENT|1960-06-23||||1963-09-09||1965-05-30|1973-07-19||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/7.5 ML|CYTOGENETIC MINOR RESPONSE||U/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|STUDY SUBJECT|ADJUDICATOR 2|NA|5||7||RUN-IN|1972-12-27||||1970-07-27||1963-06-02|1960-03-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/L|NR||BQ/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|FAMILY MEMBER|CARDIOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1962-09-08||||1972-03-28||1962-10-25|1961-10-19||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||PATHRESP|PATHOLOGIC RESPONSE||||L/DAY|PR||CAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|SIGNIFICANT OTHER|MICROSCOPIST 2|U|1||38||TREATMENT|1968-06-20||||1967-12-08||1964-10-26|1964-06-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||TMRESP|TUMOR MARKER RESPONSE||||VIRTUAL PIXEL|PR-CT||UMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|INVESTIGATOR|READER 1|U|1||38||WASHOUT|1964-12-08||||1964-03-07||1968-11-30|1972-01-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||PATHRESP|PATHOLOGIC RESPONSE||||GY|FAVORABLE RESPONSE||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|VENDOR|RADIOLOGIST 2|U|2||58||TREATMENT|1964-10-09||||1967-09-22||1967-10-03|1963-09-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UM2|NE||ML/CAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|ADJUDICATOR|READER 3|Y|2||58||LONG-TERM FOLLOW-UP|1964-01-28||||1963-04-11||1968-12-12|1972-01-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||METSIND|METASTATIC INDICATOR||||OSM|NOT ALL EVALUATED||L/MIN/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1971-04-23||||1966-05-20||1960-06-24|1963-12-30||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||CYTORESP|CYTOGENETIC RESPONSE||||FRAMES/S|EQUIVOCAL||10^9 ORGANISMS/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|STUDY SUBJECT|NEUROLOGIST 2|NA|3||39||SCREENING|1960-06-24||||1968-09-23||1964-08-06|1967-10-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||NEWLIND|NEW LESION INDICATOR||||TUBERCULIN UNIT|COMPLETE MRD RESPONSE||CD|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|4||88||WASHOUT|1963-07-06||||1973-02-08||1962-07-16|1971-06-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||BONERESP|BONE RESPONSE||||/LPF|MAJOR PATHOLOGIC RESPONSE||MEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|SPOUSE|PATHOLOGIST 2|Y|4||88||TREATMENT|1965-12-15||||1971-04-28||1968-07-19|1961-12-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MMHG*MIN/L|ICR||SV|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||BASELINE|1969-03-21||||1966-06-30||1961-02-06|1964-08-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||% INHIBITION|NED||MBP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|PROXY|RATER|NA|5||7||FOLLOW-UP|1963-03-12||||1970-03-15||1970-11-23|1964-06-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CM H2O|HI-N||RFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|FRIEND|ENDOCRINOLOGIST|Y|1||38||FOLLOW-UP|1971-07-08||||1965-11-20||1963-06-22|1969-04-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||BESTRESP|BEST OVERALL RESPONSE||||OHM|ISD||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CHILD|PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1960-08-23||||1961-07-22||1971-10-07|1968-01-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TBSP|ABSENT MORPHOLOGIC RESPONSE||G/CAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|2||58||CONTINUATION TREATMENT|1973-03-18||||1964-11-10||1968-03-05|1967-12-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MNFI|ICR||U|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|STUDY SUBJECT|PATHOLOGIST 2|N|2||58||OBSERVATION|1968-03-22||||1972-11-23||1972-02-04|1971-05-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||BONERESP|BONE RESPONSE||||MG/G/MIN|VGPR||NG/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|PARENT|ONCOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1971-01-20||||1965-12-20||1967-05-07|1966-04-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DAMOL/L|RELAPSED DISEASE||ML/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|PROXY|UROLOGIST|NA|3||39||FOLLOW-UP|1961-11-11||||1969-03-03||1966-02-07|1972-11-27||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||LIVRRESP|LIVER RESPONSE||||K|MOLECULAR CR||NKAT/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|4||88||OBSERVATION|1963-12-04||||1963-01-24||1966-12-04|1960-06-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||NTRGRESP|NON-TARGET RESPONSE||||MPH|INDETERMINATE RESPONSE||10^11/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|4||88||RUN-IN|1966-05-10||||1972-07-15||1968-08-11|1960-09-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SFC/10^6 PBMC|CHR||10^3 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|ADJUDICATOR|NEUROLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1964-08-27||||1960-08-09||1965-01-26|1962-05-31||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KAT|CYTOGENETIC CR||PIXEL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|INVESTIGATOR|PATHOLOGIST 1|NA|5||7||INDUCTION TREATMENT|1971-08-02||||1963-09-24||1967-04-22|1972-12-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ECL UNIT|PSA PROGRESSION||ML/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|INDEPENDENT ASSESSOR|MICROSCOPIST|U|1||38||TREATMENT|1971-05-02||||1962-03-14||1960-12-03|1962-04-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||RDIORESP|RADIOLOGIC RESPONSE||||LOG10 IU/ML|MOLECULAR CR||RAD|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|GUARDIAN|MICROSCOPIST 1|N|1||38||SCREENING|1961-04-26||||1970-10-27||1964-11-21|1968-12-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PFU|PDU||UL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|INDEPENDENT ASSESSOR|READER 1|N|2||58||SCREENING|1963-11-04||||1962-10-13||1969-10-06|1964-03-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/KG|MOLECULAR MAJOR RESPONSE||USP U|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|2||58||OBSERVATION|1969-12-22||||1961-11-23||1961-02-04|1967-06-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MANSON U/ML|HI-N||LOG10 ELISA UNIT/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|3||39||SCREENING|1967-10-17||||1963-01-24||1960-04-27|1970-01-06||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MSEC|PARTIAL MORPHOLOGIC RESPONSE||KBQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|3||39||OPEN LABEL TREATMENT|1969-02-03||||1963-04-21||1966-07-21|1969-07-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/M2/DAY|EQUIVOCAL||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|SIGNIFICANT OTHER|RADIOLOGIST|NA|4||88||RUN-IN|1973-06-18||||1961-10-15||1970-12-16|1973-03-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||METSIND|METASTATIC INDICATOR||||UM|CRI||PSEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||SCREENING|1965-07-19||||1973-03-10||1969-06-10|1970-11-07||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MEQ/G|CCR||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|SPOUSE|RATER 2|Y|5||7||BLINDED TREATMENT|1968-03-23||||1970-06-09||1966-05-18|1966-03-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PM|IMPROVED||GRAVITATIONAL UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|CLINICAL STUDY SPONSOR|RATER|U|5||7||WASHOUT|1964-10-12||||1966-10-12||1966-10-02|1963-09-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||APS U|PDU||G/CM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|INVESTIGATOR|OPTOMETRIST|U|1||38||CONTINUATION TREATMENT|1968-05-10||||1963-10-11||1962-06-12|1961-06-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FMOL/G|PD-CT||MG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|1||38||CONTINUATION TREATMENT|1971-05-23||||1965-02-10||1964-05-27|1968-05-09||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||LIVRRESP|LIVER RESPONSE||||GY/H|SD-CT||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|Y|SPOUSE|PHYSIOTHERAPIST|NA|2||58||BASELINE|1972-09-14||||1960-10-25||1971-07-05|1965-09-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||METBRESP|METABOLIC RESPONSE||||%/S|IUPD||INHALATION|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|DOMESTIC PARTNER|RATER|NA|2||58||CONTINUATION TREATMENT|1972-03-19||||1968-06-27||1968-08-31|1961-12-11||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/KG|CA125 75% RESPONSE||UG/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|3||39||CONTINUATION TREATMENT|1967-12-19||||1961-07-11||1971-06-20|1967-10-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/L/H|PR WITH LYMPHOCYTOSIS||RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|CAREGIVER|ONCOLOGIST|N|3||39||RUN-IN|1970-04-13||||1961-01-03||1960-06-05|1964-08-31||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NCI|TREATMENT FAILURE||BOTTLE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|CAREGIVER|MICROSCOPIST 2|Y|4||88||TREATMENT|1962-10-26||||1965-04-21||1964-11-11|1964-06-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/CAGE|CYTOGENETIC MINOR RESPONSE||MPH|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|GUARDIAN|DERMATOLOGIST|NA|4||88||BASELINE|1965-12-31||||1969-07-25||1971-02-18|1972-04-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOSM/L|QUANTIFIABLE MRD POSITIVITY||UMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|5||7||BLINDED TREATMENT|1963-06-26||||1961-12-29||1972-05-06|1967-11-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UM/S|CA125 75% RESPONSE||CARTRIDGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|CAREGIVER|MICROSCOPIST 3|N|5||7||OPEN LABEL TREATMENT|1960-05-13||||1960-04-29||1963-12-31|1970-08-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||EU|PSA PROGRESSION||PIXELS/IN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|DOMESTIC PARTNER|READER 2|NA|1||38||SCREENING|1968-04-28||||1972-12-07||1966-02-22|1971-06-21||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||MOLRESP|MOLECULAR RESPONSE||||10^6 CFU/ML|CYTOGENETIC MINOR RESPONSE||UG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1970-01-04||||1961-08-17||1973-03-11|1972-02-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BQ/ML|DECREASED||CI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|N|2||58||INDUCTION TREATMENT|1963-09-17||||1971-04-25||1961-09-15|1969-09-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/G/DAY|MORPHOLOGIC CRI||SACHET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1972-08-28||||1967-06-23||1971-01-17|1973-01-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/M2/DAY|NED||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|INTERVIEWER|RADIOLOGIST 1|N|3||39||OBSERVATION|1969-01-18||||1972-06-04||1969-11-07|1973-05-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||METSIND|METASTATIC INDICATOR||||SCM|PR||DPM/0.5 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|3||39||OPEN LABEL TREATMENT|1967-01-15||||1967-07-23||1967-07-20|1961-04-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||NEWLPROG|NEW LESION PROGRESSION||||MMAL|PMD||DPM/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|VENDOR|PATHOLOGIST 1|U|4||88||OBSERVATION|1967-12-16||||1964-08-02||1962-05-21|1966-06-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||TMRESP|TUMOR MARKER RESPONSE||||TBSP|IMPROVED||U/M2/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||CONTINUATION TREATMENT|1964-06-28||||1972-02-24||1971-11-13|1961-10-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||AU/ML|CA125 50% RESPONSE||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|DOMESTIC PARTNER|PATHOLOGIST 2|N|5||7||TREATMENT|1961-11-02||||1960-03-02||1967-08-03|1968-03-31||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||CYTORESP|CYTOGENETIC RESPONSE||||EJACULATE U|EQUIVOCAL||MILE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1966-01-11||||1960-12-28||1963-12-23|1962-09-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||BONERESP|BONE RESPONSE||||MEQ/KG|PARTIAL MORPHOLOGIC RESPONSE||UU/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|RATER 1|NA|1||38||OBSERVATION|1967-02-15||||1970-09-28||1971-04-29|1964-07-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||JDF UNIT|PMR||U.CARR|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|ADJUDICATOR|INTERNIST|U|1||38||LONG-TERM FOLLOW-UP|1970-08-13||||1971-05-31||1966-11-04|1966-01-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MANSON U/ML|PARTIAL MORPHOLOGIC RESPONSE||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|2||58||WASHOUT|1969-01-30||||1966-06-27||1970-08-06|1961-01-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||BESTRESP|BEST OVERALL RESPONSE||||FG|IMPROVED||UG|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|2||58||SCREENING|1961-12-29||||1972-04-05||1963-01-21|1967-10-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MMOL/KG|NON-ICR/NON-IUPD||UG/H|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|3||39||FOLLOW-UP|1964-01-25||||1966-09-13||1962-12-31|1965-07-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NMOL|CYTOGENETIC NO RESPONSE||POINT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|3||39||OPEN LABEL TREATMENT|1971-04-17||||1969-02-06||1964-05-29|1967-08-28||AFTER||DURING|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ROENTGEN|PMR||G/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|INTERVIEWER|CLINICAL PATHOLOGIST|N|4||88||RUN-IN|1967-04-15||||1965-09-06||1961-06-23|1963-07-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||TRGRESP|TARGET RESPONSE||||%(W/V)|MOLECULAR CR||MM/SEC|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||BASELINE|1969-04-01||||1968-04-09||1964-09-15|1973-08-07||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||CLINRESP|CLINICAL RESPONSE||||MMHG*MIN/L|PR||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|5||7||TREATMENT|1969-09-25||||1971-06-24||1968-12-13|1967-03-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||LOG10 ELISA UNIT/DOSE|MOLECULAR MAJOR RESPONSE||10^9/L|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|FRIEND|ENDOCRINOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1961-09-14||||1967-07-14||1964-09-26|1966-03-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PA|MAJOR PATHOLOGIC RESPONSE||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1||38||SCREENING|1968-07-06||||1970-05-16||1968-06-02|1972-04-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||SPLNRESP|SPLEEN RESPONSE||||IU/KG|PD/RELAPSE AFTER HI||UG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|INTERVIEWER|HEMATOLOGIST|NA|1||38||OBSERVATION|1962-02-03||||1961-10-12||1964-02-05|1966-06-11||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||MOLRESP|MOLECULAR RESPONSE||||PA|IMPROVED||DYN|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|INTERVIEWER|FORENSIC PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1969-03-07||||1967-04-25||1968-10-14|1972-06-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TROCHE|ISD||TSP|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|ADJUDICATION COMMITTEE|ONCOLOGIST 2|N|2||58||LONG-TERM FOLLOW-UP|1962-05-09||||1963-12-24||1964-03-02|1964-03-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/CAGE/DAY|NED||K|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|STUDY SUBJECT|OPHTHALMOLOGIST|Y|3||39||INDUCTION TREATMENT|1963-07-08||||1966-06-03||1965-09-06|1966-08-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||NEWLIND|NEW LESION INDICATOR||||VG/KG|MRD NEGATIVITY||CD*S/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|FRIEND|MICROSCOPIST|N|3||39||OPEN LABEL TREATMENT|1962-02-15||||1964-03-09||1962-01-02|1963-08-12||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||CLINRESP|CLINICAL RESPONSE||||G/L|HI-E||/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1965-05-16||||1963-09-03||1966-11-22|1964-11-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU|ICPD||UGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|4||88||BASELINE|1972-11-06||||1961-04-04||1968-09-27|1960-04-28||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||SPLNRESP|SPLEEN RESPONSE||||DAYS|PMR||UKAT|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|CAREGIVER|RATER|U|5||7||FOLLOW-UP|1962-01-30||||1962-12-18||1967-11-19|1963-09-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MM3/MM2/YEAR|CMR||MASK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|SIGNIFICANT OTHER|OPHTHALMOLOGIST|Y|5||7||RUN-IN|1963-07-21||||1961-01-03||1963-10-07|1969-02-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GRAIN|PARTIAL MORPHOLOGIC RESPONSE||MEQ|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|READER|N|1||38||INDUCTION TREATMENT|1963-12-07||||1969-08-09||1963-04-26|1970-02-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||TRGRESP|TARGET RESPONSE||||ML/CAGE/DAY|ICR||MOSM/KG|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|INDEPENDENT ASSESSOR|OPTOMETRIST|N|1||38||LONG-TERM FOLLOW-UP|1966-02-12||||1964-05-05||1971-03-26|1962-10-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||TRGRESP|TARGET RESPONSE||||CL|NON-QUANTIFIABLE MRD POSITIVITY||10^6/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|FAMILY MEMBER|NEUROLOGIST|U|2||58||WASHOUT|1962-09-19||||1961-01-16||1967-03-16|1960-05-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||TMRESP|TUMOR MARKER RESPONSE||||KAT|NR||FMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|VENDOR|OTOLARYNGOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1967-10-04||||1963-07-05||1971-09-05|1967-07-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||MOLRESP|MOLECULAR RESPONSE||||10^7 CFU|RELAPSED DISEASE FROM CR||HOMEOPATHIC DILUTION|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1973-08-18||||1967-12-06||1963-02-13|1971-03-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||BESTRESP|BEST OVERALL RESPONSE||||CUP EQ|OPTIMAL MORPHOLOGIC RESPONSE||RFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|U|3||39||RUN-IN|1968-02-05||||1969-02-02||1968-06-24|1972-03-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||LIVRRESP|LIVER RESPONSE||||PMOL|CR||FFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|VENDOR|NEUROLOGIST 2|U|4||88||BASELINE|1965-04-14||||1965-05-21||1963-01-14|1964-04-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||MOLRESP|MOLECULAR RESPONSE||||10^9 CFU/ML|MOLECULAR MAJOR RESPONSE||%(W/W)|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|PARENT|ADJUDICATOR|NA|4||88||OBSERVATION|1970-08-04||||1963-05-06||1969-06-16|1967-04-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||TRGRESP|TARGET RESPONSE||||MG/DAY|HI-E||MEQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|5||7||BLINDED TREATMENT|1964-08-10||||1969-07-16||1970-03-18|1963-05-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/G/H|DISEASE TRANSFORMATION||BU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|FAMILY MEMBER|ADJUDICATOR 2|Y|5||7||SCREENING|1967-12-24||||1968-09-02||1970-01-15|1966-12-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||CLINRESP|CLINICAL RESPONSE||||MOL/ML|ICR||NM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|1||38||BASELINE|1965-02-19||||1970-12-30||1961-05-18|1968-05-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DRAM|CCR||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|FRIEND|ADJUDICATOR|Y|1||38||LONG-TERM FOLLOW-UP|1962-02-19||||1965-07-31||1963-12-10|1964-02-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||METBRESP|METABOLIC RESPONSE||||JAR|PARTIAL MORPHOLOGIC RESPONSE||HOMEOPATHIC DILUTION|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|SPOUSE|ADJUDICATOR|Y|2||58||WASHOUT|1968-08-30||||1963-10-10||1961-05-16|1973-05-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||STRUSTAT|STEROID USE STATUS||||ML/MIN/MMHG|CPR||MNFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|SPOUSE|RADIOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1960-08-14||||1963-12-09||1963-11-06|1961-04-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ECL UNIT|MOLECULAR CR||UG/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|PARENT|READER 2|NA|3||39||BLINDED TREATMENT|1966-11-15||||1960-03-02||1970-08-15|1972-05-08||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||METSIND|METASTATIC INDICATOR||||U/CL|MAJOR PATHOLOGIC RESPONSE||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|FRIEND|READER 1|N|3||39||WASHOUT|1973-04-16||||1972-07-02||1963-02-08|1968-04-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||ANATRESP|ANATOMIC RESPONSE||||S*KPA|RELAPSED DISEASE FROM CR OR PR||BQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|4||88||INDUCTION TREATMENT|1963-03-11||||1970-03-21||1970-02-06|1968-04-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||TRGRESP|TARGET RESPONSE||||IU/MMOL|CR-CT||MMOL/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|4||88||CONTINUATION TREATMENT|1964-04-29||||1967-12-19||1971-06-07|1960-05-02||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||NEWLIND|NEW LESION INDICATOR||||RING|ICR||L/S/KPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|ADJUDICATOR|UROLOGIST|NA|5||7||RUN-IN|1963-02-20||||1960-03-24||1961-02-18|1962-02-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||TMRESP|TUMOR MARKER RESPONSE||||/H|PR-CT||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|INVESTIGATOR|ADJUDICATOR|U|5||7||OPEN LABEL TREATMENT|1968-01-03||||1969-10-01||1962-04-25|1964-10-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|NR||PT_BR|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|STUDY SUBJECT|OTOLARYNGOLOGIST|Y|1||38||FOLLOW-UP|1962-10-26||||1971-02-14||1969-08-25|1968-11-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||MOLRESP|MOLECULAR RESPONSE||||PPTR|CHR||DB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|1||38||BASELINE|1966-12-18||||1967-01-24||1962-02-21|1960-08-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||OVRLRESP|OVERALL RESPONSE||||10^9/DOSE|SD-CT||COULOMB|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|2||58||BASELINE|1967-05-19||||1972-11-24||1966-09-05|1971-03-09||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||1/(S*KPA)|ICR||K|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|2||58||SCREENING|1970-03-12||||1960-10-28||1968-10-01|1964-04-25||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TSP EQ|PARTIAL MORPHOLOGIC RESPONSE||NU/CL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|3||39||OBSERVATION|1960-10-26||||1964-03-21||1963-06-27|1967-07-02||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||SPLNRESP|SPLEEN RESPONSE||||UG/L|WORSENED||CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|3||39||BASELINE|1961-01-22||||1971-10-19||1970-08-04|1970-09-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||NEWLPROG|NEW LESION PROGRESSION||||NMOL BCE/MMOL|PD/RELAPSE AFTER HI||MMHG/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|ADJUDICATOR|INTERNIST|U|4||88||SCREENING|1968-03-29||||1965-10-21||1970-06-16|1960-08-16||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||BESTRESP|BEST OVERALL RESPONSE||||DROP|PD||MBP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|NA|4||88||OBSERVATION|1965-12-24||||1961-01-17||1970-07-26|1967-09-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||NEWLIND|NEW LESION INDICATOR||||U/MMOL|ABSENT MORPHOLOGIC RESPONSE||FG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|5||7||INDUCTION TREATMENT|1972-05-10||||1962-03-29||1963-01-24|1963-11-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||NEWLIND|NEW LESION INDICATOR||||U/M2|HI-P||CP|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1961-02-21||||1961-02-05||1965-01-12|1971-02-20||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PT_US|HI-E||PG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SIGNIFICANT OTHER|PATHOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1962-06-18||||1962-10-28||1963-10-08|1970-08-14||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||METBRESP|METABOLIC RESPONSE||||KN/CM2|CPR||MEQ/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|DOMESTIC PARTNER|NEUROLOGIST|U|1||38||RUN-IN|1962-09-16||||1963-03-08||1967-08-27|1970-08-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||TRGRESP|TARGET RESPONSE||||MOL|PD||L/H/M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|SPOUSE|INTERNIST|NA|2||58||OPEN LABEL TREATMENT|1962-04-19||||1965-12-23||1971-09-18|1968-07-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/U|RELAPSED DISEASE||NG/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|PARENT|INTERNIST|Y|2||58||OPEN LABEL TREATMENT|1966-04-24||||1972-03-12||1966-05-13|1972-12-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||NEWLIND|NEW LESION INDICATOR||||UMOL/KG/MIN|DISEASE TRANSFORMATION||UG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|FRIEND|FORENSIC PATHOLOGIST|U|3||39||RUN-IN|1968-03-14||||1960-06-01||1960-05-27|1966-05-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||STRUSTAT|STEROID USE STATUS||||POUCH|DISEASE TRANSFORMATION||TESLA|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|FAMILY MEMBER|OPHTHALMOLOGIST|N|3||39||CONTINUATION TREATMENT|1971-02-07||||1966-10-12||1960-01-29|1966-10-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FFU|PSA PROGRESSION||GLOBULE|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|U|4||88||BLINDED TREATMENT|1970-08-17||||1965-04-12||1972-05-27|1965-10-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ANTI-XA IU|HI-N||MMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|PARENT|PHYSIOTHERAPIST|NA|4||88||WASHOUT|1966-04-20||||1968-10-15||1971-02-20|1969-11-26||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/KG/DAY|ABSENT MORPHOLOGIC RESPONSE||UG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|FRIEND|READER 1|NA|5||7||LONG-TERM FOLLOW-UP|1971-06-27||||1960-04-05||1960-10-05|1960-07-31||DURING||AFTER|
TRIAL STUDY 134XCP|RS|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/KG/MIN|PCR||M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|5||7||CONTINUATION TREATMENT|1973-06-29||||1969-11-20||1968-06-25|1961-01-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CM2|PD/RELAPSE AFTER HI||MANSON U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|1||38||BASELINE|1962-11-19||||1963-09-16||1967-11-25|1961-01-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MOSM|ABSENT MORPHOLOGIC RESPONSE||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|ADJUDICATION COMMITTEE|OPTOMETRIST|U|1||38||SCREENING|1964-09-06||||1968-12-26||1964-02-04|1973-07-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||ANATRESP|ANATOMIC RESPONSE||||U/G/DAY|PR WITH LYMPHOCYTOSIS||M3|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|STUDY SUBJECT|DERMATOLOGIST|Y|2||58||SCREENING|1973-01-18||||1969-09-05||1967-06-14|1970-12-17||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||LOG10 ELISA UNIT/DOSE|NR||BQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||SCREENING|1970-08-29||||1968-02-17||1971-06-05|1960-01-10||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TSP EQ|SD-CT||K|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||TREATMENT|1969-07-28||||1961-09-26||1970-01-28|1962-12-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||STRUSTAT|STEROID USE STATUS||||10^7 PFU|MCR||U/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|CHILD|ONCOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1973-04-10||||1967-05-03||1972-10-31|1964-01-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UMOL/MIN|ABSENT MORPHOLOGIC RESPONSE||AMFI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|VENDOR|RADIOLOGIST 2|U|4||88||BASELINE|1961-09-29||||1965-06-21||1971-09-07|1969-04-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||ANATRESP|ANATOMIC RESPONSE||||UG/KG/DAY|IUPD||G/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|INTERVIEWER|ONCOLOGIST|Y|4||88||BASELINE|1965-10-25||||1963-08-17||1968-05-24|1966-06-29||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/G/MIN|INCREASED||ATM|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FAMILY MEMBER|ADJUDICATOR 2|Y|5||7||RUN-IN|1968-03-28||||1970-07-20||1972-09-09|1965-01-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||NEWLPROG|NEW LESION PROGRESSION||||CUP EQ|CYTOGENETIC CR||SPRAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1972-12-21||||1972-03-10||1965-07-23|1969-10-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||HPA|MOLECULAR CR||APL U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|CHILD|ONCOLOGIST|U|1||38||OBSERVATION|1963-06-07||||1968-04-20||1968-01-01|1973-04-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||NEWLIND|NEW LESION INDICATOR||||MNFI|PR||PFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|1||38||OBSERVATION|1970-09-05||||1970-05-08||1961-04-18|1965-06-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MJOULE/CM2|PMR||MBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|FRIEND|ENDOCRINOLOGIST|U|2||58||TREATMENT|1971-05-14||||1970-12-09||1968-09-17|1967-08-11||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NG/L|CR||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|PARENT|CARDIOLOGIST|NA|2||58||TREATMENT|1972-11-09||||1970-03-16||1968-02-24|1966-03-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CL|NED||CAPSULE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIBLING|CARDIOLOGIST|N|3||39||BASELINE|1965-11-12||||1961-01-06||1960-11-05|1966-08-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ELISA UNIT|EQUIVOCAL||/100 HPFS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|3||39||INDUCTION TREATMENT|1961-09-05||||1966-11-24||1961-06-15|1966-10-09||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||STRUSTAT|STEROID USE STATUS||||ENZYME U/M2|CMR||MEQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|STUDY SUBJECT|MICROSCOPIST|U|4||88||SCREENING|1972-02-24||||1970-09-09||1969-09-16|1962-10-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PHERESIS UNIT|MRD RELAPSE||CM/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|PROXY|RADIOLOGIST|NA|4||88||TREATMENT|1966-10-30||||1966-05-14||1971-02-05|1961-06-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||NEWLIND|NEW LESION INDICATOR||||LINEAR FT*LB|RELAPSED DISEASE FROM CR OR PR||MCI/KG|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||WASHOUT|1960-01-26||||1961-12-08||1961-06-09|1971-01-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CCID 50/DOSE|PSEUDORESPONSE||UOSM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CHILD|RADIOLOGIST 1|Y|5||7||OBSERVATION|1963-02-16||||1970-04-22||1967-05-16|1970-07-28||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/S|CMR||UG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|1||38||INDUCTION TREATMENT|1964-04-21||||1966-10-16||1967-02-11|1960-12-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UM|INCREASED||POINT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|INDEPENDENT ASSESSOR|HEMATOLOGIST|N|1||38||BASELINE|1973-07-07||||1961-04-13||1962-11-26|1961-10-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||METBRESP|METABOLIC RESPONSE||||RATIO|CYTOGENETIC MINOR RESPONSE||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|CHILD|PEDIATRIC NEUROLOGIST|NA|2||58||OBSERVATION|1965-02-11||||1969-07-04||1960-12-07|1965-10-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||LIVRRESP|LIVER RESPONSE||||/2500 WBC|PMD||COAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|FRIEND|PATHOLOGIST|NA|2||58||WASHOUT|1967-02-15||||1961-08-31||1970-09-27|1969-09-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||QUANTITY SUFFICIENT|HI-N||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|3||39||TREATMENT|1964-10-13||||1962-10-20||1971-08-07|1971-11-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||LIVRRESP|LIVER RESPONSE||||CD|DISEASE TRANSFORMATION||PMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 1|NA|3||39||RUN-IN|1972-11-12||||1965-11-11||1965-10-26|1970-09-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||VG/DOSE|QUANTIFIABLE MRD POSITIVITY||OHM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|SIBLING|NEUROLOGIST 1|U|4||88||BLINDED TREATMENT|1961-12-10||||1972-11-18||1962-01-22|1961-11-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UL/KG/DAY|NR||PFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|4||88||SCREENING|1973-04-12||||1963-11-08||1973-01-10|1965-12-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||CLINRESP|CLINICAL RESPONSE||||G/G|SCR||VP/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||INDUCTION TREATMENT|1961-11-17||||1968-04-22||1972-03-22|1960-04-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||STEPS/MIN|NON-QUANTIFIABLE MRD POSITIVITY||DISK|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|STUDY SUBJECT|RADIOLOGIST 2|N|5||7||SCREENING|1967-03-17||||1963-04-11||1961-05-05|1971-09-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||MOLRESP|MOLECULAR RESPONSE||||GBQ|DECREASED||10^12/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|1||38||BASELINE|1973-05-25||||1961-04-23||1964-08-07|1970-03-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||METSIND|METASTATIC INDICATOR||||MEQ|IPR||PG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|CAREGIVER|MICROSCOPIST|NA|1||38||BASELINE|1971-06-01||||1961-08-28||1969-06-10|1973-07-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/M2/MIN|CHR||SCM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|VENDOR|RADIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1965-01-20||||1966-06-08||1969-08-31|1961-03-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||NEWLPROG|NEW LESION PROGRESSION||||UL/ML|CMR||MBP|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|VENDOR|RADIOLOGIST|N|2||58||RUN-IN|1966-04-12||||1960-10-30||1968-08-03|1962-09-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||NEWLPROG|NEW LESION PROGRESSION||||KPA/L/SEC|CYTOGENETIC CR||OZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1965-10-06||||1968-11-05||1960-12-12|1962-11-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||TMRESP|TUMOR MARKER RESPONSE||||DRUM|NED||GRAVITATIONAL UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|ADJUDICATION COMMITTEE|READER 1|U|3||39||LONG-TERM FOLLOW-UP|1972-06-15||||1970-06-19||1963-10-15|1971-02-23||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||CLINRESP|CLINICAL RESPONSE||||BQ/UL|WORSENED||INHALATION|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CAREGIVER|READER 2|NA|4||88||OBSERVATION|1960-05-11||||1968-09-13||1971-05-13|1966-02-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||BQ/ML|MOLECULAR MAJOR RESPONSE||UG/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|CHILD|NEUROLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1966-05-18||||1970-02-19||1961-03-26|1965-02-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||LIVRRESP|LIVER RESPONSE||||FMOL|VGPR||ELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 1|Y|5||7||INDUCTION TREATMENT|1960-12-20||||1973-07-02||1970-08-25|1967-11-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||CLINRESP|CLINICAL RESPONSE||||U/KG/MIN|IUPD||USIEMENS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|VENDOR|READER|U|5||7||OBSERVATION|1962-12-20||||1968-07-31||1965-11-02|1971-07-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML*CMH2O|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|INTERVIEWER|ONCOLOGIST 2|U|1||38||BASELINE|1971-01-20||||1962-08-17||1960-06-01|1961-11-14||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KBQ|CR||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|FAMILY MEMBER|ADJUDICATOR 3|Y|1||38||INDUCTION TREATMENT|1960-03-10||||1960-03-05||1962-02-22|1970-05-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||LIVRRESP|LIVER RESPONSE||||CCID 50/ML|PR WITH LYMPHOCYTOSIS||%(V/V)|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|PARENT|NEUROLOGIST 1|U|2||58||FOLLOW-UP|1967-03-09||||1971-10-22||1973-06-24|1969-12-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACKET|DECREASED||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||RUN-IN|1971-07-10||||1962-09-16||1969-03-28|1967-02-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||MOLRESP|MOLECULAR RESPONSE||||G/ANIMAL/DAY|IMPROVED||LOG10 ELISA UNIT/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|INVESTIGATOR|READER 3|Y|3||39||SCREENING|1962-06-21||||1968-03-28||1962-11-05|1967-09-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||METSIND|METASTATIC INDICATOR||||USIEMENS|QUANTIFIABLE MRD POSITIVITY||KV|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||OBSERVATION|1966-11-28||||1962-06-04||1970-07-23|1963-08-14||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PACK YEAR|PDU||10^3 CFU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|ADJUDICATOR|PATHOLOGIST|N|4||88||BASELINE|1973-07-15||||1961-08-12||1960-02-24|1965-01-02||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/DAY|HI-N||KEV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|READER 3|N|4||88||BASELINE|1966-01-17||||1970-11-20||1962-06-02|1966-08-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||CLINRESP|CLINICAL RESPONSE||||ML/DOSE|INDETERMINATE RESPONSE||NM|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|READER|U|5||7||RUN-IN|1961-12-09||||1973-05-06||1972-11-26|1965-11-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||METBRESP|METABOLIC RESPONSE||||/LSQN|MOLECULAR CR||MS/MMHG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|5||7||BLINDED TREATMENT|1963-06-15||||1966-11-12||1964-04-22|1971-03-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||CLINRESP|CLINICAL RESPONSE||||DEG/S|PD FROM PR||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|DOMESTIC PARTNER|ADJUDICATOR 2|NA|1||38||WASHOUT|1966-11-15||||1964-12-02||1962-08-30|1968-12-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TUBE|PMR||ANTI-XA IU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|1||38||BASELINE|1973-03-23||||1972-07-23||1967-12-08|1964-12-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||SPLNRESP|SPLEEN RESPONSE||||FOZ_US|SD-CT||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|2||58||BASELINE|1970-09-29||||1967-06-29||1969-02-10|1962-02-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||CLINRESP|CLINICAL RESPONSE||||MG/KG/DOSE|PSEUDORESPONSE||U/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|2||58||INDUCTION TREATMENT|1967-12-11||||1973-08-19||1968-12-03|1968-03-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UMOL/MOL|ISD||ML/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|3||39||BLINDED TREATMENT|1965-03-12||||1966-10-18||1960-07-04|1972-02-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^5/L|PD||EIA UNIT|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|CAREGIVER|READER 3|Y|3||39||CONTINUATION TREATMENT|1965-08-12||||1963-09-27||1971-12-21|1967-05-09||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||CLINRESP|CLINICAL RESPONSE||||FEU|RELAPSED DISEASE FROM CR OR PR||/10^3|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|ADJUDICATOR|RATER|NA|4||88||CONTINUATION TREATMENT|1963-11-04||||1973-02-21||1967-12-27|1967-12-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||LOG10 TCID 50/ML|ISD||KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|STUDY SUBJECT|ONCOLOGIST 1|N|4||88||SCREENING|1972-07-26||||1964-09-24||1963-12-25|1970-03-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||TMRESP|TUMOR MARKER RESPONSE||||MV2/HZ|CYTOGENETIC PR||PMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|CHILD|OPHTHALMOLOGIST|NA|5||7||SCREENING|1965-07-30||||1971-10-21||1965-09-04|1969-12-31||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||METSIND|METASTATIC INDICATOR||||KS|CRI||KHZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|PARENT|MICROSCOPIST|Y|5||7||INDUCTION TREATMENT|1960-02-17||||1963-07-04||1971-12-24|1965-04-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||METBRESP|METABOLIC RESPONSE||||PG/L|RELAPSED DISEASE||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|INDEPENDENT ASSESSOR|READER 1|U|1||38||LONG-TERM FOLLOW-UP|1970-06-16||||1968-07-02||1972-04-07|1967-11-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GBQ|ICR||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|1||38||TREATMENT|1961-05-12||||1971-08-12||1965-10-17|1969-07-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||STRUSTAT|STEROID USE STATUS||||LOG10 PFU/ML|HI-N||PFU/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|2||58||LONG-TERM FOLLOW-UP|1962-09-15||||1964-11-01||1962-10-31|1971-01-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/MIN|NR||MG/KG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|2||58||BASELINE|1971-09-04||||1960-07-15||1961-11-20|1972-06-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/ANIMAL|OPTIMAL MORPHOLOGIC RESPONSE||UOSM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|VENDOR|ADJUDICATOR 2|Y|3||39||TREATMENT|1961-01-15||||1964-09-20||1970-09-15|1969-04-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMOL/MOL|INCREASED||CMOL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|PARENT|READER 1|U|3||39||BASELINE|1970-12-31||||1971-12-29||1961-12-16|1964-08-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CCID 50/DOSE|FAVORABLE RESPONSE||NMOL/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|HEALTH CARE PROFESSIONAL|INTERNIST|NA|4||88||WASHOUT|1966-09-23||||1962-09-07||1973-06-12|1967-05-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||BESTRESP|BEST OVERALL RESPONSE||||FIU|DISEASE TRANSFORMATION||U/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|4||88||INDUCTION TREATMENT|1970-02-13||||1960-10-04||1972-07-16|1967-04-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||METBRESP|METABOLIC RESPONSE||||LOG10 ELISA UNIT/DOSE|NON-CR/NON-PD||MG/ML/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||OPEN LABEL TREATMENT|1963-11-16||||1962-11-27||1967-11-20|1960-12-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DNA COPIES/UG|PR WITH LYMPHOCYTOSIS||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|5||7||FOLLOW-UP|1963-10-05||||1972-10-19||1962-05-09|1964-01-02||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/G|CR-CT||NEWTON|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|1||38||TREATMENT|1965-01-06||||1967-03-27||1972-09-15|1972-08-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BQ/MG|CCR||DPM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|VENDOR|NEUROLOGIST|Y|1||38||OPEN LABEL TREATMENT|1973-05-27||||1972-06-04||1972-11-25|1968-09-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||LIVRRESP|LIVER RESPONSE||||CM/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|STUDY SUBJECT|READER 3|U|2||58||BLINDED TREATMENT|1971-07-04||||1971-08-10||1961-01-27|1968-08-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||TRGRESP|TARGET RESPONSE||||MEQ/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||TORR|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|PROXY|PHYSIOTHERAPIST|NA|2||58||FOLLOW-UP|1973-06-18||||1963-09-25||1963-05-05|1973-04-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||RAD|NON-PD||IU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|3||39||RUN-IN|1972-01-22||||1963-08-25||1966-05-14|1969-06-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||MOLRESP|MOLECULAR RESPONSE||||DB|WORSENED||CL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|FRIEND|RADIOLOGIST 2|N|3||39||CONTINUATION TREATMENT|1960-05-27||||1972-01-05||1966-12-23|1962-05-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||LIVRRESP|LIVER RESPONSE||||HOUNSFIELD UNIT|IMMUNOPHENOTYPIC CR||CMH2O*S2/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|INDEPENDENT ASSESSOR|RATER|N|4||88||SCREENING|1968-06-01||||1963-01-07||1965-07-02|1968-05-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||CLINRESP|CLINICAL RESPONSE||||PPTR|NON-ICR/NON-IUPD||MG/L FEU|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|4||88||OBSERVATION|1962-08-09||||1968-03-20||1968-02-12|1964-10-05||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||METSIND|METASTATIC INDICATOR||||MG/KG/DAY|PD||BAU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1973-05-22||||1968-08-17||1969-07-26|1963-05-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||NTRGRESP|NON-TARGET RESPONSE||||KS|DISEASE TRANSFORMATION||U/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|VENDOR|OPHTHALMOLOGIST|Y|5||7||BASELINE|1962-01-14||||1961-04-10||1967-11-15|1967-06-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||METBRESP|METABOLIC RESPONSE||||BQ|PMR||PA|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|FRIEND|RATER|Y|1||38||FOLLOW-UP|1969-11-06||||1964-01-01||1966-02-07|1966-09-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PSEC|PR-CT||MG/ML/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|GUARDIAN|OTOLARYNGOLOGIST|U|1||38||WASHOUT|1965-11-27||||1971-09-07||1960-03-11|1972-10-13||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^6 IU|CR||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|CAREGIVER|HEMATOLOGIST|N|2||58||FOLLOW-UP|1965-11-24||||1963-08-29||1967-04-05|1967-08-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^7 CFU/ML|DECREASED||EP U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|PROXY|FORENSIC PATHOLOGIST|U|2||58||CONTINUATION TREATMENT|1963-01-12||||1966-05-25||1967-01-07|1963-06-02||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BU/ML|MOLECULAR MAJOR RESPONSE||U/KG/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|SIBLING|PATHOLOGIST 1|N|3||39||WASHOUT|1965-06-04||||1966-01-14||1970-08-07|1963-12-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||NEWLPROG|NEW LESION PROGRESSION||||RPM|NON-CR/NON-PD||U/KG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||BLINDED TREATMENT|1964-05-18||||1972-09-05||1964-10-12|1967-08-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||BQ/L|ISD||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|GUARDIAN|OPHTHALMOLOGIST|Y|4||88||INDUCTION TREATMENT|1961-12-12||||1962-08-12||1972-11-27|1973-04-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||STRUSTAT|STEROID USE STATUS||||MG/MIN|UNFAVORABLE RESPONSE||CUP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|INVESTIGATOR|CLINICAL PATHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1960-02-10||||1960-03-21||1968-10-09|1973-07-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||OHM|CYTOGENETIC NO RESPONSE||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|SIBLING|READER 2|Y|5||7||OBSERVATION|1969-10-10||||1969-01-22||1971-01-16|1967-09-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||%/S|MAJOR PATHOLOGIC RESPONSE||PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|SPOUSE|NEUROLOGIST 1|NA|5||7||INDUCTION TREATMENT|1972-05-28||||1964-01-19||1971-06-15|1972-12-26||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||METBRESP|METABOLIC RESPONSE||||MBQ/UL|MOLECULAR CR||10^7 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|ADJUDICATION COMMITTEE|PATHOLOGIST|Y|1||38||BASELINE|1968-01-02||||1971-09-07||1960-08-03|1972-03-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IU/G|HI-N||10^8/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|SPOUSE|READER 2|N|1||38||RUN-IN|1971-09-22||||1967-07-08||1967-11-04|1966-08-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UIU/DL|HI-E||GTT|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|STUDY SUBJECT|ADJUDICATOR 1|U|2||58||BLINDED TREATMENT|1965-11-09||||1965-11-24||1964-02-17|1961-11-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||OVRLRESP|OVERALL RESPONSE||||FOZ_BR|CCR||MAMP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|INVESTIGATOR|ONCOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1968-05-07||||1960-05-25||1972-12-03|1973-02-01||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KPA/L/SEC|ABSENT MORPHOLOGIC RESPONSE||PSI|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|SIBLING|DERMATOLOGIST|U|3||39||INDUCTION TREATMENT|1961-07-10||||1971-07-02||1964-12-12|1966-05-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ENZYME U/M2|PR||MASK|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|INTERVIEWER|HEMATOLOGIST|Y|3||39||SCREENING|1971-09-22||||1966-01-21||1960-06-17|1962-05-25||DURING||DURING|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BREATHS/30S|VGPR||G/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||FOLLOW-UP|1965-08-05||||1964-08-19||1965-01-23|1961-07-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BAU|MINOR PATHOLOGIC RESPONSE||UV|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INVESTIGATOR|NEUROLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1966-06-09||||1967-08-26||1964-07-27|1961-03-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACK YEAR|MORPHOLOGIC CRI||DAYS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|5||7||FOLLOW-UP|1965-05-28||||1973-06-24||1966-08-22|1973-01-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CAL|PD-CT||V/V|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|STUDY SUBJECT|MICROSCOPIST 3|Y|5||7||RUN-IN|1968-12-19||||1969-03-02||1967-02-02|1965-10-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||CLINRESP|CLINICAL RESPONSE||||CS|NED||U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|SIBLING|RADIOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1973-06-09||||1973-08-21||1970-04-01|1963-12-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||CYTORESP|CYTOGENETIC RESPONSE||||TRANSDUCING UNIT/ML|CYTOGENETIC PR||BOLUS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1||38||FOLLOW-UP|1962-08-10||||1965-02-15||1962-05-01|1969-08-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||CLINRESP|CLINICAL RESPONSE||||NKAT/L|UNFAVORABLE RESPONSE||KG/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|STUDY SUBJECT|MICROSCOPIST 2|NA|2||58||CONTINUATION TREATMENT|1968-08-10||||1961-04-06||1960-12-03|1960-12-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3 ORGANISMS/G|UNEQUIVOCAL||G/CAGE/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1960-12-01||||1964-10-07||1971-02-07|1966-05-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||MOLRESP|MOLECULAR RESPONSE||||KEV|NON-ICR/NON-IUPD||MMOL/S|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|FRIEND|MICROSCOPIST 2|Y|3||39||BLINDED TREATMENT|1965-08-29||||1969-12-24||1972-09-14|1969-07-14||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/HPF|DECREASED||/4.0 ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|SPOUSE|HEMATOLOGIST|U|3||39||RUN-IN|1962-04-01||||1963-05-08||1960-12-01|1962-02-07||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||HZ|MRD PERSISTENCE||FMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|INDEPENDENT ASSESSOR|HEMATOLOGIST|N|4||88||OPEN LABEL TREATMENT|1967-03-14||||1973-04-06||1968-09-26|1967-04-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||NTRGRESP|NON-TARGET RESPONSE||||KG/MOL|MORPHOLOGIC LEUKEMIA-FREE STATE||NKAT/G HB|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|INTERVIEWER|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1963-08-13||||1961-11-27||1962-01-27|1970-10-31||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||LIVRRESP|LIVER RESPONSE||||/LPF|CYTOGENETIC MINIMAL RESPONSE||UCI/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|INTERVIEWER|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1972-01-21||||1972-03-03||1962-07-28|1971-12-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PT_BR|PSA PROGRESSION||%|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|Y|5||7||SCREENING|1960-08-06||||1973-06-08||1965-09-15|1971-11-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||ANATRESP|ANATOMIC RESPONSE||||RPM|CA125 50% RESPONSE||10^6 IU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-04-15||||1961-08-30||1967-02-25|1970-11-20||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||TMRESP|TUMOR MARKER RESPONSE||||OHM|RELAPSED DISEASE FROM CR OR PR||NMOL BCE/NMOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|INVESTIGATOR|OPHTHALMOLOGIST|Y|1||38||INDUCTION TREATMENT|1968-05-29||||1968-04-28||1962-01-07|1960-01-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UMOL/KG/MIN|NON-PD||L/KG|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1960-06-25||||1961-04-04||1972-10-26|1966-05-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||NEWLPROG|NEW LESION PROGRESSION||||/2500 WBC|RELAPSED DISEASE FROM CR||ATM|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|FAMILY MEMBER|RADIOLOGIST|Y|2||58||BLINDED TREATMENT|1962-09-14||||1960-05-17||1973-04-06|1966-06-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/KG|DECREASED||CI/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|CAREGIVER|MICROSCOPIST 2|N|3||39||OBSERVATION|1963-06-16||||1969-05-21||1972-09-19|1963-07-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TBSP|HI-P||10^7 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|3||39||BASELINE|1965-01-22||||1968-01-26||1969-02-26|1964-09-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||SPLNRESP|SPLEEN RESPONSE||||FFU|INDETERMINATE RESPONSE||MOL/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|N|4||88||LONG-TERM FOLLOW-UP|1962-08-25||||1972-01-09||1961-09-14|1969-05-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||METBRESP|METABOLIC RESPONSE||||CG|PSEUDORESPONSE||GPS U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|4||88||FOLLOW-UP|1965-12-12||||1971-09-10||1973-01-21|1961-07-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APL U|NON-PD||HR/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|FAMILY MEMBER|PATHOLOGIST|N|5||7||OPEN LABEL TREATMENT|1961-12-11||||1971-05-07||1966-12-19|1960-09-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||TRGRESP|TARGET RESPONSE||||PSI|PSEUDOPROGRESSION||PELLET|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|5||7||SCREENING|1972-12-29||||1967-04-15||1960-06-17|1964-02-07||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6 U|MRD NEGATIVITY||10^6 IU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|1||38||RUN-IN|1972-10-20||||1970-04-25||1966-02-19|1967-07-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||BESTRESP|BEST OVERALL RESPONSE||||KG|IPR||10^5/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|STUDY SUBJECT|RADIOLOGIST 2|NA|1||38||TREATMENT|1969-12-26||||1961-04-19||1972-10-20|1973-02-18||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NEEDLE GAUGE|CYTOGENETIC PR||V/V|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|SIGNIFICANT OTHER|MICROSCOPIST 1|NA|2||58||CONTINUATION TREATMENT|1967-02-18||||1964-11-04||1966-06-16|1970-07-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/G/MIN|OPTIMAL MORPHOLOGIC RESPONSE||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|2||58||BASELINE|1972-08-11||||1971-06-25||1963-10-20|1961-09-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ABSORBANCE U/MIN|INCREASED||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|STUDY SUBJECT|RADIOLOGIST 2|NA|3||39||INDUCTION TREATMENT|1971-07-20||||1970-07-21||1970-10-29|1967-07-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NG/DAY|WORSENED||U/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|DOMESTIC PARTNER|DERMATOLOGIST|NA|3||39||TREATMENT|1972-12-11||||1966-04-10||1966-07-11|1966-11-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||BONERESP|BONE RESPONSE||||NMOL/ML/MIN|MOLECULAR MAJOR RESPONSE||U/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|CHILD|MICROSCOPIST 1|U|4||88||LONG-TERM FOLLOW-UP|1964-05-08||||1964-11-07||1965-07-01|1966-11-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||ANATRESP|ANATOMIC RESPONSE||||GENEQ/ML|SD||PKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4||88||TREATMENT|1963-03-27||||1965-10-05||1970-08-20|1967-12-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||M/SEC|IMPROVED||%/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|GUARDIAN|RADIOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1968-09-26||||1960-03-04||1968-04-27|1963-01-03||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||LIVRRESP|LIVER RESPONSE||||10^3 CFU|MR||CI/KG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|5||7||FOLLOW-UP|1969-01-21||||1966-09-03||1960-07-13|1962-05-09||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KN/CM2|MR||USIEMENS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|FAMILY MEMBER|PATHOLOGIST 1|N|1||38||BLINDED TREATMENT|1969-03-28||||1973-06-01||1964-03-15|1968-10-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||S/H|PD-CT||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|GUARDIAN|ADJUDICATOR|N|1||38||OPEN LABEL TREATMENT|1964-09-04||||1963-01-03||1969-08-23|1964-08-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||CLINRESP|CLINICAL RESPONSE||||/SEC|MORPHOLOGIC CR||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|GUARDIAN|PATHOLOGIST 2|N|2||58||LONG-TERM FOLLOW-UP|1971-02-12||||1968-04-19||1971-06-01|1961-06-15||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/ANIMAL|ICPD||BAU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|SPOUSE|OTOLARYNGOLOGIST|N|2||58||TREATMENT|1962-05-11||||1962-12-02||1965-06-12|1964-01-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/MIN|CYTOGENETIC MINIMAL RESPONSE||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|INTERVIEWER|READER 3|U|3||39||WASHOUT|1972-08-10||||1970-01-16||1971-01-23|1960-12-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FOZ_BR|HI-P||IU/G HB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CHILD|NEUROLOGIST 2|Y|3||39||BASELINE|1971-06-17||||1961-11-28||1967-04-24|1966-08-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||TMRESP|TUMOR MARKER RESPONSE||||PIXELS/CM|ABSENT MORPHOLOGIC RESPONSE||GENEQ|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|PARENT|PATHOLOGIST 1|U|4||88||WASHOUT|1970-04-11||||1970-03-30||1960-02-05|1972-07-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MOL/MOL|NON-QUANTIFIABLE MRD POSITIVITY||IU/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|CAREGIVER|ENDOCRINOLOGIST|N|4||88||SCREENING|1970-01-14||||1972-09-14||1968-11-11|1962-10-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||NTRGRESP|NON-TARGET RESPONSE||||UKAT/L|PMR||S/H|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|PARENT|NEUROLOGIST 1|U|5||7||SCREENING|1973-03-06||||1972-02-21||1963-08-26|1968-09-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||NEWLPROG|NEW LESION PROGRESSION||||KV|NON-CR/NON-PD||MV*MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|CHILD|RATER 2|Y|5||7||BLINDED TREATMENT|1963-06-08||||1963-12-04||1965-11-11|1966-10-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||METBRESP|METABOLIC RESPONSE||||FT3|HI-N||MG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INDEPENDENT ASSESSOR|RATER|NA|1||38||OBSERVATION|1969-02-25||||1973-02-18||1965-09-01|1966-03-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PG/CELL|COMPLETE MRD RESPONSE||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|INVESTIGATOR|RATER 2|Y|1||38||SCREENING|1964-03-19||||1964-11-06||1968-09-17|1961-03-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/CM H2O|PCR||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|CHILD|ONCOLOGIST 2|Y|2||58||WASHOUT|1960-01-20||||1966-10-29||1960-10-13|1970-06-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UEQ|IPR||10^6/EJACULATE U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||TREATMENT|1968-01-31||||1968-04-07||1967-05-27|1964-08-01||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MANSON U/ML|NED||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|SIBLING|MICROSCOPIST 3|Y|3||39||TREATMENT|1964-08-11||||1967-11-17||1970-04-28|1962-03-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DPM/100MG|MRD NEGATIVITY||DAGU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|INVESTIGATOR|ADJUDICATOR|U|3||39||INDUCTION TREATMENT|1972-11-05||||1967-04-13||1963-11-05|1968-11-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/CAGE/WK|NON-ICR/NON-IUPD||TSP EQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|GUARDIAN|RATER|U|4||88||CONTINUATION TREATMENT|1968-12-30||||1963-09-08||1967-04-29|1963-12-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DPM/100MG|PR||NCI|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|PROXY|ONCOLOGIST|Y|4||88||CONTINUATION TREATMENT|1961-03-12||||1964-09-17||1962-03-15|1965-09-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||LIVRRESP|LIVER RESPONSE||||MG/M2|ABSENT MORPHOLOGIC RESPONSE||LOG10 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5||7||WASHOUT|1973-06-01||||1971-04-20||1966-01-15|1966-08-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GBQ/UG|SD||DIP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|CLINICAL RESEARCH COORDINATOR|READER 2|U|5||7||OBSERVATION|1970-03-06||||1964-01-18||1969-01-15|1964-04-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MV|PD||ELISA UNIT/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|1||38||BLINDED TREATMENT|1969-08-03||||1970-07-02||1972-11-09|1967-12-28||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||BESTRESP|BEST OVERALL RESPONSE||||GBQ/MG|CA125 50% RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|FRIEND|INTERNIST|N|1||38||TREATMENT|1963-06-18||||1964-01-14||1970-12-27|1962-08-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/DL|MOLECULAR CR||MG/H|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|2||58||WASHOUT|1961-04-17||||1972-03-23||1966-03-25|1970-07-30||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||METSIND|METASTATIC INDICATOR||||KG/M2|IUPD||WATT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|STUDY SUBJECT|RADIOLOGIST|Y|2||58||RUN-IN|1973-07-21||||1960-08-31||1961-04-09|1963-06-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||APL U|IMPROVED||BAR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|FAMILY MEMBER|HEMATOLOGIST|N|3||39||CONTINUATION TREATMENT|1970-12-31||||1972-10-02||1972-09-26|1961-06-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/KG/DAY|MCR||APL U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|ADJUDICATOR|ONCOLOGIST|N|3||39||INDUCTION TREATMENT|1966-09-19||||1965-07-24||1972-09-01|1967-12-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||NTRGRESP|NON-TARGET RESPONSE||||GBQ|PR||MG/L FEU|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|CAREGIVER|INTERNIST|U|4||88||INDUCTION TREATMENT|1972-04-16||||1972-01-30||1971-09-02|1962-02-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MOL/L|PR||KG/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|ADJUDICATOR|READER 1|N|4||88||FOLLOW-UP|1960-04-12||||1961-12-01||1971-05-12|1962-07-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/ML/DAY|NON-QUANTIFIABLE MRD POSITIVITY||BAR|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|5||7||BASELINE|1965-07-09||||1960-01-25||1964-05-09|1968-04-08||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML*CMH2O|PD FROM PR||DAGU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST|N|5||7||BASELINE|1971-10-21||||1964-06-15||1970-02-27|1965-11-11||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||BONERESP|BONE RESPONSE||||MM/SEC|INCREASED||MOSM|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|VENDOR|PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1972-04-30||||1972-07-14||1967-04-25|1965-02-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ENZYME U|MRD NEGATIVITY||PSEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|1||38||FOLLOW-UP|1972-01-25||||1964-01-08||1963-07-12|1967-07-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||TMRESP|TUMOR MARKER RESPONSE||||DRUM|CYTOGENETIC NO RESPONSE||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|PROXY|ADJUDICATOR 3|U|2||58||OBSERVATION|1964-09-15||||1972-10-07||1961-12-19|1960-10-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NG|NON-ICR/NON-IUPD||UV|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|2||58||TREATMENT|1970-09-01||||1964-05-22||1969-05-20|1968-04-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||RFU|DISEASE TRANSFORMATION||10^3/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|FRIEND|READER 1|NA|3||39||LONG-TERM FOLLOW-UP|1965-03-22||||1968-04-14||1961-04-01|1973-04-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||BESTRESP|BEST OVERALL RESPONSE||||/H|NON-QUANTIFIABLE MRD POSITIVITY||TITER|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|PARENT|OTOLARYNGOLOGIST|U|3||39||TREATMENT|1969-03-08||||1967-06-17||1972-01-16|1968-12-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/H|PD||FL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||SCREENING|1973-04-21||||1964-09-17||1966-03-23|1965-06-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IU/KG|HI-E||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|INTERNIST|Y|4||88||CONTINUATION TREATMENT|1969-12-16||||1960-10-05||1966-08-27|1971-03-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CY/CM|QUANTIFIABLE MRD POSITIVITY||DRUM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|FRIEND|PATHOLOGIST 1|NA|5||7||TREATMENT|1962-12-31||||1970-06-28||1968-10-26|1971-10-15||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||VP/DOSE|MOLECULAR CR||10^3 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|INVESTIGATOR|NEUROLOGIST|N|5||7||WASHOUT|1962-04-09||||1972-07-04||1963-03-11|1963-01-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||ANATRESP|ANATOMIC RESPONSE||||MG/ML/MIN|UNEQUIVOCAL||BQ/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|DOMESTIC PARTNER|HEMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1963-02-05||||1973-08-07||1967-11-28|1964-10-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||BESTRESP|BEST OVERALL RESPONSE||||LX|NOT ALL EVALUATED||CUP EQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|1||38||OBSERVATION|1967-08-03||||1964-02-01||1964-02-16|1971-10-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||METBRESP|METABOLIC RESPONSE||||%(W/W)|CYTOGENETIC MINOR RESPONSE||KS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|VENDOR|CLINICAL PATHOLOGIST|Y|2||58||INDUCTION TREATMENT|1970-12-19||||1966-07-19||1964-04-06|1965-05-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||NEWLIND|NEW LESION INDICATOR||||10^3 ORGANISMS/G|OPTIMAL MORPHOLOGIC RESPONSE||WEBER|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|INTERVIEWER|ADJUDICATOR 1|N|2||58||INDUCTION TREATMENT|1971-01-29||||1972-01-05||1968-04-14|1970-11-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||ANATRESP|ANATOMIC RESPONSE||||PMOL/DAY|MRD PERSISTENCE||DB|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|PROXY|READER 1|Y|3||39||RUN-IN|1964-01-07||||1971-01-04||1967-08-05|1967-05-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||CLINRESP|CLINICAL RESPONSE||||10^3 CFU|RELAPSED DISEASE||U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|3||39||SCREENING|1969-03-01||||1969-10-15||1961-08-05|1965-04-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||NEWLIND|NEW LESION INDICATOR||||/HPF|PSEUDOPROGRESSION||MMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CAREGIVER|ADJUDICATOR|Y|4||88||BLINDED TREATMENT|1965-04-14||||1970-04-30||1968-12-29|1960-03-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||OVRLRESP|OVERALL RESPONSE||||IU/KG|NON-QUANTIFIABLE MRD POSITIVITY||ANTI-XA IU|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|INTERVIEWER|PEDIATRIC NEUROLOGIST|N|4||88||FOLLOW-UP|1960-06-15||||1961-07-26||1965-10-22|1971-01-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G/KG/DAY|HI-P||BAU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|CLINICAL RESEARCH ASSOCIATE|READER|NA|5||7||LONG-TERM FOLLOW-UP|1965-07-19||||1961-06-07||1973-07-01|1965-09-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||ANATRESP|ANATOMIC RESPONSE||||COPIES/UG|IUPD||AMP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|INTERVIEWER|DERMATOLOGIST|U|5||7||WASHOUT|1963-08-07||||1960-07-22||1968-02-24|1973-03-10||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||TRGRESP|TARGET RESPONSE||||EP U|CPR||UG/L DDU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|DOMESTIC PARTNER|OPHTHALMOLOGIST|N|1||38||OBSERVATION|1964-10-07||||1967-02-03||1968-07-05|1961-11-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UMOL/L/SEC|PD/RELAPSE AFTER HI||TABLET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1960-03-24||||1964-11-30||1970-09-11|1967-01-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||LIVRRESP|LIVER RESPONSE||||UG/CM2|MCR||ML/MMHG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|VENDOR|PATHOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1966-03-09||||1966-03-24||1963-11-21|1972-12-01||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/4.0 ML|CPR||YD|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|CAREGIVER|ADJUDICATOR 2|Y|2||58||CONTINUATION TREATMENT|1967-06-02||||1972-11-16||1962-08-20|1972-05-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||NEWLPROG|NEW LESION PROGRESSION||||WATT|CHR||/SEC|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|SIGNIFICANT OTHER|RATER 2|NA|3||39||LONG-TERM FOLLOW-UP|1963-03-09||||1971-01-16||1962-08-11|1971-07-22||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^9 ORGANISMS|IMMUNOPHENOTYPIC CR||CMOL/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|SIGNIFICANT OTHER|ONCOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1970-09-09||||1966-01-12||1964-07-26|1966-02-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||OVRLRESP|OVERALL RESPONSE||||IU|PSEUDOPROGRESSION||10^7 PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|4||88||CONTINUATION TREATMENT|1965-11-21||||1966-08-04||1961-09-28|1968-02-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||MOLRESP|MOLECULAR RESPONSE||||MM/SEC|QUANTIFIABLE MRD POSITIVITY||POUCH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|CHILD|ADJUDICATOR|Y|4||88||OPEN LABEL TREATMENT|1961-12-07||||1965-10-25||1968-01-17|1972-01-16||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/MIN|RELAPSED DISEASE FROM CR||AMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|GUARDIAN|MICROSCOPIST|N|5||7||OBSERVATION|1964-09-29||||1962-05-13||1968-06-22|1966-03-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||MOLRESP|MOLECULAR RESPONSE||||PRESSOR UNITS|NE||UG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||FOLLOW-UP|1961-04-18||||1968-09-13||1965-09-20|1967-06-25||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/L/H|UNFAVORABLE RESPONSE||MIN/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|DOMESTIC PARTNER|ONCOLOGIST 2|Y|1||38||OPEN LABEL TREATMENT|1972-07-23||||1960-08-14||1962-06-04|1971-07-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PM|DISEASE TRANSFORMATION||UG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|STUDY SUBJECT|MICROSCOPIST 1|NA|1||38||BLINDED TREATMENT|1961-06-11||||1963-12-02||1962-02-11|1972-01-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|1||||||NTRGRESP|NON-TARGET RESPONSE||||UGEQ|MR||NMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|SIGNIFICANT OTHER|READER|NA|2||58||CONTINUATION TREATMENT|1961-05-19||||1966-03-09||1969-09-15|1967-10-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|2||||||LIVRRESP|LIVER RESPONSE||||C|NON-ICR/NON-IUPD||MEQ/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|2||58||BASELINE|1972-03-21||||1961-06-25||1967-09-10|1961-12-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI|MRD PERSISTENCE||FT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|VENDOR|HEMATOLOGIST|U|3||39||BLINDED TREATMENT|1973-09-02||||1961-03-19||1965-08-30|1966-04-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|2||||||STRUSTAT|STEROID USE STATUS||||UIU/L|CMR||UMOL/L/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|INTERVIEWER|ONCOLOGIST 2|U|3||39||FOLLOW-UP|1969-02-08||||1966-03-05||1962-05-31|1963-10-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DIOPTER|VGPR||L/MIN/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|SPOUSE|RATER 2|U|4||88||OBSERVATION|1972-05-11||||1967-03-13||1973-01-05|1968-04-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MCI/L|PD-CT||AMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|CAREGIVER|MICROSCOPIST 1|U|4||88||SCREENING|1969-11-04||||1971-09-03||1961-04-03|1965-06-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^7 CFU/ML|MCR||NG/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|FAMILY MEMBER|PATHOLOGIST 2|NA|5||7||SCREENING|1973-07-17||||1969-06-19||1966-10-24|1968-11-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|30419F44-B519-488C-A505-F23D88A46024|2||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL BCE/MMOL|MRD NEGATIVITY||MET*H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|GUARDIAN|PATHOLOGIST 2|Y|5||7||SCREENING|1967-09-17||||1969-05-12||1964-05-09|1965-01-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MN|PD/RELAPSE AFTER HI||UIU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|STUDY SUBJECT|HEMATOLOGIST|NA|1||38||CONTINUATION TREATMENT|1973-07-14||||1973-04-22||1969-02-15|1964-08-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||CLINRESP|CLINICAL RESPONSE||||NKAT|PDU||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|1||38||WASHOUT|1960-12-15||||1970-08-09||1973-08-30|1960-09-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/ANIMAL|IPR||%|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 1|U|2||58||CONTINUATION TREATMENT|1971-04-10||||1966-11-15||1964-10-30|1963-12-18||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||CLINRESP|CLINICAL RESPONSE||||ML/KG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||HEP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|INTERVIEWER|OPTOMETRIST|N|2||58||OBSERVATION|1973-01-25||||1973-09-06||1967-07-09|1972-09-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/ML/H|NOT ALL EVALUATED||KG/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|GUARDIAN|UROLOGIST|Y|3||39||RUN-IN|1965-04-03||||1969-01-07||1961-05-08|1972-04-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||STRUSTAT|STEROID USE STATUS||||SIEMENS|IMMUNOPHENOTYPIC CR||ANTI-XA IU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|SIGNIFICANT OTHER|CARDIOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1966-10-19||||1964-05-05||1972-08-08|1969-06-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||NTRGRESP|NON-TARGET RESPONSE||||MEQ/G|DISEASE TRANSFORMATION||ANSON U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1964-05-28||||1964-05-24||1972-05-19|1971-12-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^4 CFU/ML|UNFAVORABLE RESPONSE||U/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|4||88||WASHOUT|1967-11-19||||1973-02-04||1970-01-04|1961-10-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||BONERESP|BONE RESPONSE||||10^7 CFU|OPTIMAL MORPHOLOGIC RESPONSE||CPM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|5||7||BLINDED TREATMENT|1965-06-13||||1962-12-12||1969-05-03|1967-02-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||NEWLIND|NEW LESION INDICATOR||||KUSP|CYTOGENETIC PR||MG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|PROXY|ADJUDICATOR 2|Y|5||7||WASHOUT|1971-08-10||||1965-12-15||1961-12-06|1973-05-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/DAY|PD/RELAPSE AFTER HI||CS|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|ADJUDICATION COMMITTEE|READER 2|N|1||38||FOLLOW-UP|1969-05-30||||1966-10-27||1961-04-18|1970-11-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CIGAR|NON-CR/NON-PD||KUSP|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|1||38||FOLLOW-UP|1972-01-17||||1971-08-09||1967-11-26|1963-12-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UIU/L|MINOR PATHOLOGIC RESPONSE||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|SPOUSE|ONCOLOGIST|NA|2||58||RUN-IN|1965-12-01||||1973-03-23||1964-12-31|1970-09-21||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MS/MMHG|MOLECULAR CR||DIOPTER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|VENDOR|ONCOLOGIST 1|U|2||58||CONTINUATION TREATMENT|1968-10-03||||1962-07-10||1970-07-13|1964-08-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||BONERESP|BONE RESPONSE||||MOSM/KG|HI-N||MM2|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|CHILD|ADJUDICATOR 2|U|3||39||OBSERVATION|1967-06-22||||1960-07-03||1969-03-22|1971-06-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL/MG/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||MCI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|CHILD|PHYSIOTHERAPIST|U|3||39||OPEN LABEL TREATMENT|1963-10-31||||1963-01-06||1973-05-10|1971-10-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G|PD||APL U/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|4||88||CONTINUATION TREATMENT|1969-10-27||||1960-03-02||1964-10-16|1968-03-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||STRIP|PD-CT||PT_BR|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|SPOUSE|INTERNIST|N|4||88||FOLLOW-UP|1965-06-08||||1961-09-04||1971-04-02|1970-06-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||LIVRRESP|LIVER RESPONSE||||SACHET|PSA PROGRESSION||YD|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|5||7||WASHOUT|1971-06-30||||1971-12-19||1963-09-26|1964-05-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||METBRESP|METABOLIC RESPONSE||||STEPS/MIN|PR||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|CLINICAL RESEARCH COORDINATOR|READER 1|U|5||7||INDUCTION TREATMENT|1961-06-14||||1968-06-16||1973-02-11|1961-10-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|1||||||NEWLIND|NEW LESION INDICATOR||||BQ|MRD RELAPSE||DRINK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|U|1||38||OPEN LABEL TREATMENT|1961-10-13||||1962-09-04||1960-11-02|1967-04-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|2||||||METBRESP|METABOLIC RESPONSE||||HENRY|NE||IU/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|GUARDIAN|READER|N|1||38||OBSERVATION|1970-02-11||||1968-11-30||1964-04-06|1965-07-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/BEAT|HI-P||FMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|CHILD|MICROSCOPIST|N|2||58||TREATMENT|1963-01-10||||1961-01-25||1970-12-17|1967-07-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|2||||||NEWLIND|NEW LESION INDICATOR||||KV|MORPHOLOGIC LEUKEMIA-FREE STATE||10^6/HPF|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|VENDOR|ADJUDICATOR 3|Y|2||58||BLINDED TREATMENT|1972-10-24||||1960-08-24||1970-10-16|1970-08-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CGY|SD||PG/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|GUARDIAN|PEDIATRIC NEUROLOGIST|NA|3||39||INDUCTION TREATMENT|1960-12-07||||1970-09-15||1968-06-06|1969-06-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PKAT|ABSENT MORPHOLOGIC RESPONSE||MM3/MM2/YEAR|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|INTERVIEWER|NEUROLOGIST 1|U|3||39||CONTINUATION TREATMENT|1962-01-25||||1973-02-11||1961-07-17|1965-05-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|1||||||NEWLIND|NEW LESION INDICATOR||||G/KG/DAY|WORSENED||/10^3|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|SIGNIFICANT OTHER|RADIOLOGIST|N|4||88||OPEN LABEL TREATMENT|1971-07-19||||1960-07-05||1961-04-01|1968-03-31||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|2||||||LIVRRESP|LIVER RESPONSE||||CAPFUL|CA125 50% RESPONSE||KM/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|4||88||RUN-IN|1963-11-12||||1960-10-30||1967-12-05|1970-09-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PMOL/DL|MR||G/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|CAREGIVER|FORENSIC PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1961-12-14||||1973-03-05||1963-01-12|1973-06-30||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|94F4C997-3114-4444-BF89-E762226AAC89|2||||||SPLNRESP|SPLEEN RESPONSE||||KG/CM|PD-CT||BREATHS/30S|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|FAMILY MEMBER|ONCOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1969-06-24||||1968-03-12||1966-05-06|1964-08-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||CYTORESP|CYTOGENETIC RESPONSE||||IU/L|VGPR||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|PROXY|RATER|NA|1||38||OBSERVATION|1961-08-23||||1973-05-06||1969-06-02|1960-06-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||VP/DOSE|PD||/VF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|PARENT|NEUROLOGIST 1|NA|1||38||RUN-IN|1963-11-22||||1972-10-03||1971-04-11|1963-07-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||NTRGRESP|NON-TARGET RESPONSE||||MG/KG/DOSE|PR||10^6 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|SPOUSE|READER 3|U|2||58||RUN-IN|1960-08-11||||1960-12-06||1965-06-26|1970-09-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||OVRLRESP|OVERALL RESPONSE||||MBP|WORSENED||AGU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|VENDOR|ADJUDICATOR 1|NA|2||58||OPEN LABEL TREATMENT|1966-01-11||||1969-01-05||1969-01-28|1969-05-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||TMRESP|TUMOR MARKER RESPONSE||||ECL UNIT|IMPROVED||ML/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|PROXY|OPHTHALMOLOGIST|NA|3||39||BLINDED TREATMENT|1966-02-07||||1961-12-17||1967-01-15|1962-08-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||TRGRESP|TARGET RESPONSE||||MU/L|UNEQUIVOCAL||CAPFUL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|PROXY|ADJUDICATOR 3|NA|3||39||FOLLOW-UP|1965-11-19||||1967-06-29||1971-03-30|1962-11-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KPA|MRD PERSISTENCE||/5X10^4 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 2|NA|4||88||LONG-TERM FOLLOW-UP|1968-05-01||||1966-06-03||1965-03-09|1970-09-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MCI/KG|PMD||G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|INTERVIEWER|ADJUDICATOR 3|NA|4||88||OBSERVATION|1968-01-13||||1961-09-19||1972-07-08|1971-09-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||CLINRESP|CLINICAL RESPONSE||||NM|CPR||MOSM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|SIBLING|PEDIATRIC NEUROLOGIST|U|5||7||OBSERVATION|1973-04-04||||1961-06-04||1964-02-27|1964-12-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||TRGRESP|TARGET RESPONSE||||NCI|MINOR PATHOLOGIC RESPONSE||MMHG*MIN/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|VENDOR|RADIOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1967-10-21||||1966-12-28||1967-03-29|1967-11-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||NEWLPROG|NEW LESION PROGRESSION||||BOLUS|NE||NFIU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|CHILD|OTOLARYNGOLOGIST|U|1||38||INDUCTION TREATMENT|1966-04-14||||1960-12-01||1965-09-21|1968-01-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||METSIND|METASTATIC INDICATOR||||HENRY|MORPHOLOGIC LEUKEMIA-FREE STATE||DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|RATER 2|NA|1||38||RUN-IN|1962-11-28||||1965-07-18||1972-04-09|1962-08-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/H/M2|ICPD||M/SEC|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|SIBLING|MICROSCOPIST 2|N|2||58||BLINDED TREATMENT|1972-02-15||||1969-10-22||1961-02-21|1962-09-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMOL/MIN/KPA|IPR||CUP|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|SIBLING|RATER 1|U|2||58||OBSERVATION|1961-04-24||||1973-06-16||1961-11-04|1961-10-03||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 TCID 50/ML|MRD PERSISTENCE||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|3||39||WASHOUT|1965-03-13||||1967-01-19||1962-05-30|1970-02-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BREATHS/MIN|CRI||UG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|PROXY|ONCOLOGIST 1|N|3||39||TREATMENT|1963-12-24||||1966-07-27||1967-08-19|1965-05-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||NTRGRESP|NON-TARGET RESPONSE||||DEG|CRI||G/M2|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|4||88||OPEN LABEL TREATMENT|1969-10-21||||1964-12-30||1967-10-09|1964-01-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||NEWLPROG|NEW LESION PROGRESSION||||MHZ|HI-E||/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|CAREGIVER|CLINICAL PATHOLOGIST|N|4||88||TREATMENT|1964-09-16||||1963-09-04||1968-11-29|1969-01-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||PATHRESP|PATHOLOGIC RESPONSE||||GENEQ/ML|HI-P||/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST|U|5||7||FOLLOW-UP|1968-12-14||||1966-10-19||1969-06-07|1960-03-18||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||MOLRESP|MOLECULAR RESPONSE||||S/H|IUPD||FEU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|SPOUSE|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1967-08-30||||1972-03-27||1965-05-18|1972-05-11||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||RDIORESP|RADIOLOGIC RESPONSE||||HENRY|MRD RELAPSE||IU/G HB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|SIGNIFICANT OTHER|RATER 1|U|1||38||WASHOUT|1973-07-06||||1961-12-20||1970-04-03|1972-07-28||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MILE|UNFAVORABLE RESPONSE||UG/M2/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1973-07-16||||1963-05-07||1965-08-01|1972-04-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KBQ|PMD||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|GUARDIAN|FORENSIC PATHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1967-01-20||||1960-08-25||1963-05-02|1966-10-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/M2/DAY|NOT ALL EVALUATED||MG/MOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|SIBLING|UROLOGIST|N|2||58||SCREENING|1967-01-26||||1965-04-22||1970-07-13|1962-10-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UM2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||JOULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|FAMILY MEMBER|ADJUDICATOR 3|U|3||39||TREATMENT|1972-04-28||||1964-10-23||1972-11-15|1972-04-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||TRGRESP|TARGET RESPONSE||||ENZYME U/G HB|PR-CT||IU/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|3||39||WASHOUT|1971-09-24||||1968-05-26||1965-01-27|1967-08-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||MOLRESP|MOLECULAR RESPONSE||||COULOMB|PD/RELAPSE AFTER HI||LINEAR FT*LB|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|PARENT|ADJUDICATOR|U|4||88||RUN-IN|1968-02-15||||1962-10-04||1962-04-26|1965-10-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BREATHS/MIN|DECREASED||VG/KG|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|DOMESTIC PARTNER|HEMATOLOGIST|N|4||88||BLINDED TREATMENT|1963-06-09||||1963-07-25||1971-11-16|1961-11-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||MOLRESP|MOLECULAR RESPONSE||||UV2|VGPR||UG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|GUARDIAN|RADIOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1960-03-31||||1961-05-29||1960-06-02|1962-11-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ABSORBANCE U|PMR||STRIP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|SIGNIFICANT OTHER|ONCOLOGIST|U|5||7||SCREENING|1969-06-17||||1965-01-07||1965-12-14|1961-03-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|1||||||NEWLIND|NEW LESION INDICATOR||||VIRTUAL PIXEL|RELAPSED DISEASE FROM CR OR PR||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|FRIEND|RADIOLOGIST|NA|1||38||RUN-IN|1968-04-11||||1962-10-25||1971-05-01|1972-12-22||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|2||||||SPLNRESP|SPLEEN RESPONSE||||EQ|PD FROM PR||M3|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|INTERVIEWER|READER 2|Y|1||38||TREATMENT|1966-12-05||||1971-11-13||1960-09-09|1963-03-31||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CFU/ML|HI-N||FT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|2||58||FOLLOW-UP|1961-09-18||||1966-05-27||1966-07-09|1965-09-02||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|2||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL BCE/L|SMD||GY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1970-08-11||||1964-11-25||1960-05-22|1973-06-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|1||||||SPLNRESP|SPLEEN RESPONSE||||ANTI-XA IU|PSEUDORESPONSE||NMOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|CHILD|OTOLARYNGOLOGIST|N|3||39||OBSERVATION|1968-07-26||||1966-10-22||1960-11-12|1967-10-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|2||||||OVRLRESP|OVERALL RESPONSE||||LINEAR FT*LB|PCR||MG/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|PARENT|UROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1965-11-08||||1972-05-21||1972-05-23|1966-04-29||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||SBE/ML|CYTOGENETIC MINIMAL RESPONSE||DROP|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|INTERVIEWER|NEUROLOGIST|N|4||88||RUN-IN|1971-06-02||||1963-07-04||1964-12-15|1972-06-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|2||||||MOLRESP|MOLECULAR RESPONSE||||MMU/ML|CYTOGENETIC PR||BAG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|PARENT|PATHOLOGIST 1|Y|4||88||OBSERVATION|1963-02-02||||1968-01-14||1966-05-29|1966-01-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/H|MORPHOLOGIC LEUKEMIA-FREE STATE||BEL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|INTERVIEWER|RADIOLOGIST|U|5||7||SCREENING|1971-10-06||||1965-02-14||1966-08-19|1962-06-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F20939CF-C668-4514-A2CF-63723560FA46|2||||||LIVRRESP|LIVER RESPONSE||||10^4 CFU/ML|MR||UG/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|SIBLING|CARDIOLOGIST|N|5||7||BASELINE|1968-11-13||||1964-01-31||1965-12-10|1968-06-30||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||NEWLIND|NEW LESION INDICATOR||||KA_U/DL|CR||NKAT/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|PARENT|PEDIATRIC NEUROLOGIST|U|1||38||BASELINE|1961-05-12||||1967-09-03||1966-04-11|1970-08-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SYRINGE|PD-CT||%(W/V)|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|1||38||BASELINE|1965-02-03||||1970-04-19||1971-09-20|1965-11-15||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||TRGRESP|TARGET RESPONSE||||10^9 ORGANISMS/MG|NED||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|FAMILY MEMBER|PHYSIOTHERAPIST|N|2||58||TREATMENT|1971-04-09||||1972-08-09||1960-08-30|1971-11-03||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||TRGRESP|TARGET RESPONSE||||/4.0 ML|PCR||BISCUIT|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|2||58||BLINDED TREATMENT|1961-10-14||||1965-12-06||1964-01-11|1964-12-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||IU/G HB|MRD NEGATIVITY||MMHG/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||CONTINUATION TREATMENT|1960-09-01||||1960-03-30||1969-10-08|1973-01-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NGEQ/L|SD-CT||ML/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|INVESTIGATOR|MICROSCOPIST 2|Y|3||39||OPEN LABEL TREATMENT|1965-06-20||||1969-01-22||1961-05-19|1962-04-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||MOLRESP|MOLECULAR RESPONSE||||%/S|MINOR PATHOLOGIC RESPONSE||10^6 IU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|VENDOR|ADJUDICATOR|U|4||88||LONG-TERM FOLLOW-UP|1965-01-25||||1965-09-05||1965-12-21|1960-07-23||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/7.5 ML|MORPHOLOGIC LEUKEMIA-FREE STATE||10^6 CFU|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1973-01-22||||1965-10-19||1960-03-17|1962-01-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FFU|ICPD||RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1963-11-06||||1967-04-11||1967-09-11|1969-05-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NG/MOL|HI-N||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|DOMESTIC PARTNER|PATHOLOGIST|N|5||7||WASHOUT|1968-04-19||||1961-07-31||1968-04-02|1966-06-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||METSIND|METASTATIC INDICATOR||||UG/M2/DAY|MCR||RATIO|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|1||38||INDUCTION TREATMENT|1970-08-27||||1970-11-25||1967-05-21|1962-10-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||SPLNRESP|SPLEEN RESPONSE||||BP|MORPHOLOGIC CRI||WATT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|SIBLING|ONCOLOGIST|Y|1||38||TREATMENT|1967-04-10||||1972-10-23||1963-09-03|1961-04-02||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||METSIND|METASTATIC INDICATOR||||DAGU|MR||%(V/V)|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|INVESTIGATOR|NEUROLOGIST 2|N|2||58||OBSERVATION|1972-03-25||||1964-07-15||1970-02-26|1960-11-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||L/S|PCR||PUFF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|2||58||INDUCTION TREATMENT|1971-12-09||||1969-10-22||1961-02-09|1965-04-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DRUM|CR||10^9 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|READER 3|U|3||39||FOLLOW-UP|1966-06-04||||1968-07-20||1970-07-31|1961-08-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L|PR||NMOL BCE/MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|PROXY|RADIOLOGIST|NA|3||39||OBSERVATION|1965-07-24||||1965-04-04||1967-12-16|1965-06-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||STRUSTAT|STEROID USE STATUS||||UV*SEC|MRD RELAPSE||U/M2/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CHILD|CARDIOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1972-05-07||||1969-11-12||1964-07-09|1971-04-14||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||METBRESP|METABOLIC RESPONSE||||MG/G/MIN|QUANTIFIABLE MRD POSITIVITY||MET*H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|PARENT|ENDOCRINOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1963-08-14||||1972-05-26||1971-01-26|1967-01-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/M2/DAY|NON-PD||BQ/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|FRIEND|OPHTHALMOLOGIST|NA|5||7||SCREENING|1963-03-01||||1965-03-26||1970-12-11|1970-02-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6/L|MOLECULAR CR||EP U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|FAMILY MEMBER|HEMATOLOGIST|U|5||7||RUN-IN|1963-09-11||||1961-01-09||1961-02-19|1962-08-17||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/ANIMAL|MR||YEARS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|DOMESTIC PARTNER|RADIOLOGIST|N|1||38||OBSERVATION|1960-07-26||||1972-04-12||1961-11-16|1961-01-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 ELISA UNIT|SMD||MMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|FAMILY MEMBER|RATER|N|1||38||BLINDED TREATMENT|1969-06-23||||1962-05-28||1964-01-12|1963-01-11||DURING||DURING|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^6/EJACULATE U|ICPD||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|ADJUDICATOR|ONCOLOGIST 1|U|2||58||OBSERVATION|1960-08-17||||1973-01-16||1960-09-26|1963-11-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CI/ML|PR WITH LYMPHOCYTOSIS||ML/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|GUARDIAN|PATHOLOGIST 1|NA|2||58||INDUCTION TREATMENT|1966-11-23||||1972-09-23||1964-07-27|1969-05-25||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MONTHS|CPR||MV/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|3||39||BLINDED TREATMENT|1961-10-02||||1963-05-15||1968-08-31|1968-10-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||C|CCR||BQ|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|VENDOR|UROLOGIST|NA|3||39||CONTINUATION TREATMENT|1973-08-21||||1964-03-20||1962-12-31|1967-02-20||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||LIVRRESP|LIVER RESPONSE||||ML/M2|PR-CT||PUFF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|4||88||BLINDED TREATMENT|1970-07-29||||1966-10-02||1972-11-22|1969-04-12||DURING||AFTER|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||NEWLIND|NEW LESION INDICATOR||||MCI/KG|IPR||KG/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|INVESTIGATOR|RADIOLOGIST|NA|4||88||SCREENING|1965-05-20||||1962-06-03||1966-07-24|1960-12-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||OVRLRESP|OVERALL RESPONSE||||DNA COPIES/UG|OPTIMAL MORPHOLOGIC RESPONSE||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|CAREGIVER|ADJUDICATOR|Y|5||7||RUN-IN|1963-02-12||||1962-10-17||1966-03-12|1969-07-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG|NOT ALL EVALUATED||10^3/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|FAMILY MEMBER|READER 3|NA|5||7||BASELINE|1970-11-08||||1964-08-16||1970-12-10|1972-03-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/G/DAY|CRI||JAR|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|SPOUSE|DERMATOLOGIST|U|1||38||OBSERVATION|1969-12-19||||1967-04-01||1962-07-09|1973-02-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||METBRESP|METABOLIC RESPONSE||||KN/CM2|PMR||MS/MMHG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|STUDY SUBJECT|RATER|N|1||38||TREATMENT|1967-08-22||||1961-05-11||1960-12-15|1967-05-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/100 HPFS|IPR||MPH|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|SPOUSE|RADIOLOGIST|NA|2||58||FOLLOW-UP|1961-12-13||||1963-11-07||1965-08-19|1964-09-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||G/ANIMAL|PR||CM2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|ADJUDICATION COMMITTEE|PATHOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1962-01-20||||1967-11-22||1971-05-13|1964-02-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||METBRESP|METABOLIC RESPONSE||||TITER|CYTOGENETIC PR||FMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|PROXY|PATHOLOGIST 2|NA|3||39||OBSERVATION|1964-11-18||||1972-08-25||1968-02-02|1968-05-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||NEWLPROG|NEW LESION PROGRESSION||||L/S/KPA|NR||AG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|3||39||CONTINUATION TREATMENT|1972-11-29||||1962-06-15||1972-11-23|1968-01-22||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||CLINRESP|CLINICAL RESPONSE||||GPS U|IMPROVED||MM/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|4||88||SCREENING|1960-04-01||||1968-04-15||1971-10-11|1964-08-13||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/ANIMAL/DAY|COMPLETE MRD RESPONSE||U.CARR|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|SIGNIFICANT OTHER|RATER|NA|4||88||BLINDED TREATMENT|1973-08-20||||1965-04-26||1960-01-26|1960-05-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/(MIN*100ML)|WORSENED||/LSQN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|VENDOR|MICROSCOPIST 3|N|5||7||CONTINUATION TREATMENT|1966-09-10||||1966-02-26||1972-08-17|1963-05-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||BONERESP|BONE RESPONSE||||FIU|DECREASED||L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|5||7||RUN-IN|1970-03-08||||1960-06-29||1965-05-19|1968-04-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MEQ/MMOL|MORPHOLOGIC CRI||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|FRIEND|PEDIATRIC NEUROLOGIST|U|1||38||TREATMENT|1963-12-23||||1972-01-02||1970-08-24|1962-08-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^3 ORGANISMS|ISD||DRAM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|FAMILY MEMBER|READER 1|N|1||38||INDUCTION TREATMENT|1963-12-15||||1962-06-10||1960-04-28|1971-07-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G/DL|PSEUDORESPONSE||BREATHS/30S|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|2||58||WASHOUT|1960-02-22||||1962-04-03||1965-05-08|1973-07-15||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL|HI-P||10^5/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1969-06-08||||1972-11-22||1963-05-21|1971-05-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||TRGRESP|TARGET RESPONSE||||FT|PR-CT||CMH2O/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||BLINDED TREATMENT|1961-05-17||||1973-05-27||1968-11-08|1961-01-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||NEWLPROG|NEW LESION PROGRESSION||||NM|IMMUNOPHENOTYPIC CR||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|CAREGIVER|ONCOLOGIST 1|N|3||39||FOLLOW-UP|1970-03-02||||1972-10-08||1969-02-20|1967-11-22||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||ANATRESP|ANATOMIC RESPONSE||||MMHG|NR||KCAL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|FRIEND|INTERNIST|N|4||88||OPEN LABEL TREATMENT|1965-10-20||||1961-07-31||1960-03-05|1966-03-21||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||METBRESP|METABOLIC RESPONSE||||/MS|CPR||BE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|INTERVIEWER|ADJUDICATOR|Y|4||88||SCREENING|1964-08-01||||1971-04-01||1966-07-24|1973-02-14||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PT_US|MOLECULAR MAJOR RESPONSE||CIGAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|5||7||TREATMENT|1973-04-19||||1962-06-09||1964-05-03|1961-07-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL/10^9 CELLS|FAVORABLE RESPONSE||UV|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|PROXY|OPHTHALMOLOGIST|Y|5||7||TREATMENT|1961-08-28||||1961-05-13||1961-12-01|1969-10-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/DOSE|HI-N||UG/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|STUDY SUBJECT|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1969-04-29||||1961-07-22||1964-09-27|1963-03-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SV|CRI||MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|VENDOR|HEMATOLOGIST|U|1||38||TREATMENT|1966-09-27||||1970-04-06||1967-08-28|1970-06-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||NEWLIND|NEW LESION INDICATOR||||LOG10 COPIES/ML|CCR||G/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||SCREENING|1964-01-22||||1973-02-12||1964-01-08|1960-07-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||MOLRESP|MOLECULAR RESPONSE||||KALLIKREIN INHIBITOR UNIT|RELAPSED DISEASE||VG/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|FAMILY MEMBER|ONCOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1967-12-08||||1960-05-08||1970-02-08|1967-02-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||VG/KG|TREATMENT FAILURE||/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|3||39||OBSERVATION|1968-06-13||||1969-01-08||1964-12-08|1960-05-16||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NG/DAY|CYTOGENETIC CR||TORR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|3||39||FOLLOW-UP|1966-08-01||||1969-11-03||1963-03-12|1973-08-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||BONERESP|BONE RESPONSE||||UU/L|HI-P||U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|STUDY SUBJECT|ENDOCRINOLOGIST|U|4||88||WASHOUT|1960-10-22||||1973-02-10||1972-09-11|1960-05-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CUP|CYTOGENETIC CR||UG/L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|INTERVIEWER|READER 1|Y|4||88||SCREENING|1972-12-17||||1965-03-27||1963-05-31|1971-01-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CM/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OPEN LABEL TREATMENT|1969-03-03||||1966-03-25||1971-08-07|1963-06-10||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||TRGRESP|TARGET RESPONSE||||MAC50|RELAPSED DISEASE||FT2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|ADJUDICATOR|MICROSCOPIST|Y|5||7||RUN-IN|1964-10-15||||1968-02-16||1968-08-01|1972-11-29||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/G/DAY|CA125 50% RESPONSE||G/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1||38||BLINDED TREATMENT|1969-08-03||||1971-04-22||1970-02-20|1960-06-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||PATHRESP|PATHOLOGIC RESPONSE||||QUANTITY SUFFICIENT|NED||/VF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1968-03-14||||1962-04-07||1961-12-10|1960-08-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3/HPF|RELAPSED DISEASE FROM CR OR PR||ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|INDEPENDENT ASSESSOR|RATER|N|2||58||FOLLOW-UP|1971-01-29||||1965-07-06||1968-01-28|1962-08-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||NTRGRESP|NON-TARGET RESPONSE||||PT_BR|PD||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CHILD|NEUROLOGIST 1|N|2||58||TREATMENT|1966-02-07||||1967-03-21||1967-03-05|1962-07-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^3 ORGANISMS/ML|MORPHOLOGIC CRI||MPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|CAREGIVER|PATHOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1973-07-12||||1963-08-08||1966-10-23|1964-05-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||NTRGRESP|NON-TARGET RESPONSE||||CI/UL|CYTOGENETIC MINOR RESPONSE||LOG10 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|ADJUDICATOR|CARDIOLOGIST|U|3||39||CONTINUATION TREATMENT|1972-08-31||||1967-10-08||1969-05-25|1970-02-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||NEWLPROG|NEW LESION PROGRESSION||||PPB|PMR||BISCUIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|FRIEND|OPTOMETRIST|N|4||88||RUN-IN|1970-02-04||||1960-05-29||1965-06-14|1967-09-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||BESTRESP|BEST OVERALL RESPONSE||||U/G|RELAPSED DISEASE||CMHG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|INVESTIGATOR|FORENSIC PATHOLOGIST|U|4||88||BLINDED TREATMENT|1967-06-23||||1961-04-27||1966-08-11|1962-04-24||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UM/DAY|CCR||GMFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|INVESTIGATOR|MICROSCOPIST|N|5||7||BASELINE|1973-02-20||||1966-11-29||1965-01-19|1962-06-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/L|MR||APS U|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|SIBLING|HEMATOLOGIST|Y|5||7||INDUCTION TREATMENT|1970-08-22||||1964-11-23||1962-04-28|1966-04-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||CLINRESP|CLINICAL RESPONSE||||C|NON-ICR/NON-IUPD||ELISA UNIT|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|VENDOR|PHYSIOTHERAPIST|Y|1||38||CONTINUATION TREATMENT|1971-02-02||||1967-08-26||1972-02-17|1967-07-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BQ/UL|PDU||CD*S/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|FAMILY MEMBER|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1971-08-01||||1964-08-28||1960-08-16|1969-12-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||BQ/UL|MOLECULAR MAJOR RESPONSE||U/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|2||58||BASELINE|1966-08-25||||1960-11-11||1964-11-02|1967-02-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PNU/ML|PDU||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||INDUCTION TREATMENT|1972-07-13||||1960-09-12||1971-10-28|1961-01-28||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/H|ICPD||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|SIBLING|MICROSCOPIST 1|N|3||39||BASELINE|1970-08-05||||1964-09-26||1962-01-21|1968-09-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG EID 50/DOSE|MINOR PATHOLOGIC RESPONSE||KUSP|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|INTERVIEWER|ADJUDICATOR 3|N|3||39||TREATMENT|1972-09-27||||1969-07-29||1963-12-14|1972-03-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NSEC|HI-N||%(W/V)|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|4||88||FOLLOW-UP|1964-03-30||||1960-05-06||1973-04-24|1966-03-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||OVRLRESP|OVERALL RESPONSE||||/LSQN|MAJOR PATHOLOGIC RESPONSE||NM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|CAREGIVER|PHYSIOTHERAPIST|Y|4||88||BASELINE|1965-01-02||||1960-11-04||1968-01-08|1962-12-31||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||NTRGRESP|NON-TARGET RESPONSE||||HR/DAY|CR||/VF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|DOMESTIC PARTNER|PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1972-08-24||||1965-10-19||1968-03-27|1972-12-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||NEWLPROG|NEW LESION PROGRESSION||||KG/L|NON-ICR/NON-IUPD||MOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|5||7||WASHOUT|1965-04-20||||1963-08-21||1962-10-11|1962-03-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MIN*MG/ML|MOLECULAR MAJOR RESPONSE||POUCH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|CAREGIVER|RADIOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1961-05-25||||1967-01-30||1968-03-09|1968-10-06||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||NTRGRESP|NON-TARGET RESPONSE||||VIAL|MRD RELAPSE||LOZENGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|READER 1|NA|1||38||INDUCTION TREATMENT|1960-07-30||||1966-01-04||1969-04-20|1967-04-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||BONERESP|BONE RESPONSE||||MEQ/MMOL|MORPHOLOGIC CRI||SCOOPFUL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|SIBLING|RATER 1|N|2||58||CONTINUATION TREATMENT|1973-06-25||||1960-02-28||1960-10-16|1966-02-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||NEWLPROG|NEW LESION PROGRESSION||||MBQ/UL|SCR||CMHG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|VENDOR|ADJUDICATOR 1|N|2||58||CONTINUATION TREATMENT|1963-07-26||||1961-07-31||1973-05-18|1961-01-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||MOLRESP|MOLECULAR RESPONSE||||MU/G|STABLE||FOZ_BR|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|VENDOR|ONCOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1968-05-06||||1967-02-23||1967-08-04|1961-02-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||OVRLRESP|OVERALL RESPONSE||||AFU|CYTOGENETIC MINIMAL RESPONSE||PMOL/10^9 CELLS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|SIBLING|ENDOCRINOLOGIST|N|3||39||TREATMENT|1971-07-16||||1971-11-25||1971-10-05|1967-04-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MNFI|IPR||LM|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|GUARDIAN|PEDIATRIC NEUROLOGIST|N|4||88||BASELINE|1972-07-01||||1966-05-28||1972-07-28|1965-05-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||CYTORESP|CYTOGENETIC RESPONSE||||VIRTUAL PIXEL|IMMUNOPHENOTYPIC CR||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1961-08-28||||1964-01-04||1962-03-07|1972-11-27||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||EU|DECREASED||MG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|ADJUDICATOR|ENDOCRINOLOGIST|Y|5||7||OBSERVATION|1961-10-17||||1973-01-28||1962-09-19|1973-03-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||BESTRESP|BEST OVERALL RESPONSE||||G/G/DAY|TREATMENT FAILURE||UMOL/L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|CAREGIVER|PEDIATRIC NEUROLOGIST|U|5||7||BASELINE|1963-02-18||||1973-07-27||1972-03-04|1967-03-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||NEWLIND|NEW LESION INDICATOR||||10^9 CFU|NR||L/H/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|U|1||38||BASELINE|1967-05-23||||1961-12-11||1960-10-22|1963-10-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MEQ/L|CRI||KG/CM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||BLINDED TREATMENT|1962-12-21||||1961-10-03||1968-01-20|1966-06-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||TMRESP|TUMOR MARKER RESPONSE||||VG/ML|QUANTIFIABLE MRD POSITIVITY||COULOMB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|INVESTIGATOR|ONCOLOGIST|U|2||58||WASHOUT|1970-08-25||||1968-04-26||1973-08-24|1969-01-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||CYTORESP|CYTOGENETIC RESPONSE||||USIEMENS|PSEUDOPROGRESSION||LOG10 PFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|PROXY|RATER|Y|2||58||RUN-IN|1966-12-09||||1961-06-04||1972-10-23|1961-07-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||%(V/V)|CHR||BLOCKS|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|PARENT|RATER 1|Y|3||39||TREATMENT|1965-01-28||||1971-05-23||1963-12-14|1967-01-28||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/ANIMAL|PDU||MHZ|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|3||39||RUN-IN|1962-09-14||||1963-02-14||1965-06-08|1968-07-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||CLINRESP|CLINICAL RESPONSE||||MV|PDU||ML/BEAT|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|INVESTIGATOR|HEMATOLOGIST|N|4||88||FOLLOW-UP|1964-02-04||||1966-02-17||1969-07-25|1969-05-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 PFU/ML|PR WITH LYMPHOCYTOSIS||UG/L|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|PARENT|NEUROLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1961-01-12||||1964-08-05||1968-08-07|1973-08-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/L FEU|CPR||ML/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|GUARDIAN|READER|Y|5||7||INDUCTION TREATMENT|1968-02-25||||1971-02-01||1966-10-21|1960-01-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||SPLNRESP|SPLEEN RESPONSE||||DAGU|CHR||MMU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|SPOUSE|ONCOLOGIST 1|N|5||7||TREATMENT|1960-06-14||||1971-10-04||1966-04-24|1963-05-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||RAD|COMPLETE MRD RESPONSE||G/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|FAMILY MEMBER|READER 1|NA|1||38||SCREENING|1970-07-16||||1965-04-25||1967-02-04|1973-02-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/KG/H|CCR||EQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|1||38||FOLLOW-UP|1972-06-09||||1969-11-03||1971-03-17|1973-08-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|1||||||METSIND|METASTATIC INDICATOR||||CD|SMD||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|2||58||TREATMENT|1969-02-28||||1960-11-09||1966-03-27|1967-02-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|2||||||METSIND|METASTATIC INDICATOR||||TORR|CR||L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|N|2||58||OPEN LABEL TREATMENT|1965-07-18||||1963-12-03||1963-12-21|1968-08-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/ANIMAL|PMR||10^8/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|GUARDIAN|READER 1|NA|3||39||FOLLOW-UP|1960-02-15||||1960-01-28||1965-06-05|1963-05-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|2||||||STRUSTAT|STEROID USE STATUS||||APS U|RELAPSED DISEASE||PSI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|ADJUDICATOR|MICROSCOPIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1961-11-06||||1967-08-14||1962-08-28|1973-03-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|1||||||NTRGRESP|NON-TARGET RESPONSE||||RAD|CA125 50% RESPONSE||100 IU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|ADJUDICATION COMMITTEE|RATER 1|N|4||88||BLINDED TREATMENT|1967-10-20||||1972-12-09||1969-02-26|1969-12-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|2||||||NTRGRESP|NON-TARGET RESPONSE||||BQ/G|ABSENT MORPHOLOGIC RESPONSE||UG/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|4||88||OBSERVATION|1964-04-14||||1961-02-22||1969-07-13|1973-03-29||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|1||||||ANATRESP|ANATOMIC RESPONSE||||KG/MOL|WORSENED||PUFF|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|5||7||TREATMENT|1965-07-22||||1967-05-12||1967-05-25|1968-12-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|11A6144A-895B-4143-85D2-69952C6D452C|2||||||METBRESP|METABOLIC RESPONSE||||TSP|CYTOGENETIC MINOR RESPONSE||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|PARENT|ADJUDICATOR 2|U|5||7||TREATMENT|1967-04-26||||1963-09-08||1962-08-17|1973-05-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MKAT|PMR||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|1||38||BASELINE|1967-10-29||||1969-07-02||1963-12-22|1973-02-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||EU|CYTOGENETIC NO RESPONSE||POINT|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|1||38||OBSERVATION|1969-03-02||||1962-01-09||1963-01-13|1960-11-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||BONERESP|BONE RESPONSE||||MPL U|CR||PACK YEAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||TREATMENT|1973-02-08||||1972-05-02||1963-09-30|1967-03-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CM|UNFAVORABLE RESPONSE||CYLINDER|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|FRIEND|ADJUDICATOR 1|NA|2||58||OBSERVATION|1964-10-23||||1973-01-09||1971-07-13|1968-01-30||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||NEWLIND|NEW LESION INDICATOR||||CONTAINER|PSA PROGRESSION||KIU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|CAREGIVER|ONCOLOGIST 1|U|3||39||BASELINE|1964-08-09||||1963-05-02||1961-11-27|1965-05-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||NEWLPROG|NEW LESION PROGRESSION||||MMHG/SEC|CA125 50% RESPONSE||USP U|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|SIBLING|ADJUDICATOR 3|Y|3||39||OPEN LABEL TREATMENT|1965-03-09||||1968-06-06||1971-03-09|1962-01-31||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ABSORBANCE U/ML|PARTIAL MORPHOLOGIC RESPONSE||SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||OBSERVATION|1965-01-25||||1966-03-12||1960-10-11|1968-10-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MIN*MG/ML|PD/RELAPSE AFTER HI||MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|ADJUDICATOR|RADIOLOGIST 2|U|4||88||RUN-IN|1964-04-02||||1969-04-03||1964-10-18|1961-05-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||BESTRESP|BEST OVERALL RESPONSE||||AMPULE|ABSENT MORPHOLOGIC RESPONSE||ENZYME U/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CAREGIVER|ONCOLOGIST 1|NA|5||7||BASELINE|1961-08-22||||1968-05-13||1972-05-08|1968-10-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||TRGRESP|TARGET RESPONSE||||/CMH2O|ICR||FRACTION OF 1|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||INDUCTION TREATMENT|1962-02-11||||1962-11-30||1969-02-05|1965-01-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML|INDETERMINATE RESPONSE||CI/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|PROXY|ONCOLOGIST 1|U|1||38||FOLLOW-UP|1965-12-24||||1960-12-09||1969-11-27|1962-12-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|2||||||NTRGRESP|NON-TARGET RESPONSE||||M2|MR||MEQ/UG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|1||38||OBSERVATION|1962-09-21||||1965-07-09||1964-05-09|1965-03-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/2500 WBC|PARTIAL MORPHOLOGIC RESPONSE||PIPE|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|SIGNIFICANT OTHER|RATER 1|NA|2||58||OPEN LABEL TREATMENT|1960-02-11||||1971-09-07||1970-05-04|1973-04-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ABSORBANCE U|SD||MOSM/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|PROXY|RADIOLOGIST 1|Y|2||58||RUN-IN|1967-08-08||||1962-12-18||1960-06-04|1968-08-14||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||WEEKS|PD/RELAPSE AFTER HI||SCM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|FAMILY MEMBER|OPTOMETRIST|Y|3||39||INDUCTION TREATMENT|1972-09-29||||1967-02-15||1968-08-30|1964-06-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6 CFU/ML|CCR||PG/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1967-09-03||||1969-06-11||1967-12-14|1964-02-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GAUSS|HI-P||MOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|FRIEND|INTERNIST|U|4||88||LONG-TERM FOLLOW-UP|1964-04-17||||1965-10-15||1963-05-05|1964-05-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 TCID 50/ML|NON-QUANTIFIABLE MRD POSITIVITY||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|INTERVIEWER|PATHOLOGIST|Y|4||88||BASELINE|1963-03-15||||1968-05-05||1960-01-04|1962-01-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|1||||||ANATRESP|ANATOMIC RESPONSE||||VG/DOSE|FAVORABLE RESPONSE||UG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|SIBLING|NEUROLOGIST|Y|5||7||INDUCTION TREATMENT|1973-07-21||||1971-06-01||1970-06-18|1960-07-21||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|00982640-C826-4CD4-B927-A311227E63CC|2||||||METSIND|METASTATIC INDICATOR||||GPS U|UNFAVORABLE RESPONSE||MBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|INDEPENDENT ASSESSOR|UROLOGIST|NA|5||7||INDUCTION TREATMENT|1972-04-04||||1963-07-07||1964-02-07|1971-11-18||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||CLINRESP|CLINICAL RESPONSE||||10^9 ORGANISMS|MORPHOLOGIC CRI||UG/G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|ADJUDICATION COMMITTEE|READER 1|U|1||38||SCREENING|1970-12-14||||1967-02-07||1967-07-19|1971-08-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||ANATRESP|ANATOMIC RESPONSE||||GY/MIN|CYTOGENETIC MINIMAL RESPONSE||V|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 2|NA|1||38||RUN-IN|1969-12-26||||1972-06-07||1971-03-15|1967-10-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||SPLNRESP|SPLEEN RESPONSE||||WEEKS|NE||PELLET|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|SIBLING|READER|Y|2||58||TREATMENT|1969-04-01||||1971-11-05||1963-02-18|1964-11-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/M2/H|NON-CR/NON-PD||UKAT/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|2||58||WASHOUT|1973-08-26||||1966-01-05||1965-02-06|1968-04-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L DDU|NPR||/LSQN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1960-08-02||||1968-05-30||1965-05-22|1965-06-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/KG/MIN|COMPLETE MRD RESPONSE||BISCUIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|INTERVIEWER|NEUROLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1966-02-24||||1961-02-03||1964-05-11|1966-09-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/G/MIN|SD||UM/S|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|SPOUSE|CARDIOLOGIST|Y|4||88||INDUCTION TREATMENT|1963-05-02||||1965-01-05||1968-03-12|1961-01-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SACHET|UNFAVORABLE RESPONSE||UG/G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|U|4||88||BASELINE|1972-10-23||||1971-12-08||1962-02-04|1970-10-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ|HI-E||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||SCREENING|1971-10-14||||1966-09-28||1966-08-03|1960-06-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||METSIND|METASTATIC INDICATOR||||EP U|CYTOGENETIC MINIMAL RESPONSE||NMOL BCE/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||BASELINE|1966-04-08||||1963-04-24||1969-11-24|1963-06-03||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DIOPTER|OPTIMAL MORPHOLOGIC RESPONSE||BAG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|VENDOR|HEMATOLOGIST|N|1||38||OPEN LABEL TREATMENT|1972-01-08||||1966-11-12||1962-05-22|1971-01-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|2||||||NEWLIND|NEW LESION INDICATOR||||10^6 ORGANISMS/ML|PD/RELAPSE AFTER HI||10^4/HPF|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|INVESTIGATOR|ADJUDICATOR|NA|1||38||BLINDED TREATMENT|1965-05-28||||1961-08-16||1966-07-30|1965-04-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|1||||||NEWLIND|NEW LESION INDICATOR||||/10^5|NE||PT_US|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|SIBLING|RADIOLOGIST|NA|2||58||RUN-IN|1964-03-06||||1966-08-21||1960-08-27|1960-09-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|2||||||CLINRESP|CLINICAL RESPONSE||||NCI|PMD||LB|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|FRIEND|RATER|NA|2||58||INDUCTION TREATMENT|1966-06-19||||1968-05-30||1964-03-30|1962-12-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|1||||||CYTORESP|CYTOGENETIC RESPONSE||||ANTI-XA IU/ML|SD-CT||ML/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|3||39||SCREENING|1965-04-12||||1966-09-15||1969-04-30|1963-02-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|2||||||TMRESP|TUMOR MARKER RESPONSE||||MG/M2/H|TREATMENT FAILURE||KAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|PROXY|RADIOLOGIST 2|U|3||39||TREATMENT|1964-11-03||||1961-06-04||1966-12-13|1970-02-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|1||||||NTRGRESP|NON-TARGET RESPONSE||||/500 WBC|CR||GBQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CAREGIVER|OPTOMETRIST|N|4||88||LONG-TERM FOLLOW-UP|1970-07-17||||1963-04-23||1964-06-03|1972-11-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|2||||||LIVRRESP|LIVER RESPONSE||||PFU|OPTIMAL MORPHOLOGIC RESPONSE||L/MIN/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|SIBLING|ADJUDICATOR|Y|4||88||BASELINE|1964-05-14||||1962-04-05||1964-08-25|1963-11-05||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|1||||||ANATRESP|ANATOMIC RESPONSE||||TRANSDUCING UNIT|ISD||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|STUDY SUBJECT|ONCOLOGIST|Y|5||7||BASELINE|1972-06-15||||1965-02-16||1968-07-28|1971-09-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F0559682-CD36-4ED0-8082-A54D40305512|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CM H2O|MRD PERSISTENCE||EID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CAREGIVER|RATER 2|U|5||7||OBSERVATION|1960-01-08||||1970-01-25||1971-05-21|1963-05-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/CM2|HI-E||PMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|INDEPENDENT ASSESSOR|RADIOLOGIST|Y|1||38||FOLLOW-UP|1964-04-21||||1970-01-17||1969-02-22|1960-12-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||LIVRRESP|LIVER RESPONSE||||MMOL/G|CHR||LOG10 TCID 50/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|STUDY SUBJECT|MICROSCOPIST|NA|1||38||OPEN LABEL TREATMENT|1962-03-16||||1963-03-28||1960-02-07|1961-02-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||OHM|CCR||VG/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|2||58||OBSERVATION|1970-09-19||||1970-08-14||1962-04-15|1960-09-06||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||NEWLIND|NEW LESION INDICATOR||||MANSON U/ML|UNFAVORABLE RESPONSE||ANTI-XA IU|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|SIGNIFICANT OTHER|ADJUDICATOR 3|U|2||58||LONG-TERM FOLLOW-UP|1961-03-04||||1970-01-14||1965-05-10|1967-06-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||AU/ML|IMMUNOPHENOTYPIC CR||COAT|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|READER 3|Y|3||39||WASHOUT|1968-01-26||||1968-04-12||1960-04-09|1969-06-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MOSM/L|CMR||UCI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|FRIEND|OPHTHALMOLOGIST|NA|3||39||TREATMENT|1962-10-07||||1962-05-22||1961-05-03|1967-02-04||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GAUSS|SCR||MCI/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|VENDOR|DERMATOLOGIST|U|4||88||BLINDED TREATMENT|1969-05-05||||1973-02-06||1973-04-11|1969-09-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||METBRESP|METABOLIC RESPONSE||||INHALATION|IMPROVED||ML/MMHG/MIN/L|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|4||88||FOLLOW-UP|1960-02-09||||1973-06-30||1960-01-31|1970-08-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||NEWLIND|NEW LESION INDICATOR||||IU/KG/H|PD-CT||10^6/HPF|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|FRIEND|ADJUDICATOR|NA|5||7||BASELINE|1965-04-06||||1969-10-17||1972-04-24|1969-02-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^6 ORGANISMS/MG|MINOR PATHOLOGIC RESPONSE||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|FRIEND|RATER|U|5||7||INDUCTION TREATMENT|1969-08-08||||1961-05-24||1966-07-11|1969-06-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UMOL/L/SEC|MORPHOLOGIC LEUKEMIA-FREE STATE||JAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|CAREGIVER|RADIOLOGIST|NA|1||38||SCREENING|1962-03-06||||1965-06-03||1961-05-23|1968-02-21||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PIXEL|ISD||TESLA|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|CHILD|PATHOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1967-01-15||||1971-09-03||1971-10-13|1970-07-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MKAT|CR-CT||/200 HPFS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|PARENT|OTOLARYNGOLOGIST|N|2||58||OPEN LABEL TREATMENT|1971-09-12||||1972-02-19||1970-07-05|1973-03-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DEG2|ICPD||G/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|2||58||OBSERVATION|1966-01-03||||1971-10-16||1964-06-22|1965-02-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/MOL|PR||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|GUARDIAN|OPHTHALMOLOGIST|U|3||39||RUN-IN|1963-01-20||||1960-12-13||1964-06-22|1962-04-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||METSIND|METASTATIC INDICATOR||||EID 50/ML|NR||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|SIGNIFICANT OTHER|RADIOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1960-03-09||||1973-04-15||1965-08-15|1968-04-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||LIVRRESP|LIVER RESPONSE||||CGY|NPR||PT_BR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|SPOUSE|PATHOLOGIST|NA|4||88||OBSERVATION|1962-07-23||||1965-12-21||1968-06-08|1965-02-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||MOLRESP|MOLECULAR RESPONSE||||KG/MOL|PSEUDOPROGRESSION||UKAT/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|SIGNIFICANT OTHER|DERMATOLOGIST|N|4||88||RUN-IN|1972-05-14||||1964-04-28||1964-07-09|1961-05-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||METSIND|METASTATIC INDICATOR||||ML/M2/DAY|PD/RELAPSE AFTER HI||U/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|SIBLING|MICROSCOPIST|NA|5||7||OPEN LABEL TREATMENT|1972-01-03||||1963-04-07||1966-06-11|1971-11-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||OVRLRESP|OVERALL RESPONSE||||UGEQ/L|PARTIAL MORPHOLOGIC RESPONSE||10^6/HPF|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|STUDY SUBJECT|OTOLARYNGOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1971-09-18||||1960-07-18||1970-01-30|1961-11-28||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||M|CR||NSEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|VENDOR|PHYSIOTHERAPIST|N|1||38||FOLLOW-UP|1965-11-08||||1966-08-03||1971-04-05|1963-10-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^9/L|IPR||BU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1967-02-26||||1968-10-04||1965-06-25|1966-10-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CP|MRD NEGATIVITY||10^9/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1966-12-31||||1964-05-05||1961-09-07|1962-07-28||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|2||||||METSIND|METASTATIC INDICATOR||||MANSON U/ML|HI-E||L/S/KPA|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|PARENT|MICROSCOPIST 3|N|2||58||RUN-IN|1966-08-29||||1964-12-16||1963-12-24|1973-05-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|1||||||BONERESP|BONE RESPONSE||||ML/(MIN*100ML)|STABLE||FT2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3||39||INDUCTION TREATMENT|1963-11-28||||1970-03-11||1970-05-10|1969-01-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|2||||||BONERESP|BONE RESPONSE||||MOL/DAY|CCR||ABSORBANCE U|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 1|U|3||39||FOLLOW-UP|1965-08-28||||1965-07-24||1961-01-17|1967-04-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||USIEMENS|PMR||MM/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|SPOUSE|RADIOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1972-06-29||||1964-06-19||1963-08-03|1970-03-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||/7.5 ML|COMPLETE MRD RESPONSE||/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|SIGNIFICANT OTHER|READER 1|NA|4||88||LONG-TERM FOLLOW-UP|1971-05-22||||1962-06-30||1963-08-04|1968-06-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG|PD/RELAPSE AFTER HI||ML/MMHG/MIN/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|DOMESTIC PARTNER|RADIOLOGIST|N|5||7||BASELINE|1964-09-29||||1972-06-05||1960-03-13|1966-08-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|88126417-8564-4659-AA60-63642067113D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||/MM|QUANTIFIABLE MRD POSITIVITY||/LSQN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|VENDOR|MICROSCOPIST 1|NA|5||7||OBSERVATION|1964-12-03||||1962-06-06||1972-01-16|1962-07-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMHG|ICR||JAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||INDUCTION TREATMENT|1972-11-11||||1960-01-24||1967-11-06|1964-12-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||MOLRESP|MOLECULAR RESPONSE||||RNA COPIES/ML|CA125 50% RESPONSE||FINGERTIP UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|SIBLING|ADJUDICATOR 1|U|1||38||WASHOUT|1961-02-19||||1960-09-17||1973-03-11|1973-06-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||M/SEC2|CR-CT||/HPF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|INTERVIEWER|CLINICAL PATHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1972-08-23||||1966-01-26||1963-04-16|1966-06-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||TMRESP|TUMOR MARKER RESPONSE||||CM/MIN|PSEUDOPROGRESSION||ANTIBODY UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|2||58||SCREENING|1972-06-09||||1963-01-17||1965-03-12|1966-03-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3/HPF|NOT ALL EVALUATED||IU/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|FRIEND|PHYSIOTHERAPIST|N|3||39||CONTINUATION TREATMENT|1962-10-14||||1962-03-09||1972-01-16|1967-08-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||LIVRRESP|LIVER RESPONSE||||G/ANIMAL|NON-ICR/NON-IUPD||MASK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|3||39||INDUCTION TREATMENT|1967-06-20||||1966-11-23||1966-06-28|1967-12-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/CAGE/WK|MRD PERSISTENCE||UL/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|RATER 1|U|4||88||WASHOUT|1969-09-10||||1965-03-16||1969-04-29|1960-01-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||TRGRESP|TARGET RESPONSE||||10^4 CFU|COMPLETE MRD RESPONSE||CMH2O/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|4||88||OBSERVATION|1968-04-12||||1971-03-17||1967-06-30|1964-05-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/M2/DAY|DISEASE TRANSFORMATION||UG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|SPOUSE|ADJUDICATOR|N|5||7||CONTINUATION TREATMENT|1967-10-04||||1964-10-09||1968-07-02|1967-12-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EIA UNIT|CRI||VP/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|5||7||RUN-IN|1968-07-25||||1965-12-26||1961-12-16|1971-08-01||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||NTRGRESP|NON-TARGET RESPONSE||||PFU|CYTOGENETIC MINOR RESPONSE||CUP|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|GUARDIAN|ADJUDICATOR 3|Y|1||38||INDUCTION TREATMENT|1970-05-27||||1969-07-18||1961-09-29|1972-12-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BQ/MG|SCR||/2500 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|STUDY SUBJECT|INTERNIST|NA|1||38||INDUCTION TREATMENT|1967-05-19||||1964-01-20||1972-07-08|1972-09-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ABSORBANCE U/ML|UNFAVORABLE RESPONSE||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|CHILD|ADJUDICATOR 1|Y|2||58||BASELINE|1971-07-16||||1969-06-26||1968-11-21|1968-02-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||STEPS/MIN|NON-PD||KIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|DOMESTIC PARTNER|MICROSCOPIST 3|U|2||58||OBSERVATION|1967-09-12||||1961-12-12||1969-07-13|1964-07-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/CM|CYTOGENETIC NO RESPONSE||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|PARENT|RADIOLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-12-30||||1962-06-25||1970-09-10|1968-10-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^5/HPF|IPR||CMHG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|3||39||SCREENING|1967-05-24||||1960-03-30||1965-09-14|1969-06-01||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CAPLET|PCR||10^12 IU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|STUDY SUBJECT|INTERNIST|NA|4||88||OPEN LABEL TREATMENT|1969-01-27||||1966-05-21||1966-10-13|1969-11-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||TMRESP|TUMOR MARKER RESPONSE||||KDA|PD-CT||NEWTON|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|N|4||88||CONTINUATION TREATMENT|1961-06-12||||1971-05-09||1960-08-09|1966-01-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||L|PD||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|INVESTIGATOR|MICROSCOPIST|N|5||7||WASHOUT|1962-12-26||||1971-07-17||1972-12-02|1972-01-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TITER|NON-QUANTIFIABLE MRD POSITIVITY||IN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|FRIEND|PATHOLOGIST 1|NA|5||7||INDUCTION TREATMENT|1965-08-12||||1966-05-11||1972-05-20|1961-10-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CMH2O*S2/ML|UNEQUIVOCAL||MV2/HZ|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|FAMILY MEMBER|RATER 2|U|1||38||WASHOUT|1962-06-12||||1967-08-12||1973-08-31|1961-03-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||METSIND|METASTATIC INDICATOR||||ECL UNIT|MAJOR PATHOLOGIC RESPONSE||MG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1965-09-06||||1970-08-24||1963-06-30|1973-05-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MEQ/KG|PMD||L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|CAREGIVER|MICROSCOPIST 1|NA|2||58||FOLLOW-UP|1967-04-09||||1967-03-28||1972-06-23|1967-03-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DAYS|NON-ICR/NON-IUPD||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|PARENT|ONCOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1962-04-03||||1964-11-19||1963-07-27|1961-08-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||CLINRESP|CLINICAL RESPONSE||||NMOL/DAY|PSEUDOPROGRESSION||U/G/H|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|SIBLING|ONCOLOGIST|NA|3||39||SCREENING|1960-06-06||||1972-04-12||1970-05-26|1967-12-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/M2/DAY|MINOR PATHOLOGIC RESPONSE||MAC50|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|STUDY SUBJECT|READER 3|U|3||39||CONTINUATION TREATMENT|1966-03-05||||1969-08-03||1973-03-30|1968-01-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EID 50/ML|HI-N||GMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|4||88||BLINDED TREATMENT|1967-08-14||||1960-05-20||1972-02-19|1960-01-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||IN|CYTOGENETIC PR||COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|4||88||FOLLOW-UP|1969-11-07||||1970-08-05||1969-02-21|1972-12-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KUSP|PR-CT||DIP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|INTERVIEWER|PATHOLOGIST 2|Y|5||7||RUN-IN|1965-04-15||||1961-04-20||1971-06-05|1968-05-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||CLINRESP|CLINICAL RESPONSE||||MG/KG/H|PMD||CI/KG|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|5||7||BLINDED TREATMENT|1971-06-29||||1963-08-18||1964-07-24|1971-04-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/M2/H|HI-E||DMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|INDEPENDENT ASSESSOR|ONCOLOGIST 2|Y|1||38||BASELINE|1966-07-28||||1967-04-10||1963-01-24|1970-07-08||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||METSIND|METASTATIC INDICATOR||||PHERESIS UNIT|SMD||G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|CAREGIVER|PATHOLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1969-05-02||||1960-09-20||1972-12-22|1972-03-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||OVRLRESP|OVERALL RESPONSE||||G/G/DAY|CPR||NG/L|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|SPOUSE|ENDOCRINOLOGIST|Y|2||58||INDUCTION TREATMENT|1973-03-15||||1967-09-21||1967-03-31|1973-02-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GPS U|CCR||DEG2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|DOMESTIC PARTNER|RADIOLOGIST 1|Y|2||58||FOLLOW-UP|1964-05-20||||1963-07-18||1967-07-12|1969-04-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||LIVRRESP|LIVER RESPONSE||||KPA/L/SEC|MORPHOLOGIC CRI||CI/UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|PARENT|MICROSCOPIST 1|N|3||39||TREATMENT|1964-09-18||||1965-11-09||1964-12-04|1970-01-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||BONERESP|BONE RESPONSE||||ML/KG/H|SD-CT||MEQ/MMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|INVESTIGATOR|OPTOMETRIST|N|3||39||WASHOUT|1962-11-15||||1960-08-06||1961-02-20|1965-01-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||METBRESP|METABOLIC RESPONSE||||/HPF|PSEUDORESPONSE||AGU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|READER 2|Y|4||88||BLINDED TREATMENT|1970-03-24||||1961-08-30||1967-10-20|1969-11-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CM H2O|ISD||OSM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|INDEPENDENT ASSESSOR|READER 2|N|4||88||CONTINUATION TREATMENT|1960-02-14||||1971-08-10||1963-01-07|1965-07-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||LIVRRESP|LIVER RESPONSE||||EID 50/ML|CYTOGENETIC MINOR RESPONSE||SBE/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|5||7||FOLLOW-UP|1967-10-08||||1965-12-26||1970-01-11|1967-01-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/10^9 CELLS|MORPHOLOGIC CR||LOG EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|FAMILY MEMBER|CARDIOLOGIST|U|5||7||SCREENING|1964-06-22||||1960-02-03||1970-06-04|1963-10-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/KG/DAY|UNFAVORABLE RESPONSE||10^6 ORGANISMS|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|PARENT|NEUROLOGIST 1|U|1||38||TREATMENT|1965-01-28||||1965-05-23||1966-02-09|1969-01-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||ANATRESP|ANATOMIC RESPONSE||||AMP|PR||LENS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|1||38||CONTINUATION TREATMENT|1967-09-22||||1968-08-01||1962-07-02|1970-01-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||STRUSTAT|STEROID USE STATUS||||PPM|PD/RELAPSE AFTER HI||FFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|INDEPENDENT ASSESSOR|RATER 2|N|2||58||BLINDED TREATMENT|1967-09-17||||1965-06-03||1967-11-24|1973-02-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||NEWLIND|NEW LESION INDICATOR||||MMHG*MIN/L|CHR||OSM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|INVESTIGATOR|READER 3|NA|2||58||FOLLOW-UP|1965-01-16||||1960-07-09||1969-06-06|1972-05-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||BONERESP|BONE RESPONSE||||10^6 RNA COPIES/ML|SCR||COAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|3||39||RUN-IN|1969-03-08||||1969-08-23||1971-03-14|1961-01-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BREATHS/MIN|INCREASED||DYN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|3||39||BASELINE|1967-09-30||||1967-01-18||1967-01-02|1970-12-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/BEAT|PMD||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|SIGNIFICANT OTHER|INTERNIST|U|4||88||FOLLOW-UP|1962-03-21||||1972-05-01||1969-01-29|1973-04-28||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||OVRLRESP|OVERALL RESPONSE||||UG/G/DAY|SMD||CI/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|U|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1966-11-05||||1965-05-01||1963-04-14|1972-01-20||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MEQ|DECREASED||ML/MIN/MMHG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|READER|N|5||7||INDUCTION TREATMENT|1968-01-06||||1970-02-02||1970-04-18|1971-04-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/DAY|MOLECULAR CR||CAN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|CAREGIVER|ENDOCRINOLOGIST|NA|5||7||WASHOUT|1969-12-31||||1965-05-17||1969-07-25|1963-10-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UV2|VGPR||PL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1||38||WASHOUT|1966-07-05||||1966-05-22||1962-08-16|1968-11-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||TMRESP|TUMOR MARKER RESPONSE||||KG|STABLE||MMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|GUARDIAN|RADIOLOGIST 2|Y|1||38||OBSERVATION|1968-04-04||||1966-07-29||1962-06-19|1972-01-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||% INHIBITION|CRI||MMOL/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|ADJUDICATOR|INTERNIST|U|2||58||INDUCTION TREATMENT|1963-02-28||||1960-06-05||1962-11-03|1966-10-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||AGU/ML|RELAPSED DISEASE FROM CR||UG/G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|SIBLING|UROLOGIST|Y|2||58||CONTINUATION TREATMENT|1960-12-16||||1969-08-17||1962-09-07|1966-08-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||EU|ICPD||UG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|3||39||TREATMENT|1964-04-28||||1962-09-28||1964-08-09|1962-03-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||S^-1(%O2)^-1|PR-CT||VP/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|FRIEND|RADIOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1964-10-08||||1965-06-19||1960-10-15|1960-06-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MMOL/KG|PD FROM PR||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|GUARDIAN|DERMATOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1972-08-24||||1967-03-10||1965-03-25|1969-12-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||TRGRESP|TARGET RESPONSE||||FMOL/L/SEC|SCR||NCI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|INTERVIEWER|HEMATOLOGIST|Y|4||88||SCREENING|1961-12-12||||1964-09-17||1964-11-29|1960-05-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||LIVRRESP|LIVER RESPONSE||||DAGU/ML|TREATMENT FAILURE||ML/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|PROXY|HEMATOLOGIST|Y|5||7||WASHOUT|1961-08-02||||1970-01-23||1971-12-03|1961-12-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||NEWLPROG|NEW LESION PROGRESSION||||MOSM|ICR||TUBE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|5||7||WASHOUT|1968-03-18||||1971-02-10||1963-06-06|1969-02-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|1||||||STRUSTAT|STEROID USE STATUS||||NMOL BCE/L|CYTOGENETIC MINOR RESPONSE||GBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|Y|1||38||OPEN LABEL TREATMENT|1962-02-25||||1969-07-11||1970-07-03|1967-01-02||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG2/DL2|CMR||CD*S/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||RUN-IN|1961-07-12||||1969-08-14||1971-06-06|1963-10-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|1||||||METBRESP|METABOLIC RESPONSE||||CAPFUL|TREATMENT FAILURE||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|2||58||BLINDED TREATMENT|1972-06-22||||1970-04-04||1966-08-26|1971-04-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|2||||||SPLNRESP|SPLEEN RESPONSE||||MG/M2/DAY|NE||DMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|FRIEND|MICROSCOPIST 2|U|2||58||SCREENING|1969-12-12||||1965-01-06||1969-07-24|1969-05-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|1||||||CLINRESP|CLINICAL RESPONSE||||HEP|UNFAVORABLE RESPONSE||FMOL/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|INVESTIGATOR|CLINICAL PATHOLOGIST|N|3||39||BLINDED TREATMENT|1971-12-30||||1972-11-19||1966-10-09|1960-01-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|2||||||TRGRESP|TARGET RESPONSE||||KS|PSA PROGRESSION||L/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|FRIEND|NEUROLOGIST 1|NA|3||39||RUN-IN|1971-05-05||||1972-08-09||1964-10-29|1969-01-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|1||||||LIVRRESP|LIVER RESPONSE||||C|IMMUNOPHENOTYPIC CR||UG/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|4||88||FOLLOW-UP|1971-06-01||||1973-05-29||1973-08-14|1962-05-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MASK|MOLECULAR CR||MG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|ADJUDICATION COMMITTEE|NEUROLOGIST|U|4||88||TREATMENT|1961-01-22||||1969-10-04||1973-08-12|1971-09-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|1||||||LIVRRESP|LIVER RESPONSE||||MG/M2/DAY|PD-CT||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|5||7||FOLLOW-UP|1960-10-26||||1972-04-28||1968-01-05|1965-12-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4395486D-C521-4478-9442-68CF0344C6FB|2||||||LIVRRESP|LIVER RESPONSE||||10^6 CFU|MRD PERSISTENCE||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|PROXY|PEDIATRIC NEUROLOGIST|N|5||7||RUN-IN|1963-06-04||||1965-05-08||1972-03-22|1962-02-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||TMRESP|TUMOR MARKER RESPONSE||||/10^3|IPR||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|INDEPENDENT ASSESSOR|READER 2|Y|1||38||OBSERVATION|1972-02-24||||1966-10-06||1973-02-26|1966-01-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/S|MORPHOLOGIC CR||DPM/0.5 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|CAREGIVER|ONCOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1967-11-10||||1963-10-28||1966-08-01|1963-07-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CAPSULE|NON-CR/NON-PD||G/CAGE/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|2||58||FOLLOW-UP|1971-03-23||||1968-07-23||1964-09-17|1973-06-02||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG|NPR||/10^3|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|DOMESTIC PARTNER|UROLOGIST|N|2||58||SCREENING|1971-01-29||||1967-11-30||1969-03-18|1967-04-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||METSIND|METASTATIC INDICATOR||||ECL UNIT|CYTOGENETIC PR||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|VENDOR|MICROSCOPIST 1|N|3||39||BLINDED TREATMENT|1960-07-08||||1961-11-10||1967-01-30|1962-12-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/G/DAY|COMPLETE MRD RESPONSE||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|ADJUDICATION COMMITTEE|PATHOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1967-10-28||||1969-08-14||1962-10-23|1971-02-20||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BAU|PR||SCM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|SIBLING|ENDOCRINOLOGIST|N|4||88||OBSERVATION|1963-06-10||||1963-02-15||1973-01-17|1967-05-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG|DISEASE TRANSFORMATION||GMFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|FRIEND|NEUROLOGIST 2|Y|4||88||FOLLOW-UP|1971-10-02||||1973-05-29||1972-09-11|1972-11-05||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||TMRESP|TUMOR MARKER RESPONSE||||DNA COPIES/ML|NON-QUANTIFIABLE MRD POSITIVITY||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|N|FRIEND|PATHOLOGIST 2|U|5||7||INDUCTION TREATMENT|1962-03-06||||1964-08-25||1972-04-01|1964-07-31||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CAGE/WK|CYTOGENETIC MINOR RESPONSE||L/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|PROXY|PATHOLOGIST 2|U|5||7||OBSERVATION|1969-12-20||||1961-11-10||1970-11-12|1964-09-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||ANATRESP|ANATOMIC RESPONSE||||TRACE|DISEASE TRANSFORMATION||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|1||38||INDUCTION TREATMENT|1960-09-29||||1969-08-01||1969-10-21|1966-08-18||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CAN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|CHILD|ADJUDICATOR 1|N|1||38||OBSERVATION|1962-01-05||||1972-05-17||1972-10-25|1970-09-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/L|NON-QUANTIFIABLE MRD POSITIVITY||CI/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|DOMESTIC PARTNER|PATHOLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1964-08-05||||1970-08-16||1966-07-31|1960-11-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||TMRESP|TUMOR MARKER RESPONSE||||AMPULE|CYTOGENETIC NO RESPONSE||INHALATION|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|STUDY SUBJECT|NEUROLOGIST|N|2||58||FOLLOW-UP|1969-05-15||||1970-12-21||1966-09-23|1971-05-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/M2/MIN|MR||ML/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|PROXY|FORENSIC PATHOLOGIST|U|3||39||BASELINE|1968-09-03||||1963-11-01||1969-08-22|1965-01-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||NEWLPROG|NEW LESION PROGRESSION||||M3|PD-CT||LOG10 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|VENDOR|PATHOLOGIST|U|3||39||OBSERVATION|1962-06-27||||1972-11-01||1963-06-06|1967-04-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||ANATRESP|ANATOMIC RESPONSE||||UGEQ/L|MOLECULAR CR||DRAM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|4||88||OBSERVATION|1966-08-25||||1969-03-31||1965-01-07|1962-12-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/MIN|TREATMENT FAILURE||SHOCK WAVE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|DOMESTIC PARTNER|ADJUDICATOR 2|Y|4||88||INDUCTION TREATMENT|1970-10-20||||1965-07-24||1970-04-13|1960-11-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||TRGRESP|TARGET RESPONSE||||/WK|PSEUDOPROGRESSION||L/H/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|GUARDIAN|ADJUDICATOR|U|5||7||RUN-IN|1968-09-30||||1973-01-28||1973-07-27|1967-09-19||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||TMRESP|TUMOR MARKER RESPONSE||||KM|NR||ML/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|5||7||OPEN LABEL TREATMENT|1963-02-01||||1973-07-22||1968-02-01|1966-04-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/H|CYTOGENETIC MINIMAL RESPONSE||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|1||38||CONTINUATION TREATMENT|1962-06-11||||1971-09-08||1965-04-16|1973-01-27||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MU|PSEUDORESPONSE||10^6 U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|ADJUDICATOR|NEUROLOGIST 2|N|1||38||BASELINE|1971-01-21||||1960-09-14||1967-10-13|1968-03-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 COPIES/ML|MORPHOLOGIC CRI||DB|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|PROXY|FORENSIC PATHOLOGIST|Y|2||58||TREATMENT|1965-07-12||||1964-01-13||1960-04-02|1972-10-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||CLINRESP|CLINICAL RESPONSE||||MMAL|MOLECULAR MAJOR RESPONSE||UG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|INTERVIEWER|NEUROLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1965-01-15||||1972-06-10||1972-06-12|1965-05-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||STRUSTAT|STEROID USE STATUS||||EIA UNIT|INDETERMINATE RESPONSE||UG/L DDU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|GUARDIAN|ADJUDICATOR|Y|3||39||LONG-TERM FOLLOW-UP|1960-08-28||||1960-01-10||1960-07-13|1965-09-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||APS U|NON-PD||FOZ_BR|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|STUDY SUBJECT|OPTOMETRIST|NA|3||39||FOLLOW-UP|1963-12-28||||1960-03-22||1969-02-26|1965-02-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||SPLNRESP|SPLEEN RESPONSE||||PELLET|OPTIMAL MORPHOLOGIC RESPONSE||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|FRIEND|CLINICAL PATHOLOGIST|U|4||88||WASHOUT|1962-11-04||||1972-04-05||1972-11-11|1965-08-20||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||BONERESP|BONE RESPONSE||||10^3 ORGANISMS/G|ICR||10^6 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|4||88||RUN-IN|1968-04-22||||1964-03-15||1965-06-10|1960-07-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/DL|MRD PERSISTENCE||U/M2/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|SIBLING|CARDIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1973-09-01||||1970-04-06||1960-03-08|1970-07-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||TMRESP|TUMOR MARKER RESPONSE||||L/S/KPA|FAVORABLE RESPONSE||LOG10 TCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|INVESTIGATOR|RATER 2|Y|5||7||OPEN LABEL TREATMENT|1971-06-03||||1961-10-16||1968-04-02|1969-03-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IN|STABLE||VIAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|1||38||CONTINUATION TREATMENT|1973-06-22||||1966-03-07||1970-11-10|1961-10-12||DURING||DURING|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MCI|HI-N||10^6 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|SPOUSE|UROLOGIST|N|1||38||OPEN LABEL TREATMENT|1964-03-19||||1965-07-10||1963-05-10|1965-07-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|1||||||NEWLIND|NEW LESION INDICATOR||||PMOL/DAY|MORPHOLOGIC CRI||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|GUARDIAN|ENDOCRINOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1964-03-26||||1962-12-17||1965-10-27|1967-11-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/10^5|MOLECULAR CR||MEQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|2||58||CONTINUATION TREATMENT|1968-01-10||||1961-07-22||1962-09-01|1973-05-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BAR|CYTOGENETIC NO RESPONSE||LOG10 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|INDEPENDENT ASSESSOR|UROLOGIST|N|3||39||RUN-IN|1969-06-11||||1963-06-24||1968-06-10|1960-09-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|2||||||OVRLRESP|OVERALL RESPONSE||||MNFI|NOT ALL EVALUATED||FFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|3||39||FOLLOW-UP|1972-05-22||||1963-11-16||1971-08-16|1971-08-29||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|1||||||CYTORESP|CYTOGENETIC RESPONSE||||%(V/V)|IUPD||10^6 U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|GUARDIAN|ONCOLOGIST|N|4||88||FOLLOW-UP|1968-04-25||||1967-08-09||1963-06-27|1968-10-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|2||||||NEWLIND|NEW LESION INDICATOR||||IN2|INCREASED||UG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|PARENT|PATHOLOGIST 1|NA|4||88||RUN-IN|1963-12-21||||1970-06-09||1965-01-09|1973-04-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/MIN/MMHG|SD||GPL U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|FAMILY MEMBER|RATER 1|Y|5||7||OBSERVATION|1970-01-21||||1960-02-20||1963-12-18|1969-08-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|19394300-46A6-484F-AE02-50BDD39096E3|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CY/CM|CA125 50% RESPONSE||ML/SEC/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|PARENT|ADJUDICATOR 2|NA|5||7||LONG-TERM FOLLOW-UP|1962-11-04||||1962-07-29||1960-12-15|1961-06-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CY/CM|COMPLETE MRD RESPONSE||UKAT/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1||38||BASELINE|1968-04-04||||1960-08-11||1962-06-20|1971-01-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||MOLRESP|MOLECULAR RESPONSE||||CP|MAJOR PATHOLOGIC RESPONSE||UV2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|SPOUSE|ENDOCRINOLOGIST|N|1||38||FOLLOW-UP|1967-10-11||||1966-03-12||1970-09-05|1968-10-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||BESTRESP|BEST OVERALL RESPONSE||||NKAT/G HB|CMR||LOZENGE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|2||58||SCREENING|1972-01-22||||1961-07-15||1960-07-15|1960-08-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 ELISA UNIT/DOSE|MORPHOLOGIC CR||10^12 IU/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1969-07-19||||1970-10-10||1973-03-08|1960-08-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/G/H|HI-N||/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|VENDOR|CLINICAL PATHOLOGIST|N|3||39||TREATMENT|1967-07-01||||1961-06-26||1966-06-02|1962-10-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||OVRLRESP|OVERALL RESPONSE||||L/MIN/M2|MOLECULAR CR||K|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|STUDY SUBJECT|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1962-06-16||||1960-04-30||1965-05-09|1971-06-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||MOLRESP|MOLECULAR RESPONSE||||TAMPON|CPR||L/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|DOMESTIC PARTNER|OTOLARYNGOLOGIST|U|4||88||BASELINE|1964-01-24||||1964-09-22||1970-02-20|1960-02-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||METBRESP|METABOLIC RESPONSE||||PMOL/L|NON-ICR/NON-IUPD||UG/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|SPOUSE|CLINICAL PATHOLOGIST|Y|4||88||CONTINUATION TREATMENT|1969-11-02||||1968-01-02||1969-11-23|1963-01-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||BESTRESP|BEST OVERALL RESPONSE||||BQ/MG|MCR||CP|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|INTERVIEWER|ONCOLOGIST|N|5||7||OBSERVATION|1971-12-30||||1968-10-15||1968-10-28|1971-07-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UKAT|IMMUNOPHENOTYPIC CR||LOG10 COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|5||7||TREATMENT|1962-05-16||||1972-01-28||1961-10-22|1972-08-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||METBRESP|METABOLIC RESPONSE||||10^6 CFU/ML|SMD||DEG/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|1||38||TREATMENT|1960-03-06||||1971-06-17||1966-10-14|1965-09-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMU/ML|HI-N||DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|ADJUDICATOR|UROLOGIST|Y|1||38||WASHOUT|1967-08-20||||1968-03-10||1972-08-09|1969-08-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BE/ML|INDETERMINATE RESPONSE||KG/CM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|VENDOR|DERMATOLOGIST|U|2||58||OBSERVATION|1962-08-31||||1969-09-11||1972-02-11|1966-11-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||/HPF|DECREASED||U/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|VENDOR|READER 1|N|2||58||SCREENING|1972-12-11||||1964-10-31||1971-07-14|1964-11-28||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CMHG|CMR||IU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|INTERVIEWER|DERMATOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1964-04-21||||1973-06-26||1967-03-19|1960-11-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^9 ORGANISMS/MG|NE||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|3||39||CONTINUATION TREATMENT|1971-07-05||||1965-10-26||1960-11-27|1968-04-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||L/L|IUPD||MOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|ADJUDICATOR|RADIOLOGIST 2|N|4||88||CONTINUATION TREATMENT|1962-12-27||||1969-07-10||1970-10-17|1965-04-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||STRUSTAT|STEROID USE STATUS||||MS/MMHG|RELAPSED DISEASE||AMP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|INDEPENDENT ASSESSOR|MICROSCOPIST|U|4||88||WASHOUT|1969-12-06||||1963-03-17||1963-12-20|1965-10-14||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||METBRESP|METABOLIC RESPONSE||||MMOL|INCREASED||PG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|CAREGIVER|ONCOLOGIST 2|N|5||7||INDUCTION TREATMENT|1969-02-03||||1971-06-11||1969-11-11|1971-06-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NFIU|PD/RELAPSE AFTER HI||10^8/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|CAREGIVER|READER|U|5||7||INDUCTION TREATMENT|1962-06-14||||1971-03-02||1973-06-04|1967-01-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||CLINRESP|CLINICAL RESPONSE||||KM|CR-CT||FOZ_US|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|SIBLING|PEDIATRIC NEUROLOGIST|U|1||38||INDUCTION TREATMENT|1961-05-08||||1963-02-16||1960-03-12|1972-07-22||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NG/DL|MRD NEGATIVITY||IU/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 2|Y|1||38||BLINDED TREATMENT|1973-03-05||||1961-04-09||1970-03-22|1964-07-01||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TROCHE|FAVORABLE RESPONSE||ML/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|PARENT|NEUROLOGIST 1|U|2||58||SCREENING|1967-12-05||||1973-01-21||1965-01-11|1961-12-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||ANATRESP|ANATOMIC RESPONSE||||CI/L|PMR||POUCH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|GUARDIAN|PATHOLOGIST|Y|2||58||SCREENING|1972-11-12||||1960-09-30||1963-04-24|1972-01-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GTT|NOT ALL EVALUATED||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|INTERVIEWER|UROLOGIST|Y|3||39||OBSERVATION|1970-08-07||||1965-04-23||1960-09-13|1964-09-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||CLINRESP|CLINICAL RESPONSE||||MM/SEC|OPTIMAL MORPHOLOGIC RESPONSE||DPM/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-07-22||||1964-01-16||1972-02-26|1969-04-09||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||LIVRRESP|LIVER RESPONSE||||CD*S/M2|SD||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|PROXY|ONCOLOGIST 1|N|4||88||TREATMENT|1962-06-01||||1973-08-05||1961-04-02|1962-06-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KBQ|SMD||U/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|VENDOR|CLINICAL PATHOLOGIST|U|4||88||BASELINE|1965-10-19||||1965-03-21||1972-10-24|1971-06-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BOWL|CR-CT||MCI/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|5||7||FOLLOW-UP|1971-02-24||||1969-10-22||1962-10-25|1960-11-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||LIVRRESP|LIVER RESPONSE||||10^4/HPF|SD-CT||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|5||7||CONTINUATION TREATMENT|1970-04-07||||1973-04-24||1961-04-24|1968-04-20||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MILE|PR-CT||MM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|1||38||RUN-IN|1972-11-25||||1964-11-29||1963-07-29|1961-12-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2|CMR||PMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|STUDY SUBJECT|NEUROLOGIST 2|NA|1||38||TREATMENT|1973-07-05||||1962-05-12||1962-09-03|1960-07-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|1||||||BESTRESP|BEST OVERALL RESPONSE||||MEQ/KG|ABSENT MORPHOLOGIC RESPONSE||10^9 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|U|2||58||CONTINUATION TREATMENT|1971-11-25||||1960-07-11||1971-03-06|1960-06-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||STEPS/MIN|NOT ALL EVALUATED||KIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|STUDY SUBJECT|DERMATOLOGIST|U|2||58||OBSERVATION|1961-11-29||||1969-11-17||1966-09-23|1969-04-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|1||||||OVRLRESP|OVERALL RESPONSE||||%(W/W)|PDU||CY/CM|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|INVESTIGATOR|FORENSIC PATHOLOGIST|N|3||39||TREATMENT|1970-06-01||||1971-10-06||1964-09-01|1962-11-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PG|PSEUDOPROGRESSION||OSM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|SIBLING|OTOLARYNGOLOGIST|NA|3||39||BLINDED TREATMENT|1972-02-02||||1970-06-18||1965-10-21|1963-08-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|1||||||NEWLIND|NEW LESION INDICATOR||||NKAT/G HB|MR||MMOL/MIN/KPA/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|4||88||WASHOUT|1962-09-17||||1960-12-01||1964-10-13|1971-09-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|2||||||ANATRESP|ANATOMIC RESPONSE||||PMOL/10^10 CELLS|CR-CT||MN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|DOMESTIC PARTNER|MICROSCOPIST|U|4||88||OPEN LABEL TREATMENT|1971-05-19||||1961-04-16||1973-06-20|1967-12-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||%(W/W)|PCR||ML/CM3/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|5||7||BLINDED TREATMENT|1961-07-29||||1968-08-01||1960-01-01|1960-06-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|04F5220E-7A8C-4982-9379-496306612E33|2||||||BESTRESP|BEST OVERALL RESPONSE||||L/S|RELAPSED DISEASE FROM CR OR PR||MPL U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|5||7||INDUCTION TREATMENT|1961-07-31||||1963-11-26||1971-05-25|1970-10-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 U|NED||UV*SEC|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|1||38||OPEN LABEL TREATMENT|1966-03-03||||1969-05-11||1960-11-10|1963-09-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/SEC/1.73M2|CPR||% INHIBITION|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INTERVIEWER|OTOLARYNGOLOGIST|Y|1||38||OBSERVATION|1962-10-29||||1969-01-14||1965-08-25|1971-01-06||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||OVRLRESP|OVERALL RESPONSE||||NG/L|NOT ALL EVALUATED||ML/BEAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|SPOUSE|ADJUDICATOR|NA|2||58||FOLLOW-UP|1966-12-31||||1967-01-04||1962-01-19|1969-03-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NG/L|SCR||U/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|STUDY SUBJECT|OPHTHALMOLOGIST|NA|2||58||WASHOUT|1967-10-06||||1960-03-24||1969-05-15|1971-04-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DDU|ISD||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|RATER 2|N|3||39||BASELINE|1960-08-06||||1962-04-05||1962-07-05|1961-10-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||DPM/ML|PD FROM PR||DDU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|INVESTIGATOR|MICROSCOPIST|Y|3||39||RUN-IN|1967-05-30||||1962-12-16||1966-06-05|1962-03-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CI/ML|DISEASE TRANSFORMATION||UG/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|FRIEND|READER 2|N|4||88||SCREENING|1972-05-02||||1966-02-19||1966-08-15|1972-03-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||CYTORESP|CYTOGENETIC RESPONSE||||AMU|MR||OZ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||RUN-IN|1963-06-08||||1969-03-20||1968-02-16|1971-06-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PT_BR|CYTOGENETIC MINIMAL RESPONSE||10^3 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|CHILD|OTOLARYNGOLOGIST|N|5||7||TREATMENT|1971-11-12||||1969-08-23||1963-02-27|1967-08-04||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||BESTRESP|BEST OVERALL RESPONSE||||MIU/L|CYTOGENETIC MINIMAL RESPONSE||RNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|INVESTIGATOR|ONCOLOGIST|N|5||7||OPEN LABEL TREATMENT|1967-12-30||||1971-04-23||1971-09-03|1971-10-27||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PPM|PMR||/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|1||38||TREATMENT|1964-11-18||||1961-08-24||1972-11-25|1963-07-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||NEWLPROG|NEW LESION PROGRESSION||||ML/CM H2O|NOT ALL EVALUATED||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|SIBLING|ADJUDICATOR 1|U|1||38||RUN-IN|1971-02-12||||1964-08-27||1965-07-24|1972-01-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||NTRGRESP|NON-TARGET RESPONSE||||MG/KG|CYTOGENETIC MINOR RESPONSE||10^6/EJACULATE U|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|2||58||TREATMENT|1961-04-17||||1973-09-02||1962-04-20|1967-11-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MOL/ML|CYTOGENETIC PR||HZ/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|2||58||SCREENING|1966-02-27||||1972-11-04||1973-02-17|1969-06-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CY/CM|INDETERMINATE RESPONSE||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|ADJUDICATOR|OTOLARYNGOLOGIST|N|3||39||BASELINE|1969-05-22||||1972-10-18||1973-05-07|1961-06-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MPL U/ML|PMD||NMOL/L/H|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|SIBLING|MICROSCOPIST 3|U|3||39||SCREENING|1969-03-20||||1961-11-14||1967-08-22|1962-03-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||ANATRESP|ANATOMIC RESPONSE||||SCM|PD/RELAPSE AFTER HI||UG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|4||88||SCREENING|1961-04-15||||1961-11-15||1972-11-10|1964-03-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||MOLRESP|MOLECULAR RESPONSE||||G/L|RELAPSED DISEASE FROM CR||HPA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|STUDY SUBJECT|RATER 1|NA|4||88||WASHOUT|1961-09-09||||1961-09-20||1970-01-09|1967-12-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/200 HPFS|COMPLETE MRD RESPONSE||VG/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|5||7||TREATMENT|1969-08-24||||1962-08-01||1960-05-17|1962-11-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||TRGRESP|TARGET RESPONSE||||10^3 ORGANISMS/ML|CPR||U/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|5||7||FOLLOW-UP|1961-11-01||||1960-07-29||1960-07-18|1972-02-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||CLINRESP|CLINICAL RESPONSE||||TUBE|TREATMENT FAILURE||LOG10 ELISA UNIT|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|CHILD|OTOLARYNGOLOGIST|Y|1||38||SCREENING|1966-04-27||||1973-06-19||1972-12-22|1968-02-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||SPLNRESP|SPLEEN RESPONSE||||KUSP|PARTIAL MORPHOLOGIC RESPONSE||10^7 TCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|CAREGIVER|READER 2|Y|1||38||INDUCTION TREATMENT|1969-09-11||||1964-06-24||1960-02-24|1972-11-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CAL|PARTIAL MORPHOLOGIC RESPONSE||JOULE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|DOMESTIC PARTNER|ONCOLOGIST 2|NA|2||58||OBSERVATION|1964-03-30||||1965-11-09||1966-09-16|1971-11-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||BONERESP|BONE RESPONSE||||BISCUIT|PCR||U/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|PROXY|PATHOLOGIST 1|Y|2||58||WASHOUT|1967-12-05||||1961-05-02||1961-09-01|1970-05-19||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||STRUSTAT|STEROID USE STATUS||||ML/MIN/1.73M2|HI-E||CGY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|PARENT|MICROSCOPIST 1|U|3||39||OBSERVATION|1965-02-13||||1970-05-20||1972-12-25|1965-06-27||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||METBRESP|METABOLIC RESPONSE||||CI/ML|CYTOGENETIC CR||MOSM/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||OPEN LABEL TREATMENT|1970-05-23||||1968-08-04||1964-09-01|1962-07-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BLOCKS|MRD RELAPSE||FARAD|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|FRIEND|MICROSCOPIST 2|Y|4||88||OBSERVATION|1960-11-07||||1966-10-04||1960-07-03|1973-02-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||STRUSTAT|STEROID USE STATUS||||UEQ/L|PSEUDORESPONSE||ML/S/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1966-05-30||||1971-09-13||1972-08-04|1971-10-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BOTTLE|CYTOGENETIC MINOR RESPONSE||ML/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|GUARDIAN|RADIOLOGIST 2|NA|5||7||BASELINE|1961-03-20||||1965-09-28||1965-04-07|1972-12-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UU/DL|STABLE||CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|GUARDIAN|OPTOMETRIST|NA|5||7||SCREENING|1971-08-18||||1973-06-18||1961-06-08|1971-03-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||ANATRESP|ANATOMIC RESPONSE||||10^6 ORGANISMS/ML|NOT ALL EVALUATED||BQ/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|INTERVIEWER|CLINICAL PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-03-16||||1964-01-29||1962-10-12|1970-11-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2/H|CYTOGENETIC MINOR RESPONSE||NKAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|SIBLING|READER 2|Y|1||38||SCREENING|1966-08-26||||1966-02-12||1966-05-15|1972-01-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||METBRESP|METABOLIC RESPONSE||||MMOL/MIN/KPA/L|CYTOGENETIC CR||ML/CM H2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|2||58||OPEN LABEL TREATMENT|1967-01-21||||1973-01-24||1968-08-14|1963-09-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||BONERESP|BONE RESPONSE||||MAC50|HI-N||G/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|PROXY|READER 1|NA|2||58||WASHOUT|1962-04-15||||1966-07-18||1966-06-23|1965-11-24||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||MOLRESP|MOLECULAR RESPONSE||||ML/CM|PD||IU/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|CHILD|ADJUDICATOR|N|3||39||WASHOUT|1965-01-21||||1964-08-21||1965-04-24|1970-02-02||DURING||DURING|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KPA|MORPHOLOGIC CR||KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|VENDOR|ADJUDICATOR 3|N|3||39||RUN-IN|1960-01-01||||1968-10-14||1972-06-28|1972-11-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||MOLRESP|MOLECULAR RESPONSE||||/40 HPFS|MORPHOLOGIC LEUKEMIA-FREE STATE||COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4||88||LONG-TERM FOLLOW-UP|1961-06-18||||1970-09-23||1960-09-11|1970-12-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CI/G|DISEASE TRANSFORMATION||MEQ/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|PARENT|MICROSCOPIST 2|NA|4||88||OBSERVATION|1973-06-15||||1964-03-16||1967-03-16|1962-01-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||MOLRESP|MOLECULAR RESPONSE||||HOURS|PMD||APPLICATION|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|SPOUSE|RATER 2|N|5||7||TREATMENT|1964-10-03||||1967-07-09||1967-02-16|1964-01-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6 ORGANISMS/G|PD/RELAPSE AFTER HI||OZ EQ|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|CAREGIVER|MICROSCOPIST|Y|5||7||CONTINUATION TREATMENT|1973-02-21||||1965-08-26||1963-12-05|1960-03-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||METBRESP|METABOLIC RESPONSE||||GPL U/ML|ICR||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|1||38||OBSERVATION|1964-06-21||||1963-12-12||1965-01-01|1962-06-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DEG/MM|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||INHALATION|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|VENDOR|MICROSCOPIST 3|N|1||38||SCREENING|1973-05-29||||1963-08-20||1971-12-17|1972-09-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BREATHS/30S|PD FROM PR||G/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|FRIEND|FORENSIC PATHOLOGIST|N|2||58||FOLLOW-UP|1968-08-14||||1970-06-30||1963-12-19|1973-06-19||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||METSIND|METASTATIC INDICATOR||||GBQ/G|VGPR||FARAD|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|CHILD|RATER|NA|2||58||TREATMENT|1960-08-11||||1969-08-23||1961-08-16|1961-10-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PA|CCR||NMOL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|VENDOR|DERMATOLOGIST|NA|3||39||RUN-IN|1961-04-14||||1970-07-21||1967-08-22|1968-12-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||LIVRRESP|LIVER RESPONSE||||FARAD|NPR||LB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|DOMESTIC PARTNER|PATHOLOGIST 1|U|3||39||FOLLOW-UP|1964-03-13||||1967-01-17||1969-01-23|1962-05-13||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^6 IU/ML|PCR||MMHG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|PROXY|PATHOLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1963-02-27||||1973-06-19||1965-04-07|1968-10-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/KG/DAY|PSA PROGRESSION||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|4||88||SCREENING|1972-04-01||||1968-10-11||1962-07-18|1970-09-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L/H|RELAPSED DISEASE FROM CR||ML/CM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5||7||INDUCTION TREATMENT|1973-07-13||||1970-01-03||1965-05-05|1961-11-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||VIRTUAL PIXEL|VGPR||PPTH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|CAREGIVER|MICROSCOPIST|NA|5||7||TREATMENT|1966-09-24||||1962-02-14||1966-01-11|1960-03-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/M2/H|PSA PROGRESSION||MOSM/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIBLING|RADIOLOGIST 2|U|1||38||WASHOUT|1962-04-29||||1963-03-19||1967-10-11|1972-06-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/ML/H|HI-N||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST|NA|1||38||OBSERVATION|1960-06-27||||1964-02-29||1960-04-18|1963-12-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||SPLNRESP|SPLEEN RESPONSE||||10^3 CFU/ML|NON-ICR/NON-IUPD||/VF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|STUDY SUBJECT|DERMATOLOGIST|Y|2||58||WASHOUT|1960-03-30||||1963-06-22||1971-12-22|1969-07-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SYRINGE|CYTOGENETIC CR||TRACE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|SIGNIFICANT OTHER|ADJUDICATOR 1|N|2||58||LONG-TERM FOLLOW-UP|1961-05-14||||1960-03-07||1963-01-08|1961-04-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^7/L|WORSENED||TESLA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|PARENT|PEDIATRIC NEUROLOGIST|N|3||39||CONTINUATION TREATMENT|1963-10-20||||1971-11-04||1960-09-16|1970-07-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||PATHRESP|PATHOLOGIC RESPONSE||||INHALATION|WORSENED||NU/CL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|GUARDIAN|DERMATOLOGIST|N|3||39||BLINDED TREATMENT|1966-10-13||||1960-08-02||1967-03-24|1964-05-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||NEWLPROG|NEW LESION PROGRESSION||||U/KG|TREATMENT FAILURE||GBQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|4||88||SCREENING|1961-04-29||||1971-05-04||1967-01-22|1963-11-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MEQ/UL|DECREASED||ML/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|4||88||SCREENING|1964-09-27||||1968-08-04||1964-12-30|1973-03-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||CLINRESP|CLINICAL RESPONSE||||JDF UNIT|SD||ML/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|SIBLING|ONCOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1963-01-04||||1967-11-30||1962-11-07|1969-06-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||SPLNRESP|SPLEEN RESPONSE||||10^7 CFU|ICR||NMOL BCE/L|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|VENDOR|NEUROLOGIST 2|U|5||7||TREATMENT|1961-02-21||||1971-06-16||1969-12-25|1969-11-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||TRGRESP|TARGET RESPONSE||||MPL U|EQUIVOCAL||/10^5|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|1||38||OBSERVATION|1972-10-19||||1973-04-13||1960-10-12|1960-09-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UKAT/L|CYTOGENETIC MINOR RESPONSE||10^10/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|1||38||OBSERVATION|1971-05-04||||1967-11-08||1966-01-01|1961-09-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BQ|STABLE||UCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|2||58||FOLLOW-UP|1968-01-13||||1965-11-06||1964-09-22|1969-12-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||NEWLPROG|NEW LESION PROGRESSION||||DDU|MRD PERSISTENCE||%(W/V)|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|HEALTH CARE PROFESSIONAL|RATER 2|NA|2||58||OPEN LABEL TREATMENT|1962-03-24||||1966-03-06||1963-11-02|1965-04-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||USEC|PCR||ENZYME U/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||SCREENING|1973-02-06||||1960-08-11||1964-07-09|1970-03-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||TMRESP|TUMOR MARKER RESPONSE||||VG/KG|INDETERMINATE RESPONSE||U/KG/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|FAMILY MEMBER|MICROSCOPIST|Y|3||39||BLINDED TREATMENT|1971-05-19||||1963-01-02||1960-04-24|1960-02-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/UG|COMPLETE MRD RESPONSE||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|FRIEND|RADIOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1962-03-18||||1961-04-10||1961-05-23|1963-12-27||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DMOL|PR-CT||/100 HPFS|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|SIGNIFICANT OTHER|UROLOGIST|N|4||88||BLINDED TREATMENT|1963-01-23||||1966-06-06||1960-06-23|1968-03-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/MM|CYTOGENETIC NO RESPONSE||SV|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|FRIEND|ONCOLOGIST 2|NA|5||7||WASHOUT|1961-09-14||||1967-01-16||1960-01-29|1971-06-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^4 CFU/ML|CMR||TESLA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1960-02-10||||1971-03-12||1962-11-06|1971-09-04||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UCI/L|DECREASED||DRAM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1||38||BLINDED TREATMENT|1968-10-14||||1971-06-11||1969-04-18|1964-04-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PA|IMMUNOPHENOTYPIC CR||MG/L FEU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|GUARDIAN|OPTOMETRIST|NA|1||38||OPEN LABEL TREATMENT|1968-08-26||||1971-04-26||1971-11-16|1967-02-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/S/M2|INCREASED||10^3 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|SIBLING|MICROSCOPIST 2|NA|2||58||INDUCTION TREATMENT|1971-04-07||||1970-04-23||1960-10-29|1973-02-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||SPLNRESP|SPLEEN RESPONSE||||ML/G/H|PR||/LPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|2||58||OPEN LABEL TREATMENT|1960-02-15||||1960-09-26||1967-12-23|1971-08-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||SPLNRESP|SPLEEN RESPONSE||||10^9 ORGANISMS/ML|DECREASED||CD|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|ADJUDICATOR|READER|Y|3||39||SCREENING|1972-12-30||||1965-06-17||1969-06-01|1963-04-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%/S|IMMUNOPHENOTYPIC CR||TAMPON|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|VENDOR|CARDIOLOGIST|Y|3||39||WASHOUT|1960-11-22||||1965-05-02||1965-12-18|1967-02-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/LSQN|NED||S^-1(%O2)^-1|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|INVESTIGATOR|ADJUDICATOR|NA|4||88||OPEN LABEL TREATMENT|1960-11-02||||1969-05-25||1961-09-24|1973-05-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||ANATRESP|ANATOMIC RESPONSE||||NMOL BCE/L|IMPROVED||L/H/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|PARENT|FORENSIC PATHOLOGIST|N|4||88||OPEN LABEL TREATMENT|1964-12-29||||1971-01-17||1966-04-25|1961-10-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/ML|HI-N||CAN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|INDEPENDENT ASSESSOR|DERMATOLOGIST|N|5||7||RUN-IN|1972-03-12||||1967-03-21||1967-03-28|1971-01-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||STRUSTAT|STEROID USE STATUS||||CM|SMD||PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1964-09-17||||1969-07-07||1970-02-20|1965-11-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CFU/G|PR-CT||MMHG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|ADJUDICATOR|MICROSCOPIST|U|1||38||CONTINUATION TREATMENT|1973-05-20||||1971-12-22||1968-05-02|1961-06-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DAYS/WK|ISD||MG/ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|SIBLING|PATHOLOGIST 1|NA|1||38||RUN-IN|1961-02-11||||1963-03-31||1967-03-26|1962-06-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KUSP|CPR||V/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|INDEPENDENT ASSESSOR|READER 1|Y|2||58||BLINDED TREATMENT|1960-10-18||||1973-06-06||1973-06-18|1973-07-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||MOLRESP|MOLECULAR RESPONSE||||PIPE|MAJOR PATHOLOGIC RESPONSE||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|ADJUDICATOR|RADIOLOGIST 2|NA|2||58||FOLLOW-UP|1964-10-01||||1972-08-21||1961-09-26|1970-07-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||NTRGRESP|NON-TARGET RESPONSE||||UG/G/DAY|IPR||MOL/MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|SIBLING|PHYSIOTHERAPIST|U|3||39||LONG-TERM FOLLOW-UP|1967-05-17||||1969-10-27||1962-07-24|1968-03-03||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||1/(S*KPA)|PARTIAL MORPHOLOGIC RESPONSE||GPS U|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|INVESTIGATOR|OPHTHALMOLOGIST|U|3||39||BASELINE|1971-05-14||||1962-05-27||1964-01-09|1969-12-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CYCLE/MIN|RELAPSED DISEASE FROM CR||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|FRIEND|RADIOLOGIST|NA|4||88||RUN-IN|1973-08-12||||1970-03-24||1963-11-09|1967-10-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/M2|PD-CT||KCAL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|4||88||INDUCTION TREATMENT|1973-04-22||||1966-08-30||1967-04-23|1963-04-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||LIVRRESP|LIVER RESPONSE||||OSM|INCREASED||CG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|CAREGIVER|MICROSCOPIST 2|Y|5||7||SCREENING|1966-03-16||||1971-02-14||1968-03-25|1969-02-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 TCID 50/ML|MRD PERSISTENCE||MCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|FRIEND|OPTOMETRIST|NA|5||7||WASHOUT|1966-10-19||||1963-05-12||1973-07-29|1968-02-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||SPLNRESP|SPLEEN RESPONSE||||L/DAY|NE||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1||38||RUN-IN|1971-05-09||||1967-04-12||1971-06-09|1972-08-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||FMOL/G|PCR||SUPPOSITORY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|STUDY SUBJECT|READER 3|U|1||38||LONG-TERM FOLLOW-UP|1967-07-10||||1971-01-07||1973-03-15|1962-04-19||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^9 CFU/ML|NON-PD||10^3 ORGANISMS/G|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|SIGNIFICANT OTHER|HEMATOLOGIST|NA|2||58||SCREENING|1963-12-12||||1965-04-29||1973-01-09|1963-05-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CMH2O*S/ML|PSEUDORESPONSE||LOG10 PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|DOMESTIC PARTNER|ADJUDICATOR|NA|2||58||RUN-IN|1962-01-18||||1964-06-19||1960-07-22|1968-11-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||METSIND|METASTATIC INDICATOR||||AFU|MORPHOLOGIC LEUKEMIA-FREE STATE||MNFI|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1962-02-18||||1965-12-29||1968-08-10|1973-06-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UU/L|NPR||GBQ/UG|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|INDEPENDENT ASSESSOR|INTERNIST|U|3||39||TREATMENT|1970-12-24||||1972-07-03||1969-01-12|1965-07-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE/WK|CHR||MESF|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|INTERVIEWER|ENDOCRINOLOGIST|N|4||88||FOLLOW-UP|1965-07-15||||1963-11-02||1961-06-19|1969-04-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||SPLNRESP|SPLEEN RESPONSE||||U/ML|DISEASE TRANSFORMATION||PIXEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|4||88||SCREENING|1962-09-20||||1963-04-22||1970-04-09|1968-07-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CFU/G|PD/RELAPSE AFTER HI||G/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|5||7||INDUCTION TREATMENT|1970-07-30||||1963-10-12||1971-01-12|1961-04-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/G|IMPROVED||10^4/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1971-08-02||||1964-02-10||1965-11-24|1969-05-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BOWL|COMPLETE MRD RESPONSE||LOG10 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|1||38||OBSERVATION|1970-04-12||||1968-03-23||1971-11-20|1960-12-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DPM/ML|CYTOGENETIC PR||MEQ/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|SIBLING|READER|N|1||38||RUN-IN|1969-08-12||||1966-03-13||1968-06-20|1967-05-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||HPA|CA125 75% RESPONSE||ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|FRIEND|RADIOLOGIST|U|2||58||SCREENING|1972-05-17||||1972-08-06||1965-11-24|1962-03-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||NTRGRESP|NON-TARGET RESPONSE||||BQ/UL|RELAPSED DISEASE||CI/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|SPOUSE|MICROSCOPIST 3|Y|2||58||BLINDED TREATMENT|1960-04-14||||1967-04-04||1964-07-09|1969-01-24||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||METSIND|METASTATIC INDICATOR||||G/ANIMAL|PSEUDOPROGRESSION||G/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|3||39||FOLLOW-UP|1972-03-09||||1963-12-20||1971-04-05|1972-11-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CUP EQ|CA125 50% RESPONSE||TUBERCULIN UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|PROXY|READER 3|U|3||39||LONG-TERM FOLLOW-UP|1971-06-21||||1963-07-24||1960-10-22|1970-09-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||STRUSTAT|STEROID USE STATUS||||G/L|MAJOR PATHOLOGIC RESPONSE||UCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|SPOUSE|MICROSCOPIST|NA|4||88||TREATMENT|1967-01-19||||1969-09-15||1965-04-17|1969-12-22||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||HOUNSFIELD UNIT|UNEQUIVOCAL||10^6 IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|INTERVIEWER|ONCOLOGIST|Y|4||88||CONTINUATION TREATMENT|1967-02-25||||1965-09-18||1970-08-20|1960-07-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UG/DL|IMMUNOPHENOTYPIC CR||NU/CL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|CAREGIVER|READER|Y|5||7||TREATMENT|1965-09-24||||1973-03-17||1965-09-06|1968-12-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 U|MINOR PATHOLOGIC RESPONSE||LOG10 IU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|GUARDIAN|ONCOLOGIST|U|5||7||OPEN LABEL TREATMENT|1964-07-04||||1965-09-18||1970-01-18|1970-05-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||OVRLRESP|OVERALL RESPONSE||||U|PD-CT||BQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|SPOUSE|PATHOLOGIST|U|1||38||SCREENING|1961-01-03||||1963-06-15||1968-02-02|1969-02-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||MOLRESP|MOLECULAR RESPONSE||||/100 WBC|PMR||GAUSS|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|PARENT|FORENSIC PATHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1970-03-21||||1965-09-23||1961-07-04|1965-07-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||STRUSTAT|STEROID USE STATUS||||MG/KG/MIN|NON-QUANTIFIABLE MRD POSITIVITY||FOZ_US|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|SIBLING|CLINICAL PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1960-02-29||||1973-03-13||1967-12-24|1972-07-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FL|CCR||L/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|CHILD|ONCOLOGIST 1|NA|2||58||BLINDED TREATMENT|1970-07-09||||1966-03-16||1967-08-21|1961-09-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||METSIND|METASTATIC INDICATOR||||UMOL/MOL|PD-CT||MS2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||BLINDED TREATMENT|1970-11-15||||1964-03-09||1964-10-10|1966-11-03||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||MOLRESP|MOLECULAR RESPONSE||||KBQ/UL|MORPHOLOGIC CR||L/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|CHILD|ENDOCRINOLOGIST|N|3||39||TREATMENT|1963-03-11||||1964-10-05||1960-12-23|1965-05-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^6/L|PDU||NG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|VENDOR|MICROSCOPIST 2|N|4||88||CONTINUATION TREATMENT|1971-09-01||||1967-07-07||1967-09-15|1972-04-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ANTI-XA IU|NON-ICR/NON-IUPD||NMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|CHILD|RADIOLOGIST|U|4||88||FOLLOW-UP|1966-11-04||||1967-05-21||1968-08-31|1967-10-03||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UGEQ/L|IPR||YD|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|SIGNIFICANT OTHER|OPTOMETRIST|N|5||7||CONTINUATION TREATMENT|1962-04-24||||1961-07-07||1963-06-07|1964-02-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CMH2O*S/ML|SD||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|SIGNIFICANT OTHER|READER 1|N|5||7||INDUCTION TREATMENT|1960-02-17||||1960-10-24||1967-01-06|1966-09-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|1||||||LIVRRESP|LIVER RESPONSE||||MM/SEC|SCR||PG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|SPOUSE|OPTOMETRIST|NA|1||38||BASELINE|1969-01-10||||1969-02-20||1968-04-02|1967-08-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/KG/WEEK|CPR||%/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|INTERVIEWER|MICROSCOPIST 2|U|1||38||INDUCTION TREATMENT|1965-08-12||||1973-04-21||1969-10-04|1968-01-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|1||||||SPLNRESP|SPLEEN RESPONSE||||MASK|NON-CR/NON-PD||MG/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CAREGIVER|FORENSIC PATHOLOGIST|N|2||58||FOLLOW-UP|1965-04-28||||1964-06-18||1964-06-21|1971-05-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GRAVITATIONAL UNIT|ISD||U/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|CHILD|CLINICAL PATHOLOGIST|Y|2||58||WASHOUT|1963-01-14||||1965-07-23||1965-05-31|1971-11-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/DAY|MRD RELAPSE||MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INVESTIGATOR|MICROSCOPIST 1|U|3||39||OBSERVATION|1973-04-03||||1970-09-29||1960-10-12|1966-12-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|2||||||OVRLRESP|OVERALL RESPONSE||||MET|INCREASED||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1963-11-14||||1969-09-06||1973-03-04|1966-12-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/M2/DAY|PR WITH LYMPHOCYTOSIS||%|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||CONTINUATION TREATMENT|1968-08-23||||1962-04-22||1962-09-19|1963-06-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|2||||||NEWLIND|NEW LESION INDICATOR||||UG/KG/DAY|SMD||BAU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|SPOUSE|READER 3|NA|4||88||TREATMENT|1971-04-18||||1966-01-10||1961-12-29|1971-07-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/M2|PSEUDORESPONSE||G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|CLINICAL RESEARCH COORDINATOR|READER|Y|5||7||LONG-TERM FOLLOW-UP|1962-07-20||||1962-08-26||1965-11-30|1969-09-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E884C56C-1612-49CC-A594-B65E7B354842|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/G|MRD NEGATIVITY||UCI/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|SPOUSE|MICROSCOPIST|Y|5||7||LONG-TERM FOLLOW-UP|1972-03-25||||1962-05-23||1968-09-14|1972-07-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^3 DNA COPIES/ML|NON-CR/NON-PD||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|VENDOR|MICROSCOPIST 1|Y|1||38||INDUCTION TREATMENT|1965-12-29||||1966-09-04||1973-01-11|1969-08-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/MIN/KPA/L|HI-N||CS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|1||38||RUN-IN|1963-12-19||||1967-02-01||1963-03-24|1963-10-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||SACHET|CMR||/MM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|2||58||OPEN LABEL TREATMENT|1968-10-07||||1973-08-26||1964-07-30|1965-03-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||NTRGRESP|NON-TARGET RESPONSE||||DAYS/MONTH|PSEUDORESPONSE||MG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||OPEN LABEL TREATMENT|1965-01-25||||1962-07-01||1966-01-06|1962-04-09||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PT_BR|PR-CT||AMU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|VENDOR|ADJUDICATOR|U|3||39||CONTINUATION TREATMENT|1961-02-28||||1961-04-16||1967-10-19|1960-10-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/MOL|HI-P||U/MMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|PROXY|NEUROLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1968-12-15||||1962-02-01||1971-11-21|1964-03-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||METSIND|METASTATIC INDICATOR||||CAL|PD-CT||G/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|GUARDIAN|ENDOCRINOLOGIST|U|4||88||SCREENING|1960-01-02||||1964-03-25||1960-07-12|1967-11-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/500 WBC|NOT ALL EVALUATED||/VF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|CAREGIVER|READER|Y|4||88||OBSERVATION|1968-01-16||||1970-07-04||1971-04-13|1970-11-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||METSIND|METASTATIC INDICATOR||||GBQ|RELAPSED DISEASE FROM CR OR PR||RPM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|ADJUDICATOR|READER 2|Y|5||7||RUN-IN|1964-09-02||||1971-11-24||1964-08-02|1972-03-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EJACULATE U|RELAPSED DISEASE FROM CR OR PR||10^3/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|FRIEND|ADJUDICATOR 2|NA|5||7||RUN-IN|1966-10-22||||1964-08-06||1967-08-13|1961-07-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NEEDLE GAUGE|NED||MM/SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1||38||OPEN LABEL TREATMENT|1961-01-12||||1970-11-10||1970-10-20|1966-08-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 CFU/G|FAVORABLE RESPONSE||RING|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SIGNIFICANT OTHER|RADIOLOGIST 1|U|1||38||LONG-TERM FOLLOW-UP|1967-08-11||||1971-03-22||1960-12-11|1962-07-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^4/L|PR-CT||BAU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||WASHOUT|1961-08-02||||1961-08-28||1969-09-07|1971-03-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||NEWLIND|NEW LESION INDICATOR||||G/ANIMAL/DAY|TREATMENT FAILURE||ML/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|VENDOR|NEUROLOGIST 1|Y|2||58||SCREENING|1969-12-09||||1965-08-29||1962-01-05|1960-09-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/DAY|CRI||MG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|SPOUSE|ONCOLOGIST 2|Y|3||39||OBSERVATION|1960-10-19||||1969-04-07||1960-01-01|1970-01-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||C|NON-ICR/NON-IUPD||L/H/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|FRIEND|PEDIATRIC NEUROLOGIST|NA|3||39||BASELINE|1968-07-08||||1972-07-06||1969-06-12|1961-12-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||CLINRESP|CLINICAL RESPONSE||||MG/MIN|MOLECULAR CR||MEQ/MMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|SIBLING|HEMATOLOGIST|Y|4||88||FOLLOW-UP|1963-07-03||||1962-04-05||1972-06-28|1965-01-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||TMRESP|TUMOR MARKER RESPONSE||||PSEC|CRI||PNU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|Y|4||88||WASHOUT|1969-06-05||||1972-02-25||1964-09-02|1970-03-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MIN/DAY|NED||/LSQN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|ADJUDICATOR|ONCOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1965-06-28||||1969-05-06||1966-07-06|1962-08-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||CLINRESP|CLINICAL RESPONSE||||DAYS/MONTH|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||PMOL/10^10 CELLS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|N|5||7||FOLLOW-UP|1963-03-07||||1963-11-12||1965-08-09|1960-07-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TRANSDUCING UNIT/ML|HI-E||M/SEC|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1960-07-28||||1961-07-07||1966-12-13|1966-01-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||SPLNRESP|SPLEEN RESPONSE||||MILE|PARTIAL MORPHOLOGIC RESPONSE||TUBERCULIN UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|PROXY|DERMATOLOGIST|U|1||38||WASHOUT|1961-03-15||||1961-08-23||1971-05-02|1964-09-08||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/CAGE/WK|MRD RELAPSE||NMOL/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|U|INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|2||58||BLINDED TREATMENT|1966-03-26||||1969-11-05||1961-08-16|1967-01-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||STRUSTAT|STEROID USE STATUS||||NMOL/ML/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||BP|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|PARENT|PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1971-04-15||||1960-02-22||1965-11-08|1960-09-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||METBRESP|METABOLIC RESPONSE||||ML/(MIN*100ML)|QUANTIFIABLE MRD POSITIVITY||MM/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|FRIEND|CARDIOLOGIST|NA|3||39||WASHOUT|1960-05-03||||1971-01-07||1972-08-24|1969-01-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||OVRLRESP|OVERALL RESPONSE||||ML/M2/MIN|MINOR PATHOLOGIC RESPONSE||AMFI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|3||39||WASHOUT|1967-05-23||||1960-06-15||1966-07-17|1972-05-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||JOULE|CR||KM|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|CHILD|NEUROLOGIST|N|4||88||BLINDED TREATMENT|1969-05-17||||1960-11-09||1963-02-28|1972-03-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GPS U|CCR||G/CAGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|SIGNIFICANT OTHER|NEUROLOGIST|N|4||88||OPEN LABEL TREATMENT|1965-09-23||||1961-02-02||1966-01-25|1971-08-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||OVRLRESP|OVERALL RESPONSE||||GPL U/ML|PDU||MIN*MG/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|INVESTIGATOR|MICROSCOPIST 3|NA|5||7||FOLLOW-UP|1963-12-24||||1965-06-12||1970-10-16|1965-09-02||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||METBRESP|METABOLIC RESPONSE||||FG|SD-CT||UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|SPOUSE|RADIOLOGIST 2|NA|5||7||SCREENING|1971-02-23||||1973-05-06||1970-12-19|1964-07-08||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||NEWLPROG|NEW LESION PROGRESSION||||KCAL|CMR||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|DOMESTIC PARTNER|INTERNIST|N|1||38||SCREENING|1972-03-13||||1971-03-11||1965-04-18|1973-01-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/G|MCR||MU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|FAMILY MEMBER|ONCOLOGIST 2|NA|1||38||BLINDED TREATMENT|1963-06-21||||1962-09-27||1961-11-24|1966-05-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||SPLNRESP|SPLEEN RESPONSE||||ELISA UNIT/ML|UNFAVORABLE RESPONSE||TCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|2||58||OBSERVATION|1968-11-20||||1967-08-16||1964-02-15|1962-10-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3/L|IPR||G/G/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|PARENT|PEDIATRIC NEUROLOGIST|U|2||58||OPEN LABEL TREATMENT|1963-03-22||||1960-07-11||1960-11-10|1962-04-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||MOLRESP|MOLECULAR RESPONSE||||KALLIKREIN INHIBITOR UNIT|IMPROVED||DRUM|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|INTERVIEWER|UROLOGIST|Y|3||39||SCREENING|1964-07-28||||1962-03-13||1972-06-26|1967-08-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NEBULE|WORSENED||H*%|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|3||39||RUN-IN|1970-08-14||||1969-08-04||1970-02-14|1961-01-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||TMRESP|TUMOR MARKER RESPONSE||||TUBERCULIN UNIT|RELAPSED DISEASE||ELISA UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|FAMILY MEMBER|HEMATOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1962-03-29||||1968-12-19||1966-12-28|1960-10-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||SPLNRESP|SPLEEN RESPONSE||||IU/ML|PMR||BQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|INTERVIEWER|ADJUDICATOR 2|NA|4||88||OBSERVATION|1972-06-28||||1963-02-27||1962-06-28|1964-04-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PACKET|ICPD||UG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||LONG-TERM FOLLOW-UP|1965-05-01||||1960-02-24||1964-02-23|1962-03-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||OVRLRESP|OVERALL RESPONSE||||10^11/L|NR||MG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|5||7||WASHOUT|1964-08-07||||1967-06-01||1964-08-16|1968-03-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/MMOL|CMR||10^9 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|VENDOR|READER 1|U|1||38||LONG-TERM FOLLOW-UP|1970-11-03||||1965-12-28||1973-01-21|1967-08-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KG/CM2|MCR||UEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|1||38||FOLLOW-UP|1969-12-14||||1968-03-07||1965-03-11|1967-11-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||CLINRESP|CLINICAL RESPONSE||||UG/G/MIN|HI-E||IU/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|PROXY|OPHTHALMOLOGIST|Y|2||58||CONTINUATION TREATMENT|1971-05-21||||1964-06-14||1960-11-08|1973-06-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||BONERESP|BONE RESPONSE||||BQ|CRI||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|2||58||RUN-IN|1967-01-30||||1967-04-29||1969-07-23|1965-04-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^3 RNA COPIES/ML|IPR||%(W/W)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|INTERVIEWER|PHYSIOTHERAPIST|N|3||39||OPEN LABEL TREATMENT|1961-04-29||||1967-12-30||1968-02-15|1960-08-31||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||NEWLPROG|NEW LESION PROGRESSION||||DRAM|CR-CT||PIPE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|STUDY SUBJECT|NEUROLOGIST|U|3||39||RUN-IN|1973-02-28||||1973-04-02||1967-11-26|1972-05-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MV*MIN|IPR||M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|CAREGIVER|READER 3|N|4||88||FOLLOW-UP|1963-11-04||||1965-07-23||1960-09-19|1964-11-17||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||NEWLPROG|NEW LESION PROGRESSION||||DROP|RELAPSED DISEASE||MSEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|4||88||TREATMENT|1960-04-17||||1966-09-26||1961-01-26|1965-08-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BQ/UL|PD-CT||PA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|GUARDIAN|MICROSCOPIST 3|NA|5||7||TREATMENT|1972-12-16||||1971-09-05||1962-03-01|1961-06-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/KG|PD/RELAPSE AFTER HI||STEPS/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|PARENT|OPHTHALMOLOGIST|Y|5||7||SCREENING|1973-09-01||||1968-05-15||1973-04-02|1971-12-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||CLINRESP|CLINICAL RESPONSE||||APL U/ML|ISD||MG/CM2|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|1||38||TREATMENT|1960-01-22||||1971-03-20||1973-01-31|1968-01-28||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL/ML/MIN|UNFAVORABLE RESPONSE||MEQ/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|1||38||FOLLOW-UP|1966-07-16||||1968-07-24||1960-02-29|1962-12-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CI/L|DECREASED||G/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|SIGNIFICANT OTHER|MICROSCOPIST 1|N|2||58||BLINDED TREATMENT|1972-01-21||||1961-12-17||1970-12-29|1967-05-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/KG/H|CRI||BAU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|FRIEND|READER 2|N|2||58||WASHOUT|1968-05-27||||1963-01-28||1970-04-14|1969-08-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/G|EQUIVOCAL||G/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|ADJUDICATION COMMITTEE|ONCOLOGIST|U|3||39||BASELINE|1964-10-19||||1969-11-29||1968-10-27|1972-10-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||NTRGRESP|NON-TARGET RESPONSE||||MIN*MG/ML|MORPHOLOGIC CR||%(W/W)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||WASHOUT|1969-02-06||||1971-12-14||1963-12-21|1960-04-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BEL|CYTOGENETIC CR||TROCHE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|INTERNIST|U|4||88||TREATMENT|1972-11-12||||1973-04-05||1963-02-07|1964-03-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||ANATRESP|ANATOMIC RESPONSE||||10^9 ORGANISMS/MG|CYTOGENETIC MINIMAL RESPONSE||FFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|SIGNIFICANT OTHER|OPTOMETRIST|Y|4||88||OPEN LABEL TREATMENT|1961-10-07||||1969-02-28||1963-03-31|1967-07-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||WAFER|QUANTIFIABLE MRD POSITIVITY||COAT|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|SIBLING|READER|NA|5||7||BLINDED TREATMENT|1972-02-05||||1967-08-29||1964-10-11|1962-02-15||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||NTRGRESP|NON-TARGET RESPONSE||||LB|HI-N||S^-1(%O2)^-1|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|DOMESTIC PARTNER|MICROSCOPIST 3|U|5||7||RUN-IN|1963-08-29||||1965-11-26||1972-08-14|1963-12-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PT_US|PD||UMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|1||38||FOLLOW-UP|1966-09-19||||1961-12-18||1970-01-23|1972-06-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UV2|IPR||KPA/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|PROXY|ADJUDICATOR 3|N|1||38||OBSERVATION|1969-03-09||||1966-01-15||1970-08-28|1962-02-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL/G|CR-CT||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|2||58||RUN-IN|1965-04-10||||1972-08-08||1965-07-13|1968-05-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||NEWLIND|NEW LESION INDICATOR||||UMOL/L/H|MORPHOLOGIC CRI||MG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|FRIEND|MICROSCOPIST 2|Y|2||58||SCREENING|1965-12-28||||1966-09-16||1960-05-19|1973-08-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL|MOLECULAR MAJOR RESPONSE||U/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|SPOUSE|ADJUDICATOR 2|N|3||39||WASHOUT|1960-06-05||||1971-04-03||1968-07-28|1972-09-05||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||OVRLRESP|OVERALL RESPONSE||||UG/ANIMAL|RELAPSED DISEASE||KIU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|3||39||WASHOUT|1968-05-18||||1964-07-21||1961-02-03|1968-11-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||LIVRRESP|LIVER RESPONSE||||MAC50|PR||AMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|SPOUSE|PHYSIOTHERAPIST|NA|4||88||LONG-TERM FOLLOW-UP|1965-04-17||||1963-03-28||1972-10-22|1966-03-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MIN*MG/ML|CYTOGENETIC MINIMAL RESPONSE||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|4||88||BLINDED TREATMENT|1972-09-19||||1970-11-18||1963-12-23|1963-07-31||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||TRGRESP|TARGET RESPONSE||||UEQ/L|SD||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|CHILD|PATHOLOGIST 1|U|5||7||INDUCTION TREATMENT|1964-04-20||||1961-03-15||1961-05-08|1963-03-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||LIVRRESP|LIVER RESPONSE||||10^6 COPIES/ML|DECREASED||BQ/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1960-04-18||||1965-04-23||1963-08-20|1967-10-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||LIVRRESP|LIVER RESPONSE||||KPA/L/SEC|PD/RELAPSE AFTER HI||UG/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||SCREENING|1961-05-29||||1970-11-14||1960-09-26|1963-10-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^3 CFU/G|MR||AMP|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|CHILD|ADJUDICATOR|Y|1||38||BASELINE|1966-09-18||||1960-02-03||1962-02-27|1964-09-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||NEWLPROG|NEW LESION PROGRESSION||||FEU|DISEASE TRANSFORMATION||FIU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|N|2||58||FOLLOW-UP|1972-06-09||||1967-01-22||1970-06-26|1966-08-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||CLINRESP|CLINICAL RESPONSE||||10^6 CFU|CA125 75% RESPONSE||ML/MIN/MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|DOMESTIC PARTNER|ADJUDICATOR 3|U|2||58||BLINDED TREATMENT|1970-12-11||||1963-06-07||1969-10-04|1969-01-15||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/4.0 ML|PSEUDOPROGRESSION||UG/L/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|3||39||OBSERVATION|1961-06-25||||1969-06-06||1971-05-30|1960-06-21||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||OVRLRESP|OVERALL RESPONSE||||KN/CM2|TREATMENT FAILURE||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|3||39||INDUCTION TREATMENT|1964-02-22||||1971-08-04||1970-05-24|1965-01-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^4 CFU/ML|QUANTIFIABLE MRD POSITIVITY||10^7 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|FAMILY MEMBER|INTERNIST|NA|4||88||OBSERVATION|1973-07-22||||1972-03-28||1961-12-13|1962-08-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||METSIND|METASTATIC INDICATOR||||FMOL/G|PD/RELAPSE AFTER HI||FRACTION OF 1|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|4||88||INDUCTION TREATMENT|1969-07-01||||1970-05-29||1973-08-29|1967-07-01||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/G/MIN|CMR||LM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1963-03-10||||1965-10-03||1973-04-26|1970-06-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||TRGRESP|TARGET RESPONSE||||GTT|MORPHOLOGIC CR||F|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|5||7||LONG-TERM FOLLOW-UP|1972-09-12||||1966-06-21||1964-01-02|1962-08-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||STRUSTAT|STEROID USE STATUS||||/100 WBC|EQUIVOCAL||FMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|1||38||BLINDED TREATMENT|1960-02-03||||1964-08-03||1969-11-09|1970-11-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||METBRESP|METABOLIC RESPONSE||||KG/L|MINOR PATHOLOGIC RESPONSE||FL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||RUN-IN|1966-01-12||||1973-01-23||1972-03-03|1966-04-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||SPLNRESP|SPLEEN RESPONSE||||UG/DAY|ICR||VG/KG|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|2||58||OBSERVATION|1961-10-19||||1973-03-08||1962-06-10|1972-01-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||NEWLPROG|NEW LESION PROGRESSION||||CFU/G|NOT ALL EVALUATED||UG/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1964-08-21||||1970-09-04||1966-05-13|1973-02-03||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||SPLNRESP|SPLEEN RESPONSE||||10^9/L|CMR||DRUM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|READER 1|Y|3||39||LONG-TERM FOLLOW-UP|1973-07-28||||1965-05-21||1969-07-06|1972-07-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 COPIES/ML|EQUIVOCAL||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|CHILD|ADJUDICATOR|Y|3||39||SCREENING|1967-02-13||||1973-01-14||1967-02-20|1962-09-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/BEAT|PR WITH LYMPHOCYTOSIS||MG/KG/WEEK|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1973-05-07||||1960-11-03||1960-02-28|1971-09-01||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/MMHG/MIN/L|CR-CT||CMOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|4||88||BLINDED TREATMENT|1960-07-16||||1967-09-05||1961-10-10|1963-11-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||BONERESP|BONE RESPONSE||||G/ANIMAL/DAY|NE||10^6/EJACULATE U|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|INTERVIEWER|ENDOCRINOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1961-10-30||||1961-08-15||1972-12-21|1972-01-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||V|NPR||U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||FOLLOW-UP|1963-06-08||||1965-03-30||1971-12-17|1960-07-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/MIN|ICPD||EQ|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|PARENT|ADJUDICATOR|NA|1||38||OPEN LABEL TREATMENT|1968-03-11||||1971-03-04||1961-04-13|1968-05-26||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IMPLANT|MOLECULAR MAJOR RESPONSE||U/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|1||38||BLINDED TREATMENT|1965-10-09||||1961-07-04||1968-12-15|1960-08-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MAC50|NOT ALL EVALUATED||ML/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|CHILD|MICROSCOPIST 2|Y|2||58||CONTINUATION TREATMENT|1968-10-08||||1963-03-17||1971-07-09|1962-10-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||LIVRRESP|LIVER RESPONSE||||U/DL|INCREASED||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|SIGNIFICANT OTHER|ONCOLOGIST|N|2||58||TREATMENT|1960-02-11||||1972-12-10||1972-09-27|1969-08-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||METSIND|METASTATIC INDICATOR||||CAL|CYTOGENETIC PR||MMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|STUDY SUBJECT|PATHOLOGIST|U|3||39||OBSERVATION|1971-10-24||||1968-08-12||1960-08-05|1965-09-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||METBRESP|METABOLIC RESPONSE||||VIRTUAL PIXEL|MINOR PATHOLOGIC RESPONSE||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|PROXY|NEUROLOGIST 1|NA|3||39||INDUCTION TREATMENT|1971-08-26||||1964-03-05||1969-06-08|1960-11-30||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MM/MIN|DECREASED||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|PROXY|ONCOLOGIST|U|4||88||WASHOUT|1971-04-06||||1972-03-16||1960-07-22|1968-06-28||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/100G/MIN|CA125 50% RESPONSE||UM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|DOMESTIC PARTNER|PHYSIOTHERAPIST|U|4||88||RUN-IN|1961-02-08||||1963-03-19||1970-03-24|1968-03-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9 ORGANISMS/ML|CHR||UU/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||RUN-IN|1966-06-03||||1969-02-21||1960-01-29|1965-11-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||METBRESP|METABOLIC RESPONSE||||NFIU|MOLECULAR MAJOR RESPONSE||%(W/W)|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|SIBLING|READER 1|Y|5||7||BASELINE|1969-04-13||||1968-11-28||1969-03-22|1967-02-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||METSIND|METASTATIC INDICATOR||||ML/MIN/1.73M2|MRD NEGATIVITY||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|CHILD|MICROSCOPIST 2|Y|1||38||OBSERVATION|1963-02-16||||1967-12-22||1963-01-26|1970-01-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||BESTRESP|BEST OVERALL RESPONSE||||UM/S|NED||MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|FAMILY MEMBER|ADJUDICATOR 1|NA|1||38||BASELINE|1966-02-06||||1961-12-16||1968-01-30|1973-08-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BQ/ML|UNFAVORABLE RESPONSE||GBQ/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FRIEND|ADJUDICATOR|U|2||58||BLINDED TREATMENT|1961-05-29||||1973-05-03||1972-03-30|1971-02-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||NTRGRESP|NON-TARGET RESPONSE||||CIGARETTE|CRI||MMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|2||58||RUN-IN|1969-09-12||||1970-06-12||1972-05-19|1960-03-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||PATHRESP|PATHOLOGIC RESPONSE||||COPIES/UL|OPTIMAL MORPHOLOGIC RESPONSE||U/M2/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|VENDOR|ONCOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1961-04-16||||1965-08-17||1971-07-07|1965-12-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MOL/MOL|MAJOR PATHOLOGIC RESPONSE||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|SPOUSE|FORENSIC PATHOLOGIST|Y|3||39||FOLLOW-UP|1967-04-13||||1963-11-13||1964-11-05|1971-03-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||STRUSTAT|STEROID USE STATUS||||LOG10 IU/ML|PSEUDOPROGRESSION||UG/G/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|INTERVIEWER|PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1971-05-24||||1968-01-05||1972-03-05|1963-08-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||METSIND|METASTATIC INDICATOR||||NMOL/L|DECREASED||NG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|CHILD|DERMATOLOGIST|U|4||88||BASELINE|1971-04-08||||1962-03-01||1969-08-05|1969-11-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||SFC/10^6 PBMC|PR-CT||RNA COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|5||7||BLINDED TREATMENT|1970-07-26||||1971-07-19||1964-12-09|1969-11-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||STRUSTAT|STEROID USE STATUS||||MEQ|PARTIAL MORPHOLOGIC RESPONSE||PATCH|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|5||7||CONTINUATION TREATMENT|1965-10-08||||1973-05-30||1972-05-23|1969-10-15||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||NTRGRESP|NON-TARGET RESPONSE||||BOTTLE|TREATMENT FAILURE||NMOL BCE/NMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|SIBLING|INTERNIST|NA|1||38||FOLLOW-UP|1972-05-05||||1970-02-23||1967-05-23|1973-06-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||METSIND|METASTATIC INDICATOR||||OZ EQ|CR||NMOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|FAMILY MEMBER|MICROSCOPIST|Y|1||38||LONG-TERM FOLLOW-UP|1961-04-06||||1966-01-21||1972-12-30|1966-10-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UEQ/L|CHR||ML/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|CLINICAL RESEARCH ASSOCIATE|INTERNIST|N|2||58||LONG-TERM FOLLOW-UP|1972-10-25||||1972-11-17||1970-02-04|1970-11-18||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||METSIND|METASTATIC INDICATOR||||DPM/MG|CA125 50% RESPONSE||UEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|SPOUSE|PATHOLOGIST 2|N|2||58||RUN-IN|1970-09-23||||1965-07-22||1972-07-27|1962-06-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/KG/MIN|ICPD||/MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|CHILD|ADJUDICATOR 1|N|3||39||OBSERVATION|1961-07-23||||1961-01-03||1963-03-04|1971-05-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||CLINRESP|CLINICAL RESPONSE||||PACK|PSA PROGRESSION||G/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|FRIEND|ADJUDICATOR 2|U|3||39||OPEN LABEL TREATMENT|1965-12-22||||1970-08-25||1971-12-30|1969-07-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||BONERESP|BONE RESPONSE||||U/KG/DAY|CYTOGENETIC NO RESPONSE||FOZ_BR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|STUDY SUBJECT|PATHOLOGIST|Y|4||88||BLINDED TREATMENT|1972-07-05||||1960-11-10||1962-11-10|1970-09-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||RDIORESP|RADIOLOGIC RESPONSE||||WEEKS|IMPROVED||KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|4||88||SCREENING|1962-10-16||||1968-10-12||1968-05-16|1962-06-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||METSIND|METASTATIC INDICATOR||||COAT|ABSENT MORPHOLOGIC RESPONSE||/CMH2O|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|INTERVIEWER|READER|U|5||7||OBSERVATION|1966-04-13||||1969-08-11||1962-09-11|1973-08-16||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||CLINRESP|CLINICAL RESPONSE||||10^9 CFU|EQUIVOCAL||MG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|VENDOR|ADJUDICATOR 2|U|5||7||FOLLOW-UP|1964-04-21||||1973-02-01||1972-09-14|1968-11-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||BESTRESP|BEST OVERALL RESPONSE||||NU/CL|PR-CT||APL U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|INDEPENDENT ASSESSOR|PATHOLOGIST|NA|1||38||OBSERVATION|1964-02-07||||1965-03-21||1963-04-26|1966-02-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||ANATRESP|ANATOMIC RESPONSE||||10^3/L|WORSENED||MESF|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|1||38||BASELINE|1967-10-04||||1967-09-03||1970-12-14|1973-07-12||DURING||DURING|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||AMFI|MOLECULAR CR||10^3/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|2||58||FOLLOW-UP|1971-09-30||||1970-08-31||1966-03-23|1962-11-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||H*%|ICPD||ML/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|CLINICAL STUDY SPONSOR|READER 3|NA|2||58||TREATMENT|1963-03-16||||1960-02-23||1961-05-30|1970-05-07||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||BESTRESP|BEST OVERALL RESPONSE||||CI/L|CYTOGENETIC NO RESPONSE||UG/M2/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|SIGNIFICANT OTHER|NEUROLOGIST|NA|3||39||INDUCTION TREATMENT|1964-01-03||||1960-07-21||1972-04-05|1962-06-09||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||L/DAY|SCR||CMOL|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|U|3||39||BLINDED TREATMENT|1970-01-07||||1973-07-26||1964-11-04|1961-11-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||TRGRESP|TARGET RESPONSE||||KBQ/UL|FAVORABLE RESPONSE||NGEQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|INDEPENDENT ASSESSOR|READER 2|NA|4||88||BLINDED TREATMENT|1962-07-19||||1971-08-13||1966-05-23|1963-07-27||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/MOL|MORPHOLOGIC CR||NEEDLE GAUGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|U|4||88||TREATMENT|1960-02-18||||1970-12-04||1965-01-12|1968-05-05||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^3 ORGANISMS/G|INDETERMINATE RESPONSE||DISK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|CLINICAL RESEARCH ASSOCIATE|RATER|U|5||7||WASHOUT|1960-02-05||||1965-06-21||1966-05-12|1964-06-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||VP/DOSE|MOLECULAR MAJOR RESPONSE||10^3 CFU/G|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|U|5||7||INDUCTION TREATMENT|1966-10-28||||1966-09-01||1967-10-25|1972-01-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^3 DNA COPIES/ML|INCREASED||MOL/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|INVESTIGATOR|READER 2|N|1||38||BASELINE|1961-02-20||||1971-06-08||1960-07-22|1966-11-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||METSIND|METASTATIC INDICATOR||||CGY|NR||ML/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|RATER|NA|1||38||RUN-IN|1970-01-04||||1961-11-20||1966-02-17|1965-08-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CAPFUL|PR WITH LYMPHOCYTOSIS||HENRY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|N|SIBLING|DERMATOLOGIST|N|2||58||BASELINE|1962-05-04||||1970-08-14||1963-11-04|1970-02-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LX|ICPD||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|FRIEND|FORENSIC PATHOLOGIST|NA|2||58||TREATMENT|1964-02-26||||1970-04-22||1963-07-10|1969-08-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/2000 RBC|DECREASED||10^7/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|PROXY|READER 3|Y|3||39||WASHOUT|1968-08-23||||1970-09-26||1972-12-05|1969-01-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||BONERESP|BONE RESPONSE||||MCI/KG|MR||10^8/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|INTERVIEWER|UROLOGIST|N|3||39||INDUCTION TREATMENT|1961-09-03||||1969-06-02||1967-06-12|1963-05-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/G/DAY|MOLECULAR CR||MG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|FAMILY MEMBER|ADJUDICATOR 3|N|4||88||CONTINUATION TREATMENT|1966-03-23||||1962-03-04||1963-06-07|1964-12-28||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||TMRESP|TUMOR MARKER RESPONSE||||RATIO|MORPHOLOGIC CR||QUANTITY SUFFICIENT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|4||88||SCREENING|1969-12-26||||1960-09-18||1968-11-01|1962-05-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||SPLNRESP|SPLEEN RESPONSE||||/500 WBC|DISEASE TRANSFORMATION||AMFI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|SIBLING|FORENSIC PATHOLOGIST|NA|5||7||OBSERVATION|1973-04-26||||1971-06-22||1970-04-20|1967-12-28||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||METSIND|METASTATIC INDICATOR||||KS|PR||ML/BEAT|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|FRIEND|RADIOLOGIST 2|NA|5||7||TREATMENT|1964-04-24||||1962-02-06||1972-12-13|1969-01-07||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||LIVRRESP|LIVER RESPONSE||||L/S/KPA|PSA PROGRESSION||ENZYME U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|NA|1||38||SCREENING|1965-07-05||||1965-03-26||1961-02-02|1960-11-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||NEWLIND|NEW LESION INDICATOR||||USP U|CCR||MG/KG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|1||38||FOLLOW-UP|1972-11-01||||1963-01-27||1964-12-21|1973-04-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/ANIMAL/WK|CYTOGENETIC NO RESPONSE||BQ/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|ADJUDICATOR|ONCOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1969-05-29||||1969-10-10||1970-12-15|1964-09-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||METBRESP|METABOLIC RESPONSE||||10^6/L|PSEUDORESPONSE||ROENTGEN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|PARENT|PATHOLOGIST|N|2||58||FOLLOW-UP|1964-02-23||||1972-01-09||1962-06-21|1968-09-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PA|PR||DDU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|SPOUSE|OPHTHALMOLOGIST|NA|3||39||SCREENING|1970-05-24||||1973-03-25||1960-04-16|1970-04-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI/KG|CYTOGENETIC MINIMAL RESPONSE||MIU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|CHILD|ADJUDICATOR 3|NA|3||39||FOLLOW-UP|1971-08-20||||1967-11-11||1964-09-23|1960-09-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||RATIO|PR WITH LYMPHOCYTOSIS||/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|VENDOR|RATER 1|N|4||88||INDUCTION TREATMENT|1963-12-13||||1965-06-04||1965-12-01|1972-09-02||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MDFI|NON-ICR/NON-IUPD||MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|FAMILY MEMBER|MICROSCOPIST|NA|4||88||SCREENING|1965-08-03||||1963-12-01||1965-10-28|1971-10-11||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||MOLRESP|MOLECULAR RESPONSE||||10^5/HPF|PMR||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||FOLLOW-UP|1961-11-16||||1968-01-07||1971-07-27|1960-12-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||METBRESP|METABOLIC RESPONSE||||JDF UNIT|CYTOGENETIC MINOR RESPONSE||UG/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|5||7||BLINDED TREATMENT|1965-04-14||||1968-02-26||1966-07-10|1968-04-15||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^3 ORGANISMS/ML|SCR||MG/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|ADJUDICATOR|ONCOLOGIST 2|N|1||38||OPEN LABEL TREATMENT|1969-02-23||||1964-09-30||1970-03-07|1961-01-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL/L/H|UNEQUIVOCAL||UL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||OBSERVATION|1969-06-12||||1961-10-28||1966-09-04|1967-03-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||U/KG/DAY|NE||/MM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|INTERVIEWER|ADJUDICATOR 2|N|2||58||RUN-IN|1961-05-24||||1966-08-20||1969-10-27|1971-09-26||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||NTRGRESP|NON-TARGET RESPONSE||||G/ANIMAL/DAY|INCREASED||VP/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|2||58||INDUCTION TREATMENT|1966-04-09||||1966-04-28||1971-09-22|1971-12-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PLUG|CA125 50% RESPONSE||NG|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|3||39||WASHOUT|1972-06-20||||1972-09-22||1967-11-26|1961-08-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||SPLNRESP|SPLEEN RESPONSE||||MG/KG/DAY|NED||PG/DL|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|SPOUSE|READER 3|N|3||39||WASHOUT|1964-07-14||||1964-12-21||1962-07-19|1964-08-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/M2/DAY|PDU||HZ/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|CHILD|ADJUDICATOR 1|NA|4||88||FOLLOW-UP|1965-03-15||||1968-07-11||1967-04-16|1967-08-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^7/L|ISD||RFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|GUARDIAN|OPTOMETRIST|N|4||88||BASELINE|1965-10-13||||1964-10-05||1969-01-24|1971-11-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG|ABSENT MORPHOLOGIC RESPONSE||U/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|GUARDIAN|READER|U|5||7||CONTINUATION TREATMENT|1971-10-25||||1963-09-02||1964-02-20|1969-02-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||STRUSTAT|STEROID USE STATUS||||10^6/L|RELAPSED DISEASE||PT_US|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST|Y|5||7||SCREENING|1968-01-04||||1963-06-27||1973-03-19|1969-01-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SEC|RELAPSED DISEASE||COPIES/UG|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|1||38||BASELINE|1970-09-29||||1972-04-20||1973-08-04|1962-12-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ECL UNIT|CYTOGENETIC MINOR RESPONSE||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|DOMESTIC PARTNER|ONCOLOGIST 2|Y|1||38||BASELINE|1968-09-06||||1964-12-30||1972-09-29|1961-04-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PA|QUANTIFIABLE MRD POSITIVITY||/WK|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|SIBLING|RATER|U|2||58||TREATMENT|1966-01-26||||1961-06-19||1967-07-19|1969-10-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||CLINRESP|CLINICAL RESPONSE||||PRESSOR UNITS|SCR||CARTRIDGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|2||58||OBSERVATION|1969-03-24||||1972-10-20||1966-03-16|1967-01-31||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||NEWLPROG|NEW LESION PROGRESSION||||G/MOL|MAJOR PATHOLOGIC RESPONSE||/5X10^4 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||WASHOUT|1971-08-16||||1972-12-28||1968-12-15|1966-08-04||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/HPF|MORPHOLOGIC CRI||/100 HPFS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|INVESTIGATOR|ADJUDICATOR 2|Y|3||39||OBSERVATION|1968-04-29||||1969-10-09||1964-02-06|1971-04-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||ANATRESP|ANATOMIC RESPONSE||||10^9 ORGANISMS/ML|CA125 50% RESPONSE||SFC/10^6 PBMC|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|INDEPENDENT ASSESSOR|READER 1|NA|4||88||TREATMENT|1960-09-07||||1971-12-26||1971-05-10|1968-02-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/M2/H|QUANTIFIABLE MRD POSITIVITY||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|4||88||SCREENING|1972-07-15||||1963-11-15||1962-05-05|1964-01-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||MOLRESP|MOLECULAR RESPONSE||||CI|MAJOR PATHOLOGIC RESPONSE||MEQ/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|SIBLING|READER 2|N|5||7||BASELINE|1970-01-21||||1960-07-12||1962-05-09|1961-04-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||RFU|SCR||10^6/EJACULATE U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|N|5||7||WASHOUT|1966-09-04||||1967-12-08||1963-09-17|1962-07-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MOL/MG|PR||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|1||38||CONTINUATION TREATMENT|1965-07-03||||1969-01-14||1973-08-07|1972-10-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ANTI-XA IU|WORSENED||DAYS/MONTH|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|1||38||OBSERVATION|1969-11-26||||1965-08-30||1971-01-31|1972-03-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||STRUSTAT|STEROID USE STATUS||||MMU/ML|PD FROM PR||VG/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|DOMESTIC PARTNER|NEUROLOGIST 1|Y|2||58||TREATMENT|1960-04-19||||1963-02-24||1972-09-10|1965-07-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||BONERESP|BONE RESPONSE||||ML/CAGE/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||10^9 CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|VENDOR|PHYSIOTHERAPIST|N|2||58||BLINDED TREATMENT|1965-04-25||||1973-06-04||1972-07-16|1961-06-06||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||BESTRESP|BEST OVERALL RESPONSE||||NM|RELAPSED DISEASE FROM CR||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|CAREGIVER|NEUROLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1973-08-05||||1966-02-04||1963-04-19|1969-06-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||MOLRESP|MOLECULAR RESPONSE||||CM H2O|SD||APS U|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|FRIEND|ONCOLOGIST 2|N|3||39||OBSERVATION|1960-04-07||||1960-09-23||1963-06-08|1963-06-11||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||PATHRESP|PATHOLOGIC RESPONSE||||FOZ_US|NR||S/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|4||88||WASHOUT|1963-02-17||||1967-01-04||1966-07-13|1961-01-25||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BE/ML|CCR||M|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|SPOUSE|ONCOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1967-10-30||||1969-09-10||1960-03-09|1971-10-01||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MMHG|CYTOGENETIC PR||EP U|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|SIBLING|ONCOLOGIST|NA|5||7||WASHOUT|1963-02-18||||1967-05-28||1972-10-27|1971-06-19||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/S/KPA|IPR||PA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|PROXY|RADIOLOGIST 1|Y|5||7||RUN-IN|1967-04-07||||1973-02-01||1969-02-16|1965-02-16||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ANTIBODY UNIT|PSA PROGRESSION||TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|CLINICAL STUDY SPONSOR|RATER 2|U|1||38||LONG-TERM FOLLOW-UP|1970-10-08||||1964-10-22||1967-10-23|1965-11-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CAPLET|ISD||G/ANIMAL/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|SIGNIFICANT OTHER|RATER|U|1||38||BLINDED TREATMENT|1972-01-10||||1965-07-26||1971-01-07|1970-10-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/KG/H|CRI||NMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||WASHOUT|1967-12-13||||1961-11-13||1964-02-09|1971-09-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PPTH|CYTOGENETIC NO RESPONSE||CI/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|STUDY SUBJECT|ADJUDICATOR 3|N|2||58||CONTINUATION TREATMENT|1965-04-16||||1965-07-23||1969-06-27|1972-07-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/ANIMAL/DAY|QUANTIFIABLE MRD POSITIVITY||IU/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INTERVIEWER|FORENSIC PATHOLOGIST|NA|3||39||TREATMENT|1964-05-17||||1972-08-29||1970-10-07|1965-03-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||NTRGRESP|NON-TARGET RESPONSE||||CIGARETTE|MORPHOLOGIC LEUKEMIA-FREE STATE||L/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|FRIEND|CLINICAL PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1972-07-13||||1963-10-10||1971-11-13|1968-09-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||NTRGRESP|NON-TARGET RESPONSE||||MEQ/DAY|IMPROVED||ML/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|FAMILY MEMBER|NEUROLOGIST|N|4||88||WASHOUT|1963-01-20||||1963-03-02||1963-07-31|1971-01-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||SPLNRESP|SPLEEN RESPONSE||||UG/KG/H|DECREASED||PM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|NA|4||88||INDUCTION TREATMENT|1973-08-20||||1965-10-25||1968-07-13|1969-12-15||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||TRGRESP|TARGET RESPONSE||||FMOL|MOLECULAR CR||PMOL/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|VENDOR|ADJUDICATOR 2|Y|5||7||BASELINE|1965-09-10||||1965-06-14||1963-04-13|1971-03-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||LIVRRESP|LIVER RESPONSE||||PSI|MORPHOLOGIC CR||NMOL BCE/NMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|GUARDIAN|HEMATOLOGIST|Y|5||7||TREATMENT|1972-02-24||||1961-05-21||1965-08-15|1970-08-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CIGARETTE|PCR||10^6 COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|SPOUSE|RADIOLOGIST 1|N|1||38||TREATMENT|1960-05-12||||1967-07-31||1965-12-28|1964-04-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DPM/ML|NR||UG/DL|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|FAMILY MEMBER|MICROSCOPIST 1|NA|1||38||BLINDED TREATMENT|1964-11-12||||1972-02-01||1965-11-04|1964-07-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CS|NPR||NMOL/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|2||58||INDUCTION TREATMENT|1973-07-24||||1965-09-22||1968-04-25|1973-01-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/G/DAY|IMMUNOPHENOTYPIC CR||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|DOMESTIC PARTNER|PATHOLOGIST|N|2||58||BASELINE|1960-03-26||||1970-10-18||1966-10-04|1961-11-08||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/DL|FAVORABLE RESPONSE||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|INTERVIEWER|READER 3|NA|3||39||BLINDED TREATMENT|1973-08-11||||1963-12-04||1968-10-04|1965-02-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NG/DAY|ABSENT MORPHOLOGIC RESPONSE||MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|N|3||39||SCREENING|1972-06-18||||1961-12-13||1961-07-04|1960-10-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DRAM|NE||BREATHS/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|INDEPENDENT ASSESSOR|RATER 1|Y|4||88||BLINDED TREATMENT|1960-11-17||||1969-12-04||1967-05-15|1968-06-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MET|PD FROM PR||1/(S*KPA)|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|INDEPENDENT ASSESSOR|CARDIOLOGIST|U|4||88||BASELINE|1969-03-05||||1971-06-25||1972-04-30|1965-07-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/CAGE/WK|PD||ML/SEC/1.73M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|STUDY SUBJECT|ADJUDICATOR 3|N|5||7||OBSERVATION|1963-04-11||||1969-12-01||1968-05-26|1970-01-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UIU/L|MOLECULAR MAJOR RESPONSE||KS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|ADJUDICATION COMMITTEE|MICROSCOPIST|U|5||7||BLINDED TREATMENT|1960-08-17||||1963-10-15||1970-09-16|1962-01-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^3 CFU|HI-P||10^9 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|ADJUDICATOR|RATER 2|N|1||38||TREATMENT|1962-09-27||||1968-07-19||1962-01-06|1960-10-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||CLINRESP|CLINICAL RESPONSE||||MOL/G|PD FROM PR||/10^3|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|SIBLING|NEUROLOGIST|NA|1||38||TREATMENT|1966-10-27||||1962-04-13||1964-11-01|1966-10-31||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||BONERESP|BONE RESPONSE||||TABLET|SD-CT||MMU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1961-12-27||||1966-10-29||1965-12-04|1968-12-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||NTRGRESP|NON-TARGET RESPONSE||||%(V/V)|PSEUDORESPONSE||GAUSS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|PROXY|MICROSCOPIST 2|U|2||58||OBSERVATION|1970-03-10||||1961-07-20||1965-06-12|1971-09-27||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/CAGE/DAY|MORPHOLOGIC CRI||DPM/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|3||39||OBSERVATION|1964-06-28||||1965-10-10||1969-10-28|1971-09-14||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||CLINRESP|CLINICAL RESPONSE||||10^8/L|NOT ALL EVALUATED||MU/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|INVESTIGATOR|MICROSCOPIST 2|Y|3||39||WASHOUT|1971-12-16||||1970-01-14||1964-12-06|1971-05-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/HPF|SD-CT||ML/CAGE/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|CAREGIVER|MICROSCOPIST 2|Y|4||88||RUN-IN|1967-12-07||||1971-03-27||1971-10-16|1963-07-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GLOBULE|TREATMENT FAILURE||SCOOPFUL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1969-12-27||||1966-05-13||1961-03-08|1960-03-31||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BQ/KG|SCR||BOX|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|INVESTIGATOR|ADJUDICATOR 2|NA|5||7||LONG-TERM FOLLOW-UP|1968-12-14||||1960-11-08||1961-07-25|1964-06-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||TSP EQ|CYTOGENETIC PR||G/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|CHILD|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1960-06-21||||1972-12-25||1971-04-01|1969-07-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||METBRESP|METABOLIC RESPONSE||||UG/ML/H|PD||NG/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|N|1||38||INDUCTION TREATMENT|1967-11-06||||1960-01-05||1960-06-02|1972-01-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||RDIORESP|RADIOLOGIC RESPONSE||||LENS|PSA PROGRESSION||LOZENGE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|1||38||RUN-IN|1970-11-16||||1965-12-17||1972-05-27|1968-07-30||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||CLINRESP|CLINICAL RESPONSE||||FT3|PR-CT||DRAM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|FAMILY MEMBER|NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1967-04-03||||1969-07-15||1970-05-30|1969-05-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||STRUSTAT|STEROID USE STATUS||||VOXEL|HI-P||KM/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|GUARDIAN|RADIOLOGIST|U|2||58||FOLLOW-UP|1963-08-18||||1968-05-27||1971-05-05|1961-11-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||LIVRRESP|LIVER RESPONSE||||10^5/HPF|IMMUNOPHENOTYPIC CR||L/S/KPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|SPOUSE|RADIOLOGIST|NA|3||39||SCREENING|1961-12-06||||1964-05-30||1965-09-30|1971-03-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MCI|CA125 75% RESPONSE||U/G/H|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|INVESTIGATOR|OPHTHALMOLOGIST|N|3||39||FOLLOW-UP|1971-05-30||||1967-03-10||1971-06-26|1972-08-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MS/MMHG|PMD||AMFI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|SIGNIFICANT OTHER|RATER|N|4||88||OPEN LABEL TREATMENT|1967-03-08||||1970-01-06||1968-10-15|1960-11-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/KG/H|SMD||KS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|STUDY SUBJECT|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1965-11-05||||1971-04-12||1969-09-03|1962-02-24||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||NEWLIND|NEW LESION INDICATOR||||FRAMES/S|MOLECULAR CR||MCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|FRIEND|NEUROLOGIST|Y|5||7||BLINDED TREATMENT|1968-05-18||||1964-04-24||1962-01-15|1968-07-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^9 CFU|CRI||BAR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|FAMILY MEMBER|ONCOLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1964-06-03||||1966-09-10||1963-12-27|1972-11-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||SPLNRESP|SPLEEN RESPONSE||||COPIES/UG|UNFAVORABLE RESPONSE||L/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|PROXY|ENDOCRINOLOGIST|NA|1||38||CONTINUATION TREATMENT|1972-02-13||||1966-05-07||1962-03-27|1966-08-29||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||KIT|DISEASE TRANSFORMATION||PM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CAREGIVER|UROLOGIST|Y|1||38||BASELINE|1965-12-17||||1968-08-13||1961-11-29|1967-07-21||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/KG/DAY|INCREASED||MEQ/G|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|INTERVIEWER|RADIOLOGIST 1|NA|2||58||BLINDED TREATMENT|1970-04-28||||1968-03-10||1966-11-07|1960-09-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||METBRESP|METABOLIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|PSEUDOPROGRESSION||G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|Y|2||58||SCREENING|1968-08-11||||1960-07-01||1967-11-26|1961-02-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||SUPPOSITORY|IMPROVED||BU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||BLINDED TREATMENT|1960-04-26||||1961-05-02||1965-08-28|1962-10-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||BONERESP|BONE RESPONSE||||10^9/L|CCR||PACKET|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|SPOUSE|PEDIATRIC NEUROLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1972-10-27||||1964-03-11||1960-01-11|1973-08-07||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/M2/MIN|CR-CT||ENZYME U/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4||88||TREATMENT|1960-10-06||||1967-10-14||1967-09-07|1967-11-06||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||NTRGRESP|NON-TARGET RESPONSE||||KG/L|IPR||PMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|CHILD|MICROSCOPIST 1|Y|4||88||RUN-IN|1967-09-19||||1960-12-09||1966-07-24|1967-05-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||BONERESP|BONE RESPONSE||||NL|COMPLETE MRD RESPONSE||BLOCKS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CHILD|UROLOGIST|NA|5||7||BLINDED TREATMENT|1967-06-21||||1963-12-03||1967-03-19|1971-02-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/ANIMAL|MOLECULAR CR||UG/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|5||7||FOLLOW-UP|1961-01-16||||1960-01-18||1971-05-27|1962-10-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||NTRGRESP|NON-TARGET RESPONSE||||G/CAGE/WK|CHR||NMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|SPOUSE|ONCOLOGIST|U|1||38||RUN-IN|1961-02-07||||1970-11-20||1963-02-20|1963-10-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PACKET|CR||CL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|CHILD|PATHOLOGIST 2|N|1||38||OPEN LABEL TREATMENT|1971-07-10||||1970-11-27||1973-01-02|1964-02-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MM/SEC|IMPROVED||PACKAGE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||FOLLOW-UP|1963-11-15||||1963-01-09||1971-09-08|1967-08-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MEQ/DL|PD||L/MIN/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|VENDOR|HEMATOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1970-07-12||||1971-05-30||1962-06-26|1965-08-29||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||RDIORESP|RADIOLOGIC RESPONSE||||WAFER|INCREASED||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|FAMILY MEMBER|ONCOLOGIST|Y|3||39||OBSERVATION|1964-03-14||||1960-05-12||1971-08-25|1967-09-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||SPLNRESP|SPLEEN RESPONSE||||G/G/DAY|OPTIMAL MORPHOLOGIC RESPONSE||DAYS/MONTH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|INTERVIEWER|NEUROLOGIST|NA|3||39||TREATMENT|1963-07-07||||1962-12-15||1964-06-29|1966-06-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||M2|CHR||TRANSDUCING UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|SPOUSE|RATER 2|N|4||88||OPEN LABEL TREATMENT|1965-08-15||||1962-11-23||1971-07-15|1970-04-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||OVRLRESP|OVERALL RESPONSE||||NG|PD-CT||CCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|CAREGIVER|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1968-05-10||||1962-05-08||1962-04-14|1972-04-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||TMRESP|TUMOR MARKER RESPONSE||||HR/DAY|PD FROM PR||PMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|5||7||BLINDED TREATMENT|1972-02-01||||1964-09-18||1966-10-27|1966-12-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O/ML|PR-CT||AFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|INTERVIEWER|MICROSCOPIST 1|N|5||7||OPEN LABEL TREATMENT|1962-07-15||||1960-08-15||1965-08-14|1963-04-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||JOULE|MAJOR PATHOLOGIC RESPONSE||G/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1960-12-20||||1961-09-17||1971-03-25|1973-06-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/H|NON-ICR/NON-IUPD||UCI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|1||38||RUN-IN|1964-03-18||||1969-07-18||1970-10-01|1964-08-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PL|UNFAVORABLE RESPONSE||DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|SIBLING|READER 1|U|2||58||BLINDED TREATMENT|1965-10-10||||1972-01-10||1968-02-05|1963-03-14||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||SPLNRESP|SPLEEN RESPONSE||||NMOL/KG/DAY|PSA PROGRESSION||CI|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|CHILD|NEUROLOGIST 1|N|2||58||SCREENING|1961-11-18||||1973-07-30||1967-12-18|1960-04-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||NEWLIND|NEW LESION INDICATOR||||10^7 CFU|IPR||10^3 CFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|VENDOR|OPTOMETRIST|NA|3||39||FOLLOW-UP|1961-03-04||||1963-07-06||1970-03-11|1966-03-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DDU|HI-E||ML/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|GUARDIAN|READER 3|N|3||39||OBSERVATION|1965-04-04||||1970-12-15||1964-04-08|1971-06-30||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PA|MORPHOLOGIC CR||PPM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|STUDY SUBJECT|READER|U|4||88||CONTINUATION TREATMENT|1970-12-04||||1966-10-14||1968-10-23|1961-07-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||METSIND|METASTATIC INDICATOR||||CM/MIN|PMR||G/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|DOMESTIC PARTNER|CARDIOLOGIST|U|4||88||OPEN LABEL TREATMENT|1973-02-15||||1961-11-16||1961-11-10|1961-06-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CARTRIDGE|PSA PROGRESSION||MAMP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|SIBLING|ONCOLOGIST 1|U|5||7||INDUCTION TREATMENT|1970-09-07||||1967-10-05||1966-03-03|1969-09-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 CFU/G|IMMUNOPHENOTYPIC CR||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|CHILD|OPTOMETRIST|U|5||7||BASELINE|1964-03-08||||1966-03-09||1963-06-23|1963-02-22||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||MOLRESP|MOLECULAR RESPONSE||||UV*SEC|IUPD||BQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|SPOUSE|OPHTHALMOLOGIST|Y|1||38||BLINDED TREATMENT|1967-04-23||||1961-06-09||1963-04-23|1968-09-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DIP|CYTOGENETIC NO RESPONSE||DPM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|1||38||WASHOUT|1960-07-25||||1969-08-02||1961-06-12|1962-02-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||TRGRESP|TARGET RESPONSE||||CFU/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MM/2H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|SPOUSE|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1964-03-23||||1971-09-08||1967-12-01|1963-12-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BOWL|NON-ICR/NON-IUPD||NMOL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|STUDY SUBJECT|MICROSCOPIST 1|U|2||58||BLINDED TREATMENT|1971-11-07||||1961-01-24||1973-02-25|1972-02-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NG/MOL|DISEASE TRANSFORMATION||BQ/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|ADJUDICATOR|INTERNIST|Y|3||39||WASHOUT|1963-07-11||||1969-04-20||1965-05-02|1972-12-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/KG|PMD||DIOPTER|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|NA|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|3||39||BASELINE|1969-04-09||||1965-09-08||1973-03-04|1964-10-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||CLINRESP|CLINICAL RESPONSE||||WEBER|IPR||G/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|VENDOR|MICROSCOPIST 2|NA|4||88||CONTINUATION TREATMENT|1969-12-27||||1960-06-21||1966-10-18|1967-08-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||ANATRESP|ANATOMIC RESPONSE||||CUP|CR-CT||KIU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|GUARDIAN|RADIOLOGIST 2|U|4||88||TREATMENT|1968-02-02||||1973-02-18||1963-01-27|1963-02-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||TRGRESP|TARGET RESPONSE||||/H|MORPHOLOGIC CRI||/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|DOMESTIC PARTNER|ADJUDICATOR 1|Y|5||7||CONTINUATION TREATMENT|1960-08-08||||1971-01-10||1972-12-21|1961-02-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KM/H|INCREASED||KEV|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|FRIEND|RADIOLOGIST 1|U|5||7||WASHOUT|1962-10-26||||1960-06-23||1970-08-25|1970-12-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||METBRESP|METABOLIC RESPONSE||||KBQ|NON-QUANTIFIABLE MRD POSITIVITY||U/M2/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|1||38||SCREENING|1964-12-10||||1964-03-24||1966-01-04|1969-07-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||PATHRESP|PATHOLOGIC RESPONSE||||BEL|IMPROVED||SQU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|PROXY|MICROSCOPIST 1|U|1||38||OBSERVATION|1972-06-11||||1971-03-10||1972-10-23|1969-07-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^12/L|SD||CGY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1962-04-26||||1962-04-08||1967-03-20|1961-11-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MCI/L|MORPHOLOGIC CRI||KAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|INTERVIEWER|OPTOMETRIST|U|2||58||BASELINE|1969-10-28||||1960-06-10||1968-01-21|1966-03-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG/H|PD-CT||IN2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|3||39||FOLLOW-UP|1965-05-21||||1968-06-19||1967-07-10|1961-01-13||DURING||DURING|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||SPLNRESP|SPLEEN RESPONSE||||HR/DAY|NED||MET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|PROXY|RADIOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1967-03-27||||1971-06-14||1972-03-21|1972-08-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||CLINRESP|CLINICAL RESPONSE||||NEBULE|INCREASED||/CMH2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|SPOUSE|READER|N|4||88||BASELINE|1973-06-15||||1970-05-12||1972-10-19|1965-08-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||MOLRESP|MOLECULAR RESPONSE||||10^8/L|CR-CT||GPL U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|ADJUDICATOR|READER 1|N|4||88||OPEN LABEL TREATMENT|1960-06-30||||1966-02-15||1964-02-28|1960-01-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||OVRLRESP|OVERALL RESPONSE||||PFU|PMR||BQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|GUARDIAN|INTERNIST|N|5||7||BASELINE|1970-10-24||||1971-06-11||1965-11-09|1964-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||CYTORESP|CYTOGENETIC RESPONSE||||BQ/G|PSA PROGRESSION||ML/MMHG/MIN/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|5||7||BLINDED TREATMENT|1964-12-11||||1965-01-23||1967-08-21|1968-03-06||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||BONERESP|BONE RESPONSE||||HOURS|MOLECULAR CR||MV/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|ADJUDICATION COMMITTEE|READER 3|U|1||38||OPEN LABEL TREATMENT|1970-02-18||||1967-12-09||1964-07-27|1963-08-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CI/MG|VGPR||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|INTERVIEWER|OPTOMETRIST|N|1||38||SCREENING|1968-02-04||||1970-12-16||1972-11-16|1967-10-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||TRGRESP|TARGET RESPONSE||||IMPLANT|CPR||PATCH|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|INVESTIGATOR|READER 3|U|2||58||SCREENING|1960-06-09||||1966-08-31||1972-08-07|1968-07-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||SPLNRESP|SPLEEN RESPONSE||||MM/2H|PDU||MEQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|2||58||LONG-TERM FOLLOW-UP|1972-06-14||||1973-04-03||1973-05-11|1968-02-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||TRGRESP|TARGET RESPONSE||||ML/CM|UNEQUIVOCAL||UMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|DOMESTIC PARTNER|READER 1|N|3||39||FOLLOW-UP|1967-02-10||||1970-11-19||1967-02-23|1969-11-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 IU/ML|MINOR PATHOLOGIC RESPONSE||/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|3||39||BASELINE|1967-11-18||||1969-01-11||1970-10-31|1966-04-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||VOXEL|UNFAVORABLE RESPONSE||BOLUS|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|STUDY SUBJECT|RADIOLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1961-11-06||||1971-02-21||1973-08-15|1960-04-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||STRUSTAT|STEROID USE STATUS||||SYRINGE|INCREASED||MMHG/SEC|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|4||88||FOLLOW-UP|1972-03-20||||1961-08-07||1971-05-18|1965-04-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PIXELS/IN|MRD PERSISTENCE||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|FRIEND|ONCOLOGIST 1|N|5||7||WASHOUT|1967-01-19||||1960-09-07||1972-11-05|1967-04-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||APPLICATION|EQUIVOCAL||CM/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|5||7||WASHOUT|1962-10-12||||1970-06-19||1963-06-08|1972-12-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||LIVRRESP|LIVER RESPONSE||||BAR|CA125 50% RESPONSE||TAMPON|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|1||38||OBSERVATION|1971-05-17||||1960-07-15||1962-04-13|1963-06-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||OVRLRESP|OVERALL RESPONSE||||MG/KG/MIN|MRD RELAPSE||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|CAREGIVER|READER 3|NA|1||38||OPEN LABEL TREATMENT|1966-04-27||||1960-11-16||1969-10-29|1972-11-03||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/KG/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UCI/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|CAREGIVER|PATHOLOGIST|N|2||58||BLINDED TREATMENT|1968-01-31||||1963-09-06||1965-04-08|1961-05-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ELISA UNIT|PSA PROGRESSION||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|INVESTIGATOR|OPTOMETRIST|NA|2||58||LONG-TERM FOLLOW-UP|1965-09-13||||1969-08-11||1964-12-22|1972-05-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||ANATRESP|ANATOMIC RESPONSE||||MAMP|INCREASED||BEAM BREAKS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|3||39||RUN-IN|1964-03-20||||1971-01-04||1964-02-09|1968-08-03||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IN|HI-N||ABSORBANCE U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|3||39||RUN-IN|1969-05-20||||1962-02-24||1960-06-13|1972-11-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 IU/ML|SCR||UCI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|INVESTIGATOR|MICROSCOPIST 2|NA|4||88||BLINDED TREATMENT|1969-04-15||||1961-09-26||1972-11-16|1964-04-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||STRUSTAT|STEROID USE STATUS||||VIAL|PDU||UEQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|4||88||RUN-IN|1970-02-03||||1968-02-21||1967-09-11|1962-01-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PG|CYTOGENETIC MINIMAL RESPONSE||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|INDEPENDENT ASSESSOR|READER 2|N|5||7||WASHOUT|1971-12-05||||1973-08-21||1962-09-17|1965-08-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9 ORGANISMS/MG|CYTOGENETIC MINIMAL RESPONSE||GPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1971-04-09||||1963-01-12||1969-09-21|1960-09-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/CAGE/WK|CPR||%/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|CHILD|OTOLARYNGOLOGIST|Y|1||38||INDUCTION TREATMENT|1969-07-16||||1964-02-22||1971-09-17|1967-09-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LOG EID 50/DOSE|CCR||FEU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|ADJUDICATOR|ONCOLOGIST|Y|1||38||SCREENING|1971-03-08||||1969-04-28||1971-08-22|1963-10-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UG/G/H|CYTOGENETIC MINIMAL RESPONSE||/10^5|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|SPOUSE|ADJUDICATOR 2|N|2||58||BLINDED TREATMENT|1964-10-31||||1962-06-14||1973-07-17|1972-11-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||TRGRESP|TARGET RESPONSE||||10^6 CFU|PR WITH LYMPHOCYTOSIS||/500 WBC|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|READER|Y|2||58||OPEN LABEL TREATMENT|1960-07-29||||1961-12-16||1964-08-19|1969-08-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||TRGRESP|TARGET RESPONSE||||PELLET|PR||ML/(MIN*100ML)|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|ADJUDICATION COMMITTEE|RATER 1|N|3||39||OBSERVATION|1967-03-31||||1962-04-15||1965-09-03|1971-06-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/MMOL|RELAPSED DISEASE FROM CR||BLOCKS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|Y|3||39||OPEN LABEL TREATMENT|1965-05-29||||1962-01-18||1965-10-09|1969-04-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||MOLRESP|MOLECULAR RESPONSE||||DPM/0.5 ML|EQUIVOCAL||MESF|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|SIGNIFICANT OTHER|MICROSCOPIST 2|U|4||88||WASHOUT|1971-02-19||||1966-05-28||1961-09-11|1963-11-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BREATHS/MIN|SMD||10^3 CFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|4||88||CONTINUATION TREATMENT|1970-10-25||||1967-05-03||1968-04-13|1969-03-04||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/ML|CCR||INHALATION|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|ADJUDICATION COMMITTEE|RATER|Y|5||7||OBSERVATION|1962-08-22||||1973-01-08||1965-05-12|1962-09-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||CYTORESP|CYTOGENETIC RESPONSE||||GBQ/MG|MRD RELAPSE||PMOL/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|GUARDIAN|RATER|N|5||7||TREATMENT|1972-01-16||||1973-06-18||1969-06-02|1969-07-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||BONERESP|BONE RESPONSE||||ML/KG/MIN|WORSENED||PLUG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|FAMILY MEMBER|PATHOLOGIST|N|1||38||BLINDED TREATMENT|1968-06-11||||1964-04-10||1963-08-30|1970-10-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MM2|IMPROVED||CY/CM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CAREGIVER|CARDIOLOGIST|Y|1||38||BLINDED TREATMENT|1968-09-14||||1963-03-27||1960-08-22|1964-06-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^9 CFU/G|NOT ALL EVALUATED||MMHG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|VENDOR|PATHOLOGIST|Y|2||58||BLINDED TREATMENT|1960-02-29||||1971-08-31||1971-11-18|1967-04-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||CYTORESP|CYTOGENETIC RESPONSE||||APS U|PDU||NMOL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|INTERVIEWER|PATHOLOGIST 1|Y|2||58||SCREENING|1963-12-14||||1966-05-15||1973-08-05|1973-04-15||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||LB|NE||UOSM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|SPOUSE|PATHOLOGIST 1|Y|3||39||RUN-IN|1962-08-01||||1970-07-18||1965-08-27|1966-02-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^9 CFU/G|PMR||10^3 ORGANISMS|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|FRIEND|NEUROLOGIST 1|Y|3||39||FOLLOW-UP|1965-02-28||||1967-03-28||1973-05-31|1966-03-14||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PT_BR|VGPR||ML/MMHG|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|CHILD|HEMATOLOGIST|N|4||88||CONTINUATION TREATMENT|1964-06-16||||1962-09-03||1969-09-13|1965-10-31||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UL|CRI||G/CAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|ADJUDICATOR|READER 3|U|4||88||BASELINE|1970-06-02||||1966-03-12||1964-04-17|1967-08-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||METBRESP|METABOLIC RESPONSE||||PMOL/L/H|ICPD||G/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|5||7||SCREENING|1960-10-28||||1970-03-24||1963-01-31|1962-02-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||LIVRRESP|LIVER RESPONSE||||CM|HI-P||MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|ADJUDICATOR|READER 2|NA|5||7||RUN-IN|1971-07-04||||1965-02-24||1970-11-23|1965-03-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/L|CMR||GY/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|GUARDIAN|PATHOLOGIST 1|NA|1||38||BLINDED TREATMENT|1964-06-02||||1962-09-10||1971-06-17|1970-06-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||METBRESP|METABOLIC RESPONSE||||QUANTITY SUFFICIENT|PD-CT||OHM|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|ADJUDICATOR|MICROSCOPIST|NA|1||38||CONTINUATION TREATMENT|1963-04-04||||1962-05-22||1972-12-25|1972-10-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||NMOL/DAY|NED||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|FRIEND|RADIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1961-01-24||||1972-07-21||1966-10-27|1962-12-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/M2/DAY|NR||COAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|PROXY|NEUROLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1960-06-28||||1964-12-05||1972-05-27|1972-01-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TESLA|SD||UMOL/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1963-02-20||||1961-10-28||1962-11-12|1965-03-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||METSIND|METASTATIC INDICATOR||||CCID 50/ML|TREATMENT FAILURE||MSEC|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|3||39||WASHOUT|1969-06-03||||1970-05-11||1960-01-22|1970-04-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/BEAT|CA125 75% RESPONSE||MASK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|INTERVIEWER|OPTOMETRIST|N|4||88||OBSERVATION|1973-05-21||||1968-05-19||1962-08-18|1971-09-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||TRGRESP|TARGET RESPONSE||||CAPSULE|COMPLETE MRD RESPONSE||MEQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|4||88||OPEN LABEL TREATMENT|1962-08-28||||1962-06-27||1963-05-17|1964-11-15||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UMOL/H/MMOL|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5||7||INDUCTION TREATMENT|1965-03-03||||1968-08-25||1963-07-28|1973-05-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ABSORBANCE U/ML|MORPHOLOGIC CR||U/G/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|SPOUSE|ENDOCRINOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1966-09-02||||1969-02-28||1962-12-17|1969-01-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/G/DAY|CCR||MNFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|1||38||BLINDED TREATMENT|1973-06-29||||1967-08-17||1964-08-19|1969-01-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||RDIORESP|RADIOLOGIC RESPONSE||||BQ/ML|MORPHOLOGIC CRI||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|STUDY SUBJECT|PATHOLOGIST 2|N|1||38||TREATMENT|1973-08-07||||1971-03-15||1967-02-24|1970-12-28||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||BESTRESP|BEST OVERALL RESPONSE||||VOXEL|IPR||UM/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|CAREGIVER|OPHTHALMOLOGIST|U|2||58||INDUCTION TREATMENT|1961-06-21||||1973-05-08||1967-02-03|1963-06-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CMOL|VGPR||IU/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|SIBLING|ADJUDICATOR 3|NA|2||58||CONTINUATION TREATMENT|1963-02-07||||1971-12-08||1965-01-31|1960-06-29||DURING||DURING|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||RDIORESP|RADIOLOGIC RESPONSE||||KPA/L/SEC|EQUIVOCAL||LOG10 TCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|3||39||SCREENING|1969-07-03||||1971-07-08||1969-07-10|1968-11-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||WEBER|PMR||TBSP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||FOLLOW-UP|1961-03-26||||1973-07-26||1965-01-26|1967-05-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UU/DL|UNFAVORABLE RESPONSE||MG/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|FAMILY MEMBER|READER 2|U|4||88||BASELINE|1973-08-26||||1962-02-28||1971-06-24|1972-06-29||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||NTRGRESP|NON-TARGET RESPONSE||||MV|SD||10^6 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|PARENT|CARDIOLOGIST|N|4||88||RUN-IN|1969-01-15||||1964-10-17||1971-12-03|1967-05-11||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MONTHS|MORPHOLOGIC CR||L/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|5||7||BLINDED TREATMENT|1962-03-07||||1963-07-06||1963-07-03|1967-05-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PELLET|OPTIMAL MORPHOLOGIC RESPONSE||UMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|ADJUDICATOR|MICROSCOPIST|N|5||7||INDUCTION TREATMENT|1966-02-07||||1961-10-17||1970-03-03|1967-01-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KBQ|EQUIVOCAL||10^9 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|FAMILY MEMBER|CARDIOLOGIST|NA|1||38||SCREENING|1970-08-01||||1964-08-16||1971-02-21|1972-03-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||LIVRRESP|LIVER RESPONSE||||DIP|CMR||10^6 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|1||38||INDUCTION TREATMENT|1972-12-12||||1960-08-06||1966-10-12|1960-04-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||MOLRESP|MOLECULAR RESPONSE||||G/ANIMAL|VGPR||MM/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|CAREGIVER|READER 1|U|2||58||OBSERVATION|1968-02-27||||1960-07-24||1960-03-30|1970-01-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||MOLRESP|MOLECULAR RESPONSE||||DEG|SMD||10^3 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|GUARDIAN|READER 3|N|2||58||SCREENING|1972-11-02||||1961-04-28||1973-04-08|1963-09-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||NEWLIND|NEW LESION INDICATOR||||BOTTLE|QUANTIFIABLE MRD POSITIVITY||UMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1960-10-22||||1970-06-29||1969-10-21|1966-05-31||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^9 CFU/ML|PD FROM PR||CAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|3||39||BASELINE|1962-04-14||||1965-03-28||1972-01-08|1973-01-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||APL U/ML|CR||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|SPOUSE|MICROSCOPIST 2|N|4||88||TREATMENT|1961-05-29||||1968-07-13||1971-07-18|1970-08-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/BREATH|NE||G/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|CLINICAL STUDY SPONSOR|PATHOLOGIST|N|4||88||SCREENING|1962-09-07||||1966-04-29||1965-06-28|1966-11-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/2500 WBC|PARTIAL MORPHOLOGIC RESPONSE||G/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|STUDY SUBJECT|ONCOLOGIST|NA|5||7||WASHOUT|1968-06-15||||1971-08-29||1964-12-29|1970-03-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/100G/MIN|MRD RELAPSE||MG/M2/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|5||7||WASHOUT|1971-07-08||||1963-10-20||1960-09-04|1967-04-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||MOLRESP|MOLECULAR RESPONSE||||MHZ|CYTOGENETIC MINOR RESPONSE||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|CLINICAL STUDY SPONSOR|INTERNIST|Y|1||38||FOLLOW-UP|1970-05-14||||1968-08-23||1965-05-31|1971-07-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||NEWLIND|NEW LESION INDICATOR||||NMOL/L/MIN|RELAPSED DISEASE FROM CR||IMPLANT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1||38||BLINDED TREATMENT|1969-08-03||||1969-01-10||1964-12-19|1966-04-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MPA|MORPHOLOGIC CRI||/10^5|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|NON-HEALTH CARE PROFESSIONAL|RATER|U|2||58||BASELINE|1968-03-14||||1961-04-28||1962-11-17|1963-03-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||METSIND|METASTATIC INDICATOR||||TUBE|COMPLETE MRD RESPONSE||SIEMENS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|INTERVIEWER|READER|NA|2||58||BASELINE|1971-05-10||||1965-05-24||1965-10-14|1970-07-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG10 TCID 50/DOSE|CHR||ARBITRARY U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|ADJUDICATOR|PHYSIOTHERAPIST|N|3||39||CONTINUATION TREATMENT|1964-08-28||||1961-03-02||1969-11-17|1965-08-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||BESTRESP|BEST OVERALL RESPONSE||||L/S|MINOR PATHOLOGIC RESPONSE||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|INDEPENDENT ASSESSOR|RATER|Y|3||39||RUN-IN|1970-01-05||||1964-03-01||1963-03-22|1973-09-02||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||ANATRESP|ANATOMIC RESPONSE||||%/S|STABLE||U/DL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|FRIEND|MICROSCOPIST 2|N|4||88||OBSERVATION|1960-04-21||||1966-12-11||1969-03-03|1973-01-21||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||CLINRESP|CLINICAL RESPONSE||||MBP|CYTOGENETIC MINIMAL RESPONSE||U/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|SIBLING|PATHOLOGIST 2|NA|4||88||BASELINE|1963-12-01||||1968-08-27||1973-08-23|1969-10-07||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IU/ML|MR||MG/CM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|FAMILY MEMBER|ONCOLOGIST|NA|5||7||BLINDED TREATMENT|1960-07-07||||1962-04-19||1961-12-04|1971-06-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/DOSE|PSEUDOPROGRESSION||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|INTERVIEWER|RATER 2|U|5||7||SCREENING|1961-11-11||||1966-08-21||1965-02-06|1970-03-25||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||TRGRESP|TARGET RESPONSE||||PSEC|SCR||OZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|CHILD|PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1970-03-13||||1963-11-02||1964-12-08|1962-06-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/M2|PD FROM PR||DAGU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|GUARDIAN|ONCOLOGIST|Y|1||38||TREATMENT|1963-07-18||||1961-09-01||1969-06-02|1961-04-01||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||BONERESP|BONE RESPONSE||||LOG10 COPIES/ML|CYTOGENETIC CR||AGU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|2||58||BASELINE|1968-07-28||||1968-06-09||1973-02-22|1962-03-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||CLINRESP|CLINICAL RESPONSE||||AMP|SD-CT||ML/MIN/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|2||58||WASHOUT|1966-09-28||||1963-07-11||1967-04-21|1967-06-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MEQ/KG|CR||/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||TREATMENT|1961-06-29||||1963-10-02||1960-01-12|1961-11-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BEL|NR||HEP|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|3||39||BASELINE|1965-04-13||||1962-06-13||1972-07-25|1960-02-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||METSIND|METASTATIC INDICATOR||||PRESSOR UNITS|RELAPSED DISEASE FROM CR||K|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|PROXY|ONCOLOGIST 1|NA|4||88||TREATMENT|1961-02-02||||1962-03-11||1964-08-13|1966-03-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LB|PMD||SHOCK WAVE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|FAMILY MEMBER|READER 2|N|4||88||BASELINE|1961-12-26||||1970-08-19||1965-08-13|1963-12-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MILE|ICPD||BQ/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|5||7||WASHOUT|1965-06-15||||1966-04-03||1962-06-30|1967-02-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||CYTORESP|CYTOGENETIC RESPONSE||||U/M2|MORPHOLOGIC CR||GBQ/UG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|INVESTIGATOR|READER 3|Y|5||7||OBSERVATION|1961-03-13||||1969-12-11||1962-06-01|1963-04-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||OVRLRESP|OVERALL RESPONSE||||G/U|HI-P||PATCH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|CHILD|NEUROLOGIST 1|Y|1||38||RUN-IN|1960-05-23||||1967-06-13||1968-04-02|1973-04-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PPM|WORSENED||ELISA UNIT|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|1||38||BASELINE|1973-07-07||||1970-06-07||1970-02-25|1964-01-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||ANATRESP|ANATOMIC RESPONSE||||KG/MOL|IUPD||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|2||58||SCREENING|1969-01-28||||1962-07-16||1968-12-24|1964-03-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPLET|DECREASED||PA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|PROXY|RATER 1|Y|2||58||WASHOUT|1970-04-13||||1972-03-20||1962-04-16|1960-05-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||MOLRESP|MOLECULAR RESPONSE||||UKAT|CPR||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|3||39||CONTINUATION TREATMENT|1966-12-15||||1961-05-12||1963-11-20|1967-04-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||OVRLRESP|OVERALL RESPONSE||||BEATS/MIN|IUPD||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|INTERVIEWER|UROLOGIST|U|3||39||SCREENING|1973-05-07||||1972-11-23||1968-05-14|1973-06-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||RDIORESP|RADIOLOGIC RESPONSE||||%(V/V)|ABSENT MORPHOLOGIC RESPONSE||/100 HPFS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|SPOUSE|INTERNIST|Y|4||88||BLINDED TREATMENT|1962-01-04||||1960-11-10||1969-04-21|1965-04-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPSULE|PD-CT||PLUG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|PROXY|PATHOLOGIST|NA|4||88||RUN-IN|1969-04-06||||1970-06-27||1964-11-19|1963-04-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU/KG|CHR||ARBITRARY U|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||SCREENING|1967-01-19||||1967-04-04||1965-08-21|1967-09-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/M2/H|MORPHOLOGIC LEUKEMIA-FREE STATE||10^6 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|FAMILY MEMBER|PATHOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1968-07-03||||1968-02-10||1961-09-24|1970-06-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|1||||||NEWLPROG|NEW LESION PROGRESSION||||UMOL/MIN|PARTIAL MORPHOLOGIC RESPONSE||ML/DL|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|PARENT|DERMATOLOGIST|Y|1||38||OBSERVATION|1969-04-19||||1964-12-09||1969-04-17|1969-02-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^6 ORGANISMS|CA125 50% RESPONSE||EU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|INTERVIEWER|DERMATOLOGIST|U|1||38||WASHOUT|1967-06-04||||1964-04-06||1961-06-12|1969-01-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6/EJACULATE U|SMD||ML/100G/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||FOLLOW-UP|1960-04-22||||1960-10-11||1962-10-15|1960-02-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3/L|STABLE||EID 50/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|2||58||SCREENING|1965-05-07||||1965-04-24||1963-02-23|1972-07-31||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||RNA COPIES/ML|NR||NGEQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|FRIEND|ADJUDICATOR 2|NA|3||39||CONTINUATION TREATMENT|1963-08-13||||1968-09-26||1973-09-01|1972-11-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||GPS U|DECREASED||PIXEL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|STUDY SUBJECT|DERMATOLOGIST|Y|3||39||SCREENING|1962-02-26||||1967-08-28||1965-02-05|1966-07-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|1||||||ANATRESP|ANATOMIC RESPONSE||||PPTR|CYTOGENETIC MINIMAL RESPONSE||TUBERCULIN UNIT|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|U|4||88||TREATMENT|1967-01-01||||1972-01-21||1966-12-31|1973-02-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/L|MOLECULAR CR||CMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|SPOUSE|OTOLARYNGOLOGIST|NA|4||88||FOLLOW-UP|1971-03-18||||1967-01-05||1963-10-30|1966-04-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|1||||||OVRLRESP|OVERALL RESPONSE||||IU/KG/H|MR||PIXEL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|5||7||OPEN LABEL TREATMENT|1972-12-15||||1960-10-31||1965-07-23|1966-02-20||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E7958F8B-D987-4929-993A-8960EB30A309|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AMP|DISEASE TRANSFORMATION||BAU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|INTERVIEWER|RADIOLOGIST 1|U|5||7||BLINDED TREATMENT|1968-01-31||||1960-01-30||1969-01-09|1965-03-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||NTRGRESP|NON-TARGET RESPONSE||||U/CL|ABSENT MORPHOLOGIC RESPONSE||ML/G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|SPOUSE|OPTOMETRIST|N|1||38||BLINDED TREATMENT|1964-04-13||||1968-09-28||1965-07-14|1961-06-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PHERESIS UNIT|PCR||ML/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|ADJUDICATOR|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1971-05-31||||1968-01-26||1970-08-15|1963-10-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DAGU/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|FAMILY MEMBER|ONCOLOGIST|U|2||58||WASHOUT|1963-06-16||||1967-09-29||1970-06-27|1967-11-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^9 ORGANISMS/G|NPR||CI|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1972-02-09||||1961-04-04||1969-02-04|1964-06-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DYN|MINOR PATHOLOGIC RESPONSE||G/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|3||39||FOLLOW-UP|1969-03-11||||1969-03-29||1970-07-28|1970-08-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||NEWLIND|NEW LESION INDICATOR||||10^12 IU/L|ABSENT MORPHOLOGIC RESPONSE||ML/S/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|CLINICAL STUDY SPONSOR|READER 3|N|3||39||FOLLOW-UP|1965-06-22||||1964-06-23||1968-02-05|1972-09-14||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/2000 RBC|CA125 50% RESPONSE||ML/MMHG|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 3|NA|4||88||INDUCTION TREATMENT|1970-11-11||||1960-02-02||1960-02-05|1962-07-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||NEWLPROG|NEW LESION PROGRESSION||||KG/M2|MRD RELAPSE||/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|SPOUSE|ONCOLOGIST 2|Y|4||88||RUN-IN|1960-03-16||||1962-02-19||1967-12-06|1970-05-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CI/KG|CA125 75% RESPONSE||JDF UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|SIBLING|ONCOLOGIST 1|N|5||7||WASHOUT|1964-10-13||||1969-12-01||1965-05-23|1969-01-02||DURING||DURING|
TRIAL STUDY 134XCP|RS|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||LOG10 COPIES/ML|WORSENED||U/10^12 RBC|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|CHILD|PATHOLOGIST 2|Y|5||7||BLINDED TREATMENT|1962-01-02||||1962-11-24||1960-10-03|1972-08-01||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UCI/KG|PDU||IU|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|1||38||TREATMENT|1971-03-04||||1971-06-24||1968-03-10|1961-10-29||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/KG/H|MRD PERSISTENCE||PMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|HEALTH CARE PROFESSIONAL|READER 2|Y|1||38||WASHOUT|1969-04-16||||1970-08-26||1971-07-30|1971-04-03||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||BESTRESP|BEST OVERALL RESPONSE||||/MM2|NON-ICR/NON-IUPD||BQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|VENDOR|READER 3|U|2||58||OPEN LABEL TREATMENT|1966-01-19||||1963-11-03||1963-12-27|1966-03-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||BONERESP|BONE RESPONSE||||U/ML|DECREASED||10^9/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||BLINDED TREATMENT|1962-02-26||||1962-11-25||1960-01-12|1961-03-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||SPLNRESP|SPLEEN RESPONSE||||ANSON U|MORPHOLOGIC CRI||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|CAREGIVER|ONCOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1962-09-10||||1967-10-18||1962-03-17|1969-12-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||LIVRRESP|LIVER RESPONSE||||U/G|CPR||PKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|CHILD|OPHTHALMOLOGIST|NA|3||39||RUN-IN|1967-07-16||||1968-03-24||1970-07-26|1968-04-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||BESTRESP|BEST OVERALL RESPONSE||||/MONTH|NE||NMOL/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|INTERVIEWER|PHYSIOTHERAPIST|Y|4||88||OPEN LABEL TREATMENT|1963-10-31||||1960-08-03||1972-03-05|1968-06-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||USIEMENS|DISEASE TRANSFORMATION||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|VENDOR|MICROSCOPIST|Y|4||88||RUN-IN|1968-05-10||||1973-05-26||1972-06-18|1973-03-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||NEWLIND|NEW LESION INDICATOR||||CI/G|ICR||CMH2O*S2/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|VENDOR|RADIOLOGIST 2|NA|5||7||BLINDED TREATMENT|1973-05-27||||1960-03-29||1973-04-26|1966-12-20||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||CLINRESP|CLINICAL RESPONSE||||10^9 ORGANISMS/MG|CPR||LOZENGE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|5||7||TREATMENT|1967-09-19||||1970-08-15||1964-05-22|1961-04-23||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||RDIORESP|RADIOLOGIC RESPONSE||||F|PDU||MBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|1||38||CONTINUATION TREATMENT|1968-10-14||||1964-10-13||1966-06-19|1971-10-27||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^6 ORGANISMS/ML|MCR||CARTRIDGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|ADJUDICATOR|DERMATOLOGIST|Y|1||38||SCREENING|1972-02-02||||1963-04-02||1969-01-07|1962-09-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EU|NR||ML/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|CHILD|ADJUDICATOR 1|Y|2||58||BASELINE|1966-10-29||||1961-02-25||1971-10-04|1961-10-20||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UKAT/10^12 RBC|MR||10^4/HPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|DOMESTIC PARTNER|ONCOLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1965-10-15||||1970-02-06||1973-06-14|1968-06-09||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||NTRGRESP|NON-TARGET RESPONSE||||NG/DL|SD-CT||U/CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1963-10-21||||1962-12-04||1960-08-27|1969-07-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UMOL/L|PD/RELAPSE AFTER HI||FG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||BASELINE|1969-09-15||||1963-11-09||1967-06-16|1964-11-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ANTIBODY UNIT|EQUIVOCAL||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|4||88||TREATMENT|1972-01-22||||1968-06-04||1968-04-05|1963-07-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9/G|IUPD||ML/KG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|CAREGIVER|READER 2|NA|4||88||SCREENING|1969-08-21||||1968-05-15||1962-07-12|1967-02-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||CLINRESP|CLINICAL RESPONSE||||PFU/DOSE|NON-QUANTIFIABLE MRD POSITIVITY||NL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|STUDY SUBJECT|CLINICAL PATHOLOGIST|N|5||7||BLINDED TREATMENT|1966-02-05||||1970-11-30||1967-09-14|1966-02-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||SFC/10^6 PBMC|SCR||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|PARENT|NEUROLOGIST|Y|5||7||BASELINE|1965-12-11||||1964-12-09||1970-05-15|1961-11-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||METSIND|METASTATIC INDICATOR||||GBQ/UG|CR||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|1||38||OPEN LABEL TREATMENT|1970-11-24||||1969-09-12||1965-05-08|1966-04-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/DL|PSEUDOPROGRESSION||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|INVESTIGATOR|PHYSIOTHERAPIST|NA|1||38||BLINDED TREATMENT|1969-03-29||||1965-06-13||1967-12-24|1962-06-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||NTRGRESP|NON-TARGET RESPONSE||||ABSORBANCE U|ABSENT MORPHOLOGIC RESPONSE||BOX|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|INVESTIGATOR|ADJUDICATOR|U|2||58||BLINDED TREATMENT|1966-06-13||||1970-03-02||1972-08-25|1968-11-28||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/G/DAY|PD||MKAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|PARENT|NEUROLOGIST 1|U|2||58||OBSERVATION|1960-04-18||||1966-10-12||1964-09-30|1962-05-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||NEWLPROG|NEW LESION PROGRESSION||||AG|MR||UKAT/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|STUDY SUBJECT|ENDOCRINOLOGIST|Y|3||39||SCREENING|1973-01-22||||1960-12-23||1963-04-22|1966-07-28||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NMOL/KG/DAY|NR||10^9/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|INVESTIGATOR|OPHTHALMOLOGIST|U|3||39||INDUCTION TREATMENT|1971-05-08||||1968-07-06||1970-10-01|1964-07-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||TMRESP|TUMOR MARKER RESPONSE||||L/DAY|MORPHOLOGIC CR||MOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|DOMESTIC PARTNER|ONCOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1969-06-26||||1965-05-12||1973-05-17|1964-01-07||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||F|MOLECULAR MAJOR RESPONSE||SQU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|N|4||88||FOLLOW-UP|1966-04-02||||1964-09-17||1969-06-24|1970-10-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||SPLNRESP|SPLEEN RESPONSE||||UKAT|PD||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|FRIEND|MICROSCOPIST 1|N|5||7||OPEN LABEL TREATMENT|1966-08-07||||1963-07-27||1965-12-15|1972-11-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||SPLNRESP|SPLEEN RESPONSE||||LM|RELAPSED DISEASE FROM CR OR PR||LOG10 ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|5||7||WASHOUT|1967-03-14||||1973-04-01||1973-07-10|1966-05-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/ML/MIN|MAJOR PATHOLOGIC RESPONSE||GLOBULE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|1||38||FOLLOW-UP|1969-09-29||||1966-01-15||1962-03-10|1964-05-30||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||TRGRESP|TARGET RESPONSE||||KG/CM|PR WITH LYMPHOCYTOSIS||MOSM/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1968-03-08||||1967-08-20||1961-08-04|1967-10-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PM|MORPHOLOGIC CRI||PM|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|PARENT|RADIOLOGIST 2|NA|2||58||FOLLOW-UP|1966-06-24||||1967-11-09||1965-05-25|1971-05-31||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PA|HI-N||MPL U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||RUN-IN|1963-10-02||||1961-08-28||1963-01-17|1962-03-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||METSIND|METASTATIC INDICATOR||||UV2|NED||UG/G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|SIBLING|PHYSIOTHERAPIST|NA|3||39||SCREENING|1969-11-01||||1968-03-21||1964-04-15|1967-08-29||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||MOLRESP|MOLECULAR RESPONSE||||MILE|ABSENT MORPHOLOGIC RESPONSE||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|INTERVIEWER|ADJUDICATOR|U|3||39||SCREENING|1968-08-31||||1970-03-03||1968-10-06|1966-12-26||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||NEWLPROG|NEW LESION PROGRESSION||||RAD|MORPHOLOGIC CR||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|ADJUDICATOR|OPTOMETRIST|N|4||88||CONTINUATION TREATMENT|1962-09-09||||1962-01-10||1963-02-28|1963-05-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||TRGRESP|TARGET RESPONSE||||NFIU|CA125 75% RESPONSE||MJOULE/CM2|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|FRIEND|MICROSCOPIST 2|N|4||88||INDUCTION TREATMENT|1971-03-14||||1966-12-31||1963-06-23|1967-02-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9 CFU/ML|RELAPSED DISEASE FROM CR||WAFER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|GUARDIAN|PATHOLOGIST 1|N|5||7||INDUCTION TREATMENT|1963-08-25||||1962-02-15||1961-04-14|1961-07-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMHG*MIN/L|NPR||UGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|5||7||BLINDED TREATMENT|1970-12-18||||1965-09-02||1960-06-17|1970-09-29||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CARTRIDGE|MOLECULAR CR||U/CL|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|SIBLING|PATHOLOGIST|U|1||38||FOLLOW-UP|1969-09-28||||1967-10-27||1961-05-24|1963-06-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|2||||||CLINRESP|CLINICAL RESPONSE||||LB|NE||10^10/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|VENDOR|NEUROLOGIST|U|1||38||FOLLOW-UP|1960-06-04||||1972-06-04||1967-02-12|1971-01-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/MIN|PSA PROGRESSION||CGY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|PROXY|ONCOLOGIST 1|NA|2||58||RUN-IN|1970-09-08||||1968-12-04||1971-10-01|1962-11-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|2||||||METBRESP|METABOLIC RESPONSE||||KG|CPR||/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|FAMILY MEMBER|PHYSIOTHERAPIST|NA|2||58||SCREENING|1970-08-28||||1968-05-31||1960-01-31|1972-11-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||M/SEC2|MINOR PATHOLOGIC RESPONSE||CMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|STUDY SUBJECT|ADJUDICATOR 3|N|3||39||FOLLOW-UP|1963-06-23||||1970-11-05||1970-05-09|1966-03-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|2||||||NTRGRESP|NON-TARGET RESPONSE||||AGU/ML|RELAPSED DISEASE FROM CR OR PR||UL/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|3||39||BLINDED TREATMENT|1960-09-04||||1967-01-30||1972-07-21|1960-02-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|1||||||CLINRESP|CLINICAL RESPONSE||||NSEC|CA125 75% RESPONSE||VG/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|RATER 1|U|4||88||SCREENING|1969-08-01||||1967-03-29||1962-03-08|1971-12-02||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BQ/ML|NON-CR/NON-PD||CAL|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|PROXY|ADJUDICATOR 1|N|4||88||WASHOUT|1961-03-30||||1964-04-28||1966-07-31|1965-06-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CONTAINER|MORPHOLOGIC CRI||UCI/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|SIGNIFICANT OTHER|READER 2|NA|5||7||INDUCTION TREATMENT|1970-08-04||||1964-03-28||1960-05-30|1968-02-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|872942E9-A575-4929-9B21-D30DE51B367B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/KG/MIN|FAVORABLE RESPONSE||KPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|5||7||OBSERVATION|1963-06-09||||1968-01-24||1968-11-24|1962-06-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PIXELS/CM|IUPD||SACHET|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|GUARDIAN|NEUROLOGIST|NA|1||38||FOLLOW-UP|1961-08-14||||1965-01-13||1965-05-08|1960-06-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/MG/MIN|EQUIVOCAL||GENEQ/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|VENDOR|NEUROLOGIST 2|U|1||38||BLINDED TREATMENT|1965-09-17||||1964-04-23||1965-12-01|1968-10-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DRINK|NON-ICR/NON-IUPD||UG/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|U|2||58||SCREENING|1965-04-15||||1960-10-26||1969-03-17|1967-08-22||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^9 ORGANISMS|CA125 75% RESPONSE||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|U|2||58||INDUCTION TREATMENT|1967-01-17||||1972-10-30||1969-10-06|1966-03-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||NTRGRESP|NON-TARGET RESPONSE||||U.CARR|QUANTIFIABLE MRD POSITIVITY||MOSM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|CHILD|NEUROLOGIST 2|Y|3||39||SCREENING|1963-10-10||||1968-08-08||1966-05-08|1961-10-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||SPLNRESP|SPLEEN RESPONSE||||U/KG|CHR||UMOL/MG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|3||39||CONTINUATION TREATMENT|1970-05-13||||1966-04-13||1968-09-21|1965-10-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||RDIORESP|RADIOLOGIC RESPONSE||||GPL U|CYTOGENETIC MINIMAL RESPONSE||MOSM/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|CHILD|FORENSIC PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1960-12-10||||1971-08-21||1961-07-19|1967-03-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/MM2|PSEUDORESPONSE||10^9 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|FRIEND|MICROSCOPIST|U|4||88||LONG-TERM FOLLOW-UP|1969-08-12||||1969-02-27||1967-06-08|1970-12-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||OVRLRESP|OVERALL RESPONSE||||CUP EQ|MINOR PATHOLOGIC RESPONSE||TCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|U|5||7||INDUCTION TREATMENT|1963-11-17||||1969-09-11||1973-02-04|1968-03-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CFU/ML|INCREASED||MG/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|VENDOR|MICROSCOPIST 2|N|5||7||FOLLOW-UP|1965-03-11||||1969-07-18||1969-10-06|1964-09-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||OVRLRESP|OVERALL RESPONSE||||10^6 IU|CPR||UGEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|INTERNIST|NA|1||38||CONTINUATION TREATMENT|1964-05-27||||1969-05-21||1966-10-27|1963-08-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||SPLNRESP|SPLEEN RESPONSE||||ELISA UNIT/DOSE|SD||GENEQ/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|1||38||LONG-TERM FOLLOW-UP|1963-11-23||||1966-05-14||1964-09-08|1962-06-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||CLINRESP|CLINICAL RESPONSE||||DEG/MM|NPR||MN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|SIBLING|ADJUDICATOR 2|N|2||58||FOLLOW-UP|1971-11-30||||1972-04-10||1972-07-19|1970-05-08||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/10^5|EQUIVOCAL||10^9 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|CHILD|ONCOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1967-03-26||||1973-07-10||1973-04-20|1967-12-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||BONERESP|BONE RESPONSE||||SIEMENS|MRD NEGATIVITY||U/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|INTERVIEWER|OTOLARYNGOLOGIST|N|3||39||INDUCTION TREATMENT|1967-06-09||||1970-01-26||1963-02-10|1968-07-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||CLINRESP|CLINICAL RESPONSE||||MMOL/L|DISEASE TRANSFORMATION||MM/2H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|3||39||OPEN LABEL TREATMENT|1965-09-15||||1965-08-16||1968-07-26|1964-11-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MET|ABSENT MORPHOLOGIC RESPONSE||/LPF|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|CAREGIVER|MICROSCOPIST 2|N|4||88||TREATMENT|1973-07-20||||1968-08-05||1971-03-13|1966-10-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||APL U|QUANTIFIABLE MRD POSITIVITY||CAPLET|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|INTERVIEWER|READER 1|U|4||88||WASHOUT|1967-02-13||||1963-03-27||1969-03-13|1973-03-01||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MM/MIN|PD-CT||DDU|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|ADJUDICATION COMMITTEE|READER|U|5||7||TREATMENT|1962-08-12||||1970-04-10||1962-04-02|1965-08-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/MIN|RELAPSED DISEASE FROM CR OR PR||G/ANIMAL/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|READER|N|5||7||OPEN LABEL TREATMENT|1963-01-26||||1971-05-23||1973-04-10|1962-07-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||RDIORESP|RADIOLOGIC RESPONSE||||BREATHS/MIN|PR||/2500 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|STUDY SUBJECT|NEUROLOGIST 2|Y|1||38||BLINDED TREATMENT|1972-07-14||||1972-05-16||1965-11-27|1968-08-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||NEWLPROG|NEW LESION PROGRESSION||||PA|IMPROVED||IU/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|CAREGIVER|MICROSCOPIST 2|Y|1||38||INDUCTION TREATMENT|1969-07-26||||1969-12-31||1966-04-22|1970-09-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PIXELS/CM|PARTIAL MORPHOLOGIC RESPONSE||MIU/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|CAREGIVER|OPTOMETRIST|Y|2||58||BLINDED TREATMENT|1965-08-29||||1962-02-09||1970-02-11|1960-01-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/G/MIN|NED||CY/CM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|INDEPENDENT ASSESSOR|READER|NA|2||58||BLINDED TREATMENT|1962-10-10||||1961-06-27||1960-11-22|1973-04-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/KG|MORPHOLOGIC CR||MBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|3||39||BASELINE|1967-06-11||||1972-06-08||1967-04-17|1961-12-01||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GY/MIN|INDETERMINATE RESPONSE||KA_U/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|CAREGIVER|RATER 2|N|3||39||OPEN LABEL TREATMENT|1967-06-11||||1965-08-17||1972-05-25|1963-03-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||TMRESP|TUMOR MARKER RESPONSE||||TORR|PD FROM PR||AMPULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|INTERVIEWER|MICROSCOPIST 2|N|4||88||WASHOUT|1962-09-07||||1972-10-06||1972-05-27|1970-07-24||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ANTIBODY UNIT|INDETERMINATE RESPONSE||/LSQN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|SIBLING|ONCOLOGIST 1|U|4||88||TREATMENT|1963-11-21||||1965-08-17||1968-03-21|1966-10-12||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6/EJACULATE U|ICR||BLOCKS|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|SPOUSE|OPHTHALMOLOGIST|N|5||7||WASHOUT|1964-03-11||||1968-08-16||1964-04-06|1972-01-09||DURING||DURING|
TRIAL STUDY 134XCP|RS|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MU|SCR||BQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|INDEPENDENT ASSESSOR|READER 3|Y|5||7||RUN-IN|1967-09-04||||1964-04-11||1966-02-22|1963-09-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||STRUSTAT|STEROID USE STATUS||||MOSM/L|FAVORABLE RESPONSE||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|PROXY|READER|Y|1||38||INDUCTION TREATMENT|1972-06-29||||1970-01-08||1965-12-20|1972-07-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|FAVORABLE RESPONSE||CI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|1||38||INDUCTION TREATMENT|1963-12-06||||1966-05-09||1961-08-31|1973-08-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/G/MIN|CR||MOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1964-07-18||||1962-02-14||1961-06-30|1971-04-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FMOL|INCREASED||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|FAMILY MEMBER|DERMATOLOGIST|U|2||58||SCREENING|1969-10-15||||1966-03-06||1963-06-14|1965-10-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PFU|NON-CR/NON-PD||SPRAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3||39||CONTINUATION TREATMENT|1968-07-05||||1971-10-04||1965-09-22|1966-02-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EJACULATE U|UNFAVORABLE RESPONSE||CS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|3||39||FOLLOW-UP|1970-02-19||||1969-12-16||1967-12-12|1971-04-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GPL U|UNEQUIVOCAL||10^3 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|PROXY|CARDIOLOGIST|U|4||88||BLINDED TREATMENT|1964-04-19||||1962-05-27||1968-07-17|1969-06-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||PATHRESP|PATHOLOGIC RESPONSE||||%(V/V)|CHR||PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CHILD|MICROSCOPIST 3|Y|4||88||WASHOUT|1968-06-26||||1972-07-21||1966-11-11|1963-01-04||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/ML/DAY|MAJOR PATHOLOGIC RESPONSE||L/S/KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||OBSERVATION|1966-03-17||||1960-03-11||1968-11-22|1970-09-28||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||OZ|DISEASE TRANSFORMATION||SFC/10^6 PBMC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|PARENT|HEMATOLOGIST|U|5||7||BLINDED TREATMENT|1967-08-08||||1966-11-25||1970-09-28|1961-04-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TUBE|PMD||UMOL/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|1||38||TREATMENT|1961-02-08||||1969-08-16||1962-12-31|1960-11-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL/L|MAJOR PATHOLOGIC RESPONSE||PPB|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|DOMESTIC PARTNER|ADJUDICATOR 1|U|1||38||FOLLOW-UP|1973-04-15||||1969-09-28||1966-06-11|1972-09-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMU/ML|NOT ALL EVALUATED||UCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|PARENT|FORENSIC PATHOLOGIST|U|2||58||BASELINE|1968-12-26||||1968-04-25||1964-12-08|1968-10-31||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||NEWLIND|NEW LESION INDICATOR||||CUP EQ|PD FROM PR||ANSON U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|2||58||INDUCTION TREATMENT|1963-06-22||||1960-09-11||1963-03-05|1962-12-06||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||EP U|NPR||OZ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|3||39||SCREENING|1965-04-15||||1965-01-17||1972-04-29|1969-04-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||MOLRESP|MOLECULAR RESPONSE||||MOL/MG|UNFAVORABLE RESPONSE||KG/L|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR|N|3||39||FOLLOW-UP|1969-01-03||||1971-07-08||1972-02-24|1967-07-30||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||CYTORESP|CYTOGENETIC RESPONSE||||U/M2/MIN|HI-E||UG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CAREGIVER|ADJUDICATOR|NA|4||88||CONTINUATION TREATMENT|1960-06-09||||1962-06-28||1961-06-03|1966-04-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||M/SEC2|VGPR||ML/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|4||88||SCREENING|1965-01-29||||1968-10-14||1972-11-16|1970-10-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/G HB|MINOR PATHOLOGIC RESPONSE||AGU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|SIGNIFICANT OTHER|RATER 2|Y|5||7||OPEN LABEL TREATMENT|1969-10-31||||1966-12-03||1966-04-22|1964-03-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||OVRLRESP|OVERALL RESPONSE||||MMHG|PSA PROGRESSION||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1964-11-28||||1967-02-12||1972-03-12|1964-11-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||V/SEC|UNFAVORABLE RESPONSE||PA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|FAMILY MEMBER|ONCOLOGIST|Y|1||38||RUN-IN|1966-12-31||||1972-11-30||1965-06-16|1970-04-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||GENEQ|PR-CT||MG/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|SPOUSE|PHYSIOTHERAPIST|Y|1||38||CONTINUATION TREATMENT|1961-06-08||||1971-10-14||1961-02-14|1964-06-04||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/10^12 RBC|SD-CT||GBQ/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|PROXY|PATHOLOGIST 2|U|2||58||INDUCTION TREATMENT|1973-02-01||||1972-11-20||1966-10-18|1968-03-29||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||OVRLRESP|OVERALL RESPONSE||||UL/KG/DAY|CYTOGENETIC MINOR RESPONSE||NKAT/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|ADJUDICATION COMMITTEE|RATER|Y|2||58||TREATMENT|1966-12-04||||1962-04-12||1966-11-13|1965-09-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ/UG|MOLECULAR MAJOR RESPONSE||NKAT/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|3||39||TREATMENT|1967-01-11||||1960-05-03||1960-12-09|1970-07-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MMOL/DAY|MINOR PATHOLOGIC RESPONSE||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|3||39||OPEN LABEL TREATMENT|1972-05-13||||1969-05-16||1961-04-14|1970-01-23||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||NEWLIND|NEW LESION INDICATOR||||TUBE|CRI||APL U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|SIBLING|ADJUDICATOR 3|NA|4||88||CONTINUATION TREATMENT|1967-12-19||||1961-11-30||1967-12-23|1972-04-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||BONERESP|BONE RESPONSE||||PMOL/L/H|CYTOGENETIC CR||MG/KG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||CONTINUATION TREATMENT|1970-04-19||||1968-11-30||1960-09-13|1965-03-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^10/L|PSEUDORESPONSE||KN/CM2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|5||7||WASHOUT|1968-03-01||||1967-04-13||1970-03-12|1973-07-04||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||TRGRESP|TARGET RESPONSE||||TAMPON|PSEUDORESPONSE||NG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|5||7||OBSERVATION|1967-01-06||||1965-02-13||1967-04-29|1963-07-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||OVRLRESP|OVERALL RESPONSE||||PMOL/10^9 CELLS|CPR||ML/BEAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|STUDY SUBJECT|MICROSCOPIST 1|N|1||38||TREATMENT|1970-11-14||||1963-01-15||1969-05-21|1960-04-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||TRGRESP|TARGET RESPONSE||||CMOL/L|CR-CT||ROENTGEN|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||BASELINE|1972-04-29||||1968-05-25||1960-01-24|1968-11-20||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||%(V/V)|NON-CR/NON-PD||U/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|FAMILY MEMBER|PATHOLOGIST 1|Y|2||58||BASELINE|1961-02-17||||1973-05-05||1966-03-18|1960-11-12||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GRAVITATIONAL UNIT|PDU||CMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|2||58||RUN-IN|1967-03-02||||1968-09-09||1960-09-25|1962-01-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||SPLNRESP|SPLEEN RESPONSE||||GLOBULE|TREATMENT FAILURE||U/G/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|3||39||LONG-TERM FOLLOW-UP|1970-04-02||||1966-01-02||1971-07-21|1965-01-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||WEEKS|HI-E||/100 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|SIBLING|NEUROLOGIST 1|N|3||39||RUN-IN|1972-06-13||||1972-10-10||1962-03-10|1966-09-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FFU|SMD||CYLINDER|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|CHILD|PHYSIOTHERAPIST|N|4||88||OBSERVATION|1965-07-25||||1963-07-12||1965-05-13|1971-07-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||AG|NON-PD||MMHG|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|DOMESTIC PARTNER|RADIOLOGIST 1|N|4||88||BASELINE|1967-10-04||||1961-07-19||1972-12-20|1960-10-11||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||METBRESP|METABOLIC RESPONSE||||PKAT/L|HI-P||EU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|GUARDIAN|FORENSIC PATHOLOGIST|U|5||7||BASELINE|1967-09-11||||1968-03-21||1969-12-25|1961-08-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||NEWLIND|NEW LESION INDICATOR||||10^6 ORGANISMS|CRI||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|SIGNIFICANT OTHER|READER 3|Y|5||7||TREATMENT|1960-01-15||||1969-07-30||1969-11-23|1966-06-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||TMRESP|TUMOR MARKER RESPONSE||||LX|MORPHOLOGIC CRI||/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|SPOUSE|CARDIOLOGIST|NA|1||38||BASELINE|1973-07-12||||1971-06-10||1960-04-07|1961-05-10||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||BESTRESP|BEST OVERALL RESPONSE||||GRAVITATIONAL UNIT|STABLE||DRINK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|READER 2|N|1||38||WASHOUT|1970-07-06||||1964-01-19||1963-10-24|1966-12-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||BONERESP|BONE RESPONSE||||MU/G|CCR||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|2||58||OPEN LABEL TREATMENT|1970-04-13||||1973-08-21||1968-11-26|1968-09-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||SPLNRESP|SPLEEN RESPONSE||||BQ/G|UNFAVORABLE RESPONSE||OZ|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|CAREGIVER|FORENSIC PATHOLOGIST|Y|2||58||RUN-IN|1972-12-03||||1969-01-28||1970-01-12|1970-04-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2/DAY|FAVORABLE RESPONSE||AGU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|SPOUSE|READER 1|Y|3||39||SCREENING|1966-08-03||||1961-02-04||1969-06-21|1966-11-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^4 CFU/ML|HI-E||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|PARENT|CLINICAL PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1961-02-13||||1961-06-23||1972-01-08|1961-05-11||DURING||DURING|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||MOLRESP|MOLECULAR RESPONSE||||BU|IMPROVED||V/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|SPOUSE|RATER 1|U|4||88||INDUCTION TREATMENT|1966-09-07||||1969-07-04||1965-03-16|1961-12-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||TRGRESP|TARGET RESPONSE||||MET*H|CYTOGENETIC MINOR RESPONSE||MM3/MM2/YEAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|VENDOR|ADJUDICATOR 3|NA|4||88||BLINDED TREATMENT|1964-02-25||||1964-02-25||1973-04-24|1966-07-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^8/L|CYTOGENETIC MINIMAL RESPONSE||CMH2O/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||BASELINE|1968-10-17||||1972-01-09||1969-02-08|1972-05-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MESF|CYTOGENETIC MINOR RESPONSE||MV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|5||7||WASHOUT|1969-10-27||||1960-05-05||1963-11-28|1972-09-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||U/KG/DAY|DECREASED||MG/L FEU|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|DOMESTIC PARTNER|PATHOLOGIST|N|1||38||BASELINE|1970-10-14||||1968-09-01||1963-01-31|1962-10-31||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|2||||||BONERESP|BONE RESPONSE||||MOL/L|STABLE||FT2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|PROXY|READER 2|N|1||38||WASHOUT|1969-09-04||||1963-04-19||1962-03-23|1972-06-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 CFU/ML|CHR||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|ADJUDICATION COMMITTEE|DERMATOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1963-07-03||||1964-06-09||1966-07-26|1962-09-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/G/DAY|MRD PERSISTENCE||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|SIBLING|UROLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1961-10-27||||1966-09-07||1962-08-19|1967-01-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|1||||||NEWLIND|NEW LESION INDICATOR||||10^4 CFU|CYTOGENETIC MINOR RESPONSE||MG/ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|3||39||SCREENING|1972-10-22||||1971-03-19||1963-04-18|1967-07-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||INHALATION|IPR||FL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||BLINDED TREATMENT|1973-04-28||||1966-01-29||1967-04-01|1972-04-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|1||||||STRUSTAT|STEROID USE STATUS||||DEG2|UNFAVORABLE RESPONSE||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|CHILD|NEUROLOGIST 2|Y|4||88||INDUCTION TREATMENT|1966-12-28||||1971-12-26||1969-08-18|1960-09-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|2||||||TMRESP|TUMOR MARKER RESPONSE||||S*KPA|NE||10^9/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|4||88||RUN-IN|1970-08-25||||1971-10-22||1970-12-24|1971-12-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|1||||||MOLRESP|MOLECULAR RESPONSE||||IU/MMOL|CPR||ML/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|INVESTIGATOR|READER 1|Y|5||7||RUN-IN|1962-05-08||||1967-09-25||1968-03-03|1973-06-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|60B57F98-61FF-4322-8084-7A536964F60A|2||||||LIVRRESP|LIVER RESPONSE||||TSP|IMMUNOPHENOTYPIC CR||G/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|INDEPENDENT ASSESSOR|RATER 1|NA|5||7||OBSERVATION|1967-10-25||||1962-06-04||1967-08-19|1967-12-18||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||SBE/ML|PMR||CMH2O*S2/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|DOMESTIC PARTNER|ONCOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1968-10-13||||1965-08-21||1972-02-26|1967-12-01||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||CLINRESP|CLINICAL RESPONSE||||10^9/G|COMPLETE MRD RESPONSE||NMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|ADJUDICATOR|ONCOLOGIST 1|N|1||38||RUN-IN|1963-12-05||||1964-02-05||1967-05-17|1968-08-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DNA COPIES/UG|CYTOGENETIC MINIMAL RESPONSE||UM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|2||58||TREATMENT|1963-07-10||||1970-06-08||1968-08-09|1966-01-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||ANATRESP|ANATOMIC RESPONSE||||U/M2|SCR||MG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|UROLOGIST|Y|2||58||OBSERVATION|1964-03-20||||1970-09-05||1962-07-28|1967-06-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KEV|ICR||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|INVESTIGATOR|PHYSIOTHERAPIST|U|3||39||SCREENING|1969-01-05||||1960-05-09||1968-02-20|1968-12-16||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^6 COPIES/ML|PR WITH LYMPHOCYTOSIS||IU/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|PROXY|RATER 1|N|3||39||INDUCTION TREATMENT|1971-10-10||||1968-02-18||1969-01-27|1968-04-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||COPIES/ML|SCR||VOXEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||FOLLOW-UP|1960-02-24||||1973-08-24||1962-03-14|1968-06-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/CM H2O|CPR||MV|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|4||88||TREATMENT|1965-11-01||||1968-07-07||1964-10-22|1960-08-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^4/L|MCR||10^11/L|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|FAMILY MEMBER|ADJUDICATOR 2|NA|5||7||LONG-TERM FOLLOW-UP|1965-11-14||||1972-01-12||1967-10-27|1964-06-08||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/KG/H|CR-CT||PPTR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||CONTINUATION TREATMENT|1965-08-03||||1963-06-24||1968-04-16|1971-07-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/L|RELAPSED DISEASE FROM CR OR PR||10^6 IU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|ADJUDICATOR|MICROSCOPIST 1|N|1||38||SCREENING|1964-05-20||||1966-04-15||1965-12-15|1965-01-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MS2|INDETERMINATE RESPONSE||DAYS/MONTH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|1||38||FOLLOW-UP|1971-08-03||||1972-06-12||1967-02-24|1971-08-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/L DDU|ISD||CMHG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|FAMILY MEMBER|NEUROLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1973-03-11||||1970-04-17||1965-10-24|1964-10-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||TMRESP|TUMOR MARKER RESPONSE||||ECL UNIT|INCREASED||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|INTERVIEWER|RATER 2|U|2||58||INDUCTION TREATMENT|1967-09-03||||1965-06-25||1970-10-11|1964-08-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||SPLNRESP|SPLEEN RESPONSE||||MCI/KG|CA125 75% RESPONSE||HOURS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|SIGNIFICANT OTHER|RATER 1|NA|3||39||LONG-TERM FOLLOW-UP|1969-11-22||||1962-11-17||1961-10-22|1965-11-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/MIN|PCR||ML/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|FRIEND|OTOLARYNGOLOGIST|U|3||39||OBSERVATION|1971-01-15||||1961-12-29||1967-02-23|1968-05-28||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MV/SEC|IUPD||KCAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|VENDOR|RADIOLOGIST|U|4||88||SCREENING|1968-02-25||||1964-06-08||1971-10-13|1965-05-28||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^3 ORGANISMS/ML|CPR||ML/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||OPEN LABEL TREATMENT|1960-04-06||||1964-07-09||1972-12-09|1967-01-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/KG|EQUIVOCAL||PM|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|INTERVIEWER|CARDIOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1962-12-13||||1965-10-18||1960-07-09|1964-05-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||NEWLIND|NEW LESION INDICATOR||||L/H/M2|CYTOGENETIC CR||BREATHS/30S|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1973-01-25||||1963-09-10||1965-10-24|1968-02-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MEQ/L|MORPHOLOGIC CRI||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|SIBLING|ADJUDICATOR|U|1||38||FOLLOW-UP|1960-06-29||||1973-08-04||1963-10-24|1962-07-17||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OSM|NPR||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|INTERVIEWER|INTERNIST|U|1||38||OPEN LABEL TREATMENT|1963-04-16||||1963-10-17||1971-01-02|1964-04-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6 DNA COPIES/ML|TREATMENT FAILURE||NG/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|VENDOR|MICROSCOPIST 2|U|2||58||RUN-IN|1972-10-02||||1966-07-08||1970-12-27|1966-02-04||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||METSIND|METASTATIC INDICATOR||||SEC|CMR||NMOL BCE/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|SIBLING|READER 3|N|2||58||RUN-IN|1966-11-12||||1966-01-15||1965-08-07|1969-06-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||U.CARR|NOT ALL EVALUATED||DRINK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|SPOUSE|HEMATOLOGIST|U|3||39||WASHOUT|1973-03-24||||1968-08-29||1962-01-02|1973-02-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL2/L2|MOLECULAR CR||ABSORBANCE U|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|VENDOR|READER 1|N|3||39||CONTINUATION TREATMENT|1961-04-16||||1963-03-18||1969-10-14|1964-11-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FG|ABSENT MORPHOLOGIC RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|PARENT|RATER 1|N|4||88||INDUCTION TREATMENT|1973-01-27||||1971-09-14||1970-02-19|1961-04-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||RDIORESP|RADIOLOGIC RESPONSE||||COPIES/UL|NE||RPM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|CHILD|ADJUDICATOR 1|Y|4||88||OPEN LABEL TREATMENT|1962-02-11||||1970-05-03||1972-06-24|1967-10-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CMOL/L|PD/RELAPSE AFTER HI||MEQ/DL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|DOMESTIC PARTNER|OTOLARYNGOLOGIST|NA|5||7||RUN-IN|1966-02-22||||1970-12-16||1965-02-26|1962-04-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ENZYME U/G HB|MRD RELAPSE||PACKET|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|INVESTIGATOR|MICROSCOPIST 2|NA|5||7||INDUCTION TREATMENT|1973-04-21||||1973-08-20||1968-08-11|1971-02-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||CLINRESP|CLINICAL RESPONSE||||U/KG/MIN|CCR||VG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|CHILD|OPTOMETRIST|Y|1||38||BASELINE|1961-03-25||||1962-05-28||1962-12-12|1973-02-19||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||NEWLIND|NEW LESION INDICATOR||||10^3/HPF|NPR||ML/BREATH|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|1||38||CONTINUATION TREATMENT|1964-05-16||||1967-12-17||1960-12-29|1960-10-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI/KG|OPTIMAL MORPHOLOGIC RESPONSE||HR/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|2||58||INDUCTION TREATMENT|1961-04-07||||1969-11-19||1960-10-07|1968-06-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||TRGRESP|TARGET RESPONSE||||ML/ANIMAL/WK|HI-N||COULOMB|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|SPOUSE|PATHOLOGIST 2|N|2||58||FOLLOW-UP|1969-04-24||||1963-10-07||1969-06-10|1963-01-31||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TITER|MOLECULAR CR||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||TREATMENT|1961-04-16||||1961-11-25||1972-05-15|1961-12-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||NEWLPROG|NEW LESION PROGRESSION||||MEQ|MAJOR PATHOLOGIC RESPONSE||GAUSS|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|3||39||SCREENING|1965-08-21||||1963-01-12||1968-06-01|1963-05-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NG|CCR||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|4||88||INDUCTION TREATMENT|1972-11-15||||1960-03-11||1973-05-31|1963-12-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||STRUSTAT|STEROID USE STATUS||||MS/MMHG|NON-CR/NON-PD||MPS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|SIBLING|PEDIATRIC NEUROLOGIST|NA|4||88||SCREENING|1963-07-25||||1965-11-03||1960-12-01|1970-11-26||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||NEWLIND|NEW LESION INDICATOR||||10^4 CFU/ML|NON-QUANTIFIABLE MRD POSITIVITY||/LSQN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|SIGNIFICANT OTHER|PATHOLOGIST 2|N|5||7||SCREENING|1961-12-27||||1966-11-05||1963-12-14|1970-06-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||PATHRESP|PATHOLOGIC RESPONSE||||U/M2|PMR||AFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|PARENT|PATHOLOGIST 2|N|5||7||SCREENING|1965-08-09||||1966-01-22||1962-03-30|1962-03-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||NTRGRESP|NON-TARGET RESPONSE||||MEQ/G|IPR||U/MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|1||38||FOLLOW-UP|1966-05-06||||1961-02-13||1961-08-01|1961-06-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^12 IU/L|SD-CT||MCI/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1969-10-28||||1966-06-11||1960-06-17|1970-09-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||AMU|DISEASE TRANSFORMATION||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|INTERVIEWER|ONCOLOGIST 2|Y|2||58||SCREENING|1967-02-26||||1971-05-25||1966-06-04|1961-05-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/KG/H|STABLE||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|VENDOR|OTOLARYNGOLOGIST|U|2||58||BASELINE|1971-05-28||||1972-10-14||1965-09-29|1968-05-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UKAT/L|RELAPSED DISEASE FROM CR||KIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|DOMESTIC PARTNER|ONCOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1962-10-09||||1970-10-05||1972-11-03|1964-07-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||MOLRESP|MOLECULAR RESPONSE||||JDF UNIT|NED||CM H2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|VENDOR|FORENSIC PATHOLOGIST|N|3||39||TREATMENT|1970-05-25||||1962-12-09||1969-01-09|1972-02-18||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||NEWLPROG|NEW LESION PROGRESSION||||SIEMENS|INCREASED||G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|GUARDIAN|PATHOLOGIST 1|NA|4||88||TREATMENT|1971-04-14||||1967-02-22||1962-09-03|1968-04-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||STRUSTAT|STEROID USE STATUS||||SCOOPFUL|SMD||BOLUS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|FRIEND|ADJUDICATOR 2|U|4||88||WASHOUT|1965-12-01||||1966-04-05||1969-08-28|1970-06-14||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UKAT|RELAPSED DISEASE FROM CR OR PR||ML*CMH2O|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|INTERVIEWER|PATHOLOGIST 1|NA|5||7||FOLLOW-UP|1972-04-17||||1966-10-04||1960-06-22|1960-12-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||METSIND|METASTATIC INDICATOR||||10^3 DNA COPIES/ML|CPR||CMOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|5||7||WASHOUT|1969-06-08||||1970-10-13||1971-10-04|1964-01-28||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||LIVRRESP|LIVER RESPONSE||||UOSM|INCREASED||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|1||38||OBSERVATION|1969-01-28||||1972-03-14||1967-05-11|1963-05-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||SPLNRESP|SPLEEN RESPONSE||||10^9 ORGANISMS/ML|ICR||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|1||38||CONTINUATION TREATMENT|1972-04-26||||1961-10-16||1960-09-01|1965-02-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/L|SD||LX|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|SPOUSE|UROLOGIST|NA|2||58||TREATMENT|1968-01-07||||1969-09-20||1970-09-08|1960-02-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/M2/MIN|ICPD||ML/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|INTERVIEWER|MICROSCOPIST 3|NA|2||58||BASELINE|1963-04-25||||1962-08-19||1966-12-30|1970-08-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||NEWLIND|NEW LESION INDICATOR||||LOG10 TCID 50/ML|IMMUNOPHENOTYPIC CR||ML/100G/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|PARENT|UROLOGIST|Y|3||39||BLINDED TREATMENT|1960-09-23||||1970-09-30||1967-01-27|1970-09-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||BESTRESP|BEST OVERALL RESPONSE||||KG|PD FROM PR||/5X10^4 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|3||39||WASHOUT|1970-02-21||||1966-01-31||1970-04-09|1971-09-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||BONERESP|BONE RESPONSE||||ABSORBANCE U/ML|ICPD||10^6 IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|PARENT|HEMATOLOGIST|NA|4||88||FOLLOW-UP|1960-12-14||||1965-08-14||1961-12-21|1972-08-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/H|NON-ICR/NON-IUPD||IMPLANT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|SIGNIFICANT OTHER|READER 2|NA|4||88||WASHOUT|1972-11-22||||1967-02-17||1968-04-29|1971-03-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MV2/HZ|SMD||AMP|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|PROXY|RATER 2|Y|5||7||RUN-IN|1962-11-08||||1970-11-15||1960-07-22|1963-08-25||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6/G|PARTIAL MORPHOLOGIC RESPONSE||MMOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|INVESTIGATOR|ENDOCRINOLOGIST|Y|5||7||CONTINUATION TREATMENT|1968-03-18||||1969-05-23||1970-10-16|1964-05-03||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||ANATRESP|ANATOMIC RESPONSE||||BQ/UL|RELAPSED DISEASE FROM CR||DMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1||38||FOLLOW-UP|1972-10-18||||1970-11-19||1973-02-27|1966-04-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^9/DOSE|STABLE||%/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|FAMILY MEMBER|ADJUDICATOR 1|Y|1||38||BASELINE|1972-07-28||||1962-03-16||1973-07-03|1962-12-31||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KG/CM|QUANTIFIABLE MRD POSITIVITY||DISK|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|2||58||BASELINE|1963-10-29||||1961-06-27||1964-08-12|1961-03-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/H/MMOL|CA125 50% RESPONSE||PLUG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|ADJUDICATION COMMITTEE|RATER|Y|2||58||OPEN LABEL TREATMENT|1972-12-06||||1965-10-29||1965-04-30|1961-10-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||RNA COPIES/ML|PR WITH LYMPHOCYTOSIS||LOG10 TCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|FRIEND|UROLOGIST|N|3||39||BLINDED TREATMENT|1960-08-12||||1963-11-24||1960-05-17|1972-02-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FIU|COMPLETE MRD RESPONSE||10^3 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|ADJUDICATOR|CARDIOLOGIST|NA|3||39||OBSERVATION|1960-02-11||||1971-03-21||1966-03-06|1965-02-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||OVRLRESP|OVERALL RESPONSE||||OZ|NON-ICR/NON-IUPD||GPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|ADJUDICATOR|READER 3|NA|4||88||CONTINUATION TREATMENT|1965-02-15||||1966-11-25||1965-10-15|1963-06-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||SPLNRESP|SPLEEN RESPONSE||||MEQ/KG|CRI||FOZ_US|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|SPOUSE|PATHOLOGIST|U|4||88||OBSERVATION|1961-05-19||||1966-09-26||1968-01-09|1962-06-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||KIU|INDETERMINATE RESPONSE||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||OBSERVATION|1971-03-06||||1962-03-05||1964-04-11|1966-03-24||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MS2|CPR||IMPLANT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|SIBLING|CARDIOLOGIST|U|5||7||OBSERVATION|1960-07-26||||1964-04-03||1969-08-05|1973-03-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/DL|IPR||FIU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|1||38||BASELINE|1971-08-19||||1962-12-04||1970-04-19|1962-09-05||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CI/L|PDU||DAYS/MONTH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|INTERVIEWER|ADJUDICATOR 1|NA|1||38||CONTINUATION TREATMENT|1964-03-13||||1965-07-18||1963-12-13|1971-06-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MDFI|PR||PT_US|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|PARENT|INTERNIST|Y|2||58||RUN-IN|1961-12-30||||1961-10-02||1966-07-05|1972-08-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||MOLRESP|MOLECULAR RESPONSE||||10^7 PFU|CYTOGENETIC NO RESPONSE||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|CAREGIVER|PATHOLOGIST|N|2||58||WASHOUT|1965-02-09||||1973-07-29||1960-08-16|1967-10-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||STRUSTAT|STEROID USE STATUS||||CI/KG|CYTOGENETIC NO RESPONSE||CCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|3||39||TREATMENT|1971-04-28||||1965-08-24||1970-03-25|1964-01-12||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||TRGRESP|TARGET RESPONSE||||CUP EQ|MAJOR PATHOLOGIC RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|Y|PARENT|NEUROLOGIST 1|U|3||39||RUN-IN|1965-01-11||||1960-03-03||1963-01-27|1965-02-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||HOURS|MOLECULAR CR||G/CAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|PROXY|PEDIATRIC NEUROLOGIST|U|4||88||RUN-IN|1960-05-07||||1967-03-17||1969-03-18|1961-07-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/DOSE|MRD RELAPSE||PFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|4||88||BLINDED TREATMENT|1969-06-03||||1965-07-06||1964-04-22|1967-02-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||METBRESP|METABOLIC RESPONSE||||CYLINDER|CA125 75% RESPONSE||PT_BR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|5||7||INDUCTION TREATMENT|1969-07-30||||1971-08-14||1964-04-07|1966-06-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||METBRESP|METABOLIC RESPONSE||||ML/KG|CA125 75% RESPONSE||KN/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|5||7||RUN-IN|1967-08-19||||1964-02-05||1967-07-02|1964-01-02||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||TRGRESP|TARGET RESPONSE||||CD|PMR||INHALATION|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|FRIEND|READER|N|1||38||CONTINUATION TREATMENT|1962-04-15||||1967-02-12||1969-07-31|1970-05-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||NEWLIND|NEW LESION INDICATOR||||NMOL/DAY|MOLECULAR CR||EIA UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|INVESTIGATOR|READER 2|NA|1||38||RUN-IN|1962-01-01||||1973-03-16||1966-08-02|1960-09-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/H|CYTOGENETIC MINOR RESPONSE||BAU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|GUARDIAN|ADJUDICATOR|Y|2||58||BLINDED TREATMENT|1970-06-12||||1966-06-29||1970-05-30|1966-02-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL|PR-CT||KG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|INVESTIGATOR|ENDOCRINOLOGIST|N|2||58||TREATMENT|1966-03-28||||1960-10-31||1968-12-01|1965-10-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||NEWLIND|NEW LESION INDICATOR||||PACK YEAR|CHR||S*KPA|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|3||39||RUN-IN|1968-10-11||||1968-09-10||1970-05-17|1964-09-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||ANATRESP|ANATOMIC RESPONSE||||C|MAJOR PATHOLOGIC RESPONSE||AMU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||TREATMENT|1965-09-13||||1962-09-15||1973-04-23|1967-11-02||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PACK|MCR||KG/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|ADJUDICATOR|MICROSCOPIST 1|Y|4||88||INDUCTION TREATMENT|1970-04-09||||1972-03-29||1969-01-03|1960-09-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GPL U|MORPHOLOGIC CRI||ABSORBANCE U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|4||88||SCREENING|1968-06-23||||1962-06-09||1960-05-09|1963-06-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||CLINRESP|CLINICAL RESPONSE||||PKAT|ABSENT MORPHOLOGIC RESPONSE||COAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 1|NA|5||7||SCREENING|1970-06-01||||1960-05-16||1968-10-24|1961-08-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IN2|CMR||UM2|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|FAMILY MEMBER|READER|U|5||7||LONG-TERM FOLLOW-UP|1969-06-04||||1961-09-03||1969-06-17|1971-12-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MOSM/L|MAJOR PATHOLOGIC RESPONSE||FRAMES/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|VENDOR|OPTOMETRIST|Y|1||38||FOLLOW-UP|1966-06-29||||1961-11-01||1970-08-26|1965-12-04||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||BESTRESP|BEST OVERALL RESPONSE||||OHM|CYTOGENETIC NO RESPONSE||U/MG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|CHILD|RATER 2|U|1||38||BLINDED TREATMENT|1973-02-21||||1968-04-15||1968-04-13|1963-01-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OI50|HI-P||UGEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|2||58||FOLLOW-UP|1972-02-08||||1960-11-20||1972-01-09|1961-06-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FL|CRI||NMOL BCE/NMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|2||58||CONTINUATION TREATMENT|1963-07-05||||1972-12-24||1973-01-11|1967-06-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CI/MG|MRD NEGATIVITY||SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|PROXY|RADIOLOGIST 2|U|3||39||BASELINE|1969-01-28||||1964-06-11||1965-12-21|1964-06-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MEQ/L|ABSENT MORPHOLOGIC RESPONSE||CMH2O*S2/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1973-07-31||||1967-04-07||1967-07-24|1966-03-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||OI50|OPTIMAL MORPHOLOGIC RESPONSE||NMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|4||88||SCREENING|1973-08-26||||1960-09-21||1970-11-06|1965-05-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||METSIND|METASTATIC INDICATOR||||EJACULATE U|NPR||OZ EQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||BLINDED TREATMENT|1963-05-26||||1967-04-05||1968-06-18|1970-08-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CD|UNFAVORABLE RESPONSE||/5X10^4 WBC|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|N|FAMILY MEMBER|ADJUDICATOR 2|NA|5||7||INDUCTION TREATMENT|1972-04-28||||1972-06-18||1965-07-30|1969-01-29||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||METSIND|METASTATIC INDICATOR||||UG/KG/H|CYTOGENETIC NO RESPONSE||KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|INVESTIGATOR|READER 3|Y|5||7||WASHOUT|1961-06-05||||1960-04-24||1964-08-20|1967-12-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||BONERESP|BONE RESPONSE||||OSM|PARTIAL MORPHOLOGIC RESPONSE||HR/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|FAMILY MEMBER|PATHOLOGIST 1|U|1||38||BLINDED TREATMENT|1969-03-04||||1973-01-08||1965-01-09|1964-05-31||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||PATHRESP|PATHOLOGIC RESPONSE||||TUBERCULIN UNIT|DECREASED||MG/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|HEALTH CARE PROFESSIONAL|RATER 2|N|1||38||OPEN LABEL TREATMENT|1968-02-07||||1968-05-30||1961-09-05|1973-07-13||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||SPLNRESP|SPLEEN RESPONSE||||G/M2/DAY|MCR||10^3 COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||TREATMENT|1964-10-25||||1963-06-25||1967-12-03|1962-06-20||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||CYTORESP|CYTOGENETIC RESPONSE||||V|INCREASED||UGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|2||58||RUN-IN|1971-12-30||||1960-04-12||1966-02-20|1967-11-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||METSIND|METASTATIC INDICATOR||||G/DL|MORPHOLOGIC CRI||SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|FAMILY MEMBER|UROLOGIST|Y|3||39||TREATMENT|1965-08-01||||1971-06-13||1960-02-26|1963-01-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BAR|MRD NEGATIVITY||DAMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|3||39||BLINDED TREATMENT|1967-09-07||||1965-05-13||1967-10-28|1966-06-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BU|CYTOGENETIC MINIMAL RESPONSE||BAR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|INTERVIEWER|CLINICAL PATHOLOGIST|NA|4||88||RUN-IN|1973-08-29||||1971-04-14||1962-12-19|1964-07-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MV2/HZ|VGPR||NMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|4||88||BASELINE|1963-03-12||||1970-11-06||1970-02-25|1963-08-18||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MOL/L|NON-PD||ABSORBANCE U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|INTERVIEWER|PEDIATRIC NEUROLOGIST|Y|5||7||OBSERVATION|1965-09-07||||1973-08-20||1962-09-10|1962-05-31||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||CLINRESP|CLINICAL RESPONSE||||AMFI|CRI||V/V|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|SIBLING|READER 1|Y|5||7||LONG-TERM FOLLOW-UP|1972-12-25||||1971-12-11||1971-08-03|1967-08-31||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/G HB|PSA PROGRESSION||G/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|CLINICAL RESEARCH COORDINATOR|READER 3|NA|1||38||BASELINE|1965-10-25||||1971-09-03||1963-10-17|1962-04-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||TMRESP|TUMOR MARKER RESPONSE||||SYRINGE|PARTIAL MORPHOLOGIC RESPONSE||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|SIBLING|PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1967-12-22||||1967-12-05||1964-01-27|1968-01-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^12 IU/L|PD||ANSON U|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|2||58||LONG-TERM FOLLOW-UP|1969-05-13||||1968-04-24||1971-01-09|1964-01-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||CLINRESP|CLINICAL RESPONSE||||STEPS/MIN|RELAPSED DISEASE FROM CR OR PR||CYLINDER|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|VENDOR|RADIOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1970-06-03||||1965-03-19||1973-01-09|1973-08-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||TMRESP|TUMOR MARKER RESPONSE||||%|CYTOGENETIC MINIMAL RESPONSE||DAYS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|3||39||TREATMENT|1967-02-23||||1968-11-21||1962-08-22|1968-10-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 CFU/ML|STABLE||NG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|ADJUDICATOR|PHYSIOTHERAPIST|U|3||39||SCREENING|1966-10-16||||1971-09-16||1969-07-12|1968-11-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^3 RNA COPIES/ML|NON-QUANTIFIABLE MRD POSITIVITY||DAYS|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|STUDY SUBJECT|RATER 2|NA|4||88||INDUCTION TREATMENT|1969-07-23||||1966-07-08||1973-08-26|1972-09-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||NEWLPROG|NEW LESION PROGRESSION||||CI/UL|CA125 75% RESPONSE||U/MMOL|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|READER 1|U|4||88||BLINDED TREATMENT|1973-05-19||||1966-09-15||1968-05-16|1973-02-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||BONERESP|BONE RESPONSE||||ABSORBANCE U/ML|IMPROVED||MG/M2/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|5||7||BASELINE|1962-07-15||||1967-08-27||1973-04-03|1965-09-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DAGU/ML|CMR||CI/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|SPOUSE|ADJUDICATOR 3|Y|5||7||OPEN LABEL TREATMENT|1972-10-25||||1971-07-13||1966-07-29|1972-04-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/G|FAVORABLE RESPONSE||PMOL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||WASHOUT|1972-02-01||||1973-04-17||1965-07-10|1964-10-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||RPM|NE||ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|INTERVIEWER|PHYSIOTHERAPIST|NA|1||38||RUN-IN|1962-05-15||||1966-06-17||1961-10-21|1963-05-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MU/L|CPR||MM3/MM2/YEAR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|PARENT|RATER 2|N|2||58||BLINDED TREATMENT|1962-10-09||||1967-11-28||1968-08-17|1962-05-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||OVRLRESP|OVERALL RESPONSE||||UG/L FEU|IPR||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|2||58||BLINDED TREATMENT|1971-03-08||||1973-08-08||1970-04-14|1966-09-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||BONERESP|BONE RESPONSE||||CMH2O*S/ML|CA125 75% RESPONSE||L/H/M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||SCREENING|1961-02-17||||1963-02-17||1969-04-18|1961-05-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7 PFU|MOLECULAR CR||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|3||39||TREATMENT|1967-11-11||||1966-08-28||1964-03-20|1967-01-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UGEQ|CYTOGENETIC MINIMAL RESPONSE||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|SIGNIFICANT OTHER|ADJUDICATOR 3|N|4||88||BLINDED TREATMENT|1967-02-12||||1968-02-20||1973-07-25|1965-08-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||TMRESP|TUMOR MARKER RESPONSE||||APL U|VGPR||10^5/HPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||TREATMENT|1967-02-28||||1962-05-20||1972-08-09|1970-12-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||TMRESP|TUMOR MARKER RESPONSE||||BQ/ML|MR||ML/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|INVESTIGATOR|CARDIOLOGIST|NA|5||7||TREATMENT|1969-09-30||||1962-05-21||1968-11-15|1961-09-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FT3|MRD PERSISTENCE||10^6/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|ADJUDICATION COMMITTEE|INTERNIST|Y|5||7||WASHOUT|1962-04-20||||1970-03-24||1963-09-23|1968-03-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|1||||||METBRESP|METABOLIC RESPONSE||||V/V|VGPR||KBQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|VENDOR|INTERNIST|U|1||38||LONG-TERM FOLLOW-UP|1967-09-13||||1960-03-17||1971-12-05|1971-07-22||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|2||||||BONERESP|BONE RESPONSE||||DAYS|IPR||/MM2|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|1||38||SCREENING|1966-03-23||||1968-08-18||1967-08-17|1967-10-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|1||||||LIVRRESP|LIVER RESPONSE||||NMOL BCE/NMOL|SD-CT||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||CONTINUATION TREATMENT|1964-06-23||||1964-09-06||1972-02-03|1966-10-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NG/MOL|MRD PERSISTENCE||NMOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|FRIEND|ADJUDICATOR 1|U|2||58||TREATMENT|1971-01-13||||1970-01-11||1968-10-03|1973-01-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/KG/H|CMR||ML*CMH2O|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|FAMILY MEMBER|CARDIOLOGIST|NA|3||39||INDUCTION TREATMENT|1972-12-06||||1968-11-18||1962-11-13|1971-03-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|2||||||OVRLRESP|OVERALL RESPONSE||||UG/KG|PR WITH LYMPHOCYTOSIS||UG/L/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|GUARDIAN|PEDIATRIC NEUROLOGIST|U|3||39||OPEN LABEL TREATMENT|1960-06-28||||1972-05-11||1964-07-01|1964-05-31||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|1||||||LIVRRESP|LIVER RESPONSE||||%(W/W)|PD-CT||MCI/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|SPOUSE|FORENSIC PATHOLOGIST|U|4||88||BLINDED TREATMENT|1966-12-03||||1973-01-22||1968-06-23|1971-04-27||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MAC50|PD||CFU/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|VENDOR|PATHOLOGIST 1|N|4||88||TREATMENT|1968-07-18||||1962-07-31||1967-07-31|1962-11-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|1||||||OVRLRESP|OVERALL RESPONSE||||10^11/L|PD-CT||DAGU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|HEALTH CARE PROFESSIONAL|INTERNIST|Y|5||7||LONG-TERM FOLLOW-UP|1963-09-08||||1964-05-20||1964-10-12|1968-06-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CD69750D-957B-405C-A397-AFA331D30535|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/M2|PSA PROGRESSION||UG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|INVESTIGATOR|CLINICAL PATHOLOGIST|N|5||7||BLINDED TREATMENT|1965-10-08||||1965-04-14||1972-10-01|1960-02-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||AMOL|MR||ML/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|FRIEND|READER 3|NA|1||38||SCREENING|1961-07-09||||1960-07-28||1971-11-16|1968-10-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MET*MIN|SCR||NFIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|1||38||INDUCTION TREATMENT|1962-06-15||||1969-06-14||1969-03-27|1961-10-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||NTRGRESP|NON-TARGET RESPONSE||||MNFI|SD||V|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|SIGNIFICANT OTHER|PATHOLOGIST|N|2||58||TREATMENT|1963-05-21||||1970-10-09||1962-04-23|1972-03-10||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||TMRESP|TUMOR MARKER RESPONSE||||/H|RELAPSED DISEASE FROM CR OR PR||%/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|INTERVIEWER|RATER|U|2||58||OPEN LABEL TREATMENT|1969-08-07||||1962-10-09||1971-10-16|1971-08-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||BONERESP|BONE RESPONSE||||MONTHS|ISD||ML/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|PARENT|READER|U|3||39||FOLLOW-UP|1963-10-02||||1962-01-25||1967-08-29|1963-11-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^8/L|CR||MU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1969-06-12||||1960-02-08||1966-12-14|1961-05-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AMOL|UNFAVORABLE RESPONSE||HPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|4||88||WASHOUT|1968-03-30||||1971-12-08||1971-09-01|1973-01-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||OVRLRESP|OVERALL RESPONSE||||%/S|CMR||DROP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|FRIEND|MICROSCOPIST 3|Y|4||88||BASELINE|1961-05-28||||1969-11-09||1963-11-03|1967-11-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||METSIND|METASTATIC INDICATOR||||PA|IMMUNOPHENOTYPIC CR||CYLINDER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|STUDY SUBJECT|READER 1|NA|5||7||WASHOUT|1964-11-15||||1963-01-14||1962-09-18|1965-01-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||EQ|PDU||L/MIN/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|PROXY|RADIOLOGIST 2|NA|5||7||WASHOUT|1970-06-05||||1964-11-17||1962-12-03|1962-05-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KPA/L/SEC|ICR||VG/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|SPOUSE|ONCOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1961-03-25||||1962-12-07||1967-06-06|1963-04-30||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||BESTRESP|BEST OVERALL RESPONSE||||ECL UNIT|INDETERMINATE RESPONSE||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||LONG-TERM FOLLOW-UP|1969-04-11||||1966-01-07||1964-07-10|1973-02-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CI/UL|UNFAVORABLE RESPONSE||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1970-07-08||||1969-12-15||1965-09-03|1966-01-10||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||METBRESP|METABOLIC RESPONSE||||ML/S/M2|MINOR PATHOLOGIC RESPONSE||NU/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|FAMILY MEMBER|ADJUDICATOR 3|Y|2||58||FOLLOW-UP|1967-02-07||||1966-02-19||1971-12-25|1963-07-05||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||METBRESP|METABOLIC RESPONSE||||MANSON U/ML|UNFAVORABLE RESPONSE||CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|3||39||BASELINE|1965-05-20||||1961-06-07||1964-12-06|1971-08-28||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||OVRLRESP|OVERALL RESPONSE||||MAMP|IMMUNOPHENOTYPIC CR||MG/KG|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|DOMESTIC PARTNER|READER|Y|3||39||BLINDED TREATMENT|1972-05-06||||1971-03-13||1965-03-19|1969-05-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CD/M2|CA125 75% RESPONSE||UG/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|4||88||WASHOUT|1965-06-23||||1962-07-09||1972-12-27|1973-01-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KCAL|PCR||MET*H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|4||88||SCREENING|1973-06-17||||1966-01-18||1961-09-02|1961-10-05||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI|NOT ALL EVALUATED||UG/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|DOMESTIC PARTNER|MICROSCOPIST 2|N|5||7||SCREENING|1972-08-26||||1965-11-17||1960-10-30|1963-02-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^12/L|CRI||MET*H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|VENDOR|OTOLARYNGOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1968-06-03||||1969-08-03||1961-08-05|1968-08-10||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TRANSDUCING UNIT|PSEUDOPROGRESSION||KIU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|FRIEND|OTOLARYNGOLOGIST|U|1||38||TREATMENT|1964-10-05||||1964-08-10||1968-01-20|1970-09-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/MMHG|CHR||CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|U|1||38||WASHOUT|1963-12-17||||1964-04-08||1960-04-23|1964-08-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||SPLNRESP|SPLEEN RESPONSE||||GENEQ|CMR||UV2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|ADJUDICATOR|RADIOLOGIST 1|U|2||58||TREATMENT|1963-10-01||||1971-12-02||1964-09-17|1968-03-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PA|PMR||SCOOPFUL|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1966-03-07||||1970-10-18||1962-02-13|1971-07-21||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||SPLNRESP|SPLEEN RESPONSE||||CAPSULE|PD FROM PR||BEAM BREAKS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|3||39||RUN-IN|1970-10-26||||1969-04-14||1971-09-17|1971-07-31||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||SPLNRESP|SPLEEN RESPONSE||||MOL/ML|SD||MKAT|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|SIGNIFICANT OTHER|RADIOLOGIST 2|U|3||39||OBSERVATION|1961-10-24||||1963-04-05||1961-12-04|1966-02-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^3 CFU/ML|SCR||DRAM|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|FAMILY MEMBER|MICROSCOPIST 2|Y|4||88||WASHOUT|1970-07-22||||1966-09-18||1968-09-12|1963-09-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BP|NE||UMOL/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|CAREGIVER|ONCOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1970-01-07||||1972-08-14||1963-06-21|1969-07-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 CFU/ML|CCR||DAYS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|DOMESTIC PARTNER|UROLOGIST|NA|5||7||WASHOUT|1964-03-04||||1964-02-12||1961-08-12|1971-09-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NMOL/L/H|SD||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|5||7||BASELINE|1971-03-03||||1969-04-29||1964-07-10|1966-04-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SEC|INCREASED||NG/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|STUDY SUBJECT|UROLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1969-02-03||||1972-04-17||1970-07-27|1971-12-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%/MIN|QUANTIFIABLE MRD POSITIVITY||PIPE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|ADJUDICATION COMMITTEE|UROLOGIST|Y|1||38||INDUCTION TREATMENT|1965-10-18||||1965-04-18||1962-12-29|1973-04-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/DAY|NOT ALL EVALUATED||UMOL/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|U|2||58||OPEN LABEL TREATMENT|1964-10-08||||1967-02-25||1964-10-08|1968-07-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/MOL|NED||PPTR|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||CONTINUATION TREATMENT|1971-01-15||||1968-05-09||1964-11-17|1969-09-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|1||||||METBRESP|METABOLIC RESPONSE||||CG|NED||BOX|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|READER 3|Y|3||39||RUN-IN|1967-10-30||||1971-11-09||1972-04-15|1969-06-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|2||||||MOLRESP|MOLECULAR RESPONSE||||FIU|SD||STRIP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|ADJUDICATOR|RATER 2|Y|3||39||SCREENING|1961-01-29||||1971-03-25||1969-09-14|1972-08-18||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^9 ORGANISMS/G|MCR||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|DOMESTIC PARTNER|RADIOLOGIST 1|Y|4||88||BASELINE|1967-02-28||||1961-06-19||1966-09-17|1964-04-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SACHET|NON-ICR/NON-IUPD||FMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|4||88||LONG-TERM FOLLOW-UP|1972-02-03||||1962-03-28||1964-10-14|1972-08-05||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|1||||||BONERESP|BONE RESPONSE||||POUCH|CA125 75% RESPONSE||ATM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||TREATMENT|1962-01-16||||1966-11-16||1965-06-02|1964-11-30||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|77CF8795-CFF5-40C6-A811-624972806A38|2||||||LIVRRESP|LIVER RESPONSE||||PMOL/10^9 CELLS|PARTIAL MORPHOLOGIC RESPONSE||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|5||7||INDUCTION TREATMENT|1960-11-19||||1970-10-22||1965-01-08|1973-01-06||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UM2|NON-QUANTIFIABLE MRD POSITIVITY||ML/S/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|CAREGIVER|FORENSIC PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1971-03-04||||1961-03-05||1971-08-26|1968-03-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||BONERESP|BONE RESPONSE||||MEQ/KG|WORSENED||CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|INDEPENDENT ASSESSOR|RATER|N|1||38||LONG-TERM FOLLOW-UP|1963-09-26||||1967-05-27||1965-12-17|1964-01-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^6 ORGANISMS|MRD RELAPSE||H/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||OBSERVATION|1965-10-01||||1972-01-02||1968-09-28|1962-10-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||CLINRESP|CLINICAL RESPONSE||||/10^4|NED||UG/KG|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|2||58||BASELINE|1966-12-26||||1967-05-15||1963-11-14|1967-10-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MV/SEC|CYTOGENETIC MINOR RESPONSE||PMOL/DL|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|GUARDIAN|ONCOLOGIST|U|3||39||BLINDED TREATMENT|1966-07-03||||1964-06-25||1972-04-14|1971-11-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||STRUSTAT|STEROID USE STATUS||||G/M2/DAY|NOT ALL EVALUATED||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|3||39||OPEN LABEL TREATMENT|1969-03-10||||1960-10-21||1965-06-10|1967-09-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/KG/DAY|ABSENT MORPHOLOGIC RESPONSE||10^4 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|4||88||OBSERVATION|1971-12-29||||1971-07-07||1964-12-02|1966-09-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||LOG10 TCID 50/ML|MOLECULAR CR||MS2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|VENDOR|ONCOLOGIST 1|N|4||88||BLINDED TREATMENT|1967-12-18||||1972-03-24||1969-04-09|1964-05-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BQ|NE||BEATS/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BASELINE|1966-11-09||||1963-08-01||1970-04-14|1970-12-31||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^6 ORGANISMS/MG|IMPROVED||PLUG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1967-09-08||||1967-09-05||1965-03-07|1967-07-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/BEAT|RELAPSED DISEASE||/MM|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|STUDY SUBJECT|ENDOCRINOLOGIST|NA|1||38||BLINDED TREATMENT|1964-10-11||||1970-01-26||1967-11-28|1967-04-22||DURING||AFTER|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UU/DL|MAJOR PATHOLOGIC RESPONSE||MV|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|STUDY SUBJECT|ENDOCRINOLOGIST|NA|1||38||SCREENING|1968-06-13||||1965-02-25||1961-05-24|1963-12-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||NEWLPROG|NEW LESION PROGRESSION||||ELISA UNIT/ML|MORPHOLOGIC CR||GMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|SPOUSE|ONCOLOGIST 2|U|2||58||BLINDED TREATMENT|1963-01-17||||1961-03-16||1969-05-27|1962-04-18||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||% INHIBITION|NON-ICR/NON-IUPD||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|FAMILY MEMBER|OPTOMETRIST|NA|2||58||BASELINE|1964-01-23||||1971-08-14||1972-09-09|1967-04-24||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||STRUSTAT|STEROID USE STATUS||||CAPLET|PMD||CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|GUARDIAN|FORENSIC PATHOLOGIST|U|3||39||CONTINUATION TREATMENT|1967-01-06||||1971-11-18||1966-09-10|1972-11-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||NTRGRESP|NON-TARGET RESPONSE||||FMOL/G|ICPD||BP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||RUN-IN|1972-12-05||||1963-08-25||1969-12-17|1961-03-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||STRUSTAT|STEROID USE STATUS||||UG|CYTOGENETIC MINIMAL RESPONSE||CMH2O/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|PROXY|HEMATOLOGIST|U|4||88||BASELINE|1965-06-11||||1962-08-02||1965-06-13|1967-03-09||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||BONERESP|BONE RESPONSE||||ML/CM|DISEASE TRANSFORMATION||OD UNIT|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|INVESTIGATOR|READER 1|NA|4||88||OPEN LABEL TREATMENT|1968-09-19||||1966-02-01||1964-03-16|1970-04-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^9 ORGANISMS/MG|PD||/5X10^4 WBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OBSERVATION|1960-01-16||||1963-03-20||1961-10-27|1971-02-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6 U|TREATMENT FAILURE||/CMH2O|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|VENDOR|READER 3|N|5||7||SCREENING|1966-01-28||||1968-04-07||1972-11-21|1966-08-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/MIN|STABLE||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|FRIEND|HEMATOLOGIST|NA|1||38||WASHOUT|1960-03-14||||1963-01-21||1964-10-10|1969-04-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||STRUSTAT|STEROID USE STATUS||||JDF UNIT|PMD||KCAL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|PROXY|NEUROLOGIST|U|1||38||BLINDED TREATMENT|1966-12-14||||1968-10-09||1970-06-07|1965-03-31||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||BONERESP|BONE RESPONSE||||UG/DOSE|PR WITH LYMPHOCYTOSIS||VG/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|STUDY SUBJECT|CARDIOLOGIST|NA|2||58||TREATMENT|1969-11-21||||1962-01-28||1968-02-07|1968-04-15||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BP|TREATMENT FAILURE||SUPPOSITORY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|DOMESTIC PARTNER|MICROSCOPIST 1|U|2||58||FOLLOW-UP|1972-12-31||||1961-11-08||1966-07-02|1973-04-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||BONERESP|BONE RESPONSE||||OD UNIT|MRD RELAPSE||U/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|PARENT|DERMATOLOGIST|NA|3||39||SCREENING|1964-07-23||||1965-02-15||1966-04-22|1961-02-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||NEWLPROG|NEW LESION PROGRESSION||||ABSORBANCE U/MIN|ISD||CY/CM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|3||39||SCREENING|1971-07-09||||1967-12-13||1968-04-29|1970-05-11||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||SPLNRESP|SPLEEN RESPONSE||||GRAIN|SD-CT||ML/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|INTERNIST|N|4||88||INDUCTION TREATMENT|1970-08-17||||1973-05-12||1968-12-16|1961-02-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ANSON U|PR-CT||MG2/DL2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||SCREENING|1972-02-18||||1972-01-04||1968-03-17|1971-12-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BQ/G|RELAPSED DISEASE FROM CR OR PR||MG/ML/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|HEALTH CARE PROFESSIONAL|RATER|NA|5||7||WASHOUT|1973-01-20||||1973-04-04||1965-08-17|1962-07-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/ANIMAL|SD||STEPS|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|INTERVIEWER|MICROSCOPIST 3|N|5||7||OBSERVATION|1971-05-03||||1962-06-14||1962-09-02|1960-12-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||MOLRESP|MOLECULAR RESPONSE||||H/WK|NR||MG/L FEU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|Y|GUARDIAN|MICROSCOPIST|U|1||38||WASHOUT|1971-01-16||||1969-11-20||1961-01-05|1962-08-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||MOLRESP|MOLECULAR RESPONSE||||BQ/UG|PD||KCAL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1||38||CONTINUATION TREATMENT|1967-08-07||||1973-01-30||1962-05-02|1966-09-05||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||TMRESP|TUMOR MARKER RESPONSE||||SUPPOSITORY|MAJOR PATHOLOGIC RESPONSE||CAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||RUN-IN|1972-11-04||||1973-04-09||1966-08-20|1969-02-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||ANATRESP|ANATOMIC RESPONSE||||UGEQ|CA125 50% RESPONSE||SBE/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|STUDY SUBJECT|ADJUDICATOR 2|N|2||58||LONG-TERM FOLLOW-UP|1962-01-02||||1967-01-27||1966-08-19|1970-11-17||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||RPM|INDETERMINATE RESPONSE||ML/BEAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|FAMILY MEMBER|PHYSIOTHERAPIST|U|3||39||RUN-IN|1970-01-22||||1971-07-27||1963-12-02|1960-04-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 COPIES/ML|IPR||UG/CM2|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|INTERVIEWER|NEUROLOGIST 1|N|3||39||LONG-TERM FOLLOW-UP|1966-07-11||||1968-11-14||1971-07-16|1973-07-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||MOLRESP|MOLECULAR RESPONSE||||DEG2|MINOR PATHOLOGIC RESPONSE||ANSON U|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|4||88||SCREENING|1961-01-16||||1964-02-28||1966-05-30|1965-04-04||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^4 CFU/ML|MCR||UL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4||88||INDUCTION TREATMENT|1962-04-19||||1969-09-01||1966-03-22|1971-01-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 ELISA UNIT|PMR||RATIO|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|5||7||RUN-IN|1973-07-18||||1964-12-31||1966-11-21|1964-06-11||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||METBRESP|METABOLIC RESPONSE||||UG/G/DAY|NOT ALL EVALUATED||U/G HB|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|5||7||OBSERVATION|1972-12-14||||1965-07-16||1964-12-17|1961-04-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||OVRLRESP|OVERALL RESPONSE||||RFU|IMPROVED||UG/ML/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|FRIEND|PATHOLOGIST 1|Y|1||38||TREATMENT|1963-08-18||||1971-07-10||1966-02-10|1961-03-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||SPLNRESP|SPLEEN RESPONSE||||MM/H|NED||KEV|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|1||38||BLINDED TREATMENT|1961-01-23||||1969-06-11||1973-01-28|1965-07-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||RDIORESP|RADIOLOGIC RESPONSE||||GPL U/ML|DECREASED||STEPS/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|FRIEND|HEMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1962-04-20||||1970-08-01||1972-04-03|1966-01-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||OVRLRESP|OVERALL RESPONSE||||MCI/KG|PMD||/10^4|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|FAMILY MEMBER|READER|N|2||58||OBSERVATION|1967-12-02||||1971-10-12||1960-03-02|1973-08-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DIP|NPR||MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CHILD|RATER|Y|3||39||CONTINUATION TREATMENT|1966-05-10||||1969-04-11||1972-08-30|1967-08-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MKAT|OPTIMAL MORPHOLOGIC RESPONSE||CMH2O/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|HEALTH CARE PROFESSIONAL|READER 3|U|3||39||WASHOUT|1963-11-15||||1964-05-23||1963-12-05|1970-03-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||U/G/H|PSEUDORESPONSE||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|DOMESTIC PARTNER|ONCOLOGIST 1|N|4||88||FOLLOW-UP|1961-10-08||||1970-10-21||1971-08-07|1960-12-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AG|CPR||/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|PROXY|READER 2|Y|4||88||FOLLOW-UP|1971-10-02||||1967-05-06||1960-10-02|1970-07-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||NEWLIND|NEW LESION INDICATOR||||CI|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|FRIEND|UROLOGIST|NA|5||7||BLINDED TREATMENT|1966-09-09||||1970-10-14||1966-06-18|1961-11-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 CFU/G|PD-CT||CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|FRIEND|OTOLARYNGOLOGIST|U|5||7||BLINDED TREATMENT|1967-10-30||||1961-01-24||1962-02-27|1963-03-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^6/HPF|PD-CT||MG/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|SIBLING|RADIOLOGIST|NA|1||38||SCREENING|1967-07-12||||1961-05-01||1966-06-10|1973-08-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/H|NPR||MIN/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|CAREGIVER|ENDOCRINOLOGIST|N|1||38||BLINDED TREATMENT|1968-12-29||||1961-11-05||1966-08-10|1964-06-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^9/G|PSEUDOPROGRESSION||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|CAREGIVER|READER 2|NA|2||58||CONTINUATION TREATMENT|1966-04-04||||1971-04-01||1965-11-21|1970-10-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KPA/L/SEC|CYTOGENETIC MINOR RESPONSE||SPRAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|DOMESTIC PARTNER|OPTOMETRIST|U|2||58||INDUCTION TREATMENT|1972-03-21||||1968-12-14||1969-12-31|1969-06-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CAPLET|PMR||CI/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|3||39||INDUCTION TREATMENT|1972-03-01||||1972-11-21||1962-10-26|1962-09-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||OVRLRESP|OVERALL RESPONSE||||SHOCK WAVE|MORPHOLOGIC CRI||MG/ML/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|3||39||TREATMENT|1972-07-27||||1966-04-01||1960-12-15|1964-12-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||STRUSTAT|STEROID USE STATUS||||%(W/W)|CR||10^4/HPF|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||LONG-TERM FOLLOW-UP|1961-11-01||||1964-08-17||1967-04-24|1967-08-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||V|SCR||%/S|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|4||88||SCREENING|1969-04-09||||1969-07-08||1966-09-09|1966-06-21||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UCI|CMR||DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|PROXY|ADJUDICATOR 1|Y|5||7||RUN-IN|1962-03-31||||1963-08-14||1971-09-06|1965-10-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||LIVRRESP|LIVER RESPONSE||||10^4/L|ISD||DEG/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|ADJUDICATOR|NEUROLOGIST 2|Y|5||7||OBSERVATION|1963-04-28||||1965-06-20||1968-08-02|1962-05-04||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||NEWLIND|NEW LESION INDICATOR||||BREATHS/MIN|ISD||EID 50/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|SPOUSE|CLINICAL PATHOLOGIST|U|1||38||RUN-IN|1968-11-18||||1970-11-06||1966-10-23|1964-06-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TSP EQ|CYTOGENETIC CR||%(W/V)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|1||38||INDUCTION TREATMENT|1960-07-30||||1971-08-04||1965-12-19|1961-06-09||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||SBE/ML|PMD||ML/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-08-12||||1965-12-26||1973-01-04|1969-11-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PMOL/G|NON-PD||SHOCK WAVE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|INDEPENDENT ASSESSOR|READER|NA|2||58||OBSERVATION|1961-08-04||||1969-07-06||1964-08-27|1963-12-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||MOLRESP|MOLECULAR RESPONSE||||PL|SD-CT||BAU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|CHILD|READER 2|N|3||39||CONTINUATION TREATMENT|1962-02-10||||1970-06-19||1963-03-17|1971-10-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^7 PFU|INCREASED||KCAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|GUARDIAN|RADIOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1962-01-19||||1962-12-15||1962-09-08|1961-01-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||BONERESP|BONE RESPONSE||||UL|IMPROVED||10^3 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|4||88||BLINDED TREATMENT|1972-08-02||||1966-12-10||1972-11-20|1964-01-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||NEWLIND|NEW LESION INDICATOR||||VG/DOSE|NON-CR/NON-PD||PPTH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|GUARDIAN|DERMATOLOGIST|Y|4||88||RUN-IN|1967-12-06||||1972-10-27||1966-01-10|1969-01-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL/KG/DAY|NR||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||WASHOUT|1962-06-23||||1961-03-13||1969-10-18|1965-08-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||STRUSTAT|STEROID USE STATUS||||CP|CYTOGENETIC MINIMAL RESPONSE||PIPE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||LONG-TERM FOLLOW-UP|1967-09-30||||1971-06-20||1969-05-18|1964-06-20||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||NEWLPROG|NEW LESION PROGRESSION||||ECL UNIT|MOLECULAR CR||UG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|ADJUDICATION COMMITTEE|READER 2|N|1||38||RUN-IN|1971-11-19||||1964-02-19||1963-11-23|1969-10-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||L/S|IMPROVED||TABLET|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|FAMILY MEMBER|ONCOLOGIST|N|1||38||OPEN LABEL TREATMENT|1970-04-16||||1961-11-05||1971-04-22|1964-08-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||METSIND|METASTATIC INDICATOR||||FT2|CHR||CI/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|FAMILY MEMBER|CARDIOLOGIST|U|2||58||INDUCTION TREATMENT|1966-11-15||||1966-01-27||1969-11-01|1964-02-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^12 IU/L|NR||PL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|2||58||OPEN LABEL TREATMENT|1963-03-04||||1970-05-29||1971-01-07|1964-07-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||METBRESP|METABOLIC RESPONSE||||ML/M2/MIN|PD-CT||/500 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|3||39||LONG-TERM FOLLOW-UP|1960-10-19||||1960-04-20||1970-06-24|1971-06-07||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||BONERESP|BONE RESPONSE||||ML/G/DAY|NON-PD||MG/M2/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|3||39||OPEN LABEL TREATMENT|1967-10-09||||1963-08-31||1962-10-14|1960-04-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BEATS/MIN|RELAPSED DISEASE FROM CR OR PR||LX|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|PROXY|MICROSCOPIST 1|NA|4||88||INDUCTION TREATMENT|1964-05-07||||1970-05-04||1961-09-28|1970-03-02||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CD/M2|SCR||U/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|4||88||FOLLOW-UP|1971-04-08||||1960-07-31||1964-04-30|1969-03-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FG|DISEASE TRANSFORMATION||%(W/W)|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|FRIEND|PHYSIOTHERAPIST|NA|5||7||WASHOUT|1969-10-23||||1972-07-04||1965-08-27|1971-04-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MMOL|COMPLETE MRD RESPONSE||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|5||7||WASHOUT|1967-05-29||||1968-07-09||1968-10-10|1965-03-21||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/MIN/1.73M2|QUANTIFIABLE MRD POSITIVITY||DRUM|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CLINICAL STUDY SPONSOR|RATER 1|N|1||38||RUN-IN|1967-06-21||||1969-11-01||1962-11-15|1965-10-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HEP|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/MBP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|CAREGIVER|CLINICAL PATHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1964-07-29||||1973-08-18||1960-09-23|1965-11-01||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||COPIES/UL|IMMUNOPHENOTYPIC CR||HZ/S|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|VENDOR|PATHOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1971-10-08||||1969-06-04||1968-11-22|1970-07-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||OVRLRESP|OVERALL RESPONSE||||/7.5 ML|PD||/7.5 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|GUARDIAN|NEUROLOGIST 2|U|2||58||BLINDED TREATMENT|1967-03-31||||1973-06-11||1965-04-02|1972-04-25||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MOSM|PSEUDOPROGRESSION||IU/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|INDEPENDENT ASSESSOR|RATER 1|U|3||39||BLINDED TREATMENT|1968-12-31||||1965-08-15||1967-06-15|1962-12-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PPB|WORSENED||10^4 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|ADJUDICATOR|NEUROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1972-01-22||||1966-05-28||1964-01-31|1965-02-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||G/KG|CR-CT||L/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|PARENT|OPTOMETRIST|U|4||88||SCREENING|1971-03-02||||1962-12-10||1968-05-04|1970-04-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||CYTORESP|CYTOGENETIC RESPONSE||||SBE/ML|INCREASED||U/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|4||88||SCREENING|1969-04-19||||1972-07-04||1972-10-30|1963-05-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||TRGRESP|TARGET RESPONSE||||CMOL|MINOR PATHOLOGIC RESPONSE||UG/M2/DAY|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|N|VENDOR|ONCOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-01-18||||1962-02-08||1962-11-27|1970-11-11||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||METSIND|METASTATIC INDICATOR||||PT_BR|NED||UG/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|ADJUDICATOR|ADJUDICATOR 1|Y|5||7||LONG-TERM FOLLOW-UP|1969-06-23||||1961-12-04||1962-10-03|1962-12-31||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CM/MIN|VGPR||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|ADJUDICATOR|ADJUDICATOR 3|NA|1||38||OPEN LABEL TREATMENT|1973-05-30||||1969-05-01||1961-09-18|1962-02-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/DAY|IMPROVED||FG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|GUARDIAN|ONCOLOGIST|U|1||38||WASHOUT|1968-12-31||||1964-11-13||1973-03-01|1971-06-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CMOL/L|DISEASE TRANSFORMATION||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-07-21||||1968-05-03||1972-09-03|1964-11-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||BESTRESP|BEST OVERALL RESPONSE||||L/S/KPA|TREATMENT FAILURE||APL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|2||58||WASHOUT|1971-09-05||||1970-12-02||1972-03-20|1965-08-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||NTRGRESP|NON-TARGET RESPONSE||||UV*SEC|CYTOGENETIC PR||MIN/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL STUDY SPONSOR|RATER 1|NA|3||39||TREATMENT|1962-03-11||||1962-11-08||1973-07-27|1964-08-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||OVRLRESP|OVERALL RESPONSE||||10^12/L|PR-CT||BAU|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|CHILD|FORENSIC PATHOLOGIST|Y|3||39||FOLLOW-UP|1972-06-18||||1966-03-07||1972-08-23|1966-06-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UGEQ/L|PR||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|SIBLING|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1960-06-06||||1970-01-05||1966-08-01|1972-12-05||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PIXEL|RELAPSED DISEASE FROM CR OR PR||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|SIGNIFICANT OTHER|RATER 2|N|4||88||OBSERVATION|1960-07-27||||1966-12-19||1972-11-02|1964-09-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||OVRLRESP|OVERALL RESPONSE||||%/S|FAVORABLE RESPONSE||CM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|SPOUSE|ONCOLOGIST 2|Y|5||7||OBSERVATION|1963-08-02||||1972-06-12||1965-06-26|1972-02-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UMOL/MOL|COMPLETE MRD RESPONSE||KM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|ADJUDICATOR|HEMATOLOGIST|U|5||7||BASELINE|1967-03-29||||1966-12-30||1966-11-04|1969-07-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PG/DL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CAPFUL|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|1||38||WASHOUT|1968-04-19||||1970-06-10||1972-02-01|1965-03-23||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PMOL/DAY|MR||G/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|1||38||TREATMENT|1971-07-11||||1969-07-24||1964-02-08|1965-01-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||OVRLRESP|OVERALL RESPONSE||||MEQ/DAY|MOLECULAR MAJOR RESPONSE||KBQ/UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|CHILD|ONCOLOGIST 1|U|2||58||OBSERVATION|1972-08-27||||1966-12-15||1973-01-07|1960-01-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DAGU/ML|PD-CT||M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|ADJUDICATION COMMITTEE|INTERNIST|Y|2||58||OPEN LABEL TREATMENT|1973-06-20||||1972-09-23||1965-12-25|1961-12-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||TRGRESP|TARGET RESPONSE||||KALLIKREIN INHIBITOR UNIT|SD-CT||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|CAREGIVER|ADJUDICATOR 3|N|3||39||WASHOUT|1970-03-31||||1972-07-16||1968-04-01|1968-06-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||L/MIN|CYTOGENETIC CR||BQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|VENDOR|RATER|U|3||39||BLINDED TREATMENT|1969-11-30||||1970-12-13||1970-05-19|1964-12-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/G/MIN|CYTOGENETIC MINOR RESPONSE||ML/M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|4||88||TREATMENT|1965-08-07||||1966-07-07||1961-12-19|1960-02-11||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||ANATRESP|ANATOMIC RESPONSE||||K|MORPHOLOGIC LEUKEMIA-FREE STATE||KG/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|PROXY|RATER 1|N|4||88||LONG-TERM FOLLOW-UP|1968-01-01||||1962-02-18||1962-10-15|1960-06-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||LIVRRESP|LIVER RESPONSE||||GAUSS|VGPR||BAU|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|5||7||WASHOUT|1972-02-25||||1966-06-06||1960-06-03|1964-07-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6 U|HI-N||KUSP|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||OBSERVATION|1962-11-01||||1972-12-25||1965-03-02|1972-01-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/CAGE/DAY|CR-CT||AMFI|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|1||38||TREATMENT|1963-10-19||||1968-11-26||1962-03-21|1973-09-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UOSM|MRD PERSISTENCE||HR/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|PARENT|ONCOLOGIST 1|Y|1||38||OBSERVATION|1965-07-05||||1964-02-20||1969-04-16|1968-08-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KAT|RELAPSED DISEASE FROM CR OR PR||UG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|2||58||CONTINUATION TREATMENT|1963-01-09||||1968-01-26||1964-01-21|1973-08-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL/G|CCR||DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|INVESTIGATOR|HEMATOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1972-03-08||||1964-05-28||1967-12-16|1964-01-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||NEWLPROG|NEW LESION PROGRESSION||||/500 WBC|MINOR PATHOLOGIC RESPONSE||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|STUDY SUBJECT|READER 1|N|3||39||CONTINUATION TREATMENT|1962-12-07||||1963-06-19||1971-04-06|1964-08-14||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||METSIND|METASTATIC INDICATOR||||MM3/MM2/YEAR|PCR||BP|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|CHILD|PATHOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1970-03-24||||1962-11-22||1969-08-22|1960-02-13||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||TRGRESP|TARGET RESPONSE||||10^6 ORGANISMS/G|SD||NMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|SPOUSE|MICROSCOPIST 3|Y|4||88||TREATMENT|1961-02-03||||1966-05-14||1965-02-18|1962-12-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||OD UNIT|NON-PD||KN/CM2|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|SIGNIFICANT OTHER|NEUROLOGIST|U|4||88||SCREENING|1968-01-09||||1962-11-05||1965-10-07|1966-10-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||%|MRD RELAPSE||M/SEC2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|PARENT|PATHOLOGIST|Y|5||7||FOLLOW-UP|1964-08-06||||1968-04-09||1965-09-28|1967-11-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||H*%|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|INVESTIGATOR|INTERNIST|NA|5||7||BASELINE|1968-08-20||||1971-06-20||1967-08-28|1961-12-06||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MEQ/UL|PR-CT||MPL U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|STUDY SUBJECT|ONCOLOGIST 2|N|1||38||BASELINE|1971-08-09||||1964-07-27||1965-07-20|1965-11-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACK|NON-QUANTIFIABLE MRD POSITIVITY||UMOL/L/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|SIGNIFICANT OTHER|NEUROLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1964-06-21||||1961-06-26||1972-12-08|1962-04-03||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||METSIND|METASTATIC INDICATOR||||UG/M2/DAY|DISEASE TRANSFORMATION||POINT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1970-04-18||||1964-08-07||1967-03-22|1965-08-14||AFTER||DURING|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||ANATRESP|ANATOMIC RESPONSE||||U/G|CA125 75% RESPONSE||BQ/G|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|SIBLING|PATHOLOGIST 1|N|2||58||CONTINUATION TREATMENT|1965-02-18||||1965-10-09||1970-03-19|1972-07-04||DURING||AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||CYTORESP|CYTOGENETIC RESPONSE||||%(W/V)|ICR||ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|3||39||BASELINE|1960-11-03||||1962-12-20||1972-05-13|1962-05-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||SPLNRESP|SPLEEN RESPONSE||||MOSM|EQUIVOCAL||UM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|3||39||TREATMENT|1973-05-29||||1972-10-27||1960-12-04|1967-03-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CD*S/M2|PMR||NMOL/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|CAREGIVER|FORENSIC PATHOLOGIST|Y|4||88||BLINDED TREATMENT|1965-09-15||||1968-08-05||1967-08-07|1967-10-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||LIVRRESP|LIVER RESPONSE||||ABSORBANCE U/MIN|PR-CT||MEQ/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|FRIEND|RADIOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1972-08-06||||1971-05-27||1970-04-21|1972-11-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UU/L|DISEASE TRANSFORMATION||FRACTION OF 1|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|READER 3|NA|5||7||CONTINUATION TREATMENT|1967-07-29||||1961-05-23||1972-01-26|1967-04-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||BESTRESP|BEST OVERALL RESPONSE||||AFU|UNEQUIVOCAL||UG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|5||7||FOLLOW-UP|1962-08-31||||1971-04-04||1963-10-30|1962-12-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/DL|HI-N||DISK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|STUDY SUBJECT|ONCOLOGIST 1|U|1||38||RUN-IN|1964-02-28||||1964-09-25||1968-11-22|1960-05-21||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MAMP|SD-CT||VOXEL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||SCREENING|1965-12-19||||1966-04-09||1963-08-27|1973-08-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||APL U|MRD NEGATIVITY||FARAD|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|ADJUDICATOR|PATHOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1960-03-14||||1971-12-25||1973-02-18|1960-08-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||TRGRESP|TARGET RESPONSE||||MMOL|CCR||APS U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|PROXY|MICROSCOPIST 2|U|2||58||INDUCTION TREATMENT|1970-05-12||||1967-05-05||1967-11-24|1964-07-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CMHG|IMMUNOPHENOTYPIC CR||UOSM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|FRIEND|RATER 2|N|3||39||WASHOUT|1961-05-17||||1962-06-02||1967-12-09|1961-10-26||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||PATHRESP|PATHOLOGIC RESPONSE||||SEC|PD-CT||MU|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|FAMILY MEMBER|NEUROLOGIST 2|NA|3||39||FOLLOW-UP|1965-06-02||||1966-12-29||1969-12-16|1972-11-30||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||STRUSTAT|STEROID USE STATUS||||V/V|UNFAVORABLE RESPONSE||CI|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|STUDY SUBJECT|ONCOLOGIST 1|Y|4||88||OBSERVATION|1967-01-25||||1967-12-17||1968-01-14|1973-08-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||FINGERTIP UNIT|SCR||STRIP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1963-07-16||||1962-11-15||1973-04-06|1964-11-24||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^5/HPF|STABLE||MPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5||7||FOLLOW-UP|1961-08-04||||1970-06-04||1960-12-01|1972-12-24||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UKAT|TREATMENT FAILURE||PL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|5||7||BASELINE|1967-06-04||||1964-11-13||1969-04-24|1969-07-31||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|1||||||TRGRESP|TARGET RESPONSE||||G/DL|IMPROVED||MPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|1||38||INDUCTION TREATMENT|1971-08-26||||1970-10-31||1972-10-21|1971-09-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DPM/MG|CR-CT||FMOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|1||38||OBSERVATION|1973-01-23||||1961-06-11||1967-01-04|1970-09-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|1||||||NEWLPROG|NEW LESION PROGRESSION||||MOL/L|CRI||BQ/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|2||58||FOLLOW-UP|1968-03-05||||1971-12-24||1968-01-05|1972-09-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|2||||||STRUSTAT|STEROID USE STATUS||||10^3 ORGANISMS/G|SMD||L/H/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|SIBLING|UROLOGIST|U|2||58||SCREENING|1964-08-02||||1965-06-16||1962-07-20|1969-07-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ANTIBODY UNIT|RELAPSED DISEASE FROM CR||ML/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|CAREGIVER|ONCOLOGIST 1|N|3||39||RUN-IN|1969-04-26||||1961-07-26||1962-07-16|1967-11-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|2||||||OVRLRESP|OVERALL RESPONSE||||IU/ML|PARTIAL MORPHOLOGIC RESPONSE||BEAM BREAKS|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|SPOUSE|FORENSIC PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1961-11-26||||1973-03-22||1961-11-20|1962-02-04||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|1||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL/DAY|PCR||FFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|RATER|N|4||88||OBSERVATION|1964-02-06||||1966-01-23||1962-12-18|1973-06-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|2||||||NEWLIND|NEW LESION INDICATOR||||10^6 ORGANISMS|ICR||L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|VENDOR|READER 1|NA|4||88||WASHOUT|1964-11-25||||1968-01-06||1960-02-26|1960-10-13||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|1||||||BONERESP|BONE RESPONSE||||/100 HPFS|CR||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BLINDED TREATMENT|1960-01-06||||1961-03-31||1972-05-24|1963-09-17||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|57455593-8872-4B17-8B3F-8A02FE855290|2||||||METSIND|METASTATIC INDICATOR||||UL/DOSE|CR-CT||DIOPTER|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|FAMILY MEMBER|INTERNIST|Y|5||7||WASHOUT|1960-01-08||||1966-01-30||1960-04-16|1972-08-19||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||CLINRESP|CLINICAL RESPONSE||||/10^4|PD FROM PR||LOG10 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|INTERVIEWER|RADIOLOGIST 1|N|1||38||FOLLOW-UP|1961-07-06||||1961-02-06||1962-07-13|1963-08-05||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||USIEMENS|CHR||UM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|INTERVIEWER|ONCOLOGIST 1|U|1||38||RUN-IN|1969-03-20||||1968-09-27||1971-03-02|1969-01-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/DOSE|PSEUDORESPONSE||U/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|CHILD|PHYSIOTHERAPIST|N|2||58||LONG-TERM FOLLOW-UP|1967-08-24||||1967-12-21||1960-03-02|1961-10-16||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||COAT|TREATMENT FAILURE||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|CHILD|PATHOLOGIST 1|N|2||58||OBSERVATION|1968-09-07||||1964-07-09||1961-11-10|1970-08-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||NEWLIND|NEW LESION INDICATOR||||TSP|MORPHOLOGIC CR||FMOL/G|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1962-05-11||||1971-09-13||1971-11-26|1970-06-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||CLINRESP|CLINICAL RESPONSE||||PKAT|SMD||NMOL BCE/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|SIBLING|HEMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1961-10-08||||1961-09-13||1963-04-16|1966-08-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/M2/DAY|INCREASED||UG/L DDU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|GUARDIAN|MICROSCOPIST 3|Y|4||88||INDUCTION TREATMENT|1971-05-19||||1964-05-05||1965-03-15|1967-09-17||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/M2/MIN|CCR||L/H|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|CLINICAL STUDY SPONSOR|READER 3|U|4||88||SCREENING|1963-08-07||||1969-05-05||1961-10-27|1970-11-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||NEWLPROG|NEW LESION PROGRESSION||||NL|VGPR||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|SIGNIFICANT OTHER|NEUROLOGIST|U|5||7||FOLLOW-UP|1969-12-01||||1964-04-08||1971-01-12|1967-03-19||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||BONERESP|BONE RESPONSE||||U/MMOL|PD-CT||GPELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1963-07-25||||1972-11-21||1971-12-21|1972-03-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CM/S|MINOR PATHOLOGIC RESPONSE||U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|1||38||BASELINE|1966-12-14||||1960-09-23||1967-07-29|1963-09-29||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MM/SEC|PSEUDOPROGRESSION||CY/CM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|SIBLING|DERMATOLOGIST|U|1||38||INDUCTION TREATMENT|1969-11-15||||1962-12-20||1960-02-04|1973-08-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||JOULE|MOLECULAR CR||CPM|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|VENDOR|ENDOCRINOLOGIST|N|2||58||INDUCTION TREATMENT|1965-03-04||||1971-05-14||1962-07-01|1972-09-03||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||MOLRESP|MOLECULAR RESPONSE||||U/KG/MIN|PSEUDORESPONSE||ML*CMH2O|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|READER 2|N|2||58||RUN-IN|1968-01-08||||1966-09-09||1960-03-03|1972-01-11||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PRESSOR UNITS|DECREASED||TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|VENDOR|RADIOLOGIST|U|3||39||BASELINE|1964-05-14||||1973-01-15||1960-05-17|1965-08-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^9 CFU|CYTOGENETIC MINOR RESPONSE||UG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CAREGIVER|UROLOGIST|U|3||39||INDUCTION TREATMENT|1969-01-30||||1966-02-11||1972-05-07|1964-01-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MMOL/MIN/KPA|PDU||TITER|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|U|4||88||OPEN LABEL TREATMENT|1960-03-22||||1963-09-28||1971-01-04|1970-06-08||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PKAT|INDETERMINATE RESPONSE||UG/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|ADJUDICATOR|MICROSCOPIST 2|U|4||88||BASELINE|1967-09-13||||1965-11-17||1972-01-08|1970-05-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PFU|PD/RELAPSE AFTER HI||PSI|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OBSERVATION|1965-10-29||||1971-07-24||1969-06-15|1967-01-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||NMOL/L|UNEQUIVOCAL||PIXELS/CM|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|INTERVIEWER|OPHTHALMOLOGIST|NA|5||7||RUN-IN|1970-01-04||||1971-12-20||1964-11-15|1964-09-24||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMHG|PR-CT||NGEQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|N|1||38||FOLLOW-UP|1969-10-27||||1971-12-08||1962-05-26|1973-07-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^9 CFU|MRD PERSISTENCE||ANTI-XA IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||OBSERVATION|1969-08-22||||1973-05-12||1963-06-28|1965-03-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMHG/L/MIN|MOLECULAR CR||GMFI|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|CAREGIVER|ADJUDICATOR 3|N|2||58||TREATMENT|1970-03-10||||1962-07-04||1961-05-16|1964-12-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/G/MIN|INDETERMINATE RESPONSE||MMHG/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|2||58||FOLLOW-UP|1966-03-07||||1960-01-09||1961-01-31|1971-07-06||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||TRGRESP|TARGET RESPONSE||||ROENTGEN|CMR||PMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||BASELINE|1966-05-13||||1963-02-18||1972-02-06|1972-08-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FARAD|SCR||UG/G/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CHILD|UROLOGIST|NA|3||39||BLINDED TREATMENT|1969-04-18||||1962-07-31||1964-11-17|1970-05-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CM/MIN|CA125 75% RESPONSE||CD*S/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|INVESTIGATOR|MICROSCOPIST 3|U|4||88||BLINDED TREATMENT|1973-08-06||||1962-07-01||1971-01-24|1973-06-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/M2/DAY|PCR||GAUSS|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1962-03-16||||1969-11-25||1966-02-23|1973-03-18||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||NTRGRESP|NON-TARGET RESPONSE||||LOG10 COPIES/ML|NON-PD||POUCH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||TREATMENT|1963-04-03||||1963-10-22||1964-07-29|1966-07-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||PATHRESP|PATHOLOGIC RESPONSE||||FG|COMPLETE MRD RESPONSE||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|FAMILY MEMBER|ADJUDICATOR 3|U|5||7||WASHOUT|1960-03-12||||1964-10-09||1965-10-05|1970-12-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MM/H|CA125 75% RESPONSE||ANTIBODY UNIT|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|FRIEND|RATER|NA|1||38||TREATMENT|1971-08-08||||1971-07-25||1960-02-20|1964-02-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||BONERESP|BONE RESPONSE||||BU/ML|IMMUNOPHENOTYPIC CR||NGEQ/L|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INTERVIEWER|HEMATOLOGIST|N|1||38||WASHOUT|1967-05-18||||1970-09-09||1968-01-23|1963-02-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||STRUSTAT|STEROID USE STATUS||||AMP|MOLECULAR CR||GPS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|CHILD|CARDIOLOGIST|N|2||58||TREATMENT|1961-12-25||||1962-11-05||1967-07-30|1960-03-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UM|PDU||BOLUS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|PROXY|PEDIATRIC NEUROLOGIST|NA|2||58||INDUCTION TREATMENT|1967-09-17||||1972-12-29||1967-07-17|1962-10-14||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CMH2O*S2/ML|CCR||U/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|3||39||RUN-IN|1960-07-21||||1963-04-23||1965-10-20|1964-10-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GY/H|HI-P||TBSP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|CHILD|NEUROLOGIST 2|N|3||39||FOLLOW-UP|1965-06-27||||1971-08-16||1966-04-01|1969-10-05||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UKAT/L|WORSENED||NCI|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|CAREGIVER|RADIOLOGIST 1|Y|4||88||SCREENING|1966-10-24||||1966-05-16||1968-06-25|1962-12-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||PATHRESP|PATHOLOGIC RESPONSE||||G/G/DAY|ICR||ML/MIN/1.73M2|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|4||88||CONTINUATION TREATMENT|1960-03-09||||1970-03-04||1968-10-13|1967-08-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG2/DL2|NED||MG/KG/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|SPOUSE|PATHOLOGIST 2|N|5||7||CONTINUATION TREATMENT|1971-05-02||||1972-02-26||1969-05-06|1966-10-11||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||LIVRRESP|LIVER RESPONSE||||MMAL|NON-QUANTIFIABLE MRD POSITIVITY||TRACE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|CLINICAL STUDY SPONSOR|UROLOGIST|Y|5||7||SCREENING|1966-09-10||||1967-03-08||1966-11-01|1966-09-21||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|1||||||BONERESP|BONE RESPONSE||||NFIU|RELAPSED DISEASE FROM CR||MG2/DL2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|U|1||38||OBSERVATION|1963-06-04||||1963-06-01||1966-05-29|1960-03-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/KG|SD||KBQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|CHILD|FORENSIC PATHOLOGIST|U|1||38||WASHOUT|1965-12-23||||1973-04-30||1965-11-10|1961-11-17||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|1||||||BONERESP|BONE RESPONSE||||LOG10 CFU/G|NON-CR/NON-PD||U.CARR|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|CAREGIVER|PATHOLOGIST|NA|2||58||RUN-IN|1967-10-04||||1970-06-20||1968-04-24|1960-05-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||HOMEOPATHIC DILUTION|MAJOR PATHOLOGIC RESPONSE||MHZ|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|2||58||SCREENING|1971-06-16||||1967-11-16||1963-09-12|1964-09-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|1||||||TMRESP|TUMOR MARKER RESPONSE||||BP|WORSENED||DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|FAMILY MEMBER|OPHTHALMOLOGIST|U|3||39||CONTINUATION TREATMENT|1961-04-07||||1963-09-15||1971-06-04|1972-04-29||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|2||||||SPLNRESP|SPLEEN RESPONSE||||10^9 CFU/G|COMPLETE MRD RESPONSE||UG/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|INVESTIGATOR|ADJUDICATOR 2|Y|3||39||BASELINE|1963-09-09||||1967-12-22||1969-08-12|1966-04-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/SEC|MRD NEGATIVITY||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1964-02-01||||1966-08-22||1961-10-03|1967-09-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||OZ|CR-CT||WEEKS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|PARENT|RADIOLOGIST 2|NA|4||88||SCREENING|1966-03-05||||1969-03-19||1972-11-22|1972-04-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||%(V/V)|MRD PERSISTENCE||U/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|SIBLING|RADIOLOGIST|U|5||7||CONTINUATION TREATMENT|1961-03-13||||1964-07-06||1963-09-25|1960-09-18||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B386B813-1175-4421-9C86-F9AB597877FA|2||||||NTRGRESP|NON-TARGET RESPONSE||||UG/H|RELAPSED DISEASE FROM CR OR PR||%|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|CAREGIVER|ADJUDICATOR 3|NA|5||7||LONG-TERM FOLLOW-UP|1962-01-02||||1971-12-06||1969-08-27|1970-09-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/UL|MR||MMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||OPEN LABEL TREATMENT|1966-03-31||||1961-12-22||1965-12-06|1965-01-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||MOLRESP|MOLECULAR RESPONSE||||CAN|MORPHOLOGIC CRI||V|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|STUDY SUBJECT|OPHTHALMOLOGIST|NA|1||38||CONTINUATION TREATMENT|1969-05-27||||1963-10-05||1973-02-25|1970-04-14||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BEATS/MIN|PSEUDOPROGRESSION||DEG/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|STUDY SUBJECT|OPHTHALMOLOGIST|Y|2||58||SCREENING|1971-08-07||||1965-08-29||1972-12-24|1962-01-27||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KG|PD||UG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|2||58||CONTINUATION TREATMENT|1961-11-08||||1960-03-21||1962-03-09|1971-10-14||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||BONERESP|BONE RESPONSE||||UU/DL|PDU||WATT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|3||39||CONTINUATION TREATMENT|1967-11-23||||1972-05-25||1962-07-07|1960-02-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||MOLRESP|MOLECULAR RESPONSE||||10^8 PFU|PD/RELAPSE AFTER HI||CAPFUL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|SIBLING|PHYSIOTHERAPIST|Y|3||39||INDUCTION TREATMENT|1973-07-26||||1968-08-29||1962-05-22|1963-04-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||TRGRESP|TARGET RESPONSE||||DIOPTER|PCR||CCID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|FAMILY MEMBER|MICROSCOPIST 1|N|4||88||SCREENING|1968-10-23||||1967-03-18||1961-08-12|1967-10-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MANSON U/ML|DECREASED||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|N|4||88||WASHOUT|1964-07-02||||1965-10-10||1962-11-01|1970-07-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MCI|STABLE||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 1|Y|5||7||TREATMENT|1962-08-12||||1971-03-09||1973-02-04|1973-08-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||OD UNIT|OPTIMAL MORPHOLOGIC RESPONSE||CS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||BASELINE|1973-07-20||||1968-09-08||1969-05-23|1961-09-03||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/SEC/1.73M2|MORPHOLOGIC CRI||GY/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|1||38||TREATMENT|1973-07-26||||1964-01-03||1970-01-13|1971-07-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||ANATRESP|ANATOMIC RESPONSE||||MMOL/MIN/KPA|PR-CT||MONTHS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|GUARDIAN|OPTOMETRIST|Y|1||38||BLINDED TREATMENT|1962-09-09||||1970-06-20||1969-01-19|1972-04-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FG|INCREASED||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|DOMESTIC PARTNER|UROLOGIST|Y|2||58||CONTINUATION TREATMENT|1973-02-15||||1969-06-18||1968-10-25|1962-07-17||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PL|UNFAVORABLE RESPONSE||RAD|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|SIBLING|PATHOLOGIST|NA|2||58||SCREENING|1963-06-09||||1967-02-10||1969-01-29|1966-01-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/MIN/MMHG|MAJOR PATHOLOGIC RESPONSE||UMOL/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|FAMILY MEMBER|PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1964-08-01||||1971-11-14||1968-11-04|1968-04-16||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||NEWLIND|NEW LESION INDICATOR||||UMOL/H/MMOL|HI-E||10^4 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|CHILD|FORENSIC PATHOLOGIST|U|3||39||FOLLOW-UP|1966-09-09||||1973-08-13||1971-05-17|1963-05-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||CLINRESP|CLINICAL RESPONSE||||UMOL/MOL|PD||DNA COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|VENDOR|OPTOMETRIST|NA|4||88||SCREENING|1961-04-12||||1962-01-19||1965-06-06|1967-05-03||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||STRUSTAT|STEROID USE STATUS||||UG/G/DAY|NON-QUANTIFIABLE MRD POSITIVITY||MG/KG|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|SPOUSE|PHYSIOTHERAPIST|NA|4||88||TREATMENT|1967-06-23||||1967-01-23||1972-08-03|1965-08-01||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||SUPPOSITORY|SMD||HENRY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|SPOUSE|HEMATOLOGIST|NA|5||7||BASELINE|1962-07-19||||1960-02-04||1968-12-18|1969-11-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3 ORGANISMS/G|IMMUNOPHENOTYPIC CR||CGY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||BASELINE|1969-11-12||||1960-02-10||1967-02-01|1964-10-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DYN|ISD||/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|RATER|NA|1||38||OBSERVATION|1963-01-01||||1972-04-07||1966-08-17|1969-09-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/M2/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/4.0 ML|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|PROXY|CLINICAL PATHOLOGIST|Y|1||38||TREATMENT|1963-02-27||||1969-05-10||1967-07-07|1969-08-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||METSIND|METASTATIC INDICATOR||||FT|SMD||UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|SIGNIFICANT OTHER|ADJUDICATOR|U|2||58||OBSERVATION|1970-07-07||||1960-04-03||1970-04-27|1965-07-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CAPLET|IMPROVED||CMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|2||58||FOLLOW-UP|1964-07-25||||1973-08-18||1971-11-16|1962-06-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UMOL/MIN|NON-QUANTIFIABLE MRD POSITIVITY||DISK|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|INVESTIGATOR|HEMATOLOGIST|N|3||39||FOLLOW-UP|1961-07-21||||1972-10-08||1964-06-25|1964-04-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||NEWLPROG|NEW LESION PROGRESSION||||IU|PSA PROGRESSION||/CMH2O|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|DOMESTIC PARTNER|MICROSCOPIST|NA|3||39||BASELINE|1966-10-27||||1970-10-06||1963-04-18|1965-07-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||LIVRRESP|LIVER RESPONSE||||GENEQ/ML|PARTIAL MORPHOLOGIC RESPONSE||UM2|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|VENDOR|RADIOLOGIST 2|Y|4||88||OBSERVATION|1969-09-23||||1972-09-24||1966-06-14|1972-01-21||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||LIVRRESP|LIVER RESPONSE||||JOULE|VGPR||MU|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||OBSERVATION|1969-12-05||||1970-05-14||1965-05-25|1963-09-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||METBRESP|METABOLIC RESPONSE||||YEARS|MORPHOLOGIC CR||MG/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|5||7||SCREENING|1960-12-07||||1962-12-22||1972-10-28|1961-10-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MM/H|PD/RELAPSE AFTER HI||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|ADJUDICATOR|ENDOCRINOLOGIST|U|5||7||OBSERVATION|1966-09-30||||1962-07-05||1970-04-17|1962-03-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CD|MRD RELAPSE||BQ/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|1||38||OBSERVATION|1967-10-15||||1961-09-18||1970-01-24|1961-01-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||METBRESP|METABOLIC RESPONSE||||POUCH|DISEASE TRANSFORMATION||JAR|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|CAREGIVER|DERMATOLOGIST|N|1||38||OBSERVATION|1972-06-26||||1963-05-16||1963-06-11|1963-06-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||TMRESP|TUMOR MARKER RESPONSE||||G/DAY|CYTOGENETIC NO RESPONSE||HOUNSFIELD UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|PARENT|READER 2|N|2||58||CONTINUATION TREATMENT|1971-12-27||||1972-07-31||1970-05-16|1964-02-21||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TORR|CR||ML/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|INDEPENDENT ASSESSOR|READER|Y|2||58||BASELINE|1966-04-21||||1972-06-26||1965-03-18|1970-10-09||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||SPLNRESP|SPLEEN RESPONSE||||IU/DL|INCREASED||U/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|ADJUDICATION COMMITTEE|READER 2|NA|3||39||TREATMENT|1964-05-10||||1961-03-06||1960-03-31|1968-03-30||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||STRUSTAT|STEROID USE STATUS||||LOG10 ELISA UNIT/DOSE|PCR||POUCH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|3||39||SCREENING|1961-08-10||||1969-07-25||1961-06-21|1961-07-31||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||LIVRRESP|LIVER RESPONSE||||NMOL BCE/NMOL|SD||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4||88||INDUCTION TREATMENT|1962-05-24||||1963-05-10||1973-07-25|1967-07-01||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CI/UG|VGPR||G/CAGE/DAY|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1963-07-11||||1963-12-13||1966-01-12|1967-12-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||OVRLRESP|OVERALL RESPONSE||||UV2|PARTIAL MORPHOLOGIC RESPONSE||MMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|SIGNIFICANT OTHER|RADIOLOGIST 2|N|5||7||WASHOUT|1971-10-06||||1968-06-28||1965-11-12|1973-07-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^4/L|RELAPSED DISEASE FROM CR||SHOCK WAVE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1962-08-17||||1969-05-26||1964-01-10|1961-04-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/G/DAY|HI-E||UOSM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|1||38||FOLLOW-UP|1965-07-24||||1963-01-21||1966-12-14|1962-07-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||TMRESP|TUMOR MARKER RESPONSE||||NEBULE|MINOR PATHOLOGIC RESPONSE||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||INDUCTION TREATMENT|1966-08-02||||1960-03-22||1968-05-31|1967-07-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CP|HI-E||MCI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|2||58||CONTINUATION TREATMENT|1965-03-09||||1966-09-22||1960-06-02|1965-03-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||MOLRESP|MOLECULAR RESPONSE||||COPIES/UL|HI-E||U/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|CHILD|ADJUDICATOR 3|Y|2||58||LONG-TERM FOLLOW-UP|1973-06-10||||1968-04-28||1972-05-13|1968-03-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||LIVRRESP|LIVER RESPONSE||||MIN*MG/ML|CR||MSEC|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|PARENT|RADIOLOGIST|Y|3||39||BASELINE|1963-06-02||||1968-08-08||1965-08-09|1966-07-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||BONERESP|BONE RESPONSE||||G/CAGE/DAY|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||IU/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|3||39||RUN-IN|1966-05-07||||1960-10-07||1973-01-07|1962-01-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DAMOL/L|CMR||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|INVESTIGATOR|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1964-11-16||||1964-02-04||1967-06-12|1972-07-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NEEDLE GAUGE|MCR||MG/M2/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|CLINICAL STUDY SPONSOR|READER 3|U|4||88||WASHOUT|1967-03-30||||1960-12-06||1970-04-18|1968-10-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TRACE|QUANTIFIABLE MRD POSITIVITY||LM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|5||7||OPEN LABEL TREATMENT|1973-09-02||||1973-06-10||1962-07-09|1964-10-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MG/KG/H|QUANTIFIABLE MRD POSITIVITY||10^6 IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|CAREGIVER|UROLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1972-04-29||||1971-01-06||1969-06-03|1966-09-09||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL/10^10 CELLS|PR WITH LYMPHOCYTOSIS||MV*MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|1||38||BLINDED TREATMENT|1971-02-15||||1965-01-13||1969-05-18|1971-03-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||LOG EID 50/DOSE|CYTOGENETIC NO RESPONSE||LOG10 PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|SPOUSE|CARDIOLOGIST|U|1||38||SCREENING|1965-09-17||||1960-01-08||1967-05-12|1970-07-06||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MV|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||NG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|FRIEND|MICROSCOPIST 2|NA|2||58||CONTINUATION TREATMENT|1963-03-03||||1967-02-01||1973-04-03|1967-04-14||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||TMRESP|TUMOR MARKER RESPONSE||||CMHG|PD||MEQ/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||BASELINE|1968-03-14||||1971-09-19||1970-01-09|1967-03-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/KG/MIN|CPR||CMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|FRIEND|RATER 2|U|3||39||SCREENING|1970-10-02||||1962-03-02||1971-05-27|1972-07-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PMOL/DAY|RELAPSED DISEASE FROM CR||U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|3||39||OPEN LABEL TREATMENT|1969-04-26||||1972-07-19||1966-03-17|1967-08-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MG/M2|MINOR PATHOLOGIC RESPONSE||CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1960-01-25||||1971-02-13||1963-06-15|1968-07-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||LIVRRESP|LIVER RESPONSE||||ML/SEC/1.73M2|NR||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|FAMILY MEMBER|ADJUDICATOR 3|NA|4||88||OPEN LABEL TREATMENT|1960-12-06||||1964-02-21||1964-09-30|1970-09-09||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GPL U|CYTOGENETIC PR||MBQ/UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|CHILD|ONCOLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1967-01-26||||1969-08-31||1964-07-17|1965-07-19||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||COAT|PDU||ENZYME U/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|INVESTIGATOR|PATHOLOGIST|Y|5||7||TREATMENT|1962-03-02||||1970-12-30||1970-10-22|1972-09-19||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||STRUSTAT|STEROID USE STATUS||||%(W/V)|CHR||NU/CL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|1||38||BASELINE|1965-04-16||||1963-06-19||1971-10-04|1966-05-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||STRUSTAT|STEROID USE STATUS||||ATM|PD FROM PR||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|PROXY|CARDIOLOGIST|NA|1||38||WASHOUT|1965-07-05||||1961-07-17||1972-10-17|1960-04-20||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BOWL|SD||CONTAINER|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|FAMILY MEMBER|READER 1|Y|2||58||BLINDED TREATMENT|1969-04-09||||1968-01-31||1970-08-28|1965-07-27||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||TMRESP|TUMOR MARKER RESPONSE||||MG/ANIMAL|OPTIMAL MORPHOLOGIC RESPONSE||UV2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|INDEPENDENT ASSESSOR|READER 1|U|2||58||WASHOUT|1968-08-31||||1963-01-26||1961-08-03|1969-05-24||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CG|CYTOGENETIC CR||MET*H|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|SIBLING|ONCOLOGIST|Y|3||39||FOLLOW-UP|1962-03-27||||1966-10-09||1964-09-20|1973-05-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||LIVRRESP|LIVER RESPONSE||||MV*MIN|MRD PERSISTENCE||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|3||39||OPEN LABEL TREATMENT|1972-08-05||||1963-09-21||1964-09-03|1965-08-28||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/M2/DAY|VGPR||U/MMOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|FAMILY MEMBER|ADJUDICATOR 1|Y|4||88||LONG-TERM FOLLOW-UP|1968-08-09||||1968-12-23||1960-03-03|1969-01-29||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||SPLNRESP|SPLEEN RESPONSE||||MU/L|MORPHOLOGIC LEUKEMIA-FREE STATE||GY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4||88||SCREENING|1966-11-25||||1971-04-06||1967-04-28|1971-06-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/M2/H|CYTOGENETIC PR||FL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CHILD|DERMATOLOGIST|N|5||7||OBSERVATION|1960-09-14||||1971-07-20||1966-10-22|1964-05-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CS|CA125 50% RESPONSE||MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|PARENT|RATER 2|N|5||7||CONTINUATION TREATMENT|1967-12-28||||1962-10-01||1961-03-09|1966-03-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DISK|MOLECULAR MAJOR RESPONSE||UMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|SPOUSE|READER 3|NA|1||38||CONTINUATION TREATMENT|1967-01-04||||1963-10-25||1968-07-21|1966-09-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPSULE|PR WITH LYMPHOCYTOSIS||KG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|SIBLING|MICROSCOPIST 3|U|1||38||FOLLOW-UP|1973-02-25||||1969-09-05||1960-08-21|1970-04-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||NTRGRESP|NON-TARGET RESPONSE||||GBQ/G|CR-CT||COAT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|READER 1|NA|2||58||OPEN LABEL TREATMENT|1966-01-04||||1966-05-26||1972-08-12|1964-05-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||CYTORESP|CYTOGENETIC RESPONSE||||GTT|RELAPSED DISEASE FROM CR OR PR||10^7 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||BASELINE|1964-09-22||||1966-04-26||1970-04-30|1961-06-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||NEWLPROG|NEW LESION PROGRESSION||||MOL/ML|MAJOR PATHOLOGIC RESPONSE||AG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|ADJUDICATOR|PATHOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1962-03-17||||1960-10-22||1968-05-30|1967-04-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL BCE/MMOL|PSEUDORESPONSE||10^7 PFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|CAREGIVER|OPTOMETRIST|U|3||39||WASHOUT|1964-05-24||||1964-11-28||1964-12-26|1971-05-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||USIEMENS|HI-P||BE/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|CHILD|RADIOLOGIST|U|4||88||WASHOUT|1961-12-22||||1965-11-26||1960-02-24|1961-03-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||ANATRESP|ANATOMIC RESPONSE||||CFU/ML|NR||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|PROXY|OPTOMETRIST|N|4||88||SCREENING|1967-10-27||||1967-10-23||1961-11-13|1969-01-07||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||STRUSTAT|STEROID USE STATUS||||LOG10 TCID 50/DOSE|IMMUNOPHENOTYPIC CR||KCAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|5||7||BLINDED TREATMENT|1966-01-13||||1973-07-12||1963-07-29|1973-05-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||LIVRRESP|LIVER RESPONSE||||MOL/L|MR||OZ EQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|5||7||SCREENING|1961-03-10||||1966-02-18||1965-02-26|1964-04-05||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||BESTRESP|BEST OVERALL RESPONSE||||UG/CM2|PMR||LOG10 TCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1973-01-30||||1960-01-21||1962-08-26|1965-08-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||BONERESP|BONE RESPONSE||||BQ|HI-P||PM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|GUARDIAN|ADJUDICATOR 1|U|1||38||INDUCTION TREATMENT|1962-03-06||||1962-02-06||1965-04-19|1966-11-14||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NFIU|PARTIAL MORPHOLOGIC RESPONSE||BEATS/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|INTERVIEWER|PATHOLOGIST 1|N|2||58||CONTINUATION TREATMENT|1971-02-04||||1960-03-07||1969-03-14|1970-10-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/L|STABLE||/10^4|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|ADJUDICATOR|RADIOLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1960-08-12||||1961-02-04||1961-12-19|1973-02-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MS2|MORPHOLOGIC CRI||TABLET|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||SCREENING|1964-06-24||||1967-12-24||1964-04-22|1966-10-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||BONERESP|BONE RESPONSE||||CMH2O*S/ML|PD||/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|3||39||SCREENING|1964-07-08||||1967-10-29||1963-04-20|1960-08-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MIN*MG/ML|PSEUDORESPONSE||ARBITRARY U|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|READER|NA|4||88||FOLLOW-UP|1960-03-04||||1971-08-23||1963-01-13|1972-12-28||DURING||AFTER|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MCI/L|NON-QUANTIFIABLE MRD POSITIVITY||MET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|4||88||WASHOUT|1965-03-03||||1972-12-23||1971-03-14|1966-07-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PACK|DECREASED||PMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1973-04-10||||1966-03-23||1972-02-20|1966-10-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||PATHRESP|PATHOLOGIC RESPONSE||||KCAL|ICPD||MET|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|CHILD|RATER 2|NA|5||7||LONG-TERM FOLLOW-UP|1970-11-11||||1965-09-22||1965-09-23|1965-02-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CM/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||KUSP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|FAMILY MEMBER|RATER 1|N|1||38||TREATMENT|1964-06-18||||1973-08-30||1973-08-01|1963-08-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ANSON U|CRI||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|FRIEND|MICROSCOPIST 2|U|1||38||LONG-TERM FOLLOW-UP|1971-08-24||||1967-09-13||1970-04-04|1969-12-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||METBRESP|METABOLIC RESPONSE||||PACK YEAR|DISEASE TRANSFORMATION||/7.5 ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|2||58||INDUCTION TREATMENT|1968-01-24||||1966-01-27||1971-04-13|1973-06-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||RDIORESP|RADIOLOGIC RESPONSE||||1/(S*KPA)|MCR||U/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|2||58||SCREENING|1963-05-02||||1964-07-08||1970-09-15|1965-02-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DRINK|NOT ALL EVALUATED||UG/MOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|PARENT|HEMATOLOGIST|U|3||39||WASHOUT|1966-01-26||||1961-04-22||1960-05-19|1962-12-20||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||SPLNRESP|SPLEEN RESPONSE||||NEEDLE GAUGE|MOLECULAR MAJOR RESPONSE||KG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|3||39||FOLLOW-UP|1969-06-22||||1961-04-13||1967-02-18|1968-06-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||CLINRESP|CLINICAL RESPONSE||||SPRAY|MAJOR PATHOLOGIC RESPONSE||MMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4||88||FOLLOW-UP|1972-12-07||||1972-09-07||1960-05-03|1962-03-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||PATHRESP|PATHOLOGIC RESPONSE||||U/KG/DAY|PD||FG|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|INTERVIEWER|RATER 2|U|4||88||OBSERVATION|1966-12-28||||1972-02-29||1963-05-29|1961-04-16||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||STRUSTAT|STEROID USE STATUS||||MMOL/L|CCR||FT3|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|5||7||BLINDED TREATMENT|1963-09-29||||1966-04-06||1964-10-17|1969-11-12||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^12/L|VGPR||IU/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|5||7||OBSERVATION|1963-04-04||||1961-03-14||1963-08-11|1973-06-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||CLINRESP|CLINICAL RESPONSE||||MPL U|INCREASED||IN|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|INVESTIGATOR|INTERNIST|Y|1||38||OBSERVATION|1965-07-07||||1963-12-27||1972-09-15|1967-07-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MET|MOLECULAR CR||CMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|PARENT|MICROSCOPIST 2|Y|1||38||FOLLOW-UP|1963-07-24||||1969-07-06||1969-11-02|1962-08-14||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||TMRESP|TUMOR MARKER RESPONSE||||PELLET|INCREASED||/10^3|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIGNIFICANT OTHER|MICROSCOPIST 1|N|2||58||BASELINE|1967-03-14||||1968-03-04||1965-10-22|1968-06-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KG/CM2|EQUIVOCAL||10^3 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|DOMESTIC PARTNER|NEUROLOGIST|U|2||58||WASHOUT|1965-12-24||||1969-12-08||1966-08-18|1963-12-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MPL U/ML|MCR||10^7 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|GUARDIAN|NEUROLOGIST|Y|3||39||BASELINE|1960-05-01||||1963-08-16||1960-10-24|1966-11-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/CAGE/WK|PMD||10^3/HPF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|3||39||INDUCTION TREATMENT|1961-01-13||||1971-06-13||1965-03-18|1968-08-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/M2|CRI||TUBE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|SIGNIFICANT OTHER|RATER|U|4||88||SCREENING|1964-05-10||||1969-12-31||1965-07-04|1973-02-16||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CY/CM|CMR||GPELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|PROXY|FORENSIC PATHOLOGIST|U|4||88||OBSERVATION|1965-12-19||||1964-08-11||1967-10-10|1972-07-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||METBRESP|METABOLIC RESPONSE||||IU/ML|CA125 50% RESPONSE||TSP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|5||7||CONTINUATION TREATMENT|1963-03-02||||1969-10-12||1961-08-29|1968-04-07||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||LIVRRESP|LIVER RESPONSE||||UEQ/L|CA125 50% RESPONSE||MG/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|STUDY SUBJECT|RADIOLOGIST 2|U|5||7||CONTINUATION TREATMENT|1967-10-29||||1972-05-25||1969-04-29|1968-07-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||OVRLRESP|OVERALL RESPONSE||||CI/ML|MR||UMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|1||38||SCREENING|1965-12-14||||1963-07-31||1969-05-18|1963-06-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MEQ/KG|HI-N||CONTAINER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|INVESTIGATOR|CARDIOLOGIST|N|1||38||FOLLOW-UP|1966-05-19||||1967-01-20||1969-04-28|1962-03-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/G/H|CYTOGENETIC PR||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|SIBLING|READER 3|U|2||58||OPEN LABEL TREATMENT|1968-07-01||||1970-05-15||1970-08-08|1963-07-03||DURING||DURING|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||NEWLPROG|NEW LESION PROGRESSION||||UMOL/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||ML/MMHG/MIN/L|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2||58||CONTINUATION TREATMENT|1972-01-20||||1969-04-16||1964-05-29|1961-01-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CM/S|NON-PD||ML/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|3||39||OPEN LABEL TREATMENT|1963-09-18||||1965-02-02||1973-04-19|1967-11-28||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DL|RELAPSED DISEASE FROM CR||UMOL/MOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|3||39||BLINDED TREATMENT|1971-06-01||||1968-04-16||1963-03-23|1972-03-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/M2/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||ANTI-XA IU|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|STUDY SUBJECT|ONCOLOGIST 1|N|4||88||CONTINUATION TREATMENT|1964-02-19||||1964-01-14||1963-12-28|1973-04-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/200 HPFS|CYTOGENETIC NO RESPONSE||APPLICATION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||SCREENING|1965-05-26||||1972-02-25||1971-04-14|1960-11-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||TRGRESP|TARGET RESPONSE||||G/CAGE/WK|UNFAVORABLE RESPONSE||ML/100G/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|CHILD|NEUROLOGIST 2|U|5||7||WASHOUT|1963-09-07||||1971-06-30||1970-03-26|1970-03-04||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||GBQ/UG|PSEUDOPROGRESSION||BQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|GUARDIAN|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1968-08-04||||1966-03-29||1963-08-15|1972-09-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||CLINRESP|CLINICAL RESPONSE||||CMH2O*S2/ML|ISD||UG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|GUARDIAN|RATER 2|NA|1||38||FOLLOW-UP|1970-12-21||||1961-11-05||1966-07-21|1968-09-14||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||LIVRRESP|LIVER RESPONSE||||SBE/ML|MRD PERSISTENCE||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|STUDY SUBJECT|READER 2|U|1||38||BASELINE|1971-03-05||||1966-08-04||1971-02-24|1967-01-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||OD UNIT|HI-P||PACKAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|FRIEND|CLINICAL PATHOLOGIST|Y|2||58||TREATMENT|1961-01-03||||1963-07-31||1965-04-26|1973-01-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||BESTRESP|BEST OVERALL RESPONSE||||AG|UNEQUIVOCAL||STEPS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|ADJUDICATION COMMITTEE|READER 2|U|2||58||SCREENING|1970-12-12||||1965-05-15||1962-04-15|1968-06-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^3/HPF|COMPLETE MRD RESPONSE||MMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|PARENT|INTERNIST|N|3||39||BASELINE|1967-11-15||||1966-11-12||1960-09-01|1961-08-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMHG|MOLECULAR CR||POUCH|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|STUDY SUBJECT|ONCOLOGIST|Y|3||39||BLINDED TREATMENT|1960-10-23||||1962-06-28||1968-05-01|1963-12-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/G|WORSENED||CUP EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|SIGNIFICANT OTHER|RATER 2|N|4||88||INDUCTION TREATMENT|1962-12-07||||1965-05-06||1969-05-19|1967-02-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||BESTRESP|BEST OVERALL RESPONSE||||MIU/L|PMR||CM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|ADJUDICATOR|MICROSCOPIST 1|U|4||88||LONG-TERM FOLLOW-UP|1961-01-17||||1965-01-28||1963-05-15|1968-09-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LX|RELAPSED DISEASE||PT_US|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|5||7||INDUCTION TREATMENT|1968-09-28||||1966-09-23||1963-05-02|1971-06-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PUFF|MRD NEGATIVITY||VIAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|INVESTIGATOR|RATER 2|NA|5||7||CONTINUATION TREATMENT|1972-04-15||||1965-04-18||1968-07-28|1972-12-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||JDF UNIT|MR||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|STUDY SUBJECT|PATHOLOGIST 1|NA|1||38||INDUCTION TREATMENT|1971-03-12||||1971-12-22||1964-10-02|1963-06-16||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/M2|SMD||MPL U/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|FRIEND|MICROSCOPIST|N|1||38||BASELINE|1964-05-31||||1969-12-05||1971-03-06|1971-07-14||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||MOLRESP|MOLECULAR RESPONSE||||U/G/MIN|INDETERMINATE RESPONSE||GPS U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|SIBLING|NEUROLOGIST 1|Y|2||58||FOLLOW-UP|1966-05-17||||1970-03-21||1962-11-17|1966-01-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||SPLNRESP|SPLEEN RESPONSE||||M/SEC|FAVORABLE RESPONSE||VIAL|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|FRIEND|NEUROLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1971-08-19||||1969-11-08||1970-05-07|1970-08-15||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/KG|HI-E||G/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|PARENT|NEUROLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1962-05-14||||1973-01-30||1971-12-20|1963-01-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||CLINRESP|CLINICAL RESPONSE||||UG/KG/DAY|ICPD||10^3 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|INDEPENDENT ASSESSOR|PATHOLOGIST|U|3||39||SCREENING|1973-03-11||||1960-11-05||1964-06-11|1968-04-06||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||NMOL BCE/L|NOT ALL EVALUATED||/4.0 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|CAREGIVER|ONCOLOGIST|U|4||88||SCREENING|1972-05-11||||1967-10-09||1962-11-19|1967-03-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/M2/DAY|NON-CR/NON-PD||MV|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|VENDOR|CLINICAL PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1969-08-17||||1973-02-23||1964-05-30|1972-05-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/KG/DAY|PCR||NG/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|VENDOR|NEUROLOGIST|U|5||7||FOLLOW-UP|1962-12-12||||1970-12-23||1970-06-13|1969-09-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||BONERESP|BONE RESPONSE||||ML/CAGE/DAY|MCR||U/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|GUARDIAN|PATHOLOGIST 1|U|5||7||BLINDED TREATMENT|1961-12-26||||1971-01-21||1964-01-28|1960-10-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G/KG/DAY|MRD NEGATIVITY||MMOL/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|FRIEND|RATER|NA|1||38||CONTINUATION TREATMENT|1973-08-15||||1964-09-15||1961-04-08|1971-01-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||STRUSTAT|STEROID USE STATUS||||10^6 U|CRI||BEATS/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|SIGNIFICANT OTHER|OPTOMETRIST|NA|1||38||LONG-TERM FOLLOW-UP|1961-12-16||||1963-04-26||1960-08-30|1968-10-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||OVRLRESP|OVERALL RESPONSE||||CS|CPR||UMOL/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|SPOUSE|MICROSCOPIST 1|U|2||58||RUN-IN|1971-03-31||||1968-12-11||1960-05-08|1968-02-21||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KG/CM2|PR||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|STUDY SUBJECT|READER 3|U|2||58||BASELINE|1967-05-26||||1962-10-10||1969-08-22|1967-12-09||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||VIAL|EQUIVOCAL||PMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|SIBLING|CLINICAL PATHOLOGIST|N|3||39||BASELINE|1962-09-15||||1966-05-21||1962-03-08|1970-10-20||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CYCLE/MIN|HI-P||IU/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1960-06-26||||1971-08-01||1962-06-12|1972-06-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/M2/MIN|SCR||PSEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|INTERVIEWER|READER|N|4||88||LONG-TERM FOLLOW-UP|1966-05-31||||1969-11-19||1964-10-31|1961-06-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||S/H|INCREASED||G/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|SIBLING|PEDIATRIC NEUROLOGIST|N|4||88||TREATMENT|1972-03-11||||1968-07-26||1962-11-09|1961-05-24||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EVENTS|SCR||CCID 50/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|DOMESTIC PARTNER|ONCOLOGIST 2|U|5||7||RUN-IN|1964-01-27||||1961-08-02||1963-04-15|1961-10-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ENZYME U/L|ICR||G/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|PARENT|MICROSCOPIST 2|U|5||7||BASELINE|1961-02-02||||1970-03-17||1965-11-25|1961-04-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||CLINRESP|CLINICAL RESPONSE||||G/CAGE/WK|PARTIAL MORPHOLOGIC RESPONSE||KUSP|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|1||38||BLINDED TREATMENT|1967-02-17||||1965-05-01||1970-08-30|1965-09-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||MOLRESP|MOLECULAR RESPONSE||||RNA COPIES/ML|CYTOGENETIC PR||ATM|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|INTERVIEWER|READER 3|NA|1||38||RUN-IN|1970-01-25||||1965-10-21||1972-10-01|1973-06-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||RDIORESP|RADIOLOGIC RESPONSE||||SV|CRI||FT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|PROXY|HEMATOLOGIST|U|2||58||OPEN LABEL TREATMENT|1966-01-13||||1965-05-15||1964-08-14|1962-09-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/G/MIN|NED||MKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|2||58||INDUCTION TREATMENT|1969-10-04||||1966-03-10||1964-07-16|1970-10-30||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PMOL/DAY|RELAPSED DISEASE FROM CR OR PR||UG/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|CLINICAL STUDY SPONSOR|READER|Y|3||39||SCREENING|1969-01-24||||1969-12-20||1972-05-27|1968-05-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||TMRESP|TUMOR MARKER RESPONSE||||G/CM2|NON-ICR/NON-IUPD||GY/H|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|DOMESTIC PARTNER|MICROSCOPIST 3|N|3||39||BLINDED TREATMENT|1971-11-24||||1970-04-07||1964-12-01|1965-04-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||MOLRESP|MOLECULAR RESPONSE||||GBQ/G|HI-P||/MS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1960-06-09||||1972-08-09||1967-06-11|1963-12-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GRAVITATIONAL UNIT|NOT ALL EVALUATED||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|ADJUDICATION COMMITTEE|RATER 1|NA|4||88||OBSERVATION|1963-10-09||||1973-02-03||1963-04-24|1967-06-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||TRGRESP|TARGET RESPONSE||||CUP|ABSENT MORPHOLOGIC RESPONSE||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|STUDY SUBJECT|ONCOLOGIST|U|5||7||FOLLOW-UP|1970-12-29||||1966-03-30||1967-02-03|1965-07-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||NEWLPROG|NEW LESION PROGRESSION||||APS U|SD-CT||/HPF|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|RATER|U|5||7||LONG-TERM FOLLOW-UP|1973-02-12||||1969-08-14||1962-11-06|1969-04-09||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CI/KG|MCR||CMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|1||38||OBSERVATION|1967-06-20||||1972-11-09||1971-01-08|1964-02-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||OVRLRESP|OVERALL RESPONSE||||MG/M2|HI-P||DAMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|GUARDIAN|OPTOMETRIST|NA|1||38||OBSERVATION|1969-01-31||||1964-02-06||1965-11-21|1965-09-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||ANATRESP|ANATOMIC RESPONSE||||MMOL2/L2|MR||DAYS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|NA|SPOUSE|PHYSIOTHERAPIST|N|2||58||OPEN LABEL TREATMENT|1973-05-23||||1965-07-17||1960-01-14|1964-09-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||TMRESP|TUMOR MARKER RESPONSE||||U/CL|UNEQUIVOCAL||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|PARENT|PEDIATRIC NEUROLOGIST|Y|2||58||SCREENING|1965-05-07||||1972-12-06||1962-08-12|1969-02-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||SCM|NE||MOSM/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|3||39||BLINDED TREATMENT|1960-06-15||||1971-03-31||1967-03-13|1966-10-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||SPLNRESP|SPLEEN RESPONSE||||CI/UG|HI-P||ML/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|3||39||FOLLOW-UP|1971-05-19||||1973-04-19||1971-03-09|1969-12-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||OZ EQ|PMD||MHZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|VENDOR|ONCOLOGIST 1|Y|4||88||RUN-IN|1973-03-16||||1971-08-30||1966-03-07|1960-02-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7/L|NON-ICR/NON-IUPD||GLOBULE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BLINDED TREATMENT|1970-11-06||||1967-02-09||1964-08-18|1963-09-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ|ICR||LOG10 TCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|DOMESTIC PARTNER|RADIOLOGIST 2|Y|5||7||OBSERVATION|1968-11-19||||1967-03-15||1961-08-16|1964-03-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||LIVRRESP|LIVER RESPONSE||||MMAL|MINOR PATHOLOGIC RESPONSE||IU/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1970-07-29||||1965-12-16||1962-12-23|1963-07-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ABSORBANCE U|PD||CMH2O/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|PARENT|ONCOLOGIST 1|U|1||38||WASHOUT|1966-08-27||||1961-04-10||1972-03-08|1967-07-31||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||TRGRESP|TARGET RESPONSE||||KCAL/DAY|NON-CR/NON-PD||ML/CM H2O|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|ADJUDICATOR|INTERNIST|U|1||38||BASELINE|1965-10-18||||1962-04-22||1969-11-01|1964-08-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CAPSULE|PSEUDORESPONSE||TUBE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1966-07-24||||1971-07-20||1972-02-07|1971-04-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||STRUSTAT|STEROID USE STATUS||||10^6/L|DISEASE TRANSFORMATION||PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|ADJUDICATOR|OTOLARYNGOLOGIST|U|2||58||FOLLOW-UP|1968-08-21||||1965-07-02||1966-11-25|1966-03-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||ANATRESP|ANATOMIC RESPONSE||||/100 WBC|PSEUDOPROGRESSION||UG/ML/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|READER 1|Y|3||39||WASHOUT|1963-02-03||||1960-07-07||1964-12-13|1970-12-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PKAT/L|PD-CT||G/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|3||39||FOLLOW-UP|1966-12-22||||1971-02-21||1962-06-13|1968-10-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/CL|MRD PERSISTENCE||ML/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|VENDOR|MICROSCOPIST 3|Y|4||88||SCREENING|1970-08-15||||1970-07-10||1960-08-08|1970-07-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||METSIND|METASTATIC INDICATOR||||MG/L FEU|CHR||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|4||88||WASHOUT|1963-06-08||||1970-04-06||1971-08-16|1962-05-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ENZYME U/G HB|PSA PROGRESSION||KG/M2|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|5||7||BASELINE|1961-01-20||||1962-05-26||1971-12-25|1967-10-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||METSIND|METASTATIC INDICATOR||||MG/KG/DAY|PMR||/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1968-01-28||||1969-06-19||1964-03-14|1969-07-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NMOL|CPR||AMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|1||38||SCREENING|1971-04-01||||1964-07-30||1973-06-02|1966-11-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 CFU/G|CA125 50% RESPONSE||MG/L FEU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|SIBLING|DERMATOLOGIST|U|1||38||SCREENING|1971-09-23||||1960-07-12||1964-12-27|1965-09-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||OHM|PARTIAL MORPHOLOGIC RESPONSE||GENEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|2||58||TREATMENT|1966-02-16||||1963-11-27||1971-04-20|1963-06-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MJOULE/CM2|UNFAVORABLE RESPONSE||BE/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|PROXY|ADJUDICATOR 2|Y|2||58||TREATMENT|1960-05-17||||1966-03-08||1965-05-11|1968-04-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/HPF|INCREASED||U/CL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1962-10-26||||1970-08-12||1963-07-04|1968-04-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^12/L|ICR||MDFI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|PARENT|READER 3|N|3||39||INDUCTION TREATMENT|1964-12-02||||1964-04-02||1964-12-18|1963-12-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||GRAVITATIONAL UNIT|PCR||ROENTGEN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|ADJUDICATOR|RADIOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1963-07-22||||1960-04-26||1964-05-28|1961-05-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||NEWLPROG|NEW LESION PROGRESSION||||PUFF|ICPD||APL U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|FAMILY MEMBER|CARDIOLOGIST|Y|4||88||BASELINE|1962-07-20||||1972-08-18||1971-09-04|1964-04-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||BESTRESP|BEST OVERALL RESPONSE||||MEQ/L|NON-ICR/NON-IUPD||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1961-03-29||||1971-01-24||1973-01-16|1967-01-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||TRGRESP|TARGET RESPONSE||||PMOL|RELAPSED DISEASE||LOG10 TCID 50/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|CAREGIVER|PEDIATRIC NEUROLOGIST|U|5||7||RUN-IN|1965-11-01||||1968-05-06||1960-04-03|1969-06-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||%/MIN|NPR||UL/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|1||38||OBSERVATION|1966-11-19||||1963-07-30||1960-01-04|1965-05-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NFIU|HI-E||MHZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|CAREGIVER|READER 2|NA|1||38||SCREENING|1960-04-17||||1973-03-08||1963-12-06|1973-08-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/LPF|NE||DAYS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|FRIEND|ADJUDICATOR 1|N|2||58||CONTINUATION TREATMENT|1971-01-22||||1968-01-28||1968-11-06|1967-10-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/CM3/MIN|NOT ALL EVALUATED||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|2||58||BLINDED TREATMENT|1966-03-17||||1963-04-09||1971-08-11|1973-08-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||METSIND|METASTATIC INDICATOR||||ML/DAY|DISEASE TRANSFORMATION||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|SPOUSE|READER 1|NA|3||39||CONTINUATION TREATMENT|1962-05-06||||1963-03-17||1964-12-17|1960-05-24||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||NEWLPROG|NEW LESION PROGRESSION||||IU|NON-CR/NON-PD||CY/CM|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|SPOUSE|UROLOGIST|NA|3||39||OPEN LABEL TREATMENT|1966-01-18||||1963-09-27||1963-11-21|1961-04-03||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UIU/DL|RELAPSED DISEASE FROM CR OR PR||ML/BREATH|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1972-06-14||||1965-06-06||1967-02-03|1964-11-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||OVRLRESP|OVERALL RESPONSE||||INHALATION|INCREASED||UG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|SPOUSE|ONCOLOGIST|N|4||88||BASELINE|1969-08-25||||1963-12-08||1960-08-08|1970-07-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||NEWLIND|NEW LESION INDICATOR||||UG/DAY|MINOR PATHOLOGIC RESPONSE||MG/ML/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|CHILD|PATHOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1966-06-18||||1960-02-19||1969-11-13|1961-08-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||STRUSTAT|STEROID USE STATUS||||TITER|SMD||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||INDUCTION TREATMENT|1963-01-29||||1971-03-17||1962-08-16|1965-05-25||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ANTIBODY UNIT|HI-N||10^6 DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|INVESTIGATOR|ONCOLOGIST 1|NA|1||38||WASHOUT|1969-04-22||||1972-03-13||1968-06-22|1965-03-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||PATHRESP|PATHOLOGIC RESPONSE||||SYRINGE|PR WITH LYMPHOCYTOSIS||AMFI|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|PROXY|RADIOLOGIST|NA|1||38||BASELINE|1962-05-28||||1962-04-07||1973-01-16|1970-12-17||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||METSIND|METASTATIC INDICATOR||||/200 HPFS|ABSENT MORPHOLOGIC RESPONSE||WAFER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|CLINICAL STUDY SPONSOR|READER 2|Y|2||58||FOLLOW-UP|1970-07-27||||1970-04-24||1969-10-31|1960-08-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||NTRGRESP|NON-TARGET RESPONSE||||NKAT/L|IMMUNOPHENOTYPIC CR||UCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|2||58||WASHOUT|1965-12-28||||1960-01-27||1969-07-03|1965-01-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CI/KG|CMR||FRAMES/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|INVESTIGATOR|CLINICAL PATHOLOGIST|U|3||39||OBSERVATION|1973-07-30||||1961-02-07||1971-11-23|1972-11-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||NTRGRESP|NON-TARGET RESPONSE||||PKAT/L|CHR||DPM/100MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|SIBLING|NEUROLOGIST 1|N|3||39||WASHOUT|1970-06-26||||1969-08-19||1973-09-04|1968-01-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||APS U|SD||MMHG/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|4||88||WASHOUT|1969-03-27||||1963-05-30||1961-10-17|1964-08-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||%(W/W)|HI-P||MBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|PROXY|CLINICAL PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1966-05-03||||1970-04-06||1968-12-01|1969-09-12||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||STRUSTAT|STEROID USE STATUS||||10^12/L|CMR||UG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|5||7||INDUCTION TREATMENT|1972-04-18||||1968-07-25||1961-12-30|1964-09-09||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^3 COPIES/ML|TREATMENT FAILURE||YEARS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|ADJUDICATION COMMITTEE|INTERNIST|NA|5||7||BLINDED TREATMENT|1967-08-10||||1969-06-24||1962-02-17|1960-11-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||CLINRESP|CLINICAL RESPONSE||||NMOL BCE/MMOL|NON-QUANTIFIABLE MRD POSITIVITY||PIXEL|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1||38||INDUCTION TREATMENT|1969-10-20||||1962-05-14||1962-08-15|1971-09-10||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||SPLNRESP|SPLEEN RESPONSE||||DAGU|EQUIVOCAL||/MM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|PARENT|NEUROLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1971-05-04||||1963-05-18||1963-02-04|1968-12-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/BEAT|OPTIMAL MORPHOLOGIC RESPONSE||L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|SIGNIFICANT OTHER|ADJUDICATOR|Y|2||58||BASELINE|1969-09-14||||1962-03-07||1966-01-23|1969-06-05||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/KG/H|CYTOGENETIC MINOR RESPONSE||10^8/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|SIBLING|CARDIOLOGIST|U|2||58||TREATMENT|1968-10-06||||1963-11-05||1971-06-15|1965-03-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/G|UNFAVORABLE RESPONSE||NFIU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|CLINICAL STUDY SPONSOR|UROLOGIST|Y|3||39||WASHOUT|1968-06-14||||1973-05-29||1968-11-11|1967-06-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||NEWLIND|NEW LESION INDICATOR||||AMPULE|PSEUDORESPONSE||TESLA|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|3||39||INDUCTION TREATMENT|1961-11-29||||1962-05-28||1961-02-07|1960-03-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL BCE/NMOL|DISEASE TRANSFORMATION||MU/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|CAREGIVER|ONCOLOGIST 2|NA|4||88||SCREENING|1964-11-18||||1965-10-18||1972-04-23|1969-08-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||METBRESP|METABOLIC RESPONSE||||GENEQ|CYTOGENETIC MINIMAL RESPONSE||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|SIBLING|PHYSIOTHERAPIST|Y|4||88||BASELINE|1970-02-06||||1961-03-31||1967-04-14|1968-10-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||BONERESP|BONE RESPONSE||||EVENTS|CR||MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|FAMILY MEMBER|ADJUDICATOR 3|N|5||7||FOLLOW-UP|1968-02-19||||1961-03-03||1971-01-23|1972-11-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/CL|PCR||KIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|INVESTIGATOR|ADJUDICATOR 2|U|5||7||OBSERVATION|1971-06-30||||1964-02-25||1963-07-03|1969-02-19||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^3 CFU|RELAPSED DISEASE FROM CR||MG/G/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|CAREGIVER|READER|NA|1||38||TREATMENT|1968-07-29||||1966-04-26||1968-06-26|1962-10-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||TRGRESP|TARGET RESPONSE||||MG|HI-N||10^6 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|PARENT|INTERNIST|U|1||38||INDUCTION TREATMENT|1964-10-10||||1960-02-03||1966-08-13|1966-08-06||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||NEWLIND|NEW LESION INDICATOR||||HOURS|RELAPSED DISEASE FROM CR||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|VENDOR|ADJUDICATOR 3|U|2||58||OBSERVATION|1966-01-03||||1964-01-18||1972-12-31|1961-10-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||VG/KG|CR-CT||FT3|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|CAREGIVER|ONCOLOGIST 2|N|2||58||BLINDED TREATMENT|1968-05-15||||1973-06-24||1968-06-15|1961-08-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KIU|MORPHOLOGIC CR||PMOL/10^10 CELLS|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|3||39||INDUCTION TREATMENT|1960-11-13||||1966-10-18||1960-10-16|1973-05-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^4 CFU/ML|NON-PD||MDFI|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|PARENT|PATHOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1962-08-02||||1964-08-24||1969-01-08|1960-09-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/S/M2|ICR||UGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|FRIEND|MICROSCOPIST 1|Y|4||88||OPEN LABEL TREATMENT|1971-03-25||||1970-12-27||1970-01-08|1971-03-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MET*H|DECREASED||OSM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|NA|4||88||CONTINUATION TREATMENT|1965-06-07||||1965-07-01||1960-07-15|1963-11-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CAL|VGPR||LOG10 TCID 50/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|RATER 2|NA|5||7||RUN-IN|1969-11-03||||1961-08-04||1960-09-14|1964-09-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SYRINGE|MRD NEGATIVITY||UMOL/H/MMOL|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|INDEPENDENT ASSESSOR|READER 2|NA|5||7||WASHOUT|1969-12-22||||1970-12-19||1969-07-31|1964-07-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||OVRLRESP|OVERALL RESPONSE||||%/S|CYTOGENETIC NO RESPONSE||MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|GUARDIAN|ADJUDICATOR 1|N|1||38||SCREENING|1964-12-16||||1967-06-09||1968-02-28|1963-11-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/G/MIN|INDETERMINATE RESPONSE||DPM|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|VENDOR|MICROSCOPIST|N|1||38||WASHOUT|1962-02-15||||1968-12-02||1962-07-19|1969-09-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||OZ EQ|MORPHOLOGIC LEUKEMIA-FREE STATE||UMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|VENDOR|ONCOLOGIST|N|2||58||BLINDED TREATMENT|1964-09-23||||1962-10-25||1960-07-24|1972-01-15||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/L|PSEUDORESPONSE||U/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|FRIEND|READER 1|NA|2||58||BLINDED TREATMENT|1963-10-19||||1963-05-05||1961-05-19|1969-07-22||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||TRGRESP|TARGET RESPONSE||||UG/MIN|SCR||TSP|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|GUARDIAN|ADJUDICATOR 2|NA|3||39||FOLLOW-UP|1968-08-26||||1963-02-17||1962-09-07|1968-12-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/ANIMAL/WK|MRD NEGATIVITY||BQ/UG|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|FRIEND|MICROSCOPIST 2|U|3||39||INDUCTION TREATMENT|1970-05-18||||1969-08-05||1963-08-28|1973-07-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||STRUSTAT|STEROID USE STATUS||||BU/ML|UNEQUIVOCAL||G/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|PARENT|ADJUDICATOR 2|Y|4||88||CONTINUATION TREATMENT|1964-09-28||||1961-10-03||1972-07-27|1973-03-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||TMRESP|TUMOR MARKER RESPONSE||||IU/KG|CA125 50% RESPONSE||RING|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|VENDOR|INTERNIST|N|4||88||INDUCTION TREATMENT|1969-11-08||||1963-04-03||1971-10-07|1967-11-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/VF|NE||/MM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|5||7||RUN-IN|1965-05-08||||1969-07-02||1971-06-13|1970-05-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||BONERESP|BONE RESPONSE||||FARAD|PSEUDOPROGRESSION||DRAM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|HEALTH CARE PROFESSIONAL|READER 2|U|5||7||FOLLOW-UP|1969-12-27||||1961-10-14||1961-09-27|1971-04-27||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/MOL|CYTOGENETIC CR||DRAM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|CAREGIVER|CLINICAL PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1972-07-24||||1970-02-18||1966-05-09|1966-10-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||NEWLIND|NEW LESION INDICATOR||||ML/M2/DAY|PCR||U/G/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|SPOUSE|OPTOMETRIST|Y|1||38||OBSERVATION|1973-03-14||||1967-01-15||1973-07-01|1971-09-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||NEWLPROG|NEW LESION PROGRESSION||||DPM/100MG|CRI||S/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|DOMESTIC PARTNER|MICROSCOPIST|Y|2||58||SCREENING|1963-09-04||||1960-03-01||1968-08-01|1965-08-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||OVRLRESP|OVERALL RESPONSE||||ML/MMHG/MIN/L|CHR||U/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|2||58||OBSERVATION|1963-03-04||||1962-09-09||1969-11-02|1964-12-31||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KAT|NED||EU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|3||39||LONG-TERM FOLLOW-UP|1972-07-01||||1971-02-12||1969-03-03|1972-10-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||ANATRESP|ANATOMIC RESPONSE||||MCI|MOLECULAR CR||GY/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|ADJUDICATOR|ADJUDICATOR 2|N|3||39||WASHOUT|1960-07-19||||1965-09-21||1967-07-29|1967-04-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/2000 RBC|MR||BQ/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|PARENT|PATHOLOGIST 2|Y|4||88||OBSERVATION|1965-08-11||||1967-04-05||1968-12-15|1961-11-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||TRGRESP|TARGET RESPONSE||||ECL UNIT|IPR||GAUSS|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|SPOUSE|PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1971-06-04||||1960-03-28||1967-08-13|1964-09-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FIU|MOLECULAR CR||KM/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|SIBLING|PATHOLOGIST 1|Y|5||7||BLINDED TREATMENT|1967-08-19||||1972-03-05||1969-02-14|1962-05-20||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||NTRGRESP|NON-TARGET RESPONSE||||L/MIN/M2|FAVORABLE RESPONSE||UG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|SIBLING|READER|N|5||7||OBSERVATION|1971-09-18||||1968-08-23||1963-12-29|1960-02-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||C|RELAPSED DISEASE FROM CR OR PR||BU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|SIBLING|PATHOLOGIST|N|1||38||SCREENING|1966-01-04||||1969-05-15||1969-10-19|1965-04-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|2||||||BESTRESP|BEST OVERALL RESPONSE||||FRACTION OF 1|UNFAVORABLE RESPONSE||PRESSOR UNITS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|PARENT|HEMATOLOGIST|NA|1||38||CONTINUATION TREATMENT|1961-06-29||||1961-09-22||1969-07-02|1962-12-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UMOL/L|INDETERMINATE RESPONSE||G/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1962-01-27||||1968-03-11||1965-07-16|1969-04-14||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|2||||||TMRESP|TUMOR MARKER RESPONSE||||U/CL|TREATMENT FAILURE||10^3 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|INVESTIGATOR|ONCOLOGIST|Y|2||58||WASHOUT|1971-09-25||||1967-06-30||1965-11-25|1968-02-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|1||||||STRUSTAT|STEROID USE STATUS||||UL/ML|PSEUDOPROGRESSION||PIPE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|FAMILY MEMBER|RATER 1|N|3||39||OPEN LABEL TREATMENT|1960-05-10||||1965-05-02||1967-03-08|1970-02-19||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CI/KG|FAVORABLE RESPONSE||KBQ/UL|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|3||39||CONTINUATION TREATMENT|1966-05-29||||1969-01-27||1964-10-14|1961-09-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG|CPR||UG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|PROXY|MICROSCOPIST|Y|4||88||BASELINE|1969-11-05||||1970-03-08||1961-10-18|1967-03-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||FEU|MOLECULAR MAJOR RESPONSE||KCAL|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|STUDY SUBJECT|UROLOGIST|U|4||88||OPEN LABEL TREATMENT|1967-08-24||||1963-05-31||1969-02-09|1973-07-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||V/V|RELAPSED DISEASE||UMOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|U|5||7||OBSERVATION|1965-08-16||||1964-05-09||1967-10-26|1972-06-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|215E4E69-70C3-493C-9D67-F717363E8138|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PPB|MRD NEGATIVITY||UMOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|PARENT|CARDIOLOGIST|Y|5||7||INDUCTION TREATMENT|1960-11-27||||1963-02-24||1972-02-26|1961-04-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||TMRESP|TUMOR MARKER RESPONSE||||UU/L|CMR||CPM|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|VENDOR|ENDOCRINOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1962-07-24||||1961-12-24||1963-01-01|1968-02-27||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||OHM|EQUIVOCAL||MET|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|INTERVIEWER|MICROSCOPIST 2|Y|1||38||BASELINE|1970-02-26||||1961-07-20||1963-05-06|1962-07-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||ANATRESP|ANATOMIC RESPONSE||||MV|PD FROM PR||GMFI|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|2||58||SCREENING|1967-12-09||||1970-06-15||1965-07-03|1970-09-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||NEWLIND|NEW LESION INDICATOR||||CCID 50/ML|EQUIVOCAL||PMOL/10^10 CELLS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|STUDY SUBJECT|INTERNIST|U|2||58||TREATMENT|1969-09-11||||1964-03-22||1971-10-05|1966-07-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||OVRLRESP|OVERALL RESPONSE||||MG/KG/H|VGPR||KG/CM2|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CAREGIVER|NEUROLOGIST 1|U|3||39||OBSERVATION|1971-01-17||||1971-10-09||1970-10-14|1972-11-17||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||CLINRESP|CLINICAL RESPONSE||||EQ|MAJOR PATHOLOGIC RESPONSE||ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|3||39||WASHOUT|1971-06-24||||1964-12-09||1962-06-14|1961-02-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMOL/KG|PCR||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|SIGNIFICANT OTHER|RATER 2|Y|4||88||SCREENING|1960-09-10||||1969-02-15||1965-09-09|1969-04-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||STRUSTAT|STEROID USE STATUS||||PMOL/L/H|MRD NEGATIVITY||KS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|INVESTIGATOR|MICROSCOPIST 2|N|4||88||CONTINUATION TREATMENT|1960-07-12||||1970-12-21||1965-01-25|1972-11-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GLOBULE|CRI||U/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|DOMESTIC PARTNER|ADJUDICATOR 2|Y|5||7||LONG-TERM FOLLOW-UP|1961-03-26||||1969-06-18||1961-09-09|1972-01-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/CM3/MIN|PSEUDORESPONSE||BISCUIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1960-12-03||||1971-03-27||1968-11-11|1961-11-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||NTRGRESP|NON-TARGET RESPONSE||||FT3|CYTOGENETIC CR||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|1||38||INDUCTION TREATMENT|1961-07-30||||1964-09-12||1964-10-06|1969-10-19||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||TMRESP|TUMOR MARKER RESPONSE||||CI/UL|MR||ENZYME U/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|N|1||38||BASELINE|1969-10-10||||1964-06-24||1970-06-13|1973-08-01||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||OVRLRESP|OVERALL RESPONSE||||U.CARR|HI-P||/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|FRIEND|OTOLARYNGOLOGIST|U|2||58||CONTINUATION TREATMENT|1961-05-26||||1964-11-02||1965-09-26|1966-04-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||CYTORESP|CYTOGENETIC RESPONSE||||FEU|UNEQUIVOCAL||EID 50/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|VENDOR|ONCOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1962-12-24||||1960-08-11||1964-09-15|1970-03-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG EID 50/DOSE|SD-CT||KA_U/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|FRIEND|MICROSCOPIST|Y|3||39||INDUCTION TREATMENT|1968-09-26||||1968-01-11||1970-10-02|1968-08-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||CLINRESP|CLINICAL RESPONSE||||ABSORBANCE U|NON-CR/NON-PD||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|INDEPENDENT ASSESSOR|RATER 1|NA|3||39||LONG-TERM FOLLOW-UP|1967-09-02||||1961-06-04||1964-11-04|1971-08-13||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||SPLNRESP|SPLEEN RESPONSE||||NMOL/MOL|CR-CT||%/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|SPOUSE|OPHTHALMOLOGIST|Y|4||88||BLINDED TREATMENT|1968-11-23||||1973-05-23||1968-04-18|1967-12-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||BESTRESP|BEST OVERALL RESPONSE||||CD*S/M2|PR||UG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|FRIEND|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1972-11-06||||1967-10-16||1966-10-27|1971-02-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MOSM/KG|PSEUDORESPONSE||ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|ADJUDICATOR|NEUROLOGIST 2|N|5||7||BLINDED TREATMENT|1963-04-21||||1969-05-23||1968-08-02|1972-12-14||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||TORR|PD||/MM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|SIGNIFICANT OTHER|CARDIOLOGIST|U|5||7||OPEN LABEL TREATMENT|1970-05-19||||1965-06-27||1961-01-25|1971-12-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||ANATRESP|ANATOMIC RESPONSE||||MM/H|FAVORABLE RESPONSE||PMOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|1||38||OPEN LABEL TREATMENT|1961-08-02||||1963-05-02||1966-11-09|1964-02-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MU/G|DISEASE TRANSFORMATION||MGEQ|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|STUDY SUBJECT|DERMATOLOGIST|U|1||38||TREATMENT|1967-04-14||||1969-09-02||1963-11-29|1973-03-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||NTRGRESP|NON-TARGET RESPONSE||||/WK|PR||BEAM BREAKS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|ADJUDICATOR|ADJUDICATOR 3|NA|2||58||RUN-IN|1969-09-11||||1967-01-04||1969-08-26|1960-03-09||AFTER||DURING|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^7 CFU/ML|CMR||ML/BREATH|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|2||58||OPEN LABEL TREATMENT|1960-02-05||||1971-02-04||1960-12-21|1964-03-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||METSIND|METASTATIC INDICATOR||||PPTR|UNEQUIVOCAL||PIXELS/IN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|INTERVIEWER|ENDOCRINOLOGIST|Y|3||39||BASELINE|1961-11-02||||1969-05-15||1960-04-25|1964-12-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||TMRESP|TUMOR MARKER RESPONSE||||DAGU|CA125 50% RESPONSE||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|INDEPENDENT ASSESSOR|RATER 2|N|3||39||LONG-TERM FOLLOW-UP|1971-04-10||||1973-04-21||1971-05-21|1970-10-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||METBRESP|METABOLIC RESPONSE||||U|CCR||K|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|STUDY SUBJECT|ENDOCRINOLOGIST|Y|4||88||SCREENING|1964-06-18||||1960-08-16||1964-10-23|1966-03-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/BREATH|PD||10^9/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|CHILD|DERMATOLOGIST|Y|4||88||OBSERVATION|1965-09-06||||1969-12-11||1971-10-22|1967-02-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/CM2|CCR||OD UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|INVESTIGATOR|READER|U|5||7||BASELINE|1970-12-07||||1964-05-13||1968-12-30|1960-10-09||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||SPLNRESP|SPLEEN RESPONSE||||10^6/HPF|ISD||CM H2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||INDUCTION TREATMENT|1968-03-22||||1971-06-18||1972-12-22|1966-09-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^6/EJACULATE U|DECREASED||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|DOMESTIC PARTNER|ADJUDICATOR 1|U|1||38||WASHOUT|1961-11-03||||1968-03-16||1966-12-20|1964-01-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||METBRESP|METABOLIC RESPONSE||||MG/ML/MIN|INDETERMINATE RESPONSE||MMOL/G|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1||38||TREATMENT|1962-06-07||||1969-08-02||1971-08-31|1969-04-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||BESTRESP|BEST OVERALL RESPONSE||||UG|MAJOR PATHOLOGIC RESPONSE||10^6 DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|2||58||BASELINE|1966-05-23||||1960-05-05||1967-07-28|1968-10-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||STRUSTAT|STEROID USE STATUS||||L|RELAPSED DISEASE FROM CR||TITER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|2||58||FOLLOW-UP|1967-09-01||||1964-09-23||1969-01-30|1970-06-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||TRGRESP|TARGET RESPONSE||||10^4 CFU|WORSENED||LOZENGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|PROXY|NEUROLOGIST|Y|3||39||TREATMENT|1968-02-20||||1960-07-20||1960-02-21|1973-02-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||TMRESP|TUMOR MARKER RESPONSE||||IU/MMOL|PD-CT||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1963-10-08||||1970-01-19||1960-02-24|1967-11-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||ANATRESP|ANATOMIC RESPONSE||||NG|PMR||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|CHILD|ADJUDICATOR 3|NA|4||88||OBSERVATION|1970-04-01||||1965-09-17||1962-02-11|1966-08-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||METBRESP|METABOLIC RESPONSE||||VIAL|INCREASED||IU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|VENDOR|HEMATOLOGIST|N|4||88||BLINDED TREATMENT|1963-09-03||||1960-11-16||1961-12-18|1966-02-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TRACE|PSEUDORESPONSE||UG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|CHILD|CLINICAL PATHOLOGIST|N|5||7||FOLLOW-UP|1963-08-18||||1968-07-21||1960-03-09|1973-07-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KIT|RELAPSED DISEASE FROM CR OR PR||USEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|SIBLING|DERMATOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1970-08-24||||1970-05-11||1961-07-18|1967-09-20||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||ANATRESP|ANATOMIC RESPONSE||||10^7 PFU|MOLECULAR MAJOR RESPONSE||NCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|FRIEND|DERMATOLOGIST|NA|1||38||TREATMENT|1961-01-29||||1965-02-21||1961-08-03|1970-09-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NKAT/G HB|MR||U/CL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|DOMESTIC PARTNER|RADIOLOGIST 2|Y|1||38||WASHOUT|1963-10-23||||1965-12-02||1965-09-16|1962-03-02||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||LIVRRESP|LIVER RESPONSE||||IU/KG|CYTOGENETIC NO RESPONSE||CMOL/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|PARENT|MICROSCOPIST 2|NA|2||58||OPEN LABEL TREATMENT|1962-05-21||||1961-01-07||1969-01-30|1971-05-01||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||MOLRESP|MOLECULAR RESPONSE||||BREATHS/30S|SMD||AMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|GUARDIAN|HEMATOLOGIST|U|2||58||OBSERVATION|1965-10-23||||1969-05-07||1965-04-10|1972-09-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||METSIND|METASTATIC INDICATOR||||DRINK|QUANTIFIABLE MRD POSITIVITY||KIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|SIBLING|MICROSCOPIST|NA|3||39||WASHOUT|1965-04-07||||1966-03-07||1968-09-27|1961-01-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3 CFU/G|PARTIAL MORPHOLOGIC RESPONSE||10^9 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|INVESTIGATOR|OTOLARYNGOLOGIST|Y|3||39||TREATMENT|1963-07-31||||1962-06-30||1966-10-17|1973-09-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||STRUSTAT|STEROID USE STATUS||||VIRTUAL PIXEL|CPR||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|STUDY SUBJECT|RATER|NA|4||88||BLINDED TREATMENT|1964-09-18||||1967-12-21||1969-11-19|1972-02-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||NEWLIND|NEW LESION INDICATOR||||NSEC|MR||ANSON U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|PARENT|ADJUDICATOR 3|U|4||88||WASHOUT|1967-12-10||||1967-06-03||1970-11-02|1960-02-09||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/KG/MIN|OPTIMAL MORPHOLOGIC RESPONSE||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|5||7||WASHOUT|1973-05-13||||1971-09-18||1971-07-10|1965-12-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MIU/L|WORSENED||APL U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INTERVIEWER|RADIOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1961-01-24||||1969-05-05||1973-03-23|1973-06-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||CLINRESP|CLINICAL RESPONSE||||FG|RELAPSED DISEASE||CI/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|FRIEND|READER|N|1||38||BASELINE|1964-08-25||||1962-02-07||1973-01-22|1968-04-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UU/L|SCR||PMOL/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|1||38||TREATMENT|1967-07-26||||1965-09-09||1963-06-18|1972-07-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DEG/MM|PD||UG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1966-11-30||||1971-01-21||1965-07-17|1969-04-08||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||M3|PMD||MANSON U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|SPOUSE|NEUROLOGIST 1|Y|2||58||FOLLOW-UP|1960-06-10||||1973-02-20||1968-03-02|1964-05-24||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL/MOL|NOT ALL EVALUATED||/MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|INVESTIGATOR|PATHOLOGIST 1|Y|3||39||TREATMENT|1964-11-18||||1972-05-01||1960-08-08|1972-05-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/G/MIN|SMD||10^3 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|PARENT|NEUROLOGIST|U|3||39||CONTINUATION TREATMENT|1961-02-12||||1967-10-13||1972-02-10|1967-11-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||LIVRRESP|LIVER RESPONSE||||PNU/ML|EQUIVOCAL||V/V|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|4||88||RUN-IN|1966-08-31||||1961-02-01||1972-08-27|1967-11-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PPTH|CCR||PKAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|SPOUSE|NEUROLOGIST|Y|4||88||INDUCTION TREATMENT|1973-05-29||||1973-04-21||1971-10-25|1963-05-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/U|RELAPSED DISEASE FROM CR||/10^5|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|GUARDIAN|RATER 1|Y|5||7||SCREENING|1969-07-28||||1965-05-26||1970-01-13|1967-06-28||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||NEWLIND|NEW LESION INDICATOR||||MM3/MM2/YEAR|NON-ICR/NON-IUPD||UG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|DOMESTIC PARTNER|ADJUDICATOR|U|5||7||OBSERVATION|1969-11-08||||1973-01-06||1970-07-10|1966-04-29||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU|PSEUDORESPONSE||/200 HPFS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||BASELINE|1965-12-31||||1962-06-02||1969-04-01|1971-06-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ANTI-XA IU|EQUIVOCAL||CM/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|1||38||OBSERVATION|1971-10-17||||1968-06-03||1970-01-22|1971-11-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|1||||||OVRLRESP|OVERALL RESPONSE||||VP/ML|ISD||MMHG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|SPOUSE|OPHTHALMOLOGIST|U|2||58||FOLLOW-UP|1967-09-09||||1963-01-03||1966-12-03|1969-03-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|2||||||NEWLPROG|NEW LESION PROGRESSION||||DEG/S|PD/RELAPSE AFTER HI||U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|SPOUSE|OTOLARYNGOLOGIST|NA|2||58||SCREENING|1965-04-25||||1963-11-20||1960-08-12|1969-02-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PIXEL|RELAPSED DISEASE FROM CR||CCID 50/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|PARENT|PHYSIOTHERAPIST|N|3||39||BASELINE|1965-01-07||||1962-02-13||1964-01-29|1962-02-22||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PM|OPTIMAL MORPHOLOGIC RESPONSE||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|3||39||INDUCTION TREATMENT|1965-01-09||||1970-01-31||1972-12-28|1962-09-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MEQ/ML|MAJOR PATHOLOGIC RESPONSE||UMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|4||88||WASHOUT|1962-01-02||||1967-01-15||1971-09-07|1960-01-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|2||||||PATHRESP|PATHOLOGIC RESPONSE||||BE/ML|ABSENT MORPHOLOGIC RESPONSE||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1971-07-16||||1960-03-03||1972-05-03|1970-01-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6/HPF|IUPD||MOSM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|CAREGIVER|PHYSIOTHERAPIST|N|5||7||RUN-IN|1964-09-13||||1970-01-23||1971-08-31|1973-06-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|859D9297-58D0-4740-899D-E7BEC931D419|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||% INHIBITION|SCR||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||RUN-IN|1960-09-08||||1968-04-23||1973-06-24|1969-07-09||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||TRGRESP|TARGET RESPONSE||||UCI/L|WORSENED||MV*MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|VENDOR|MICROSCOPIST 1|NA|1||38||OBSERVATION|1962-01-24||||1964-01-14||1970-02-24|1971-11-03||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||METSIND|METASTATIC INDICATOR||||ENZYME U/L|UNEQUIVOCAL||10^5/HPF|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1||38||FOLLOW-UP|1966-02-05||||1963-04-07||1964-04-27|1965-10-18||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SACHET|OPTIMAL MORPHOLOGIC RESPONSE||AMPULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|2||58||OBSERVATION|1960-02-09||||1964-08-14||1973-06-11|1972-08-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/CAGE|SD-CT||MOL/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|STUDY SUBJECT|UROLOGIST|U|2||58||OPEN LABEL TREATMENT|1973-06-13||||1963-08-16||1961-04-15|1963-03-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UL/KG/DAY|CA125 75% RESPONSE||PMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|3||39||LONG-TERM FOLLOW-UP|1967-10-03||||1964-11-16||1965-12-19|1960-05-25||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/ANIMAL|MOLECULAR MAJOR RESPONSE||SYRINGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|PARENT|ADJUDICATOR 1|NA|3||39||WASHOUT|1962-03-17||||1965-10-15||1967-01-10|1964-06-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UMOL/H/MMOL|MINOR PATHOLOGIC RESPONSE||TUBERCULIN UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||SCREENING|1968-06-21||||1964-03-26||1964-06-05|1963-08-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^8/L|PR-CT||GRAIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|PARENT|ONCOLOGIST 1|U|4||88||BASELINE|1970-04-30||||1960-06-29||1973-01-08|1972-04-28||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MU/G|MORPHOLOGIC CR||LOG10 PFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|5||7||WASHOUT|1962-02-28||||1966-04-19||1970-05-13|1964-07-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU/KG|CYTOGENETIC MINIMAL RESPONSE||L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|Y|5||7||CONTINUATION TREATMENT|1971-04-04||||1961-03-13||1966-04-24|1967-03-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||METSIND|METASTATIC INDICATOR||||BQ/UG|MRD PERSISTENCE||G/CAGE/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|1||38||INDUCTION TREATMENT|1961-11-17||||1964-02-27||1962-12-21|1968-11-17||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||TRGRESP|TARGET RESPONSE||||NCI|PR WITH LYMPHOCYTOSIS||MG/ML/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|SPOUSE|MICROSCOPIST|U|1||38||OBSERVATION|1968-02-06||||1970-02-18||1962-09-11|1970-01-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||NEWLPROG|NEW LESION PROGRESSION||||GLOBULE|NED||G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|RATER|N|2||58||OPEN LABEL TREATMENT|1972-06-13||||1966-01-14||1960-02-05|1970-01-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MEQ/DL|INDETERMINATE RESPONSE||PPTR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|2||58||TREATMENT|1966-04-08||||1971-01-27||1960-07-29|1970-03-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 ORGANISMS|QUANTIFIABLE MRD POSITIVITY||NU/CL|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|STUDY SUBJECT|CLINICAL PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1962-02-08||||1963-04-19||1966-04-21|1962-11-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||NEWLPROG|NEW LESION PROGRESSION||||FOZ_US|INDETERMINATE RESPONSE||BU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|FAMILY MEMBER|ADJUDICATOR 1|NA|3||39||FOLLOW-UP|1967-10-19||||1963-06-17||1960-07-08|1964-05-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||CLINRESP|CLINICAL RESPONSE||||SACHET|MRD NEGATIVITY||UM/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|PARENT|MICROSCOPIST 3|Y|4||88||OPEN LABEL TREATMENT|1970-03-23||||1963-09-27||1969-01-07|1967-08-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/2500 WBC|MORPHOLOGIC LEUKEMIA-FREE STATE||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|ADJUDICATION COMMITTEE|ADJUDICATOR|N|4||88||OPEN LABEL TREATMENT|1969-05-08||||1969-12-06||1968-08-07|1960-02-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 COPIES/ML|ISD||APL U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|CAREGIVER|RADIOLOGIST 1|N|5||7||WASHOUT|1972-07-09||||1964-09-28||1961-09-21|1960-04-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||OI50|CR||PFU/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5||7||FOLLOW-UP|1965-02-11||||1964-06-25||1964-02-22|1971-05-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MMHG|IUPD||IU/MG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|GUARDIAN|PHYSIOTHERAPIST|NA|1||38||RUN-IN|1966-04-30||||1971-10-09||1960-09-26|1967-01-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/100 WBC|MINOR PATHOLOGIC RESPONSE||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|1||38||WASHOUT|1968-12-16||||1968-06-09||1966-01-08|1962-12-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||OVRLRESP|OVERALL RESPONSE||||MOL/MOL|FAVORABLE RESPONSE||MG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|CLINICAL STUDY SPONSOR|UROLOGIST|U|2||58||RUN-IN|1960-02-09||||1971-01-06||1964-07-14|1963-02-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||TRGRESP|TARGET RESPONSE||||10^3 CFU/G|TREATMENT FAILURE||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|CHILD|ADJUDICATOR 2|Y|2||58||CONTINUATION TREATMENT|1972-05-20||||1964-03-04||1973-05-26|1972-11-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||LIVRRESP|LIVER RESPONSE||||FG|SD-CT||VG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|PROXY|NEUROLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1966-08-02||||1969-09-26||1961-08-23|1970-01-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/500 WBC|VGPR||10^6/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|FRIEND|RATER|Y|3||39||TREATMENT|1965-02-02||||1966-12-03||1964-11-29|1970-11-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||BONERESP|BONE RESPONSE||||FFU|CYTOGENETIC MINIMAL RESPONSE||CD*S/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|CAREGIVER|ENDOCRINOLOGIST|Y|4||88||BASELINE|1970-06-28||||1971-01-31||1964-10-25|1970-06-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||ANATRESP|ANATOMIC RESPONSE||||G/CAGE/WK|COMPLETE MRD RESPONSE||MG/ML/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|FAMILY MEMBER|PATHOLOGIST 2|U|4||88||TREATMENT|1968-11-27||||1968-11-28||1967-11-02|1970-01-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||ANATRESP|ANATOMIC RESPONSE||||SQU/ML|MOLECULAR CR||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 1|U|5||7||INDUCTION TREATMENT|1961-11-22||||1965-01-01||1972-09-08|1973-05-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||STRUSTAT|STEROID USE STATUS||||VG/KG|NON-QUANTIFIABLE MRD POSITIVITY||G/CAGE|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|STUDY SUBJECT|ONCOLOGIST|N|5||7||OPEN LABEL TREATMENT|1960-11-13||||1970-06-07||1968-02-22|1967-02-22||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||SPLNRESP|SPLEEN RESPONSE||||BOWL|PARTIAL MORPHOLOGIC RESPONSE||G/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|ADJUDICATOR|ONCOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1965-09-09||||1965-12-17||1963-04-01|1967-02-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/CAGE/WK|PSA PROGRESSION||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CHILD|MICROSCOPIST 2|N|1||38||CONTINUATION TREATMENT|1966-08-03||||1965-09-13||1966-08-31|1964-06-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BAG|PMD||TRACE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2||58||FOLLOW-UP|1965-03-02||||1964-03-25||1967-10-23|1966-10-21||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||CLINRESP|CLINICAL RESPONSE||||G/CM2|NR||MESF|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|2||58||OPEN LABEL TREATMENT|1965-09-19||||1973-01-01||1968-08-22|1967-06-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MM/SEC|IPR||BEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|GUARDIAN|READER 3|NA|3||39||BASELINE|1965-06-21||||1973-06-08||1969-07-01|1962-04-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 COPIES/ML|FAVORABLE RESPONSE||/10^3|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|INDEPENDENT ASSESSOR|UROLOGIST|NA|3||39||BASELINE|1972-04-15||||1969-07-11||1967-10-05|1966-02-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/G|PMD||OI50|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|CHILD|FORENSIC PATHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1973-05-14||||1960-08-30||1970-09-02|1964-08-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/7.5 ML|CYTOGENETIC CR||UG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|GUARDIAN|RADIOLOGIST|U|4||88||SCREENING|1970-04-05||||1969-09-20||1963-09-28|1964-05-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/4.0 ML|CA125 75% RESPONSE||PM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|HEALTH CARE PROFESSIONAL|RATER|Y|5||7||BLINDED TREATMENT|1970-07-05||||1962-11-06||1966-02-09|1973-06-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||STRUSTAT|STEROID USE STATUS||||MET*MIN|MOLECULAR CR||VG/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|INVESTIGATOR|MICROSCOPIST 1|N|5||7||OBSERVATION|1963-10-22||||1962-03-18||1963-04-03|1969-12-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||OVRLRESP|OVERALL RESPONSE||||10^8 PFU|MRD RELAPSE||HOURS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|INTERVIEWER|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1962-04-26||||1970-11-24||1972-09-21|1961-11-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/M2|STABLE||LOG10 CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|INVESTIGATOR|ONCOLOGIST 1|N|1||38||WASHOUT|1963-02-24||||1968-11-19||1965-09-16|1960-10-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||BONERESP|BONE RESPONSE||||10^9/DOSE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|SPOUSE|READER|NA|2||58||BLINDED TREATMENT|1964-03-21||||1963-12-28||1964-03-06|1961-07-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||SPLNRESP|SPLEEN RESPONSE||||MCI|MCR||EJACULATE U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|SPOUSE|PHYSIOTHERAPIST|Y|2||58||INDUCTION TREATMENT|1967-09-06||||1969-04-24||1970-08-03|1962-03-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/KG/DAY|SD-CT||MMOL2/L2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|FRIEND|OPHTHALMOLOGIST|NA|3||39||RUN-IN|1963-08-15||||1961-03-11||1962-07-07|1965-07-27||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/ML|QUANTIFIABLE MRD POSITIVITY||PMOL/G|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|SPOUSE|CARDIOLOGIST|N|3||39||SCREENING|1960-08-02||||1969-08-03||1961-07-29|1966-12-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL/DAY|CYTOGENETIC CR||FT2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|4||88||OBSERVATION|1962-06-13||||1972-01-29||1966-01-09|1972-06-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UM|CYTOGENETIC CR||ML/BEAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1971-02-06||||1963-04-20||1961-02-14|1972-12-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||OVRLRESP|OVERALL RESPONSE||||MG/MIN|CR-CT||PMOL/10^10 CELLS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|5||7||WASHOUT|1963-05-09||||1966-12-09||1961-12-08|1971-02-16||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||PATHRESP|PATHOLOGIC RESPONSE||||TSP EQ|PMD||ML/CAGE/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|GUARDIAN|NEUROLOGIST|U|5||7||WASHOUT|1968-09-08||||1970-10-10||1972-08-29|1962-09-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||METSIND|METASTATIC INDICATOR||||HZ/S|IUPD||TITER|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|SIBLING|RADIOLOGIST 2|NA|1||38||TREATMENT|1972-11-11||||1967-09-25||1965-04-10|1960-12-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||ANATRESP|ANATOMIC RESPONSE||||GY/H|CCR||KM/H|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||RUN-IN|1973-05-27||||1963-02-01||1963-05-15|1966-06-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 COPIES/ML|SMD||U/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|VENDOR|RATER 2|NA|2||58||CONTINUATION TREATMENT|1960-10-25||||1968-07-21||1971-09-10|1964-01-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||LIVRRESP|LIVER RESPONSE||||MG/KG/H|RELAPSED DISEASE FROM CR||IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|CHILD|ONCOLOGIST 1|U|2||58||WASHOUT|1964-07-29||||1968-12-14||1962-07-28|1969-05-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||NEWLPROG|NEW LESION PROGRESSION||||VG/DOSE|MOLECULAR MAJOR RESPONSE||K|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|3||39||SCREENING|1972-08-28||||1967-01-09||1967-02-01|1960-10-05||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||NEWLIND|NEW LESION INDICATOR||||EP U|COMPLETE MRD RESPONSE||APPLICATION|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3||39||FOLLOW-UP|1962-06-24||||1961-10-05||1968-08-14|1970-01-02||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||CLINRESP|CLINICAL RESPONSE||||MIN*MG/ML|UNEQUIVOCAL||P|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|DOMESTIC PARTNER|RADIOLOGIST 1|U|4||88||BLINDED TREATMENT|1965-10-28||||1961-03-28||1969-11-24|1961-07-22||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 ORGANISMS/MG|MAJOR PATHOLOGIC RESPONSE||WEBER|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4||88||BASELINE|1964-12-24||||1971-03-01||1965-07-07|1966-12-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||L/H/M2|PD FROM PR||MS2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|5||7||TREATMENT|1965-01-31||||1970-10-19||1968-12-18|1963-09-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 CFU/ML|MAJOR PATHOLOGIC RESPONSE||RPM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|SIBLING|ADJUDICATOR 3|Y|5||7||SCREENING|1966-12-22||||1963-12-30||1960-07-01|1964-11-10||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||STRUSTAT|STEROID USE STATUS||||MG/M2|NON-ICR/NON-IUPD||U/G HB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|INVESTIGATOR|ADJUDICATOR 3|NA|1||38||CONTINUATION TREATMENT|1969-06-07||||1972-04-23||1967-09-22|1966-07-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||NTRGRESP|NON-TARGET RESPONSE||||G/G/DAY|MRD RELAPSE||ABSORBANCE U|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|U|1||38||WASHOUT|1973-07-22||||1973-04-09||1971-08-14|1963-12-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/ML|WORSENED||PMOL/10^9 CELLS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|GUARDIAN|MICROSCOPIST|NA|2||58||WASHOUT|1962-06-27||||1973-04-15||1961-07-17|1970-12-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||METSIND|METASTATIC INDICATOR||||U/G/H|NON-ICR/NON-IUPD||GTT|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|2||58||OBSERVATION|1969-11-12||||1972-05-07||1961-07-18|1966-06-04||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/MM|FAVORABLE RESPONSE||U/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|PARENT|RATER|NA|3||39||OBSERVATION|1960-01-20||||1972-07-18||1968-08-24|1962-06-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||ANATRESP|ANATOMIC RESPONSE||||AMFI|ISD||DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|SPOUSE|MICROSCOPIST|NA|3||39||BLINDED TREATMENT|1970-11-20||||1962-02-06||1973-06-25|1973-06-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GLOBULE|SD||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|CHILD|ADJUDICATOR|U|4||88||OBSERVATION|1962-11-08||||1968-10-26||1972-08-02|1969-08-26||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FOZ_US|VGPR||KM/H|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|DOMESTIC PARTNER|ONCOLOGIST 2|NA|4||88||OPEN LABEL TREATMENT|1968-04-24||||1967-12-15||1962-10-29|1968-06-05||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||CLINRESP|CLINICAL RESPONSE||||10^12/L|STABLE||U/M2/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|CHILD|READER 1|NA|5||7||CONTINUATION TREATMENT|1969-05-18||||1967-01-10||1960-06-12|1963-11-11||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/MOL|CA125 50% RESPONSE||10^3/HPF|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|CAREGIVER|MICROSCOPIST 2|N|5||7||LONG-TERM FOLLOW-UP|1963-10-30||||1965-12-17||1963-08-31|1961-06-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||OVRLRESP|OVERALL RESPONSE||||DPM|NON-QUANTIFIABLE MRD POSITIVITY||KIT|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|1||38||SCREENING|1973-05-20||||1967-08-18||1967-02-19|1961-03-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||CLINRESP|CLINICAL RESPONSE||||MS2|IPR||UMOL/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|SIBLING|ADJUDICATOR 1|Y|1||38||INDUCTION TREATMENT|1973-09-07||||1971-10-05||1972-11-23|1965-10-29||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DAGU/ML|HI-E||ENZYME U/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CHILD|INTERNIST|N|2||58||OPEN LABEL TREATMENT|1961-08-24||||1961-09-15||1963-03-24|1961-12-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CM/MIN|RELAPSED DISEASE FROM CR||OHM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CLINICAL STUDY SPONSOR|UROLOGIST|NA|2||58||RUN-IN|1968-07-23||||1960-10-16||1968-09-18|1960-10-17||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||SPLNRESP|SPLEEN RESPONSE||||MEQ/G|CA125 75% RESPONSE||G/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|3||39||RUN-IN|1970-08-30||||1971-07-11||1966-03-19|1966-12-03||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||CYTORESP|CYTOGENETIC RESPONSE||||G/G/DAY|IPR||BAR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|PARENT|MICROSCOPIST 2|N|3||39||CONTINUATION TREATMENT|1964-02-19||||1969-08-02||1962-11-06|1968-06-27||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||CLINRESP|CLINICAL RESPONSE||||IN|EQUIVOCAL||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|4||88||BLINDED TREATMENT|1963-08-16||||1964-05-13||1966-08-26|1969-02-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MIN*MG/ML|PD FROM PR||TUBE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|4||88||TREATMENT|1963-07-23||||1962-04-03||1960-05-09|1960-07-13||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/KG/DOSE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MG/H|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|GUARDIAN|MICROSCOPIST 1|U|5||7||SCREENING|1971-11-20||||1967-11-07||1973-01-23|1961-06-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||OVRLRESP|OVERALL RESPONSE||||GMFI|CR-CT||JOULE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|SIGNIFICANT OTHER|RADIOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1966-06-18||||1965-06-13||1970-12-22|1970-09-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||STRUSTAT|STEROID USE STATUS||||COULOMB|PSEUDOPROGRESSION||FT3|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|STUDY SUBJECT|ENDOCRINOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1972-03-18||||1960-07-04||1968-08-26|1965-02-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||LIVRRESP|LIVER RESPONSE||||KG/L|MCR||NMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|1||38||SCREENING|1972-09-30||||1970-12-20||1963-11-21|1973-04-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^7 PFU|PSA PROGRESSION||IU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|INVESTIGATOR|MICROSCOPIST 3|Y|2||58||OBSERVATION|1967-07-31||||1967-07-04||1966-02-01|1968-10-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||LIVRRESP|LIVER RESPONSE||||/10^4|MR||/10^5|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|STUDY SUBJECT|READER|U|2||58||WASHOUT|1970-05-29||||1964-11-25||1960-10-16|1968-05-06||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||METBRESP|METABOLIC RESPONSE||||KG/MOL|CR||UV|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|DOMESTIC PARTNER|MICROSCOPIST|N|3||39||FOLLOW-UP|1963-11-08||||1973-02-18||1971-10-05|1966-05-12||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MCI/KG|SD||/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|GUARDIAN|ADJUDICATOR 2|NA|3||39||RUN-IN|1960-09-17||||1968-04-01||1970-11-04|1967-04-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MEQ/G|WORSENED||10^6 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||SCREENING|1970-06-28||||1966-01-04||1969-07-25|1963-03-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^3 COPIES/ML|MRD NEGATIVITY||UG/L/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|4||88||OBSERVATION|1961-09-04||||1964-11-16||1972-01-07|1961-08-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG|SMD||CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|PARENT|RADIOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1971-11-11||||1962-03-19||1965-05-17|1969-04-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||TRGRESP|TARGET RESPONSE||||MEQ/ML|STABLE||RPM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|5||7||RUN-IN|1971-07-19||||1966-04-11||1963-08-08|1968-03-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MET*H|INDETERMINATE RESPONSE||GBQ|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||FOLLOW-UP|1961-10-30||||1962-08-15||1969-10-15|1961-07-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||ANATRESP|ANATOMIC RESPONSE||||/WK|IMMUNOPHENOTYPIC CR||G/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|FRIEND|RADIOLOGIST 1|Y|1||38||TREATMENT|1971-09-15||||1972-05-16||1971-10-30|1965-07-23||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||SPLNRESP|SPLEEN RESPONSE||||OSM|CYTOGENETIC NO RESPONSE||L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|FRIEND|ENDOCRINOLOGIST|U|2||58||OBSERVATION|1966-10-16||||1963-07-31||1973-04-13|1969-01-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PT_US|COMPLETE MRD RESPONSE||PMOL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|FRIEND|READER 1|U|2||58||RUN-IN|1972-03-29||||1970-06-26||1968-04-13|1960-12-31||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BQ/UG|QUANTIFIABLE MRD POSITIVITY||MU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|SIGNIFICANT OTHER|UROLOGIST|U|3||39||CONTINUATION TREATMENT|1961-02-04||||1960-12-27||1970-02-20|1966-02-19||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PIPE|NON-PD||U/M2/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|DOMESTIC PARTNER|OPTOMETRIST|Y|3||39||OPEN LABEL TREATMENT|1966-08-03||||1965-05-22||1962-09-14|1966-05-24||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NM|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|PARENT|READER|N|4||88||OPEN LABEL TREATMENT|1973-03-22||||1971-09-26||1960-10-22|1961-05-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||SPLNRESP|SPLEEN RESPONSE||||CAPLET|EQUIVOCAL||G/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|FAMILY MEMBER|NEUROLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1971-11-20||||1971-05-07||1964-04-24|1969-03-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NG/MOL|SMD||MOL/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|VENDOR|ADJUDICATOR 3|Y|5||7||SCREENING|1966-10-08||||1967-10-01||1968-02-19|1973-05-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG/L FEU|IMMUNOPHENOTYPIC CR||F|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|SIGNIFICANT OTHER|PATHOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1973-05-02||||1971-08-04||1960-01-05|1972-08-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||NTRGRESP|NON-TARGET RESPONSE||||/10^5|RELAPSED DISEASE FROM CR OR PR||CIGAR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|FRIEND|ONCOLOGIST 1|U|1||38||LONG-TERM FOLLOW-UP|1962-01-25||||1968-09-28||1965-08-14|1960-07-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/DAY|IMMUNOPHENOTYPIC CR||NCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|ADJUDICATOR|NEUROLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1964-11-19||||1964-07-30||1968-01-14|1967-04-01||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UU/DL|MOLECULAR CR||PMOL/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|CHILD|CLINICAL PATHOLOGIST|NA|2||58||WASHOUT|1962-07-04||||1973-08-30||1964-12-04|1960-01-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NMOL BCE/NMOL|SMD||DISK|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|DOMESTIC PARTNER|RATER|Y|2||58||OBSERVATION|1961-09-25||||1961-06-30||1970-09-10|1967-02-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||LIVRRESP|LIVER RESPONSE||||YD|CYTOGENETIC MINIMAL RESPONSE||10^6 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|FAMILY MEMBER|MICROSCOPIST 2|U|3||39||CONTINUATION TREATMENT|1964-08-08||||1961-09-22||1969-02-16|1961-11-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UCI/KG|IPR||MSEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|3||39||OBSERVATION|1962-11-14||||1971-07-24||1970-09-29|1967-11-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||LIVRRESP|LIVER RESPONSE||||MG/ANIMAL|DECREASED||LB|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|GUARDIAN|PATHOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1960-02-04||||1960-09-24||1960-09-07|1969-09-20||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||TRGRESP|TARGET RESPONSE||||10^3 COPIES/ML|PD||UV2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|STUDY SUBJECT|READER 2|U|4||88||BASELINE|1973-06-22||||1972-01-20||1965-10-22|1962-10-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PT_US|PMD||MILE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5||7||RUN-IN|1960-05-22||||1962-07-06||1963-08-05|1963-06-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||TRGRESP|TARGET RESPONSE||||10^7/L|PSEUDORESPONSE||UV|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|PARENT|ENDOCRINOLOGIST|N|5||7||SCREENING|1969-04-02||||1971-05-28||1967-05-15|1960-03-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||ANATRESP|ANATOMIC RESPONSE||||UMOL/L/SEC|NPR||FL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|SIBLING|PHYSIOTHERAPIST|NA|1||38||OBSERVATION|1967-03-30||||1966-03-15||1971-07-26|1960-08-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SYRINGE|IUPD||ML/CM H2O|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|CLINICAL STUDY SPONSOR|RATER 1|NA|1||38||BASELINE|1968-04-30||||1969-09-25||1960-12-12|1973-08-05||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||OVRLRESP|OVERALL RESPONSE||||GENEQ|NON-PD||/10^4|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|2||58||BASELINE|1960-07-23||||1972-01-01||1962-08-14|1968-08-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/M2|CMR||UG/MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1962-05-26||||1964-05-04||1960-08-20|1967-10-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MAC50|INCREASED||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|ADJUDICATOR|READER 1|U|3||39||OPEN LABEL TREATMENT|1973-05-29||||1971-05-21||1964-06-13|1969-03-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/ML|ABSENT MORPHOLOGIC RESPONSE||FFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|SIBLING|READER|N|3||39||RUN-IN|1969-08-17||||1961-03-06||1960-12-30|1967-07-07||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||ANATRESP|ANATOMIC RESPONSE||||/2000 RBC|PDU||UGEQ/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|STUDY SUBJECT|ADJUDICATOR|Y|4||88||WASHOUT|1969-07-10||||1962-06-22||1967-06-13|1968-01-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||LIVRRESP|LIVER RESPONSE||||COAT|NON-QUANTIFIABLE MRD POSITIVITY||UG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|ADJUDICATOR|ONCOLOGIST 1|N|4||88||BASELINE|1969-11-11||||1960-11-06||1970-07-04|1962-08-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BOWL|CYTOGENETIC MINIMAL RESPONSE||MESF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|N|FAMILY MEMBER|PATHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1965-05-21||||1970-06-11||1966-03-18|1971-04-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||RAD|NON-PD||GRAVITATIONAL UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|SPOUSE|MICROSCOPIST 2|N|5||7||TREATMENT|1973-02-22||||1971-07-17||1969-09-08|1966-09-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HZ/S|CR||LOG10 CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|INTERVIEWER|ENDOCRINOLOGIST|U|1||38||INDUCTION TREATMENT|1970-08-24||||1963-09-17||1964-01-27|1972-01-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||RDIORESP|RADIOLOGIC RESPONSE||||G/CAGE|NED||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|FAMILY MEMBER|READER|N|1||38||BLINDED TREATMENT|1960-08-08||||1972-06-02||1969-04-06|1971-04-11||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 CFU/ML|INDETERMINATE RESPONSE||IU/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|2||58||BASELINE|1967-10-29||||1972-06-19||1960-04-22|1961-07-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||SPLNRESP|SPLEEN RESPONSE||||F|CYTOGENETIC PR||10^6 COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|STUDY SUBJECT|READER 3|N|2||58||RUN-IN|1969-06-17||||1973-01-10||1962-02-24|1966-12-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||MOLRESP|MOLECULAR RESPONSE||||10^6 ORGANISMS/MG|CYTOGENETIC MINOR RESPONSE||M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|STUDY SUBJECT|RATER|Y|3||39||CONTINUATION TREATMENT|1966-09-01||||1972-12-13||1960-10-22|1969-02-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^6 CFU/G|OPTIMAL MORPHOLOGIC RESPONSE||10^6 CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|INTERVIEWER|CLINICAL PATHOLOGIST|Y|3||39||RUN-IN|1969-05-12||||1964-04-24||1967-05-19|1966-05-17||AFTER||DURING|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/MIN/1.73M2|VGPR||10^12 IU/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|STUDY SUBJECT|ONCOLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1969-02-02||||1963-09-13||1972-05-01|1963-02-28||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||YEARS|OPTIMAL MORPHOLOGIC RESPONSE||L/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|ADJUDICATOR|PATHOLOGIST 1|Y|4||88||RUN-IN|1969-06-29||||1969-08-05||1962-07-13|1960-01-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/LSQN|DISEASE TRANSFORMATION||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|GUARDIAN|READER 2|Y|5||7||OBSERVATION|1962-08-12||||1971-12-17||1969-06-26|1963-03-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||PATHRESP|PATHOLOGIC RESPONSE||||KDA|UNFAVORABLE RESPONSE||MU|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|INTERVIEWER|READER 3|Y|5||7||TREATMENT|1965-11-21||||1962-12-21||1962-10-20|1973-06-09||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||LIVRRESP|LIVER RESPONSE||||10^3 ORGANISMS/ML|MRD NEGATIVITY||G/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|INDEPENDENT ASSESSOR|READER 3|U|1||38||TREATMENT|1973-04-06||||1968-12-01||1971-12-20|1970-10-27||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||BESTRESP|BEST OVERALL RESPONSE||||DPM/MG|STABLE||MG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-10-03||||1964-11-27||1964-08-24|1963-07-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3 CFU/ML|PSEUDORESPONSE||MET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|2||58||BASELINE|1964-09-30||||1968-02-20||1969-12-11|1964-11-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||MOLRESP|MOLECULAR RESPONSE||||ECL UNIT|MORPHOLOGIC CRI||CM/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|DOMESTIC PARTNER|PATHOLOGIST|U|2||58||INDUCTION TREATMENT|1971-11-22||||1972-04-03||1965-12-12|1968-07-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^6/HPF|FAVORABLE RESPONSE||GTT|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|FAMILY MEMBER|ONCOLOGIST 1|NA|3||39||SCREENING|1960-07-20||||1971-06-08||1968-03-19|1965-02-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||GRAVITATIONAL UNIT|PMR||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|INVESTIGATOR|RADIOLOGIST 2|NA|3||39||FOLLOW-UP|1964-04-04||||1965-09-03||1972-10-04|1961-01-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||METBRESP|METABOLIC RESPONSE||||10^9 CFU/G|PARTIAL MORPHOLOGIC RESPONSE||U/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|4||88||INDUCTION TREATMENT|1969-08-13||||1962-12-07||1964-08-02|1973-01-04||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||METBRESP|METABOLIC RESPONSE||||10^3 ORGANISMS/G|IPR||UKAT/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|SIBLING|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1969-05-03||||1964-08-21||1971-02-03|1971-06-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GBQ/MG|MINOR PATHOLOGIC RESPONSE||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5||7||TREATMENT|1972-08-27||||1967-08-30||1967-03-22|1969-03-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||MOLRESP|MOLECULAR RESPONSE||||CI/UG|PD FROM PR||ML/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|5||7||BLINDED TREATMENT|1964-07-29||||1970-07-11||1971-06-12|1968-11-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^7 TCID 50/DOSE|CHR||UG/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|VENDOR|ENDOCRINOLOGIST|N|1||38||BLINDED TREATMENT|1962-09-18||||1972-12-04||1972-02-29|1967-09-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||RDIORESP|RADIOLOGIC RESPONSE||||OHM|CR-CT||MG/L FEU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|INVESTIGATOR|RATER 2|U|1||38||WASHOUT|1962-05-15||||1961-05-30||1971-12-17|1972-10-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||LIVRRESP|LIVER RESPONSE||||KPA|IMMUNOPHENOTYPIC CR||MV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|SIGNIFICANT OTHER|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-08-19||||1964-06-16||1963-01-01|1961-01-13||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||NEWLPROG|NEW LESION PROGRESSION||||UOSM|MRD PERSISTENCE||VG/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|U|2||58||OBSERVATION|1962-04-25||||1960-12-12||1963-06-28|1971-04-06||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PIXEL|NON-CR/NON-PD||GENEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|SPOUSE|RADIOLOGIST 1|N|3||39||BLINDED TREATMENT|1960-09-13||||1973-07-25||1961-10-16|1965-06-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||CLINRESP|CLINICAL RESPONSE||||U/G|UNEQUIVOCAL||APS U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|STUDY SUBJECT|RADIOLOGIST 1|Y|3||39||RUN-IN|1972-02-09||||1964-12-27||1969-09-20|1963-09-06||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||LIVRRESP|LIVER RESPONSE||||DAYS/WK|NE||DPM/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|CHILD|RADIOLOGIST 2|NA|4||88||WASHOUT|1960-01-08||||1971-05-22||1967-11-30|1964-02-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||ANATRESP|ANATOMIC RESPONSE||||G/G|EQUIVOCAL||CAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|FAMILY MEMBER|ONCOLOGIST 1|Y|4||88||SCREENING|1968-01-22||||1969-12-25||1967-08-12|1968-05-29||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DRINK|IPR||ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|SIGNIFICANT OTHER|RATER 1|Y|5||7||OBSERVATION|1967-11-25||||1969-09-26||1968-07-30|1962-10-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||LIVRRESP|LIVER RESPONSE||||10^6 IU/ML|MR||DAYS/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|PROXY|OTOLARYNGOLOGIST|Y|5||7||BASELINE|1960-04-22||||1972-08-29||1971-04-04|1961-10-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BAR|IUPD||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1||38||OBSERVATION|1962-07-22||||1965-03-28||1961-02-12|1961-11-16||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CFU/G|PD-CT||MMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|1||38||TREATMENT|1973-05-19||||1970-08-14||1960-08-22|1963-05-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/ANIMAL/WK|DISEASE TRANSFORMATION||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|INTERVIEWER|PATHOLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1965-04-08||||1960-09-13||1971-03-19|1972-01-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KBQ/UL|MCR||ANSON U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||TREATMENT|1963-01-21||||1968-07-24||1968-09-30|1964-07-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FOZ_BR|CR||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1964-11-06||||1972-02-01||1966-10-11|1962-02-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||BESTRESP|BEST OVERALL RESPONSE||||UU/L|TREATMENT FAILURE||ABSORBANCE U|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|INDEPENDENT ASSESSOR|READER 3|U|3||39||SCREENING|1962-06-17||||1965-01-07||1968-09-16|1970-11-29||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FOZ_BR|INCREASED||MG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||OBSERVATION|1965-11-30||||1968-10-08||1970-07-29|1972-08-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||STRUSTAT|STEROID USE STATUS||||CYCLE/MIN|SMD||MAC50|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|N|4||88||SCREENING|1972-04-25||||1963-09-09||1972-07-01|1961-12-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||ANATRESP|ANATOMIC RESPONSE||||TUBE|CYTOGENETIC PR||MPL U|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|STUDY SUBJECT|READER 2|N|5||7||OBSERVATION|1971-05-21||||1961-10-28||1960-03-22|1972-09-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||CLINRESP|CLINICAL RESPONSE||||G/ANIMAL/DAY|NOT ALL EVALUATED||10^11/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5||7||BLINDED TREATMENT|1970-03-12||||1962-04-11||1964-02-25|1960-07-21||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||%/MIN|PSA PROGRESSION||ML/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|DOMESTIC PARTNER|ADJUDICATOR|Y|1||38||TREATMENT|1970-01-11||||1965-03-02||1965-02-21|1965-06-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||METBRESP|METABOLIC RESPONSE||||F|MOLECULAR CR||TITER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1973-05-03||||1973-04-03||1962-08-18|1971-12-11||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ANTI-XA IU/ML|WORSENED||INHALATION|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|2||58||RUN-IN|1967-09-04||||1969-05-01||1972-10-13|1964-04-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/DL|FAVORABLE RESPONSE||PPM|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|CLINICAL STUDY SPONSOR|RATER|Y|2||58||SCREENING|1967-03-05||||1970-03-28||1967-03-14|1972-02-20||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||NEWLPROG|NEW LESION PROGRESSION||||MMU/ML|CYTOGENETIC MINIMAL RESPONSE||BE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|STUDY SUBJECT|INTERNIST|N|3||39||OBSERVATION|1970-08-19||||1963-10-28||1971-04-05|1960-11-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||NTRGRESP|NON-TARGET RESPONSE||||KAT|HI-E||KM/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|VENDOR|RATER 1|NA|3||39||TREATMENT|1962-05-22||||1969-11-30||1961-05-02|1962-12-14||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||STRUSTAT|STEROID USE STATUS||||G|CPR||MCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|CAREGIVER|RATER 2|Y|4||88||LONG-TERM FOLLOW-UP|1973-07-07||||1964-05-10||1971-08-25|1965-08-30||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||STRUSTAT|STEROID USE STATUS||||G/CAGE|RELAPSED DISEASE FROM CR||DAYS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|STUDY SUBJECT|RATER 1|U|4||88||WASHOUT|1963-03-22||||1963-10-27||1960-05-22|1963-06-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||STRUSTAT|STEROID USE STATUS||||KUSP|PCR||LB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5||7||TREATMENT|1961-08-31||||1965-05-08||1963-09-20|1971-11-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||HOUNSFIELD UNIT|PCR||UMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|5||7||SCREENING|1968-04-14||||1961-06-08||1967-09-16|1968-07-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|1||||||NTRGRESP|NON-TARGET RESPONSE||||MEQ/MMOL|OPTIMAL MORPHOLOGIC RESPONSE||ML/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|GUARDIAN|RATER 2|NA|1||38||SCREENING|1961-07-17||||1963-10-18||1971-10-11|1961-06-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 COPIES/ML|SMD||PELLET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|SIGNIFICANT OTHER|ONCOLOGIST 2|U|1||38||SCREENING|1966-12-04||||1965-06-26||1973-08-27|1973-03-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|1||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 PFU|RELAPSED DISEASE||G/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|FRIEND|ONCOLOGIST 1|N|2||58||INDUCTION TREATMENT|1968-11-23||||1969-01-25||1969-12-07|1964-04-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|2||||||LIVRRESP|LIVER RESPONSE||||CM|CHR||10^4 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|2||58||BASELINE|1972-11-28||||1973-05-16||1964-10-24|1972-12-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/ANIMAL/DAY|PR-CT||IU/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|SPOUSE|NEUROLOGIST 2|U|3||39||RUN-IN|1967-03-31||||1973-01-08||1972-12-12|1963-06-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|2||||||NEWLPROG|NEW LESION PROGRESSION||||DAYS/MONTH|MRD RELAPSE||UIU/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|STUDY SUBJECT|MICROSCOPIST 2|N|3||39||OBSERVATION|1973-03-20||||1970-12-13||1971-10-11|1964-03-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|1||||||TRGRESP|TARGET RESPONSE||||CFU/ML|CPR||UM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|PARENT|CLINICAL PATHOLOGIST|N|4||88||CONTINUATION TREATMENT|1970-06-06||||1961-04-16||1963-04-18|1971-06-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||G/MOL|CYTOGENETIC NO RESPONSE||DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|FAMILY MEMBER|PHYSIOTHERAPIST|NA|4||88||CONTINUATION TREATMENT|1968-01-12||||1966-08-25||1960-08-21|1967-02-06||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 IU/ML|PSEUDOPROGRESSION||DYN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|5||7||FOLLOW-UP|1963-09-28||||1961-10-07||1970-06-22|1967-05-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|AAC3113C-793D-43F4-87E9-111246E03003|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^6 DNA COPIES/ML|UNFAVORABLE RESPONSE||EID 50/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|FAMILY MEMBER|ONCOLOGIST 2|N|5||7||RUN-IN|1965-01-28||||1961-09-29||1971-11-06|1964-06-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||FRACTION OF 1|DISEASE TRANSFORMATION||U/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|CHILD|RADIOLOGIST 2|NA|1||38||WASHOUT|1964-03-29||||1964-12-19||1970-02-22|1970-11-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||TRGRESP|TARGET RESPONSE||||MEQ|PDU||DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|GUARDIAN|FORENSIC PATHOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1965-11-25||||1964-07-14||1967-02-24|1972-04-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||M/SEC2|NR||GENEQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|VENDOR|UROLOGIST|Y|2||58||BASELINE|1960-06-26||||1965-05-22||1968-08-30|1962-03-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||TMRESP|TUMOR MARKER RESPONSE||||PELLET|MR||PFU/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|SIBLING|MICROSCOPIST 2|Y|2||58||SCREENING|1970-05-29||||1973-09-06||1972-02-01|1971-05-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||METSIND|METASTATIC INDICATOR||||PLUG|CA125 50% RESPONSE||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|CAREGIVER|PATHOLOGIST 2|Y|3||39||BASELINE|1965-11-11||||1963-09-16||1964-05-28|1960-09-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||NTRGRESP|NON-TARGET RESPONSE||||CM H2O|PSEUDOPROGRESSION||UIU/L|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|PROXY|ONCOLOGIST 2|NA|3||39||FOLLOW-UP|1961-01-18||||1960-06-09||1972-06-30|1960-01-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^5/HPF|PD FROM PR||ML/MMHG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|STUDY SUBJECT|PATHOLOGIST 1|N|4||88||SCREENING|1971-01-28||||1967-10-25||1963-01-10|1972-01-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NCI|MINOR PATHOLOGIC RESPONSE||/MM|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|GUARDIAN|ADJUDICATOR 3|N|4||88||OPEN LABEL TREATMENT|1972-08-14||||1967-10-29||1968-09-10|1972-08-28||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||NEWLIND|NEW LESION INDICATOR||||/MM|MORPHOLOGIC CR||S/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|PROXY|ONCOLOGIST 2|NA|5||7||LONG-TERM FOLLOW-UP|1961-05-26||||1973-02-28||1971-10-07|1967-04-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||LIVRRESP|LIVER RESPONSE||||YD|PSA PROGRESSION||RPM|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|U|CHILD|INTERNIST|Y|5||7||FOLLOW-UP|1960-12-17||||1962-05-10||1971-05-24|1961-11-06||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||M|VGPR||10^5/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|STUDY SUBJECT|MICROSCOPIST 2|NA|1||38||FOLLOW-UP|1971-12-14||||1968-11-10||1962-04-15|1967-02-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||S/H|UNFAVORABLE RESPONSE||DAGU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|1||38||RUN-IN|1961-06-09||||1970-03-06||1968-06-17|1964-10-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||STRUSTAT|STEROID USE STATUS||||HEP|MORPHOLOGIC LEUKEMIA-FREE STATE||IU/DL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|2||58||FOLLOW-UP|1962-10-26||||1971-10-03||1971-06-03|1960-06-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||ANATRESP|ANATOMIC RESPONSE||||KIT|QUANTIFIABLE MRD POSITIVITY||UG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|FRIEND|DERMATOLOGIST|Y|2||58||CONTINUATION TREATMENT|1962-11-13||||1962-04-16||1967-05-19|1971-05-28||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||NEWLPROG|NEW LESION PROGRESSION||||BEATS/MIN|CYTOGENETIC MINOR RESPONSE||ML/SEC/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|INTERVIEWER|DERMATOLOGIST|N|3||39||RUN-IN|1972-10-15||||1965-02-04||1969-08-22|1961-09-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||M/SEC2|MRD RELAPSE||BQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|SPOUSE|RATER 1|Y|3||39||LONG-TERM FOLLOW-UP|1969-07-06||||1967-02-09||1969-12-22|1968-03-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MU|NED||HOMEOPATHIC DILUTION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|VENDOR|RADIOLOGIST|NA|4||88||SCREENING|1973-03-12||||1965-05-03||1972-09-13|1971-11-21||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||NEWLPROG|NEW LESION PROGRESSION||||%/MIN|CA125 75% RESPONSE||MG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|INDEPENDENT ASSESSOR|RATER|U|4||88||OBSERVATION|1962-03-12||||1965-06-12||1970-05-11|1966-07-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/H|MOLECULAR MAJOR RESPONSE||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|FAMILY MEMBER|RADIOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1966-09-25||||1966-11-22||1960-12-27|1962-11-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||LIVRRESP|LIVER RESPONSE||||/VF|HI-N||/200 HPFS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|SIBLING|ONCOLOGIST|NA|5||7||FOLLOW-UP|1973-08-06||||1967-04-12||1960-01-11|1967-07-31||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||ANATRESP|ANATOMIC RESPONSE||||UM2|NON-ICR/NON-IUPD||MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|1||38||OBSERVATION|1969-04-14||||1972-12-10||1960-03-14|1968-05-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||MOLRESP|MOLECULAR RESPONSE||||MG/H|MCR||PLUG|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|U|1||38||BASELINE|1969-06-26||||1971-12-19||1965-12-23|1963-12-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/MMHG|PR WITH LYMPHOCYTOSIS||MG/ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|PARENT|ONCOLOGIST 1|U|2||58||SCREENING|1964-11-07||||1962-12-05||1965-09-18|1969-04-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MPA|PD FROM PR||SFC/10^6 PBMC|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|INVESTIGATOR|READER 1|Y|2||58||LONG-TERM FOLLOW-UP|1967-03-22||||1961-04-09||1967-12-20|1973-01-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UKAT|NON-QUANTIFIABLE MRD POSITIVITY||FARAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|3||39||WASHOUT|1973-07-19||||1971-03-02||1962-12-31|1960-11-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^7/L|PR||G/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|CHILD|ONCOLOGIST 1|N|3||39||LONG-TERM FOLLOW-UP|1968-12-16||||1969-01-10||1972-03-20|1961-02-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||CYTORESP|CYTOGENETIC RESPONSE||||LOG10 CCID 50/DOSE|CHR||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|INVESTIGATOR|HEMATOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1969-02-19||||1960-03-11||1973-05-28|1965-06-10||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||METBRESP|METABOLIC RESPONSE||||ENZYME U|PSA PROGRESSION||NG/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|STUDY SUBJECT|MICROSCOPIST 1|Y|4||88||SCREENING|1972-10-26||||1968-05-21||1962-08-02|1965-12-31||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||NEWLPROG|NEW LESION PROGRESSION||||MPA|PD||UL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|FAMILY MEMBER|NEUROLOGIST 2|U|5||7||FOLLOW-UP|1963-08-03||||1962-06-20||1971-06-10|1963-01-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/ML|CYTOGENETIC MINOR RESPONSE||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CAREGIVER|MICROSCOPIST 3|NA|5||7||TREATMENT|1968-07-31||||1964-08-27||1966-01-11|1970-09-24||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||BONERESP|BONE RESPONSE||||FINGERTIP UNIT|COMPLETE MRD RESPONSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1968-03-15||||1961-10-30||1970-02-27|1972-03-31||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||BESTRESP|BEST OVERALL RESPONSE||||CI|MRD PERSISTENCE||BOWL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|VENDOR|NEUROLOGIST 2|N|1||38||TREATMENT|1968-06-10||||1967-04-20||1962-03-27|1964-02-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||BESTRESP|BEST OVERALL RESPONSE||||AMU|SCR||G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2||58||INDUCTION TREATMENT|1971-11-05||||1967-08-09||1971-08-08|1968-07-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PUFF|PSEUDOPROGRESSION||10^6 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|2||58||LONG-TERM FOLLOW-UP|1960-05-01||||1962-12-29||1962-07-01|1967-08-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||METBRESP|METABOLIC RESPONSE||||UL/ML|ICR||YD|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|3||39||SCREENING|1960-08-05||||1971-06-23||1968-09-09|1970-02-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||HR/DAY|CR||CMH2O/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|SIGNIFICANT OTHER|READER 3|U|3||39||WASHOUT|1970-10-03||||1962-02-26||1967-03-19|1969-08-20||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||BONERESP|BONE RESPONSE||||MILE|RELAPSED DISEASE FROM CR OR PR||BQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|GUARDIAN|MICROSCOPIST|Y|4||88||BLINDED TREATMENT|1960-10-30||||1960-02-28||1969-11-14|1964-11-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/DL|MCR||SIEMENS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|GUARDIAN|CARDIOLOGIST|U|4||88||CONTINUATION TREATMENT|1969-11-24||||1967-11-09||1961-10-08|1962-11-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||NEWLIND|NEW LESION INDICATOR||||HEP|PSEUDORESPONSE||KG/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|5||7||INDUCTION TREATMENT|1962-06-01||||1971-02-12||1966-12-15|1972-12-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KG/MOL|MINOR PATHOLOGIC RESPONSE||CCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|Y|ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|5||7||RUN-IN|1967-11-07||||1964-08-15||1971-08-21|1971-02-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL BCE/L|MORPHOLOGIC LEUKEMIA-FREE STATE||MMOL2/L2|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|PARENT|ADJUDICATOR|U|1||38||RUN-IN|1971-09-06||||1960-12-28||1968-12-03|1963-08-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||TRGRESP|TARGET RESPONSE||||MEQ/DAY|HI-E||KG/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|STUDY SUBJECT|ONCOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1969-03-06||||1969-05-31||1967-12-05|1971-12-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||OVRLRESP|OVERALL RESPONSE||||PG/CELL|MOLECULAR CR||DRINK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|STUDY SUBJECT|READER|Y|2||58||CONTINUATION TREATMENT|1961-03-07||||1965-02-11||1962-11-14|1960-07-06||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||QUANTITY SUFFICIENT|CR||UKAT/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|DOMESTIC PARTNER|ADJUDICATOR 2|Y|2||58||BASELINE|1967-12-08||||1963-07-18||1966-08-09|1961-04-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PMOL/G|MORPHOLOGIC CRI||/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|3||39||TREATMENT|1967-11-11||||1967-03-23||1971-03-26|1969-10-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U.CARR|DISEASE TRANSFORMATION||MG/ML/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|CHILD|MICROSCOPIST 2|Y|3||39||WASHOUT|1964-08-21||||1960-05-02||1969-11-12|1964-04-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||OVRLRESP|OVERALL RESPONSE||||KG/L|ISD||10^6 IU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|U|4||88||OBSERVATION|1971-11-08||||1961-10-19||1964-07-30|1972-06-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||NTRGRESP|NON-TARGET RESPONSE||||G/CM2|PARTIAL MORPHOLOGIC RESPONSE||KN/CM2|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|ADJUDICATOR|PATHOLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1966-12-16||||1966-07-19||1968-01-25|1970-08-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/DAY|MRD PERSISTENCE||U/CL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|CHILD|CLINICAL PATHOLOGIST|N|5||7||FOLLOW-UP|1971-11-20||||1965-09-14||1972-12-29|1960-09-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||RDIORESP|RADIOLOGIC RESPONSE||||GPS U|QUANTIFIABLE MRD POSITIVITY||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|DOMESTIC PARTNER|RATER 2|N|5||7||TREATMENT|1971-03-08||||1964-02-22||1962-11-08|1964-09-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BAU|PARTIAL MORPHOLOGIC RESPONSE||ARBITRARY U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|1||38||RUN-IN|1973-06-18||||1973-02-07||1965-08-23|1968-08-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 COPIES/ML|PD-CT||LX|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|FRIEND|CLINICAL PATHOLOGIST|Y|1||38||TREATMENT|1964-09-03||||1961-07-14||1969-07-16|1972-02-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/M2/MIN|SD||PMOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|CAREGIVER|RATER 2|U|2||58||BLINDED TREATMENT|1969-09-11||||1964-05-24||1967-03-13|1968-04-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^5/HPF|HI-P||L/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|2||58||FOLLOW-UP|1972-09-19||||1972-07-22||1966-12-07|1962-03-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UKAT|PR-CT||PPTR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||INDUCTION TREATMENT|1970-12-01||||1972-05-24||1964-04-02|1960-03-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||LOG10 ELISA UNIT|CR-CT||MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|DOMESTIC PARTNER|ADJUDICATOR 3|Y|3||39||BASELINE|1963-02-11||||1964-06-16||1970-06-20|1970-03-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||TCID 50/DOSE|CRI||MMHG*MIN/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|CAREGIVER|MICROSCOPIST|U|4||88||SCREENING|1972-05-08||||1962-07-07||1971-02-04|1971-02-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||TRGRESP|TARGET RESPONSE||||U/KG|HI-P||KHZ|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|4||88||BLINDED TREATMENT|1965-03-18||||1960-08-20||1968-05-02|1971-06-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||NG/L|PSA PROGRESSION||COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|PROXY|RADIOLOGIST|U|5||7||CONTINUATION TREATMENT|1967-12-24||||1972-09-10||1973-07-21|1970-11-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DRUM|MOLECULAR CR||PMOL/L/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|FRIEND|PATHOLOGIST 2|N|5||7||WASHOUT|1969-05-07||||1966-12-24||1971-11-14|1960-08-11||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||SPLNRESP|SPLEEN RESPONSE||||NKAT/G HB|COMPLETE MRD RESPONSE||DIOPTER|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|PARENT|RATER 1|NA|1||38||SCREENING|1971-06-28||||1968-12-09||1964-11-25|1966-12-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||CLINRESP|CLINICAL RESPONSE||||PG/L|CYTOGENETIC NO RESPONSE||MKAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|SIGNIFICANT OTHER|READER 3|U|1||38||WASHOUT|1960-06-23||||1967-05-04||1967-03-09|1969-12-25||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||TMRESP|TUMOR MARKER RESPONSE||||CAPLET|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^7 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|CAREGIVER|RATER 1|Y|2||58||LONG-TERM FOLLOW-UP|1962-09-19||||1968-07-06||1969-09-06|1970-02-08||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KG/CM2|TREATMENT FAILURE||PKAT/L|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|CHILD|ENDOCRINOLOGIST|U|2||58||INDUCTION TREATMENT|1967-12-07||||1965-06-19||1966-05-19|1965-03-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||HZ|CA125 50% RESPONSE||PMOL/L/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|SPOUSE|PEDIATRIC NEUROLOGIST|U|3||39||FOLLOW-UP|1972-01-17||||1962-07-22||1967-07-17|1971-06-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PMOL/L/H|PSEUDOPROGRESSION||JOULE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|FAMILY MEMBER|NEUROLOGIST|Y|3||39||CONTINUATION TREATMENT|1966-04-23||||1963-08-19||1968-01-14|1967-12-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/M2|CYTOGENETIC NO RESPONSE||/2500 WBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|4||88||TREATMENT|1972-06-01||||1960-05-16||1967-02-26|1967-03-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL/KG|NOT ALL EVALUATED||BOLUS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|4||88||BASELINE|1969-04-25||||1969-03-12||1962-06-11|1970-05-04||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||RDIORESP|RADIOLOGIC RESPONSE||||G/ANIMAL/DAY|EQUIVOCAL||%(V/V)|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BLINDED TREATMENT|1971-12-30||||1965-05-14||1966-04-21|1967-06-01||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6 CFU/ML|NR||10^6 ORGANISMS/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|5||7||FOLLOW-UP|1970-10-04||||1964-05-10||1968-08-23|1971-04-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||METSIND|METASTATIC INDICATOR||||NGEQ/L|PR||ELISA UNIT/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|FAMILY MEMBER|INTERNIST|NA|1||38||INDUCTION TREATMENT|1964-09-26||||1973-05-02||1971-02-28|1963-12-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BOLUS|PCR||L/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|PARENT|ADJUDICATOR|N|1||38||BLINDED TREATMENT|1972-11-08||||1970-12-27||1966-04-14|1961-03-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/G/MIN|HI-P||UKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|FRIEND|RATER 1|U|2||58||OBSERVATION|1964-05-16||||1968-08-15||1965-01-12|1962-08-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/L/SEC|WORSENED||U/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|SIGNIFICANT OTHER|PHYSIOTHERAPIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-07-24||||1960-10-22||1960-04-21|1960-08-30||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||AFU|COMPLETE MRD RESPONSE||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|DOMESTIC PARTNER|ONCOLOGIST 1|U|3||39||FOLLOW-UP|1962-10-17||||1967-07-13||1965-03-04|1967-08-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PMOL|SCR||UG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|N|3||39||RUN-IN|1968-05-12||||1963-06-08||1971-02-15|1966-07-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||MOLRESP|MOLECULAR RESPONSE||||CI/UL|INDETERMINATE RESPONSE||CI/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|4||88||FOLLOW-UP|1970-04-03||||1960-07-08||1971-09-01|1963-09-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||STRUSTAT|STEROID USE STATUS||||MILE|SD-CT||EID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|CHILD|RATER 2|NA|4||88||LONG-TERM FOLLOW-UP|1967-05-28||||1961-04-01||1966-07-13|1964-01-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/CM H2O|EQUIVOCAL||CFU/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|VENDOR|ONCOLOGIST|U|5||7||BLINDED TREATMENT|1961-09-29||||1968-06-27||1971-09-15|1967-02-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PL|CCR||CIGAR|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|SIBLING|MICROSCOPIST 1|U|5||7||WASHOUT|1971-10-29||||1965-09-08||1968-03-21|1970-01-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^7/L|NON-PD||/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1966-07-27||||1973-02-25||1966-10-10|1960-04-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MIN*MG/ML|PARTIAL MORPHOLOGIC RESPONSE||PIPE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|1||38||BLINDED TREATMENT|1967-03-15||||1967-09-26||1965-10-20|1964-11-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/KG/MIN|CHR||MS2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1969-09-05||||1968-07-30||1960-03-29|1966-06-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||AMFI|CR-CT||AG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|2||58||BLINDED TREATMENT|1964-04-09||||1972-02-12||1969-08-30|1967-05-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||NTRGRESP|NON-TARGET RESPONSE||||DB|NED||ML/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|PROXY|READER 1|U|3||39||BASELINE|1968-09-17||||1968-04-11||1960-11-25|1961-04-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TORR|PD/RELAPSE AFTER HI||MPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|FRIEND|READER 3|U|3||39||INDUCTION TREATMENT|1972-06-21||||1970-06-28||1968-01-24|1972-04-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MM2|MRD PERSISTENCE||10^9 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|CAREGIVER|DERMATOLOGIST|Y|4||88||FOLLOW-UP|1967-09-13||||1961-11-03||1965-08-06|1967-12-12||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NMOL/KG/DAY|PR||MCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|4||88||WASHOUT|1961-06-20||||1968-02-04||1971-02-27|1967-09-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||SPLNRESP|SPLEEN RESPONSE||||UG/MIN|DECREASED||10^12 IU/L|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|SIBLING|MICROSCOPIST 3|NA|5||7||TREATMENT|1972-02-23||||1964-09-13||1972-04-05|1963-11-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMHG/SEC|PSA PROGRESSION||MOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|HEALTH CARE PROFESSIONAL|READER 3|NA|5||7||BASELINE|1961-08-12||||1972-05-19||1969-03-25|1971-12-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BEAM BREAKS|NON-CR/NON-PD||MOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|CHILD|RADIOLOGIST 2|Y|1||38||FOLLOW-UP|1969-10-31||||1967-07-07||1960-01-31|1962-08-13||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||% INHIBITION|PSA PROGRESSION||PPM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|1||38||SCREENING|1972-04-15||||1973-04-02||1971-11-23|1971-10-07||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||STRUSTAT|STEROID USE STATUS||||10^3/HPF|CYTOGENETIC MINIMAL RESPONSE||MPS U|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|SPOUSE|READER 2|NA|2||58||BASELINE|1973-03-31||||1967-09-14||1962-02-11|1960-03-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UGEQ/L|PR-CT||/500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|CHILD|PEDIATRIC NEUROLOGIST|NA|2||58||WASHOUT|1968-11-17||||1968-09-14||1961-04-16|1973-07-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CI/UG|PSEUDORESPONSE||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|CHILD|ADJUDICATOR 1|NA|3||39||WASHOUT|1970-08-17||||1968-11-08||1967-06-04|1971-06-19||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||MOLRESP|MOLECULAR RESPONSE||||PT_BR|QUANTIFIABLE MRD POSITIVITY||10^6 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|SIBLING|RATER 2|N|3||39||SCREENING|1972-11-30||||1964-06-11||1965-12-05|1960-09-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||STRUSTAT|STEROID USE STATUS||||SEC|CYTOGENETIC CR||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|4||88||INDUCTION TREATMENT|1973-05-20||||1969-02-24||1965-06-08|1968-03-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||TRGRESP|TARGET RESPONSE||||U/G/MIN|PMR||ML/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|SIBLING|NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1973-04-24||||1960-09-07||1961-05-05|1968-01-31||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DEG|ISD||FFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CAREGIVER|READER|Y|5||7||WASHOUT|1972-08-11||||1964-03-27||1962-11-27|1971-05-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||RDIORESP|RADIOLOGIC RESPONSE||||BAU|MORPHOLOGIC LEUKEMIA-FREE STATE||ARBITRARY U|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||CONTINUATION TREATMENT|1971-03-08||||1970-12-17||1971-02-28|1970-01-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||VP/DOSE|RELAPSED DISEASE FROM CR OR PR||10^3 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|CAREGIVER|PATHOLOGIST|NA|1||38||RUN-IN|1963-11-25||||1970-01-07||1962-03-27|1969-07-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 CFU/ML|PMR||GY/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|1||38||TREATMENT|1964-11-22||||1964-07-17||1964-06-22|1963-02-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||MOLRESP|MOLECULAR RESPONSE||||DPM|INDETERMINATE RESPONSE||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|SIGNIFICANT OTHER|ONCOLOGIST|Y|2||58||CONTINUATION TREATMENT|1966-06-16||||1963-05-15||1960-02-24|1970-11-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/4.0 ML|COMPLETE MRD RESPONSE||U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|GUARDIAN|HEMATOLOGIST|N|2||58||TREATMENT|1972-06-01||||1970-01-10||1960-12-25|1960-08-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||METSIND|METASTATIC INDICATOR||||PMOL|NED||ML/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||RUN-IN|1971-02-20||||1973-05-16||1973-06-26|1967-10-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||BQ/L|CYTOGENETIC NO RESPONSE||/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|SPOUSE|RATER 1|Y|3||39||OBSERVATION|1966-03-26||||1968-09-15||1964-04-16|1962-09-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||OVRLRESP|OVERALL RESPONSE||||DEG/MM|RELAPSED DISEASE FROM CR||MU|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|CHILD|PEDIATRIC NEUROLOGIST|U|4||88||OBSERVATION|1970-07-03||||1971-06-27||1969-05-08|1960-01-13||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||METSIND|METASTATIC INDICATOR||||BOTTLE|MAJOR PATHOLOGIC RESPONSE||NCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|CAREGIVER|READER|NA|4||88||CONTINUATION TREATMENT|1969-02-25||||1970-06-12||1961-07-21|1960-09-17||DURING||AFTER|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/ML|PDU||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|FRIEND|MICROSCOPIST 1|U|5||7||WASHOUT|1972-03-16||||1972-04-20||1966-02-14|1964-06-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||NTRGRESP|NON-TARGET RESPONSE||||GENEQ|SMD||ML/CM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|FRIEND|RATER 1|U|5||7||FOLLOW-UP|1965-05-19||||1970-10-16||1966-06-22|1964-09-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CG|COMPLETE MRD RESPONSE||G/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|ADJUDICATOR|ADJUDICATOR 2|Y|1||38||BLINDED TREATMENT|1968-04-01||||1961-10-25||1965-09-28|1969-07-15||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||CLINRESP|CLINICAL RESPONSE||||TRANSDUCING UNIT/ML|UNFAVORABLE RESPONSE||MEQ/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|SPOUSE|ADJUDICATOR 2|Y|1||38||BLINDED TREATMENT|1966-06-17||||1967-04-15||1968-04-09|1964-07-13||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/H|HI-P||MBQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|GUARDIAN|ONCOLOGIST|NA|2||58||WASHOUT|1967-08-18||||1969-02-16||1960-12-15|1969-09-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BLOCKS|NON-QUANTIFIABLE MRD POSITIVITY||V/V|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|FRIEND|RATER 2|N|2||58||RUN-IN|1969-03-28||||1965-08-17||1961-08-15|1968-05-28||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CCID 50/DOSE|IPR||UMOL/MG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|CAREGIVER|ONCOLOGIST|Y|3||39||BASELINE|1961-09-20||||1964-01-27||1960-06-07|1971-07-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KM|NED||UKAT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||INDUCTION TREATMENT|1962-08-12||||1962-01-19||1962-01-18|1965-06-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/L FEU|DISEASE TRANSFORMATION||IN2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|UROLOGIST|Y|4||88||WASHOUT|1971-10-27||||1968-11-16||1968-03-01|1973-03-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^10/L|PD-CT||ML/MMHG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|SIBLING|MICROSCOPIST 1|U|4||88||TREATMENT|1972-06-24||||1970-08-18||1960-03-15|1963-04-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||NEWLPROG|NEW LESION PROGRESSION||||ELISA UNIT/DOSE|IUPD||MV|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|ADJUDICATOR|INTERNIST|N|5||7||WASHOUT|1961-05-08||||1968-11-26||1972-02-16|1964-11-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PLUG|PCR||UG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|INDEPENDENT ASSESSOR|CARDIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1961-09-27||||1966-08-21||1969-04-28|1964-09-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NGEQ/L|CR||UGEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|GUARDIAN|RATER|N|1||38||RUN-IN|1964-03-24||||1963-05-09||1967-02-21|1960-04-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||BONERESP|BONE RESPONSE||||PIXEL|ABSENT MORPHOLOGIC RESPONSE||MMOL/MIN/KPA/L|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|ADJUDICATION COMMITTEE|RADIOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1962-09-28||||1966-03-13||1967-09-21|1967-09-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PA|MRD NEGATIVITY||CUP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||RUN-IN|1973-07-08||||1960-09-01||1964-05-03|1968-03-10||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||TRGRESP|TARGET RESPONSE||||FMOL|DECREASED||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CAREGIVER|PATHOLOGIST 2|N|2||58||CONTINUATION TREATMENT|1973-05-21||||1964-07-02||1969-04-28|1965-01-05||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||METBRESP|METABOLIC RESPONSE||||CD|MCR||10^7 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|INVESTIGATOR|CLINICAL PATHOLOGIST|N|3||39||CONTINUATION TREATMENT|1966-03-16||||1971-06-20||1963-08-26|1971-09-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||COPIES/ML|MCR||FIU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|FAMILY MEMBER|ADJUDICATOR|N|3||39||INDUCTION TREATMENT|1967-08-13||||1966-01-18||1973-01-16|1969-05-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||OVRLRESP|OVERALL RESPONSE||||COPIES/UL|WORSENED||BOTTLE|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|ADJUDICATOR|PHYSIOTHERAPIST|N|4||88||LONG-TERM FOLLOW-UP|1960-03-12||||1972-05-20||1960-10-08|1963-10-15||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RPM|UNFAVORABLE RESPONSE||UG/ML/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|VENDOR|ONCOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1964-04-14||||1972-07-31||1962-08-28|1967-12-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||METBRESP|METABOLIC RESPONSE||||M/SEC2|CA125 75% RESPONSE||10^5/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|5||7||INDUCTION TREATMENT|1969-05-03||||1967-04-14||1973-03-02|1968-05-02||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||TRGRESP|TARGET RESPONSE||||STEPS/MIN|CYTOGENETIC MINIMAL RESPONSE||L/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|INTERVIEWER|ENDOCRINOLOGIST|NA|5||7||BLINDED TREATMENT|1964-01-16||||1963-05-04||1967-10-20|1968-04-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||METSIND|METASTATIC INDICATOR||||WATT|OPTIMAL MORPHOLOGIC RESPONSE||PL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|1||38||FOLLOW-UP|1966-06-29||||1971-10-26||1972-01-18|1960-06-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||RDIORESP|RADIOLOGIC RESPONSE||||WAFER|RELAPSED DISEASE FROM CR OR PR||/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|SPOUSE|ADJUDICATOR 3|U|1||38||OPEN LABEL TREATMENT|1970-10-01||||1961-08-30||1966-01-17|1968-07-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||OVRLRESP|OVERALL RESPONSE||||NSEC|PSEUDORESPONSE||PKAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|FRIEND|NEUROLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1972-11-15||||1967-02-23||1964-07-02|1961-01-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||MOLRESP|MOLECULAR RESPONSE||||UMOL|PARTIAL MORPHOLOGIC RESPONSE||/MM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|ADJUDICATOR|READER 2|Y|2||58||OPEN LABEL TREATMENT|1960-03-06||||1972-04-30||1968-04-24|1970-12-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||NMOL/L/MIN|NOT ALL EVALUATED||DPM/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|SIGNIFICANT OTHER|ONCOLOGIST 1|N|3||39||WASHOUT|1971-02-14||||1966-06-05||1961-10-17|1967-09-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CIGAR|VGPR||10^7/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|FAMILY MEMBER|RADIOLOGIST 2|NA|3||39||RUN-IN|1960-12-06||||1968-06-01||1963-12-22|1966-11-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||TRGRESP|TARGET RESPONSE||||IU/MG|CCR||IU/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|PARENT|RADIOLOGIST 1|NA|4||88||OBSERVATION|1962-04-17||||1964-04-23||1965-11-23|1970-09-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KBQ|IMPROVED||10^9 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|CHILD|OPTOMETRIST|U|4||88||OBSERVATION|1961-04-13||||1963-03-03||1960-02-15|1968-05-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/KG|SMD||U/G/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|5||7||FOLLOW-UP|1967-06-20||||1966-09-16||1969-06-19|1968-02-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||SPLNRESP|SPLEEN RESPONSE||||MG/KG/DOSE|MR||UCI/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|FAMILY MEMBER|ADJUDICATOR 2|U|5||7||LONG-TERM FOLLOW-UP|1967-11-27||||1970-08-19||1960-03-29|1968-05-02||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/ANIMAL|CMR||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|ADJUDICATOR|CLINICAL PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1973-01-03||||1971-12-25||1973-08-23|1969-12-12||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||TRGRESP|TARGET RESPONSE||||ML/H|MRD PERSISTENCE||MEQ/UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|1||38||SCREENING|1968-08-04||||1963-12-30||1973-07-04|1964-05-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||SPLNRESP|SPLEEN RESPONSE||||SV|CCR||MESF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|PROXY|PHYSIOTHERAPIST|Y|2||58||BLINDED TREATMENT|1969-05-09||||1971-06-17||1970-11-01|1964-08-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||CYTORESP|CYTOGENETIC RESPONSE||||/10^4|PDU||/VF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|PARENT|RADIOLOGIST 2|NA|2||58||SCREENING|1971-03-11||||1965-12-12||1973-06-14|1971-11-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||PATHRESP|PATHOLOGIC RESPONSE||||U/ANIMAL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/LSQN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|SPOUSE|NEUROLOGIST|Y|3||39||INDUCTION TREATMENT|1964-07-18||||1971-09-23||1971-08-05|1962-09-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||TMRESP|TUMOR MARKER RESPONSE||||YEARS|PSA PROGRESSION||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|SIBLING|MICROSCOPIST 3|Y|3||39||TREATMENT|1970-11-13||||1962-12-09||1968-06-13|1960-12-25||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||NTRGRESP|NON-TARGET RESPONSE||||PIXELS/IN|TREATMENT FAILURE||LOG10 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|GUARDIAN|NEUROLOGIST|N|4||88||OBSERVATION|1964-09-17||||1962-04-04||1961-01-19|1963-05-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FOZ_BR|MORPHOLOGIC CR||G/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|STUDY SUBJECT|RADIOLOGIST 1|NA|4||88||TREATMENT|1961-03-17||||1963-03-06||1971-06-13|1973-04-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^6 IU|MOLECULAR MAJOR RESPONSE||NU/CL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|PARENT|PATHOLOGIST 1|N|5||7||SCREENING|1970-11-05||||1965-12-09||1969-02-27|1973-05-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||CLINRESP|CLINICAL RESPONSE||||UG/L FEU|CYTOGENETIC CR||USIEMENS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|FAMILY MEMBER|PATHOLOGIST 1|U|5||7||WASHOUT|1973-08-25||||1970-09-14||1960-04-25|1970-12-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/ML|IPR||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|CAREGIVER|MICROSCOPIST 3|U|1||38||BASELINE|1963-10-22||||1971-05-08||1973-04-11|1972-08-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CFU/G|MRD RELAPSE||G/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|SIBLING|OTOLARYNGOLOGIST|N|1||38||FOLLOW-UP|1965-01-04||||1971-05-01||1964-02-12|1966-09-19||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/MS|PR-CT||U/KG/H|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|CHILD|PEDIATRIC NEUROLOGIST|Y|2||58||SCREENING|1963-08-21||||1969-07-23||1965-08-05|1969-02-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||TMRESP|TUMOR MARKER RESPONSE||||WATT|PR WITH LYMPHOCYTOSIS||BEATS/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|SIBLING|DERMATOLOGIST|NA|2||58||RUN-IN|1972-12-21||||1970-12-24||1972-02-20|1966-01-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FARAD|CA125 75% RESPONSE||BOWL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OBSERVATION|1963-09-28||||1967-03-29||1962-04-04|1971-06-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||STRUSTAT|STEROID USE STATUS||||NMOL BCE/L|MR||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||INDUCTION TREATMENT|1962-07-11||||1969-06-23||1971-11-22|1971-09-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||M/SEC|MRD NEGATIVITY||ML/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|INVESTIGATOR|PHYSIOTHERAPIST|U|4||88||TREATMENT|1961-04-28||||1961-12-01||1963-12-18|1971-08-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||NEWLIND|NEW LESION INDICATOR||||PL|IMPROVED||KPA/L/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|INTERVIEWER|CARDIOLOGIST|Y|4||88||RUN-IN|1960-11-23||||1965-07-02||1964-11-23|1969-10-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||ANATRESP|ANATOMIC RESPONSE||||/2500 WBC|MRD RELAPSE||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|FRIEND|READER 3|U|5||7||BASELINE|1969-07-05||||1960-07-21||1965-02-11|1967-02-26||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||QUANTITY SUFFICIENT|MRD NEGATIVITY||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|INVESTIGATOR|ENDOCRINOLOGIST|U|5||7||WASHOUT|1971-12-19||||1964-06-30||1962-05-13|1962-10-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/KG|UNEQUIVOCAL||MG/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|SIBLING|PATHOLOGIST|N|1||38||SCREENING|1964-07-03||||1972-09-12||1969-12-25|1962-06-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CM2|NON-CR/NON-PD||JAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|N|STUDY SUBJECT|RADIOLOGIST 1|U|1||38||RUN-IN|1961-04-12||||1973-02-18||1965-08-04|1972-08-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||LIVRRESP|LIVER RESPONSE||||UG/MIN|TREATMENT FAILURE||FINGERTIP UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|2||58||TREATMENT|1968-07-15||||1960-06-23||1969-10-29|1969-02-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||AFU|PDU||UG/L DDU|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|2||58||OBSERVATION|1971-05-22||||1960-02-07||1963-05-20|1970-02-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||METBRESP|METABOLIC RESPONSE||||ENZYME U/G HB|IMPROVED||CAN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|GUARDIAN|READER 3|U|3||39||LONG-TERM FOLLOW-UP|1964-05-07||||1967-09-22||1960-04-18|1972-11-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||MOLRESP|MOLECULAR RESPONSE||||QUANTITY SUFFICIENT|VGPR||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|3||39||BASELINE|1960-08-23||||1963-10-13||1971-02-17|1960-11-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^12 IU/L|RELAPSED DISEASE FROM CR||UG/ML/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|FRIEND|NEUROLOGIST|U|4||88||OPEN LABEL TREATMENT|1971-04-17||||1967-03-01||1971-01-09|1972-08-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/2000 RBC|MRD NEGATIVITY||CI/L|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|4||88||OBSERVATION|1970-06-27||||1972-03-06||1963-02-21|1966-02-05||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||STRUSTAT|STEROID USE STATUS||||DAYS/WK|CR-CT||UCI/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|FAMILY MEMBER|OPTOMETRIST|U|5||7||LONG-TERM FOLLOW-UP|1972-02-15||||1967-07-19||1968-11-04|1963-10-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/G HB|NON-ICR/NON-IUPD||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|CHILD|ADJUDICATOR 1|U|5||7||RUN-IN|1961-01-05||||1964-04-16||1965-08-29|1970-10-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/CM3/MIN|PSEUDOPROGRESSION||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|RATER 1|N|1||38||SCREENING|1971-09-29||||1968-07-31||1966-08-29|1964-08-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL/MOL|DECREASED||BREATHS/30S|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||INDUCTION TREATMENT|1961-01-02||||1970-07-26||1963-12-13|1971-06-19||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|1||||||BONERESP|BONE RESPONSE||||PPM|ISD||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|DOMESTIC PARTNER|READER|Y|2||58||WASHOUT|1962-05-24||||1971-10-02||1963-03-17|1972-10-03||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NL|NON-ICR/NON-IUPD||UMOL/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|READER|U|2||58||RUN-IN|1967-12-22||||1964-10-24||1971-04-25|1962-03-26||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|1||||||TRGRESP|TARGET RESPONSE||||VIRTUAL PIXEL|MORPHOLOGIC CRI||CI/UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|STUDY SUBJECT|RATER 1|Y|3||39||FOLLOW-UP|1965-03-19||||1962-02-02||1965-12-08|1960-03-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MASK|DECREASED||U/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|FAMILY MEMBER|RATER 1|Y|3||39||OBSERVATION|1967-03-14||||1960-08-16||1967-03-28|1966-07-20||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/H|DISEASE TRANSFORMATION||TUBE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|INVESTIGATOR|DERMATOLOGIST|Y|4||88||SCREENING|1961-09-04||||1963-05-05||1970-05-20|1965-09-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|2||||||LIVRRESP|LIVER RESPONSE||||MG/M2/MIN|CR-CT||ML*CMH2O|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|STUDY SUBJECT|RATER 2|N|4||88||WASHOUT|1962-06-06||||1962-09-06||1971-08-12|1969-02-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MOL/MOL|OPTIMAL MORPHOLOGIC RESPONSE||PL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|FAMILY MEMBER|RATER|Y|5||7||OBSERVATION|1961-02-18||||1965-05-28||1969-12-02|1966-09-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|21934F6E-8333-413B-931C-DF115519F394|2||||||TRGRESP|TARGET RESPONSE||||UG|ISD||BOLUS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|READER 1|U|5||7||BLINDED TREATMENT|1970-03-11||||1971-06-23||1965-12-03|1960-03-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MONTHS|ISD||PPB|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|GUARDIAN|MICROSCOPIST 2|N|1||38||SCREENING|1966-12-06||||1970-12-30||1971-10-17|1963-10-29||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MEQ/G|IUPD||NSEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|INDEPENDENT ASSESSOR|UROLOGIST|NA|1||38||TREATMENT|1969-10-29||||1972-03-01||1961-06-22|1960-02-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/KG/H|EQUIVOCAL||BQ/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|INTERVIEWER|READER 1|U|2||58||FOLLOW-UP|1972-03-06||||1973-01-19||1967-04-11|1960-04-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^9 ORGANISMS/ML|PMR||MEQ/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|CAREGIVER|ADJUDICATOR 2|NA|2||58||OPEN LABEL TREATMENT|1968-04-14||||1960-07-01||1967-01-26|1968-06-22||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MET|CYTOGENETIC NO RESPONSE||MBP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|SIBLING|ONCOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1972-06-24||||1965-03-24||1961-08-21|1963-04-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMHG|CHR||GY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|PARENT|NEUROLOGIST 1|U|3||39||INDUCTION TREATMENT|1969-11-30||||1969-08-07||1971-02-12|1967-04-05||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/M2/MIN|PR WITH LYMPHOCYTOSIS||MNFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|SPOUSE|RADIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1966-04-14||||1964-10-16||1963-05-03|1969-08-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NM|NON-CR/NON-PD||/200 HPFS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|VENDOR|OPTOMETRIST|U|4||88||INDUCTION TREATMENT|1971-05-21||||1973-04-09||1973-02-19|1967-07-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||TRGRESP|TARGET RESPONSE||||ML/DAY|CMR||SQU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1964-11-10||||1973-05-15||1968-06-14|1967-05-31||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MDFI|MOLECULAR CR||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|SPOUSE|MICROSCOPIST 3|N|5||7||LONG-TERM FOLLOW-UP|1961-02-20||||1965-07-01||1969-01-05|1971-07-04||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||STRUSTAT|STEROID USE STATUS||||ANTI-XA IU|INCREASED||PPTR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|ADJUDICATION COMMITTEE|ADJUDICATOR|U|1||38||RUN-IN|1970-05-29||||1967-07-05||1964-04-30|1970-04-30||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MEQ/G|HI-N||C|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|CAREGIVER|INTERNIST|Y|1||38||WASHOUT|1965-12-20||||1972-07-24||1961-09-24|1966-09-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||LIVRRESP|LIVER RESPONSE||||L/L|MORPHOLOGIC CRI||SQU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|FRIEND|PATHOLOGIST 1|N|2||58||TREATMENT|1965-01-31||||1963-10-03||1960-09-26|1968-03-27||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PSEC|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|PROXY|ADJUDICATOR 2|N|2||58||BASELINE|1962-08-10||||1969-01-18||1964-06-23|1962-04-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DISK|NED||FARAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|SIGNIFICANT OTHER|RADIOLOGIST 2|U|3||39||BASELINE|1960-09-25||||1972-01-04||1966-11-25|1973-02-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||TRGRESP|TARGET RESPONSE||||CI/UG|DISEASE TRANSFORMATION||IU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|SIGNIFICANT OTHER|ADJUDICATOR 1|N|3||39||WASHOUT|1964-06-08||||1960-10-26||1961-08-15|1963-04-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||NEWLIND|NEW LESION INDICATOR||||KBQ|MR||MBQ/UL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4||88||FOLLOW-UP|1961-02-23||||1971-10-24||1973-01-15|1963-09-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 PFU|INDETERMINATE RESPONSE||MPL U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|NA|4||88||TREATMENT|1965-05-05||||1961-02-21||1967-06-08|1963-03-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||RDIORESP|RADIOLOGIC RESPONSE||||EU|WORSENED||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|GUARDIAN|UROLOGIST|N|5||7||WASHOUT|1967-10-25||||1964-10-18||1971-02-03|1966-03-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||L/L|PR-CT||ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|SPOUSE|RATER 2|NA|5||7||BLINDED TREATMENT|1968-12-27||||1960-08-08||1962-12-03|1968-11-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||OVRLRESP|OVERALL RESPONSE||||MG/G/H|MR||USEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|FAMILY MEMBER|RATER 2|U|1||38||BASELINE|1964-05-06||||1961-11-17||1969-12-20|1964-04-28||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||NEWLPROG|NEW LESION PROGRESSION||||NGEQ/L|MORPHOLOGIC LEUKEMIA-FREE STATE||KBQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||BLINDED TREATMENT|1965-04-11||||1964-05-23||1964-02-15|1968-12-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||SPLNRESP|SPLEEN RESPONSE||||SBE/ML|DECREASED||SEC|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|ADJUDICATOR|HEMATOLOGIST|N|2||58||OPEN LABEL TREATMENT|1961-10-02||||1972-03-15||1965-12-05|1962-02-27||DURING||DURING|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PMOL/10^9 CELLS|SCR||BQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|ADJUDICATOR|READER 2|Y|2||58||FOLLOW-UP|1966-12-25||||1960-12-04||1965-02-21|1961-08-11||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MPA|MOLECULAR CR||10^5/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|3||39||RUN-IN|1965-06-07||||1968-08-06||1968-09-05|1970-09-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||TMRESP|TUMOR MARKER RESPONSE||||QUANTITY SUFFICIENT|PR WITH LYMPHOCYTOSIS||IN2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||TREATMENT|1965-01-30||||1970-09-22||1961-07-04|1971-05-25||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||ANATRESP|ANATOMIC RESPONSE||||HZ/S|SD||/2000 RBC|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|HEALTH CARE PROFESSIONAL|RATER 1|U|4||88||OBSERVATION|1960-06-20||||1962-09-07||1966-05-25|1968-03-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||NEWLIND|NEW LESION INDICATOR||||CMHG|NE||AMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|4||88||BASELINE|1966-10-20||||1969-01-07||1972-07-20|1972-06-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||LM|PR||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|PARENT|ADJUDICATOR 1|U|5||7||BLINDED TREATMENT|1972-01-18||||1965-03-16||1963-11-25|1973-03-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||SPLNRESP|SPLEEN RESPONSE||||VP/DOSE|QUANTIFIABLE MRD POSITIVITY||MEQ/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1964-02-29||||1960-02-04||1972-07-23|1973-08-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||CLINRESP|CLINICAL RESPONSE||||G/G/DAY|DECREASED||DB|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|1||38||OBSERVATION|1969-11-25||||1966-02-09||1965-02-24|1970-07-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BAU|HI-P||DEG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|1||38||OBSERVATION|1965-04-25||||1962-07-05||1971-03-31|1970-07-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||LIVRRESP|LIVER RESPONSE||||UG/M2/DAY|IMMUNOPHENOTYPIC CR||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1965-02-11||||1970-07-29||1970-12-02|1960-08-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ELISA UNIT/DOSE|MCR||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|PARENT|READER 2|NA|2||58||SCREENING|1967-10-25||||1963-11-21||1962-04-20|1962-02-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^4/L|CYTOGENETIC MINIMAL RESPONSE||U/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|3||39||OPEN LABEL TREATMENT|1970-08-26||||1970-11-29||1966-06-17|1962-12-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SACHET|CYTOGENETIC MINOR RESPONSE||BAU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|SPOUSE|READER 1|NA|3||39||TREATMENT|1972-12-27||||1968-07-17||1961-12-04|1972-03-27||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||BONERESP|BONE RESPONSE||||10^3 CFU|DECREASED||C|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|VENDOR|ADJUDICATOR 1|U|4||88||BASELINE|1969-07-12||||1964-01-05||1964-10-15|1961-01-28||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||HENRY|NON-CR/NON-PD||DNA COPIES/UG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|INTERVIEWER|NEUROLOGIST 1|NA|4||88||FOLLOW-UP|1966-02-10||||1964-04-14||1970-10-15|1961-04-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||TMRESP|TUMOR MARKER RESPONSE||||GBQ/MG|PSA PROGRESSION||G/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|5||7||FOLLOW-UP|1970-12-21||||1967-04-24||1972-08-04|1960-05-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PUFF|UNFAVORABLE RESPONSE||BQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|VENDOR|PATHOLOGIST 2|N|5||7||RUN-IN|1967-10-14||||1971-05-03||1968-10-14|1961-10-03||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^4/HPF|PD FROM PR||MEQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|PROXY|UROLOGIST|U|1||38||OBSERVATION|1963-01-16||||1960-04-30||1966-10-10|1971-08-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||LIVRRESP|LIVER RESPONSE||||MEQ/UL|PCR||TBSP|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1||38||TREATMENT|1967-03-25||||1960-05-21||1961-01-09|1968-08-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BQ/KG|ABSENT MORPHOLOGIC RESPONSE||ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SPOUSE|MICROSCOPIST 1|U|2||58||FOLLOW-UP|1965-07-29||||1966-05-21||1965-01-11|1972-09-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||STRUSTAT|STEROID USE STATUS||||PG/CELL|PDU||10^9 ORGANISMS|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|GUARDIAN|OTOLARYNGOLOGIST|Y|2||58||BASELINE|1965-12-09||||1970-09-27||1968-04-08|1972-04-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/CM|RELAPSED DISEASE FROM CR||YEARS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||LONG-TERM FOLLOW-UP|1967-05-12||||1967-02-04||1971-09-14|1970-02-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||ANATRESP|ANATOMIC RESPONSE||||LINEAR FT*LB|CMR||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|ADJUDICATION COMMITTEE|READER 2|N|3||39||FOLLOW-UP|1971-06-07||||1967-05-13||1967-03-09|1963-12-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CM/MIN|OPTIMAL MORPHOLOGIC RESPONSE||10^6/EJACULATE U|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||WASHOUT|1972-01-27||||1960-05-06||1960-03-31|1970-09-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/ANIMAL/WK|CR||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|INVESTIGATOR|RATER|NA|4||88||BASELINE|1963-03-05||||1968-09-22||1970-11-10|1960-02-04||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||METSIND|METASTATIC INDICATOR||||AMFI|MINOR PATHOLOGIC RESPONSE||10^8/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5||7||FOLLOW-UP|1966-09-27||||1960-02-07||1964-08-24|1971-01-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||AMP|CPR||KBQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1970-10-12||||1970-10-18||1971-07-13|1969-12-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||BONERESP|BONE RESPONSE||||10^6 U|NON-ICR/NON-IUPD||ML/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|PARENT|RATER 1|U|1||38||BASELINE|1962-12-01||||1970-03-24||1972-06-29|1967-06-25||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SIEMENS|VGPR||KHZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|VENDOR|READER 1|NA|1||38||CONTINUATION TREATMENT|1971-06-21||||1963-08-18||1967-06-15|1966-10-21||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 CFU/ML|RELAPSED DISEASE||MU/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|2||58||OBSERVATION|1963-04-15||||1969-02-01||1973-07-07|1964-01-16||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/MMHG/MIN/L|MORPHOLOGIC CRI||IU/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|STUDY SUBJECT|READER 1|N|2||58||INDUCTION TREATMENT|1962-03-22||||1960-02-07||1961-12-11|1967-07-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FMOL|MOLECULAR MAJOR RESPONSE||GENEQ|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|SPOUSE|RADIOLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1966-10-26||||1965-08-13||1965-05-12|1972-09-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||CLINRESP|CLINICAL RESPONSE||||PFU|MAJOR PATHOLOGIC RESPONSE||BP|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|PARENT|ADJUDICATOR|U|3||39||BASELINE|1964-03-15||||1961-03-15||1968-08-15|1970-03-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||ANATRESP|ANATOMIC RESPONSE||||NEBULE|INCREASED||UG/L DDU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|PARENT|RATER 1|Y|4||88||CONTINUATION TREATMENT|1964-01-23||||1960-03-19||1965-07-20|1962-05-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||NEWLIND|NEW LESION INDICATOR||||NMOL BCE/MMOL|INCREASED||APS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|SPOUSE|MICROSCOPIST|NA|4||88||OBSERVATION|1966-10-31||||1965-11-11||1964-06-05|1970-08-14||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||NEWLPROG|NEW LESION PROGRESSION||||MOL/MOL|EQUIVOCAL||CG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|STUDY SUBJECT|ONCOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1964-06-23||||1970-11-01||1963-01-05|1968-01-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||LIVRRESP|LIVER RESPONSE||||MEQ|RELAPSED DISEASE FROM CR OR PR||BLOCKS|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|5||7||BASELINE|1968-12-03||||1960-03-23||1966-04-20|1965-02-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||METBRESP|METABOLIC RESPONSE||||CM/S|PD-CT||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|PROXY|MICROSCOPIST|U|1||38||INDUCTION TREATMENT|1966-10-16||||1962-09-04||1965-01-13|1963-12-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||TRGRESP|TARGET RESPONSE||||IU/MG|NON-QUANTIFIABLE MRD POSITIVITY||G/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|FAMILY MEMBER|INTERNIST|U|1||38||BASELINE|1966-07-23||||1971-06-25||1970-11-13|1966-12-05||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||SPLNRESP|SPLEEN RESPONSE||||MOSM|PCR||COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|FRIEND|OPTOMETRIST|NA|2||58||CONTINUATION TREATMENT|1967-03-11||||1966-07-23||1968-07-13|1969-06-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/S/M2|ABSENT MORPHOLOGIC RESPONSE||EU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|U|2||58||OBSERVATION|1967-05-03||||1969-07-27||1973-09-06|1966-06-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||ANATRESP|ANATOMIC RESPONSE||||BE/ML|PMD||NMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|FAMILY MEMBER|RATER|U|3||39||RUN-IN|1963-12-16||||1972-06-04||1969-06-29|1971-12-12||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||RDIORESP|RADIOLOGIC RESPONSE||||/4.0 ML|PSA PROGRESSION||SHOCK WAVE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|NA|3||39||OBSERVATION|1961-04-02||||1967-06-09||1963-08-10|1965-10-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||OVRLRESP|OVERALL RESPONSE||||BQ/UG|ICR||ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|FAMILY MEMBER|READER 1|Y|4||88||SCREENING|1973-02-05||||1970-01-04||1971-08-28|1968-06-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML|CMR||G/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|HEALTH CARE PROFESSIONAL|READER 3|U|4||88||RUN-IN|1972-10-28||||1961-01-19||1963-01-19|1966-11-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||QUANTITY SUFFICIENT|CA125 50% RESPONSE||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|5||7||OPEN LABEL TREATMENT|1962-12-10||||1962-05-03||1972-04-17|1966-01-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/KG/MIN|NON-QUANTIFIABLE MRD POSITIVITY||SBE/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INTERVIEWER|RATER 2|N|5||7||RUN-IN|1969-03-24||||1968-01-12||1964-11-15|1964-12-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||OVRLRESP|OVERALL RESPONSE||||JOULE|RELAPSED DISEASE||PATCH|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|CAREGIVER|PATHOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1961-12-22||||1960-10-12||1964-09-07|1963-07-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MESF|RELAPSED DISEASE FROM CR||PPTR|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|CHILD|RATER 1|U|1||38||LONG-TERM FOLLOW-UP|1966-12-07||||1961-12-24||1972-11-18|1972-02-12||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||BONERESP|BONE RESPONSE||||TUBE|ICPD||DYN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|INTERVIEWER|READER 2|U|2||58||SCREENING|1967-11-17||||1971-02-23||1963-03-23|1965-06-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||U/G/H|CA125 50% RESPONSE||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CLINICAL RESEARCH COORDINATOR|READER 2|N|2||58||INDUCTION TREATMENT|1965-08-28||||1970-08-06||1970-11-13|1963-08-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||BONERESP|BONE RESPONSE||||PACK YEAR|PMD||MU/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|FRIEND|RADIOLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1960-05-24||||1970-09-15||1968-01-08|1960-10-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SYRINGE|IUPD||DPM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|FAMILY MEMBER|NEUROLOGIST|U|3||39||BLINDED TREATMENT|1962-12-30||||1972-05-04||1965-10-02|1965-06-04||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6 ORGANISMS/ML|EQUIVOCAL||GY/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|SIBLING|NEUROLOGIST 1|N|4||88||FOLLOW-UP|1969-05-12||||1972-09-07||1962-09-10|1970-01-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PKAT/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^3 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|INVESTIGATOR|RADIOLOGIST 1|Y|4||88||BASELINE|1967-08-04||||1960-01-16||1962-11-20|1973-07-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^12/L|PD||PG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|5||7||FOLLOW-UP|1961-11-29||||1972-01-02||1961-03-20|1968-08-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CD/M2|MOLECULAR MAJOR RESPONSE||L|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|5||7||FOLLOW-UP|1971-08-21||||1968-08-05||1961-07-04|1967-03-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UL/ML|HI-E||HPA|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|CHILD|NEUROLOGIST 2|Y|1||38||BASELINE|1973-02-19||||1963-06-29||1961-11-17|1963-07-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KBQ|INDETERMINATE RESPONSE||GBQ|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CAREGIVER|READER|NA|1||38||SCREENING|1970-08-21||||1963-10-28||1968-09-18|1962-08-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MEQ/ML|UNFAVORABLE RESPONSE||BAR|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|PARENT|PEDIATRIC NEUROLOGIST|Y|2||58||BASELINE|1969-03-20||||1960-01-10||1963-08-13|1961-01-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CMOL|IMPROVED||ML/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|INVESTIGATOR|ENDOCRINOLOGIST|NA|2||58||OBSERVATION|1966-05-06||||1971-04-02||1973-02-22|1972-12-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||METBRESP|METABOLIC RESPONSE||||CARTRIDGE|TREATMENT FAILURE||ENZYME U|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|FRIEND|HEMATOLOGIST|N|3||39||TREATMENT|1965-02-23||||1973-08-23||1973-06-10|1972-02-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||METBRESP|METABOLIC RESPONSE||||CPM|ICPD||MPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|GUARDIAN|PHYSIOTHERAPIST|Y|3||39||WASHOUT|1965-12-14||||1962-07-23||1972-09-21|1961-12-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MET*MIN|MINOR PATHOLOGIC RESPONSE||NMOL BCE/MMOL|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|CAREGIVER|ADJUDICATOR 3|U|4||88||BASELINE|1966-12-09||||1973-06-28||1961-10-08|1969-01-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||YEARS|CYTOGENETIC PR||ANSON U|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|CAREGIVER|DERMATOLOGIST|U|4||88||CONTINUATION TREATMENT|1972-01-09||||1970-01-16||1966-06-22|1968-01-16||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/DAY|RELAPSED DISEASE FROM CR||/VF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|GUARDIAN|RADIOLOGIST|U|5||7||CONTINUATION TREATMENT|1962-11-23||||1962-11-28||1964-08-16|1966-11-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^9/L|RELAPSED DISEASE FROM CR OR PR||KPA/L/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|5||7||FOLLOW-UP|1971-07-09||||1972-10-11||1972-01-10|1964-06-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/ANIMAL|CR-CT||UCI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|CHILD|READER|Y|1||38||OBSERVATION|1960-12-06||||1962-07-15||1967-05-13|1964-07-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||IU/DAY|SD-CT||UEQ/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1970-04-13||||1967-04-04||1962-01-10|1961-03-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||STRUSTAT|STEROID USE STATUS||||10^6 RNA COPIES/ML|NE||%(V/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|CHILD|ADJUDICATOR|N|2||58||SCREENING|1963-12-28||||1973-01-31||1970-02-23|1965-11-16||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||PATHRESP|PATHOLOGIC RESPONSE||||QUANTITY SUFFICIENT|ISD||OHM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|ADJUDICATOR|READER|N|2||58||INDUCTION TREATMENT|1965-11-01||||1963-04-12||1973-05-09|1962-02-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||NTRGRESP|NON-TARGET RESPONSE||||ELISA UNIT/ML|MINOR PATHOLOGIC RESPONSE||U/DL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1961-05-01||||1970-01-13||1971-12-13|1969-05-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/500 WBC|CA125 50% RESPONSE||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|ADJUDICATOR|RATER|Y|3||39||BLINDED TREATMENT|1970-10-26||||1964-10-01||1968-10-08|1970-09-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^9 ORGANISMS|NON-QUANTIFIABLE MRD POSITIVITY||DRINK|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|SPOUSE|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1963-05-20||||1971-07-04||1963-03-12|1961-04-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/KG/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||10^12/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|4||88||FOLLOW-UP|1973-06-08||||1969-07-12||1970-08-30|1968-09-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||ANATRESP|ANATOMIC RESPONSE||||UMOL/L|RELAPSED DISEASE FROM CR||SHOCK WAVE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|STUDY SUBJECT|OPHTHALMOLOGIST|NA|5||7||SCREENING|1965-10-03||||1972-07-11||1967-04-23|1971-10-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||ANATRESP|ANATOMIC RESPONSE||||10^8/L|MR||V/V|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|INTERVIEWER|INTERNIST|U|5||7||WASHOUT|1962-01-16||||1971-06-04||1971-01-19|1963-03-21||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||SIEMENS|PDU||DRINK|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|NA|INVESTIGATOR|HEMATOLOGIST|N|1||38||TREATMENT|1962-09-26||||1973-07-18||1972-09-06|1972-03-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||IN2|NPR||%(W/W)|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|VENDOR|NEUROLOGIST 1|Y|1||38||BASELINE|1960-01-23||||1967-07-08||1969-02-21|1967-03-24||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||NEWLPROG|NEW LESION PROGRESSION||||G/DL|CCR||UG/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|DOMESTIC PARTNER|NEUROLOGIST|N|2||58||INDUCTION TREATMENT|1971-11-20||||1961-01-16||1971-08-26|1969-11-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/DAY|CYTOGENETIC NO RESPONSE||NM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|SIGNIFICANT OTHER|RATER 2|U|2||58||SCREENING|1961-10-31||||1973-06-03||1969-09-05|1972-08-20||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 TCID 50/UL|IMPROVED||AMPULE|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|HEALTH CARE PROFESSIONAL|READER 3|U|3||39||WASHOUT|1965-04-11||||1965-07-30||1963-06-30|1973-05-28||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||RATIO|MAJOR PATHOLOGIC RESPONSE||KUSP|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|SPOUSE|ADJUDICATOR 3|Y|3||39||LONG-TERM FOLLOW-UP|1969-10-30||||1971-06-09||1966-04-09|1960-04-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CM2|CYTOGENETIC MINOR RESPONSE||10^9/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|STUDY SUBJECT|MICROSCOPIST 2|N|4||88||LONG-TERM FOLLOW-UP|1969-07-16||||1968-12-27||1960-06-15|1970-01-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KG|UNFAVORABLE RESPONSE||10^8/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|4||88||RUN-IN|1962-05-19||||1961-10-18||1960-12-19|1964-12-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||CLINRESP|CLINICAL RESPONSE||||OZ EQ|NPR||CAPLET|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|CLINICAL RESEARCH COORDINATOR|READER 3|N|5||7||FOLLOW-UP|1960-05-12||||1961-03-18||1961-09-20|1962-08-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PMOL/G|MRD PERSISTENCE||10^7/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|5||7||WASHOUT|1973-05-28||||1970-01-06||1961-03-20|1962-08-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||BONERESP|BONE RESPONSE||||TUBERCULIN UNIT|MR||BAU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|SIGNIFICANT OTHER|NEUROLOGIST 2|NA|1||38||BASELINE|1961-04-28||||1969-08-23||1961-03-10|1966-11-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FG|NE||MHZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|VENDOR|NEUROLOGIST 1|N|1||38||BLINDED TREATMENT|1963-12-18||||1966-12-28||1967-08-06|1966-02-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MOSM/KG|DISEASE TRANSFORMATION||MBP|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|2||58||OBSERVATION|1964-12-03||||1961-09-17||1972-03-29|1968-02-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||%|ISD||MG/KG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|FAMILY MEMBER|PATHOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1964-07-01||||1971-06-06||1968-12-10|1968-08-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||SPLNRESP|SPLEEN RESPONSE||||GRAIN|RELAPSED DISEASE FROM CR OR PR||SCM|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|ADJUDICATOR|DERMATOLOGIST|U|3||39||RUN-IN|1964-06-21||||1961-02-02||1967-10-30|1970-10-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||LIVRRESP|LIVER RESPONSE||||PACKAGE|PMR||JAR|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|FRIEND|ADJUDICATOR|N|3||39||CONTINUATION TREATMENT|1970-10-13||||1960-03-22||1968-10-19|1965-06-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||STRUSTAT|STEROID USE STATUS||||BQ/G|MINOR PATHOLOGIC RESPONSE||L/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|SPOUSE|NEUROLOGIST 1|NA|4||88||INDUCTION TREATMENT|1964-01-07||||1961-10-20||1972-03-12|1964-01-08||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MCI/KG|PR-CT||PG/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|VENDOR|PATHOLOGIST|NA|4||88||OBSERVATION|1966-10-29||||1961-08-15||1963-12-10|1973-07-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EQ|NON-PD||STEPS|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|READER 3|N|5||7||LONG-TERM FOLLOW-UP|1966-10-03||||1970-10-12||1967-09-23|1962-01-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||METSIND|METASTATIC INDICATOR||||UG/DL|VGPR||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|5||7||BASELINE|1972-05-31||||1962-11-05||1965-09-29|1961-11-30||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||KS|PMR||LM|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|GUARDIAN|NEUROLOGIST|NA|1||38||INDUCTION TREATMENT|1963-09-08||||1966-07-04||1971-01-15|1972-07-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^6 CFU/G|RELAPSED DISEASE FROM CR||TORR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|SPOUSE|OTOLARYNGOLOGIST|U|1||38||BASELINE|1961-06-24||||1972-03-06||1970-12-25|1966-02-02||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UKAT/10^12 RBC|MAJOR PATHOLOGIC RESPONSE||/LPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|SIBLING|ADJUDICATOR 1|N|2||58||CONTINUATION TREATMENT|1972-04-27||||1963-06-28||1973-04-02|1970-10-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DPM|DISEASE TRANSFORMATION||OHM|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|SIBLING|ADJUDICATOR 2|N|2||58||OBSERVATION|1972-02-18||||1965-06-10||1972-12-12|1969-03-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/DAY|ABSENT MORPHOLOGIC RESPONSE||BU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1970-01-22||||1963-06-16||1960-12-13|1969-04-01||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MANSON U/ML|INDETERMINATE RESPONSE||PACKET|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|CHILD|PATHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1963-06-22||||1963-07-17||1966-03-24|1967-10-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||NEWLIND|NEW LESION INDICATOR||||SCM|CPR||/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|4||88||TREATMENT|1973-07-30||||1963-02-11||1971-11-09|1960-11-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||VOXEL|PR-CT||SFC/10^6 PBMC|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|4||88||OBSERVATION|1961-05-20||||1960-03-09||1971-09-12|1972-10-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||NEWLIND|NEW LESION INDICATOR||||MG/M2/H|ISD||KG/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|5||7||TREATMENT|1970-01-31||||1970-10-09||1971-07-17|1962-08-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KUSP|NED||UG/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|SIGNIFICANT OTHER|PATHOLOGIST|N|5||7||OBSERVATION|1960-12-10||||1961-08-09||1962-06-03|1961-04-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/DAY|PARTIAL MORPHOLOGIC RESPONSE||G/G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|FAMILY MEMBER|READER 3|NA|1||38||WASHOUT|1966-12-31||||1973-04-03||1972-08-20|1965-11-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||S*KPA|CRI||UKAT/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|PROXY|ENDOCRINOLOGIST|Y|1||38||OBSERVATION|1963-01-12||||1964-02-13||1972-10-02|1965-11-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||BONERESP|BONE RESPONSE||||NMOL|WORSENED||VOXEL|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|2||58||FOLLOW-UP|1970-06-28||||1969-10-06||1964-07-11|1968-07-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MCI/L|PCR||10^6 U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|SIGNIFICANT OTHER|PATHOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1972-09-01||||1969-07-14||1971-10-10|1960-08-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||METSIND|METASTATIC INDICATOR||||MM2|CR||NMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1971-12-07||||1973-05-12||1970-08-07|1969-01-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||C|CPR||NEBULE|NOT DONE|||LIKERT SCALE 5-POINT|N|N|U|INTERVIEWER|CARDIOLOGIST|U|3||39||BASELINE|1962-05-17||||1962-07-30||1966-09-08|1962-12-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||BQ/L|MORPHOLOGIC CR||MG2/DL2|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|CHILD|NEUROLOGIST 1|N|4||88||SCREENING|1969-02-09||||1963-08-31||1964-04-12|1972-09-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||LIVRRESP|LIVER RESPONSE||||LB|PR||MPH|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|4||88||BASELINE|1961-10-15||||1968-10-11||1961-02-24|1972-03-17||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||CLINRESP|CLINICAL RESPONSE||||HOMEOPATHIC DILUTION|PDU||CAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|SIBLING|ONCOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1963-04-01||||1969-09-19||1961-12-07|1960-11-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/L|MOLECULAR MAJOR RESPONSE||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|5||7||BASELINE|1972-01-01||||1965-01-09||1964-12-19|1968-08-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||METBRESP|METABOLIC RESPONSE||||UG/DAY|EQUIVOCAL||NKAT/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|SIBLING|ONCOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1961-10-12||||1971-09-22||1972-02-21|1971-12-07||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||CYTORESP|CYTOGENETIC RESPONSE||||APS U|OPTIMAL MORPHOLOGIC RESPONSE||NMOL/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|FRIEND|OPHTHALMOLOGIST|Y|1||38||OBSERVATION|1969-02-12||||1962-12-16||1960-09-08|1961-04-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/CAGE/WK|PMR||ML/CM H2O|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|U|2||58||TREATMENT|1970-10-12||||1963-09-06||1968-11-13|1961-07-27||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/KG/H|MCR||10^4 CFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|SPOUSE|READER 2|N|2||58||CONTINUATION TREATMENT|1969-09-14||||1968-03-10||1967-08-09|1962-11-04||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||TRGRESP|TARGET RESPONSE||||/4.0 ML|PD FROM PR||UMOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|CAREGIVER|ADJUDICATOR 1|NA|3||39||BASELINE|1960-11-19||||1970-01-01||1971-11-26|1962-10-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||NEWLIND|NEW LESION INDICATOR||||GLOBULE|CHR||U/MMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|3||39||INDUCTION TREATMENT|1961-06-15||||1966-03-17||1965-03-02|1960-04-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^9 ORGANISMS/G|MORPHOLOGIC LEUKEMIA-FREE STATE||UG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|CHILD|PHYSIOTHERAPIST|N|4||88||WASHOUT|1973-08-17||||1960-01-28||1973-01-09|1968-05-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^10/L|INCREASED||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|SPOUSE|MICROSCOPIST 1|Y|4||88||BASELINE|1966-01-17||||1970-12-11||1971-10-06|1967-08-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPSULE|HI-N||UM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|Y|5||7||INDUCTION TREATMENT|1967-04-22||||1963-11-20||1970-02-23|1968-01-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||SPLNRESP|SPLEEN RESPONSE||||/40 HPFS|CRI||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|FAMILY MEMBER|MICROSCOPIST 2|Y|5||7||OBSERVATION|1972-01-14||||1971-12-26||1970-07-25|1968-06-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||COPIES/UL|PCR||LX|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|GUARDIAN|MICROSCOPIST 1|U|1||38||OPEN LABEL TREATMENT|1971-06-21||||1970-11-22||1970-08-18|1966-05-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||BONERESP|BONE RESPONSE||||BQ|NPR||UG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|1||38||RUN-IN|1970-08-08||||1962-12-06||1969-08-10|1964-04-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||METSIND|METASTATIC INDICATOR||||UEQ|INDETERMINATE RESPONSE||MG/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|STUDY SUBJECT|RADIOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1964-11-06||||1963-09-26||1965-12-03|1971-06-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||BESTRESP|BEST OVERALL RESPONSE||||JAR|SCR||G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1963-07-20||||1960-11-16||1971-07-18|1969-01-03||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PPTR|NR||TABLET|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|NON-HEALTH CARE PROFESSIONAL|READER|NA|3||39||OBSERVATION|1961-03-17||||1965-06-10||1970-12-08|1963-05-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UV2|PD FROM PR||L/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|SIBLING|DERMATOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1973-01-23||||1972-07-30||1962-01-21|1963-02-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||NEWLIND|NEW LESION INDICATOR||||/10^5|PR||G/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|INVESTIGATOR|NEUROLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1968-12-11||||1964-01-19||1961-05-04|1966-12-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||LENS|SD-CT||10^4 CFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|SPOUSE|INTERNIST|NA|4||88||OPEN LABEL TREATMENT|1965-01-11||||1973-02-23||1962-03-06|1962-01-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/MIN|MOLECULAR MAJOR RESPONSE||U/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|SPOUSE|RADIOLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1972-07-11||||1966-02-10||1973-02-12|1973-09-05||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||TRGRESP|TARGET RESPONSE||||UG/M2/MIN|ICR||ML/M2/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|FAMILY MEMBER|RADIOLOGIST 1|N|5||7||FOLLOW-UP|1972-08-01||||1961-09-28||1966-09-15|1967-03-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||NTRGRESP|NON-TARGET RESPONSE||||KIT|NOT ALL EVALUATED||YD|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|FRIEND|RATER 2|U|1||38||OPEN LABEL TREATMENT|1968-01-13||||1962-10-14||1962-11-16|1962-08-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||TMRESP|TUMOR MARKER RESPONSE||||BEAM BREAKS|STABLE||%|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|ADJUDICATOR|READER|N|1||38||RUN-IN|1971-08-17||||1961-08-02||1968-04-22|1965-08-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||BONERESP|BONE RESPONSE||||M2|MR||MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|2||58||BLINDED TREATMENT|1962-09-14||||1966-02-24||1971-03-20|1967-06-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||L/L|UNEQUIVOCAL||/10^3|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|SIGNIFICANT OTHER|MICROSCOPIST 3|N|2||58||BASELINE|1961-06-23||||1965-11-24||1961-01-30|1962-12-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||TRGRESP|TARGET RESPONSE||||U/CL|PD FROM PR||H*%|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|SPOUSE|MICROSCOPIST 1|NA|3||39||WASHOUT|1972-08-09||||1961-12-07||1960-11-30|1968-05-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||MOLRESP|MOLECULAR RESPONSE||||10^5/HPF|INDETERMINATE RESPONSE||KG/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|3||39||OBSERVATION|1965-02-15||||1962-10-22||1970-04-10|1967-10-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||ANATRESP|ANATOMIC RESPONSE||||MV/SEC|MRD NEGATIVITY||FMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|STUDY SUBJECT|MICROSCOPIST 2|NA|4||88||TREATMENT|1964-08-06||||1964-03-31||1970-04-01|1961-11-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/200 HPFS|HI-N||COAT|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|GUARDIAN|ONCOLOGIST|N|4||88||WASHOUT|1965-03-16||||1970-09-03||1965-01-16|1967-10-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||OVRLRESP|OVERALL RESPONSE||||10^3/HPF|PSA PROGRESSION||U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|GUARDIAN|RATER 2|N|5||7||FOLLOW-UP|1966-06-12||||1972-02-21||1961-07-25|1968-09-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||TMRESP|TUMOR MARKER RESPONSE||||MONTHS|PMD||1/(S*KPA)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|5||7||BASELINE|1972-12-11||||1961-07-22||1965-12-31|1963-10-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|1||||||STRUSTAT|STEROID USE STATUS||||MMOL/S|INDETERMINATE RESPONSE||SUPPOSITORY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|1||38||WASHOUT|1963-10-15||||1969-02-22||1973-06-11|1964-11-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LENS|SMD||GTT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|INVESTIGATOR|NEUROLOGIST|NA|1||38||INDUCTION TREATMENT|1968-06-08||||1964-04-30||1963-07-01|1970-09-16||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|1||||||METSIND|METASTATIC INDICATOR||||L/L|PR-CT||S^-1(%O2)^-1|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|SIBLING|MICROSCOPIST|Y|2||58||OBSERVATION|1963-08-29||||1965-06-22||1966-09-22|1972-10-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DDU|HI-N||PMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|PARENT|PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1964-11-14||||1972-04-16||1965-09-16|1966-12-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|1||||||NEWLPROG|NEW LESION PROGRESSION||||FEU|PCR||MOSM/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|GUARDIAN|PATHOLOGIST 1|NA|3||39||SCREENING|1960-02-14||||1970-04-20||1971-10-26|1966-05-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/MG|CR-CT||MAC50|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|CHILD|OTOLARYNGOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1971-02-09||||1962-06-13||1971-02-17|1964-02-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PG/DL|STABLE||USP U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|4||88||CONTINUATION TREATMENT|1962-02-22||||1968-07-04||1971-04-13|1962-08-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/KG/H|CA125 50% RESPONSE||MG/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|DOMESTIC PARTNER|READER 3|N|4||88||RUN-IN|1962-03-05||||1967-11-20||1972-04-30|1967-07-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|1||||||NEWLIND|NEW LESION INDICATOR||||ML/CAGE/DAY|PSA PROGRESSION||/SEC|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|GUARDIAN|OTOLARYNGOLOGIST|Y|5||7||INDUCTION TREATMENT|1964-03-02||||1971-01-31||1962-02-23|1972-05-11||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFF30783-4496-4134-8201-67C727683A7D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NKAT|PSEUDORESPONSE||10^6 CFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||OBSERVATION|1966-05-15||||1963-04-17||1965-11-01|1966-05-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||STRUSTAT|STEROID USE STATUS||||PLUG|HI-E||MMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||BLINDED TREATMENT|1965-09-25||||1966-09-17||1971-08-31|1965-11-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U/ANIMAL|RELAPSED DISEASE FROM CR||BE/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|1||38||SCREENING|1971-06-22||||1968-09-20||1962-09-25|1968-09-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||METBRESP|METABOLIC RESPONSE||||GY/H|ICR||DEG/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|CHILD|OTOLARYNGOLOGIST|U|2||58||SCREENING|1967-02-28||||1965-12-23||1963-05-31|1970-10-09||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||CYTORESP|CYTOGENETIC RESPONSE||||AGU/ML|PSA PROGRESSION||NG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|ADJUDICATOR|OPHTHALMOLOGIST|N|2||58||BASELINE|1970-02-14||||1967-02-24||1969-03-26|1969-05-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MCI/KG|PR-CT||CD|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|STUDY SUBJECT|OPHTHALMOLOGIST|NA|3||39||SCREENING|1963-09-05||||1973-06-18||1971-06-04|1967-09-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||METSIND|METASTATIC INDICATOR||||10^4/HPF|UNFAVORABLE RESPONSE||LOG EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CAREGIVER|OTOLARYNGOLOGIST|Y|3||39||CONTINUATION TREATMENT|1973-06-03||||1962-06-06||1970-04-28|1969-11-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/CMH2O|NON-QUANTIFIABLE MRD POSITIVITY||ML/DL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|CHILD|PATHOLOGIST 2|U|4||88||OBSERVATION|1970-09-13||||1964-07-27||1971-10-18|1970-09-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||METBRESP|METABOLIC RESPONSE||||MGEQ|CYTOGENETIC CR||NU/CL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|ADJUDICATOR|ADJUDICATOR 3|N|4||88||FOLLOW-UP|1969-08-14||||1969-06-01||1972-09-01|1971-02-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||JAR|MRD NEGATIVITY||FMOL/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|PARENT|RATER 2|NA|5||7||CONTINUATION TREATMENT|1964-08-11||||1964-06-20||1972-09-25|1962-02-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MG|MORPHOLOGIC CR||U/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|SIBLING|ADJUDICATOR 2|Y|5||7||BLINDED TREATMENT|1970-08-26||||1973-08-25||1963-07-15|1973-05-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||RDIORESP|RADIOLOGIC RESPONSE||||%(W/W)|NON-QUANTIFIABLE MRD POSITIVITY||BAU|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|PARENT|ONCOLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1969-05-04||||1973-05-10||1967-02-10|1967-06-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/DAY|DECREASED||RATIO|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||BLINDED TREATMENT|1963-02-10||||1969-07-04||1964-07-05|1970-08-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||METSIND|METASTATIC INDICATOR||||G/M2/DAY|MORPHOLOGIC CR||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|SPOUSE|ONCOLOGIST|N|2||58||OPEN LABEL TREATMENT|1963-12-29||||1972-03-26||1966-11-19|1965-10-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||CLINRESP|CLINICAL RESPONSE||||/2500 WBC|SCR||RATIO|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|PARENT|NEUROLOGIST 1|Y|2||58||BASELINE|1960-09-15||||1971-05-17||1964-07-11|1970-03-31||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MILE|WORSENED||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|INTERVIEWER|READER 3|Y|3||39||WASHOUT|1973-05-09||||1961-06-08||1971-12-11|1963-04-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||NMOL BCE/NMOL|CYTOGENETIC MINOR RESPONSE||100 IU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|INVESTIGATOR|READER|N|3||39||RUN-IN|1968-03-22||||1961-06-06||1966-08-07|1971-02-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||YD|CHR||FOZ_BR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|SIGNIFICANT OTHER|ONCOLOGIST|N|4||88||BASELINE|1961-12-19||||1967-10-14||1970-05-29|1968-07-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||TBSP|PDU||/4.0 ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|GUARDIAN|MICROSCOPIST 2|N|4||88||TREATMENT|1964-11-20||||1966-10-21||1964-11-14|1969-02-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^7 CFU|ISD||DPM/0.5 ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|PROXY|UROLOGIST|Y|5||7||RUN-IN|1963-10-12||||1969-08-16||1963-06-07|1961-09-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||TMRESP|TUMOR MARKER RESPONSE||||PG/L|CYTOGENETIC CR||DAYS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|SIGNIFICANT OTHER|ONCOLOGIST|Y|5||7||WASHOUT|1970-11-09||||1962-09-05||1965-06-20|1971-03-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||ANATRESP|ANATOMIC RESPONSE||||IU|NON-PD||10^3/HPF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|CAREGIVER|NEUROLOGIST|U|1||38||SCREENING|1967-08-22||||1964-12-07||1968-11-17|1961-04-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||NTRGRESP|NON-TARGET RESPONSE||||VOXEL|RELAPSED DISEASE FROM CR OR PR||AMFI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|INVESTIGATOR|PATHOLOGIST 1|U|1||38||TREATMENT|1972-11-11||||1964-12-31||1971-01-23|1963-11-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UCI/L|MRD PERSISTENCE||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|CHILD|READER 3|Y|2||58||INDUCTION TREATMENT|1970-01-14||||1972-11-09||1964-06-02|1971-10-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/KG/H|MRD RELAPSE||PLUG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||OPEN LABEL TREATMENT|1973-08-25||||1965-04-03||1968-07-17|1960-03-26||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^9 ORGANISMS|PR-CT||/4.0 ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|PARENT|OTOLARYNGOLOGIST|U|3||39||OPEN LABEL TREATMENT|1970-08-26||||1966-01-08||1970-07-06|1967-10-07||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||BONERESP|BONE RESPONSE||||UG/L FEU|PCR||ML/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|3||39||WASHOUT|1960-07-23||||1961-10-03||1964-01-19|1967-11-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||METSIND|METASTATIC INDICATOR||||UG/L/H|PD FROM PR||MG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|4||88||CONTINUATION TREATMENT|1963-12-27||||1973-07-30||1965-07-12|1972-03-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/100G/MIN|CMR||ML/G/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|CAREGIVER|NEUROLOGIST 2|U|4||88||CONTINUATION TREATMENT|1963-11-13||||1962-11-13||1962-03-30|1970-03-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||BONERESP|BONE RESPONSE||||RING|MRD RELAPSE||10^6 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|5||7||OBSERVATION|1964-06-27||||1972-12-08||1972-07-08|1972-11-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||NEWLIND|NEW LESION INDICATOR||||LOG10 ELISA UNIT/DOSE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/10^4|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|GUARDIAN|READER|Y|5||7||RUN-IN|1968-11-06||||1971-02-19||1966-10-09|1960-04-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||CLINRESP|CLINICAL RESPONSE||||L/L|COMPLETE MRD RESPONSE||MOSM/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|CHILD|ADJUDICATOR|NA|1||38||RUN-IN|1972-12-28||||1967-10-16||1960-05-01|1962-06-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MEQ|CA125 75% RESPONSE||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1||38||WASHOUT|1965-04-04||||1964-11-10||1972-04-12|1973-05-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/KG|SMD||IU/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|CHILD|RADIOLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1960-11-18||||1967-08-22||1964-10-25|1972-11-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||NEWLPROG|NEW LESION PROGRESSION||||MEQ/DL|ICR||MMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|FRIEND|RATER 1|NA|2||58||OPEN LABEL TREATMENT|1962-11-25||||1963-05-22||1966-07-23|1971-02-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 TCID 50/DOSE|MRD RELAPSE||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|N|INTERVIEWER|ADJUDICATOR 3|U|3||39||SCREENING|1962-06-20||||1973-03-27||1968-05-27|1962-12-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||SPLNRESP|SPLEEN RESPONSE||||UEQ/L|PMR||ANTI-XA IU|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1963-10-01||||1961-10-07||1963-08-26|1963-10-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL/DAY|PCR||VIRTUAL PIXEL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|VENDOR|HEMATOLOGIST|NA|4||88||INDUCTION TREATMENT|1965-10-21||||1961-07-20||1969-02-22|1960-02-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||NTRGRESP|NON-TARGET RESPONSE||||U/M2/MIN|INDETERMINATE RESPONSE||MEQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1964-04-02||||1971-01-13||1961-07-18|1960-11-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/MOL|CRI||CI/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|ADJUDICATOR|ADJUDICATOR 2|Y|5||7||LONG-TERM FOLLOW-UP|1961-07-04||||1971-09-26||1963-03-22|1968-10-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||TRGRESP|TARGET RESPONSE||||CFU/G|PR||UG/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|GUARDIAN|DERMATOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1966-04-10||||1972-10-29||1971-02-14|1972-04-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/SEC/1.73M2|CPR||BOLUS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|1||38||BLINDED TREATMENT|1968-10-18||||1970-08-26||1961-11-29|1971-11-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||1/(S*KPA)|HI-P||F|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|FRIEND|RADIOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1969-05-15||||1966-04-30||1968-12-29|1969-03-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MEQ/ML|STABLE||PA|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|N|2||58||FOLLOW-UP|1967-08-12||||1966-12-08||1967-11-13|1968-10-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GRAIN|ISD||UL/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|CHILD|READER 1|NA|2||58||LONG-TERM FOLLOW-UP|1960-08-25||||1970-05-10||1973-05-31|1966-10-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||STRUSTAT|STEROID USE STATUS||||DEG/S|PMR||10^3 CFU|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|DOMESTIC PARTNER|ADJUDICATOR 3|U|3||39||BLINDED TREATMENT|1966-05-24||||1962-06-02||1962-03-22|1970-01-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||TUBERCULIN UNIT/ML|CA125 50% RESPONSE||NMOL BCE/MMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|SPOUSE|READER 2|U|3||39||BASELINE|1962-11-28||||1960-07-29||1966-01-23|1971-06-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PFU/ANIMAL|QUANTIFIABLE MRD POSITIVITY||ML/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||SCREENING|1968-12-28||||1972-02-13||1973-09-08|1960-08-31||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||STRUSTAT|STEROID USE STATUS||||ANTIBODY UNIT|VGPR||ML/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|4||88||CONTINUATION TREATMENT|1972-09-04||||1968-01-14||1963-09-20|1963-07-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||TMRESP|TUMOR MARKER RESPONSE||||NGEQ/L|CR-CT||DPM/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|CAREGIVER|ADJUDICATOR 3|Y|5||7||INDUCTION TREATMENT|1967-02-28||||1960-03-28||1964-06-08|1962-02-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/L/H|MRD NEGATIVITY||UMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|VENDOR|MICROSCOPIST 2|NA|5||7||BASELINE|1973-04-15||||1962-06-19||1970-10-11|1970-04-12||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||LIVRRESP|LIVER RESPONSE||||10^7 PFU|IUPD||LOG10 PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|N|1||38||RUN-IN|1964-12-31||||1965-01-09||1967-12-20|1971-09-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MOSM/L|CHR||KAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|SIGNIFICANT OTHER|ADJUDICATOR|N|1||38||OPEN LABEL TREATMENT|1971-11-16||||1973-04-06||1970-03-01|1968-12-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||TRGRESP|TARGET RESPONSE||||AMU|IUPD||DAYS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||BLINDED TREATMENT|1971-08-04||||1964-10-03||1960-06-05|1964-07-03||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 CFU/ML|ICPD||MMOL/S|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|VENDOR|UROLOGIST|U|2||58||OPEN LABEL TREATMENT|1970-07-08||||1968-01-19||1972-12-05|1961-07-11||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||MOLRESP|MOLECULAR RESPONSE||||JDF UNIT|PSA PROGRESSION||COULOMB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|GUARDIAN|OPHTHALMOLOGIST|N|3||39||OPEN LABEL TREATMENT|1961-11-09||||1964-02-22||1965-04-13|1963-08-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||OVRLRESP|OVERALL RESPONSE||||UM|WORSENED||MMHG/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|3||39||BASELINE|1965-01-08||||1968-06-16||1972-08-07|1966-03-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||OVRLRESP|OVERALL RESPONSE||||10^6 IU/ML|MR||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|GUARDIAN|CARDIOLOGIST|N|4||88||TREATMENT|1963-12-11||||1972-10-18||1971-01-16|1966-01-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 RNA COPIES/ML|STABLE||U/KG/H|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|4||88||TREATMENT|1970-01-13||||1971-10-07||1970-11-07|1966-07-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UGEQ|MCR||UV2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|N|5||7||SCREENING|1963-02-02||||1960-12-23||1962-02-23|1972-01-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KG/MOL|PMD||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|VENDOR|PATHOLOGIST|U|5||7||INDUCTION TREATMENT|1961-01-20||||1966-12-08||1962-07-05|1964-03-17||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TAMPON|NON-QUANTIFIABLE MRD POSITIVITY||/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|1||38||OPEN LABEL TREATMENT|1967-08-29||||1973-08-20||1960-01-26|1973-04-16||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||STRUSTAT|STEROID USE STATUS||||QUANTITY SUFFICIENT|CYTOGENETIC PR||ABSORBANCE U/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|FAMILY MEMBER|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1971-02-19||||1966-04-08||1963-07-01|1971-04-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||V|QUANTIFIABLE MRD POSITIVITY||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|HEALTH CARE PROFESSIONAL|READER 2|N|2||58||BASELINE|1970-10-16||||1962-06-24||1970-05-15|1962-11-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||NEWLIND|NEW LESION INDICATOR||||MOL/MG|RELAPSED DISEASE FROM CR OR PR||ML/CM3/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|PROXY|ADJUDICATOR 3|N|2||58||WASHOUT|1969-10-03||||1971-09-24||1969-11-01|1962-04-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/S|ABSENT MORPHOLOGIC RESPONSE||MU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|INVESTIGATOR|CARDIOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1962-02-04||||1973-04-30||1962-12-13|1967-02-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KG/CM2|MORPHOLOGIC CR||MOL/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|INVESTIGATOR|ONCOLOGIST 1|NA|3||39||WASHOUT|1966-09-07||||1961-01-16||1973-04-14|1963-07-09||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||MOLRESP|MOLECULAR RESPONSE||||TABLET|IMPROVED||ML/(MIN*100ML)|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|DOMESTIC PARTNER|RATER|Y|4||88||INDUCTION TREATMENT|1969-01-07||||1968-06-26||1965-10-14|1961-11-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||TRGRESP|TARGET RESPONSE||||MG/M2/MIN|UNFAVORABLE RESPONSE||ML/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|DOMESTIC PARTNER|DERMATOLOGIST|NA|4||88||RUN-IN|1973-03-31||||1967-09-13||1970-02-23|1960-03-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||VG/ML|MRD PERSISTENCE||HOMEOPATHIC DILUTION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|5||7||BASELINE|1966-11-20||||1969-11-05||1965-09-23|1969-03-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||BONERESP|BONE RESPONSE||||ML/CAGE|NR||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1963-12-24||||1962-10-01||1967-06-15|1970-04-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UOSM|WORSENED||MCI/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|INVESTIGATOR|READER 1|NA|1||38||LONG-TERM FOLLOW-UP|1965-05-01||||1971-08-09||1969-09-20|1962-01-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^8 PFU|CYTOGENETIC PR||VP/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|CHILD|CLINICAL PATHOLOGIST|Y|1||38||WASHOUT|1965-01-10||||1970-02-25||1964-07-12|1970-12-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||BONERESP|BONE RESPONSE||||10^3 DNA COPIES/ML|SD-CT||SFC/10^6 PBMC|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|2||58||INDUCTION TREATMENT|1970-06-14||||1970-08-23||1973-05-19|1971-04-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||METSIND|METASTATIC INDICATOR||||10^6 ORGANISMS/ML|INDETERMINATE RESPONSE||PPTH|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|STUDY SUBJECT|INTERNIST|Y|2||58||TREATMENT|1968-08-27||||1969-01-22||1966-05-03|1970-04-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/DAY|INCREASED||NCI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|PARENT|ADJUDICATOR 1|U|3||39||FOLLOW-UP|1973-04-22||||1966-09-03||1970-03-09|1968-09-13||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||CYTORESP|CYTOGENETIC RESPONSE||||BAU/ML|CR||UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|3||39||WASHOUT|1973-07-01||||1969-10-30||1960-06-05|1971-01-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||L/KG|UNEQUIVOCAL||HOURS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|ADJUDICATOR|ENDOCRINOLOGIST|NA|4||88||CONTINUATION TREATMENT|1970-08-29||||1972-06-14||1972-09-10|1962-09-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MET|IUPD||MOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|FRIEND|ONCOLOGIST 2|Y|4||88||BLINDED TREATMENT|1966-12-16||||1971-03-26||1964-01-21|1968-05-26||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/G/MIN|PDU||VOXEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|SPOUSE|HEMATOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1971-11-25||||1969-10-18||1961-03-18|1968-02-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||CLINRESP|CLINICAL RESPONSE||||ATM|CYTOGENETIC MINOR RESPONSE||100 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|GUARDIAN|INTERNIST|Y|5||7||RUN-IN|1964-08-16||||1969-07-18||1963-09-04|1963-04-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^4 CFU|WORSENED||ANTI-XA IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|PARENT|MICROSCOPIST 3|U|1||38||INDUCTION TREATMENT|1961-04-24||||1969-08-13||1971-02-06|1966-07-29||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||NEWLPROG|NEW LESION PROGRESSION||||U/L|WORSENED||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|CHILD|RADIOLOGIST|N|1||38||FOLLOW-UP|1964-05-19||||1967-09-21||1971-02-16|1967-09-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||TRGRESP|TARGET RESPONSE||||ML/MIN|CYTOGENETIC NO RESPONSE||BQ/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|CAREGIVER|PHYSIOTHERAPIST|N|2||58||INDUCTION TREATMENT|1961-07-11||||1966-04-28||1963-02-18|1965-12-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GPL U|CYTOGENETIC CR||COAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|PROXY|INTERNIST|NA|2||58||CONTINUATION TREATMENT|1963-04-16||||1969-12-04||1964-06-30|1963-03-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L|MRD NEGATIVITY||CAPFUL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|PARENT|RADIOLOGIST 2|NA|3||39||SCREENING|1971-08-04||||1968-08-25||1962-10-17|1967-04-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||BESTRESP|BEST OVERALL RESPONSE||||COPIES/UG|CPR||KDA|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|PARENT|MICROSCOPIST|NA|3||39||FOLLOW-UP|1964-09-12||||1964-07-16||1969-01-26|1967-05-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/DAY|PDU||/7.5 ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|4||88||BLINDED TREATMENT|1966-10-13||||1972-10-27||1971-01-23|1969-07-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/MMHG|CA125 75% RESPONSE||MOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|SPOUSE|RATER|NA|4||88||TREATMENT|1962-09-14||||1965-11-20||1962-07-11|1972-04-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||METSIND|METASTATIC INDICATOR||||G/MOL|MORPHOLOGIC LEUKEMIA-FREE STATE||DAYS/MONTH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|GUARDIAN|RADIOLOGIST 1|N|5||7||BASELINE|1970-02-26||||1968-10-03||1964-01-16|1969-11-03||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^6/L|SMD||COPIES/UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|5||7||OPEN LABEL TREATMENT|1970-02-27||||1960-09-30||1962-07-18|1963-11-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FEU|CYTOGENETIC NO RESPONSE||UMOL/MG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|1||38||FOLLOW-UP|1972-08-27||||1973-02-19||1962-03-26|1964-11-20||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||TRGRESP|TARGET RESPONSE||||G/L|VGPR||FL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|DOMESTIC PARTNER|OPTOMETRIST|Y|1||38||WASHOUT|1960-11-19||||1970-11-24||1965-02-22|1972-11-03||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||TRGRESP|TARGET RESPONSE||||MMOL/L|MORPHOLOGIC LEUKEMIA-FREE STATE||UG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|GUARDIAN|PHYSIOTHERAPIST|Y|2||58||OBSERVATION|1961-11-24||||1965-12-20||1965-12-24|1961-03-29||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||L/S/KPA|CYTOGENETIC MINOR RESPONSE||TROCHE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|CAREGIVER|MICROSCOPIST 2|N|2||58||TREATMENT|1965-07-25||||1960-03-08||1966-08-17|1972-10-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^7 CFU|SD-CT||DYN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|3||39||RUN-IN|1962-02-07||||1972-08-07||1962-01-13|1972-07-05||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||LOZENGE|NPR||MIN/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|DOMESTIC PARTNER|MICROSCOPIST 3|NA|3||39||RUN-IN|1969-06-08||||1970-09-26||1968-03-14|1965-12-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/CAGE/DAY|CHR||DEG/S|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|INTERVIEWER|RATER 1|NA|4||88||RUN-IN|1961-05-25||||1960-09-02||1967-01-11|1966-03-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||ANATRESP|ANATOMIC RESPONSE||||10^3/L|CHR||KG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|ADJUDICATOR|OPHTHALMOLOGIST|Y|4||88||RUN-IN|1960-08-07||||1961-08-15||1970-08-20|1970-05-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||BONERESP|BONE RESPONSE||||G/CAGE/DAY|CYTOGENETIC MINOR RESPONSE||MG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|5||7||INDUCTION TREATMENT|1964-03-17||||1973-03-11||1967-06-17|1966-12-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||NEWLIND|NEW LESION INDICATOR||||BP|PR-CT||UU/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|FAMILY MEMBER|ADJUDICATOR 2|NA|5||7||OBSERVATION|1964-12-18||||1962-01-28||1960-07-19|1961-08-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||CLINRESP|CLINICAL RESPONSE||||L/KG|DISEASE TRANSFORMATION||10^9 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||LONG-TERM FOLLOW-UP|1970-02-23||||1960-01-21||1964-03-28|1965-10-11||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||STRUSTAT|STEROID USE STATUS||||FFU|NON-CR/NON-PD||LENS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|1||38||SCREENING|1966-01-23||||1962-01-15||1962-12-25|1972-09-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||V/V|DISEASE TRANSFORMATION||M/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|FRIEND|ONCOLOGIST 1|NA|2||58||BASELINE|1971-11-27||||1964-08-07||1960-07-02|1971-05-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O/ML|MCR||BOX|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|DOMESTIC PARTNER|UROLOGIST|U|2||58||CONTINUATION TREATMENT|1965-02-14||||1967-12-13||1970-05-13|1972-04-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 COPIES/ML|MOLECULAR CR||LX|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|ADJUDICATION COMMITTEE|NEUROLOGIST|Y|3||39||INDUCTION TREATMENT|1960-03-24||||1970-03-05||1970-09-26|1965-09-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/H|RELAPSED DISEASE FROM CR OR PR||OZ EQ|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|3||39||CONTINUATION TREATMENT|1964-06-05||||1966-02-08||1968-12-24|1972-07-29||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||LIVRRESP|LIVER RESPONSE||||MG/DL|MOLECULAR MAJOR RESPONSE||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|4||88||BASELINE|1973-02-15||||1961-02-27||1965-06-14|1966-12-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/G/MIN|RELAPSED DISEASE||IU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||RUN-IN|1969-01-05||||1973-05-23||1969-11-06|1967-01-18||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||METBRESP|METABOLIC RESPONSE||||UMOL/MG/MIN|PSEUDORESPONSE||COAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CHILD|CLINICAL PATHOLOGIST|U|5||7||WASHOUT|1970-02-21||||1966-11-19||1968-10-24|1970-07-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||LIVRRESP|LIVER RESPONSE||||HEP|PR||MS/MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|SIBLING|PATHOLOGIST 1|U|5||7||BASELINE|1971-04-10||||1965-04-03||1967-03-15|1973-04-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||METSIND|METASTATIC INDICATOR||||MG/CM2|NE||SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|PROXY|ONCOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1971-10-08||||1961-02-15||1971-06-30|1970-02-07||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AGU/ML|NON-CR/NON-PD||/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|SPOUSE|FORENSIC PATHOLOGIST|NA|1||38||TREATMENT|1968-09-25||||1965-03-27||1971-03-15|1970-12-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^6 COPIES/ML|CYTOGENETIC NO RESPONSE||UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|CHILD|HEMATOLOGIST|N|2||58||INDUCTION TREATMENT|1966-09-16||||1973-05-24||1969-11-19|1962-08-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||METBRESP|METABOLIC RESPONSE||||FT3|NPR||MIN*MG/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||BASELINE|1972-02-06||||1962-10-24||1960-01-30|1967-01-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||METSIND|METASTATIC INDICATOR||||DDU|PMR||MCI|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|CAREGIVER|MICROSCOPIST|Y|3||39||BASELINE|1963-09-18||||1967-09-18||1971-02-20|1967-06-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||NEWLPROG|NEW LESION PROGRESSION||||ATM|NOT ALL EVALUATED||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|PARENT|ADJUDICATOR 3|N|3||39||CONTINUATION TREATMENT|1965-08-14||||1969-04-21||1968-07-18|1971-12-25||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CAN|MRD PERSISTENCE||FT3|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|DOMESTIC PARTNER|READER 1|NA|4||88||RUN-IN|1961-11-18||||1961-05-26||1968-05-13|1969-09-14||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MET*H|EQUIVOCAL||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|STUDY SUBJECT|DERMATOLOGIST|NA|4||88||RUN-IN|1968-12-05||||1972-06-10||1973-03-27|1963-06-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||CLINRESP|CLINICAL RESPONSE||||DPM|HI-P||DEG/S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|U|5||7||FOLLOW-UP|1963-10-20||||1960-06-21||1968-03-09|1961-05-17||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL|PR WITH LYMPHOCYTOSIS||NKAT|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|N|5||7||SCREENING|1967-02-28||||1969-11-29||1965-04-26|1972-06-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^3 RNA COPIES/ML|MINOR PATHOLOGIC RESPONSE||10^6 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|HEALTH CARE PROFESSIONAL|RATER|U|1||38||OBSERVATION|1963-11-04||||1970-11-21||1968-10-04|1972-05-29||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||%/S|CA125 75% RESPONSE||CD*S/M2|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|VENDOR|ADJUDICATOR 1|U|1||38||LONG-TERM FOLLOW-UP|1972-10-11||||1973-03-11||1970-08-16|1961-09-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||CLINRESP|CLINICAL RESPONSE||||KUSP|INDETERMINATE RESPONSE||MV|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|ADJUDICATOR|RADIOLOGIST 1|NA|2||58||BASELINE|1969-08-01||||1963-07-09||1962-11-04|1972-04-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||%(W/V)|SCR||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|2||58||BLINDED TREATMENT|1960-07-31||||1961-04-10||1960-07-01|1960-11-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||NEWLPROG|NEW LESION PROGRESSION||||CFU/ML|IUPD||HR/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|INDEPENDENT ASSESSOR|INTERNIST|N|3||39||LONG-TERM FOLLOW-UP|1963-06-15||||1962-12-27||1961-04-10|1968-01-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||LIVRRESP|LIVER RESPONSE||||/5X10^4 WBC|RELAPSED DISEASE FROM CR||BU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|3||39||RUN-IN|1972-10-27||||1964-05-08||1969-01-16|1961-12-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MOL/G|MINOR PATHOLOGIC RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|VENDOR|ADJUDICATOR 2|U|4||88||RUN-IN|1962-09-07||||1964-01-27||1960-03-07|1962-09-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||RFU|HI-P||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|FAMILY MEMBER|OPTOMETRIST|N|4||88||WASHOUT|1961-02-10||||1964-12-20||1961-01-07|1971-01-25||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||ANATRESP|ANATOMIC RESPONSE||||U/G HB|NPR||U/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|FAMILY MEMBER|RATER 2|U|5||7||WASHOUT|1961-12-16||||1964-10-04||1972-12-17|1965-02-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||PATHRESP|PATHOLOGIC RESPONSE||||AMU|CR||DDU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|5||7||BASELINE|1969-02-09||||1960-11-15||1971-10-12|1967-09-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||NTRGRESP|NON-TARGET RESPONSE||||MIN*MG/ML|HI-N||CCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|1||38||OBSERVATION|1967-01-11||||1966-03-09||1970-10-02|1961-02-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ABSORBANCE U/MIN|PR||BAR|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|INVESTIGATOR|ADJUDICATOR 1|NA|1||38||BASELINE|1967-12-23||||1970-07-27||1972-05-31|1969-05-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||OVRLRESP|OVERALL RESPONSE||||MCI/KG|ABSENT MORPHOLOGIC RESPONSE||CMHG|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|PROXY|MICROSCOPIST 3|U|2||58||OBSERVATION|1960-04-15||||1966-07-02||1963-08-31|1965-01-02||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||BESTRESP|BEST OVERALL RESPONSE||||QUANTITY SUFFICIENT|ICR||BQ/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|INVESTIGATOR|HEMATOLOGIST|Y|2||58||BASELINE|1972-07-28||||1963-04-13||1971-12-08|1973-02-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||SPLNRESP|SPLEEN RESPONSE||||FOZ_US|CR-CT||UEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|PARENT|ONCOLOGIST 1|N|3||39||LONG-TERM FOLLOW-UP|1966-08-22||||1973-07-14||1968-06-05|1969-04-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||BESTRESP|BEST OVERALL RESPONSE||||CAPLET|CHR||PG/CELL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|FAMILY MEMBER|RATER 1|U|3||39||RUN-IN|1966-05-28||||1970-11-19||1967-10-10|1960-01-29||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/ANIMAL|HI-N||G/CAGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|4||88||WASHOUT|1968-07-10||||1965-03-09||1971-05-08|1960-06-17||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||NEWLIND|NEW LESION INDICATOR||||OSM|COMPLETE MRD RESPONSE||CI/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1973-04-30||||1961-10-08||1969-07-15|1971-04-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KPA/L/SEC|VGPR||OZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|PROXY|ENDOCRINOLOGIST|U|5||7||SCREENING|1965-08-29||||1968-04-28||1973-04-20|1973-07-31||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||CLINRESP|CLINICAL RESPONSE||||NEWTON|PD/RELAPSE AFTER HI||U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|5||7||OBSERVATION|1962-06-12||||1966-08-05||1965-07-06|1961-04-25||DURING||DURING|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NEEDLE GAUGE|PR WITH LYMPHOCYTOSIS||FOZ_US|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|U|1||38||WASHOUT|1967-11-10||||1962-11-20||1967-09-10|1961-11-27||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UL|FAVORABLE RESPONSE||NMOL BCE/NMOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|PARENT|READER 2|Y|1||38||BLINDED TREATMENT|1973-02-14||||1970-09-01||1962-03-06|1969-04-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||COPIES/ML|MRD RELAPSE||ANTI-XA IU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1972-07-12||||1968-05-15||1964-10-25|1971-08-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||STRUSTAT|STEROID USE STATUS||||MAC50|NOT ALL EVALUATED||MET*H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|N|2||58||FOLLOW-UP|1968-06-24||||1967-01-09||1963-03-08|1966-04-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||NEWLIND|NEW LESION INDICATOR||||MG/L|CR||TBSP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|SIBLING|RATER 2|Y|3||39||OBSERVATION|1963-04-03||||1971-05-02||1966-01-28|1971-02-14||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/M2/MIN|MAJOR PATHOLOGIC RESPONSE||MV2/HZ|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|GUARDIAN|PHYSIOTHERAPIST|U|3||39||CONTINUATION TREATMENT|1973-09-02||||1968-08-04||1964-09-06|1965-05-03||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/G/DAY|MAJOR PATHOLOGIC RESPONSE||CAPFUL|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|SIGNIFICANT OTHER|RADIOLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1963-02-26||||1960-08-27||1967-05-04|1971-09-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||L/MIN|PD/RELAPSE AFTER HI||HENRY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|4||88||BASELINE|1969-12-02||||1961-07-20||1962-04-29|1967-03-19||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/BEAT|CYTOGENETIC PR||CONTAINER|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|PROXY|PATHOLOGIST 1|Y|5||7||FOLLOW-UP|1969-09-22||||1973-05-13||1961-05-31|1973-08-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KG|RELAPSED DISEASE FROM CR OR PR||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|U|SIBLING|NEUROLOGIST 1|Y|5||7||BASELINE|1962-10-22||||1968-06-15||1963-11-29|1970-10-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/MIN/MMHG|PSA PROGRESSION||MOSM/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|CHILD|OPHTHALMOLOGIST|Y|1||38||TREATMENT|1973-05-31||||1973-08-05||1972-12-06|1961-09-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||BONERESP|BONE RESPONSE||||G/G/DAY|SMD||MG/KG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|STUDY SUBJECT|UROLOGIST|U|1||38||RUN-IN|1970-03-20||||1972-12-21||1966-06-07|1960-03-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/CL|PD||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|INTERVIEWER|NEUROLOGIST 1|Y|2||58||SCREENING|1970-09-12||||1972-02-05||1964-07-06|1961-12-14||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||NTRGRESP|NON-TARGET RESPONSE||||KIU|NED||MMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|2||58||TREATMENT|1961-03-24||||1964-10-28||1968-12-10|1964-02-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UIU/L|HI-N||MG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||TREATMENT|1970-05-07||||1970-11-29||1971-01-26|1963-06-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MOL|FAVORABLE RESPONSE||GY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|ADJUDICATOR|PATHOLOGIST 2|N|3||39||SCREENING|1960-11-24||||1972-11-25||1960-02-05|1969-11-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NKAT/L|PR-CT||MCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|FRIEND|OTOLARYNGOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1971-11-25||||1966-03-19||1963-12-20|1963-11-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BEATS/MIN|CA125 50% RESPONSE||PELLET|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|4||88||OPEN LABEL TREATMENT|1964-10-28||||1960-08-01||1961-07-14|1966-06-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DAMOL/L|CYTOGENETIC MINIMAL RESPONSE||FMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|INVESTIGATOR|ADJUDICATOR 3|N|5||7||BLINDED TREATMENT|1961-04-12||||1973-06-26||1970-03-10|1966-08-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||TMRESP|TUMOR MARKER RESPONSE||||MBQ|CMR||FT3|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|VENDOR|MICROSCOPIST 2|U|5||7||SCREENING|1969-08-10||||1961-07-28||1960-10-07|1961-05-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/MIN/1.73M2|CCR||EP U|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|ADJUDICATOR|ONCOLOGIST 1|U|1||38||RUN-IN|1961-02-08||||1963-04-06||1962-11-01|1967-12-31||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||STEPS|CR||10^12/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|FRIEND|MICROSCOPIST 3|N|1||38||BASELINE|1972-10-04||||1968-06-10||1967-10-28|1960-10-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||CLINRESP|CLINICAL RESPONSE||||DAYS/WK|CYTOGENETIC MINOR RESPONSE||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|STUDY SUBJECT|PATHOLOGIST|NA|2||58||SCREENING|1969-06-03||||1963-09-22||1963-10-02|1962-01-19||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||OVRLRESP|OVERALL RESPONSE||||G/DL|CA125 50% RESPONSE||DB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|INDEPENDENT ASSESSOR|READER|Y|2||58||BLINDED TREATMENT|1966-10-31||||1972-02-27||1966-11-14|1970-09-14||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||NEWLIND|NEW LESION INDICATOR||||UG/DAY|PD||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|STUDY SUBJECT|RADIOLOGIST 2|NA|3||39||INDUCTION TREATMENT|1968-09-16||||1969-02-07||1961-06-08|1965-06-17||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||TMRESP|TUMOR MARKER RESPONSE||||MOL/MOL|NED||VG/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|CHILD|RATER 2|Y|3||39||SCREENING|1968-03-18||||1969-11-26||1971-01-03|1971-05-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML|CPR||MGEQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|CAREGIVER|PATHOLOGIST|N|4||88||OBSERVATION|1973-04-05||||1970-06-07||1963-10-23|1967-10-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SEC|SMD||MCI/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|SIBLING|ADJUDICATOR|N|4||88||RUN-IN|1970-04-17||||1968-05-22||1967-05-26|1972-06-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||V/V|NON-CR/NON-PD||G/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|DOMESTIC PARTNER|RATER 2|Y|5||7||RUN-IN|1965-09-07||||1969-10-02||1963-08-23|1968-11-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||OVRLRESP|OVERALL RESPONSE||||MEQ/ML|ICR||TABLET|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|5||7||LONG-TERM FOLLOW-UP|1966-09-11||||1965-04-25||1970-03-06|1973-04-21||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/DAY|RELAPSED DISEASE FROM CR||GBQ/MG|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|1||38||OBSERVATION|1968-10-31||||1969-10-19||1962-02-08|1965-10-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CD/M2|VGPR||DIP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1||38||BASELINE|1965-04-29||||1970-08-18||1971-11-03|1960-02-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UIU/DL|PCR||/MM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|GUARDIAN|NEUROLOGIST|Y|2||58||TREATMENT|1972-03-15||||1971-08-28||1968-11-11|1960-08-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||BONERESP|BONE RESPONSE||||MMOL|DISEASE TRANSFORMATION||ENZYME U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|FAMILY MEMBER|RATER 2|U|2||58||TREATMENT|1971-03-25||||1962-04-28||1971-02-23|1965-12-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||NEWLPROG|NEW LESION PROGRESSION||||HEP|MAJOR PATHOLOGIC RESPONSE||UG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||TREATMENT|1969-06-15||||1972-05-03||1966-11-25|1972-06-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TUBERCULIN UNIT/ML|PSA PROGRESSION||10^6/HPF|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|CHILD|HEMATOLOGIST|Y|3||39||FOLLOW-UP|1961-09-08||||1971-12-11||1965-04-17|1963-10-19||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/HPF|INDETERMINATE RESPONSE||L/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|CHILD|RATER|N|4||88||INDUCTION TREATMENT|1963-03-23||||1964-10-13||1968-07-05|1965-01-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||TMRESP|TUMOR MARKER RESPONSE||||DROP|SMD||USEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|FRIEND|RADIOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1971-04-03||||1967-08-25||1973-02-16|1963-06-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||TRGRESP|TARGET RESPONSE||||UCI/L|IUPD||UG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|5||7||TREATMENT|1967-07-24||||1960-04-25||1969-02-12|1960-04-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||CLINRESP|CLINICAL RESPONSE||||MBP|MOLECULAR CR||UMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|5||7||OBSERVATION|1967-01-28||||1961-08-29||1962-09-27|1970-03-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||SPLNRESP|SPLEEN RESPONSE||||FFU|EQUIVOCAL||U/M2/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|N|1||38||SCREENING|1969-04-09||||1965-02-21||1964-02-11|1967-06-16||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PA|PR WITH LYMPHOCYTOSIS||ARBITRARY U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|FAMILY MEMBER|NEUROLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1961-12-08||||1964-09-21||1971-04-20|1964-05-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||MOLRESP|MOLECULAR RESPONSE||||G/CAGE|HI-N||MNFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|DOMESTIC PARTNER|READER 1|Y|2||58||FOLLOW-UP|1966-12-29||||1972-10-09||1960-11-17|1973-07-20||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/KG/DAY|CYTOGENETIC PR||TUBERCULIN UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|N|Y|PARENT|READER 1|NA|2||58||BLINDED TREATMENT|1960-11-22||||1962-11-26||1961-07-24|1966-09-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||CLINRESP|CLINICAL RESPONSE||||ML/CM H2O|WORSENED||NMOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|PROXY|NEUROLOGIST|Y|3||39||RUN-IN|1960-09-30||||1962-02-06||1964-01-31|1967-04-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||MOLRESP|MOLECULAR RESPONSE||||MG2/DL2|CR-CT||UKAT/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|INTERVIEWER|ONCOLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1966-03-02||||1970-11-15||1970-08-15|1962-11-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||CLINRESP|CLINICAL RESPONSE||||PG|MRD PERSISTENCE||DAYS/WK|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1962-11-14||||1971-12-31||1965-03-13|1973-04-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PA|EQUIVOCAL||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|SIGNIFICANT OTHER|RADIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-01-26||||1963-01-07||1970-02-28|1961-09-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||NEWLIND|NEW LESION INDICATOR||||10^3 CFU|RELAPSED DISEASE FROM CR||NG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|PARENT|OTOLARYNGOLOGIST|NA|5||7||FOLLOW-UP|1965-07-06||||1962-08-17||1963-01-05|1963-12-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||METBRESP|METABOLIC RESPONSE||||/10^4|NON-QUANTIFIABLE MRD POSITIVITY||ARBITRARY U|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|PARENT|RATER 2|U|5||7||BASELINE|1973-03-11||||1964-09-07||1972-05-10|1967-02-15||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL/DL|CRI||MS2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|FRIEND|HEMATOLOGIST|NA|1||38||FOLLOW-UP|1970-01-21||||1966-03-29||1969-10-29|1972-04-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|2||||||STRUSTAT|STEROID USE STATUS||||BU|NON-QUANTIFIABLE MRD POSITIVITY||PL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|FRIEND|CLINICAL PATHOLOGIST|U|1||38||FOLLOW-UP|1972-05-28||||1971-12-11||1968-07-07|1964-10-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|1||||||METBRESP|METABOLIC RESPONSE||||EU|UNFAVORABLE RESPONSE||MG/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|STUDY SUBJECT|ADJUDICATOR 3|Y|2||58||CONTINUATION TREATMENT|1967-04-09||||1972-11-05||1964-05-05|1973-01-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|2||||||STRUSTAT|STEROID USE STATUS||||TRANSDUCING UNIT|RELAPSED DISEASE FROM CR OR PR||U/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|2||58||INDUCTION TREATMENT|1960-09-28||||1970-01-28||1963-09-12|1972-04-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/MIN|RELAPSED DISEASE FROM CR OR PR||10^3/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|SIBLING|READER 3|U|3||39||INDUCTION TREATMENT|1961-09-14||||1962-09-29||1971-05-25|1966-10-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NSEC|PARTIAL MORPHOLOGIC RESPONSE||NKAT/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||LONG-TERM FOLLOW-UP|1972-03-30||||1972-04-30||1973-07-19|1964-02-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KG/M2|NR||KDA|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|SIBLING|CLINICAL PATHOLOGIST|U|4||88||BASELINE|1965-09-20||||1965-03-24||1968-10-03|1966-09-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|2||||||TRGRESP|TARGET RESPONSE||||/HPF|PDU||MU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|U|INTERVIEWER|ONCOLOGIST|N|4||88||INDUCTION TREATMENT|1962-07-17||||1962-09-11||1968-12-05|1962-10-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG EID 50/DOSE|PR WITH LYMPHOCYTOSIS||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|5||7||RUN-IN|1971-12-15||||1970-05-27||1968-05-31|1970-09-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|59A9826F-4C2F-482A-8888-F649544318BE|2||||||TRGRESP|TARGET RESPONSE||||COPIES/UG|PARTIAL MORPHOLOGIC RESPONSE||QUANTITY SUFFICIENT|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||OPEN LABEL TREATMENT|1963-01-25||||1966-02-13||1963-04-27|1962-04-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||NTRGRESP|NON-TARGET RESPONSE||||UMOL/L/MIN|OPTIMAL MORPHOLOGIC RESPONSE||SHOCK WAVE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|SPOUSE|ADJUDICATOR 2|U|1||38||OPEN LABEL TREATMENT|1960-05-07||||1972-06-19||1972-12-17|1966-12-07||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||MOLRESP|MOLECULAR RESPONSE||||KG/CM2|PMR||GPS U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|INTERVIEWER|UROLOGIST|Y|1||38||BASELINE|1964-01-09||||1962-10-21||1968-03-21|1971-09-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||LIVRRESP|LIVER RESPONSE||||S/H|HI-E||CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|FAMILY MEMBER|MICROSCOPIST 1|U|2||58||CONTINUATION TREATMENT|1970-12-01||||1971-02-14||1970-04-18|1965-05-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||MOLRESP|MOLECULAR RESPONSE||||HEP|CHR||LOG10 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|INVESTIGATOR|RADIOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1967-01-20||||1966-10-01||1972-09-01|1964-08-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^9 CFU/G|NR||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|3||39||BASELINE|1968-07-25||||1961-12-16||1962-02-05|1962-03-31||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PACKAGE|MR||IMPLANT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|SIGNIFICANT OTHER|NEUROLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1968-03-16||||1973-06-13||1960-12-10|1965-10-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KG/MOL|SCR||ECL UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|SPOUSE|ONCOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1966-07-11||||1967-05-20||1972-07-05|1965-08-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||METSIND|METASTATIC INDICATOR||||CMH2O/ML|PD FROM PR||UMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|STUDY SUBJECT|PATHOLOGIST 1|N|4||88||BASELINE|1961-09-12||||1964-07-13||1972-05-26|1969-12-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KV|WORSENED||UG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|5||7||BLINDED TREATMENT|1971-12-25||||1970-08-21||1960-04-27|1961-04-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FT2|CR||TRANSDUCING UNIT/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|CHILD|CARDIOLOGIST|NA|5||7||BASELINE|1972-11-10||||1963-11-18||1963-11-29|1968-12-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/M2/MIN|PR||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|1||38||SCREENING|1968-10-12||||1967-10-24||1964-11-12|1966-11-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||NEWLPROG|NEW LESION PROGRESSION||||TITER|CRI||ML/(MIN*100ML)|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|PROXY|FORENSIC PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1966-04-13||||1971-06-15||1961-05-27|1970-01-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||METBRESP|METABOLIC RESPONSE||||ML/MIN/MMHG|CYTOGENETIC CR||%|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|CHILD|PHYSIOTHERAPIST|NA|2||58||BLINDED TREATMENT|1966-04-29||||1965-11-21||1961-01-23|1968-11-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TAMPON|INCREASED||PMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|SPOUSE|INTERNIST|Y|2||58||FOLLOW-UP|1960-03-19||||1973-08-29||1961-02-10|1969-09-11||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||NEWLIND|NEW LESION INDICATOR||||KHZ|PD/RELAPSE AFTER HI||STRIP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|CAREGIVER|OPHTHALMOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1968-06-29||||1966-12-27||1966-09-15|1964-12-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/L DDU|PD-CT||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|ADJUDICATOR|READER 3|Y|3||39||WASHOUT|1966-02-03||||1966-12-05||1967-09-19|1965-07-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||STRUSTAT|STEROID USE STATUS||||KUSP|MINOR PATHOLOGIC RESPONSE||LX|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|STUDY SUBJECT|INTERNIST|NA|4||88||BASELINE|1969-04-03||||1967-08-11||1963-12-22|1967-07-21||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 TCID 50/DOSE|MAJOR PATHOLOGIC RESPONSE||PA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|DOMESTIC PARTNER|MICROSCOPIST 1|N|4||88||CONTINUATION TREATMENT|1967-09-01||||1962-09-07||1961-10-05|1968-02-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||CLINRESP|CLINICAL RESPONSE||||FINGERTIP UNIT|PR||MEQ/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|PROXY|MICROSCOPIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1962-04-11||||1965-03-16||1971-01-11|1965-12-28||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||STRUSTAT|STEROID USE STATUS||||UKAT|MRD PERSISTENCE||TITER|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|CHILD|HEMATOLOGIST|U|5||7||OBSERVATION|1962-05-11||||1965-01-23||1960-02-29|1962-05-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PPTR|IPR||10^3 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|SPOUSE|ONCOLOGIST|Y|1||38||INDUCTION TREATMENT|1964-10-21||||1963-10-24||1962-10-29|1969-12-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||BESTRESP|BEST OVERALL RESPONSE||||UG/L/H|IMPROVED||MG/L FEU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|CLINICAL RESEARCH ASSOCIATE|READER|N|1||38||OPEN LABEL TREATMENT|1964-10-15||||1967-08-12||1960-10-19|1972-08-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/4.0 ML|CCR||BEAM BREAKS|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|FRIEND|PATHOLOGIST|N|2||58||BLINDED TREATMENT|1964-07-07||||1962-09-05||1971-12-28|1970-03-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/MOL|PSEUDOPROGRESSION||LOG10 PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|VENDOR|ENDOCRINOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1965-09-19||||1968-06-11||1970-07-28|1970-03-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/M2/DAY|HI-P||MOL/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|FRIEND|RATER 2|Y|3||39||LONG-TERM FOLLOW-UP|1967-08-01||||1973-05-08||1965-05-06|1967-10-07||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||TRGRESP|TARGET RESPONSE||||MEQ/G|INDETERMINATE RESPONSE||COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|FAMILY MEMBER|PATHOLOGIST 1|NA|3||39||SCREENING|1964-07-25||||1970-04-19||1960-02-22|1961-05-06||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/ANIMAL|CR||GPL U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|PROXY|RATER|Y|4||88||SCREENING|1970-08-21||||1961-12-24||1964-04-28|1968-01-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||M3|PMD||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|4||88||FOLLOW-UP|1970-11-05||||1960-12-07||1960-07-01|1969-02-25||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||NEWLIND|NEW LESION INDICATOR||||DRAM|HI-P||MG/M2/H|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|STUDY SUBJECT|RATER|U|5||7||OPEN LABEL TREATMENT|1964-02-03||||1967-05-12||1969-12-02|1963-04-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||DIP|MR||FRACTION OF 1|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|SIBLING|MICROSCOPIST 2|N|5||7||OPEN LABEL TREATMENT|1962-12-18||||1964-02-18||1968-04-14|1970-03-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||NEWLIND|NEW LESION INDICATOR||||MAMP|INCREASED||MHZ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|INDEPENDENT ASSESSOR|READER 1|N|1||38||INDUCTION TREATMENT|1971-01-09||||1970-09-04||1972-01-18|1968-02-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||TRGRESP|TARGET RESPONSE||||UG/L/H|CR-CT||L/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|1||38||INDUCTION TREATMENT|1971-01-08||||1964-01-09||1961-12-14|1966-06-29||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 CFU|RELAPSED DISEASE FROM CR||ML/MMHG/MIN/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|SPOUSE|DERMATOLOGIST|N|2||58||INDUCTION TREATMENT|1963-04-30||||1965-03-09||1965-08-24|1968-09-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||AFU|PARTIAL MORPHOLOGIC RESPONSE||CI/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|FRIEND|ONCOLOGIST|Y|2||58||BLINDED TREATMENT|1960-05-09||||1962-12-30||1963-10-13|1969-05-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KPA|HI-E||MM/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|3||39||CONTINUATION TREATMENT|1961-08-03||||1971-12-19||1961-10-08|1960-12-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TUBERCULIN UNIT|QUANTIFIABLE MRD POSITIVITY||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|FAMILY MEMBER|RATER 1|N|3||39||CONTINUATION TREATMENT|1964-11-27||||1960-07-09||1967-05-03|1973-04-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/7.5 ML|CYTOGENETIC MINIMAL RESPONSE||S/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|GUARDIAN|ADJUDICATOR 2|N|4||88||RUN-IN|1962-10-01||||1963-05-03||1971-05-29|1972-10-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||METBRESP|METABOLIC RESPONSE||||/500 WBC|TREATMENT FAILURE||ELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1970-02-25||||1962-06-05||1965-07-01|1962-02-24||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CUP|NON-QUANTIFIABLE MRD POSITIVITY||U/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|DOMESTIC PARTNER|UROLOGIST|N|5||7||FOLLOW-UP|1967-11-26||||1965-12-28||1963-04-03|1960-11-10||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||STRUSTAT|STEROID USE STATUS||||UG/DOSE|VGPR||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|5||7||BLINDED TREATMENT|1969-04-27||||1967-08-06||1969-02-11|1963-05-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||OVRLRESP|OVERALL RESPONSE||||CI|CA125 75% RESPONSE||G/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|INVESTIGATOR|ADJUDICATOR 2|Y|1||38||INDUCTION TREATMENT|1960-06-29||||1961-03-04||1969-02-03|1966-04-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||METSIND|METASTATIC INDICATOR||||PFU|CMR||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|INTERVIEWER|PATHOLOGIST 2|N|1||38||BASELINE|1963-10-03||||1973-04-30||1962-07-22|1970-06-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/L|PD/RELAPSE AFTER HI||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|2||58||BLINDED TREATMENT|1970-12-10||||1964-07-11||1965-05-17|1962-08-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||LIVRRESP|LIVER RESPONSE||||10^3 ORGANISMS/ML|SCR||PPTH|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|SPOUSE|PATHOLOGIST 2|Y|2||58||TREATMENT|1965-08-12||||1966-06-10||1971-06-08|1968-08-26||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||STRUSTAT|STEROID USE STATUS||||/SEC|PR||NGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|SPOUSE|ADJUDICATOR 2|NA|3||39||LONG-TERM FOLLOW-UP|1972-04-21||||1970-10-28||1961-11-14|1964-06-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||TMRESP|TUMOR MARKER RESPONSE||||MU/L|CR||U/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|SIBLING|ONCOLOGIST 2|N|3||39||SCREENING|1960-01-25||||1967-08-27||1969-09-28|1964-04-20||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI/KG|OPTIMAL MORPHOLOGIC RESPONSE||CMH2O*S/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|CHILD|OPTOMETRIST|N|4||88||TREATMENT|1964-03-14||||1972-04-30||1973-04-02|1967-08-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/MBP|PDU||G/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|SIBLING|MICROSCOPIST 3|N|4||88||OBSERVATION|1967-02-11||||1960-09-24||1971-09-23|1970-06-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MIN*MG/ML|PR-CT||CI/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|5||7||LONG-TERM FOLLOW-UP|1969-06-06||||1969-12-14||1963-11-27|1962-03-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||TRGRESP|TARGET RESPONSE||||FEU|MOLECULAR CR||ELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|INTERVIEWER|ADJUDICATOR|NA|5||7||FOLLOW-UP|1964-06-19||||1972-10-06||1966-08-11|1970-12-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CI/UG|PSA PROGRESSION||PSEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|PARENT|PATHOLOGIST 1|Y|1||38||OBSERVATION|1961-10-10||||1969-10-03||1973-07-15|1970-07-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||NEWLIND|NEW LESION INDICATOR||||IU/L|PR-CT||OHM|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|1||38||RUN-IN|1968-10-24||||1964-05-03||1967-11-02|1972-11-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/H|INDETERMINATE RESPONSE||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|INVESTIGATOR|RATER 2|Y|2||58||INDUCTION TREATMENT|1963-01-20||||1971-11-10||1961-03-24|1971-04-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||MOLRESP|MOLECULAR RESPONSE||||U/G/DAY|TREATMENT FAILURE||PMOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|CAREGIVER|OPHTHALMOLOGIST|Y|2||58||CONTINUATION TREATMENT|1969-11-13||||1971-11-11||1960-07-12|1962-04-09||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||METSIND|METASTATIC INDICATOR||||NKAT/G HB|CCR||GLOBULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|VENDOR|ONCOLOGIST|U|3||39||WASHOUT|1962-12-28||||1961-01-26||1964-09-25|1960-04-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/2500 WBC|MRD PERSISTENCE||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|PROXY|OTOLARYNGOLOGIST|N|3||39||FOLLOW-UP|1969-02-23||||1973-08-23||1969-09-18|1967-01-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||NTRGRESP|NON-TARGET RESPONSE||||PACKET|MCR||/5X10^4 WBC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|HEALTH CARE PROFESSIONAL|READER 1|Y|4||88||WASHOUT|1972-06-15||||1970-06-03||1960-02-08|1969-12-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||SPLNRESP|SPLEEN RESPONSE||||L|MINOR PATHOLOGIC RESPONSE||10^6 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|CHILD|RADIOLOGIST 1|N|4||88||RUN-IN|1964-09-24||||1965-02-15||1963-08-17|1968-07-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||NEWLIND|NEW LESION INDICATOR||||UL|PARTIAL MORPHOLOGIC RESPONSE||UKAT/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|5||7||OPEN LABEL TREATMENT|1963-06-18||||1964-10-13||1971-02-25|1971-05-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PFU/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|FRIEND|PATHOLOGIST 2|U|5||7||INDUCTION TREATMENT|1962-04-04||||1967-01-03||1970-03-01|1968-09-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||MOLRESP|MOLECULAR RESPONSE||||MS2|MCR||POUCH|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|RATER|Y|1||38||OPEN LABEL TREATMENT|1964-10-13||||1968-04-19||1970-01-26|1972-12-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||NEWLIND|NEW LESION INDICATOR||||MAMP|COMPLETE MRD RESPONSE||AMP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|1||38||WASHOUT|1968-04-26||||1961-05-16||1968-09-13|1964-08-07||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOSM/KG|HI-N||UM/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 1|N|2||58||INDUCTION TREATMENT|1971-11-18||||1962-08-27||1966-05-04|1964-07-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MEQ/ML|HI-N||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|2||58||SCREENING|1960-12-08||||1966-01-26||1968-04-11|1969-01-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||NEWLPROG|NEW LESION PROGRESSION||||BQ/MG|CR||PFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|SPOUSE|NEUROLOGIST 2|U|3||39||BASELINE|1972-04-07||||1960-11-24||1962-02-11|1973-06-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/CMH2O|PR||MG/CM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|CLINICAL RESEARCH COORDINATOR|READER 1|Y|3||39||LONG-TERM FOLLOW-UP|1962-11-04||||1967-04-11||1964-10-27|1970-10-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||STRUSTAT|STEROID USE STATUS||||EIA UNIT|CR-CT||UG/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|INTERVIEWER|RADIOLOGIST|NA|4||88||SCREENING|1969-04-01||||1969-01-20||1970-05-09|1966-06-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DL|NON-QUANTIFIABLE MRD POSITIVITY||EP U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|N|4||88||BASELINE|1968-05-04||||1964-07-06||1971-05-09|1972-02-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/S/M2|INCREASED||MMHG|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|SPOUSE|RATER|U|5||7||WASHOUT|1960-03-01||||1960-02-07||1969-10-18|1963-12-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||NTRGRESP|NON-TARGET RESPONSE||||G/CM2|RELAPSED DISEASE||SCM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|PROXY|ADJUDICATOR|U|5||7||FOLLOW-UP|1963-08-07||||1970-02-24||1970-03-10|1969-01-17||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ARBITRARY U|NOT ALL EVALUATED||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|INVESTIGATOR|PATHOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1971-04-24||||1970-10-11||1961-02-02|1973-09-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MPS U|MR||MBQ/UL|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|SIGNIFICANT OTHER|HEMATOLOGIST|Y|1||38||WASHOUT|1968-08-21||||1971-03-03||1960-10-13|1960-09-16||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/KG/WEEK|PD-CT||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|FRIEND|OPHTHALMOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1969-03-21||||1966-03-05||1973-01-09|1966-07-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||METBRESP|METABOLIC RESPONSE||||UM2|PD-CT||SQU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CAREGIVER|PATHOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1969-07-28||||1971-03-12||1961-06-04|1972-10-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||METSIND|METASTATIC INDICATOR||||BQ/KG|SD||ABSORBANCE U/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|CHILD|UROLOGIST|N|3||39||OPEN LABEL TREATMENT|1962-07-24||||1965-08-26||1964-05-15|1960-02-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL/MOL|CYTOGENETIC MINIMAL RESPONSE||SUPPOSITORY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|PARENT|OTOLARYNGOLOGIST|N|3||39||RUN-IN|1964-10-01||||1964-07-17||1965-05-23|1970-07-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/MM2|CR||10^6 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|STUDY SUBJECT|RATER 2|N|4||88||INDUCTION TREATMENT|1963-09-18||||1962-03-06||1962-07-24|1972-12-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||ANATRESP|ANATOMIC RESPONSE||||ML/KG/DAY|OPTIMAL MORPHOLOGIC RESPONSE||MG2/DL2|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|CAREGIVER|MICROSCOPIST 2|N|4||88||LONG-TERM FOLLOW-UP|1966-03-20||||1963-04-27||1961-08-25|1969-11-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EQ|SD-CT||COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|STUDY SUBJECT|ADJUDICATOR 2|N|5||7||BLINDED TREATMENT|1960-06-30||||1971-05-28||1960-03-18|1961-03-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||MOLRESP|MOLECULAR RESPONSE||||MPL U|PMD||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|VENDOR|MICROSCOPIST 3|N|5||7||BLINDED TREATMENT|1973-04-05||||1962-12-09||1972-11-28|1966-08-23||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KN/CM2|RELAPSED DISEASE||H*%|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|FAMILY MEMBER|NEUROLOGIST 2|NA|1||38||BASELINE|1967-07-30||||1967-09-10||1961-08-20|1973-01-22||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/M2/DAY|NR||STRIP|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|VENDOR|PHYSIOTHERAPIST|U|1||38||OBSERVATION|1960-08-05||||1973-01-18||1972-04-29|1964-10-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ABSORBANCE U/MIN|STABLE||EP U|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|INTERVIEWER|DERMATOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1960-05-02||||1970-02-03||1961-07-08|1963-04-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||AMOL|MOLECULAR CR||ML/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|CHILD|INTERNIST|NA|2||58||WASHOUT|1963-05-24||||1966-03-02||1969-01-09|1968-07-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|1||||||METSIND|METASTATIC INDICATOR||||KG/L|CA125 75% RESPONSE||/10^5|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1971-05-24||||1963-12-18||1973-08-19|1964-11-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 ORGANISMS/G|HI-P||BQ/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|3||39||WASHOUT|1962-01-27||||1969-11-04||1968-09-04|1962-05-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UKAT|HI-E||NMOL BCE/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|SIBLING|ONCOLOGIST|U|4||88||RUN-IN|1968-03-05||||1964-04-28||1961-12-23|1970-05-19||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||AMOL|PCR||PSEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|STUDY SUBJECT|MICROSCOPIST 3|N|4||88||WASHOUT|1970-05-25||||1973-06-29||1965-10-03|1972-11-06||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|1||||||BONERESP|BONE RESPONSE||||U/G HB|CRI||NG/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|U|5||7||TREATMENT|1972-12-01||||1967-09-02||1967-09-21|1963-04-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7BAC399A-0523-476E-A294-C57309E573AF|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/M2/DAY|CHR||L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|PROXY|PATHOLOGIST 2|N|5||7||INDUCTION TREATMENT|1971-03-09||||1969-07-01||1964-07-14|1968-02-25||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UU/L|UNFAVORABLE RESPONSE||LOG EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1||38||SCREENING|1970-12-03||||1970-08-11||1962-12-01|1960-03-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/L/H|MR||10^7 CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|1||38||WASHOUT|1961-12-25||||1968-02-02||1972-12-19|1971-10-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||FMOL/L|NE||MBP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|SIGNIFICANT OTHER|RATER|N|2||58||RUN-IN|1963-07-06||||1972-12-22||1963-05-04|1972-06-28||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||EQ|MINOR PATHOLOGIC RESPONSE||10^6/EJACULATE U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|2||58||BLINDED TREATMENT|1972-01-09||||1960-12-03||1966-08-27|1961-11-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||SPLNRESP|SPLEEN RESPONSE||||ROENTGEN|INDETERMINATE RESPONSE||OZ EQ|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|STUDY SUBJECT|MICROSCOPIST 2|NA|3||39||RUN-IN|1965-05-20||||1972-07-10||1967-10-08|1972-02-09||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/ANIMAL|NON-QUANTIFIABLE MRD POSITIVITY||/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|FAMILY MEMBER|CARDIOLOGIST|U|3||39||WASHOUT|1965-12-27||||1965-05-15||1969-07-22|1972-10-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||TMRESP|TUMOR MARKER RESPONSE||||MAMP|PR||TAMPON|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|4||88||SCREENING|1970-10-18||||1968-12-13||1969-03-04|1969-05-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||LIVRRESP|LIVER RESPONSE||||MG/KG|PSA PROGRESSION||/10^5|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|FAMILY MEMBER|OPTOMETRIST|N|4||88||TREATMENT|1961-03-29||||1960-04-05||1967-11-28|1960-08-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MET*H|NON-CR/NON-PD||ML/MIN/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|CLINICAL STUDY SPONSOR|CARDIOLOGIST|N|5||7||INDUCTION TREATMENT|1961-07-06||||1969-12-30||1961-11-06|1973-03-03||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||LIVRRESP|LIVER RESPONSE||||ELISA UNIT/ML|NOT ALL EVALUATED||BQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|INVESTIGATOR|OPTOMETRIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-02-02||||1961-03-04||1968-05-13|1972-12-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/WK|PARTIAL MORPHOLOGIC RESPONSE||MG/ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|FRIEND|DERMATOLOGIST|U|1||38||OBSERVATION|1971-12-25||||1961-02-15||1973-07-16|1973-08-24||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||METSIND|METASTATIC INDICATOR||||NMOL|PD-CT||MESF|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|CHILD|NEUROLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1966-01-09||||1963-08-07||1970-10-29|1965-06-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CM H2O|MRD NEGATIVITY||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|ADJUDICATOR|INTERNIST|NA|2||58||SCREENING|1961-11-07||||1960-07-26||1961-07-13|1970-04-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||OVRLRESP|OVERALL RESPONSE||||KG/M2|PARTIAL MORPHOLOGIC RESPONSE||10^9 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|INVESTIGATOR|PATHOLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1971-11-14||||1968-01-18||1962-09-24|1965-01-13||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||TMRESP|TUMOR MARKER RESPONSE||||MPL U|PSA PROGRESSION||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|CHILD|NEUROLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1966-10-07||||1962-01-27||1969-12-10|1966-09-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^11/L|MRD RELAPSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|3||39||OPEN LABEL TREATMENT|1965-05-21||||1968-11-17||1966-03-05|1961-04-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||SPLNRESP|SPLEEN RESPONSE||||10^4/HPF|PD/RELAPSE AFTER HI||SV|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|FRIEND|NEUROLOGIST 1|Y|4||88||OBSERVATION|1973-04-26||||1971-05-21||1961-08-18|1966-02-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KG/CM2|SD-CT||/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|CHILD|MICROSCOPIST 1|N|4||88||OBSERVATION|1965-12-24||||1968-06-16||1971-08-03|1971-10-24||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||CLINRESP|CLINICAL RESPONSE||||UG/G/DAY|PR WITH LYMPHOCYTOSIS||ML/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|SIBLING|RADIOLOGIST 1|NA|5||7||TREATMENT|1962-12-27||||1964-08-09||1972-11-06|1963-02-06||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/DAY|ISD||PL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|RATER|NA|5||7||SCREENING|1969-05-15||||1968-03-06||1964-03-02|1973-01-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 DNA COPIES/ML|STABLE||MG/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|CHILD|ENDOCRINOLOGIST|Y|1||38||BLINDED TREATMENT|1971-08-23||||1967-12-25||1971-04-21|1966-05-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||SPLNRESP|SPLEEN RESPONSE||||MBQ/UL|ABSENT MORPHOLOGIC RESPONSE||OSM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1960-04-14||||1968-12-17||1964-02-26|1960-09-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||AU/ML|HI-P||SCOOPFUL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|STUDY SUBJECT|INTERNIST|U|2||58||BLINDED TREATMENT|1962-12-20||||1962-12-01||1960-09-09|1960-07-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CY/CM|SD||10^7 CFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|INTERVIEWER|READER 2|Y|2||58||OBSERVATION|1966-10-12||||1972-08-16||1963-09-22|1961-05-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||OVRLRESP|OVERALL RESPONSE||||KEV|CR||CGY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|CHILD|PATHOLOGIST|U|3||39||BLINDED TREATMENT|1964-06-15||||1968-08-08||1968-04-04|1963-12-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MEQ/ML|MR||FOZ_BR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|INTERVIEWER|CARDIOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1973-08-29||||1961-06-24||1963-10-28|1970-07-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||CLINRESP|CLINICAL RESPONSE||||10^7/L|NR||M/SEC2|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|Y|4||88||WASHOUT|1966-02-12||||1965-04-30||1966-06-18|1963-10-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CUP|ISD||10^3 RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|ADJUDICATION COMMITTEE|RATER 2|NA|4||88||OBSERVATION|1969-11-18||||1964-10-23||1960-09-01|1960-07-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UMOL/MG/MIN|EQUIVOCAL||MET*H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|GUARDIAN|ONCOLOGIST|N|5||7||OPEN LABEL TREATMENT|1967-08-08||||1971-07-07||1963-03-14|1970-05-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KN/CM2|DISEASE TRANSFORMATION||K|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|INTERVIEWER|PATHOLOGIST 2|U|5||7||TREATMENT|1960-02-26||||1966-08-08||1966-09-24|1960-06-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||BONERESP|BONE RESPONSE||||L/KG|PSEUDORESPONSE||NMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|1||38||TREATMENT|1968-10-07||||1972-10-28||1969-07-26|1973-02-07||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||SPLNRESP|SPLEEN RESPONSE||||DPM/0.5 ML|CR-CT||CMH2O*S/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|ADJUDICATOR|NEUROLOGIST 2|N|1||38||OBSERVATION|1961-01-25||||1971-10-02||1964-11-13|1961-06-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/HPF|IMPROVED||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||FOLLOW-UP|1961-08-29||||1972-03-21||1965-01-29|1973-04-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||METBRESP|METABOLIC RESPONSE||||H/WK|NON-PD||CUP EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|CHILD|UROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1963-04-27||||1965-01-08||1970-09-24|1967-05-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||MOLRESP|MOLECULAR RESPONSE||||COULOMB|VGPR||H/WK|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|SPOUSE|MICROSCOPIST 2|N|3||39||LONG-TERM FOLLOW-UP|1972-12-17||||1971-04-23||1961-01-22|1960-09-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||TSP EQ|NPR||VG/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||BLINDED TREATMENT|1961-10-04||||1969-03-30||1967-12-17|1964-03-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||NEWLIND|NEW LESION INDICATOR||||TESLA|MINOR PATHOLOGIC RESPONSE||MM/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|DOMESTIC PARTNER|HEMATOLOGIST|Y|4||88||WASHOUT|1970-04-07||||1961-12-29||1973-07-05|1962-11-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||MOLRESP|MOLECULAR RESPONSE||||UMOL/H/MMOL|NR||ROENTGEN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|ADJUDICATOR|DERMATOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1969-06-29||||1961-03-01||1971-08-24|1964-07-15||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||METSIND|METASTATIC INDICATOR||||10^9/DOSE|PSEUDOPROGRESSION||UG/M2/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1969-10-03||||1962-10-18||1970-07-03|1971-04-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||NEWLPROG|NEW LESION PROGRESSION||||CD|NPR||UG/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|5||7||RUN-IN|1969-09-11||||1960-04-09||1966-03-20|1973-01-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KDA|IMMUNOPHENOTYPIC CR||TABLET|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|ADJUDICATOR|ONCOLOGIST|U|1||38||OBSERVATION|1968-03-18||||1962-12-28||1967-06-11|1970-10-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/CM2|MRD RELAPSE||UG/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|GUARDIAN|CARDIOLOGIST|NA|1||38||OBSERVATION|1967-03-16||||1969-01-29||1972-04-09|1964-03-05||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PL|TREATMENT FAILURE||G/ANIMAL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|VENDOR|READER 2|N|2||58||FOLLOW-UP|1966-01-28||||1971-12-27||1971-01-13|1972-01-22||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KCAL/DAY|ICPD||G/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|FAMILY MEMBER|RADIOLOGIST 2|NA|2||58||BASELINE|1962-11-08||||1969-02-02||1963-02-27|1968-02-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||TRGRESP|TARGET RESPONSE||||VG/KG|IUPD||PPB|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|3||39||OPEN LABEL TREATMENT|1970-06-01||||1965-11-23||1961-01-18|1967-05-02||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||BESTRESP|BEST OVERALL RESPONSE||||U/G/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||CI|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|PROXY|PATHOLOGIST 1|NA|3||39||BLINDED TREATMENT|1964-11-24||||1962-06-11||1968-09-05|1969-08-16||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||BONERESP|BONE RESPONSE||||FT2|INCREASED||10^7 CFU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|STUDY SUBJECT|OPTOMETRIST|U|4||88||OBSERVATION|1973-08-20||||1968-08-13||1966-08-14|1961-11-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||STRUSTAT|STEROID USE STATUS||||KPA/L/SEC|ISD||CMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|INTERVIEWER|UROLOGIST|NA|4||88||TREATMENT|1970-04-17||||1973-01-10||1971-06-27|1973-01-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||TRGRESP|TARGET RESPONSE||||APPLICATION|MORPHOLOGIC LEUKEMIA-FREE STATE||V/V|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|INVESTIGATOR|NEUROLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1971-10-07||||1968-04-05||1961-05-24|1969-10-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||METBRESP|METABOLIC RESPONSE||||10^9 ORGANISMS|RELAPSED DISEASE FROM CR||MEQ/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|VENDOR|READER|U|5||7||FOLLOW-UP|1963-07-26||||1965-01-06||1971-12-08|1973-06-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||YEARS|MORPHOLOGIC CR||ML/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|SIBLING|ONCOLOGIST 1|N|1||38||RUN-IN|1967-12-10||||1964-11-09||1961-07-24|1967-09-14||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MNFI|QUANTIFIABLE MRD POSITIVITY||OZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|SIGNIFICANT OTHER|ONCOLOGIST|N|1||38||BLINDED TREATMENT|1970-11-29||||1964-10-14||1960-01-08|1966-10-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PLUG|PMD||CAPLET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|PARENT|MICROSCOPIST 3|N|2||58||FOLLOW-UP|1962-01-01||||1961-03-21||1961-08-14|1965-02-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||METBRESP|METABOLIC RESPONSE||||CCID 50/DOSE|PD-CT||U/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|PROXY|RADIOLOGIST|Y|2||58||CONTINUATION TREATMENT|1963-03-20||||1967-07-08||1965-11-18|1964-01-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||BONERESP|BONE RESPONSE||||QUANTITY SUFFICIENT|MINOR PATHOLOGIC RESPONSE||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CHILD|ADJUDICATOR 3|Y|3||39||BLINDED TREATMENT|1973-04-12||||1968-06-11||1968-01-02|1972-08-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||BESTRESP|BEST OVERALL RESPONSE||||IU/MMOL|MOLECULAR MAJOR RESPONSE||UMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|INVESTIGATOR|NEUROLOGIST 1|U|3||39||BASELINE|1960-03-02||||1971-06-29||1964-04-20|1962-02-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||EID 50/ML|ICR||G/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|4||88||OPEN LABEL TREATMENT|1960-01-13||||1962-09-11||1962-04-09|1971-11-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CONTAINER|RELAPSED DISEASE||CMHG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|ADJUDICATOR|RADIOLOGIST 1|Y|4||88||RUN-IN|1962-02-09||||1963-11-14||1960-06-24|1972-12-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 IU/ML|DISEASE TRANSFORMATION||10^6 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|5||7||FOLLOW-UP|1961-04-07||||1960-10-09||1964-10-25|1961-01-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||ANATRESP|ANATOMIC RESPONSE||||CI/UL|PD-CT||ENZYME U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|PROXY|READER 2|Y|5||7||SCREENING|1972-09-26||||1973-01-16||1965-04-17|1970-12-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||LIVRRESP|LIVER RESPONSE||||COPIES/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|VENDOR|UROLOGIST|NA|1||38||OPEN LABEL TREATMENT|1964-07-13||||1973-06-05||1962-03-12|1963-01-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||CYTORESP|CYTOGENETIC RESPONSE||||USIEMENS|IMMUNOPHENOTYPIC CR||V/V|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|SIBLING|HEMATOLOGIST|Y|1||38||WASHOUT|1965-11-04||||1968-12-01||1967-02-03|1960-10-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 ELISA UNIT|QUANTIFIABLE MRD POSITIVITY||PSI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|U|2||58||FOLLOW-UP|1960-11-01||||1963-12-01||1964-11-23|1964-06-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/DL|MAJOR PATHOLOGIC RESPONSE||MM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|CAREGIVER|RATER|NA|2||58||OBSERVATION|1965-05-23||||1965-10-24||1963-10-07|1968-06-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||MOLRESP|MOLECULAR RESPONSE||||U|NON-PD||CD|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|FAMILY MEMBER|RATER 1|U|3||39||BASELINE|1960-06-25||||1967-01-25||1970-10-22|1963-05-13||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||ANATRESP|ANATOMIC RESPONSE||||CAL|NON-CR/NON-PD||BU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|SIGNIFICANT OTHER|ADJUDICATOR 3|N|3||39||OPEN LABEL TREATMENT|1960-03-14||||1967-04-17||1961-03-25|1964-03-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||LIVRRESP|LIVER RESPONSE||||FT|MORPHOLOGIC LEUKEMIA-FREE STATE||MANSON U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|SIBLING|OPHTHALMOLOGIST|NA|4||88||WASHOUT|1966-10-06||||1972-09-17||1965-05-18|1960-06-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||NEWLIND|NEW LESION INDICATOR||||CD|CYTOGENETIC MINIMAL RESPONSE||ML/SEC/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|ADJUDICATION COMMITTEE|ONCOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1960-07-04||||1969-01-10||1968-05-10|1967-01-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/MOL|PR-CT||KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1966-07-30||||1972-01-14||1970-04-27|1971-04-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ANTIBODY UNIT|STABLE||MV/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|5||7||TREATMENT|1967-02-20||||1972-08-29||1963-08-07|1968-09-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||NEWLPROG|NEW LESION PROGRESSION||||GBQ|ICR||CAN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|ADJUDICATOR|ADJUDICATOR 1|NA|1||38||TREATMENT|1962-10-13||||1965-07-14||1965-08-14|1969-06-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PACKET|CHR||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|DOMESTIC PARTNER|MICROSCOPIST 3|NA|1||38||SCREENING|1961-12-24||||1967-10-28||1962-06-07|1966-02-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/KG/H|NON-QUANTIFIABLE MRD POSITIVITY||BAU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|2||58||SCREENING|1960-08-12||||1967-12-25||1960-08-17|1963-09-15||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||METBRESP|METABOLIC RESPONSE||||MEQ/MMOL|PD/RELAPSE AFTER HI||UMOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1972-01-15||||1965-02-21||1961-03-08|1960-04-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||NEWLIND|NEW LESION INDICATOR||||LOG10 PFU|CRI||/4.0 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|INTERVIEWER|INTERNIST|NA|3||39||WASHOUT|1960-08-25||||1967-04-26||1971-01-31|1966-07-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/KG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||LOG10 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|INVESTIGATOR|RADIOLOGIST 1|NA|3||39||RUN-IN|1972-08-31||||1970-03-30||1969-11-23|1965-01-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||MOLRESP|MOLECULAR RESPONSE||||DAYS|SD-CT||OI50|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|ADJUDICATION COMMITTEE|OPTOMETRIST|NA|4||88||BLINDED TREATMENT|1967-06-28||||1968-10-13||1965-04-25|1964-05-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DPM/MG|NON-QUANTIFIABLE MRD POSITIVITY||U/CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1964-03-25||||1972-03-12||1968-12-11|1962-05-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/7.5 ML|OPTIMAL MORPHOLOGIC RESPONSE||ABSORBANCE U/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|PARENT|RATER|NA|5||7||BASELINE|1969-06-16||||1972-02-17||1972-08-15|1965-05-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||NEWLPROG|NEW LESION PROGRESSION||||CI/KG|PR-CT||FT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|PARENT|DERMATOLOGIST|Y|5||7||WASHOUT|1971-03-04||||1965-10-17||1970-03-31|1962-03-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DAGU/ML|RELAPSED DISEASE||DEG/MM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|SIBLING|CARDIOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1967-11-06||||1966-10-29||1968-08-01|1972-01-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||VG/ML|PSEUDOPROGRESSION||UG/L/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1963-06-25||||1961-03-24||1970-11-23|1973-08-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||SPLNRESP|SPLEEN RESPONSE||||LOG10 ELISA UNIT/DOSE|SD||C|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|INVESTIGATOR|UROLOGIST|U|2||58||BASELINE|1960-05-16||||1971-11-09||1963-09-11|1971-02-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/G/H|SMD||UM/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|2||58||TREATMENT|1964-08-05||||1968-01-16||1966-05-01|1968-06-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DAGU|CYTOGENETIC CR||MHZ|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|3||39||INDUCTION TREATMENT|1965-07-16||||1964-10-13||1969-07-31|1960-05-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||BONERESP|BONE RESPONSE||||MMAL|ICPD||WEBER|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|READER|Y|3||39||TREATMENT|1973-08-11||||1964-05-20||1967-01-10|1966-11-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KIU|CYTOGENETIC CR||MMOL/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|GUARDIAN|ADJUDICATOR 3|N|4||88||FOLLOW-UP|1970-03-23||||1967-01-15||1967-12-31|1961-03-27||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^3/HPF|PARTIAL MORPHOLOGIC RESPONSE||CM/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|CHILD|CLINICAL PATHOLOGIST|NA|4||88||RUN-IN|1968-05-11||||1968-10-27||1966-10-09|1966-10-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CMHG|DECREASED||CMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|5||7||SCREENING|1965-08-22||||1971-12-15||1964-06-14|1969-09-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APPLICATION|WORSENED||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|INTERVIEWER|RATER 1|NA|5||7||BASELINE|1964-01-17||||1965-05-13||1960-02-24|1967-06-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UL/DOSE|CR||LOG10 PFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|PARENT|CARDIOLOGIST|N|1||38||BLINDED TREATMENT|1970-05-02||||1966-11-24||1968-11-25|1964-10-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||SPLNRESP|SPLEEN RESPONSE||||DAGU|SMD||PG/DL|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST 1|N|1||38||SCREENING|1972-10-02||||1966-12-21||1970-02-11|1960-01-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/G HB|NON-QUANTIFIABLE MRD POSITIVITY||G/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||CONTINUATION TREATMENT|1972-05-21||||1962-12-19||1962-03-24|1969-05-16||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^3 ORGANISMS/G|MORPHOLOGIC CR||MOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|DOMESTIC PARTNER|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-07-20||||1962-04-10||1971-09-04|1966-07-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||L/H|MCR||TABLET|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1961-05-29||||1969-10-11||1971-01-24|1968-06-04||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||HR/DAY|DECREASED||MM/SEC|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|FRIEND|READER 3|U|3||39||INDUCTION TREATMENT|1969-10-17||||1961-01-10||1966-12-22|1967-07-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||NEWLPROG|NEW LESION PROGRESSION||||/100 HPFS|CA125 75% RESPONSE||HR/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|SPOUSE|READER 1|U|4||88||RUN-IN|1967-03-07||||1967-08-04||1972-11-09|1965-01-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||DRINK|CA125 50% RESPONSE||LOG10 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|SPOUSE|READER 1|Y|4||88||OBSERVATION|1972-02-23||||1966-05-22||1973-02-25|1969-04-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CFU/G|PCR||MS2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|NA|5||7||INDUCTION TREATMENT|1964-01-29||||1963-11-18||1961-01-19|1960-01-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CCID 50/ML|PD/RELAPSE AFTER HI||NKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|PARENT|OPHTHALMOLOGIST|N|5||7||BASELINE|1960-07-20||||1965-08-21||1967-10-31|1964-08-22||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||TRGRESP|TARGET RESPONSE||||UG/M2/DAY|PD||IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|PROXY|PATHOLOGIST 1|NA|1||38||OBSERVATION|1961-07-12||||1969-08-07||1970-03-11|1971-10-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/MOL|NON-CR/NON-PD||LOG10 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|SIBLING|MICROSCOPIST 2|Y|1||38||RUN-IN|1960-04-23||||1965-08-19||1965-01-10|1960-10-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||NEWLPROG|NEW LESION PROGRESSION||||MPS U|MINOR PATHOLOGIC RESPONSE||MM2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|NON-HEALTH CARE PROFESSIONAL|READER 3|Y|2||58||OBSERVATION|1960-05-30||||1962-07-20||1966-05-13|1960-08-31||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PNU/ML|NON-ICR/NON-IUPD||BU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|DOMESTIC PARTNER|UROLOGIST|Y|2||58||WASHOUT|1965-10-21||||1973-07-29||1969-12-09|1966-10-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||OVRLRESP|OVERALL RESPONSE||||BQ/ML|CPR||EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|3||39||RUN-IN|1962-11-05||||1973-01-05||1972-06-15|1963-05-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||NTRGRESP|NON-TARGET RESPONSE||||CMH2O*S/ML|OPTIMAL MORPHOLOGIC RESPONSE||MM/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|3||39||TREATMENT|1967-05-04||||1964-01-16||1973-08-29|1972-07-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/G|CYTOGENETIC MINIMAL RESPONSE||EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|CLINICAL STUDY SPONSOR|READER|N|4||88||OPEN LABEL TREATMENT|1961-10-23||||1965-06-07||1972-08-04|1968-07-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^7 TCID 50/DOSE|UNFAVORABLE RESPONSE||MNFI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|CAREGIVER|ADJUDICATOR 2|N|4||88||TREATMENT|1968-07-07||||1966-08-14||1969-04-19|1971-06-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/UL|SCR||KPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|GUARDIAN|PATHOLOGIST 2|N|5||7||OBSERVATION|1965-06-09||||1960-05-01||1962-04-27|1969-01-11||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||BESTRESP|BEST OVERALL RESPONSE||||PATCH|UNFAVORABLE RESPONSE||MV/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|DOMESTIC PARTNER|ONCOLOGIST 2|Y|5||7||OBSERVATION|1973-07-27||||1964-07-28||1969-01-19|1969-12-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CI/UG|RELAPSED DISEASE||UEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|VENDOR|ADJUDICATOR 3|NA|1||38||TREATMENT|1964-04-14||||1964-03-24||1961-09-27|1964-07-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CYCLE/MIN|CHR||/CMH2O|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|INDEPENDENT ASSESSOR|PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-04-11||||1967-06-06||1969-03-07|1965-11-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||CLINRESP|CLINICAL RESPONSE||||UG/M2|CA125 50% RESPONSE||MV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|SPOUSE|FORENSIC PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1970-04-19||||1967-08-01||1961-10-14|1961-04-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UG/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||V/V|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|GUARDIAN|OTOLARYNGOLOGIST|Y|2||58||BASELINE|1963-05-01||||1961-12-28||1969-05-19|1967-03-12||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||BONERESP|BONE RESPONSE||||DMOL|UNFAVORABLE RESPONSE||UL|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|GUARDIAN|DERMATOLOGIST|U|3||39||TREATMENT|1960-12-06||||1961-05-27||1964-05-27|1960-08-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L|NON-CR/NON-PD||MCI/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CAREGIVER|RATER 1|NA|3||39||TREATMENT|1961-02-10||||1973-08-05||1972-10-15|1963-11-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/ML/DAY|SCR||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|CLINICAL STUDY SPONSOR|MICROSCOPIST|U|4||88||SCREENING|1960-05-16||||1964-05-29||1965-11-04|1970-03-19||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PIXELS/CM|CPR||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|4||88||RUN-IN|1966-10-08||||1962-08-25||1970-09-17|1971-12-12||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/KG|TREATMENT FAILURE||10^6 RNA COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|INTERVIEWER|ADJUDICATOR 2|NA|5||7||INDUCTION TREATMENT|1972-09-29||||1966-11-18||1967-01-09|1973-01-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/MS|PARTIAL MORPHOLOGIC RESPONSE||GY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|INVESTIGATOR|ENDOCRINOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1973-06-15||||1962-09-08||1968-06-17|1972-07-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KS|SD-CT||EP U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|GUARDIAN|ADJUDICATOR 3|N|1||38||TREATMENT|1970-11-30||||1965-09-24||1973-08-23|1966-02-13||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE|NON-PD||ML/MIN/MMHG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|1||38||CONTINUATION TREATMENT|1963-01-16||||1960-06-13||1967-12-25|1968-06-19||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||TRGRESP|TARGET RESPONSE||||EID 50/DOSE|CYTOGENETIC MINOR RESPONSE||MG/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|CAREGIVER|PATHOLOGIST 2|N|2||58||SCREENING|1961-08-22||||1968-11-27||1967-09-27|1966-04-09||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BQ/MG|HI-P||U/M2/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|SPOUSE|NEUROLOGIST|Y|2||58||CONTINUATION TREATMENT|1961-08-05||||1966-08-29||1966-06-20|1962-04-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||VP/DOSE|SCR||RAD|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|DOMESTIC PARTNER|READER 1|NA|3||39||OPEN LABEL TREATMENT|1965-12-17||||1965-05-16||1969-10-16|1968-08-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PA|MRD NEGATIVITY||LOG10 ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|CHILD|MICROSCOPIST 3|N|3||39||TREATMENT|1968-01-16||||1961-05-18||1961-02-08|1968-06-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||BESTRESP|BEST OVERALL RESPONSE||||OI50|MORPHOLOGIC CR||NCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|CAREGIVER|ADJUDICATOR 3|NA|4||88||INDUCTION TREATMENT|1965-07-12||||1969-01-18||1973-08-20|1962-12-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PKAT/L|PSEUDORESPONSE||LOG10 TCID 50/UL|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|4||88||OBSERVATION|1971-02-25||||1968-07-25||1965-10-17|1971-10-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||LIVRRESP|LIVER RESPONSE||||IU/DL|FAVORABLE RESPONSE||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||RUN-IN|1960-04-19||||1970-11-14||1961-12-14|1962-11-01||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||METSIND|METASTATIC INDICATOR||||UV2|OPTIMAL MORPHOLOGIC RESPONSE||10^6 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|FAMILY MEMBER|ONCOLOGIST|NA|5||7||BLINDED TREATMENT|1962-10-14||||1964-06-10||1965-08-16|1964-10-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||TMRESP|TUMOR MARKER RESPONSE||||IU/MMOL|CPR||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|SIBLING|ADJUDICATOR 3|U|1||38||FOLLOW-UP|1971-05-28||||1962-12-22||1961-07-22|1963-05-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||STRUSTAT|STEROID USE STATUS||||10^7 TCID 50/DOSE|CYTOGENETIC MINIMAL RESPONSE||MOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1||38||CONTINUATION TREATMENT|1960-02-15||||1961-05-16||1964-02-18|1964-08-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||%|ICR||U.CARR|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|PARENT|NEUROLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1969-06-13||||1972-08-02||1965-07-28|1969-04-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/M2/DAY|IMPROVED||UCI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|2||58||WASHOUT|1964-03-23||||1968-06-16||1965-09-04|1963-10-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DIOPTER|MRD PERSISTENCE||MG/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|3||39||RUN-IN|1967-08-24||||1968-12-22||1966-11-10|1964-11-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||RING|CRI||10^6 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1970-02-26||||1971-01-15||1960-04-25|1966-01-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||TMRESP|TUMOR MARKER RESPONSE||||G/KG/DAY|MR||NMOL/L/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|Y|4||88||OBSERVATION|1961-05-02||||1970-03-06||1971-01-07|1969-09-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||METSIND|METASTATIC INDICATOR||||10^4 CFU|IMPROVED||ML/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|INTERVIEWER|ADJUDICATOR 1|NA|4||88||BASELINE|1971-10-12||||1968-05-24||1965-04-21|1962-06-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||EIA UNIT|MINOR PATHOLOGIC RESPONSE||COPIES/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|5||7||CONTINUATION TREATMENT|1970-02-21||||1960-05-07||1969-04-13|1960-12-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UCI/KG|PSEUDORESPONSE||PATCH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|CAREGIVER|READER 3|U|5||7||CONTINUATION TREATMENT|1965-05-22||||1968-11-21||1969-07-26|1961-09-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||NTRGRESP|NON-TARGET RESPONSE||||U/G/MIN|UNEQUIVOCAL||/2000 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|VENDOR|RADIOLOGIST 2|Y|1||38||SCREENING|1960-06-06||||1972-11-05||1965-07-30|1968-05-02||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^5/L|RELAPSED DISEASE FROM CR OR PR||LOG10 ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|STUDY SUBJECT|ADJUDICATOR|U|1||38||OPEN LABEL TREATMENT|1963-03-04||||1970-09-20||1969-09-07|1967-12-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||NTRGRESP|NON-TARGET RESPONSE||||S/H|MRD RELAPSE||BLOCKS|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|PARENT|UROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1972-12-05||||1972-01-06||1968-09-19|1965-10-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||FRAMES/S|NE||U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|2||58||TREATMENT|1964-10-26||||1972-10-01||1960-07-25|1972-12-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||TRGRESP|TARGET RESPONSE||||RPM|SMD||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|VENDOR|READER 3|U|3||39||BASELINE|1971-11-11||||1960-11-02||1972-02-21|1964-12-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||CLINRESP|CLINICAL RESPONSE||||KBQ/UL|WORSENED||SBE/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1968-02-14||||1973-06-30||1967-08-26|1971-09-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||BESTRESP|BEST OVERALL RESPONSE||||RATIO|PD-CT||MEQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|ADJUDICATOR|PHYSIOTHERAPIST|Y|4||88||TREATMENT|1971-09-14||||1968-09-01||1961-09-21|1965-06-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NFIU|EQUIVOCAL||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4||88||BLINDED TREATMENT|1966-03-25||||1964-02-10||1965-04-24|1960-01-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||LIVRRESP|LIVER RESPONSE||||MMOL/MIN/KPA/L|PSEUDORESPONSE||U/KG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|GUARDIAN|PATHOLOGIST 2|Y|5||7||BLINDED TREATMENT|1972-01-15||||1970-04-21||1972-08-21|1971-08-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MG/KG/H|OPTIMAL MORPHOLOGIC RESPONSE||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|SIGNIFICANT OTHER|HEMATOLOGIST|N|5||7||OBSERVATION|1966-02-28||||1970-08-29||1971-04-06|1971-03-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ANTI-XA IU|PR WITH LYMPHOCYTOSIS||10^7 CFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|1||38||BLINDED TREATMENT|1964-04-09||||1965-11-15||1967-02-13|1967-11-28||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KPA/L/SEC|QUANTIFIABLE MRD POSITIVITY||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|U|1||38||BLINDED TREATMENT|1967-09-03||||1970-06-05||1968-03-17|1970-05-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/LPF|MRD PERSISTENCE||PFU/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|2||58||OBSERVATION|1963-12-31||||1960-04-01||1967-08-12|1961-04-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NEBULE|PCR||FRACTION OF 1|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|ADJUDICATOR|ENDOCRINOLOGIST|Y|2||58||FOLLOW-UP|1973-06-25||||1971-12-07||1969-10-05|1970-02-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||STRUSTAT|STEROID USE STATUS||||GY/H|DISEASE TRANSFORMATION||PMOL/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|CHILD|PHYSIOTHERAPIST|NA|3||39||SCREENING|1967-12-24||||1970-03-11||1971-05-22|1967-08-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||ANATRESP|ANATOMIC RESPONSE||||MET*H|TREATMENT FAILURE||SUPPOSITORY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|ADJUDICATOR|FORENSIC PATHOLOGIST|NA|3||39||SCREENING|1970-02-03||||1968-01-26||1970-01-10|1960-07-31||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||METSIND|METASTATIC INDICATOR||||HOURS|SCR||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|4||88||SCREENING|1962-05-23||||1961-01-13||1969-04-16|1963-05-24||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BREATHS/30S|PD/RELAPSE AFTER HI||MMOL/MIN/KPA|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|GUARDIAN|DERMATOLOGIST|Y|4||88||BLINDED TREATMENT|1970-01-09||||1961-02-19||1966-06-03|1963-06-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||SPLNRESP|SPLEEN RESPONSE||||CONTAINER|PR WITH LYMPHOCYTOSIS||ELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1963-01-17||||1965-09-21||1973-03-14|1966-01-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PPTH|PMR||MET*MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|VENDOR|UROLOGIST|U|5||7||BLINDED TREATMENT|1963-08-06||||1970-05-07||1964-01-17|1961-09-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CMOL|NOT ALL EVALUATED||IN2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|READER 1|Y|1||38||SCREENING|1969-11-11||||1968-04-01||1971-08-26|1964-04-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|2||||||METSIND|METASTATIC INDICATOR||||UKAT/L|CCR||NMOL/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|1||38||INDUCTION TREATMENT|1971-10-20||||1964-12-30||1964-08-29|1961-05-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PIXELS/IN|CR-CT||BEAM BREAKS|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|FAMILY MEMBER|HEMATOLOGIST|U|2||58||FOLLOW-UP|1968-01-25||||1963-06-22||1970-08-24|1972-12-01||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||OZ|CR||TUBERCULIN UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|INVESTIGATOR|NEUROLOGIST|Y|2||58||BLINDED TREATMENT|1971-06-05||||1965-08-18||1972-10-01|1973-04-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|1||||||CYTORESP|CYTOGENETIC RESPONSE||||VOXEL|TREATMENT FAILURE||/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|GUARDIAN|ADJUDICATOR 2|Y|3||39||OBSERVATION|1966-01-26||||1968-10-20||1963-04-27|1972-05-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NSEC|PR-CT||V|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|STUDY SUBJECT|RADIOLOGIST|N|3||39||WASHOUT|1967-04-03||||1967-10-13||1973-08-21|1969-01-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/MIN|CYTOGENETIC MINOR RESPONSE||UMOL/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|4||88||RUN-IN|1972-10-29||||1962-06-02||1968-11-26|1963-06-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|2||||||CLINRESP|CLINICAL RESPONSE||||ML/G/MIN|PMR||PPB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|VENDOR|OTOLARYNGOLOGIST|N|4||88||OBSERVATION|1970-10-14||||1969-07-23||1967-11-13|1969-05-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L DDU|HI-E||CIGAR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|SPOUSE|CARDIOLOGIST|NA|5||7||RUN-IN|1972-02-06||||1971-05-27||1966-09-18|1961-10-28||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3461C227-E30F-482B-B404-026FE0CA3549|2||||||NTRGRESP|NON-TARGET RESPONSE||||QUANTITY SUFFICIENT|UNEQUIVOCAL||BAU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|CHILD|ONCOLOGIST 2|U|5||7||CONTINUATION TREATMENT|1969-12-26||||1971-12-31||1961-04-30|1967-01-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||G|SCR||UCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|SIBLING|ONCOLOGIST 2|N|1||38||BASELINE|1970-03-09||||1967-08-09||1961-03-03|1963-02-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MAC50|MORPHOLOGIC CR||PG/CELL|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|INTERVIEWER|OTOLARYNGOLOGIST|Y|1||38||SCREENING|1964-11-13||||1969-02-28||1962-01-09|1967-05-04||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||JDF UNIT|SD-CT||HEP|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|2||58||INDUCTION TREATMENT|1965-12-01||||1968-05-27||1967-08-12|1970-11-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NCI|CHR||ML/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|DOMESTIC PARTNER|HEMATOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1964-06-15||||1960-12-23||1967-06-09|1969-06-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PMOL/10^10 CELLS|MRD PERSISTENCE||CD|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|NA|3||39||OBSERVATION|1972-07-29||||1967-08-05||1961-02-23|1968-11-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||CLINRESP|CLINICAL RESPONSE||||U/M2/MIN|RELAPSED DISEASE FROM CR||ENZYME U/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|NA|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|NA|3||39||SCREENING|1961-04-05||||1961-09-10||1965-04-03|1973-01-27||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NMOL/L|MORPHOLOGIC CR||OI50|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|4||88||OBSERVATION|1970-01-26||||1961-02-05||1966-11-16|1961-04-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MOL/ML|PD-CT||UG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|SPOUSE|DERMATOLOGIST|NA|4||88||CONTINUATION TREATMENT|1969-09-28||||1970-03-16||1963-12-14|1967-01-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 TCID 50/ML|ISD||BREATHS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|STUDY SUBJECT|ENDOCRINOLOGIST|NA|5||7||OBSERVATION|1966-11-27||||1972-11-21||1965-03-01|1967-09-14||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KG/CM2|CYTOGENETIC MINIMAL RESPONSE||MET*MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|ADJUDICATOR|READER 2|U|5||7||BASELINE|1971-05-21||||1960-01-16||1965-05-14|1968-07-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||ANATRESP|ANATOMIC RESPONSE||||UMOL/L/H|EQUIVOCAL||UG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|SPOUSE|CARDIOLOGIST|NA|1||38||INDUCTION TREATMENT|1966-04-11||||1961-12-24||1965-10-02|1973-05-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||ANATRESP|ANATOMIC RESPONSE||||UM/DAY|NR||MMU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|VENDOR|DERMATOLOGIST|N|1||38||BLINDED TREATMENT|1970-08-04||||1971-05-17||1967-01-30|1966-09-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/ML|SD||CAPFUL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||OBSERVATION|1960-08-13||||1965-09-05||1965-12-15|1964-03-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DAYS/MONTH|CA125 50% RESPONSE||NEEDLE GAUGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|ADJUDICATION COMMITTEE|READER 2|Y|2||58||TREATMENT|1970-10-29||||1964-11-03||1960-11-29|1961-09-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^4 CFU/ML|CCR||MPL U|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|INTERVIEWER|PATHOLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1966-11-28||||1963-11-07||1971-04-29|1968-07-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UV2|SMD||MG/M2/H|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|INTERVIEWER|ONCOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1962-10-22||||1965-09-04||1967-04-14|1972-07-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FARAD|CYTOGENETIC PR||ABSORBANCE U/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|ADJUDICATOR|ENDOCRINOLOGIST|Y|4||88||WASHOUT|1968-02-17||||1964-09-16||1969-03-13|1965-08-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GTT|RELAPSED DISEASE||NG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|INVESTIGATOR|ADJUDICATOR 1|U|4||88||RUN-IN|1970-08-30||||1962-03-13||1966-06-20|1961-07-05||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/G/MIN|INCREASED||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|CLINICAL RESEARCH ASSOCIATE|READER 1|U|5||7||CONTINUATION TREATMENT|1964-10-24||||1968-09-06||1967-01-04|1970-05-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||LOG10 TCID 50/DOSE|MRD NEGATIVITY||KG/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BLINDED TREATMENT|1968-12-19||||1962-10-26||1973-05-12|1963-02-03||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||METBRESP|METABOLIC RESPONSE||||ENZYME U/G HB|CYTOGENETIC MINIMAL RESPONSE||DPM/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|INDEPENDENT ASSESSOR|READER|Y|1||38||TREATMENT|1970-07-20||||1971-11-05||1969-08-12|1971-10-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||LIVRRESP|LIVER RESPONSE||||L|IUPD||TORR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|U|1||38||BASELINE|1969-09-15||||1968-07-22||1969-04-27|1961-02-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||METSIND|METASTATIC INDICATOR||||MM/MIN|QUANTIFIABLE MRD POSITIVITY||10^6 DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|2||58||INDUCTION TREATMENT|1963-02-15||||1969-04-11||1964-01-17|1971-04-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||STRUSTAT|STEROID USE STATUS||||10^3 RNA COPIES/ML|DISEASE TRANSFORMATION||MU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|VENDOR|RADIOLOGIST 2|U|2||58||BLINDED TREATMENT|1960-03-19||||1970-04-17||1966-09-10|1967-11-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||MOLRESP|MOLECULAR RESPONSE||||CD*S/M2|PARTIAL MORPHOLOGIC RESPONSE||DROP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1972-06-19||||1964-02-28||1966-05-21|1967-03-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/CM H2O|PD FROM PR||MEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|3||39||WASHOUT|1970-12-26||||1962-12-22||1962-08-03|1960-06-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||SPLNRESP|SPLEEN RESPONSE||||EJACULATE U|EQUIVOCAL||DNA COPIES/UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|CHILD|ENDOCRINOLOGIST|N|4||88||OBSERVATION|1969-02-03||||1969-03-05||1961-10-07|1961-10-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||TMRESP|TUMOR MARKER RESPONSE||||CS|COMPLETE MRD RESPONSE||U/M2|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|CHILD|INTERNIST|U|4||88||WASHOUT|1969-10-19||||1966-12-23||1968-12-19|1972-07-29||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||NEWLPROG|NEW LESION PROGRESSION||||KAT|CMR||10^6 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|SIBLING|MICROSCOPIST 2|NA|5||7||BLINDED TREATMENT|1960-08-25||||1964-11-08||1960-08-20|1963-03-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||LIVRRESP|LIVER RESPONSE||||UKAT/10^12 RBC|OPTIMAL MORPHOLOGIC RESPONSE||MM|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|5||7||WASHOUT|1967-11-20||||1966-05-18||1961-06-21|1968-07-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||G/CM2|NON-QUANTIFIABLE MRD POSITIVITY||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|FAMILY MEMBER|READER 1|NA|1||38||SCREENING|1970-10-06||||1968-11-18||1962-10-27|1970-08-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||STRUSTAT|STEROID USE STATUS||||LOG10 CFU/G|SMD||DPM/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|1||38||CONTINUATION TREATMENT|1970-07-29||||1973-07-10||1964-06-08|1967-02-24||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||TRGRESP|TARGET RESPONSE||||MG/L|PSA PROGRESSION||DPM/MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|STUDY SUBJECT|CLINICAL PATHOLOGIST|Y|2||58||WASHOUT|1963-10-29||||1967-09-10||1963-09-09|1965-01-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AMPULE|NON-ICR/NON-IUPD||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||TREATMENT|1967-05-31||||1962-09-29||1964-02-08|1967-07-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||OVRLRESP|OVERALL RESPONSE||||/200 HPFS|ISD||NMOL BCE/L|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|RATER|N|3||39||CONTINUATION TREATMENT|1973-05-21||||1973-02-14||1970-11-26|1962-03-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||METBRESP|METABOLIC RESPONSE||||BOWL|CYTOGENETIC PR||CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|3||39||OBSERVATION|1960-06-11||||1966-01-12||1968-08-12|1970-01-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MILE|OPTIMAL MORPHOLOGIC RESPONSE||MG/G/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|INVESTIGATOR|READER 3|Y|4||88||FOLLOW-UP|1960-03-23||||1960-10-14||1969-04-15|1964-02-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||CLINRESP|CLINICAL RESPONSE||||PHERESIS UNIT|MR||CIGAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|STUDY SUBJECT|PATHOLOGIST|Y|4||88||CONTINUATION TREATMENT|1972-08-30||||1970-07-23||1971-04-22|1964-08-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG|PMD||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|ADJUDICATION COMMITTEE|ONCOLOGIST|N|5||7||FOLLOW-UP|1970-09-21||||1966-06-07||1960-12-14|1969-07-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||TMRESP|TUMOR MARKER RESPONSE||||MV2/HZ|CR||KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|5||7||TREATMENT|1963-12-08||||1968-04-02||1961-09-05|1960-03-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||NEWLPROG|NEW LESION PROGRESSION||||MJOULE/CM2|NE||G/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|1||38||BASELINE|1969-03-07||||1972-10-14||1961-03-13|1962-05-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/L|COMPLETE MRD RESPONSE||CIGAR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|1||38||OBSERVATION|1965-05-04||||1961-02-09||1963-07-09|1961-05-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/M2/MIN|RELAPSED DISEASE||UG/L FEU|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|ADJUDICATION COMMITTEE|RATER 2|Y|2||58||RUN-IN|1964-05-29||||1965-01-13||1967-10-19|1961-05-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||OVRLRESP|OVERALL RESPONSE||||SACHET|CR-CT||UG/H|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|PARENT|UROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1961-03-17||||1969-04-28||1961-07-23|1965-02-12||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CYLINDER|PR WITH LYMPHOCYTOSIS||10^6 U|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|CAREGIVER|NEUROLOGIST 1|N|3||39||WASHOUT|1972-03-06||||1961-04-15||1969-02-06|1963-03-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NKAT|PARTIAL MORPHOLOGIC RESPONSE||TRANSDUCING UNIT|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|ADJUDICATION COMMITTEE|RADIOLOGIST|U|3||39||WASHOUT|1960-04-30||||1968-10-24||1971-09-25|1972-07-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L/H|CYTOGENETIC CR||10^3 ORGANISMS|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|4||88||BASELINE|1972-05-26||||1961-01-29||1968-10-24|1960-02-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||SPLNRESP|SPLEEN RESPONSE||||FT3|CPR||ML/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|4||88||INDUCTION TREATMENT|1960-12-07||||1961-07-03||1962-10-28|1963-09-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||BESTRESP|BEST OVERALL RESPONSE||||BQ/KG|MCR||PELLET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|SIGNIFICANT OTHER|INTERNIST|NA|5||7||OBSERVATION|1962-10-07||||1966-02-09||1962-10-29|1960-03-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||SPLNRESP|SPLEEN RESPONSE||||KAT|OPTIMAL MORPHOLOGIC RESPONSE||MG/G/H|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|STUDY SUBJECT|RATER 2|NA|5||7||OBSERVATION|1970-03-13||||1972-12-08||1964-04-01|1973-06-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/MIN|UNEQUIVOCAL||MEQ/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|FAMILY MEMBER|READER 2|U|1||38||WASHOUT|1965-09-11||||1965-12-31||1971-12-30|1973-02-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%|MOLECULAR MAJOR RESPONSE||PL|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|GUARDIAN|PATHOLOGIST|U|1||38||INDUCTION TREATMENT|1969-08-21||||1972-08-24||1969-05-16|1969-05-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||SPLNRESP|SPLEEN RESPONSE||||10^7 CFU/ML|NON-QUANTIFIABLE MRD POSITIVITY||TUBERCULIN UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|RATER|N|2||58||FOLLOW-UP|1963-09-24||||1963-11-03||1964-12-15|1962-04-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||WATT|CYTOGENETIC NO RESPONSE||MPL U|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|2||58||LONG-TERM FOLLOW-UP|1972-11-04||||1969-02-20||1969-10-16|1967-08-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UIU/L|ICR||KV|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|INDEPENDENT ASSESSOR|RADIOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1971-06-05||||1972-02-24||1967-08-18|1971-11-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CIGARETTE|INDETERMINATE RESPONSE||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|SIBLING|ENDOCRINOLOGIST|Y|3||39||SCREENING|1966-09-25||||1965-07-06||1967-06-20|1973-09-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/ANIMAL|MR||FT3|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|CHILD|ADJUDICATOR 1|N|4||88||FOLLOW-UP|1969-11-17||||1972-10-09||1964-09-26|1966-12-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/U|NOT ALL EVALUATED||UG/ML/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|4||88||OBSERVATION|1966-07-20||||1961-08-16||1971-07-07|1970-11-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||LINEAR FT*LB|STABLE||V/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|GUARDIAN|PATHOLOGIST 1|Y|5||7||BASELINE|1962-02-04||||1964-06-12||1962-02-11|1960-10-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||YEARS|PR WITH LYMPHOCYTOSIS||MEQ/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|ADJUDICATION COMMITTEE|READER|NA|5||7||TREATMENT|1972-05-23||||1963-04-06||1971-11-09|1967-04-24||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||BONERESP|BONE RESPONSE||||CCID 50/DOSE|RELAPSED DISEASE||LOG10 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|ADJUDICATOR|ONCOLOGIST 2|NA|1||38||OBSERVATION|1966-02-08||||1973-04-29||1965-12-23|1966-04-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||GY|RELAPSED DISEASE FROM CR||UG/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|STUDY SUBJECT|OTOLARYNGOLOGIST|N|1||38||BASELINE|1972-09-08||||1961-09-25||1966-12-08|1973-03-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/MM2|SMD||ML/M2/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|ADJUDICATOR|MICROSCOPIST 3|U|2||58||CONTINUATION TREATMENT|1965-07-21||||1961-08-03||1964-04-30|1962-04-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||OVRLRESP|OVERALL RESPONSE||||/MIN|MAJOR PATHOLOGIC RESPONSE||EQ|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|CHILD|RATER 1|Y|2||58||WASHOUT|1961-08-24||||1965-06-19||1967-08-01|1963-03-18||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DEG|UNFAVORABLE RESPONSE||PT_US|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|STUDY SUBJECT|INTERNIST|N|3||39||BASELINE|1972-11-10||||1964-05-29||1970-06-02|1965-11-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||LIVRRESP|LIVER RESPONSE||||CMHG|SD-CT||NMOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|CAREGIVER|ONCOLOGIST|Y|3||39||RUN-IN|1973-08-16||||1971-01-01||1971-09-08|1965-10-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MG/L|PR WITH LYMPHOCYTOSIS||UL/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|4||88||RUN-IN|1972-02-18||||1968-07-19||1962-08-08|1970-07-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%|OPTIMAL MORPHOLOGIC RESPONSE||CAPLET|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1962-05-09||||1966-05-14||1967-06-22|1965-08-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||TMRESP|TUMOR MARKER RESPONSE||||BOWL|TREATMENT FAILURE||DAYS/MONTH|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|CAREGIVER|OTOLARYNGOLOGIST|Y|5||7||TREATMENT|1962-11-18||||1962-11-05||1970-11-06|1962-11-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CG|PD/RELAPSE AFTER HI||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|ADJUDICATOR|CARDIOLOGIST|N|5||7||INDUCTION TREATMENT|1967-09-21||||1969-11-09||1962-08-30|1962-07-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||OVRLRESP|OVERALL RESPONSE||||G/CAGE|MRD NEGATIVITY||LM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|FRIEND|OTOLARYNGOLOGIST|NA|1||38||FOLLOW-UP|1970-07-27||||1970-06-28||1961-03-04|1966-06-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PMOL/G|STABLE||IMPLANT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|1||38||TREATMENT|1966-07-31||||1966-01-22||1972-09-01|1962-12-05||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||STRUSTAT|STEROID USE STATUS||||MMOL2/L2|SD||CPM|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|GUARDIAN|NEUROLOGIST 1|NA|2||58||BASELINE|1961-12-13||||1967-09-13||1971-01-05|1968-01-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^7 CFU/ML|CYTOGENETIC CR||CI/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|HEALTH CARE PROFESSIONAL|RATER 2|N|2||58||RUN-IN|1973-03-09||||1970-05-24||1969-03-27|1964-01-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^6 CFU/ML|CR-CT||S^-1(%O2)^-1|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|3||39||RUN-IN|1960-03-03||||1967-06-07||1970-10-18|1967-05-09||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||PATHRESP|PATHOLOGIC RESPONSE||||VG/ML|CPR||FFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|FRIEND|RATER 2|N|3||39||LONG-TERM FOLLOW-UP|1966-09-06||||1972-03-09||1966-01-22|1965-11-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/SEC/1.73M2|NR||KUSP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|FRIEND|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1960-11-28||||1966-05-24||1963-08-15|1968-02-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||NEWLPROG|NEW LESION PROGRESSION||||ML/MIN/MMHG|NED||MANSON U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|FAMILY MEMBER|PATHOLOGIST 2|U|4||88||BASELINE|1966-12-27||||1962-04-13||1969-09-22|1973-03-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||BESTRESP|BEST OVERALL RESPONSE||||WEBER|CR-CT||GENEQ/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1969-07-14||||1972-05-09||1963-11-10|1961-02-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||METBRESP|METABOLIC RESPONSE||||GPL U|PR||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|N|5||7||SCREENING|1971-01-11||||1972-10-30||1966-12-02|1960-10-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||ANATRESP|ANATOMIC RESPONSE||||MEQ|EQUIVOCAL||IU/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|PARENT|PATHOLOGIST|U|1||38||WASHOUT|1961-06-06||||1970-07-29||1970-04-03|1971-04-13||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PELLET|INCREASED||MV*MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|INTERVIEWER|RADIOLOGIST|NA|1||38||CONTINUATION TREATMENT|1967-10-25||||1966-02-25||1962-07-11|1970-08-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||NEWLPROG|NEW LESION PROGRESSION||||HR/DAY|IUPD||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|DOMESTIC PARTNER|READER 2|N|2||58||INDUCTION TREATMENT|1964-03-01||||1972-02-22||1966-11-10|1973-08-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/DAY|CA125 75% RESPONSE||GBQ/UG|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|FRIEND|PATHOLOGIST 1|U|2||58||INDUCTION TREATMENT|1960-09-14||||1964-01-25||1972-01-16|1960-05-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CMH2O*S/ML|PD||MN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|READER 2|U|3||39||OBSERVATION|1970-09-21||||1972-08-02||1964-12-22|1963-11-30||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|SIGNIFICANT OTHER|MICROSCOPIST 2|U|3||39||LONG-TERM FOLLOW-UP|1971-12-21||||1967-05-02||1967-04-02|1968-04-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||RING|NON-PD||PATCH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1972-10-27||||1969-03-09||1973-07-05|1964-01-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||CLINRESP|CLINICAL RESPONSE||||PUFF|INCREASED||MOL/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|SPOUSE|INTERNIST|N|4||88||BLINDED TREATMENT|1961-07-22||||1961-12-26||1972-12-26|1961-07-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HENRY|PSEUDOPROGRESSION||AMOL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|STUDY SUBJECT|ENDOCRINOLOGIST|N|5||7||BASELINE|1969-02-06||||1966-07-08||1972-01-09|1964-01-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||TMRESP|TUMOR MARKER RESPONSE||||CM/S|COMPLETE MRD RESPONSE||KN/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|NA|FRIEND|INTERNIST|NA|5||7||LONG-TERM FOLLOW-UP|1966-07-16||||1972-12-05||1967-03-28|1969-01-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CCID 50/ML|MAJOR PATHOLOGIC RESPONSE||PACKAGE|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|INDEPENDENT ASSESSOR|INTERNIST|N|1||38||FOLLOW-UP|1960-01-09||||1966-11-10||1972-05-18|1965-04-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KG/CM|PD/RELAPSE AFTER HI||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIGNIFICANT OTHER|ADJUDICATOR 2|U|1||38||FOLLOW-UP|1961-05-23||||1965-01-21||1971-08-07|1969-06-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||BESTRESP|BEST OVERALL RESPONSE||||GBQ/UG|FAVORABLE RESPONSE||ML/M2/H|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|ADJUDICATION COMMITTEE|READER 2|Y|2||58||CONTINUATION TREATMENT|1960-03-16||||1964-06-23||1970-06-01|1969-06-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||NEWLPROG|NEW LESION PROGRESSION||||DRINK|IMPROVED||PMOL/G|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|GUARDIAN|RADIOLOGIST 2|U|2||58||BLINDED TREATMENT|1970-07-04||||1967-03-11||1967-08-16|1967-04-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||NEWLIND|NEW LESION INDICATOR||||AMP|RELAPSED DISEASE||U/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|INTERVIEWER|NEUROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1967-03-08||||1963-08-21||1971-03-21|1961-10-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||METBRESP|METABOLIC RESPONSE||||UCI/L|PARTIAL MORPHOLOGIC RESPONSE||10^6/G|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|VENDOR|INTERNIST|Y|3||39||OPEN LABEL TREATMENT|1963-07-04||||1968-09-27||1967-01-08|1972-08-31||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GBQ/G|PR WITH LYMPHOCYTOSIS||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|STUDY SUBJECT|ADJUDICATOR|Y|4||88||WASHOUT|1968-08-23||||1964-07-16||1963-04-10|1961-08-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||METSIND|METASTATIC INDICATOR||||L/DAY|MOLECULAR MAJOR RESPONSE||MEQ/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|SPOUSE|CLINICAL PATHOLOGIST|Y|4||88||SCREENING|1963-08-08||||1973-04-04||1964-06-19|1966-01-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||MOLRESP|MOLECULAR RESPONSE||||UEQ|PSEUDOPROGRESSION||10^3/L|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|RATER 1|U|5||7||CONTINUATION TREATMENT|1968-05-14||||1964-08-18||1971-07-19|1969-11-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||BESTRESP|BEST OVERALL RESPONSE||||WAFER|HI-P||/7.5 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|Y|CAREGIVER|RADIOLOGIST 2|Y|5||7||TREATMENT|1970-05-23||||1963-04-20||1972-10-05|1966-09-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||NEWLIND|NEW LESION INDICATOR||||HOURS|ICPD||VIAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|1||38||SCREENING|1960-09-28||||1964-01-27||1967-02-09|1970-10-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CM/S|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UCI/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1961-05-03||||1972-04-14||1971-12-21|1968-01-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/MS|PD-CT||U/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|DOMESTIC PARTNER|MICROSCOPIST 2|N|2||58||BLINDED TREATMENT|1965-11-17||||1970-04-02||1971-09-15|1966-08-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/ANIMAL|MR||100 IU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|PROXY|OTOLARYNGOLOGIST|N|2||58||WASHOUT|1963-06-03||||1970-04-17||1962-07-03|1968-07-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ENZYME U/G HB|NOT ALL EVALUATED||U/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|3||39||OPEN LABEL TREATMENT|1964-11-25||||1966-09-15||1972-08-01|1968-10-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||OVRLRESP|OVERALL RESPONSE||||LOG10 CFU/G|MR||ML/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|DOMESTIC PARTNER|ADJUDICATOR 2|N|3||39||BLINDED TREATMENT|1960-05-20||||1966-03-12||1970-02-08|1973-08-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||LIVRRESP|LIVER RESPONSE||||MILE|HI-P||M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|CHILD|OTOLARYNGOLOGIST|U|4||88||OBSERVATION|1961-03-31||||1969-04-28||1966-03-29|1962-02-21||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/KG/DAY|CCR||UEQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|PARENT|MICROSCOPIST 3|NA|4||88||WASHOUT|1971-12-28||||1963-06-13||1969-06-29|1968-11-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||LIVRRESP|LIVER RESPONSE||||S/H|IMPROVED||H*%|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|SIGNIFICANT OTHER|RATER 2|N|5||7||WASHOUT|1972-02-16||||1960-11-27||1967-11-03|1960-09-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||NTRGRESP|NON-TARGET RESPONSE||||BE/ML|CYTOGENETIC NO RESPONSE||MBP|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|CAREGIVER|PHYSIOTHERAPIST|U|5||7||LONG-TERM FOLLOW-UP|1969-05-07||||1964-02-23||1965-06-10|1969-09-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||NEWLIND|NEW LESION INDICATOR||||CAN|NON-QUANTIFIABLE MRD POSITIVITY||UL/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|VENDOR|OTOLARYNGOLOGIST|U|1||38||WASHOUT|1972-11-06||||1963-08-07||1970-12-12|1966-05-30||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NG|NR||KPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|HEALTH CARE PROFESSIONAL|READER 2|NA|1||38||WASHOUT|1967-11-26||||1972-11-20||1964-08-28|1963-09-11||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TRANSDUCING UNIT|NON-CR/NON-PD||ML/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|2||58||CONTINUATION TREATMENT|1967-08-29||||1968-10-15||1965-04-07|1969-09-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||SPLNRESP|SPLEEN RESPONSE||||UV|INDETERMINATE RESPONSE||UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|CHILD|CARDIOLOGIST|NA|2||58||BLINDED TREATMENT|1970-01-05||||1961-06-23||1964-07-08|1969-12-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KAT|PMR||MASK|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|DOMESTIC PARTNER|MICROSCOPIST 3|U|3||39||TREATMENT|1970-01-28||||1960-07-08||1963-01-07|1960-10-31||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BQ/G|CR||10^5/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||BASELINE|1963-08-14||||1963-01-07||1968-03-26|1972-04-18||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||IU/KG|SD-CT||FARAD|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CAREGIVER|RATER 1|U|4||88||LONG-TERM FOLLOW-UP|1971-06-24||||1966-03-11||1967-09-16|1965-01-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||BONERESP|BONE RESPONSE||||SYRINGE|CMR||PUFF|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|4||88||OPEN LABEL TREATMENT|1971-04-02||||1970-03-06||1970-11-02|1970-03-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||NTRGRESP|NON-TARGET RESPONSE||||UV|HI-E||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|PARENT|ONCOLOGIST 1|Y|5||7||SCREENING|1967-10-08||||1965-01-31||1965-09-21|1969-12-29||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||TMRESP|TUMOR MARKER RESPONSE||||UCI/KG|ICPD||MMOL2/L2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|SIGNIFICANT OTHER|RADIOLOGIST 2|U|5||7||TREATMENT|1966-07-15||||1969-09-03||1961-10-23|1961-03-31||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FIU|CCR||GY/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|1||38||CONTINUATION TREATMENT|1965-03-12||||1970-02-28||1966-03-01|1970-08-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PA|COMPLETE MRD RESPONSE||PELLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|1||38||SCREENING|1965-04-30||||1967-01-15||1962-04-28|1969-05-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BQ/G|COMPLETE MRD RESPONSE||L/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|FRIEND|NEUROLOGIST 2|NA|2||58||BLINDED TREATMENT|1963-11-22||||1973-05-22||1963-04-19|1961-11-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||WAFER|SD||LOG10 TCID 50/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|GUARDIAN|ADJUDICATOR 1|U|2||58||BLINDED TREATMENT|1961-03-20||||1965-02-13||1964-11-25|1964-05-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PIPE|UNEQUIVOCAL||/100 WBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|STUDY SUBJECT|MICROSCOPIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1969-11-05||||1963-06-23||1965-04-01|1967-09-30||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||CLINRESP|CLINICAL RESPONSE||||L/H|MR||IMPLANT|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|3||39||SCREENING|1971-09-05||||1964-06-09||1963-12-30|1961-11-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||NTRGRESP|NON-TARGET RESPONSE||||OHM|VGPR||MG/M2/H|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|4||88||SCREENING|1973-01-08||||1968-10-15||1961-05-02|1967-04-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||GRAIN|PDU||ML/M2/H|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|STUDY SUBJECT|ENDOCRINOLOGIST|N|4||88||TREATMENT|1969-10-14||||1968-09-27||1962-01-29|1969-12-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||LINEAR FT*LB|RELAPSED DISEASE||TUBERCULIN UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|U|5||7||BASELINE|1965-02-17||||1962-07-21||1973-01-01|1969-10-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MS2|MCR||MESF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|PARENT|MICROSCOPIST 1|NA|5||7||WASHOUT|1967-12-28||||1964-10-01||1964-06-06|1969-12-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||BESTRESP|BEST OVERALL RESPONSE||||STRIP|SCR||MOL|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|FAMILY MEMBER|UROLOGIST|N|1||38||OPEN LABEL TREATMENT|1960-06-03||||1971-06-30||1966-11-23|1967-07-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/EJACULATE U|ICPD||UG/L DDU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|DOMESTIC PARTNER|READER 1|N|1||38||RUN-IN|1969-10-31||||1967-08-03||1973-08-11|1971-09-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||METBRESP|METABOLIC RESPONSE||||ML/H|PR WITH LYMPHOCYTOSIS||NSEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|SIBLING|PHYSIOTHERAPIST|U|2||58||RUN-IN|1969-06-02||||1960-11-16||1967-02-20|1965-02-13||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^3/L|PDU||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|PROXY|RADIOLOGIST|U|2||58||RUN-IN|1967-05-30||||1963-12-18||1964-11-03|1962-01-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||METBRESP|METABOLIC RESPONSE||||U/KG/MIN|CR||10^6/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|HEALTH CARE PROFESSIONAL|INTERNIST|U|3||39||OPEN LABEL TREATMENT|1971-03-05||||1964-07-18||1966-01-27|1971-03-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||OVRLRESP|OVERALL RESPONSE||||BOWL|NE||KPA/L/SEC|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|SIBLING|PEDIATRIC NEUROLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1966-07-02||||1963-09-30||1970-12-19|1961-12-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ABSORBANCE U|RELAPSED DISEASE FROM CR OR PR||UG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|VENDOR|OPTOMETRIST|U|4||88||OBSERVATION|1961-10-27||||1973-04-20||1963-11-10|1960-02-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PG/CELL|MCR||/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|4||88||BLINDED TREATMENT|1965-06-03||||1968-05-27||1970-10-06|1970-07-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL/DL|CA125 75% RESPONSE||OHM|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|STUDY SUBJECT|READER|NA|5||7||RUN-IN|1966-09-18||||1961-01-12||1960-11-01|1961-08-30||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG/ML/DAY|MOLECULAR MAJOR RESPONSE||TORR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||OBSERVATION|1961-01-04||||1964-01-01||1972-03-02|1967-06-25||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||ANATRESP|ANATOMIC RESPONSE||||DAMOL/L|HI-E||VP/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|SIGNIFICANT OTHER|RATER|Y|1||38||LONG-TERM FOLLOW-UP|1962-01-27||||1961-01-29||1968-01-28|1969-12-25||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DIP|NON-CR/NON-PD||PT_BR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|INDEPENDENT ASSESSOR|PATHOLOGIST|N|1||38||OPEN LABEL TREATMENT|1960-12-25||||1962-02-28||1972-12-26|1973-02-10||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||BESTRESP|BEST OVERALL RESPONSE||||CAPFUL|PDU||TUBE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|SIBLING|PEDIATRIC NEUROLOGIST|N|2||58||WASHOUT|1970-06-24||||1969-08-21||1968-08-14|1969-03-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/CAGE/WK|PD/RELAPSE AFTER HI||BOWL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|CHILD|NEUROLOGIST|N|2||58||SCREENING|1967-11-25||||1969-11-20||1966-10-18|1960-08-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||LIVRRESP|LIVER RESPONSE||||KM/H|HI-N||/2500 WBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|ADJUDICATION COMMITTEE|READER 3|N|3||39||WASHOUT|1967-03-21||||1960-06-24||1971-07-13|1963-06-05||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||MOLRESP|MOLECULAR RESPONSE||||/VF|PSA PROGRESSION||RATIO|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|VENDOR|DERMATOLOGIST|U|3||39||OPEN LABEL TREATMENT|1960-03-29||||1969-05-26||1970-01-29|1970-11-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||STRUSTAT|STEROID USE STATUS||||KPA|MORPHOLOGIC LEUKEMIA-FREE STATE||CS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|RATER 1|NA|4||88||BASELINE|1967-11-08||||1972-07-21||1968-02-04|1971-05-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||SPLNRESP|SPLEEN RESPONSE||||10^6 IU/ML|QUANTIFIABLE MRD POSITIVITY||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|FAMILY MEMBER|RADIOLOGIST 1|N|4||88||FOLLOW-UP|1973-05-07||||1964-10-12||1962-02-06|1965-10-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BOTTLE|ABSENT MORPHOLOGIC RESPONSE||CAN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|ADJUDICATION COMMITTEE|READER 3|NA|5||7||INDUCTION TREATMENT|1965-04-27||||1960-06-13||1961-08-25|1973-07-26||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MV|NPR||ENZYME U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|INVESTIGATOR|RADIOLOGIST 2|N|5||7||WASHOUT|1966-06-25||||1963-10-20||1971-06-15|1970-12-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UL|VGPR||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|INVESTIGATOR|PATHOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1966-03-04||||1963-12-28||1965-06-25|1968-05-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||BESTRESP|BEST OVERALL RESPONSE||||COPIES/UG|RELAPSED DISEASE FROM CR OR PR||STEPS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|1||38||OPEN LABEL TREATMENT|1962-04-19||||1965-06-22||1972-04-23|1969-11-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||NTRGRESP|NON-TARGET RESPONSE||||ROENTGEN|CHR||PLUG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|2||58||RUN-IN|1972-03-14||||1962-07-07||1969-01-28|1962-04-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||LIVRRESP|LIVER RESPONSE||||KN/CM2|NOT ALL EVALUATED||UV|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|STUDY SUBJECT|PATHOLOGIST|NA|2||58||BASELINE|1968-06-24||||1973-04-01||1962-01-23|1964-11-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||FOZ_US|MINOR PATHOLOGIC RESPONSE||U/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|PROXY|MICROSCOPIST 2|NA|3||39||CONTINUATION TREATMENT|1973-06-22||||1970-05-10||1970-10-13|1968-09-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||METBRESP|METABOLIC RESPONSE||||CP|CRI||V/V|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|CAREGIVER|RADIOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1967-04-13||||1967-08-26||1961-01-05|1964-08-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||M3|NE||ML/KG/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|INTERVIEWER|ENDOCRINOLOGIST|NA|4||88||BLINDED TREATMENT|1961-12-04||||1969-10-19||1964-06-01|1967-09-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||CYTORESP|CYTOGENETIC RESPONSE||||NFIU|NON-PD||MOSM/L|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|4||88||OBSERVATION|1971-05-03||||1972-10-04||1966-01-04|1963-04-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UL/KG/DAY|SCR||DAGU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|FAMILY MEMBER|READER 3|Y|5||7||LONG-TERM FOLLOW-UP|1968-09-22||||1973-04-10||1965-10-14|1971-06-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NEWTON|NON-QUANTIFIABLE MRD POSITIVITY||HOURS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|STUDY SUBJECT|HEMATOLOGIST|Y|5||7||BLINDED TREATMENT|1962-11-10||||1971-10-14||1967-12-30|1968-12-23||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||METSIND|METASTATIC INDICATOR||||MKAT|QUANTIFIABLE MRD POSITIVITY||MEQ/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|SPOUSE|ONCOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1970-03-07||||1962-12-14||1962-08-13|1966-03-12||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||LIVRRESP|LIVER RESPONSE||||UMOL/H/MMOL|ABSENT MORPHOLOGIC RESPONSE||/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|INVESTIGATOR|CLINICAL PATHOLOGIST|NA|1||38||INDUCTION TREATMENT|1964-05-06||||1963-01-01||1960-06-03|1968-04-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||LIVRRESP|LIVER RESPONSE||||KUSP|MAJOR PATHOLOGIC RESPONSE||10^3 RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INTERVIEWER|OTOLARYNGOLOGIST|U|2||58||BLINDED TREATMENT|1961-11-10||||1960-02-29||1967-02-06|1971-02-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^3 CFU/ML|MOLECULAR CR||U/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|2||58||BASELINE|1961-10-08||||1961-12-17||1962-02-19|1968-02-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 IU/ML|STABLE||10^9 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INTERVIEWER|READER 3|Y|3||39||OBSERVATION|1964-10-04||||1961-07-15||1966-09-02|1967-01-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||SPLNRESP|SPLEEN RESPONSE||||10^3 ORGANISMS|ICPD||G/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3||39||BASELINE|1960-05-17||||1962-12-15||1965-04-29|1962-04-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||%(V/V)|SCR||MG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||INDUCTION TREATMENT|1964-03-02||||1972-01-07||1969-05-13|1960-08-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||NEWLIND|NEW LESION INDICATOR||||NKAT/L|NOT ALL EVALUATED||MMOL/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|NA|INTERVIEWER|RATER 1|U|4||88||BLINDED TREATMENT|1972-05-10||||1967-07-01||1969-11-05|1961-01-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MIU/L|IMPROVED||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|5||7||INDUCTION TREATMENT|1972-03-01||||1963-09-15||1969-11-22|1970-03-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||SPLNRESP|SPLEEN RESPONSE||||UKAT/10^12 RBC|IUPD||SBE/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|5||7||TREATMENT|1973-08-22||||1968-03-22||1960-02-20|1969-11-26||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||OVRLRESP|OVERALL RESPONSE||||10^7 TCID 50/DOSE|ABSENT MORPHOLOGIC RESPONSE||UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|VENDOR|OPTOMETRIST|U|1||38||RUN-IN|1961-10-14||||1970-01-24||1960-10-01|1973-06-26||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||STRUSTAT|STEROID USE STATUS||||ABSORBANCE U|MRD PERSISTENCE||10^7 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|PARENT|RADIOLOGIST 2|U|1||38||FOLLOW-UP|1967-01-22||||1965-07-22||1967-10-11|1971-08-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||TMRESP|TUMOR MARKER RESPONSE||||/10^5|HI-E||KA_U/DL|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2||58||SCREENING|1970-08-15||||1962-10-19||1972-08-24|1970-05-15||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||STRUSTAT|STEROID USE STATUS||||10^6/L|MRD RELAPSE||LINEAR FT*LB|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|FAMILY MEMBER|INTERNIST|U|2||58||CONTINUATION TREATMENT|1972-09-12||||1971-11-19||1960-11-16|1965-02-06||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||BONERESP|BONE RESPONSE||||PIPE|ISD||NEBULE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|3||39||LONG-TERM FOLLOW-UP|1968-05-11||||1961-08-04||1966-01-08|1960-02-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||NEWLIND|NEW LESION INDICATOR||||AMU|INDETERMINATE RESPONSE||LX|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|FRIEND|PATHOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1971-06-27||||1961-03-01||1968-01-29|1965-05-14||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/(MIN*100ML)|STABLE||UG/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|4||88||CONTINUATION TREATMENT|1964-12-18||||1964-05-12||1966-09-02|1961-04-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AMPULE|OPTIMAL MORPHOLOGIC RESPONSE||BREATHS/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|GUARDIAN|INTERNIST|Y|4||88||CONTINUATION TREATMENT|1968-02-29||||1961-01-20||1967-11-07|1961-01-30||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CUP|MOLECULAR MAJOR RESPONSE||UG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||BLINDED TREATMENT|1962-06-24||||1960-02-18||1972-03-29|1960-02-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||COPIES/UG|SMD||BISCUIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|5||7||INDUCTION TREATMENT|1973-01-29||||1963-02-10||1965-06-05|1970-04-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||CLINRESP|CLINICAL RESPONSE||||MG/KG/WEEK|ABSENT MORPHOLOGIC RESPONSE||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|1||38||LONG-TERM FOLLOW-UP|1965-04-09||||1962-11-23||1970-12-28|1970-11-21||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/SEC/1.73M2|COMPLETE MRD RESPONSE||UOSM|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|DOMESTIC PARTNER|UROLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1970-04-10||||1964-10-15||1962-10-01|1964-07-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||U/MMOL|PR-CT||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|N|STUDY SUBJECT|MICROSCOPIST|N|2||58||INDUCTION TREATMENT|1968-03-27||||1964-05-13||1967-09-10|1964-05-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||BESTRESP|BEST OVERALL RESPONSE||||BISCUIT|WORSENED||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|ADJUDICATOR|RATER 1|Y|2||58||CONTINUATION TREATMENT|1962-05-05||||1961-10-11||1963-02-16|1972-10-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||FT3|UNEQUIVOCAL||MM/H|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|3||39||BLINDED TREATMENT|1961-01-10||||1970-08-13||1969-01-27|1966-11-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/KG|RELAPSED DISEASE FROM CR||MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|PARENT|RATER|NA|3||39||INDUCTION TREATMENT|1963-07-04||||1960-04-22||1965-11-14|1963-04-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UCI/L|MCR||U/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|SIGNIFICANT OTHER|INTERNIST|U|4||88||OBSERVATION|1967-01-01||||1971-06-11||1960-08-13|1964-07-17||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NMOL/DAY|NON-QUANTIFIABLE MRD POSITIVITY||KALLIKREIN INHIBITOR UNIT|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|CHILD|READER|Y|4||88||OBSERVATION|1966-05-08||||1970-01-06||1965-04-13|1962-12-20||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/G/DAY|PR||L/S|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|GUARDIAN|PATHOLOGIST 2|NA|5||7||WASHOUT|1970-12-17||||1960-04-01||1965-09-25|1965-04-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||HOURS|PR WITH LYMPHOCYTOSIS||YEARS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|N|5||7||BLINDED TREATMENT|1967-01-27||||1967-03-07||1973-04-10|1966-03-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOZENGE|PMD||ATM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|PARENT|OPTOMETRIST|Y|1||38||TREATMENT|1963-12-18||||1965-08-12||1961-04-12|1973-07-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||F|WORSENED||AMU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|1||38||INDUCTION TREATMENT|1960-04-26||||1961-02-09||1960-06-18|1965-09-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||OZ|CHR||MM|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|FAMILY MEMBER|RADIOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1960-01-29||||1968-03-04||1972-10-20|1966-06-25||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/DAY|IUPD||UOSM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2||58||TREATMENT|1970-01-28||||1970-07-05||1969-08-05|1965-06-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/MMOL|NON-ICR/NON-IUPD||AGU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SPOUSE|OPTOMETRIST|Y|3||39||FOLLOW-UP|1963-07-29||||1960-08-13||1969-12-14|1960-12-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||QUANTITY SUFFICIENT|CR-CT||MMU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|SIBLING|OTOLARYNGOLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-10-20||||1965-09-28||1971-08-12|1973-07-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||METBRESP|METABOLIC RESPONSE||||HENRY|NPR||PIXELS/CM|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|4||88||FOLLOW-UP|1965-07-26||||1972-01-28||1967-01-02|1961-11-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||KIU|PCR||TUBERCULIN UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|SPOUSE|PEDIATRIC NEUROLOGIST|NA|4||88||CONTINUATION TREATMENT|1964-11-19||||1966-10-19||1963-04-16|1964-09-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||TRGRESP|TARGET RESPONSE||||APL U|CR||U/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|ADJUDICATOR|INTERNIST|U|5||7||TREATMENT|1968-09-10||||1961-04-06||1961-05-25|1966-11-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KG/MOL|INDETERMINATE RESPONSE||ML/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|DOMESTIC PARTNER|MICROSCOPIST 2|U|5||7||WASHOUT|1960-07-03||||1967-10-03||1964-09-04|1973-06-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||AMFI|COMPLETE MRD RESPONSE||NKAT|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1960-12-02||||1965-02-27||1966-12-19|1970-09-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||NEWLPROG|NEW LESION PROGRESSION||||CMH2O/ML|CR||AMFI|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|GUARDIAN|CLINICAL PATHOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1963-01-12||||1970-07-09||1973-03-27|1971-11-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DAGU/ML|STABLE||SUPPOSITORY|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|ADJUDICATOR|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1965-12-21||||1960-11-21||1970-02-17|1969-12-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/DAY|PSEUDORESPONSE||BREATHS/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|INVESTIGATOR|PATHOLOGIST 2|NA|2||58||OBSERVATION|1972-02-18||||1971-06-16||1961-07-10|1971-01-27||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||LIVRRESP|LIVER RESPONSE||||U/MMOL|IMMUNOPHENOTYPIC CR||CI/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|SIGNIFICANT OTHER|ADJUDICATOR 1|U|3||39||BLINDED TREATMENT|1972-03-17||||1964-04-26||1967-05-31|1960-09-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ROENTGEN|NON-PD||ANTIBODY UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|VENDOR|PEDIATRIC NEUROLOGIST|Y|3||39||BASELINE|1964-06-14||||1963-08-31||1964-08-31|1966-08-02||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DEG/MM|PSA PROGRESSION||10^9 CFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|4||88||RUN-IN|1963-11-27||||1967-12-12||1960-01-06|1973-07-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ANTIBODY UNIT|PD-CT||UMOL/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|4||88||FOLLOW-UP|1969-12-25||||1962-09-02||1960-11-15|1961-01-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||%/S|ISD||AMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5||7||BLINDED TREATMENT|1961-02-03||||1965-08-19||1967-09-07|1973-08-05||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FRAMES/S|PD-CT||CMH2O*S/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|5||7||WASHOUT|1969-09-08||||1962-04-02||1960-02-28|1965-09-28||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MCI|PR||CM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|1||38||TREATMENT|1966-06-09||||1971-04-26||1972-01-25|1973-05-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||LIVRRESP|LIVER RESPONSE||||U/MG|NON-ICR/NON-IUPD||MAMP|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|PARENT|PEDIATRIC NEUROLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1964-09-11||||1966-10-16||1969-11-12|1961-02-09||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PIXELS/CM|PSEUDOPROGRESSION||GENEQ|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|2||58||LONG-TERM FOLLOW-UP|1966-10-05||||1965-06-03||1962-08-22|1968-05-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||MOLRESP|MOLECULAR RESPONSE||||COPIES/UG|CYTOGENETIC PR||SCM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|2||58||SCREENING|1962-02-01||||1966-07-08||1967-06-13|1966-08-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/L|NR||TRANSDUCING UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|FRIEND|READER|N|3||39||FOLLOW-UP|1960-01-28||||1967-10-14||1963-04-18|1973-04-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||SPLNRESP|SPLEEN RESPONSE||||VIRTUAL PIXEL|PSEUDORESPONSE||PFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|SIBLING|NEUROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1967-07-03||||1960-03-20||1964-10-12|1971-03-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||TMRESP|TUMOR MARKER RESPONSE||||P|PMD||EVENTS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|INVESTIGATOR|CLINICAL PATHOLOGIST|NA|4||88||INDUCTION TREATMENT|1967-04-25||||1970-02-23||1972-10-14|1960-07-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||METBRESP|METABOLIC RESPONSE||||DEG/MM|SCR||NMOL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1969-08-09||||1968-02-08||1960-08-14|1972-10-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||METBRESP|METABOLIC RESPONSE||||HOUNSFIELD UNIT|HI-E||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|VENDOR|ENDOCRINOLOGIST|NA|5||7||BASELINE|1972-08-14||||1963-04-14||1973-07-02|1972-05-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||CLINRESP|CLINICAL RESPONSE||||GRAIN|NOT ALL EVALUATED||UOSM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|ADJUDICATOR|RATER 1|Y|5||7||LONG-TERM FOLLOW-UP|1972-09-05||||1967-09-22||1962-10-11|1972-03-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/KG|IMPROVED||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|1||38||OBSERVATION|1963-02-13||||1970-01-17||1972-06-10|1965-09-14||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^3/L|NON-ICR/NON-IUPD||PACK YEAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL RESEARCH COORDINATOR|READER|N|1||38||OPEN LABEL TREATMENT|1973-01-08||||1968-07-11||1969-07-22|1966-10-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MMOL/KG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|CHILD|PEDIATRIC NEUROLOGIST|U|2||58||INDUCTION TREATMENT|1966-03-11||||1969-07-24||1971-05-16|1973-04-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||BONERESP|BONE RESPONSE||||MBP|NE||G/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|2||58||TREATMENT|1962-11-14||||1963-03-28||1967-03-19|1966-06-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/KG/DAY|PSEUDORESPONSE||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|SPOUSE|ONCOLOGIST|N|3||39||BLINDED TREATMENT|1968-05-12||||1964-07-23||1970-08-20|1965-08-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GBQ/MG|SD||10^3 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|3||39||INDUCTION TREATMENT|1969-01-07||||1971-03-27||1972-05-13|1968-04-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||TRGRESP|TARGET RESPONSE||||GLOBULE|RELAPSED DISEASE FROM CR OR PR||MG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|DOMESTIC PARTNER|ONCOLOGIST 2|N|4||88||WASHOUT|1970-08-08||||1969-05-28||1961-11-20|1962-12-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MS/MMHG|NON-CR/NON-PD||DEG/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|FAMILY MEMBER|INTERNIST|U|4||88||BLINDED TREATMENT|1962-07-20||||1966-03-18||1963-04-20|1969-08-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||G/G/DAY|SD||ML/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|FRIEND|READER 1|N|5||7||TREATMENT|1968-10-31||||1961-07-08||1973-06-17|1960-02-18||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||METBRESP|METABOLIC RESPONSE||||G|STABLE||FL|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|VENDOR|READER 1|U|5||7||OBSERVATION|1967-07-16||||1960-02-18||1962-12-21|1964-12-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||NEWLPROG|NEW LESION PROGRESSION||||PLUG|MRD RELAPSE||APL U|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|SIGNIFICANT OTHER|READER|N|1||38||OBSERVATION|1969-12-28||||1972-06-11||1969-03-11|1972-02-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||STRUSTAT|STEROID USE STATUS||||HPA|ICR||CS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|1||38||WASHOUT|1968-08-18||||1971-07-24||1960-05-15|1969-09-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||STRUSTAT|STEROID USE STATUS||||ML/CM H2O|RELAPSED DISEASE FROM CR||ENZYME U/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|ADJUDICATOR|ENDOCRINOLOGIST|Y|2||58||BASELINE|1971-02-23||||1969-06-03||1969-09-19|1964-11-13||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||OVRLRESP|OVERALL RESPONSE||||ML/SEC/1.73M2|UNEQUIVOCAL||RAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|HEALTH CARE PROFESSIONAL|RATER 2|N|2||58||INDUCTION TREATMENT|1967-01-01||||1970-04-02||1969-09-17|1965-11-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||L/KG|PD FROM PR||C|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|PROXY|CLINICAL PATHOLOGIST|U|3||39||WASHOUT|1964-03-05||||1964-06-01||1963-07-14|1965-03-28||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||NTRGRESP|NON-TARGET RESPONSE||||MG/ANIMAL|PSEUDORESPONSE||IU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|INVESTIGATOR|NEUROLOGIST 1|N|3||39||BLINDED TREATMENT|1968-02-05||||1967-12-11||1970-10-18|1964-10-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||NEWLIND|NEW LESION INDICATOR||||SUPPOSITORY|TREATMENT FAILURE||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|VENDOR|UROLOGIST|N|4||88||WASHOUT|1969-12-21||||1962-01-15||1966-10-13|1962-07-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||BESTRESP|BEST OVERALL RESPONSE||||IU/MG|SCR||ELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|STUDY SUBJECT|MICROSCOPIST 2|U|4||88||WASHOUT|1964-12-16||||1971-09-29||1961-11-21|1968-07-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||NTRGRESP|NON-TARGET RESPONSE||||L/S|OPTIMAL MORPHOLOGIC RESPONSE||AMPULE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|Y|ADJUDICATOR|RATER|NA|5||7||INDUCTION TREATMENT|1964-11-04||||1960-06-22||1969-11-17|1965-04-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||NTRGRESP|NON-TARGET RESPONSE||||PMOL/G|PMR||UL/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|ADJUDICATION COMMITTEE|ADJUDICATOR|U|5||7||WASHOUT|1961-01-02||||1967-02-03||1969-01-14|1965-03-30||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/G|OPTIMAL MORPHOLOGIC RESPONSE||ELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|SPOUSE|CARDIOLOGIST|N|1||38||OBSERVATION|1963-01-17||||1961-05-15||1972-03-18|1961-04-27||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||PATHRESP|PATHOLOGIC RESPONSE||||1/(S*KPA)|SD||MU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||WASHOUT|1971-12-17||||1969-06-26||1966-04-01|1966-10-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||BONERESP|BONE RESPONSE||||FIU|NED||UKAT/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|CHILD|MICROSCOPIST 1|Y|2||58||BLINDED TREATMENT|1971-06-21||||1969-02-15||1964-04-12|1961-09-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||TMRESP|TUMOR MARKER RESPONSE||||GPL U|UNEQUIVOCAL||NFIU|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|2||58||INDUCTION TREATMENT|1967-11-10||||1964-05-03||1966-07-16|1972-02-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||TMRESP|TUMOR MARKER RESPONSE||||MSEC|PSEUDORESPONSE||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|FRIEND|PEDIATRIC NEUROLOGIST|N|3||39||WASHOUT|1963-10-23||||1963-11-27||1962-08-30|1969-02-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||AMPULE|PSEUDORESPONSE||NMOL BCE/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|SIBLING|RADIOLOGIST 2|U|3||39||BLINDED TREATMENT|1972-02-04||||1960-07-28||1971-08-26|1963-04-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^12 IU/L|NON-QUANTIFIABLE MRD POSITIVITY||G/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|STUDY SUBJECT|DERMATOLOGIST|NA|4||88||WASHOUT|1961-01-08||||1971-10-08||1967-06-16|1964-08-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||%(V/V)|SMD||MCI/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|FAMILY MEMBER|RATER 2|NA|4||88||FOLLOW-UP|1964-11-20||||1964-09-28||1965-04-09|1971-09-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||LIVRRESP|LIVER RESPONSE||||UG/L FEU|PMD||NM|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|ADJUDICATION COMMITTEE|ONCOLOGIST 1|Y|5||7||TREATMENT|1970-07-29||||1965-05-12||1964-01-21|1969-08-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||OVRLRESP|OVERALL RESPONSE||||UG/DL|ISD||EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|DOMESTIC PARTNER|RATER|N|5||7||BASELINE|1971-12-05||||1972-06-06||1963-10-14|1969-01-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||BESTRESP|BEST OVERALL RESPONSE||||MEQ/MMOL|MINOR PATHOLOGIC RESPONSE||10^3 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|PROXY|RATER|U|1||38||BLINDED TREATMENT|1973-08-06||||1971-03-19||1965-05-04|1963-04-23||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||QUANTITY SUFFICIENT|CPR||PUFF|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|FRIEND|RADIOLOGIST 1|Y|1||38||RUN-IN|1967-12-20||||1969-08-17||1969-06-15|1973-02-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||OVRLRESP|OVERALL RESPONSE||||NSEC|NPR||UG/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|INVESTIGATOR|NEUROLOGIST 2|Y|2||58||BLINDED TREATMENT|1967-04-28||||1968-03-28||1970-08-02|1969-11-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/L|PD FROM PR||CD|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|CHILD|CLINICAL PATHOLOGIST|NA|2||58||OBSERVATION|1964-05-22||||1965-05-24||1960-07-14|1967-09-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||OVRLRESP|OVERALL RESPONSE||||MG/M2/H|NON-ICR/NON-IUPD||MOL/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|INVESTIGATOR|ONCOLOGIST 2|U|3||39||OBSERVATION|1967-08-04||||1973-05-06||1961-10-30|1961-12-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||NTRGRESP|NON-TARGET RESPONSE||||LOG10 TCID 50/DOSE|PD/RELAPSE AFTER HI||PATCH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OBSERVATION|1962-09-19||||1968-10-09||1972-12-15|1972-08-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||CLINRESP|CLINICAL RESPONSE||||KUSP|NON-ICR/NON-IUPD||MCI/KG|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1969-07-05||||1965-02-02||1961-05-16|1972-08-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||METBRESP|METABOLIC RESPONSE||||ML/MIN|FAVORABLE RESPONSE||10^3 DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|STUDY SUBJECT|MICROSCOPIST|NA|4||88||SCREENING|1963-05-01||||1961-05-25||1965-08-03|1966-07-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||NTRGRESP|NON-TARGET RESPONSE||||PMOL|MOLECULAR CR||WEBER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OBSERVATION|1967-11-11||||1970-12-19||1960-08-12|1963-02-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||MOLRESP|MOLECULAR RESPONSE||||PACKAGE|CCR||PACK YEAR|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|PARENT|RADIOLOGIST|NA|5||7||TREATMENT|1973-05-02||||1962-05-25||1963-08-22|1972-11-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG|PMR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|FRIEND|CLINICAL PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1967-11-02||||1970-12-28||1960-12-13|1962-06-25||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/G/H|PD/RELAPSE AFTER HI||ML/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|FAMILY MEMBER|READER 3|Y|1||38||CONTINUATION TREATMENT|1961-03-21||||1972-07-24||1967-06-02|1971-06-01||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||STRUSTAT|STEROID USE STATUS||||/DAY|CYTOGENETIC NO RESPONSE||DEG/MM|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|2||58||BASELINE|1971-02-09||||1972-06-11||1968-07-05|1962-04-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG2/DL2|PD||DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|FRIEND|RADIOLOGIST|U|2||58||SCREENING|1972-01-12||||1967-08-18||1972-12-02|1972-09-16||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||METBRESP|METABOLIC RESPONSE||||NMOL BCE/L|CRI||10^9/G|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|3||39||SCREENING|1973-05-10||||1963-06-12||1967-07-28|1963-09-02||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||CLINRESP|CLINICAL RESPONSE||||PRESSOR UNITS|ICR||V/V|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|DOMESTIC PARTNER|UROLOGIST|Y|3||39||OPEN LABEL TREATMENT|1967-02-19||||1965-06-07||1964-07-30|1960-11-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PUFF|CYTOGENETIC NO RESPONSE||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|ADJUDICATOR|RATER 2|U|4||88||WASHOUT|1971-09-26||||1960-09-07||1966-04-11|1963-09-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DEG/S|PD-CT||BQ/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|FRIEND|ADJUDICATOR 1|U|4||88||OBSERVATION|1971-09-04||||1970-11-12||1972-08-20|1973-01-01||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EIA UNIT|INDETERMINATE RESPONSE||SPRAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|GUARDIAN|READER 2|N|5||7||INDUCTION TREATMENT|1962-01-04||||1968-03-19||1970-07-07|1972-08-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||LIVRRESP|LIVER RESPONSE||||KM|CR-CT||APS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|SIGNIFICANT OTHER|READER 2|N|5||7||CONTINUATION TREATMENT|1969-08-21||||1972-04-25||1963-01-10|1964-12-07||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||NTRGRESP|NON-TARGET RESPONSE||||CS|ICPD||MM/2H|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||FOLLOW-UP|1969-01-17||||1972-02-12||1973-09-08|1964-11-25||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||GBQ/UG|PDU||LOG10 TCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|INTERVIEWER|PATHOLOGIST 2|NA|1||38||BASELINE|1969-04-15||||1963-12-02||1971-01-25|1961-05-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||NEWLPROG|NEW LESION PROGRESSION||||%/S|CCR||ML/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|2||58||OBSERVATION|1972-05-09||||1970-03-10||1968-11-04|1970-05-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/DL|PR WITH LYMPHOCYTOSIS||G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|ADJUDICATOR|MICROSCOPIST 3|U|2||58||RUN-IN|1969-06-21||||1962-03-06||1970-12-27|1962-08-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UMOL/L/MIN|EQUIVOCAL||CD|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|PARENT|READER 1|N|3||39||OPEN LABEL TREATMENT|1971-03-08||||1972-11-30||1961-04-14|1963-09-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/ML/H|PMD||MCI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|PROXY|PATHOLOGIST 2|N|3||39||FOLLOW-UP|1960-07-06||||1965-06-05||1964-09-19|1971-08-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KIT|NON-ICR/NON-IUPD||NSEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|4||88||TREATMENT|1967-06-28||||1968-01-09||1960-03-19|1969-02-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||TRGRESP|TARGET RESPONSE||||DNA COPIES/ML|MRD PERSISTENCE||MEQ/DL|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|GUARDIAN|OPTOMETRIST|N|4||88||SCREENING|1961-08-18||||1968-12-15||1969-06-21|1968-12-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||NEWLPROG|NEW LESION PROGRESSION||||MASK|ISD||UG/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|PARENT|DERMATOLOGIST|N|5||7||TREATMENT|1967-01-04||||1966-12-14||1965-11-10|1967-06-30||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||ANATRESP|ANATOMIC RESPONSE||||EJACULATE U|NED||IU/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|PARENT|RATER|U|5||7||WASHOUT|1963-05-29||||1971-09-20||1960-02-17|1968-08-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||BONERESP|BONE RESPONSE||||ANSON U|RELAPSED DISEASE||MG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|GUARDIAN|RADIOLOGIST 1|Y|1||38||FOLLOW-UP|1970-05-23||||1962-11-21||1967-09-16|1960-07-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DAYS|IPR||AMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|SIGNIFICANT OTHER|READER 2|Y|1||38||FOLLOW-UP|1966-01-18||||1970-03-11||1960-11-13|1972-06-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MONTHS|MOLECULAR CR||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|INTERVIEWER|MICROSCOPIST|NA|2||58||LONG-TERM FOLLOW-UP|1967-12-25||||1962-07-18||1963-02-20|1973-05-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||METSIND|METASTATIC INDICATOR||||G|WORSENED||MPS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1962-07-14||||1972-08-22||1972-09-25|1970-08-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||CYTORESP|CYTOGENETIC RESPONSE||||EID 50/DOSE|SMD||M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|INVESTIGATOR|RATER|Y|3||39||SCREENING|1962-10-16||||1960-12-28||1966-05-06|1968-04-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||TRGRESP|TARGET RESPONSE||||BE/ML|OPTIMAL MORPHOLOGIC RESPONSE||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|3||39||OPEN LABEL TREATMENT|1972-12-09||||1969-07-14||1968-01-05|1973-05-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||TMRESP|TUMOR MARKER RESPONSE||||ATM|HI-E||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|SPOUSE|READER 2|NA|4||88||BASELINE|1967-09-03||||1965-03-22||1968-09-14|1960-09-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||ANATRESP|ANATOMIC RESPONSE||||LOG EID 50/DOSE|QUANTIFIABLE MRD POSITIVITY||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|SPOUSE|READER 1|Y|4||88||CONTINUATION TREATMENT|1970-07-12||||1972-08-12||1960-08-20|1961-09-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||L/H|ABSENT MORPHOLOGIC RESPONSE||M/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|ADJUDICATION COMMITTEE|RATER 2|NA|5||7||CONTINUATION TREATMENT|1970-02-27||||1970-11-23||1971-01-26|1962-05-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BAU/ML|NPR||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5||7||SCREENING|1964-02-08||||1973-04-07||1971-07-14|1962-07-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ANTIBODY UNIT|ICPD||/7.5 ML|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|STUDY SUBJECT|NEUROLOGIST 1|N|1||38||TREATMENT|1968-05-27||||1963-12-02||1965-11-21|1965-07-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||NEWLIND|NEW LESION INDICATOR||||H*%|COMPLETE MRD RESPONSE||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|DOMESTIC PARTNER|CARDIOLOGIST|NA|1||38||TREATMENT|1967-07-22||||1965-12-27||1964-04-21|1972-07-27||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%|NON-CR/NON-PD||BQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|DOMESTIC PARTNER|ONCOLOGIST 1|U|2||58||WASHOUT|1969-02-16||||1963-06-16||1967-12-07|1962-06-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 CFU/G|PR-CT||PPTR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|N|2||58||WASHOUT|1969-08-05||||1970-11-10||1966-07-16|1965-08-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG/CM2|UNEQUIVOCAL||ATM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|3||39||WASHOUT|1968-06-13||||1968-02-13||1961-04-29|1969-08-25||DURING||DURING|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/G/H|HI-E||PL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||BLINDED TREATMENT|1965-02-03||||1970-03-16||1972-11-26|1965-06-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||METBRESP|METABOLIC RESPONSE||||10^7/L|RELAPSED DISEASE||MEQ/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1969-09-07||||1969-12-31||1966-10-22|1966-03-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/MOL|ABSENT MORPHOLOGIC RESPONSE||MMHG/L/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|PROXY|ADJUDICATOR 3|U|4||88||FOLLOW-UP|1962-11-14||||1961-08-12||1962-07-21|1967-07-13||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/CM2|COMPLETE MRD RESPONSE||TROCHE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|CAREGIVER|NEUROLOGIST 2|Y|5||7||TREATMENT|1963-03-26||||1966-01-07||1971-03-24|1969-04-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||%(V/V)|MORPHOLOGIC LEUKEMIA-FREE STATE||10^6 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|CAREGIVER|READER 2|U|5||7||CONTINUATION TREATMENT|1969-05-11||||1963-10-07||1973-03-21|1968-12-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/KG/H|MRD PERSISTENCE||MBQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|VENDOR|MICROSCOPIST 3|NA|1||38||FOLLOW-UP|1972-04-24||||1970-05-25||1968-11-15|1960-12-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||STRUSTAT|STEROID USE STATUS||||PIXEL|NON-ICR/NON-IUPD||LOG10 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|INVESTIGATOR|ONCOLOGIST 1|NA|1||38||INDUCTION TREATMENT|1968-03-02||||1961-04-30||1962-06-19|1966-07-03||DURING||DURING|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU|IUPD||/2500 WBC|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|2||58||WASHOUT|1968-04-11||||1971-02-10||1968-11-30|1962-10-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||TSP EQ|ISD||GRAVITATIONAL UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|SPOUSE|NEUROLOGIST 1|N|2||58||BASELINE|1966-10-30||||1971-12-11||1963-01-21|1969-03-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NSEC|NE||DAGU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|PROXY|DERMATOLOGIST|Y|3||39||TREATMENT|1968-10-11||||1972-09-04||1964-11-22|1962-08-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^9 CFU|CR||MBQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|PROXY|ADJUDICATOR 1|U|3||39||INDUCTION TREATMENT|1968-02-22||||1965-06-28||1963-03-03|1962-03-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||MOLRESP|MOLECULAR RESPONSE||||U/G HB|CYTOGENETIC NO RESPONSE||H/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|CHILD|DERMATOLOGIST|U|4||88||WASHOUT|1967-12-22||||1964-03-23||1969-04-17|1965-04-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||BONERESP|BONE RESPONSE||||/2000 RBC|FAVORABLE RESPONSE||%/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|STUDY SUBJECT|OPTOMETRIST|U|4||88||RUN-IN|1963-12-15||||1967-08-11||1966-07-21|1972-08-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||METSIND|METASTATIC INDICATOR||||PMOL/DAY|NPR||G/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|5||7||CONTINUATION TREATMENT|1963-03-04||||1964-03-02||1960-12-05|1961-10-13||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||METBRESP|METABOLIC RESPONSE||||MG/DOSE|PR WITH LYMPHOCYTOSIS||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|5||7||FOLLOW-UP|1960-07-06||||1965-07-15||1962-08-16|1964-02-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IN2|PCR||MG/CM2|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|DOMESTIC PARTNER|ADJUDICATOR 2|Y|1||38||OBSERVATION|1963-02-10||||1962-02-14||1964-06-11|1967-11-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||OVRLRESP|OVERALL RESPONSE||||MIN/DAY|PSEUDOPROGRESSION||IU/MG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|SIGNIFICANT OTHER|NEUROLOGIST 1|Y|1||38||TREATMENT|1966-01-29||||1969-03-01||1967-09-27|1966-01-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^6 RNA COPIES/ML|PARTIAL MORPHOLOGIC RESPONSE||INHALATION|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|PARENT|ENDOCRINOLOGIST|Y|2||58||RUN-IN|1971-05-25||||1967-05-25||1967-06-17|1965-06-07||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||GLOBULE|NE||CY/CM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|VENDOR|NEUROLOGIST 1|NA|2||58||BASELINE|1972-02-15||||1968-06-03||1961-11-07|1971-04-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||METSIND|METASTATIC INDICATOR||||MPA|PD||/200 HPFS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|INTERVIEWER|PATHOLOGIST 2|N|3||39||WASHOUT|1972-03-28||||1973-06-28||1971-11-07|1970-06-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||KPA|NE||MG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|SPOUSE|OTOLARYNGOLOGIST|Y|3||39||TREATMENT|1967-07-23||||1972-01-15||1966-03-31|1961-05-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MMOL/MOL|CYTOGENETIC MINOR RESPONSE||KCAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|GUARDIAN|OPHTHALMOLOGIST|N|4||88||RUN-IN|1967-10-03||||1964-03-18||1965-08-24|1973-03-11||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MM/MIN|EQUIVOCAL||M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|SPOUSE|CARDIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-11-20||||1964-04-02||1960-03-03|1961-09-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||ANATRESP|ANATOMIC RESPONSE||||NG/DL|MOLECULAR CR||G/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||TREATMENT|1963-11-15||||1972-04-15||1966-12-13|1970-08-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||BONERESP|BONE RESPONSE||||L/DAY|CYTOGENETIC PR||KDA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|5||7||FOLLOW-UP|1973-08-13||||1971-11-08||1964-03-16|1966-04-11||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||JAR|IMPROVED||EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|ADJUDICATION COMMITTEE|ONCOLOGIST 1|N|1||38||OBSERVATION|1963-11-04||||1965-06-22||1964-04-26|1960-03-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MONTHS|PDU||ENZYME U/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|SIGNIFICANT OTHER|DERMATOLOGIST|NA|1||38||FOLLOW-UP|1965-08-14||||1961-03-04||1968-12-03|1969-10-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/CL|MCR||NMOL BCE/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|VENDOR|PEDIATRIC NEUROLOGIST|NA|2||58||SCREENING|1961-08-10||||1967-06-30||1963-09-18|1970-01-05||DURING||AFTER|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9 ORGANISMS/ML|IPR||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|ADJUDICATOR|READER 2|Y|2||58||BASELINE|1969-11-03||||1960-12-29||1971-06-30|1963-04-25||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||ANATRESP|ANATOMIC RESPONSE||||EID 50/DOSE|HI-N||CMH2O/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|PARENT|CLINICAL PATHOLOGIST|N|3||39||WASHOUT|1965-04-14||||1964-06-02||1966-03-30|1972-07-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^8 PFU|MINOR PATHOLOGIC RESPONSE||POUCH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|STUDY SUBJECT|READER|NA|3||39||FOLLOW-UP|1968-06-09||||1963-09-22||1972-06-14|1966-11-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GRAIN|UNEQUIVOCAL||UU/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|GUARDIAN|RATER 1|N|4||88||SCREENING|1961-10-26||||1962-01-08||1968-05-28|1968-10-17||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^7 CFU|CYTOGENETIC MINOR RESPONSE||VG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|ADJUDICATOR|ONCOLOGIST 1|U|4||88||SCREENING|1967-12-03||||1963-05-19||1968-03-21|1962-06-14||AFTER||DURING|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DIP|CYTOGENETIC CR||MEQ/UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|DOMESTIC PARTNER|ADJUDICATOR 3|NA|5||7||WASHOUT|1963-08-11||||1973-08-23||1972-03-22|1967-12-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||ANATRESP|ANATOMIC RESPONSE||||PA|IMMUNOPHENOTYPIC CR||/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|PARENT|NEUROLOGIST 1|NA|5||7||OBSERVATION|1964-09-30||||1967-01-16||1966-10-23|1962-09-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BQ/L|MOLECULAR MAJOR RESPONSE||PMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|U|GUARDIAN|CLINICAL PATHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1964-06-16||||1961-08-26||1964-12-29|1966-05-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||NEWLIND|NEW LESION INDICATOR||||DNA COPIES/UG|PD FROM PR||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|PARENT|NEUROLOGIST 2|Y|1||38||INDUCTION TREATMENT|1963-09-12||||1965-08-25||1962-11-11|1970-09-30||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||OZ EQ|MR||/4.0 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|PARENT|MICROSCOPIST 3|NA|2||58||RUN-IN|1960-02-14||||1973-07-31||1969-07-30|1969-01-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||NEWLIND|NEW LESION INDICATOR||||CM2|CR||LENS|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|PARENT|PEDIATRIC NEUROLOGIST|N|2||58||OBSERVATION|1972-06-29||||1962-03-16||1962-12-16|1967-02-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||TMRESP|TUMOR MARKER RESPONSE||||G/U|CCR||GBQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1964-03-08||||1970-04-25||1964-07-29|1968-07-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||TRGRESP|TARGET RESPONSE||||MOSM/KG|CMR||ML/CAGE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|CHILD|HEMATOLOGIST|N|3||39||OBSERVATION|1966-12-27||||1968-07-11||1971-02-22|1969-03-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||METSIND|METASTATIC INDICATOR||||MOL/MOL|PSEUDORESPONSE||10^9 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|CHILD|ONCOLOGIST 1|N|4||88||BLINDED TREATMENT|1973-01-21||||1967-03-15||1963-04-13|1963-04-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^9 ORGANISMS/G|CR||ML/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|INTERVIEWER|RATER|Y|4||88||FOLLOW-UP|1961-06-07||||1961-05-28||1962-10-03|1964-09-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||NEWLIND|NEW LESION INDICATOR||||PUFF|PARTIAL MORPHOLOGIC RESPONSE||DAYS/WK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|SPOUSE|RADIOLOGIST|NA|5||7||BLINDED TREATMENT|1970-09-01||||1966-04-30||1970-03-08|1971-10-13||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||SPLNRESP|SPLEEN RESPONSE||||PL|PD-CT||S*KPA|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|FAMILY MEMBER|NEUROLOGIST 2|Y|5||7||INDUCTION TREATMENT|1962-09-20||||1965-11-10||1967-06-14|1969-06-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|1||||||NEWLIND|NEW LESION INDICATOR||||UG/L|CPR||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|CAREGIVER|UROLOGIST|NA|1||38||INDUCTION TREATMENT|1960-10-10||||1961-02-27||1966-05-06|1971-12-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|2||||||OVRLRESP|OVERALL RESPONSE||||NMOL/KG/DAY|PD||EVENTS|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||WASHOUT|1960-03-01||||1965-04-25||1967-06-28|1968-07-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|1||||||TRGRESP|TARGET RESPONSE||||AU/ML|ICR||ENZYME U/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||BLINDED TREATMENT|1960-05-30||||1968-08-27||1964-08-27|1970-07-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|2||||||OVRLRESP|OVERALL RESPONSE||||U/ML|UNEQUIVOCAL||MIN/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|VENDOR|OTOLARYNGOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1967-01-17||||1963-01-13||1961-09-08|1963-05-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PACK|TREATMENT FAILURE||U.CARR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|FAMILY MEMBER|ADJUDICATOR|U|3||39||OPEN LABEL TREATMENT|1969-06-11||||1962-12-07||1971-07-01|1963-05-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|2||||||BONERESP|BONE RESPONSE||||10^6 CFU|NE||MANSON U/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|SIGNIFICANT OTHER|PATHOLOGIST 1|U|3||39||LONG-TERM FOLLOW-UP|1961-08-21||||1969-03-19||1966-04-14|1965-08-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|1||||||OVRLRESP|OVERALL RESPONSE||||10^8 PFU|MRD PERSISTENCE||ECL UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|DOMESTIC PARTNER|READER 3|N|4||88||OBSERVATION|1971-03-01||||1961-12-10||1970-04-03|1968-01-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|2||||||BONERESP|BONE RESPONSE||||BISCUIT|PCR||MEQ/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|4||88||BLINDED TREATMENT|1968-12-12||||1965-01-09||1969-07-02|1970-01-23||DURING||AFTER|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|1||||||NEWLPROG|NEW LESION PROGRESSION||||MV|CCR||/100 HPFS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|5||7||OBSERVATION|1972-07-14||||1973-04-26||1971-12-17|1967-03-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|83938342-C01F-491A-84A7-F85D327F112D|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6/G|CYTOGENETIC PR||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|SIGNIFICANT OTHER|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1963-02-26||||1961-07-15||1964-05-11|1972-01-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|1||38||WASHOUT|1970-02-14||||1973-04-13||1972-02-24|1963-10-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MSEC|MOLECULAR MAJOR RESPONSE||UEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|SIGNIFICANT OTHER|PATHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1968-08-31||||1963-04-14||1968-08-10|1965-11-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||CLINRESP|CLINICAL RESPONSE||||KG/M2|PDU||BQ/UG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|SIBLING|NEUROLOGIST 2|Y|2||58||BASELINE|1970-04-22||||1963-06-12||1964-01-04|1964-12-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SBE/ML|PD/RELAPSE AFTER HI||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|SIBLING|CLINICAL PATHOLOGIST|Y|2||58||FOLLOW-UP|1969-10-09||||1960-01-07||1964-02-07|1963-07-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||METSIND|METASTATIC INDICATOR||||DYN|DECREASED||MJOULE/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|3||39||RUN-IN|1968-05-16||||1965-04-19||1960-10-11|1961-02-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||OVRLRESP|OVERALL RESPONSE||||10^3 RNA COPIES/ML|MRD NEGATIVITY||10^4/HPF|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|NA|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|3||39||BASELINE|1962-12-05||||1972-07-28||1971-02-13|1969-05-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^9/L|RELAPSED DISEASE FROM CR||GPL U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|4||88||RUN-IN|1962-12-18||||1971-08-26||1961-04-13|1969-12-29||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||NEWLIND|NEW LESION INDICATOR||||/200 HPFS|NED||PMOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|PROXY|READER 1|N|4||88||OPEN LABEL TREATMENT|1970-02-14||||1966-12-20||1964-12-26|1963-07-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||METSIND|METASTATIC INDICATOR||||TRANSDUCING UNIT/ML|CR||MKAT|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|5||7||SCREENING|1966-06-11||||1961-08-01||1963-09-07|1970-06-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||OVRLRESP|OVERALL RESPONSE||||EJACULATE U|MORPHOLOGIC LEUKEMIA-FREE STATE||%/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|SIGNIFICANT OTHER|ADJUDICATOR 3|N|5||7||SCREENING|1965-07-30||||1971-06-07||1973-03-08|1964-08-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||CLINRESP|CLINICAL RESPONSE||||10^9/DOSE|UNFAVORABLE RESPONSE||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|DOMESTIC PARTNER|ADJUDICATOR|Y|1||38||INDUCTION TREATMENT|1968-02-22||||1962-12-14||1965-04-07|1970-12-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NMOL BCE/NMOL|PD-CT||UMOL/MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|GUARDIAN|RATER 2|U|1||38||OPEN LABEL TREATMENT|1963-02-21||||1966-04-15||1964-09-02|1967-09-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||RDIORESP|RADIOLOGIC RESPONSE||||CFU/ML|EQUIVOCAL||HPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|CHILD|ADJUDICATOR 2|Y|2||58||RUN-IN|1964-05-16||||1962-01-29||1973-03-03|1972-03-03||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||METSIND|METASTATIC INDICATOR||||COULOMB|PSA PROGRESSION||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|CHILD|ADJUDICATOR 2|U|2||58||TREATMENT|1963-05-22||||1962-10-30||1965-11-27|1970-04-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||ANATRESP|ANATOMIC RESPONSE||||JOULE|SCR||KM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|INDEPENDENT ASSESSOR|NEUROLOGIST|N|3||39||FOLLOW-UP|1967-03-21||||1961-01-29||1971-10-03|1964-04-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||TRGRESP|TARGET RESPONSE||||USIEMENS|MORPHOLOGIC CRI||NMOL BCE/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|3||39||INDUCTION TREATMENT|1970-02-21||||1965-05-15||1973-07-07|1966-10-10||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||TRGRESP|TARGET RESPONSE||||UV2|NON-CR/NON-PD||DRINK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|DOMESTIC PARTNER|MICROSCOPIST 2|Y|4||88||INDUCTION TREATMENT|1964-01-22||||1963-04-25||1964-02-06|1969-11-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/M2|PSA PROGRESSION||10^5/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|VENDOR|MICROSCOPIST 1|U|4||88||BASELINE|1969-04-23||||1968-10-07||1965-02-22|1960-10-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||NTRGRESP|NON-TARGET RESPONSE||||LOG10 PFU/ML|PD/RELAPSE AFTER HI||UG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|STUDY SUBJECT|ADJUDICATOR 1|Y|5||7||OBSERVATION|1964-09-02||||1970-04-08||1961-04-01|1961-02-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^4/HPF|INDETERMINATE RESPONSE||FRAMES/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|SIGNIFICANT OTHER|RATER|Y|5||7||WASHOUT|1970-01-21||||1968-07-14||1960-12-10|1969-05-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||STRUSTAT|STEROID USE STATUS||||/KG|CR||OZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|CHILD|MICROSCOPIST 3|U|1||38||SCREENING|1970-02-09||||1960-02-01||1967-11-02|1967-10-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||NTRGRESP|NON-TARGET RESPONSE||||UG/M2|MAJOR PATHOLOGIC RESPONSE||ML/G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|ADJUDICATOR|FORENSIC PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1960-06-26||||1963-02-10||1961-12-21|1963-09-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||LIVRRESP|LIVER RESPONSE||||NFIU|CYTOGENETIC CR||NMOL/L/H|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1965-10-17||||1963-10-04||1971-02-03|1972-10-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||OVRLRESP|OVERALL RESPONSE||||NMOL/MOL|NON-QUANTIFIABLE MRD POSITIVITY||M/SEC2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|PARENT|OTOLARYNGOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1971-04-02||||1972-10-24||1962-12-29|1971-07-23||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PKAT/L|CYTOGENETIC NO RESPONSE||VG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|PARENT|CLINICAL PATHOLOGIST|NA|3||39||OBSERVATION|1965-03-28||||1970-07-13||1964-05-31|1973-02-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||SPLNRESP|SPLEEN RESPONSE||||UIU/DL|VGPR||10^9 CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|PARENT|UROLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1965-08-05||||1962-09-07||1970-04-26|1965-06-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||NTRGRESP|NON-TARGET RESPONSE||||UG/L/H|NON-PD||UMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|CHILD|NEUROLOGIST 1|Y|4||88||SCREENING|1969-07-08||||1964-10-04||1972-07-25|1973-07-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||BESTRESP|BEST OVERALL RESPONSE||||IU/L|PR WITH LYMPHOCYTOSIS||MG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|DOMESTIC PARTNER|OPTOMETRIST|N|4||88||SCREENING|1969-04-20||||1969-12-08||1969-04-16|1969-05-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TUBE|PSEUDORESPONSE||VP/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|5||7||TREATMENT|1971-12-18||||1973-05-06||1969-06-12|1966-06-13||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||TRANSDUCING UNIT|NE||MCI/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|5||7||OBSERVATION|1973-04-24||||1961-09-29||1965-10-17|1966-07-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||BONERESP|BONE RESPONSE||||V|MORPHOLOGIC LEUKEMIA-FREE STATE||TABLET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1||38||CONTINUATION TREATMENT|1964-10-29||||1968-04-04||1966-07-07|1961-04-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ARBITRARY U|MRD NEGATIVITY||MOL/MOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|PARENT|DERMATOLOGIST|Y|1||38||WASHOUT|1961-05-24||||1969-08-01||1965-05-27|1968-02-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KA_U/DL|HI-E||L/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|INVESTIGATOR|ADJUDICATOR|NA|2||58||CONTINUATION TREATMENT|1968-03-24||||1960-01-19||1960-06-30|1969-11-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 CFU/G|HI-N||1/(S*KPA)|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|NA|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|N|2||58||BLINDED TREATMENT|1963-06-07||||1972-09-04||1970-06-30|1969-11-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||METSIND|METASTATIC INDICATOR||||U/G|PD FROM PR||ML/MMHG/MIN/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|SIBLING|RADIOLOGIST|U|3||39||BASELINE|1973-03-08||||1969-10-26||1971-08-06|1967-03-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||MOLRESP|MOLECULAR RESPONSE||||/40 HPFS|CYTOGENETIC NO RESPONSE||%/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CAREGIVER|PATHOLOGIST 1|NA|3||39||BASELINE|1973-06-02||||1972-05-26||1970-10-23|1963-07-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||NTRGRESP|NON-TARGET RESPONSE||||BEAM BREAKS|CHR||DIP|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|INDEPENDENT ASSESSOR|PATHOLOGIST|N|4||88||CONTINUATION TREATMENT|1969-08-01||||1973-05-08||1968-07-28|1970-05-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||MOLRESP|MOLECULAR RESPONSE||||PACKET|CCR||/40 HPFS|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|GUARDIAN|ADJUDICATOR 1|N|4||88||RUN-IN|1967-01-17||||1971-04-17||1966-03-02|1965-01-02||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 IU|MCR||PFU/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|GUARDIAN|ONCOLOGIST 2|N|5||7||TREATMENT|1961-05-21||||1963-08-30||1965-11-15|1960-05-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/MOL|CA125 75% RESPONSE||TRACE|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|INVESTIGATOR|ONCOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1960-07-22||||1965-10-12||1963-02-19|1962-07-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NFIU|PD-CT||UMOL/MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|CLINICAL STUDY SPONSOR|ONCOLOGIST|NA|1||38||CONTINUATION TREATMENT|1968-06-19||||1971-06-08||1965-09-30|1961-02-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||METBRESP|METABOLIC RESPONSE||||LENS|PSA PROGRESSION||UMOL/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|PROXY|NEUROLOGIST|N|1||38||TREATMENT|1967-04-09||||1971-03-29||1962-06-07|1972-12-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||MOLRESP|MOLECULAR RESPONSE||||DAYS/MONTH|PSEUDOPROGRESSION||USEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|CLINICAL RESEARCH ASSOCIATE|READER|U|2||58||INDUCTION TREATMENT|1963-09-09||||1961-06-12||1970-09-05|1973-03-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||OVRLRESP|OVERALL RESPONSE||||ML/(MIN*100ML)|PARTIAL MORPHOLOGIC RESPONSE||COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||CONTINUATION TREATMENT|1966-03-02||||1970-11-29||1966-03-21|1973-08-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DDU|STABLE||KS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|SIGNIFICANT OTHER|OPTOMETRIST|U|3||39||BLINDED TREATMENT|1960-03-29||||1969-06-15||1967-06-19|1967-10-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||NTRGRESP|NON-TARGET RESPONSE||||BOTTLE|HI-E||10^3 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3||39||SCREENING|1963-09-28||||1964-05-09||1968-09-10|1970-03-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||NEBULE|PD||TBSP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1965-04-08||||1972-01-15||1966-09-09|1970-10-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||TRGRESP|TARGET RESPONSE||||ANTIBODY UNIT|PD FROM PR||FRAMES/S|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|CLINICAL STUDY SPONSOR|READER|NA|4||88||BLINDED TREATMENT|1963-04-06||||1966-04-14||1964-05-09|1963-06-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG10 ELISA UNIT|INCREASED||MG/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|5||7||BLINDED TREATMENT|1967-06-18||||1973-07-23||1969-08-20|1960-10-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||ANATRESP|ANATOMIC RESPONSE||||SEC|CYTOGENETIC MINIMAL RESPONSE||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|HEALTH CARE PROFESSIONAL|INTERNIST|Y|5||7||CONTINUATION TREATMENT|1967-06-10||||1966-01-08||1972-11-21|1961-07-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||NEWLPROG|NEW LESION PROGRESSION||||MAC50|PR-CT||L/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|1||38||SCREENING|1965-06-28||||1970-01-27||1970-05-15|1967-05-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UL/ML|MAJOR PATHOLOGIC RESPONSE||EQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|1||38||WASHOUT|1969-09-16||||1973-07-10||1970-01-17|1966-04-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/M2|CPR||SIEMENS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|PROXY|RADIOLOGIST 2|Y|2||58||BASELINE|1965-06-19||||1960-03-30||1970-08-26|1972-11-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMHG|PMR||UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|CAREGIVER|PATHOLOGIST 2|N|2||58||BLINDED TREATMENT|1967-11-16||||1971-07-03||1961-06-21|1966-04-16||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||CLINRESP|CLINICAL RESPONSE||||DAGU/ML|SD||PRESSOR UNITS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|3||39||BASELINE|1970-03-19||||1963-06-15||1961-07-30|1965-03-15||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||SPLNRESP|SPLEEN RESPONSE||||/7.5 ML|MOLECULAR CR||FOZ_US|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|DOMESTIC PARTNER|MICROSCOPIST 1|Y|3||39||CONTINUATION TREATMENT|1961-04-15||||1968-04-09||1965-06-23|1969-06-11||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||NEWLIND|NEW LESION INDICATOR||||10^6 ORGANISMS|CMR||U.CARR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|4||88||INDUCTION TREATMENT|1971-06-02||||1967-10-04||1970-06-16|1971-02-24||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MM2|CR-CT||CI/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|VENDOR|DERMATOLOGIST|Y|4||88||TREATMENT|1963-07-26||||1964-10-26||1971-11-29|1972-11-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||AMOL|ABSENT MORPHOLOGIC RESPONSE||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|SIGNIFICANT OTHER|CARDIOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1967-03-21||||1972-08-08||1972-02-21|1966-10-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||SPLNRESP|SPLEEN RESPONSE||||10^9 ORGANISMS/MG|MAJOR PATHOLOGIC RESPONSE||CS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|INTERVIEWER|RADIOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1967-01-21||||1964-01-15||1969-02-08|1973-04-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ENZYME U/G HB|HI-E||IU/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|1||38||CONTINUATION TREATMENT|1971-08-23||||1965-03-02||1970-06-24|1968-08-18||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||CYTORESP|CYTOGENETIC RESPONSE||||G/G/DAY|CPR||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|INTERVIEWER|DERMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1964-08-24||||1960-07-13||1962-05-31|1963-05-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PFU/DOSE|PARTIAL MORPHOLOGIC RESPONSE||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|GUARDIAN|UROLOGIST|NA|2||58||INDUCTION TREATMENT|1961-02-28||||1967-03-09||1962-04-19|1962-02-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||NEWLIND|NEW LESION INDICATOR||||MG/G/MIN|MRD PERSISTENCE||PKAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|2||58||INDUCTION TREATMENT|1966-10-06||||1970-07-23||1960-05-29|1971-04-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||METBRESP|METABOLIC RESPONSE||||UG/M2/DAY|NED||MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|SIBLING|READER 3|N|3||39||FOLLOW-UP|1963-09-20||||1961-09-18||1965-12-31|1969-07-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||NTRGRESP|NON-TARGET RESPONSE||||MM2|VGPR||WEBER|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|3||39||WASHOUT|1966-11-06||||1961-09-26||1967-05-15|1962-05-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FIU|PD||10^6/HPF|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|CAREGIVER|NEUROLOGIST 1|U|4||88||RUN-IN|1970-06-25||||1964-09-16||1962-12-26|1960-03-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/MG/MIN|INCREASED||PKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|CAREGIVER|ADJUDICATOR|NA|4||88||SCREENING|1965-09-28||||1968-06-12||1965-03-15|1964-10-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||STRUSTAT|STEROID USE STATUS||||OSM|PR-CT||KBQ/UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|U|PROXY|READER 2|N|5||7||INDUCTION TREATMENT|1971-12-16||||1964-11-02||1963-06-22|1969-06-23||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||MOLRESP|MOLECULAR RESPONSE||||10^7 TCID 50/DOSE|PCR||U/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|CAREGIVER|MICROSCOPIST 2|U|5||7||OPEN LABEL TREATMENT|1968-12-20||||1967-07-19||1967-07-02|1960-01-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||CLINRESP|CLINICAL RESPONSE||||TITER|PR-CT||IN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|SPOUSE|RATER|NA|1||38||SCREENING|1973-05-18||||1964-11-23||1964-12-07|1963-02-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||RDIORESP|RADIOLOGIC RESPONSE||||G/M2/DAY|SMD||/VF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|1||38||RUN-IN|1973-07-07||||1963-03-18||1965-06-14|1962-07-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/DL|HI-P||PL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|2||58||BASELINE|1970-08-19||||1964-01-23||1961-04-07|1968-12-04||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||STRUSTAT|STEROID USE STATUS||||TSP EQ|CA125 75% RESPONSE||OZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1969-10-03||||1963-02-02||1969-08-20|1961-08-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||NEWLIND|NEW LESION INDICATOR||||DROP|TREATMENT FAILURE||FT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|FRIEND|MICROSCOPIST 1|N|3||39||SCREENING|1965-12-22||||1960-04-25||1973-06-19|1965-02-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI/MG|MORPHOLOGIC LEUKEMIA-FREE STATE||STRIP|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|READER 3|Y|3||39||RUN-IN|1965-08-15||||1966-01-02||1966-07-17|1964-12-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||NEWLIND|NEW LESION INDICATOR||||VIRTUAL PIXEL|PDU||BQ/MG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|CHILD|READER 2|U|4||88||BLINDED TREATMENT|1965-09-03||||1969-07-10||1967-10-13|1969-06-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||CLINRESP|CLINICAL RESPONSE||||WEBER|PSA PROGRESSION||PRESSOR UNITS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|SIBLING|ADJUDICATOR 3|NA|4||88||RUN-IN|1961-02-01||||1965-12-17||1966-07-08|1970-08-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||CYTORESP|CYTOGENETIC RESPONSE||||LOG10 TCID 50/ML|MR||FRAMES/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|5||7||BASELINE|1973-01-24||||1971-05-03||1965-10-02|1960-10-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||SPLNRESP|SPLEEN RESPONSE||||KM|MORPHOLOGIC LEUKEMIA-FREE STATE||IU/MMOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|SIBLING|NEUROLOGIST|Y|5||7||SCREENING|1965-05-14||||1964-01-10||1960-12-25|1973-02-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/M2|MRD NEGATIVITY||/MM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|DOMESTIC PARTNER|NEUROLOGIST 2|NA|1||38||WASHOUT|1965-10-16||||1973-05-09||1971-08-03|1971-09-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3/L|ISD||NU/CL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|1||38||INDUCTION TREATMENT|1962-02-08||||1968-07-23||1971-03-07|1966-10-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KCAL/DAY|CYTOGENETIC MINOR RESPONSE||OD UNIT|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|CHILD|ADJUDICATOR 1|U|2||58||OBSERVATION|1972-05-03||||1960-07-15||1972-02-20|1965-07-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||NTRGRESP|NON-TARGET RESPONSE||||AMOL|NON-QUANTIFIABLE MRD POSITIVITY||MV/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|ADJUDICATOR|READER 3|Y|2||58||SCREENING|1961-11-01||||1973-05-25||1964-09-03|1962-04-12||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||RDIORESP|RADIOLOGIC RESPONSE||||VP/ML|RELAPSED DISEASE||10^6 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|CAREGIVER|FORENSIC PATHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1965-07-19||||1971-08-20||1963-11-23|1970-06-02||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CMOL|NON-CR/NON-PD||G/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|GUARDIAN|READER|NA|3||39||WASHOUT|1970-06-25||||1972-11-27||1970-12-26|1964-05-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||METBRESP|METABOLIC RESPONSE||||SIEMENS|NE||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||BLINDED TREATMENT|1967-05-29||||1964-08-03||1965-08-17|1960-12-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||BONERESP|BONE RESPONSE||||MKAT|PD FROM PR||10^9 CFU|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|4||88||SCREENING|1964-04-22||||1967-06-21||1969-06-27|1964-04-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||MOLRESP|MOLECULAR RESPONSE||||MV/SEC|SD-CT||MOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|5||7||INDUCTION TREATMENT|1966-05-02||||1968-02-24||1963-05-03|1960-06-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BOTTLE|NPR||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|5||7||OBSERVATION|1971-08-15||||1961-07-01||1973-06-29|1961-07-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||JAR|ICR||VG/KG|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|INTERVIEWER|ADJUDICATOR 1|NA|1||38||BASELINE|1964-11-18||||1970-07-06||1969-10-15|1968-05-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||NEWLIND|NEW LESION INDICATOR||||ML/G/H|SMD||BEL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1966-03-03||||1961-05-04||1963-06-05|1969-02-14||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||BONERESP|BONE RESPONSE||||UU/DL|SCR||GPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|VENDOR|FORENSIC PATHOLOGIST|N|2||58||INDUCTION TREATMENT|1973-02-23||||1970-12-09||1966-12-17|1972-06-30||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||ANATRESP|ANATOMIC RESPONSE||||CARTRIDGE|TREATMENT FAILURE||/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|RATER 1|N|2||58||FOLLOW-UP|1969-08-16||||1966-03-04||1960-06-13|1972-07-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PIXELS/IN|SD||TSP|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|3||39||INDUCTION TREATMENT|1968-12-17||||1973-07-12||1968-01-21|1968-03-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||SPLNRESP|SPLEEN RESPONSE||||/100 HPFS|MORPHOLOGIC LEUKEMIA-FREE STATE||U/G/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|FRIEND|RADIOLOGIST 2|U|3||39||TREATMENT|1969-12-20||||1964-08-12||1971-07-22|1965-09-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||NEWLPROG|NEW LESION PROGRESSION||||L/S|ICR||LOG10 COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|FAMILY MEMBER|RATER 2|NA|4||88||BASELINE|1963-12-04||||1965-07-24||1971-02-24|1973-07-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CUP|SD-CT||K|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|4||88||OPEN LABEL TREATMENT|1967-09-06||||1967-04-07||1970-09-15|1966-08-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KHZ|NON-ICR/NON-IUPD||AMFI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|VENDOR|ADJUDICATOR|NA|5||7||INDUCTION TREATMENT|1972-09-17||||1969-09-07||1962-02-01|1967-08-31||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TSP|PR||UKAT/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|INTERVIEWER|ONCOLOGIST 1|Y|5||7||BASELINE|1963-04-11||||1962-09-22||1968-04-13|1969-01-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|1||||||LIVRRESP|LIVER RESPONSE||||SACHET|PD FROM PR||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|1||38||FOLLOW-UP|1970-03-02||||1962-04-23||1962-08-30|1970-05-11||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|2||||||NEWLPROG|NEW LESION PROGRESSION||||GBQ|IMMUNOPHENOTYPIC CR||ML*CMH2O|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|ADJUDICATOR|ONCOLOGIST 1|U|1||38||OBSERVATION|1968-12-12||||1973-04-09||1963-11-14|1973-06-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MIU/L|UNEQUIVOCAL||UM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|STUDY SUBJECT|PATHOLOGIST|Y|2||58||OBSERVATION|1970-10-18||||1964-08-07||1961-04-04|1970-12-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|2||||||RDIORESP|RADIOLOGIC RESPONSE||||DEG2|FAVORABLE RESPONSE||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|CAREGIVER|DERMATOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1961-05-02||||1971-09-11||1970-01-18|1964-12-06||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|1||||||OVRLRESP|OVERALL RESPONSE||||AGU/ML|EQUIVOCAL||DEG/MM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|FAMILY MEMBER|ADJUDICATOR 1|NA|3||39||SCREENING|1968-03-14||||1962-05-17||1967-01-12|1969-11-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MOL/ML|PR WITH LYMPHOCYTOSIS||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|3||39||BLINDED TREATMENT|1965-02-02||||1966-04-29||1966-01-31|1963-07-22||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|1||||||CLINRESP|CLINICAL RESPONSE||||PNU/ML|PSEUDOPROGRESSION||KCAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|GUARDIAN|MICROSCOPIST|N|4||88||LONG-TERM FOLLOW-UP|1969-09-04||||1968-05-15||1964-07-28|1966-02-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|2||||||NEWLIND|NEW LESION INDICATOR||||MET*MIN|NPR||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|CAREGIVER|RADIOLOGIST 1|N|4||88||CONTINUATION TREATMENT|1960-03-19||||1965-07-20||1968-08-09|1961-02-25||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/BREATH|COMPLETE MRD RESPONSE||MPA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||RUN-IN|1966-11-16||||1968-06-10||1972-04-29|1968-07-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|55985646-0224-4442-90C5-EFEDF990E88C|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/HPF|PR||DPM|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|STUDY SUBJECT|OPHTHALMOLOGIST|U|5||7||TREATMENT|1962-04-03||||1966-02-05||1970-03-11|1961-02-11||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/L/SEC|PD FROM PR||MG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|VENDOR|CARDIOLOGIST|NA|1||38||TREATMENT|1961-04-14||||1961-05-27||1968-05-20|1961-02-21||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/100G/MIN|CYTOGENETIC CR||UM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|1||38||WASHOUT|1967-10-22||||1971-08-17||1967-10-22|1960-06-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||U/DL|PR-CT||CD|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|2||58||BLINDED TREATMENT|1972-02-06||||1967-02-21||1965-10-11|1968-08-14||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|2||||||METSIND|METASTATIC INDICATOR||||UG/L/H|CYTOGENETIC MINOR RESPONSE||UU/L|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|STUDY SUBJECT|ENDOCRINOLOGIST|NA|2||58||SCREENING|1961-02-12||||1962-01-13||1965-10-22|1969-11-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|1||||||STRUSTAT|STEROID USE STATUS||||FG|MAJOR PATHOLOGIC RESPONSE||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|DOMESTIC PARTNER|READER 2|NA|3||39||FOLLOW-UP|1964-10-11||||1971-02-28||1972-03-10|1963-10-05||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|2||||||STRUSTAT|STEROID USE STATUS||||MG/ML/DAY|DISEASE TRANSFORMATION||PPB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|INVESTIGATOR|READER 2|N|3||39||BASELINE|1967-11-16||||1963-10-29||1960-11-03|1961-06-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|1||||||BESTRESP|BEST OVERALL RESPONSE||||UIU/L|MORPHOLOGIC CRI||DRINK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|PARENT|FORENSIC PATHOLOGIST|Y|4||88||BLINDED TREATMENT|1972-01-11||||1962-08-16||1961-11-10|1969-10-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMAL|UNEQUIVOCAL||UIU/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|VENDOR|RATER 1|NA|4||88||RUN-IN|1967-11-15||||1968-06-16||1969-09-22|1965-12-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NEWTON|PD-CT||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|VENDOR|NEUROLOGIST 2|NA|5||7||SCREENING|1972-02-27||||1972-12-27||1969-03-20|1960-02-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|86509C90-3C57-4755-A06F-79C620779371|2||||||STRUSTAT|STEROID USE STATUS||||SEC|NR||10^6 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1965-04-14||||1967-07-16||1964-01-08|1965-12-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^4/HPF|ISD||PPTH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|1||38||CONTINUATION TREATMENT|1964-04-01||||1964-06-21||1970-02-15|1972-06-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||GY/H|CRI||YD|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|VENDOR|PATHOLOGIST 2|U|1||38||WASHOUT|1973-08-22||||1968-06-13||1971-01-13|1967-12-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/CAGE/DAY|HI-E||UG/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|PROXY|NEUROLOGIST|NA|2||58||RUN-IN|1965-04-08||||1960-10-11||1963-04-12|1963-11-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||TMRESP|TUMOR MARKER RESPONSE||||VIAL|CRI||K|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|CHILD|ONCOLOGIST 2|Y|2||58||RUN-IN|1963-12-03||||1971-02-08||1963-06-02|1967-06-05||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6 ORGANISMS|SCR||DPM/0.5 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|SPOUSE|ONCOLOGIST|N|3||39||INDUCTION TREATMENT|1963-06-29||||1969-08-06||1968-12-14|1962-06-13||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MBP|IUPD||BLOCKS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|ADJUDICATOR|MICROSCOPIST 1|N|3||39||OPEN LABEL TREATMENT|1973-01-09||||1968-09-05||1961-12-20|1964-11-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||NEWLPROG|NEW LESION PROGRESSION||||PPTR|RELAPSED DISEASE FROM CR||ML/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|4||88||CONTINUATION TREATMENT|1961-07-04||||1961-09-04||1966-04-07|1969-11-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||BONERESP|BONE RESPONSE||||10^6 IU|VGPR||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|PARENT|DERMATOLOGIST|Y|4||88||CONTINUATION TREATMENT|1960-08-01||||1965-12-15||1966-05-29|1971-01-02||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||STRUSTAT|STEROID USE STATUS||||MOL/MOL|PARTIAL MORPHOLOGIC RESPONSE||/10^3|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|CHILD|HEMATOLOGIST|NA|5||7||BASELINE|1964-05-26||||1969-09-03||1969-09-18|1969-10-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||MOLRESP|MOLECULAR RESPONSE||||DPM/ML|MCR||UG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|CHILD|RADIOLOGIST 2|NA|5||7||BASELINE|1967-04-05||||1960-07-05||1966-06-27|1971-06-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PT_US|CYTOGENETIC NO RESPONSE||/WK|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|SPOUSE|READER 3|U|1||38||FOLLOW-UP|1965-09-06||||1960-11-11||1963-06-16|1960-11-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ANTI-XA IU|PCR||LOG10 TCID 50/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|1||38||BASELINE|1966-07-09||||1961-07-30||1962-11-01|1961-02-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||SPLNRESP|SPLEEN RESPONSE||||NMOL BCE/L|NON-PD||MG/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|VENDOR|ADJUDICATOR|U|2||58||RUN-IN|1972-01-16||||1967-07-22||1971-03-30|1966-02-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%|PR-CT||MM/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|GUARDIAN|CLINICAL PATHOLOGIST|U|2||58||RUN-IN|1968-03-06||||1961-07-04||1961-07-09|1960-05-08||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NL|EQUIVOCAL||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|DOMESTIC PARTNER|HEMATOLOGIST|N|3||39||TREATMENT|1969-07-08||||1960-07-22||1972-07-23|1966-09-01||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||POINT|RELAPSED DISEASE FROM CR||10^3 DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|CHILD|ADJUDICATOR 2|NA|3||39||CONTINUATION TREATMENT|1971-04-08||||1964-10-14||1971-10-14|1969-04-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PG/CELL|PD||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|SIBLING|RATER|N|4||88||WASHOUT|1968-09-07||||1961-02-12||1971-04-17|1962-11-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||HOUNSFIELD UNIT|PD-CT||ML/MIN/MMHG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|GUARDIAN|NEUROLOGIST 2|N|4||88||BLINDED TREATMENT|1968-11-02||||1971-11-05||1968-12-23|1961-07-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/H|MRD NEGATIVITY||ML/G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|U|DOMESTIC PARTNER|OPTOMETRIST|NA|5||7||OBSERVATION|1960-09-17||||1961-06-06||1962-02-22|1967-09-03||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||STRUSTAT|STEROID USE STATUS||||APL U|CMR||APL U|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1967-06-21||||1968-11-09||1969-05-07|1966-04-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ABSORBANCE U|PDU||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|CHILD|READER 2|Y|1||38||WASHOUT|1968-02-08||||1967-02-25||1971-05-13|1961-03-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||CYTORESP|CYTOGENETIC RESPONSE||||/LPF|NR||UL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|CAREGIVER|HEMATOLOGIST|N|1||38||OBSERVATION|1971-07-23||||1968-12-21||1969-11-28|1972-02-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PACK YEAR|PD||L/MIN/M2|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|PARENT|ADJUDICATOR 2|NA|2||58||BASELINE|1967-07-04||||1970-03-25||1960-08-04|1968-08-31||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||STRUSTAT|STEROID USE STATUS||||U.CARR|PR WITH LYMPHOCYTOSIS||ML/100G/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|INDEPENDENT ASSESSOR|OPTOMETRIST|NA|2||58||OPEN LABEL TREATMENT|1969-09-21||||1970-02-25||1972-03-03|1973-01-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BOLUS|DECREASED||LOG10 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|3||39||BASELINE|1971-03-11||||1970-03-23||1973-01-12|1968-08-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||M/SEC|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^6 CFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|PARENT|OTOLARYNGOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1966-04-07||||1969-07-29||1966-12-15|1965-01-08||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||MOLRESP|MOLECULAR RESPONSE||||MU/G|MRD PERSISTENCE||MEQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|INTERVIEWER|ONCOLOGIST 1|U|4||88||WASHOUT|1961-06-10||||1961-09-29||1965-08-17|1973-09-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CP|PMD||LOG EID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|PROXY|MICROSCOPIST|Y|4||88||CONTINUATION TREATMENT|1970-12-14||||1971-08-26||1971-07-08|1962-05-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BQ/G|INDETERMINATE RESPONSE||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|GUARDIAN|ADJUDICATOR|Y|5||7||LONG-TERM FOLLOW-UP|1964-12-01||||1968-08-03||1967-08-29|1971-06-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||SHOCK WAVE|ICR||NSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|SPOUSE|RADIOLOGIST|U|5||7||INDUCTION TREATMENT|1963-01-15||||1969-06-01||1972-05-09|1963-07-22||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||CLINRESP|CLINICAL RESPONSE||||PFU/ANIMAL|COMPLETE MRD RESPONSE||KM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|CHILD|ONCOLOGIST 1|NA|1||38||OBSERVATION|1968-01-20||||1963-10-19||1973-06-02|1961-07-30||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 IU/ML|SD-CT||CI/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|SIGNIFICANT OTHER|MICROSCOPIST|Y|1||38||BASELINE|1971-10-15||||1963-04-19||1972-04-12|1962-10-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||CLINRESP|CLINICAL RESPONSE||||UG/M2/DAY|MCR||H*%|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|CHILD|FORENSIC PATHOLOGIST|U|2||58||OBSERVATION|1963-01-11||||1968-08-02||1972-03-22|1966-12-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||PATHRESP|PATHOLOGIC RESPONSE||||G/DL|MORPHOLOGIC LEUKEMIA-FREE STATE||UG/M2/MIN|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|FRIEND|ADJUDICATOR|Y|2||58||OPEN LABEL TREATMENT|1968-10-12||||1967-10-24||1965-01-05|1964-01-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||METSIND|METASTATIC INDICATOR||||UG/M2/DAY|INDETERMINATE RESPONSE||MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|CHILD|RADIOLOGIST 2|U|3||39||TREATMENT|1972-10-14||||1965-05-03||1962-10-14|1960-12-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||VP/DOSE|CR-CT||DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|FRIEND|RATER 2|NA|3||39||WASHOUT|1966-03-05||||1966-05-15||1961-04-24|1960-09-16||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||AMP|PSEUDOPROGRESSION||V/SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|NON-HEALTH CARE PROFESSIONAL|READER 1|U|4||88||CONTINUATION TREATMENT|1971-06-30||||1971-12-30||1960-12-19|1970-09-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||OVRLRESP|OVERALL RESPONSE||||PFU/ANIMAL|MORPHOLOGIC LEUKEMIA-FREE STATE||MEQ/KG|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|DOMESTIC PARTNER|ONCOLOGIST 2|U|4||88||FOLLOW-UP|1962-04-28||||1971-03-26||1971-06-28|1969-07-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||ANATRESP|ANATOMIC RESPONSE||||10^9 ORGANISMS/MG|NR||10^12/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|5||7||OBSERVATION|1965-09-22||||1967-07-21||1963-05-29|1968-09-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FMOL|SD||MMOL/MIN/KPA/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|VENDOR|UROLOGIST|NA|5||7||WASHOUT|1970-12-16||||1969-04-27||1973-05-31|1966-05-22||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||METSIND|METASTATIC INDICATOR||||NSEC|MRD PERSISTENCE||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|1||38||CONTINUATION TREATMENT|1971-01-05||||1967-03-12||1964-07-21|1969-03-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||NEWLPROG|NEW LESION PROGRESSION||||MG/M2|MORPHOLOGIC LEUKEMIA-FREE STATE||BQ/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|ADJUDICATOR|NEUROLOGIST 1|Y|1||38||SCREENING|1969-05-06||||1970-08-23||1969-06-22|1968-11-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^7 TCID 50/DOSE|MINOR PATHOLOGIC RESPONSE||%|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|PARENT|READER 1|NA|2||58||BASELINE|1971-05-11||||1960-07-17||1969-06-12|1969-07-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MMHG/SEC|NON-ICR/NON-IUPD||%(V/V)|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|SIBLING|OPHTHALMOLOGIST|Y|2||58||BLINDED TREATMENT|1968-04-25||||1965-06-30||1971-03-01|1961-08-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CD/M2|CA125 75% RESPONSE||/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||WASHOUT|1968-09-21||||1966-06-21||1964-04-25|1963-01-21||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||METBRESP|METABOLIC RESPONSE||||%(V/V)|NON-QUANTIFIABLE MRD POSITIVITY||C|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|SIGNIFICANT OTHER|PATHOLOGIST 2|Y|3||39||BLINDED TREATMENT|1971-12-21||||1962-12-10||1973-02-14|1967-03-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MASK|PSEUDOPROGRESSION||TUBERCULIN UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|4||88||BASELINE|1963-01-07||||1968-08-12||1969-08-31|1972-05-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||TRGRESP|TARGET RESPONSE||||10^9 CFU/ML|COMPLETE MRD RESPONSE||USIEMENS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1962-09-11||||1961-04-25||1969-03-23|1964-06-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||H*%|IMPROVED||UMOL/L/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|5||7||RUN-IN|1967-03-03||||1968-10-06||1965-10-14|1967-11-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||LOZENGE|CYTOGENETIC MINIMAL RESPONSE||OD UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|GUARDIAN|CLINICAL PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1965-10-19||||1963-04-08||1967-10-25|1966-08-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||AMP|NON-CR/NON-PD||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|ADJUDICATOR|MICROSCOPIST 3|NA|1||38||SCREENING|1960-11-20||||1970-06-13||1963-04-21|1969-12-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||METSIND|METASTATIC INDICATOR||||U/G HB|MRD RELAPSE||PHERESIS UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|INVESTIGATOR|INTERNIST|NA|1||38||RUN-IN|1964-10-09||||1966-09-26||1970-11-05|1963-01-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/M2|ICPD||MKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|INTERVIEWER|RADIOLOGIST|NA|2||58||BLINDED TREATMENT|1965-08-07||||1970-02-26||1965-07-22|1962-03-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||STRUSTAT|STEROID USE STATUS||||MU/L|PR||GPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||WASHOUT|1961-07-03||||1970-04-20||1966-04-23|1968-09-03||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NU/CL|VGPR||U/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|CLINICAL STUDY SPONSOR|RATER 2|N|3||39||SCREENING|1960-05-20||||1964-03-14||1961-03-29|1969-05-30||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||TRGRESP|TARGET RESPONSE||||MU/G|CA125 50% RESPONSE||DAYS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|PROXY|RADIOLOGIST 1|NA|3||39||OBSERVATION|1969-01-13||||1961-05-30||1960-01-11|1962-04-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^4/HPF|NE||MM/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|SIBLING|READER 2|N|4||88||OPEN LABEL TREATMENT|1970-11-05||||1965-06-18||1971-10-24|1965-04-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/MIN|WORSENED||KV|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|DOMESTIC PARTNER|UROLOGIST|U|4||88||SCREENING|1968-07-13||||1963-01-30||1965-12-23|1964-06-19||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 IU|HI-E||PKAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|5||7||OBSERVATION|1961-03-30||||1969-07-11||1972-11-21|1970-10-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||METBRESP|METABOLIC RESPONSE||||UG/M2|CR-CT||SHOCK WAVE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|PARENT|MICROSCOPIST|Y|5||7||FOLLOW-UP|1963-06-23||||1964-04-09||1965-04-14|1961-02-20||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||PATHRESP|PATHOLOGIC RESPONSE||||L/MIN|CHR||MG/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|SIGNIFICANT OTHER|READER 3|NA|1||38||OBSERVATION|1960-09-11||||1972-07-26||1965-10-27|1970-08-30||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||ANATRESP|ANATOMIC RESPONSE||||G/CAGE|PCR||ML/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|1||38||SCREENING|1973-03-30||||1971-04-25||1966-04-20|1967-12-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||STRUSTAT|STEROID USE STATUS||||10^9 ORGANISMS/MG|CHR||NMOL BCE/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|2||58||BASELINE|1967-01-10||||1967-09-09||1969-01-05|1961-12-07||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IN2|DECREASED||PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|SIBLING|OTOLARYNGOLOGIST|N|2||58||TREATMENT|1965-07-06||||1961-11-12||1970-03-03|1970-12-18||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||LIVRRESP|LIVER RESPONSE||||EVENTS|CYTOGENETIC MINOR RESPONSE||ATM|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|3||39||SCREENING|1965-12-10||||1963-08-11||1972-10-01|1962-11-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^6/L|PSA PROGRESSION||PNU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|ADJUDICATOR|NEUROLOGIST 1|N|3||39||BLINDED TREATMENT|1967-09-21||||1960-03-05||1960-03-23|1964-10-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^9 ORGANISMS/G|STABLE||G/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|CAREGIVER|READER 1|Y|4||88||BASELINE|1972-08-18||||1973-07-01||1972-04-28|1968-08-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CAPSULE|CMR||ML/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|GUARDIAN|FORENSIC PATHOLOGIST|N|4||88||SCREENING|1972-03-05||||1969-10-22||1966-07-07|1964-05-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||FG|SD||PNU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|DOMESTIC PARTNER|READER 1|NA|5||7||WASHOUT|1966-01-11||||1972-09-07||1969-03-02|1962-03-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/M2|INDETERMINATE RESPONSE||ML/M2|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|5||7||RUN-IN|1965-02-26||||1965-04-15||1970-09-15|1970-12-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/40 HPFS|UNEQUIVOCAL||MMOL2/L2|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|1||38||RUN-IN|1966-07-31||||1964-06-15||1972-12-04|1969-11-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||IU/L|MORPHOLOGIC CR||MET*MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|SIBLING|INTERNIST|N|1||38||WASHOUT|1964-01-31||||1972-11-11||1961-06-17|1961-04-28||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL/L|STABLE||PSI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|STUDY SUBJECT|RATER 1|N|2||58||TREATMENT|1969-06-26||||1967-10-19||1967-04-20|1971-11-16||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||RAD|HI-N||ML/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|CAREGIVER|NEUROLOGIST|NA|2||58||CONTINUATION TREATMENT|1964-12-15||||1962-07-16||1970-05-01|1964-01-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 CFU|ICPD||DDU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|PARENT|RATER 2|U|3||39||RUN-IN|1968-07-25||||1965-04-25||1973-09-02|1973-06-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PATCH|CR-CT||MPH|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|GUARDIAN|READER|N|3||39||RUN-IN|1971-07-17||||1972-12-13||1973-03-24|1966-04-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/L|HI-N||10^3 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1960-08-06||||1968-11-17||1964-11-17|1968-11-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||BONERESP|BONE RESPONSE||||MPA|TREATMENT FAILURE||BLOCKS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|ADJUDICATOR|FORENSIC PATHOLOGIST|N|4||88||SCREENING|1963-01-24||||1969-11-07||1960-05-27|1969-02-04||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||METSIND|METASTATIC INDICATOR||||APS U|NOT ALL EVALUATED||LOG10 PFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|CAREGIVER|RATER 2|U|5||7||INDUCTION TREATMENT|1973-06-15||||1965-04-05||1969-12-28|1966-10-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||LIVRRESP|LIVER RESPONSE||||WEBER|CMR||CI/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|STUDY SUBJECT|RADIOLOGIST 2|Y|5||7||OPEN LABEL TREATMENT|1966-07-15||||1966-02-19||1963-12-17|1971-04-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||NTRGRESP|NON-TARGET RESPONSE||||TITER|PR||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|CAREGIVER|PATHOLOGIST 1|N|1||38||OBSERVATION|1971-10-07||||1965-09-12||1966-01-08|1960-04-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FARAD|CA125 50% RESPONSE||ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|STUDY SUBJECT|ENDOCRINOLOGIST|Y|1||38||BASELINE|1972-08-08||||1962-07-14||1963-10-26|1972-12-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UKAT/10^12 RBC|CPR||FT3|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|CLINICAL RESEARCH COORDINATOR|RATER|U|2||58||SCREENING|1968-05-09||||1972-10-12||1963-10-08|1966-12-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CCID 50/ML|IUPD||MM3/MM2/YEAR|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INTERVIEWER|READER|Y|2||58||OBSERVATION|1968-06-26||||1968-11-23||1960-08-27|1971-10-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||U/KG/MIN|MINOR PATHOLOGIC RESPONSE||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|SPOUSE|READER 1|N|3||39||SCREENING|1968-09-28||||1967-06-07||1969-09-04|1971-04-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ENZYME U/M2|ISD||%(V/V)|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|PARENT|HEMATOLOGIST|Y|3||39||TREATMENT|1962-06-01||||1963-03-10||1970-12-25|1972-08-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||MOLRESP|MOLECULAR RESPONSE||||PMOL/10^10 CELLS|SCR||ML/SEC/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|SIGNIFICANT OTHER|READER 3|Y|4||88||OBSERVATION|1961-12-13||||1964-09-06||1966-08-03|1971-02-22||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ELISA UNIT|CYTOGENETIC MINOR RESPONSE||DB|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|SIBLING|INTERNIST|Y|4||88||WASHOUT|1968-06-20||||1960-11-06||1963-04-25|1965-02-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||BESTRESP|BEST OVERALL RESPONSE||||KHZ|WORSENED||UKAT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|U|5||7||LONG-TERM FOLLOW-UP|1973-05-13||||1973-07-28||1963-12-14|1973-01-19||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||ANATRESP|ANATOMIC RESPONSE||||TUBERCULIN UNIT|UNEQUIVOCAL||ML/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|STUDY SUBJECT|RADIOLOGIST 2|NA|5||7||TREATMENT|1967-02-07||||1970-02-28||1960-12-07|1962-02-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PKAT/L|INDETERMINATE RESPONSE||CM/S|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|SIBLING|RATER|U|1||38||LONG-TERM FOLLOW-UP|1967-09-09||||1967-02-09||1969-02-09|1969-09-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||ANATRESP|ANATOMIC RESPONSE||||UG/M2/H|PCR||DPM/0.5 ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|1||38||WASHOUT|1961-05-14||||1971-11-09||1962-08-06|1961-12-22||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||RDIORESP|RADIOLOGIC RESPONSE||||G/CAGE|RELAPSED DISEASE||10^6 CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|CLINICAL STUDY SPONSOR|READER 3|N|2||58||FOLLOW-UP|1967-06-16||||1965-06-04||1967-03-04|1963-05-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||ANATRESP|ANATOMIC RESPONSE||||ML/DL|WORSENED||APS U|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1965-04-15||||1972-12-31||1965-05-17|1970-04-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CI/MG|PSA PROGRESSION||10^6 IU|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|3||39||OBSERVATION|1972-05-18||||1970-05-29||1970-08-23|1969-08-21||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NMOL/DAY|PARTIAL MORPHOLOGIC RESPONSE||U/MMOL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|PARENT|UROLOGIST|U|3||39||OBSERVATION|1964-11-29||||1960-11-20||1964-09-03|1972-10-24||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/M2/DAY|VGPR||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|GUARDIAN|ENDOCRINOLOGIST|NA|4||88||TREATMENT|1970-01-12||||1961-10-21||1962-03-04|1966-10-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||SPLNRESP|SPLEEN RESPONSE||||CAN|ICPD||10^7 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|VENDOR|ADJUDICATOR|NA|4||88||BLINDED TREATMENT|1967-01-04||||1964-06-23||1969-11-30|1970-10-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||TMRESP|TUMOR MARKER RESPONSE||||G/ANIMAL/WK|CR||10^9/L|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|Y|INTERVIEWER|CARDIOLOGIST|NA|5||7||CONTINUATION TREATMENT|1967-10-23||||1973-04-06||1964-07-23|1963-09-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||NTRGRESP|NON-TARGET RESPONSE||||UM/DAY|ICR||CYCLE/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|NON-HEALTH CARE PROFESSIONAL|INTERNIST|U|5||7||BLINDED TREATMENT|1966-05-29||||1964-01-04||1967-05-20|1963-06-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||NEWLIND|NEW LESION INDICATOR||||10^9 CFU/G|RELAPSED DISEASE FROM CR OR PR||ELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|SPOUSE|PEDIATRIC NEUROLOGIST|U|1||38||FOLLOW-UP|1973-04-01||||1963-07-26||1971-08-08|1973-04-13||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MONTHS|PD||G/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|VENDOR|PATHOLOGIST 2|Y|1||38||INDUCTION TREATMENT|1968-12-07||||1973-04-20||1963-06-23|1968-03-20||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MEQ/ML|NE||G/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|GUARDIAN|CLINICAL PATHOLOGIST|U|2||58||BASELINE|1970-08-14||||1971-10-19||1965-07-19|1961-03-05||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UKAT/10^12 RBC|PMD||G/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|FAMILY MEMBER|RADIOLOGIST|NA|2||58||TREATMENT|1962-01-04||||1961-07-20||1966-09-28|1969-01-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||STRUSTAT|STEROID USE STATUS||||QUANTITY SUFFICIENT|PMD||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|GUARDIAN|MICROSCOPIST 1|U|3||39||BASELINE|1967-06-26||||1967-11-09||1972-12-16|1967-06-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||STRUSTAT|STEROID USE STATUS||||PRESSOR UNITS|HI-N||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|RATER|U|3||39||BLINDED TREATMENT|1965-11-09||||1961-10-14||1963-11-14|1962-01-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||STRUSTAT|STEROID USE STATUS||||DPM|PR||MG/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|SPOUSE|PATHOLOGIST 2|NA|4||88||WASHOUT|1963-09-19||||1961-04-30||1966-02-04|1961-10-30||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/BEAT|NED||GLOBULE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|4||88||LONG-TERM FOLLOW-UP|1968-08-19||||1960-04-11||1967-01-31|1968-08-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||CLINRESP|CLINICAL RESPONSE||||KG/M2|MR||MMHG/L/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|5||7||INDUCTION TREATMENT|1970-08-12||||1965-02-09||1972-10-21|1960-07-28||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||METSIND|METASTATIC INDICATOR||||NMOL/KG/DAY|MAJOR PATHOLOGIC RESPONSE||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|CAREGIVER|RADIOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1969-01-28||||1971-11-01||1963-12-29|1969-10-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||METSIND|METASTATIC INDICATOR||||NKAT/L|PD/RELAPSE AFTER HI||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|VENDOR|PEDIATRIC NEUROLOGIST|N|1||38||SCREENING|1966-06-08||||1964-11-23||1962-03-26|1968-06-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||MOLRESP|MOLECULAR RESPONSE||||UIU/DL|CA125 50% RESPONSE||TSP EQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|N|INDEPENDENT ASSESSOR|NEUROLOGIST|U|1||38||TREATMENT|1961-09-25||||1968-12-23||1967-05-04|1961-03-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||LIVRRESP|LIVER RESPONSE||||FT3|IUPD||HENRY|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|ADJUDICATOR|MICROSCOPIST|N|2||58||SCREENING|1962-11-30||||1969-03-22||1973-07-07|1966-07-28||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CD/M2|UNEQUIVOCAL||/10^3|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|FRIEND|PEDIATRIC NEUROLOGIST|N|2||58||SCREENING|1973-06-23||||1960-05-24||1963-05-28|1965-05-26||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||BONERESP|BONE RESPONSE||||ABSORBANCE U|CCR||PMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|INTERVIEWER|RADIOLOGIST 2|Y|3||39||WASHOUT|1963-11-20||||1965-02-12||1961-08-16|1963-11-21||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||METSIND|METASTATIC INDICATOR||||BREATHS/MIN|MCR||UCI|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||RUN-IN|1965-10-07||||1971-07-15||1964-06-07|1962-12-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DRAM|CYTOGENETIC PR||FMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 1|Y|4||88||SCREENING|1973-05-22||||1966-12-05||1963-10-02|1962-03-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PMOL/G|HI-N||PG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|SPOUSE|CARDIOLOGIST|Y|4||88||WASHOUT|1968-05-26||||1967-07-31||1960-06-15|1966-04-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LX|IUPD||MPA|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|SIBLING|UROLOGIST|Y|5||7||FOLLOW-UP|1972-01-23||||1969-10-21||1972-09-05|1962-11-28||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MANSON U/ML|QUANTIFIABLE MRD POSITIVITY||SCM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|DOMESTIC PARTNER|UROLOGIST|U|5||7||FOLLOW-UP|1967-02-04||||1964-08-13||1971-07-31|1962-06-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PACK|MOLECULAR CR||MDFI|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|FRIEND|INTERNIST|U|1||38||CONTINUATION TREATMENT|1960-09-22||||1964-01-17||1966-12-16|1966-06-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||M|CR-CT||/2500 WBC|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|1||38||BASELINE|1966-08-06||||1966-09-10||1969-11-29|1969-09-29||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/ML|CYTOGENETIC NO RESPONSE||L/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|STUDY SUBJECT|RATER 2|U|2||58||LONG-TERM FOLLOW-UP|1969-04-03||||1968-08-23||1971-12-02|1967-05-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||ANATRESP|ANATOMIC RESPONSE||||BQ/ML|MRD PERSISTENCE||APL U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|SPOUSE|READER|N|2||58||SCREENING|1965-11-02||||1972-04-08||1967-11-02|1962-09-09||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||SPLNRESP|SPLEEN RESPONSE||||PMOL/L/H|DECREASED||U/M2/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|INVESTIGATOR|NEUROLOGIST 2|N|3||39||OBSERVATION|1962-11-06||||1970-01-07||1963-02-09|1968-11-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||HR/DAY|SMD||DAYS/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|SPOUSE|OPHTHALMOLOGIST|U|3||39||INDUCTION TREATMENT|1973-03-01||||1968-03-01||1960-09-29|1967-07-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||ANATRESP|ANATOMIC RESPONSE||||ENZYME U/G HB|NE||U/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|4||88||FOLLOW-UP|1969-10-10||||1962-09-15||1963-11-06|1962-10-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||CLINRESP|CLINICAL RESPONSE||||PPTR|INDETERMINATE RESPONSE||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|4||88||FOLLOW-UP|1961-10-20||||1966-11-13||1969-09-26|1968-01-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NMOL BCE/MMOL|MOLECULAR CR||USP U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|5||7||OPEN LABEL TREATMENT|1960-01-18||||1962-05-25||1968-04-29|1963-12-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||METSIND|METASTATIC INDICATOR||||MM/MIN|MAJOR PATHOLOGIC RESPONSE||BP|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|PARENT|MICROSCOPIST 1|N|5||7||CONTINUATION TREATMENT|1961-05-26||||1963-08-21||1966-04-08|1970-06-21||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||ANATRESP|ANATOMIC RESPONSE||||ENZYME U/L|MCR||V/V|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|CAREGIVER|RADIOLOGIST 1|NA|1||38||LONG-TERM FOLLOW-UP|1965-02-09||||1971-06-12||1967-05-15|1969-03-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||GY/MIN|PSEUDOPROGRESSION||MV/SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|SIBLING|ADJUDICATOR|N|1||38||FOLLOW-UP|1964-06-26||||1972-02-06||1973-01-18|1972-10-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||STRUSTAT|STEROID USE STATUS||||10^3/HPF|IMMUNOPHENOTYPIC CR||ML/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||TREATMENT|1962-01-30||||1964-07-20||1967-03-18|1962-10-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||SBE/ML|MRD RELAPSE||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|PROXY|ONCOLOGIST 1|U|2||58||WASHOUT|1966-05-18||||1960-06-29||1962-01-26|1970-09-16||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||HOMEOPATHIC DILUTION|CMR||MASK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|FAMILY MEMBER|READER 2|NA|3||39||INDUCTION TREATMENT|1972-12-01||||1964-03-08||1960-01-09|1965-03-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||OVRLRESP|OVERALL RESPONSE||||MEQ/ML|CMR||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|DOMESTIC PARTNER|MICROSCOPIST|NA|3||39||SCREENING|1965-03-16||||1965-01-22||1960-06-08|1965-06-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||VIAL|RELAPSED DISEASE FROM CR||PMOL/10^10 CELLS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|ADJUDICATOR|FORENSIC PATHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1963-11-28||||1964-04-09||1963-05-01|1965-05-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||EP U|NPR||ABSORBANCE U/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|READER 2|NA|4||88||LONG-TERM FOLLOW-UP|1972-08-13||||1971-11-14||1963-06-25|1973-04-20||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/CM2|PSEUDORESPONSE||UV2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|INTERVIEWER|RATER|Y|5||7||WASHOUT|1965-07-06||||1966-03-18||1963-06-06|1963-12-12||DURING||DURING|
TRIAL STUDY 134XCP|RS|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MU/G|ICR||MG2/DL2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|GUARDIAN|ONCOLOGIST|NA|5||7||BASELINE|1965-06-09||||1962-10-13||1966-04-16|1967-08-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||TMRESP|TUMOR MARKER RESPONSE||||G/G|CYTOGENETIC PR||L/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|STUDY SUBJECT|ADJUDICATOR 2|Y|1||38||WASHOUT|1967-06-11||||1962-06-11||1970-03-18|1963-03-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||BESTRESP|BEST OVERALL RESPONSE||||G/U|NPR||MM3/MM2/YEAR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|PARENT|PATHOLOGIST 1|U|1||38||LONG-TERM FOLLOW-UP|1970-04-01||||1972-09-19||1967-10-23|1966-07-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||OVRLRESP|OVERALL RESPONSE||||U/MG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^7 CFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|SPOUSE|HEMATOLOGIST|N|2||58||INDUCTION TREATMENT|1969-07-30||||1972-08-31||1972-02-04|1972-04-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||MOLRESP|MOLECULAR RESPONSE||||UU/DL|SMD||TRANSDUCING UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|SIBLING|PATHOLOGIST 1|N|2||58||CONTINUATION TREATMENT|1967-04-14||||1971-02-08||1966-11-13|1967-09-07||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||TRGRESP|TARGET RESPONSE||||U/MG|UNEQUIVOCAL||UG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|PARENT|PATHOLOGIST|N|3||39||BASELINE|1968-03-13||||1961-07-28||1963-06-01|1971-06-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/ANIMAL|CRI||GPL U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1969-07-05||||1961-05-20||1966-03-15|1973-01-16||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||OVRLRESP|OVERALL RESPONSE||||NMOL/KG/DAY|COMPLETE MRD RESPONSE||PA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|DOMESTIC PARTNER|PATHOLOGIST|U|4||88||BLINDED TREATMENT|1972-11-06||||1969-05-30||1971-05-29|1972-03-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||STRUSTAT|STEROID USE STATUS||||LINEAR FT*LB|VGPR||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|4||88||BASELINE|1970-03-25||||1973-06-28||1972-01-22|1965-06-17||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 COPIES/ML|CYTOGENETIC MINIMAL RESPONSE||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|INTERVIEWER|NEUROLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1971-10-14||||1963-08-23||1961-11-24|1969-01-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MMOL/MIN/KPA/L|NON-QUANTIFIABLE MRD POSITIVITY||/10^3|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|FAMILY MEMBER|ADJUDICATOR 2|U|5||7||RUN-IN|1971-11-25||||1972-07-30||1972-08-24|1973-05-16||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/L|SD||MG/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|1||38||TREATMENT|1964-04-03||||1960-11-30||1965-05-22|1966-07-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||TRGRESP|TARGET RESPONSE||||M/SEC2|HI-N||FT3|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|ADJUDICATOR|READER 3|U|1||38||BLINDED TREATMENT|1964-09-05||||1969-11-21||1961-03-05|1972-07-15||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||BESTRESP|BEST OVERALL RESPONSE||||LINEAR FT*LB|PSEUDORESPONSE||MG/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|DOMESTIC PARTNER|MICROSCOPIST|NA|2||58||RUN-IN|1964-01-09||||1972-09-22||1972-08-27|1966-04-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||LIVRRESP|LIVER RESPONSE||||PIXEL|NON-ICR/NON-IUPD||DAYS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|2||58||OBSERVATION|1967-05-20||||1963-09-07||1969-02-12|1961-02-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MCI/KG|PR||FEU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|FRIEND|RATER 2|NA|3||39||OPEN LABEL TREATMENT|1973-05-30||||1967-09-01||1970-05-17|1964-03-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/ANIMAL|MORPHOLOGIC CRI||FRAMES/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|GUARDIAN|ADJUDICATOR|Y|3||39||INDUCTION TREATMENT|1961-04-14||||1963-02-11||1963-10-02|1971-05-31||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||BESTRESP|BEST OVERALL RESPONSE||||MSEC|NED||10^6 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|4||88||TREATMENT|1962-03-02||||1972-03-06||1970-05-21|1960-11-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KG|CA125 50% RESPONSE||U/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|ADJUDICATOR|READER 3|U|4||88||CONTINUATION TREATMENT|1961-10-13||||1973-03-17||1966-11-02|1971-06-21||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||NTRGRESP|NON-TARGET RESPONSE||||G/G|PDU||BQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|INVESTIGATOR|READER 2|Y|5||7||TREATMENT|1963-03-13||||1971-10-18||1971-09-10|1962-12-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DPM/0.5 ML|PD||BEAM BREAKS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|5||7||LONG-TERM FOLLOW-UP|1960-05-12||||1970-10-25||1961-08-18|1966-05-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/KG/H|PD FROM PR||PACK|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1||38||TREATMENT|1973-03-14||||1960-02-07||1962-03-08|1968-07-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MM2|MAJOR PATHOLOGIC RESPONSE||MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|SIBLING|PATHOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1966-04-15||||1969-02-27||1972-04-23|1972-04-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/DL|QUANTIFIABLE MRD POSITIVITY||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|SIBLING|NEUROLOGIST|NA|2||58||BASELINE|1960-09-03||||1971-10-28||1969-04-17|1971-11-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||BQ|MCR||UMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|2||58||BASELINE|1969-05-23||||1969-02-06||1965-10-09|1973-03-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/KG/MIN|EQUIVOCAL||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|GUARDIAN|RATER|U|3||39||WASHOUT|1968-06-19||||1972-02-04||1970-03-25|1968-03-08||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||LIVRRESP|LIVER RESPONSE||||%(W/V)|CYTOGENETIC MINOR RESPONSE||PG/DL|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|STUDY SUBJECT|ONCOLOGIST 1|Y|3||39||OBSERVATION|1970-08-04||||1973-08-07||1973-03-02|1971-02-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PFU/ML|MORPHOLOGIC CR||MMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|ADJUDICATOR|INTERNIST|Y|4||88||SCREENING|1967-09-15||||1972-03-03||1973-02-08|1961-01-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||MOLRESP|MOLECULAR RESPONSE||||BEAM BREAKS|UNEQUIVOCAL||OZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|CHILD|READER 2|U|4||88||LONG-TERM FOLLOW-UP|1960-02-11||||1968-11-29||1971-12-16|1964-01-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||BONERESP|BONE RESPONSE||||LOG10 PFU|DISEASE TRANSFORMATION||ML/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|INVESTIGATOR|READER 2|NA|5||7||BLINDED TREATMENT|1967-03-07||||1970-09-16||1971-03-06|1967-05-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||/100 HPFS|IPR||10^6/G|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1962-01-04||||1962-11-19||1972-06-29|1960-10-21||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||MOLRESP|MOLECULAR RESPONSE||||MMOL/DAY|MAJOR PATHOLOGIC RESPONSE||SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|VENDOR|MICROSCOPIST 3|U|1||38||BLINDED TREATMENT|1968-04-06||||1964-07-02||1972-02-05|1962-08-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||NTRGRESP|NON-TARGET RESPONSE||||UM/S|UNEQUIVOCAL||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CAREGIVER|NEUROLOGIST 1|Y|1||38||BLINDED TREATMENT|1970-12-13||||1962-07-12||1966-10-14|1970-10-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^6 IU/ML|CYTOGENETIC CR||ML/G/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|DOMESTIC PARTNER|ADJUDICATOR 2|NA|2||58||FOLLOW-UP|1967-04-03||||1964-05-19||1965-07-15|1963-06-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||TRGRESP|TARGET RESPONSE||||UV2|CRI||/HPF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|DOMESTIC PARTNER|RADIOLOGIST|Y|2||58||INDUCTION TREATMENT|1971-07-17||||1961-07-15||1970-11-01|1966-06-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||BQ/G|FAVORABLE RESPONSE||%/S|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|N|3||39||OBSERVATION|1963-09-26||||1966-03-18||1963-03-24|1970-08-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||LIVRRESP|LIVER RESPONSE||||BREATHS/30S|SMD||PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|SIBLING|OPHTHALMOLOGIST|NA|3||39||WASHOUT|1961-02-07||||1964-07-19||1967-03-22|1963-03-26||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||SPLNRESP|SPLEEN RESPONSE||||CMH2O*S2/ML|CYTOGENETIC MINIMAL RESPONSE||/40 HPFS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1962-01-01||||1961-01-08||1961-06-25|1971-05-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||OVRLRESP|OVERALL RESPONSE||||MV|CCR||OD UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|U|INVESTIGATOR|OPHTHALMOLOGIST|Y|4||88||CONTINUATION TREATMENT|1970-12-31||||1969-06-07||1965-07-08|1969-07-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||METBRESP|METABOLIC RESPONSE||||10^6 DNA COPIES/ML|INCREASED||LOG10 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|FRIEND|READER 2|Y|5||7||RUN-IN|1969-08-25||||1961-09-01||1969-04-06|1964-09-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MEQ/ML|MR||DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|STUDY SUBJECT|ADJUDICATOR 3|NA|5||7||TREATMENT|1972-09-04||||1967-08-18||1965-03-30|1972-02-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||TRGRESP|TARGET RESPONSE||||ECL UNIT|PARTIAL MORPHOLOGIC RESPONSE||LOZENGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-05-24||||1970-05-23||1960-04-17|1962-01-22||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/KG|COMPLETE MRD RESPONSE||G/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|CHILD|RATER|N|1||38||BLINDED TREATMENT|1967-01-13||||1971-07-09||1968-07-09|1960-09-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||SPLNRESP|SPLEEN RESPONSE||||MEQ/ML|MRD PERSISTENCE||ML/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|SIBLING|FORENSIC PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1962-09-16||||1970-07-18||1968-06-06|1960-01-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TAMPON|MRD NEGATIVITY||DRUM|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|2||58||OBSERVATION|1972-12-16||||1967-07-26||1973-05-10|1960-03-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/DAY|NED||MN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|FRIEND|FORENSIC PATHOLOGIST|U|3||39||INDUCTION TREATMENT|1967-08-31||||1964-06-18||1969-04-09|1965-03-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/CAGE/WK|PR WITH LYMPHOCYTOSIS||ENZYME U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|CHILD|CLINICAL PATHOLOGIST|Y|3||39||BASELINE|1968-09-17||||1970-05-14||1963-06-23|1962-09-20||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||CLINRESP|CLINICAL RESPONSE||||MEQ/UL|CRI||KM/H|NOT DONE|||LIKERT SCALE 7-POINT|N|U|N|SPOUSE|READER 1|N|4||88||INDUCTION TREATMENT|1965-03-18||||1966-02-21||1966-05-22|1966-04-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||KEV|PMR||LOG10 ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|4||88||SCREENING|1960-12-29||||1961-09-13||1966-01-17|1964-02-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KV|ABSENT MORPHOLOGIC RESPONSE||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|INVESTIGATOR|NEUROLOGIST 1|Y|5||7||SCREENING|1970-10-02||||1961-08-01||1973-04-06|1962-06-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OZ|NR||U/M2|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|CAREGIVER|PEDIATRIC NEUROLOGIST|N|5||7||INDUCTION TREATMENT|1973-08-02||||1961-12-16||1966-09-29|1969-12-31||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||STRUSTAT|STEROID USE STATUS||||EID 50/ML|PDU||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|CHILD|RADIOLOGIST 2|Y|1||38||RUN-IN|1970-10-02||||1965-07-03||1970-03-31|1967-04-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PG|CA125 50% RESPONSE||EIA UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|FAMILY MEMBER|RATER 1|N|1||38||TREATMENT|1963-09-04||||1960-04-11||1973-07-18|1967-05-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/M2|MORPHOLOGIC LEUKEMIA-FREE STATE||MM/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|VENDOR|ONCOLOGIST|U|2||58||TREATMENT|1968-10-18||||1966-05-26||1968-12-01|1960-09-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||LIVRRESP|LIVER RESPONSE||||GTT|PR||CMH2O*S2/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||OBSERVATION|1970-05-29||||1971-06-03||1973-02-05|1960-04-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||TRGRESP|TARGET RESPONSE||||OSM|CCR||UV*SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|INVESTIGATOR|MICROSCOPIST 2|Y|3||39||BLINDED TREATMENT|1967-02-08||||1972-09-07||1970-03-26|1971-06-18||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||AMPULE|PMD||ML/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|GUARDIAN|HEMATOLOGIST|U|3||39||CONTINUATION TREATMENT|1963-07-12||||1963-09-01||1964-01-30|1969-08-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||CLINRESP|CLINICAL RESPONSE||||CUP|MINOR PATHOLOGIC RESPONSE||1/(S*KPA)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|SIGNIFICANT OTHER|MICROSCOPIST|NA|4||88||BASELINE|1971-12-18||||1963-04-09||1962-06-19|1960-04-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||TRGRESP|TARGET RESPONSE||||NMOL/L/MIN|CR-CT||ML/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|N|CHILD|ONCOLOGIST 1|U|4||88||INDUCTION TREATMENT|1961-05-24||||1960-01-13||1967-05-21|1965-01-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/2500 WBC|NON-CR/NON-PD||U/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|PARENT|MICROSCOPIST|U|5||7||CONTINUATION TREATMENT|1962-12-18||||1971-01-09||1969-09-18|1967-05-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||ANATRESP|ANATOMIC RESPONSE||||HENRY|NPR||IU/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|SPOUSE|ONCOLOGIST 1|N|5||7||FOLLOW-UP|1968-07-31||||1969-12-14||1972-03-23|1961-06-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DIOPTER|PDU||MV*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|INTERVIEWER|INTERNIST|N|1||38||BLINDED TREATMENT|1960-01-13||||1968-07-19||1961-04-11|1963-01-14||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/G/MIN|MRD PERSISTENCE||KBQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|GUARDIAN|RADIOLOGIST 1|Y|1||38||SCREENING|1973-08-18||||1964-03-31||1962-02-05|1972-11-20||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||OVRLRESP|OVERALL RESPONSE||||UG/KG|IUPD||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|GUARDIAN|HEMATOLOGIST|NA|2||58||SCREENING|1966-06-18||||1966-03-27||1961-02-18|1972-02-03||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MET|MCR||/40 HPFS|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|2||58||RUN-IN|1965-04-15||||1967-05-10||1973-03-21|1961-03-01||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||LIVRRESP|LIVER RESPONSE||||BQ/G|NPR||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|INVESTIGATOR|MICROSCOPIST|N|3||39||WASHOUT|1966-09-18||||1971-07-19||1965-06-28|1972-07-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/MIN|NON-PD||POUCH|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|CLINICAL RESEARCH COORDINATOR|READER|NA|3||39||WASHOUT|1966-03-11||||1966-01-02||1965-02-05|1970-01-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PHERESIS UNIT|STABLE||UL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|FAMILY MEMBER|ADJUDICATOR|U|4||88||INDUCTION TREATMENT|1969-08-11||||1960-04-04||1964-04-11|1971-04-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ENZYME U/M2|MINOR PATHOLOGIC RESPONSE||MM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|ADJUDICATION COMMITTEE|RATER 1|NA|4||88||FOLLOW-UP|1963-07-04||||1971-04-27||1965-04-28|1969-07-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||TSP|QUANTIFIABLE MRD POSITIVITY||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|DOMESTIC PARTNER|MICROSCOPIST|N|5||7||SCREENING|1969-08-22||||1961-10-14||1961-01-12|1966-03-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||PA|MOLECULAR CR||CM|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|ADJUDICATOR|CLINICAL PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1967-05-01||||1970-04-28||1971-09-16|1964-05-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/10^4|NPR||PACK YEAR|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|VENDOR|DERMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1968-06-18||||1973-02-10||1961-12-05|1971-04-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MIN/DAY|PD FROM PR||10^7 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|ADJUDICATION COMMITTEE|READER|NA|1||38||SCREENING|1964-12-28||||1967-11-25||1969-01-22|1972-01-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||METSIND|METASTATIC INDICATOR||||EIA UNIT|CYTOGENETIC MINIMAL RESPONSE||KPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|ADJUDICATION COMMITTEE|RATER 1|N|2||58||OPEN LABEL TREATMENT|1961-03-29||||1966-04-02||1965-09-06|1967-08-07||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/10^3|NOT ALL EVALUATED||UM/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|SIBLING|MICROSCOPIST 3|N|2||58||CONTINUATION TREATMENT|1971-03-28||||1967-01-24||1973-01-27|1967-07-22||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML|COMPLETE MRD RESPONSE||10^3/HPF|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|VENDOR|READER 3|NA|3||39||CONTINUATION TREATMENT|1962-05-16||||1966-01-14||1968-12-15|1961-12-03||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||TMRESP|TUMOR MARKER RESPONSE||||SUPPOSITORY|PR WITH LYMPHOCYTOSIS||DMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|CAREGIVER|DERMATOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1967-08-09||||1968-09-13||1960-07-18|1967-09-17||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DNA COPIES/ML|IMPROVED||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|PARENT|ADJUDICATOR|Y|4||88||TREATMENT|1967-10-05||||1965-12-07||1970-01-26|1968-10-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^7 TCID 50/DOSE|IUPD||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BASELINE|1970-01-05||||1964-01-09||1969-08-30|1970-02-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NU/CL|NR||VG/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|5||7||BASELINE|1972-05-02||||1965-11-24||1971-02-04|1970-07-08||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||S/H|MR||LENS|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OBSERVATION|1964-09-29||||1964-12-21||1961-12-10|1972-05-08||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AMOL|UNFAVORABLE RESPONSE||PSI|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|SIGNIFICANT OTHER|INTERNIST|N|1||38||OBSERVATION|1962-12-22||||1965-04-20||1969-01-10|1971-01-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|2||||||NEWLPROG|NEW LESION PROGRESSION||||JOULE|NPR||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|GUARDIAN|OPTOMETRIST|N|1||38||OBSERVATION|1965-03-18||||1968-06-28||1969-11-02|1970-09-01||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|1||||||NEWLIND|NEW LESION INDICATOR||||ML/CM3/MIN|PCR||PG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|INTERVIEWER|NEUROLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1960-10-28||||1969-07-20||1963-10-06|1961-04-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|2||||||STRUSTAT|STEROID USE STATUS||||PATCH|DECREASED||ML/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|N|N|U|STUDY SUBJECT|READER 3|NA|2||58||LONG-TERM FOLLOW-UP|1972-06-05||||1968-10-02||1968-06-20|1971-05-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BU/ML|OPTIMAL MORPHOLOGIC RESPONSE||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|3||39||RUN-IN|1962-09-16||||1969-10-30||1973-01-12|1964-03-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||100 IU/ML|DISEASE TRANSFORMATION||PACKAGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|CLINICAL STUDY SPONSOR|MICROSCOPIST|N|3||39||INDUCTION TREATMENT|1963-08-25||||1965-06-21||1972-12-18|1966-01-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|1||||||BESTRESP|BEST OVERALL RESPONSE||||RFU|CYTOGENETIC MINOR RESPONSE||10^9 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|4||88||CONTINUATION TREATMENT|1966-12-14||||1969-05-04||1961-01-27|1965-05-21||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|2||||||TRGRESP|TARGET RESPONSE||||G/MOL|ISD||V/V|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1967-11-22||||1965-12-21||1968-04-11|1961-04-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|1||||||TMRESP|TUMOR MARKER RESPONSE||||BEAM BREAKS|IUPD||KHZ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||LONG-TERM FOLLOW-UP|1960-03-25||||1971-07-14||1965-02-08|1965-03-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F149BD98-0802-4C18-8599-426C5258D513|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MG/KG/WEEK|MORPHOLOGIC CR||ML/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|READER|Y|5||7||TREATMENT|1969-06-19||||1960-08-13||1973-04-26|1960-09-28||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML*CMH2O|CPR||G/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|DOMESTIC PARTNER|RATER 1|NA|1||38||WASHOUT|1972-11-22||||1969-08-25||1961-03-18|1972-04-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MCI/L|SMD||H/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|PARENT|RATER 1|NA|1||38||FOLLOW-UP|1966-05-30||||1972-06-21||1960-12-14|1973-07-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||TMRESP|TUMOR MARKER RESPONSE||||GRAVITATIONAL UNIT|MRD PERSISTENCE||BISCUIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|VENDOR|RADIOLOGIST 2|Y|2||58||WASHOUT|1966-04-11||||1971-02-05||1962-10-14|1967-11-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||NEWLPROG|NEW LESION PROGRESSION||||MM/MIN|STABLE||CS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|VENDOR|HEMATOLOGIST|Y|2||58||OBSERVATION|1962-02-07||||1962-04-29||1972-04-20|1962-02-04||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||TMRESP|TUMOR MARKER RESPONSE||||NG/MOL|OPTIMAL MORPHOLOGIC RESPONSE||BAU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|Y|SPOUSE|PATHOLOGIST|Y|3||39||BASELINE|1963-02-22||||1966-06-26||1973-07-04|1961-07-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||BESTRESP|BEST OVERALL RESPONSE||||CM/S|PMR||MBQ/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|VENDOR|READER 1|NA|3||39||OPEN LABEL TREATMENT|1967-01-08||||1965-10-01||1972-09-27|1961-06-29||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||CYTORESP|CYTOGENETIC RESPONSE||||SEC|HI-N||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|PARENT|PEDIATRIC NEUROLOGIST|U|4||88||BASELINE|1972-09-27||||1967-04-18||1967-05-02|1967-11-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/L DDU|ABSENT MORPHOLOGIC RESPONSE||LOG10 PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|PARENT|HEMATOLOGIST|Y|4||88||OBSERVATION|1965-07-30||||1967-11-24||1963-02-26|1967-03-05||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||OVRLRESP|OVERALL RESPONSE||||OSM|UNEQUIVOCAL||EQ|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|CHILD|CARDIOLOGIST|N|5||7||INDUCTION TREATMENT|1965-05-31||||1970-10-23||1961-01-05|1964-01-17||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||OVRLRESP|OVERALL RESPONSE||||IN2|CYTOGENETIC CR||AMU|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|PROXY|CARDIOLOGIST|N|5||7||INDUCTION TREATMENT|1964-04-25||||1972-08-04||1964-01-30|1970-03-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||NTRGRESP|NON-TARGET RESPONSE||||LOG10 CCID 50/DOSE|QUANTIFIABLE MRD POSITIVITY||U/M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|1||38||TREATMENT|1963-08-17||||1967-10-02||1972-12-12|1971-09-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||METBRESP|METABOLIC RESPONSE||||ML/M2|COMPLETE MRD RESPONSE||G/M2/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|PARENT|READER 2|Y|1||38||INDUCTION TREATMENT|1970-11-08||||1968-04-04||1965-07-24|1962-07-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9/G|NE||RAD|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|INDEPENDENT ASSESSOR|READER 3|U|2||58||OPEN LABEL TREATMENT|1961-01-06||||1969-12-09||1971-08-21|1966-06-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||METBRESP|METABOLIC RESPONSE||||TORR|RELAPSED DISEASE||HZ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|FRIEND|MICROSCOPIST 2|Y|2||58||SCREENING|1961-02-28||||1961-12-17||1970-03-02|1964-10-29||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||SPLNRESP|SPLEEN RESPONSE||||WEEKS|OPTIMAL MORPHOLOGIC RESPONSE||10^3/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||BASELINE|1967-05-18||||1965-12-16||1972-08-11|1960-06-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^9 CFU|MCR||COPIES/UG|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|ADJUDICATOR|NEUROLOGIST 2|U|3||39||BASELINE|1964-12-02||||1962-05-27||1971-04-27|1971-09-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^7 CFU/ML|CA125 50% RESPONSE||H/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|N|INTERVIEWER|ONCOLOGIST|U|4||88||TREATMENT|1966-08-03||||1971-12-11||1972-12-03|1969-09-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||NEWLIND|NEW LESION INDICATOR||||NG/DAY|MORPHOLOGIC CRI||UMOL/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4||88||TREATMENT|1965-03-08||||1961-06-14||1964-09-28|1960-04-14||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/MIN|STABLE||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|5||7||BASELINE|1972-11-28||||1973-05-28||1960-06-25|1966-04-30||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||OVRLRESP|OVERALL RESPONSE||||AGU/ML|ISD||MEQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|5||7||RUN-IN|1964-12-06||||1965-11-18||1971-03-09|1969-09-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||NEWLPROG|NEW LESION PROGRESSION||||OZ EQ|PSA PROGRESSION||MMU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1968-12-30||||1961-04-16||1961-12-18|1972-01-19||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||KBQ|CHR||STEPS/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|SPOUSE|ONCOLOGIST 2|N|1||38||OBSERVATION|1967-06-30||||1969-06-21||1965-03-29|1968-12-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||ANATRESP|ANATOMIC RESPONSE||||CYLINDER|EQUIVOCAL||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|PARENT|MICROSCOPIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1967-10-20||||1973-04-06||1971-02-18|1971-11-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UMOL/H/MMOL|PSEUDORESPONSE||VIRTUAL PIXEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|GUARDIAN|NEUROLOGIST 2|Y|2||58||BLINDED TREATMENT|1963-11-23||||1969-04-23||1965-11-06|1966-08-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||NTRGRESP|NON-TARGET RESPONSE||||ML/ANIMAL/WK|INCREASED||PIXELS/CM|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|GUARDIAN|MICROSCOPIST|Y|3||39||FOLLOW-UP|1963-07-03||||1960-05-14||1969-04-01|1963-05-23||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PPM|MCR||/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|ADJUDICATOR|ADJUDICATOR 1|Y|3||39||FOLLOW-UP|1973-07-20||||1968-04-13||1969-11-12|1969-06-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||APPLICATION|VGPR||ML/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|PROXY|CARDIOLOGIST|N|4||88||FOLLOW-UP|1967-01-07||||1967-10-05||1969-11-03|1970-10-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||ANATRESP|ANATOMIC RESPONSE||||NMOL/ML/MIN|SMD||NMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|4||88||SCREENING|1961-11-23||||1964-06-13||1965-03-12|1966-09-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^9 CFU/ML|CR||CM/S|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|SPOUSE|READER|N|5||7||LONG-TERM FOLLOW-UP|1969-04-29||||1968-04-10||1971-08-16|1964-10-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||CLINRESP|CLINICAL RESPONSE||||HZ|DECREASED||UM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5||7||WASHOUT|1972-08-08||||1960-06-02||1966-06-11|1965-07-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||STRUSTAT|STEROID USE STATUS||||U/G HB|OPTIMAL MORPHOLOGIC RESPONSE||CY/CM|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|INTERVIEWER|MICROSCOPIST 2|U|1||38||SCREENING|1965-11-08||||1971-04-04||1966-04-07|1960-11-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||MOLRESP|MOLECULAR RESPONSE||||PMOL/10^10 CELLS|PD-CT||CG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1||38||WASHOUT|1960-04-17||||1971-05-31||1965-12-07|1964-08-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||CLINRESP|CLINICAL RESPONSE||||G/U|PR||LINEAR FT*LB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|INVESTIGATOR|ONCOLOGIST 2|NA|2||58||FOLLOW-UP|1973-08-19||||1969-03-05||1961-09-28|1962-01-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MAMP|MCR||MEQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2||58||BLINDED TREATMENT|1964-12-25||||1967-08-13||1960-01-31|1972-05-18||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||BONERESP|BONE RESPONSE||||MSEC|HI-N||KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|ADJUDICATOR|OPTOMETRIST|N|3||39||BLINDED TREATMENT|1967-10-25||||1970-04-13||1965-11-06|1965-01-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||RING|VGPR||MM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|INVESTIGATOR|OTOLARYNGOLOGIST|N|3||39||INDUCTION TREATMENT|1966-05-28||||1968-07-18||1965-12-10|1969-12-07||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GY/MIN|INDETERMINATE RESPONSE||PT_BR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|4||88||FOLLOW-UP|1960-07-08||||1965-01-05||1966-09-20|1968-01-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||TMRESP|TUMOR MARKER RESPONSE||||TRANSDUCING UNIT|NON-ICR/NON-IUPD||USEC|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|ADJUDICATION COMMITTEE|READER 1|NA|4||88||RUN-IN|1961-08-20||||1962-01-28||1968-04-21|1968-08-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||OVRLRESP|OVERALL RESPONSE||||IU|CYTOGENETIC PR||10^3 COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|SIGNIFICANT OTHER|CARDIOLOGIST|Y|5||7||SCREENING|1962-11-22||||1971-11-06||1971-02-23|1967-10-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||OVRLRESP|OVERALL RESPONSE||||10^3 ORGANISMS/G|NON-ICR/NON-IUPD||IU/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|SIBLING|INTERNIST|N|5||7||TREATMENT|1964-06-05||||1965-10-07||1966-05-24|1966-02-18||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||KCAL|COMPLETE MRD RESPONSE||POINT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|INTERVIEWER|UROLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1967-02-14||||1960-12-07||1969-01-18|1971-11-05||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^6/G|RELAPSED DISEASE FROM CR OR PR||MG/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|VENDOR|READER 2|N|1||38||SCREENING|1960-03-21||||1971-08-15||1963-07-06|1967-06-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||ANATRESP|ANATOMIC RESPONSE||||IU/L|PR-CT||U/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|INTERVIEWER|RATER|N|2||58||WASHOUT|1963-12-17||||1961-10-19||1969-03-25|1960-01-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||CONTAINER|MOLECULAR MAJOR RESPONSE||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|N|2||58||SCREENING|1971-02-09||||1961-11-25||1970-05-29|1960-05-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||METSIND|METASTATIC INDICATOR||||LM|SD||PLUG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|ADJUDICATION COMMITTEE|RATER 2|N|3||39||FOLLOW-UP|1961-11-22||||1972-05-24||1961-10-31|1966-01-21||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||SPLNRESP|SPLEEN RESPONSE||||MOL/DAY|CYTOGENETIC CR||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|3||39||FOLLOW-UP|1968-04-26||||1962-11-26||1973-08-10|1961-09-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||CLINRESP|CLINICAL RESPONSE||||AFU|CYTOGENETIC MINIMAL RESPONSE||/CMH2O|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||FOLLOW-UP|1966-04-13||||1965-08-21||1969-09-22|1970-09-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||OVRLRESP|OVERALL RESPONSE||||ENZYME U|PARTIAL MORPHOLOGIC RESPONSE||BISCUIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|4||88||INDUCTION TREATMENT|1960-12-21||||1964-02-07||1973-03-08|1966-11-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MIN/DAY|NPR||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|GUARDIAN|ADJUDICATOR 1|N|5||7||BASELINE|1970-08-31||||1961-07-09||1970-03-19|1965-12-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DB|RELAPSED DISEASE FROM CR||CP|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|VENDOR|MICROSCOPIST 2|NA|5||7||BLINDED TREATMENT|1962-02-01||||1965-09-16||1961-07-08|1967-03-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DAYS/MONTH|SD||KM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|U|1||38||BLINDED TREATMENT|1965-08-11||||1969-10-28||1965-03-09|1971-09-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DRUM|HI-P||MANSON U/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|DOMESTIC PARTNER|ONCOLOGIST|NA|1||38||OBSERVATION|1971-06-28||||1961-11-21||1963-06-11|1970-03-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||PATHRESP|PATHOLOGIC RESPONSE||||EQ|OPTIMAL MORPHOLOGIC RESPONSE||ABSORBANCE U/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|PARENT|ADJUDICATOR 1|Y|2||58||WASHOUT|1966-11-11||||1962-09-12||1969-11-22|1965-10-09||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||NTRGRESP|NON-TARGET RESPONSE||||INHALATION|FAVORABLE RESPONSE||%(W/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|2||58||FOLLOW-UP|1965-10-12||||1964-12-24||1963-08-09|1965-07-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||MOLRESP|MOLECULAR RESPONSE||||L/DAY|PMD||PG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|SPOUSE|UROLOGIST|N|3||39||OBSERVATION|1963-07-22||||1961-07-16||1966-05-19|1971-12-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DRINK|PDU||BEAM BREAKS|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|3||39||RUN-IN|1969-01-28||||1970-11-04||1965-12-29|1970-12-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/G/MIN|INDETERMINATE RESPONSE||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|SIBLING|PATHOLOGIST 1|N|4||88||BLINDED TREATMENT|1963-11-28||||1962-09-10||1971-09-04|1966-09-16||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/MIN/KPA/L|MRD RELAPSE||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|FAMILY MEMBER|ONCOLOGIST 1|U|4||88||TREATMENT|1964-11-13||||1971-12-20||1964-07-03|1969-10-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||OVRLRESP|OVERALL RESPONSE||||BQ/MG|EQUIVOCAL||ENZYME U/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|SIGNIFICANT OTHER|READER 3|Y|5||7||INDUCTION TREATMENT|1970-06-13||||1968-04-11||1961-09-08|1968-12-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TBSP|CYTOGENETIC MINIMAL RESPONSE||CYCLE/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|STUDY SUBJECT|MICROSCOPIST 2|Y|5||7||BASELINE|1973-04-21||||1961-01-12||1960-01-14|1971-09-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ANSON U|HI-N||LOG10 TCID 50/UL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|READER|N|1||38||BASELINE|1960-06-10||||1961-10-13||1969-07-01|1961-07-31||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^6 ORGANISMS/G|INDETERMINATE RESPONSE||MG/KG/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|INVESTIGATOR|ONCOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1969-10-09||||1961-03-04||1971-08-21|1971-07-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||METSIND|METASTATIC INDICATOR||||10^3/L|CYTOGENETIC CR||/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|2||58||OBSERVATION|1961-07-23||||1963-09-29||1962-07-10|1970-08-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||METBRESP|METABOLIC RESPONSE||||10^3 CFU/ML|PDU||UG/M2/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|VENDOR|INTERNIST|Y|2||58||INDUCTION TREATMENT|1960-01-14||||1960-01-17||1963-11-11|1967-07-01||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||WEBER|MOLECULAR MAJOR RESPONSE||ANTI-XA IU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|FRIEND|ONCOLOGIST 1|N|3||39||BLINDED TREATMENT|1969-02-20||||1961-04-26||1964-04-13|1969-03-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||TRACE|RELAPSED DISEASE FROM CR OR PR||CAPFUL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|3||39||OBSERVATION|1960-05-04||||1967-11-02||1961-02-04|1964-06-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||TRGRESP|TARGET RESPONSE||||DAYS/MONTH|CRI||G/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||SCREENING|1969-11-13||||1972-06-04||1971-08-27|1965-10-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||TRGRESP|TARGET RESPONSE||||/KG|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||KG/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|INTERVIEWER|ADJUDICATOR 2|N|4||88||INDUCTION TREATMENT|1962-10-16||||1964-03-26||1964-06-27|1960-12-31||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||BEAM BREAKS|PSEUDORESPONSE||BOWL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1960-06-28||||1969-02-04||1966-01-19|1969-09-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||G/U|SCR||ENZYME U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|SIGNIFICANT OTHER|NEUROLOGIST 2|U|5||7||RUN-IN|1973-01-21||||1960-04-30||1972-05-26|1960-03-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||BESTRESP|BEST OVERALL RESPONSE||||MMAL|MRD RELAPSE||10^9 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|FAMILY MEMBER|MICROSCOPIST 1|NA|1||38||TREATMENT|1973-04-29||||1973-03-08||1962-09-26|1972-08-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||BONERESP|BONE RESPONSE||||FT3|MORPHOLOGIC LEUKEMIA-FREE STATE||KPA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1969-09-11||||1960-05-05||1969-10-06|1963-01-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 TCID 50/ML|IUPD||ML/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||BASELINE|1971-02-04||||1964-02-01||1963-07-25|1971-04-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||STRUSTAT|STEROID USE STATUS||||KPA|PSEUDOPROGRESSION||10^6 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|SIBLING|UROLOGIST|NA|2||58||INDUCTION TREATMENT|1962-06-08||||1971-02-23||1965-12-08|1963-09-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMOL/MOL|TREATMENT FAILURE||/7.5 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|PROXY|NEUROLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1966-05-27||||1973-06-26||1968-05-26|1966-12-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PM|STABLE||LM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|PARENT|NEUROLOGIST 2|NA|3||39||BASELINE|1961-07-09||||1970-10-20||1964-09-09|1971-10-26||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/MIN/1.73M2|EQUIVOCAL||IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|READER 3|U|4||88||CONTINUATION TREATMENT|1967-07-20||||1961-11-07||1970-04-15|1962-08-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||G/CAGE/WK|MORPHOLOGIC CRI||AFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4||88||BASELINE|1962-07-30||||1972-09-25||1969-10-28|1960-06-08||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||SPLNRESP|SPLEEN RESPONSE||||V/V|WORSENED||ML/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|INVESTIGATOR|PHYSIOTHERAPIST|N|5||7||WASHOUT|1971-08-12||||1969-12-04||1965-08-02|1960-10-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 CFU|HI-E||WATT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|5||7||BASELINE|1965-12-26||||1968-03-20||1971-06-13|1962-07-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||M3|NOT ALL EVALUATED||/MM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|GUARDIAN|ONCOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1969-01-22||||1960-09-18||1960-08-08|1964-12-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/CM H2O|UNEQUIVOCAL||CCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|ADJUDICATION COMMITTEE|READER 1|Y|1||38||OBSERVATION|1963-01-13||||1968-05-05||1968-01-09|1964-05-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||STRUSTAT|STEROID USE STATUS||||MMOL/KG|MRD PERSISTENCE||TROCHE|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|SPOUSE|ONCOLOGIST 1|U|2||58||OBSERVATION|1973-03-30||||1964-05-31||1966-08-13|1964-05-16||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||%(W/W)|SCR||KCAL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|INVESTIGATOR|UROLOGIST|N|2||58||WASHOUT|1960-05-26||||1960-06-13||1966-03-10|1962-06-24||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||SFC/10^6 PBMC|TREATMENT FAILURE||GY/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|NA|FRIEND|INTERNIST|Y|3||39||SCREENING|1963-11-09||||1970-01-15||1971-05-17|1961-07-21||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||STRUSTAT|STEROID USE STATUS||||/100 HPFS|OPTIMAL MORPHOLOGIC RESPONSE||MG/DL|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|3||39||SCREENING|1961-11-30||||1968-02-21||1962-06-03|1972-07-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||SPLNRESP|SPLEEN RESPONSE||||MMOL/S|MRD RELAPSE||/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|PROXY|MICROSCOPIST|NA|4||88||FOLLOW-UP|1965-01-07||||1973-05-02||1969-09-21|1960-05-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APL U|NPR||PG/CELL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|ADJUDICATOR|MICROSCOPIST 1|Y|4||88||INDUCTION TREATMENT|1967-01-18||||1967-03-28||1968-08-19|1963-12-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LOG EID 50/DOSE|CCR||PACKAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|FRIEND|ADJUDICATOR 2|N|5||7||BLINDED TREATMENT|1970-03-08||||1972-05-30||1967-01-20|1965-01-24||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 PFU/ML|HI-P||UMOL/H/MMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||TREATMENT|1965-11-29||||1968-11-18||1967-01-08|1963-11-12||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||CLINRESP|CLINICAL RESPONSE||||MG/ML/DAY|CYTOGENETIC MINIMAL RESPONSE||/200 HPFS|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|STUDY SUBJECT|DERMATOLOGIST|U|1||38||BASELINE|1962-02-06||||1963-04-07||1972-02-10|1961-03-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||TMRESP|TUMOR MARKER RESPONSE||||DAYS|QUANTIFIABLE MRD POSITIVITY||YD|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||OBSERVATION|1971-09-04||||1964-04-29||1969-03-11|1972-05-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/CM3/MIN|CYTOGENETIC PR||NMOL/ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CAREGIVER|ONCOLOGIST|NA|2||58||CONTINUATION TREATMENT|1961-12-06||||1963-04-11||1972-05-28|1973-03-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CD/M2|NR||UU/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|2||58||TREATMENT|1966-11-22||||1971-04-27||1962-08-03|1970-11-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||METBRESP|METABOLIC RESPONSE||||/LSQN|DECREASED||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|FRIEND|READER|Y|3||39||INDUCTION TREATMENT|1969-01-09||||1970-08-22||1960-06-16|1968-02-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||METBRESP|METABOLIC RESPONSE||||SCOOPFUL|CRI||UG/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|NA|3||39||LONG-TERM FOLLOW-UP|1972-10-05||||1965-10-05||1968-08-14|1963-11-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||NEWLPROG|NEW LESION PROGRESSION||||MMHG/SEC|NR||DPM/100MG|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|4||88||SCREENING|1964-08-07||||1961-11-12||1963-03-18|1963-07-13||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||TMRESP|TUMOR MARKER RESPONSE||||BREATHS/MIN|IMMUNOPHENOTYPIC CR||DB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|INTERVIEWER|READER 2|NA|4||88||WASHOUT|1965-04-02||||1963-05-17||1966-08-21|1969-06-29||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||LIVRRESP|LIVER RESPONSE||||ENZYME U|NON-ICR/NON-IUPD||U/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|STUDY SUBJECT|RATER 2|N|5||7||OBSERVATION|1963-03-21||||1972-11-11||1961-02-10|1961-04-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||SPLNRESP|SPLEEN RESPONSE||||UOSM|DECREASED||U/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|INVESTIGATOR|PATHOLOGIST 2|Y|5||7||OBSERVATION|1968-09-27||||1963-11-04||1962-05-04|1965-07-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GAUSS|EQUIVOCAL||EIA UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|INVESTIGATOR|ONCOLOGIST 2|NA|1||38||OPEN LABEL TREATMENT|1966-06-09||||1962-12-10||1972-06-28|1966-04-14||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TUBERCULIN UNIT|IMPROVED||BQ/KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|INVESTIGATOR|MICROSCOPIST 2|N|1||38||SCREENING|1966-11-30||||1960-07-23||1971-06-17|1969-06-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||TUBE|HI-N||V/V|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|INVESTIGATOR|ONCOLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1962-05-08||||1960-11-12||1961-05-07|1963-11-28||DURING||AFTER|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||PATHRESP|PATHOLOGIC RESPONSE||||G/MOL|NON-ICR/NON-IUPD||LOG10 ELISA UNIT/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|PROXY|CARDIOLOGIST|NA|2||58||OBSERVATION|1966-07-24||||1963-01-19||1961-01-31|1969-08-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/L|MORPHOLOGIC CRI||MET|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|GUARDIAN|PHYSIOTHERAPIST|N|3||39||CONTINUATION TREATMENT|1970-12-05||||1960-06-10||1971-12-25|1965-02-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||STRUSTAT|STEROID USE STATUS||||ENZYME U/L|PMR||BQ/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|ADJUDICATOR|ADJUDICATOR 3|N|3||39||BASELINE|1964-08-01||||1971-05-05||1967-04-09|1961-02-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/100 HPFS|INDETERMINATE RESPONSE||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|GUARDIAN|CARDIOLOGIST|Y|4||88||BLINDED TREATMENT|1962-11-27||||1960-11-21||1961-11-13|1970-02-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MHZ|CYTOGENETIC MINIMAL RESPONSE||FMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|CAREGIVER|PHYSIOTHERAPIST|N|4||88||WASHOUT|1962-06-13||||1961-11-14||1961-01-07|1961-12-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||LIVRRESP|LIVER RESPONSE||||L/S|VGPR||PA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|ADJUDICATION COMMITTEE|OPTOMETRIST|U|5||7||SCREENING|1965-01-30||||1963-08-08||1961-02-10|1960-05-03||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||NEWLIND|NEW LESION INDICATOR||||UL|MRD PERSISTENCE||U/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|5||7||INDUCTION TREATMENT|1963-02-06||||1962-10-24||1960-05-30|1964-06-07||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|1||||||CLINRESP|CLINICAL RESPONSE||||GLOBULE|PSEUDOPROGRESSION||GTT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|Y|STUDY SUBJECT|RATER|Y|1||38||FOLLOW-UP|1971-06-29||||1964-11-13||1972-12-03|1966-04-28||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MN|CYTOGENETIC MINIMAL RESPONSE||MG/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|1||38||OBSERVATION|1967-10-05||||1973-03-27||1969-04-25|1960-04-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|1||||||LIVRRESP|LIVER RESPONSE||||UG/L/H|CA125 75% RESPONSE||NEEDLE GAUGE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|INTERVIEWER|RADIOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1967-03-04||||1962-02-18||1964-06-03|1972-02-22||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|2||||||SPLNRESP|SPLEEN RESPONSE||||VG/ML|SMD||LX|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|2||58||BLINDED TREATMENT|1967-12-17||||1964-11-28||1961-10-09|1964-08-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UM2|MRD RELAPSE||CGY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|RATER|N|3||39||INDUCTION TREATMENT|1962-10-24||||1963-11-26||1968-02-24|1970-03-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|2||||||OVRLRESP|OVERALL RESPONSE||||AMU|COMPLETE MRD RESPONSE||POUCH|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||LONG-TERM FOLLOW-UP|1973-03-15||||1967-07-29||1960-11-16|1965-04-02||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U.CARR|MINOR PATHOLOGIC RESPONSE||TORR|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|SPOUSE|ONCOLOGIST|Y|4||88||SCREENING|1960-10-20||||1960-02-11||1973-08-01|1961-03-14||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|2||||||STRUSTAT|STEROID USE STATUS||||CAPFUL|CA125 50% RESPONSE||NMOL/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|CHILD|READER 3|U|4||88||BLINDED TREATMENT|1966-07-05||||1966-06-06||1961-03-04|1969-05-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||USP U|IMPROVED||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|SIGNIFICANT OTHER|HEMATOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1972-04-20||||1970-09-16||1962-12-24|1966-04-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|BFFB5321-5FC7-4465-8579-D75865306359|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 CCID 50/DOSE|CA125 50% RESPONSE||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|FRIEND|NEUROLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1971-09-12||||1969-06-15||1965-03-16|1960-12-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||CLINRESP|CLINICAL RESPONSE||||MIN|UNFAVORABLE RESPONSE||DRUM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|ADJUDICATION COMMITTEE|RATER|NA|1||38||BASELINE|1960-11-10||||1972-07-19||1960-09-28|1964-02-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||TMRESP|TUMOR MARKER RESPONSE||||ML/KG/H|IMMUNOPHENOTYPIC CR||CAPLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|CAREGIVER|ADJUDICATOR 2|U|1||38||WASHOUT|1972-09-25||||1971-07-23||1964-04-23|1962-08-16||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/KG/DAY|OPTIMAL MORPHOLOGIC RESPONSE||WAFER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|PARENT|MICROSCOPIST 3|U|2||58||BASELINE|1969-07-16||||1967-02-22||1968-10-28|1969-07-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DAYS/WK|HI-N||ML*CMH2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|ADJUDICATION COMMITTEE|INTERNIST|NA|2||58||OBSERVATION|1967-03-26||||1970-06-08||1973-01-12|1969-09-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||L/H|DECREASED||SFC/10^6 PBMC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|INVESTIGATOR|ONCOLOGIST 1|NA|3||39||BLINDED TREATMENT|1968-11-14||||1971-06-26||1966-05-24|1968-04-25||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||ANATRESP|ANATOMIC RESPONSE||||IU/KG/H|VGPR||COPIES/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|FAMILY MEMBER|CARDIOLOGIST|N|3||39||RUN-IN|1960-02-02||||1969-06-30||1973-07-25|1960-08-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||PATHRESP|PATHOLOGIC RESPONSE||||TUBERCULIN UNIT/ML|SMD||10^4 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|4||88||BLINDED TREATMENT|1969-08-21||||1967-10-09||1968-12-31|1972-06-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MIU/L|HI-P||10^8/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|4||88||FOLLOW-UP|1968-07-10||||1970-03-19||1962-06-10|1970-09-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||OVRLRESP|OVERALL RESPONSE||||CD*S/M2|MRD RELAPSE||G/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|DOMESTIC PARTNER|NEUROLOGIST 2|N|5||7||BASELINE|1965-07-02||||1973-03-24||1961-01-30|1970-05-15||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UGEQ/L|PR WITH LYMPHOCYTOSIS||MDFI|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|DOMESTIC PARTNER|RATER 2|NA|5||7||RUN-IN|1971-09-05||||1962-07-15||1964-05-14|1970-04-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||OVRLRESP|OVERALL RESPONSE||||CM|MRD RELAPSE||UU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|ADJUDICATION COMMITTEE|ADJUDICATOR 1|NA|1||38||BASELINE|1964-11-26||||1968-01-15||1964-01-15|1965-04-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||NEWLPROG|NEW LESION PROGRESSION||||KBQ/UL|DECREASED||% INHIBITION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|SPOUSE|CLINICAL PATHOLOGIST|NA|1||38||SCREENING|1962-10-06||||1961-08-05||1964-05-12|1961-04-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||METBRESP|METABOLIC RESPONSE||||PPM|IPR||GBQ|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|FRIEND|RADIOLOGIST 2|NA|2||58||INDUCTION TREATMENT|1968-12-25||||1969-12-22||1963-08-09|1970-06-15||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||BESTRESP|BEST OVERALL RESPONSE||||L/H/M2|QUANTIFIABLE MRD POSITIVITY||CIGARETTE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|INVESTIGATOR|ADJUDICATOR|U|2||58||WASHOUT|1960-05-19||||1969-07-17||1961-08-26|1966-10-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PACKAGE|HI-N||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|VENDOR|OPHTHALMOLOGIST|Y|3||39||RUN-IN|1962-10-06||||1968-09-30||1967-11-03|1971-06-29||AFTER||DURING|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/CAGE/WK|RELAPSED DISEASE||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|3||39||OPEN LABEL TREATMENT|1970-07-09||||1964-05-31||1966-07-06|1965-05-28||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||TRGRESP|TARGET RESPONSE||||G/ANIMAL/DAY|SCR||10^7 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|CHILD|ADJUDICATOR 3|Y|4||88||TREATMENT|1971-11-08||||1967-06-06||1967-04-14|1971-05-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||METSIND|METASTATIC INDICATOR||||DL|SD-CT||PPTH|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|STUDY SUBJECT|PATHOLOGIST 2|NA|4||88||OBSERVATION|1962-06-07||||1972-12-15||1973-08-24|1972-03-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MG2/DL2|ABSENT MORPHOLOGIC RESPONSE||H*%|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|GUARDIAN|OPHTHALMOLOGIST|N|5||7||OPEN LABEL TREATMENT|1971-12-04||||1969-11-14||1962-01-09|1966-05-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/G/DAY|PCR||FT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|SIBLING|ADJUDICATOR|N|5||7||OBSERVATION|1968-05-30||||1969-03-06||1967-09-25|1973-06-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|1||||||STRUSTAT|STEROID USE STATUS||||U/KG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||U/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|CHILD|FORENSIC PATHOLOGIST|U|1||38||SCREENING|1967-02-22||||1971-03-18||1965-05-21|1962-09-12||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AG|PD/RELAPSE AFTER HI||UU/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|INTERVIEWER|READER 3|Y|1||38||SCREENING|1964-07-20||||1971-07-28||1971-06-03|1967-03-05||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|1||||||BESTRESP|BEST OVERALL RESPONSE||||APL U|VGPR||SQU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|CAREGIVER|READER|U|2||58||FOLLOW-UP|1961-09-11||||1961-12-01||1970-12-22|1971-10-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CD*S/M2|CRI||MASK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|INVESTIGATOR|MICROSCOPIST|U|2||58||RUN-IN|1964-05-16||||1961-02-17||1972-11-17|1968-01-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|1||||||METSIND|METASTATIC INDICATOR||||DIOPTER|RELAPSED DISEASE||10^7/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|U|SIGNIFICANT OTHER|ADJUDICATOR 1|NA|3||39||FOLLOW-UP|1962-10-04||||1960-02-13||1968-12-11|1968-10-31||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UM/S|HI-P||10^7 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|SPOUSE|READER 2|N|3||39||FOLLOW-UP|1967-06-25||||1966-03-19||1972-05-27|1961-12-22||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|1||||||CLINRESP|CLINICAL RESPONSE||||HZ/S|CYTOGENETIC CR||ML/G/H|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|INVESTIGATOR|MICROSCOPIST 3|NA|4||88||RUN-IN|1960-01-27||||1964-06-29||1966-01-23|1967-02-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^9 ORGANISMS/MG|PSA PROGRESSION||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|SIGNIFICANT OTHER|RATER 1|U|4||88||RUN-IN|1964-01-27||||1970-08-31||1972-04-06|1966-02-04||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|1||||||MOLRESP|MOLECULAR RESPONSE||||BLOCKS|CA125 75% RESPONSE||STEPS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|GUARDIAN|ADJUDICATOR|NA|5||7||TREATMENT|1961-02-20||||1963-05-29||1967-10-09|1960-11-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|37693A38-D8A0-4313-A4D1-56E282579636|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UKAT/L|RELAPSED DISEASE FROM CR||GPS U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|FAMILY MEMBER|MICROSCOPIST 3|Y|5||7||WASHOUT|1965-10-15||||1968-11-12||1972-01-22|1967-04-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||NTRGRESP|NON-TARGET RESPONSE||||TROCHE|NPR||DPM/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|U|FAMILY MEMBER|ENDOCRINOLOGIST|U|1||38||BASELINE|1970-01-23||||1966-06-13||1971-04-24|1963-03-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||NTRGRESP|NON-TARGET RESPONSE||||L/MIN/M2|INCREASED||PIXELS/IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|CHILD|RADIOLOGIST 1|NA|1||38||BASELINE|1969-06-17||||1970-11-20||1963-01-22|1961-10-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BQ/MG|NON-QUANTIFIABLE MRD POSITIVITY||APL U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|SIGNIFICANT OTHER|MICROSCOPIST|U|2||58||BASELINE|1960-06-22||||1966-02-06||1970-01-06|1970-10-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/DL|VGPR||PMOL/10^10 CELLS|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|2||58||SCREENING|1971-11-14||||1960-05-24||1970-08-18|1972-02-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||SPLNRESP|SPLEEN RESPONSE||||/MM|NON-QUANTIFIABLE MRD POSITIVITY||MCI/KG|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||LONG-TERM FOLLOW-UP|1971-05-24||||1961-12-13||1963-09-30|1963-05-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MMAL|HI-E||PIXELS/CM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|3||39||OBSERVATION|1970-03-09||||1965-07-10||1968-10-30|1972-07-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||STRUSTAT|STEROID USE STATUS||||OD UNIT|CCR||TORR|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|SPOUSE|ONCOLOGIST|N|4||88||TREATMENT|1973-05-07||||1970-01-21||1968-12-03|1966-09-01||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||TRGRESP|TARGET RESPONSE||||PACKET|PR-CT||GBQ/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|4||88||SCREENING|1968-06-30||||1962-05-01||1970-02-17|1967-03-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/KG/H|CYTOGENETIC NO RESPONSE||ML/G/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|5||7||FOLLOW-UP|1967-01-04||||1969-10-19||1972-10-17|1960-06-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||BESTRESP|BEST OVERALL RESPONSE||||L/L|NON-PD||COPIES/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|SIBLING|DERMATOLOGIST|N|5||7||CONTINUATION TREATMENT|1967-06-07||||1965-08-03||1963-05-11|1971-06-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||STRUSTAT|STEROID USE STATUS||||NM|INDETERMINATE RESPONSE||GBQ/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|STUDY SUBJECT|INTERNIST|NA|1||38||BASELINE|1961-08-16||||1962-02-08||1966-11-12|1969-03-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||METBRESP|METABOLIC RESPONSE||||DEG2|PMR||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|SPOUSE|PHYSIOTHERAPIST|Y|1||38||INDUCTION TREATMENT|1971-12-12||||1971-06-09||1965-05-07|1970-03-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||OVRLRESP|OVERALL RESPONSE||||L/H|NON-QUANTIFIABLE MRD POSITIVITY||JDF UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|GUARDIAN|MICROSCOPIST|Y|2||58||CONTINUATION TREATMENT|1969-04-03||||1963-04-28||1969-04-12|1970-12-12||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/L/H|PSEUDOPROGRESSION||1/(S*KPA)|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|FAMILY MEMBER|NEUROLOGIST 2|N|2||58||TREATMENT|1971-04-28||||1971-01-31||1972-05-10|1969-11-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UU/DL|NON-CR/NON-PD||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|FAMILY MEMBER|RADIOLOGIST|N|3||39||OBSERVATION|1970-06-20||||1960-10-20||1965-03-06|1972-10-03||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/G/H|ISD||CONTAINER|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|3||39||OBSERVATION|1967-10-08||||1965-09-29||1972-01-08|1961-07-20||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||BONERESP|BONE RESPONSE||||ML/KG/DAY|OPTIMAL MORPHOLOGIC RESPONSE||G/G|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|GUARDIAN|MICROSCOPIST 2|NA|4||88||WASHOUT|1964-09-13||||1966-01-05||1971-11-05|1963-07-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FMOL/L/SEC|MRD PERSISTENCE||CI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|STUDY SUBJECT|ONCOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1967-01-27||||1960-02-08||1972-10-03|1964-12-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||KG/L|INCREASED||ML/KG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||SCREENING|1964-04-15||||1962-02-18||1960-08-02|1969-10-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||NTRGRESP|NON-TARGET RESPONSE||||KCAL/DAY|HI-P||V/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||WASHOUT|1962-09-20||||1961-06-11||1967-05-04|1972-05-15||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||RDIORESP|RADIOLOGIC RESPONSE||||FMOL/G|SMD||PKAT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|INTERVIEWER|READER|Y|1||38||OBSERVATION|1972-11-10||||1970-06-04||1970-03-04|1968-02-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||NEWLIND|NEW LESION INDICATOR||||TORR|OPTIMAL MORPHOLOGIC RESPONSE||ROENTGEN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|FAMILY MEMBER|ADJUDICATOR 3|NA|1||38||OPEN LABEL TREATMENT|1966-03-19||||1970-01-28||1971-03-11|1961-09-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||MOLRESP|MOLECULAR RESPONSE||||MEQ/UG|HI-E||EIA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|ADJUDICATOR|ADJUDICATOR 1|Y|2||58||OPEN LABEL TREATMENT|1970-03-12||||1965-06-30||1967-12-29|1964-01-19||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||SPLNRESP|SPLEEN RESPONSE||||MMOL2/L2|ICR||ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|PARENT|OPHTHALMOLOGIST|N|2||58||BLINDED TREATMENT|1961-10-16||||1971-10-11||1966-06-14|1961-05-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||STRUSTAT|STEROID USE STATUS||||10^3 DNA COPIES/ML|NPR||M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|INVESTIGATOR|READER|N|3||39||SCREENING|1970-07-16||||1963-01-18||1963-06-04|1968-01-15||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MOL/DAY|NON-ICR/NON-IUPD||RAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|SPOUSE|HEMATOLOGIST|N|3||39||OBSERVATION|1968-04-10||||1963-10-21||1971-12-17|1960-10-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CIGAR|CR||CM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1970-06-29||||1968-12-11||1972-08-26|1967-03-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL/L/H|UNFAVORABLE RESPONSE||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|SIGNIFICANT OTHER|ONCOLOGIST|NA|4||88||WASHOUT|1961-03-05||||1969-04-16||1964-10-09|1966-05-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||TMRESP|TUMOR MARKER RESPONSE||||BEATS/MIN|NED||KBQ|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|SIBLING|CARDIOLOGIST|N|5||7||TREATMENT|1966-11-27||||1973-04-11||1960-07-31|1969-12-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MEQ/G|DECREASED||UG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|INVESTIGATOR|RATER 1|N|5||7||RUN-IN|1969-04-11||||1972-05-23||1972-09-04|1961-04-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CM2|MOLECULAR CR||UKAT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|INTERVIEWER|READER|U|1||38||LONG-TERM FOLLOW-UP|1969-11-02||||1966-02-02||1968-11-16|1965-01-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||NEWLPROG|NEW LESION PROGRESSION||||MPL U/ML|HI-E||CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|N|N|Y|VENDOR|READER 1|N|1||38||BLINDED TREATMENT|1967-07-10||||1967-06-11||1962-06-28|1963-08-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/ANIMAL/WK|SD-CT||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|ADJUDICATOR|MICROSCOPIST 3|Y|2||58||SCREENING|1963-10-08||||1963-11-02||1972-08-11|1965-07-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||LIVRRESP|LIVER RESPONSE||||MG2/DL2|OPTIMAL MORPHOLOGIC RESPONSE||SYRINGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|2||58||BASELINE|1972-02-05||||1968-06-28||1964-02-13|1961-12-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FL|UNEQUIVOCAL||/10^3|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|PROXY|HEMATOLOGIST|Y|3||39||OBSERVATION|1965-10-18||||1969-06-30||1968-07-26|1970-08-25||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^4/HPF|MR||PFU/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|3||39||INDUCTION TREATMENT|1963-11-29||||1963-03-16||1972-04-23|1960-08-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||KHZ|CA125 75% RESPONSE||ML/G/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1962-08-08||||1971-11-06||1962-11-23|1963-04-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||OVRLRESP|OVERALL RESPONSE||||UCI|FAVORABLE RESPONSE||MG/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|SPOUSE|MICROSCOPIST 1|U|4||88||BLINDED TREATMENT|1967-04-25||||1971-09-23||1971-12-16|1971-10-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||KPA/L/SEC|PD/RELAPSE AFTER HI||MG/KG/WEEK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1960-04-12||||1970-02-02||1963-01-12|1967-08-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||OVRLRESP|OVERALL RESPONSE||||KG/MOL|DECREASED||KN/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|CHILD|PEDIATRIC NEUROLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1967-09-18||||1966-01-28||1968-05-23|1964-12-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NG/DAY|MRD NEGATIVITY||MKAT|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|SIBLING|RADIOLOGIST 2|U|1||38||INDUCTION TREATMENT|1963-06-03||||1966-05-15||1961-01-30|1970-03-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/MG/MIN|CPR||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|1||38||OBSERVATION|1972-10-26||||1960-04-03||1970-10-25|1967-03-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||TRGRESP|TARGET RESPONSE||||PPTH|PARTIAL MORPHOLOGIC RESPONSE||WEEKS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1960-08-20||||1967-12-09||1966-05-11|1965-06-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG/MIN|PMR||MG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 1|N|2||58||WASHOUT|1972-03-13||||1960-10-13||1965-04-06|1968-04-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CM/MIN|NOT ALL EVALUATED||PT_US|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|SIGNIFICANT OTHER|READER 2|N|3||39||INDUCTION TREATMENT|1964-05-06||||1961-07-11||1965-08-24|1965-07-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^4/L|HI-P||LOG10 CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|FRIEND|OTOLARYNGOLOGIST|Y|3||39||SCREENING|1961-07-05||||1966-02-27||1973-08-20|1972-11-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||STRUSTAT|STEROID USE STATUS||||BOWL|INDETERMINATE RESPONSE||COAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|N|FRIEND|HEMATOLOGIST|U|4||88||TREATMENT|1964-09-08||||1962-08-09||1972-01-24|1966-10-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||CLINRESP|CLINICAL RESPONSE||||V/SEC|PARTIAL MORPHOLOGIC RESPONSE||DAGU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|PROXY|MICROSCOPIST 2|Y|4||88||BASELINE|1970-06-12||||1966-12-30||1972-04-07|1964-01-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CAPFUL|NED||IU/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||SCREENING|1968-04-10||||1964-09-30||1967-05-21|1970-01-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||STRUSTAT|STEROID USE STATUS||||MM/MIN|CR||/10^4|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|GUARDIAN|MICROSCOPIST 2|N|5||7||FOLLOW-UP|1973-05-06||||1966-04-27||1971-01-22|1961-04-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||NTRGRESP|NON-TARGET RESPONSE||||RNA COPIES/ML|CHR||ABSORBANCE U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|SPOUSE|ADJUDICATOR 3|Y|1||38||CONTINUATION TREATMENT|1968-08-31||||1963-12-03||1968-03-15|1964-06-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CAPLET|CR||MU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|N|ADJUDICATOR|OPHTHALMOLOGIST|U|1||38||TREATMENT|1961-06-25||||1963-09-26||1971-11-15|1965-11-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||CLINRESP|CLINICAL RESPONSE||||PELLET|VGPR||BOLUS|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|FAMILY MEMBER|ONCOLOGIST 1|U|2||58||WASHOUT|1962-01-19||||1967-10-18||1964-09-05|1966-11-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||GMFI|PD-CT||CD/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|CAREGIVER|NEUROLOGIST 1|Y|2||58||RUN-IN|1967-02-08||||1963-10-29||1973-09-04|1960-08-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||METBRESP|METABOLIC RESPONSE||||BEATS/MIN|NON-PD||FG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||TREATMENT|1965-09-12||||1960-02-05||1962-04-18|1971-07-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APS U|MRD NEGATIVITY||CAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|INVESTIGATOR|OPTOMETRIST|N|3||39||LONG-TERM FOLLOW-UP|1964-07-05||||1966-11-21||1969-08-25|1972-01-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ECL UNIT|MINOR PATHOLOGIC RESPONSE||UG/CM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|4||88||SCREENING|1966-03-25||||1973-07-14||1960-03-10|1964-09-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||OVRLRESP|OVERALL RESPONSE||||MG/CM2|TREATMENT FAILURE||UG/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|4||88||OBSERVATION|1966-09-28||||1971-04-28||1967-10-04|1969-04-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||BONERESP|BONE RESPONSE||||TSP EQ|DECREASED||OHM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|CHILD|READER 3|NA|5||7||SCREENING|1963-01-10||||1961-05-19||1962-11-12|1967-04-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||NEWLPROG|NEW LESION PROGRESSION||||/5X10^4 WBC|NON-QUANTIFIABLE MRD POSITIVITY||WATT|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|INVESTIGATOR|HEMATOLOGIST|N|5||7||RUN-IN|1961-12-23||||1964-09-17||1973-01-23|1960-08-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||METBRESP|METABOLIC RESPONSE||||TSP EQ|MRD PERSISTENCE||PFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|1||38||CONTINUATION TREATMENT|1970-08-06||||1966-03-05||1962-03-27|1968-03-19||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||LIVRRESP|LIVER RESPONSE||||G/ANIMAL/DAY|MRD NEGATIVITY||BQ/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1||38||BLINDED TREATMENT|1970-12-01||||1966-08-12||1960-12-02|1967-11-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||BONERESP|BONE RESPONSE||||UCI/KG|PARTIAL MORPHOLOGIC RESPONSE||KS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|INTERVIEWER|CARDIOLOGIST|Y|2||58||RUN-IN|1963-06-10||||1963-03-06||1961-09-02|1961-03-17||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PG/L|NR||ML/S|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2||58||FOLLOW-UP|1966-06-03||||1963-10-16||1968-11-16|1972-12-30||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||OVRLRESP|OVERALL RESPONSE||||FARAD|CR-CT||UGEQ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|RATER 2|N|3||39||BASELINE|1963-11-10||||1971-03-14||1960-08-07|1965-03-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||STRUSTAT|STEROID USE STATUS||||WATT|NR||MET|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|PARENT|RADIOLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1971-01-30||||1967-03-29||1961-01-05|1970-07-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||ANATRESP|ANATOMIC RESPONSE||||ANTI-XA IU|CPR||CIGARETTE|NOT DONE|||LIKERT SCALE 3-POINT|N|U|NA|PROXY|RATER 2|Y|4||88||WASHOUT|1969-10-08||||1962-12-28||1968-08-12|1961-01-15||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9/DOSE|MRD RELAPSE||M/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|GUARDIAN|MICROSCOPIST 3|N|4||88||LONG-TERM FOLLOW-UP|1973-07-09||||1969-10-19||1967-02-12|1963-12-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DPM|NON-CR/NON-PD||CY/CM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|5||7||BLINDED TREATMENT|1964-04-29||||1971-06-16||1961-03-03|1965-04-12||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||BONERESP|BONE RESPONSE||||DRUM|CYTOGENETIC MINIMAL RESPONSE||BP|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|PARENT|CLINICAL PATHOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1965-04-05||||1971-05-25||1962-05-21|1960-09-04||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||TMRESP|TUMOR MARKER RESPONSE||||IU/G HB|MRD NEGATIVITY||MG/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 1|U|1||38||FOLLOW-UP|1973-09-02||||1971-04-26||1964-10-24|1963-12-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||VOXEL|INDETERMINATE RESPONSE||LENS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|INTERVIEWER|DERMATOLOGIST|NA|1||38||WASHOUT|1962-09-30||||1962-11-27||1971-01-10|1960-11-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||NEWLPROG|NEW LESION PROGRESSION||||FMOL|COMPLETE MRD RESPONSE||/MBP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|FAMILY MEMBER|PATHOLOGIST|U|2||58||BASELINE|1961-08-07||||1969-04-28||1970-12-03|1961-08-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||BONERESP|BONE RESPONSE||||G/CM2|SCR||UMOL/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|INDEPENDENT ASSESSOR|INTERNIST|U|2||58||BLINDED TREATMENT|1972-07-16||||1960-02-11||1964-11-10|1960-07-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||METBRESP|METABOLIC RESPONSE||||LOG10 CFU/G|NPR||KPA|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|DOMESTIC PARTNER|INTERNIST|NA|3||39||OBSERVATION|1972-04-15||||1966-05-07||1963-09-04|1971-03-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||TMRESP|TUMOR MARKER RESPONSE||||U/G/DAY|DECREASED||/5X10^4 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|FRIEND|INTERNIST|N|3||39||BASELINE|1971-11-23||||1961-09-28||1962-03-17|1968-09-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||METBRESP|METABOLIC RESPONSE||||CL|PDU||ENZYME U/M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|SIBLING|READER 3|N|4||88||FOLLOW-UP|1971-03-06||||1968-01-27||1970-06-12|1969-03-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 ORGANISMS/G|RELAPSED DISEASE FROM CR||MMOL/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|U|4||88||WASHOUT|1972-08-01||||1967-12-02||1965-11-20|1964-01-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PPTH|TREATMENT FAILURE||PMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1972-11-06||||1971-03-31||1960-07-02|1960-10-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/L FEU|PDU||ML/100G/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|CAREGIVER|ADJUDICATOR|NA|5||7||LONG-TERM FOLLOW-UP|1971-07-17||||1960-09-22||1961-10-28|1972-06-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/KG|MORPHOLOGIC LEUKEMIA-FREE STATE||ML/MIN/MMHG|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|VENDOR|UROLOGIST|N|1||38||OBSERVATION|1971-01-31||||1966-01-02||1967-02-02|1964-02-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||METSIND|METASTATIC INDICATOR||||BP|STABLE||/500 WBC|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|PARENT|ADJUDICATOR|N|1||38||OBSERVATION|1971-01-25||||1973-04-17||1962-10-19|1970-10-10||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||TSP EQ|INCREASED||UL/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|SPOUSE|MICROSCOPIST 2|N|2||58||RUN-IN|1969-11-04||||1965-04-14||1965-07-12|1970-12-21||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||V|IMPROVED||ABSORBANCE U/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|2||58||OBSERVATION|1965-07-12||||1960-05-04||1962-09-14|1970-08-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^11/L|CRI||PMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||OBSERVATION|1966-07-26||||1966-06-18||1963-12-26|1968-08-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GENEQ|PD/RELAPSE AFTER HI||TSP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1972-03-08||||1964-09-03||1970-02-16|1967-11-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^3 DNA COPIES/ML|NE||DIOPTER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|4||88||OPEN LABEL TREATMENT|1970-07-09||||1962-03-02||1971-04-25|1970-07-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^9 ORGANISMS/G|CR-CT||GRAIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1961-03-11||||1968-11-29||1962-08-07|1962-05-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||1/(S*KPA)|UNFAVORABLE RESPONSE||PPTH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|ADJUDICATOR|DERMATOLOGIST|N|5||7||OBSERVATION|1970-05-02||||1969-04-05||1971-09-28|1964-07-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||BESTRESP|BEST OVERALL RESPONSE||||MBQ|PMR||G/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|INDEPENDENT ASSESSOR|PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1962-05-25||||1965-02-25||1967-08-11|1963-06-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||BESTRESP|BEST OVERALL RESPONSE||||V/V|NON-PD||ML/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|1||38||SCREENING|1962-05-12||||1970-12-03||1963-02-25|1968-02-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||SPLNRESP|SPLEEN RESPONSE||||/WK|PCR||/10^5|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|CLINICAL STUDY SPONSOR|INTERNIST|N|1||38||INDUCTION TREATMENT|1968-11-15||||1961-08-05||1969-10-19|1965-01-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/CAGE/DAY|MORPHOLOGIC CRI||TUBERCULIN UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|VENDOR|PATHOLOGIST 2|NA|2||58||RUN-IN|1970-05-09||||1972-11-28||1970-07-08|1971-01-03||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||NEWLPROG|NEW LESION PROGRESSION||||MPA|NE||DAGU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|FAMILY MEMBER|RADIOLOGIST|NA|2||58||FOLLOW-UP|1964-09-14||||1960-02-17||1962-02-05|1966-10-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||CLINRESP|CLINICAL RESPONSE||||UG/DAY|MORPHOLOGIC CRI||FARAD|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|ADJUDICATOR|ONCOLOGIST 2|Y|3||39||RUN-IN|1971-09-16||||1966-09-08||1962-03-30|1963-05-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||MOLRESP|MOLECULAR RESPONSE||||EP U|PSA PROGRESSION||RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|FAMILY MEMBER|DERMATOLOGIST|N|3||39||OBSERVATION|1970-03-07||||1970-07-17||1971-02-20|1963-10-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||BESTRESP|BEST OVERALL RESPONSE||||BQ/UL|CYTOGENETIC MINOR RESPONSE||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|DOMESTIC PARTNER|OTOLARYNGOLOGIST|N|4||88||RUN-IN|1967-06-18||||1962-03-02||1960-10-05|1964-08-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||TRGRESP|TARGET RESPONSE||||PM|CYTOGENETIC MINIMAL RESPONSE||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|SIGNIFICANT OTHER|READER 1|N|4||88||INDUCTION TREATMENT|1970-07-12||||1963-02-27||1960-08-30|1966-02-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||KPA/L/SEC|CYTOGENETIC CR||CS|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|READER 1|NA|5||7||TREATMENT|1971-10-02||||1963-11-21||1960-08-18|1972-08-23||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||TMRESP|TUMOR MARKER RESPONSE||||USIEMENS|CYTOGENETIC CR||G/ANIMAL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|VENDOR|RATER 1|U|5||7||FOLLOW-UP|1971-03-31||||1972-10-23||1967-09-09|1969-02-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||BONERESP|BONE RESPONSE||||MMU/ML|IPR||UL/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|STUDY SUBJECT|RATER 2|U|1||38||BLINDED TREATMENT|1967-04-05||||1963-10-25||1967-03-30|1972-07-19||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||/MS|SCR||/LPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|NA|CHILD|OPHTHALMOLOGIST|N|1||38||INDUCTION TREATMENT|1970-11-30||||1971-11-21||1963-08-30|1964-11-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 RNA COPIES/ML|ICPD||FL|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|N|2||58||FOLLOW-UP|1966-09-12||||1967-08-20||1966-04-25|1973-01-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||NTRGRESP|NON-TARGET RESPONSE||||MG/CM2|MRD RELAPSE||%/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|U|CHILD|MICROSCOPIST 2|NA|2||58||RUN-IN|1963-01-31||||1960-05-14||1967-07-05|1960-06-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||NTRGRESP|NON-TARGET RESPONSE||||SHOCK WAVE|PMD||CYLINDER|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|U|ADJUDICATOR|MICROSCOPIST 3|Y|3||39||FOLLOW-UP|1966-11-19||||1972-03-11||1961-04-17|1971-04-03||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||STRUSTAT|STEROID USE STATUS||||VIRTUAL PIXEL|CYTOGENETIC MINOR RESPONSE||NSEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|3||39||BASELINE|1960-12-31||||1960-04-29||1970-09-24|1960-06-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||NEWLIND|NEW LESION INDICATOR||||MG/KG/MIN|PARTIAL MORPHOLOGIC RESPONSE||HR/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|ADJUDICATION COMMITTEE|ONCOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1972-08-28||||1966-03-10||1971-07-03|1961-08-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL|CHR||/500 WBC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||RUN-IN|1963-10-01||||1966-07-29||1960-12-24|1969-10-19||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||STRUSTAT|STEROID USE STATUS||||DPM/ML|CMR||GLOBULE|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|CAREGIVER|INTERNIST|Y|5||7||CONTINUATION TREATMENT|1967-11-21||||1965-07-24||1969-02-01|1962-10-18||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PA|HI-P||ML/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|CHILD|PATHOLOGIST 1|NA|5||7||OBSERVATION|1960-01-29||||1968-09-18||1966-09-17|1960-04-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/10^10 CELLS|RELAPSED DISEASE FROM CR OR PR||PSI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1963-05-29||||1968-07-16||1969-03-20|1962-06-01||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||RDIORESP|RADIOLOGIC RESPONSE||||100 IU/ML|VGPR||ENZYME U/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|STUDY SUBJECT|DERMATOLOGIST|N|1||38||TREATMENT|1970-06-08||||1971-12-11||1971-04-18|1973-02-27||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||METBRESP|METABOLIC RESPONSE||||/MIN|CRI||G/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|READER 2|U|2||58||RUN-IN|1969-07-12||||1964-05-06||1964-02-20|1963-02-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||OVRLRESP|OVERALL RESPONSE||||MET*MIN|NE||BEATS/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|FRIEND|UROLOGIST|U|2||58||WASHOUT|1962-06-17||||1963-11-04||1972-09-26|1960-03-15||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/KG|CA125 75% RESPONSE||VOXEL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|SIBLING|RATER 2|Y|3||39||BASELINE|1965-08-05||||1969-09-24||1963-05-14|1964-11-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL/KG|MORPHOLOGIC CRI||DEG|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3||39||RUN-IN|1966-07-28||||1970-09-18||1960-01-22|1965-09-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||GLOBULE|CR||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|CHILD|UROLOGIST|Y|4||88||INDUCTION TREATMENT|1967-07-17||||1962-12-12||1963-02-09|1962-12-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||MOLRESP|MOLECULAR RESPONSE||||GRAIN|CPR||10^3 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|PARENT|FORENSIC PATHOLOGIST|U|4||88||SCREENING|1965-02-21||||1965-03-03||1971-09-27|1969-08-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/H|COMPLETE MRD RESPONSE||%(V/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|5||7||OPEN LABEL TREATMENT|1963-02-24||||1969-11-14||1964-11-24|1970-10-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||NEWLPROG|NEW LESION PROGRESSION||||BQ/L|NON-PD||CI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|SPOUSE|CARDIOLOGIST|NA|5||7||BLINDED TREATMENT|1965-01-10||||1963-08-08||1966-11-23|1971-04-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||SACHET|RELAPSED DISEASE FROM CR OR PR||MMU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|FAMILY MEMBER|ONCOLOGIST 1|U|1||38||OBSERVATION|1960-06-04||||1966-01-11||1969-04-17|1970-10-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/L FEU|PD-CT||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|ADJUDICATION COMMITTEE|READER 2|U|1||38||BASELINE|1961-01-27||||1963-01-08||1971-06-17|1966-07-24||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||BESTRESP|BEST OVERALL RESPONSE||||IU/ML|SMD||KS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|INDEPENDENT ASSESSOR|RADIOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1962-05-18||||1966-05-03||1963-05-08|1965-07-29||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||RDIORESP|RADIOLOGIC RESPONSE||||DAYS/MONTH|PMD||KM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|2||58||INDUCTION TREATMENT|1972-01-22||||1967-08-08||1965-04-15|1971-06-08||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UOSM|MORPHOLOGIC CR||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||CONTINUATION TREATMENT|1973-01-23||||1960-05-27||1970-03-15|1964-07-26||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||GENEQ|HI-P||QUANTITY SUFFICIENT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|SPOUSE|INTERNIST|U|3||39||BASELINE|1972-08-15||||1965-08-01||1972-10-27|1970-11-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||NEWLIND|NEW LESION INDICATOR||||JOULE|MAJOR PATHOLOGIC RESPONSE||OSM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|CHILD|PEDIATRIC NEUROLOGIST|U|4||88||SCREENING|1971-07-07||||1962-02-10||1961-12-20|1960-05-22||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||OVRLRESP|OVERALL RESPONSE||||UG/L FEU|IMMUNOPHENOTYPIC CR||NEEDLE GAUGE|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|PROXY|FORENSIC PATHOLOGIST|U|4||88||RUN-IN|1961-09-19||||1971-09-17||1969-07-29|1964-12-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||APS U|MRD NEGATIVITY||UMOL/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|PROXY|RATER|NA|5||7||BLINDED TREATMENT|1972-05-10||||1961-12-21||1967-01-24|1972-03-07||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NMOL|VGPR||ML/KG/H|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|SIBLING|PATHOLOGIST 1|N|5||7||INDUCTION TREATMENT|1964-09-08||||1966-04-17||1973-06-10|1966-10-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||STRUSTAT|STEROID USE STATUS||||IU/DL|DISEASE TRANSFORMATION||TRACE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|GUARDIAN|READER 2|NA|1||38||LONG-TERM FOLLOW-UP|1961-05-09||||1971-05-15||1972-11-14|1963-01-22||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||SPLNRESP|SPLEEN RESPONSE||||COAT|NED||MMU/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|CHILD|OPTOMETRIST|U|1||38||INDUCTION TREATMENT|1965-10-21||||1960-04-02||1969-11-23|1966-10-10||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 CFU/G|ICR||AMPULE|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||FOLLOW-UP|1971-03-23||||1967-08-17||1961-06-21|1966-10-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||NTRGRESP|NON-TARGET RESPONSE||||MU|PSEUDORESPONSE||UM/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|SPOUSE|NEUROLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-10-10||||1969-08-25||1965-08-01|1970-07-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||ANATRESP|ANATOMIC RESPONSE||||FFU|STABLE||DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|3||39||SCREENING|1971-09-26||||1970-11-21||1967-04-23|1970-02-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||OVRLRESP|OVERALL RESPONSE||||UG/M2/H|CYTOGENETIC MINIMAL RESPONSE||IU/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|SIGNIFICANT OTHER|INTERNIST|Y|3||39||OBSERVATION|1973-03-10||||1973-02-04||1969-01-18|1970-07-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/DOSE|PMD||GY/H|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|4||88||INDUCTION TREATMENT|1963-03-07||||1968-09-11||1962-06-19|1965-10-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/CAGE/DAY|UNFAVORABLE RESPONSE||FOZ_US|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|4||88||OBSERVATION|1967-05-23||||1967-09-27||1969-04-09|1969-08-10||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||METSIND|METASTATIC INDICATOR||||10^9/L|NOT ALL EVALUATED||DRINK|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|5||7||WASHOUT|1964-04-06||||1963-02-26||1973-03-10|1968-05-14||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||METSIND|METASTATIC INDICATOR||||GPELISA UNIT/ML|IMPROVED||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|INDEPENDENT ASSESSOR|OPTOMETRIST|NA|5||7||CONTINUATION TREATMENT|1966-11-07||||1962-02-26||1969-08-04|1966-02-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DROP|UNFAVORABLE RESPONSE||G/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|PARENT|MICROSCOPIST 3|U|1||38||OPEN LABEL TREATMENT|1971-09-23||||1973-05-03||1969-12-25|1971-11-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|2||||||STRUSTAT|STEROID USE STATUS||||KEV|NON-CR/NON-PD||KAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|FAMILY MEMBER|ONCOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1965-12-07||||1969-04-09||1971-10-26|1966-03-06||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/KG/MIN|WORSENED||L/MIN/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|READER 3|U|2||58||RUN-IN|1973-05-01||||1967-11-03||1973-03-07|1965-05-13||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|2||||||NEWLPROG|NEW LESION PROGRESSION||||OSM|CMR||GPL U|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|SPOUSE|RATER 1|N|2||58||WASHOUT|1963-08-25||||1960-10-20||1969-11-05|1967-02-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/KG/MIN|PSEUDOPROGRESSION||EP U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|INTERVIEWER|ONCOLOGIST|N|3||39||SCREENING|1962-11-05||||1964-10-30||1972-11-24|1960-03-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|2||||||STRUSTAT|STEROID USE STATUS||||BQ/UG|RELAPSED DISEASE FROM CR||UG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|CHILD|RADIOLOGIST 1|NA|3||39||SCREENING|1971-12-23||||1973-02-22||1962-09-11|1970-11-27||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UCI/KG|CYTOGENETIC MINOR RESPONSE||CD*S/M2|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|4||88||TREATMENT|1965-06-16||||1968-06-15||1966-06-21|1963-10-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|2||||||OVRLRESP|OVERALL RESPONSE||||KG/CM2|SCR||VOXEL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|PARENT|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1971-10-31||||1964-05-11||1971-08-01|1972-04-21||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|1||||||TRGRESP|TARGET RESPONSE||||ANTIBODY UNIT|PCR||DRINK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|HEALTH CARE PROFESSIONAL|READER|NA|5||7||INDUCTION TREATMENT|1967-11-06||||1970-07-08||1962-09-20|1965-12-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|740D80F1-8BD5-4409-8087-E48F94363362|2||||||METSIND|METASTATIC INDICATOR||||OSM|MRD NEGATIVITY||U/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|ADJUDICATOR|READER 3|Y|5||7||TREATMENT|1961-12-19||||1961-07-09||1966-10-24|1964-09-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CCID 50/DOSE|PD||U/KG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|N|GUARDIAN|OTOLARYNGOLOGIST|U|1||38||INDUCTION TREATMENT|1964-05-24||||1960-06-27||1970-06-14|1971-05-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||BONERESP|BONE RESPONSE||||BQ|MOLECULAR CR||10^3 DNA COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST|Y|1||38||TREATMENT|1969-06-24||||1971-04-18||1966-01-07|1964-06-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BQ/MG|MOLECULAR CR||10^6 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|SPOUSE|RATER|N|2||58||OPEN LABEL TREATMENT|1971-08-05||||1968-01-26||1969-11-05|1969-02-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/DL|MAJOR PATHOLOGIC RESPONSE||UOSM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|PROXY|RADIOLOGIST 1|N|2||58||WASHOUT|1971-09-21||||1970-07-11||1961-03-10|1960-08-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||NEWLIND|NEW LESION INDICATOR||||MG/H|SCR||KG/CM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|3||39||CONTINUATION TREATMENT|1972-10-16||||1969-06-07||1965-12-19|1964-02-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||METSIND|METASTATIC INDICATOR||||AMOL|OPTIMAL MORPHOLOGIC RESPONSE||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|DOMESTIC PARTNER|NEUROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1966-10-21||||1971-01-18||1961-03-23|1962-10-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||MOLRESP|MOLECULAR RESPONSE||||UIU/L|DECREASED||CGY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|4||88||WASHOUT|1962-10-28||||1961-01-15||1965-05-16|1967-03-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 PFU/ML|PMD||UMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|INTERVIEWER|ADJUDICATOR|NA|4||88||RUN-IN|1960-05-03||||1965-06-14||1969-07-24|1964-07-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MBQ|QUANTIFIABLE MRD POSITIVITY||CAPLET|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|SIGNIFICANT OTHER|ADJUDICATOR 1|Y|5||7||SCREENING|1967-08-09||||1966-06-12||1966-08-06|1966-01-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/CM|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||HENRY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|5||7||RUN-IN|1969-09-27||||1967-06-17||1966-08-19|1972-07-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||LIVRRESP|LIVER RESPONSE||||MMOL/MIN/KPA/L|NED||BREATHS/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|FAMILY MEMBER|READER 2|Y|1||38||INDUCTION TREATMENT|1965-11-12||||1970-06-18||1972-01-18|1969-06-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/KG/MIN|COMPLETE MRD RESPONSE||EU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|PROXY|MICROSCOPIST 2|NA|1||38||FOLLOW-UP|1961-05-25||||1961-03-14||1970-08-24|1963-08-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^9/L|RELAPSED DISEASE FROM CR OR PR||CCID 50/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|2||58||INDUCTION TREATMENT|1960-10-08||||1965-03-08||1968-06-12|1962-04-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||TMRESP|TUMOR MARKER RESPONSE||||DAYS/MONTH|VGPR||MM/SEC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|ADJUDICATOR|PATHOLOGIST 2|U|2||58||WASHOUT|1966-01-10||||1967-08-15||1966-09-26|1964-01-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||NEWLPROG|NEW LESION PROGRESSION||||BEATS/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3||39||WASHOUT|1962-09-27||||1964-11-17||1963-12-06|1965-04-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||OVRLRESP|OVERALL RESPONSE||||MG/DL|RELAPSED DISEASE FROM CR||CI/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|NA|PROXY|READER 3|U|3||39||OBSERVATION|1969-01-29||||1960-09-15||1966-04-10|1971-09-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||METBRESP|METABOLIC RESPONSE||||L/H/M2|MRD NEGATIVITY||S/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|ADJUDICATOR|RATER 2|N|4||88||TREATMENT|1962-11-18||||1969-02-16||1973-04-03|1962-02-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||LOG10 CCID 50/DOSE|PD FROM PR||TRACE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|FRIEND|INTERNIST|N|4||88||FOLLOW-UP|1964-09-14||||1964-08-14||1960-09-28|1967-08-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/CAGE/DAY|NED||BQ/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|STUDY SUBJECT|OPTOMETRIST|U|5||7||LONG-TERM FOLLOW-UP|1969-08-01||||1967-02-27||1970-10-13|1966-11-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||NL|PD FROM PR||BISCUIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|5||7||CONTINUATION TREATMENT|1963-06-15||||1969-01-17||1966-02-28|1962-01-19||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|1||||||LIVRRESP|LIVER RESPONSE||||PACK YEAR|PMR||UG/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|ADJUDICATOR|ADJUDICATOR 2|Y|1||38||CONTINUATION TREATMENT|1971-12-05||||1962-07-09||1968-04-22|1965-06-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||SHOCK WAVE|IPR||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|SIGNIFICANT OTHER|READER 3|NA|1||38||SCREENING|1968-06-16||||1970-05-30||1967-01-26|1966-02-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UCI/L|UNFAVORABLE RESPONSE||AMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|GUARDIAN|RATER 2|U|2||58||BLINDED TREATMENT|1964-12-17||||1972-08-07||1961-06-10|1967-01-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|2||||||ANATRESP|ANATOMIC RESPONSE||||G/U|ABSENT MORPHOLOGIC RESPONSE||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|CHILD|INTERNIST|N|2||58||CONTINUATION TREATMENT|1971-06-25||||1969-03-17||1962-01-28|1969-12-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|1||||||MOLRESP|MOLECULAR RESPONSE||||CD|IUPD||PACKAGE|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|SIBLING|RATER|U|3||39||BLINDED TREATMENT|1969-04-15||||1963-09-18||1962-10-16|1967-12-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BQ/UG|CPR||KCAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1962-06-26||||1961-02-08||1961-09-28|1968-09-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/10^10 CELLS|CHR||CMHG|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|VENDOR|RADIOLOGIST|Y|4||88||TREATMENT|1960-02-23||||1969-09-07||1971-11-05|1963-09-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NG/L|MORPHOLOGIC CRI||PMOL/10^10 CELLS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|SIGNIFICANT OTHER|INTERNIST|N|4||88||BASELINE|1970-11-20||||1966-04-09||1960-03-07|1969-02-11||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PMOL/L|UNEQUIVOCAL||MMHG/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1973-08-03||||1972-03-10||1962-08-25|1965-10-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|441F1A21-6350-478A-9719-75B053182B78|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/CM2|UNFAVORABLE RESPONSE||IU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|NA|STUDY SUBJECT|DERMATOLOGIST|NA|5||7||OBSERVATION|1961-07-02||||1967-12-20||1961-06-03|1971-12-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||NTRGRESP|NON-TARGET RESPONSE||||M/SEC2|MORPHOLOGIC CR||MM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|INVESTIGATOR|OPTOMETRIST|N|1||38||CONTINUATION TREATMENT|1970-03-18||||1968-01-01||1969-06-17|1962-07-03||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CAPSULE|COMPLETE MRD RESPONSE||MDFI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|PROXY|HEMATOLOGIST|N|1||38||BASELINE|1972-04-27||||1969-02-20||1964-09-14|1965-11-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||FOZ_BR|PMR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|FAMILY MEMBER|ONCOLOGIST|U|2||58||TREATMENT|1967-06-05||||1963-03-10||1962-07-15|1962-03-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MU/G|NON-PD||EIA UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|PROXY|READER 1|NA|2||58||LONG-TERM FOLLOW-UP|1961-08-02||||1962-03-16||1965-07-02|1965-12-30||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||GLOBULE|HI-N||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|SPOUSE|READER 1|N|3||39||OBSERVATION|1966-09-22||||1969-05-26||1962-05-27|1970-05-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||CLINRESP|CLINICAL RESPONSE||||IU/MMOL|PD/RELAPSE AFTER HI||PG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|INVESTIGATOR|PHYSIOTHERAPIST|U|3||39||CONTINUATION TREATMENT|1962-10-03||||1964-05-14||1964-12-17|1969-03-01||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||TRGRESP|TARGET RESPONSE||||RATIO|CR||DPM/MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|4||88||OPEN LABEL TREATMENT|1964-12-12||||1964-01-17||1964-11-17|1962-09-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||STRUSTAT|STEROID USE STATUS||||SBE/ML|PMD||DMOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|NA|GUARDIAN|NEUROLOGIST 1|N|4||88||CONTINUATION TREATMENT|1961-07-12||||1970-01-02||1960-03-30|1964-02-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||MOLRESP|MOLECULAR RESPONSE||||CM/S|SD||MMHG/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|INTERVIEWER|PATHOLOGIST|Y|5||7||WASHOUT|1968-11-06||||1960-08-28||1964-07-08|1963-05-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ/L|CR||IU/MG|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|CHILD|OPTOMETRIST|Y|5||7||TREATMENT|1970-12-04||||1962-09-19||1966-12-21|1964-02-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KIU|CYTOGENETIC NO RESPONSE||RING|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1970-04-05||||1961-04-14||1971-05-31|1963-01-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GY/H|HI-N||U/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|ADJUDICATOR|OPHTHALMOLOGIST|N|1||38||SCREENING|1962-10-08||||1969-10-14||1961-09-05|1969-04-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||NEWLIND|NEW LESION INDICATOR||||SFC/10^6 PBMC|CYTOGENETIC PR||G/CAGE|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|SPOUSE|READER 3|NA|2||58||WASHOUT|1960-11-24||||1971-01-06||1971-01-11|1966-03-22||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||TMRESP|TUMOR MARKER RESPONSE||||IU/MG|PARTIAL MORPHOLOGIC RESPONSE||IU/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|N|2||58||BLINDED TREATMENT|1965-06-13||||1969-02-25||1970-09-25|1962-01-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UCI/KG|PD||WATT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|PARENT|RADIOLOGIST 1|NA|3||39||OBSERVATION|1963-11-26||||1961-04-25||1968-01-14|1971-09-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||METSIND|METASTATIC INDICATOR||||MG/DL|ISD||NCI|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|PARENT|UROLOGIST|N|3||39||OBSERVATION|1962-07-08||||1964-01-14||1969-11-27|1966-06-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MMAL|MRD NEGATIVITY||VIRTUAL PIXEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR|U|4||88||INDUCTION TREATMENT|1965-07-22||||1969-06-22||1969-10-26|1968-05-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NMOL/ML/MIN|CCR||CMH2O*S/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|INTERVIEWER|ENDOCRINOLOGIST|U|4||88||BLINDED TREATMENT|1964-08-27||||1967-09-25||1960-01-20|1962-05-24||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||NEWLIND|NEW LESION INDICATOR||||PA|PR WITH LYMPHOCYTOSIS||EID 50/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|VENDOR|PEDIATRIC NEUROLOGIST|NA|5||7||RUN-IN|1960-04-06||||1967-10-17||1968-04-19|1961-10-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||SUPPOSITORY|NON-PD||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|5||7||SCREENING|1967-04-17||||1961-06-03||1971-10-07|1968-08-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^3 CFU|CYTOGENETIC CR||UG/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|1||38||RUN-IN|1965-04-26||||1973-04-30||1963-06-10|1971-01-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||IN2|RELAPSED DISEASE||CCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|FAMILY MEMBER|NEUROLOGIST 2|N|1||38||FOLLOW-UP|1963-02-23||||1970-10-14||1971-07-09|1969-11-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|1||||||RDIORESP|RADIOLOGIC RESPONSE||||NMOL/L|IUPD||NM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|VENDOR|PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1965-10-06||||1969-01-25||1962-11-06|1972-05-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TRACE|QUANTIFIABLE MRD POSITIVITY||MMU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|STUDY SUBJECT|PHYSIOTHERAPIST|N|2||58||SCREENING|1971-07-17||||1969-11-25||1972-08-11|1971-07-17||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|1||||||BESTRESP|BEST OVERALL RESPONSE||||MESF|UNFAVORABLE RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|NA|3||39||BLINDED TREATMENT|1965-12-28||||1970-03-13||1965-11-04|1966-10-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|2||||||CLINRESP|CLINICAL RESPONSE||||IU|MORPHOLOGIC CRI||MET|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|FRIEND|ADJUDICATOR 3|U|3||39||WASHOUT|1972-04-16||||1962-01-11||1964-12-30|1963-03-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NKAT/G HB|VGPR||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|CAREGIVER|ONCOLOGIST|Y|4||88||INDUCTION TREATMENT|1961-02-10||||1972-12-11||1969-07-10|1961-05-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|2||||||LIVRRESP|LIVER RESPONSE||||TUBERCULIN UNIT/ML|NON-QUANTIFIABLE MRD POSITIVITY||IU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|CAREGIVER|MICROSCOPIST 1|U|4||88||RUN-IN|1968-07-11||||1963-10-25||1960-03-10|1965-05-10||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|1||||||METBRESP|METABOLIC RESPONSE||||NMOL/L/H|PSEUDORESPONSE||/HPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|CHILD|PATHOLOGIST 1|U|5||7||TREATMENT|1964-01-15||||1964-07-01||1964-10-12|1962-11-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C361B153-4623-4F03-9D81-8316B1046F35|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG2/DL2|MOLECULAR CR||DISK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|FRIEND|RATER|Y|5||7||FOLLOW-UP|1968-01-08||||1970-06-25||1971-08-03|1971-08-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/H|MORPHOLOGIC CR||DRINK|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||BLINDED TREATMENT|1968-08-08||||1963-01-21||1967-10-04|1964-06-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IU/DAY|UNEQUIVOCAL||% INHIBITION|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1||38||BLINDED TREATMENT|1972-05-19||||1962-03-01||1960-10-03|1967-12-07||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/MONTH|MINOR PATHOLOGIC RESPONSE||EU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|HEALTH CARE PROFESSIONAL|RATER 1|NA|2||58||INDUCTION TREATMENT|1970-07-27||||1965-10-15||1963-04-04|1961-01-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/M2/H|INCREASED||NSEC|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||CONTINUATION TREATMENT|1963-08-28||||1964-11-06||1968-08-21|1969-01-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||TRGRESP|TARGET RESPONSE||||U/G/H|VGPR||UKAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|INTERVIEWER|ONCOLOGIST|N|3||39||OBSERVATION|1970-01-21||||1962-12-05||1967-12-31|1965-11-12||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MCI|NOT ALL EVALUATED||G/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|SPOUSE|NEUROLOGIST 2|Y|3||39||BASELINE|1966-07-21||||1962-12-15||1972-09-09|1962-12-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PKAT/L|MORPHOLOGIC CRI||10^6 U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4||88||WASHOUT|1960-10-14||||1964-04-20||1973-07-13|1965-04-11||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/10^12 RBC|QUANTIFIABLE MRD POSITIVITY||UMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|READER|U|4||88||TREATMENT|1971-07-09||||1968-07-30||1969-11-06|1965-08-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KDA|CYTOGENETIC CR||10^6 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|5||7||BASELINE|1960-04-04||||1962-03-09||1966-07-17|1969-11-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||V/V|CR||BE/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|SPOUSE|OPHTHALMOLOGIST|NA|5||7||SCREENING|1969-03-26||||1961-09-04||1969-04-17|1972-12-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||WEBER|MORPHOLOGIC CR||C|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|CAREGIVER|CLINICAL PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1962-07-11||||1968-01-11||1966-03-22|1960-12-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 PFU|PR WITH LYMPHOCYTOSIS||MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|VENDOR|ADJUDICATOR 2|N|1||38||LONG-TERM FOLLOW-UP|1967-01-29||||1960-01-21||1969-02-20|1967-07-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|1||||||BONERESP|BONE RESPONSE||||UU/L|PR WITH LYMPHOCYTOSIS||IU/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|CAREGIVER|PATHOLOGIST 1|N|2||58||TREATMENT|1973-07-11||||1966-03-14||1969-11-30|1963-11-08||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|2||||||STRUSTAT|STEROID USE STATUS||||ENZYME U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||DAYS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|VENDOR|ADJUDICATOR|N|2||58||LONG-TERM FOLLOW-UP|1963-06-06||||1962-07-22||1966-05-13|1960-03-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UM|SD||ML/SEC/1.73M2|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|NA|3||39||OPEN LABEL TREATMENT|1961-05-03||||1968-06-22||1964-07-23|1961-03-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|2||||||SPLNRESP|SPLEEN RESPONSE||||MU/G|IPR||GBQ/MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|PROXY|ADJUDICATOR|NA|3||39||INDUCTION TREATMENT|1961-05-31||||1961-04-26||1969-01-26|1960-07-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PHERESIS UNIT|PDU||PSEC|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|GUARDIAN|MICROSCOPIST 3|U|4||88||OPEN LABEL TREATMENT|1969-12-29||||1964-05-30||1966-06-27|1972-03-04||AFTER||DURING|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||WEBER|MRD NEGATIVITY||DROP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|PROXY|MICROSCOPIST 3|NA|4||88||CONTINUATION TREATMENT|1968-01-27||||1972-09-13||1967-05-23|1962-01-29||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|1||||||OVRLRESP|OVERALL RESPONSE||||WAFER|NR||ML/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|5||7||BASELINE|1972-11-06||||1969-12-13||1970-06-17|1960-08-08||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|31D8814B-5542-4540-B955-24410D42F1EF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PIXEL|MCR||UG/ML/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|ADJUDICATOR|MICROSCOPIST 1|U|5||7||TREATMENT|1968-10-03||||1969-11-29||1963-12-29|1962-09-19||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||METBRESP|METABOLIC RESPONSE||||MIN|CA125 50% RESPONSE||CS|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CAREGIVER|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1968-03-30||||1968-07-06||1964-07-05|1967-07-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||MOLRESP|MOLECULAR RESPONSE||||TBSP|INDETERMINATE RESPONSE||S/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|PROXY|ONCOLOGIST 2|N|1||38||SCREENING|1973-08-25||||1961-02-14||1966-10-27|1969-02-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||NEWLIND|NEW LESION INDICATOR||||UG/KG/MIN|CYTOGENETIC PR||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|2||58||WASHOUT|1961-11-16||||1961-03-05||1965-11-10|1961-02-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||BESTRESP|BEST OVERALL RESPONSE||||CAL|MCR||%(W/W)|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|SIBLING|MICROSCOPIST|N|2||58||BLINDED TREATMENT|1970-03-12||||1965-02-01||1972-04-25|1967-08-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||BONERESP|BONE RESPONSE||||CYLINDER|MORPHOLOGIC CR||MM/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|SPOUSE|FORENSIC PATHOLOGIST|N|3||39||BASELINE|1966-11-18||||1962-09-05||1963-05-29|1960-08-13||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 CFU/G|RELAPSED DISEASE FROM CR OR PR||PL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|READER 3|N|3||39||WASHOUT|1964-03-28||||1967-01-28||1960-06-13|1964-01-25||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||BONERESP|BONE RESPONSE||||AU/ML|SMD||POINT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|4||88||BLINDED TREATMENT|1968-11-19||||1970-07-01||1966-04-08|1967-11-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||CYTORESP|CYTOGENETIC RESPONSE||||LB|CYTOGENETIC MINOR RESPONSE||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|GUARDIAN|HEMATOLOGIST|Y|4||88||BLINDED TREATMENT|1962-03-14||||1964-09-12||1963-08-05|1970-06-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||TRGRESP|TARGET RESPONSE||||10^3 DNA COPIES/ML|PD-CT||SCOOPFUL|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|INTERVIEWER|UROLOGIST|NA|5||7||BLINDED TREATMENT|1967-11-04||||1969-06-02||1966-04-09|1966-01-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||ANATRESP|ANATOMIC RESPONSE||||MG/G/H|DISEASE TRANSFORMATION||BU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1965-06-19||||1969-06-26||1968-03-20|1967-01-05||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^8/L|MRD NEGATIVITY||DEG/MM|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|1||38||TREATMENT|1969-06-10||||1967-04-01||1960-05-16|1963-02-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||CLINRESP|CLINICAL RESPONSE||||MHZ|UNEQUIVOCAL||USP U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|GUARDIAN|CLINICAL PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1968-11-18||||1968-11-29||1960-09-30|1960-10-15||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||MPS U|IMMUNOPHENOTYPIC CR||POINT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|SPOUSE|PEDIATRIC NEUROLOGIST|U|2||58||SCREENING|1972-06-04||||1961-11-13||1972-04-02|1961-09-26||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||MOLRESP|MOLECULAR RESPONSE||||U/G/H|MORPHOLOGIC CRI||DPM/100MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|CLINICAL RESEARCH COORDINATOR|READER|NA|2||58||FOLLOW-UP|1972-02-20||||1967-02-22||1963-05-24|1970-05-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NGEQ/L|PD-CT||SCM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|SPOUSE|MICROSCOPIST|Y|3||39||FOLLOW-UP|1964-03-18||||1965-10-02||1970-03-01|1965-10-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 U|QUANTIFIABLE MRD POSITIVITY||MIU/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|INDEPENDENT ASSESSOR|RATER 1|N|3||39||WASHOUT|1967-06-28||||1972-09-14||1960-10-01|1963-06-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/SEC/1.73M2|PD FROM PR||10^6 U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|STUDY SUBJECT|PATHOLOGIST 1|U|4||88||BLINDED TREATMENT|1971-02-05||||1969-09-23||1962-02-27|1961-07-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||SPLNRESP|SPLEEN RESPONSE||||MMAL|CCR||KN/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|DOMESTIC PARTNER|RATER 2|Y|4||88||WASHOUT|1970-05-16||||1965-05-02||1963-03-07|1963-03-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||/200 HPFS|MORPHOLOGIC CR||TSP EQ|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||TREATMENT|1968-06-30||||1971-07-31||1970-02-02|1963-10-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||BONERESP|BONE RESPONSE||||/7.5 ML|ICR||10^6 IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|FRIEND|PATHOLOGIST|U|5||7||TREATMENT|1967-06-16||||1964-03-30||1969-10-18|1966-03-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UL/ML|NOT ALL EVALUATED||BAR|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|FRIEND|RADIOLOGIST 1|NA|1||38||SCREENING|1973-04-10||||1963-01-06||1968-05-12|1968-01-14||AFTER||DURING|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||METBRESP|METABOLIC RESPONSE||||10^3 CFU/ML|NON-CR/NON-PD||PG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|SPOUSE|RADIOLOGIST|U|1||38||BASELINE|1967-04-10||||1967-05-13||1966-04-15|1962-08-09||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||NEWLIND|NEW LESION INDICATOR||||DNA COPIES/UG|MR||ML/ANIMAL/WK|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|ADJUDICATOR|ENDOCRINOLOGIST|N|2||58||RUN-IN|1968-11-13||||1968-11-29||1961-05-08|1960-07-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BISCUIT|COMPLETE MRD RESPONSE||KM|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|STUDY SUBJECT|READER 2|N|2||58||LONG-TERM FOLLOW-UP|1972-05-03||||1972-10-26||1963-12-25|1969-02-17||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6/G|VGPR||MU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|VENDOR|HEMATOLOGIST|N|3||39||RUN-IN|1971-09-09||||1961-10-07||1968-07-11|1973-06-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ECL UNIT|CR-CT||EID 50/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|U|3||39||WASHOUT|1960-06-12||||1969-08-09||1964-08-09|1966-01-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/MOL|CYTOGENETIC CR||UG/L DDU|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||SCREENING|1969-08-26||||1970-10-09||1961-03-02|1969-03-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/G/H|NON-QUANTIFIABLE MRD POSITIVITY||G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|4||88||SCREENING|1969-06-15||||1971-11-24||1967-02-02|1966-09-11||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||TRGRESP|TARGET RESPONSE||||10^6/HPF|CA125 75% RESPONSE||BREATHS/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|PROXY|MICROSCOPIST|Y|5||7||OBSERVATION|1963-08-08||||1964-12-23||1966-01-02|1961-04-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MM/MIN|CYTOGENETIC NO RESPONSE||UM/S|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|CHILD|CARDIOLOGIST|N|5||7||WASHOUT|1965-10-14||||1966-09-22||1961-01-04|1971-08-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MGEQ|MINOR PATHOLOGIC RESPONSE||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|VENDOR|MICROSCOPIST 3|NA|1||38||WASHOUT|1973-05-25||||1963-07-01||1965-07-28|1966-09-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||EVENTS|CPR||TROCHE|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|GUARDIAN|PATHOLOGIST 2|Y|1||38||OPEN LABEL TREATMENT|1960-02-25||||1962-12-03||1968-10-30|1967-01-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FT|IPR||10^3 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1966-11-11||||1964-07-26||1960-06-06|1963-02-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MEQ/ML|MINOR PATHOLOGIC RESPONSE||HZ/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|2||58||TREATMENT|1964-05-12||||1967-11-10||1961-11-16|1965-03-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/G|PR-CT||MPA|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|PROXY|ADJUDICATOR 2|U|3||39||SCREENING|1973-06-18||||1966-05-10||1967-11-23|1970-09-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||NEWLIND|NEW LESION INDICATOR||||TUBERCULIN UNIT/ML|CPR||/100 HPFS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|STUDY SUBJECT|MICROSCOPIST|U|3||39||BLINDED TREATMENT|1969-10-27||||1965-06-16||1968-02-02|1962-07-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||TRGRESP|TARGET RESPONSE||||MG/G/H|ISD||10^8/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|4||88||BLINDED TREATMENT|1965-07-01||||1964-08-17||1970-11-24|1969-02-18||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||RDIORESP|RADIOLOGIC RESPONSE||||GENEQ/ML|MOLECULAR MAJOR RESPONSE||PG|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|ADJUDICATION COMMITTEE|INTERNIST|NA|4||88||LONG-TERM FOLLOW-UP|1970-01-28||||1967-07-16||1960-07-12|1963-12-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||CLINRESP|CLINICAL RESPONSE||||WEBER|PDU||MS/MMHG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|ADJUDICATION COMMITTEE|PATHOLOGIST|N|5||7||FOLLOW-UP|1970-03-14||||1964-04-12||1962-01-28|1970-11-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||NEWLIND|NEW LESION INDICATOR||||KS|DISEASE TRANSFORMATION||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|SIGNIFICANT OTHER|READER 2|U|5||7||OPEN LABEL TREATMENT|1961-02-26||||1963-07-07||1971-04-25|1965-04-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/G/H|DISEASE TRANSFORMATION||MPS U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|1||38||WASHOUT|1971-05-26||||1970-01-14||1963-05-16|1969-01-07||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||BESTRESP|BEST OVERALL RESPONSE||||MG/M2/H|PR WITH LYMPHOCYTOSIS||SPRAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|1||38||RUN-IN|1971-06-27||||1968-11-23||1960-08-24|1969-01-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ML/KG/MIN|PD FROM PR||CAPSULE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|2||58||WASHOUT|1969-10-16||||1972-04-26||1961-11-18|1965-07-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||STRUSTAT|STEROID USE STATUS||||/500 WBC|DECREASED||MM/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|FRIEND|RATER 2|NA|2||58||CONTINUATION TREATMENT|1963-09-23||||1971-08-22||1965-04-20|1966-01-01||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/KG|PDU||U/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|3||39||BLINDED TREATMENT|1972-02-16||||1968-06-04||1969-07-16|1964-06-30||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||LIVRRESP|LIVER RESPONSE||||DAGU|PSEUDORESPONSE||CI/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|DOMESTIC PARTNER|OPTOMETRIST|Y|3||39||RUN-IN|1960-01-18||||1961-07-03||1972-03-15|1961-07-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||BONERESP|BONE RESPONSE||||AU/ML|PR-CT||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|STUDY SUBJECT|ENDOCRINOLOGIST|N|4||88||WASHOUT|1963-04-20||||1966-10-04||1962-01-02|1971-08-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||ANATRESP|ANATOMIC RESPONSE||||10^6 DNA COPIES/ML|PD||FOZ_BR|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|CLINICAL STUDY SPONSOR|UROLOGIST|Y|4||88||BASELINE|1965-04-12||||1964-06-03||1963-04-09|1967-01-28||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||BESTRESP|BEST OVERALL RESPONSE||||HOURS|FAVORABLE RESPONSE||BQ/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|PARENT|RATER|U|5||7||OPEN LABEL TREATMENT|1972-05-15||||1968-06-09||1968-08-30|1970-02-05||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||SPLNRESP|SPLEEN RESPONSE||||10^6 CFU|CR-CT||RFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||RUN-IN|1961-07-02||||1973-08-24||1964-09-21|1968-09-06||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||METSIND|METASTATIC INDICATOR||||EJACULATE U|INDETERMINATE RESPONSE||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|READER 2|NA|1||38||TREATMENT|1973-03-11||||1967-07-10||1968-10-09|1970-07-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||L/H|NON-QUANTIFIABLE MRD POSITIVITY||UKAT/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|ADJUDICATOR|READER 2|N|1||38||INDUCTION TREATMENT|1971-03-26||||1961-10-12||1963-07-31|1967-02-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||METBRESP|METABOLIC RESPONSE||||MG/L FEU|NR||UKAT/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|STUDY SUBJECT|ONCOLOGIST 2|Y|2||58||FOLLOW-UP|1969-04-09||||1971-11-21||1961-10-25|1970-05-11||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||SPLNRESP|SPLEEN RESPONSE||||HR/DAY|IUPD||MG/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|PARENT|ADJUDICATOR 1|N|2||58||TREATMENT|1969-06-14||||1965-07-19||1973-06-04|1960-02-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/DOSE|MRD RELAPSE||FRACTION OF 1|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|GUARDIAN|MICROSCOPIST 3|N|3||39||RUN-IN|1965-09-02||||1965-03-16||1971-11-13|1965-11-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||METSIND|METASTATIC INDICATOR||||ENZYME U|NON-ICR/NON-IUPD||UMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|INVESTIGATOR|CARDIOLOGIST|U|3||39||TREATMENT|1969-06-21||||1966-12-07||1960-06-07|1973-09-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/DAY|UNEQUIVOCAL||UG/KG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|4||88||FOLLOW-UP|1965-10-29||||1972-03-13||1967-04-20|1964-02-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MG/ANIMAL|SMD||OHM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|4||88||RUN-IN|1964-12-02||||1961-05-16||1970-12-28|1966-12-31||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||PATHRESP|PATHOLOGIC RESPONSE||||LM|QUANTIFIABLE MRD POSITIVITY||IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|INVESTIGATOR|MICROSCOPIST 2|NA|5||7||OPEN LABEL TREATMENT|1968-08-19||||1960-04-19||1966-05-31|1973-05-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||METBRESP|METABOLIC RESPONSE||||MIN*MG/ML|MINOR PATHOLOGIC RESPONSE||10^9 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|SIBLING|ADJUDICATOR 3|NA|5||7||WASHOUT|1968-07-01||||1971-01-12||1971-12-31|1966-08-07||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BE/ML|UNEQUIVOCAL||WATT|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|1||38||CONTINUATION TREATMENT|1964-08-06||||1971-10-16||1960-03-06|1963-04-06||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||OVRLRESP|OVERALL RESPONSE||||M|CYTOGENETIC CR||KALLIKREIN INHIBITOR UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|PROXY|ADJUDICATOR 1|N|1||38||INDUCTION TREATMENT|1963-05-20||||1965-02-14||1973-06-15|1961-01-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||OVRLRESP|OVERALL RESPONSE||||MEQ/L|PD/RELAPSE AFTER HI||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|2||58||INDUCTION TREATMENT|1967-07-29||||1968-04-15||1967-10-05|1971-10-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||NEWLPROG|NEW LESION PROGRESSION||||ML/KG/MIN|IMPROVED||TSP|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|CAREGIVER|ONCOLOGIST 2|NA|2||58||BASELINE|1971-08-26||||1971-09-25||1964-11-29|1962-12-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MET*MIN|CRI||NMOL BCE/L|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|N|3||39||BLINDED TREATMENT|1973-01-23||||1962-02-11||1963-05-12|1969-01-12||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||LIVRRESP|LIVER RESPONSE||||10^3/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||CAN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|FRIEND|RADIOLOGIST 2|U|3||39||RUN-IN|1968-01-07||||1973-02-10||1971-07-31|1970-10-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/MBP|CRI||PPTR|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||BLINDED TREATMENT|1969-04-01||||1971-10-30||1972-04-10|1968-03-08||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UU/DL|RELAPSED DISEASE||UMOL/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|NA|CHILD|ADJUDICATOR 3|U|4||88||OBSERVATION|1961-07-07||||1963-09-23||1967-12-13|1966-01-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||STRUSTAT|STEROID USE STATUS||||IU/KG/H|ABSENT MORPHOLOGIC RESPONSE||USEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|CHILD|PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1969-12-01||||1973-09-07||1965-09-02|1969-10-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||LIVRRESP|LIVER RESPONSE||||MOSM/L|PD-CT||BREATHS/30S|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|NA|ADJUDICATOR|INTERNIST|U|5||7||TREATMENT|1968-02-08||||1970-07-05||1968-03-19|1966-06-04||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||TRGRESP|TARGET RESPONSE||||UGEQ/L|MCR||FT2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|INTERVIEWER|ADJUDICATOR|NA|1||38||BLINDED TREATMENT|1961-08-03||||1965-09-08||1972-10-18|1972-04-04||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||NEWLIND|NEW LESION INDICATOR||||DROP|NON-ICR/NON-IUPD||DAYS/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1960-04-25||||1967-10-08||1966-01-09|1966-08-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||MOLRESP|MOLECULAR RESPONSE||||MMHG*MIN/L|NED||ML/KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||SCREENING|1966-08-15||||1973-01-18||1967-08-02|1969-07-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||LIVRRESP|LIVER RESPONSE||||10^6 CFU/ML|MRD RELAPSE||APS U|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|2||58||LONG-TERM FOLLOW-UP|1970-02-12||||1960-09-07||1960-10-21|1968-02-04||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 PFU/ML|MRD RELAPSE||PMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1966-05-07||||1960-12-28||1969-01-21|1962-11-13||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/M2/H|INCREASED||TORR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|3||39||OBSERVATION|1967-06-16||||1967-03-30||1969-01-25|1967-11-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DPM/0.5 ML|FAVORABLE RESPONSE||PMOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|DOMESTIC PARTNER|READER 1|Y|4||88||OBSERVATION|1968-08-17||||1972-03-03||1962-10-25|1964-02-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||METBRESP|METABOLIC RESPONSE||||CI|PR-CT||CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|INTERVIEWER|OPTOMETRIST|N|4||88||CONTINUATION TREATMENT|1973-01-10||||1967-01-06||1973-07-18|1966-07-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/MOL|SMD||H/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|FRIEND|INTERNIST|U|5||7||OBSERVATION|1970-02-28||||1962-02-13||1972-01-17|1965-12-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/CAGE|COMPLETE MRD RESPONSE||MASK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|5||7||BASELINE|1971-02-09||||1969-09-03||1962-07-20|1964-12-16||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CI/UL|NED||U/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1971-12-06||||1971-07-23||1967-09-12|1964-04-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||MOLRESP|MOLECULAR RESPONSE||||KIT|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|NA|GUARDIAN|INTERNIST|N|1||38||INDUCTION TREATMENT|1969-01-10||||1964-09-01||1971-03-27|1973-02-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||BESTRESP|BEST OVERALL RESPONSE||||USIEMENS|RELAPSED DISEASE||IN|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|U|ADJUDICATOR|MICROSCOPIST 3|U|2||58||BASELINE|1965-06-17||||1970-07-18||1964-01-06|1971-04-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DEG|PD||KEV|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|SIBLING|INTERNIST|U|2||58||OPEN LABEL TREATMENT|1963-08-17||||1966-02-20||1961-12-06|1961-08-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||STRUSTAT|STEROID USE STATUS||||MOL/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|ADJUDICATOR|ADJUDICATOR 1|U|3||39||RUN-IN|1965-03-20||||1973-02-28||1960-05-06|1973-03-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||NEWLIND|NEW LESION INDICATOR||||NFIU|WORSENED||DDU|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|STUDY SUBJECT|READER 3|U|3||39||BASELINE|1964-09-12||||1960-03-21||1973-05-29|1962-12-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||/200 HPFS|PR-CT||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1969-10-19||||1960-04-13||1967-10-27|1972-12-14||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||OVRLRESP|OVERALL RESPONSE||||HPA|NE||IU/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|CAREGIVER|ADJUDICATOR 3|Y|4||88||WASHOUT|1970-11-24||||1961-06-08||1966-05-24|1965-04-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||METBRESP|METABOLIC RESPONSE||||10^6 DNA COPIES/ML|PDU||UG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|PROXY|HEMATOLOGIST|Y|5||7||TREATMENT|1962-11-23||||1970-09-28||1967-11-08|1963-03-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DMOL|DISEASE TRANSFORMATION||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|5||7||TREATMENT|1966-04-03||||1963-12-04||1967-01-11|1963-07-04||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^3 COPIES/ML|MOLECULAR CR||MEQ/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|ADJUDICATOR|READER 2|U|1||38||WASHOUT|1971-07-26||||1965-03-05||1969-03-22|1964-05-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/U|HI-E||ML/S|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|U|SIGNIFICANT OTHER|ENDOCRINOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1963-03-31||||1962-01-28||1967-01-29|1966-10-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/BEAT|PMD||KS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|SIGNIFICANT OTHER|MICROSCOPIST 1|U|2||58||OBSERVATION|1961-07-02||||1960-05-03||1970-10-02|1968-01-22||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MG/KG/H|PCR||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|INTERVIEWER|READER 1|Y|2||58||LONG-TERM FOLLOW-UP|1972-08-07||||1967-02-23||1963-11-03|1963-08-08||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||CLINRESP|CLINICAL RESPONSE||||MG/G/MIN|DISEASE TRANSFORMATION||UG/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|SIBLING|NEUROLOGIST|NA|3||39||SCREENING|1966-04-11||||1961-09-28||1961-07-19|1961-07-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||ANATRESP|ANATOMIC RESPONSE||||TSP|VGPR||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|PROXY|PHYSIOTHERAPIST|N|3||39||TREATMENT|1968-03-26||||1961-12-27||1965-04-16|1971-05-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MET|CCR||MILE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|PROXY|UROLOGIST|N|4||88||OBSERVATION|1971-01-12||||1967-12-25||1968-05-20|1973-08-10||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/MOL|INCREASED||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|FAMILY MEMBER|INTERNIST|N|4||88||CONTINUATION TREATMENT|1969-05-30||||1969-11-11||1961-04-14|1973-01-28||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MDFI|RELAPSED DISEASE||10^3 RNA COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|ADJUDICATOR|UROLOGIST|Y|5||7||OPEN LABEL TREATMENT|1968-06-07||||1963-03-19||1969-01-31|1971-04-25||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UM/S|NON-ICR/NON-IUPD||UMOL/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|INTERVIEWER|OTOLARYNGOLOGIST|U|5||7||WASHOUT|1960-06-10||||1963-06-19||1963-08-03|1965-09-08||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/G|CMR||GY/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||BASELINE|1969-02-04||||1962-05-21||1972-09-18|1961-03-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PUFF|SCR||HOUNSFIELD UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|GUARDIAN|RATER|U|1||38||SCREENING|1960-01-03||||1970-07-08||1970-11-16|1961-07-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|1||||||STRUSTAT|STEROID USE STATUS||||MANSON U/ML|ISD||TAMPON|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|SPOUSE|CARDIOLOGIST|U|2||58||SCREENING|1971-02-23||||1968-07-30||1965-01-19|1972-04-20||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|2||||||ANATRESP|ANATOMIC RESPONSE||||NSEC|OPTIMAL MORPHOLOGIC RESPONSE||ANTI-XA IU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|READER 3|U|2||58||CONTINUATION TREATMENT|1964-03-22||||1970-10-24||1963-08-06|1963-08-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|1||||||CLINRESP|CLINICAL RESPONSE||||IU/G HB|PDU||FRACTION OF 1|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|3||39||CONTINUATION TREATMENT|1960-09-25||||1965-11-01||1972-07-27|1970-01-06||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|2||||||MOLRESP|MOLECULAR RESPONSE||||BEL|PCR||U/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3||39||OPEN LABEL TREATMENT|1965-06-16||||1972-05-17||1963-08-17|1969-04-04||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|1||||||NEWLIND|NEW LESION INDICATOR||||/MIN|MOLECULAR CR||S*KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|ADJUDICATION COMMITTEE|RADIOLOGIST|U|4||88||WASHOUT|1960-01-12||||1962-04-09||1960-04-28|1966-02-09||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/ANIMAL/DAY|ISD||L/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|INTERVIEWER|HEMATOLOGIST|U|4||88||OPEN LABEL TREATMENT|1966-11-29||||1961-11-28||1973-04-12|1966-05-04||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/MIN|CYTOGENETIC PR||UMOL/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|VENDOR|READER|NA|5||7||BASELINE|1968-10-14||||1963-11-13||1969-03-30|1963-04-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9995CD08-2650-4711-8F04-E41183E28B21|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RFU|NED||GRAIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|5||7||RUN-IN|1972-06-14||||1964-06-19||1969-05-12|1962-04-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KBQ/UL|INCREASED||AU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CHILD|PATHOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1969-02-14||||1961-05-04||1960-04-03|1972-07-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||SPLNRESP|SPLEEN RESPONSE||||V/V|MORPHOLOGIC CRI||MS2|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|VENDOR|MICROSCOPIST 1|N|1||38||BASELINE|1961-05-26||||1962-04-22||1973-05-12|1966-10-26||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG|INCREASED||1/(S*KPA)|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|SPOUSE|RATER|Y|2||58||FOLLOW-UP|1971-08-29||||1966-03-07||1972-01-03|1967-05-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||METBRESP|METABOLIC RESPONSE||||VG/ML|PDU||MV/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|SPOUSE|NEUROLOGIST 1|N|2||58||OBSERVATION|1963-05-16||||1972-12-19||1967-04-24|1968-03-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/M2|ABSENT MORPHOLOGIC RESPONSE||INHALATION|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|PROXY|PATHOLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1960-10-16||||1961-05-05||1973-06-02|1969-02-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||NTRGRESP|NON-TARGET RESPONSE||||UMOL/KG/MIN|CA125 50% RESPONSE||U/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|SPOUSE|READER 3|NA|3||39||OPEN LABEL TREATMENT|1965-12-12||||1969-04-13||1971-09-13|1963-02-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||BONERESP|BONE RESPONSE||||U/M2/MIN|RELAPSED DISEASE FROM CR OR PR||G/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|SIBLING|PHYSIOTHERAPIST|Y|4||88||WASHOUT|1968-02-26||||1972-02-09||1967-02-09|1972-04-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LOG10 TCID 50/DOSE|RELAPSED DISEASE FROM CR||10^3/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|4||88||TREATMENT|1967-08-18||||1968-05-02||1971-05-03|1973-05-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/MM|PCR||TSP EQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1962-10-03||||1968-04-24||1968-06-20|1963-01-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^7 CFU|NON-PD||CI/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|FAMILY MEMBER|RATER 2|N|5||7||LONG-TERM FOLLOW-UP|1960-11-27||||1965-12-18||1966-01-13|1965-01-14||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KPA|CMR||CMOL/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|INTERVIEWER|OPHTHALMOLOGIST|Y|1||38||BLINDED TREATMENT|1968-04-15||||1965-07-11||1972-10-16|1966-04-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UKAT/L|FAVORABLE RESPONSE||COAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|1||38||BASELINE|1968-05-29||||1972-04-10||1971-04-22|1967-09-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||NEWLPROG|NEW LESION PROGRESSION||||VIAL|NR||NEBULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|INVESTIGATOR|OTOLARYNGOLOGIST|NA|2||58||TREATMENT|1970-09-06||||1973-01-05||1964-01-09|1966-06-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/M2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/100 HPFS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|2||58||TREATMENT|1972-10-06||||1966-01-08||1963-08-17|1961-12-20||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||TMRESP|TUMOR MARKER RESPONSE||||PACK|EQUIVOCAL||TESLA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|SIBLING|ENDOCRINOLOGIST|NA|3||39||BASELINE|1960-01-03||||1965-02-15||1960-08-13|1971-04-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UMOL/H/MMOL|PSEUDORESPONSE||MMU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|VENDOR|PEDIATRIC NEUROLOGIST|U|3||39||BASELINE|1962-10-28||||1967-04-13||1960-06-24|1964-11-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||SPLNRESP|SPLEEN RESPONSE||||ML/MIN/MMHG|IMPROVED||CAL|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|DOMESTIC PARTNER|NEUROLOGIST 2|U|4||88||SCREENING|1964-06-26||||1968-07-15||1970-04-03|1966-04-25||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/L/H|MORPHOLOGIC CRI||KPA|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|4||88||OPEN LABEL TREATMENT|1964-02-01||||1968-11-15||1963-10-31|1962-06-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/G/MIN|PD/RELAPSE AFTER HI||H/WK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|SPOUSE|UROLOGIST|Y|5||7||FOLLOW-UP|1965-07-06||||1970-11-26||1967-05-04|1960-07-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PFU|MRD PERSISTENCE||G/U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|SIGNIFICANT OTHER|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1971-10-01||||1960-10-26||1964-10-21|1965-01-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||RDIORESP|RADIOLOGIC RESPONSE||||NCI|SD-CT||ML/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|Y|U|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|1||38||OBSERVATION|1969-12-19||||1973-04-12||1973-02-05|1960-09-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CS|SD-CT||MASK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|1||38||OBSERVATION|1965-08-06||||1971-10-22||1971-04-25|1966-09-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||NEWLIND|NEW LESION INDICATOR||||GPS U|PR WITH LYMPHOCYTOSIS||NEEDLE GAUGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1962-10-16||||1960-08-16||1965-05-18|1970-01-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||MOLRESP|MOLECULAR RESPONSE||||AMPULE|RELAPSED DISEASE FROM CR OR PR||ML/CM3/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1966-01-21||||1972-06-30||1970-01-07|1968-01-15||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||BONERESP|BONE RESPONSE||||S/H|WORSENED||PL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|ADJUDICATOR|NEUROLOGIST 2|NA|3||39||RUN-IN|1968-01-28||||1967-11-06||1972-06-24|1969-02-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||METBRESP|METABOLIC RESPONSE||||BE/ML|PR||MS/MMHG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|FAMILY MEMBER|ADJUDICATOR|N|3||39||LONG-TERM FOLLOW-UP|1966-07-25||||1972-11-18||1972-07-28|1962-12-21||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TORR|ABSENT MORPHOLOGIC RESPONSE||BLOCKS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|SIBLING|OPTOMETRIST|U|4||88||TREATMENT|1968-04-07||||1961-12-08||1972-01-18|1964-11-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||TRACE|NED||RPM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|GUARDIAN|PATHOLOGIST 2|N|4||88||INDUCTION TREATMENT|1964-03-22||||1972-11-26||1968-01-03|1960-11-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||MOLRESP|MOLECULAR RESPONSE||||ML/M2/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||UU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|PARENT|ADJUDICATOR|N|5||7||FOLLOW-UP|1961-08-10||||1963-04-13||1965-07-19|1966-12-21||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||STRUSTAT|STEROID USE STATUS||||10^12/L|NOT ALL EVALUATED||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|STUDY SUBJECT|PATHOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1970-10-08||||1964-06-21||1969-01-17|1973-08-10||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CI/MG|OPTIMAL MORPHOLOGIC RESPONSE||VG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|FAMILY MEMBER|INTERNIST|N|1||38||BLINDED TREATMENT|1970-01-20||||1968-12-19||1968-09-01|1968-10-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/KG|STABLE||YD|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|INVESTIGATOR|PATHOLOGIST 2|Y|1||38||INDUCTION TREATMENT|1973-08-27||||1967-12-14||1963-05-15|1965-01-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||LOG10 PFU|PR-CT||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|FAMILY MEMBER|RADIOLOGIST 1|NA|2||58||TREATMENT|1962-07-26||||1968-05-06||1972-06-22|1967-07-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||NEWLIND|NEW LESION INDICATOR||||AMP|MINOR PATHOLOGIC RESPONSE||ML/ANIMAL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|PARENT|OTOLARYNGOLOGIST|U|2||58||INDUCTION TREATMENT|1972-12-15||||1961-09-24||1966-04-15|1970-01-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||TMRESP|TUMOR MARKER RESPONSE||||CAL|MINOR PATHOLOGIC RESPONSE||10^4/L|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|SIBLING|NEUROLOGIST 1|N|3||39||BLINDED TREATMENT|1963-05-01||||1965-03-01||1961-03-27|1966-08-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||TRGRESP|TARGET RESPONSE||||AMU|MINOR PATHOLOGIC RESPONSE||DPM/100MG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|FAMILY MEMBER|NEUROLOGIST|N|3||39||RUN-IN|1961-08-26||||1972-08-16||1969-05-14|1969-11-09||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^9/L|MRD PERSISTENCE||KS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|4||88||CONTINUATION TREATMENT|1965-08-30||||1964-08-20||1965-09-10|1970-10-04||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^6/EJACULATE U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/VF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|FRIEND|RATER|U|4||88||RUN-IN|1966-05-06||||1962-03-05||1966-07-10|1967-10-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||STRUSTAT|STEROID USE STATUS||||PG/CELL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||STRIP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|INTERVIEWER|RADIOLOGIST|NA|5||7||OBSERVATION|1972-02-19||||1970-11-18||1964-08-02|1970-05-11||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||STRUSTAT|STEROID USE STATUS||||ML/MIN/1.73M2|CA125 75% RESPONSE||DISK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|DOMESTIC PARTNER|PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1973-05-29||||1973-06-28||1961-03-25|1969-01-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^5/HPF|EQUIVOCAL||NMOL/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|U|SIBLING|OPHTHALMOLOGIST|N|1||38||FOLLOW-UP|1960-12-15||||1960-11-14||1969-11-12|1966-04-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||BREATHS/30S|CR-CT||IU/G HB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|CHILD|READER 1|Y|1||38||RUN-IN|1970-04-08||||1962-04-03||1969-07-03|1961-08-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||RDIORESP|RADIOLOGIC RESPONSE||||L/L|CHR||M/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|2||58||BLINDED TREATMENT|1971-01-12||||1972-11-08||1963-03-08|1962-09-06||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GBQ/MG|SCR||UG/L DDU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|VENDOR|UROLOGIST|N|2||58||OPEN LABEL TREATMENT|1973-02-19||||1972-06-22||1965-12-23|1968-12-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^7 CFU/ML|MOLECULAR MAJOR RESPONSE||BQ/UL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|3||39||FOLLOW-UP|1971-03-24||||1973-08-31||1971-07-07|1960-03-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||CLINRESP|CLINICAL RESPONSE||||L/DAY|MCR||10^7 TCID 50/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 1|NA|3||39||RUN-IN|1964-06-24||||1961-01-24||1967-01-07|1960-09-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PA|IUPD||MMOL2/L2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|ADJUDICATOR|READER|NA|4||88||OBSERVATION|1968-10-07||||1962-12-04||1973-04-08|1960-08-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||MOLRESP|MOLECULAR RESPONSE||||/100 WBC|CA125 50% RESPONSE||NG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|4||88||OBSERVATION|1973-04-25||||1962-08-30||1967-10-23|1965-01-27||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||ANATRESP|ANATOMIC RESPONSE||||MEQ/KG|DISEASE TRANSFORMATION||/5X10^4 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|VENDOR|READER|U|5||7||BASELINE|1971-11-04||||1960-06-02||1961-04-12|1973-06-18||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UMOL/MG/MIN|IPR||PPB|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|5||7||WASHOUT|1964-07-25||||1972-05-16||1961-02-03|1964-07-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||WEBER|PARTIAL MORPHOLOGIC RESPONSE||/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|READER 3|Y|1||38||OBSERVATION|1967-02-23||||1961-10-25||1964-03-21|1967-02-06||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||OD UNIT|CYTOGENETIC NO RESPONSE||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|1||38||INDUCTION TREATMENT|1963-02-04||||1966-11-14||1970-06-01|1960-03-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||RDIORESP|RADIOLOGIC RESPONSE||||BQ/MG|INCREASED||YEARS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|VENDOR|READER|Y|2||58||FOLLOW-UP|1971-01-10||||1971-05-11||1973-02-07|1973-04-10||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||LIVRRESP|LIVER RESPONSE||||UMOL/L/MIN|CA125 75% RESPONSE||MG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|2||58||OBSERVATION|1969-08-03||||1967-10-06||1973-03-18|1961-07-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||ANATRESP|ANATOMIC RESPONSE||||OZ|NR||G/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|CHILD|HEMATOLOGIST|U|3||39||OBSERVATION|1962-09-03||||1972-06-10||1973-08-29|1960-11-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||PATHRESP|PATHOLOGIC RESPONSE||||U/M2|CRI||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|STUDY SUBJECT|RATER 1|Y|3||39||WASHOUT|1961-01-09||||1964-04-18||1967-05-30|1972-07-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UM2|CHR||POINT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|4||88||RUN-IN|1960-09-24||||1967-08-11||1964-06-06|1960-02-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||STRUSTAT|STEROID USE STATUS||||CI/MG|MORPHOLOGIC CRI||PUFF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1972-08-28||||1962-09-25||1972-07-05|1970-03-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||OVRLRESP|OVERALL RESPONSE||||COULOMB|MORPHOLOGIC CR||SCOOPFUL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|5||7||CONTINUATION TREATMENT|1968-10-29||||1967-04-15||1973-06-30|1965-12-08||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||CYTORESP|CYTOGENETIC RESPONSE||||DNA COPIES/UG|OPTIMAL MORPHOLOGIC RESPONSE||MG/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|CLINICAL RESEARCH COORDINATOR|RATER 2|U|5||7||INDUCTION TREATMENT|1965-08-31||||1970-05-09||1968-06-15|1968-06-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NEBULE|NON-PD||BREATHS/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1966-02-10||||1967-04-27||1965-02-16|1968-11-29||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||OVRLRESP|OVERALL RESPONSE||||LX|CYTOGENETIC MINIMAL RESPONSE||ML/MIN/MMHG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1973-01-28||||1963-03-31||1960-05-03|1972-05-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||EIA UNIT|NR||HOMEOPATHIC DILUTION|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|STUDY SUBJECT|PHYSIOTHERAPIST|N|2||58||SCREENING|1967-01-30||||1971-03-19||1971-02-07|1973-06-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI/KG|WORSENED||IMPLANT|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|PROXY|ONCOLOGIST|U|2||58||BASELINE|1964-06-28||||1971-07-11||1967-06-16|1967-01-10||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||GENEQ|PSEUDOPROGRESSION||10^6/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|PARENT|UROLOGIST|N|3||39||TREATMENT|1970-12-07||||1971-10-14||1973-07-20|1962-08-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL|CYTOGENETIC PR||NEWTON|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|3||39||OBSERVATION|1968-07-06||||1972-10-08||1971-12-28|1972-12-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DRUM|PSEUDOPROGRESSION||UMOL/H/MMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||TREATMENT|1962-12-19||||1961-03-05||1963-12-01|1969-03-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||NEWLIND|NEW LESION INDICATOR||||DISK|COMPLETE MRD RESPONSE||DYN|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|CAREGIVER|CLINICAL PATHOLOGIST|NA|4||88||FOLLOW-UP|1962-04-26||||1966-07-31||1971-05-01|1965-04-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 ORGANISMS/MG|RELAPSED DISEASE FROM CR||LOG10 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|INDEPENDENT ASSESSOR|OPTOMETRIST|N|5||7||BASELINE|1963-02-25||||1961-07-04||1960-05-01|1963-11-25||DURING||AFTER|
TRIAL STUDY 134XCP|RS|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PA|WORSENED||USIEMENS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|5||7||RUN-IN|1962-01-17||||1973-02-26||1964-01-01|1965-03-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ENZYME U/M2|CPR||FIU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|SIBLING|MICROSCOPIST 2|Y|1||38||BASELINE|1971-10-26||||1960-05-28||1972-03-22|1973-08-02||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||NEWLPROG|NEW LESION PROGRESSION||||UG/KG/DAY|NON-QUANTIFIABLE MRD POSITIVITY||TSP EQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|GUARDIAN|DERMATOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1962-05-13||||1965-11-02||1972-08-13|1966-01-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DB|STABLE||MG/KG/WEEK|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|FRIEND|READER 1|NA|2||58||CONTINUATION TREATMENT|1967-08-03||||1960-02-07||1960-11-28|1963-09-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UEQ|ICR||CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|FAMILY MEMBER|ONCOLOGIST|Y|2||58||BLINDED TREATMENT|1965-11-04||||1973-01-31||1964-12-07|1965-08-28||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^7 TCID 50/DOSE|NR||CL|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|CAREGIVER|READER 3|U|3||39||OPEN LABEL TREATMENT|1964-03-25||||1962-12-01||1970-11-02|1968-08-19||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||TMRESP|TUMOR MARKER RESPONSE||||KM/H|HI-N||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|INTERVIEWER|RADIOLOGIST 1|Y|3||39||FOLLOW-UP|1968-12-21||||1961-10-13||1968-04-15|1972-06-28||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||LIVRRESP|LIVER RESPONSE||||SYRINGE|CYTOGENETIC NO RESPONSE||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|GUARDIAN|READER 2|NA|4||88||BLINDED TREATMENT|1963-11-25||||1970-11-11||1973-02-22|1972-01-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||BESTRESP|BEST OVERALL RESPONSE||||MU|CYTOGENETIC MINOR RESPONSE||MOSM|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|INTERVIEWER|ADJUDICATOR 3|NA|4||88||BASELINE|1971-11-17||||1971-08-25||1972-07-16|1970-09-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||NEWLIND|NEW LESION INDICATOR||||DEG/S|FAVORABLE RESPONSE||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|SPOUSE|NEUROLOGIST 2|U|5||7||BASELINE|1972-10-29||||1967-05-06||1966-05-21|1966-11-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/M2/H|CYTOGENETIC PR||L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|PARENT|READER 3|NA|5||7||INDUCTION TREATMENT|1966-07-19||||1965-08-02||1970-12-23|1967-12-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PT_US|CHR||MAMP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|SPOUSE|CARDIOLOGIST|N|1||38||SCREENING|1965-12-03||||1962-02-03||1962-11-08|1965-10-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||METSIND|METASTATIC INDICATOR||||TUBE|CPR||UMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|STUDY SUBJECT|READER 2|U|1||38||OBSERVATION|1967-08-02||||1972-01-16||1966-10-22|1961-11-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||STRUSTAT|STEROID USE STATUS||||U/MMOL|CA125 75% RESPONSE||MG/G/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|PARENT|RADIOLOGIST 2|U|2||58||BASELINE|1970-12-05||||1971-09-12||1962-10-06|1968-10-13||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DAYS|TREATMENT FAILURE||AMOL|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|ADJUDICATOR|READER|N|2||58||CONTINUATION TREATMENT|1968-01-01||||1962-07-29||1960-05-21|1971-08-28||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||BEATS/MIN|UNEQUIVOCAL||FL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||INDUCTION TREATMENT|1965-02-14||||1966-09-29||1964-12-24|1961-11-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||TMRESP|TUMOR MARKER RESPONSE||||U|INCREASED||EP U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|GUARDIAN|CARDIOLOGIST|U|3||39||SCREENING|1973-07-27||||1968-05-18||1968-03-18|1960-04-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||TMRESP|TUMOR MARKER RESPONSE||||MMOL/L|PSEUDOPROGRESSION||ML/BREATH|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|PROXY|READER 1|N|4||88||RUN-IN|1967-01-11||||1962-02-13||1960-11-19|1971-05-02||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||AU/ML|MAJOR PATHOLOGIC RESPONSE||UMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|SPOUSE|PEDIATRIC NEUROLOGIST|U|4||88||BASELINE|1962-04-18||||1965-06-06||1960-03-12|1962-02-12||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||TMRESP|TUMOR MARKER RESPONSE||||MG/M2/MIN|SD-CT||CAN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|PROXY|DERMATOLOGIST|U|5||7||OBSERVATION|1973-03-29||||1963-11-19||1973-02-06|1968-10-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||MOLRESP|MOLECULAR RESPONSE||||UG/L DDU|MR||TROCHE|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5||7||FOLLOW-UP|1967-06-15||||1967-03-26||1967-02-05|1964-04-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||MOLRESP|MOLECULAR RESPONSE||||FOZ_US|CYTOGENETIC MINIMAL RESPONSE||PSEC|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|1||38||INDUCTION TREATMENT|1967-07-25||||1962-11-21||1963-01-05|1970-03-25||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BAG|CCR||KIT|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||FOLLOW-UP|1966-12-27||||1971-07-27||1966-01-16|1965-06-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||TRGRESP|TARGET RESPONSE||||KG/CM|PD-CT||MM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|2||58||RUN-IN|1963-08-13||||1965-08-02||1972-07-29|1965-09-13||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||BONERESP|BONE RESPONSE||||CIGARETTE|MR||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|U|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||RUN-IN|1961-02-17||||1964-04-03||1973-08-08|1964-04-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UV*SEC|PD FROM PR||UU/L|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|3||39||FOLLOW-UP|1962-12-29||||1973-04-18||1971-03-24|1972-07-25||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||METBRESP|METABOLIC RESPONSE||||10^12 IU/L|QUANTIFIABLE MRD POSITIVITY||K|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|3||39||TREATMENT|1965-01-29||||1968-06-30||1965-04-23|1964-04-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 IU/ML|SCR||V/V|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|4||88||RUN-IN|1960-06-18||||1962-08-24||1965-08-14|1964-08-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||CLINRESP|CLINICAL RESPONSE||||10^10/L|PD FROM PR||/500 WBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|4||88||LONG-TERM FOLLOW-UP|1968-01-11||||1970-07-15||1964-11-28|1973-08-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||NTRGRESP|NON-TARGET RESPONSE||||UG|CYTOGENETIC NO RESPONSE||BQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|DOMESTIC PARTNER|OPHTHALMOLOGIST|U|5||7||OBSERVATION|1960-01-26||||1968-01-06||1965-10-26|1970-10-05||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||SPLNRESP|SPLEEN RESPONSE||||HZ/S|PSA PROGRESSION||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|SIBLING|HEMATOLOGIST|NA|5||7||WASHOUT|1969-06-26||||1966-08-06||1962-09-05|1961-12-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||VOXEL|CCR||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|ADJUDICATION COMMITTEE|READER 3|Y|1||38||SCREENING|1973-08-10||||1961-03-08||1970-03-17|1962-11-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||CLINRESP|CLINICAL RESPONSE||||U/M2/DAY|PR WITH LYMPHOCYTOSIS||10^12/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|NA|1||38||SCREENING|1964-05-03||||1972-10-22||1962-01-06|1970-11-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||G/M2|CYTOGENETIC PR||OZ EQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|2||58||FOLLOW-UP|1964-08-31||||1969-09-06||1963-08-10|1966-12-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MSEC|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UCI/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|SIGNIFICANT OTHER|MICROSCOPIST 3|N|2||58||BASELINE|1969-12-30||||1962-06-10||1967-03-13|1962-01-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL|SD-CT||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|INVESTIGATOR|RADIOLOGIST 1|Y|3||39||BLINDED TREATMENT|1970-07-24||||1969-04-11||1971-08-17|1970-02-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/CMH2O|IPR||CAN|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|3||39||SCREENING|1972-04-18||||1963-08-01||1964-12-14|1971-06-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CYCLE/MIN|IMPROVED||G/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|CHILD|READER 1|N|4||88||TREATMENT|1971-12-12||||1973-08-28||1970-09-27|1960-08-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DRUM|PD-CT||DDU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1960-08-29||||1971-01-29||1973-02-12|1964-05-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||ANATRESP|ANATOMIC RESPONSE||||FEU|PSA PROGRESSION||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|5||7||BLINDED TREATMENT|1973-06-17||||1961-01-01||1960-05-25|1962-10-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KM|RELAPSED DISEASE FROM CR||CI/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|FRIEND|OPHTHALMOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1963-03-31||||1962-07-24||1968-08-13|1964-09-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||ANATRESP|ANATOMIC RESPONSE||||L/MIN/M2|CA125 50% RESPONSE||MEQ/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|1||38||FOLLOW-UP|1966-10-08||||1968-04-05||1960-12-26|1970-10-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||METSIND|METASTATIC INDICATOR||||AGU/ML|PSA PROGRESSION||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|SIBLING|INTERNIST|U|1||38||LONG-TERM FOLLOW-UP|1969-12-06||||1964-05-07||1966-08-25|1973-07-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^3 ORGANISMS/G|MRD PERSISTENCE||H/WK|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|SPOUSE|ADJUDICATOR 2|U|2||58||LONG-TERM FOLLOW-UP|1964-05-27||||1961-11-09||1962-12-07|1962-04-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||MOLRESP|MOLECULAR RESPONSE||||MMOL2/L2|EQUIVOCAL||CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|INVESTIGATOR|READER|Y|2||58||LONG-TERM FOLLOW-UP|1973-08-28||||1973-01-27||1963-11-01|1964-08-14||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^9 ORGANISMS/MG|NR||VOXEL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|GUARDIAN|READER 2|Y|3||39||LONG-TERM FOLLOW-UP|1968-07-02||||1969-06-17||1962-11-28|1963-06-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||NEWLPROG|NEW LESION PROGRESSION||||PMOL|IMPROVED||SACHET|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|U|INDEPENDENT ASSESSOR|MICROSCOPIST|Y|3||39||OBSERVATION|1960-07-10||||1968-01-11||1972-06-16|1971-12-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||TRGRESP|TARGET RESPONSE||||DAMOL/L|INCREASED||KS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|GUARDIAN|ONCOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1970-11-22||||1967-11-02||1971-09-30|1960-06-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL2/L2|IMPROVED||DPM/0.5 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|INTERVIEWER|ENDOCRINOLOGIST|NA|4||88||RUN-IN|1964-05-28||||1962-10-26||1962-08-25|1968-07-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||METBRESP|METABOLIC RESPONSE||||10^5/HPF|SD-CT||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|CAREGIVER|INTERNIST|Y|5||7||SCREENING|1960-02-09||||1963-09-14||1962-01-08|1960-06-22||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||ANATRESP|ANATOMIC RESPONSE||||10^7/L|PDU||/MS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|STUDY SUBJECT|MICROSCOPIST 1|Y|5||7||WASHOUT|1967-10-05||||1970-07-20||1965-08-02|1965-08-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||SPLNRESP|SPLEEN RESPONSE||||IU/KG|MOLECULAR CR||IU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|INTERVIEWER|READER 1|NA|1||38||LONG-TERM FOLLOW-UP|1962-02-22||||1973-07-12||1971-11-03|1964-08-31||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MM/SEC|IMMUNOPHENOTYPIC CR||USEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|GUARDIAN|RATER 1|Y|1||38||SCREENING|1963-07-28||||1972-02-10||1970-02-09|1962-11-05||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||GY|MRD PERSISTENCE||IN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||INDUCTION TREATMENT|1964-11-20||||1965-02-26||1969-06-18|1971-06-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/ANIMAL|WORSENED||UG/G/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|2||58||BLINDED TREATMENT|1968-06-08||||1962-08-20||1965-07-16|1963-09-04||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||METSIND|METASTATIC INDICATOR||||MM2|RELAPSED DISEASE FROM CR||COAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|PARENT|OPHTHALMOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1973-02-22||||1971-02-25||1966-12-20|1965-08-25||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BOX|PR-CT||UG/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|SIBLING|PATHOLOGIST 2|Y|3||39||WASHOUT|1961-11-20||||1963-05-10||1972-01-25|1960-09-29||DURING||AFTER|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NMOL BCE/MMOL|PCR||FFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|FRIEND|UROLOGIST|Y|4||88||SCREENING|1968-09-12||||1969-07-07||1972-04-19|1972-11-19||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||OVRLRESP|OVERALL RESPONSE||||NMOL/L/H|PR||SIEMENS|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|VENDOR|DERMATOLOGIST|U|4||88||SCREENING|1969-08-07||||1964-06-06||1962-11-08|1973-03-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||STRUSTAT|STEROID USE STATUS||||TROCHE|IMMUNOPHENOTYPIC CR||%|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1969-05-22||||1967-08-05||1966-05-18|1969-12-04||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||BONERESP|BONE RESPONSE||||ELISA UNIT|CMR||LOG10 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|5||7||BLINDED TREATMENT|1968-08-10||||1965-10-25||1968-10-16|1962-10-15||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BE/ML|NOT ALL EVALUATED||HPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|1||38||RUN-IN|1968-01-14||||1973-08-27||1967-11-30|1969-01-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/KG|MRD RELAPSE||MM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|1||38||WASHOUT|1966-07-14||||1964-11-16||1964-09-13|1969-03-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GY/MIN|CMR||IMPLANT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|2||58||CONTINUATION TREATMENT|1973-08-04||||1966-12-29||1965-01-16|1960-06-19||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/DL|PR WITH LYMPHOCYTOSIS||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|ADJUDICATOR|RATER 1|NA|2||58||RUN-IN|1973-05-14||||1962-09-15||1962-12-21|1969-07-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/S|NON-PD||DDU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|GUARDIAN|MICROSCOPIST 1|NA|3||39||SCREENING|1962-05-13||||1970-07-10||1968-04-26|1961-05-25||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||SPLNRESP|SPLEEN RESPONSE||||CAPLET|RELAPSED DISEASE||DEG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|SIBLING|PATHOLOGIST 1|NA|3||39||TREATMENT|1972-09-11||||1962-03-21||1967-12-07|1971-07-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UMOL/MIN|PMR||TABLET|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||FOLLOW-UP|1963-10-02||||1970-04-22||1962-04-27|1966-01-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||NTRGRESP|NON-TARGET RESPONSE||||UMOL/MIN|MORPHOLOGIC CR||APPLICATION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|PARENT|READER 2|N|4||88||OBSERVATION|1972-06-18||||1962-07-23||1968-02-10|1970-04-06||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MM2|CHR||ML/H|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|DOMESTIC PARTNER|READER 1|U|5||7||WASHOUT|1970-04-26||||1963-12-11||1971-04-16|1966-07-10||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||METSIND|METASTATIC INDICATOR||||10^6/EJACULATE U|INCREASED||PPM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|U|STUDY SUBJECT|INTERNIST|U|5||7||OPEN LABEL TREATMENT|1967-07-07||||1963-01-23||1971-04-15|1966-06-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||OVRLRESP|OVERALL RESPONSE||||GPL U|MORPHOLOGIC CRI||PT_BR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|1||38||INDUCTION TREATMENT|1970-05-16||||1964-03-03||1968-08-24|1969-03-08||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||SPLNRESP|SPLEEN RESPONSE||||NMOL/DAY|PDU||COULOMB|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1963-06-14||||1963-04-23||1972-04-23|1962-10-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/MBP|NON-ICR/NON-IUPD||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|NA|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|2||58||WASHOUT|1964-08-06||||1968-05-22||1968-11-29|1971-06-29||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||CYTORESP|CYTOGENETIC RESPONSE||||NMOL/L/H|NPR||MG/ML/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|2||58||WASHOUT|1972-03-01||||1962-02-17||1964-01-13|1961-04-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||STRUSTAT|STEROID USE STATUS||||L/MIN/M2|IMMUNOPHENOTYPIC CR||10^3 CFU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|ADJUDICATOR|READER 3|U|3||39||SCREENING|1973-06-01||||1962-03-27||1970-06-19|1964-05-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||IU|CYTOGENETIC MINOR RESPONSE||MASK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|ADJUDICATION COMMITTEE|RATER 2|NA|3||39||OBSERVATION|1963-09-23||||1971-06-02||1969-02-22|1970-07-16||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/KG/H|MOLECULAR MAJOR RESPONSE||/40 HPFS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|STUDY SUBJECT|MICROSCOPIST 2|Y|4||88||OBSERVATION|1964-10-10||||1962-11-25||1964-12-11|1967-06-15||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||LIVRRESP|LIVER RESPONSE||||ML/DL|PMR||KBQ|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|CHILD|READER 2|NA|4||88||FOLLOW-UP|1968-10-04||||1966-12-21||1967-12-10|1962-10-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||NEWLPROG|NEW LESION PROGRESSION||||CI|STABLE||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|Y|FAMILY MEMBER|ONCOLOGIST|N|5||7||TREATMENT|1971-08-01||||1968-09-02||1966-03-15|1964-12-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||METSIND|METASTATIC INDICATOR||||NKAT/G HB|SD||/2500 WBC|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|CLINICAL STUDY SPONSOR|RATER|U|5||7||TREATMENT|1965-07-26||||1964-09-13||1965-04-17|1971-08-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||ANATRESP|ANATOMIC RESPONSE||||/2000 RBC|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||BOX|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|NA|SPOUSE|MICROSCOPIST 2|N|1||38||WASHOUT|1968-01-08||||1972-05-22||1962-01-11|1964-02-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||OVRLRESP|OVERALL RESPONSE||||ML/ANIMAL/DAY|DECREASED||MM3/MM2/YEAR|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|1||38||RUN-IN|1967-07-15||||1962-09-05||1971-12-09|1969-09-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^10/L|SD-CT||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|GUARDIAN|MICROSCOPIST 2|Y|2||58||BLINDED TREATMENT|1972-04-15||||1968-02-16||1970-05-18|1966-01-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/KG/DAY|UNFAVORABLE RESPONSE||CG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|SIBLING|FORENSIC PATHOLOGIST|N|2||58||TREATMENT|1963-10-27||||1973-04-03||1971-01-08|1968-07-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMHG/L/MIN|CYTOGENETIC CR||RPM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|NA|ADJUDICATOR|INTERNIST|Y|3||39||WASHOUT|1967-01-15||||1964-05-06||1967-05-16|1971-02-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||NTRGRESP|NON-TARGET RESPONSE||||NMOL/MOL|PMR||UCI|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|CHILD|READER 2|N|3||39||OPEN LABEL TREATMENT|1962-03-25||||1960-08-10||1967-10-14|1971-06-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||NTRGRESP|NON-TARGET RESPONSE||||USEC|DECREASED||BISCUIT|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|GUARDIAN|ONCOLOGIST|N|4||88||CONTINUATION TREATMENT|1963-11-09||||1970-11-08||1962-05-10|1969-11-22||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MKAT|EQUIVOCAL||/MONTH|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|4||88||TREATMENT|1972-08-09||||1968-08-03||1964-02-18|1960-07-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||MOLRESP|MOLECULAR RESPONSE||||CY/CM|COMPLETE MRD RESPONSE||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|U|PROXY|OTOLARYNGOLOGIST|U|5||7||TREATMENT|1964-03-24||||1965-05-04||1971-11-21|1970-12-14||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||MOLRESP|MOLECULAR RESPONSE||||MANSON U/ML|MAJOR PATHOLOGIC RESPONSE||PIXELS/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|DOMESTIC PARTNER|RADIOLOGIST|NA|5||7||OBSERVATION|1966-09-07||||1970-12-12||1967-05-11|1971-10-29||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NFIU|PSA PROGRESSION||MU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|SPOUSE|ADJUDICATOR 1|Y|1||38||OBSERVATION|1962-08-28||||1972-05-03||1971-11-22|1969-02-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||BESTRESP|BEST OVERALL RESPONSE||||TUBE|MRD NEGATIVITY||MV*MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|DOMESTIC PARTNER|PATHOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1960-07-12||||1965-04-30||1972-11-18|1970-12-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||BONERESP|BONE RESPONSE||||G/MOL|UNFAVORABLE RESPONSE||KM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|CHILD|MICROSCOPIST 2|U|2||58||LONG-TERM FOLLOW-UP|1968-01-14||||1965-11-30||1964-05-10|1964-08-13||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||OVRLRESP|OVERALL RESPONSE||||ML/MIN|CCR||KG/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|PROXY|ENDOCRINOLOGIST|N|2||58||WASHOUT|1965-11-28||||1962-06-23||1965-06-11|1965-02-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||TRGRESP|TARGET RESPONSE||||AFU|MRD PERSISTENCE||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1960-11-11||||1966-04-21||1971-10-07|1965-05-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||NEWLIND|NEW LESION INDICATOR||||/10^3|STABLE||DAMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|SIBLING|MICROSCOPIST 3|U|3||39||FOLLOW-UP|1966-01-23||||1963-12-20||1963-01-27|1969-06-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||M/SEC2|SD-CT||RAD|NOT DONE|||LIKERT SCALE 5-POINT|U|U|Y|PROXY|RATER 1|Y|4||88||INDUCTION TREATMENT|1973-08-17||||1961-07-27||1969-11-29|1972-08-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||L/DAY|RELAPSED DISEASE FROM CR OR PR||MG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|INTERVIEWER|NEUROLOGIST|N|4||88||INDUCTION TREATMENT|1968-02-22||||1961-08-06||1966-02-11|1971-02-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DIP|INDETERMINATE RESPONSE||/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|CAREGIVER|RADIOLOGIST|NA|5||7||RUN-IN|1968-06-30||||1971-07-24||1970-11-01|1962-11-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||TRGRESP|TARGET RESPONSE||||SV|HI-P||EQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|DOMESTIC PARTNER|PATHOLOGIST 2|NA|5||7||BASELINE|1972-02-08||||1969-02-03||1963-06-11|1968-11-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||NEWLIND|NEW LESION INDICATOR||||MEQ|COMPLETE MRD RESPONSE||CUP|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|INVESTIGATOR|PHYSIOTHERAPIST|NA|1||38||WASHOUT|1971-01-23||||1966-07-08||1964-06-20|1960-07-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||STRUSTAT|STEROID USE STATUS||||ML/100G/MIN|MAJOR PATHOLOGIC RESPONSE||PLUG|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|PROXY|ENDOCRINOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1968-10-25||||1963-11-30||1965-04-09|1972-01-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ|SCR||U/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|INDEPENDENT ASSESSOR|READER 1|N|2||58||FOLLOW-UP|1971-12-12||||1966-01-15||1965-02-04|1962-02-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NFIU|HI-N||MET*H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|2||58||RUN-IN|1970-09-22||||1965-01-06||1970-05-21|1971-04-27||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||METBRESP|METABOLIC RESPONSE||||BAU/ML|HI-E||APL U/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|INTERVIEWER|OPHTHALMOLOGIST|NA|3||39||RUN-IN|1973-01-03||||1973-02-16||1961-03-16|1973-09-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CM/S|NON-QUANTIFIABLE MRD POSITIVITY||MIN/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||BASELINE|1962-08-01||||1969-09-14||1964-01-20|1969-09-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/M2/H|WORSENED||L/H|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|ADJUDICATOR|INTERNIST|N|4||88||BLINDED TREATMENT|1961-02-03||||1969-01-01||1961-04-10|1963-09-13||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DIP|TREATMENT FAILURE||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|NA|INTERVIEWER|NEUROLOGIST 1|N|4||88||BLINDED TREATMENT|1972-06-13||||1965-11-14||1961-05-18|1967-01-30||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||BONERESP|BONE RESPONSE||||NMOL/MOL|PSA PROGRESSION||VIRTUAL PIXEL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|ADJUDICATOR|MICROSCOPIST 3|Y|5||7||OPEN LABEL TREATMENT|1968-03-19||||1962-09-29||1965-11-05|1968-11-11||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||OZ|STABLE||UG/M2/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|DOMESTIC PARTNER|RADIOLOGIST 2|Y|5||7||INDUCTION TREATMENT|1964-11-19||||1972-01-05||1962-08-14|1972-07-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PNU/ML|CCR||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|1||38||RUN-IN|1963-10-09||||1966-07-23||1967-06-02|1970-08-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||TRANSDUCING UNIT/ML|CMR||MOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|1||38||FOLLOW-UP|1966-09-18||||1962-11-24||1963-01-11|1967-10-04||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MMOL/MOL|CMR||MG/M2/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|PROXY|READER 3|U|2||58||CONTINUATION TREATMENT|1969-06-15||||1970-09-23||1972-09-24|1964-07-31||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KDA|CYTOGENETIC CR||ANSON U|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|CHILD|PEDIATRIC NEUROLOGIST|U|2||58||OPEN LABEL TREATMENT|1970-08-12||||1969-10-14||1972-09-29|1969-05-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CI/L|IPR||UG/ML/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|U|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|3||39||OBSERVATION|1966-11-25||||1967-01-10||1964-01-22|1968-10-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MILE|SD-CT||UG/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|ADJUDICATOR|OTOLARYNGOLOGIST|U|3||39||BASELINE|1962-10-03||||1968-05-28||1960-08-28|1960-09-02||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||MOLRESP|MOLECULAR RESPONSE||||MIU/L|SD-CT||PMOL/L/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|DOMESTIC PARTNER|READER|U|4||88||TREATMENT|1971-05-04||||1963-03-29||1970-11-09|1960-01-01||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/DL|CA125 75% RESPONSE||CI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|4||88||OPEN LABEL TREATMENT|1968-11-14||||1960-09-02||1968-10-31|1972-08-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||BONERESP|BONE RESPONSE||||G/ANIMAL/DAY|INDETERMINATE RESPONSE||UG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|STUDY SUBJECT|RADIOLOGIST|N|5||7||BASELINE|1963-01-14||||1971-07-28||1963-05-31|1967-02-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/10^3|IMPROVED||MG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|INVESTIGATOR|READER|U|5||7||TREATMENT|1970-07-11||||1971-04-16||1968-01-28|1967-10-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||LIVRRESP|LIVER RESPONSE||||NEBULE|RELAPSED DISEASE FROM CR OR PR||MM/2H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|NA|GUARDIAN|ONCOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1964-04-06||||1964-10-07||1964-03-12|1969-11-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||NEWLPROG|NEW LESION PROGRESSION||||PFU/ANIMAL|NON-CR/NON-PD||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|VENDOR|INTERNIST|U|1||38||TREATMENT|1962-06-27||||1961-12-10||1962-06-21|1971-03-06||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||SPLNRESP|SPLEEN RESPONSE||||M2|NON-QUANTIFIABLE MRD POSITIVITY||DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||BLINDED TREATMENT|1965-10-01||||1972-01-05||1961-07-27|1971-12-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||RDIORESP|RADIOLOGIC RESPONSE||||COAT|CYTOGENETIC NO RESPONSE||K|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|2||58||SCREENING|1968-11-07||||1964-11-02||1964-04-09|1963-05-25||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/ANIMAL/WK|CHR||RAD|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|3||39||TREATMENT|1961-07-16||||1973-03-31||1962-06-24|1965-05-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||RDIORESP|RADIOLOGIC RESPONSE||||LOG10 IU/ML|MOLECULAR MAJOR RESPONSE||COULOMB|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|PARENT|ADJUDICATOR|Y|3||39||INDUCTION TREATMENT|1973-03-21||||1968-08-22||1971-12-10|1971-06-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||OVRLRESP|OVERALL RESPONSE||||MHZ|DISEASE TRANSFORMATION||GENEQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|INVESTIGATOR|ADJUDICATOR|NA|4||88||BASELINE|1970-06-21||||1969-03-30||1962-09-06|1968-11-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||SPLNRESP|SPLEEN RESPONSE||||PL|FAVORABLE RESPONSE||GBQ/UG|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|STUDY SUBJECT|UROLOGIST|NA|4||88||TREATMENT|1961-03-08||||1972-11-03||1968-02-10|1968-02-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||NEWLPROG|NEW LESION PROGRESSION||||USEC|NED||G/ANIMAL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|VENDOR|OPTOMETRIST|NA|5||7||OPEN LABEL TREATMENT|1960-05-05||||1968-07-03||1964-10-31|1965-12-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||METSIND|METASTATIC INDICATOR||||EQ|STABLE||G/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|NA|GUARDIAN|INTERNIST|U|5||7||FOLLOW-UP|1963-11-28||||1965-12-31||1968-04-07|1969-03-13||AFTER||DURING|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DB|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|INVESTIGATOR|RATER|U|1||38||TREATMENT|1961-01-06||||1966-01-05||1961-09-29|1965-06-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/UG|IMPROVED||/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|ADJUDICATOR|ADJUDICATOR 2|Y|1||38||FOLLOW-UP|1964-02-25||||1965-05-06||1971-02-04|1967-03-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/M2/DAY|PR-CT||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|FRIEND|READER 2|Y|2||58||RUN-IN|1965-07-11||||1967-08-14||1961-10-16|1960-11-21||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/G/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|CAREGIVER|NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1969-02-13||||1965-04-05||1968-02-27|1973-03-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/MIN|MORPHOLOGIC CR||CGY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|NA|3||39||BLINDED TREATMENT|1960-09-03||||1962-11-17||1972-05-19|1971-06-27||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/L FEU|VGPR||10^8 PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|3||39||LONG-TERM FOLLOW-UP|1962-12-27||||1962-01-01||1968-09-01|1962-06-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NGEQ/L|NOT ALL EVALUATED||10^7 PFU|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|4||88||INDUCTION TREATMENT|1966-04-02||||1963-07-12||1972-07-08|1969-05-04||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|2||||||BESTRESP|BEST OVERALL RESPONSE||||COPIES/UG|PDU||TAMPON|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|SPOUSE|CARDIOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1971-04-16||||1967-08-07||1970-09-18|1971-12-13||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|1||||||TRGRESP|TARGET RESPONSE||||NEEDLE GAUGE|PD||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|SPOUSE|FORENSIC PATHOLOGIST|N|5||7||OPEN LABEL TREATMENT|1963-06-21||||1969-09-26||1964-10-29|1966-09-26||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|415F9206-A793-437C-B227-BD245DBF40AB|2||||||NTRGRESP|NON-TARGET RESPONSE||||PFU|TREATMENT FAILURE||UL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|INDEPENDENT ASSESSOR|RATER 2|NA|5||7||BLINDED TREATMENT|1964-03-13||||1964-12-06||1967-07-17|1965-04-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UV|CMR||STEPS/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|1||38||OBSERVATION|1971-03-27||||1960-07-07||1969-02-16|1963-06-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||LIVRRESP|LIVER RESPONSE||||CMH2O/ML|PMD||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||SCREENING|1960-07-05||||1961-01-03||1966-10-19|1963-12-09||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^9 CFU/G|CYTOGENETIC CR||S/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|PARENT|NEUROLOGIST|N|2||58||CONTINUATION TREATMENT|1963-03-16||||1969-04-30||1967-05-09|1967-09-23||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/KG/DOSE|PARTIAL MORPHOLOGIC RESPONSE||DPM/0.5 ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|2||58||OPEN LABEL TREATMENT|1960-03-08||||1961-04-10||1965-02-18|1961-07-12||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||PATHRESP|PATHOLOGIC RESPONSE||||C|HI-P||10^3 ORGANISMS/G|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3||39||BASELINE|1965-12-31||||1968-11-22||1960-10-02|1962-08-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||LIVRRESP|LIVER RESPONSE||||ARBITRARY U|CMR||L/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|ADJUDICATOR|READER 3|NA|3||39||RUN-IN|1970-08-08||||1960-07-17||1964-09-27|1970-05-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/L/MIN|IMMUNOPHENOTYPIC CR||MG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|4||88||TREATMENT|1964-10-16||||1973-03-31||1969-07-24|1972-02-04||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||METBRESP|METABOLIC RESPONSE||||ENZYME U/G HB|PR-CT||UMOL/L/SEC|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|4||88||BLINDED TREATMENT|1969-06-14||||1971-01-11||1960-03-06|1968-11-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/DAY|MRD RELAPSE||NMOL/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|DOMESTIC PARTNER|HEMATOLOGIST|Y|5||7||RUN-IN|1964-11-24||||1965-09-01||1968-02-29|1962-11-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||TRGRESP|TARGET RESPONSE||||UGEQ|HI-P||MPH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|SIBLING|OPHTHALMOLOGIST|U|5||7||INDUCTION TREATMENT|1973-03-03||||1969-09-25||1968-04-13|1970-09-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MDFI|PD/RELAPSE AFTER HI||MG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|ADJUDICATOR|ONCOLOGIST|U|1||38||RUN-IN|1965-12-08||||1966-02-10||1970-10-30|1967-04-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CP|PCR||/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|1||38||BASELINE|1960-11-02||||1967-12-28||1963-08-15|1966-11-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||/2500 WBC|INDETERMINATE RESPONSE||KN/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|2||58||OBSERVATION|1970-12-01||||1969-11-10||1963-10-08|1963-05-09||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BQ/L|PD||MU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|INTERVIEWER|READER 3|N|2||58||CONTINUATION TREATMENT|1973-02-27||||1972-06-17||1962-10-28|1969-01-29||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||STRUSTAT|STEROID USE STATUS||||CI/G|MRD PERSISTENCE||PIXEL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|INVESTIGATOR|NEUROLOGIST 1|Y|3||39||BASELINE|1968-02-24||||1971-03-02||1962-02-17|1967-06-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UGEQ/L|CYTOGENETIC MINIMAL RESPONSE||U/MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|SIBLING|INTERNIST|U|3||39||RUN-IN|1972-09-25||||1971-06-01||1961-06-08|1967-07-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^4/HPF|CYTOGENETIC NO RESPONSE||MMHG/SEC|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|FRIEND|ADJUDICATOR 2|Y|4||88||SCREENING|1960-02-10||||1970-04-26||1968-06-07|1965-02-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MPL U|MR||IMPLANT|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|NA|PARENT|ADJUDICATOR 2|Y|4||88||WASHOUT|1972-11-05||||1960-04-16||1972-11-07|1971-11-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/KG|DECREASED||UKAT/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|VENDOR|READER 2|NA|5||7||BASELINE|1970-09-15||||1970-04-03||1972-09-03|1967-09-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^5/HPF|PD||PL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|RATER|NA|5||7||RUN-IN|1960-11-27||||1972-12-22||1961-11-30|1964-01-27||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KG/CM|FAVORABLE RESPONSE||PFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||BLINDED TREATMENT|1966-11-09||||1964-03-08||1972-05-27|1964-12-08||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MU|PR-CT||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|SPOUSE|HEMATOLOGIST|Y|1||38||BASELINE|1967-11-28||||1965-03-04||1963-11-22|1961-05-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UM|PR-CT||PMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|SIBLING|ONCOLOGIST 1|U|2||58||INDUCTION TREATMENT|1960-12-05||||1969-10-25||1968-11-25|1969-09-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|QUANTIFIABLE MRD POSITIVITY||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|PROXY|ONCOLOGIST|N|2||58||WASHOUT|1973-05-19||||1972-06-27||1972-09-17|1960-04-06||DURING||DURING|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PL|MOLECULAR CR||U/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1961-01-23||||1966-07-17||1965-05-31|1969-04-28||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||CYTORESP|CYTOGENETIC RESPONSE||||U/MG|MCR||KEV|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|FRIEND|ONCOLOGIST|U|3||39||OBSERVATION|1961-10-25||||1972-04-22||1967-05-03|1972-08-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||S^-1(%O2)^-1|PSEUDOPROGRESSION||ML/CM|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|ADJUDICATOR|ADJUDICATOR 1|N|4||88||CONTINUATION TREATMENT|1971-02-09||||1967-10-02||1961-06-13|1970-03-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL BCE/NMOL|RELAPSED DISEASE FROM CR||PACK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|U|4||88||INDUCTION TREATMENT|1960-09-03||||1965-11-04||1962-12-12|1965-11-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||BONERESP|BONE RESPONSE||||ML/S/M2|QUANTIFIABLE MRD POSITIVITY||KAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|U|HEALTH CARE PROFESSIONAL|READER|N|5||7||OBSERVATION|1965-08-30||||1967-09-24||1964-11-15|1963-07-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||METSIND|METASTATIC INDICATOR||||STRIP|ABSENT MORPHOLOGIC RESPONSE||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|DOMESTIC PARTNER|HEMATOLOGIST|Y|5||7||BASELINE|1960-10-26||||1962-04-08||1972-09-20|1968-12-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||LIVRRESP|LIVER RESPONSE||||G/ANIMAL/DAY|PMR||L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|VENDOR|RADIOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1961-08-30||||1965-08-21||1972-01-24|1960-04-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/H|PD||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|READER 3|N|1||38||BASELINE|1962-12-27||||1969-11-20||1971-10-16|1968-12-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||SPLNRESP|SPLEEN RESPONSE||||RNA COPIES/ML|CYTOGENETIC CR||MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||RUN-IN|1969-01-18||||1960-06-22||1964-08-17|1965-08-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||NTRGRESP|NON-TARGET RESPONSE||||CIGAR|CA125 75% RESPONSE||UG/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||BLINDED TREATMENT|1967-01-25||||1962-05-03||1967-09-07|1960-09-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||PATHRESP|PATHOLOGIC RESPONSE||||IU/KG|PD-CT||MEQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|READER 1|U|3||39||CONTINUATION TREATMENT|1964-06-17||||1960-02-18||1968-03-25|1973-01-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||METSIND|METASTATIC INDICATOR||||UM/DAY|PD FROM PR||10^9 CFU|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3||39||WASHOUT|1966-12-03||||1960-11-13||1961-07-09|1966-02-16||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||METBRESP|METABOLIC RESPONSE||||MG|PR-CT||KIU|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|INVESTIGATOR|NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1960-03-20||||1965-03-10||1965-01-15|1962-10-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||TMRESP|TUMOR MARKER RESPONSE||||PIPE|NOT ALL EVALUATED||F|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|INTERVIEWER|DERMATOLOGIST|N|4||88||WASHOUT|1964-12-21||||1965-12-08||1962-07-20|1960-04-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||STRIP|HI-P||PATCH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|PROXY|FORENSIC PATHOLOGIST|N|5||7||TREATMENT|1972-01-17||||1966-09-27||1966-09-05|1972-12-19||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MEQ/UL|CHR||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|SIBLING|NEUROLOGIST 2|NA|5||7||BASELINE|1964-06-24||||1967-04-15||1970-11-08|1960-02-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PACK YEAR|MCR||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|CHILD|ONCOLOGIST 2|U|1||38||SCREENING|1969-06-11||||1960-08-06||1966-07-12|1965-12-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||TUBE|PSEUDOPROGRESSION||U/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|PARENT|INTERNIST|Y|1||38||WASHOUT|1965-08-18||||1966-05-14||1966-09-15|1968-11-13||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CMOL|MINOR PATHOLOGIC RESPONSE||AMP|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|PROXY|CARDIOLOGIST|U|2||58||OBSERVATION|1970-11-17||||1964-05-26||1964-09-06|1968-03-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||APPLICATION|PD/RELAPSE AFTER HI||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|2||58||OBSERVATION|1971-10-11||||1967-01-24||1961-09-13|1961-11-03||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UMOL/L/H|ISD||KS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|ADJUDICATOR|OTOLARYNGOLOGIST|U|3||39||OPEN LABEL TREATMENT|1963-10-04||||1964-05-07||1969-08-19|1967-04-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||CYTORESP|CYTOGENETIC RESPONSE||||/40 HPFS|CRI||KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|RATER|U|3||39||RUN-IN|1962-09-16||||1973-07-29||1961-07-11|1965-08-06||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||SPLNRESP|SPLEEN RESPONSE||||PLUG|UNEQUIVOCAL||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|INTERVIEWER|ONCOLOGIST|N|4||88||WASHOUT|1967-11-22||||1970-07-08||1969-11-04|1962-03-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TUBERCULIN UNIT/ML|WORSENED||ML/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|STUDY SUBJECT|HEMATOLOGIST|U|4||88||FOLLOW-UP|1971-11-22||||1966-02-02||1965-11-27|1964-09-15||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||YEARS|PR||DRUM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|5||7||SCREENING|1967-02-04||||1973-08-04||1972-08-04|1968-04-09||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||BONERESP|BONE RESPONSE||||ML/G/MIN|PD-CT||CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|U|SIBLING|MICROSCOPIST 1|U|5||7||LONG-TERM FOLLOW-UP|1964-09-29||||1960-12-03||1966-04-26|1962-06-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||RDIORESP|RADIOLOGIC RESPONSE||||NKAT|PD||MMHG*MIN/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|GUARDIAN|READER 3|U|1||38||WASHOUT|1960-12-26||||1962-09-19||1963-02-19|1969-02-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||BONERESP|BONE RESPONSE||||V/SEC|PDU||MG/L FEU|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|INTERVIEWER|NEUROLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1964-05-23||||1970-03-05||1964-04-14|1965-04-01||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||RDIORESP|RADIOLOGIC RESPONSE||||G/KG|CR-CT||IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|SIBLING|RADIOLOGIST 2|U|2||58||TREATMENT|1962-09-29||||1961-10-28||1960-11-05|1972-08-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||METSIND|METASTATIC INDICATOR||||PFU/ANIMAL|MCR||MCI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SIGNIFICANT OTHER|ADJUDICATOR 2|N|2||58||OBSERVATION|1972-10-31||||1966-03-31||1964-01-27|1973-06-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KDA|MOLECULAR CR||LOG10 ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|INTERVIEWER|ONCOLOGIST|U|3||39||OPEN LABEL TREATMENT|1961-07-23||||1973-04-07||1970-05-28|1963-10-17||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MU/L|MORPHOLOGIC LEUKEMIA-FREE STATE||VIAL|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|STUDY SUBJECT|RATER|Y|3||39||BLINDED TREATMENT|1966-10-25||||1964-03-03||1972-05-29|1967-04-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||METBRESP|METABOLIC RESPONSE||||FFU|NON-PD||10^4 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|N|4||88||INDUCTION TREATMENT|1965-06-20||||1971-02-27||1972-10-16|1961-10-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||BESTRESP|BEST OVERALL RESPONSE||||MSEC|UNFAVORABLE RESPONSE||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST|Y|4||88||CONTINUATION TREATMENT|1971-04-03||||1965-03-03||1961-06-18|1972-06-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||TRGRESP|TARGET RESPONSE||||UM|IMMUNOPHENOTYPIC CR||AMP|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|ADJUDICATOR|UROLOGIST|Y|5||7||FOLLOW-UP|1964-07-26||||1967-03-22||1963-08-15|1966-01-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||NMOL/MOL|CCR||MG/M2/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|ADJUDICATOR|RATER 1|N|5||7||INDUCTION TREATMENT|1972-04-07||||1965-01-02||1970-08-20|1966-06-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||TRGRESP|TARGET RESPONSE||||10^9 ORGANISMS|CCR||MM/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|PROXY|FORENSIC PATHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1969-03-23||||1972-03-21||1965-12-16|1966-06-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/CAGE|PSA PROGRESSION||MM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|VENDOR|OTOLARYNGOLOGIST|Y|1||38||WASHOUT|1968-04-12||||1966-06-09||1963-07-07|1962-08-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||DEG/S|CHR||UG/KG/H|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|VENDOR|OPTOMETRIST|U|2||58||RUN-IN|1962-06-20||||1970-07-24||1963-04-21|1973-07-06||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||%(W/W)|CYTOGENETIC MINIMAL RESPONSE||DIP|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|PROXY|RADIOLOGIST 1|Y|2||58||SCREENING|1962-08-11||||1962-10-01||1972-03-25|1963-09-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||DAYS/MONTH|MCR||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|VENDOR|NEUROLOGIST 1|NA|3||39||OBSERVATION|1964-11-18||||1973-02-17||1964-03-29|1973-06-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CI|RELAPSED DISEASE||UG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|PARENT|ADJUDICATOR|NA|3||39||BLINDED TREATMENT|1960-04-24||||1964-05-21||1962-09-19|1960-10-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/H|MOLECULAR CR||U/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|4||88||OBSERVATION|1973-01-18||||1966-06-07||1969-01-21|1968-09-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||L/DAY|NE||GY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|VENDOR|NEUROLOGIST 1|U|4||88||FOLLOW-UP|1964-02-02||||1970-04-28||1969-01-13|1963-04-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||METBRESP|METABOLIC RESPONSE||||HENRY|MAJOR PATHOLOGIC RESPONSE||STEPS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|STUDY SUBJECT|HEMATOLOGIST|U|5||7||TREATMENT|1967-06-29||||1973-02-13||1967-03-23|1972-12-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PMOL/DAY|WORSENED||DRINK|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|5||7||FOLLOW-UP|1963-09-10||||1964-05-04||1963-07-12|1970-08-24||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||BONERESP|BONE RESPONSE||||UG/MOL|ISD||COPIES/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||FOLLOW-UP|1962-10-08||||1960-04-18||1967-08-20|1967-03-19||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||RDIORESP|RADIOLOGIC RESPONSE||||AG|PR-CT||10^3 COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|CAREGIVER|MICROSCOPIST 2|NA|1||38||BASELINE|1968-03-13||||1972-11-01||1969-09-02|1965-10-07||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ELISA UNIT|PR WITH LYMPHOCYTOSIS||UMOL/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1972-03-29||||1968-12-29||1971-05-22|1967-01-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NSEC|NON-PD||DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|FAMILY MEMBER|READER 1|N|2||58||RUN-IN|1965-09-23||||1964-08-10||1962-10-11|1968-03-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||PATHRESP|PATHOLOGIC RESPONSE||||WAFER|RELAPSED DISEASE FROM CR OR PR||NEWTON|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|3||39||BLINDED TREATMENT|1967-12-27||||1963-01-10||1969-03-30|1966-01-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||NTRGRESP|NON-TARGET RESPONSE||||UG/DOSE|CA125 50% RESPONSE||APL U/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|3||39||CONTINUATION TREATMENT|1960-05-04||||1966-02-03||1968-05-28|1964-06-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||G/DAY|PR||G/ANIMAL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|N|PROXY|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1967-03-10||||1965-09-14||1973-05-05|1971-09-28||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||LIVRRESP|LIVER RESPONSE||||MG/DL|MCR||L/H|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|STUDY SUBJECT|PATHOLOGIST 2|Y|4||88||OPEN LABEL TREATMENT|1963-03-15||||1962-10-17||1963-01-14|1973-03-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||IU|IUPD||10^9/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|STUDY SUBJECT|OPTOMETRIST|Y|5||7||BLINDED TREATMENT|1962-04-10||||1967-11-20||1965-07-17|1970-08-31||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UMOL/L|CR||UM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|CAREGIVER|MICROSCOPIST 3|U|5||7||BASELINE|1969-04-29||||1968-04-03||1967-10-04|1970-04-09||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/DOSE|ICPD||CI/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|1||38||TREATMENT|1972-11-25||||1965-03-27||1968-11-26|1968-04-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/MIN|PR||UG/M2/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|VENDOR|RATER|NA|1||38||OBSERVATION|1966-05-10||||1964-05-31||1961-01-19|1968-02-19||DURING||DURING|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DAYS/WK|ICR||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|FRIEND|NEUROLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1968-08-20||||1968-10-04||1963-05-11|1972-02-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PKAT/L|HI-N||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|2||58||CONTINUATION TREATMENT|1969-12-29||||1970-01-10||1967-01-24|1960-08-25||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||L/MIN|HI-E||UM/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|N|SIBLING|INTERNIST|NA|3||39||OBSERVATION|1969-01-12||||1960-03-14||1968-05-02|1971-07-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/G/MIN|INDETERMINATE RESPONSE||10^12/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|INVESTIGATOR|RATER|NA|3||39||SCREENING|1966-02-01||||1966-08-22||1973-06-02|1971-10-11||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||LIVRRESP|LIVER RESPONSE||||FMOL|CA125 50% RESPONSE||DEG/MM|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|PARENT|HEMATOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1961-09-21||||1970-01-09||1966-07-12|1965-11-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^9/DOSE|WORSENED||P|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|PROXY|ADJUDICATOR|U|4||88||BLINDED TREATMENT|1962-01-22||||1970-02-03||1969-12-09|1962-11-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/CL|MCR||ML/CAGE/WK|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||CONTINUATION TREATMENT|1962-05-30||||1966-10-07||1970-05-30|1971-01-14||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||OVRLRESP|OVERALL RESPONSE||||CM H2O|PCR||IU|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|GUARDIAN|RATER|NA|5||7||TREATMENT|1968-05-04||||1969-03-23||1969-12-04|1971-01-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|1||||||CLINRESP|CLINICAL RESPONSE||||M3|NON-QUANTIFIABLE MRD POSITIVITY||KV|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|SIGNIFICANT OTHER|NEUROLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1963-03-07||||1971-09-10||1960-03-10|1963-06-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|2||||||SPLNRESP|SPLEEN RESPONSE||||U/M2/H|PARTIAL MORPHOLOGIC RESPONSE||JDF UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|N|SIGNIFICANT OTHER|UROLOGIST|U|1||38||RUN-IN|1969-06-08||||1966-12-27||1960-06-22|1970-07-12||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/10^4|INCREASED||JOULE|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|CLINICAL RESEARCH COORDINATOR|RATER 1|Y|2||58||CONTINUATION TREATMENT|1960-11-06||||1963-10-24||1965-07-22|1972-11-11||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||%|PR-CT||UGEQ|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|SPOUSE|READER|U|2||58||OBSERVATION|1961-05-12||||1963-06-25||1963-08-23|1971-06-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|1||||||NEWLIND|NEW LESION INDICATOR||||DNA COPIES/UG|NR||L/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|U|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|3||39||OBSERVATION|1970-10-12||||1961-03-01||1969-02-03|1968-07-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|2||||||ANATRESP|ANATOMIC RESPONSE||||DNA COPIES/UG|VGPR||U/M2/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|3||39||CONTINUATION TREATMENT|1961-09-25||||1967-06-18||1961-05-10|1962-08-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/M2/H|MAJOR PATHOLOGIC RESPONSE||G/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|4||88||BLINDED TREATMENT|1969-02-08||||1973-06-21||1961-09-15|1971-12-29||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|2||||||STRUSTAT|STEROID USE STATUS||||PMOL/DL|FAVORABLE RESPONSE||U/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|CAREGIVER|READER 1|NA|4||88||BLINDED TREATMENT|1970-10-25||||1969-02-19||1962-02-08|1970-10-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^10/L|EQUIVOCAL||ML/ANIMAL/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|ADJUDICATOR|UROLOGIST|NA|5||7||BASELINE|1968-01-25||||1970-06-23||1962-04-06|1966-01-11||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|30108497-140B-499E-8924-8BFCDC57457A|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MM|SMD||ML/SEC/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|5||7||INDUCTION TREATMENT|1966-02-12||||1965-10-30||1966-03-08|1969-10-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CIGARETTE|WORSENED||PFU/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|FRIEND|NEUROLOGIST|Y|1||38||INDUCTION TREATMENT|1967-12-26||||1967-11-21||1961-04-08|1964-05-04||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||OVRLRESP|OVERALL RESPONSE||||L/MIN/M2|UNEQUIVOCAL||10^6/G|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|PROXY|CLINICAL PATHOLOGIST|NA|1||38||WASHOUT|1963-11-22||||1971-02-13||1968-05-24|1971-06-18||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||LIVRRESP|LIVER RESPONSE||||10^6 ORGANISMS/ML|CYTOGENETIC MINIMAL RESPONSE||/100 WBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|INTERVIEWER|READER 1|Y|2||58||BLINDED TREATMENT|1967-01-22||||1960-02-01||1968-01-31|1964-07-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KG/CM|SD||NMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|INDEPENDENT ASSESSOR|PATHOLOGIST|N|2||58||TREATMENT|1963-08-04||||1967-05-28||1965-06-11|1970-08-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||TMRESP|TUMOR MARKER RESPONSE||||UG/L/H|HI-N||10^8/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||CONTINUATION TREATMENT|1969-02-08||||1971-08-12||1963-01-15|1963-12-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MN|PSEUDOPROGRESSION||MET|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|INVESTIGATOR|PATHOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1965-11-15||||1966-02-05||1971-02-24|1966-08-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||METBRESP|METABOLIC RESPONSE||||V|NR||IU/MMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|4||88||SCREENING|1965-02-03||||1970-10-13||1965-12-08|1960-07-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/KG/MIN|PD||MOSM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|ADJUDICATOR|FORENSIC PATHOLOGIST|U|4||88||BLINDED TREATMENT|1963-08-24||||1967-09-02||1972-06-19|1972-10-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||TRGRESP|TARGET RESPONSE||||FFU|MOLECULAR CR||ML/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|INTERVIEWER|ONCOLOGIST 2|N|5||7||TREATMENT|1972-11-18||||1965-12-19||1964-07-23|1963-01-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/M2/H|NPR||MG/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|5||7||TREATMENT|1968-02-24||||1971-04-08||1968-09-21|1970-03-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UM/S|CA125 75% RESPONSE||ML/MIN/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|INTERVIEWER|HEMATOLOGIST|U|1||38||TREATMENT|1967-01-31||||1969-03-04||1967-01-10|1965-12-28||DURING||DURING|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||MOLRESP|MOLECULAR RESPONSE||||L/L|INCREASED||V|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|1||38||BLINDED TREATMENT|1962-12-20||||1966-02-05||1972-09-14|1969-11-29||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MM/MIN|MORPHOLOGIC CRI||BEL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|ADJUDICATOR|READER 3|N|2||58||OBSERVATION|1970-07-12||||1972-11-02||1960-10-23|1967-03-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/ANIMAL/WK|SMD||UM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|2||58||WASHOUT|1970-08-14||||1966-08-07||1965-10-15|1968-09-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||LIVRRESP|LIVER RESPONSE||||BU/ML|WORSENED||CIGARETTE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|GUARDIAN|OPTOMETRIST|N|3||39||FOLLOW-UP|1964-12-07||||1967-04-05||1970-05-14|1969-12-07||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||STRUSTAT|STEROID USE STATUS||||10^7/L|PR||ML/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|RATER|Y|3||39||OPEN LABEL TREATMENT|1963-10-04||||1961-09-11||1969-12-10|1960-09-22||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||SPLNRESP|SPLEEN RESPONSE||||FARAD|NON-CR/NON-PD||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|INTERVIEWER|RATER 2|U|4||88||FOLLOW-UP|1969-04-02||||1963-06-09||1964-06-10|1970-01-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%(V/V)|UNFAVORABLE RESPONSE||CAPLET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|PROXY|NEUROLOGIST 2|NA|4||88||INDUCTION TREATMENT|1961-08-10||||1963-09-27||1973-07-18|1965-05-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/100 HPFS|NE||PMOL/10^9 CELLS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1969-12-14||||1968-04-10||1960-01-04|1968-06-10||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UM|OPTIMAL MORPHOLOGIC RESPONSE||VIRTUAL PIXEL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|INVESTIGATOR|CLINICAL PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1967-10-16||||1972-06-29||1961-07-09|1963-09-07||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||SPLNRESP|SPLEEN RESPONSE||||KG/L|NON-PD||UG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|1||38||BLINDED TREATMENT|1969-11-30||||1973-06-06||1963-02-25|1963-05-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^5/L|MAJOR PATHOLOGIC RESPONSE||CI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|PROXY|RATER 2|NA|1||38||BASELINE|1967-03-06||||1971-04-28||1967-06-16|1962-11-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||TMRESP|TUMOR MARKER RESPONSE||||KPA/L/SEC|MRD RELAPSE||U/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|2||58||LONG-TERM FOLLOW-UP|1970-09-15||||1963-01-01||1962-04-23|1970-04-18||DURING||AFTER|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/KG/MIN|CR||MV2/HZ|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|DOMESTIC PARTNER|RATER 2|U|2||58||SCREENING|1962-10-11||||1966-02-13||1962-12-26|1967-06-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||LIVRRESP|LIVER RESPONSE||||G/DAY|IPR||COPIES/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|VENDOR|READER 2|N|3||39||SCREENING|1963-07-24||||1963-05-26||1969-02-09|1970-07-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||BESTRESP|BEST OVERALL RESPONSE||||PFU/DOSE|NON-QUANTIFIABLE MRD POSITIVITY||PACKET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|FAMILY MEMBER|RADIOLOGIST 2|NA|3||39||RUN-IN|1968-12-19||||1963-08-15||1969-04-04|1969-12-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^7 CFU|INCREASED||P|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|DOMESTIC PARTNER|OPTOMETRIST|U|4||88||CONTINUATION TREATMENT|1972-10-19||||1965-11-11||1965-12-11|1970-03-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||NEWLPROG|NEW LESION PROGRESSION||||ATM|RELAPSED DISEASE FROM CR OR PR||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1965-12-20||||1967-07-04||1962-09-28|1967-09-28||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||SPLNRESP|SPLEEN RESPONSE||||10^6 ORGANISMS/MG|PR||%|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|PROXY|ADJUDICATOR 3|U|5||7||SCREENING|1960-01-07||||1968-12-03||1970-08-05|1963-03-01||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||BESTRESP|BEST OVERALL RESPONSE||||GPS U|CCR||KM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|Y|STUDY SUBJECT|NEUROLOGIST 1|Y|5||7||OBSERVATION|1960-03-17||||1973-07-23||1970-08-30|1968-01-31||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MEQ/ML|MCR||MEQ/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|STUDY SUBJECT|NEUROLOGIST 2|N|1||38||LONG-TERM FOLLOW-UP|1968-08-08||||1972-11-24||1960-09-01|1973-09-03||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|2||||||TRGRESP|TARGET RESPONSE||||MEQ/L|CA125 50% RESPONSE||GTT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||CONTINUATION TREATMENT|1960-05-23||||1961-12-21||1973-03-04|1960-08-01||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|1||||||MOLRESP|MOLECULAR RESPONSE||||YD|SCR||PACK YEAR|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|INDEPENDENT ASSESSOR|READER 2|U|2||58||TREATMENT|1972-09-20||||1967-01-10||1962-07-31|1960-01-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|2||||||NTRGRESP|NON-TARGET RESPONSE||||1/(S*KPA)|SMD||BOWL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|PROXY|NEUROLOGIST 1|NA|2||58||INDUCTION TREATMENT|1969-11-23||||1961-09-17||1966-03-31|1963-04-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|1||||||BESTRESP|BEST OVERALL RESPONSE||||WATT|CYTOGENETIC MINOR RESPONSE||L/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|PARENT|MICROSCOPIST 2|N|3||39||CONTINUATION TREATMENT|1973-03-19||||1968-08-30||1972-01-25|1972-03-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||G/CAGE/DAY|IPR||ML/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|CAREGIVER|DERMATOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1971-05-23||||1972-02-21||1961-08-05|1971-08-11||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PLUG|DISEASE TRANSFORMATION||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|4||88||BASELINE|1960-04-04||||1963-02-05||1971-09-07|1960-01-31||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UL/KG/DAY|ABSENT MORPHOLOGIC RESPONSE||KG/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|VENDOR|FORENSIC PATHOLOGIST|N|4||88||OBSERVATION|1967-06-10||||1965-11-18||1969-05-26|1966-07-18||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMHG*MIN/L|CCR||SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|FAMILY MEMBER|MICROSCOPIST|NA|5||7||CONTINUATION TREATMENT|1972-08-08||||1964-04-29||1973-06-29|1972-08-18||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|981B890E-1257-4F04-A974-6006401F78CC|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KBQ|IMPROVED||PHERESIS UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|INVESTIGATOR|RADIOLOGIST 2|NA|5||7||TREATMENT|1960-09-20||||1968-07-01||1967-12-21|1971-06-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||NEWLIND|NEW LESION INDICATOR||||MOL/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|INTERVIEWER|ADJUDICATOR 3|NA|1||38||CONTINUATION TREATMENT|1970-06-14||||1961-11-19||1970-04-23|1969-10-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KS|PR-CT||JDF UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1968-05-27||||1969-06-28||1972-09-10|1965-01-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||DPM|MORPHOLOGIC CRI||UV|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|2||58||SCREENING|1969-05-16||||1964-08-30||1968-01-28|1965-06-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||STRUSTAT|STEROID USE STATUS||||CI/G|RELAPSED DISEASE FROM CR||UG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|PROXY|INTERNIST|U|2||58||INDUCTION TREATMENT|1968-10-27||||1971-03-18||1971-05-10|1966-09-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||LIVRRESP|LIVER RESPONSE||||NMOL/L/MIN|NON-PD||S^-1(%O2)^-1|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|3||39||FOLLOW-UP|1963-12-13||||1968-08-04||1969-03-03|1967-01-17||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MOSM/KG|MOLECULAR MAJOR RESPONSE||CAPFUL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|FAMILY MEMBER|ADJUDICATOR 2|NA|3||39||BLINDED TREATMENT|1960-10-12||||1960-11-01||1960-07-27|1972-07-01||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||TMRESP|TUMOR MARKER RESPONSE||||TUBERCULIN UNIT/ML|RELAPSED DISEASE||DNA COPIES/UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|4||88||BASELINE|1973-04-24||||1969-03-30||1973-03-14|1968-11-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL/KG/DAY|CYTOGENETIC MINIMAL RESPONSE||NG/MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|FAMILY MEMBER|UROLOGIST|N|4||88||INDUCTION TREATMENT|1973-06-06||||1968-05-24||1960-10-21|1971-07-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/G/DAY|INDETERMINATE RESPONSE||U/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|VENDOR|MICROSCOPIST|U|5||7||BLINDED TREATMENT|1961-04-15||||1965-02-12||1965-12-11|1964-07-13||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||BESTRESP|BEST OVERALL RESPONSE||||SV|IMMUNOPHENOTYPIC CR||IU/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|INVESTIGATOR|FORENSIC PATHOLOGIST|U|5||7||BASELINE|1965-01-17||||1962-12-01||1964-10-25|1964-10-08||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||BONERESP|BONE RESPONSE||||BU|COMPLETE MRD RESPONSE||MG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|INDEPENDENT ASSESSOR|READER 2|Y|1||38||BASELINE|1964-11-06||||1960-05-19||1961-08-20|1961-11-28||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||RDIORESP|RADIOLOGIC RESPONSE||||BAG|CYTOGENETIC PR||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||CONTINUATION TREATMENT|1961-06-20||||1960-05-20||1960-03-23|1967-01-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PMOL/DAY|MOLECULAR CR||GMFI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|ADJUDICATOR|DERMATOLOGIST|NA|2||58||FOLLOW-UP|1961-01-15||||1962-07-04||1965-05-01|1969-03-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PACK YEAR|PMR||DMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|STUDY SUBJECT|MICROSCOPIST|NA|2||58||WASHOUT|1964-05-27||||1969-02-20||1962-10-25|1970-02-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/MBP|CMR||LOG10 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||OPEN LABEL TREATMENT|1965-06-04||||1962-08-05||1973-01-12|1965-10-28||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MEQ/UL|RELAPSED DISEASE||M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1971-11-16||||1967-02-03||1963-05-25|1972-08-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||METSIND|METASTATIC INDICATOR||||10^6 COPIES/ML|PARTIAL MORPHOLOGIC RESPONSE||BP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|STUDY SUBJECT|NEUROLOGIST 1|NA|4||88||OBSERVATION|1960-06-01||||1967-11-28||1965-12-13|1969-10-03||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||NMOL/ML/MIN|DECREASED||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|SIGNIFICANT OTHER|READER 2|Y|4||88||TREATMENT|1967-06-21||||1969-01-07||1967-02-11|1968-08-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||TMRESP|TUMOR MARKER RESPONSE||||UCI/KG|NON-PD||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|5||7||BASELINE|1960-12-08||||1962-03-04||1968-07-07|1966-04-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOSM/L|MR||PM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|FAMILY MEMBER|READER 1|Y|5||7||TREATMENT|1961-01-25||||1966-12-16||1973-08-13|1960-09-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MM|RELAPSED DISEASE FROM CR OR PR||G/CAGE/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|SPOUSE|PEDIATRIC NEUROLOGIST|Y|1||38||OBSERVATION|1961-08-03||||1962-02-16||1960-08-18|1966-06-22||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||OVRLRESP|OVERALL RESPONSE||||UG/M2/MIN|CA125 75% RESPONSE||10^9 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|ADJUDICATION COMMITTEE|UROLOGIST|NA|1||38||FOLLOW-UP|1972-10-29||||1971-08-15||1961-07-25|1972-09-15||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/KG/MIN|MR||EVENTS|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|FRIEND|PATHOLOGIST|U|2||58||BASELINE|1972-10-18||||1972-12-15||1966-05-01|1967-09-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/L FEU|PSA PROGRESSION||FL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|NA|INTERVIEWER|CARDIOLOGIST|U|2||58||SCREENING|1967-12-01||||1968-06-18||1969-10-10|1960-01-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BQ/MG|PCR||10^6 IU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|SIGNIFICANT OTHER|RATER 2|N|3||39||CONTINUATION TREATMENT|1960-09-22||||1970-09-11||1968-01-01|1962-09-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||SPRAY|MRD RELAPSE||/40 HPFS|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|FRIEND|ADJUDICATOR 3|NA|3||39||RUN-IN|1964-10-29||||1972-04-14||1969-07-19|1966-11-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||NTRGRESP|NON-TARGET RESPONSE||||KM/H|CYTOGENETIC MINOR RESPONSE||KG/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|GUARDIAN|OPTOMETRIST|NA|4||88||INDUCTION TREATMENT|1966-10-30||||1969-02-26||1969-03-19|1965-12-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||BESTRESP|BEST OVERALL RESPONSE||||KG/CM2|PARTIAL MORPHOLOGIC RESPONSE||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|SPOUSE|MICROSCOPIST 2|Y|4||88||OBSERVATION|1965-09-07||||1960-04-28||1968-11-20|1963-07-05||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||SBE/ML|RELAPSED DISEASE FROM CR OR PR||KDA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|FRIEND|ENDOCRINOLOGIST|NA|5||7||FOLLOW-UP|1972-03-20||||1966-10-07||1972-05-12|1973-01-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IU/DL|ISD||MMOL2/L2|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|ADJUDICATION COMMITTEE|ONCOLOGIST|Y|5||7||TREATMENT|1961-08-20||||1961-01-13||1971-08-20|1967-02-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||LENS|OPTIMAL MORPHOLOGIC RESPONSE||MU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|INTERVIEWER|ONCOLOGIST 2|NA|1||38||BASELINE|1970-03-15||||1966-05-31||1973-05-18|1973-08-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CFU/ML|CRI||MMOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|1||38||WASHOUT|1965-05-27||||1962-12-08||1967-01-28|1964-05-31||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L/MIN|SMD||10^4 CFU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|PROXY|NEUROLOGIST 2|NA|2||58||SCREENING|1969-05-05||||1968-04-19||1966-04-30|1966-12-19||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^7 PFU|CPR||V/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|FAMILY MEMBER|INTERNIST|NA|2||58||WASHOUT|1962-01-19||||1964-12-21||1961-01-29|1962-11-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||NEWLIND|NEW LESION INDICATOR||||F|MORPHOLOGIC CRI||10^3 ORGANISMS/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|STUDY SUBJECT|HEMATOLOGIST|U|3||39||CONTINUATION TREATMENT|1970-12-05||||1968-07-06||1972-07-04|1972-01-01||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||BESTRESP|BEST OVERALL RESPONSE||||EID 50/DOSE|SCR||10^3 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||LONG-TERM FOLLOW-UP|1970-11-25||||1962-08-27||1973-03-18|1967-03-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||GRAIN|NPR||MIN/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|ADJUDICATOR|ONCOLOGIST 1|Y|4||88||INDUCTION TREATMENT|1964-01-20||||1968-09-16||1960-03-15|1962-04-12||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/DL|CA125 75% RESPONSE||FL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1960-06-05||||1969-06-27||1968-11-03|1961-03-03||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||EVENTS|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||G/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|5||7||OPEN LABEL TREATMENT|1970-04-07||||1972-11-02||1965-12-27|1971-05-10||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||OVRLRESP|OVERALL RESPONSE||||UMOL/H/MMOL|NON-ICR/NON-IUPD||HZ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|SIBLING|PHYSIOTHERAPIST|U|5||7||SCREENING|1960-07-29||||1960-03-28||1968-07-28|1960-02-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/UG|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|GUARDIAN|ADJUDICATOR 2|U|1||38||RUN-IN|1967-03-28||||1966-05-11||1971-07-12|1970-11-28||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UMOL/KG/MIN|CMR||MCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|INVESTIGATOR|MICROSCOPIST|U|1||38||WASHOUT|1971-12-10||||1966-02-17||1969-07-19|1966-10-10||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|1||||||BONERESP|BONE RESPONSE||||KBQ/UL|PR-CT||MCI/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|N|ADJUDICATOR|MICROSCOPIST|N|2||58||OBSERVATION|1965-12-01||||1969-05-16||1971-01-27|1969-04-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||BEAM BREAKS|ICPD||UL/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|STUDY SUBJECT|ONCOLOGIST 2|NA|2||58||INDUCTION TREATMENT|1969-11-23||||1962-11-29||1971-05-27|1972-06-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||POINT|INCREASED||CY/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|DOMESTIC PARTNER|ONCOLOGIST|N|3||39||CONTINUATION TREATMENT|1960-05-18||||1965-11-03||1967-01-23|1973-01-24||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|2||||||TRGRESP|TARGET RESPONSE||||MBQ/UL|NED||UL/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|STUDY SUBJECT|ADJUDICATOR 2|Y|3||39||BLINDED TREATMENT|1968-01-02||||1972-12-27||1969-11-15|1963-08-23||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|1||||||STRUSTAT|STEROID USE STATUS||||AG|WORSENED||DROP|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1964-05-05||||1970-09-07||1972-02-15|1970-01-27||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|2||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/DAY|CA125 75% RESPONSE||BREATHS/30S|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|PARENT|ADJUDICATOR 3|U|4||88||CONTINUATION TREATMENT|1968-06-02||||1962-11-22||1969-05-26|1972-02-14||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|1||||||CLINRESP|CLINICAL RESPONSE||||10^9 ORGANISMS/G|VGPR||ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|GUARDIAN|CLINICAL PATHOLOGIST|U|5||7||FOLLOW-UP|1965-02-10||||1969-11-28||1969-06-17|1960-04-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7F014394-ABE2-45F8-891F-2DE808762532|2||||||NEWLIND|NEW LESION INDICATOR||||ROENTGEN|MINOR PATHOLOGIC RESPONSE||SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|CHILD|RATER 2|N|5||7||WASHOUT|1964-11-03||||1962-06-07||1960-06-19|1962-08-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||METBRESP|METABOLIC RESPONSE||||CAPSULE|MORPHOLOGIC CRI||10^9/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|DOMESTIC PARTNER|MICROSCOPIST 2|Y|1||38||RUN-IN|1971-10-02||||1961-02-01||1961-08-30|1970-03-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||SPLNRESP|SPLEEN RESPONSE||||IU/ML|MOLECULAR CR||PFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|INVESTIGATOR|ONCOLOGIST 1|NA|1||38||WASHOUT|1969-06-16||||1969-06-24||1971-06-21|1968-05-07||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||METBRESP|METABOLIC RESPONSE||||PG/CELL|PMR||U/DL|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|2||58||BASELINE|1968-10-24||||1970-07-23||1961-04-01|1972-10-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^4 CFU|IPR||/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|2||58||RUN-IN|1961-07-31||||1963-04-19||1963-05-18|1969-05-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3 COPIES/ML|HI-N||KM|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|GUARDIAN|ONCOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1966-12-26||||1962-07-30||1971-09-11|1972-03-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||TMRESP|TUMOR MARKER RESPONSE||||DISK|WORSENED||V/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|U|CHILD|NEUROLOGIST 1|NA|3||39||OPEN LABEL TREATMENT|1965-07-01||||1969-09-23||1965-06-18|1962-03-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||CLINRESP|CLINICAL RESPONSE||||10^3 ORGANISMS/G|PD FROM PR||FRACTION OF 1|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|CAREGIVER|ADJUDICATOR 3|U|4||88||INDUCTION TREATMENT|1966-03-26||||1966-05-30||1964-03-25|1961-05-07||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 CCID 50/DOSE|CYTOGENETIC CR||KEV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||CONTINUATION TREATMENT|1969-09-08||||1973-08-08||1962-08-03|1971-01-01||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||OVRLRESP|OVERALL RESPONSE||||MMU/ML|CPR||BEL|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||OPEN LABEL TREATMENT|1970-03-06||||1972-11-30||1963-03-26|1967-10-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||OI50|MORPHOLOGIC CR||EU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|5||7||SCREENING|1960-03-28||||1964-07-09||1966-03-24|1965-07-13||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/40 HPFS|PSEUDORESPONSE||10^6 U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|GUARDIAN|FORENSIC PATHOLOGIST|U|1||38||BASELINE|1969-01-22||||1962-06-15||1960-10-02|1960-05-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||METSIND|METASTATIC INDICATOR||||IU/ML|CR-CT||HOUNSFIELD UNIT|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|FAMILY MEMBER|READER 1|Y|1||38||FOLLOW-UP|1964-12-24||||1962-07-12||1971-08-18|1969-07-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TESLA|PD-CT||G/KG|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|PARENT|RATER|Y|2||58||SCREENING|1967-01-01||||1970-01-20||1964-09-21|1963-06-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PIXELS/CM|OPTIMAL MORPHOLOGIC RESPONSE||/VF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|FAMILY MEMBER|RATER|Y|2||58||TREATMENT|1964-04-25||||1960-01-03||1969-08-22|1963-06-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||BESTRESP|BEST OVERALL RESPONSE||||ML/MMHG|NON-ICR/NON-IUPD||DEG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|SIGNIFICANT OTHER|ADJUDICATOR 2|U|3||39||RUN-IN|1962-02-27||||1970-05-06||1966-05-17|1972-01-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||SACHET|MORPHOLOGIC CR||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|GUARDIAN|MICROSCOPIST 3|N|3||39||WASHOUT|1962-06-19||||1971-06-30||1970-11-09|1970-10-17||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||METSIND|METASTATIC INDICATOR||||DPM/100MG|MORPHOLOGIC CRI||MMOL/MIN/KPA/L|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|SPOUSE|INTERNIST|Y|4||88||OPEN LABEL TREATMENT|1972-04-04||||1966-05-21||1971-01-15|1971-04-05||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||LIVRRESP|LIVER RESPONSE||||UU/DL|CR||NGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|FAMILY MEMBER|ADJUDICATOR 1|NA|4||88||CONTINUATION TREATMENT|1962-03-24||||1965-04-29||1965-11-24|1960-08-30||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||METSIND|METASTATIC INDICATOR||||/4.0 ML|STABLE||/HPF|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|SPOUSE|READER 3|NA|5||7||OBSERVATION|1965-12-04||||1963-09-01||1969-08-08|1967-03-05||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||METBRESP|METABOLIC RESPONSE||||UIU/DL|NR||UU/DL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|PROXY|READER|N|5||7||OBSERVATION|1968-08-13||||1965-05-19||1971-01-14|1967-10-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CI/UG|HI-P||U/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|FAMILY MEMBER|MICROSCOPIST 1|Y|1||38||FOLLOW-UP|1966-08-03||||1971-03-28||1962-07-08|1971-04-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML|WORSENED||MG/ML/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|STUDY SUBJECT|OPTOMETRIST|NA|1||38||INDUCTION TREATMENT|1961-08-18||||1960-12-30||1967-08-10|1968-12-29||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NMOL BCE/MMOL|MORPHOLOGIC CR||PELLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|PARENT|NEUROLOGIST|U|2||58||SCREENING|1968-02-22||||1963-05-23||1964-12-22|1966-10-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||CLINRESP|CLINICAL RESPONSE||||/SEC|HI-E||DEG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|2||58||RUN-IN|1967-05-20||||1971-10-29||1966-03-05|1969-09-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||INHALATION|ICR||TSP EQ|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|INDEPENDENT ASSESSOR|READER|N|3||39||RUN-IN|1961-03-20||||1961-03-22||1965-01-27|1960-01-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||RAD|MRD NEGATIVITY||IU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|HEALTH CARE PROFESSIONAL|RATER 1|U|3||39||FOLLOW-UP|1967-08-01||||1970-01-30||1973-08-13|1965-01-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||BONERESP|BONE RESPONSE||||IU/L|PMR||/500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|SIGNIFICANT OTHER|UROLOGIST|N|4||88||RUN-IN|1963-05-23||||1961-05-18||1973-08-01|1969-04-10||DURING||AFTER|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||SPLNRESP|SPLEEN RESPONSE||||UGEQ|MRD RELAPSE||FEU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|PARENT|MICROSCOPIST 3|NA|4||88||RUN-IN|1963-06-26||||1967-10-24||1968-08-29|1963-12-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PFU/DOSE|COMPLETE MRD RESPONSE||LOG10 COPIES/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|STUDY SUBJECT|ONCOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1964-06-03||||1960-02-09||1972-07-05|1962-12-04||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MOL/MOL|CRI||MM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|DOMESTIC PARTNER|MICROSCOPIST 3|N|5||7||LONG-TERM FOLLOW-UP|1966-10-23||||1966-09-30||1966-10-07|1963-05-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||VOXEL|PD||CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|CLINICAL STUDY SPONSOR|READER 3|N|1||38||FOLLOW-UP|1963-12-30||||1971-10-29||1968-03-05|1966-12-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||METSIND|METASTATIC INDICATOR||||LOG10 CFU/G|MOLECULAR CR||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|ADJUDICATOR|RADIOLOGIST 1|Y|1||38||RUN-IN|1967-09-18||||1964-01-06||1964-05-31|1960-07-02||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||OVRLRESP|OVERALL RESPONSE||||/5X10^4 WBC|PMD||KCAL/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|FRIEND|READER|U|2||58||RUN-IN|1973-02-27||||1973-02-25||1968-03-14|1960-03-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||NTRGRESP|NON-TARGET RESPONSE||||UMOL/L/H|CA125 75% RESPONSE||G/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|INVESTIGATOR|READER|N|2||58||RUN-IN|1962-10-18||||1971-03-14||1960-02-10|1963-05-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PL|PMR||10^9 ORGANISMS/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|STUDY SUBJECT|MICROSCOPIST|Y|3||39||OPEN LABEL TREATMENT|1970-07-31||||1973-03-11||1964-01-24|1969-07-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||IU/MMOL|PD FROM PR||MM/2H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|SIBLING|RADIOLOGIST 2|Y|3||39||SCREENING|1971-07-07||||1962-02-26||1964-04-22|1962-04-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||BONERESP|BONE RESPONSE||||CM/MIN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||KPA/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1966-12-02||||1970-02-01||1965-04-24|1970-08-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/MM2|PD FROM PR||HENRY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|SIGNIFICANT OTHER|ONCOLOGIST 2|U|4||88||OBSERVATION|1961-11-06||||1967-02-20||1971-08-06|1960-02-16||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||LIVRRESP|LIVER RESPONSE||||UMOL/DL|DECREASED||GPL U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|PROXY|RADIOLOGIST 2|Y|5||7||FOLLOW-UP|1970-02-18||||1965-11-16||1964-02-24|1965-12-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MILE|PSA PROGRESSION||CPM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|INDEPENDENT ASSESSOR|UROLOGIST|N|5||7||BLINDED TREATMENT|1972-08-30||||1968-08-09||1961-12-12|1962-11-16||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||LIVRRESP|LIVER RESPONSE||||IU/L|PMR||PACK YEAR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|INDEPENDENT ASSESSOR|RATER|N|1||38||INDUCTION TREATMENT|1965-10-30||||1967-03-30||1971-09-03|1960-11-27||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MIU/L|PD/RELAPSE AFTER HI||BAU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|INDEPENDENT ASSESSOR|OPTOMETRIST|N|1||38||BLINDED TREATMENT|1972-04-06||||1968-04-18||1962-02-18|1964-11-17||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||BESTRESP|BEST OVERALL RESPONSE||||CAPSULE|RELAPSED DISEASE FROM CR||/200 HPFS|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|INTERVIEWER|CLINICAL PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1973-04-29||||1972-06-10||1963-02-28|1971-12-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/MG|CA125 75% RESPONSE||ELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CAREGIVER|INTERNIST|NA|2||58||WASHOUT|1971-10-05||||1972-12-27||1963-01-05|1961-12-12||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MU/L|MOLECULAR MAJOR RESPONSE||G/ANIMAL/WK|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|CHILD|MICROSCOPIST 2|NA|3||39||CONTINUATION TREATMENT|1961-01-13||||1960-03-26||1972-04-24|1973-02-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DAYS/WK|CA125 50% RESPONSE||JDF UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|SIGNIFICANT OTHER|READER 2|N|3||39||INDUCTION TREATMENT|1961-06-20||||1965-04-11||1968-06-13|1962-03-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||CLINRESP|CLINICAL RESPONSE||||CI/G|CR-CT||AMFI|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|SIBLING|FORENSIC PATHOLOGIST|NA|4||88||RUN-IN|1966-02-18||||1964-11-22||1961-09-22|1963-09-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||COPIES/UL|MAJOR PATHOLOGIC RESPONSE||/4.0 ML|NOT DONE|||LIKERT SCALE 3-POINT|U|N|U|CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|4||88||SCREENING|1971-07-14||||1969-10-22||1963-11-07|1970-12-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||NTRGRESP|NON-TARGET RESPONSE||||DRAM|IMPROVED||10^7 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|5||7||SCREENING|1971-02-24||||1961-07-24||1967-11-04|1970-11-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||NTRGRESP|NON-TARGET RESPONSE||||CD|MORPHOLOGIC CR||UG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|5||7||BASELINE|1964-11-08||||1963-08-11||1960-10-11|1972-06-12||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||OVRLRESP|OVERALL RESPONSE||||HEP|DISEASE TRANSFORMATION||PMOL/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||INDUCTION TREATMENT|1966-10-21||||1961-05-14||1963-04-26|1968-11-20||DURING||DURING|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/DAY|EQUIVOCAL||/10^3|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|CAREGIVER|FORENSIC PATHOLOGIST|NA|1||38||INDUCTION TREATMENT|1967-12-12||||1965-08-16||1967-11-17|1967-11-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||AMPULE|CYTOGENETIC PR||CAPSULE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|2||58||RUN-IN|1962-10-20||||1966-12-06||1968-02-16|1968-02-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||NEWLPROG|NEW LESION PROGRESSION||||BEL|PCR||KG/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|FAMILY MEMBER|UROLOGIST|U|2||58||BLINDED TREATMENT|1972-02-08||||1962-07-27||1960-02-10|1969-07-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||MOLRESP|MOLECULAR RESPONSE||||DYN|PMD||UG/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|U|FAMILY MEMBER|MICROSCOPIST 2|U|3||39||BLINDED TREATMENT|1966-01-23||||1960-09-13||1969-09-07|1960-05-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||LIVRRESP|LIVER RESPONSE||||NGEQ/L|ICR||U/L|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|DOMESTIC PARTNER|READER 3|U|3||39||TREATMENT|1969-03-13||||1969-08-29||1965-04-02|1972-05-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||METBRESP|METABOLIC RESPONSE||||10^6 ORGANISMS/ML|FAVORABLE RESPONSE||DIOPTER|NOT DONE|||LIKERT SCALE 7-POINT|N|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|4||88||RUN-IN|1961-10-30||||1971-09-22||1972-04-01|1964-08-20||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||CLINRESP|CLINICAL RESPONSE||||/CMH2O|MORPHOLOGIC LEUKEMIA-FREE STATE||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|VENDOR|ENDOCRINOLOGIST|N|4||88||INDUCTION TREATMENT|1965-01-18||||1963-09-29||1968-05-21|1965-01-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||KUSP|CA125 50% RESPONSE||ANSON U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|SPOUSE|ONCOLOGIST|NA|5||7||INDUCTION TREATMENT|1962-12-02||||1966-07-01||1968-08-15|1961-10-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||TMRESP|TUMOR MARKER RESPONSE||||CIGAR|HI-N||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|Y|ADJUDICATOR|OPHTHALMOLOGIST|U|5||7||OPEN LABEL TREATMENT|1967-12-04||||1965-08-15||1968-01-31|1964-01-17||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||/4.0 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||CONTINUATION TREATMENT|1970-10-15||||1964-11-01||1962-11-26|1968-04-05||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||F|RELAPSED DISEASE FROM CR||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|CAREGIVER|CLINICAL PATHOLOGIST|Y|1||38||FOLLOW-UP|1962-09-30||||1964-05-17||1962-03-08|1973-04-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||WAFER|MR||/2500 WBC|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|ADJUDICATION COMMITTEE|READER|N|2||58||WASHOUT|1971-02-02||||1967-03-27||1970-01-19|1969-10-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||100 IU/ML|MRD RELAPSE||G/M2/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|ADJUDICATOR|OTOLARYNGOLOGIST|Y|2||58||WASHOUT|1965-04-13||||1970-01-01||1965-10-20|1966-02-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/10^5|CCR||10^6 IU|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|3||39||RUN-IN|1965-10-07||||1964-08-13||1968-02-08|1960-08-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^7 CFU/ML|NR||FMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|GUARDIAN|READER 1|N|3||39||INDUCTION TREATMENT|1966-12-02||||1973-04-21||1964-02-17|1970-04-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||L/MIN|CYTOGENETIC PR||KDA|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|FRIEND|ADJUDICATOR 1|U|4||88||CONTINUATION TREATMENT|1960-06-07||||1969-09-10||1966-01-26|1966-06-19||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL/L/H|PSA PROGRESSION||KCAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|CLINICAL RESEARCH COORDINATOR|READER 1|NA|4||88||WASHOUT|1970-11-03||||1972-08-31||1963-05-22|1969-02-17||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||L/DAY|MRD RELAPSE||IU/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|PROXY|READER 2|N|5||7||OPEN LABEL TREATMENT|1967-05-05||||1965-12-02||1962-01-04|1973-02-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||SYRINGE|SMD||G/ANIMAL/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|FRIEND|OPHTHALMOLOGIST|NA|5||7||SCREENING|1964-03-20||||1969-04-08||1965-09-04|1970-10-08||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6 RNA COPIES/ML|MOLECULAR CR||/MBP|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1972-11-29||||1961-10-01||1961-04-25|1970-12-31||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||CLINRESP|CLINICAL RESPONSE||||MM/2H|EQUIVOCAL||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||OBSERVATION|1967-03-09||||1971-02-14||1960-04-07|1964-08-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMOL/G|MOLECULAR MAJOR RESPONSE||ENZYME U/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|FAMILY MEMBER|ADJUDICATOR 2|N|2||58||WASHOUT|1971-01-21||||1961-08-07||1966-01-21|1973-08-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KG/M2|VGPR||TORR|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1965-04-11||||1972-04-06||1961-01-14|1971-02-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||SPLNRESP|SPLEEN RESPONSE||||IU/MG|NE||CM H2O|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|CAREGIVER|NEUROLOGIST|N|3||39||OBSERVATION|1969-01-24||||1961-06-17||1969-12-27|1969-06-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DNA COPIES/UG|COMPLETE MRD RESPONSE||PACK YEAR|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|GUARDIAN|MICROSCOPIST 2|Y|3||39||CONTINUATION TREATMENT|1963-09-06||||1969-05-26||1970-02-07|1964-04-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||FL|NPR||MOL/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|SIGNIFICANT OTHER|RATER|N|4||88||TREATMENT|1970-05-21||||1967-09-11||1967-07-10|1963-05-02||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DAMOL/L|ABSENT MORPHOLOGIC RESPONSE||FMOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|4||88||FOLLOW-UP|1966-04-10||||1973-08-13||1964-07-03|1962-05-31||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PMOL/DAY|ISD||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|INTERVIEWER|MICROSCOPIST 3|U|5||7||CONTINUATION TREATMENT|1968-08-23||||1960-06-25||1961-12-27|1972-05-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MILE|SMD||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|5||7||WASHOUT|1961-07-28||||1963-09-22||1968-07-29|1964-03-31||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||LIVRRESP|LIVER RESPONSE||||U/ANIMAL|IMMUNOPHENOTYPIC CR||ML/CM|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1||38||FOLLOW-UP|1966-05-18||||1960-02-27||1962-07-02|1966-06-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||AMU|RELAPSED DISEASE FROM CR||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|CLINICAL RESEARCH ASSOCIATE|READER|NA|1||38||CONTINUATION TREATMENT|1960-04-04||||1964-06-02||1970-04-03|1964-08-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PNU/ML|DISEASE TRANSFORMATION||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||CONTINUATION TREATMENT|1963-08-21||||1972-06-28||1970-11-18|1960-01-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DIOPTER|HI-N||TESLA|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|2||58||BLINDED TREATMENT|1962-10-15||||1962-04-29||1961-12-21|1971-08-29||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOSM/KG|CRI||UMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|SIBLING|NEUROLOGIST 1|Y|3||39||WASHOUT|1961-04-07||||1967-03-01||1966-05-27|1961-01-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||TMRESP|TUMOR MARKER RESPONSE||||PACKET|NON-PD||UG/M2/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|FRIEND|ADJUDICATOR 3|U|3||39||INDUCTION TREATMENT|1973-07-01||||1973-07-13||1971-03-01|1973-04-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||BONERESP|BONE RESPONSE||||RATIO|IMPROVED||HOMEOPATHIC DILUTION|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||BLINDED TREATMENT|1965-02-08||||1963-02-15||1973-08-21|1967-03-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||OSM|PDU||MG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|4||88||BLINDED TREATMENT|1963-11-05||||1960-11-13||1973-04-27|1962-02-05||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||NEWLPROG|NEW LESION PROGRESSION||||GY|RELAPSED DISEASE||CAPSULE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|5||7||WASHOUT|1961-07-14||||1971-01-26||1971-07-08|1972-01-28||AFTER||DURING|
TRIAL STUDY 134XCP|RS|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^5/HPF|ABSENT MORPHOLOGIC RESPONSE||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|5||7||OBSERVATION|1968-10-31||||1960-10-08||1972-04-12|1965-06-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/S/M2|CA125 50% RESPONSE||UG/MOL|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|VENDOR|CARDIOLOGIST|U|1||38||INDUCTION TREATMENT|1965-02-06||||1961-07-13||1963-08-29|1962-01-01||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||IU/KG|PD FROM PR||WAFER|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|GUARDIAN|ADJUDICATOR 3|U|1||38||SCREENING|1966-04-18||||1969-06-16||1969-11-03|1971-11-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||ANATRESP|ANATOMIC RESPONSE||||MG/DL|NPR||DROP|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|SIBLING|PATHOLOGIST 1|Y|2||58||BASELINE|1962-02-28||||1966-08-04||1962-07-22|1967-02-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^10/L|SD||KG/CM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|2||58||SCREENING|1961-06-10||||1967-01-13||1963-03-31|1960-04-26||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||NEWLIND|NEW LESION INDICATOR||||UG/MOL|MCR||NU/CL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|SIGNIFICANT OTHER|MICROSCOPIST 2|N|3||39||LONG-TERM FOLLOW-UP|1965-01-20||||1965-05-24||1967-11-15|1970-03-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||NEWLIND|NEW LESION INDICATOR||||DAYS/WK|PD FROM PR||L/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|Y|CAREGIVER|ONCOLOGIST 1|Y|3||39||FOLLOW-UP|1969-11-23||||1960-04-03||1970-01-04|1966-04-30||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||/KG|MINOR PATHOLOGIC RESPONSE||MM3/MM2/YEAR|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||WASHOUT|1964-03-29||||1962-12-06||1963-08-08|1967-01-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||MOLRESP|MOLECULAR RESPONSE||||S^-1(%O2)^-1|INCREASED||MG/KG/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|4||88||SCREENING|1969-01-18||||1966-12-02||1961-04-21|1962-07-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/MG|PCR||LOG10 PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1965-04-13||||1967-10-04||1964-10-01|1971-06-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/DAY|MAJOR PATHOLOGIC RESPONSE||G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|Y|ADJUDICATOR|RADIOLOGIST|N|5||7||OBSERVATION|1961-06-15||||1961-02-21||1967-08-21|1960-06-28||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^9 CFU/ML|DISEASE TRANSFORMATION||PACKET|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|INDEPENDENT ASSESSOR|ADJUDICATOR 1|Y|1||38||OBSERVATION|1968-06-22||||1966-08-19||1961-06-06|1962-07-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/H|STABLE||AMOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|1||38||OPEN LABEL TREATMENT|1967-04-05||||1973-08-20||1963-01-22|1972-07-21||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KIU|VGPR||TABLET|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|FRIEND|FORENSIC PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1970-07-29||||1970-08-05||1964-11-08|1960-07-21||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||NEWLIND|NEW LESION INDICATOR||||10^7/L|PCR||M|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|INVESTIGATOR|MICROSCOPIST 1|NA|2||58||OBSERVATION|1968-08-07||||1969-07-13||1965-04-20|1964-08-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||BESTRESP|BEST OVERALL RESPONSE||||UM2|NON-QUANTIFIABLE MRD POSITIVITY||BE/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|PHYSIOTHERAPIST|U|3||39||OBSERVATION|1966-07-07||||1969-11-19||1968-11-25|1970-10-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CD/M2|IPR||MOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|SPOUSE|ADJUDICATOR 2|U|3||39||TREATMENT|1966-01-03||||1972-04-23||1962-04-18|1961-01-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||LIVRRESP|LIVER RESPONSE||||ATM|PD FROM PR||MPA|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|N|CAREGIVER|READER|Y|4||88||FOLLOW-UP|1967-08-15||||1960-11-30||1973-08-13|1971-06-21||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/2000 RBC|UNFAVORABLE RESPONSE||ARBITRARY U|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|NA|PROXY|MICROSCOPIST 2|NA|4||88||LONG-TERM FOLLOW-UP|1966-09-03||||1972-01-23||1967-08-16|1964-03-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||BONERESP|BONE RESPONSE||||10^6 CFU/G|ICPD||DAGU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|INVESTIGATOR|PATHOLOGIST|N|5||7||BASELINE|1972-11-05||||1962-03-02||1966-11-21|1967-11-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||CLINRESP|CLINICAL RESPONSE||||PATCH|CCR||IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|PARENT|OPHTHALMOLOGIST|NA|5||7||INDUCTION TREATMENT|1972-09-25||||1970-06-14||1965-07-02|1972-12-14||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^9 ORGANISMS/G|TREATMENT FAILURE||UG/G/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|U|INVESTIGATOR|READER 2|U|1||38||FOLLOW-UP|1965-07-04||||1960-03-16||1960-05-11|1967-04-15||DURING||AFTER|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CFU/G|PMR||POUCH|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|PARENT|NEUROLOGIST|Y|1||38||OBSERVATION|1962-11-22||||1968-09-22||1968-01-25|1966-03-01||DURING||AFTER|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|1||||||OVRLRESP|OVERALL RESPONSE||||MJOULE/CM2|PR-CT||10^9 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|2||58||FOLLOW-UP|1964-06-14||||1961-09-21||1960-12-04|1960-11-10||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|2||||||NTRGRESP|NON-TARGET RESPONSE||||KHZ|MCR||IU/KG/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2||58||SCREENING|1971-04-24||||1973-05-23||1966-09-02|1971-02-21||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||100 IU/ML|QUANTIFIABLE MRD POSITIVITY||UG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|CHILD|NEUROLOGIST 2|N|3||39||RUN-IN|1969-03-28||||1968-01-16||1964-07-03|1968-09-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|2||||||METSIND|METASTATIC INDICATOR||||10^3/L|RELAPSED DISEASE FROM CR||LX|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|U|SIGNIFICANT OTHER|OPTOMETRIST|U|3||39||RUN-IN|1966-12-18||||1970-01-08||1961-07-30|1963-07-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/ML/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||/CMH2O|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|FAMILY MEMBER|CARDIOLOGIST|NA|4||88||RUN-IN|1973-06-14||||1968-10-31||1971-03-31|1964-02-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|2||||||NEWLIND|NEW LESION INDICATOR||||MG/KG|DECREASED||UG/M2/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||SCREENING|1964-01-14||||1964-11-10||1967-09-29|1964-01-18||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/DOSE|CMR||UMOL/MG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|5||7||TREATMENT|1962-04-05||||1964-03-08||1972-07-12|1966-11-18||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|58661394-906E-43F3-8935-150DF240A04C|2||||||ANATRESP|ANATOMIC RESPONSE||||10^3 DNA COPIES/ML|CYTOGENETIC CR||DAYS/WK|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|FAMILY MEMBER|NEUROLOGIST|Y|5||7||WASHOUT|1973-06-12||||1968-08-23||1961-09-20|1972-01-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/MIN/1.73M2|QUANTIFIABLE MRD POSITIVITY||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|CHILD|OTOLARYNGOLOGIST|N|1||38||CONTINUATION TREATMENT|1972-05-07||||1966-01-22||1960-09-13|1971-02-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^7/L|WORSENED||UMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|CHILD|READER 1|N|1||38||BASELINE|1960-05-05||||1965-02-10||1962-07-02|1963-09-14||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||BESTRESP|BEST OVERALL RESPONSE||||MG/KG/WEEK|PSA PROGRESSION||SYRINGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|Y|PROXY|ADJUDICATOR 3|Y|2||58||WASHOUT|1970-02-11||||1966-03-19||1972-10-10|1964-11-19||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/10^12 RBC|TREATMENT FAILURE||MMHG/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|2||58||TREATMENT|1965-03-22||||1972-09-07||1964-11-10|1964-01-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||LIVRRESP|LIVER RESPONSE||||CMH2O/ML|ISD||DEG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|INTERVIEWER|ADJUDICATOR|Y|3||39||SCREENING|1972-12-28||||1968-08-02||1969-01-12|1972-10-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML/CM H2O|CA125 50% RESPONSE||KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|FRIEND|MICROSCOPIST 1|U|3||39||OBSERVATION|1963-10-21||||1964-09-19||1973-03-10|1968-11-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/UG|CPR||U/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|FAMILY MEMBER|HEMATOLOGIST|N|4||88||OPEN LABEL TREATMENT|1965-11-13||||1970-01-16||1971-11-12|1969-10-22||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ENZYME U/M2|PDU||SACHET|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|GUARDIAN|NEUROLOGIST 1|Y|4||88||WASHOUT|1965-12-10||||1961-02-26||1966-01-27|1973-04-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||METBRESP|METABOLIC RESPONSE||||DPM/100MG|PD FROM PR||MG/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|SPOUSE|READER 3|N|5||7||LONG-TERM FOLLOW-UP|1972-10-11||||1966-09-01||1961-11-03|1970-07-23||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/MIN|CYTOGENETIC MINIMAL RESPONSE||COULOMB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|VENDOR|CLINICAL PATHOLOGIST|N|5||7||OBSERVATION|1967-07-30||||1967-10-17||1972-10-28|1965-12-26||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||CFU/ML|MAJOR PATHOLOGIC RESPONSE||DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|ADJUDICATOR|NEUROLOGIST|Y|1||38||WASHOUT|1962-11-12||||1960-02-14||1967-01-21|1966-05-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||BOTTLE|MRD RELAPSE||MMOL/L|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|U|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|1||38||TREATMENT|1960-03-06||||1962-05-19||1968-03-19|1969-01-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||METBRESP|METABOLIC RESPONSE||||ML/BEAT|PSA PROGRESSION||UM|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|FRIEND|FORENSIC PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1970-12-03||||1968-11-01||1961-04-09|1969-07-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/KG/DAY|MRD NEGATIVITY||LINEAR FT*LB|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|SIGNIFICANT OTHER|RATER|NA|2||58||OPEN LABEL TREATMENT|1969-01-08||||1970-04-04||1965-05-15|1967-02-24||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||OVRLRESP|OVERALL RESPONSE||||FMOL/L|SMD||TBSP|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|3||39||CONTINUATION TREATMENT|1966-06-18||||1968-05-08||1968-11-29|1962-01-09||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||GPL U/ML|MCR||DEG/MM|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|CHILD|OTOLARYNGOLOGIST|N|3||39||WASHOUT|1961-04-30||||1960-05-29||1965-02-15|1965-06-14||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||U/G/H|EQUIVOCAL||%/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|FRIEND|ADJUDICATOR 3|NA|4||88||OPEN LABEL TREATMENT|1966-02-02||||1967-10-20||1970-05-15|1969-06-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ANTI-XA IU/ML|ICPD||MG/KG|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|SIBLING|UROLOGIST|N|4||88||FOLLOW-UP|1970-01-22||||1963-12-09||1967-03-06|1969-08-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||ANATRESP|ANATOMIC RESPONSE||||%|RELAPSED DISEASE FROM CR OR PR||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|VENDOR|INTERNIST|Y|5||7||OBSERVATION|1971-03-23||||1968-10-26||1960-05-17|1972-11-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HOUNSFIELD UNIT|PD-CT||PG/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|PROXY|PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1960-12-01||||1968-10-14||1968-12-17|1961-01-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CI/MG|NON-PD||MG/KG/WEEK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|FRIEND|HEMATOLOGIST|NA|1||38||OBSERVATION|1963-11-16||||1968-06-01||1967-05-10|1965-02-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||M|RELAPSED DISEASE||ML/G/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|FAMILY MEMBER|ADJUDICATOR 2|U|1||38||SCREENING|1968-06-17||||1967-05-20||1973-02-07|1963-01-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||POINT|PR-CT||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|ADJUDICATOR|ADJUDICATOR|Y|2||58||OPEN LABEL TREATMENT|1964-06-18||||1971-07-30||1972-12-08|1969-12-18||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||STRUSTAT|STEROID USE STATUS||||LX|DECREASED||PACKET|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1968-02-22||||1965-01-24||1966-05-31|1960-12-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||SPLNRESP|SPLEEN RESPONSE||||FOZ_US|CA125 50% RESPONSE||IU/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|PARENT|FORENSIC PATHOLOGIST|N|3||39||BASELINE|1964-10-04||||1969-09-15||1963-03-19|1972-09-17||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 DNA COPIES/ML|CYTOGENETIC MINIMAL RESPONSE||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|U|FAMILY MEMBER|READER 1|N|3||39||RUN-IN|1973-01-17||||1963-01-20||1965-07-08|1961-06-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||NTRGRESP|NON-TARGET RESPONSE||||/MBP|INCREASED||ANSON U|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|CLINICAL STUDY SPONSOR|RATER 1|Y|4||88||TREATMENT|1965-07-04||||1964-12-26||1961-10-08|1963-08-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||NEWLIND|NEW LESION INDICATOR||||TORR|CA125 75% RESPONSE||NKAT|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|PROXY|CARDIOLOGIST|U|4||88||BASELINE|1966-03-23||||1964-05-23||1962-03-23|1965-02-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TABLET|CYTOGENETIC MINIMAL RESPONSE||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|CAREGIVER|CLINICAL PATHOLOGIST|Y|5||7||BLINDED TREATMENT|1969-09-14||||1972-06-06||1968-02-14|1968-02-25||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MET*H|IMPROVED||ML/MIN/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|NA|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5||7||BASELINE|1967-05-19||||1973-08-24||1972-03-16|1963-01-02||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||STRUSTAT|STEROID USE STATUS||||ML/CAGE|CR||PHERESIS UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|INTERVIEWER|OPTOMETRIST|N|1||38||OPEN LABEL TREATMENT|1962-01-04||||1971-12-06||1967-05-10|1971-07-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||CLINRESP|CLINICAL RESPONSE||||CI/MG|CCR||VG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER|U|1||38||BLINDED TREATMENT|1963-03-28||||1963-05-01||1961-06-14|1962-04-07||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||BESTRESP|BEST OVERALL RESPONSE||||COPIES/UG|SMD||RFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|Y|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||CONTINUATION TREATMENT|1965-08-04||||1961-06-01||1972-04-04|1969-05-20||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||OVRLRESP|OVERALL RESPONSE||||U/KG|RELAPSED DISEASE||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|2||58||INDUCTION TREATMENT|1962-08-13||||1973-05-20||1971-06-17|1969-09-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MMOL/MOL|ABSENT MORPHOLOGIC RESPONSE||UG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|SPOUSE|READER|Y|3||39||BLINDED TREATMENT|1972-07-17||||1970-07-01||1972-11-05|1967-12-17||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||TRGRESP|TARGET RESPONSE||||AMU|DISEASE TRANSFORMATION||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|SIGNIFICANT OTHER|ONCOLOGIST|Y|3||39||OBSERVATION|1960-02-15||||1970-05-09||1961-04-27|1967-06-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||LIVRRESP|LIVER RESPONSE||||GPL U/ML|NPR||S/H|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|4||88||OBSERVATION|1969-10-23||||1970-02-05||1972-02-23|1963-09-03||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||TMRESP|TUMOR MARKER RESPONSE||||KG/CM2|CHR||CMH2O*S2/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||WASHOUT|1962-08-15||||1970-03-08||1963-11-18|1963-01-23||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||/KG|MOLECULAR MAJOR RESPONSE||EID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|CAREGIVER|RATER 1|U|5||7||LONG-TERM FOLLOW-UP|1967-08-30||||1973-06-29||1964-05-28|1964-11-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||NTRGRESP|NON-TARGET RESPONSE||||/SEC|PCR||10^6/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||FOLLOW-UP|1965-04-29||||1962-06-05||1962-05-02|1963-04-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||BESTRESP|BEST OVERALL RESPONSE||||MS2|EQUIVOCAL||UM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|FRIEND|DERMATOLOGIST|U|1||38||TREATMENT|1960-10-06||||1966-05-04||1971-02-28|1968-06-09||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^9/G|WORSENED||UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||BASELINE|1961-05-14||||1962-11-16||1970-07-03|1973-03-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MPH|PSEUDOPROGRESSION||10^6/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1960-07-09||||1963-12-23||1967-05-18|1964-06-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NMOL BCE/MMOL|PCR||PMOL/G|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|2||58||BASELINE|1969-05-26||||1963-04-20||1972-07-27|1971-02-14||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||NEWLIND|NEW LESION INDICATOR||||TRANSDUCING UNIT|MORPHOLOGIC CRI||PMOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|PARENT|ADJUDICATOR 2|Y|3||39||WASHOUT|1972-09-22||||1973-06-15||1968-11-10|1967-10-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TSP|CR||% INHIBITION|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|HEALTH CARE PROFESSIONAL|READER 1|U|3||39||OBSERVATION|1972-08-13||||1963-04-25||1967-01-04|1967-10-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||CLINRESP|CLINICAL RESPONSE||||H*%|CRI||MM/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|SPOUSE|PATHOLOGIST 1|U|4||88||BASELINE|1968-08-20||||1971-01-13||1963-10-08|1968-05-08||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||MOLRESP|MOLECULAR RESPONSE||||CYCLE/MIN|RELAPSED DISEASE FROM CR||UG/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|DOMESTIC PARTNER|RADIOLOGIST 1|NA|4||88||FOLLOW-UP|1969-06-27||||1965-02-09||1963-03-06|1971-08-25||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PSI|INDETERMINATE RESPONSE||NEWTON|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|DOMESTIC PARTNER|OTOLARYNGOLOGIST|Y|5||7||TREATMENT|1969-05-07||||1962-06-27||1971-08-11|1970-03-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NMOL/ML/MIN|NON-CR/NON-PD||PIXEL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|5||7||CONTINUATION TREATMENT|1973-01-24||||1967-05-27||1972-03-31|1962-11-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||STRUSTAT|STEROID USE STATUS||||MHZ|CHR||M3|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|PARENT|ADJUDICATOR 2|N|1||38||FOLLOW-UP|1962-08-17||||1967-09-13||1972-01-25|1962-06-30||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MAMP|CR||UM/S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|VENDOR|ENDOCRINOLOGIST|N|1||38||OPEN LABEL TREATMENT|1960-07-03||||1968-01-30||1965-01-20|1960-06-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||METSIND|METASTATIC INDICATOR||||H/WK|NON-QUANTIFIABLE MRD POSITIVITY||/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|INVESTIGATOR|RADIOLOGIST 2|U|2||58||BLINDED TREATMENT|1963-08-30||||1962-04-10||1970-06-24|1969-02-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||NEWLIND|NEW LESION INDICATOR||||DEG2|INDETERMINATE RESPONSE||CCID 50/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|DOMESTIC PARTNER|MICROSCOPIST 2|N|2||58||CONTINUATION TREATMENT|1961-02-28||||1962-02-21||1971-11-13|1968-09-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||NEWLIND|NEW LESION INDICATOR||||BQ/MG|STABLE||MCI/KG|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|INTERVIEWER|FORENSIC PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1967-02-07||||1968-04-12||1968-02-05|1964-02-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||/LSQN|CA125 50% RESPONSE||GRAVITATIONAL UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|STUDY SUBJECT|OPTOMETRIST|Y|3||39||INDUCTION TREATMENT|1970-12-08||||1968-02-13||1961-09-08|1964-11-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/DL|MORPHOLOGIC CR||MOL/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|INDEPENDENT ASSESSOR|INTERNIST|NA|4||88||BASELINE|1964-08-01||||1966-02-11||1961-09-07|1964-11-08||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ENZYME U|CR-CT||MV/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|4||88||OPEN LABEL TREATMENT|1967-09-12||||1960-01-27||1965-06-19|1970-11-05||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/MMHG/MIN/L|IPR||TBSP|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|INVESTIGATOR|INTERNIST|NA|5||7||SCREENING|1965-02-20||||1967-12-27||1971-02-07|1972-03-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||METBRESP|METABOLIC RESPONSE||||/MS|WORSENED||MV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|FAMILY MEMBER|ONCOLOGIST|U|5||7||TREATMENT|1962-05-29||||1972-05-12||1968-12-28|1965-07-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||NEWLPROG|NEW LESION PROGRESSION||||DEG/MM|PSEUDOPROGRESSION||L/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|INVESTIGATOR|PATHOLOGIST 2|NA|1||38||RUN-IN|1969-06-22||||1971-01-05||1960-12-24|1973-06-09||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||CYTORESP|CYTOGENETIC RESPONSE||||%/MIN|COMPLETE MRD RESPONSE||MET|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|CHILD|NEUROLOGIST 1|NA|1||38||WASHOUT|1973-02-09||||1963-05-20||1961-05-28|1970-02-04||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||RDIORESP|RADIOLOGIC RESPONSE||||AFU|IUPD||/HPF|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||RUN-IN|1971-08-06||||1973-05-06||1964-04-06|1961-07-02||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||LIVRRESP|LIVER RESPONSE||||MG/G/H|CHR||PHERESIS UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|INVESTIGATOR|OTOLARYNGOLOGIST|N|2||58||WASHOUT|1966-08-15||||1967-07-12||1965-09-13|1968-04-30||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||STRUSTAT|STEROID USE STATUS||||10^12 IU/L|CYTOGENETIC NO RESPONSE||10^6 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|CHILD|ADJUDICATOR 3|N|3||39||SCREENING|1969-03-30||||1961-03-18||1970-02-19|1961-10-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||BESTRESP|BEST OVERALL RESPONSE||||U/M2|SCR||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|Y|CAREGIVER|MICROSCOPIST 1|U|3||39||SCREENING|1964-10-30||||1968-10-29||1966-03-16|1971-08-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ABSORBANCE U|CPR||G/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|READER 2|Y|4||88||BASELINE|1962-12-26||||1968-04-20||1966-02-02|1965-11-09||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||EQ|VGPR||ENZYME U/G HB|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|PROXY|READER 2|NA|4||88||SCREENING|1969-10-10||||1967-09-21||1969-01-30|1960-02-02||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/KG/DAY|MR||TUBE|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|Y|FAMILY MEMBER|ADJUDICATOR 2|Y|5||7||OBSERVATION|1966-01-12||||1965-02-28||1971-11-11|1970-08-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PELLET|CYTOGENETIC PR||PFU/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|ADJUDICATION COMMITTEE|ONCOLOGIST|U|5||7||FOLLOW-UP|1971-01-25||||1968-02-27||1967-12-25|1971-02-11||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|1||||||OVRLRESP|OVERALL RESPONSE||||PKAT|VGPR||CIGARETTE|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|1||38||CONTINUATION TREATMENT|1968-06-17||||1965-02-24||1973-05-14|1962-08-12||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/H|PDU||ML/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|RATER|U|1||38||INDUCTION TREATMENT|1966-01-31||||1963-09-25||1964-01-15|1971-12-22||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|1||||||OVRLRESP|OVERALL RESPONSE||||MASK|PD-CT||G/CAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|CLINICAL STUDY SPONSOR|NEUROLOGIST|N|2||58||OPEN LABEL TREATMENT|1969-05-31||||1963-02-04||1962-05-22|1961-11-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MHZ|MRD RELAPSE||BOTTLE|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|INVESTIGATOR|RATER 2|U|2||58||FOLLOW-UP|1972-12-31||||1968-08-11||1973-03-06|1967-01-29||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ENZYME U/G HB|MOLECULAR CR||MV2/HZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|3||39||WASHOUT|1961-10-19||||1970-03-16||1970-10-31|1973-07-26||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CM/S|WORSENED||UEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|N|SPOUSE|RADIOLOGIST|U|3||39||RUN-IN|1969-04-15||||1969-07-16||1969-07-26|1971-09-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/L|IUPD||MMOL/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|READER 3|N|4||88||INDUCTION TREATMENT|1961-02-07||||1961-10-19||1967-09-09|1972-08-14||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||L/DAY|IPR||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|GUARDIAN|ADJUDICATOR 3|Y|4||88||BLINDED TREATMENT|1972-05-15||||1972-10-01||1973-03-20|1970-08-06||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|1||||||CLINRESP|CLINICAL RESPONSE||||%(W/V)|WORSENED||CI|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|5||7||RUN-IN|1960-10-12||||1972-09-29||1973-05-17|1962-04-30||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|DC79E350-1B89-4518-8B42-5858F5270928|2||||||TMRESP|TUMOR MARKER RESPONSE||||FMOL/L|PD/RELAPSE AFTER HI||NMOL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|VENDOR|READER 3|U|5||7||RUN-IN|1963-08-14||||1965-06-15||1966-02-11|1962-11-26||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||OVRLRESP|OVERALL RESPONSE||||V|CYTOGENETIC MINOR RESPONSE||NKAT/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|1||38||WASHOUT|1960-04-08||||1971-05-03||1963-09-12|1971-10-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NMOL/DAY|CYTOGENETIC MINOR RESPONSE||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|DOMESTIC PARTNER|ONCOLOGIST|N|1||38||OPEN LABEL TREATMENT|1973-05-24||||1964-02-09||1969-06-05|1968-11-06||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CD|CYTOGENETIC NO RESPONSE||PACK|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|ADJUDICATOR|RADIOLOGIST 2|Y|2||58||SCREENING|1965-11-17||||1969-09-25||1970-07-10|1968-06-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||IU/ML|PMR||/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|FAMILY MEMBER|RADIOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1966-01-14||||1961-04-14||1969-01-13|1972-03-24||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL BCE/NMOL|PR||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|FAMILY MEMBER|ENDOCRINOLOGIST|U|3||39||WASHOUT|1969-08-21||||1961-06-06||1964-01-10|1972-05-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||TRGRESP|TARGET RESPONSE||||10^8 PFU|ICR||EIA UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|N|DOMESTIC PARTNER|CARDIOLOGIST|U|3||39||INDUCTION TREATMENT|1965-05-03||||1972-06-04||1960-03-23|1963-10-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UL/KG/DAY|VGPR||/MS|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|4||88||OBSERVATION|1971-09-22||||1969-06-03||1972-08-25|1967-02-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||NEWLPROG|NEW LESION PROGRESSION||||OZ|IPR||ML/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|SIBLING|INTERNIST|Y|4||88||INDUCTION TREATMENT|1969-06-18||||1963-02-11||1967-12-27|1967-07-23||DURING||DURING|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||OVRLRESP|OVERALL RESPONSE||||10^3 DNA COPIES/ML|PCR||BEATS/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|FRIEND|ONCOLOGIST 1|N|5||7||WASHOUT|1964-12-17||||1967-10-07||1960-09-17|1965-10-29||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||LIVRRESP|LIVER RESPONSE||||IU/G HB|MRD RELAPSE||CMH2O/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|N|ADJUDICATOR|NEUROLOGIST 1|NA|5||7||OBSERVATION|1970-01-22||||1965-11-15||1969-02-01|1971-09-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||BONERESP|BONE RESPONSE||||MMOL/MIN/KPA|FAVORABLE RESPONSE||POUCH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|INVESTIGATOR|OPTOMETRIST|N|1||38||OBSERVATION|1960-03-07||||1960-10-25||1972-06-26|1961-03-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 PFU/ML|NON-QUANTIFIABLE MRD POSITIVITY||MPL U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|DOMESTIC PARTNER|ADJUDICATOR 3|NA|1||38||BLINDED TREATMENT|1969-02-05||||1966-06-23||1971-08-21|1968-04-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NM|MRD NEGATIVITY||KPA|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||BLINDED TREATMENT|1963-05-22||||1969-01-29||1960-10-12|1968-11-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||OVRLRESP|OVERALL RESPONSE||||USIEMENS|PARTIAL MORPHOLOGIC RESPONSE||UIU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|NA|2||58||CONTINUATION TREATMENT|1966-05-17||||1972-09-20||1971-11-07|1965-01-28||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||M/SEC|ABSENT MORPHOLOGIC RESPONSE||CMOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|UROLOGIST|N|3||39||INDUCTION TREATMENT|1961-01-15||||1962-08-02||1963-12-18|1962-08-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UMOL|IUPD||10^3 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|HEALTH CARE PROFESSIONAL|READER 1|NA|3||39||WASHOUT|1966-05-17||||1966-04-17||1967-11-07|1963-01-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||EID 50/ML|DISEASE TRANSFORMATION||/MONTH|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|N|4||88||BLINDED TREATMENT|1972-05-25||||1964-10-11||1961-08-06|1962-07-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UMOL/DL|NON-QUANTIFIABLE MRD POSITIVITY||PACK YEAR|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|4||88||SCREENING|1969-01-18||||1964-10-16||1968-01-17|1962-06-12||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NEEDLE GAUGE|CRI||KEV|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|PROXY|MICROSCOPIST 2|Y|5||7||WASHOUT|1971-02-17||||1967-11-03||1965-08-23|1963-02-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MS2|SD||PACKAGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|STUDY SUBJECT|RATER 1|NA|5||7||BASELINE|1968-06-15||||1967-04-30||1960-11-28|1967-12-11||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||METSIND|METASTATIC INDICATOR||||MOSM/L|QUANTIFIABLE MRD POSITIVITY||FMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|VENDOR|RADIOLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1967-05-31||||1966-04-14||1971-03-22|1969-11-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 ORGANISMS|MINOR PATHOLOGIC RESPONSE||FFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||OBSERVATION|1960-06-18||||1961-06-23||1965-12-21|1970-10-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||CLINRESP|CLINICAL RESPONSE||||NM|CYTOGENETIC PR||LOG10 ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|ADJUDICATION COMMITTEE|PATHOLOGIST|N|2||58||CONTINUATION TREATMENT|1970-06-16||||1960-09-20||1962-10-27|1966-02-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||SCM|PSA PROGRESSION||U/MMOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|SIGNIFICANT OTHER|ENDOCRINOLOGIST|NA|2||58||FOLLOW-UP|1962-04-19||||1969-11-28||1964-06-01|1966-07-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||CMOL|CYTOGENETIC PR||CM/S|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|READER|N|3||39||TREATMENT|1967-01-20||||1972-02-04||1973-07-30|1962-08-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||STRUSTAT|STEROID USE STATUS||||JOULE|RELAPSED DISEASE||NMOL BCE/MMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|3||39||INDUCTION TREATMENT|1963-12-17||||1973-04-29||1972-07-30|1967-12-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^5/HPF|MAJOR PATHOLOGIC RESPONSE||10^9 CFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|U|ADJUDICATOR|ADJUDICATOR 3|NA|4||88||BASELINE|1969-10-24||||1963-03-25||1964-04-14|1960-10-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^3 ORGANISMS/ML|MORPHOLOGIC CRI||GY/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|PROXY|OPHTHALMOLOGIST|NA|4||88||INDUCTION TREATMENT|1972-08-05||||1969-03-08||1970-05-03|1973-02-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||IU/G|PCR||CD/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|INTERVIEWER|READER|NA|5||7||CONTINUATION TREATMENT|1960-03-03||||1970-03-10||1960-11-29|1969-12-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MASK|PD-CT||APS U|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|FRIEND|ADJUDICATOR 3|Y|5||7||WASHOUT|1966-07-05||||1961-02-24||1966-06-08|1970-12-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||NTRGRESP|NON-TARGET RESPONSE||||1/(S*KPA)|MRD NEGATIVITY||MV2/HZ|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|1||38||INDUCTION TREATMENT|1967-03-23||||1973-04-27||1965-06-29|1963-06-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/4.0 ML|CPR||U/G|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|FRIEND|ONCOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1971-05-15||||1967-06-09||1966-08-12|1969-05-10||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MHZ|ABSENT MORPHOLOGIC RESPONSE||PM|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|INTERVIEWER|MICROSCOPIST 1|NA|2||58||SCREENING|1972-01-28||||1960-06-26||1969-11-01|1971-02-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||TRGRESP|TARGET RESPONSE||||UIU/DL|RELAPSED DISEASE FROM CR||/500 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|INTERVIEWER|MICROSCOPIST 3|NA|2||58||TREATMENT|1971-08-12||||1960-02-26||1971-02-11|1971-06-06||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||NEWLIND|NEW LESION INDICATOR||||AGU/ML|CR||ARBITRARY U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|3||39||RUN-IN|1967-10-25||||1960-09-03||1963-08-04|1960-12-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||SPLNRESP|SPLEEN RESPONSE||||LOG10 TCID 50/UL|SMD||PELLET|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|PROXY|FORENSIC PATHOLOGIST|NA|3||39||OBSERVATION|1970-10-31||||1969-08-25||1967-05-08|1971-06-17||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MV2/HZ|PARTIAL MORPHOLOGIC RESPONSE||L/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|ADJUDICATOR|RATER 1|N|4||88||TREATMENT|1969-10-25||||1965-09-10||1966-05-15|1972-12-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||METSIND|METASTATIC INDICATOR||||DNA COPIES/ML|PD-CT||10^9 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|SPOUSE|ADJUDICATOR|U|4||88||BLINDED TREATMENT|1970-05-13||||1967-09-28||1968-05-05|1965-12-11||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KCAL/DAY|HI-P||ML/CM H2O|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|N|ADJUDICATION COMMITTEE|UROLOGIST|Y|5||7||OBSERVATION|1965-08-03||||1965-07-07||1962-01-09|1970-11-25||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG/MIN|RELAPSED DISEASE||FIU|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|STUDY SUBJECT|PHYSIOTHERAPIST|U|5||7||SCREENING|1972-09-01||||1966-11-02||1970-03-06|1964-01-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||NTRGRESP|NON-TARGET RESPONSE||||LX|IMPROVED||PA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|FAMILY MEMBER|UROLOGIST|U|1||38||OPEN LABEL TREATMENT|1962-01-18||||1962-03-30||1960-01-12|1971-12-31||DURING||DURING|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ENZYME U/M2|CA125 75% RESPONSE||ARBITRARY U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|1||38||CONTINUATION TREATMENT|1962-01-14||||1965-07-25||1964-09-28|1969-04-30||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/L DDU|NON-PD||UL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|2||58||BASELINE|1970-07-27||||1968-01-02||1965-05-28|1960-05-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CM/S|PD FROM PR||MGEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|2||58||WASHOUT|1962-08-03||||1961-11-13||1971-09-12|1963-07-27||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||BONERESP|BONE RESPONSE||||UMOL/L|COMPLETE MRD RESPONSE||10^9 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1968-06-11||||1968-06-19||1960-07-14|1972-12-29||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||NEWLPROG|NEW LESION PROGRESSION||||SHOCK WAVE|NED||UMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|CLINICAL RESEARCH COORDINATOR|READER 1|Y|3||39||LONG-TERM FOLLOW-UP|1968-02-18||||1962-07-05||1972-11-18|1962-12-24||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/H|ABSENT MORPHOLOGIC RESPONSE||U/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|PARENT|DERMATOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1970-07-23||||1962-01-01||1964-01-07|1970-10-15||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NG|NR||ANTI-XA IU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|INVESTIGATOR|ENDOCRINOLOGIST|Y|4||88||RUN-IN|1961-01-30||||1963-05-16||1966-09-19|1960-05-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||METSIND|METASTATIC INDICATOR||||CGY|CA125 75% RESPONSE||ML/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|STUDY SUBJECT|RADIOLOGIST 1|Y|5||7||WASHOUT|1973-05-31||||1971-10-05||1971-11-19|1961-09-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/LSQN|PD||MM/SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|INTERVIEWER|FORENSIC PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1973-07-15||||1960-07-14||1964-08-16|1962-06-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||NEWLPROG|NEW LESION PROGRESSION||||MMHG/L/MIN|STABLE||CAPSULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|FRIEND|MICROSCOPIST|N|1||38||OBSERVATION|1973-06-11||||1971-03-15||1968-08-24|1966-02-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||METBRESP|METABOLIC RESPONSE||||WEBER|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^7 TCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|ADJUDICATOR|OTOLARYNGOLOGIST|NA|1||38||WASHOUT|1968-07-25||||1960-10-30||1971-07-01|1968-01-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||CLINRESP|CLINICAL RESPONSE||||HOMEOPATHIC DILUTION|ICR||MPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|Y|INTERVIEWER|CLINICAL PATHOLOGIST|Y|2||58||SCREENING|1963-01-22||||1971-09-20||1966-09-29|1964-11-22||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||NEWLPROG|NEW LESION PROGRESSION||||KM|MORPHOLOGIC LEUKEMIA-FREE STATE||ML*CMH2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|2||58||SCREENING|1973-03-01||||1964-06-13||1970-03-06|1972-03-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 CFU/ML|MR||U/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|SIGNIFICANT OTHER|OPTOMETRIST|Y|3||39||TREATMENT|1960-05-30||||1971-01-30||1965-03-09|1961-01-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||OVRLRESP|OVERALL RESPONSE||||FEU|ICR||/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|SIGNIFICANT OTHER|RATER 2|NA|3||39||SCREENING|1965-05-31||||1967-11-13||1969-02-19|1968-07-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||TMRESP|TUMOR MARKER RESPONSE||||LM|FAVORABLE RESPONSE||CGY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|VENDOR|NEUROLOGIST 1|NA|4||88||INDUCTION TREATMENT|1968-02-20||||1968-10-26||1969-04-26|1962-05-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PMOL/DL|PARTIAL MORPHOLOGIC RESPONSE||DPM/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|CAREGIVER|ADJUDICATOR|NA|4||88||BLINDED TREATMENT|1971-08-16||||1968-01-25||1962-03-19|1970-11-14||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||RDIORESP|RADIOLOGIC RESPONSE||||M/SEC|TREATMENT FAILURE||IU/MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|5||7||TREATMENT|1965-07-25||||1964-09-01||1963-10-28|1965-12-09||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||/2000 RBC|QUANTIFIABLE MRD POSITIVITY||PKAT/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|FAMILY MEMBER|MICROSCOPIST 3|NA|5||7||INDUCTION TREATMENT|1968-04-25||||1961-10-16||1970-04-24|1968-11-07||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/L/H|MRD RELAPSE||10^6 DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1965-08-15||||1971-12-12||1970-09-03|1965-07-22||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||BONERESP|BONE RESPONSE||||ML/CAGE|INDETERMINATE RESPONSE||G/CAGE/WK|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1964-04-04||||1963-04-18||1969-06-29|1963-04-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PUFF|PR WITH LYMPHOCYTOSIS||UCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-01-11||||1964-04-26||1964-10-23|1967-01-21||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/G/DAY|NON-ICR/NON-IUPD||MMHG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|SIBLING|PATHOLOGIST|N|2||58||WASHOUT|1972-04-10||||1962-01-03||1962-06-10|1966-12-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||USIEMENS|CYTOGENETIC CR||ML/MIN/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|SIGNIFICANT OTHER|UROLOGIST|N|3||39||CONTINUATION TREATMENT|1963-07-04||||1960-05-31||1960-11-21|1962-01-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||AMFI|NON-CR/NON-PD||ENZYME U/G HB|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||TREATMENT|1964-03-27||||1972-01-19||1965-11-10|1968-02-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UU/DL|MORPHOLOGIC LEUKEMIA-FREE STATE||ML/MMHG/MIN/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|4||88||BLINDED TREATMENT|1970-12-19||||1966-02-15||1969-03-08|1961-06-25||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||HENRY|NON-CR/NON-PD||EID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|FAMILY MEMBER|ADJUDICATOR 1|NA|4||88||OBSERVATION|1966-06-19||||1973-01-21||1972-02-01|1961-04-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UG/L DDU|MORPHOLOGIC CRI||FMOL/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||TREATMENT|1960-11-10||||1973-04-04||1962-05-26|1962-10-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||BEL|PD/RELAPSE AFTER HI||MG/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|PROXY|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||FOLLOW-UP|1971-03-02||||1965-05-13||1960-04-20|1972-01-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||NEWLIND|NEW LESION INDICATOR||||10^4 CFU/ML|CRI||DYN|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|SPOUSE|ONCOLOGIST 1|NA|1||38||CONTINUATION TREATMENT|1961-01-01||||1971-02-28||1965-01-12|1969-06-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||ANATRESP|ANATOMIC RESPONSE||||U/KG/H|IPR||PIPE|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|1||38||WASHOUT|1971-01-17||||1968-12-29||1970-12-24|1969-04-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MPS U|ISD||EIA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||BLINDED TREATMENT|1969-02-15||||1961-01-11||1970-02-03|1966-07-14||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PFU|HI-P||KUSP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|NA|2||58||BLINDED TREATMENT|1963-10-01||||1967-10-22||1972-06-20|1962-07-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||LIVRRESP|LIVER RESPONSE||||MM2|PR||U/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|3||39||BLINDED TREATMENT|1969-10-01||||1960-01-05||1967-06-19|1963-08-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KS|MRD PERSISTENCE||/MBP|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|VENDOR|ONCOLOGIST|Y|3||39||BASELINE|1965-10-04||||1965-12-27||1971-03-05|1966-06-28||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MMOL/MOL|MRD NEGATIVITY||UMOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|GUARDIAN|ADJUDICATOR|NA|4||88||OPEN LABEL TREATMENT|1964-03-26||||1971-06-24||1972-03-03|1966-05-14||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||BONERESP|BONE RESPONSE||||COAT|RELAPSED DISEASE||GRAVITATIONAL UNIT|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|4||88||WASHOUT|1966-04-24||||1973-07-09||1965-02-24|1967-07-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||SPLNRESP|SPLEEN RESPONSE||||GMFI|NON-PD||PG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|5||7||LONG-TERM FOLLOW-UP|1972-03-04||||1972-11-22||1971-11-27|1966-02-23||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FEU|IMMUNOPHENOTYPIC CR||IU/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|ADJUDICATOR|READER|Y|5||7||INDUCTION TREATMENT|1972-04-08||||1967-12-14||1970-04-27|1963-11-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||TMRESP|TUMOR MARKER RESPONSE||||SCOOPFUL|SMD||BP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|INVESTIGATOR|ADJUDICATOR|N|1||38||BASELINE|1961-02-02||||1965-12-08||1965-09-01|1964-07-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||STRUSTAT|STEROID USE STATUS||||MCI|RELAPSED DISEASE FROM CR OR PR||FMOL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|GUARDIAN|DERMATOLOGIST|U|1||38||SCREENING|1971-04-24||||1967-12-29||1968-04-12|1962-02-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||GY|CA125 50% RESPONSE||MJOULE/CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||SCREENING|1960-05-18||||1972-09-14||1970-02-12|1971-05-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||TRGRESP|TARGET RESPONSE||||1/(S*KPA)|SD||G/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|ADJUDICATOR|MICROSCOPIST 2|NA|2||58||BASELINE|1971-01-27||||1960-03-19||1964-07-06|1966-05-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||TRGRESP|TARGET RESPONSE||||10^6 ORGANISMS/G|PSEUDOPROGRESSION||U/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CAREGIVER|MICROSCOPIST 1|NA|3||39||TREATMENT|1973-05-28||||1970-01-06||1973-01-12|1961-04-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||MOLRESP|MOLECULAR RESPONSE||||ML/MMHG/MIN/L|SD||PFU/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|PARENT|READER|Y|3||39||BLINDED TREATMENT|1961-04-10||||1961-07-03||1961-07-20|1960-08-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||CLINRESP|CLINICAL RESPONSE||||JOULE|PR WITH LYMPHOCYTOSIS||M/SEC|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|VENDOR|PATHOLOGIST 1|N|4||88||WASHOUT|1969-05-09||||1961-08-14||1968-06-10|1970-11-14||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||EQ|PD FROM PR||OI50|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|U|VENDOR|OTOLARYNGOLOGIST|U|4||88||SCREENING|1970-02-15||||1964-01-13||1963-09-10|1961-04-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/KG/DAY|IMMUNOPHENOTYPIC CR||MG/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|5||7||FOLLOW-UP|1966-12-09||||1968-07-27||1961-08-29|1964-10-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||TRGRESP|TARGET RESPONSE||||BQ/G|SD||NU/CL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|CAREGIVER|MICROSCOPIST|Y|5||7||BASELINE|1964-10-12||||1970-08-19||1971-11-02|1970-09-11||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/G/DAY|EQUIVOCAL||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|ADJUDICATOR|HEMATOLOGIST|N|1||38||OPEN LABEL TREATMENT|1966-06-15||||1967-07-02||1970-06-04|1962-07-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MOL/G|IMPROVED||KIU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|PARENT|READER 3|Y|1||38||OPEN LABEL TREATMENT|1970-11-27||||1972-01-11||1961-07-25|1970-05-31||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||TMRESP|TUMOR MARKER RESPONSE||||CYLINDER|SD||MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|2||58||CONTINUATION TREATMENT|1971-02-07||||1972-10-31||1963-10-08|1961-01-17||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||OVRLRESP|OVERALL RESPONSE||||%/S|FAVORABLE RESPONSE||GRAVITATIONAL UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|STUDY SUBJECT|MICROSCOPIST|U|2||58||WASHOUT|1965-11-18||||1963-12-16||1966-01-07|1973-07-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||TMRESP|TUMOR MARKER RESPONSE||||BEATS/MIN|ISD||HENRY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|N|GUARDIAN|ADJUDICATOR 2|NA|3||39||LONG-TERM FOLLOW-UP|1962-09-30||||1965-01-09||1966-04-12|1972-09-12||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||LIVRRESP|LIVER RESPONSE||||BQ/G|SD-CT||ENZYME U|NOT DONE|||LIKERT SCALE 3-POINT|N|N|U|ADJUDICATOR|NEUROLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1969-09-24||||1969-04-03||1971-03-22|1961-11-25||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||STEPS/MIN|MINOR PATHOLOGIC RESPONSE||CCID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|ADJUDICATOR|RATER|NA|4||88||TREATMENT|1973-04-07||||1972-11-19||1973-05-01|1960-08-05||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/M2/DAY|WORSENED||UMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|PARENT|MICROSCOPIST 1|Y|4||88||FOLLOW-UP|1966-11-19||||1973-02-05||1971-03-30|1969-04-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||MOLRESP|MOLECULAR RESPONSE||||SUPPOSITORY|IUPD||PELLET|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|5||7||FOLLOW-UP|1972-03-15||||1966-03-17||1964-12-14|1968-03-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||EQ|DISEASE TRANSFORMATION||FARAD|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|5||7||RUN-IN|1968-06-24||||1964-12-20||1972-06-02|1961-06-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UKAT|TREATMENT FAILURE||WATT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|FAMILY MEMBER|READER 1|U|1||38||OBSERVATION|1963-10-25||||1972-10-25||1960-04-22|1970-10-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KIU|MCR||PPTR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|HEALTH CARE PROFESSIONAL|RATER|NA|1||38||OBSERVATION|1967-07-27||||1973-01-08||1969-07-02|1960-04-23||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||TRGRESP|TARGET RESPONSE||||L/S/KPA|MOLECULAR MAJOR RESPONSE||MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|Y|INVESTIGATOR|PATHOLOGIST 1|N|2||58||BLINDED TREATMENT|1969-12-20||||1969-09-20||1965-05-05|1973-04-19||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||BESTRESP|BEST OVERALL RESPONSE||||CAL|MRD RELAPSE||DDU|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|2||58||BLINDED TREATMENT|1966-09-23||||1965-01-16||1966-08-10|1964-12-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||ANATRESP|ANATOMIC RESPONSE||||NEEDLE GAUGE|NOT ALL EVALUATED||VIAL|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|PROXY|NEUROLOGIST 2|NA|3||39||RUN-IN|1968-09-23||||1965-08-15||1961-02-02|1967-04-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BOX|MRD RELAPSE||KG/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|SPOUSE|DERMATOLOGIST|Y|3||39||INDUCTION TREATMENT|1970-10-08||||1966-01-09||1967-06-24|1972-02-13||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UMOL/MOL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UG/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|ADJUDICATOR|RADIOLOGIST 2|NA|4||88||FOLLOW-UP|1964-08-13||||1969-12-10||1971-08-17|1961-10-02||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||TRGRESP|TARGET RESPONSE||||OD UNIT|OPTIMAL MORPHOLOGIC RESPONSE||UG/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|U|CHILD|MICROSCOPIST 1|Y|4||88||BLINDED TREATMENT|1972-05-05||||1966-01-27||1972-06-07|1967-09-30||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NFIU|PSA PROGRESSION||KBQ/UL|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|DOMESTIC PARTNER|OPTOMETRIST|NA|5||7||CONTINUATION TREATMENT|1967-02-07||||1961-11-04||1961-06-16|1962-02-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||TMRESP|TUMOR MARKER RESPONSE||||GY|CYTOGENETIC NO RESPONSE||KAT|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|PARENT|NEUROLOGIST 1|U|5||7||SCREENING|1960-10-03||||1963-08-26||1968-06-08|1969-11-19||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||METSIND|METASTATIC INDICATOR||||L/S/KPA|PSEUDORESPONSE||HOURS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|1||38||SCREENING|1970-06-18||||1960-02-23||1966-06-10|1963-06-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||U|CA125 75% RESPONSE||UCI/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|1||38||RUN-IN|1970-12-05||||1968-01-19||1962-11-05|1961-08-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||CLINRESP|CLINICAL RESPONSE||||UG/DOSE|CCR||MG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|SPOUSE|MICROSCOPIST 1|U|2||58||FOLLOW-UP|1970-01-15||||1969-03-02||1966-02-11|1972-07-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||NEWLIND|NEW LESION INDICATOR||||AMU|ISD||TRANSDUCING UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|FRIEND|READER|NA|2||58||FOLLOW-UP|1964-11-19||||1971-11-17||1970-06-01|1966-06-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||TMRESP|TUMOR MARKER RESPONSE||||CI/L|MORPHOLOGIC CR||MG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|3||39||INDUCTION TREATMENT|1969-03-28||||1969-09-12||1969-09-22|1968-06-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||BESTRESP|BEST OVERALL RESPONSE||||L|INDETERMINATE RESPONSE||UMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|3||39||RUN-IN|1969-12-12||||1969-10-20||1961-11-08|1963-04-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||LIVRRESP|LIVER RESPONSE||||PMOL/DL|CA125 50% RESPONSE||LOG10 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|4||88||BASELINE|1964-10-06||||1960-02-17||1966-03-03|1967-02-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||RDIORESP|RADIOLOGIC RESPONSE||||FINGERTIP UNIT|MRD PERSISTENCE||UGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|STUDY SUBJECT|HEMATOLOGIST|Y|4||88||OBSERVATION|1961-06-15||||1969-10-27||1969-10-07|1970-10-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PL|RELAPSED DISEASE||MV/SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|5||7||CONTINUATION TREATMENT|1968-05-24||||1960-06-19||1971-02-10|1971-06-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BOTTLE|SMD||10^9/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|VENDOR|PHYSIOTHERAPIST|N|5||7||SCREENING|1966-09-07||||1961-10-09||1973-08-24|1965-06-05||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||NEWLPROG|NEW LESION PROGRESSION||||BISCUIT|PR-CT||PACKAGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|N|SIGNIFICANT OTHER|UROLOGIST|NA|1||38||FOLLOW-UP|1970-02-20||||1960-10-01||1968-07-23|1971-09-01||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^3/HPF|MRD NEGATIVITY||U/M2/H|NOT DONE|||LIKERT SCALE 7-POINT|N|U|NA|CLINICAL RESEARCH COORDINATOR|RATER 2|Y|1||38||WASHOUT|1964-11-15||||1960-06-29||1969-04-04|1964-04-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||NEWLIND|NEW LESION INDICATOR||||ENZYME U/L|PD FROM PR||10^3 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|INVESTIGATOR|MICROSCOPIST|N|2||58||CONTINUATION TREATMENT|1968-12-18||||1972-12-24||1969-06-04|1969-03-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||BQ/UL|CR||UG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||FOLLOW-UP|1970-03-04||||1972-08-08||1965-07-07|1969-09-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||MOLRESP|MOLECULAR RESPONSE||||ECL UNIT|PSEUDOPROGRESSION||PT_US|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INVESTIGATOR|MICROSCOPIST 3|N|3||39||INDUCTION TREATMENT|1971-02-19||||1962-04-22||1960-06-13|1967-09-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||LIVRRESP|LIVER RESPONSE||||L|CYTOGENETIC CR||U/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|FAMILY MEMBER|ONCOLOGIST 1|NA|3||39||WASHOUT|1963-09-13||||1965-09-12||1970-09-06|1962-11-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||H*%|MRD PERSISTENCE||M/SEC|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|GUARDIAN|ADJUDICATOR 1|U|4||88||OPEN LABEL TREATMENT|1960-04-20||||1970-03-07||1972-11-29|1963-01-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LOG10 PFU/ML|IPR||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|Y|4||88||OPEN LABEL TREATMENT|1969-06-05||||1961-04-29||1973-06-07|1970-04-29||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/MBP|MR||/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|Y|VENDOR|MICROSCOPIST 1|NA|5||7||SCREENING|1966-04-20||||1962-11-07||1961-12-03|1966-05-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||LIVRRESP|LIVER RESPONSE||||MBP|PSEUDORESPONSE||EP U|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|GUARDIAN|ADJUDICATOR 2|U|5||7||RUN-IN|1970-05-21||||1965-01-16||1968-03-02|1972-05-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ENZYME U/L|ABSENT MORPHOLOGIC RESPONSE||/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|1||38||OPEN LABEL TREATMENT|1961-10-21||||1961-01-13||1971-05-11|1967-11-11||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||/10^3|FAVORABLE RESPONSE||PSI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|INTERVIEWER|MICROSCOPIST 2|NA|1||38||WASHOUT|1969-04-10||||1960-03-19||1968-01-12|1962-11-22||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KPA/L/SEC|CR||MG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|SIGNIFICANT OTHER|CARDIOLOGIST|Y|2||58||CONTINUATION TREATMENT|1961-04-02||||1969-05-27||1969-06-16|1964-08-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||NTRGRESP|NON-TARGET RESPONSE||||FL|CYTOGENETIC MINIMAL RESPONSE||VP/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|SIBLING|ONCOLOGIST|Y|2||58||WASHOUT|1973-03-29||||1962-02-07||1970-02-10|1961-08-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MHZ|PCR||EJACULATE U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|NA|3||39||RUN-IN|1961-12-22||||1964-04-15||1963-07-16|1966-06-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||OVRLRESP|OVERALL RESPONSE||||KHZ|IUPD||MMOL/MIN/KPA/L|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|CAREGIVER|RATER 2|N|3||39||OPEN LABEL TREATMENT|1968-06-30||||1973-06-02||1966-10-26|1968-07-01||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||NEWLIND|NEW LESION INDICATOR||||GY|TREATMENT FAILURE||/200 HPFS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4||88||SCREENING|1970-03-18||||1969-01-16||1970-10-21|1961-08-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DAMOL/L|PSEUDOPROGRESSION||/4.0 ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|INTERVIEWER|MICROSCOPIST 3|NA|4||88||CONTINUATION TREATMENT|1971-01-06||||1961-06-07||1973-06-18|1966-11-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||L/L|NON-ICR/NON-IUPD||MG/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5||7||OPEN LABEL TREATMENT|1972-04-19||||1966-07-15||1971-06-16|1971-01-03||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||RDIORESP|RADIOLOGIC RESPONSE||||IU/L|UNFAVORABLE RESPONSE||BEATS/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|FRIEND|PATHOLOGIST 2|NA|5||7||SCREENING|1961-08-12||||1965-08-01||1960-11-30|1965-10-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/M2|QUANTIFIABLE MRD POSITIVITY||UG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|INVESTIGATOR|ONCOLOGIST 1|Y|1||38||CONTINUATION TREATMENT|1968-06-07||||1965-02-06||1967-03-30|1964-09-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MOL/ML|DECREASED||U/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST|NA|1||38||BASELINE|1963-04-07||||1971-01-15||1968-01-21|1964-09-08||DURING||AFTER|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||OZ EQ|INDETERMINATE RESPONSE||L/MIN/M2|NOT DONE|||LIKERT SCALE 5-POINT|N|N|NA|VENDOR|FORENSIC PATHOLOGIST|NA|2||58||SCREENING|1969-01-06||||1960-10-14||1964-07-24|1972-08-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||OVRLRESP|OVERALL RESPONSE||||BU|NON-ICR/NON-IUPD||PACK YEAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|SPOUSE|RADIOLOGIST|N|2||58||OBSERVATION|1964-05-23||||1960-08-24||1964-03-22|1970-09-06||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||METSIND|METASTATIC INDICATOR||||ANSON U|NON-CR/NON-PD||/MS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|FAMILY MEMBER|ADJUDICATOR 3|N|3||39||TREATMENT|1962-04-28||||1973-04-18||1973-08-14|1969-03-18||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MSEC|PD FROM PR||FOZ_BR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|PARENT|UROLOGIST|Y|3||39||CONTINUATION TREATMENT|1962-02-06||||1965-02-11||1963-10-13|1966-07-15||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||METBRESP|METABOLIC RESPONSE||||MIN/DAY|NE||SUPPOSITORY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|N|4||88||BLINDED TREATMENT|1971-12-07||||1970-12-10||1970-12-02|1968-05-10||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CONTAINER|MRD PERSISTENCE||MEQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|SPOUSE|READER 2|NA|4||88||LONG-TERM FOLLOW-UP|1961-11-03||||1971-01-27||1963-05-29|1972-02-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||MOLRESP|MOLECULAR RESPONSE||||G/ANIMAL|INCREASED||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|5||7||WASHOUT|1967-02-28||||1971-06-12||1964-10-25|1969-04-01||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||VOXEL|MOLECULAR CR||10^4/HPF|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|CAREGIVER|MICROSCOPIST 3|U|5||7||SCREENING|1967-09-17||||1970-02-20||1964-10-08|1963-06-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG|HI-N||U/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|Y|1||38||BLINDED TREATMENT|1972-04-16||||1964-03-20||1966-10-11|1968-09-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/CAGE/WK|UNFAVORABLE RESPONSE||G/ANIMAL/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|CHILD|RATER 1|NA|1||38||LONG-TERM FOLLOW-UP|1973-05-31||||1963-01-30||1970-11-22|1966-02-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||GBQ|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|U|2||58||INDUCTION TREATMENT|1966-10-10||||1964-08-01||1963-04-12|1962-08-23||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||MOLRESP|MOLECULAR RESPONSE||||MS/MMHG|IMMUNOPHENOTYPIC CR||/LPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|2||58||WASHOUT|1964-10-16||||1960-01-19||1971-05-12|1968-02-27||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||BESTRESP|BEST OVERALL RESPONSE||||SEC|PARTIAL MORPHOLOGIC RESPONSE||PM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|SPOUSE|MICROSCOPIST 3|U|3||39||WASHOUT|1968-02-08||||1969-04-05||1972-07-18|1969-08-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PFU|CR-CT||UV*SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|CAREGIVER|HEMATOLOGIST|N|3||39||OPEN LABEL TREATMENT|1973-07-17||||1968-11-24||1971-09-19|1973-06-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CONTAINER|ISD||OI50|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|CLINICAL RESEARCH COORDINATOR|READER 1|U|4||88||OBSERVATION|1966-08-08||||1966-10-17||1966-12-14|1964-04-22||AFTER||DURING|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/CM2|CCR||RING|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|4||88||TREATMENT|1968-11-27||||1965-11-14||1967-01-19|1966-07-16||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||MOLRESP|MOLECULAR RESPONSE||||HR/DAY|MOLECULAR MAJOR RESPONSE||CI/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|HEALTH CARE PROFESSIONAL|RATER 2|NA|5||7||BLINDED TREATMENT|1966-03-21||||1971-07-14||1962-12-03|1972-03-14||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CI/G|MINOR PATHOLOGIC RESPONSE||UG/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|5||7||CONTINUATION TREATMENT|1963-10-16||||1962-01-13||1967-01-10|1968-01-29||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||STRUSTAT|STEROID USE STATUS||||IU/KG/H|PMD||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|INTERVIEWER|UROLOGIST|U|1||38||INDUCTION TREATMENT|1968-12-06||||1973-06-28||1968-04-13|1972-04-13||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UKAT/L|HI-N||ML/MIN/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|1||38||RUN-IN|1966-07-18||||1970-03-16||1968-04-05|1971-03-29||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||ANATRESP|ANATOMIC RESPONSE||||10^5/HPF|COMPLETE MRD RESPONSE||G/CAGE|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|CLINICAL RESEARCH COORDINATOR|RATER|Y|2||58||WASHOUT|1965-01-15||||1971-03-30||1965-04-02|1963-08-16||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MIN|DECREASED||MJOULE/CM2|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|ADJUDICATOR|OPTOMETRIST|U|2||58||TREATMENT|1968-09-13||||1964-07-14||1969-04-04|1962-04-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^4 CFU|COMPLETE MRD RESPONSE||LOZENGE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|VENDOR|RATER|NA|3||39||OPEN LABEL TREATMENT|1961-01-15||||1972-10-02||1966-04-14|1967-11-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||METSIND|METASTATIC INDICATOR||||LOG10 COPIES/ML|QUANTIFIABLE MRD POSITIVITY||BISCUIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||LONG-TERM FOLLOW-UP|1968-08-05||||1967-11-05||1961-08-12|1972-11-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/DL|CR-CT||COAT|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|4||88||WASHOUT|1973-06-27||||1967-10-28||1962-01-22|1964-09-02||DURING||DURING|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU|CR-CT||CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|INTERVIEWER|PATHOLOGIST|U|4||88||BASELINE|1969-03-31||||1967-09-16||1972-04-21|1969-04-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FT3|MOLECULAR MAJOR RESPONSE||MG/ML/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|CAREGIVER|MICROSCOPIST 2|U|5||7||TREATMENT|1963-02-24||||1972-09-18||1963-05-19|1965-10-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/M2/MIN|SD-CT||U/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|GUARDIAN|OPTOMETRIST|U|5||7||INDUCTION TREATMENT|1971-03-01||||1965-10-22||1966-09-17|1960-09-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||OD UNIT|CYTOGENETIC PR||UG/G/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|SIGNIFICANT OTHER|CARDIOLOGIST|N|1||38||OBSERVATION|1961-05-21||||1973-07-10||1960-12-03|1962-12-31||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MAC50|PR WITH LYMPHOCYTOSIS||%|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|NA|ADJUDICATION COMMITTEE|OPTOMETRIST|N|1||38||TREATMENT|1970-02-20||||1965-06-27||1970-02-03|1967-04-29||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|1||||||METBRESP|METABOLIC RESPONSE||||EU|RELAPSED DISEASE||NM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|CAREGIVER|UROLOGIST|NA|2||58||CONTINUATION TREATMENT|1964-10-01||||1966-02-19||1968-11-03|1972-04-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|2||||||METSIND|METASTATIC INDICATOR||||MU/L|PD||DPM|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|2||58||RUN-IN|1962-07-21||||1960-07-04||1964-07-06|1970-12-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UMOL/DAY|CYTOGENETIC MINOR RESPONSE||G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|NA|HEALTH CARE PROFESSIONAL|READER 1|U|3||39||BLINDED TREATMENT|1965-08-23||||1970-06-29||1967-04-28|1964-05-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^7 TCID 50/DOSE|IMMUNOPHENOTYPIC CR||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|INTERVIEWER|DERMATOLOGIST|N|3||39||BLINDED TREATMENT|1963-10-08||||1968-01-07||1961-07-14|1966-12-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|1||||||STRUSTAT|STEROID USE STATUS||||HOUNSFIELD UNIT|NOT ALL EVALUATED||UMOL/L/SEC|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|PARENT|PATHOLOGIST 1|NA|4||88||RUN-IN|1968-11-15||||1967-02-03||1966-11-11|1970-02-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ENZYME U/L|INDETERMINATE RESPONSE||SCOOPFUL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|FRIEND|MICROSCOPIST 1|NA|4||88||OPEN LABEL TREATMENT|1971-02-07||||1971-06-23||1973-03-12|1971-09-05||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|1||||||METSIND|METASTATIC INDICATOR||||BQ|MINOR PATHOLOGIC RESPONSE||PG|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|DOMESTIC PARTNER|PHYSIOTHERAPIST|N|5||7||LONG-TERM FOLLOW-UP|1965-08-26||||1960-05-13||1969-10-14|1961-05-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C817A043-1331-47AB-A627-D85893F9D61A|2||||||BESTRESP|BEST OVERALL RESPONSE||||KM|NON-ICR/NON-IUPD||TRANSDUCING UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|STUDY SUBJECT|RADIOLOGIST 2|N|5||7||WASHOUT|1965-05-16||||1965-01-17||1960-09-16|1964-05-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||OVRLRESP|OVERALL RESPONSE||||10^6 IU|IMMUNOPHENOTYPIC CR||GPL U|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|PARENT|ADJUDICATOR 3|Y|1||38||CONTINUATION TREATMENT|1970-08-13||||1973-05-26||1973-04-15|1968-02-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||METSIND|METASTATIC INDICATOR||||LOG10 TCID 50/ML|OPTIMAL MORPHOLOGIC RESPONSE||10^3 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|CHILD|ONCOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1966-04-07||||1966-08-15||1962-05-14|1973-07-29||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ENZYME U/G HB|STABLE||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|CAREGIVER|RATER 2|U|2||58||BLINDED TREATMENT|1967-11-13||||1970-03-19||1967-01-08|1968-08-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||NTRGRESP|NON-TARGET RESPONSE||||PFU/DOSE|MCR||ECL UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|GUARDIAN|RATER|N|2||58||LONG-TERM FOLLOW-UP|1969-07-03||||1965-05-15||1963-09-07|1967-05-18||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||MOLRESP|MOLECULAR RESPONSE||||MG/L|PCR||AMPULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|INTERVIEWER|READER|Y|3||39||OBSERVATION|1963-02-04||||1966-12-20||1967-02-21|1963-07-20||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KS|NR||UMOL/DL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|CLINICAL RESEARCH ASSOCIATE|READER 2|N|3||39||RUN-IN|1964-12-08||||1967-05-17||1963-03-16|1962-07-08||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||TMRESP|TUMOR MARKER RESPONSE||||APL U|RELAPSED DISEASE FROM CR||U/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|SPOUSE|READER 3|N|4||88||WASHOUT|1968-04-25||||1963-08-01||1962-03-26|1966-04-18||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TRACE|MORPHOLOGIC CR||10^9/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|NA|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|4||88||WASHOUT|1963-12-29||||1966-02-20||1960-08-23|1963-10-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||NTRGRESP|NON-TARGET RESPONSE||||IU/MMOL|INDETERMINATE RESPONSE||MEQ/UL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1963-03-21||||1961-12-22||1960-06-15|1961-03-30||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/MIN|EQUIVOCAL||G/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|DOMESTIC PARTNER|MICROSCOPIST 1|NA|5||7||BLINDED TREATMENT|1961-04-29||||1962-09-01||1960-04-06|1963-10-03||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||BONERESP|BONE RESPONSE||||/5X10^4 WBC|CA125 50% RESPONSE||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|DOMESTIC PARTNER|OTOLARYNGOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1969-01-03||||1970-08-23||1972-06-13|1962-03-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||PATHRESP|PATHOLOGIC RESPONSE||||VP/ML|NR||U/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|1||38||CONTINUATION TREATMENT|1964-08-11||||1963-12-13||1961-04-22|1968-08-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PHERESIS UNIT|PR||U/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|VENDOR|DERMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1963-03-20||||1960-11-09||1968-11-12|1973-01-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||TRGRESP|TARGET RESPONSE||||KPA|CYTOGENETIC MINOR RESPONSE||G/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|N|INTERVIEWER|PATHOLOGIST 1|Y|2||58||OBSERVATION|1966-09-05||||1967-07-15||1962-01-09|1962-01-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||NEWLPROG|NEW LESION PROGRESSION||||10^6 ORGANISMS/MG|CR-CT||BOLUS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|FRIEND|RADIOLOGIST 1|Y|3||39||FOLLOW-UP|1969-11-06||||1971-08-31||1969-09-27|1971-09-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||OVRLRESP|OVERALL RESPONSE||||CYLINDER|MCR||FIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|CAREGIVER|PEDIATRIC NEUROLOGIST|U|3||39||CONTINUATION TREATMENT|1972-10-01||||1973-02-27||1968-07-07|1964-06-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||SPLNRESP|SPLEEN RESPONSE||||MM/SEC|MORPHOLOGIC LEUKEMIA-FREE STATE||JAR|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|FAMILY MEMBER|NEUROLOGIST 2|U|4||88||CONTINUATION TREATMENT|1964-08-02||||1962-05-12||1963-12-05|1965-03-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL/DAY|SD-CT||UMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|CHILD|ONCOLOGIST 1|U|4||88||INDUCTION TREATMENT|1967-08-30||||1965-02-18||1964-01-03|1963-09-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||METSIND|METASTATIC INDICATOR||||BISCUIT|NON-QUANTIFIABLE MRD POSITIVITY||NG/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|STUDY SUBJECT|NEUROLOGIST|NA|5||7||FOLLOW-UP|1967-05-27||||1971-10-14||1969-02-07|1967-11-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||NMOL/DAY|INCREASED||IU/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|U|VENDOR|INTERNIST|U|5||7||LONG-TERM FOLLOW-UP|1967-12-22||||1963-07-21||1971-06-09|1962-11-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||METBRESP|METABOLIC RESPONSE||||AFU|IPR||MOL/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|1||38||SCREENING|1968-08-31||||1968-02-07||1963-12-20|1972-10-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||METSIND|METASTATIC INDICATOR||||LENS|NON-QUANTIFIABLE MRD POSITIVITY||DRUM|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||BASELINE|1970-08-21||||1962-01-02||1971-11-09|1973-01-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||METBRESP|METABOLIC RESPONSE||||DPM/0.5 ML|CA125 50% RESPONSE||CGY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|FAMILY MEMBER|ADJUDICATOR 2|Y|2||58||INDUCTION TREATMENT|1963-02-07||||1969-11-21||1973-05-08|1963-03-26||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MIN|DECREASED||UV|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|FAMILY MEMBER|MICROSCOPIST 2|Y|2||58||FOLLOW-UP|1967-11-02||||1969-11-08||1968-03-02|1960-12-09||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||METBRESP|METABOLIC RESPONSE||||UMOL/MG/MIN|IMMUNOPHENOTYPIC CR||FIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|ADJUDICATOR|ONCOLOGIST 1|N|3||39||LONG-TERM FOLLOW-UP|1966-06-29||||1963-01-25||1964-05-10|1973-04-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SHOCK WAVE|NE||ABSORBANCE U/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|3||39||BLINDED TREATMENT|1964-10-04||||1973-07-22||1966-04-30|1960-05-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MOSM/KG|EQUIVOCAL||NEWTON|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|U|VENDOR|RATER|N|4||88||RUN-IN|1971-07-17||||1962-11-23||1971-08-24|1967-09-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||TRGRESP|TARGET RESPONSE||||UL|VGPR||EQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|4||88||OPEN LABEL TREATMENT|1968-05-21||||1970-02-16||1969-06-15|1965-07-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||KUSP|CYTOGENETIC CR||HZ|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|ADJUDICATION COMMITTEE|READER 3|U|5||7||INDUCTION TREATMENT|1964-09-07||||1968-06-27||1973-05-27|1961-01-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O/ML|STABLE||HZ|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|FRIEND|PHYSIOTHERAPIST|NA|5||7||BASELINE|1965-11-28||||1967-07-09||1966-12-14|1969-01-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/WK|IPR||GBQ/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|VENDOR|PATHOLOGIST|U|1||38||WASHOUT|1961-10-29||||1965-12-01||1970-06-04|1973-01-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||U/10^12 RBC|CA125 75% RESPONSE||ANTIBODY UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||WASHOUT|1961-11-13||||1966-03-24||1962-03-07|1970-12-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UCI/KG|MORPHOLOGIC LEUKEMIA-FREE STATE||LOG10 ELISA UNIT/DOSE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|NA|STUDY SUBJECT|RATER|NA|2||58||BLINDED TREATMENT|1969-02-28||||1970-08-10||1964-11-19|1960-07-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||LIVRRESP|LIVER RESPONSE||||SACHET|ICPD||BEAM BREAKS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|SPOUSE|MICROSCOPIST|Y|2||58||BLINDED TREATMENT|1973-05-26||||1964-10-16||1964-03-25|1964-07-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||NTRGRESP|NON-TARGET RESPONSE||||MEQ|PD-CT||GPL U/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|3||39||WASHOUT|1967-06-25||||1965-10-28||1960-05-01|1971-11-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||METBRESP|METABOLIC RESPONSE||||HEP|RELAPSED DISEASE FROM CR OR PR||DRUM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|U|INTERVIEWER|READER|Y|3||39||RUN-IN|1963-05-12||||1961-05-10||1961-10-08|1960-05-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||ANATRESP|ANATOMIC RESPONSE||||MMOL/MIN/KPA/L|MORPHOLOGIC LEUKEMIA-FREE STATE||KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|Y|SIBLING|RADIOLOGIST 2|U|4||88||FOLLOW-UP|1970-01-25||||1962-07-24||1966-05-14|1965-11-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/ML/MIN|PD-CT||STEPS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||LONG-TERM FOLLOW-UP|1968-09-10||||1970-12-17||1969-08-31|1965-05-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UM|MOLECULAR CR||BREATHS/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|U|5||7||SCREENING|1962-09-23||||1970-08-18||1970-12-06|1966-07-04||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||NTRGRESP|NON-TARGET RESPONSE||||/2000 RBC|ICR||NMOL/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|CAREGIVER|RATER 2|NA|5||7||BLINDED TREATMENT|1970-10-03||||1969-08-16||1971-07-30|1965-08-30||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||TMRESP|TUMOR MARKER RESPONSE||||/2000 RBC|CYTOGENETIC CR||YEARS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1964-07-04||||1963-05-17||1968-09-21|1973-01-30||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/H/MMOL|ICR||ML/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|N|CHILD|CLINICAL PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1967-04-14||||1971-05-03||1969-12-09|1965-05-13||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||METBRESP|METABOLIC RESPONSE||||/SEC|DISEASE TRANSFORMATION||CMH2O/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|PARENT|ONCOLOGIST 2|N|2||58||TREATMENT|1971-07-17||||1969-11-30||1964-08-15|1972-01-30||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||MOLRESP|MOLECULAR RESPONSE||||U/L|MAJOR PATHOLOGIC RESPONSE||MG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|INVESTIGATOR|MICROSCOPIST 1|NA|2||58||SCREENING|1969-11-21||||1966-12-14||1961-01-24|1972-02-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DB|MRD PERSISTENCE||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|SIGNIFICANT OTHER|INTERNIST|NA|3||39||INDUCTION TREATMENT|1969-10-28||||1970-09-02||1968-05-22|1961-04-24||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||OVRLRESP|OVERALL RESPONSE||||ML/M2|INCREASED||MMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|NA|ADJUDICATOR|ADJUDICATOR 3|U|3||39||WASHOUT|1962-07-15||||1961-11-20||1967-02-12|1961-04-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||ANATRESP|ANATOMIC RESPONSE||||MIN*MG/ML|OPTIMAL MORPHOLOGIC RESPONSE||PACKAGE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1961-07-05||||1968-12-29||1964-12-03|1972-12-12||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/MIN|RELAPSED DISEASE FROM CR||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|STUDY SUBJECT|INTERNIST|Y|4||88||OBSERVATION|1962-05-12||||1970-03-19||1972-01-10|1969-11-07||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||%(W/V)|IMMUNOPHENOTYPIC CR||UG/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|SIGNIFICANT OTHER|READER 1|NA|5||7||WASHOUT|1967-04-08||||1969-08-07||1965-10-05|1966-11-10||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||LIVRRESP|LIVER RESPONSE||||MMOL/G|NPR||OI50|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|Y|DOMESTIC PARTNER|ADJUDICATOR 1|N|5||7||CONTINUATION TREATMENT|1970-06-02||||1970-09-09||1968-05-05|1967-09-17||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NCI|NON-QUANTIFIABLE MRD POSITIVITY||UMOL/MG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|SPOUSE|DERMATOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1962-04-15||||1962-02-19||1969-03-23|1965-04-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MPA|PD-CT||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|GUARDIAN|OPHTHALMOLOGIST|N|1||38||OBSERVATION|1970-02-24||||1960-01-03||1966-02-12|1964-12-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/200 HPFS|MINOR PATHOLOGIC RESPONSE||ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|GUARDIAN|RADIOLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1969-11-29||||1961-03-22||1968-01-18|1972-03-22||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CMOL|MR||LOG10 TCID 50/DOSE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|2||58||INDUCTION TREATMENT|1964-04-15||||1964-05-25||1966-04-12|1962-08-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||BESTRESP|BEST OVERALL RESPONSE||||S/H|MINOR PATHOLOGIC RESPONSE||UMOL/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1969-08-25||||1965-09-20||1971-10-02|1960-08-11||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||CYTORESP|CYTOGENETIC RESPONSE||||FIU|CYTOGENETIC CR||MMHG*MIN/L|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|3||39||SCREENING|1967-10-21||||1964-09-06||1965-01-04|1965-05-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||GBQ/G|IPR||MG/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1965-02-21||||1973-03-07||1962-05-16|1969-04-06||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||SPLNRESP|SPLEEN RESPONSE||||JOULE|PMR||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||FOLLOW-UP|1970-04-10||||1973-09-08||1960-04-15|1963-06-02||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CARTRIDGE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||MG/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|5||7||BASELINE|1966-08-24||||1960-06-11||1967-10-19|1967-07-07||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DEG/S|PD||HZ/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|STUDY SUBJECT|ADJUDICATOR|NA|5||7||SCREENING|1968-12-04||||1971-08-01||1970-12-27|1962-11-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/KG/DAY|PD/RELAPSE AFTER HI||DNA COPIES/UG|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|1||38||INDUCTION TREATMENT|1971-03-14||||1972-03-14||1964-02-07|1962-05-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||CYTORESP|CYTOGENETIC RESPONSE||||DPM|NON-PD||MEQ/UL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|N|PROXY|RADIOLOGIST|Y|1||38||TREATMENT|1963-12-26||||1967-08-06||1972-10-23|1966-11-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||LIVRRESP|LIVER RESPONSE||||ML/CM H2O|MR||10^9 CFU/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|2||58||BLINDED TREATMENT|1964-12-21||||1969-01-09||1960-05-07|1960-06-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||BESTRESP|BEST OVERALL RESPONSE||||FG|CMR||/KG|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|2||58||BLINDED TREATMENT|1961-02-20||||1967-08-31||1965-10-24|1968-07-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||NEWLPROG|NEW LESION PROGRESSION||||ENZYME U/G HB|MAJOR PATHOLOGIC RESPONSE||MG/ML/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|3||39||OPEN LABEL TREATMENT|1965-01-08||||1960-03-30||1971-01-08|1973-09-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||SPLNRESP|SPLEEN RESPONSE||||KCAL|ICR||C|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|FRIEND|RADIOLOGIST 2|N|3||39||INDUCTION TREATMENT|1966-10-16||||1968-07-29||1966-01-22|1960-06-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||NEWLIND|NEW LESION INDICATOR||||MIN/DAY|CMR||HR/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|NA|FAMILY MEMBER|MICROSCOPIST 2|U|4||88||TREATMENT|1960-01-14||||1962-12-06||1967-06-22|1968-03-11||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL BCE/L|CRI||FFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|N|INVESTIGATOR|NEUROLOGIST 2|N|4||88||LONG-TERM FOLLOW-UP|1963-02-05||||1966-06-26||1961-01-15|1964-01-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/KG/MIN|RELAPSED DISEASE FROM CR||BEAM BREAKS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|U|SIBLING|RADIOLOGIST|NA|5||7||BLINDED TREATMENT|1963-12-05||||1971-04-16||1967-01-22|1973-04-05||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||MOLRESP|MOLECULAR RESPONSE||||MOL/G|PSA PROGRESSION||JOULE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|SPOUSE|ONCOLOGIST 1|N|5||7||WASHOUT|1972-10-31||||1960-01-16||1962-04-02|1961-02-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||NEWLPROG|NEW LESION PROGRESSION||||MEQ/G|IUPD||JOULE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|INDEPENDENT ASSESSOR|READER 3|N|1||38||FOLLOW-UP|1968-07-22||||1972-09-20||1960-06-08|1963-01-03||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||PATHRESP|PATHOLOGIC RESPONSE||||IN2|MCR||EJACULATE U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|INDEPENDENT ASSESSOR|RADIOLOGIST 1|N|1||38||RUN-IN|1962-03-02||||1964-03-14||1971-11-19|1971-01-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||STRUSTAT|STEROID USE STATUS||||UCI/KG|VGPR||APS U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|2||58||WASHOUT|1960-05-30||||1963-12-11||1973-07-24|1965-04-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DPM/MG|PSA PROGRESSION||BAU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|INVESTIGATOR|HEMATOLOGIST|Y|2||58||BLINDED TREATMENT|1968-02-13||||1963-12-04||1964-01-03|1972-03-12||DURING||AFTER|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||APL U|RELAPSED DISEASE FROM CR OR PR||KCAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|Y|STUDY SUBJECT|RADIOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1963-10-22||||1968-05-18||1970-06-06|1965-12-06||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||SPLNRESP|SPLEEN RESPONSE||||%/MIN|ICR||MM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|CAREGIVER|FORENSIC PATHOLOGIST|U|3||39||BASELINE|1967-11-05||||1971-12-03||1972-07-14|1964-10-28||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||RDIORESP|RADIOLOGIC RESPONSE||||AMPULE|PD/RELAPSE AFTER HI||MEQ/UL|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|N|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1963-12-03||||1972-09-18||1968-03-26|1963-10-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||F|PSEUDORESPONSE||NMOL/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|INTERVIEWER|ONCOLOGIST|U|4||88||OBSERVATION|1964-06-26||||1967-02-15||1961-12-15|1972-07-23||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||LIVRRESP|LIVER RESPONSE||||PHERESIS UNIT|MINOR PATHOLOGIC RESPONSE||ML/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|INTERVIEWER|PATHOLOGIST 2|U|5||7||SCREENING|1971-02-21||||1967-02-01||1972-05-16|1964-06-08||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||CLINRESP|CLINICAL RESPONSE||||U/ML|CYTOGENETIC MINIMAL RESPONSE||MCI/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|CHILD|READER 3|Y|5||7||SCREENING|1968-11-02||||1967-05-27||1967-06-18|1968-09-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MM/SEC|HI-P||M3|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|SPOUSE|HEMATOLOGIST|U|1||38||RUN-IN|1973-07-02||||1964-11-05||1960-05-31|1963-11-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||STRUSTAT|STEROID USE STATUS||||MCI/L|MOLECULAR CR||PG/CELL|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|1||38||BASELINE|1966-09-28||||1960-08-07||1971-10-10|1965-07-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||CLINRESP|CLINICAL RESPONSE||||ML/ANIMAL/WK|CR||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|CHILD|ADJUDICATOR 2|N|2||58||LONG-TERM FOLLOW-UP|1962-12-09||||1965-04-19||1960-12-13|1963-10-13||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/KG/MIN|IMPROVED||BQ/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|Y|ADJUDICATOR|RATER 2|NA|2||58||OBSERVATION|1967-11-12||||1965-05-07||1968-08-26|1964-01-26||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||SACHET|IMPROVED||ENZYME U/G HB|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|3||39||BLINDED TREATMENT|1961-12-08||||1970-01-15||1970-05-17|1964-07-20||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MOL/L|CA125 50% RESPONSE||APS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|INTERVIEWER|UROLOGIST|N|3||39||BLINDED TREATMENT|1960-09-11||||1971-07-23||1968-06-23|1963-02-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||METBRESP|METABOLIC RESPONSE||||1/(S*KPA)|PD-CT||10^3/HPF|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|FAMILY MEMBER|NEUROLOGIST 2|NA|4||88||OBSERVATION|1960-01-03||||1970-10-29||1965-10-14|1962-06-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||TRGRESP|TARGET RESPONSE||||NG/L|DECREASED||ENZYME U/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|INVESTIGATOR|PATHOLOGIST 2|Y|4||88||OBSERVATION|1970-12-08||||1971-11-05||1972-05-19|1963-12-21||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||STRUSTAT|STEROID USE STATUS||||CFU/ML|MRD NEGATIVITY||LOG10 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|INVESTIGATOR|NEUROLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1970-12-20||||1962-12-08||1966-05-16|1970-10-06||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/BREATH|PMD||KN/CM2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|U|5||7||SCREENING|1962-08-19||||1966-02-13||1960-11-15|1964-07-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||OVRLRESP|OVERALL RESPONSE||||10^6 IU|HI-P||KDA|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|N|CAREGIVER|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1960-05-18||||1968-02-22||1965-12-22|1961-02-06||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BAU|CMR||/WK|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|CAREGIVER|RATER|NA|1||38||OPEN LABEL TREATMENT|1968-10-12||||1960-08-12||1960-09-15|1962-12-24||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DPM/0.5 ML|PD FROM PR||AMOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|VENDOR|FORENSIC PATHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1968-08-30||||1962-04-20||1967-07-22|1967-11-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||OVRLRESP|OVERALL RESPONSE||||DRAM|CPR||M3|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|ADJUDICATION COMMITTEE|RATER 1|Y|2||58||BASELINE|1971-06-30||||1970-05-12||1968-04-17|1961-12-01||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PA|ABSENT MORPHOLOGIC RESPONSE||% INHIBITION|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|3||39||OPEN LABEL TREATMENT|1970-07-02||||1968-02-24||1966-06-05|1968-05-09||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||BESTRESP|BEST OVERALL RESPONSE||||FARAD|HI-E||MOL/MG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|INTERVIEWER|ADJUDICATOR|NA|3||39||RUN-IN|1973-04-29||||1965-02-03||1966-05-24|1962-04-21||DURING||DURING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CARTRIDGE|RELAPSED DISEASE||U/10^12 RBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|U|PROXY|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1965-02-22||||1969-11-21||1965-11-22|1972-05-04||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||ML/MIN|MR||S/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1968-06-07||||1962-03-27||1967-08-28|1961-07-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/DL|RELAPSED DISEASE||UU/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|NA|ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|5||7||TREATMENT|1971-08-10||||1971-06-21||1967-06-23|1964-01-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||NTRGRESP|NON-TARGET RESPONSE||||MG/M2/MIN|PSEUDORESPONSE||DIOPTER|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|VENDOR|OPTOMETRIST|U|5||7||RUN-IN|1965-03-23||||1972-12-11||1969-05-10|1962-08-08||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ABSORBANCE U/MIN|PD/RELAPSE AFTER HI||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|NA|ADJUDICATION COMMITTEE|READER 3|N|1||38||WASHOUT|1962-08-17||||1961-09-19||1969-04-15|1961-06-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||HR/DAY|ICR||CFU/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|1||38||FOLLOW-UP|1972-04-20||||1964-04-25||1966-02-21|1961-06-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||M2|MRD RELAPSE||PNU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|INTERVIEWER|MICROSCOPIST 2|NA|2||58||SCREENING|1965-06-29||||1971-05-05||1962-12-21|1963-05-02||DURING||AFTER|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||PLUG|SD||ML/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|STUDY SUBJECT|INTERNIST|U|2||58||INDUCTION TREATMENT|1970-04-27||||1971-04-26||1964-12-16|1973-09-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||FMOL/G|NON-QUANTIFIABLE MRD POSITIVITY||DEG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|INTERVIEWER|ADJUDICATOR 3|Y|3||39||WASHOUT|1960-08-20||||1967-08-11||1967-08-06|1965-07-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||MOLRESP|MOLECULAR RESPONSE||||L/MIN|MR||BU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|FRIEND|NEUROLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1970-04-30||||1972-08-19||1965-10-02|1966-04-10||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/KG|MORPHOLOGIC CRI||G/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|SIGNIFICANT OTHER|PATHOLOGIST 2|NA|4||88||OBSERVATION|1964-10-01||||1963-06-27||1971-04-13|1969-04-09||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TUBERCULIN UNIT/ML|NON-PD||MM/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|4||88||WASHOUT|1968-09-04||||1964-09-04||1968-02-01|1970-09-08||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||AG|HI-P||UMOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|SIBLING|RATER 2|NA|5||7||RUN-IN|1966-01-25||||1967-10-09||1972-11-18|1964-04-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 ORGANISMS/MG|STABLE||MPS U|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|DOMESTIC PARTNER|RATER 2|Y|5||7||TREATMENT|1960-10-13||||1971-01-30||1962-07-21|1969-12-20||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||NTRGRESP|NON-TARGET RESPONSE||||UG/KG|DISEASE TRANSFORMATION||U/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|NA|GUARDIAN|RATER|Y|1||38||BLINDED TREATMENT|1963-04-18||||1961-01-02||1965-02-15|1968-08-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||SUPPOSITORY|IPR||MMHG*MIN/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|SIBLING|ONCOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1965-07-29||||1960-01-30||1965-03-01|1966-06-24||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MEQ/KG|DECREASED||WAFER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|VENDOR|FORENSIC PATHOLOGIST|NA|2||58||BASELINE|1962-12-13||||1960-06-10||1968-11-03|1966-01-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||TMRESP|TUMOR MARKER RESPONSE||||APPLICATION|IUPD||UG/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST|Y|2||58||WASHOUT|1970-04-11||||1961-02-14||1966-09-19|1961-07-29||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/ANIMAL|CPR||NG/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|SPOUSE|OPHTHALMOLOGIST|Y|3||39||TREATMENT|1968-10-21||||1963-08-07||1968-10-27|1971-10-27||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||METBRESP|METABOLIC RESPONSE||||SQU/ML|NPR||CG|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|CHILD|MICROSCOPIST 3|NA|3||39||FOLLOW-UP|1968-02-24||||1965-11-19||1972-11-04|1963-07-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||METSIND|METASTATIC INDICATOR||||UIU/DL|SD||BQ/L|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|SIBLING|ONCOLOGIST|N|4||88||WASHOUT|1963-04-16||||1972-12-25||1970-04-09|1967-01-13||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/ANIMAL/WK|ICPD||BAU/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|INTERVIEWER|OPHTHALMOLOGIST|Y|4||88||CONTINUATION TREATMENT|1972-10-05||||1963-04-07||1964-06-28|1962-12-27||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||BONERESP|BONE RESPONSE||||MCI|VGPR||APL U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|SIBLING|RATER 1|N|5||7||OPEN LABEL TREATMENT|1968-12-21||||1960-11-21||1966-07-31|1972-06-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||TMRESP|TUMOR MARKER RESPONSE||||UM2|SMD||NG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|CAREGIVER|NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1962-05-01||||1963-02-17||1964-04-12|1968-04-24||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|1||||||METSIND|METASTATIC INDICATOR||||MG/M2/DAY|HI-P||PMOL|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|VENDOR|NEUROLOGIST 1|N|1||38||BASELINE|1961-10-11||||1963-02-21||1967-07-02|1971-06-21||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|2||||||METSIND|METASTATIC INDICATOR||||EVENTS|PCR||MOSM/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|Y|CAREGIVER|ONCOLOGIST 1|NA|1||38||WASHOUT|1962-02-08||||1968-10-23||1973-02-21|1971-10-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GTT|PR WITH LYMPHOCYTOSIS||/LPF|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2||58||OBSERVATION|1966-08-28||||1968-04-17||1966-01-16|1963-04-07||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MILE|NR||CIGAR|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST|N|2||58||OBSERVATION|1967-09-10||||1971-06-02||1963-03-26|1971-11-07||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||GPL U/ML|HI-P||10^4/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|PARENT|CLINICAL PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1970-01-24||||1967-03-01||1972-12-11|1967-09-22||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|2||||||TMRESP|TUMOR MARKER RESPONSE||||FINGERTIP UNIT|SD||/MS|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|3||39||CONTINUATION TREATMENT|1962-11-22||||1961-02-22||1970-02-23|1962-03-24||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KM/H|INDETERMINATE RESPONSE||LOG10 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1968-07-28||||1966-03-05||1966-06-04|1962-09-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^3 CFU|QUANTIFIABLE MRD POSITIVITY||GTT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|4||88||SCREENING|1961-03-01||||1964-12-27||1964-06-28|1964-03-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|1||||||ANATRESP|ANATOMIC RESPONSE||||ANTIBODY UNIT|CR-CT||FOZ_BR|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|FAMILY MEMBER|READER 1|NA|5||7||BASELINE|1973-05-07||||1965-10-24||1972-06-29|1969-06-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|D807C3F6-0955-4742-A29B-815682559530|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MMOL/MIN/KPA|IMPROVED||MS/MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|FAMILY MEMBER|OPHTHALMOLOGIST|N|5||7||BLINDED TREATMENT|1960-04-03||||1973-06-21||1969-03-28|1963-10-07||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PIXEL|INCREASED||CM/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|FAMILY MEMBER|UROLOGIST|U|1||38||BASELINE|1962-04-02||||1964-03-16||1972-10-09|1969-07-11||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||BESTRESP|BEST OVERALL RESPONSE||||NMOL/MOL|CYTOGENETIC MINOR RESPONSE||HENRY|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|1||38||INDUCTION TREATMENT|1964-02-02||||1965-03-28||1960-08-16|1964-04-28||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||CLINRESP|CLINICAL RESPONSE||||CM/S|MOLECULAR MAJOR RESPONSE||JDF UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|2||58||SCREENING|1964-02-14||||1971-02-07||1972-01-11|1961-05-02||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||/LSQN|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|GUARDIAN|ONCOLOGIST 2|U|2||58||BLINDED TREATMENT|1968-04-04||||1972-11-01||1972-07-18|1968-04-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||CLINRESP|CLINICAL RESPONSE||||MMHG|PMR||/5X10^4 WBC|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|ADJUDICATOR|PATHOLOGIST 1|Y|3||39||TREATMENT|1972-11-10||||1964-03-08||1965-07-17|1970-09-09||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||OVRLRESP|OVERALL RESPONSE||||UOSM|NOT ALL EVALUATED||FMOL/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|NA|INVESTIGATOR|MICROSCOPIST 2|U|3||39||INDUCTION TREATMENT|1962-05-09||||1961-07-20||1960-08-24|1963-08-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||STRUSTAT|STEROID USE STATUS||||LOG EID 50/DOSE|NED||/2000 RBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||OPEN LABEL TREATMENT|1962-11-03||||1971-09-06||1971-07-03|1960-10-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/M2/H|MORPHOLOGIC LEUKEMIA-FREE STATE||EU|NOT DONE|||LIKERT SCALE 7-POINT|N|N|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|4||88||WASHOUT|1962-12-06||||1963-02-06||1969-12-03|1965-06-16||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||CLINRESP|CLINICAL RESPONSE||||CI|MINOR PATHOLOGIC RESPONSE||PPM|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|INDEPENDENT ASSESSOR|READER 3|N|5||7||INDUCTION TREATMENT|1971-03-24||||1966-11-30||1960-10-21|1965-09-08||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DB|RELAPSED DISEASE FROM CR||NKAT|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|GUARDIAN|READER 1|U|5||7||OBSERVATION|1964-04-05||||1963-12-09||1961-12-04|1969-07-28||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/H|NPR||BQ/L|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|ADJUDICATION COMMITTEE|READER 2|Y|1||38||LONG-TERM FOLLOW-UP|1971-06-17||||1964-03-21||1966-06-06|1965-02-17||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FRACTION OF 1|VGPR||M|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|INVESTIGATOR|NEUROLOGIST 2|U|1||38||OPEN LABEL TREATMENT|1962-12-12||||1964-05-04||1972-01-25|1969-08-19||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/KG/DAY|CR||UV2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|INVESTIGATOR|RATER 1|NA|2||58||FOLLOW-UP|1962-09-13||||1967-02-14||1960-07-12|1965-04-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||NEWLPROG|NEW LESION PROGRESSION||||HEP|CPR||GPS U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|2||58||TREATMENT|1960-12-09||||1960-04-02||1964-11-04|1969-05-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||BONERESP|BONE RESPONSE||||AG|PD/RELAPSE AFTER HI||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|PARENT|MICROSCOPIST 2|NA|3||39||WASHOUT|1971-07-09||||1962-06-26||1964-06-13|1971-01-29||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/M2/H|VGPR||MEQ/MMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|3||39||OBSERVATION|1962-06-10||||1969-04-21||1961-09-04|1972-01-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/KG|RELAPSED DISEASE FROM CR OR PR||OI50|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|SIGNIFICANT OTHER|ADJUDICATOR|NA|4||88||BASELINE|1961-03-18||||1968-10-20||1960-02-13|1960-07-13||DURING||AFTER|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||LIVRRESP|LIVER RESPONSE||||/10^4|MORPHOLOGIC CRI||POUCH|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|INVESTIGATOR|ONCOLOGIST 2|U|4||88||WASHOUT|1960-09-09||||1970-10-10||1963-04-02|1971-09-08||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/ML/MIN|PDU||MEQ/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|SPOUSE|READER|N|5||7||RUN-IN|1962-02-12||||1966-11-23||1968-08-30|1970-02-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||BESTRESP|BEST OVERALL RESPONSE||||GMFI|MRD PERSISTENCE||DAGU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1961-10-21||||1966-09-24||1961-07-16|1973-06-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/CM|INCREASED||G/U|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|VENDOR|READER 1|U|1||38||FOLLOW-UP|1962-03-02||||1966-12-23||1969-05-20|1973-07-24||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||LOG10 ELISA UNIT|SMD||G/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|NA|STUDY SUBJECT|ADJUDICATOR|Y|1||38||FOLLOW-UP|1971-07-01||||1972-11-17||1970-07-22|1972-07-08||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/BEAT|PD FROM PR||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|STUDY SUBJECT|READER 2|U|2||58||BLINDED TREATMENT|1961-07-15||||1969-10-17||1960-11-21|1972-07-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/G/H|PSEUDOPROGRESSION||ML/G/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|2||58||CONTINUATION TREATMENT|1971-02-10||||1968-08-14||1968-08-11|1971-10-15||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CI/UG|CYTOGENETIC NO RESPONSE||USEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|CAREGIVER|OTOLARYNGOLOGIST|Y|3||39||FOLLOW-UP|1960-03-01||||1973-07-02||1972-08-05|1967-07-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/H|OPTIMAL MORPHOLOGIC RESPONSE||/7.5 ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||TREATMENT|1962-03-13||||1964-07-11||1961-01-22|1960-02-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||NEWLPROG|NEW LESION PROGRESSION||||RFU|ICPD||CI/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|NA|PARENT|RADIOLOGIST 1|NA|4||88||BLINDED TREATMENT|1967-03-27||||1968-08-15||1964-07-30|1963-01-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/M2|MOLECULAR CR||BP|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|FAMILY MEMBER|ONCOLOGIST 2|U|4||88||BLINDED TREATMENT|1964-08-31||||1964-06-18||1969-08-17|1961-02-24||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NG/MOL|ABSENT MORPHOLOGIC RESPONSE||GBQ/UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|Y|INVESTIGATOR|READER 2|N|5||7||RUN-IN|1972-08-05||||1961-10-14||1963-05-07|1968-01-28||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||BESTRESP|BEST OVERALL RESPONSE||||BQ/MG|NE||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||OPEN LABEL TREATMENT|1965-02-05||||1960-05-17||1965-02-04|1967-07-19||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CMHG|PARTIAL MORPHOLOGIC RESPONSE||GMFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|U|STUDY SUBJECT|ENDOCRINOLOGIST|N|1||38||OBSERVATION|1962-08-13||||1967-05-13||1960-12-26|1968-05-22||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||CLINRESP|CLINICAL RESPONSE||||BOLUS|CYTOGENETIC PR||HPA|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|ADJUDICATOR|PATHOLOGIST|U|1||38||CONTINUATION TREATMENT|1967-06-01||||1962-03-26||1967-01-02|1965-08-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||DAGU|PD||VIRTUAL PIXEL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|2||58||TREATMENT|1972-04-24||||1966-04-10||1961-04-19|1972-07-01||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||NEWLIND|NEW LESION INDICATOR||||UCI/L|PD/RELAPSE AFTER HI||KCAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|2||58||BLINDED TREATMENT|1963-01-06||||1966-02-24||1966-01-27|1973-02-22||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||MOLRESP|MOLECULAR RESPONSE||||M2|NED||KS|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|INTERVIEWER|NEUROLOGIST 1|N|3||39||WASHOUT|1967-11-29||||1970-04-02||1960-11-26|1960-02-19||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||TMRESP|TUMOR MARKER RESPONSE||||HPA|NON-PD||M/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|3||39||OBSERVATION|1970-08-06||||1960-11-07||1968-08-21|1960-01-14||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||RNA COPIES/ML|PR||MBQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|4||88||BLINDED TREATMENT|1970-10-28||||1965-08-09||1968-06-26|1970-08-16||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||METBRESP|METABOLIC RESPONSE||||MM/MIN|NPR||NKAT/G HB|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|FAMILY MEMBER|ONCOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1971-03-16||||1960-04-19||1960-12-11|1972-07-21||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MET*MIN|HI-N||G/ANIMAL/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|ADJUDICATOR|MICROSCOPIST 3|Y|5||7||TREATMENT|1969-03-28||||1971-02-01||1960-04-02|1967-06-08||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^7 PFU|MORPHOLOGIC CR||GPELISA UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|CHILD|INTERNIST|NA|5||7||OPEN LABEL TREATMENT|1965-02-24||||1967-02-20||1962-11-20|1966-11-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UG/M2|NPR||PFU/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|Y|ADJUDICATOR|ONCOLOGIST 2|U|1||38||OBSERVATION|1963-03-22||||1964-03-13||1970-02-16|1971-12-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|2||||||TMRESP|TUMOR MARKER RESPONSE||||MMOL/G|NPR||%/S|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|FAMILY MEMBER|ADJUDICATOR 1|Y|1||38||SCREENING|1973-05-17||||1960-08-30||1961-02-12|1962-01-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PATCH|RELAPSED DISEASE||G/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|N|INTERVIEWER|PATHOLOGIST 2|U|2||58||BASELINE|1968-05-12||||1965-07-17||1962-09-05|1973-03-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||M/SEC|PR-CT||/MM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1970-08-29||||1972-12-06||1972-01-07|1973-01-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CIGAR|MCR||S*KPA|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|U|SIGNIFICANT OTHER|READER 1|N|3||39||WASHOUT|1972-03-17||||1965-04-20||1964-08-12|1969-06-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/KG/DAY|CYTOGENETIC CR||UG/L DDU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|3||39||RUN-IN|1967-04-09||||1970-03-30||1971-03-13|1969-05-30||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ATM|INDETERMINATE RESPONSE||MEQ|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|FRIEND|MICROSCOPIST|Y|4||88||FOLLOW-UP|1972-05-07||||1971-09-15||1970-12-24|1961-02-26||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||COAT|CYTOGENETIC CR||ML/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|N|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|4||88||TREATMENT|1967-06-11||||1968-01-28||1967-03-30|1962-10-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|1||||||CLINRESP|CLINICAL RESPONSE||||G/CAGE/WK|MRD PERSISTENCE||USP U|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|INVESTIGATOR|PATHOLOGIST 1|NA|5||7||RUN-IN|1972-03-08||||1960-09-23||1962-10-22|1967-06-13||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|49B857CF-22F2-406F-A269-54944B23C236|2||||||RDIORESP|RADIOLOGIC RESPONSE||||L/S|CPR||CI/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|N|DOMESTIC PARTNER|UROLOGIST|NA|5||7||RUN-IN|1967-09-14||||1964-07-19||1970-05-23|1961-12-14||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|1||||||CLINRESP|CLINICAL RESPONSE||||FMOL|NPR||G/CAGE/WK|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|INTERVIEWER|INTERNIST|N|1||38||OBSERVATION|1965-01-25||||1967-09-03||1966-05-12|1961-10-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|2||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/BREATH|SMD||DAYS/MONTH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|STUDY SUBJECT|OPTOMETRIST|NA|1||38||OBSERVATION|1973-01-05||||1966-05-17||1970-07-09|1971-04-05||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|1||||||ANATRESP|ANATOMIC RESPONSE||||ML/H|MRD NEGATIVITY||IU/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|SPOUSE|RADIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1968-09-26||||1965-04-18||1972-10-19|1973-07-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/MIN|NON-PD||MDFI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|ADJUDICATION COMMITTEE|READER 3|NA|2||58||INDUCTION TREATMENT|1961-11-18||||1969-01-27||1960-07-31|1969-05-30||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/G/H|INCREASED||MV*MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|CAREGIVER|OPHTHALMOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1970-04-30||||1969-06-13||1965-01-05|1964-11-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|2||||||NTRGRESP|NON-TARGET RESPONSE||||GMFI|CYTOGENETIC PR||MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||BASELINE|1960-05-30||||1963-06-01||1968-10-28|1970-05-25||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||/SEC|MORPHOLOGIC CRI||/2000 RBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|FAMILY MEMBER|ONCOLOGIST|U|4||88||RUN-IN|1962-03-16||||1966-02-13||1971-01-19|1971-11-29||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|2||||||METBRESP|METABOLIC RESPONSE||||NMOL/MOL|DISEASE TRANSFORMATION||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|CHILD|RATER|U|4||88||FOLLOW-UP|1965-06-22||||1965-12-02||1962-08-29|1966-02-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|1||||||NEWLPROG|NEW LESION PROGRESSION||||HR/DAY|MAJOR PATHOLOGIC RESPONSE||MG/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|FRIEND|PATHOLOGIST|N|5||7||BLINDED TREATMENT|1961-12-15||||1962-10-29||1969-05-19|1964-07-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|E09B394B-9E48-4132-B430-991DF1953A81|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MN|PD||10^6 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|5||7||RUN-IN|1960-04-29||||1962-04-07||1972-04-11|1962-05-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||MOLRESP|MOLECULAR RESPONSE||||10^7/L|CCR||TAMPON|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|1||38||INDUCTION TREATMENT|1971-09-30||||1962-05-14||1965-08-24|1964-02-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||ANATRESP|ANATOMIC RESPONSE||||COAT|MR||CM H2O|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|CAREGIVER|RATER|NA|1||38||WASHOUT|1962-03-11||||1966-07-19||1966-06-12|1963-07-16||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CUP EQ|PD||10^9 CFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|INDEPENDENT ASSESSOR|RATER|NA|2||58||BLINDED TREATMENT|1971-08-21||||1962-05-25||1971-05-02|1971-11-23||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GENEQ/ML|NON-ICR/NON-IUPD||MG/L FEU|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|2||58||INDUCTION TREATMENT|1966-03-04||||1963-04-01||1962-02-21|1973-06-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||RDIORESP|RADIOLOGIC RESPONSE||||IU/L|SCR||MM3/MM2/YEAR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|3||39||INDUCTION TREATMENT|1971-03-18||||1969-02-11||1973-06-02|1960-05-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||OVRLRESP|OVERALL RESPONSE||||HPA|NON-ICR/NON-IUPD||KCAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|U|SPOUSE|NEUROLOGIST|N|3||39||BASELINE|1969-04-29||||1970-09-10||1967-01-28|1961-11-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||LIVRRESP|LIVER RESPONSE||||BOX|CPR||UCI/KG|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|ADJUDICATOR|READER 3|N|4||88||OBSERVATION|1960-01-05||||1960-01-11||1968-06-10|1960-06-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||ANATRESP|ANATOMIC RESPONSE||||TORR|CCR||MV2/HZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|4||88||WASHOUT|1969-09-01||||1964-07-17||1963-08-31|1965-09-21||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MSEC|IPR||LM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|5||7||INDUCTION TREATMENT|1960-01-09||||1972-06-02||1963-09-24|1960-02-04||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/L|SD||ML/M2/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|FAMILY MEMBER|PHYSIOTHERAPIST|Y|5||7||OPEN LABEL TREATMENT|1965-06-29||||1964-02-18||1963-12-19|1971-10-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TITER|MRD NEGATIVITY||ABSORBANCE U|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|N|SIGNIFICANT OTHER|HEMATOLOGIST|U|1||38||FOLLOW-UP|1972-12-08||||1968-06-26||1973-07-31|1961-07-16||DURING||AFTER|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||G/CAGE|NR||IN2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|STUDY SUBJECT|PHYSIOTHERAPIST|N|1||38||RUN-IN|1964-09-20||||1968-02-01||1964-04-24|1970-12-29||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MPL U/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||NEBULE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|U|ADJUDICATOR|RADIOLOGIST|U|2||58||BLINDED TREATMENT|1967-08-08||||1971-11-23||1967-04-15|1972-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PMOL/L/H|SD-CT||MEQ/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|U|FRIEND|RATER 2|Y|2||58||BLINDED TREATMENT|1968-01-09||||1966-02-13||1973-07-08|1968-10-13||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||NEWLPROG|NEW LESION PROGRESSION||||MEQ/DAY|WORSENED||TITER|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|SIBLING|HEMATOLOGIST|NA|3||39||TREATMENT|1964-12-16||||1963-12-19||1965-03-18|1960-08-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||OVRLRESP|OVERALL RESPONSE||||STEPS/MIN|OPTIMAL MORPHOLOGIC RESPONSE||U/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|PARENT|ADJUDICATOR 2|Y|3||39||TREATMENT|1960-11-19||||1972-01-29||1970-10-17|1964-12-09||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KG/CM2|NON-PD||HEP|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|PARENT|OPTOMETRIST|NA|4||88||BASELINE|1972-09-17||||1964-09-30||1971-04-14|1962-10-12||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MG|PSEUDORESPONSE||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|N|CHILD|INTERNIST|N|4||88||CONTINUATION TREATMENT|1965-02-17||||1970-03-12||1967-06-27|1971-05-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||/MBP|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|N|5||7||OPEN LABEL TREATMENT|1962-05-25||||1960-01-05||1963-04-22|1962-08-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||M3|DECREASED||U|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|INVESTIGATOR|ADJUDICATOR 3|U|5||7||INDUCTION TREATMENT|1960-12-17||||1966-06-10||1966-06-24|1963-08-05||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UMOL/H/MMOL|SCR||ML/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|DOMESTIC PARTNER|RATER 1|U|1||38||CONTINUATION TREATMENT|1964-04-06||||1960-01-14||1971-03-02|1970-11-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PKAT/L|CMR||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|CAREGIVER|ONCOLOGIST|Y|1||38||OBSERVATION|1969-12-08||||1965-11-28||1961-10-08|1970-04-20||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||OVRLRESP|OVERALL RESPONSE||||/MONTH|NON-QUANTIFIABLE MRD POSITIVITY||10^4/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|FAMILY MEMBER|ADJUDICATOR|N|2||58||CONTINUATION TREATMENT|1969-04-14||||1967-02-05||1969-04-29|1962-11-21||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/KG|IMPROVED||/MIN|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|RATER 2|NA|2||58||WASHOUT|1970-03-07||||1960-09-15||1971-01-22|1962-03-25||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||RDIORESP|RADIOLOGIC RESPONSE||||MMOL/G|PR||BQ/MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|FRIEND|FORENSIC PATHOLOGIST|N|3||39||WASHOUT|1967-05-26||||1965-11-25||1969-03-23|1964-10-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||STRUSTAT|STEROID USE STATUS||||COPIES/ML|PD/RELAPSE AFTER HI||BU|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|N|VENDOR|FORENSIC PATHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1968-02-23||||1970-05-22||1963-03-13|1962-04-01||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||METSIND|METASTATIC INDICATOR||||MMHG|NR||YD|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||INDUCTION TREATMENT|1960-12-21||||1964-03-21||1962-01-16|1970-08-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||NEWLPROG|NEW LESION PROGRESSION||||BU|EQUIVOCAL||10^3 CFU/G|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|DOMESTIC PARTNER|INTERNIST|U|4||88||BLINDED TREATMENT|1968-11-02||||1965-05-30||1965-04-07|1972-06-24||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||OVRLRESP|OVERALL RESPONSE||||WEBER|MORPHOLOGIC CRI||PATCH|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|GUARDIAN|MICROSCOPIST 3|N|5||7||INDUCTION TREATMENT|1964-06-11||||1964-09-18||1965-10-18|1961-05-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||STRUSTAT|STEROID USE STATUS||||PPTH|SCR||UL/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|GUARDIAN|READER 3|N|5||7||RUN-IN|1965-04-09||||1967-01-04||1967-02-23|1962-07-21||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PNU/ML|HI-N||10^6 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|1||38||RUN-IN|1973-05-21||||1970-09-29||1965-09-08|1966-06-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NMOL/G|CA125 75% RESPONSE||IMPLANT|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|SIBLING|OPTOMETRIST|Y|1||38||OPEN LABEL TREATMENT|1965-04-20||||1963-11-06||1962-09-02|1971-08-25||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/M2/DAY|MORPHOLOGIC LEUKEMIA-FREE STATE||DAYS|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|CHILD|NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1968-09-21||||1965-04-08||1961-08-14|1960-11-06||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/KG/WEEK|ICPD||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|NA|CHILD|PATHOLOGIST 2|N|2||58||FOLLOW-UP|1960-08-20||||1972-09-05||1969-10-27|1971-06-24||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/MMHG|NPR||FMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|U|PARENT|ENDOCRINOLOGIST|NA|3||39||INDUCTION TREATMENT|1969-05-02||||1967-01-04||1968-02-26|1964-09-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UG/L|RELAPSED DISEASE FROM CR OR PR||CM/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3||39||WASHOUT|1961-01-03||||1962-09-30||1970-03-12|1964-04-17||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||STRUSTAT|STEROID USE STATUS||||UG/G/MIN|PD||G/KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|SPOUSE|READER 3|NA|4||88||TREATMENT|1964-07-18||||1962-09-22||1963-11-26|1966-02-14||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UG/MOL|WORSENED||HENRY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|4||88||RUN-IN|1969-03-02||||1973-06-12||1965-12-27|1971-11-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||ANATRESP|ANATOMIC RESPONSE||||NEWTON|ABSENT MORPHOLOGIC RESPONSE||G/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|VENDOR|OPHTHALMOLOGIST|U|5||7||OPEN LABEL TREATMENT|1960-02-11||||1965-06-08||1960-10-05|1972-05-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MS2|WORSENED||CM2|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|5||7||BLINDED TREATMENT|1963-11-20||||1967-11-12||1961-04-18|1964-07-10||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^3 CFU/ML|CRI||BQ/MG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|PROXY|UROLOGIST|N|1||38||BASELINE|1963-10-18||||1960-01-19||1972-03-28|1968-09-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UIU/L|UNEQUIVOCAL||ML/M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|SIBLING|OPHTHALMOLOGIST|U|1||38||TREATMENT|1972-01-25||||1964-05-16||1966-06-11|1964-09-26||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MG|DECREASED||NMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|PROXY|INTERNIST|NA|2||58||OPEN LABEL TREATMENT|1968-09-09||||1961-10-26||1961-06-05|1963-05-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||BESTRESP|BEST OVERALL RESPONSE||||PMOL/10^10 CELLS|ICR||IU/KG/H|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2||58||CONTINUATION TREATMENT|1963-03-12||||1970-09-16||1971-04-01|1964-04-26||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||AFU|VGPR||RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|INTERVIEWER|READER 3|Y|3||39||CONTINUATION TREATMENT|1962-08-25||||1963-11-20||1968-09-19|1970-08-03||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BE/ML|PR WITH LYMPHOCYTOSIS||TABLET|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|CAREGIVER|NEUROLOGIST 2|U|3||39||SCREENING|1967-03-03||||1966-06-06||1960-05-02|1973-01-09||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||YD|EQUIVOCAL||MOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||TREATMENT|1973-04-22||||1964-07-26||1962-12-19|1969-06-26||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||SPLNRESP|SPLEEN RESPONSE||||PA|HI-P||K|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|FAMILY MEMBER|READER 2|Y|4||88||OBSERVATION|1963-04-06||||1962-02-12||1971-08-17|1963-07-31||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||NEWLPROG|NEW LESION PROGRESSION||||MET|CHR||CY/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|DOMESTIC PARTNER|RATER 1|U|5||7||OBSERVATION|1968-06-01||||1963-11-14||1970-01-07|1963-11-26||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PKAT/L|IUPD||PUFF|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|N|PARENT|ADJUDICATOR 1|U|5||7||TREATMENT|1965-04-15||||1967-09-02||1972-05-04|1967-01-27||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||EU|MRD NEGATIVITY||VP/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|1||38||OBSERVATION|1970-05-14||||1967-04-20||1963-06-29|1962-05-28||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/MIN/MMHG|CR||IU/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|1||38||WASHOUT|1967-09-07||||1969-04-29||1962-08-17|1967-01-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IN|MORPHOLOGIC LEUKEMIA-FREE STATE||DNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|PROXY|ENDOCRINOLOGIST|N|2||58||INDUCTION TREATMENT|1963-01-06||||1967-07-22||1970-08-20|1971-05-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||NEWLPROG|NEW LESION PROGRESSION||||GRAVITATIONAL UNIT|PCR||10^5/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||RUN-IN|1968-03-07||||1969-12-14||1972-01-23|1970-03-17||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI/UL|CYTOGENETIC NO RESPONSE||10^6 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|STUDY SUBJECT|OPHTHALMOLOGIST|U|3||39||FOLLOW-UP|1968-12-17||||1968-03-06||1962-08-18|1962-05-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BQ/UL|RELAPSED DISEASE||VP/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|3||39||LONG-TERM FOLLOW-UP|1967-03-21||||1965-08-12||1968-04-25|1967-02-05||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CGY|PD FROM PR||ML/ANIMAL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|NA|GUARDIAN|RADIOLOGIST 1|N|4||88||LONG-TERM FOLLOW-UP|1968-04-16||||1966-03-16||1963-06-08|1962-10-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UG/M2|STABLE||MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|4||88||BLINDED TREATMENT|1964-10-19||||1962-10-12||1973-08-24|1972-08-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||BESTRESP|BEST OVERALL RESPONSE||||MAC50|CA125 50% RESPONSE||NKAT/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|PARENT|RATER|N|5||7||CONTINUATION TREATMENT|1972-07-30||||1969-06-03||1970-10-01|1969-06-25||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||ANATRESP|ANATOMIC RESPONSE||||SACHET|IUPD||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|SIBLING|READER 3|U|5||7||LONG-TERM FOLLOW-UP|1968-02-29||||1971-04-16||1970-01-14|1961-03-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||SQU/ML|MOLECULAR MAJOR RESPONSE||MG/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 2|NA|1||38||BASELINE|1970-04-28||||1968-11-29||1963-04-29|1969-06-26||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||TRGRESP|TARGET RESPONSE||||MOSM/KG|OPTIMAL MORPHOLOGIC RESPONSE||LINEAR FT*LB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|1||38||FOLLOW-UP|1961-05-05||||1973-06-29||1961-12-26|1962-09-03||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||UKAT|FAVORABLE RESPONSE||PIXELS/CM|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|2||58||OBSERVATION|1971-11-25||||1972-09-12||1970-01-31|1966-02-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||LIVRRESP|LIVER RESPONSE||||MBP|MORPHOLOGIC CRI||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|NA|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1971-07-16||||1960-01-23||1963-11-23|1972-09-23||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^6/EJACULATE U|RELAPSED DISEASE FROM CR OR PR||MG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|Y|ADJUDICATOR|RATER|U|3||39||LONG-TERM FOLLOW-UP|1965-04-06||||1963-10-08||1960-10-29|1961-08-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MGEQ|PMD||CONTAINER|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|SPOUSE|DERMATOLOGIST|U|3||39||INDUCTION TREATMENT|1965-12-07||||1962-10-19||1971-02-20|1970-11-14||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||METSIND|METASTATIC INDICATOR||||/MM2|CYTOGENETIC MINIMAL RESPONSE||NFIU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1961-06-02||||1965-08-13||1961-10-09|1968-02-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||METBRESP|METABOLIC RESPONSE||||UG/M2|UNFAVORABLE RESPONSE||MEQ/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|CAREGIVER|UROLOGIST|Y|4||88||WASHOUT|1972-01-18||||1961-05-15||1967-07-31|1963-07-22||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APL U/ML|ICR||MEQ/MMOL|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|GUARDIAN|READER 3|U|5||7||BASELINE|1962-07-18||||1968-09-05||1966-11-12|1973-04-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6/L|MRD PERSISTENCE||MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|U|5||7||LONG-TERM FOLLOW-UP|1968-04-23||||1965-12-11||1970-08-22|1960-05-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/UG|CR-CT||CUP EQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|U|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-09-01||||1969-10-31||1963-08-31|1967-09-06||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||COAT|ICR||FT2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|FRIEND|READER 3|Y|1||38||TREATMENT|1972-07-25||||1965-12-08||1961-12-08|1962-11-04||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/KG/DAY|RELAPSED DISEASE||DAMOL/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|CHILD|RADIOLOGIST|N|2||58||OPEN LABEL TREATMENT|1965-12-11||||1970-05-22||1966-01-29|1962-05-11||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||MOLRESP|MOLECULAR RESPONSE||||CI/MG|CYTOGENETIC NO RESPONSE||SFC/10^6 PBMC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|CHILD|RATER|U|2||58||BASELINE|1961-01-17||||1962-08-10||1960-05-10|1961-08-04||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||METSIND|METASTATIC INDICATOR||||OI50|PMD||PFU/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|CHILD|ADJUDICATOR|NA|3||39||INDUCTION TREATMENT|1971-09-27||||1965-06-09||1966-08-07|1961-04-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||BONERESP|BONE RESPONSE||||BOX|ISD||CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|N|INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|3||39||TREATMENT|1965-12-31||||1967-07-20||1968-06-08|1968-11-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||NEWLPROG|NEW LESION PROGRESSION||||MET*MIN|ISD||MOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|4||88||SCREENING|1962-11-03||||1971-03-22||1968-09-01|1964-02-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||TMRESP|TUMOR MARKER RESPONSE||||BISCUIT|NE||RATIO|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|NA|4||88||INDUCTION TREATMENT|1973-03-21||||1973-03-05||1965-04-05|1960-02-23||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||OVRLRESP|OVERALL RESPONSE||||%/MIN|HI-N||UV|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|CLINICAL RESEARCH COORDINATOR|RATER 1|NA|5||7||FOLLOW-UP|1970-07-14||||1969-04-01||1962-06-20|1965-12-14||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||ANATRESP|ANATOMIC RESPONSE||||EU|PARTIAL MORPHOLOGIC RESPONSE||MDFI|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5||7||SCREENING|1972-11-23||||1960-09-03||1969-12-15|1967-08-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DISK|CYTOGENETIC NO RESPONSE||UMOL/KG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|1||38||BLINDED TREATMENT|1973-01-05||||1973-06-23||1969-02-16|1969-03-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMOL/L|PR||CM H2O|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|INVESTIGATOR|MICROSCOPIST 2|NA|1||38||OBSERVATION|1963-10-29||||1973-09-07||1969-04-24|1972-01-16||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/G|PSEUDORESPONSE||ENZYME U/M2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1968-10-19||||1969-10-19||1961-10-23|1966-01-11||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||ANATRESP|ANATOMIC RESPONSE||||ANTIBODY UNIT|STABLE||ABSORBANCE U/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|NA|CAREGIVER|RADIOLOGIST 2|U|2||58||RUN-IN|1963-01-21||||1963-09-20||1966-04-23|1967-12-10||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||LINEAR FT*LB|RELAPSED DISEASE FROM CR||DAYS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|PROXY|DERMATOLOGIST|U|3||39||SCREENING|1966-07-31||||1961-08-15||1971-04-05|1962-05-03||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||ANATRESP|ANATOMIC RESPONSE||||G/KG|CYTOGENETIC MINIMAL RESPONSE||ML/CM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|3||39||BLINDED TREATMENT|1963-12-14||||1965-02-05||1965-01-06|1960-01-16||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||MOLRESP|MOLECULAR RESPONSE||||UM/DAY|MRD PERSISTENCE||PL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|ADJUDICATOR|ONCOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1972-06-13||||1971-01-03||1970-08-28|1965-05-25||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||VG/KG|CYTOGENETIC MINOR RESPONSE||TRANSDUCING UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|4||88||RUN-IN|1963-09-28||||1968-03-04||1967-01-13|1961-04-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/S|HI-N||L/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|U|GUARDIAN|OPHTHALMOLOGIST|Y|5||7||CONTINUATION TREATMENT|1969-04-23||||1969-12-25||1963-06-17|1972-10-01||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2|PSA PROGRESSION||UG/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|N|FRIEND|PEDIATRIC NEUROLOGIST|N|5||7||CONTINUATION TREATMENT|1964-02-16||||1965-02-14||1962-03-21|1970-02-04||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||STRUSTAT|STEROID USE STATUS||||CMOL/L|PSEUDORESPONSE||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|STUDY SUBJECT|PHYSIOTHERAPIST|N|1||38||OPEN LABEL TREATMENT|1963-01-28||||1971-11-01||1965-04-17|1971-07-06||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||DDU|WORSENED||SCM|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|1||38||WASHOUT|1961-07-10||||1967-05-20||1967-06-08|1971-03-08||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CONTAINER|CYTOGENETIC MINOR RESPONSE||CM H2O|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|ADJUDICATOR|MICROSCOPIST 1|Y|2||58||OBSERVATION|1961-12-19||||1964-12-05||1962-12-17|1973-04-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||BESTRESP|BEST OVERALL RESPONSE||||PATCH|RELAPSED DISEASE FROM CR OR PR||UMOL/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|PROXY|RADIOLOGIST 2|N|2||58||SCREENING|1963-12-10||||1961-11-24||1962-09-08|1966-10-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||TMRESP|TUMOR MARKER RESPONSE||||FMOL|ICPD||UG/M2/H|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|PROXY|MICROSCOPIST 3|Y|3||39||FOLLOW-UP|1971-04-16||||1973-03-12||1970-04-02|1971-01-05||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PHERESIS UNIT|CMR||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|ADJUDICATOR|READER 3|U|3||39||CONTINUATION TREATMENT|1962-08-31||||1965-09-25||1969-04-14|1963-10-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||NEWLPROG|NEW LESION PROGRESSION||||SCOOPFUL|PSA PROGRESSION||10^8 PFU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|PROXY|ADJUDICATOR 1|U|4||88||CONTINUATION TREATMENT|1969-05-13||||1972-02-14||1971-07-18|1964-02-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||IN|RELAPSED DISEASE FROM CR||U/G/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|4||88||BASELINE|1972-05-23||||1963-02-26||1969-05-23|1961-09-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||M|PR||LOZENGE|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|5||7||LONG-TERM FOLLOW-UP|1972-12-03||||1962-08-30||1962-09-20|1967-01-18||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG/KG/WEEK|MRD RELAPSE||MG/KG/WEEK|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|CAREGIVER|READER 1|NA|5||7||BASELINE|1964-04-27||||1970-11-03||1965-10-05|1962-10-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NEBULE|RELAPSED DISEASE FROM CR OR PR||MKAT|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|1||38||OPEN LABEL TREATMENT|1972-10-06||||1969-01-26||1969-07-31|1961-03-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/MOL|NR||UG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|INTERVIEWER|CARDIOLOGIST|Y|1||38||BLINDED TREATMENT|1962-10-31||||1965-12-14||1968-05-27|1960-11-18||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ABSORBANCE U|MOLECULAR MAJOR RESPONSE||U/CL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|PARENT|OPHTHALMOLOGIST|NA|2||58||INDUCTION TREATMENT|1965-09-04||||1968-05-10||1966-06-03|1962-04-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/G|RELAPSED DISEASE FROM CR||HENRY|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|U|2||58||INDUCTION TREATMENT|1967-10-15||||1971-02-10||1962-08-10|1967-10-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||MOLRESP|MOLECULAR RESPONSE||||NMOL/KG/DAY|MORPHOLOGIC CR||KM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|READER 3|N|3||39||SCREENING|1963-01-11||||1971-02-21||1960-03-10|1970-04-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BOTTLE|NON-ICR/NON-IUPD||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|FAMILY MEMBER|ADJUDICATOR 3|N|3||39||TREATMENT|1969-08-21||||1971-10-14||1966-08-28|1961-09-08||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||TMRESP|TUMOR MARKER RESPONSE||||YEARS|MCR||CONTAINER|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|ADJUDICATOR|DERMATOLOGIST|NA|4||88||RUN-IN|1967-04-26||||1960-07-31||1967-11-07|1962-01-02||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||%(V/V)|NED||DYN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|GUARDIAN|RADIOLOGIST 1|Y|4||88||FOLLOW-UP|1960-07-30||||1965-05-21||1962-01-01|1966-05-19||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BQ/ML|PD/RELAPSE AFTER HI||ML/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|SPOUSE|ADJUDICATOR 2|NA|5||7||CONTINUATION TREATMENT|1962-03-23||||1960-06-16||1963-01-11|1964-11-23||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||NEWLIND|NEW LESION INDICATOR||||CS|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/MIN/1.73M2|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|ADJUDICATOR|MICROSCOPIST 1|U|5||7||FOLLOW-UP|1964-09-23||||1966-09-13||1971-07-21|1966-10-26||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||LIVRRESP|LIVER RESPONSE||||KN/CM2|FAVORABLE RESPONSE||CM2|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||WASHOUT|1968-02-19||||1960-04-15||1964-04-06|1960-01-25||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/ANIMAL/WK|INDETERMINATE RESPONSE||CP|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|N|1||38||WASHOUT|1966-11-17||||1967-06-25||1962-08-30|1971-07-14||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||METSIND|METASTATIC INDICATOR||||SPRAY|ISD||UG/L FEU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1970-10-08||||1963-04-01||1965-06-19|1962-12-26||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||SQU/ML|FAVORABLE RESPONSE||ELISA UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|PARENT|ADJUDICATOR 2|NA|2||58||RUN-IN|1967-07-06||||1964-08-20||1971-12-05|1960-02-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||BONERESP|BONE RESPONSE||||M/SEC|ISD||MJOULE/CM2|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|N|FRIEND|INTERNIST|Y|3||39||INDUCTION TREATMENT|1971-11-09||||1966-11-13||1962-05-24|1960-03-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||METSIND|METASTATIC INDICATOR||||CI/MG|PDU||BEL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1961-10-05||||1973-08-21||1973-02-22|1963-11-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MS/MMHG|PR-CT||ANTI-XA IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|INVESTIGATOR|HEMATOLOGIST|NA|4||88||FOLLOW-UP|1966-10-27||||1971-01-17||1967-09-10|1961-11-07||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/M2/MIN|PMR||MM/H|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|U|SIGNIFICANT OTHER|NEUROLOGIST|Y|4||88||OBSERVATION|1963-12-04||||1969-05-18||1962-10-22|1971-12-19||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL BCE/MMOL|RELAPSED DISEASE||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|5||7||BLINDED TREATMENT|1961-11-26||||1972-12-25||1964-03-04|1970-09-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/H|CYTOGENETIC MINOR RESPONSE||/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|5||7||SCREENING|1963-07-04||||1967-10-05||1966-02-11|1965-09-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2/DAY|CYTOGENETIC CR||MPH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|FRIEND|CARDIOLOGIST|NA|1||38||BASELINE|1963-09-20||||1972-09-03||1967-05-12|1970-07-03||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NG/DL|RELAPSED DISEASE FROM CR OR PR||MG/DL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|SIGNIFICANT OTHER|INTERNIST|NA|1||38||FOLLOW-UP|1969-11-13||||1965-09-03||1965-07-18|1972-07-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/ANIMAL/DAY|UNFAVORABLE RESPONSE||MOSM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|U|VENDOR|RADIOLOGIST 1|NA|2||58||RUN-IN|1966-02-10||||1970-07-03||1971-02-01|1969-01-20||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||C|CA125 75% RESPONSE||UOSM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|STUDY SUBJECT|PATHOLOGIST|U|2||58||FOLLOW-UP|1966-08-20||||1962-07-13||1967-06-16|1961-10-24||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||NEWLIND|NEW LESION INDICATOR||||ML/CAGE/DAY|CMR||MMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||BLINDED TREATMENT|1964-10-07||||1964-12-19||1961-01-30|1960-11-13||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||LIVRRESP|LIVER RESPONSE||||MG/CM2|UNEQUIVOCAL||DEG2|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|N|ADJUDICATOR|MICROSCOPIST 1|NA|3||39||RUN-IN|1972-12-01||||1970-10-23||1965-04-12|1970-09-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||METBRESP|METABOLIC RESPONSE||||10^3 ORGANISMS|COMPLETE MRD RESPONSE||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|CAREGIVER|MICROSCOPIST 3|N|4||88||INDUCTION TREATMENT|1969-06-01||||1967-12-10||1960-07-05|1970-01-20||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 CFU|CRI||KIU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|Y|ADJUDICATOR|PHYSIOTHERAPIST|U|4||88||BASELINE|1973-07-17||||1963-09-21||1973-08-20|1973-04-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||SPLNRESP|SPLEEN RESPONSE||||/WK|MORPHOLOGIC LEUKEMIA-FREE STATE||S^-1(%O2)^-1|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|ADJUDICATOR|READER 2|Y|5||7||CONTINUATION TREATMENT|1970-11-23||||1970-06-30||1971-04-25|1961-09-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||ANATRESP|ANATOMIC RESPONSE||||DEG/MM|MAJOR PATHOLOGIC RESPONSE||G/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|ADJUDICATOR|ENDOCRINOLOGIST|N|5||7||TREATMENT|1965-05-21||||1960-04-12||1965-02-05|1969-05-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||SPLNRESP|SPLEEN RESPONSE||||PKAT|INDETERMINATE RESPONSE||CD*S/M2|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|INVESTIGATOR|RATER|NA|1||38||RUN-IN|1965-08-12||||1962-05-01||1963-05-22|1960-07-04||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||ML/100G/MIN|PD-CT||MG/M2/H|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|INVESTIGATOR|MICROSCOPIST 3|NA|1||38||CONTINUATION TREATMENT|1963-05-26||||1970-02-04||1961-02-15|1960-09-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||CLINRESP|CLINICAL RESPONSE||||MG/KG/DAY|DISEASE TRANSFORMATION||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|STUDY SUBJECT|OTOLARYNGOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1973-06-18||||1971-03-17||1970-01-02|1968-01-02||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MGEQ|IUPD||DEG2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|CLINICAL STUDY SPONSOR|READER 2|Y|2||58||TREATMENT|1969-06-20||||1969-04-29||1960-11-18|1960-05-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||TRGRESP|TARGET RESPONSE||||ANSON U|PSA PROGRESSION||MMOL/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|ADJUDICATION COMMITTEE|OPTOMETRIST|N|3||39||WASHOUT|1968-05-11||||1964-01-22||1966-05-08|1963-04-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^6 ORGANISMS|EQUIVOCAL||MU/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|3||39||WASHOUT|1965-03-23||||1970-06-07||1969-04-23|1966-10-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||MOLRESP|MOLECULAR RESPONSE||||%(W/W)|CR-CT||V/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|SIBLING|PATHOLOGIST 1|N|4||88||INDUCTION TREATMENT|1961-01-29||||1962-04-19||1972-01-24|1964-02-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||VOXEL|WORSENED||ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|CHILD|RATER|U|4||88||OPEN LABEL TREATMENT|1970-09-24||||1961-11-03||1962-09-19|1969-10-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||CLINRESP|CLINICAL RESPONSE||||PMOL/G|DECREASED||MMOL/MIN/KPA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|Y|PROXY|CARDIOLOGIST|NA|5||7||WASHOUT|1972-09-07||||1965-12-16||1970-10-14|1962-08-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||SPLNRESP|SPLEEN RESPONSE||||MG/G/MIN|NPR||U/M2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|PROXY|ADJUDICATOR 3|NA|5||7||OPEN LABEL TREATMENT|1961-09-12||||1968-06-21||1963-05-05|1962-08-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||BONERESP|BONE RESPONSE||||GENEQ/ML|ABSENT MORPHOLOGIC RESPONSE||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|INVESTIGATOR|READER 1|N|1||38||FOLLOW-UP|1965-07-27||||1967-07-29||1968-01-29|1963-07-30||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PFU/ML|PSEUDOPROGRESSION||UOSM|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1969-07-27||||1965-08-13||1964-02-17|1966-01-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PA|MCR||NMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|GUARDIAN|CLINICAL PATHOLOGIST|NA|2||58||TREATMENT|1965-12-27||||1969-01-28||1965-12-26|1973-03-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||VG/DOSE|EQUIVOCAL||G/ANIMAL|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|N|GUARDIAN|ADJUDICATOR|U|2||58||BASELINE|1968-03-26||||1964-04-27||1968-04-17|1971-03-16||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||TRGRESP|TARGET RESPONSE||||MMOL/MIN/KPA|PMR||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|3||39||FOLLOW-UP|1967-03-20||||1965-12-22||1965-01-03|1968-12-14||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||DPM/MG|CR||ABSORBANCE U|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|PROXY|INTERNIST|Y|3||39||FOLLOW-UP|1964-10-24||||1963-01-17||1968-03-15|1969-11-28||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MMHG*MIN/L|INDETERMINATE RESPONSE||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|FRIEND|CLINICAL PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1965-06-05||||1965-08-27||1968-07-14|1965-01-21||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||M2|CCR||UG/G/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||LONG-TERM FOLLOW-UP|1973-04-22||||1962-05-18||1973-02-23|1961-01-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||OVRLRESP|OVERALL RESPONSE||||UCI/L|PSA PROGRESSION||MEQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CHILD|HEMATOLOGIST|Y|5||7||INDUCTION TREATMENT|1960-03-09||||1973-03-06||1968-08-14|1961-01-01||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||TRGRESP|TARGET RESPONSE||||NMOL/KG/DAY|MOLECULAR MAJOR RESPONSE||VG/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|SIBLING|ONCOLOGIST 1|Y|5||7||OBSERVATION|1971-10-18||||1962-02-22||1961-06-25|1967-08-04||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FMOL/L|CPR||PACKAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|PROXY|RADIOLOGIST|N|1||38||WASHOUT|1973-07-14||||1969-10-05||1966-09-22|1968-08-07||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ML/CM|QUANTIFIABLE MRD POSITIVITY||CPM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1||38||SCREENING|1965-12-15||||1967-01-26||1965-04-17|1964-05-19||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/MS|PD-CT||MEQ/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|STUDY SUBJECT|DERMATOLOGIST|NA|2||58||TREATMENT|1960-05-28||||1965-11-06||1972-11-10|1971-06-08||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||BESTRESP|BEST OVERALL RESPONSE||||BU|NON-CR/NON-PD||/MONTH|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|2||58||OBSERVATION|1961-04-18||||1966-05-06||1969-08-18|1972-02-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||LOZENGE|HI-E||DYN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|Y|NA|INVESTIGATOR|CARDIOLOGIST|U|3||39||OPEN LABEL TREATMENT|1972-05-12||||1964-02-03||1960-08-20|1965-06-23||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||CLINRESP|CLINICAL RESPONSE||||SYRINGE|CHR||IMPLANT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|SPOUSE|RATER 1|N|3||39||OBSERVATION|1970-11-10||||1962-04-15||1969-02-17|1970-01-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||LIVRRESP|LIVER RESPONSE||||MMHG|NE||CUP EQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|CHILD|HEMATOLOGIST|N|4||88||INDUCTION TREATMENT|1964-11-12||||1962-07-27||1969-01-27|1967-09-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||LIVRRESP|LIVER RESPONSE||||CAPSULE|PR-CT||EJACULATE U|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|U|PROXY|RATER 1|N|4||88||OPEN LABEL TREATMENT|1963-09-11||||1963-07-17||1964-10-13|1968-02-16||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||MOLRESP|MOLECULAR RESPONSE||||BE/ML|PSEUDORESPONSE||UMOL/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|PARENT|PEDIATRIC NEUROLOGIST|Y|5||7||OBSERVATION|1969-02-05||||1966-07-18||1967-09-11|1969-08-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||NEWLPROG|NEW LESION PROGRESSION||||G/DAY|CYTOGENETIC CR||ABSORBANCE U/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|NA|DOMESTIC PARTNER|DERMATOLOGIST|NA|5||7||INDUCTION TREATMENT|1963-12-30||||1960-03-10||1973-06-02|1967-12-11||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PG/CELL|PMR||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||LONG-TERM FOLLOW-UP|1963-12-03||||1964-10-07||1961-01-04|1965-03-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||AMU|PARTIAL MORPHOLOGIC RESPONSE||PFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|1||38||BASELINE|1961-10-08||||1968-09-03||1968-07-27|1965-03-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||TMRESP|TUMOR MARKER RESPONSE||||LOG10 ELISA UNIT/DOSE|PD/RELAPSE AFTER HI||L/MIN/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|N|FAMILY MEMBER|READER 3|Y|2||58||OBSERVATION|1973-07-31||||1968-03-23||1965-03-16|1969-03-09||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||OVRLRESP|OVERALL RESPONSE||||BREATHS/MIN|CCR||ML/SEC/1.73M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|FAMILY MEMBER|READER 1|NA|2||58||BASELINE|1961-11-03||||1963-09-10||1962-04-15|1963-07-26||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||STRUSTAT|STEROID USE STATUS||||G|SCR||UKAT/10^12 RBC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|GUARDIAN|READER 1|Y|3||39||LONG-TERM FOLLOW-UP|1965-07-06||||1960-02-03||1969-10-02|1964-04-20||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||COPIES/UG|DECREASED||MMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|3||39||OBSERVATION|1965-06-02||||1970-11-19||1963-09-25|1962-02-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||LIVRRESP|LIVER RESPONSE||||PA|MOLECULAR MAJOR RESPONSE||M/SEC2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|PARENT|OPHTHALMOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1960-11-20||||1971-04-07||1967-08-31|1970-04-30||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||NEWLPROG|NEW LESION PROGRESSION||||BQ/UG|PD||KM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|SIBLING|DERMATOLOGIST|N|4||88||FOLLOW-UP|1969-05-16||||1972-11-29||1969-02-01|1970-07-16||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FEU|MRD PERSISTENCE||BQ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||LONG-TERM FOLLOW-UP|1963-04-09||||1969-01-26||1967-07-20|1971-03-09||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MS2|MAJOR PATHOLOGIC RESPONSE||ML*CMH2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|NA|INVESTIGATOR|NEUROLOGIST 2|Y|5||7||TREATMENT|1968-12-10||||1960-06-13||1965-05-13|1973-08-11||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||TMRESP|TUMOR MARKER RESPONSE||||MOL/DAY|NON-ICR/NON-IUPD||MNFI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|1||38||WASHOUT|1964-05-14||||1964-10-01||1973-06-05|1964-01-14||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/L|OPTIMAL MORPHOLOGIC RESPONSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|INTERVIEWER|NEUROLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1970-01-11||||1966-12-06||1962-09-21|1971-07-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||U/KG/DAY|PARTIAL MORPHOLOGIC RESPONSE||10^9 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|INVESTIGATOR|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1961-04-24||||1961-05-06||1966-03-31|1961-09-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||BOX|MOLECULAR MAJOR RESPONSE||MG/L FEU|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|PARENT|MICROSCOPIST 1|NA|2||58||BASELINE|1971-05-01||||1967-04-14||1970-03-07|1971-01-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||NSEC|MRD RELAPSE||G/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|PROXY|MICROSCOPIST|U|3||39||LONG-TERM FOLLOW-UP|1965-06-12||||1961-12-01||1966-04-05|1964-04-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||PUFF|HI-P||OZ|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|SPOUSE|INTERNIST|U|3||39||BASELINE|1971-04-08||||1961-12-20||1960-09-07|1963-08-12||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||CYTORESP|CYTOGENETIC RESPONSE||||/5X10^4 WBC|MAJOR PATHOLOGIC RESPONSE||BQ/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|4||88||CONTINUATION TREATMENT|1962-03-23||||1961-04-28||1972-10-23|1972-06-30||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||OVRLRESP|OVERALL RESPONSE||||ML/KG/MIN|MRD PERSISTENCE||NM|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|4||88||OPEN LABEL TREATMENT|1972-08-02||||1966-05-05||1967-05-06|1962-03-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||RDIORESP|RADIOLOGIC RESPONSE||||ML/KG/H|NON-CR/NON-PD||CM|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|5||7||BASELINE|1965-12-31||||1964-01-01||1966-03-08|1968-12-12||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL BCE/MMOL|HI-P||10^6 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||WASHOUT|1966-07-29||||1970-06-26||1964-05-05|1970-07-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||FINGERTIP UNIT|IMPROVED||YEARS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|U|INTERVIEWER|PEDIATRIC NEUROLOGIST|N|1||38||OPEN LABEL TREATMENT|1968-11-14||||1965-01-10||1961-05-17|1960-02-26||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|2||||||ANATRESP|ANATOMIC RESPONSE||||RATIO|FAVORABLE RESPONSE||CMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|HEALTH CARE PROFESSIONAL|READER 1|NA|1||38||BLINDED TREATMENT|1967-02-03||||1971-01-23||1967-09-10|1964-04-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|1||||||SPLNRESP|SPLEEN RESPONSE||||FARAD|CR-CT||COPIES/UG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|ADJUDICATOR|UROLOGIST|U|2||58||BLINDED TREATMENT|1967-01-11||||1964-05-30||1972-02-05|1961-02-28||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|2||||||BESTRESP|BEST OVERALL RESPONSE||||GLOBULE|HI-E||KS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||OPEN LABEL TREATMENT|1971-02-01||||1969-11-26||1970-02-25|1960-10-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||DIP|CYTOGENETIC NO RESPONSE||DAYS/MONTH|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|FAMILY MEMBER|UROLOGIST|NA|3||39||TREATMENT|1967-06-28||||1970-09-15||1966-11-14|1964-11-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NEWTON|PD||UG/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|INVESTIGATOR|HEMATOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1961-11-23||||1966-07-01||1963-04-23|1971-12-10||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|1||||||LIVRRESP|LIVER RESPONSE||||10^6 ORGANISMS/G|MRD PERSISTENCE||PATCH|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|4||88||WASHOUT|1963-05-02||||1972-01-29||1962-10-06|1960-03-01||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|2||||||OVRLRESP|OVERALL RESPONSE||||IU/G|FAVORABLE RESPONSE||UG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|NA|ADJUDICATION COMMITTEE|RATER|N|4||88||WASHOUT|1972-10-18||||1962-11-27||1965-03-10|1971-06-09||DURING||DURING|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|1||||||METBRESP|METABOLIC RESPONSE||||UM/S|VGPR||UMOL/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|Y|5||7||RUN-IN|1963-05-21||||1962-11-06||1965-04-10|1973-02-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|E3310689-5727-4970-A675-A58931E406FA|2||||||TRGRESP|TARGET RESPONSE||||MU|CMR||KPA/L/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|ADJUDICATION COMMITTEE|NEUROLOGIST|U|5||7||CONTINUATION TREATMENT|1960-09-27||||1969-03-28||1965-05-03|1971-03-12||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||METBRESP|METABOLIC RESPONSE||||MEQ/DAY|OPTIMAL MORPHOLOGIC RESPONSE||10^6 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|1||38||FOLLOW-UP|1971-08-16||||1965-05-14||1965-04-12|1966-10-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/500 WBC|CRI||FG|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|U|FRIEND|ONCOLOGIST 2|N|1||38||OBSERVATION|1963-05-11||||1970-08-06||1965-04-03|1966-04-19||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NL|MR||UG/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|NA|ADJUDICATOR|UROLOGIST|Y|2||58||SCREENING|1969-03-12||||1963-01-19||1969-03-22|1971-07-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||TRGRESP|TARGET RESPONSE||||%|ABSENT MORPHOLOGIC RESPONSE||UM/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|SIGNIFICANT OTHER|READER 2|U|2||58||TREATMENT|1969-08-23||||1962-11-30||1960-05-27|1960-12-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||METBRESP|METABOLIC RESPONSE||||H*%|NOT ALL EVALUATED||UU/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1969-11-10||||1967-05-09||1965-02-08|1973-02-03||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||LIVRRESP|LIVER RESPONSE||||10^3/HPF|QUANTIFIABLE MRD POSITIVITY||10^9 CFU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|3||39||RUN-IN|1963-04-13||||1967-04-01||1966-12-27|1961-06-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/MOL|COMPLETE MRD RESPONSE||MPA|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|PARENT|ADJUDICATOR 1|U|4||88||INDUCTION TREATMENT|1969-03-14||||1960-05-17||1971-12-31|1962-07-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PUFF|PD||MOL|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|Y|CHILD|INTERNIST|Y|4||88||LONG-TERM FOLLOW-UP|1967-11-28||||1969-02-21||1968-09-25|1972-02-29||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DAGU|PDU||MG/G/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|CHILD|PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1962-04-15||||1964-11-18||1962-03-18|1973-06-04||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||FRAMES/S|ABSENT MORPHOLOGIC RESPONSE||KV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|N|INVESTIGATOR|READER 2|NA|5||7||SCREENING|1962-05-09||||1971-02-07||1964-12-08|1962-03-17||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||METSIND|METASTATIC INDICATOR||||BQ/UG|MR||G/ANIMAL/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|HEALTH CARE PROFESSIONAL|READER|NA|1||38||FOLLOW-UP|1971-12-09||||1964-01-02||1965-09-13|1968-02-12||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||GBQ/G|NE||SEC|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|Y|GUARDIAN|FORENSIC PATHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-09-27||||1972-03-05||1963-03-13|1960-11-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GAUSS|PMR||TESLA|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|2||58||TREATMENT|1971-10-28||||1960-11-25||1971-08-28|1961-01-10||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PACK YEAR|MOLECULAR MAJOR RESPONSE||CY/CM|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1964-06-15||||1968-04-29||1970-01-02|1972-12-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||STRUSTAT|STEROID USE STATUS||||MHZ|EQUIVOCAL||GPELISA UNIT/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|3||39||FOLLOW-UP|1960-01-29||||1967-12-13||1960-03-30|1965-07-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||BONERESP|BONE RESPONSE||||UU/DL|CR-CT||/MS|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|PARENT|RADIOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1968-07-05||||1965-05-09||1966-12-17|1962-10-09||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||SPLNRESP|SPLEEN RESPONSE||||COULOMB|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^6 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|SIGNIFICANT OTHER|PATHOLOGIST 2|Y|4||88||BLINDED TREATMENT|1963-01-12||||1966-02-12||1972-09-11|1961-02-15||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KA_U/DL|CR-CT||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|U|VENDOR|MICROSCOPIST 3|NA|4||88||FOLLOW-UP|1968-05-03||||1973-01-05||1967-08-06|1969-10-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||MOLRESP|MOLECULAR RESPONSE||||TRANSDUCING UNIT|RELAPSED DISEASE FROM CR||ML/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|N|STUDY SUBJECT|RATER 2|Y|5||7||RUN-IN|1960-10-27||||1960-12-23||1963-07-01|1969-06-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BAG|PR-CT||G/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|NA|CAREGIVER|READER 3|Y|5||7||SCREENING|1967-05-09||||1966-09-11||1966-03-21|1968-07-02||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||NTRGRESP|NON-TARGET RESPONSE||||BAU/ML|MORPHOLOGIC CR||10^6 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|1||38||WASHOUT|1970-03-17||||1964-07-08||1965-03-01|1970-02-21||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||OVRLRESP|OVERALL RESPONSE||||% INHIBITION|CPR||G/L|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|STUDY SUBJECT|INTERNIST|Y|1||38||BLINDED TREATMENT|1960-07-15||||1970-12-04||1961-07-26|1962-05-01||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||BESTRESP|BEST OVERALL RESPONSE||||UKAT/L|SD||MG/G/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|U|GUARDIAN|MICROSCOPIST 1|U|2||58||TREATMENT|1969-10-31||||1966-04-26||1971-09-09|1963-08-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||NKAT/L|NON-CR/NON-PD||G/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1961-11-26||||1971-09-14||1969-09-17|1967-05-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MMOL2/L2|PARTIAL MORPHOLOGIC RESPONSE||CCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|PARENT|READER 3|U|3||39||BASELINE|1965-03-26||||1970-01-10||1970-05-23|1964-12-25||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||OVRLRESP|OVERALL RESPONSE||||PFU/ML|CA125 50% RESPONSE||LOG10 TCID 50/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|SPOUSE|READER 2|N|3||39||BLINDED TREATMENT|1968-06-24||||1968-07-20||1972-07-21|1960-06-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2/H|CR||P|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|U|ADJUDICATION COMMITTEE|READER 1|U|4||88||OBSERVATION|1963-03-03||||1970-04-11||1965-11-03|1969-09-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||RDIORESP|RADIOLOGIC RESPONSE||||YD|CR||FG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1964-04-26||||1971-06-27||1970-05-21|1972-09-22||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UL|CA125 75% RESPONSE||MMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|NA|ADJUDICATOR|MICROSCOPIST 2|N|5||7||WASHOUT|1964-12-09||||1961-01-19||1968-06-30|1963-11-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||BESTRESP|BEST OVERALL RESPONSE||||10^9 ORGANISMS|FAVORABLE RESPONSE||10^6 DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|STUDY SUBJECT|READER 1|Y|5||7||WASHOUT|1961-07-01||||1970-05-27||1967-06-25|1962-06-25||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/M2|EQUIVOCAL||FG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|1||38||INDUCTION TREATMENT|1967-06-27||||1967-11-24||1966-06-11|1971-03-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||NTRGRESP|NON-TARGET RESPONSE||||U/M2/H|IPR||100 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|DOMESTIC PARTNER|READER 2|NA|1||38||TREATMENT|1960-11-13||||1969-09-10||1965-07-04|1972-05-27||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||ANATRESP|ANATOMIC RESPONSE||||BQ/UL|PDU||ML/MIN/1.73M2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|SPOUSE|RADIOLOGIST 1|N|2||58||BASELINE|1967-08-13||||1971-08-23||1962-10-15|1963-07-25||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^5/HPF|PSEUDOPROGRESSION||OZ EQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|NA|CAREGIVER|RATER 2|U|2||58||BASELINE|1969-06-13||||1960-05-23||1962-10-03|1966-10-15||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||CCID 50/DOSE|PD||PACKAGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1973-06-04||||1971-04-30||1973-09-01|1966-06-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||METSIND|METASTATIC INDICATOR||||ML/BREATH|HI-N||AMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|3||39||FOLLOW-UP|1960-12-09||||1972-12-29||1970-05-27|1967-06-11||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^9 ORGANISMS/MG|DECREASED||IU|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|FAMILY MEMBER|READER|U|4||88||WASHOUT|1969-10-06||||1966-12-17||1964-09-19|1969-06-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ANTI-XA IU/ML|ICPD||PKAT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|N|PARENT|READER 1|N|4||88||BASELINE|1962-02-20||||1970-06-21||1961-02-12|1970-07-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^9/L|MCR||CMH2O*S/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|PROXY|ADJUDICATOR 3|N|5||7||WASHOUT|1972-05-13||||1966-05-31||1966-09-11|1971-12-13||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||LIVRRESP|LIVER RESPONSE||||ARBITRARY U|NON-QUANTIFIABLE MRD POSITIVITY||PA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|5||7||TREATMENT|1973-05-08||||1963-11-07||1965-10-12|1968-01-08||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/M2/DAY|SD-CT||CONTAINER|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|1||38||LONG-TERM FOLLOW-UP|1965-12-16||||1972-02-18||1973-04-18|1971-03-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||IU/KG|IMPROVED||SEC|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|N|1||38||RUN-IN|1973-06-29||||1967-11-22||1970-06-10|1968-11-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6/L|PR||ML/CM H2O|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|2||58||TREATMENT|1969-09-29||||1972-01-17||1966-01-13|1972-07-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||G/L|PD/RELAPSE AFTER HI||KBQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|SPOUSE|OTOLARYNGOLOGIST|U|2||58||CONTINUATION TREATMENT|1964-04-16||||1960-03-10||1966-04-07|1973-01-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||NTRGRESP|NON-TARGET RESPONSE||||PKAT|NON-ICR/NON-IUPD||HPA|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|VENDOR|UROLOGIST|NA|3||39||WASHOUT|1972-03-21||||1968-11-04||1972-01-13|1963-01-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||MOLRESP|MOLECULAR RESPONSE||||FRACTION OF 1|INDETERMINATE RESPONSE||TABLET|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|SIGNIFICANT OTHER|MICROSCOPIST|NA|3||39||LONG-TERM FOLLOW-UP|1965-12-30||||1968-11-25||1972-08-30|1968-09-05||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/MIN|FAVORABLE RESPONSE||CMH2O/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|INVESTIGATOR|ADJUDICATOR 3|U|4||88||BLINDED TREATMENT|1964-07-17||||1961-02-16||1969-09-03|1962-08-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||CLINRESP|CLINICAL RESPONSE||||NEBULE|RELAPSED DISEASE FROM CR||U/KG/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|PROXY|NEUROLOGIST|U|4||88||OBSERVATION|1968-04-13||||1967-07-17||1960-01-03|1969-12-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CG|CA125 75% RESPONSE||OD UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|FRIEND|PATHOLOGIST 1|N|5||7||SCREENING|1973-02-13||||1971-04-06||1966-08-10|1973-06-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CI|UNFAVORABLE RESPONSE||G/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|INVESTIGATOR|ONCOLOGIST 2|U|5||7||FOLLOW-UP|1966-08-11||||1968-07-30||1970-10-29|1965-04-29||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||BONERESP|BONE RESPONSE||||KEV|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||DAGU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|ADJUDICATOR|ADJUDICATOR 1|NA|1||38||INDUCTION TREATMENT|1971-05-30||||1967-04-21||1964-02-08|1963-05-01||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||JAR|PR WITH LYMPHOCYTOSIS||U.CARR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|Y|CHILD|RATER 2|U|1||38||CONTINUATION TREATMENT|1965-03-09||||1964-11-14||1965-03-27|1960-02-29||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||NEWLPROG|NEW LESION PROGRESSION||||M/SEC2|PSEUDOPROGRESSION||DAGU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|NA|ADJUDICATION COMMITTEE|RATER 2|NA|2||58||RUN-IN|1973-01-07||||1962-01-07||1967-11-09|1970-06-13||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||METSIND|METASTATIC INDICATOR||||UL|NPR||10^3/HPF|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|2||58||BLINDED TREATMENT|1971-05-05||||1960-11-22||1973-02-01|1972-01-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||NEWLIND|NEW LESION INDICATOR||||RING|SD||DPM/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|CHILD|RADIOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1962-11-11||||1970-07-30||1963-02-25|1961-05-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CYLINDER|RELAPSED DISEASE FROM CR||MOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|U|ADJUDICATOR|PHYSIOTHERAPIST|NA|3||39||TREATMENT|1966-12-17||||1968-03-09||1961-01-05|1969-07-27||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||TRGRESP|TARGET RESPONSE||||MMHG/L/MIN|PMD||K|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|N|INVESTIGATOR|FORENSIC PATHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1966-06-10||||1967-01-11||1960-08-12|1963-10-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||MOLRESP|MOLECULAR RESPONSE||||UG/MIN|CA125 75% RESPONSE||KHZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|DOMESTIC PARTNER|ONCOLOGIST 2|N|4||88||CONTINUATION TREATMENT|1960-10-02||||1967-07-28||1963-09-11|1964-02-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||NEWLPROG|NEW LESION PROGRESSION||||%(W/W)|MORPHOLOGIC CRI||MG/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|DOMESTIC PARTNER|RADIOLOGIST 2|N|5||7||BASELINE|1964-07-11||||1963-06-21||1970-04-11|1962-12-03||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/DAY|NE||LOG10 TCID 50/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|Y|INTERVIEWER|RADIOLOGIST|N|5||7||RUN-IN|1968-03-13||||1961-03-08||1966-03-27|1965-09-21||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||OVRLRESP|OVERALL RESPONSE||||ML/CM|UNFAVORABLE RESPONSE||1/(S*KPA)|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CLINICAL STUDY SPONSOR|RATER 2|U|1||38||RUN-IN|1968-10-27||||1963-09-23||1960-10-14|1972-10-24||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||NTRGRESP|NON-TARGET RESPONSE||||MG/MIN|MRD PERSISTENCE||MV|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|SIBLING|OPTOMETRIST|N|1||38||WASHOUT|1966-01-01||||1973-04-30||1972-07-06|1970-05-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||CYTORESP|CYTOGENETIC RESPONSE||||LOG10 CFU/ML|RELAPSED DISEASE FROM CR||KUSP|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|2||58||WASHOUT|1963-02-04||||1961-10-29||1970-06-26|1972-08-24||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||OVRLRESP|OVERALL RESPONSE||||MG/DOSE|HI-P||MM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|STUDY SUBJECT|RATER 1|U|2||58||OPEN LABEL TREATMENT|1973-04-10||||1962-03-29||1969-12-12|1962-07-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||PATHRESP|PATHOLOGIC RESPONSE||||IU/KG|NON-CR/NON-PD||NG/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|STUDY SUBJECT|MICROSCOPIST 2|Y|3||39||WASHOUT|1967-05-15||||1968-03-15||1967-05-25|1970-12-07||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||CLINRESP|CLINICAL RESPONSE||||BU/ML|HI-P||STRIP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|U|GUARDIAN|RADIOLOGIST|N|3||39||WASHOUT|1971-12-07||||1966-10-11||1963-09-26|1972-02-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ABSORBANCE U/MIN|MRD NEGATIVITY||CI/KG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|SIGNIFICANT OTHER|RADIOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1965-04-13||||1967-05-09||1970-03-15|1961-09-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||NEWLIND|NEW LESION INDICATOR||||ML/M2|CYTOGENETIC CR||10^9 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|N|PARENT|PHYSIOTHERAPIST|U|4||88||OBSERVATION|1968-04-15||||1967-10-01||1967-01-31|1962-03-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||GAUSS|HI-N||ML/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|Y|CHILD|READER 3|NA|5||7||INDUCTION TREATMENT|1971-01-07||||1961-09-10||1965-01-04|1969-11-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||CLINRESP|CLINICAL RESPONSE||||BAG|INCREASED||AMP|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|VENDOR|HEMATOLOGIST|U|5||7||RUN-IN|1972-06-08||||1962-07-24||1963-11-10|1970-05-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||TMRESP|TUMOR MARKER RESPONSE||||KG/MOL|UNFAVORABLE RESPONSE||G/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|NA|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|1||38||WASHOUT|1970-03-16||||1966-07-14||1962-09-09|1971-04-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GBQ|MOLECULAR CR||BU|NOT DONE|||LIKERT SCALE 5-POINT|N|U|Y|CHILD|RATER 1|N|1||38||CONTINUATION TREATMENT|1964-01-04||||1969-03-25||1964-10-11|1964-10-21||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||U/ANIMAL|IPR||ML/CM3/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|SIBLING|PHYSIOTHERAPIST|U|2||58||TREATMENT|1968-06-28||||1965-02-12||1970-11-21|1967-03-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||LIVRRESP|LIVER RESPONSE||||%/MIN|DISEASE TRANSFORMATION||ML/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|STUDY SUBJECT|MICROSCOPIST 2|NA|2||58||CONTINUATION TREATMENT|1969-01-20||||1964-01-19||1961-04-16|1973-03-12||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||RDIORESP|RADIOLOGIC RESPONSE||||/7.5 ML|CR-CT||ML/ANIMAL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|DOMESTIC PARTNER|RADIOLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1972-05-17||||1961-06-05||1964-06-09|1961-06-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||BONERESP|BONE RESPONSE||||UG/L/H|PD FROM PR||APL U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|CLINICAL STUDY SPONSOR|READER 3|U|3||39||BLINDED TREATMENT|1962-12-28||||1972-06-22||1964-06-02|1964-07-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MCI/KG|UNFAVORABLE RESPONSE||10^11/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|NA|NON-HEALTH CARE PROFESSIONAL|READER|Y|4||88||WASHOUT|1965-12-05||||1972-12-04||1972-07-19|1971-11-14||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CD|SD||PMOL/10^10 CELLS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|ADJUDICATION COMMITTEE|INTERNIST|Y|4||88||OPEN LABEL TREATMENT|1966-08-19||||1965-07-08||1962-07-22|1960-10-01||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||ANATRESP|ANATOMIC RESPONSE||||10^6 COPIES/ML|CPR||MPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|VENDOR|NEUROLOGIST 1|U|5||7||BLINDED TREATMENT|1971-07-14||||1966-05-27||1962-04-17|1962-08-11||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||NEWLIND|NEW LESION INDICATOR||||MG/M2/DAY|IUPD||JOULE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|DOMESTIC PARTNER|RADIOLOGIST 1|N|5||7||WASHOUT|1972-03-06||||1970-03-16||1964-08-09|1967-08-26||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|1||||||LIVRRESP|LIVER RESPONSE||||/KG|CRI||UCI/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|INTERVIEWER|RADIOLOGIST 2|Y|1||38||SCREENING|1968-12-19||||1960-12-08||1971-01-23|1969-03-28||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|2||||||NEWLIND|NEW LESION INDICATOR||||TUBERCULIN UNIT/ML|INCREASED||UV|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|CHILD|OTOLARYNGOLOGIST|Y|1||38||RUN-IN|1965-05-28||||1968-10-24||1961-10-14|1969-04-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MILE|CR-CT||ML/CAGE|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2||58||WASHOUT|1970-08-27||||1969-05-07||1971-10-01|1964-06-27||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/ANIMAL/WK|CRI||%/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|Y|SIBLING|MICROSCOPIST 1|NA|2||58||TREATMENT|1973-08-02||||1960-11-03||1973-02-24|1966-04-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/MG|PR-CT||NMOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|3||39||BLINDED TREATMENT|1966-01-09||||1965-12-09||1967-06-18|1973-04-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BAG|CCR||GPELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|FRIEND|RATER|Y|3||39||CONTINUATION TREATMENT|1960-06-17||||1965-01-01||1961-11-28|1965-12-31||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|1||||||LIVRRESP|LIVER RESPONSE||||/2500 WBC|CYTOGENETIC CR||CPM|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1961-09-24||||1968-03-09||1969-11-09|1960-11-02||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3 CFU|CA125 75% RESPONSE||10^4/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|RATER|U|4||88||INDUCTION TREATMENT|1969-08-09||||1961-02-21||1964-03-03|1968-08-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL/DL|PD/RELAPSE AFTER HI||/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|5||7||INDUCTION TREATMENT|1970-08-09||||1964-12-26||1962-12-26|1968-08-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FE955CB9-9992-4521-8788-7597AF40F214|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PIXEL|PARTIAL MORPHOLOGIC RESPONSE||ML/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|5||7||BASELINE|1973-03-04||||1970-02-11||1966-02-27|1967-04-08||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||ANATRESP|ANATOMIC RESPONSE||||CMH2O*S2/ML|PR WITH LYMPHOCYTOSIS||DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|SIGNIFICANT OTHER|ADJUDICATOR|NA|1||38||INDUCTION TREATMENT|1973-08-08||||1960-08-11||1970-01-01|1968-01-31||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||METSIND|METASTATIC INDICATOR||||10^6 U|CA125 50% RESPONSE||DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|PROXY|ADJUDICATOR 3|NA|1||38||LONG-TERM FOLLOW-UP|1971-10-02||||1964-08-03||1966-02-05|1967-12-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||BONERESP|BONE RESPONSE||||MMOL/MIN/KPA/L|CPR||10^6 ORGANISMS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|N|SIGNIFICANT OTHER|ONCOLOGIST 2|NA|2||58||TREATMENT|1965-11-04||||1964-04-28||1969-12-03|1969-06-25||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MEQ/UL|CR||VIRTUAL PIXEL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|U|CAREGIVER|MICROSCOPIST|Y|2||58||OBSERVATION|1969-05-08||||1963-10-21||1961-08-22|1963-03-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PFU|MOLECULAR CR||DNA COPIES/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|N|INTERVIEWER|DERMATOLOGIST|U|3||39||BASELINE|1964-07-04||||1971-01-29||1961-11-03|1970-06-02||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||ANATRESP|ANATOMIC RESPONSE||||DISK|MOLECULAR CR||M|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|3||39||BASELINE|1971-12-16||||1969-03-22||1962-10-17|1965-07-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||LIVRRESP|LIVER RESPONSE||||OHM|HI-E||/7.5 ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|4||88||BASELINE|1962-11-08||||1971-09-30||1961-05-12|1961-06-28||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||SPLNRESP|SPLEEN RESPONSE||||EJACULATE U|CYTOGENETIC NO RESPONSE||COPIES/UG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1967-09-08||||1973-09-01||1961-04-03|1971-03-17||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||NEWLIND|NEW LESION INDICATOR||||KCAL/DAY|ICPD||UMOL/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|NA|VENDOR|ADJUDICATOR|Y|5||7||FOLLOW-UP|1964-04-11||||1960-06-25||1967-05-22|1965-06-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||METBRESP|METABOLIC RESPONSE||||POUCH|SD-CT||DAMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|Y|FAMILY MEMBER|PATHOLOGIST|Y|5||7||SCREENING|1968-05-22||||1963-04-15||1970-07-24|1967-04-01||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||CLINRESP|CLINICAL RESPONSE||||KN/CM2|OPTIMAL MORPHOLOGIC RESPONSE||10^7/L|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|STUDY SUBJECT|RADIOLOGIST 1|Y|1||38||RUN-IN|1972-12-24||||1968-12-02||1972-10-13|1962-10-25||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||MOLRESP|MOLECULAR RESPONSE||||10^7 CFU/ML|INDETERMINATE RESPONSE||CUP EQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|READER 1|NA|1||38||OPEN LABEL TREATMENT|1969-06-15||||1968-12-06||1971-03-20|1964-10-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GRAVITATIONAL UNIT|NON-ICR/NON-IUPD||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|SIBLING|MICROSCOPIST 1|N|2||58||SCREENING|1969-06-27||||1967-10-22||1970-09-18|1966-03-18||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||NEWLIND|NEW LESION INDICATOR||||PACKET|VGPR||DMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||WASHOUT|1961-02-02||||1961-09-10||1968-08-12|1970-09-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||BONERESP|BONE RESPONSE||||MG/ML/DAY|PR WITH LYMPHOCYTOSIS||NU/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|N|INTERVIEWER|RATER|U|3||39||WASHOUT|1964-02-26||||1962-01-12||1972-05-27|1966-05-29||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UCI/L|CMR||UL/KG/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|N|VENDOR|OPTOMETRIST|Y|3||39||RUN-IN|1966-04-22||||1968-09-04||1966-11-22|1965-01-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||TMRESP|TUMOR MARKER RESPONSE||||NMOL/DAY|ICPD||NU/CL|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|PARENT|READER|N|4||88||LONG-TERM FOLLOW-UP|1969-02-26||||1963-05-16||1964-02-25|1967-10-02||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/M2/MIN|SD-CT||NMOL/MOL|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|ADJUDICATOR|MICROSCOPIST 2|NA|4||88||FOLLOW-UP|1963-11-02||||1961-12-16||1973-01-26|1963-12-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||METBRESP|METABOLIC RESPONSE||||MEQ|MR||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|ADJUDICATOR|RADIOLOGIST|NA|5||7||SCREENING|1963-10-07||||1965-09-28||1967-12-12|1970-10-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||BESTRESP|BEST OVERALL RESPONSE||||SACHET|IPR||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|5||7||FOLLOW-UP|1966-09-24||||1972-03-24||1965-04-10|1971-11-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||MOLRESP|MOLECULAR RESPONSE||||UG/KG/MIN|CYTOGENETIC CR||L|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|1||38||CONTINUATION TREATMENT|1961-01-11||||1963-09-02||1968-12-24|1961-08-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||BONERESP|BONE RESPONSE||||CM/MIN|PD||10^3 COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|Y|CHILD|MICROSCOPIST|NA|1||38||RUN-IN|1969-08-28||||1966-04-21||1968-03-25|1971-01-16||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HPA|PSEUDORESPONSE||MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|FRIEND|CARDIOLOGIST|Y|2||58||BASELINE|1972-09-23||||1968-10-03||1967-05-18|1969-11-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||GBQ/MG|STABLE||ML/MIN/MMHG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|RATER|Y|2||58||RUN-IN|1965-03-27||||1964-03-01||1960-08-03|1961-10-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||TRGRESP|TARGET RESPONSE||||/200 HPFS|PD-CT||SUPPOSITORY|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|SIBLING|ENDOCRINOLOGIST|N|3||39||BLINDED TREATMENT|1964-12-01||||1972-05-31||1965-01-13|1967-08-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||MOLRESP|MOLECULAR RESPONSE||||TRACE|PMD||BQ/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|3||39||FOLLOW-UP|1966-04-28||||1964-09-05||1962-03-09|1971-09-30||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||L/L|MORPHOLOGIC CR||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|N|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|4||88||BASELINE|1971-10-13||||1963-09-10||1966-10-20|1969-07-18||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||NEWLIND|NEW LESION INDICATOR||||10^3 ORGANISMS|HI-E||G/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|U|U|FAMILY MEMBER|ONCOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1964-06-07||||1970-04-18||1965-07-13|1972-03-27||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||TRGRESP|TARGET RESPONSE||||UEQ|CYTOGENETIC PR||AFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-05-03||||1971-10-09||1973-06-26|1963-10-13||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||STRUSTAT|STEROID USE STATUS||||S/H|SMD||ML*CMH2O|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|STUDY SUBJECT|NEUROLOGIST 1|N|5||7||INDUCTION TREATMENT|1966-02-18||||1961-07-26||1962-04-19|1963-11-01||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/ML/DAY|PCR||10^6 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|1||38||SCREENING|1973-04-26||||1966-05-12||1970-05-19|1965-06-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU/ML|PR WITH LYMPHOCYTOSIS||%|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|GUARDIAN|RATER 1|Y|1||38||SCREENING|1968-08-12||||1972-08-29||1960-03-01|1960-10-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||PATHRESP|PATHOLOGIC RESPONSE||||LOG10 TCID 50/ML|HI-E||EIA UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|FRIEND|CARDIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1970-01-22||||1963-12-25||1963-12-26|1960-02-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||METBRESP|METABOLIC RESPONSE||||KV|ICR||10^3/HPF|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|VENDOR|OTOLARYNGOLOGIST|NA|2||58||BLINDED TREATMENT|1964-04-24||||1962-06-20||1965-01-23|1966-07-24||AFTER||DURING|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/CAGE/WK|QUANTIFIABLE MRD POSITIVITY||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|SPOUSE|RATER|NA|3||39||WASHOUT|1963-02-11||||1973-07-30||1960-11-05|1971-07-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/BEAT|HI-N||KIT|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|PROXY|ENDOCRINOLOGIST|U|3||39||BLINDED TREATMENT|1962-10-24||||1962-01-18||1969-07-16|1973-03-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||RDIORESP|RADIOLOGIC RESPONSE||||JOULE|MOLECULAR CR||10^6 IU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|GUARDIAN|MICROSCOPIST 1|N|4||88||FOLLOW-UP|1969-02-18||||1971-03-21||1971-08-30|1961-11-10||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||NTRGRESP|NON-TARGET RESPONSE||||MONTHS|NPR||TAMPON|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|NA|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||WASHOUT|1966-07-13||||1968-06-19||1965-07-17|1968-04-09||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||BONERESP|BONE RESPONSE||||YD|MRD NEGATIVITY||MBQ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|PARENT|ENDOCRINOLOGIST|NA|5||7||FOLLOW-UP|1973-07-02||||1966-10-27||1963-09-25|1962-09-06||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||MOLRESP|MOLECULAR RESPONSE||||MDFI|MOLECULAR CR||PIPE|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1961-09-17||||1965-12-09||1972-08-25|1970-09-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ABSORBANCE U/MIN|CRI||10^3 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|SIBLING|RATER 2|U|1||38||BASELINE|1970-09-16||||1971-03-23||1971-11-14|1965-01-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||IU/KG|CR||CD/M2|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|STUDY SUBJECT|MICROSCOPIST 1|U|1||38||WASHOUT|1973-02-20||||1967-02-07||1962-05-24|1961-01-25||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||/2500 WBC|PD||UG/L/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|Y|SPOUSE|MICROSCOPIST 1|Y|2||58||TREATMENT|1961-01-12||||1961-08-19||1963-06-06|1971-07-18||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ABSORBANCE U/ML|INCREASED||SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|U|INVESTIGATOR|PATHOLOGIST 1|Y|2||58||BASELINE|1964-06-14||||1970-06-21||1971-03-26|1967-04-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||METSIND|METASTATIC INDICATOR||||NCI|PR||SHOCK WAVE|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|ADJUDICATION COMMITTEE|RATER 1|Y|3||39||BASELINE|1965-07-09||||1960-08-26||1965-09-01|1968-10-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/MIN|MORPHOLOGIC CR||ML/S/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|ADJUDICATOR|MICROSCOPIST|N|3||39||OBSERVATION|1961-05-20||||1969-01-17||1972-01-07|1963-04-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||NTRGRESP|NON-TARGET RESPONSE||||L/MIN|PCR||KG/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|4||88||INDUCTION TREATMENT|1967-07-23||||1960-10-04||1969-08-13|1973-06-03||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CD|CYTOGENETIC MINOR RESPONSE||BQ/L|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|Y|FRIEND|RADIOLOGIST 2|Y|4||88||OPEN LABEL TREATMENT|1962-06-09||||1963-07-11||1969-01-13|1965-10-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||NFIU|PMR||M/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|5||7||BASELINE|1964-05-27||||1965-07-06||1969-09-24|1971-11-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||IU|PR WITH LYMPHOCYTOSIS||MIN*MG/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|SIBLING|CARDIOLOGIST|U|5||7||SCREENING|1967-10-13||||1968-08-15||1972-08-09|1960-10-26||AFTER||DURING|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||STRUSTAT|STEROID USE STATUS||||CMH2O/ML|MRD NEGATIVITY||10^3 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|DOMESTIC PARTNER|NEUROLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1967-10-31||||1969-02-08||1961-02-25|1966-02-07||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||TRGRESP|TARGET RESPONSE||||VOXEL|MOLECULAR MAJOR RESPONSE||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|CAREGIVER|MICROSCOPIST 2|N|1||38||INDUCTION TREATMENT|1960-08-06||||1969-06-26||1966-05-14|1971-03-12||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CCID 50/ML|PD/RELAPSE AFTER HI||IU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|N|PARENT|PATHOLOGIST|U|2||58||BASELINE|1963-10-05||||1971-10-07||1971-10-13|1972-08-08||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NGEQ/L|EQUIVOCAL||APS U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||FOLLOW-UP|1968-05-14||||1968-08-22||1969-06-20|1965-02-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||100 IU/ML|PMR||MG/CM2|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|U|CLINICAL STUDY SPONSOR|READER 3|N|3||39||OPEN LABEL TREATMENT|1970-02-12||||1964-07-13||1968-06-07|1969-01-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/ML|IMPROVED||/10^4|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|SIBLING|ONCOLOGIST 2|U|3||39||RUN-IN|1962-01-29||||1966-06-18||1968-12-16|1961-12-12||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PMOL/10^10 CELLS|NOT ALL EVALUATED||BOWL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1969-04-26||||1972-12-19||1972-10-05|1962-10-28||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MMOL/S|ICPD||AU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|Y|SPOUSE|ADJUDICATOR 1|NA|4||88||RUN-IN|1967-10-01||||1970-02-12||1970-05-07|1964-03-25||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||NEWLIND|NEW LESION INDICATOR||||TITER|COMPLETE MRD RESPONSE||U/CL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 3|N|5||7||BASELINE|1973-04-27||||1969-12-08||1961-11-07|1961-03-13||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||ANATRESP|ANATOMIC RESPONSE||||CUP|SCR||SEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|SPOUSE|RADIOLOGIST 2|Y|5||7||WASHOUT|1967-09-07||||1973-07-13||1965-07-18|1970-07-24||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||PATHRESP|PATHOLOGIC RESPONSE||||OD UNIT|RELAPSED DISEASE FROM CR||U/KG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1969-01-07||||1970-09-22||1967-12-02|1972-10-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||NEWLPROG|NEW LESION PROGRESSION||||ELISA UNIT|PSA PROGRESSION||NKAT|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|PROXY|PATHOLOGIST 1|Y|1||38||BASELINE|1960-07-13||||1972-07-08||1971-09-01|1963-06-21||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||SPLNRESP|SPLEEN RESPONSE||||WATT|CA125 50% RESPONSE||NKAT|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|N|2||58||SCREENING|1965-10-24||||1969-07-02||1965-11-13|1960-07-11||AFTER||DURING|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||PG/L|RELAPSED DISEASE||G/CAGE/DAY|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|SIBLING|OTOLARYNGOLOGIST|U|2||58||BLINDED TREATMENT|1961-06-24||||1968-04-02||1964-09-20|1969-04-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL|SCR||CMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|U|CLINICAL STUDY SPONSOR|RATER|NA|3||39||BLINDED TREATMENT|1967-06-09||||1969-05-14||1969-09-23|1973-03-23||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MMOL/S|NON-PD||ENZYME U/M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|SIGNIFICANT OTHER|UROLOGIST|N|3||39||WASHOUT|1962-07-29||||1961-08-15||1971-10-10|1969-01-10||AFTER||DURING|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||COPIES/ML|CYTOGENETIC MINIMAL RESPONSE||/CMH2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|FRIEND|OPTOMETRIST|NA|4||88||FOLLOW-UP|1964-08-04||||1972-11-24||1970-01-15|1972-01-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||NEWLIND|NEW LESION INDICATOR||||10^6/L|STABLE||C|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|SIBLING|RATER|Y|4||88||INDUCTION TREATMENT|1971-08-15||||1963-01-09||1970-04-27|1966-09-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||CAPFUL|HI-E||TAMPON|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|5||7||SCREENING|1971-08-29||||1964-11-07||1966-12-18|1966-02-22||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||GLOBULE|STABLE||LOG10 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|VENDOR|NEUROLOGIST 2|U|5||7||RUN-IN|1966-09-25||||1966-04-19||1971-01-09|1969-12-31||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||SPLNRESP|SPLEEN RESPONSE||||10^9 CFU/G|CRI||MU/G|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|SIGNIFICANT OTHER|MICROSCOPIST 3|N|1||38||BLINDED TREATMENT|1961-04-24||||1973-01-23||1963-05-06|1965-07-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||ANATRESP|ANATOMIC RESPONSE||||10^10/L|PMD||CAN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|1||38||RUN-IN|1967-06-03||||1964-04-02||1966-11-17|1972-12-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||TMRESP|TUMOR MARKER RESPONSE||||U/M2/H|PSEUDORESPONSE||U/G/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|FAMILY MEMBER|ADJUDICATOR 3|Y|2||58||BLINDED TREATMENT|1966-12-13||||1970-02-22||1962-03-15|1973-08-05||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||USEC|NON-ICR/NON-IUPD||DAYS/MONTH|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|SIBLING|RATER 2|U|2||58||BLINDED TREATMENT|1964-02-14||||1965-08-28||1966-12-03|1971-07-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NL|MORPHOLOGIC LEUKEMIA-FREE STATE||100 IU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|SPOUSE|OTOLARYNGOLOGIST|U|3||39||INDUCTION TREATMENT|1964-04-28||||1966-08-08||1964-12-30|1969-08-07||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||NEWLPROG|NEW LESION PROGRESSION||||UG/L DDU|CA125 75% RESPONSE||SUPPOSITORY|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|U|GUARDIAN|ADJUDICATOR 3|U|3||39||WASHOUT|1963-02-20||||1971-04-21||1968-08-16|1965-11-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||HZ/S|PDU||/KG|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|FRIEND|READER 2|N|4||88||BASELINE|1967-06-13||||1965-08-27||1964-09-29|1970-01-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||BONERESP|BONE RESPONSE||||PACKET|CYTOGENETIC MINOR RESPONSE||10^3 DNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|N|4||88||CONTINUATION TREATMENT|1970-01-21||||1960-09-25||1960-01-26|1960-06-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||CMH2O*S2/ML|PARTIAL MORPHOLOGIC RESPONSE||CI|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|U|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||LONG-TERM FOLLOW-UP|1967-06-21||||1971-01-17||1971-09-02|1963-11-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||LIVRRESP|LIVER RESPONSE||||PLUG|MORPHOLOGIC CRI||ML/M2/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|Y|ADJUDICATOR|PATHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1970-11-12||||1962-01-31||1963-07-31|1972-08-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||TRGRESP|TARGET RESPONSE||||CY/CM|MOLECULAR MAJOR RESPONSE||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|DOMESTIC PARTNER|RATER 2|NA|1||38||TREATMENT|1968-09-03||||1962-11-11||1969-09-05|1960-12-04||DURING||DURING|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/G|NOT ALL EVALUATED||UMOL/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|SIBLING|RATER 1|U|1||38||LONG-TERM FOLLOW-UP|1969-01-20||||1967-07-01||1965-05-16|1967-06-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||OVRLRESP|OVERALL RESPONSE||||FARAD|SD||STEPS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||OBSERVATION|1965-09-26||||1973-05-16||1972-07-21|1967-07-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||BONERESP|BONE RESPONSE||||U/L|OPTIMAL MORPHOLOGIC RESPONSE||ML/G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|2||58||WASHOUT|1961-03-01||||1966-07-31||1967-01-28|1964-03-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||NG/MOL|PARTIAL MORPHOLOGIC RESPONSE||KN/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|CHILD|READER 1|NA|3||39||CONTINUATION TREATMENT|1966-04-22||||1972-06-08||1970-03-23|1971-02-23||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GBQ/MG|HI-E||MEQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|N|ADJUDICATOR|OPHTHALMOLOGIST|N|3||39||BASELINE|1963-11-01||||1966-03-06||1965-01-09|1971-11-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||ANATRESP|ANATOMIC RESPONSE||||MOSM/L|HI-E||10^7/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|N|FAMILY MEMBER|ADJUDICATOR 3|U|4||88||FOLLOW-UP|1962-09-15||||1968-08-16||1962-04-20|1960-06-15||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||NEWLPROG|NEW LESION PROGRESSION||||UU/L|PCR||MAMP|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|4||88||OBSERVATION|1972-01-31||||1969-04-25||1969-03-22|1970-08-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NG/L|CYTOGENETIC MINIMAL RESPONSE||BU/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|ADJUDICATOR|PATHOLOGIST|Y|5||7||RUN-IN|1971-04-10||||1962-08-15||1961-06-07|1962-01-11||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UMOL/L/MIN|VGPR||UL/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1973-01-13||||1972-02-08||1971-05-30|1964-11-04||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||CLINRESP|CLINICAL RESPONSE||||ABSORBANCE U/MIN|MRD PERSISTENCE||NMOL/ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|U|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|NA|1||38||OBSERVATION|1963-11-13||||1964-03-18||1964-04-20|1961-10-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||NEWLPROG|NEW LESION PROGRESSION||||MMHG/SEC|PD/RELAPSE AFTER HI||ML/MIN/MMHG|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|CLINICAL STUDY SPONSOR|RATER 2|NA|1||38||TREATMENT|1970-01-02||||1969-11-28||1967-12-14|1960-06-02||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||TRGRESP|TARGET RESPONSE||||DRINK|CR-CT||CMH2O*S/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|N|STUDY SUBJECT|NEUROLOGIST|Y|2||58||CONTINUATION TREATMENT|1970-10-16||||1972-03-15||1970-09-14|1964-05-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||IU/G|NON-ICR/NON-IUPD||10^3 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|NA|CHILD|ENDOCRINOLOGIST|U|2||58||INDUCTION TREATMENT|1962-08-17||||1962-10-31||1963-12-09|1971-11-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||BESTRESP|BEST OVERALL RESPONSE||||UG/CM2|PARTIAL MORPHOLOGIC RESPONSE||PUFF|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3||39||BLINDED TREATMENT|1973-01-27||||1969-03-13||1970-02-12|1971-08-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||NEWLPROG|NEW LESION PROGRESSION||||ANSON U|MRD NEGATIVITY||G/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|3||39||BLINDED TREATMENT|1965-11-28||||1961-08-24||1963-01-03|1965-10-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||CLINRESP|CLINICAL RESPONSE||||BOLUS|SCR||UG/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|FAMILY MEMBER|PATHOLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1969-02-24||||1970-07-24||1965-11-26|1971-05-14||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||TRGRESP|TARGET RESPONSE||||G/M2/DAY|DECREASED||HEP|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|4||88||FOLLOW-UP|1963-04-03||||1973-07-15||1969-10-16|1972-06-20||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||OHM|OPTIMAL MORPHOLOGIC RESPONSE||UMOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|N|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|5||7||CONTINUATION TREATMENT|1971-08-23||||1968-07-02||1970-02-15|1965-12-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||METBRESP|METABOLIC RESPONSE||||APL U|PD/RELAPSE AFTER HI||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|Y|PROXY|MICROSCOPIST 2|NA|5||7||OPEN LABEL TREATMENT|1972-01-05||||1967-06-01||1964-11-21|1963-08-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||STRUSTAT|STEROID USE STATUS||||EP U|PD FROM PR||U/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|CHILD|RADIOLOGIST|U|1||38||CONTINUATION TREATMENT|1966-02-02||||1960-11-27||1964-02-10|1965-10-07||DURING||AFTER|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||METSIND|METASTATIC INDICATOR||||BQ/KG|PD-CT||FRAMES/S|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|PARENT|DERMATOLOGIST|U|1||38||RUN-IN|1970-04-20||||1962-05-20||1964-10-07|1969-10-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MPL U/ML|EQUIVOCAL||CD*S/M2|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|U|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|2||58||BLINDED TREATMENT|1962-01-02||||1962-07-05||1960-10-20|1963-12-02||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PFU/DOSE|NON-PD||MG/KG/H|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|2||58||TREATMENT|1962-12-26||||1961-11-18||1962-08-05|1960-10-13||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MCI/L|DISEASE TRANSFORMATION||AGU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|3||39||OBSERVATION|1962-08-21||||1972-01-10||1965-05-28|1961-08-06||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ARBITRARY U|RELAPSED DISEASE FROM CR||UMOL/KG/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||BASELINE|1971-02-22||||1969-05-25||1973-01-09|1964-01-14||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||BONERESP|BONE RESPONSE||||PNU/ML|PSEUDOPROGRESSION||UIU/L|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|PROXY|ADJUDICATOR 2|NA|4||88||TREATMENT|1967-09-05||||1968-04-19||1960-02-15|1970-02-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MG/KG/MIN|CYTOGENETIC MINIMAL RESPONSE||MMOL/MIN/KPA/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|STUDY SUBJECT|PATHOLOGIST|N|4||88||BASELINE|1964-09-04||||1962-05-11||1961-07-04|1965-03-06||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||METSIND|METASTATIC INDICATOR||||CI|CYTOGENETIC PR||NMOL BCE/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|N|ADJUDICATION COMMITTEE|READER 1|U|5||7||FOLLOW-UP|1966-11-06||||1969-06-07||1969-10-30|1971-08-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||NEWLPROG|NEW LESION PROGRESSION||||UM/S|INDETERMINATE RESPONSE||G/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|Y|VENDOR|ADJUDICATOR|Y|5||7||OPEN LABEL TREATMENT|1966-02-18||||1960-09-17||1972-02-27|1971-04-08||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/MG|PSEUDOPROGRESSION||10^9 ORGANISMS/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|1||38||RUN-IN|1964-09-27||||1961-01-29||1973-01-02|1968-10-20||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||NTRGRESP|NON-TARGET RESPONSE||||/MM|OPTIMAL MORPHOLOGIC RESPONSE||SCOOPFUL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|N|1||38||WASHOUT|1966-09-07||||1967-02-05||1962-11-17|1970-06-05||AFTER||DURING|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MAC50|CCR||MPS U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|2||58||SCREENING|1961-12-15||||1971-03-18||1970-04-08|1971-12-23||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||NEWLPROG|NEW LESION PROGRESSION||||U|CR||KAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|Y|CAREGIVER|MICROSCOPIST 1|NA|2||58||FOLLOW-UP|1971-11-22||||1963-01-16||1960-01-25|1962-01-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||LIVRRESP|LIVER RESPONSE||||CIGAR|PMD||MET*H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|3||39||OBSERVATION|1970-05-23||||1968-11-07||1973-03-26|1969-02-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||LIVRRESP|LIVER RESPONSE||||IU/KG|PARTIAL MORPHOLOGIC RESPONSE||DAYS/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||BLINDED TREATMENT|1962-07-08||||1966-07-28||1965-12-29|1961-04-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL/ML/MIN|PCR||MIU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|Y|SPOUSE|PATHOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1965-12-08||||1960-07-09||1971-01-25|1966-05-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||CLINRESP|CLINICAL RESPONSE||||MANSON U/ML|SD-CT||DRUM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|INVESTIGATOR|OTOLARYNGOLOGIST|NA|4||88||CONTINUATION TREATMENT|1964-02-20||||1961-02-24||1969-12-19|1961-07-14||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UCI/KG|NON-PD||MG/DL|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|Y|5||7||OBSERVATION|1960-10-19||||1962-05-11||1963-11-20|1969-09-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||ANATRESP|ANATOMIC RESPONSE||||MEQ/DAY|IMPROVED||STRIP|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1962-09-03||||1970-12-11||1967-04-02|1968-10-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||LIVRRESP|LIVER RESPONSE||||FMOL/G|MORPHOLOGIC CRI||DRAM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|INVESTIGATOR|NEUROLOGIST|U|1||38||BASELINE|1968-07-26||||1968-03-18||1960-10-27|1966-12-25||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||NEWLPROG|NEW LESION PROGRESSION||||U/10^12 RBC|CCR||CIGAR|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|CAREGIVER|CARDIOLOGIST|U|1||38||TREATMENT|1962-07-07||||1961-07-27||1967-07-22|1964-07-05||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MKAT|INDETERMINATE RESPONSE||CFU/G|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|N|SIGNIFICANT OTHER|RATER 2|Y|2||58||FOLLOW-UP|1961-05-23||||1967-12-11||1971-10-14|1970-06-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||VG/KG|IMMUNOPHENOTYPIC CR||UMOL/MG/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|PARENT|RADIOLOGIST 1|NA|2||58||BLINDED TREATMENT|1960-03-29||||1969-09-26||1968-09-23|1971-03-19||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^8 PFU|MRD RELAPSE||ML/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|INVESTIGATOR|RATER|U|3||39||BASELINE|1965-04-06||||1961-03-27||1968-05-06|1962-04-06||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CAPSULE|EQUIVOCAL||MPH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|U|CAREGIVER|MICROSCOPIST 1|Y|3||39||INDUCTION TREATMENT|1972-09-03||||1960-06-01||1969-05-02|1963-01-18||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^12/L|TREATMENT FAILURE||BQ/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|PARENT|PATHOLOGIST|NA|4||88||RUN-IN|1960-08-07||||1973-09-07||1968-06-14|1965-01-09||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||DIOPTER|STABLE||MG/CM2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|CHILD|CLINICAL PATHOLOGIST|Y|4||88||RUN-IN|1962-01-20||||1968-08-04||1970-06-03|1963-01-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GPS U|CCR||DAGU/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|SIBLING|ADJUDICATOR|NA|5||7||OPEN LABEL TREATMENT|1960-12-07||||1967-06-02||1962-02-23|1963-01-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||SPLNRESP|SPLEEN RESPONSE||||/5X10^4 WBC|MORPHOLOGIC CRI||GY/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|5||7||OBSERVATION|1969-09-04||||1972-09-22||1961-11-19|1960-07-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|1||||||TMRESP|TUMOR MARKER RESPONSE||||ML/MMHG|ISD||UG/DOSE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|1||38||WASHOUT|1961-07-30||||1967-01-22||1969-10-06|1960-04-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|2||||||STRUSTAT|STEROID USE STATUS||||PUFF|PMD||UM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|INTERVIEWER|ONCOLOGIST 2|Y|1||38||WASHOUT|1965-08-10||||1963-05-16||1967-01-27|1967-12-29||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|1||||||NEWLPROG|NEW LESION PROGRESSION||||UG/M2/H|NPR||BOLUS|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|2||58||TREATMENT|1969-12-03||||1969-03-19||1966-03-28|1962-04-05||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|2||||||CLINRESP|CLINICAL RESPONSE||||NMOL/ML/MIN|CA125 50% RESPONSE||ML/CAGE/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|U|ADJUDICATOR|ADJUDICATOR 3|U|2||58||CONTINUATION TREATMENT|1972-07-16||||1971-05-24||1964-07-25|1966-09-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG/ANIMAL|INCREASED||AMP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|SIBLING|RATER 1|NA|3||39||WASHOUT|1963-12-07||||1965-11-16||1968-08-29|1960-02-01||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|2||||||TMRESP|TUMOR MARKER RESPONSE||||CMH2O*S2/ML|NED||10^9/G|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|CLINICAL RESEARCH COORDINATOR|RATER 1|Y|3||39||CONTINUATION TREATMENT|1960-12-11||||1973-02-02||1968-03-12|1969-02-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||GMFI|MCR||UMOL/MG/MIN|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|U|FRIEND|OTOLARYNGOLOGIST|U|4||88||WASHOUT|1965-12-19||||1962-02-08||1969-01-19|1971-02-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|2||||||SPLNRESP|SPLEEN RESPONSE||||KG/CM2|RELAPSED DISEASE FROM CR||GAUSS|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|SIBLING|MICROSCOPIST 3|N|4||88||TREATMENT|1964-08-16||||1962-01-14||1966-11-12|1969-07-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FMOL/G|IUPD||MG/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|PARENT|FORENSIC PATHOLOGIST|N|5||7||RUN-IN|1969-08-23||||1965-09-17||1960-10-03|1960-07-31||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|91838668-D463-4728-A581-2E1987592885|2||||||STRUSTAT|STEROID USE STATUS||||ML/H|NON-PD||DISK|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|FRIEND|ENDOCRINOLOGIST|U|5||7||SCREENING|1968-05-01||||1964-07-28||1971-04-02|1964-10-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^11/L|PD FROM PR||UMOL/MG/MIN|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|N|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|1||38||RUN-IN|1964-01-08||||1966-10-17||1963-01-09|1973-04-24||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MMHG|CRI||MG/KG/WEEK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|STUDY SUBJECT|MICROSCOPIST|Y|1||38||CONTINUATION TREATMENT|1961-08-24||||1960-09-04||1967-02-17|1962-06-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||TMRESP|TUMOR MARKER RESPONSE||||UCI/L|PSEUDOPROGRESSION||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|2||58||BASELINE|1961-08-15||||1969-12-08||1969-10-03|1967-03-11||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||TMRESP|TUMOR MARKER RESPONSE||||BEL|PARTIAL MORPHOLOGIC RESPONSE||10^8/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|2||58||WASHOUT|1964-11-07||||1971-05-25||1963-01-31|1966-08-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||STRUSTAT|STEROID USE STATUS||||RING|IUPD||U/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|Y|ADJUDICATION COMMITTEE|INTERNIST|NA|3||39||BLINDED TREATMENT|1961-06-15||||1960-11-21||1968-06-04|1971-10-27||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||METBRESP|METABOLIC RESPONSE||||PUFF|SMD||LOG10 PFU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|INVESTIGATOR|MICROSCOPIST 3|N|3||39||INDUCTION TREATMENT|1964-03-21||||1965-04-24||1970-06-13|1970-09-16||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||SPLNRESP|SPLEEN RESPONSE||||10^7 CFU|PR||/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|NA|CAREGIVER|MICROSCOPIST|N|4||88||WASHOUT|1960-10-07||||1968-07-18||1972-11-30|1964-08-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||NTRGRESP|NON-TARGET RESPONSE||||VP/DOSE|CPR||ML/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|CAREGIVER|HEMATOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1967-08-21||||1968-02-26||1962-08-14|1969-10-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BEL|CHR||GTT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|U|U|PROXY|RATER 2|NA|5||7||BASELINE|1973-06-13||||1973-04-07||1962-06-01|1972-02-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^3 ORGANISMS/G|MORPHOLOGIC LEUKEMIA-FREE STATE||MMOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|N|U|N|STUDY SUBJECT|ONCOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1967-03-05||||1966-08-18||1965-04-28|1966-05-31||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||LENS|CYTOGENETIC MINOR RESPONSE||UG/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|SPOUSE|ADJUDICATOR 2|U|1||38||FOLLOW-UP|1965-12-15||||1971-03-07||1967-03-21|1962-09-26||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||ANATRESP|ANATOMIC RESPONSE||||MPS U|CR-CT||ELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|U|ADJUDICATOR|PHYSIOTHERAPIST|U|1||38||CONTINUATION TREATMENT|1971-07-05||||1964-08-26||1964-07-02|1961-04-24||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||10^4 CFU/ML|IMMUNOPHENOTYPIC CR||PT_BR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|SIGNIFICANT OTHER|MICROSCOPIST 1|N|2||58||INDUCTION TREATMENT|1965-08-15||||1971-05-04||1973-08-14|1962-07-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||MOLRESP|MOLECULAR RESPONSE||||MG/DAY|MRD NEGATIVITY||MM/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|2||58||SCREENING|1971-06-16||||1966-08-18||1971-07-05|1973-01-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||RDIORESP|RADIOLOGIC RESPONSE||||PSEC|CMR||10^9 ORGANISMS/MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|SIBLING|FORENSIC PATHOLOGIST|U|3||39||CONTINUATION TREATMENT|1960-06-24||||1966-12-05||1972-07-02|1970-11-28||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU/L|PCR||JDF UNIT|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|N|SPOUSE|READER|U|3||39||RUN-IN|1960-12-05||||1960-01-02||1961-03-09|1961-11-24||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DL|RELAPSED DISEASE FROM CR||PMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|VENDOR|RATER|NA|4||88||SCREENING|1963-05-17||||1965-06-25||1961-09-14|1965-01-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PMOL/G|CRI||MDFI|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CAREGIVER|ADJUDICATOR 2|U|4||88||INDUCTION TREATMENT|1962-02-23||||1961-01-09||1963-07-01|1973-02-03||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||ANATRESP|ANATOMIC RESPONSE||||NG/MOL|SMD||STEPS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|U|FRIEND|ADJUDICATOR|NA|5||7||FOLLOW-UP|1970-04-14||||1973-02-04||1973-08-10|1965-09-22||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||ANATRESP|ANATOMIC RESPONSE||||PT_BR|CA125 75% RESPONSE||UOSM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|U|INTERVIEWER|RADIOLOGIST 2|N|5||7||OPEN LABEL TREATMENT|1969-10-08||||1964-07-31||1972-02-12|1962-12-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||CYTORESP|CYTOGENETIC RESPONSE||||G|CYTOGENETIC PR||AG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|PROXY|ONCOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1971-07-26||||1973-01-18||1971-05-23|1971-01-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||MOLRESP|MOLECULAR RESPONSE||||PG/L|PMR||ML/BREATH|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|PARENT|ENDOCRINOLOGIST|NA|1||38||BASELINE|1971-06-15||||1961-09-24||1971-03-30|1973-08-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/G|PCR||L/H/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|ADJUDICATOR|NEUROLOGIST 2|Y|2||58||OPEN LABEL TREATMENT|1961-01-11||||1972-01-16||1967-10-22|1967-07-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||BONERESP|BONE RESPONSE||||BOLUS|MAJOR PATHOLOGIC RESPONSE||MMHG/SEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|Y|FAMILY MEMBER|CARDIOLOGIST|NA|2||58||TREATMENT|1960-07-21||||1972-11-16||1960-12-27|1969-09-29||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CUP|PMD||ML/S|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|SIGNIFICANT OTHER|CARDIOLOGIST|NA|3||39||BLINDED TREATMENT|1960-05-13||||1970-01-16||1966-01-05|1968-04-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/MIN|PMR||FT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|NA|STUDY SUBJECT|READER 2|U|3||39||INDUCTION TREATMENT|1967-10-04||||1961-05-31||1970-07-23|1971-04-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||NEWLPROG|NEW LESION PROGRESSION||||/2000 RBC|HI-P||JDF UNIT|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4||88||FOLLOW-UP|1966-07-12||||1971-03-18||1966-12-23|1973-04-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U/KG/H|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||KG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|CAREGIVER|OPTOMETRIST|N|4||88||CONTINUATION TREATMENT|1966-05-20||||1967-03-28||1971-01-02|1968-07-25||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||CYTORESP|CYTOGENETIC RESPONSE||||HPA|PMD||10^8/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|5||7||SCREENING|1966-01-13||||1963-03-07||1961-08-29|1962-02-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||CMOL|PMR||MG/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|5||7||RUN-IN|1969-07-14||||1965-06-25||1961-07-06|1965-08-06||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||LIVRRESP|LIVER RESPONSE||||AMFI|HI-E||DPM/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|INVESTIGATOR|OPHTHALMOLOGIST|Y|1||38||SCREENING|1964-11-06||||1970-01-26||1973-05-29|1963-10-28||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||INHALATION|INDETERMINATE RESPONSE||CI/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|1||38||SCREENING|1964-08-19||||1971-01-23||1961-10-29|1973-08-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||L/KG|SD||KBQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|2||58||SCREENING|1972-12-04||||1964-04-04||1968-07-01|1968-07-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||LIVRRESP|LIVER RESPONSE||||DIOPTER|PD||MG/M2/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|VENDOR|MICROSCOPIST 2|NA|2||58||WASHOUT|1972-06-21||||1972-08-27||1973-04-29|1971-02-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MG/M2/H|PD||VIRTUAL PIXEL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|GUARDIAN|RATER 1|NA|3||39||OBSERVATION|1967-08-04||||1968-05-14||1966-10-09|1964-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/DL|PD||AG|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|DOMESTIC PARTNER|PATHOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1963-09-16||||1961-10-07||1969-03-22|1965-06-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||CLINRESP|CLINICAL RESPONSE||||TITER|NE||TRACE|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|U|STUDY SUBJECT|ONCOLOGIST|NA|4||88||TREATMENT|1973-06-26||||1965-06-15||1972-06-10|1969-10-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||FT|UNFAVORABLE RESPONSE||MOL/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|Y|SPOUSE|ADJUDICATOR 1|NA|4||88||WASHOUT|1971-03-12||||1970-02-09||1972-06-26|1971-01-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||MOLRESP|MOLECULAR RESPONSE||||FT3|NED||10^9 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|CHILD|CLINICAL PATHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1967-12-16||||1963-01-20||1961-02-17|1967-04-30||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||OVRLRESP|OVERALL RESPONSE||||IU/MG|ABSENT MORPHOLOGIC RESPONSE||10^6 DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|STUDY SUBJECT|DERMATOLOGIST|NA|5||7||BLINDED TREATMENT|1967-07-18||||1970-06-28||1965-02-03|1972-03-31||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/BEAT|CPR||10^3 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|NON-HEALTH CARE PROFESSIONAL|READER|Y|1||38||OPEN LABEL TREATMENT|1972-04-25||||1967-09-07||1961-03-14|1968-07-31||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||G/CAGE|NE||U.CARR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|FRIEND|ONCOLOGIST 1|NA|1||38||BASELINE|1971-04-07||||1965-07-26||1966-10-29|1963-10-12||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CAPLET|CCR||10^8/L|NOT DONE|||LIKERT SCALE 7-POINT|N|Y|NA|INVESTIGATOR|ENDOCRINOLOGIST|U|2||58||RUN-IN|1973-07-12||||1966-10-11||1968-08-13|1970-01-06||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||BONERESP|BONE RESPONSE||||DRINK|SMD||SYRINGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|N|STUDY SUBJECT|MICROSCOPIST 3|U|2||58||WASHOUT|1969-10-08||||1973-01-08||1960-12-02|1964-04-23||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MG|MCR||USIEMENS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|CAREGIVER|READER 2|U|3||39||LONG-TERM FOLLOW-UP|1963-05-10||||1961-09-01||1968-09-18|1964-05-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||ML/M2/H|CA125 50% RESPONSE||/5X10^4 WBC|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|PARENT|PATHOLOGIST 1|Y|3||39||SCREENING|1967-05-14||||1972-08-26||1965-08-01|1973-01-20||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||BESTRESP|BEST OVERALL RESPONSE||||G/KG/DAY|RELAPSED DISEASE FROM CR OR PR||CGY|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|U|PROXY|FORENSIC PATHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1967-08-01||||1966-06-12||1961-09-18|1968-11-22||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||METSIND|METASTATIC INDICATOR||||ELISA UNIT/ML|NON-QUANTIFIABLE MRD POSITIVITY||M2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|INTERVIEWER|MICROSCOPIST 2|U|4||88||RUN-IN|1964-10-29||||1968-04-18||1965-09-04|1964-07-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU/KG/H|NON-PD||FINGERTIP UNIT|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|FRIEND|MICROSCOPIST 2|U|5||7||BLINDED TREATMENT|1966-12-09||||1962-07-15||1967-06-18|1971-06-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^11/L|PD||LOG10 TCID 50/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||FOLLOW-UP|1967-11-20||||1970-07-02||1968-01-23|1962-10-25||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||BU/ML|MCR||10^6/EJACULATE U|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|1||38||OBSERVATION|1967-01-16||||1969-11-13||1963-06-26|1966-07-15||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||BONERESP|BONE RESPONSE||||BEATS/MIN|RELAPSED DISEASE FROM CR OR PR||UIU/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|SIBLING|RATER|Y|1||38||INDUCTION TREATMENT|1963-11-28||||1971-02-24||1963-05-05|1963-03-05||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||NEWLPROG|NEW LESION PROGRESSION||||NKAT/L|MCR||CIGARETTE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|ADJUDICATOR|MICROSCOPIST 2|U|2||58||FOLLOW-UP|1970-12-15||||1970-07-10||1973-01-03|1960-04-09||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||SIEMENS|CYTOGENETIC MINOR RESPONSE||CAPFUL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|SIBLING|RATER 2|Y|2||58||OPEN LABEL TREATMENT|1969-11-11||||1968-10-11||1967-07-10|1970-05-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/S|CPR||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|3||39||BASELINE|1969-05-04||||1963-06-02||1970-09-01|1964-10-19||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PIXEL|FAVORABLE RESPONSE||PFU/DOSE|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|STUDY SUBJECT|PATHOLOGIST 1|NA|3||39||TREATMENT|1962-02-18||||1973-05-17||1971-03-27|1968-04-21||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||BONERESP|BONE RESPONSE||||C|CYTOGENETIC MINOR RESPONSE||MG/KG|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|VENDOR|ONCOLOGIST 1|Y|4||88||WASHOUT|1962-10-24||||1965-04-13||1969-02-15|1970-03-23||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/DOSE|PR-CT||MEQ/MMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|4||88||TREATMENT|1964-06-27||||1964-12-14||1963-07-11|1964-07-04||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^6 ORGANISMS/G|ICR||UMOL/H/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|VENDOR|READER 3|Y|5||7||BASELINE|1964-11-26||||1961-04-20||1963-07-03|1962-04-04||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||BONERESP|BONE RESPONSE||||MV|HI-N||P|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|PROXY|RADIOLOGIST 1|NA|5||7||OBSERVATION|1968-12-26||||1969-07-13||1964-03-21|1971-10-19||AFTER||DURING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/L|COMPLETE MRD RESPONSE||MG/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|SIGNIFICANT OTHER|PATHOLOGIST|N|1||38||OPEN LABEL TREATMENT|1965-11-16||||1964-02-11||1968-10-16|1965-01-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^6 CFU|SD||TITER|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||CONTINUATION TREATMENT|1973-09-06||||1969-05-16||1973-06-14|1960-01-04||AFTER||DURING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||SPLNRESP|SPLEEN RESPONSE||||ML/G/H|MOLECULAR MAJOR RESPONSE||H*%|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|PROXY|READER 1|U|2||58||TREATMENT|1964-02-09||||1971-11-11||1964-04-01|1967-12-27||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/H|CA125 50% RESPONSE||U/ANIMAL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|N|CHILD|READER|Y|2||58||CONTINUATION TREATMENT|1966-05-22||||1968-01-23||1971-11-18|1972-09-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^3 DNA COPIES/ML|PMR||PACKET|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|ADJUDICATOR|RATER|U|3||39||OBSERVATION|1970-11-10||||1969-03-22||1960-01-12|1969-02-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||MOLRESP|MOLECULAR RESPONSE||||ML/BEAT|CYTOGENETIC PR||RFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|ADJUDICATOR|NEUROLOGIST|Y|3||39||WASHOUT|1972-12-13||||1964-07-17||1972-12-17|1968-04-28||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KIU|CR-CT||YD|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|STUDY SUBJECT|ADJUDICATOR|U|4||88||OBSERVATION|1973-04-12||||1963-07-27||1960-10-26|1972-05-10||DURING||DURING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||SPLNRESP|SPLEEN RESPONSE||||CONTAINER|CYTOGENETIC PR||CMOL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|N|NA|SPOUSE|PATHOLOGIST 2|NA|4||88||BASELINE|1973-05-19||||1973-01-04||1966-01-28|1961-03-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DIP|INDETERMINATE RESPONSE||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|SIBLING|ADJUDICATOR 1|N|5||7||TREATMENT|1963-02-01||||1962-07-28||1967-12-24|1971-01-01||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||METBRESP|METABOLIC RESPONSE||||MCI/KG|NE||COULOMB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|PARENT|READER 1|N|5||7||OPEN LABEL TREATMENT|1972-01-24||||1971-05-09||1968-04-02|1961-04-13||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG2/DL2|DISEASE TRANSFORMATION||PLUG|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||OPEN LABEL TREATMENT|1972-10-10||||1970-05-11||1968-10-13|1961-01-14||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||METSIND|METASTATIC INDICATOR||||PPTR|ICPD||CMOL/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|U|PROXY|DERMATOLOGIST|NA|1||38||BASELINE|1964-08-02||||1973-01-07||1960-09-09|1965-04-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||TMRESP|TUMOR MARKER RESPONSE||||MG2/DL2|CYTOGENETIC MINIMAL RESPONSE||DNA COPIES/UG|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|GUARDIAN|NEUROLOGIST 2|NA|2||58||OBSERVATION|1963-09-28||||1966-03-07||1964-01-01|1962-11-16||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||NEWLIND|NEW LESION INDICATOR||||10^3 DNA COPIES/ML|NED||MMHG/L/MIN|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|U|CAREGIVER|ONCOLOGIST 1|NA|2||58||WASHOUT|1965-06-27||||1964-02-04||1966-12-31|1962-09-20||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||ANATRESP|ANATOMIC RESPONSE||||GY/H|STABLE||MG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||CONTINUATION TREATMENT|1964-07-30||||1966-05-12||1966-07-24|1973-02-07||DURING||DURING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||BONERESP|BONE RESPONSE||||DEG/S|CMR||UU/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|3||39||CONTINUATION TREATMENT|1970-05-05||||1967-08-27||1965-10-14|1965-02-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||OVRLRESP|OVERALL RESPONSE||||U/KG/MIN|PD/RELAPSE AFTER HI||GY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|STUDY SUBJECT|READER 3|Y|4||88||BLINDED TREATMENT|1966-03-27||||1960-04-21||1968-03-20|1961-09-24||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||PATHRESP|PATHOLOGIC RESPONSE||||DAGU/ML|CR-CT||/40 HPFS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|INTERVIEWER|FORENSIC PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1968-05-21||||1969-12-16||1972-10-25|1961-01-06||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KS|ICPD||100 IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|CAREGIVER|CARDIOLOGIST|U|5||7||OBSERVATION|1961-02-24||||1966-10-18||1968-05-31|1961-10-22||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||METBRESP|METABOLIC RESPONSE||||S*KPA|CR-CT||ELISA UNIT|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|U|INVESTIGATOR|ONCOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1969-02-06||||1970-11-14||1960-07-03|1967-12-04||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||KG/CM|PSEUDORESPONSE||10^3/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|1||38||WASHOUT|1972-04-10||||1967-07-22||1968-10-22|1972-04-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||SYRINGE|ICPD||BOLUS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|CAREGIVER|HEMATOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-07-04||||1962-12-21||1965-06-26|1968-10-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||POUCH|NPR||CI/MG|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|NA|DOMESTIC PARTNER|READER 3|U|2||58||INDUCTION TREATMENT|1962-06-25||||1968-07-16||1961-06-04|1971-01-03||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MAMP|NPR||L/H/M2|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|FRIEND|CARDIOLOGIST|NA|2||58||OBSERVATION|1961-08-03||||1966-10-13||1971-04-16|1964-09-18||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||METSIND|METASTATIC INDICATOR||||PIXEL|DISEASE TRANSFORMATION||CS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|U|NON-HEALTH CARE PROFESSIONAL|READER|NA|3||39||LONG-TERM FOLLOW-UP|1968-02-05||||1960-01-30||1972-06-21|1970-10-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MOSM|PSEUDOPROGRESSION||ML*CMH2O|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||BASELINE|1966-10-31||||1970-01-31||1966-06-08|1964-05-24||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||OVRLRESP|OVERALL RESPONSE||||APL U/ML|CA125 50% RESPONSE||DAYS/WK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|N|GUARDIAN|RATER 2|U|4||88||WASHOUT|1971-08-27||||1969-10-03||1968-09-14|1969-01-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||TRGRESP|TARGET RESPONSE||||EJACULATE U|INCREASED||FINGERTIP UNIT|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|SPOUSE|MICROSCOPIST|Y|4||88||TREATMENT|1968-10-23||||1966-12-03||1961-01-05|1967-12-21||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||NEWLPROG|NEW LESION PROGRESSION||||PIXEL|PCR||UOSM|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|U|CAREGIVER|READER 3|N|5||7||WASHOUT|1969-01-24||||1961-10-15||1961-12-24|1971-12-23||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/ANIMAL/WK|FAVORABLE RESPONSE||PKAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|U|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|5||7||BLINDED TREATMENT|1971-12-30||||1972-03-08||1969-04-19|1967-09-03||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||RDIORESP|RADIOLOGIC RESPONSE||||KG/MOL|CYTOGENETIC PR||MOSM/KG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1972-06-07||||1968-05-22||1965-04-09|1971-06-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||DNA COPIES/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MG/ML/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|1||38||FOLLOW-UP|1963-02-16||||1969-01-06||1967-08-06|1968-07-14||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||CYTORESP|CYTOGENETIC RESPONSE||||10^9 CFU|MCR||G/CM2|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|NA|SIGNIFICANT OTHER|RATER 1|Y|2||58||WASHOUT|1966-07-29||||1963-01-02||1962-02-05|1962-03-20||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||CYTORESP|CYTOGENETIC RESPONSE||||10^3 RNA COPIES/ML|CYTOGENETIC CR||DISK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|2||58||BLINDED TREATMENT|1963-08-14||||1965-06-18||1967-12-16|1961-03-09||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/G/H|IPR||MG/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|3||39||BASELINE|1971-12-17||||1965-03-25||1965-04-02|1966-07-24||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MOL|ISD||CFU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CHILD|CARDIOLOGIST|N|3||39||WASHOUT|1966-11-20||||1965-06-09||1960-05-16|1966-09-14||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PPTR|CYTOGENETIC MINOR RESPONSE||MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|INVESTIGATOR|PATHOLOGIST 1|Y|4||88||BLINDED TREATMENT|1966-03-05||||1962-09-22||1971-08-18|1960-12-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||TITER|PD FROM PR||L/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|PROXY|MICROSCOPIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1972-09-15||||1968-11-08||1965-11-22|1961-11-17||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||OVRLRESP|OVERALL RESPONSE||||UMOL/L/H|CA125 75% RESPONSE||BQ/UL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|Y|PROXY|UROLOGIST|U|5||7||FOLLOW-UP|1961-05-23||||1964-06-25||1972-08-20|1965-02-03||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/LPF|NPR||CI/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1972-12-28||||1960-05-13||1962-08-06|1965-12-27||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||LIVRRESP|LIVER RESPONSE||||DAGU/ML|NON-QUANTIFIABLE MRD POSITIVITY||KG/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|VENDOR|READER 3|N|1||38||BLINDED TREATMENT|1967-09-13||||1969-09-07||1969-10-09|1968-12-13||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||NTRGRESP|NON-TARGET RESPONSE||||10^9 ORGANISMS/MG|NR||MEQ/KG|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|N|CLINICAL STUDY SPONSOR|INTERNIST|NA|1||38||OPEN LABEL TREATMENT|1967-09-17||||1973-01-06||1964-07-23|1969-02-02||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||HEP|ISD||PMOL/L|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|Y|SPOUSE|READER|U|2||58||CONTINUATION TREATMENT|1969-06-15||||1963-06-04||1964-02-06|1970-05-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ARBITRARY U|INCREASED||KG/CM|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||BASELINE|1972-04-10||||1966-09-05||1967-02-05|1970-08-01||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||TMRESP|TUMOR MARKER RESPONSE||||/10^5|WORSENED||PACKAGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|CAREGIVER|ONCOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1969-10-01||||1972-10-17||1961-12-01|1968-04-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/L|MOLECULAR MAJOR RESPONSE||DAGU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|Y|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1967-07-04||||1960-02-29||1967-04-02|1963-11-02||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||OVRLRESP|OVERALL RESPONSE||||GENEQ/ML|HI-P||PKAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|N|SPOUSE|MICROSCOPIST 3|U|4||88||TREATMENT|1963-12-18||||1967-11-16||1960-05-21|1966-09-10||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||U/M2/MIN|PMD||%/MIN|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|INTERVIEWER|ENDOCRINOLOGIST|N|4||88||RUN-IN|1968-07-21||||1969-09-05||1962-03-17|1964-05-03||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||TRGRESP|TARGET RESPONSE||||MKAT|PSEUDOPROGRESSION||KPA/L/SEC|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|5||7||WASHOUT|1962-10-08||||1965-10-27||1962-11-06|1965-11-04||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/SEC/1.73M2|CRI||PG/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|Y|STUDY SUBJECT|PHYSIOTHERAPIST|Y|5||7||TREATMENT|1965-07-21||||1964-11-14||1961-09-08|1963-09-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||TMRESP|TUMOR MARKER RESPONSE||||10^6 DNA COPIES/ML|NON-QUANTIFIABLE MRD POSITIVITY||DAGU|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|ADJUDICATOR|MICROSCOPIST|U|1||38||TREATMENT|1965-06-22||||1967-02-14||1971-06-13|1972-01-01||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||NTRGRESP|NON-TARGET RESPONSE||||CYLINDER|NOT ALL EVALUATED||CP|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CHILD|RATER|N|1||38||OPEN LABEL TREATMENT|1964-08-25||||1972-10-31||1969-12-24|1968-11-27||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/M2/H|IMPROVED||CUP|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|INVESTIGATOR|READER|Y|2||58||SCREENING|1961-02-23||||1968-07-23||1964-08-21|1965-01-20||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/M2|MAJOR PATHOLOGIC RESPONSE||/7.5 ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|2||58||BASELINE|1971-06-13||||1966-08-29||1969-10-19|1967-10-29||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||CLINRESP|CLINICAL RESPONSE||||MMOL/MIN/KPA|OPTIMAL MORPHOLOGIC RESPONSE||TABLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|VENDOR|MICROSCOPIST|N|3||39||LONG-TERM FOLLOW-UP|1964-11-02||||1972-09-19||1962-08-04|1966-11-15||DURING||DURING|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||METSIND|METASTATIC INDICATOR||||KN/CM2|NPR||MM/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|N|CHILD|ADJUDICATOR 2|U|3||39||LONG-TERM FOLLOW-UP|1960-01-16||||1972-02-23||1973-08-28|1972-05-18||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||BONERESP|BONE RESPONSE||||MPL U/ML|TREATMENT FAILURE||10^12 IU/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|U|ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|4||88||SCREENING|1963-11-02||||1965-02-02||1962-10-31|1961-10-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||METSIND|METASTATIC INDICATOR||||ML/SEC/1.73M2|CR||IU/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|U|N|Y|PROXY|RATER 2|NA|4||88||OBSERVATION|1969-11-11||||1961-03-24||1960-05-11|1973-09-08||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/M2/DAY|QUANTIFIABLE MRD POSITIVITY||MET|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|PARENT|CLINICAL PATHOLOGIST|Y|5||7||WASHOUT|1961-08-25||||1966-08-21||1964-03-14|1961-12-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||PATHRESP|PATHOLOGIC RESPONSE||||V|MINOR PATHOLOGIC RESPONSE||LM|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|SIBLING|PATHOLOGIST|N|5||7||SCREENING|1965-10-27||||1973-02-09||1962-03-04|1969-09-01||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG/G/MIN|IUPD||DEG2|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|1||38||FOLLOW-UP|1973-04-11||||1962-04-06||1965-09-28|1963-09-05||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||ANATRESP|ANATOMIC RESPONSE||||10^5/HPF|WORSENED||APS U|NOT DONE|||LIKERT SCALE 5-POINT|U|U|N|ADJUDICATOR|OPTOMETRIST|N|1||38||INDUCTION TREATMENT|1968-02-27||||1970-01-07||1963-12-14|1965-12-01||DURING||DURING|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||METSIND|METASTATIC INDICATOR||||10^3 CFU/G|MORPHOLOGIC LEUKEMIA-FREE STATE||M2|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|2||58||INDUCTION TREATMENT|1968-06-08||||1968-06-09||1968-02-08|1965-08-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||METSIND|METASTATIC INDICATOR||||DIOPTER|NON-PD||GPL U|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||INDUCTION TREATMENT|1972-08-12||||1963-09-05||1960-06-12|1966-11-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||MOLRESP|MOLECULAR RESPONSE||||UL/DOSE|MINOR PATHOLOGIC RESPONSE||%(W/W)|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|ADJUDICATOR|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1963-05-25||||1972-02-06||1963-02-27|1973-07-11||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||SPLNRESP|SPLEEN RESPONSE||||MDFI|RELAPSED DISEASE FROM CR||STEPS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|INTERVIEWER|NEUROLOGIST|Y|3||39||CONTINUATION TREATMENT|1972-10-10||||1968-05-07||1967-01-23|1963-06-16||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||NEWLIND|NEW LESION INDICATOR||||CAPLET|MAJOR PATHOLOGIC RESPONSE||RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|NA|4||88||RUN-IN|1960-03-01||||1961-01-01||1967-07-19|1971-05-04||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CI/UG|CA125 75% RESPONSE||VIAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|PARENT|NEUROLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1963-05-20||||1970-11-22||1967-12-24|1962-09-29||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||CYTORESP|CYTOGENETIC RESPONSE||||ML/M2/DAY|NON-ICR/NON-IUPD||10^4 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|N|INVESTIGATOR|PATHOLOGIST 2|NA|5||7||RUN-IN|1960-10-08||||1965-06-04||1969-04-13|1967-08-09||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||OVRLRESP|OVERALL RESPONSE||||10^3/L|CYTOGENETIC CR||MEQ/UL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|CLINICAL STUDY SPONSOR|READER 3|U|5||7||LONG-TERM FOLLOW-UP|1965-10-05||||1966-10-04||1961-05-17|1969-06-01||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/G/MIN|FAVORABLE RESPONSE||MCI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|VENDOR|OPTOMETRIST|N|1||38||INDUCTION TREATMENT|1966-05-18||||1971-02-17||1973-06-03|1967-08-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||IMPLANT|IMMUNOPHENOTYPIC CR||MOL/G|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|Y|FAMILY MEMBER|NEUROLOGIST 1|NA|1||38||INDUCTION TREATMENT|1960-03-29||||1963-10-10||1963-08-03|1963-07-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/MIN|OPTIMAL MORPHOLOGIC RESPONSE||H/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||TREATMENT|1972-12-04||||1971-07-04||1960-02-06|1961-11-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|2||||||TMRESP|TUMOR MARKER RESPONSE||||CPM|CYTOGENETIC MINIMAL RESPONSE||LB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|Y|ADJUDICATOR|NEUROLOGIST 1|NA|2||58||SCREENING|1960-09-18||||1972-05-15||1961-03-31|1961-04-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||BQ/KG|CR||UCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|N|PARENT|ONCOLOGIST|Y|3||39||OBSERVATION|1969-10-22||||1962-08-02||1961-08-19|1965-12-12||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|2||||||TMRESP|TUMOR MARKER RESPONSE||||10^8/L|RELAPSED DISEASE FROM CR||SV|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|CAREGIVER|READER 2|U|3||39||SCREENING|1973-04-05||||1961-10-20||1963-05-24|1973-06-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^7/L|ICR||10^6 U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|INVESTIGATOR|INTERNIST|N|4||88||FOLLOW-UP|1967-12-21||||1971-11-09||1962-11-02|1961-08-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|2||||||METSIND|METASTATIC INDICATOR||||ATM|UNEQUIVOCAL||ARBITRARY U|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|INVESTIGATOR|RATER 1|U|4||88||BASELINE|1970-08-16||||1971-06-20||1963-02-05|1967-07-16||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|1||||||PATHRESP|PATHOLOGIC RESPONSE||||KN/CM2|HI-E||MMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|ADJUDICATOR|NEUROLOGIST 2|Y|5||7||RUN-IN|1961-05-14||||1961-06-06||1964-11-13|1963-07-20||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|20DC654F-595C-410D-A340-465A23434D42|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||VG/KG|PD||U/G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|CHILD|CLINICAL PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1965-05-21||||1961-12-08||1968-02-16|1961-07-19||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||APL U/ML|UNEQUIVOCAL||AMU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CHILD|ONCOLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1969-11-27||||1970-12-18||1964-06-30|1964-01-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IN2|ICPD||BQ/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|1||38||SCREENING|1960-12-25||||1965-05-12||1971-05-14|1972-12-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||CLINRESP|CLINICAL RESPONSE||||/DAY|TREATMENT FAILURE||KPA/L/SEC|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1963-02-03||||1963-03-11||1962-04-14|1965-05-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||TRGRESP|TARGET RESPONSE||||UG|NED||MMHG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|Y|FRIEND|CLINICAL PATHOLOGIST|Y|2||58||BASELINE|1969-03-18||||1969-06-03||1970-01-11|1971-05-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||UG|MAJOR PATHOLOGIC RESPONSE||MOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1972-03-21||||1965-02-09||1962-07-18|1961-01-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||CYTORESP|CYTOGENETIC RESPONSE||||MOL|PSEUDOPROGRESSION||STEPS|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|Y|GUARDIAN|MICROSCOPIST 1|U|3||39||WASHOUT|1960-08-12||||1972-02-18||1969-05-01|1969-10-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||ANATRESP|ANATOMIC RESPONSE||||MMHG/SEC|NON-ICR/NON-IUPD||FOZ_BR|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|4||88||OBSERVATION|1960-04-26||||1968-08-26||1966-07-28|1973-06-06||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PA|PCR||UMOL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|4||88||TREATMENT|1963-03-20||||1964-10-07||1965-01-10|1962-03-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||10^12/L|MRD NEGATIVITY||USP U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|CAREGIVER|RADIOLOGIST|U|5||7||CONTINUATION TREATMENT|1961-01-07||||1970-07-27||1970-03-16|1970-01-22||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||LIVRRESP|LIVER RESPONSE||||UCI/L|RELAPSED DISEASE FROM CR OR PR||U/G/DAY|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|Y|NA|VENDOR|HEMATOLOGIST|NA|5||7||WASHOUT|1972-02-03||||1965-05-18||1967-07-20|1965-05-23||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IMPLANT|TREATMENT FAILURE||MIN*MG/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|U|FAMILY MEMBER|RADIOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1965-11-15||||1965-12-01||1962-12-31|1969-11-23||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||ANATRESP|ANATOMIC RESPONSE||||NMOL BCE/MMOL|NR||BQ/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|1||38||OBSERVATION|1968-02-29||||1969-07-17||1968-12-14|1966-05-14||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||NTRGRESP|NON-TARGET RESPONSE||||DNA COPIES/UG|NON-CR/NON-PD||UCI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|INVESTIGATOR|UROLOGIST|Y|2||58||WASHOUT|1967-01-28||||1962-01-17||1966-07-07|1968-02-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||H*%|NR||ML/ANIMAL|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|N|2||58||BASELINE|1964-06-27||||1971-04-10||1967-03-07|1960-06-01||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MMOL2/L2|MORPHOLOGIC CR||TABLET|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|SIGNIFICANT OTHER|ADJUDICATOR 3|NA|3||39||FOLLOW-UP|1972-01-06||||1963-03-22||1967-06-17|1968-08-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MET*H|SMD||IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1970-03-22||||1966-07-12||1971-06-07|1966-07-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||METBRESP|METABOLIC RESPONSE||||TBSP|MR||ENZYME U/G HB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|GUARDIAN|RATER|Y|4||88||LONG-TERM FOLLOW-UP|1970-09-08||||1972-07-30||1964-09-04|1968-12-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||OVRLRESP|OVERALL RESPONSE||||L/MIN|MOLECULAR CR||UGEQ/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|FAMILY MEMBER|OPHTHALMOLOGIST|N|4||88||TREATMENT|1966-10-15||||1964-01-26||1969-12-13|1968-06-25||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||ANATRESP|ANATOMIC RESPONSE||||RAD|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||PT_BR|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|DOMESTIC PARTNER|NEUROLOGIST 1|U|5||7||FOLLOW-UP|1970-08-17||||1967-11-26||1961-10-08|1967-09-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||OVRLRESP|OVERALL RESPONSE||||UV*SEC|CYTOGENETIC CR||C|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|STUDY SUBJECT|OPTOMETRIST|U|5||7||OPEN LABEL TREATMENT|1972-04-02||||1965-05-06||1973-06-09|1965-08-04||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UL/DOSE|IMPROVED||UV|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1||38||INDUCTION TREATMENT|1967-11-14||||1964-03-18||1970-06-03|1967-09-19||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^3 COPIES/ML|CYTOGENETIC MINOR RESPONSE||/500 WBC|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1967-10-21||||1970-10-12||1961-03-28|1962-08-12||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||H/WK|INDETERMINATE RESPONSE||ML*CMH2O|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|CAREGIVER|CARDIOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1969-09-17||||1971-03-28||1970-01-06|1967-04-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||NTRGRESP|NON-TARGET RESPONSE||||CI/UL|VGPR||MIU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|PARENT|ADJUDICATOR 3|Y|2||58||WASHOUT|1964-07-15||||1961-05-15||1971-08-16|1970-01-09||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/ML/MIN|QUANTIFIABLE MRD POSITIVITY||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|N|INVESTIGATOR|ONCOLOGIST 1|NA|3||39||RUN-IN|1968-09-25||||1971-01-01||1971-08-02|1961-11-28||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/MIN/M2|CR||ELISA UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|CHILD|HEMATOLOGIST|Y|3||39||FOLLOW-UP|1971-06-17||||1963-11-17||1964-01-21|1972-04-20||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||U/G|UNEQUIVOCAL||/MBP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|N|PROXY|RATER|N|4||88||BASELINE|1965-10-21||||1962-02-23||1972-08-02|1971-12-02||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||OVRLRESP|OVERALL RESPONSE||||10^6 CFU/ML|CYTOGENETIC MINIMAL RESPONSE||VP/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|DOMESTIC PARTNER|HEMATOLOGIST|N|4||88||OPEN LABEL TREATMENT|1971-10-30||||1967-05-23||1968-09-13|1963-06-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||TUBE|NON-ICR/NON-IUPD||10^6 ORGANISMS/MG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|VENDOR|RADIOLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1972-07-03||||1966-09-24||1966-05-05|1960-01-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||MOLRESP|MOLECULAR RESPONSE||||MEQ/L|CCR||10^10/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|SPOUSE|ONCOLOGIST 1|Y|5||7||BLINDED TREATMENT|1966-01-24||||1966-08-13||1962-12-10|1963-12-05||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|1||||||STRUSTAT|STEROID USE STATUS||||UEQ|PR WITH LYMPHOCYTOSIS||BAR|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|GUARDIAN|CLINICAL PATHOLOGIST|Y|1||38||SCREENING|1961-05-28||||1960-01-03||1964-04-23|1964-06-23||AFTER||DURING|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KPA/L/SEC|ISD||GBQ/UG|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|1||38||TREATMENT|1966-11-10||||1961-09-09||1967-12-08|1971-07-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KBQ|RELAPSED DISEASE FROM CR OR PR||CL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|2||58||INDUCTION TREATMENT|1964-08-08||||1961-03-22||1960-09-04|1971-11-17||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|2||||||TRGRESP|TARGET RESPONSE||||KPA|FAVORABLE RESPONSE||POINT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|U|VENDOR|RATER 1|N|2||58||OBSERVATION|1965-02-28||||1965-11-12||1971-03-01|1968-08-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|1||||||BESTRESP|BEST OVERALL RESPONSE||||S*KPA|CYTOGENETIC MINOR RESPONSE||UG/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|N|CHILD|MICROSCOPIST|Y|3||39||FOLLOW-UP|1970-06-23||||1966-03-22||1964-05-10|1962-03-22||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|2||||||ANATRESP|ANATOMIC RESPONSE||||KBQ|IMPROVED||HOURS|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|NA|NA|CHILD|RATER|U|3||39||CONTINUATION TREATMENT|1971-09-12||||1960-04-04||1963-08-10|1970-06-19||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|1||||||PATHRESP|PATHOLOGIC RESPONSE||||NL|TREATMENT FAILURE||M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|N|ADJUDICATOR|OPHTHALMOLOGIST|NA|4||88||RUN-IN|1972-02-19||||1972-03-05||1966-10-09|1968-03-16||AFTER||DURING|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PELLET|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ML/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|N|VENDOR|PATHOLOGIST 1|NA|4||88||RUN-IN|1967-09-22||||1973-07-02||1964-04-24|1965-04-11||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MASK|NPR||/MM2|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|SIBLING|READER 2|N|5||7||BLINDED TREATMENT|1962-01-03||||1963-02-05||1962-05-06|1971-01-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|521B1614-9092-4F89-A47F-728C66E01B23|2||||||PATHRESP|PATHOLOGIC RESPONSE||||10^6 IU|CCR||MMOL2/L2|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|FAMILY MEMBER|ADJUDICATOR|Y|5||7||OBSERVATION|1971-05-15||||1972-06-28||1969-08-17|1965-03-12||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||DPM/0.5 ML|CYTOGENETIC NO RESPONSE||DEG/S|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|VENDOR|MICROSCOPIST 1|NA|1||38||BASELINE|1967-03-24||||1966-05-25||1960-02-26|1960-08-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||CY/CM|IPR||V/V|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|FAMILY MEMBER|PATHOLOGIST|NA|1||38||WASHOUT|1961-01-23||||1964-01-16||1962-03-15|1964-07-14||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UMOL/H/MMOL|MAJOR PATHOLOGIC RESPONSE||DNA COPIES/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|U|N|NON-HEALTH CARE PROFESSIONAL|RATER|N|2||58||BLINDED TREATMENT|1972-06-07||||1960-10-31||1962-06-30|1965-05-17||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||UMOL/KG/MIN|CA125 75% RESPONSE||FT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|Y|STUDY SUBJECT|NEUROLOGIST 1|NA|2||58||INDUCTION TREATMENT|1962-08-08||||1973-05-23||1968-02-29|1963-07-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||LIVRRESP|LIVER RESPONSE||||IU/DL|NON-ICR/NON-IUPD||/2500 WBC|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|3||39||WASHOUT|1968-07-24||||1961-12-09||1968-06-01|1972-07-02||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||BONERESP|BONE RESPONSE||||PMOL/10^10 CELLS|MORPHOLOGIC LEUKEMIA-FREE STATE||10^11/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|3||39||WASHOUT|1968-10-24||||1971-12-19||1971-05-31|1965-09-13||DURING||DURING|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||LIVRRESP|LIVER RESPONSE||||LX|ISD||PT_BR|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|STUDY SUBJECT|ADJUDICATOR 1|NA|4||88||TREATMENT|1965-03-27||||1961-07-16||1960-01-23|1971-11-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CUP|RELAPSED DISEASE||PSEC|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|NA|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|4||88||OBSERVATION|1969-04-24||||1963-04-16||1969-08-14|1972-06-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/MIN|MR||V/V|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|CAREGIVER|PATHOLOGIST|Y|5||7||TREATMENT|1966-03-10||||1962-05-02||1962-09-30|1968-03-20||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||TMRESP|TUMOR MARKER RESPONSE||||NG/DAY|PMD||M/SEC2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1970-09-29||||1969-02-26||1965-02-14|1968-06-22||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||BESTRESP|BEST OVERALL RESPONSE||||MEQ|PDU||PIPE|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|Y|INTERVIEWER|PATHOLOGIST|NA|1||38||FOLLOW-UP|1972-02-18||||1964-06-18||1972-07-22|1961-01-27||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||CLINRESP|CLINICAL RESPONSE||||10^6 COPIES/ML|NR||NMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|ADJUDICATOR|INTERNIST|NA|1||38||RUN-IN|1964-08-22||||1972-05-26||1963-03-17|1961-03-01||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^3 CFU|ICR||BQ/UL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||WASHOUT|1961-12-21||||1971-03-27||1968-12-23|1963-11-24||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PPM|RELAPSED DISEASE FROM CR||LENS|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|NA|ADJUDICATION COMMITTEE|ONCOLOGIST|N|2||58||RUN-IN|1967-07-15||||1963-12-12||1973-07-25|1964-03-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||NEWLIND|NEW LESION INDICATOR||||YD|MCR||UV|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|ADJUDICATION COMMITTEE|OPTOMETRIST|NA|3||39||OPEN LABEL TREATMENT|1960-12-20||||1964-11-24||1962-07-12|1970-09-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||APL U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||BAU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|DOMESTIC PARTNER|RADIOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1964-10-16||||1961-08-01||1973-04-20|1972-12-30||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||NEWLIND|NEW LESION INDICATOR||||/100 HPFS|INCREASED||/200 HPFS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|DOMESTIC PARTNER|NEUROLOGIST 1|U|4||88||OBSERVATION|1967-08-08||||1964-03-03||1962-01-11|1971-03-13||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CI/KG|CYTOGENETIC PR||MBQ|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||FOLLOW-UP|1968-11-25||||1970-10-30||1961-04-01|1963-08-27||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||GPL U/ML|ICR||CG|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|N|CAREGIVER|MICROSCOPIST 2|NA|5||7||TREATMENT|1960-05-04||||1965-03-22||1971-06-26|1964-09-14||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||MOLRESP|MOLECULAR RESPONSE||||MG/M2|CA125 75% RESPONSE||MOL/DAY|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|Y|SIGNIFICANT OTHER|ADJUDICATOR 3|N|5||7||BLINDED TREATMENT|1964-01-31||||1972-11-11||1964-02-10|1962-10-16||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||METSIND|METASTATIC INDICATOR||||MJOULE/CM2|CCR||CARTRIDGE|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|1||38||INDUCTION TREATMENT|1966-09-09||||1966-07-04||1963-09-02|1972-04-28||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||NTRGRESP|NON-TARGET RESPONSE||||ML|DECREASED||10^9 CFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1||38||OBSERVATION|1964-04-28||||1960-01-31||1963-06-09|1970-01-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 CFU/ML|SD||NMOL/MOL|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|SPOUSE|READER|Y|2||58||OBSERVATION|1968-01-15||||1971-08-09||1965-04-07|1969-08-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||PATHRESP|PATHOLOGIC RESPONSE||||GRAIN|MCR||DPM|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|FRIEND|READER|N|2||58||RUN-IN|1966-02-16||||1969-12-02||1968-11-22|1964-04-25||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||FINGERTIP UNIT|CYTOGENETIC NO RESPONSE||UL/KG/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|SIBLING|RATER 1|Y|3||39||SCREENING|1972-05-27||||1966-04-26||1964-11-29|1969-04-02||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||BESTRESP|BEST OVERALL RESPONSE||||CMH2O*S2/ML|PSEUDORESPONSE||LM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|STUDY SUBJECT|NEUROLOGIST 1|Y|3||39||OBSERVATION|1973-03-07||||1969-02-06||1968-03-09|1967-12-01||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||CLINRESP|CLINICAL RESPONSE||||10^3 CFU/ML|SD-CT||ML/BEAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|CLINICAL STUDY SPONSOR|READER 2|NA|4||88||SCREENING|1960-12-02||||1972-01-22||1969-11-13|1965-04-03||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MPH|MORPHOLOGIC CRI||FINGERTIP UNIT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|FRIEND|MICROSCOPIST 1|U|4||88||BLINDED TREATMENT|1972-05-15||||1961-03-23||1962-03-16|1967-07-19||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||TRGRESP|TARGET RESPONSE||||MG/KG/DOSE|PSEUDOPROGRESSION||UG/CM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|NA|5||7||FOLLOW-UP|1961-10-16||||1972-05-07||1969-10-11|1964-08-16||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MM3/MM2/YEAR|SD||HOURS|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|5||7||BASELINE|1971-11-17||||1971-01-10||1969-08-25|1973-09-07||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^3/HPF|IMPROVED||U/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|PROXY|RATER|U|1||38||INDUCTION TREATMENT|1963-03-09||||1971-10-22||1971-01-07|1965-03-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||NTRGRESP|NON-TARGET RESPONSE||||KS|PD FROM PR||PMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||OBSERVATION|1964-09-30||||1971-11-01||1964-02-18|1962-03-20||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||MOLRESP|MOLECULAR RESPONSE||||G/G/DAY|CA125 75% RESPONSE||PFU/ANIMAL|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1966-02-17||||1961-06-24||1961-04-11|1960-07-20||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||V|IPR||PFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|N|GUARDIAN|NEUROLOGIST|Y|2||58||BASELINE|1969-07-29||||1963-08-10||1961-10-09|1972-10-15||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||PATHRESP|PATHOLOGIC RESPONSE||||USP U|PD||/10^4|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1971-10-24||||1971-02-18||1970-06-11|1961-08-09||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/ANIMAL/WK|NR||NGEQ/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|N|GUARDIAN|PHYSIOTHERAPIST|N|3||39||FOLLOW-UP|1972-06-10||||1971-02-17||1972-07-18|1965-12-22||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||K|CYTOGENETIC PR||L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|CHILD|RADIOLOGIST 1|U|4||88||FOLLOW-UP|1965-08-31||||1967-02-05||1962-02-01|1969-12-09||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MET|PD FROM PR||MG/KG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|4||88||CONTINUATION TREATMENT|1964-02-19||||1970-01-11||1965-09-03|1969-06-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NMOL/L/H|TREATMENT FAILURE||DAMOL/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|5||7||TREATMENT|1973-08-25||||1964-12-31||1968-02-08|1972-10-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||L/L|CYTOGENETIC NO RESPONSE||LOZENGE|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|PROXY|ENDOCRINOLOGIST|N|5||7||OPEN LABEL TREATMENT|1964-11-07||||1965-07-23||1969-07-29|1963-04-15||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CFU/G|IMPROVED||L/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|NA|CAREGIVER|RADIOLOGIST 2|N|1||38||CONTINUATION TREATMENT|1960-11-20||||1960-04-05||1970-05-20|1962-03-18||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||TRGRESP|TARGET RESPONSE||||PPB|HI-P||FOZ_BR|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|1||38||WASHOUT|1964-04-16||||1961-09-04||1967-01-24|1972-05-03||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FRACTION OF 1|CYTOGENETIC CR||CAPSULE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|FRIEND|OTOLARYNGOLOGIST|N|2||58||SCREENING|1967-02-17||||1968-04-03||1963-04-12|1960-09-09||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||METSIND|METASTATIC INDICATOR||||NEBULE|PSA PROGRESSION||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|CAREGIVER|NEUROLOGIST|N|2||58||WASHOUT|1970-08-08||||1968-01-25||1973-05-03|1970-07-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||LIVRRESP|LIVER RESPONSE||||TUBERCULIN UNIT/ML|UNEQUIVOCAL||KA_U/DL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|3||39||OBSERVATION|1972-01-16||||1971-09-26||1972-03-12|1969-06-15||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||NTRGRESP|NON-TARGET RESPONSE||||KCAL|CHR||PA|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||RUN-IN|1965-07-11||||1960-11-23||1963-12-29|1964-05-23||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||EID 50/DOSE|SD-CT||LOG10 CCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|ADJUDICATOR|OTOLARYNGOLOGIST|N|4||88||OBSERVATION|1972-06-30||||1971-07-23||1964-09-17|1971-03-13||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||BESTRESP|BEST OVERALL RESPONSE||||UIU/L|CA125 75% RESPONSE||10^9 CFU/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|U|4||88||SCREENING|1966-09-10||||1972-06-27||1972-03-08|1966-03-12||AFTER||DURING|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||PATHRESP|PATHOLOGIC RESPONSE||||/H|PD-CT||CY/CM|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|N|CAREGIVER|CLINICAL PATHOLOGIST|Y|5||7||WASHOUT|1971-08-04||||1966-08-20||1967-11-26|1961-02-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||CGY|NON-PD||MU/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|Y|N|GUARDIAN|MICROSCOPIST 2|NA|5||7||CONTINUATION TREATMENT|1967-02-24||||1969-11-16||1970-12-21|1968-01-12||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DRAM|NON-CR/NON-PD||MV*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|N|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1||38||RUN-IN|1960-01-22||||1965-09-16||1964-05-30|1960-12-25||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||TMRESP|TUMOR MARKER RESPONSE||||L/H|MAJOR PATHOLOGIC RESPONSE||M/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||CONTINUATION TREATMENT|1970-12-22||||1964-09-18||1963-03-18|1970-03-31||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||LIVRRESP|LIVER RESPONSE||||MU/G|VGPR||ANTI-XA IU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|NA|SIBLING|MICROSCOPIST 1|N|2||58||SCREENING|1968-11-04||||1963-04-04||1973-07-01|1967-03-21||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||CLINRESP|CLINICAL RESPONSE||||%|PSEUDORESPONSE||FMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|NA|N|SIBLING|READER 2|N|2||58||LONG-TERM FOLLOW-UP|1966-06-13||||1962-08-22||1960-04-15|1970-03-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||NMOL/G|CYTOGENETIC NO RESPONSE||ML/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|ADJUDICATOR|RADIOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1973-03-29||||1971-12-30||1967-10-10|1969-08-05||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/L DDU|MR||NMOL/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|3||39||FOLLOW-UP|1972-11-29||||1973-04-17||1963-06-02|1968-02-05||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||NG/DL|MRD PERSISTENCE||DIOPTER|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|Y|SPOUSE|ONCOLOGIST|N|4||88||CONTINUATION TREATMENT|1965-08-04||||1964-07-26||1962-08-23|1960-03-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PFU/ANIMAL|NON-CR/NON-PD||LOG10 CCID 50/DOSE|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|U|CAREGIVER|NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1960-04-16||||1965-12-15||1972-08-31|1965-12-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||TRGRESP|TARGET RESPONSE||||BAU|HI-N||KG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|SIGNIFICANT OTHER|READER 1|Y|5||7||TREATMENT|1966-07-01||||1961-09-26||1971-07-14|1968-07-13||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||BOTTLE|FAVORABLE RESPONSE||NL|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|5||7||OPEN LABEL TREATMENT|1972-07-14||||1968-09-27||1960-03-31|1969-12-02||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||NEWLPROG|NEW LESION PROGRESSION||||KG/CM2|PD FROM PR||BOX|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|N|INTERVIEWER|RADIOLOGIST|U|1||38||FOLLOW-UP|1961-01-05||||1961-06-18||1966-05-12|1967-07-07||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||BAU/ML|PD-CT||MM/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|STUDY SUBJECT|PATHOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1971-07-29||||1969-12-01||1968-02-16|1965-08-19||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||ANATRESP|ANATOMIC RESPONSE||||LOG10 TCID 50/ML|SMD||/CMH2O|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|PROXY|READER 3|NA|2||58||INDUCTION TREATMENT|1969-11-26||||1964-11-23||1968-09-11|1966-12-17||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||METBRESP|METABOLIC RESPONSE||||MMOL|PMD||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|FAMILY MEMBER|RADIOLOGIST 1|NA|2||58||BASELINE|1968-12-21||||1967-07-30||1969-12-24|1972-07-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DPM|CPR||CD*S/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|STUDY SUBJECT|DERMATOLOGIST|Y|3||39||SCREENING|1960-09-05||||1971-06-10||1960-02-09|1961-01-13||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||PMOL/DAY|PD-CT||CMH2O*S2/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|N|FRIEND|MICROSCOPIST 2|U|3||39||WASHOUT|1968-11-09||||1969-12-23||1962-03-17|1969-09-19||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CMH2O/ML|CYTOGENETIC PR||MCI/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|4||88||TREATMENT|1970-03-06||||1967-11-03||1960-06-07|1965-09-18||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||M/SEC2|ICPD||ENZYME U/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4||88||SCREENING|1961-01-30||||1960-06-27||1970-04-21|1967-05-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||LIVRRESP|LIVER RESPONSE||||EQ|NED||%|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|CHILD|OPTOMETRIST|U|5||7||FOLLOW-UP|1967-05-05||||1968-03-10||1961-09-21|1966-03-12||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||KHZ|PSA PROGRESSION||MG/KG/WEEK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|NA|INVESTIGATOR|MICROSCOPIST 2|NA|5||7||SCREENING|1967-04-20||||1973-03-15||1967-08-27|1966-04-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|1||||||LIVRRESP|LIVER RESPONSE||||ML/100G/MIN|MORPHOLOGIC LEUKEMIA-FREE STATE||POUCH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|VENDOR|RATER 2|NA|1||38||LONG-TERM FOLLOW-UP|1965-10-17||||1973-04-12||1966-02-20|1970-04-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|2||||||SPLNRESP|SPLEEN RESPONSE||||MM/SEC|SCR||UMOL/L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|CHILD|UROLOGIST|N|1||38||TREATMENT|1970-10-02||||1961-11-17||1968-11-15|1970-06-08||AFTER||DURING|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|1||||||RDIORESP|RADIOLOGIC RESPONSE||||10^6 ORGANISMS/MG|SD-CT||CUP|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|DOMESTIC PARTNER|INTERNIST|NA|2||58||BASELINE|1966-02-12||||1963-04-03||1960-03-21|1961-08-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^6/G|CPR||AMU|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|CHILD|UROLOGIST|Y|2||58||INDUCTION TREATMENT|1966-11-07||||1963-08-23||1969-09-21|1964-09-03||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^5/HPF|MORPHOLOGIC CR||NEWTON|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|ADJUDICATOR|ONCOLOGIST|N|3||39||OPEN LABEL TREATMENT|1960-06-18||||1961-06-11||1967-10-10|1969-01-09||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|2||||||NEWLIND|NEW LESION INDICATOR||||GENEQ|CRI||KM/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|CHILD|OPHTHALMOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1960-08-01||||1972-09-30||1961-06-03|1968-12-26||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PHERESIS UNIT|INCREASED||UMOL/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|Y|PROXY|OPTOMETRIST|N|4||88||OPEN LABEL TREATMENT|1961-12-18||||1960-11-28||1965-11-11|1963-04-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|2||||||LIVRRESP|LIVER RESPONSE||||10^7 CFU/ML|INDETERMINATE RESPONSE||MGEQ|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||TREATMENT|1962-10-15||||1967-03-12||1968-05-12|1960-01-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|1||||||BONERESP|BONE RESPONSE||||ELISA UNIT/DOSE|CR-CT||APPLICATION|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|NA|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|5||7||RUN-IN|1966-06-24||||1971-04-19||1960-10-12|1972-07-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|16075684-F04D-4CB8-970A-0819378790EB|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^6 U|IUPD||DNA COPIES/UG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||RUN-IN|1971-01-21||||1972-01-24||1970-06-10|1973-07-14||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||BONERESP|BONE RESPONSE||||DRAM|PD/RELAPSE AFTER HI||DRUM|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|NA|INDEPENDENT ASSESSOR|RATER 1|Y|1||38||SCREENING|1973-08-12||||1964-04-21||1962-10-21|1970-09-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||TRGRESP|TARGET RESPONSE||||ML/M2/DAY|RELAPSED DISEASE||MILE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|U|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|1||38||TREATMENT|1966-02-10||||1972-08-19||1962-04-13|1966-10-10||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||NEWLPROG|NEW LESION PROGRESSION||||UV|MRD PERSISTENCE||OI50|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|Y|SIBLING|INTERNIST|U|2||58||INDUCTION TREATMENT|1963-02-10||||1962-05-02||1967-05-03|1960-11-01||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||NEWLIND|NEW LESION INDICATOR||||AMPULE|CYTOGENETIC NO RESPONSE||TABLET|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|N|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|2||58||SCREENING|1965-06-26||||1963-11-20||1962-10-28|1964-11-10||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MM/H|STABLE||L/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|3||39||TREATMENT|1962-07-14||||1968-12-30||1965-09-14|1972-10-30||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||MOLRESP|MOLECULAR RESPONSE||||ML/H|CYTOGENETIC NO RESPONSE||V|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|NA|STUDY SUBJECT|NEUROLOGIST 1|Y|3||39||OBSERVATION|1969-03-27||||1967-12-14||1964-02-14|1965-06-01||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||YD|INDETERMINATE RESPONSE||ENZYME U/M2|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|Y|GUARDIAN|RADIOLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1963-05-12||||1966-12-01||1966-10-24|1960-11-05||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||STRUSTAT|STEROID USE STATUS||||ML/MIN/1.73M2|NON-PD||FMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|NA|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|4||88||FOLLOW-UP|1972-05-31||||1973-09-08||1961-04-11|1973-08-30||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||BESTRESP|BEST OVERALL RESPONSE||||MMHG*MIN/L|RELAPSED DISEASE FROM CR||TUBE|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|PROXY|FORENSIC PATHOLOGIST|U|5||7||CONTINUATION TREATMENT|1965-05-19||||1970-12-16||1972-01-11|1963-09-14||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||METBRESP|METABOLIC RESPONSE||||PKAT|NR||NMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|5||7||FOLLOW-UP|1961-07-14||||1960-05-26||1972-02-25|1966-08-19||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/DL|WORSENED||LOG10 IU/ML|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|DOMESTIC PARTNER|ADJUDICATOR 2|U|1||38||SCREENING|1969-01-14||||1962-09-16||1966-08-03|1968-06-23||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||BAG|CYTOGENETIC NO RESPONSE||10^3 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|N|INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|1||38||WASHOUT|1963-10-09||||1969-10-22||1969-12-08|1962-12-30||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/MS|CR||10^3 CFU/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|2||58||SCREENING|1973-08-25||||1972-03-18||1960-12-14|1970-05-23||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MSEC|PMD||EIA UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|GUARDIAN|RADIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1963-11-27||||1967-11-21||1969-03-25|1966-09-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||IU/G|CMR||G/G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|N|PARENT|OTOLARYNGOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1969-02-10||||1964-01-15||1966-05-17|1964-01-31||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||RDIORESP|RADIOLOGIC RESPONSE||||MAC50|CA125 75% RESPONSE||NMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|CHILD|DERMATOLOGIST|NA|3||39||INDUCTION TREATMENT|1963-12-24||||1963-08-06||1969-04-06|1963-08-28||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||U/M2|NE||U/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|CAREGIVER|NEUROLOGIST 2|NA|4||88||OBSERVATION|1962-06-01||||1971-11-03||1960-12-07|1967-12-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CI/MG|IPR||/100 HPFS|NOT DONE|||LIKERT SCALE 7-POINT|N|N|N|PARENT|ADJUDICATOR|U|4||88||LONG-TERM FOLLOW-UP|1971-12-09||||1960-05-09||1962-05-17|1971-02-22||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||CI|MR||GENEQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|5||7||INDUCTION TREATMENT|1961-03-25||||1968-09-15||1961-12-25|1969-01-14||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||LIVRRESP|LIVER RESPONSE||||FARAD|MORPHOLOGIC CRI||GAUSS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|5||7||OBSERVATION|1961-09-25||||1963-09-26||1964-06-24|1972-09-03||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||MV/SEC|CCR||MEQ/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|HEALTH CARE PROFESSIONAL|READER 3|NA|1||38||OBSERVATION|1961-08-09||||1970-09-16||1960-06-17|1965-04-24||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||CYTORESP|CYTOGENETIC RESPONSE||||STEPS/MIN|NPR||U/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||BASELINE|1970-01-11||||1967-07-20||1960-03-27|1964-10-06||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||OVRLRESP|OVERALL RESPONSE||||MASK|CYTOGENETIC NO RESPONSE||LOG10 TCID 50/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|N|DOMESTIC PARTNER|RADIOLOGIST 2|U|2||58||FOLLOW-UP|1972-12-05||||1964-10-04||1961-01-29|1966-02-09||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||ML/DL|WORSENED||APS U|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|INVESTIGATOR|READER 3|U|2||58||INDUCTION TREATMENT|1967-04-06||||1965-09-30||1963-08-23|1963-07-11||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||G/G/DAY|UNFAVORABLE RESPONSE||/7.5 ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|CHILD|NEUROLOGIST 2|NA|3||39||BASELINE|1968-03-24||||1968-12-02||1972-04-11|1961-01-05||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||PMOL/10^9 CELLS|MORPHOLOGIC LEUKEMIA-FREE STATE||/MBP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|SPOUSE|PHYSIOTHERAPIST|NA|3||39||OBSERVATION|1963-10-04||||1964-05-25||1968-06-04|1967-09-10||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CAL|MORPHOLOGIC LEUKEMIA-FREE STATE||MEQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|Y|VENDOR|NEUROLOGIST 1|N|4||88||BLINDED TREATMENT|1963-04-30||||1971-07-03||1961-10-19|1971-04-12||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||ANATRESP|ANATOMIC RESPONSE||||MONTHS|PCR||SYRINGE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|SIGNIFICANT OTHER|PATHOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1961-01-29||||1968-03-13||1965-12-09|1965-11-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||/H|NON-PD||DEG/MM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|NA|U|INTERVIEWER|HEMATOLOGIST|NA|5||7||WASHOUT|1965-04-15||||1971-10-25||1961-10-16|1961-11-25||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||EVENTS|UNFAVORABLE RESPONSE||RING|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|5||7||TREATMENT|1967-09-16||||1964-08-23||1971-05-20|1968-06-09||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||L/S/KPA|CPR||10^3 ORGANISMS/ML|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|ADJUDICATOR|ADJUDICATOR 1|Y|1||38||BASELINE|1971-01-16||||1969-06-10||1967-06-07|1973-02-20||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PIPE|PD/RELAPSE AFTER HI||PFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|N|NA|PARENT|MICROSCOPIST 3|NA|1||38||BASELINE|1967-07-03||||1964-03-25||1967-05-26|1960-09-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CM2|FAVORABLE RESPONSE||MPL U/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||OBSERVATION|1965-03-23||||1969-10-13||1964-12-13|1973-03-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||NEWLIND|NEW LESION INDICATOR||||M3|MRD RELAPSE||MEQ/UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|VENDOR|ONCOLOGIST|N|2||58||TREATMENT|1967-10-01||||1960-11-22||1966-10-28|1964-09-01||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||SPLNRESP|SPLEEN RESPONSE||||HZ/S|QUANTIFIABLE MRD POSITIVITY||GLOBULE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|NA|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|3||39||INDUCTION TREATMENT|1966-01-04||||1960-05-02||1962-07-23|1962-12-19||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||OVRLRESP|OVERALL RESPONSE||||ML/KG/H|HI-E||PKAT|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|N|CHILD|PHYSIOTHERAPIST|Y|3||39||SCREENING|1969-05-07||||1969-06-30||1972-09-21|1967-11-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/DL|PD||10^6/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|U|FAMILY MEMBER|RATER 2|U|4||88||TREATMENT|1968-12-20||||1960-12-14||1971-01-22|1961-07-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||CYTORESP|CYTOGENETIC RESPONSE||||NL|MCR||PPTH|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|N|SIBLING|ADJUDICATOR 1|U|4||88||INDUCTION TREATMENT|1961-04-13||||1968-12-29||1969-02-21|1965-01-18||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||MU|NPR||BOX|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|GUARDIAN|NEUROLOGIST 2|U|5||7||WASHOUT|1967-02-12||||1960-11-10||1968-11-15|1967-05-20||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||STRUSTAT|STEROID USE STATUS||||G/KG/DAY|PR||MEQ/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|Y|GUARDIAN|RADIOLOGIST 2|NA|5||7||FOLLOW-UP|1961-03-14||||1971-07-14||1964-12-10|1969-06-13||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||/MM2|EQUIVOCAL||BQ/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|1||38||LONG-TERM FOLLOW-UP|1971-10-20||||1968-11-26||1971-06-08|1962-04-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ML/MIN/MMHG|UNFAVORABLE RESPONSE||KG/MOL|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|1||38||RUN-IN|1967-03-21||||1970-08-22||1967-04-18|1967-03-22||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||/CMH2O|PMR||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1963-11-21||||1972-04-05||1967-05-10|1961-04-24||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||ANATRESP|ANATOMIC RESPONSE||||MG/KG/H|RELAPSED DISEASE FROM CR OR PR||HR/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|GUARDIAN|PATHOLOGIST|Y|2||58||BLINDED TREATMENT|1966-05-23||||1963-03-09||1965-08-27|1973-08-26||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||TMRESP|TUMOR MARKER RESPONSE||||/10^5|MINOR PATHOLOGIC RESPONSE||MCI/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|U|CHILD|MICROSCOPIST 1|U|3||39||WASHOUT|1972-06-20||||1968-04-30||1965-04-01|1965-12-03||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/L|SMD||U/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|NA|Y|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|3||39||RUN-IN|1968-11-07||||1970-12-13||1963-07-17|1971-02-22||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||ANATRESP|ANATOMIC RESPONSE||||MOL/MG|NPR||AFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|N|CLINICAL STUDY SPONSOR|HEMATOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-09-30||||1970-08-29||1970-08-18|1969-01-01||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||CYTORESP|CYTOGENETIC RESPONSE||||BU|NPR||KS|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|ADJUDICATOR|OTOLARYNGOLOGIST|NA|4||88||WASHOUT|1962-04-25||||1962-01-06||1966-08-23|1971-10-15||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||OVRLRESP|OVERALL RESPONSE||||MG/G/H|QUANTIFIABLE MRD POSITIVITY||ML/CAGE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|N|CLINICAL RESEARCH ASSOCIATE|READER 3|N|5||7||OPEN LABEL TREATMENT|1967-11-20||||1969-01-09||1971-03-23|1968-03-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||STRUSTAT|STEROID USE STATUS||||%/MIN|CYTOGENETIC PR||/2000 RBC|NOT DONE|||LIKERT SCALE 5-POINT|Y|Y|NA|CAREGIVER|CLINICAL PATHOLOGIST|U|5||7||RUN-IN|1966-08-14||||1967-02-18||1961-04-19|1967-02-26||AFTER||DURING|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||METSIND|METASTATIC INDICATOR||||ML/MMHG/MIN/L|MOLECULAR CR||STEPS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1||38||OPEN LABEL TREATMENT|1969-01-20||||1971-01-21||1968-11-11|1960-10-09||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||10^11/L|CA125 75% RESPONSE||MG/M2/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|CLINICAL STUDY SPONSOR|UROLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1972-12-01||||1972-04-26||1964-10-02|1968-02-17||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/KG/H|CA125 75% RESPONSE||ENZYME U/G HB|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|VENDOR|RATER 1|U|2||58||SCREENING|1965-08-11||||1969-03-08||1967-01-31|1968-06-20||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/H|HI-N||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|FAMILY MEMBER|ONCOLOGIST 1|N|2||58||BLINDED TREATMENT|1964-12-27||||1972-05-26||1971-12-03|1962-08-30||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||ANATRESP|ANATOMIC RESPONSE||||MG/DAY|DISEASE TRANSFORMATION||TRANSDUCING UNIT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|N|INTERVIEWER|RATER 1|N|3||39||LONG-TERM FOLLOW-UP|1961-05-30||||1962-12-21||1966-09-08|1964-01-31||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||FFU|IMPROVED||NG/L|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|Y|FRIEND|RADIOLOGIST 1|NA|3||39||SCREENING|1970-08-14||||1962-05-08||1969-09-09|1971-02-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MKAT|NPR||OZ EQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|SIBLING|PATHOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1962-05-06||||1965-02-17||1960-02-29|1972-03-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PG/CELL|NON-CR/NON-PD||%/MIN|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|N|HEALTH CARE PROFESSIONAL|RATER 2|Y|4||88||FOLLOW-UP|1964-04-01||||1962-09-14||1971-11-08|1971-02-16||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||ABSORBANCE U/ML|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||G/CAGE/WK|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|5||7||INDUCTION TREATMENT|1963-11-25||||1972-08-13||1961-08-14|1972-07-18||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||BESTRESP|BEST OVERALL RESPONSE||||G/U|CYTOGENETIC CR||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|ADJUDICATOR|READER 2|Y|5||7||RUN-IN|1963-12-10||||1963-05-08||1960-08-11|1967-03-03||DURING||AFTER|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||NEWLPROG|NEW LESION PROGRESSION||||/MM2|IPR||MG/G/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|FRIEND|MICROSCOPIST 3|N|1||38||OPEN LABEL TREATMENT|1967-12-06||||1964-05-08||1972-06-20|1971-12-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||BONERESP|BONE RESPONSE||||BQ/MG|NED||DPM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||RUN-IN|1969-08-12||||1970-10-22||1965-05-07|1960-12-13||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/DL|MAJOR PATHOLOGIC RESPONSE||MOL/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|U|Y|CHILD|NEUROLOGIST 1|NA|2||58||FOLLOW-UP|1969-07-06||||1971-05-15||1966-11-23|1970-06-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||VIRTUAL PIXEL|ICR||NU/CL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|U|Y|SIBLING|HEMATOLOGIST|NA|2||58||RUN-IN|1970-05-10||||1961-09-11||1967-08-04|1971-10-15||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||SPLNRESP|SPLEEN RESPONSE||||10^6 COPIES/ML|PR WITH LYMPHOCYTOSIS||PACKET|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|N|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1970-10-30||||1968-02-18||1961-03-05|1970-03-26||DURING||DURING|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||SPLNRESP|SPLEEN RESPONSE||||MM|OPTIMAL MORPHOLOGIC RESPONSE||NMOL/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|DOMESTIC PARTNER|RADIOLOGIST|N|3||39||SCREENING|1973-04-23||||1966-01-31||1969-06-24|1964-01-27||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||RDIORESP|RADIOLOGIC RESPONSE||||G/KG|MORPHOLOGIC CR||PA|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|FRIEND|MICROSCOPIST 3|N|4||88||FOLLOW-UP|1971-04-19||||1967-09-23||1965-10-23|1963-07-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/CAGE|PMR||PMOL/L/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|Y|CAREGIVER|RADIOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1960-06-26||||1969-01-29||1972-03-21|1964-12-20||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NG/L|COMPLETE MRD RESPONSE||OZ|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|PROXY|OPTOMETRIST|NA|5||7||LONG-TERM FOLLOW-UP|1966-01-31||||1962-09-23||1967-05-07|1971-07-18||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||ANATRESP|ANATOMIC RESPONSE||||TCID 50/DOSE|OPTIMAL MORPHOLOGIC RESPONSE||10^6 ORGANISMS/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|INVESTIGATOR|PATHOLOGIST 1|Y|5||7||FOLLOW-UP|1963-12-19||||1967-03-10||1963-12-29|1965-02-22||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||10^3 DNA COPIES/ML|NON-QUANTIFIABLE MRD POSITIVITY||NMOL/L/H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|RADIOLOGIST 1|NA|1||38||BASELINE|1972-12-04||||1962-07-19||1964-12-26|1971-12-26||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||METSIND|METASTATIC INDICATOR||||ABSORBANCE U/MIN|QUANTIFIABLE MRD POSITIVITY||GENEQ/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|VENDOR|READER 3|U|1||38||CONTINUATION TREATMENT|1969-06-06||||1968-06-30||1967-08-28|1970-11-20||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||BONERESP|BONE RESPONSE||||G/KG|CYTOGENETIC MINOR RESPONSE||BREATHS/30S|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|PROXY|RATER 1|NA|2||58||WASHOUT|1968-08-03||||1972-10-06||1960-12-16|1961-09-11||DURING||AFTER|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||G/DL|NON-PD||UG/G/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|N|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||RUN-IN|1967-03-23||||1963-08-11||1972-10-28|1961-04-08||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NG/DL|CYTOGENETIC PR||LOZENGE|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|INVESTIGATOR|ADJUDICATOR 2|NA|3||39||CONTINUATION TREATMENT|1969-11-10||||1964-06-01||1965-01-21|1971-12-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||BESTRESP|BEST OVERALL RESPONSE||||NGEQ/L|MORPHOLOGIC CRI||%(V/V)|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|N|GUARDIAN|READER 2|N|3||39||OBSERVATION|1969-04-08||||1960-09-20||1964-07-28|1969-11-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||LINEAR FT*LB|CR-CT||% INHIBITION|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|SIBLING|READER|N|4||88||SCREENING|1967-07-03||||1962-12-05||1973-05-28|1969-03-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||TMRESP|TUMOR MARKER RESPONSE||||DPM/MG|UNFAVORABLE RESPONSE||GY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||CONTINUATION TREATMENT|1965-04-21||||1964-03-28||1968-07-03|1963-12-17||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||METBRESP|METABOLIC RESPONSE||||TUBERCULIN UNIT/ML|MORPHOLOGIC LEUKEMIA-FREE STATE||MMU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|NA|CHILD|ADJUDICATOR|NA|5||7||BASELINE|1960-01-06||||1969-01-14||1972-04-13|1971-07-18||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||RDIORESP|RADIOLOGIC RESPONSE||||GPL U/ML|PR WITH LYMPHOCYTOSIS||DNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||TREATMENT|1968-12-03||||1962-10-15||1971-07-25|1963-05-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||OVRLRESP|OVERALL RESPONSE||||MAC50|VGPR||UL|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||LONG-TERM FOLLOW-UP|1968-09-28||||1973-05-19||1965-09-04|1972-03-13||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||METBRESP|METABOLIC RESPONSE||||MEQ/KG|MAJOR PATHOLOGIC RESPONSE||NEEDLE GAUGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|Y|ADJUDICATION COMMITTEE|RATER 2|U|1||38||RUN-IN|1960-12-12||||1960-03-14||1970-10-22|1963-09-12||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/HPF|RELAPSED DISEASE||MPH|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|N|SIBLING|ONCOLOGIST 1|NA|2||58||TREATMENT|1971-02-10||||1965-05-16||1968-01-09|1971-12-27||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||MOLRESP|MOLECULAR RESPONSE||||10^5/L|PSA PROGRESSION||KHZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|NA|DOMESTIC PARTNER|NEUROLOGIST 2|N|2||58||TREATMENT|1961-03-31||||1971-12-17||1968-09-23|1968-09-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MG/KG/MIN|MOLECULAR MAJOR RESPONSE||MMOL/MIN/KPA/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|NA|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|3||39||RUN-IN|1962-02-18||||1971-06-09||1972-01-10|1968-04-14||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UMOL/L|MAJOR PATHOLOGIC RESPONSE||NMOL/KG/DAY|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|VENDOR|ONCOLOGIST 1|NA|3||39||RUN-IN|1962-11-29||||1966-07-16||1965-07-03|1971-05-01||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||LOG10 ELISA UNIT/DOSE|RELAPSED DISEASE FROM CR OR PR||/MONTH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|NA|SIBLING|CLINICAL PATHOLOGIST|NA|4||88||FOLLOW-UP|1969-02-13||||1969-10-08||1968-11-14|1969-03-13||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||METBRESP|METABOLIC RESPONSE||||/MM|MOLECULAR CR||G/ANIMAL/WK|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|FRIEND|RATER 2|NA|4||88||LONG-TERM FOLLOW-UP|1972-06-01||||1962-04-04||1960-07-25|1973-05-14||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||NEWLIND|NEW LESION INDICATOR||||MG/H|MAJOR PATHOLOGIC RESPONSE||PG/DL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|U|SPOUSE|ONCOLOGIST 2|U|5||7||BLINDED TREATMENT|1962-12-15||||1963-12-03||1962-10-06|1971-01-18||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||LIVRRESP|LIVER RESPONSE||||U/M2|MR||CI/G|NOT DONE|||LIKERT SCALE 7-POINT|N|N|U|DOMESTIC PARTNER|CARDIOLOGIST|U|5||7||CONTINUATION TREATMENT|1967-11-25||||1960-03-16||1965-11-26|1965-06-24||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^7 PFU|CCR||MG/G/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|N|NA|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1||38||FOLLOW-UP|1960-04-18||||1963-12-14||1968-02-14|1965-10-15||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^9 ORGANISMS/MG|DISEASE TRANSFORMATION||GRAVITATIONAL UNIT|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|PARENT|PATHOLOGIST 1|N|1||38||FOLLOW-UP|1971-11-15||||1964-01-19||1968-11-13|1970-03-06||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KIT|PARTIAL MORPHOLOGIC RESPONSE||UG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|Y|PARENT|ADJUDICATOR 2|Y|2||58||LONG-TERM FOLLOW-UP|1967-11-12||||1970-06-04||1960-07-22|1971-01-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||SPLNRESP|SPLEEN RESPONSE||||CI/MG|MOLECULAR MAJOR RESPONSE||MEQ/DL|NOT DONE|||LIKERT SCALE 5-POINT|Y|U|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|2||58||INDUCTION TREATMENT|1960-01-30||||1962-10-21||1971-02-10|1966-08-13||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||METBRESP|METABOLIC RESPONSE||||VP/ML|RELAPSED DISEASE FROM CR OR PR||10^6/EJACULATE U|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|CHILD|MICROSCOPIST 2|Y|3||39||FOLLOW-UP|1962-01-18||||1960-07-13||1965-09-16|1964-11-13||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||METSIND|METASTATIC INDICATOR||||DEG2|CR-CT||SYRINGE|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|NA|CAREGIVER|RADIOLOGIST|Y|3||39||OBSERVATION|1960-11-08||||1960-11-12||1962-05-22|1965-04-24||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/MG|ICPD||CYCLE/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|Y|STUDY SUBJECT|ONCOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1965-12-10||||1973-01-14||1968-08-09|1969-09-17||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||UU/L|CHR||SACHET|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|N|FAMILY MEMBER|OTOLARYNGOLOGIST|N|4||88||CONTINUATION TREATMENT|1971-10-28||||1971-09-18||1970-01-08|1962-05-04||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||H/WK|ICR||LOG10 CFU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|INDEPENDENT ASSESSOR|READER|U|5||7||BLINDED TREATMENT|1966-02-22||||1964-02-03||1973-01-22|1972-10-14||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||NEWLPROG|NEW LESION PROGRESSION||||IU/DAY|PARTIAL MORPHOLOGIC RESPONSE||ABSORBANCE U|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|U|PROXY|PATHOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1968-10-17||||1972-02-10||1960-04-07|1963-12-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG|PD-CT||PIXELS/IN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|GUARDIAN|MICROSCOPIST 3|Y|1||38||TREATMENT|1967-05-18||||1966-12-07||1960-06-25|1973-06-10||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CS|WORSENED||PT_US|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|U|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|1||38||INDUCTION TREATMENT|1960-07-17||||1970-02-25||1963-01-06|1965-08-18||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||CAN|CR||/MS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|STUDY SUBJECT|RATER 2|N|2||58||SCREENING|1967-04-22||||1961-01-03||1966-09-18|1971-02-08||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||STRUSTAT|STEROID USE STATUS||||KPA/L/SEC|HI-E||WATT|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|SPOUSE|RADIOLOGIST 1|NA|2||58||BLINDED TREATMENT|1964-08-24||||1964-12-13||1964-04-06|1973-07-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||V/V|PD-CT||MM/SEC|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|NA|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||SCREENING|1961-06-05||||1968-07-01||1961-05-08|1972-04-22||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||RDIORESP|RADIOLOGIC RESPONSE||||HOUNSFIELD UNIT|NE||FMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|ADJUDICATION COMMITTEE|READER 1|Y|3||39||RUN-IN|1970-01-07||||1969-02-18||1964-06-15|1962-07-01||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||METSIND|METASTATIC INDICATOR||||LOZENGE|NED||MM/2H|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|U|VENDOR|DERMATOLOGIST|N|4||88||CONTINUATION TREATMENT|1972-08-07||||1973-04-25||1960-11-12|1967-05-18||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||OVRLRESP|OVERALL RESPONSE||||MIN/DAY|CCR||10^11/L|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|Y|SIGNIFICANT OTHER|READER 3|N|4||88||OBSERVATION|1972-05-26||||1967-12-14||1973-08-11|1973-07-20||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||/10^5|CYTOGENETIC PR||PMOL|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|N|STUDY SUBJECT|RADIOLOGIST 1|U|5||7||TREATMENT|1964-04-28||||1966-11-29||1964-07-25|1961-09-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||PATHRESP|PATHOLOGIC RESPONSE||||TBSP|CHR||MM|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|NA|PARENT|ONCOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1963-07-09||||1962-05-06||1970-12-20|1962-09-22||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||NEWLPROG|NEW LESION PROGRESSION||||G/U|PSA PROGRESSION||JDF UNIT|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1963-09-26||||1969-10-06||1961-06-14|1961-04-19||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||PATHRESP|PATHOLOGIC RESPONSE||||U/KG/DAY|NPR||COAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|Y|ADJUDICATION COMMITTEE|INTERNIST|U|1||38||LONG-TERM FOLLOW-UP|1965-01-21||||1965-06-02||1971-09-01|1960-12-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MG/M2|NPR||AU/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|N|NA|PROXY|UROLOGIST|U|2||58||OBSERVATION|1964-04-18||||1968-12-29||1965-10-30|1967-12-08||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||ANATRESP|ANATOMIC RESPONSE||||NL|IPR||PFU|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|STUDY SUBJECT|PATHOLOGIST 2|Y|2||58||WASHOUT|1962-02-13||||1962-09-22||1969-04-25|1967-08-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MG/MIN|ABSENT MORPHOLOGIC RESPONSE||PIXELS/CM|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|U|CLINICAL RESEARCH ASSOCIATE|READER 3|Y|3||39||FOLLOW-UP|1968-08-18||||1965-12-10||1969-07-07|1964-10-20||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||STRUSTAT|STEROID USE STATUS||||ML/MIN/MMHG|ABSENT MORPHOLOGIC RESPONSE||10^8 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|PROXY|ENDOCRINOLOGIST|Y|3||39||FOLLOW-UP|1973-01-08||||1968-05-23||1962-03-14|1964-08-01||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||CYTORESP|CYTOGENETIC RESPONSE||||MG|PMD||U/G/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BASELINE|1960-10-22||||1965-10-30||1973-04-15|1968-03-30||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||SEC|MAJOR PATHOLOGIC RESPONSE||PPB|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|HEALTH CARE PROFESSIONAL|READER 1|N|4||88||INDUCTION TREATMENT|1966-09-15||||1961-09-14||1970-09-08|1962-08-08||DURING||DURING|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ML/BREATH|PR WITH LYMPHOCYTOSIS||UG/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|N|INTERVIEWER|ADJUDICATOR|NA|5||7||WASHOUT|1967-12-08||||1970-12-15||1968-08-27|1968-08-15||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||NEWLIND|NEW LESION INDICATOR||||MM/2H|IPR||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|INVESTIGATOR|RADIOLOGIST|Y|5||7||INDUCTION TREATMENT|1961-04-24||||1963-05-03||1962-07-31|1961-10-30||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MG/KG/H|INCREASED||G/M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|U|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|1||38||RUN-IN|1969-07-28||||1965-05-05||1968-07-08|1971-09-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MOL/L|PMR||PT_US|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|Y|PARENT|HEMATOLOGIST|N|1||38||CONTINUATION TREATMENT|1968-09-18||||1961-03-24||1972-06-04|1963-09-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/G/DAY|PMR||HOMEOPATHIC DILUTION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|SPOUSE|INTERNIST|N|2||58||INDUCTION TREATMENT|1963-03-09||||1964-05-06||1961-01-23|1961-03-04||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||CYTORESP|CYTOGENETIC RESPONSE||||KIT|CYTOGENETIC PR||CM/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|READER 1|U|2||58||WASHOUT|1964-03-08||||1970-02-17||1969-10-17|1965-11-07||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||G/CAGE/DAY|DECREASED||NMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|INVESTIGATOR|ADJUDICATOR 1|NA|3||39||TREATMENT|1960-02-29||||1969-05-21||1965-12-24|1962-05-17||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||CLINRESP|CLINICAL RESPONSE||||CFU/G|CYTOGENETIC MINOR RESPONSE||%(W/V)|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|CAREGIVER|HEMATOLOGIST|U|3||39||INDUCTION TREATMENT|1966-01-06||||1967-10-14||1971-07-17|1966-12-02||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||NTRGRESP|NON-TARGET RESPONSE||||KIT|CYTOGENETIC NO RESPONSE||TORR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|4||88||OBSERVATION|1973-04-21||||1968-03-18||1961-02-07|1962-09-28||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||NEWLPROG|NEW LESION PROGRESSION||||KG/L|HI-P||DISK|NOT DONE|||LIKERT SCALE 5-POINT|U|NA|NA|SIBLING|RADIOLOGIST 1|Y|4||88||BASELINE|1962-04-05||||1962-10-09||1966-11-10|1969-10-18||AFTER||DURING|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/H|PARTIAL MORPHOLOGIC RESPONSE||U/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|U|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|5||7||FOLLOW-UP|1973-03-11||||1968-08-03||1967-05-01|1965-08-18||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||CONTAINER|NOT ALL EVALUATED||BAU/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|NA|VENDOR|RADIOLOGIST 2|Y|5||7||OBSERVATION|1970-05-29||||1972-12-28||1963-10-29|1967-07-18||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||LIVRRESP|LIVER RESPONSE||||10^8 PFU|MINOR PATHOLOGIC RESPONSE||10^3 COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|Y|DOMESTIC PARTNER|CARDIOLOGIST|Y|1||38||WASHOUT|1964-03-29||||1966-09-07||1961-01-05|1970-03-13||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||ANATRESP|ANATOMIC RESPONSE||||POUCH|MORPHOLOGIC CRI||10^5/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1966-09-26||||1973-05-15||1962-05-13|1967-04-03||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||LIVRRESP|LIVER RESPONSE||||ML/CAGE|DECREASED||U/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|DOMESTIC PARTNER|NEUROLOGIST 2|NA|2||58||INDUCTION TREATMENT|1967-11-03||||1960-02-06||1966-03-30|1965-12-30||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||NEWLIND|NEW LESION INDICATOR||||/H|CMR||GBQ/MG|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|U|ADJUDICATOR|UROLOGIST|Y|2||58||SCREENING|1962-06-10||||1962-03-31||1969-01-21|1965-01-31||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||EJACULATE U|IUPD||FL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|Y|U|FRIEND|PHYSIOTHERAPIST|NA|3||39||SCREENING|1961-02-01||||1963-10-21||1971-05-07|1962-06-02||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MCI/KG|PSEUDORESPONSE||/2500 WBC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|3||39||LONG-TERM FOLLOW-UP|1961-10-22||||1966-08-19||1961-07-19|1963-05-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||MOLRESP|MOLECULAR RESPONSE||||/10^4|HI-P||COPIES/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|U|N|INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1963-03-11||||1963-06-10||1966-09-18|1972-06-27||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||10^6 RNA COPIES/ML|CR-CT||WATT|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|U|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||SCREENING|1961-02-01||||1962-02-06||1964-12-16|1971-12-23||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||BONERESP|BONE RESPONSE||||TCID 50/DOSE|MR||10^7 PFU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|NA|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|5||7||CONTINUATION TREATMENT|1972-10-24||||1963-09-24||1963-03-07|1970-04-06||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^5/HPF|MOLECULAR CR||SPRAY|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|FAMILY MEMBER|ENDOCRINOLOGIST|Y|5||7||BASELINE|1968-06-16||||1968-11-22||1970-10-09|1968-10-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||UG/CM2|NON-ICR/NON-IUPD||ML/S|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|Y|GUARDIAN|ONCOLOGIST 2|U|1||38||FOLLOW-UP|1961-10-16||||1970-11-07||1968-03-07|1960-09-14||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||ANATRESP|ANATOMIC RESPONSE||||U/MMOL|WORSENED||10^9 CFU|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|U|CHILD|OPTOMETRIST|Y|1||38||OPEN LABEL TREATMENT|1963-02-25||||1965-09-24||1969-03-07|1973-02-03||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||MOLRESP|MOLECULAR RESPONSE||||EU|ICR||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|U|VENDOR|CARDIOLOGIST|NA|2||58||FOLLOW-UP|1968-08-18||||1971-07-11||1973-06-17|1968-05-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||LIVRRESP|LIVER RESPONSE||||ENZYME U|CCR||L/MIN|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|NA|SPOUSE|ADJUDICATOR 1|Y|2||58||TREATMENT|1969-12-28||||1966-09-08||1966-09-17|1966-08-11||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||METSIND|METASTATIC INDICATOR||||CMH2O/ML|PD/RELAPSE AFTER HI||CI/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|SIGNIFICANT OTHER|RADIOLOGIST|Y|3||39||RUN-IN|1965-07-12||||1962-10-14||1967-10-28|1971-11-11||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||NMOL/DAY|CCR||TAMPON|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1966-06-14||||1971-04-15||1966-09-04|1964-07-19||DURING||AFTER|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||BONERESP|BONE RESPONSE||||NM|HI-P||/HPF|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|INDEPENDENT ASSESSOR|MICROSCOPIST|U|4||88||SCREENING|1972-06-26||||1966-07-24||1969-07-16|1965-07-02||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||SPLNRESP|SPLEEN RESPONSE||||/MIN|VGPR||UG/G/H|NOT DONE|||LIKERT SCALE 3-POINT|U|U|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|4||88||CONTINUATION TREATMENT|1966-05-20||||1961-02-14||1971-07-26|1967-07-16||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||SPLNRESP|SPLEEN RESPONSE||||MG/KG/MIN|PCR||/WK|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|5||7||FOLLOW-UP|1967-01-09||||1965-10-28||1971-11-25|1960-09-21||AFTER||DURING|
TRIAL STUDY 134XCP|RS|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||NEWLIND|NEW LESION INDICATOR||||MPH|OPTIMAL MORPHOLOGIC RESPONSE||MEQ/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|NA|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||OBSERVATION|1962-02-15||||1967-07-07||1963-11-01|1972-08-01||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||BESTRESP|BEST OVERALL RESPONSE||||GBQ|NON-ICR/NON-IUPD||SYRINGE|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|HEALTH CARE PROFESSIONAL|RATER 1|Y|1||38||LONG-TERM FOLLOW-UP|1960-01-01||||1967-03-17||1960-07-19|1963-12-12||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||NEWLIND|NEW LESION INDICATOR||||MMOL|MAJOR PATHOLOGIC RESPONSE||MIN/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|NA|FAMILY MEMBER|MICROSCOPIST|NA|1||38||INDUCTION TREATMENT|1961-05-29||||1964-10-27||1965-07-06|1972-07-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MG/G/H|NON-CR/NON-PD||ML/M2/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|PROXY|RADIOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1961-12-24||||1965-09-26||1971-01-07|1971-03-16||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MG/DOSE|PR-CT||G/KG|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|CHILD|ADJUDICATOR 1|U|2||58||TREATMENT|1964-11-06||||1962-11-10||1964-09-20|1973-01-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/G/DAY|HI-P||DIOPTER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|3||39||WASHOUT|1973-01-10||||1965-10-31||1963-10-11|1966-02-20||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||M3|CYTOGENETIC PR||MG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1960-08-07||||1971-12-21||1962-08-11|1968-01-29||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||CLINRESP|CLINICAL RESPONSE||||%|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||NMOL BCE/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|HEALTH CARE PROFESSIONAL|RATER 1|NA|4||88||BLINDED TREATMENT|1968-05-13||||1962-10-20||1965-07-06|1970-04-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||NEWLIND|NEW LESION INDICATOR||||CAPLET|SMD||U/KG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||RUN-IN|1968-02-26||||1967-08-28||1968-06-25|1962-02-15||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||PATHRESP|PATHOLOGIC RESPONSE||||10^6/L|HI-E||CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|ADJUDICATION COMMITTEE|NEUROLOGIST|Y|5||7||BASELINE|1968-11-03||||1972-09-27||1966-06-10|1968-10-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||SPLNRESP|SPLEEN RESPONSE||||L|OPTIMAL MORPHOLOGIC RESPONSE||RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|HEALTH CARE PROFESSIONAL|READER|N|5||7||CONTINUATION TREATMENT|1967-02-13||||1961-06-08||1965-05-10|1961-12-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||RPM|SCR||NFIU|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|SPOUSE|ADJUDICATOR 1|Y|1||38||LONG-TERM FOLLOW-UP|1970-04-03||||1970-04-22||1967-04-17|1966-07-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||UKAT/10^12 RBC|IPR||NKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|PARENT|ONCOLOGIST 2|Y|1||38||OBSERVATION|1966-09-21||||1962-07-04||1968-11-30|1966-08-02||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||NEWLIND|NEW LESION INDICATOR||||10^6 U|SCR||DPM/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|FAMILY MEMBER|INTERNIST|Y|2||58||RUN-IN|1968-08-24||||1963-09-06||1964-01-24|1960-06-07||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||G/KG|PMD||MV/SEC|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|Y|PROXY|ADJUDICATOR|NA|2||58||INDUCTION TREATMENT|1973-06-06||||1960-07-28||1960-09-04|1973-06-25||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PUFF|ISD||BQ/UG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|ADJUDICATION COMMITTEE|UROLOGIST|U|3||39||CONTINUATION TREATMENT|1968-07-14||||1961-04-10||1963-09-24|1971-09-24||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||PATHRESP|PATHOLOGIC RESPONSE||||MOL/MOL|MR||F|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|Y|SIGNIFICANT OTHER|RATER|NA|3||39||CONTINUATION TREATMENT|1963-06-28||||1960-04-19||1963-11-13|1972-07-23||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||RDIORESP|RADIOLOGIC RESPONSE||||U/KG/H|ISD||UMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|PROXY|PHYSIOTHERAPIST|U|4||88||OPEN LABEL TREATMENT|1971-02-18||||1963-11-12||1960-10-17|1963-10-10||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||SPRAY|HI-E||/MONTH|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1973-06-26||||1966-12-15||1973-08-12|1973-04-14||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ENZYME U/L|CMR||UKAT/10^12 RBC|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|5||7||CONTINUATION TREATMENT|1964-10-02||||1969-12-23||1961-03-22|1964-11-20||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||IU/MMOL|PD/RELAPSE AFTER HI||AU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|GUARDIAN|RADIOLOGIST 1|U|5||7||OPEN LABEL TREATMENT|1960-11-01||||1963-02-19||1969-05-13|1965-09-14||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||BESTRESP|BEST OVERALL RESPONSE||||L/H|IMMUNOPHENOTYPIC CR||VP/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|NA|NA|FRIEND|ADJUDICATOR 3|N|1||38||BASELINE|1971-08-10||||1961-08-18||1965-01-10|1972-07-26||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||MOLRESP|MOLECULAR RESPONSE||||VIAL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||10^3/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|Y|U|SIGNIFICANT OTHER|CARDIOLOGIST|U|1||38||TREATMENT|1973-04-20||||1962-06-12||1969-07-10|1961-02-05||DURING||DURING|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||NEWLPROG|NEW LESION PROGRESSION||||MG/DOSE|CRI||ML/KG/DAY|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|INTERVIEWER|NEUROLOGIST 1|N|2||58||BASELINE|1970-09-26||||1970-12-21||1963-01-13|1970-10-30||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||OVRLRESP|OVERALL RESPONSE||||U/DL|DECREASED||MG/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|CHILD|ONCOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1971-02-03||||1962-06-24||1970-08-02|1966-03-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||BESTRESP|BEST OVERALL RESPONSE||||USEC|PR||MG/DL|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|3||39||CONTINUATION TREATMENT|1967-06-15||||1969-08-25||1961-02-15|1960-11-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||STRUSTAT|STEROID USE STATUS||||CCID 50/DOSE|MRD NEGATIVITY||DMOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|SIBLING|CARDIOLOGIST|NA|3||39||TREATMENT|1972-10-03||||1960-11-17||1962-07-27|1967-04-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||PT_US|NED||/LSQN|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|N|NA|GUARDIAN|RATER 2|NA|4||88||CONTINUATION TREATMENT|1966-07-18||||1965-07-04||1970-08-24|1971-08-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||BAU|HI-N||NG/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|4||88||OBSERVATION|1971-05-05||||1968-09-30||1961-08-21|1964-09-30||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||ANATRESP|ANATOMIC RESPONSE||||10^3 DNA COPIES/ML|NOT ALL EVALUATED||IU/KG/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|N|N|INTERVIEWER|RATER 2|U|5||7||OBSERVATION|1972-09-05||||1966-09-18||1963-08-18|1962-09-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||SPLNRESP|SPLEEN RESPONSE||||10^7 CFU/ML|SMD||MPL U/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|NA|FAMILY MEMBER|ONCOLOGIST|N|5||7||WASHOUT|1971-03-20||||1962-12-04||1973-06-24|1967-02-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CI|MINOR PATHOLOGIC RESPONSE||CG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|FRIEND|PATHOLOGIST 1|NA|1||38||BASELINE|1968-11-16||||1965-06-09||1967-02-22|1960-12-08||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||METBRESP|METABOLIC RESPONSE||||KIT|DISEASE TRANSFORMATION||MIU/L|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|PARENT|READER 2|Y|1||38||WASHOUT|1962-08-12||||1963-04-23||1973-07-26|1965-04-29||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/L/H|HI-N||LOG10 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|N|SPOUSE|FORENSIC PATHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1964-11-06||||1961-06-28||1968-08-11|1963-12-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||NTRGRESP|NON-TARGET RESPONSE||||KCAL|ABSENT MORPHOLOGIC RESPONSE||GPELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|SIGNIFICANT OTHER|DERMATOLOGIST|Y|2||58||CONTINUATION TREATMENT|1970-12-29||||1970-07-26||1970-04-14|1961-07-24||DURING||DURING|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||CD|PMD||G/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|PROXY|RADIOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1967-08-11||||1964-07-26||1972-09-29|1968-04-18||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||STRUSTAT|STEROID USE STATUS||||BISCUIT|HI-P||L/KG|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|INDEPENDENT ASSESSOR|READER 1|Y|3||39||INDUCTION TREATMENT|1972-03-13||||1962-09-17||1965-06-19|1972-04-04||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/ML|CA125 50% RESPONSE||G/CAGE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|U|ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|4||88||RUN-IN|1963-07-08||||1973-06-09||1960-08-14|1973-06-18||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||10^7 PFU|CMR||PG/CELL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|CLINICAL STUDY SPONSOR|INTERNIST|Y|4||88||WASHOUT|1973-02-26||||1969-10-03||1962-02-10|1965-12-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||LIVRRESP|LIVER RESPONSE||||ML/S|NON-ICR/NON-IUPD||M/SEC2|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|5||7||TREATMENT|1966-05-19||||1969-11-02||1963-12-01|1967-04-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||BESTRESP|BEST OVERALL RESPONSE||||HOURS|OPTIMAL MORPHOLOGIC RESPONSE||ML/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|5||7||FOLLOW-UP|1964-02-02||||1971-10-19||1961-11-29|1960-12-24||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||UG/ML/H|CR||V/V|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|1||38||WASHOUT|1962-02-25||||1961-02-11||1962-08-13|1970-12-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||GAUSS|NOT ALL EVALUATED||MG|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|FRIEND|ADJUDICATOR|N|1||38||LONG-TERM FOLLOW-UP|1963-11-06||||1962-06-18||1963-01-07|1971-01-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||CYTORESP|CYTOGENETIC RESPONSE||||G/M2/DAY|FAVORABLE RESPONSE||ECL UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|N|Y|CAREGIVER|RATER 2|N|2||58||RUN-IN|1971-11-17||||1969-10-24||1960-03-03|1967-07-04||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||METBRESP|METABOLIC RESPONSE||||10^10/L|MORPHOLOGIC CRI||ML/BREATH|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|2||58||WASHOUT|1961-03-05||||1966-06-13||1960-06-05|1967-11-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||BESTRESP|BEST OVERALL RESPONSE||||NU/CL|PMD||10^3 RNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|INVESTIGATOR|MICROSCOPIST 3|N|3||39||FOLLOW-UP|1971-10-30||||1972-06-28||1969-05-27|1961-10-24||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||STRUSTAT|STEROID USE STATUS||||CY/CM|NON-QUANTIFIABLE MRD POSITIVITY||UG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|PROXY|PEDIATRIC NEUROLOGIST|NA|3||39||CONTINUATION TREATMENT|1960-09-21||||1972-05-17||1962-04-25|1961-12-05||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||TABLET|ISD||U/KG/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|NA|PROXY|PHYSIOTHERAPIST|U|4||88||WASHOUT|1967-04-09||||1969-10-13||1966-09-24|1966-08-24||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||BONERESP|BONE RESPONSE||||MG/G/MIN|CMR||IN2|NOT DONE|||LIKERT SCALE 5-POINT|N|N|N|PROXY|MICROSCOPIST 1|Y|4||88||BASELINE|1962-07-13||||1967-11-11||1970-08-14|1960-01-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^8 PFU|IMPROVED||BOTTLE|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|NA|STUDY SUBJECT|ADJUDICATOR 2|Y|5||7||OPEN LABEL TREATMENT|1967-12-02||||1960-03-23||1972-09-03|1973-02-27||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PFU/ML|MRD PERSISTENCE||CYLINDER|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|VENDOR|UROLOGIST|U|5||7||BLINDED TREATMENT|1968-08-07||||1961-01-18||1969-12-23|1960-07-29||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||LIVRRESP|LIVER RESPONSE||||UIU/DL|MRD RELAPSE||TSP EQ|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|DOMESTIC PARTNER|READER 3|Y|1||38||RUN-IN|1960-09-16||||1965-11-01||1960-06-23|1966-12-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||OVRLRESP|OVERALL RESPONSE||||KIT|MINOR PATHOLOGIC RESPONSE||10^3 CFU/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|Y|Y|PROXY|ENDOCRINOLOGIST|Y|1||38||BASELINE|1961-11-27||||1973-01-05||1966-11-28|1967-04-24||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||NEWLIND|NEW LESION INDICATOR||||AGU/ML|PD||G/DAY|NOT DONE|||LIKERT SCALE 7-POINT|U|NA|U|FAMILY MEMBER|RATER|Y|2||58||RUN-IN|1971-04-14||||1969-04-23||1968-07-20|1964-02-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UMOL/DAY|NON-QUANTIFIABLE MRD POSITIVITY||PA|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|INVESTIGATOR|NEUROLOGIST 2|U|2||58||OBSERVATION|1964-04-08||||1970-09-14||1972-06-15|1971-01-18||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||LB|PD-CT||COPIES/UL|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|SIBLING|MICROSCOPIST 3|NA|3||39||BASELINE|1967-04-10||||1969-10-18||1970-07-07|1961-09-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||METBRESP|METABOLIC RESPONSE||||UIU/L|PR||MKAT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||WASHOUT|1967-10-22||||1967-03-27||1965-01-18|1961-11-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||BONERESP|BONE RESPONSE||||JDF UNIT|NOT ALL EVALUATED||U/G/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|PARENT|READER|Y|4||88||RUN-IN|1973-04-26||||1967-05-25||1966-09-07|1966-07-12||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||PATHRESP|PATHOLOGIC RESPONSE||||UCI/L|ISD||GBQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|U|Y|STUDY SUBJECT|NEUROLOGIST 1|Y|4||88||BLINDED TREATMENT|1964-11-22||||1964-08-17||1967-05-02|1969-08-04||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||10^3/HPF|MCR||MMHG/SEC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|U|CLINICAL RESEARCH COORDINATOR|READER 1|NA|5||7||SCREENING|1968-03-27||||1965-07-25||1967-07-18|1965-10-22||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||CYTORESP|CYTOGENETIC RESPONSE||||PG|CA125 75% RESPONSE||CI/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|5||7||RUN-IN|1961-02-08||||1969-09-04||1966-03-19|1962-07-17||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||VOXEL|SD-CT||NEWTON|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|1||38||WASHOUT|1962-05-20||||1960-07-01||1970-12-07|1963-10-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||GBQ/UG|WORSENED||L/H/M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|SPOUSE|OPTOMETRIST|N|1||38||OPEN LABEL TREATMENT|1961-01-12||||1973-07-20||1965-06-08|1961-01-29||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||TMRESP|TUMOR MARKER RESPONSE||||SFC/10^6 PBMC|ICPD||NCI|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|NA|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|2||58||RUN-IN|1969-11-11||||1961-05-07||1961-01-13|1973-08-07||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||NKAT/L|TREATMENT FAILURE||TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|N|PROXY|UROLOGIST|Y|2||58||RUN-IN|1969-03-31||||1966-08-13||1965-09-01|1968-05-07||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||JAR|MOLECULAR CR||NL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|SIBLING|RATER|Y|3||39||SCREENING|1968-05-21||||1962-05-14||1972-09-23|1962-08-31||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||METBRESP|METABOLIC RESPONSE||||ML/BREATH|CA125 75% RESPONSE||ANSON U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|3||39||WASHOUT|1964-09-22||||1970-10-29||1964-11-04|1964-12-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||/CMH2O|MRD PERSISTENCE||NCI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|Y|FRIEND|RATER 1|NA|4||88||TREATMENT|1962-05-10||||1965-03-16||1964-04-30|1969-06-27||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||UG/M2|MINOR PATHOLOGIC RESPONSE||CG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|Y|SIGNIFICANT OTHER|UROLOGIST|NA|4||88||CONTINUATION TREATMENT|1964-02-03||||1973-06-02||1973-02-24|1960-09-23||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||NCI|PMD||MONTHS|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|5||7||WASHOUT|1970-12-04||||1964-02-24||1961-11-05|1963-02-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||NTRGRESP|NON-TARGET RESPONSE||||CUP|PD FROM PR||MG/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|U|INDEPENDENT ASSESSOR|RATER|U|5||7||BASELINE|1972-02-12||||1969-06-10||1966-09-23|1960-05-10||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||NTRGRESP|NON-TARGET RESPONSE||||FT|IMPROVED||10^6 RNA COPIES/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|SIBLING|RATER 1|N|1||38||INDUCTION TREATMENT|1968-04-29||||1963-08-16||1968-08-26|1970-04-02||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||LIVRRESP|LIVER RESPONSE||||UG/M2/H|PD-CT||PMOL/10^9 CELLS|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|Y|ADJUDICATOR|ONCOLOGIST 1|NA|1||38||WASHOUT|1968-02-04||||1970-03-15||1962-10-07|1970-06-19||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||CLINRESP|CLINICAL RESPONSE||||FARAD|PSA PROGRESSION||UU/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|NA|GUARDIAN|MICROSCOPIST 2|U|2||58||BLINDED TREATMENT|1965-04-28||||1971-06-25||1967-11-03|1971-09-24||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||TRGRESP|TARGET RESPONSE||||UM/S|RELAPSED DISEASE FROM CR OR PR||UOSM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|U|INTERVIEWER|ONCOLOGIST 1|NA|2||58||BASELINE|1970-06-29||||1960-08-09||1963-04-17|1962-07-26||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||METBRESP|METABOLIC RESPONSE||||UL/ML|PSEUDORESPONSE||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|CAREGIVER|FORENSIC PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1973-01-02||||1960-04-12||1962-04-29|1960-02-06||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||TRGRESP|TARGET RESPONSE||||SYRINGE|HI-N||DPM/ML|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|Y|PROXY|READER 1|Y|3||39||CONTINUATION TREATMENT|1967-01-09||||1964-02-12||1962-04-29|1962-12-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||SPLNRESP|SPLEEN RESPONSE||||PA|FAVORABLE RESPONSE||ABSORBANCE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|4||88||OPEN LABEL TREATMENT|1965-10-29||||1964-04-25||1963-05-04|1971-05-05||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ML/100G/MIN|IMMUNOPHENOTYPIC CR||BEATS/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|4||88||LONG-TERM FOLLOW-UP|1968-06-13||||1972-06-23||1968-04-18|1962-04-19||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CAPLET|MORPHOLOGIC LEUKEMIA-FREE STATE||/MS|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|N|ADJUDICATOR|PATHOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1966-10-23||||1966-11-10||1969-04-01|1968-04-17||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||USEC|PCR||DYN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|5||7||OBSERVATION|1960-04-05||||1970-12-31||1966-08-18|1963-07-11||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||MOLRESP|MOLECULAR RESPONSE||||LOZENGE|MORPHOLOGIC LEUKEMIA-FREE STATE||MMOL2/L2|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|DOMESTIC PARTNER|INTERNIST|U|1||38||WASHOUT|1972-05-13||||1963-08-15||1972-10-05|1963-05-27||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||HOUNSFIELD UNIT|EQUIVOCAL||G/G/DAY|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|NA|VENDOR|RADIOLOGIST|U|1||38||OBSERVATION|1970-04-19||||1969-01-16||1964-03-12|1973-03-10||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||OVRLRESP|OVERALL RESPONSE||||NM|DECREASED||CM/S|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|FRIEND|UROLOGIST|NA|2||58||OPEN LABEL TREATMENT|1971-08-24||||1965-08-30||1971-05-06|1962-09-22||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||RDIORESP|RADIOLOGIC RESPONSE||||10^3 RNA COPIES/ML|SD||TRANSDUCING UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|NA|Y|PROXY|RADIOLOGIST 1|U|2||58||FOLLOW-UP|1960-07-16||||1971-03-16||1970-12-31|1972-11-24||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||L/L|MORPHOLOGIC CRI||PACKET|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|NA|INVESTIGATOR|HEMATOLOGIST|NA|3||39||INDUCTION TREATMENT|1972-08-28||||1961-01-04||1972-08-28|1972-10-06||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||METSIND|METASTATIC INDICATOR||||CUP EQ|WORSENED||UMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|PROXY|RADIOLOGIST 1|U|3||39||TREATMENT|1963-04-12||||1972-08-15||1968-07-08|1966-08-14||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^4 CFU|ICPD||/4.0 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|SIBLING|OPTOMETRIST|N|4||88||BLINDED TREATMENT|1970-10-23||||1961-10-30||1972-09-19|1967-05-28||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||ANATRESP|ANATOMIC RESPONSE||||DB|CA125 50% RESPONSE||CI/KG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|STUDY SUBJECT|ADJUDICATOR 3|NA|4||88||BASELINE|1971-09-13||||1964-09-03||1962-07-12|1963-06-03||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||ANATRESP|ANATOMIC RESPONSE||||EQ|MOLECULAR CR||IU/MMOL|NOT DONE|||LIKERT SCALE 3-POINT|U|Y|NA|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5||7||WASHOUT|1973-04-27||||1969-08-02||1962-03-23|1962-04-03||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/M2/H|NOT ALL EVALUATED||LB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|NA|N|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|5||7||BLINDED TREATMENT|1967-11-20||||1961-06-23||1965-07-09|1966-07-10||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMOL/L|INDETERMINATE RESPONSE||LOG10 PFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|NA|INTERVIEWER|ONCOLOGIST 2|U|1||38||OPEN LABEL TREATMENT|1973-02-08||||1964-08-02||1964-03-14|1962-04-25||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||FARAD|RELAPSED DISEASE FROM CR||MKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|1||38||BASELINE|1965-07-18||||1963-11-09||1960-11-23|1969-08-20||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|1||||||SPLNRESP|SPLEEN RESPONSE||||STEPS|CA125 75% RESPONSE||LOG10 IU/ML|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|Y|CAREGIVER|ONCOLOGIST|U|2||58||FOLLOW-UP|1960-03-16||||1969-05-17||1973-07-25|1968-09-28||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|2||||||RDIORESP|RADIOLOGIC RESPONSE||||NG/MOL|PCR||UG/M2|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|2||58||FOLLOW-UP|1960-11-04||||1969-08-08||1961-02-03|1961-12-20||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||KG/MOL|STABLE||PG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|3||39||CONTINUATION TREATMENT|1965-02-14||||1962-04-29||1968-02-26|1960-04-08||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||SFC/10^6 PBMC|MINOR PATHOLOGIC RESPONSE||/MM2|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|U|CAREGIVER|DERMATOLOGIST|U|3||39||OBSERVATION|1966-12-15||||1971-05-22||1972-05-17|1963-11-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||DPM/100MG|PARTIAL MORPHOLOGIC RESPONSE||MG/DOSE|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|PROXY|PATHOLOGIST|NA|4||88||RUN-IN|1961-04-03||||1961-02-09||1966-10-12|1965-08-24||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||UV2|DISEASE TRANSFORMATION||COAT|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||CONTINUATION TREATMENT|1969-05-08||||1971-05-05||1961-03-06|1967-09-06||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|1||||||BESTRESP|BEST OVERALL RESPONSE||||ENZYME U/G HB|SD||TSP EQ|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|U|N|INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|5||7||RUN-IN|1966-03-29||||1971-08-29||1965-01-13|1961-01-10||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|8417B146-336C-4777-A566-C1D086F39430|2||||||BONERESP|BONE RESPONSE||||/10^3|SMD||JAR|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|NA|FRIEND|ONCOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1965-12-26||||1965-05-02||1961-03-14|1968-03-18||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||NEWLIND|NEW LESION INDICATOR||||HOMEOPATHIC DILUTION|PSEUDOPROGRESSION||10^6 DNA COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|N|1||38||INDUCTION TREATMENT|1972-04-25||||1965-10-13||1965-08-24|1971-01-04||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 CFU/ML|PMR||DAGU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|FAMILY MEMBER|MICROSCOPIST 2|Y|1||38||OPEN LABEL TREATMENT|1966-11-22||||1968-02-07||1969-07-09|1969-05-17||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UMOL/MIN|FAVORABLE RESPONSE||LOG10 IU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|Y|ADJUDICATOR|RADIOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1972-01-17||||1964-09-06||1963-04-16|1965-07-16||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||PG|SD-CT||CUP|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|Y|Y|FAMILY MEMBER|ONCOLOGIST 2|N|2||58||FOLLOW-UP|1968-02-15||||1968-10-14||1968-01-15|1960-01-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||NTRGRESP|NON-TARGET RESPONSE||||/HPF|MRD RELAPSE||U/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|3||39||BASELINE|1969-10-15||||1961-04-03||1969-11-19|1967-10-04||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||NEWLPROG|NEW LESION PROGRESSION||||RAD|UNFAVORABLE RESPONSE||PMOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|3||39||SCREENING|1970-04-08||||1972-12-09||1964-02-14|1960-05-06||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||PATHRESP|PATHOLOGIC RESPONSE||||COAT|IMMUNOPHENOTYPIC CR||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|4||88||WASHOUT|1965-10-08||||1963-11-01||1970-08-22|1969-01-18||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||IU/G|CA125 75% RESPONSE||UG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|Y|SIBLING|RADIOLOGIST|U|4||88||TREATMENT|1973-01-22||||1961-05-29||1973-04-14|1961-02-02||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||LOG10 PFU/ML|MORPHOLOGIC CRI||LOG10 ELISA UNIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|FAMILY MEMBER|NEUROLOGIST 1|NA|5||7||OBSERVATION|1968-12-31||||1962-12-10||1966-04-23|1972-12-30||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/DOSE|RELAPSED DISEASE FROM CR||KHZ|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|DOMESTIC PARTNER|PATHOLOGIST|U|5||7||BASELINE|1965-12-31||||1968-03-13||1973-02-03|1970-09-09||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||OVRLRESP|OVERALL RESPONSE||||10^6/G|PDU||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|Y|INVESTIGATOR|MICROSCOPIST 1|N|1||38||RUN-IN|1965-01-17||||1972-07-17||1964-06-11|1966-10-01||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MESF|IMPROVED||UG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|DOMESTIC PARTNER|ONCOLOGIST|Y|1||38||FOLLOW-UP|1965-01-06||||1960-06-23||1960-01-29|1969-08-16||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||NEWLPROG|NEW LESION PROGRESSION||||KG/CM|PARTIAL MORPHOLOGIC RESPONSE||ML/KG/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|NA|N|PARENT|READER 3|Y|2||58||INDUCTION TREATMENT|1964-02-09||||1965-01-23||1960-01-08|1966-12-31||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||L/MIN/M2|NON-QUANTIFIABLE MRD POSITIVITY||MU/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|2||58||RUN-IN|1972-10-01||||1967-01-06||1963-01-22|1961-04-16||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/KG|MR||ML/CM H2O|NOT DONE|||LIKERT SCALE 3-POINT|Y|N|U|INVESTIGATOR|RATER 1|U|3||39||RUN-IN|1962-07-17||||1970-03-05||1973-05-23|1972-05-20||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||SPRAY|PMR||FARAD|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|Y|NA|CLINICAL STUDY SPONSOR|RATER 1|Y|3||39||INDUCTION TREATMENT|1961-08-26||||1973-01-02||1961-01-11|1963-12-21||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||NEWLPROG|NEW LESION PROGRESSION||||CCID 50/DOSE|UNFAVORABLE RESPONSE||DIOPTER|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|4||88||BASELINE|1966-11-29||||1967-03-03||1972-08-31|1967-10-03||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UCI/KG|SCR||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|VENDOR|FORENSIC PATHOLOGIST|Y|4||88||INDUCTION TREATMENT|1960-05-12||||1972-07-16||1960-06-24|1961-07-02||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||CYTORESP|CYTOGENETIC RESPONSE||||L/H|NON-QUANTIFIABLE MRD POSITIVITY||10^6 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|SPOUSE|UROLOGIST|Y|5||7||INDUCTION TREATMENT|1961-11-19||||1969-11-04||1969-03-14|1966-12-28||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||LIVRRESP|LIVER RESPONSE||||FFU|MCR||PSI|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|U|SIGNIFICANT OTHER|HEMATOLOGIST|Y|5||7||SCREENING|1972-05-24||||1971-01-13||1968-10-23|1968-09-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||NTRGRESP|NON-TARGET RESPONSE||||UMOL/MG/MIN|COMPLETE MRD RESPONSE||PIXELS/IN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|N|ADJUDICATOR|ONCOLOGIST 1|NA|1||38||OBSERVATION|1967-04-02||||1973-05-13||1971-04-21|1970-02-10||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||MJOULE/CM2|MRD RELAPSE||BE/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|SIBLING|RATER 1|NA|1||38||CONTINUATION TREATMENT|1965-06-12||||1964-04-08||1960-08-17|1966-08-27||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||CP|STABLE||DMOL|NOT DONE|||LIKERT SCALE 3-POINT|N|U|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|2||58||WASHOUT|1969-11-12||||1969-06-22||1963-08-20|1964-10-05||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||WEEKS|VGPR||VOXEL|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|GUARDIAN|READER 3|U|2||58||LONG-TERM FOLLOW-UP|1963-03-08||||1971-07-30||1960-04-24|1963-03-26||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||RDIORESP|RADIOLOGIC RESPONSE||||U.CARR|UNEQUIVOCAL||MEQ/UG|NOT DONE|||LIKERT SCALE 5-POINT|N|NA|NA|SIGNIFICANT OTHER|RADIOLOGIST|N|3||39||BLINDED TREATMENT|1971-11-05||||1963-08-28||1962-02-22|1960-07-29||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||MM|MORPHOLOGIC LEUKEMIA-FREE STATE||WEBER|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|NA|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|3||39||BLINDED TREATMENT|1968-03-09||||1962-12-27||1967-11-16|1970-08-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||NTRGRESP|NON-TARGET RESPONSE||||%(W/W)|PD||MONTHS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BASELINE|1971-12-21||||1972-05-15||1971-09-09|1960-04-21||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||GPS U|MORPHOLOGIC CRI||ML/DOSE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|4||88||SCREENING|1968-05-09||||1972-02-14||1967-04-29|1962-10-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||NMOL/ML/MIN|TREATMENT FAILURE||MEQ/UG|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|SPOUSE|PATHOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1973-03-03||||1962-04-25||1970-04-10|1965-08-21||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||10^6 ORGANISMS/MG|SMD||BQ/G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|N|FAMILY MEMBER|MICROSCOPIST 1|NA|5||7||OBSERVATION|1961-10-18||||1971-11-29||1969-06-30|1963-06-16||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||MBQ/UL|PR||V/V|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|VENDOR|ADJUDICATOR 1|Y|1||38||FOLLOW-UP|1966-02-17||||1965-12-30||1968-02-03|1962-03-22||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||/100 WBC|HI-E||G/G/DAY|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||CONTINUATION TREATMENT|1965-07-15||||1960-09-25||1963-03-28|1970-04-25||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||BEAM BREAKS|NON-QUANTIFIABLE MRD POSITIVITY||TUBERCULIN UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|N|PARENT|READER 2|Y|2||58||SCREENING|1961-08-25||||1965-09-22||1963-08-21|1971-07-20||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||VG/KG|PD-CT||NSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|FAMILY MEMBER|NEUROLOGIST 1|N|2||58||WASHOUT|1971-10-05||||1971-02-23||1960-05-21|1970-11-10||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PPM|IUPD||MMOL/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|U|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|3||39||RUN-IN|1960-05-12||||1963-02-01||1969-01-11|1970-09-05||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||AMPULE|SCR||MG/ML/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|Y|FRIEND|OPTOMETRIST|Y|3||39||BASELINE|1960-10-03||||1967-05-06||1962-04-29|1964-08-20||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||10^7/L|EQUIVOCAL||RAD|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|4||88||RUN-IN|1971-07-07||||1967-02-26||1970-09-22|1968-08-22||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|2||||||METSIND|METASTATIC INDICATOR||||GRAIN|CYTOGENETIC PR||MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|N|4||88||INDUCTION TREATMENT|1960-12-31||||1964-10-15||1964-11-14|1968-02-07||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||NG/MOL|MOLECULAR MAJOR RESPONSE||UEQ/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|N|SPOUSE|RATER 1|Y|5||7||TREATMENT|1967-02-02||||1964-08-22||1971-06-05|1965-08-18||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|2926D795-9C17-4440-8411-68525E93E78D|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||NGEQ/L|NON-ICR/NON-IUPD||/7.5 ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|SPOUSE|FORENSIC PATHOLOGIST|Y|5||7||TREATMENT|1970-02-18||||1970-11-17||1962-06-08|1972-01-16||DURING||DURING|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|1||||||STRUSTAT|STEROID USE STATUS||||MCI|MCR||10^6 CFU|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|SIGNIFICANT OTHER|ONCOLOGIST|N|1||38||INDUCTION TREATMENT|1967-11-21||||1964-10-27||1973-08-25|1961-04-03||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||HOUNSFIELD UNIT|NON-CR/NON-PD||ML/SEC/1.73M2|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|CHILD|CARDIOLOGIST|Y|1||38||CONTINUATION TREATMENT|1961-02-18||||1969-09-19||1961-02-05|1963-04-20||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|1||||||ANATRESP|ANATOMIC RESPONSE||||PUFF|DISEASE TRANSFORMATION||GBQ/G|NOT DONE|||LIKERT SCALE 3-POINT|U|N|NA|PARENT|INTERNIST|N|2||58||LONG-TERM FOLLOW-UP|1967-01-28||||1971-04-30||1970-11-02|1970-04-17||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||KIT|DECREASED||MET*MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|PARENT|READER|Y|2||58||BLINDED TREATMENT|1966-05-06||||1967-11-11||1972-04-27|1970-06-15||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|1||||||METSIND|METASTATIC INDICATOR||||MOL/L|NON-CR/NON-PD||G/CAGE/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|N|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|3||39||INDUCTION TREATMENT|1968-01-25||||1966-03-18||1964-03-03|1966-02-21||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|2||||||SPLNRESP|SPLEEN RESPONSE||||10^3 ORGANISMS/ML|HI-E||IU/KG|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|N|PARENT|MICROSCOPIST|N|3||39||FOLLOW-UP|1967-03-10||||1972-09-25||1960-04-20|1972-10-17||DURING||DURING|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|1||||||SPLNRESP|SPLEEN RESPONSE||||UCI/L|HI-P||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|4||88||SCREENING|1962-05-01||||1972-02-25||1966-07-21|1965-01-27||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|2||||||LIVRRESP|LIVER RESPONSE||||10^6/G|PR-CT||NMOL/L/MIN|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|N|U|PARENT|INTERNIST|NA|4||88||WASHOUT|1962-12-24||||1961-05-05||1961-07-06|1972-03-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|1||||||ANATRESP|ANATOMIC RESPONSE||||UMOL/KG/MIN|PARTIAL MORPHOLOGIC RESPONSE||10^3 ORGANISMS|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|5||7||BLINDED TREATMENT|1960-11-24||||1972-08-28||1972-11-10|1965-12-18||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BA3378F3-C308-469F-9818-9AD811086548|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG|VGPR||MMOL/G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|N|GUARDIAN|READER|Y|5||7||TREATMENT|1962-07-18||||1970-08-10||1971-02-04|1966-07-28||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||NEWLPROG|NEW LESION PROGRESSION||||MOSM|CYTOGENETIC NO RESPONSE||CAN|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|CHILD|RADIOLOGIST 2|U|1||38||OBSERVATION|1968-07-21||||1963-12-02||1969-08-05|1967-05-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||U/MMOL|DECREASED||AMFI|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|1||38||TREATMENT|1965-12-03||||1968-10-15||1972-02-03|1963-05-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||APPLICATION|MCR||%/MIN|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|N|CHILD|DERMATOLOGIST|N|2||58||RUN-IN|1960-04-26||||1968-01-03||1972-07-12|1968-01-18||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||BESTRESP|BEST OVERALL RESPONSE||||FINGERTIP UNIT|PSEUDORESPONSE||FARAD|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|ADJUDICATOR|RADIOLOGIST 2|NA|2||58||FOLLOW-UP|1967-06-29||||1964-12-06||1962-09-29|1967-05-23||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||TRGRESP|TARGET RESPONSE||||RFU|PCR||ANTI-XA IU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|NA|SIBLING|RATER 1|NA|3||39||BASELINE|1972-09-12||||1965-08-15||1967-07-15|1967-10-18||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||APS U|PD||ML/BEAT|NOT DONE|||LIKERT SCALE 3-POINT|Y|U|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|3||39||OBSERVATION|1961-07-07||||1972-12-30||1964-12-05|1960-12-23||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UIU/L|UNEQUIVOCAL||TAMPON|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|PROXY|ADJUDICATOR 3|Y|4||88||BLINDED TREATMENT|1970-05-03||||1961-06-07||1963-09-02|1969-07-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TABLET|ICPD||TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|PROXY|RADIOLOGIST 2|U|4||88||TREATMENT|1962-04-03||||1971-05-19||1972-09-15|1961-12-14||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||TRGRESP|TARGET RESPONSE||||VIRTUAL PIXEL|NON-ICR/NON-IUPD||10^9 ORGANISMS/G|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|Y|CAREGIVER|ENDOCRINOLOGIST|Y|5||7||BASELINE|1969-03-29||||1971-05-21||1970-01-02|1965-05-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||PATHRESP|PATHOLOGIC RESPONSE||||PSEC|QUANTIFIABLE MRD POSITIVITY||10^6 CFU/G|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|NA|CAREGIVER|DERMATOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1970-10-17||||1971-05-11||1960-01-14|1969-09-27||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||ML/G/DAY|CA125 75% RESPONSE||BQ/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|PARENT|ONCOLOGIST|U|1||38||TREATMENT|1968-08-08||||1966-05-07||1969-09-10|1972-05-13||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||TRGRESP|TARGET RESPONSE||||10^4/L|RELAPSED DISEASE||KBQ|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|NA|INVESTIGATOR|INTERNIST|U|1||38||BASELINE|1961-01-30||||1965-05-31||1961-07-12|1967-09-07||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||SPLNRESP|SPLEEN RESPONSE||||VG/KG|MRD RELAPSE||PACK|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|NA|FRIEND|NEUROLOGIST|U|2||58||TREATMENT|1960-07-03||||1961-03-09||1967-04-11|1971-09-02||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||MOLRESP|MOLECULAR RESPONSE||||TSP|NON-QUANTIFIABLE MRD POSITIVITY||SIEMENS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|SIGNIFICANT OTHER|INTERNIST|U|2||58||CONTINUATION TREATMENT|1960-05-12||||1970-02-22||1966-10-26|1966-05-30||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||KG/MOL|CYTOGENETIC MINOR RESPONSE||HEP|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|U|NA|ADJUDICATOR|OPTOMETRIST|Y|3||39||FOLLOW-UP|1969-01-02||||1964-11-04||1970-02-06|1973-05-28||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MG/L|NR||GPL U/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|ADJUDICATOR|NEUROLOGIST 1|NA|3||39||WASHOUT|1969-07-18||||1971-09-29||1968-06-15|1963-04-07||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||CLINRESP|CLINICAL RESPONSE||||PACK|ISD||/WK|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|CHILD|RATER|Y|4||88||OPEN LABEL TREATMENT|1970-10-06||||1973-01-18||1960-01-05|1970-08-26||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||PATHRESP|PATHOLOGIC RESPONSE||||AMFI|CA125 50% RESPONSE||EVENTS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|N|GUARDIAN|ONCOLOGIST 1|N|4||88||CONTINUATION TREATMENT|1967-04-01||||1968-01-13||1967-01-15|1971-10-01||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||OVRLRESP|OVERALL RESPONSE||||PIXELS/IN|PDU||NKAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|5||7||TREATMENT|1966-12-18||||1972-06-21||1970-10-30|1963-12-06||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/G/MIN|PD FROM PR||10^6 ORGANISMS/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|Y|SIGNIFICANT OTHER|READER|U|5||7||BASELINE|1961-03-14||||1964-02-01||1970-01-10|1962-04-07||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||U.CARR|CPR||PT_BR|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||OBSERVATION|1969-11-11||||1964-10-17||1964-12-20|1966-11-12||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UMOL/H/MMOL|IMPROVED||MEQ/MMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|1||38||CONTINUATION TREATMENT|1969-05-23||||1966-08-10||1970-02-10|1970-11-21||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PLUG|SMD||UG/CM2|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|U|PROXY|ONCOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1969-11-24||||1965-06-06||1962-11-30|1961-01-26||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||NEWLPROG|NEW LESION PROGRESSION||||L/H|CR-CT||ML/KG/H|NOT DONE|||LIKERT SCALE 3-POINT|NA|NA|N|INVESTIGATOR|PATHOLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1960-06-02||||1968-03-04||1969-07-15|1962-08-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||MN|ICR||KIT|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|Y|SIBLING|CARDIOLOGIST|NA|3||39||TREATMENT|1965-02-26||||1966-08-12||1972-08-30|1968-04-15||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||BONERESP|BONE RESPONSE||||VP/ML|IUPD||/10^3|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|U|INVESTIGATOR|ADJUDICATOR|Y|3||39||INDUCTION TREATMENT|1967-06-19||||1963-08-03||1961-06-12|1963-03-30||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||METSIND|METASTATIC INDICATOR||||BREATHS/MIN|RELAPSED DISEASE FROM CR||GY/MIN|NOT DONE|||LIKERT SCALE 5-POINT|N|U|NA|FAMILY MEMBER|RADIOLOGIST|Y|4||88||CONTINUATION TREATMENT|1971-06-10||||1973-08-11||1969-07-06|1968-03-05||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||METSIND|METASTATIC INDICATOR||||PT_US|MORPHOLOGIC CR||AFU|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|4||88||SCREENING|1972-07-26||||1972-08-28||1966-05-01|1961-08-04||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||BESTRESP|BEST OVERALL RESPONSE||||U/M2/DAY|PD-CT||MMOL/MIN/KPA/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|U|CAREGIVER|READER 3|N|5||7||BLINDED TREATMENT|1967-03-20||||1961-04-24||1967-05-02|1971-03-03||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||STRUSTAT|STEROID USE STATUS||||SEC|PCR||PSI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|NA|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1960-06-25||||1963-06-06||1967-07-03|1965-01-17||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||CLINRESP|CLINICAL RESPONSE||||/MONTH|MORPHOLOGIC CR||MIN*MG/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|U|SPOUSE|READER 3|N|1||38||RUN-IN|1964-11-15||||1972-12-07||1964-07-26|1962-05-18||DURING||DURING|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||NTRGRESP|NON-TARGET RESPONSE||||/200 HPFS|ICR||KEV|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|U|N|ADJUDICATOR|CARDIOLOGIST|N|1||38||SCREENING|1961-10-31||||1960-11-08||1970-11-30|1970-06-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||BESTRESP|BEST OVERALL RESPONSE||||ARBITRARY U|EQUIVOCAL||BOTTLE|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|Y|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|2||58||CONTINUATION TREATMENT|1960-05-29||||1966-12-28||1970-01-25|1962-01-01||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||GENEQ/ML|PR||STRIP|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||CONTINUATION TREATMENT|1968-09-26||||1969-03-03||1965-05-02|1966-09-02||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||TRGRESP|TARGET RESPONSE||||CD/M2|MINOR PATHOLOGIC RESPONSE||BOX|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||TREATMENT|1965-06-02||||1965-04-18||1971-03-20|1966-11-01||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||CLINRESP|CLINICAL RESPONSE||||YEARS|SCR||ML/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|INVESTIGATOR|UROLOGIST|NA|3||39||FOLLOW-UP|1961-09-27||||1970-07-17||1963-08-26|1972-07-11||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TSP EQ|MR||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|SIGNIFICANT OTHER|RATER 2|N|4||88||INDUCTION TREATMENT|1968-10-31||||1967-05-12||1970-01-15|1971-12-17||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||SPLNRESP|SPLEEN RESPONSE||||ML/CM H2O|NR||VG/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|Y|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||WASHOUT|1961-02-19||||1962-12-02||1967-03-09|1963-03-04||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||MOLRESP|MOLECULAR RESPONSE||||/LPF|WORSENED||10^6 DNA COPIES/ML|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|NA|PARENT|CLINICAL PATHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1973-03-07||||1962-06-30||1962-06-26|1971-05-20||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||NEWLIND|NEW LESION INDICATOR||||UIU/DL|IPR||SFC/10^6 PBMC|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||BASELINE|1966-02-12||||1964-11-12||1966-04-27|1960-05-01||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||NEWLPROG|NEW LESION PROGRESSION||||ML/CAGE/WK|DISEASE TRANSFORMATION||TITER|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|FAMILY MEMBER|OPTOMETRIST|U|1||38||SCREENING|1970-08-18||||1967-08-19||1963-07-25|1961-07-23||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||SPLNRESP|SPLEEN RESPONSE||||APL U/ML|IMMUNOPHENOTYPIC CR||MOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|U|SIGNIFICANT OTHER|RATER 2|N|1||38||SCREENING|1968-01-24||||1970-04-22||1961-08-01|1964-05-09||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||CLINRESP|CLINICAL RESPONSE||||10^6 ORGANISMS/ML|PSA PROGRESSION||UCI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|U|INVESTIGATOR|ONCOLOGIST 1|Y|2||58||FOLLOW-UP|1973-07-22||||1968-04-29||1963-05-03|1964-12-29||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UG/M2/DAY|CR-CT||SCOOPFUL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|U|NA|SPOUSE|PEDIATRIC NEUROLOGIST|Y|2||58||INDUCTION TREATMENT|1968-05-06||||1962-07-19||1970-08-30|1965-04-25||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||NTRGRESP|NON-TARGET RESPONSE||||10^6 CFU/ML|MORPHOLOGIC CR||JOULE|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|NA|PROXY|INTERNIST|U|3||39||SCREENING|1965-03-30||||1970-07-08||1969-10-14|1970-01-19||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||RDIORESP|RADIOLOGIC RESPONSE||||CD/M2|UNFAVORABLE RESPONSE||MOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|3||39||FOLLOW-UP|1971-07-15||||1961-08-29||1962-09-28|1969-12-28||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UG/M2/DAY|MRD PERSISTENCE||PG/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|VENDOR|ONCOLOGIST|N|4||88||OBSERVATION|1963-10-05||||1964-06-22||1960-05-29|1965-10-14||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||BESTRESP|BEST OVERALL RESPONSE||||MDFI|ICPD||COULOMB|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|U|SPOUSE|READER 3|U|4||88||TREATMENT|1960-05-15||||1964-08-14||1963-11-14|1970-08-09||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||CYTORESP|CYTOGENETIC RESPONSE||||BISCUIT|RELAPSED DISEASE FROM CR OR PR||DAGU/ML|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|INTERVIEWER|READER|NA|5||7||LONG-TERM FOLLOW-UP|1969-11-07||||1966-07-05||1967-02-17|1968-02-07||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||TRGRESP|TARGET RESPONSE||||ML/KG/H|CMR||MGEQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|U|GUARDIAN|PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1970-03-22||||1969-01-12||1964-01-16|1965-03-08||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/MMOL|MOLECULAR MAJOR RESPONSE||HOURS|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|N|FRIEND|PATHOLOGIST 1|N|1||38||INDUCTION TREATMENT|1965-10-04||||1968-07-08||1972-02-19|1965-10-24||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||OVRLRESP|OVERALL RESPONSE||||10^9 ORGANISMS/ML|MRD RELAPSE||10^3 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|N|ADJUDICATOR|RADIOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1962-11-21||||1965-06-08||1968-05-19|1971-03-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||POUCH|DECREASED||MG/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|2||58||INDUCTION TREATMENT|1968-08-11||||1972-06-29||1973-04-30|1970-05-29||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||STRUSTAT|STEROID USE STATUS||||MG/MOL|NON-QUANTIFIABLE MRD POSITIVITY||MEQ/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|2||58||CONTINUATION TREATMENT|1971-11-20||||1967-09-24||1973-01-07|1965-11-15||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||IU/DL|DECREASED||KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|3||39||CONTINUATION TREATMENT|1967-02-27||||1960-07-30||1967-11-10|1969-05-19||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||RDIORESP|RADIOLOGIC RESPONSE||||PPM|PSA PROGRESSION||MMOL/MIN/KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|3||39||INDUCTION TREATMENT|1972-12-18||||1967-05-29||1969-06-13|1973-07-27||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||10^6/EJACULATE U|WORSENED||G/L|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|Y|N|DOMESTIC PARTNER|READER 3|U|4||88||WASHOUT|1967-09-17||||1961-12-06||1971-07-04|1964-10-02||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CPM|HI-N||CAL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|NA|CHILD|INTERNIST|N|4||88||SCREENING|1967-11-01||||1973-05-13||1970-12-27|1966-11-15||AFTER||DURING|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||PMOL/10^10 CELLS|PMR||PPB|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|N|ADJUDICATOR|NEUROLOGIST 2|U|5||7||OBSERVATION|1970-09-10||||1961-07-11||1969-12-05|1968-10-15||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||TRGRESP|TARGET RESPONSE||||MEQ/DAY|TREATMENT FAILURE||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|FRIEND|ADJUDICATOR|NA|5||7||BASELINE|1968-02-27||||1964-03-09||1970-04-25|1961-01-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||TORR|NPR||MOSM|NOT DONE|||LIKERT SCALE 7-POINT|U|N|NA|GUARDIAN|ONCOLOGIST|Y|1||38||FOLLOW-UP|1973-03-02||||1966-07-28||1973-03-23|1971-02-17||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MMOL/S|UNFAVORABLE RESPONSE||MG/KG/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|N|U|DOMESTIC PARTNER|READER 2|U|1||38||OBSERVATION|1968-10-07||||1969-04-03||1971-09-05|1969-07-17||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||V/V|MORPHOLOGIC LEUKEMIA-FREE STATE||/7.5 ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|NA|DOMESTIC PARTNER|PATHOLOGIST|Y|2||58||OBSERVATION|1972-11-30||||1960-07-16||1969-10-15|1970-04-26||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DMOL|CR-CT||G|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|2||58||LONG-TERM FOLLOW-UP|1963-10-06||||1962-02-11||1973-01-17|1960-08-26||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||NEWLIND|NEW LESION INDICATOR||||IU/L|PMD||LOG10 PFU/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|U|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|3||39||BLINDED TREATMENT|1971-12-26||||1970-02-05||1960-02-06|1967-11-27||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||ANATRESP|ANATOMIC RESPONSE||||HPA|OPTIMAL MORPHOLOGIC RESPONSE||FMOL/G|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|U|ADJUDICATION COMMITTEE|INTERNIST|Y|3||39||LONG-TERM FOLLOW-UP|1972-05-10||||1966-06-29||1967-04-19|1973-04-21||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CY/CM|MCR||10^4/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|CAREGIVER|FORENSIC PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1971-03-22||||1967-11-02||1963-08-04|1965-01-08||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||STRUSTAT|STEROID USE STATUS||||MKAT|HI-P||ML/CM3/MIN|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|NA|INDEPENDENT ASSESSOR|RATER|U|4||88||CONTINUATION TREATMENT|1963-07-17||||1966-09-27||1962-11-19|1961-08-22||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||METSIND|METASTATIC INDICATOR||||MOSM/L|IPR||10^12 IU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|FRIEND|RATER|U|5||7||RUN-IN|1963-11-27||||1966-02-18||1966-02-21|1961-12-15||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BQ/G|MORPHOLOGIC CR||RFU|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1971-07-13||||1962-09-20||1971-02-16|1973-05-01||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UMOL/L/H|CR||MEQ/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|NA|CHILD|ADJUDICATOR 2|U|1||38||BASELINE|1973-05-07||||1972-01-25||1962-10-11|1973-08-24||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||CFU/G|MOLECULAR CR||FFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|U|SIGNIFICANT OTHER|READER|U|1||38||INDUCTION TREATMENT|1960-04-21||||1967-09-07||1971-04-03|1971-10-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||STRUSTAT|STEROID USE STATUS||||/LPF|UNEQUIVOCAL||%|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|Y|2||58||TREATMENT|1965-04-28||||1970-03-13||1960-06-23|1969-01-06||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||ANATRESP|ANATOMIC RESPONSE||||LINEAR FT*LB|ABSENT MORPHOLOGIC RESPONSE||10^3/HPF|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|CHILD|INTERNIST|U|2||58||LONG-TERM FOLLOW-UP|1966-05-28||||1964-05-14||1972-04-20|1967-04-19||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||PATHRESP|PATHOLOGIC RESPONSE||||ML/M2/H|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||ENZYME U/G HB|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|N|U|CHILD|NEUROLOGIST|U|3||39||CONTINUATION TREATMENT|1966-07-28||||1967-12-04||1972-06-20|1968-02-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||ANATRESP|ANATOMIC RESPONSE||||L/H/M2|HI-E||TUBERCULIN UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|NA|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|3||39||LONG-TERM FOLLOW-UP|1960-04-17||||1962-10-10||1966-02-07|1962-05-11||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||STRUSTAT|STEROID USE STATUS||||/2500 WBC|QUANTIFIABLE MRD POSITIVITY||10^4/HPF|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|Y|U|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|4||88||BLINDED TREATMENT|1961-10-14||||1964-12-21||1972-07-09|1972-08-09||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||TABLET|MRD RELAPSE||% INHIBITION|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|U|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|4||88||CONTINUATION TREATMENT|1968-07-02||||1963-01-15||1970-08-30|1969-03-17||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||DPM/ML|MRD NEGATIVITY||CI|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|NA|N|FAMILY MEMBER|RATER|N|5||7||LONG-TERM FOLLOW-UP|1967-04-14||||1966-07-18||1968-01-22|1971-12-02||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||METBRESP|METABOLIC RESPONSE||||PELLET|NPR||CM H2O|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|N|Y|SIBLING|PATHOLOGIST 2|Y|5||7||RUN-IN|1965-12-12||||1966-10-14||1968-10-03|1966-08-10||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||PATHRESP|PATHOLOGIC RESPONSE||||DL|MORPHOLOGIC CRI||UIU/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|CLINICAL RESEARCH COORDINATOR|RATER 2|N|1||38||OPEN LABEL TREATMENT|1968-04-15||||1972-07-27||1961-04-01|1968-07-27||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||LOG10 COPIES/ML|CYTOGENETIC NO RESPONSE||LOG10 TCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|N|ADJUDICATOR|MICROSCOPIST 1|U|1||38||WASHOUT|1969-03-03||||1972-11-20||1963-08-17|1967-09-19||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||ANATRESP|ANATOMIC RESPONSE||||UM2|HI-P||UG/L/H|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|U|STUDY SUBJECT|ONCOLOGIST 2|U|2||58||BASELINE|1965-10-23||||1963-01-01||1960-02-22|1966-10-25||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||VOXEL|RELAPSED DISEASE FROM CR OR PR||MU/G|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|INVESTIGATOR|CARDIOLOGIST|NA|2||58||INDUCTION TREATMENT|1962-09-01||||1965-03-20||1971-08-17|1962-04-02||AFTER||DURING|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ML/G/DAY|EQUIVOCAL||VP/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|N|N|DOMESTIC PARTNER|OPTOMETRIST|U|3||39||LONG-TERM FOLLOW-UP|1972-06-16||||1968-10-10||1963-03-18|1972-09-05||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||LIVRRESP|LIVER RESPONSE||||MCI/KG|HI-E||S*KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|STUDY SUBJECT|OPTOMETRIST|N|3||39||TREATMENT|1963-11-14||||1962-08-22||1963-08-08|1968-09-04||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||ANATRESP|ANATOMIC RESPONSE||||/500 WBC|ABSENT MORPHOLOGIC RESPONSE||HOURS|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|4||88||OBSERVATION|1968-12-11||||1971-02-06||1963-04-07|1967-10-22||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||KG/CM2|CMR||UU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|U|VENDOR|DERMATOLOGIST|N|4||88||FOLLOW-UP|1960-08-01||||1960-12-03||1969-03-30|1962-10-07||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||NTRGRESP|NON-TARGET RESPONSE||||PACKAGE|CYTOGENETIC CR||DPM/100MG|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|5||7||INDUCTION TREATMENT|1969-07-03||||1968-04-21||1960-07-16|1962-03-15||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||ML/KG/MIN|NON-CR/NON-PD||FMOL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|5||7||OBSERVATION|1968-12-28||||1971-01-20||1960-09-25|1963-01-22||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/KG/DAY|COMPLETE MRD RESPONSE||G/G|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|INVESTIGATOR|FORENSIC PATHOLOGIST|Y|1||38||OBSERVATION|1969-05-24||||1969-05-02||1969-06-04|1972-12-07||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||EIA UNIT|ICR||PMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1964-12-22||||1961-11-11||1973-05-30|1970-02-12||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||LOG10 CFU/G|MORPHOLOGIC LEUKEMIA-FREE STATE||10^3 ORGANISMS/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|Y|CLINICAL RESEARCH COORDINATOR|READER 1|Y|2||58||LONG-TERM FOLLOW-UP|1961-03-04||||1962-01-03||1965-01-27|1972-10-03||AFTER||DURING|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||NEWLPROG|NEW LESION PROGRESSION||||UG/ANIMAL|PR||MOL/G|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|2||58||OBSERVATION|1960-05-15||||1963-05-29||1964-08-19|1960-09-16||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||ANTI-XA IU/ML|TREATMENT FAILURE||PELLET|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|U|NA|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|3||39||OPEN LABEL TREATMENT|1973-07-22||||1963-03-29||1960-09-08|1964-01-06||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||DEG2|CHR||GPS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|NA|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3||39||BASELINE|1963-04-14||||1961-05-21||1962-10-05|1972-02-23||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LOG10 COPIES/ML|DISEASE TRANSFORMATION||ML/DL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|SPOUSE|MICROSCOPIST 2|N|4||88||SCREENING|1962-04-23||||1972-02-17||1970-01-31|1963-05-25||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||RDIORESP|RADIOLOGIC RESPONSE||||UIU/L|RELAPSED DISEASE||UG/MOL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BLINDED TREATMENT|1970-05-18||||1970-07-13||1969-02-23|1961-10-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||MOL/DAY|NR||ROENTGEN|NOT DONE|||LIKERT SCALE 7-POINT|NA|N|NA|VENDOR|READER|NA|5||7||BLINDED TREATMENT|1963-12-12||||1965-11-03||1966-06-23|1973-05-25||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CFU/ML|DECREASED||MMHG/SEC|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5||7||WASHOUT|1967-04-05||||1967-01-15||1972-12-06|1963-04-01||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||OVRLRESP|OVERALL RESPONSE||||U/G HB|MINOR PATHOLOGIC RESPONSE||MG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|U|N|FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|1||38||WASHOUT|1961-09-14||||1972-03-24||1967-07-16|1971-05-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||SPLNRESP|SPLEEN RESPONSE||||10^5/L|NON-CR/NON-PD||PACKET|NOT DONE|||LIKERT SCALE 3-POINT|Y|NA|NA|VENDOR|ADJUDICATOR 2|N|1||38||CONTINUATION TREATMENT|1964-07-11||||1972-03-20||1960-02-15|1969-10-30||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||BONERESP|BONE RESPONSE||||UCI|MORPHOLOGIC CR||F|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|FRIEND|ADJUDICATOR 3|N|2||58||RUN-IN|1961-02-02||||1961-06-07||1968-09-27|1963-12-18||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||PG/DL|TREATMENT FAILURE||ELISA UNIT/ML|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|U|PARENT|PEDIATRIC NEUROLOGIST|N|2||58||OBSERVATION|1970-03-26||||1969-04-30||1963-06-04|1973-07-11||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||NEWLIND|NEW LESION INDICATOR||||ML/DAY|TREATMENT FAILURE||ELISA UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|NA|FRIEND|NEUROLOGIST|N|3||39||BLINDED TREATMENT|1960-08-08||||1964-06-30||1961-11-25|1972-04-09||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||10^6 IU|ICPD||TROCHE|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|3||39||OPEN LABEL TREATMENT|1963-12-28||||1972-12-02||1971-08-12|1972-12-23||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||/WK|NE||MPL U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|4||88||RUN-IN|1966-11-16||||1962-09-11||1972-04-28|1972-06-26||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MIN*MG/ML|NED||/DAY|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|CAREGIVER|MICROSCOPIST|NA|4||88||OPEN LABEL TREATMENT|1970-12-07||||1966-06-14||1963-05-18|1964-06-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||TMRESP|TUMOR MARKER RESPONSE||||GPELISA UNIT/ML|ICPD||OZ EQ|NOT DONE|||LIKERT SCALE 5-POINT|N|N|Y|VENDOR|ONCOLOGIST 1|U|5||7||RUN-IN|1963-03-22||||1971-12-02||1973-01-28|1967-06-19||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||PATHRESP|PATHOLOGIC RESPONSE||||CFU/G|CHR||RING|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|U|Y|CHILD|PHYSIOTHERAPIST|N|5||7||INDUCTION TREATMENT|1967-10-19||||1971-05-20||1960-02-11|1960-03-14||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||SPLNRESP|SPLEEN RESPONSE||||MSEC|MRD PERSISTENCE||UIU/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|NA|NA|GUARDIAN|OPHTHALMOLOGIST|U|1||38||OPEN LABEL TREATMENT|1963-04-12||||1968-01-31||1968-11-11|1962-04-01||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||BONERESP|BONE RESPONSE||||NGEQ/L|HI-P||FRAMES/S|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|NA|NA|PROXY|RADIOLOGIST 1|NA|1||38||OBSERVATION|1968-04-27||||1966-04-17||1962-06-27|1966-06-03||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||TMRESP|TUMOR MARKER RESPONSE||||DRUM|CCR||UCI/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|NA|N|FAMILY MEMBER|NEUROLOGIST 1|U|2||58||WASHOUT|1960-12-11||||1966-07-15||1968-10-08|1973-03-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||TROCHE|HI-N||PFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|U|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|2||58||FOLLOW-UP|1968-04-29||||1969-10-26||1969-08-04|1965-01-26||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||EVENTS|PARTIAL MORPHOLOGIC RESPONSE||SCM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|N|U|SPOUSE|RATER 2|NA|3||39||LONG-TERM FOLLOW-UP|1964-09-08||||1965-11-30||1961-02-17|1966-09-18||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||NTRGRESP|NON-TARGET RESPONSE||||MMOL2/L2|PD-CT||UMOL/L/SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|3||39||BLINDED TREATMENT|1966-09-17||||1962-06-30||1972-04-11|1967-05-25||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||ROENTGEN|IUPD||UU/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1966-05-30||||1965-07-15||1961-08-29|1973-07-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||CYTORESP|CYTOGENETIC RESPONSE||||COPIES/ML|FAVORABLE RESPONSE||COPIES/UL|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|CAREGIVER|ADJUDICATOR 1|U|4||88||RUN-IN|1960-06-21||||1965-06-26||1971-01-28|1971-09-30||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||DROP|ICPD||PHERESIS UNIT|NOT DONE|||LIKERT SCALE 3-POINT|NA|N|N|VENDOR|HEMATOLOGIST|U|5||7||OBSERVATION|1968-10-12||||1960-02-02||1970-02-03|1967-03-30||DURING||DURING|
TRIAL STUDY 134XCP|RS|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MN|ICPD||UMOL/L/H|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|N|SPOUSE|MICROSCOPIST 1|U|5||7||RUN-IN|1961-03-12||||1966-09-04||1964-01-28|1963-10-24||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||CAPFUL|RELAPSED DISEASE||10^7 TCID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|U|FRIEND|ADJUDICATOR 3|Y|1||38||OPEN LABEL TREATMENT|1969-12-28||||1966-12-25||1971-05-16|1963-04-29||DURING||AFTER|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||BESTRESP|BEST OVERALL RESPONSE||||MONTHS|UNEQUIVOCAL||STRIP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|1||38||SCREENING|1960-08-02||||1970-07-19||1967-02-26|1966-02-19||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||ANATRESP|ANATOMIC RESPONSE||||/HPF|PARTIAL MORPHOLOGIC RESPONSE||PATCH|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|N|PROXY|INTERNIST|N|2||58||SCREENING|1969-06-24||||1961-02-23||1967-09-08|1970-03-15||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||CGY|CYTOGENETIC PR||DRUM|NOT DONE|||LIKERT SCALE 3-POINT|N|N|N|PROXY|READER 1|NA|2||58||TREATMENT|1967-07-30||||1969-05-17||1972-11-29|1969-10-09||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MG/H|PR||DPM/100MG|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|N|NA|SPOUSE|RADIOLOGIST 2|N|3||39||OBSERVATION|1967-12-19||||1968-06-01||1966-03-22|1963-07-27||AFTER||DURING|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||WEBER|IUPD||SCM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|U|FAMILY MEMBER|NEUROLOGIST 2|NA|3||39||INDUCTION TREATMENT|1970-06-09||||1960-12-31||1973-09-06|1970-09-18||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||SPLNRESP|SPLEEN RESPONSE||||BQ/MG|PD/RELAPSE AFTER HI||BOWL|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|N|INTERVIEWER|ADJUDICATOR 1|Y|4||88||SCREENING|1969-06-06||||1960-06-03||1973-06-16|1971-01-19||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||TSP|UNFAVORABLE RESPONSE||CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|U|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4||88||LONG-TERM FOLLOW-UP|1963-08-01||||1963-10-21||1969-10-13|1968-02-08||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||FMOL|PCR||CI/KG|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|5||7||RUN-IN|1961-07-04||||1968-02-11||1963-07-24|1970-01-23||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^9/DOSE|HI-N||PIXEL|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|NA|PROXY|NEUROLOGIST|N|5||7||TREATMENT|1960-12-27||||1966-08-03||1972-09-13|1970-09-16||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MMHG/L/MIN|ICPD||HPA|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|U|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|1||38||TREATMENT|1965-12-16||||1971-05-29||1967-02-22|1970-12-09||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||GPL U|MOLECULAR CR||DISK|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|N|CHILD|RADIOLOGIST 1|N|1||38||WASHOUT|1967-04-05||||1966-12-07||1973-04-22|1970-11-23||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||KBQ/UL|PSEUDOPROGRESSION||CI/ML|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|INVESTIGATOR|MICROSCOPIST 1|NA|2||58||OBSERVATION|1960-08-01||||1966-01-12||1964-03-06|1970-08-22||DURING||AFTER|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||BESTRESP|BEST OVERALL RESPONSE||||UMOL/L/MIN|CYTOGENETIC NO RESPONSE||MEQ/UG|NOT DONE|||LIKERT SCALE 7-POINT|U|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST|Y|2||58||FOLLOW-UP|1964-04-24||||1968-03-01||1962-11-16|1960-02-07||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||NMOL BCE/MMOL|NPR||UMOL/KG/MIN|NOT DONE|||LIKERT SCALE 5-POINT|U|U|U|VENDOR|NEUROLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1969-05-31||||1964-07-22||1967-12-09|1968-12-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||CLINRESP|CLINICAL RESPONSE||||/DAY|CA125 75% RESPONSE||MESF|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|GUARDIAN|NEUROLOGIST 1|U|3||39||INDUCTION TREATMENT|1964-05-28||||1964-01-24||1968-06-19|1962-12-15||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||SUPPOSITORY|UNEQUIVOCAL||GTT|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|Y|VENDOR|PATHOLOGIST 2|NA|4||88||FOLLOW-UP|1962-10-16||||1966-09-30||1967-05-23|1964-09-07||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||RDIORESP|RADIOLOGIC RESPONSE||||GBQ|SD-CT||RATIO|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|4||88||FOLLOW-UP|1961-12-27||||1966-06-29||1963-05-10|1969-12-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||MG/KG/DOSE|MORPHOLOGIC CR||10^5/HPF|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|NA|N|INTERVIEWER|READER 2|Y|5||7||BASELINE|1972-01-02||||1967-03-28||1961-05-22|1968-01-26||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||LOG10 TCID 50/ML|NON-PD||GY/H|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|U|PARENT|UROLOGIST|NA|5||7||OPEN LABEL TREATMENT|1969-10-05||||1970-04-22||1973-05-17|1960-09-30||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||BONERESP|BONE RESPONSE||||CONTAINER|HI-P||% INHIBITION|NOT DONE|||LIKERT SCALE 5-POINT|NA|NA|NA|CAREGIVER|RADIOLOGIST 1|N|1||38||INDUCTION TREATMENT|1969-10-11||||1970-07-23||1960-12-25|1966-04-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||FMOL/L/SEC|CMR||MASK|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|U|N|STUDY SUBJECT|ADJUDICATOR 1|Y|1||38||SCREENING|1966-08-29||||1972-02-26||1967-04-01|1960-02-07||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UM2|HI-P||EID 50/DOSE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|Y|ADJUDICATOR|PATHOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1964-08-10||||1964-06-05||1967-12-13|1968-11-15||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MG/ML/MIN|CYTOGENETIC CR||MV*MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|U|PARENT|PATHOLOGIST 1|NA|2||58||FOLLOW-UP|1969-10-23||||1972-12-12||1962-05-29|1969-03-18||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||BEL|NR||10^7 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|U|NA|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|3||39||SCREENING|1968-08-11||||1973-02-08||1962-11-03|1970-09-11||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||AG|MOLECULAR CR||PNU/ML|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|Y|SPOUSE|MICROSCOPIST|NA|3||39||LONG-TERM FOLLOW-UP|1970-07-28||||1961-11-16||1960-01-11|1969-02-13||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||SPLNRESP|SPLEEN RESPONSE||||MN|CCR||G/G|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|U|N|NA|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1960-01-11||||1971-07-07||1967-08-27|1969-03-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||PFU/DOSE|CYTOGENETIC CR||10^3 ORGANISMS/G|NOT DONE|||LIKERT SCALE 7-POINT|Y|N|NA|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BLINDED TREATMENT|1968-08-14||||1969-03-29||1962-03-19|1970-02-26||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||CYTORESP|CYTOGENETIC RESPONSE||||STRIP|NED||PSI|NOT DONE|||LIKERT SCALE 7-POINT|U|U|N|SIBLING|READER 3|Y|5||7||BLINDED TREATMENT|1963-03-16||||1962-01-28||1964-09-21|1966-03-13||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||NEWLPROG|NEW LESION PROGRESSION||||MM2|UNEQUIVOCAL||MG/MOL|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|U|U|SPOUSE|PATHOLOGIST 1|Y|5||7||TREATMENT|1970-09-09||||1960-05-07||1965-04-15|1970-03-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||CAN|MRD PERSISTENCE||MG/M2/DAY|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|Y|SPOUSE|READER 1|NA|1||38||FOLLOW-UP|1968-12-02||||1968-07-10||1967-05-04|1964-10-16||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||NTRGRESP|NON-TARGET RESPONSE||||PFU/DOSE|CPR||MBQ/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|NA|NA|FRIEND|RATER|Y|1||38||BLINDED TREATMENT|1961-11-27||||1962-02-01||1963-08-12|1960-05-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||CYTORESP|CYTOGENETIC RESPONSE||||USEC|PCR||OZ EQ|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|U|Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|2||58||BASELINE|1971-10-14||||1967-11-04||1966-03-07|1967-08-30||UNKNOWN||AFTER|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||%/MIN|PARTIAL MORPHOLOGIC RESPONSE||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|SIBLING|INTERNIST|N|2||58||FOLLOW-UP|1960-05-26||||1963-08-04||1961-10-22|1964-10-02||DURING||DURING|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||CLINRESP|CLINICAL RESPONSE||||DAGU/ML|PD FROM PR||EIA UNIT|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1961-03-13||||1960-08-23||1966-07-30|1968-07-07||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||PATHRESP|PATHOLOGIC RESPONSE||||NMOL/G|RELAPSED DISEASE||PRESSOR UNITS|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|Y|Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|3||39||INDUCTION TREATMENT|1965-07-12||||1969-12-18||1973-05-31|1972-06-10||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||METBRESP|METABOLIC RESPONSE||||PACK YEAR|CA125 50% RESPONSE||ANTI-XA IU|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|PROXY|NEUROLOGIST 2|N|4||88||INDUCTION TREATMENT|1971-09-12||||1961-05-08||1967-02-06|1960-07-26||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||UG|SD-CT||MG/H|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|NA|ADJUDICATION COMMITTEE|READER 1|U|4||88||WASHOUT|1963-12-18||||1970-12-07||1964-10-16|1966-02-06||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||METSIND|METASTATIC INDICATOR||||PG/DL|WORSENED||KG/M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|N|INVESTIGATOR|OTOLARYNGOLOGIST|N|5||7||WASHOUT|1963-08-30||||1972-08-08||1972-09-12|1964-02-14||DURING||DURING|
TRIAL STUDY 134XCP|RS|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||DEG2|NPR||PPM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|5||7||CONTINUATION TREATMENT|1971-04-14||||1968-06-03||1972-08-10|1973-04-06||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||NTRGRESP|NON-TARGET RESPONSE||||RATIO|IPR||G/KG/DAY|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|INTERVIEWER|READER 3|Y|1||38||LONG-TERM FOLLOW-UP|1967-08-09||||1966-07-07||1964-07-25|1971-01-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||IU/KG/H|CMR||C|NOT DONE|||VERBAL RATING SCALE 4-POINT|N|Y|N|SIGNIFICANT OTHER|PATHOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1971-09-03||||1962-11-09||1960-10-06|1969-09-13||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||METSIND|METASTATIC INDICATOR||||PNU/ML|PDU||NMOL BCE/MMOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1972-10-17||||1963-02-25||1970-09-10|1967-09-29||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||METBRESP|METABOLIC RESPONSE||||BU/ML|CYTOGENETIC MINOR RESPONSE||/CMH2O|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|N|VENDOR|READER|Y|2||58||BLINDED TREATMENT|1971-04-25||||1964-05-24||1967-10-29|1973-04-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PG/L|NE||PKAT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|NA|Y|FAMILY MEMBER|PATHOLOGIST 1|Y|3||39||FOLLOW-UP|1966-06-23||||1968-07-06||1968-11-28|1970-07-04||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||U/KG/H|WORSENED||U/G/MIN|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|3||39||OBSERVATION|1969-11-04||||1964-06-11||1964-08-06|1973-01-19||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||RDIORESP|RADIOLOGIC RESPONSE||||YD|NR||SQU/ML|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|U|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||OBSERVATION|1960-10-12||||1967-02-26||1961-11-02|1965-03-07||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||MASK|PMR||V/V|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|U|INDEPENDENT ASSESSOR|RATER 1|N|4||88||SCREENING|1967-04-11||||1965-02-22||1969-12-25|1965-01-22||DURING||DURING|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||METSIND|METASTATIC INDICATOR||||G/DL|MOLECULAR CR||CAPLET|NOT DONE|||LIKERT SCALE 7-POINT|NA|U|Y|ADJUDICATOR|RADIOLOGIST 2|U|5||7||TREATMENT|1960-12-31||||1961-10-13||1971-05-20|1972-02-01||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||CYTORESP|CYTOGENETIC RESPONSE||||JAR|INDETERMINATE RESPONSE||MESF|NOT DONE|||LIKERT SCALE 5-POINT|N|U|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||TREATMENT|1972-07-09||||1964-06-06||1967-02-19|1963-11-08||DURING||DURING|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||SPLNRESP|SPLEEN RESPONSE||||ML/ANIMAL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||SIEMENS|NOT DONE|||LIKERT SCALE 5-POINT|U|N|Y|CHILD|RATER 2|U|1||38||CONTINUATION TREATMENT|1972-10-30||||1965-03-21||1965-08-09|1960-04-03||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||METBRESP|METABOLIC RESPONSE||||CI/KG|CCR||M2|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|FRIEND|MICROSCOPIST|Y|1||38||CONTINUATION TREATMENT|1966-08-24||||1969-12-07||1972-06-25|1969-06-29||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||LIVRRESP|LIVER RESPONSE||||PT_BR|INCREASED||MG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|NA|CHILD|PATHOLOGIST 1|U|2||58||BLINDED TREATMENT|1963-01-26||||1965-05-08||1963-03-06|1964-11-25||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||ML/DAY|NED||BQ/ML|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|INTERVIEWER|RADIOLOGIST 1|N|2||58||SCREENING|1970-04-16||||1965-10-11||1967-02-14|1967-02-19||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||OVRLRESP|OVERALL RESPONSE||||FIU|SMD||UOSM|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|Y|CAREGIVER|ONCOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1972-06-12||||1964-06-28||1965-01-09|1961-02-11||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||SPLNRESP|SPLEEN RESPONSE||||LOG10 COPIES/ML|MINOR PATHOLOGIC RESPONSE||CUP|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|Y|CLINICAL STUDY SPONSOR|RATER 1|Y|3||39||RUN-IN|1963-03-04||||1963-06-07||1962-11-01|1960-01-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||L/MIN|MRD RELAPSE||UEQ/L|NOT DONE|||LIKERT SCALE 3-POINT|Y|Y|U|INTERVIEWER|MICROSCOPIST 1|Y|4||88||RUN-IN|1964-02-15||||1969-03-11||1966-06-16|1972-08-21||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||STRUSTAT|STEROID USE STATUS||||U/MMOL|NE||G|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|NA|FRIEND|NEUROLOGIST 1|NA|4||88||INDUCTION TREATMENT|1960-10-05||||1973-02-22||1970-04-07|1965-06-16||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||CLINRESP|CLINICAL RESPONSE||||ENZYME U|SCR||/KG|NOT DONE|||LIKERT SCALE 5-POINT|U|Y|Y|CAREGIVER|RADIOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1962-10-11||||1963-02-20||1965-02-03|1971-10-30||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/CAGE/DAY|INDETERMINATE RESPONSE||DAMOL/L|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|U|ADJUDICATOR|ADJUDICATOR 2|U|5||7||OBSERVATION|1971-05-12||||1963-07-28||1962-04-06|1964-01-07||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||UMOL/DAY|CA125 50% RESPONSE||IN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|INDEPENDENT ASSESSOR|DERMATOLOGIST|N|1||38||BASELINE|1961-11-09||||1971-06-18||1965-10-08|1968-11-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/MOL|CR||COAT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|N|U|PROXY|MICROSCOPIST 2|NA|1||38||OPEN LABEL TREATMENT|1968-03-16||||1972-06-11||1973-05-20|1966-09-30||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||METSIND|METASTATIC INDICATOR||||UCI/L|PD FROM PR||LOG EID 50/DOSE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|N|U|GUARDIAN|PATHOLOGIST 2|NA|2||58||BASELINE|1963-06-07||||1963-05-27||1970-12-19|1970-09-04||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||ABSORBANCE U/ML|DISEASE TRANSFORMATION||TORR|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|2||58||WASHOUT|1972-09-10||||1966-04-12||1967-03-06|1969-04-12||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||MOLRESP|MOLECULAR RESPONSE||||NMOL|SMD||LOG10 TCID 50/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|3||39||SCREENING|1960-02-04||||1967-06-29||1967-07-25|1969-01-17||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||UG/G/MIN|PDU||BOX|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|NA|STUDY SUBJECT|INTERNIST|U|3||39||BLINDED TREATMENT|1963-03-11||||1968-06-25||1962-07-06|1968-08-27||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||METBRESP|METABOLIC RESPONSE||||UMOL/DAY|MORPHOLOGIC CRI||AFU|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|NA|N|PARENT|OTOLARYNGOLOGIST|N|4||88||OBSERVATION|1966-07-16||||1963-07-04||1969-01-19|1973-04-15||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||OZ EQ|FAVORABLE RESPONSE||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|CHILD|UROLOGIST|N|4||88||OBSERVATION|1966-03-23||||1973-08-10||1961-11-29|1963-02-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||METBRESP|METABOLIC RESPONSE||||/4.0 ML|CA125 50% RESPONSE||V|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|Y|DOMESTIC PARTNER|RADIOLOGIST 1|N|5||7||TREATMENT|1962-05-21||||1971-11-03||1962-01-03|1972-09-08||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||NTRGRESP|NON-TARGET RESPONSE||||TBSP|NE||MET*H|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|Y|U|SPOUSE|ADJUDICATOR|NA|5||7||BLINDED TREATMENT|1960-01-13||||1961-04-11||1968-06-18|1969-04-28||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||OVRLRESP|OVERALL RESPONSE||||G/CM2|PD||OD UNIT|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|CAREGIVER|RATER 2|N|1||38||CONTINUATION TREATMENT|1963-08-26||||1968-12-19||1962-11-05|1962-06-13||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||PPTR|CYTOGENETIC PR||UCI/KG|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|1||38||CONTINUATION TREATMENT|1963-11-01||||1964-08-26||1965-05-31|1961-01-06||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||IMPLANT|ICR||M2|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|N|U|ADJUDICATOR|RATER 2|N|2||58||INDUCTION TREATMENT|1965-04-03||||1972-12-24||1969-09-04|1961-03-31||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||CI/L|RELAPSED DISEASE FROM CR||CI|NOT DONE|||LIKERT SCALE 5-POINT|U|U|NA|PROXY|PHYSIOTHERAPIST|Y|2||58||OBSERVATION|1971-06-03||||1972-09-01||1966-01-31|1961-05-04||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/H|MRD RELAPSE||FT3|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|NA|CAREGIVER|RATER 1|U|3||39||TREATMENT|1971-11-18||||1966-03-25||1966-12-06|1969-09-30||DURING||AFTER|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||PATHRESP|PATHOLOGIC RESPONSE||||ARBITRARY U|NON-ICR/NON-IUPD||C|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|PROXY|MICROSCOPIST 3|NA|3||39||SCREENING|1962-09-16||||1967-05-11||1968-11-24|1960-07-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||10^3 RNA COPIES/ML|MRD RELAPSE||COPIES/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|N|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|4||88||SCREENING|1972-03-03||||1962-11-13||1964-02-18|1971-07-13||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||U/G/DAY|PMR||AMOL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|N|Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|4||88||OBSERVATION|1970-10-19||||1972-02-08||1961-01-16|1968-08-23||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||LIVRRESP|LIVER RESPONSE||||U/ANIMAL|RELAPSED DISEASE||MG/L|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|NA|NA|INVESTIGATOR|ADJUDICATOR 1|N|5||7||BASELINE|1972-04-27||||1973-08-31||1972-10-21|1963-08-29||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||OVRLRESP|OVERALL RESPONSE||||PG|SMD||PIXELS/CM|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|5||7||SCREENING|1969-01-11||||1964-05-26||1972-08-22|1966-12-29||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||G/G/DAY|PR||ANTI-XA IU/ML|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|NA|STUDY SUBJECT|PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1960-12-31||||1961-07-06||1970-12-20|1973-03-04||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||TAMPON|WORSENED||NKAT/G HB|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|GUARDIAN|MICROSCOPIST 2|Y|1||38||CONTINUATION TREATMENT|1969-02-04||||1970-01-31||1962-03-10|1970-10-27||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG/M2|MR||LOG10 ELISA UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|2||58||FOLLOW-UP|1968-01-30||||1962-05-15||1972-10-23|1964-10-18||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||TRGRESP|TARGET RESPONSE||||MJOULE/CM2|PD/RELAPSE AFTER HI||V|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|N|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||BASELINE|1962-05-07||||1967-06-15||1970-06-18|1963-02-10||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||BQ|PD/RELAPSE AFTER HI||NG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 2|U|3||39||WASHOUT|1968-02-14||||1961-11-20||1969-07-09|1967-11-09||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||NEWLPROG|NEW LESION PROGRESSION||||10^9/G|SMD||10^3 CFU/ML|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|3||39||SCREENING|1971-08-11||||1963-10-30||1967-02-18|1972-11-17||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||DYN|COMPLETE MRD RESPONSE||/10^5|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|NA|STUDY SUBJECT|ADJUDICATOR 3|U|4||88||INDUCTION TREATMENT|1972-05-26||||1971-12-18||1969-04-24|1966-12-11||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||METSIND|METASTATIC INDICATOR||||IU/DL|CCR||MPS U|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|U|Y|SIGNIFICANT OTHER|RADIOLOGIST 1|N|4||88||TREATMENT|1966-08-20||||1960-01-12||1960-08-31|1963-10-10||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||RDIORESP|RADIOLOGIC RESPONSE||||L/H/M2|CA125 50% RESPONSE||CAL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|NA|FRIEND|ONCOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1973-07-10||||1961-11-17||1963-08-20|1961-09-17||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||100 IU/ML|ABSENT MORPHOLOGIC RESPONSE||/2000 RBC|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|Y|HEALTH CARE PROFESSIONAL|READER 3|N|5||7||INDUCTION TREATMENT|1966-10-31||||1962-07-13||1960-06-23|1965-10-17||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FMOL/G|MRD NEGATIVITY||ML/DL|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|ADJUDICATOR|ONCOLOGIST 2|NA|1||38||CONTINUATION TREATMENT|1971-09-27||||1962-05-19||1964-01-20|1962-05-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||U/10^12 RBC|OPTIMAL MORPHOLOGIC RESPONSE||CMOL/L|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|N|NA|PROXY|CLINICAL PATHOLOGIST|N|1||38||RUN-IN|1969-03-31||||1960-02-13||1962-05-08|1971-04-02||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||PELLET|ISD||MOL/MOL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|U|2||58||BASELINE|1965-04-27||||1970-09-13||1970-04-11|1963-12-03||DURING/AFTER||AFTER|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||10^9 CFU/G|PMR||10^9 ORGANISMS|NOT DONE|||LIKERT SCALE 5-POINT|U|N|U|FRIEND|OPTOMETRIST|Y|2||58||WASHOUT|1961-04-06||||1964-03-29||1971-10-18|1968-02-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||BONERESP|BONE RESPONSE||||JAR|NED||BEAM BREAKS|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|INVESTIGATOR|NEUROLOGIST 2|NA|3||39||FOLLOW-UP|1963-06-17||||1965-08-19||1961-04-28|1973-02-04||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||CYTORESP|CYTOGENETIC RESPONSE||||S^-1(%O2)^-1|PCR||MBQ/UL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|U|SIGNIFICANT OTHER|MICROSCOPIST 3|U|3||39||LONG-TERM FOLLOW-UP|1962-03-31||||1960-08-25||1970-07-29|1971-07-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||MMOL/MOL|CYTOGENETIC CR||M|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|N|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|4||88||WASHOUT|1960-02-10||||1968-01-05||1973-08-29|1965-01-07||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||IU|MORPHOLOGIC CRI||VIAL|NOT DONE|||LIKERT SCALE 7-POINT|U|Y|N|SPOUSE|ENDOCRINOLOGIST|Y|4||88||FOLLOW-UP|1968-07-13||||1966-01-28||1969-04-19|1968-05-19||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||U/KG/DAY|EQUIVOCAL||KEV|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|N|5||7||SCREENING|1967-06-14||||1970-11-21||1961-06-15|1973-06-03||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||METBRESP|METABOLIC RESPONSE||||NMOL/DAY|NON-QUANTIFIABLE MRD POSITIVITY||TESLA|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|N|NA|CHILD|RADIOLOGIST 2|U|5||7||SCREENING|1967-12-25||||1971-11-22||1966-03-02|1960-06-07||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||MOLRESP|MOLECULAR RESPONSE||||LOG10 ELISA UNIT/DOSE|MINOR PATHOLOGIC RESPONSE||MG/M2/DAY|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|NA|U|FAMILY MEMBER|PATHOLOGIST 2|U|1||38||WASHOUT|1960-01-21||||1961-06-19||1971-07-21|1961-11-05||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||NTRGRESP|NON-TARGET RESPONSE||||TRANSDUCING UNIT|RELAPSED DISEASE FROM CR||ML/ANIMAL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|1||38||FOLLOW-UP|1971-05-06||||1972-04-30||1968-06-27|1967-09-24||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||CLINRESP|CLINICAL RESPONSE||||10^3 CFU/ML|NE||%|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|N|N|DOMESTIC PARTNER|ADJUDICATOR 2|U|2||58||FOLLOW-UP|1972-07-14||||1968-08-15||1963-12-08|1969-05-22||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||MRPHRESP|MORPHOLOGIC RESPONSE||||FFU|PR-CT||PG/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|2||58||SCREENING|1965-03-19||||1960-07-29||1966-10-20|1968-11-23||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||SPLNRESP|SPLEEN RESPONSE||||UMOL/DL|HI-P||MG/DL|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|Y|FAMILY MEMBER|READER 2|N|3||39||WASHOUT|1966-05-16||||1961-05-02||1963-06-09|1963-03-23||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||MOLRESP|MOLECULAR RESPONSE||||ML/SEC/1.73M2|CMR||PFU/ANIMAL|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|Y|U|SIBLING|RADIOLOGIST|N|3||39||FOLLOW-UP|1966-12-29||||1966-11-14||1965-04-29|1972-12-20||BEFORE||DURING|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||NTRGRESP|NON-TARGET RESPONSE||||MG/KG/H|CYTOGENETIC NO RESPONSE||/2500 WBC|NOT DONE|||VERBAL RATING SCALE 4-POINT|Y|U|U|PARENT|OPHTHALMOLOGIST|N|4||88||OPEN LABEL TREATMENT|1971-08-16||||1963-01-01||1968-07-04|1965-12-18||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||OVRLRESP|OVERALL RESPONSE||||AMOL|PSEUDOPROGRESSION||LOG10 TCID 50/UL|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|Y|NA|SIGNIFICANT OTHER|RATER|N|4||88||TREATMENT|1972-05-13||||1960-08-07||1966-01-07|1961-07-10||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||PATHRESP|PATHOLOGIC RESPONSE||||L/DAY|NON-CR/NON-PD||NMOL/ML/MIN|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|N|N|INTERVIEWER|ADJUDICATOR 1|NA|5||7||TREATMENT|1961-03-12||||1963-12-06||1970-05-27|1969-02-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||BONERESP|BONE RESPONSE||||ANSON U|UNEQUIVOCAL||KUSP|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|N|Y|SIBLING|RADIOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1968-08-23||||1968-08-07||1967-09-14|1972-02-22||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||CLINRESP|CLINICAL RESPONSE||||/MBP|RELAPSED DISEASE FROM CR||/VF|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|Y|VENDOR|OTOLARYNGOLOGIST|Y|1||38||CONTINUATION TREATMENT|1973-07-29||||1963-09-24||1960-08-28|1968-11-27||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||ML/S/M2|HI-N||UM/S|NOT DONE|||LIKERT SCALE 3-POINT|N|Y|Y|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|N|1||38||FOLLOW-UP|1961-07-27||||1967-08-17||1968-01-30|1966-02-15||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||NEWLIND|NEW LESION INDICATOR||||G/M2/DAY|RELAPSED DISEASE FROM CR||PMOL/L/H|NOT DONE|||LIKERT SCALE 5-POINT|U|N|N|INTERVIEWER|NEUROLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1963-02-01||||1964-11-10||1970-02-14|1971-09-10||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||METBRESP|METABOLIC RESPONSE||||U/KG|HI-N||ATM|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1965-07-30||||1967-03-29||1964-03-19|1970-01-30||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||NEWLPROG|NEW LESION PROGRESSION||||COPIES/UL|DISEASE TRANSFORMATION||SHOCK WAVE|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|Y|INVESTIGATOR|ONCOLOGIST 1|NA|3||39||TREATMENT|1964-09-07||||1968-11-17||1969-03-26|1961-12-28||COINCIDENT||UNKNOWN|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||TROCHE|NON-CR/NON-PD||KHZ|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|NA|Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1967-06-14||||1964-07-07||1962-02-07|1973-07-28||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||PA|MR||10^4 CFU/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|NA|Y|SIBLING|NEUROLOGIST|N|4||88||INDUCTION TREATMENT|1972-01-26||||1969-01-30||1969-06-22|1961-05-30||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||TMRESP|TUMOR MARKER RESPONSE||||S*KPA|NED||10^9/L|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|N|SPOUSE|ENDOCRINOLOGIST|N|4||88||OPEN LABEL TREATMENT|1966-04-29||||1962-02-02||1962-09-03|1968-01-10||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||METBRESP|METABOLIC RESPONSE||||ML/KG|HI-P||HR/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|NA|INTERVIEWER|READER 2|N|5||7||TREATMENT|1967-09-26||||1970-09-20||1968-02-09|1960-08-30||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||LIVRRESP|LIVER RESPONSE||||EU|CHR||NCI|NOT DONE|||LIKERT SCALE 3-POINT|U|U|N|CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|5||7||OBSERVATION|1966-03-17||||1969-03-10||1964-08-28|1966-08-09||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||UGEQ/L|MOLECULAR MAJOR RESPONSE||PACK|NOT DONE|||LIKERT SCALE 7-POINT|N|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|1||38||BASELINE|1962-09-30||||1965-04-01||1965-12-07|1968-03-18||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||STRUSTAT|STEROID USE STATUS||||BREATHS/MIN|MCR||NU/CL|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|Y|NA|FRIEND|PATHOLOGIST|Y|1||38||WASHOUT|1969-06-17||||1966-06-17||1960-09-09|1969-08-01||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||TRGRESP|TARGET RESPONSE||||U/M2/MIN|OPTIMAL MORPHOLOGIC RESPONSE||ML/(MIN*100ML)|NOT DONE|||LIKERT SCALE 7-POINT|NA|Y|N|SPOUSE|MICROSCOPIST|Y|2||58||BLINDED TREATMENT|1969-02-03||||1972-12-15||1965-09-12|1963-12-07||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||BESTRESP|BEST OVERALL RESPONSE||||/CMH2O|CCR||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|NA|U|CHILD|READER 1|NA|2||58||WASHOUT|1970-11-25||||1962-06-14||1963-10-31|1973-04-22||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||NKAT|CPR||TRANSDUCING UNIT/ML|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|NA|INVESTIGATOR|HEMATOLOGIST|N|3||39||OPEN LABEL TREATMENT|1963-06-30||||1972-07-05||1969-07-05|1963-08-05||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||CLINRESP|CLINICAL RESPONSE||||U/DL|PSEUDOPROGRESSION||ELISA UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|N|Y|FAMILY MEMBER|ENDOCRINOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1967-12-04||||1970-10-19||1967-07-22|1962-05-08||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||VG/KG|FAVORABLE RESPONSE||SCM|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|U|VENDOR|RATER|U|4||88||BLINDED TREATMENT|1972-04-26||||1973-02-04||1966-01-05|1963-01-04||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||MJPTHIND|MAJOR PATHOLOGICAL RESPONSE INDICATOR||||ML/100G/MIN|PD/RELAPSE AFTER HI||MMHG/L/MIN|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|4||88||BASELINE|1969-08-08||||1960-04-06||1964-03-21|1967-10-21||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||/LPF|CYTOGENETIC CR||ECL UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|Y|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1964-02-09||||1970-06-19||1962-04-20|1966-05-07||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||SPLNRESP|SPLEEN RESPONSE||||10^6/HPF|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||UMOL/DAY|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|Y|NA|SIGNIFICANT OTHER|MICROSCOPIST 1|U|5||7||WASHOUT|1966-02-27||||1965-09-14||1966-06-09|1969-02-13||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||PKAT|DISEASE TRANSFORMATION||PACKET|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|Y|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|1||38||FOLLOW-UP|1965-07-08||||1962-03-09||1971-06-28|1961-12-14||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||STRIP|CA125 50% RESPONSE||NU/CL|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|NA|NA|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|1||38||SCREENING|1963-03-03||||1969-06-15||1966-07-26|1964-04-26||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||OVRLRESP|OVERALL RESPONSE||||EID 50/DOSE|SCR||UMOL/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|NA|SPOUSE|RATER 2|Y|2||58||OPEN LABEL TREATMENT|1969-07-07||||1970-05-02||1964-04-13|1960-03-15||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||OVRLRESP|OVERALL RESPONSE||||JDF UNIT|CCR||COAT|NOT DONE|||LIKERT SCALE 5-POINT|NA|U|Y|INDEPENDENT ASSESSOR|RATER|NA|2||58||INDUCTION TREATMENT|1960-09-03||||1963-02-07||1963-03-25|1969-02-27||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||BONERESP|BONE RESPONSE||||SPRAY|NON-QUANTIFIABLE MRD POSITIVITY||BQ/L|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|Y|U|PARENT|CLINICAL PATHOLOGIST|U|3||39||BLINDED TREATMENT|1969-10-16||||1963-03-14||1966-10-14|1969-11-21||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||BESTRESP|BEST OVERALL RESPONSE||||ML/CM|MRD PERSISTENCE||RING|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|Y|N|FAMILY MEMBER|READER 1|U|3||39||FOLLOW-UP|1967-07-22||||1962-06-06||1966-02-26|1967-10-18||DURING||COINCIDENT|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||STRUSTAT|STEROID USE STATUS||||UM/S|CPR||G/KG/DAY|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|U|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|4||88||RUN-IN|1968-03-22||||1968-04-21||1960-09-21|1973-04-10||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/G|WORSENED||AG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|N|N|SIGNIFICANT OTHER|CARDIOLOGIST|NA|4||88||BLINDED TREATMENT|1968-08-02||||1964-08-09||1963-06-04|1970-08-02||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||FMOL/G|MOLECULAR CR||NFIU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|U|NA|STUDY SUBJECT|READER|N|5||7||WASHOUT|1960-11-18||||1971-03-01||1970-03-17|1964-12-26||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||MV*MIN|CYTOGENETIC MINIMAL RESPONSE||BOTTLE|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|CHILD|ADJUDICATOR 2|Y|5||7||SCREENING|1961-03-19||||1969-11-08||1965-03-02|1970-05-14||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||BU/ML|RELAPSED DISEASE FROM CR||JAR|NOT DONE|||LIKERT SCALE 7-POINT|Y|Y|N|STUDY SUBJECT|RATER 2|U|1||38||OBSERVATION|1973-01-15||||1962-05-21||1962-07-19|1968-07-26||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||SPLNRESP|SPLEEN RESPONSE||||MET*H|NE||10^6/EJACULATE U|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|U|N|VENDOR|RATER|NA|1||38||CONTINUATION TREATMENT|1967-03-30||||1969-09-30||1966-12-09|1971-10-16||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||%|NE||NCI|NOT DONE|||VERBAL RATING SCALE 5-POINT|NA|NA|NA|INTERVIEWER|ONCOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1969-12-18||||1971-12-16||1967-12-15|1960-07-23||COINCIDENT||DURING|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||NTLWIND|NON-TARGET LESION WORSENING INDICATOR||||H/WK|IMMUNOPHENOTYPIC CR||KG/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|Y|U|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|2||58||RUN-IN|1971-05-07||||1969-04-21||1961-09-02|1972-06-16||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||NEWTON|HI-P||APS U|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|Y|CAREGIVER|ADJUDICATOR 3|NA|3||39||BASELINE|1970-10-22||||1967-03-27||1968-09-21|1967-03-16||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||BONERESP|BONE RESPONSE||||CYCLE/MIN|CA125 50% RESPONSE||NMOL/MOL|NOT DONE|||LIKERT SCALE 3-POINT|NA|U|U|INVESTIGATOR|ONCOLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1969-12-09||||1963-05-06||1960-03-12|1960-10-03||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||ECL UNIT|CPR||BU/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|N|N|INVESTIGATOR|NEUROLOGIST 2|N|4||88||BLINDED TREATMENT|1962-03-24||||1960-01-09||1969-06-16|1965-01-22||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||MOLRESP|MOLECULAR RESPONSE||||U/MMOL|NE||FL|NOT DONE|||LIKERT SCALE 7-POINT|NA|NA|NA|PROXY|HEMATOLOGIST|N|4||88||INDUCTION TREATMENT|1969-08-07||||1970-03-08||1970-09-13|1963-06-03||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||SEC|MRD PERSISTENCE||MU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|NA|N|ADJUDICATION COMMITTEE|RATER 2|N|5||7||OPEN LABEL TREATMENT|1965-05-25||||1961-08-06||1969-01-06|1965-09-30||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||ANATRESP|ANATOMIC RESPONSE||||HOUNSFIELD UNIT|MINOR PATHOLOGIC RESPONSE||MMOL/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|VENDOR|FORENSIC PATHOLOGIST|U|5||7||RUN-IN|1968-12-20||||1966-09-30||1960-07-19|1973-07-01||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||OVRLRESP|OVERALL RESPONSE||||ML/CM3/MIN|PARTIAL MORPHOLOGIC RESPONSE||10^7 CFU/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|1||38||CONTINUATION TREATMENT|1965-06-18||||1960-02-10||1972-06-24|1961-07-01||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||MMOL/DAY|EQUIVOCAL||CM2|NOT DONE|||VERBAL RATING SCALE 5-POINT|U|N|Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|1||38||OBSERVATION|1964-11-22||||1961-05-10||1972-05-14|1973-01-25||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||NTRGRESP|NON-TARGET RESPONSE||||BAG|RELAPSED DISEASE||DROP|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|STUDY SUBJECT|ADJUDICATOR 1|NA|2||58||BASELINE|1964-01-15||||1969-01-19||1968-06-07|1964-11-11||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||RDIORESP|RADIOLOGIC RESPONSE||||KALLIKREIN INHIBITOR UNIT|DISEASE TRANSFORMATION||MEQ/L|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|N|N|SIBLING|FORENSIC PATHOLOGIST|U|2||58||INDUCTION TREATMENT|1965-03-15||||1970-05-03||1966-04-16|1972-11-26||AFTER||DURING|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||ANATRESP|ANATOMIC RESPONSE||||CCID 50/ML|ABSENT MORPHOLOGIC RESPONSE||CMH2O*S/ML|NOT DONE|||LIKERT SCALE 5-POINT|N|Y|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|3||39||BASELINE|1968-11-23||||1963-11-12||1960-10-03|1965-02-11||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||10^5/L|DISEASE TRANSFORMATION||TUBERCULIN UNIT/ML|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|NA|U|FAMILY MEMBER|OPHTHALMOLOGIST|NA|3||39||BLINDED TREATMENT|1965-04-08||||1971-07-28||1961-11-24|1962-05-10||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||CYTORESP|CYTOGENETIC RESPONSE||||KAT|TREATMENT FAILURE||ML/CAGE/DAY|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|U|U|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|4||88||INDUCTION TREATMENT|1961-07-01||||1965-01-26||1969-10-12|1971-12-30||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||PATHRESP|PATHOLOGIC RESPONSE||||HPA|NON-QUANTIFIABLE MRD POSITIVITY||IU/KG|NOT DONE|||VERBAL RATING SCALE 4-POINT|U|NA|Y|DOMESTIC PARTNER|MICROSCOPIST 2|U|4||88||BLINDED TREATMENT|1971-03-05||||1970-01-16||1970-05-15|1966-11-23||BEFORE||AFTER|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UG/L|CYTOGENETIC MINIMAL RESPONSE||NMOL/MOL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|NA|Y|ADJUDICATOR|ONCOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1961-04-29||||1961-10-06||1970-02-13|1971-08-25||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||METBRESP|METABOLIC RESPONSE||||SFC/10^6 PBMC|CRI||MGEQ|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|Y|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|5||7||BASELINE|1960-05-10||||1972-05-27||1971-03-10|1969-12-05||COINCIDENT||BEFORE|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||CYTORESP|CYTOGENETIC RESPONSE||||PIXEL|IUPD||%|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|NA|N|N|ADJUDICATOR|RATER 2|NA|1||38||WASHOUT|1960-12-22||||1968-05-11||1970-07-25|1966-11-24||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||CYTORESP|CYTOGENETIC RESPONSE||||UG/MIN|PSEUDOPROGRESSION||G/DL|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|N|U|GUARDIAN|PEDIATRIC NEUROLOGIST|U|1||38||BASELINE|1964-10-16||||1962-04-28||1964-07-05|1962-12-16||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||MRPHRESP|MORPHOLOGIC RESPONSE||||MEQ/G|MRD RELAPSE||TUBERCULIN UNIT/ML|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|N|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|2||58||WASHOUT|1972-05-13||||1968-12-24||1967-04-29|1961-10-22||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||STRUSTAT|STEROID USE STATUS||||/5X10^4 WBC|MOLECULAR CR||MS/MMHG|NOT DONE|||LIKERT SCALE 3-POINT|U|U|U|HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|2||58||OPEN LABEL TREATMENT|1964-10-11||||1971-07-06||1963-07-27|1970-08-21||AFTER||AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||L/L|UNEQUIVOCAL||TSP EQ|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|NA|CHILD|CARDIOLOGIST|NA|3||39||RUN-IN|1965-10-05||||1961-09-27||1961-08-17|1965-03-22||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||NTNERESP|NON-TARGET NON-ENHANCING RESPONSE||||ROENTGEN|MR||PIXEL|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|Y|Y|Y|FRIEND|CLINICAL PATHOLOGIST|NA|3||39||BASELINE|1962-11-17||||1970-09-03||1969-06-06|1972-12-06||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||ANATRESP|ANATOMIC RESPONSE||||DB|RELAPSED DISEASE FROM CR OR PR||KPA|NOT DONE|||VERBAL RATING SCALE 5-POINT|Y|N|U|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|4||88||RUN-IN|1968-06-23||||1968-02-07||1961-04-15|1966-04-14||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||TMRESP|TUMOR MARKER RESPONSE||||UG/KG/H|INDETERMINATE RESPONSE||C|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|U|CAREGIVER|READER 3|N|4||88||BLINDED TREATMENT|1971-05-14||||1961-04-18||1960-12-22|1970-05-02||ONGOING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||NTERESP|NON-TARGET ENHANCING RESPONSE||||MMU/ML|MINOR PATHOLOGIC RESPONSE||G/CM2|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|NA|U|PROXY|RADIOLOGIST|U|5||7||INDUCTION TREATMENT|1972-10-02||||1970-07-13||1965-01-31|1971-03-29||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||PATHRESP|PATHOLOGIC RESPONSE||||WAFER|CA125 50% RESPONSE||NMOL/L/MIN|NOT DONE|||LIKERT SCALE 3-POINT|N|NA|N|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||SCREENING|1969-05-10||||1960-08-12||1965-03-15|1964-09-13||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||PATHRESP|PATHOLOGIC RESPONSE||||PIPE|NOT ALL EVALUATED||DPM/100MG|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|NA|U|NA|SPOUSE|MICROSCOPIST 3|NA|1||38||FOLLOW-UP|1969-04-24||||1964-04-03||1972-06-09|1964-11-07||AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||METSIND|METASTATIC INDICATOR||||MS2|PD/RELAPSE AFTER HI||MEQ/DL|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|Y|Y|CHILD|PATHOLOGIST|NA|1||38||SCREENING|1966-12-30||||1960-06-28||1968-07-01|1966-06-15||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||ANATRESP|ANATOMIC RESPONSE||||G/CM2|CMR||NMOL/L|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|U|U|INTERVIEWER|RATER|U|2||58||LONG-TERM FOLLOW-UP|1967-05-02||||1962-11-09||1968-06-18|1960-05-17||DURING/AFTER||UNKNOWN|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||BAU|DISEASE TRANSFORMATION||CP|NOT DONE|||LIKERT SCALE 7-POINT|N|NA|U|ADJUDICATION COMMITTEE|PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1970-03-18||||1960-03-14||1960-05-20|1963-09-29||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||NEWLPROG|NEW LESION PROGRESSION||||BP|INDETERMINATE RESPONSE||G/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|Y|Y|SPOUSE|OPHTHALMOLOGIST|U|3||39||RUN-IN|1964-02-14||||1966-09-13||1960-08-21|1967-03-23||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||SPLNRESP|SPLEEN RESPONSE||||DEG/S|PSA PROGRESSION||G/M2|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|U|U|CHILD|FORENSIC PATHOLOGIST|N|3||39||OBSERVATION|1964-10-20||||1968-03-05||1972-05-14|1965-04-10||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||F|PR-CT||AMP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|4||88||INDUCTION TREATMENT|1963-05-01||||1963-02-11||1962-08-05|1961-10-21||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||TMRESP|TUMOR MARKER RESPONSE||||U/G/H|PR||U/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|FRIEND|PHYSIOTHERAPIST|U|4||88||OPEN LABEL TREATMENT|1967-09-01||||1969-06-16||1961-02-01|1961-06-20||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||NTRGRESP|NON-TARGET RESPONSE||||CD|CPR||UV*SEC|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|U|Y|N|PARENT|NEUROLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1961-10-26||||1961-10-28||1972-10-24|1961-08-05||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||BESTRESP|BEST OVERALL RESPONSE||||LOG10 TCID 50/DOSE|SMD||CAPSULE|NOT DONE|||LIKERT SCALE 5-POINT|Y|N|NA|ADJUDICATOR|MICROSCOPIST 2|NA|5||7||RUN-IN|1966-03-09||||1964-04-22||1965-09-09|1969-01-30||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||RDIORESP|RADIOLOGIC RESPONSE||||DPM/100MG|MORPHOLOGIC CR||PSEC|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|VENDOR|RADIOLOGIST 2|NA|1||38||WASHOUT|1964-10-18||||1960-11-07||1967-05-08|1972-02-11||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UMOL/L/SEC|CR||MV2/HZ|NOT DONE|||LIKERT SCALE 7-POINT|U|U|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||SCREENING|1963-02-17||||1960-02-02||1970-07-27|1961-01-10||COINCIDENT||AFTER|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||ANATRESP|ANATOMIC RESPONSE||||P|CR||MOL/MOL|NOT DONE|||LIKERT SCALE 5-POINT|Y|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|U|2||58||INDUCTION TREATMENT|1968-05-01||||1966-04-14||1972-10-26|1961-08-14||UNKNOWN||DURING/AFTER|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||BONERESP|BONE RESPONSE||||KG/M2|PSEUDORESPONSE||MCI|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|Y|NA|PROXY|UROLOGIST|NA|2||58||BLINDED TREATMENT|1966-08-26||||1970-09-23||1970-04-30|1962-03-15||DURING/AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||STRUSTAT|STEROID USE STATUS||||NEEDLE GAUGE|STABLE||POUCH|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|NA|NA|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|3||39||WASHOUT|1972-12-07||||1967-04-19||1967-07-25|1966-08-02||DURING/AFTER||DURING|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||OVRLRESP|OVERALL RESPONSE||||CM H2O|HI-N||BOTTLE|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|Y|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||INDUCTION TREATMENT|1961-09-30||||1972-06-29||1965-09-11|1971-10-08||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||BONERESP|BONE RESPONSE||||DEG/S|IMMUNOPHENOTYPIC CR||AMFI|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|U|INVESTIGATOR|NEUROLOGIST 1|N|4||88||SCREENING|1970-01-27||||1961-12-29||1968-03-06|1960-12-24||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||NTRGRESP|NON-TARGET RESPONSE||||U.CARR|MINOR PATHOLOGIC RESPONSE||10^9 ORGANISMS|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|FAMILY MEMBER|MICROSCOPIST 2|N|4||88||BASELINE|1961-10-24||||1963-09-04||1971-12-11|1970-01-22||DURING||UNKNOWN|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||ANATRESP|ANATOMIC RESPONSE||||FRACTION OF 1|PMD||MAC50|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|NA|Y|N|SIGNIFICANT OTHER|UROLOGIST|NA|5||7||BLINDED TREATMENT|1967-07-09||||1971-02-13||1964-04-09|1971-05-15||UNKNOWN||UNKNOWN|
TRIAL STUDY 134XCP|RS|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||UG/L DDU|COMPLETE MRD RESPONSE||10^6 RNA COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|U|U|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|5||7||SCREENING|1967-09-23||||1964-12-16||1970-06-15|1966-08-22||DURING||BEFORE|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||MEQ/DAY|PD/RELAPSE AFTER HI||MOL/G|NOT DONE|||VERBAL RATING SCALE 4-POINT|NA|N|U|FRIEND|RADIOLOGIST 2|NA|1||38||WASHOUT|1973-01-23||||1966-03-08||1966-04-23|1967-09-10||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||BONERESP|BONE RESPONSE||||MOL/MG|CR||MMOL2/L2|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|N|U|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|Y|1||38||WASHOUT|1960-10-20||||1965-04-07||1968-12-20|1972-07-21||AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||SPLNRESP|SPLEEN RESPONSE||||PT_BR|UNFAVORABLE RESPONSE||DRAM|NOT DONE|||VERBAL RATING SCALE 6-POINT|NA|N|Y|FAMILY MEMBER|PHYSIOTHERAPIST|NA|2||58||BLINDED TREATMENT|1969-03-04||||1964-09-26||1971-09-16|1973-08-14||ONGOING||BEFORE|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||DRCRIND|DISEASE RECURRENCE INDICATOR||||DB|PARTIAL MORPHOLOGIC RESPONSE||10^4/HPF|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|CHILD|NEUROLOGIST 2|NA|2||58||INDUCTION TREATMENT|1963-04-24||||1966-08-25||1963-03-08|1968-06-24||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||FOZ_US|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE||NMOL/KG/DAY|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|3||39||RUN-IN|1963-06-09||||1965-04-24||1964-08-29|1963-09-08||AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||TRGRESP|TARGET RESPONSE||||PMOL|NON-PD||MOSM|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|3||39||OBSERVATION|1968-06-22||||1970-05-01||1963-12-27|1965-10-12||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||PATHRESP|PATHOLOGIC RESPONSE||||LOG10 CCID 50/DOSE|MAJOR PATHOLOGIC RESPONSE||UEQ/L|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|N|U|PARENT|READER 1|Y|4||88||BASELINE|1967-01-20||||1970-07-01||1973-01-28|1962-11-03||BEFORE||BEFORE|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||KBQ/UL|CA125 75% RESPONSE||KPA|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|Y|Y|INDEPENDENT ASSESSOR|RATER 2|NA|4||88||RUN-IN|1971-11-23||||1964-12-17||1960-09-02|1968-09-23||BEFORE||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||SFTSRESP|SOFT TISSUE RESPONSE||||LX|CR-CT||/MM2|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|5||7||SCREENING|1972-08-21||||1970-01-15||1967-05-31|1969-12-03||COINCIDENT||DURING/AFTER|
TRIAL STUDY 134XCP|RS|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||LIVRRESP|LIVER RESPONSE||||MOSM/L|RELAPSED DISEASE FROM CR||%/MIN|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|U|N|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|Y|5||7||BLINDED TREATMENT|1961-09-18||||1970-09-29||1968-05-14|1971-12-27||DURING/AFTER||DURING/AFTER|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||BONERESP|BONE RESPONSE||||MEQ|NE||ABSORBANCE U/MIN|NOT DONE|||LIKERT SCALE 7-POINT|Y|NA|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||RUN-IN|1966-10-04||||1971-12-22||1973-05-02|1966-01-31||UNKNOWN||DURING|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||TMRESP|TUMOR MARKER RESPONSE||||L/H|INCREASED||KV|NOT DONE|||LIKERT SCALE 7-POINT|Y|U|NA|GUARDIAN|ONCOLOGIST|Y|1||38||SCREENING|1970-04-08||||1963-07-17||1961-12-10|1967-11-11||COINCIDENT||ONGOING|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||BESTRESP|BEST OVERALL RESPONSE||||10^9 CFU|PD-CT||10^3 COPIES/ML|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|N|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1971-04-05||||1968-05-20||1961-11-22|1963-11-12||BEFORE||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||BESTRESP|BEST OVERALL RESPONSE||||MM/2H|CCR||PA|NOT DONE|||LIKERT SCALE 3-POINT|NA|Y|U|INTERVIEWER|FORENSIC PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1972-04-29||||1972-04-27||1968-07-01|1968-08-06||COINCIDENT||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||SPLNRESP|SPLEEN RESPONSE||||PPB|MOLECULAR MAJOR RESPONSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||VISUAL ANALOG SCALE (10 CM)|Y|U|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|3||39||BASELINE|1973-08-02||||1961-10-13||1973-07-29|1960-09-02||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||LIVRRESP|LIVER RESPONSE||||NEEDLE GAUGE|NOT ALL EVALUATED||BREATHS/30S|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|N|U|N|CAREGIVER|PATHOLOGIST|U|3||39||INDUCTION TREATMENT|1969-06-17||||1969-07-12||1967-04-12|1972-02-08||AFTER||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||NEWLPROG|NEW LESION PROGRESSION||||UOSM|FAVORABLE RESPONSE||L/S|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|Y|U|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4||88||INDUCTION TREATMENT|1967-05-21||||1963-06-24||1969-11-17|1971-03-15||ONGOING||COINCIDENT|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||SPLNRESP|SPLEEN RESPONSE||||MAMP|CPR||IU/G HB|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|NA|N|U|STUDY SUBJECT|PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1961-04-25||||1972-02-04||1968-11-09|1962-03-02||DURING||ONGOING|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||G/ANIMAL/WK|PR WITH LYMPHOCYTOSIS||U/G/H|NOT DONE|||VERBAL RATING SCALE 5-POINT|N|U|NA|SIBLING|HEMATOLOGIST|N|5||7||OBSERVATION|1966-01-09||||1966-06-17||1966-08-03|1961-06-29||DURING/AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||TMRESP|TUMOR MARKER RESPONSE||||MPL U|CR||K|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|NA|U|PROXY|ADJUDICATOR|U|5||7||RUN-IN|1961-08-03||||1972-06-26||1972-01-20|1972-10-12||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||SPLNRESP|SPLEEN RESPONSE||||MG/G/H|PSA PROGRESSION||MMAL|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|Y|U|N|FAMILY MEMBER|NEUROLOGIST 2|N|1||38||RUN-IN|1972-05-14||||1970-12-27||1973-08-20|1967-06-08||AFTER||BEFORE|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||NEWLWIND|NEW LESION WORSENING INDICATOR||||G/MOL|MOLECULAR MAJOR RESPONSE||SYRINGE|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|Y|U|U|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|N|1||38||TREATMENT|1965-06-17||||1973-09-04||1972-03-24|1960-04-07||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||HEMARESP|HEMATOLOGIC RESPONSE||||V/V|NPR||PFU/DOSE|NOT DONE|||NUMERICAL RATING SCALE 11-POINT|U|NA|U|STUDY SUBJECT|PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-07-02||||1967-02-26||1966-09-04|1961-02-08||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||SFTSRESP|SOFT TISSUE RESPONSE||||MNFI|PD||DAYS/WK|NOT DONE|||VERBAL RATING SCALE 6-POINT|N|U|N|INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1969-04-07||||1969-11-26||1961-04-03|1960-11-26||ONGOING||ONGOING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||NTRGRESP|NON-TARGET RESPONSE||||BEAM BREAKS|WORSENED||FFU|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|FAMILY MEMBER|CARDIOLOGIST|N|3||39||OBSERVATION|1966-01-21||||1969-06-01||1965-04-06|1971-05-07||ONGOING||DURING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||RDIORESP|RADIOLOGIC RESPONSE||||SFC/10^6 PBMC|PSA PROGRESSION||COPIES/ML|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|DOMESTIC PARTNER|READER 2|Y|3||39||OBSERVATION|1960-12-14||||1972-04-06||1967-11-18|1962-07-13||BEFORE||UNKNOWN|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||LIVRRESP|LIVER RESPONSE||||MKAT|CYTOGENETIC NO RESPONSE||OD UNIT|NOT DONE|||VERBAL RATING SCALE 6-POINT|U|Y|Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|4||88||FOLLOW-UP|1965-11-06||||1970-05-09||1970-04-20|1961-04-28||BEFORE||ONGOING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||MNPTHIND|MINOR PATHOLOGICAL RESPONSE INDICATOR||||CYLINDER|ABSENT MORPHOLOGIC RESPONSE||KALLIKREIN INHIBITOR UNIT|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||WASHOUT|1962-10-27||||1967-12-08||1972-01-24|1968-06-19||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||CPRFSTAT|CLINICAL PERFORMANCE STATUS||||KG|NON-ICR/NON-IUPD||UG/L/H|NOT DONE|||VISUAL ANALOG SCALE (100 MM)|N|N|Y|ADJUDICATOR|MICROSCOPIST 2|U|5||7||FOLLOW-UP|1968-10-01||||1962-08-09||1966-04-11|1961-09-26||DURING||AFTER|
TRIAL STUDY 134XCP|RS|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||BMIVLIND|BONE MARROW INVOLVEMENT INDICATOR||||UM|RELAPSED DISEASE FROM CR||VIAL|NOT DONE|||LIKERT SCALE 7-POINT|U|N|U|PROXY|PATHOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1967-12-28||||1971-05-06||1971-03-07|1965-01-21||UNKNOWN||BEFORE|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||BESTRESP|BEST OVERALL RESPONSE||||FL|HI-P||PACKAGE|NOT DONE|||LIKERT SCALE 5-POINT|NA|Y|N|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|1||38||OPEN LABEL TREATMENT|1972-12-09||||1962-02-16||1972-08-22|1966-09-23||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||PMOL/G|PD-CT||NCI|NOT DONE|||NUMERICAL RATING SCALE 5-POINT|U|NA|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|1||38||TREATMENT|1969-01-19||||1969-02-01||1970-11-10|1963-11-16||DURING||DURING/AFTER|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||NTRGRESP|NON-TARGET RESPONSE||||GTT|MORPHOLOGIC CRI||UG/DAY|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|U|Y|STUDY SUBJECT|ADJUDICATOR|N|2||58||LONG-TERM FOLLOW-UP|1971-09-15||||1970-12-02||1972-04-09|1966-04-03||UNKNOWN||ONGOING|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||MRDRESP|MINIMAL RESIDUAL DISEASE RESPONSE||||GY/H|MR||BLOCKS|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|NA|Y|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|2||58||SCREENING|1969-08-21||||1965-11-26||1971-12-05|1970-12-06||AFTER||DURING|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||SYMPTDTR|SYMPTOMATIC DETERIORATION||||10^11/L|PDU||RFU|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|N|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|3||39||OBSERVATION|1971-01-14||||1971-09-02||1963-06-07|1972-02-26||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||LOG10 CFU/G|INCREASED||PG|NOT DONE|||NUMERICAL RATING SCALE 21-POINT|Y|Y|N|SIBLING|OPHTHALMOLOGIST|N|3||39||CONTINUATION TREATMENT|1964-08-04||||1970-01-31||1961-09-22|1963-04-23||ONGOING||AFTER|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||MRDIND|MINIMAL RESIDUAL DISEASE INDICATOR||||UG/CM2|PARTIAL MORPHOLOGIC RESPONSE||VG/DOSE|NOT DONE|||NUMERICAL RATING SCALE 6-POINT|U|NA|Y|VENDOR|OPHTHALMOLOGIST|NA|4||88||CONTINUATION TREATMENT|1961-12-15||||1973-03-25||1965-05-25|1963-07-20||UNKNOWN||COINCIDENT|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||HEMARESP|HEMATOLOGIC RESPONSE||||DROP|CA125 50% RESPONSE||10^7/L|NOT DONE|||LIKERT SCALE 5-POINT|NA|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|4||88||LONG-TERM FOLLOW-UP|1970-10-12||||1960-02-08||1973-01-20|1972-09-17||DURING/AFTER||ONGOING|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||BESTRESP|BEST OVERALL RESPONSE||||TROCHE|CYTOGENETIC MINIMAL RESPONSE||CFU/G|NOT DONE|||VERBAL RATING SCALE 6-POINT|Y|Y|N|ADJUDICATOR|MICROSCOPIST 2|N|5||7||BASELINE|1967-07-03||||1969-06-09||1961-10-01|1963-08-06||ONGOING||UNKNOWN|
TRIAL STUDY 134XCP|RS|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||METBRESP|METABOLIC RESPONSE||||LOG10 TCID 50/ML|CCR||DIP|NOT DONE|||VISUAL ANALOG SCALE (50 MM)|N|U|U|INVESTIGATOR|READER|N|5||7||BASELINE|1972-10-19||||1961-01-14||1966-01-12|1967-02-13||AFTER||DURING|
